PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Novak, N; Allam, JP; Hagemann, T; Jenneck, C; Laffer, S; Valenta, R; Kochan, J; Bieber, T				Novak, N; Allam, JP; Hagemann, T; Jenneck, C; Laffer, S; Valenta, R; Kochan, J; Bieber, T			Characterization of Fc epsilon RI-bearing CD123(+) blood dendritic cell antigen-2(+) plasmacytoid dendritic cells in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						plasmacytoid dendritic cells; IgE; Fc epsilon RI; atopic dermatitis; IFN-alpha/beta	EPIDERMAL LANGERHANS CELLS; HIGH-AFFINITY RECEPTOR; PERIPHERAL-BLOOD; ALLERGEN PRESENTATION; ADAPTIVE IMMUNITY; PRESENTING CELLS; IGE RECEPTORS; SERUM IGE; INTERFERON; EXPRESSION	Background: The high-affinity receptor for IgE (FcepsilonRI) on myeloid dendritic cells has been shown to play a major role in atopic dermatitis (AD). Plasmacytoid dendritic cells (pDCs), which are instrumental in the defense of viral infections, are present in reduced amounts in the skin of patients with AD, which is characterized by a high susceptibility to viral infections. Objective: We explored phenotypical and functional characteristics of pDC in the peripheral blood of patients with AD and healthy individuals. Methods: Blood dendritic cell antigen-2(+)CD123(+) pDCs were enriched from the peripheral blood of patients with AD and studied in functional assays. Results: Skin-homing molecules such as cutaneous lymphocyte antigen and L-selectin CD62L were expressed in lower levels on pDCs of patients with AD. pDCs expressed high amounts of IgE-occupied FcepsilonRI. Further, FcepsilonRI aggregation on pDCs impaired the surface expression of MHC I and II, induced the production of IL-10, and enhanced the apoptosis of pDCs. Importantly, FcepsilonRI preactivated pDC produced less IFN-alpha and IFN-beta after stimulation with CpG motifs and enhanced the outcome of immune responses of the T(H)2 type. Conclusion: From these data, we conclude that FcepsilonRI-bearing pDCs from patients with AD (1) are different from pDCs of healthy individuals, (2) might be important in the pathophysiology of AD, and (3) contribute to the enhanced susceptibility of patients with AD to viral infections.	Univ Bonn, Dept Dermatol, Immunol Lab, D-53105 Bonn, Germany; Med Univ Vienna, Dept Pathophysiol, Allgemeines Krankenhaus Wien, Vienna, Austria; Hoffmann La Roche Inc, Dept Metabol Dis, Nutley, NJ USA	University of Bonn; Medical University of Vienna; Roche Holding	Novak, N (corresponding author), Univ Bonn, Dept Dermatol, Immunol Lab, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de		Valenta, Rudolf/0000-0001-5944-3365				Banchereau J, 2003, ANN NY ACAD SCI, V987, P180, DOI 10.1111/j.1749-6632.2003.tb06047.x; Bangert C, 2003, J INVEST DERMATOL, V121, P1409, DOI 10.1111/j.1523-1747.2003.12623.x; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Charbonnier AS, 2003, J LEUKOCYTE BIOL, V73, P91, DOI 10.1189/jlb.0602289; Duramad O, 2003, BLOOD, V102, P4487, DOI 10.1182/blood-2003-07-2465; Dzionek A, 2002, HUM IMMUNOL, V63, P1133, DOI 10.1016/S0198-8859(02)00752-8; Dzionek A, 2001, J EXP MED, V194, P1823, DOI 10.1084/jem.194.12.1823; Farkas L, 2001, AM J PATHOL, V159, P237, DOI 10.1016/S0002-9440(10)61689-6; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; JURGENS M, 1995, J IMMUNOL, V155, P5184; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Krug A, 2003, J EXP MED, V197, P899, DOI 10.1084/jem.20021091; Lambrecht BN, 2001, CURR OPIN ALLERGY CL, V1, P51, DOI 10.1097/00130832-200102000-00010; Matsuda H, 2002, AM J RESP CRIT CARE, V166, P1050, DOI 10.1164/rccm.2110066; Maurer D, 1996, J IMMUNOL, V157, P607; Maurer D, 1998, J IMMUNOL, V161, P2731; Maurer D, 1997, ADV EXP MED BIOL, V417, P175; Nolan KF, 2004, J IMMUNOL, V172, P2201, DOI 10.4049/jimmunol.172.4.2201; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2004, ALLERGY, V59, P5, DOI 10.1046/j.1398-9995.2003.00337.x; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; Novak N, 2001, CURR OPIN IMMUNOL, V13, P721, DOI 10.1016/S0952-7915(01)00285-0; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Uchida Y, 2001, J ALLERGY CLIN IMMUN, V108, P1005, DOI 10.1067/mai.2001.119741; von Bubnoff D, 2002, J IMMUNOL, V169, P1810, DOI 10.4049/jimmunol.169.4.1810; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x	38	121	126	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					364	370		10.1016/j.jaci.2004.05.038	http://dx.doi.org/10.1016/j.jaci.2004.05.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316517				2022-12-18	WOS:000223405600024
J	von Hertzen, LC				von Hertzen, LC			Maternal stress and T-cell differentiation of the developing immune system: Possible implications for the development of asthma and atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; stress; maternal; T-cell differentiation; fetus	CORTICOTROPIN-RELEASING HORMONE; UNDERSTANDING HUMAN PARTURITION; PITUITARY-ADRENAL AXIS; INHALANT ALLERGENS; IL-12 PRODUCTION; PRENATAL STRESS; CD4(+) LYMPHOCYTES; CORTISOL SECRETION; HUMAN MONOCYTES; HUMAN-PLACENTA	The constant increase in asthma and atopy prevalences-despite improved treatment and knowledge of many aspects of the diseases-has raised growing concern. Accumulating evidence suggests that these increases in atopic diseases are largely attributable to environmental and lifestyle factors, and the lack of systemic childhood infections has in many studies emerged as a major factor. In addition to current high standards of hygiene and the lack or scarcity of such infections, another factor characteristic of our present-day lives could be involved. This review briefly outlines the possibility that prolonged maternal stress associated with sustained excessive cortisol secretion could affect the developing immune system-especially T(H)1/T(H)2 cell differentiation-and further increase the susceptibility to asthma and atopy in genetically predisposed individuals. This hypothesis is critically evaluated in the light of current knowledge.	Finnish Lung Hlth Assoc, Helsinki 00250, Finland		von Hertzen, LC (corresponding author), Finnish Lung Hlth Assoc, Sibeliuksenkatu 11 A 1, Helsinki 00250, Finland.							BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; Barker DJP, 1992, FETAL INFANT ORIGINS; BATEMAN A, 1989, ENDOCR REV, V10, P92, DOI 10.1210/edrv-10-1-92; BAYBUTT HN, 1990, ENDOCRINOLOGY, V127, P476, DOI 10.1210/endo-127-1-476; Benediktsson R, 1998, LANCET, V351, P913, DOI 10.1016/S0140-6736(05)70335-4; Benschop RJ, 1998, PSYCHOSOM MED, V60, P290, DOI 10.1097/00006842-199805000-00015; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; BLACK PH, 1994, ANTIMICROB AGENTS CH, V338, P7; Blotta MH, 1997, J IMMUNOL, V158, P5589; BLUMENFELD Z, 1986, J CLIN INVEST, V78, P288, DOI 10.1172/JCI112563; BUSSE WW, 1995, AM J RESP CRIT CARE, V151, P249, DOI 10.1164/ajrccm.151.1.7812562; Chrousos GP, 1998, J CLIN ENDOCR METAB, V83, P1842, DOI 10.1210/jc.83.6.1842; Chrousos GP, 2000, ANN NY ACAD SCI, V917, P38, DOI 10.1111/j.1749-6632.2000.tb05371.x; Coe CL, 2002, J CLIN ENDOCR METAB, V87, P675, DOI 10.1210/jc.87.2.675; Coe CL, 2000, ANN NY ACAD SCI, V917, P468; Coe CL, 1996, BRAIN BEHAV IMMUN, V10, P221, DOI 10.1006/brbi.1996.0020; COHEN S, 1980, AM PSYCHOL, V35, P231, DOI 10.1037/0003-066X.35.3.231; Conti A, 2000, ANN NY ACAD SCI, V917, P68; DAYNES RA, 1989, EUR J IMMUNOL, V19, P2319, DOI 10.1002/eji.1830191221; DeKruyff R, 1998, J IMMUNOL, V160, P2231; Dhabhar FS, 2000, ANN NY ACAD SCI, V917, P876, DOI 10.1111/j.1749-6632.2000.tb05454.x; Dhondt S., 1998, TIME CONSTRAINTS AUT; Elenkov IJ, 1999, TRENDS ENDOCRIN MET, V10, P359, DOI 10.1016/S1043-2760(99)00188-5; FAMELI M, 1995, PHYSIOL BEHAV, V57, P397, DOI 10.1016/0031-9384(94)00228-W; FERREIRA AJ, 1965, J NERV MENT DIS, V141, P108, DOI 10.1097/00005053-196507000-00011; FRIM DM, 1988, J CLIN INVEST, V82, P287, DOI 10.1172/JCI113585; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gitau R, 1998, LANCET, V352, P707, DOI 10.1016/S0140-6736(05)60824-0; GOLAND RS, 1994, AM J OBSTET GYNECOL, V171, P1287, DOI 10.1016/0002-9378(94)90149-X; Harbuz MS, 1995, ANN NY ACAD SCI, V771, P449, DOI 10.1111/j.1749-6632.1995.tb44701.x; HENRY C, 1994, J NEUROENDOCRINOL, V6, P341, DOI 10.1111/j.1365-2826.1994.tb00591.x; HERBERT TB, 1993, PSYCHOSOM MED, V55, P364, DOI 10.1097/00006842-199307000-00004; HEREGAAD M, 1996, EPIDEMIOLOGY, V7, P339; Holt PG, 1996, TOXICOL LETT, V86, P205, DOI 10.1016/0378-4274(96)03692-2; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; Holt PG, 1999, CLIN EXP ALLERGY, V29, P8, DOI 10.1046/j.1365-2222.1999.00003.x-i2; IKEWANA K, 1998, IMMUNOL LETT, V62, P39; IRWIN M, 1994, ADV NEUROIMMUNOL, V4, P29, DOI 10.1016/S0960-5428(06)80188-9; JONES CT, 1990, J PHYSIOL-LONDON, V430, P25, DOI 10.1113/jphysiol.1990.sp018279; Kapsenberg ML, 1998, CURR OPIN IMMUNOL, V10, P607, DOI 10.1016/S0952-7915(98)80077-0; Karalis K, 1995, ANN NY ACAD SCI, V771, P551, DOI 10.1111/j.1749-6632.1995.tb44709.x; Kay G, 1998, PHYSIOL BEHAV, V63, P397, DOI 10.1016/S0031-9384(97)00456-3; KHANSARI DN, 1990, IMMUNOL TODAY, V11, P170, DOI 10.1016/0167-5699(90)90069-L; Kivimaki M, 2000, BRIT MED J, V320, P971, DOI 10.1136/bmj.320.7240.971; Kopin IJ, 1995, ANN NY ACAD SCI, V771, P19, DOI 10.1111/j.1749-6632.1995.tb44667.x; KORT WJ, 1994, ADV NEUROIMMUNOL, V4, P1, DOI 10.1016/S0960-5428(06)80186-5; Larsson S, 1998, CYTOKINE, V10, P786, DOI 10.1006/cyto.1998.0362; Lehto AM, 1998, LOISIR SOC-SOC LEIS, V21, P491, DOI 10.1080/07053436.1998.10753666; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MURPHY BEP, 1974, AM J OBSTET GYNECOL, V118, P538, DOI 10.1016/S0002-9378(16)33697-3; Norbiato G, 1997, CLIN EXP RHEUMATOL, V15, P315; Nowak D, 1998, CLIN EXP ALLERGY, V28, P1043; PERKIN MR, 1993, BRIT J OBSTET GYNAEC, V100, P629, DOI 10.1111/j.1471-0528.1993.tb14228.x; Post RM, 1995, ANN NY ACAD SCI, V771, P677, DOI 10.1111/j.1749-6632.1995.tb44720.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Ramirez F, 1996, J IMMUNOL, V156, P2406; Reijula K, 1996, CHEST, V110, P58, DOI 10.1378/chest.110.1.58; ROBINSON BG, 1988, P NATL ACAD SCI USA, V85, P5244, DOI 10.1073/pnas.85.14.5244; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; Rosmond R, 1998, J CLIN ENDOCR METAB, V83, P1853, DOI 10.1210/jc.83.6.1853; Sacedon R, 2000, ANN NY ACAD SCI, V917, P732; Schulz P, 1998, STRESS MEDICINE, V14, P91, DOI 10.1002/(SICI)1099-1700(199804)14:2<91::AID-SMI765>3.0.CO;2-S; Schwartz LB, 1997, LANCET, V350, P1792, DOI 10.1016/S0140-6736(05)63632-X; Sears MR, 1997, LANCET, V350, P1; Sheridan JF, 2000, ANN NY ACAD SCI, V917, P894; STOTT DH, 1973, DEV MED CHILD NEUROL, V15, P770, DOI 10.1111/j.1469-8749.1973.tb04912.x; STRACHAN DP, 1994, CLIN EXP ALLERGY, V24, P603, DOI 10.1111/j.1365-2222.1994.tb00961.x; Tang C, 1999, EUR RESPIR J, V14, P106, DOI 10.1034/j.1399-3003.1999.14a18.x; TRICHIERI G, 1995, ANNU REV IMMUNOL, V13, P251; von Hertzen L, 1999, J ALLERGY CLIN IMMUN, V104, P1211, DOI 10.1016/S0091-6749(99)70015-1; von Hertzen LC, 2002, EUR RESPIR J, V19, P546, DOI 10.1183/09031936.02.00254402; Wadhwa PD, 1996, PSYCHOSOM MED, V58, P432, DOI 10.1097/00006842-199609000-00006; WADHWA PD, 1993, AM J OBSTET GYNECOL, V169, P858, DOI 10.1016/0002-9378(93)90016-C; Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0; Wright R., 1996, AM J RESP CRIT CARE, V153, pA420; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x; ZARROW MX, 1970, NATURE, V226, P1058, DOI 10.1038/2261058a0; ZITTING BS, 1994, HDB HUMAN STRESS IMM, P53; 2001, FINNISH STAT MED; 1989, FINNISH STAT MED	82	121	124	1	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					923	928		10.1067/mai.2002.124776	http://dx.doi.org/10.1067/mai.2002.124776			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063519				2022-12-18	WOS:000176442700005
J	Miotto, D; Christodoulopoulos, P; Olivenstein, R; Taha, R; Cameron, L; Tsicopoulos, A; Tonnel, AB; Fahy, O; Lafitte, JJ; Luster, AD; Wallaert, B; Mapp, CE; Hamid, Q				Miotto, D; Christodoulopoulos, P; Olivenstein, R; Taha, R; Cameron, L; Tsicopoulos, A; Tonnel, AB; Fahy, O; Lafitte, JJ; Luster, AD; Wallaert, B; Mapp, CE; Hamid, Q			Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in T(H)1-and T(H)2-mediated lung diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemokines; eotaxin; monocyte chemotactic proteins.; interferon gamma inducible protein; asthma; sarcoidosis; tuberculosis	MESSENGER-RNA; BRONCHOALVEOLAR LAVAGE; CHEMOKINE RECEPTORS; BRONCHIAL BIOPSIES; GENE-EXPRESSION; CELLS; CHEMOATTRACTANT; CYTOKINE; INFLAMMATION; MCP-1	Background: Chemokines are involved in the influx of leukocytes into the airways in inflammatory lung diseases. The differential cell recruitment characteristic of T(H)1 versus T(H)2 immune responses may be associated with differential chemokine expression, Objective: We investigated the expression of chemokines; monocyte chemotactic proteins (MCPs) 1, 3, and 4; eotaxin; and IFN-gamma -inducible protein 10 (IP-10) in both T(H)1- and T(H)2-mediated lung diseases. Methods: By using immunocytochemistry and in situ hybridization, we examined the protein and mRNA expression, respectively. in bronchoalveolar lavage and biopsy samples in subjects with asthma, tuberculosis, sarcoidosis, and chronic bronchitis. Results: Increased immunoreactivity and mRNA expression of IP-10 and of the MCPs was found in the bronchoalveolar lavage fluid and biopsy specimens of subjects with asthma and tuberculosis compared with that of control subjects (P < .005), IP-10, however. was particularly increased in subjects with sarcoidosis (P < .001), Eotaxin, on the other hand, was increased only in patients with asthma when compared with control subjects (P < .005), Conclusion: This study demonstrates that MCP-1, MCP-3, and MCP-4 expression is not specifically associated with lung diseases characterized by a particular cytokine profile, In contrast, IP-10 is mostly expressed in T(H)1-mediated diseases, and eotaxin expression seems to be specifically associated with lung diseases of a T(H)2 cytokine profile.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Univ Padua, I-35100 Padua, Italy; McGill Univ, Montreal Chest Inst, Montreal, PQ H2X 2P2, Canada; CHR, Calmette Hosp, Inst Pasteur, INSERM,U416, Lille, France; Univ Lille, Lille, France; Harvard Univ, Massachusetts Gen Hosp, Sch Med,Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	McGill University; University of Padua; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille - ISITE; Universite de Lille; Harvard University; Harvard Medical School; Massachusetts General Hospital	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Tsicopoulos, Anne/C-2260-2019; Luster, Andrew/ABE-6504-2020	Tsicopoulos, Anne/0000-0002-1579-2763; Luster, Andrew/0000-0001-9679-7912				AGOSTINI C, 1993, EUR RESPIR J, V6, P1378; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; CAR BD, 1994, AM J RESP CRIT CARE, V149, P655, DOI 10.1164/ajrccm.149.3.8118632; Chensue SW, 1996, J IMMUNOL, V157, P4602; Christodoulopoulos P, 1999, J ALLERGY CLIN IMMUN, V103, P1036, DOI 10.1016/S0091-6749(99)70176-4; CIACCIA A, 1997, AM J RESP CRIT CARE, V156, P1633; CRYSTAL RG, 1981, ANN INTERN MED, V94, P73, DOI 10.7326/0003-4819-94-1-73; DANNENBERG AM, 1989, REV INFECT DIS, V11, pS369; DENG WL, 1994, J IMMUNOL, V153, P2130; Devouassoux G, 1999, J IMMUNOL, V163, P2877; EDWARDS D, 1986, AM REV RESPIR DIS, V134, P1062, DOI 10.1164/arrd.1986.134.5.1062; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HUMBLES AA, 1997, J IMMUNOL, V158, P4129; JEFFERY PK, 1997, J EXP MED, V186, P601; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Lahrtz F, 1997, EUR J IMMUNOL, V27, P2484, DOI 10.1002/eji.1830271004; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; Mach F, 1999, J CLIN INVEST, V104, P1041, DOI 10.1172/JCI6993; Minshall EM, 1997, EUR RESPIR J, V10, P2034, DOI 10.1183/09031936.97.10092034; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Mochizuki M, 1998, J IMMUNOL, V160, P60; Moller DR, 1996, J IMMUNOL, V156, P4952; Mueller R, 1996, RESP MED, V90, P79, DOI 10.1016/S0954-6111(96)90202-4; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; PESCI A, 1994, AM J RESP CRIT CARE, V149, P1311, DOI 10.1164/ajrccm.149.5.8173772; PRIESCHL EE, 1995, INT ARCH ALLERGY IMM, V107, P475, DOI 10.1159/000237089; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; Stafford S, 1997, J IMMUNOL, V158, P4953; Taha RA, 1997, AM J RESP CRIT CARE, V155, P1135, DOI 10.1164/ajrccm.155.3.9116999; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; THOMAS PD, 1987, AM REV RESPIR DIS, V135, P747	43	121	125	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					664	670		10.1067/mai.2001.113524	http://dx.doi.org/10.1067/mai.2001.113524			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295656				2022-12-18	WOS:000168190100019
J	Busse, W; Raphael, GD; Galant, S; Kalberg, C; Goode-Sellers, S; Srebro, S; Edwards, L; Rickard, K				Busse, W; Raphael, GD; Galant, S; Kalberg, C; Goode-Sellers, S; Srebro, S; Edwards, L; Rickard, K		Fluticasone Propionate Clin Res St	Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-College-of-Allergy-Asthma-and-Immunology	NOV 03-08, 2000	SEATTLE, WA	Amer Coll Allergy Asthma & Immunol		asthma; fluticasone propionate; inhaled corticosteroid; montelukast; leukotriene modifier	INHALED CORTICOSTEROIDS; AIRWAY INFLAMMATION; ORAL ZAFIRLUKAST; TERM TREATMENT; PLACEBO; BECLOMETHASONE; INHIBITION; PREVENTION; EFFICACY; THERAPY	Background: Both inhaled corticosteroids and leukotriene modifiers are used in the maintenance treatment of persistent asthma. Objective: The goal was to compare the efficacy and safety of low-dose fluticasone propionate (FP) and montelukast as first-line maintenance therapy in symptomatic patients by using short-acting beta (2)-agonists alone to treat persistent asthma. Methods: In this multicenter, randomized, double-blind, double-dummy, parallel-group study 533 patients (>15 years old) with persistent asthma who remained symptomatic while taking short-acting beta (2)-agonists alone were treated with FP (88 mug [2 puffs of 44 mug] twice daily) or montelukast (10 mg once daily) for 24 weeks. Results: Compared with treatment with montelukast, treatment with FP resulted in significantly greater improvements at endpoint in morning predose FEV1 (22.9% vs 14.5%, P < .001), forced midexpiratory flow (0.66 vs 0.41 L/sec, P < .001), forced vital capacity (0.42 vs 0.29 L, P = .002), morning peak expiratory flow (PEF) (68.5 vs 34.1 L/min, P < .001), and evening PEF (53.9 vs 28.7 L/min, P < .001). Similar improvements in PEF were observed in patients with milder asthma (>70%-80% predicted FEV1). At endpoint, FP was more effective than montelukast at decreasing rescue albuterol use (3.1 puffs/day vs 2.3 puffs/day, P < .001), asthma symptom scores (-0.85 [48.6% decrease] vs -0.60 [30.5%], P < .001), and night-time awakenings due to asthma (-0.64 awakenings/night [62% decrease] vs -0.48 awakenings/night [47.5%], P = .023), and FP increased the percentage of symptom-free days (32.0% vs 18.4% of days, P < .001) compared with montelukast. The adverse event and asthma exacerbation profiles for FP and montelukast were similar. Conclusions: Low-dose FP is more effective than montelukast as first-line maintenance therapy for patients with persistent asthma who are undertreated and remain symptomatic while taking short-acting <beta>(2)-agonists alone.	Univ Wisconsin, Sch Med, Clin Res Unit H6 367, Madison, WI 53792 USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Clin Trials Orange Cty, Orange, CA USA	University of Wisconsin System; University of Wisconsin Madison; GlaxoSmithKline	Busse, W (corresponding author), Univ Wisconsin, Sch Med, Clin Res Unit H6 367, 600 Highland Ave, Madison, WI 53792 USA.			Edwards, Lisa/0000-0002-4867-2151				AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Balsbaugh TA, 1999, J ASTHMA, V36, P591, DOI 10.3109/02770909909087296; BARNES PJ, 1994, AM J RESP CRIT CARE, V150, pS42, DOI 10.1164/ajrccm/150.5_Pt_2.S42; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Blais L, 1998, THORAX, V53, P1025, DOI 10.1136/thx.53.12.1025; Bleecker ER, 2000, J ALLERGY CLIN IMMUN, V105, P1123, DOI 10.1067/mai.2000.106043; Busse W, 1999, AM J RESP CRIT CARE, V159, pA628; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Fish JE, 1997, CLIN THER, V19, P675, DOI 10.1016/S0149-2918(97)80092-6; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; Joyce DP, 2000, J ASTHMA, V37, P303, DOI 10.3109/02770900009055454; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Kim KT, 2000, ANN ALLERG ASTHMA IM, V85, P398, DOI 10.1016/S1081-1206(10)62555-0; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LAMAS AM, 1991, J IMMUNOL, V147, P254; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; MANTEL N, 1959, J NATL CANCER I, V22, P719; *NIH, 1997, NIH PUBL, P1; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Polgar G., 1971, PULMONARY FUNCTION T, P1; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Sano A, 1999, AM J RESP CRIT CARE, V159, P1903, DOI 10.1164/ajrccm.159.6.9810005; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Sheffer AL, 1996, J FAM PRACTICE, V42, P369; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; WALLEN N, 1991, J IMMUNOL, V147, P3490; WANG JH, 1994, J ALLERGY CLIN IMMUN, V94, P1025, DOI 10.1016/0091-6749(94)90121-X; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880	36	121	124	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					461	468		10.1067/mai.2001.114657	http://dx.doi.org/10.1067/mai.2001.114657			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	416RE	11240946	Bronze			2022-12-18	WOS:000167793300007
J	Meltzer, EO; Charous, BL; Busse, WW; Zinreich, SJ; Lorber, RR; Danzig, MR				Meltzer, EO; Charous, BL; Busse, WW; Zinreich, SJ; Lorber, RR; Danzig, MR		Nasonex Sinusitis Grp	Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sinusitis; antibiotics; nasal corticosteroids; mometasone furoate; amoxicillin clavulanate potassium	SEASONAL ALLERGIC RHINITIS; ORAL ANTIBIOTIC-THERAPY; PERENNIAL RHINITIS; CHILDREN; ADULTS; DIAGNOSIS; EFFICACY; NASONEX; CARE	Background: Intranasal glucocorticoids are effective in the treatment of allergic rhinitis, Their effectiveness as an anti-inflammatory adjunct in the treatment of acute recurrent sinusitis has not been adequately established in a controlled clinical study. Objective: The purpose of this study was to test the hypothesis that intranasal corticosteroid treatment produces additional relief in the treatment of acute sinusitis with oral antibiotics. Methods: Patients who were 12 years old and older with a history of recurrent sinusitis were treated while experiencing a new episode of acute sinusitis, which was diagnosed by symptoms and confirmed by computed tomography scan of the paranasal sinuses. Patients were treated for 21 days with amoxicillin clavulanate potassium and randomized to receive concurrent mometasone furoate nasal spray (MFNS; Nasonex [400 mug, twice daily]; n = 200 patients) or placebo spray (twice daily: n = 207 patients). Symptom scores for headache, facial pain, congestion, purulent rhinorrhea, postnasal drip, and cough were recorded at baseline and throughout treatment. Results: Baseline symptom scores showed a moderate level of symptom severity comparable in both groups. Patient-recorded twice daily symptom scores showed that adjunctive treatment with MFNS caused a significantly greater decrease in total symptom score (primary efficacy variable) and in individual scores of inflammatory symptoms associated with the obstruction process (headache, congestion, and facial pain) compared with placebo. Symptoms associated with the secretory processes were improved to a lesser degree. Therapy-related local adverse events were not significantly different between groups. Conclusion: The addition of intranasal corticosteroid, MFNS 400 mug twice daily, to antibiotics significantly reduces symptoms of acute sinusitis compared with antibiotic treatment alone.	Schering Plough Corp, Inst Res, Kenilworth, NJ 07033 USA; A Profess Corp, Allergy & Asthma Grp & Res Ctr, San Diego, CA USA; Adv Healthcare Serv Corp, Milwaukee Med Clin, Milwaukee, WI USA; Univ Wisconsin, Ctr Clin Sci, Madison, WI USA; Johns Hopkins Med Inst, Baltimore, MD 21205 USA	Merck & Company; Schering Plough Corporation; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; Johns Hopkins Medicine	Danzig, MR (corresponding author), Schering Plough Corp, Inst Res, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.							Barlan IB, 1997, ANN ALLERG ASTHMA IM, V78, P598, DOI 10.1016/S1081-1206(10)63223-1; Collins J G, 1993, Vital Health Stat 10, P1; CUENANT G, 1986, ORL J OTO-RHINO-LARY, V48, P226, DOI 10.1159/000275873; Davies RJ, 1997, CLIN THER, V19, P27; DRUCE HM, 1992, J ALLERGY CLIN IMMUN, V90, P436, DOI 10.1016/0091-6749(92)90165-X; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Hebert JR, 1996, ALLERGY, V51, P569; Kaliner M, 1997, J ALLERGY CLIN IMMUN, V99, P729, DOI 10.1016/S0091-6749(97)80003-6; KALINER M, 1998, ACI INT, V10, P141; KENNEDY DW, 1995, ANN OTO RHINOL LARYN, V104, P22; Mandl M, 1997, ANN ALLERG ASTHMA IM, V79, P370, DOI 10.1016/S1081-1206(10)63030-X; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; Meltzer EO, 1998, J ALLERGY CLIN IMMUN, V102, P39, DOI 10.1016/S0091-6749(98)70053-3; Meltzer EO, 1999, J ALLERGY CLIN IMMUN, V104, P107, DOI 10.1016/S0091-6749(99)70121-1; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1016/S0194-5998(98)70235-9; Onrust SV, 1998, DRUGS, V56, P725, DOI 10.2165/00003495-199856040-00018; Qvarnberg Yrjo, 1992, Rhinology (Utrecht), V30, P103; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P408, DOI 10.1016/S0091-6749(99)70464-1; SCHENKEL EJ, 1999, ALLERGY, V54, pB31; SCHLEIMER RP, 1993, EUR J CLIN PHARM S1, V45, P3; SHAPIRO GG, 1992, J ALLERGY CLIN IMMUN, V90, P417, DOI 10.1016/0091-6749(92)90160-4; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V82, P950, DOI 10.1016/0091-6749(88)90038-3; Smith CL, 1998, ARZNEIMITTEL-FORSCH, V48, P957; Spector S L, 1998, J Allergy Clin Immunol, V102, pS107; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; ZINREICH SJ, 1992, J ALLERGY CLIN IMMUN, V90, P445, DOI 10.1016/0091-6749(92)90167-Z	26	121	133	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					630	637		10.1067/mai.2000.109056	http://dx.doi.org/10.1067/mai.2000.109056			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031332				2022-12-18	WOS:000089980600005
J	Marquardt, DL; Walker, LL				Marquardt, DL; Walker, LL			Dependence of mast cell IgE-mediated cytokine production on nuclear factor-kappa B activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; transcription factors; mast cells	TRANSCRIPTION FACTOR; GENE-EXPRESSION; IN-VIVO; INHIBITION; ACTIVATION; INDUCTION; STIMULATION; DEGRADATION; RECEPTOR; ASTHMA	Background: The transcription factor nuclear factor-kappa B (NF-kappa B) has been implicated in the regulation of a number of inflammatory cytokines and has been the proposed target for anti-inflammatory therapeutics, Objective: Our purpose was to explore the role of NF-kappa B in the regulation of allergic inflammation. Methods: To determine whether NF-kappa B is activated during IgE-mediated reactions and what types of mediators it regulates, a mutant form of I kappa B was used to block the ability of NF-kappa B to translocate to the nucleus and promote the transcription of selected genes, Results: Mouse bone marrow-derived mast cells stimulated by IgE receptor cross-linking exhibited an activation of NF-kappa B as assessed by electrophoretic mobility shift assays. Transfected mast cells expressing the mutant I kappa B showed very little NF-kappa B activation, Both control and transfected cells released beta-hexosaminidase after specific antigen challenge, and this release could be potentiated by exogenous adenosine, Transfected mast cells that failed to develop NF-kappa B activation did not produce IL-6 messenger RNA or protein after IgE-mediated stimulation, but these cells retained the ability to produce transcripts for IL-4 and IL-5 in spite of the suppression of NF-kappa B activity. Conclusions: It appears that NF-kappa B is activated during IgE-mediated allergic inflammation and that this activity is necessary for the production of IL-6, but not IL-4 or IL-5. When considering the use of agents that target NF-kappa B to reduce inflammatory processes, it is important to know precisely which cytokines are under its control.	Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Marquardt, DL (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, 0635,9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041760] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-41760] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bennett BL, 1997, J BIOL CHEM, V272, P10212; Blackwell TS, 1997, J IMMUNOL, V158, P5934; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; GRANDISON L, 1994, MOL CELL ENDOCRINOL, V106, P9; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Lee NA, 1997, AM J RESP CELL MOL, V16, P497, DOI 10.1165/ajrcmb.16.5.9160831; MARQUARDT DL, 1994, J IMMUNOL, V152, P4508; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; Marquardt DL, 1996, J IMMUNOL, V156, P1942; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431	28	121	121	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					500	505		10.1067/mai.2000.104942	http://dx.doi.org/10.1067/mai.2000.104942			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719300				2022-12-18	WOS:000088946700016
J	Rand, CS; Butz, AM; Kolodner, K; Huss, K; Eggleston, P; Malveaux, F				Rand, CS; Butz, AM; Kolodner, K; Huss, K; Eggleston, P; Malveaux, F			Emergency department visits by urban African American children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; minority; emergency department; school absences; African American children	INNER-CITY; UNITED-STATES; CHILDHOOD ASTHMA; RISK-FACTORS; MEDICAL-CARE; HOSPITALIZATION; PREVALENCE; MANAGEMENT; MORTALITY; SENSITIZATION	Background: Asthma morbidity among African American children has been identified as a significant national health concern. High emergency department use is one index of this morbidity and may reflect disease severity, disease management, and social factors. Objective: This study examined the prevalence and correlates of emergency department use and other indices of asthma morbidity among a sample of urban, low-income, African American children. Methods: Parents of 392 elementary school children with asthma who had consented to participate in an asthma education program were interviewed by phone according to a standardized protocol. Results: Children had a mean of 6.2 days of restricted activity (SD 8.1) and 7.9 symptomatic nights (SD 8.1), The mean number of school days missed because of asthma was 9.7 (SD 13.5). Among children with asthma symptoms in the past 12 months, 73.2% could identify a specific physician or nurse who provided asthma care. For those families without an identified asthma primary care provider, 39.3% received their usual asthma care from the emergency department. A total of 43.6% of the children had been to the emergency department for asthma care without hospitalization in the previous 6 months, Close to 80% of children reported using one or more prescribed asthma medication, and of these only 12% reported using inhaled anti-inflammatory medications. Families of children who had used the emergency department in the prior 6 months reported more asthma symptoms, lower social support, problems paying for health care, and the absence of a hypoallergenic mattress cover and that they had seen a physician for regular asthma care in the past 6 months. Conclusions: We conclude that asthma management for children in the inner city relies on episodic care and emergency care, that asthma medication management does not conform to current guidelines, and that asthma symptoms resulting in school absences and workdays Lost are prevalent.	Johns Hopkins Univ, Div Pulm & Crit Care, Dept Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Pediat Allergy & Immunol, Baltimore, MD 21218 USA; Innovat Med Res, Baltimore, MD USA; Johns Hopkins Sch Nursing, Baltimore, MD USA; Howard Univ, Washington, DC 20059 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard University	Rand, CS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NHLBI NIH HHS [R01 HL45312-04] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045312] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; BUTZ AM, 1995, CLIN PEDIATR, V34, P581, DOI 10.1177/000992289503401103; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Christiansen SC, 1996, J ALLERGY CLIN IMMUN, V98, P288, DOI 10.1016/S0091-6749(96)70152-5; CORNELIUS LJ, 1993, J NATL MED ASSOC, V85, P281; CYPRESS BK, 1983, VITAL HLTH STAT, V13, P1; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FISHER EB, 1993, AM REV RESPIR DIS, V147, pA982; FISHER EB, 1994, CHEST, V106, pS248, DOI 10.1378/chest.106.4_Supplement.248S; HAIREJOSHU D, 1993, J ASTHMA, V30, P359, DOI 10.3109/02770909309056740; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; Halfon N, 1996, PEDIATRICS, V98, P28; Horowitz E., 1996, Journal of Allergy and Clinical Immunology, V97, P379, DOI 10.1016/S0091-6749(96)81004-9; HUSS K, 1994, ANN ALLERGY, V72, P173; *I MED, 1993, ACC HLTH CAR AM; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P802, DOI 10.1016/0091-6749(93)90057-M; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SLY RM, 1988, J ALLERGY CLIN IMMUN, V705, P1979; SPECTOR PE, 1993, SAS PROGRAMMING RES; SPERBER K, 1993, MT SINAI J MED, V60, P227; *US DEP HHS, 1991, GUID DIAGN MAN ASTHM; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOOD DL, 1990, PEDIATRICS, V86, P666	29	121	121	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				83	90		10.1016/S0091-6749(00)90182-9	http://dx.doi.org/10.1016/S0091-6749(00)90182-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629457				2022-12-18	WOS:000084992100012
J	Sihra, BS; Kon, OM; Grant, JA; Kay, AB				Sihra, BS; Kon, OM; Grant, JA; Kay, AB			Expression of high-affinity IgE receptors (Fc epsilon RI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects: Relationship to total serum IgE concentrations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE receptor (high affinity); atopy; IgE; basophils; monocytes; eosinophils	HISTAMINE-RELEASE; ALPHA-SUBUNIT; DERMATITIS; PARASITES	Background: High-affinity IgE receptors (Fc epsilon RI) have been identified on peripheral blood basophils, monocytes, and eosinophils; but the relative receptor expression on these cells and their relationship to atopy are unclear. Objective: The aim of this study was to compare Fc epsilon RI expression on these cell types and assess their relationship to total serum IgE concentrations in subjects with atopic asthma, rhinitis, or dermatitis compared with nonatopic control subjects, Methods: Flow cytometry was used to evaluate Fc epsilon RI expression by determining the specific mean fluorescence of the binding of two anti-Fc epsilon RI alpha-chain monoclonal antibodies (15-1, which competes with IgE for receptor binding, and 22E7, which is noncompetitive). Results: Compared with basophils Fc epsilon RI expression (determined by 22E7 specific mean fluorescence) was greatly reduced on monocytes and was only detectable on eosinophils in a small minority of subjects, Nevertheless, Fc epsilon RI expression on all three cell types was significantly increased in atopic patients compared with nonatopic control subjects (p < 0.0001 for basophils, p = 0.003 for monocytes, and p = 0.039 for eosinophils), Fc epsilon RI expression on both basophils and monocytes in all subjects correlated significantly with serum IgE concentrations (r = 0.86 and 0.55, respectively; p < 0.001). For each subject, and on all three cell types, the specific mean fluorescence after 22E7 staining was greater than with 15-1, implying some degree of receptor occupancy, Conclusion: Fc epsilon RI expression on peripheral blood monocytes was considerably less than on basophils and barely detectable on eosinophils. Elevated Fc epsilon RI expression was observed in atopic subjects with all three cell types, suggesting a role for these receptors in IgE-mediated allergic inflammation, The possibility of common regulatory mechanisms was suggested by the correlation of Fc epsilon RI expression on basophils and monocytes with serum IgE concentrations.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, LONDON SW3 6LY, ENGLAND; UNIV TEXAS, MED BRANCH, DIV ALLERGY & IMMUNOL, GALVESTON, TX 77550 USA	Imperial College London; University of Texas System; University of Texas Medical Branch Galveston				Kon, Onn Min/0000-0003-2647-4688				BARATA LT, 1997, IN PRESS EUR J IMMUN; BONNEFOY JY, 1993, CURR OPIN IMMUNOL, V5, P944, DOI 10.1016/0952-7915(93)90110-E; CASOLARO V, 1990, AM REV RESPIR DIS, V142, P1108, DOI 10.1164/ajrccm/142.5.1108; CONROY MC, 1977, J IMMUNOL, V118, P1317; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; GANE P, 1993, CYTOMETRY, V14, P344, DOI 10.1002/cyto.990140316; Gould H, 1991, Clin Exp Allergy, V21 Suppl 1, P138, DOI 10.1111/j.1365-2222.1991.tb01718.x; GOUNNI AS, 1994, J ALLERGY CLIN IMMUN, V94, P1214, DOI 10.1016/0091-6749(94)90334-4; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; KAPP A, 1995, CLIN EXP ALLERGY, V25, P210, DOI 10.1111/j.1365-2222.1995.tb01031.x; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MAURER D, 1995, J IMMUNOL, V154, P6285; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; OSTERHOFF B, 1994, J INVEST DERMATOL, V102, P315, DOI 10.1111/1523-1747.ep12371789; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Reischl IG, 1996, CLIN EXP ALLERGY, V26, P630, DOI 10.1046/j.1365-2222.1996.1047408.x; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; SHIRAKAWA T, 1994, CLIN GENET, V46, P228; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TAKENAKA M, 1995, INT ARCH ALLERGY IMM, V108, P247, DOI 10.1159/000237160; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6	27	121	125	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					699	706		10.1016/S0091-6749(97)70033-2	http://dx.doi.org/10.1016/S0091-6749(97)70033-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155838				2022-12-18	WOS:A1997WY60000019
J	Silverstein, MD; Yunginger, JW; Reed, CE; Petterson, T; Zimmerman, D; Li, JTC; OFallon, WM				Silverstein, MD; Yunginger, JW; Reed, CE; Petterson, T; Zimmerman, D; Li, JTC; OFallon, WM			Attained adult height after childhood asthma: Effect of glucocorticoid therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; height; growth; glucocorticoids	LONG-TERM TREATMENT; INHALED BECLOMETHASONE DIPROPIONATE; SKELETAL MATURATION; GROWTH-RETARDATION; LINEAR GROWTH; CHILDREN; AEROSOL; CORTICOSTEROIDS; ACTH; MILD	Background: Although oral and inhaled glucocorticoid therapy may impair growth in children with asthma, the effect of glucocorticoid therapy and asthma on attained adult height has not been extensively studied in representative children in the community. Objectives: The study was designed to compare the attained adult height of children with asthma with the attained adult height of nonasthmatic children and to compare the attained adult height of asthmatic children treated with glucocorticoids with the attained adult height of asthmatic children who did not receive glucocorticoids. Methods: Residents of Rochester, Minnesota, with onset of asthma from 1964 to 1987 and age- and sea-matched nonasthmatic residents of Rochester were studied. Glucocorticoid exposure was assessed from medical records. The mean of 5 stadiometer measurements of adult height, adjusted for sex and parental height, was analyzed. Results: One hundred fifty-three patients with asthma (mean age at onset, 6.1 +/- 4.8 years) and 153 age- and sex-matched nonasthmatic subjects were studied. Adult height of patients with asthma (mean age at measurement, 25.7 +/- 5.2 years) was not significantly different from the adult height of nonasthmatic subjects; the overall difference, adjusted for mid-parental height, was -0.20 cm (95% confidence interval from -0.27 to 1.64), The adult height of asthmatic children treated with glucocorticoids was not significantly different from the adult height of patients with asthma not treated with glucocorticoids the difference after adjusting for mid-parental height was -0.2 cm (95% confidence interval from -0.1 to 0.6). Conclusions: We conclude that the attained adult height of patients with asthma is not different from the adult height of age- and sex matched nonasthmatic subjects and that the attained adult height of asthmatic children treated with glucocorticoids is not significantly different from the adult height of children not treated with glucocorticoids.	MAYO CLIN & MAYO FDN, DIV AREA GEN INTERNAL MED, ROCHESTER, MN USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN USA; MAYO CLIN & MAYO FDN, DEPT PEDIAT & ADOLESCENT MED, ROCHESTER, MN USA; MAYO CLIN & MAYO FDN, DIV ALLERG DIS & INTERNAL MED, ROCHESTER, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI-25187] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025187] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; BALFOUR-LYNN L, 1987, Pediatrician, V14, P237; BROWN DCP, 1989, ANN ALLERGY, V63, P47; CHANG KC, 1982, CLIN ALLERGY, V12, P369, DOI 10.1111/j.1365-2222.1982.tb02541.x; COGSWELL JJ, 1982, ARCH DIS CHILD, V57, P473, DOI 10.1136/adc.57.6.473; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; FALLIERS CJ, 1963, AM J DIS CHILD, V105, P127, DOI 10.1001/archpedi.1963.02080040129002; GRAFFLONNEVIG V, 1979, ALLERGY, V34, P57, DOI 10.1111/j.1398-9995.1979.tb02001.x; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; HAUSPIE R, 1976, HUM BIOL, V48, P271; KAMADA AK, 1992, PEDIATR PULM, V12, P71, DOI 10.1002/ppul.1950120202; Kaplan S. L., 1990, CLIN PEDIAT ENDOCRIN, P1; KUZEMKO JA, 1976, LANCET, V2, P522, DOI 10.1016/S0140-6736(76)90817-5; LI JTC, 1989, MAYO CLIN PROC, V64, P205, DOI 10.1016/S0025-6196(12)65674-2; LITTLEWOOD JM, 1988, LANCET, V1, P115; MARTIN AJ, 1981, ACTA PAEDIATR SCAND, V70, P683, DOI 10.1111/j.1651-2227.1981.tb05768.x; MORRIS HG, 1975, PEDIATR RES, V9, P579, DOI 10.1203/00006450-197507000-00005; MORRIS HG, 1989, J ASTHMA, V26, P215, DOI 10.3109/02770908909073251; OBERGER E, 1986, ACTA PAEDIATR SCAND, V75, P744, DOI 10.1111/j.1651-2227.1986.tb10284.x; OBERGER E, 1990, ACTA PAEDIATR SCAND, V79, P77, DOI 10.1111/j.1651-2227.1990.tb11335.x; SHOHAT M, 1987, ARCH DIS CHILD, V62, P63, DOI 10.1136/adc.62.1.63; SOLE D, 1989, J ASTHMA, V26, P217, DOI 10.3109/02770908909073252; STECKEL RH, 1989, AUXOLOGY 88 PERSPECT, P175; TAKAISHI M, 1989, AUXOLOGY 88 PERSPECT, P203; TANNER JM, 1970, ARCH DIS CHILD, V45, P755, DOI 10.1136/adc.45.244.755; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; WOLTHERS OD, 1993, ARCH DIS CHILD, V68, P673, DOI 10.1136/adc.68.5.673; WOLTHERS OD, 1992, PEDIATRICS, V89, P839; WOLTHERS OD, 1990, BRIT MED J, V301, P145, DOI 10.1136/bmj.301.6744.145; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	30	121	127	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					466	474		10.1016/S0091-6749(97)70072-1	http://dx.doi.org/10.1016/S0091-6749(97)70072-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111490				2022-12-18	WOS:A1997WU27400008
J	Miranda, A; Blanca, M; Vega, JM; Moreno, F; Carmona, MJ; Garcia, JJ; Segurado, E; Justicia, JL; Juarez, C				Miranda, A; Blanca, M; Vega, JM; Moreno, F; Carmona, MJ; Garcia, JJ; Segurado, E; Justicia, JL; Juarez, C			Cross-reactivity between a penicillin and a cephalosporin with the same side chain	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						penicillins; cephalosporins; side chain identity; cross-reactivity	ALLERGIC REACTIONS; BETA-LACTAMS; IGE ANTIBODIES; SPECIFICITIES	Background: The cross-reactivity between penicillins and cephalosporins can be influenced by different factors, which ar not all well known. The chemical structure of the side chain may contribute to the cross-reactivity. Objective: The study was carried out in allergic subjects who are selectively responsive to amoxicillin to determine allergenic cross-reactivity with a cephalosporin containing a side chain identical to that of amoxicillin, cefadroxil, and one containing a different side chain, cefamandole. Methods: Allergic subjects with a selective response to amoxicillin were chosen according to the following criteria: history of an immediate allergic reaction to amoxicillin, negative skin test responses to benzylpenicilloyl and minor determinant mixture of benzylpenicillin, negative RAST response to benzylpenicilloyl, and good tolerance to benzylpenicillin and phenoxymethyl penicillin challenges. In addition, subjects had to have a positive skin test response to amoxicillin and/or positive RAST response to amoxicilloyl or, if these test results were negative, a positive challenge test response to amoxicillin. In vivo cross-reactivity to cefadroxil was assessed by giving oral cefadroxil at increasing doses form 5 to 500 mg. In vitro cross-reactivity was determined by RAST inhibition studies with amoxicilloyl RAST disks and the following monomeric conjugates in the fluid phase: amoxicillin-butylamine, cefadroxil-butylamine, and the side chain para-hydroxy-phenylglycine. Tolerance to cefamandole was determined by giving 100 mg and then 500 mg parenterally. Results: Twenty-one patients with a selective response to amoxicillin were included in the study. Eight subjects (38%) had a positive response to cefadroxil, and none reacted to cefamandole. In vitro RAST inhibition studies indicated that cefadroxil-butylamine monomers cross-reacted with amoxicillin butylamine and the side chain contributed relevantly to the inhibition. Conclusions: These results indicate that the percentage of cross-reactivity between penicillins and cephalosporins with an identical side chain is high and that this critical part of the molecule seems to be an important contributor to these results. The value is higher than previously reported data from similar studies of non-side-chain-related cephalosporins.	CARLOS HAYA HOSP,ALLERGY LAB,RES UNIT ALLERG DIS,MALAGA,SPAIN; CARLOS HAYA HOSP,ALLERGY SECT,MALAGA,SPAIN; CARLOS HAYA HOSP,DEPT INTERNAL MED,MALAGA,SPAIN	Hospital Carlos Haya; Hospital Carlos Haya; Hospital Carlos Haya								ABRAHAM GN, 1968, INT ARCH ALLER A IMM, V34, P65, DOI 10.1159/000230095; ADKINSON NF, 1990, CLIN EXP ALLERGY, V20, P445, DOI 10.1111/j.1365-2222.1990.tb03134.x; ASSEM ESK, 1974, IMMUNOLOGY, V27, P255; AUDICANA M, 1994, ALLERGY, V49, P108, DOI 10.1111/j.1398-9995.1994.tb00809.x; BATCHELO.FR, 1965, NATURE, V206, P362, DOI 10.1038/206362a0; BATCHELOR FR, 1966, IMMUNOLOGY, V10, P21; BLANCA M, 1989, J ALLERGY CLIN IMMUN, V83, P381, DOI 10.1016/0091-6749(89)90122-X; BLANCA M, 1994, CLIN EXP ALLERGY, V24, P407, DOI 10.1111/j.1365-2222.1994.tb00928.x; BLANCA M, 1992, J IMMUNOL METHODS, V153, P99, DOI 10.1016/0022-1759(92)90311-G; BLANCA M, 1991, CLIN EXP ALLERGY, V20, P475; DEWDNEY JM, 1977, ANTIGENS, V5, P73; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; GIRARD JP, 1968, INT ARCH ALLER A IMM, V33, P428, DOI 10.1159/000230058; IGEA JM, 1992, ANN ALLERGY, V68, P515; KABINS SA, 1965, J AMER MED ASSOC, V193, P165, DOI 10.1001/jama.1965.03090020079028; LEVINE BB, 1969, INT ARCH ALLER A IMM, V35, P445, DOI 10.1159/000230197; LEVINE BB, 1961, J EXP MED, V114, P875, DOI 10.1084/jem.114.6.875; MAYORGA C, 1995, TOXICOLOGY, V97, P225, DOI 10.1016/0300-483X(94)02983-2; MORENO F, 1995, INT ARCH ALLERGY IMM, V108, P74, DOI 10.1159/000237121; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P297; ONG R, 1988, J ALLERGY CLIN IMMUN, V81, P222, DOI 10.1016/0091-6749(88)90452-6; PETERSEN BH, 1974, J LAB CLIN MED, V83, P860; PETZ LD, 1978, J INFECT DIS, V137, pS74, DOI 10.1093/infdis/137.Supplement.S74; QUIJANO D, 1994, REV ESP ALERGOL IMMU, V9, P73; ROTHSCHILD PD, 1966, J AMER MED ASSOC, V196, P372, DOI 10.1001/jama.1966.03100170114047; VEGA JM, 1994, ALLERGY, V49, P317, DOI 10.1111/j.1398-9995.1994.tb02275.x	26	121	126	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					671	677		10.1016/S0091-6749(96)70101-X	http://dx.doi.org/10.1016/S0091-6749(96)70101-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828545				2022-12-18	WOS:A1996VJ42800024
J	SETTIPANE, RA; SCHRANK, PJ; SIMON, RA; MATHISON, DA; CHRISTIANSEN, SC; STEVENSON, DD				SETTIPANE, RA; SCHRANK, PJ; SIMON, RA; MATHISON, DA; CHRISTIANSEN, SC; STEVENSON, DD			PREVALENCE OF CROSS-SENSITIVITY WITH ACETAMINOPHEN IN ASPIRIN-SENSITIVE ASTHMATIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ACETAMINOPHEN; ASPIRIN; ANALGESIC; ASTHMA; CROSS-REACTIVITY; SENSITIVITY; CHALLENGE; PROVOCATION; CYCLOOXYGENASE	REFRACTORY PERIOD; CHALLENGES	Objective: Cross-sensitivity between aspirin and acetaminophen in aspirin-sensitive asthmatic patients has been reported with frequencies ranging from 0% to 29%. The relationship is dose-dependent for acetaminophen challenges, ranging between 300 and 1000 mg. Methods: To determine the prevalence of cross-sensitivity to high-close acetaminophen, we performed single-blind acetaminophen oral challenges with 1000 mg and 1500 mg in 50 aspirin-sensitive asthmatic patients and in 20 non-aspirin-sensitive asthmatic control subjects. Results: Overall, 17 of 50 (34%) of aspirin-sensitive asthmatic patients reacted to acetaminophen in doses of 1000 to 1500 mg (95% confidence interval: 20% to 49%). By contrast, none of the 20 non-aspirin-sensitive asthmatic patients reacted to acetaminophen (95% confidence interval: 0% to 14%). This difference was highly significant (p = 0.0013), supporting the hypothesis that cross-sensitivity between aspirin. and acetaminophen is unique in aspirin-sensitive asthmatic patients. Conclusion: Although high-dose (>1000 mg) acetaminophen cross-reactions with aspirin were significant with respect to frequency (34%), such reactions included easily reversed bronchospasm in only 22%, and were generally mild. We recommend that high doses of acetaminophen (1000 mg or greater) should be avoided in aspirin-sensitive asthmatic patients.	SCRIPPS CLIN & RES FDN,DIV ALLERGY & IMMUNOL,LA JOLLA,CA 92037	Scripps Research Institute				Settipane, Russell/0000-0002-6328-8780	NIAID NIH HHS [AI-10386] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DELANEY JC, 1976, CLIN ALLERGY, V6, P177, DOI 10.1111/j.1365-2222.1976.tb01896.x; FALLIERS CJ, 1983, J ASTHMA, V20, P39, DOI 10.3109/02770908309078051; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; SETTIPANE RA, 1989, J ALLERGY CLIN IMMUN, V84, P26, DOI 10.1016/0091-6749(89)90174-7; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2	9	121	123	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					480	485		10.1016/S0091-6749(95)70290-3	http://dx.doi.org/10.1016/S0091-6749(95)70290-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560658				2022-12-18	WOS:A1995TA09500007
J	SZEPFALUSI, Z; EBNER, C; PANDJAITAN, R; ORLICEK, F; SCHEINER, O; BOLTZNITULESCU, G; KRAFT, D; EBNER, H				SZEPFALUSI, Z; EBNER, C; PANDJAITAN, R; ORLICEK, F; SCHEINER, O; BOLTZNITULESCU, G; KRAFT, D; EBNER, H			EGG-YOLK ALPHA-LIVETIN (CHICKEN SERUM-ALBUMIN) IS A CROSS-REACTIVE ALLERGEN IN THE BIRD-EGG SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGENS; BIRD-EGG SYNDROME; EGG YOLK; CROSS-REACTIVITY; IGE ANTIBODIES; CHICKEN SERUM ALBUMIN	HENS EGG; PROTEINS; POLLEN; SENSITIZATION; WHITE; HYPERSENSITIVITY; IDENTIFICATION; SENSITIVITY; ANTIGENS; BINDING	Thirty-one patients with clinical history of egg allergy, bird allergy, or bird and egg allergy were investigated with the use of the immunoblot technique to compare IgE-binding components in bird feather and egg yolk and white extracts. Patients were classified into three groups according to clinical history, skin prick test results, and RAST results. Patients in group I were sensitized to bird feathers and egg yolk, patients in group II to egg white and patients in group III to bird feather but nor to eggs. Patients with bird-egg syndrome were mainly female adults, whereas egg white allergy was mainly observed in children without arty obvious sex predisposition. IgE from patients with bird-egg syndrome recognized a 70 kd protein in egg yolk (chicken serum albumin = alpha-livetin) and some major allergens in bird feather extract (70, 95, and 200 kd). Preincubation of pooled sera from patients with bird-egg syndrome with budgerigar or hen feather extract and egg yolk extract, respectively, led to complete blocking of IgE binding to allergens in egg yolk and bird feather extract. On the other hand, IgE from patients with egg white allergy did not react with allergens in egg yolk and bird feather extract, despite strong IgE binding to egg white allergens. Patients in group III displayed no reactivity to bird feather or egg allergens. Our results demonstrate common epitopes of budgerigar and hen feather and egg yolk alpha-livetin. Therefore we assume that alpha-livetin (chicken serum albumin) leads to a cross-sensitization and consequently to the ''bird-egg syndrome''.	ALLERGY CLIN,A-1100 VIENNA,AUSTRIA; INST GEN & EXPTL PATHOL,VIENNA,AUSTRIA					Szepfalusi, Zsolt/0000-0003-4852-3102				ANET J, 1985, INT ARCH ALLER A IMM, V77, P364, DOI 10.1159/000233846; BAUSELA BA, 1991, ALLERGY, V46, P614, DOI 10.1111/j.1398-9995.1991.tb00632.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLEY RW, 1979, ANAL BIOCHEM, V94, P53, DOI 10.1016/0003-2697(79)90789-9; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; DEBLAY F, 1990, REV FR ALLERGOL, V30, P97, DOI 10.1016/S0335-7457(05)80219-9; DEMAATBLEEKER F, 1985, ANN ALLERGY, V54, P245; DEMAATBLEEKER F, 1988, ALLERGY, V43, P83; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; FORD RPK, 1982, ARCH DIS CHILD, V57, P649, DOI 10.1136/adc.57.9.649; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P481, DOI 10.1016/0091-6749(83)90465-7; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V81, P484, DOI 10.1016/0091-6749(88)90921-9; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGELAND T, 1987, FOOD ALLERGY INTOLER, P367; MANDALLAZ MM, 1988, INT ARCH ALLER A IMM, V87, P143, DOI 10.1159/000234664; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; PAULI G, 1990, Journal of Allergy and Clinical Immunology, V85, P271; PAULI G, 1992, ACI NEWS, V4, P43; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANTOORENENBERG.AW, 1992, ALLERGY, V47, P30; WALSH BJ, 1988, INT ARCH ALLER A IMM, V87, P81, DOI 10.1159/000234653; WILLIAMS J, 1962, BIOCHEM J, V83, P346, DOI 10.1042/bj0830346	26	121	123	3	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					932	942		10.1016/0091-6749(94)90388-3	http://dx.doi.org/10.1016/0091-6749(94)90388-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182236				2022-12-18	WOS:A1994NL91900019
J	CHANYEUNG, M; MACLEAN, L; PAGGIARO, PL				CHANYEUNG, M; MACLEAN, L; PAGGIARO, PL			FOLLOW-UP-STUDY OF 232 PATIENTS WITH OCCUPATIONAL ASTHMA CAUSED BY WESTERN RED CEDAR (THUJA-PLICATA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CHANYEUNG, M (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DEPT MED,DIV RESP,2775 HEATHER ST,VANCOUVER V5Z 3J5,BC,CANADA.							BURGE PS, 1982, THORAX, V37, P348, DOI 10.1136/thx.37.5.348; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; COREY PN, 1979, J OCCUP ENVIRON MED, V21, P395; HUDSON P, 1985, J ALLERGY CLIN IMMUN, V76, P682, DOI 10.1016/0091-6749(85)90671-2; LAM S, 1985, CHEST, V88, P856, DOI 10.1378/chest.88.6.856; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; MOLLER D R, 1984, American Review of Respiratory Disease, V129, pA159; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P54; PAGGIARO PL, 1984, CLIN ALLERGY, V14, P463, DOI 10.1111/j.1365-2222.1984.tb02230.x; STEEL RGD, 1960, PRINCIPLES PROCEDURE, P277; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x	12	121	121	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					792	796		10.1016/0091-6749(87)90212-0	http://dx.doi.org/10.1016/0091-6749(87)90212-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3571771				2022-12-18	WOS:A1987H434900015
J	DAVIS, RS; LARSEN, GL; GRUNSTEIN, MM				DAVIS, RS; LARSEN, GL; GRUNSTEIN, MM			RESPIRATORY RESPONSE TO INTRAESOPHAGEAL ACID INFUSION IN ASTHMATIC-CHILDREN DURING SLEEP	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,NATL ASTHMA CTR,DEPT PEDIAT,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PEDIAT,BOULDER,CO 80309	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder								BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BENTZ LJ, 1972, GASTROENTEROLOGY, V62, P1; BERNSTEIN A, BR J DIS CHEST, V75, P320; BERNSTEIN LM, 1958, GASTROENTEROLOGY, V34, P760; BERQUIST WE, 1981, PEDIATRICS, V68, P29; BERQUIST WE, 1981, J ALLERGY CLIN IMMUN, V67, P407, DOI 10.1016/0091-6749(81)90087-7; BURKI NK, 1979, CHEST, V76, P629, DOI 10.1378/chest.76.6.629; CHADHA T, 1982, AM REV RESPIR DIS, V125, P218; DEES SC, 1974, N C MED J, V35, P230; EULER AR, 1977, PEDIATRICS, V60, P65; EULER AR, 1979, PEDIATRICS, V63, P47; GERMAN VF, 1982, J APPL PHYSIOL, V52, P1153, DOI 10.1152/jappl.1982.52.5.1153; GOYAL RK, 1973, J CLIN INVEST, V52, P337, DOI 10.1172/JCI107189; ISMAIL-BEIGI F, 1970, Gastroenterology, V58, P163; JOLLEY SG, 1978, SURGERY, V84, P16; KASSABIAN J, 1982, CHEST, V81, P536, DOI 10.1378/chest.81.5.536; MANSFIELD LE, 1981, ANN ALLERGY, V47, P431; MANSFIELD LE, 1978, ANN ALLERGY, V41, P224; MARTIN ME, 1982, ANN ALLERGY, V49, P318; MILICEMILI J, 1976, CHEST, V70, P131, DOI 10.1378/chest.70.1.131; MILICEMILI J, 1982, LUNG, V160, P1, DOI 10.1007/BF02719267; Perry WF, 1941, J PHARMACOL EXP THER, V73, P65; RACHELEFSKY G, 1982, J ALLERGY CLIN IMMUN, V69, P143; SHAPIRO GG, 1979, PEDIATRICS, V63, P207; SORLI J, 1978, CLIN SCI MOL MED, V54, P295, DOI 10.1042/cs0540295; SPAULDING HS, 1982, J ALLERGY CLIN IMMUN, V69, P516, DOI 10.1016/0091-6749(82)90176-2; STROBEL CT, 1979, J PEDIATR-US, V94, P81, DOI 10.1016/S0022-3476(79)80361-3; TABACHNIK E, 1981, J PEDIATR-US, V99, P895, DOI 10.1016/S0022-3476(81)80012-1; WATSON H, 1979, 3RD P INT S AMB MON, P537; WINER BJ, 1971, STATISTIC PRINCIPLES, P515; [No title captured]	31	121	121	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					393	398		10.1016/0091-6749(83)90505-5	http://dx.doi.org/10.1016/0091-6749(83)90505-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6619453				2022-12-18	WOS:A1983RN33000010
J	HOFFMAN, DR; HADDAD, ZH				HOFFMAN, DR; HADDAD, ZH			DIAGNOSIS OF IGE-MEDIATED REACTIONS TO FOOD ANTIGENS BY RADIOIMMUNOASSAY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV S CALIF,LOS ANGELES CTY MED CTR,DEPT PEDIAT,DIV PEDIAT IMMUNOL & ALLERGY,GEN LAB BLDG 1G 38,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,LOS ANGELES,CA	University of Southern California								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CESKA M, 1972, EUR J IMMUNOL, V2, P58, DOI 10.1002/eji.1830020112; COLLINS-WILLIAMS C, 1954, Ann Allergy, V12, P237; COLLINSWILLIAMS C, 1954, J PEDIATR-US, V45, P337, DOI 10.1016/S0022-3476(54)80199-5; GOLBERT TM, 1972, ALLERGIC DISEASES DI; GOLDMAN AS, 1963, PEDIATRICS, V32, P572; GOLDSTEIN GB, 1970, J ALLERGY, V46, P270, DOI 10.1016/0021-8707(70)90068-7; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P210, DOI 10.1016/0091-6749(72)90084-X; HADDAD ZH, 1973, EXCERPTA MEDICA ICS, V300, P16; HILL LW, 1948, NEW ENGL J MED, V238, P657, DOI 10.1056/NEJM194805062381903; HOFFMAN DR, 1973, J ALLERGY CLIN IMMUN, V51, P313; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; INGELFINGER FJ, 1949, NEW ENGL J MED, V241, P303, DOI 10.1056/NEJM194908252410805; JOHNSON P, 1965, EUR POLYMER J, V1, P65; PORATH J, 1967, NATURE, V215, P1491, DOI 10.1038/2151491a0; SHELDON JM, 1967, MANUAL CLINICAL ALLE; VENDEL S, 1948, ACTA PAEDIAT SCAN S5, V35, P1; WIDE L, 1967, LANCET, V2, P1105; WITHERS OR, 1965, J ASTHMA RES, V3, P221	20	121	121	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	3					165	173		10.1016/0091-6749(74)90053-0	http://dx.doi.org/10.1016/0091-6749(74)90053-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U0308	4851358				2022-12-18	WOS:A1974U030800005
J	Brunner, PM; Israel, A; Zhang, N; Leonard, A; Wen, HC; Huynh, T; Tran, G; Lyon, S; Rodriguez, G; Immaneni, S; Wagner, A; Zheng, XZ; Estrada, YD; Xu, H; Krueger, JG; Paller, AS; Guttman-Yassky, E				Brunner, Patrick M.; Israel, Ariel; Zhang, Ning; Leonard, Alexandra; Wen, Huei-Chi; Thy Huynh; Tran, Gary; Lyon, Sarah; Rodriguez, Giselle; Immaneni, Supriya; Wagner, Annette; Zheng, Xiuzhong; Estrada, Yeriel D.; Xu, Hui; Krueger, James G.; Paller, Amy S.; Guttman-Yassky, Emma			Early-onset pediatric atopic dermatitis is characterized by T(H)2/T(H)17/T(H)22-centered inflammation and lipid alterations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; pediatric; infant; skin barrier; skin inflammation	SKIN BARRIER DYSFUNCTION; STRATUM-CORNEUM; PERMEABILITY BARRIER; EPIDERMAL BARRIER; KERATINOCYTE DIFFERENTIATION; FILAGGRIN DEFICIENCY; MAJOR DIFFERENCES; GENE-EXPRESSION; TH17 CELLS; IN-VITRO	Background: Although atopic dermatitis (AD) often starts in early childhood, detailed tissue profiling of early-onset AD in children is lacking, hindering therapeutic development for this patient population with a particularly high unmet need for better treatments. Objective: We sought to globally profile the skin of infants with AD compared with that of adults withAD and healthy control subjects. Methods: We performed microarray, RT-PCR, and fluorescence microscopy studies in infants and young children (< 5 years old) with early-onset AD (< 6 months disease duration) compared with age-matched control subjects and adults with longstanding AD. Results: Transcriptomic analyses revealed profound differences between pediatric patients with early-onset versus adult patients with longstanding AD in not only lesional but also nonlesional tissues. Although both patient populations harbored T(H)2-centered inflammation, pediatric AD also showed significant T(H)17/T(H)22 skewing but lacked the T(H)1 upregulation that characterizes adult AD. Pediatric AD exhibited relatively normal expression of epidermal differentiation and cornification products, which is downregulated in adults with AD. Defects in the lipid barrier (eg, ELOVL fatty acid elongase 3 [ELOVL3] and diacylglycerol o-acyltransferase 2 [DGAT2]) and tight junction regulation (eg, claudins 8 and 23) were evident in both groups. However, some lipid-associated mediators (eg, fatty acyl-CoA reductase 2 and fatty acid 2-hydroxylase) showed preferential downregulation in pediatric AD, and lipid barrier genes (FA2H and DGAT2) showed inverse correlations with transepidermal water loss, a functional measure of the epidermal barrier. Conclusions: Skin samples from children and adult patients with AD share lipid metabolism and tight junction alterations, but epidermal differentiation complex defects are only present in adult AD, potentially resulting from chronic immune aberration that is not yet present in early-onset disease.	[Brunner, Patrick M.; Zheng, Xiuzhong; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10021 USA; [Israel, Ariel] Clalit Hlth Serv, Dept Family Med, Jerusalem, Israel; [Zhang, Ning; Leonard, Alexandra; Wen, Huei-Chi; Estrada, Yeriel D.; Xu, Hui; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Zhang, Ning; Leonard, Alexandra; Wen, Huei-Chi; Estrada, Yeriel D.; Xu, Hui; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Lab Inflammatory Skin Dis, New York, NY 10029 USA; [Thy Huynh; Tran, Gary; Lyon, Sarah; Rodriguez, Giselle; Immaneni, Supriya; Wagner, Annette; Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; [Thy Huynh; Tran, Gary; Lyon, Sarah; Rodriguez, Giselle; Immaneni, Supriya; Wagner, Annette; Paller, Amy S.] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA	Rockefeller University; Clalit Health Services; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, Med Ctr, 5 E 98th St, New York, NY 10029 USA.	Emma.Guttman@mountsinai.org	Wen, Huei-Chi/ABD-7417-2021; Israel, Ariel/AFL-8794-2022	Brunner, Patrick/0000-0002-3488-3345	LEO Foundation; National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program [UL1 TR0001866]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001866] Funding Source: NIH RePORTER	LEO Foundation(LEO Pharma); National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by a research grant from the LEO Foundation. P.M.B. was supported in part by grant no. UL1 TR0001866 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program.	Abelius MS, 2014, PEDIAT ALLERG IMM-UK, V25, P387, DOI 10.1111/pai.12235; Baurecht H, 2015, AM J HUM GENET, V96, P104, DOI 10.1016/j.ajhg.2014.12.004; Bin LH, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0158-5; Brandner JM, 2015, TISSUE BARRIERS, V3, DOI 10.4161/21688370.2014.974451; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Brown SJ, 2009, J INVEST DERMATOL, V129, P543, DOI 10.1038/jid.2008.413; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Brunner PM, 2016, J ALLERGY CLIN IMMUN, V138, P169, DOI 10.1016/j.jaci.2015.12.1323; Brunner PM, 2015, EXP DERMATOL, V24, P522, DOI 10.1111/exd.12709; Cabanillas B, 2016, CURR OPIN IMMUNOL, V42, P1, DOI 10.1016/j.coi.2016.05.002; Chen C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017238; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Cole C, 2014, J ALLERGY CLIN IMMUN, V134, P82, DOI 10.1016/j.jaci.2014.04.021; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; D'Erme AM, 2015, J INVEST DERMATOL, V135, P1025, DOI 10.1038/jid.2014.532; Damsker JM, 2010, ANN NY ACAD SCI, V1183, P211, DOI 10.1111/j.1749-6632.2009.05133.x; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Ewald DA, 2017, J ALLERGY CLIN IMMUN, V139, P562, DOI 10.1016/j.jaci.2016.08.029; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Feingold KR, 2014, BBA-MOL CELL BIOL L, V1841, P280, DOI 10.1016/j.bbalip.2013.11.007; Feingold KR, 2014, J INVEST DERMATOL, V134, P597, DOI 10.1038/jid.2013.440; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; Garzorz N, 2015, EXPERT REV CLIN IMMU, V11, P167, DOI 10.1586/1744666X.2015.996549; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; GRUBAUER G, 1989, J LIPID RES, V30, P89; Gruber R, 2015, AM J PATHOL, V185, P2777, DOI 10.1016/j.ajpath.2015.06.021; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Gutowska-Owsiak D, 2013, CLIN EXP ALLERGY, V43, P586, DOI 10.1111/cea.12023; Gutowska-Owsiak D, 2012, EXP DERMATOL, V21, P104, DOI 10.1111/j.1600-0625.2011.01412.x; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Han HW, 2017, IMMUNOL REV, V278, P116, DOI 10.1111/imr.12546; Harden JL, 2016, J ALLERGY CLIN IMMUN, V137, P1830, DOI 10.1016/j.jaci.2015.09.055; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Huang F, 2008, J ALLERGY CLIN IMMUN, V121, P1415, DOI 10.1016/j.jaci.2008.04.016; Hvid M, 2011, EXP DERMATOL, V20, P633, DOI 10.1111/j.1600-0625.2011.01280.x; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Ishida-Yamamoto A, 2011, J DERMATOL, V38, P645, DOI 10.1111/j.1346-8138.2011.01227.x; Janssens M, 2012, J LIPID RES, V53, P2755, DOI 10.1194/jlr.P030338; Jarnik M, 1998, J CELL SCI, V111, P1051; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Johnston A, 2011, J IMMUNOL, V186, P2613, DOI 10.4049/jimmunol.1003162; Kanda N, 2005, J ALLERGY CLIN IMMUN, V116, P1144, DOI 10.1016/j.jaci.2005.08.014; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kim BE, 2012, ALLERGY ASTHMA IMMUN, V4, P12, DOI 10.4168/aair.2012.4.1.12; Kim J, 2015, DERMATOL CLIN, V33, P13, DOI 10.1016/j.det.2014.09.002; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Kottner J, 2013, ARCH DERMATOL RES, V305, P315, DOI 10.1007/s00403-012-1313-6; Kuchler S, 2011, ATLA-ALTERN LAB ANIM, V39, P471, DOI 10.1177/026119291103900508; Kuenzli S, 2003, DERMATOLOGY, V206, P252, DOI 10.1159/000068897; Kulig P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13466; Kuo IH, 2013, AAAAI ANN M SAN ANT; Lee JN, 2008, J INVEST DERMATOL, V128, P2240, DOI 10.1038/jid.2008.82; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Mathay C, 2011, J INVEST DERMATOL, V131, P46, DOI 10.1038/jid.2010.272; Meller S, 2015, NAT IMMUNOL, V16, P970, DOI 10.1038/ni.3211; Mildner M, 2010, J INVEST DERMATOL, V130, P2286, DOI 10.1038/jid.2010.115; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noh M, 2010, EXP DERMATOL, V19, P355, DOI 10.1111/j.1600-0625.2009.00902.x; Omori-Miyake M, 2014, J INVEST DERMATOL, V134, P1342, DOI 10.1038/jid.2013.503; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Paller AS, 2017, J ALLERGY CLIN IMMUN, V140, P633, DOI 10.1016/j.jaci.2017.07.006; Paller AS, 2016, J AM ACAD DERMATOL, V75, P494, DOI 10.1016/j.jaad.2016.05.046; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Pendaries V, 2014, J INVEST DERMATOL, V134, P2938, DOI 10.1038/jid.2014.259; Pene J, 2008, J IMMUNOL, V180, P7423, DOI 10.4049/jimmunol.180.11.7423; Presland RB, 2004, J INVEST DERMATOL, V123, P603, DOI 10.1111/j.0022-202X.2004.23226.x; Quaranta M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008946; Radner FPW, 2014, BBA-MOL CELL BIOL L, V1841, P409, DOI 10.1016/j.bbalip.2013.07.013; Sheu HM, 2003, J FORMOS MED ASSOC, V102, P656; Shirakata Y, 2007, J DERMATOL SCI, V45, P69, DOI 10.1016/j.jdermsci.2006.08.010; Silverberg JI, 2017, DERMATOL CLIN, V35, P283, DOI 10.1016/j.det.2017.02.002; Suarez-Farinas M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-294; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V136, P1277, DOI 10.1016/j.jaci.2015.06.032; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Sugiura H, 2005, BRIT J DERMATOL, V152, P146, DOI 10.1111/J.1365-2133.2005.06352.X; Tawada C, 2014, J INVEST DERMATOL, V134, P712, DOI 10.1038/jid.2013.364; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Vavrova K, 2014, J INVEST DERMATOL, V134, P746, DOI 10.1038/jid.2013.402; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Witte E, 2014, J INVEST DERMATOL, V134, P2757, DOI 10.1038/jid.2014.308; Wolk K, 2014, CLIN CANCER RES, V20, P5507, DOI 10.1158/1078-0432.CCR-14-0707; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yamanaka K, 2011, CURR PROBL DERMATOL, V41, P80, DOI 10.1159/000323299; Yuki T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161759; Zadeh SA, 2017, EXP DERMATOL, V26, P352, DOI 10.1111/exd.13272; Zaniboni MC, 2016, AN BRAS DERMATOL, V91, P472, DOI 10.1590/abd1806-4841.20164412; Zheng T, 2011, ALLERGY ASTHMA IMMUN, V3, P67, DOI 10.4168/aair.2011.3.2.67	98	120	126	2	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2094	2106		10.1016/j.jaci.2018.02.040	http://dx.doi.org/10.1016/j.jaci.2018.02.040			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29731129	Bronze			2022-12-18	WOS:000434701600016
J	Eichenfield, LF; Ahluwalia, J; Waldman, A; Borok, J; Udkoff, J; Boguniewicz, M				Eichenfield, Lawrence F.; Ahluwalia, Jusleen; Waldman, Andrea; Borok, Jenna; Udkoff, Jeremy; Boguniewicz, Mark			Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; eczema; guidelines; Joint Task Force; American Academy of Dermatology; topical and systemic treatments	CARE	Atopic dermatitis (AD) is a chronic pruritic inflammatory disease that commonly presents in the pediatric population. Although definitions and diagnosis of AD have largely been agreed upon, allergists and dermatologists have similar and divergent approaches to the management of AD. This review facilitated integration of the American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Joint Task Force 2012 AD Practice Parameter and the 2014 American Academy of Dermatology guidelines to highlight the basic principles of AD management and discuss therapies and management of AD from the distinct perspectives of the allergist and dermatologist.	[Eichenfield, Lawrence F.; Ahluwalia, Jusleen; Waldman, Andrea; Borok, Jenna; Udkoff, Jeremy] Rady Childrens Hosp, Dept Pediat & Adolescent Dermatol, San Diego, CA USA; [Eichenfield, Lawrence F.; Ahluwalia, Jusleen; Waldman, Andrea; Borok, Jenna; Udkoff, Jeremy] Univ Calif San Diego, Sch Med, Dept Pediat & Adolescent Dermatol, La Jolla, CA 92093 USA; [Boguniewicz, Mark] Natl Jewish Hlth, Dept Pediat, Div Pediat Allergy Immunol, Denver, CO USA; [Boguniewicz, Mark] Univ Colorado, Sch Med, Denver, CO USA	Rady Childrens Hospital San Diego; University of California System; University of California San Diego; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Eichenfield, LF (corresponding author), 8010 Frost St, San Diego, CA 92123 USA.	Leichenfield@rchsd.org		Udkoff, Jeremy/0000-0003-1769-4910; Ahluwalia, Jusleen/0000-0002-3911-9813	Valeant; Omnia Education	Valeant; Omnia Education	L. F. Eichenfield serves as a consultant for Allergan, Anacore/Pfizer, Galderman, Lilly, Otsuka/Medimetriks, TopMD, and Valeant; serves on the board for Valeant; and receives speakers' fees from Valeant. M. Boguniewicz receives personal fees from Omnia Education. The rest of the authors declare that they have no relevant conflicts of interest.	Eichenfield LF, 2015, PEDIATRICS, V136, P554, DOI 10.1542/peds.2014-3678; Eichenfield LF, 2014, J AM ACAD DERMATOL, V71, P116, DOI 10.1016/j.jaad.2014.03.023; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Fleischer DM, 2015, J ALLERGY CLIN IMMUN, V136, P258, DOI 10.1016/j.jaci.2015.06.001; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P1218, DOI 10.1016/j.jaad.2014.08.038; Sidbury R, 2014, J AM ACAD DERMATOL, V71, P327, DOI 10.1016/j.jaad.2014.03.030; Togias A, 2017, PEDIATR DERMATOL, V34, pE1, DOI 10.1111/pde.13093	8	120	124	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4		S			S49	S57		10.1016/j.jaci.2017.01.009	http://dx.doi.org/10.1016/j.jaci.2017.01.009			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LN	28390477				2022-12-18	WOS:000398771400002
J	Lefebvre, P; Duh, MS; Lafeuille, MH; Gozalo, L; Desai, U; Robitaille, MN; Albers, F; Yancey, S; Ortega, H; Forshag, M; Lin, XW; Dalal, AA				Lefebvre, Patrick; Duh, Mei Sheng; Lafeuille, Marie-Helene; Gozalo, Laurence; Desai, Urvi; Robitaille, Marie-Noelle; Albers, Frank; Yancey, Steve; Ortega, Hector; Forshag, Mark; Lin, Xiwu; Dalal, Anand A.			Acute and chronic systemic corticosteroid-related complications in patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Systemic corticosteroids; severe asthma; health care use; dose response; corticosteroid-related complications; cost	ORAL CORTICOSTEROIDS; LUPUS-ERYTHEMATOSUS; GLUCOCORTICOID USE; REFRACTORY ASTHMA; ADVERSE EVENTS; RISK; DISEASE; MULTICENTER; FRACTURE; REGISTRY	Background: Many patients with severe asthma require maintenance treatment with systemic corticosteroids (SCSs) to control daily symptoms and prevent serious acute exacerbations, but chronic SCS use is associated with complications. Objective: We sought to evaluate the risk of SCS-related complications by SCS exposure and quantify the associated health care costs and resource use in patients with severe asthma. Methods: We performed a longitudinal, open-cohort, observational study using health insurance claims data (1997-2013: Medicaid) from Florida, Iowa, Kansas, Missouri, Mississippi, and New Jersey. Eligible patients were 12 years old or older with 2 or more asthma diagnoses and had more than 6 months of continuous SCS use. An open-cohort approach was used to classify patients' follow-up into low, medium, and high SCS exposure (<= 6, >6-12, and >12 mg/d, respectively). Multivariate generalized estimating equation models were used to estimate the adjusted risk of SCS-related complications for patients with medium and high exposure compared with patients with low exposure and quantify the resulting health care resource use and costs. Results: The study included 3628 patients (mean age, 57.6 years; 68% female). Patients with medium and high SCS exposure had significantly higher risks of SCS-related complications, including infections and cardiovascular, metabolic, psychiatric, ocular, gastrointestinal, and bone-related complications (odds ratio, 1.23-2.12 by complication; P<.05 for all but one) versus those with low (reference group) SCS exposure. Medium and high SCS exposure were also associated with significantly more emergency department visits (incidence rate ratios, 1.31 [P=.0004] and 1.78 [P<.0001]) and inpatient visits (incidence rate ratios, 1.25 [P<.0001] and 1.59 [P<.0001]) versus low SCS exposure. Conclusions: A significant dose-response relationship was demonstrated between chronic SCS use and risk of SCS-related complications in patients with severe asthma. Effective SCS-sparing strategies might reduce the burden associated with SCS-related complications in patients with severe asthma.	[Lefebvre, Patrick; Lafeuille, Marie-Helene; Gozalo, Laurence; Robitaille, Marie-Noelle] Ltee, Grp Anal, Montreal, PQ H3B 4W5, Canada; [Duh, Mei Sheng; Desai, Urvi] Anal Grp, Boston, MA USA; [Albers, Frank; Yancey, Steve; Ortega, Hector; Forshag, Mark; Lin, Xiwu; Dalal, Anand A.] GlaxoSmithKline, Durham, NC USA	Analysis Group Inc.; GlaxoSmithKline	Lefebvre, P (corresponding author), Ltee, Grp Anal, 1000 De La Gauchetiere West,Suite 1200, Montreal, PQ H3B 4W5, Canada.	Patrick.Lefebvre@analysisgroup.com		Ortega, Hector/0000-0002-2632-6370	GlaxoSmithKline [HO-13-12748]	GlaxoSmithKline(GlaxoSmithKline)	Supported by GlaxoSmithKline (study no. HO-13-12748). Editorial support was also funded by GlaxoSmithKline.	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; [Anonymous], 2014, CONS PRIC IND CPI; Asthma G., 2020, GLOB STRAT ASTHM MAN; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Curtis JR, 2006, ARTHRIT RHEUM-ARTHR, V55, P420, DOI 10.1002/art.21984; Da Silva JAP, 2006, ANN RHEUM DIS, V65, P285, DOI 10.1136/ard.2005.038638; de Vries F, 2007, ARTHRITIS RHEUM-US, V56, P208, DOI 10.1002/art.22294; Heaney LG, 2010, THORAX, V65, P787, DOI 10.1136/thx.2010.137414; Hoes JN, 2009, ANN RHEUM DIS, V68, P1833, DOI 10.1136/ard.2008.100008; Ivanova JI, 2012, J ALLERGY CLIN IMMUN, V129, P1229, DOI 10.1016/j.jaci.2012.01.039; Karp I, 2008, ARTHRIT RHEUM-ARTHR, V59, P169, DOI 10.1002/art.23352; Manson SC, 2009, RESP MED, V103, P975, DOI 10.1016/j.rmed.2009.01.003; *NAT HEART LUNG BL, 2007, GUID DIAGN MAN ASTHM; O'Neill S, 2015, THORAX, V70, P376, DOI 10.1136/thoraxjnl-2013-204114; Pakhale S, 2011, CLIN MED INSIGHTS-CI, V5, P37, DOI 10.4137/CCRPM.S5535; Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x; Richy F, 2003, OSTEOPOROSIS INT, V14, P179, DOI 10.1007/s00198-003-1398-z; Rodrigo GJ, 2004, CHEST, V125, P1081, DOI 10.1378/chest.125.3.1081; Sarnes E, 2011, CLIN THER, V33, P1413, DOI 10.1016/j.clinthera.2011.09.009; Souverein PC, 2004, HEART, V90, P859, DOI 10.1136/hrt.2003.020180; Steinbuch M, 2004, OSTEOPOROSIS INT, V15, P323, DOI 10.1007/s00198-003-1548-3; Stempel DA, 2004, CHEST, V126, P75, DOI 10.1378/chest.126.1.75; Thamer M, 2009, J RHEUMATOL, V36, P560, DOI 10.3899/jrheum.080828; van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108; Varas-Lorenzo C, 2007, ATHEROSCLEROSIS, V192, P376, DOI 10.1016/j.atherosclerosis.2006.05.019; Walsh LJ, 2001, THORAX, V56, P279, DOI 10.1136/thorax.56.4.279; Zonana-Nacach A, 2000, ARTHRITIS RHEUM, V43, P1801, DOI 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O	28	120	120	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1488	1495		10.1016/j.jaci.2015.07.046	http://dx.doi.org/10.1016/j.jaci.2015.07.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26414880	Bronze			2022-12-18	WOS:000366044300008
J	Chambers, ES; Nanzer, AM; Pfeffer, PE; Richards, DF; Timms, PM; Martineau, AR; Griffiths, CJ; Corrigan, CJ; Hawrylowicz, CM				Chambers, Emma S.; Nanzer, Alexandra M.; Pfeffer, Paul E.; Richards, David F.; Timms, Peter M.; Martineau, Adrian R.; Griffiths, Christopher J.; Corrigan, Christopher J.; Hawrylowicz, Catherine M.			Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-gamma(high) immunophenotypes: Potential benefits of calcitriol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; steroid resistant; steroid sensitive; glucocorticoids; IL-17A; vitamin D	GLUCOCORTICOID-RECEPTOR-BETA; REGULATORY T-CELLS; VITAMIN-D SUPPLEMENTATION; AIRWAY INFLAMMATION; GENE-EXPRESSION; HELPER TYPE-1; LUNG-FUNCTION; T(H)17 CELLS; TH17 CELLS; INDUCTION	Background: A small population of patients with severe asthma does not respond to glucocorticoids (steroid resistant [SR]). They have high morbidity, highlighting an urgent need for strategies to enhance glucocorticoid responsiveness. Objective: We investigated the immunologic differences between steroid-sensitive (SS) and SR asthmatic patients and the effect on immunophenotype of oral calcitriol treatment because it has been previously shown to beneficially modulate the clinical response to glucocorticoids in patients with SR asthma. Methods: CD8-depleted PBMCs were isolated from 12 patients with SS and 23 patients with SR asthma and cultured for 7 days with anti-CD3 and IL-2 with or without dexamethasone. Cytokine production was assessed in supernatants by using the Cytometric Bead Array. Patients with SR asthma were subsequently randomized to oral calcitriol or placebo therapy, and identical studies were repeated. Results: Patients with SR asthma produced significantly increased IL-17A and IFN-gamma levels compared with those in patients with SS asthma, although it was evident that cells from individual patients might overproduce one or the other of these cytokines. Production of IL-17A was inversely and production of IL-13 was positively associated with the clinical response to prednisolone. Oral calcitriol, compared with placebo, therapy of the patients with SR asthma significantly improved dexamethasone-induced IL-10 production in vitro while suppressing dexamethasone-induced IL-17A production. This effect mirrored the previously demonstrated improvement in clinical response to oral glucocorticoids in calcitriol-treated patients with SR asthma. Conclusions: IL-17A(high) and IFN-gamma(high) immunophenotypes exist in patients with SR asthma. These data identify immunologic pathways that likely underpin the beneficial clinical effects of calcitriol in patients with SR asthma by directing the SR cytokine profile toward a more SS immune phenotype, suggesting strategies for identifying vitamin D responder immunophenotypes.	[Chambers, Emma S.; Nanzer, Alexandra M.; Pfeffer, Paul E.; Richards, David F.; Griffiths, Christopher J.; Corrigan, Christopher J.; Hawrylowicz, Catherine M.] Kings Coll London, MRC, London SE1 9RT, England; [Chambers, Emma S.; Nanzer, Alexandra M.; Pfeffer, Paul E.; Richards, David F.; Griffiths, Christopher J.; Corrigan, Christopher J.; Hawrylowicz, Catherine M.] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, London SE1 9RT, England; [Nanzer, Alexandra M.; Martineau, Adrian R.; Griffiths, Christopher J.] Univ London, Blizard Inst, Ctr Primary Care & Publ Hlth, Asthma UK Ctr Appl Res,Queen Mary, London, England; [Timms, Peter M.] Homerton Univ NHS Fdn Trust, London, England	University of London; King's College London; University of London; King's College London; University of London	Hawrylowicz, CM (corresponding author), Kings Coll London, Guys Hosp, Div Asthma Allergy & Lung Biol, 5th Floor Tower Wing, London SE1 9RT, England.	catherine.hawrylowicz@kcl.ac.uk	Martineau, Adrian R/A-3083-2010; Chambers, Emma/AAI-3521-2021; Hawrylowicz, Catherine/Q-8483-2017	Chambers, Emma/0000-0003-0990-8835; Pfeffer, Paul/0000-0003-0369-2885; Hawrylowicz, Catherine/0000-0002-2337-7463; Corrigan, Chris/0000-0002-0706-6534	MRC British Thoracic Society/Morriston Davies Trust Capacity Building PhD Studentship; MRC Centenary Fellowship; Asthma UK [08/019, 11/040]; Wellcome Trust Clinical Research Training Fellowship; National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' National Health Service (NHS) Foundation Trust; NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; NIHR Biomedical Research Centre based at King's College London; Medical Research Council [G1000758B] Funding Source: researchfish; Asthma UK [AUK-IG-2014-296, AUK-AC-2012-01] Funding Source: researchfish	MRC British Thoracic Society/Morriston Davies Trust Capacity Building PhD Studentship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Centenary Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; Wellcome Trust Clinical Research Training Fellowship(Wellcome Trust); National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' National Health Service (NHS) Foundation Trust; NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; NIHR Biomedical Research Centre based at King's College London; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	E.S.C. was funded by an MRC British Thoracic Society/Morriston Davies Trust Capacity Building PhD Studentship and subsequently funded by an MRC Centenary Fellowship. A.M.N. was funded by Asthma UK (08/019 and 11/040) awarded to C.M.H. P.E.P. was the recipient of a Wellcome Trust Clinical Research Training Fellowship. The research was funded/supported by the National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' National Health Service (NHS) Foundation Trust and NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.	Adcock IM, 2008, CURR ALLERGY ASTHM R, V8, P171, DOI 10.1007/s11882-008-0028-4; Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018; Ahern PP, 2010, IMMUNITY, V33, P279, DOI 10.1016/j.immuni.2010.08.010; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Arshi S, 2014, ANN ALLERG ASTHMA IM, V113, P404, DOI 10.1016/j.anai.2014.07.005; Balic A, 2006, INT IMMUNOL, V18, P1421, DOI 10.1093/intimm/dxl075; Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Bending D, 2009, J CLIN INVEST, V119, P565, DOI 10.1172/JCI37865; Black PN, 2005, CHEST, V128, P3792, DOI 10.1378/chest.128.6.3792; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Castro M, 2014, JAMA-J AM MED ASSOC, V311, P2083, DOI 10.1001/jama.2014.5052; Chambers ES, 2012, J ALLERGY CLIN IMMUN, V130, P542, DOI 10.1016/j.jaci.2012.04.022; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Fletcher JM, 2009, J IMMUNOL, V183, P7602, DOI 10.4049/jimmunol.0901881; Goleva E, 2012, J ALLERGY CLIN IMMUN, V129, P1243, DOI 10.1016/j.jaci.2012.01.044; Gupta A, 2011, AM J RESP CRIT CARE, V184, P1342, DOI 10.1164/rccm.201107-1239OC; GYETKO MR, 1993, J LEUKOCYTE BIOL, V54, P17, DOI 10.1002/jlb.54.1.17; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hawrylowicz C, 2002, J ALLERGY CLIN IMMUN, V109, P369, DOI 10.1067/mai.2002.121455; Jeffery LE, 2009, J IMMUNOL, V183, P5458, DOI 10.4049/jimmunol.0803217; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Kebir H, 2009, ANN NEUROL, V66, P390, DOI 10.1002/ana.21748; Lange NE, 2009, EXPERT REV CLIN IMMU, V5, P693, DOI 10.1586/ECI.09.53; Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Levy Mark L, 2009, Prim Care Respir J, V18 Suppl 1, pS1, DOI 10.3132/pcrj.2008.00067; Li LB, 2010, AM J RESP CRIT CARE, V182, P877, DOI 10.1164/rccm.201001-0015OC; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Mann EH, 2014, ANN NY ACAD SCI, V1317, P57, DOI 10.1111/nyas.12410; Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Nanzer AM, 2014, J ALLERGY CLIN IMMUN, V133, P1755, DOI 10.1016/j.jaci.2014.03.015; Nanzer AM, 2013, J ALLERGY CLIN IMMUN, V132, P297, DOI 10.1016/j.jaci.2013.03.037; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Peek EJ, 2005, AM J RESP CELL MOL, V33, P105, DOI 10.1165/rcmb.2005-0100OC; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486; Sutherland ER, 2010, AM J RESP CRIT CARE, V181, P699, DOI 10.1164/rccm.200911-1710OC; Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094; Urry Z, 2012, EUR J IMMUNOL, V42, P2697, DOI 10.1002/eji.201242370; Urry Z, 2009, J CLIN INVEST, V119, P387, DOI 10.1172/JCI32354; Vazquez-Tello A, 2010, CLIN EXP ALLERGY, V40, P1312, DOI 10.1111/j.1365-2222.2010.03544.x; Vazquez-Tello A, 2013, J CLIN IMMUNOL, V33, P466, DOI 10.1007/s10875-012-9828-3; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu AC, 2012, AM J RESP CRIT CARE, V186, P508, DOI 10.1164/rccm.201202-0351OC; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Yadav M, 2014, INDIAN J PEDIATR, V81, P650, DOI 10.1007/s12098-013-1268-4; Yosef N, 2013, NATURE, V496, P461, DOI 10.1038/nature11981	58	120	129	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					628	+		10.1016/j.jaci.2015.01.026	http://dx.doi.org/10.1016/j.jaci.2015.01.026			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25772594	Green Published, hybrid			2022-12-18	WOS:000360913300013
J	Engelhardt, KR; Gertz, ME; Keles, S; Schaffer, AA; Sigmund, EC; Glocker, C; Saghafi, S; Pourpak, Z; Ceja, R; Sassi, A; Graham, LE; Massaad, MJ; Mellouli, F; Ben-Mustapha, I; Khemiri, M; Kilic, SS; Etzioni, A; Freeman, AF; Thiel, J; Schulze, I; Al-Herz, W; Metin, A; Sanal, O; Tezcan, I; Yeganeh, M; Niehues, T; Dueckers, G; Weinspach, S; Patiroglu, T; Unal, E; Dasouki, M; Yilmaz, M; Genel, F; Aytekin, C; Kutukculer, N; Somer, A; Kilic, M; Reisli, I; Camcioglu, Y; Gennery, AR; Cant, AJ; Jones, A; Gaspar, BH; Arkwright, PD; Pietrogrande, MC; Baz, Z; Al-Tamemi, S; Lougaris, V; Lefranc, G; Megarbane, A; Boutros, J; Galal, N; Bejaoui, M; Barbouche, MR; Geha, RS; Chatila, TA; Grimbacher, B				Engelhardt, Karin R.; Gertz, Michael E.; Keles, Sevgi; Schaeffer, Alejandro A.; Sigmund, Elena C.; Glocker, Cristina; Saghafi, Shiva; Pourpak, Zahra; Ceja, Ruben; Sassi, Atfa; Graham, Laura E.; Massaad, Michel J.; Mellouli, Fethi; Ben-Mustapha, Imen; Khemiri, Monia; Kilic, Sara Sebnem; Etzioni, Amos; Freeman, Alexandra F.; Thiel, Jens; Schulze, Ilka; Al-Herz, Waleed; Metin, Ayse; Sanal, Oezden; Tezcan, Ilhan; Yeganeh, Mehdi; Niehues, Tim; Dueckers, Gregor; Weinspach, Sebastian; Patiroglu, Turkan; Unal, Ekrem; Dasouki, Majed; Yilmaz, Mustafa; Genel, Ferah; Aytekin, Caner; Kutukculer, Necil; Somer, Ayper; Kilic, Mehmet; Reisli, Ismail; Camcioglu, Yildiz; Gennery, Andrew R.; Cant, Andrew J.; Jones, Alison; Gaspar, Bobby H.; Arkwright, Peter D.; Pietrogrande, Maria C.; Baz, Zeina; Al-Tamemi, Salem; Lougaris, Vassilios; Lefranc, Gerard; Megarbane, Andre; Boutros, Jeannette; Galal, Nermeen; Bejaoui, Mohamed; Barbouche, Mohamed-Ridha; Geha, Raif S.; Chatila, Talal A.; Grimbacher, Bodo			The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary combined immunodeficiency; hyper-IgE syndrome; autosomal recessive hyper-IgE syndrome; dedicator of cytokinesis 8; signal transducer and activator of transcription 3; Molluscum contagiosum	HYPER-IGE SYNDROME; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; DOCK8 DEFICIENCY; MUTATIONS; IMMUNODEFICIENCY; STAT3; GLYCOSYLATION; DISORDER; SURVIVAL	Background: Mutations in dedicator of cytokinesis 8 (DOCK8) cause a combined immunodeficiency (CID) also classified as autosomal recessive (AR) hyper-IgE syndrome (HIES). Recognizing patients with CID/HIES is of clinical importance because of the difference in prognosis and management. Objectives: We sought to define the clinical features that distinguish DOCK8 deficiency from other forms of HIES and CIDs, study the mutational spectrum of DOCK8 deficiency, and report on the frequency of specific clinical findings. Methods: Eighty-two patients from 60 families with CID and the phenotype of AR-HIES with (64 patients) and without (18 patients) DOCK8 mutations were studied. Support vector machines were used to compare clinical data from 35 patients with DOCK8 deficiency with those from 10 patients with AR-HIES without a DOCK8 mutation and 64 patients with signal transducer and activator of transcription 3 (STAT3) mutations. Results: DOCK8-deficient patients had median IgE levels of 5201 IU, high eosinophil levels of usually at least 800/mu L (92% of patients), and low IgM levels (62%). About 20% of patients were lymphopenic, mainly because of low CD4(+) and CD8(+) T-cell counts. Fewer than half of the patients tested produced normal specific antibody responses to recall antigens. Bacterial (84%), viral (78%), and fungal (70%) infections were frequently observed. Skin abscesses (60%) and allergies (73%) were common clinical problems. In contrast to STAT3 deficiency, there were few pneumatoceles, bone fractures, and teething problems. Mortality was high (34%). A combination of 5 clinical features was helpful in distinguishing patients with DOCK8 mutations from those with STAT3 mutations. Conclusions: DOCK8 deficiency is likely in patients with severe viral infections, allergies, and/or low IgM levels who have a diagnosis of HIES plus hypereosinophilia and upper respiratory tract infections in the absence of parenchymal lung abnormalities, retained primary teeth, and minimal trauma fractures.	[Engelhardt, Karin R.; Graham, Laura E.; Grimbacher, Bodo] Royal Free Hosp, Dept Immunol & Mol Pathol, London, England; [Engelhardt, Karin R.; Graham, Laura E.; Grimbacher, Bodo] UCL, London WC1E 6BT, England; [Engelhardt, Karin R.; Sigmund, Elena C.; Glocker, Cristina; Thiel, Jens; Schulze, Ilka; Grimbacher, Bodo] Univ Med Ctr Freiburg, CCI, Freiburg, Germany; [Engelhardt, Karin R.; Gennery, Andrew R.; Cant, Andrew J.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Gertz, Michael E.; Schaeffer, Alejandro A.] NIH, Natl Ctr Biotechnol Informat, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; [Keles, Sevgi; Ceja, Ruben; Chatila, Talal A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Immunol Allergy & Rheumatol, Los Angeles, CA 90095 USA; [Keles, Sevgi; Reisli, Ismail] Konya Necmettin Erbakan Univ, Div Pediat Allergy & Immunol, Konya, Turkey; [Keles, Sevgi; Ceja, Ruben; Massaad, Michel J.; Geha, Raif S.; Chatila, Talal A.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Saghafi, Shiva; Pourpak, Zahra] Univ Tehran Med Sci, Childrens Med Ctr, Immunol Asthma & Allergy Res Inst, Tehran, Iran; [Yeganeh, Mehdi] Univ Tehran Med Sci, Childrens Med Ctr, Immunol Asthma & Allergy Res Inst, Tehran, Iran; [Sassi, Atfa; Ben-Mustapha, Imen; Barbouche, Mohamed-Ridha] Pasteur Inst Tunis, Lab Immunol Vaccinol & Mol Genet, Tunis, Tunisia; [Sassi, Atfa; Ben-Mustapha, Imen; Barbouche, Mohamed-Ridha] Univ Tunis El Manar, El Manar, Tunisia; [Mellouli, Fethi; Bejaoui, Mohamed] Bone Marrow Transplantat Ctr, Dept Pediat, Tunis, Tunisia; [Khemiri, Monia] Childrens Hosp, Dept Pediat, Tunis, Tunisia; [Kilic, Sara Sebnem] Uludag Univ, Dept Pediat Immunol, Fac Med, Bursa, Turkey; [Etzioni, Amos] Rambam Hlth Care Campus, Meyers Children Hosp, Haifa, Israel; [Etzioni, Amos] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel; [Freeman, Alexandra F.] NIAID, Lab Clin Infect Dis, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; [Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Kuwait, Kuwait; [Al-Herz, Waleed] Al Sabah Hosp, Dept Pediat, Allergy & Clin Immunol Unit, Kuwait, Kuwait; [Metin, Ayse] SB Ankara Diskapi Childrens Hosp, Pediat Immunol Unit, Ankara, Turkey; [Sanal, Oezden; Tezcan, Ilhan] Hacettepe Univ, Childrens Hosp, Div Immunol, Ankara, Turkey; [Niehues, Tim; Dueckers, Gregor] HELIOS Klinikum Krefeld, Zentrum Kinder & Jugendmed, Krefeld, Germany; [Weinspach, Sebastian] Univ Dusseldorf, Dept Pediat Oncol Hematol & Clin Immunol, Ctr Child & Adolescent Med, Dusseldorf, Germany; [Patiroglu, Turkan] Erciyes Univ, Fac Med, Div Pediat Hematol & Immunol, Dept Pediat, Kayseri, Turkey; [Unal, Ekrem] Erciyes Univ, Fac Med, Div Pediat Hematol & Oncol, Dept Pediat, Kayseri, Turkey; [Dasouki, Majed] Univ Kansas, Med Ctr, Dept Pediat, Kansas City, KS USA; [Yilmaz, Mustafa] Cukurova Univ, Adana, Turkey; [Genel, Ferah] Behcet Uz State Hosp, Div Pediat Immunol, Izmir, Turkey; [Aytekin, Caner] Dr Sami Ulus Matern & Childrens Hlth & Dis Traini, Dept Pediat Immunol, Ankara, Turkey; [Kutukculer, Necil] Ege Univ, Fac Med, Dept Pediat, Izmir, Turkey; [Somer, Ayper] Istanbul Univ, Istanbul Fac Med, Div Infect Dis & Immunol, Istanbul, Turkey; [Kilic, Mehmet] Firat Univ, TR-23169 Elazig, Turkey; [Camcioglu, Yildiz] Istanbul Univ, Cerrahpasa Med Fac, Div Pediat Allergy Immunol & Infect Dis, Istanbul, Turkey; [Jones, Alison; Gaspar, Bobby H.] Great Ormond St Hosp Sick Children, Dept Immunol, London, England; [Arkwright, Peter D.] Univ Manchester, Royal Manchester Childrens Hosp, Manchester M13 9PL, Lancs, England; [Pietrogrande, Maria C.] Univ Milan, Dept Pediat, Fdn Policlin IRCCS, Milan, Italy; [Baz, Zeina] St George Hosp Univ, Med Ctr, Dept Pediat, Beirut, Lebanon; [Al-Tamemi, Salem] Sultan Qaboos Univ, Dept Pediat, Muscat, Oman; [Lougaris, Vassilios] Univ Brescia, Spedali Civili Brescia, Pediat Clin, I-25121 Brescia, Italy; [Lougaris, Vassilios] Univ Brescia, Spedali Civili Brescia, Inst Mol Med A Nocivelli, Dept Clin & Expt Sci, I-25121 Brescia, Italy; [Lefranc, Gerard] Univ Montpellier 2, Montpellier, France; [Lefranc, Gerard] CNRS, Inst Human Genet, Montpellier, France; [Megarbane, Andre] St Joseph Univ, Med Genet Unit, Beirut, Lebanon; [Boutros, Jeannette; Galal, Nermeen] Cairo Univ, Specialized Pediat Hosp, Primary Immunodeficiency Clin, Cairo, Egypt	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; University of Freiburg; Newcastle University - UK; National Institutes of Health (NIH) - USA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Necmettin Erbakan University; Harvard University; Boston Children's Hospital; Immunology Asthma & Allergy Research Institute - Iran; Tehran University of Medical Sciences; Immunology Asthma & Allergy Research Institute - Iran; Tehran University of Medical Sciences; Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Universite de Tunis-El-Manar; Universite de Tunis-El-Manar; Centre Nationale de Greffe de la Moelle Osseuse; Universite de Tunis-El-Manar; Hopital d'Enfants; Uludag University; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Kuwait University; Al Sabah Hospital; Ankara Children's Hematology Oncology Training & Research Hospital; Hacettepe University; Helios Kliniken; Heinrich Heine University Dusseldorf; Erciyes University; Erciyes University; University of Kansas; University of Kansas Medical Center; Cukurova University; Izmir Dr Behcet Uz Children's Disease & Surgery Training & Research Hospital; Dr. Sami Ulus Education & Research Hospital; Ege University; Istanbul University; Firat University; Istanbul University; Istanbul University - Cerrahpasa; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Royal Manchester Children's Hospital; University of Manchester; University of Milan; American University of Beirut; Sultan Qaboos University; Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Egyptian Knowledge Bank (EKB); Cairo University	Grimbacher, B (corresponding author), Univ Freiburg Klinikum, Ctr Chron Immunodeficiency, Engesser Str 4, D-79108 Freiburg, Germany.	bodo.grimbacher@uniklinik-freiburg.de	Kilic, Sara Sebnem/AAH-1658-2021; bejaoui, mohamed/K-2679-2016; Saghafi, Shiva/AAY-2363-2020; Al-Tamemi, Salem/T-7687-2017; Unal, Ekrem/A-5099-2019; Somer, Ayper/AAE-5459-2020; Metin, Ayşe/AAS-2382-2020; Schaffer, Alejandro A/F-2902-2012; Megarbane, Andre/ABD-5574-2021; Yılmaz, Mustafa/E-7787-2018; Schaffer, Alejandro/N-1222-2019; YILMAZ, Mustafa/C-5556-2016	Al-Tamemi, Salem/0000-0002-7232-2629; Unal, Ekrem/0000-0002-2691-4826; Metin, Ayşe/0000-0002-0731-5799; Saghafi, Shiva/0000-0001-8546-3247; Sigmund, Elena/0000-0001-5647-879X; YILMAZ, Mustafa/0000-0001-9422-1725; Arkwright, Peter/0000-0002-7411-5375; kilic, sara sebnem/0000-0001-8571-2581; Chatila, Talal/0000-0001-7439-2762	German Federal Ministry of Education and Research [BMBF 01EO1303]; European Community [Health-F5-2008-223292]; Marie Curie Excellence Grant [MEXT-CT-2006-042316-PIAID]; National Institutes of Health [5R01AI065617, 1R21AI087627]; Scientific and Technological Research Council of Turkey (Tubitak) [1059B191300622]; Intramural Research program of the National Institutes of Health; NLM; NIAID; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI087627, R01AI065617, ZIAAI000647] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [ZIALM000097] Funding Source: NIH RePORTER	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); European Community(European Commission); Marie Curie Excellence Grant(European Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Scientific and Technological Research Council of Turkey (Tubitak)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Intramural Research program of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NLM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	Supported by the German Federal Ministry of Education and Research (BMBF 01EO1303). The research was funded in part by the European Community's 7th Framework Programmes FP7/2007-2013 under grant agreement Health-F5-2008-223292 (Euro Gene Scan), by a Marie Curie Excellence Grant (to B.G.; MEXT-CT-2006-042316-PIAID), and by National Institutes of Health grants 5R01AI065617 and 1R21AI087627 (to T.A.C.). This research was supported in part by a grant from the Scientific and Technological Research Council of Turkey (Tubitak, grant no. 1059B191300622). This research was supported in part by the Intramural Research program of the National Institutes of Health, NLM, and NIAID.	Al-Herz W, 2012, CLIN IMMUNOL, V143, P266, DOI 10.1016/j.clim.2012.03.002; [Anonymous], 2009, HARRIET LANE HDB MAN; Barlogis V, 2011, J ALLERGY CLIN IMMUN, V128, P420, DOI 10.1016/j.jaci.2011.03.025; Bittner TC, 2010, KLIN PADIATR, V222, P351, DOI 10.1055/s-0030-1265135; Chu EY, 2012, ARCH DERMATOL, V148, P79, DOI 10.1001/archdermatol.2011.262; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Dasouki M, 2011, CLIN IMMUNOL, V141, P128, DOI 10.1016/j.clim.2011.06.003; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Freeman AF, 1993, GENEREVIEWS; Gatz SA, 2011, BONE MARROW TRANSPL, V46, P552, DOI 10.1038/bmt.2010.169; Gennery AR, 2000, BONE MARROW TRANSPL, V25, P1303, DOI 10.1038/sj.bmt.1702446; Goussetis E, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.005; Grimbacher B, 1999, AM J HUM GENET, V65, P735, DOI 10.1086/302547; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Harada Y, 2012, BLOOD, V119, P4451, DOI 10.1182/blood-2012-01-407098; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Janssen E, 2014, CLIN IMMUNOL, V150, P220, DOI 10.1016/j.clim.2013.12.006; Jing H, 2014, J ALLERGY CLIN IMMUN, V133, P1667, DOI 10.1016/j.jaci.2014.03.025; Lambe T, 2011, EUR J IMMUNOL, V41, P3423, DOI 10.1002/eji.201141759; McDonald DR, 2010, J ALLERGY CLIN IMMUN, V126, P1304, DOI 10.1016/j.jaci.2010.07.034; Merck & Co Inc, 2014, EOS DIS; Metin A, 2012, PEDIATR TRANSPLANT, V16, P398, DOI 10.1111/j.1399-3046.2011.01641.x; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Pai SY, 2014, J ALLERGY CLIN IMMUN, V134, P221, DOI 10.1016/j.jaci.2014.02.023; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Randall KL, 2009, NAT IMMUNOL, V10, P1283, DOI 10.1038/ni.1820; Sanal O, 2012, J CLIN IMMUNOL, V32, P698, DOI 10.1007/s10875-012-9664-5; Sassi A, 2014, J ALLERGY CLIN IMMUN, V133, P1410, DOI 10.1016/j.jaci.2014.02.025; Stray-Pedersen A, 2014, AM J HUM GENET, V95, P96, DOI 10.1016/j.ajhg.2014.05.007; Vowells SJ, 1996, J PEDIATR-US, V128, P104, DOI 10.1016/S0022-3476(96)70437-7; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506; Zhang Y, 2014, J ALLERGY CLIN IMMUN, V133, P1400, DOI 10.1016/j.jaci.2014.02.013	34	120	124	0	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					402	412		10.1016/j.jaci.2014.12.1945	http://dx.doi.org/10.1016/j.jaci.2014.12.1945			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25724123	Green Accepted			2022-12-18	WOS:000359004900022
J	Koker, MY; Camcioglu, Y; van Leeuwen, K; Kilic, SS; Barlan, I; Yilmaz, M; Metin, A; de Boer, M; Avcilar, H; Patiroglu, T; Yildiran, A; Yegin, O; Tezcan, I; Sanal, O; Roos, D				Koker, Mustafa Yavuz; Camcioglu, Yildiz; van Leeuwen, Karin; Kilic, Sara Sebnem; Barlan, Isil; Yilmaz, Mustafa; Metin, Ayse; de Boer, Martin; Avcilar, Huseyin; Patiroglu, Turkan; Yildiran, Alisan; Yegin, Olcay; Tezcan, Ilhan; Sanal, Ozden; Roos, Dirk			Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic granulomatous disease; dihydrorhodamine-1,2,3 assay; CYBB; CYBA; NCF1; NCF2; nicotinamide dinucleotide phosphate reduced oxidase; mean fluorescence intensity; stimulation index	TERM-FOLLOW-UP; MUTATIONS; FAMILIES; FEATURES; TURKEY	Background: Chronic granulomatous disease (CGD) is a rare primary immunodeficiency disorder of phagocytes resulting in impaired killing of bacteria and fungi. A mutation in one of the 4 genes encoding the components p22(phox), p47(phox), p67(phox), and p40(phox) of the leukocyte nicotinamide dinucleotide phosphate reduced (NADPH) oxidase leads to autosomal recessive (AR) CGD. A mutation in the CYBB gene encoding gp91(phox) leads to X-linked recessive CGD. Objective: The aim of this study is to show the correlation between clinical, functional, and genetic data of patients with CGD from Turkey. Methods: We report here the results of 89 patients with CGD from 73 Turkish families in a multicenter study. Results: Most of the families (55%) have an AR genotype, and 38% have an X-linked genotype; patients from 5 families with a suspected AR genotype (7%) were not fully characterized. We compared patients with CGD according to the severity of NADPH oxidase deficiency of neutrophils. Patients with A22(0), A67(0) or X91(0) phenotypes with a stimulation index of 1.5 or less have early clinical presentation and younger age at diagnosis (mean, 3.2 years). However, in p47(phox)-deficient cases and in 5 other AR cases with high residual oxidase activity (stimulation index >= 3), later and less severe clinical presentation and older age at diagnosis (mean, 7.1 years) were found. Pulmonary involvement was the most common clinical feature, followed by lymphadenitis and abscesses. Conclusion: Later and less severe clinical presentation and older age at diagnosis are related to the residual NADPH oxidase activity of neutrophils and not to the mode of inheritance. CGD caused by A22(0) and A67(0) subtypes manifests as severe as the X91(0) subtype.	[Koker, Mustafa Yavuz] Erciyes Univ, Fac Med, Dept Immunol, Kayseri, Turkey; [Koker, Mustafa Yavuz] Erciyes Univ, Fac Med, GenKok Lab Immunol, Kayseri, Turkey; [Camcioglu, Yildiz] Istanbul Univ, Pediat Infect Dis Clin Immunol & Allergy Div, Cerrahpasa Med Sch, Istanbul, Turkey; [van Leeuwen, Karin; de Boer, Martin; Roos, Dirk] Univ Amsterdam, Acad Med Ctr, Sanquin Res & Landsteiner Lab, NL-1012 WX Amsterdam, Netherlands; [Kilic, Sara Sebnem] Uludag Univ, Fac Med, Pediat Immunol Div, Bursa, Turkey; [Barlan, Isil] Univ Marmara, Pediat Allergy & Immunol Div, Fac Med, Istanbul, Turkey; [Yilmaz, Mustafa] Cukurova Univ, Fac Med, Pediat Allergy & Immunol Div, Adana, Turkey; [Metin, Ayse] Ankara Hematol Oncol Hosp Children, Pediat Immunol Div, Ankara, Turkey; [Avcilar, Huseyin] Technoc Univ Erciyes, Kok Biotek Co, Kayseri, Turkey; [Patiroglu, Turkan] Erciyes Univ, Fac Med, Pediat Hematol & Immunol Div, Kayseri, Turkey; [Yildiran, Alisan] Univ 19 Mayis, Fac Med, Pediat Allergy & Immunol Div, Samsun, Turkey; [Yegin, Olcay] Akdeniz Univ, Fac Med, Pediat Immunol Div, TR-07058 Antalya, Turkey; [Tezcan, Ilhan; Sanal, Ozden] Hacettepe Univ, Pediat Immunol Div, Fac Med, TR-06100 Ankara, Turkey	Erciyes University; Erciyes University; Istanbul University; Istanbul University - Cerrahpasa; University of Amsterdam; Academic Medical Center Amsterdam; Uludag University; Marmara University; Cukurova University; Erciyes University; Erciyes University; Ondokuz Mayis University; Akdeniz University; Hacettepe University	Koker, MY (corresponding author), Erciyes Univ, Fac Med, Dept Immunol, Kayseri, Turkey.	mykoker@erciyes.edu.tr	Kilic, Sara Sebnem/AAH-1658-2021; koker, Mustafa Yavuz/A-7296-2012; Yılmaz, Mustafa/E-7787-2018; METIN, AYSE/AAS-2382-2020	koker, Mustafa Yavuz/0000-0001-7061-8525; METIN, AYSE/0000-0002-0731-5799; kilic, sara sebnem/0000-0001-8571-2581; AVCILAR, HUSEYIN/0000-0002-3871-9673	TUBITAK (the Scientific and Technological Research Council of Turkey) [110S252]; European Union	TUBITAK (the Scientific and Technological Research Council of Turkey)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); European Union(European Commission)	Supported by TUBITAK (the Scientific and Technological Research Council of Turkey), project no. 110S252, and part of the E-Rare program of the European Union.	Agudelo-Florez P, 2006, PEDIATR BLOOD CANCER, V46, P243, DOI 10.1002/pbc.20455; Ahlin A, 1995, ACTA PAEDIATR, V84, P1386, DOI 10.1111/j.1651-2227.1995.tb13575.x; [Anonymous], [No title captured]; Fattahi F, 2011, J CLIN IMMUNOL, V31, P792, DOI 10.1007/s10875-011-9567-x; Jirapongsananuruk O, 2003, J ALLERGY CLIN IMMUN, V111, P374, DOI 10.1067/mai.2003.58; Jones LBKR, 2008, CLIN EXP IMMUNOL, V152, P211, DOI 10.1111/j.1365-2249.2008.03644.x; Kim YM, 2009, J KOREAN MED SCI, V24, P1045, DOI 10.3346/jkms.2009.24.6.1045; Kobayashi S, 2008, EUR J PEDIATR, V167, P1389, DOI 10.1007/s00431-008-0680-7; Koker MY, 2007, EUR J CLIN INVEST, V37, P589, DOI 10.1111/j.1365-2362.2007.01828.x; Koker MY, 2009, EUR J CLIN INVEST, V39, P942, DOI 10.1111/j.1365-2362.2009.02195.x; Koker MY, 2009, EUR J CLIN INVEST, V39, P311, DOI 10.1111/j.1365-2362.2009.02093.x; Koker MY, 2006, EUR J CLIN INVEST, V36, P257, DOI 10.1111/j.1365-2362.2006.01619.x; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Liese J, 2000, J PEDIATR-US, V137, P687, DOI 10.1067/mpd.2000.109112; Martire B, 2008, CLIN IMMUNOL, V126, P155, DOI 10.1016/j.clim.2007.09.008; Roos D, 1986, Methods Enzymol, V132, P225; Roos D, 2006, HUM MUTAT, V27, P1218, DOI 10.1002/humu.20413; Roos D, 2010, BLOOD CELL MOL DIS, V45, P246, DOI 10.1016/j.bcmd.2010.07.012; Roos D, 2010, BLOOD CELL MOL DIS, V44, P291, DOI 10.1016/j.bcmd.2010.01.009; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; Wolach B, 2008, CLIN IMMUNOL, V129, P103, DOI 10.1016/j.clim.2008.06.012	22	120	124	0	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1156	+		10.1016/j.jaci.2013.05.039	http://dx.doi.org/10.1016/j.jaci.2013.05.039			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23910690				2022-12-18	WOS:000326235600017
J	Grotenboer, NS; Ketelaar, ME; Koppelman, GH; Nawijn, MC				Grotenboer, Neomi S.; Ketelaar, Maria E.; Koppelman, Gerard H.; Nawijn, Martijn C.			Decoding asthma: Translating genetic variation in IL33 and IL1RL1 into disease pathophysiology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-33; IL-1RL1; ST2; genome-wide association study; nuocytes; innate helper cells; innate type 2 lymphoid cells; expression quantitative trait locus	INNATE LYMPHOID-CELLS; GENOME-WIDE ASSOCIATION; NF-KAPPA-B; MAST-CELL; AIRWAY INFLAMMATION; HUMAN BASOPHILS; IL-33; ST2; CYTOKINE; EXPRESSION	Asthma is a complex disease that results from the interaction between genetic predisposition and environmental factors. Recently, genome-wide association studies have identified a number of genes that significantly contribute to asthma. Two of these genes, IL33 and IL-1 receptor-like 1 (IL1RL1), act in one signal transduction pathway. IL33 encodes a cytokine released on damage of cells, whereas IL1RL1 encodes part of the IL-33 receptor complex. Recent progress made in functional studies in human subjects and mouse models of allergic airway disease indicate a central role of IL-33 signaling in driving T(H)2 inflammation, which is central to eosinophilic allergic asthma. Here, IL-33 acts on cells of both the adaptive and innate immune systems. Very recently, a novel population of IL-33-responsive innate immune cells, the type 2 innate lymphoid cells, was found to produce hallmark TH2 cytokines, such as IL-5 and IL-13. The relevance of these cells for asthma is underscored by the identification of retinoic acid-related orphan receptor a (RORA), the gene encoding the transcription factor critical for their differentiation, as another asthma gene in genome-wide association studies. This review describes the mechanisms through which genetic variation at the IL33 and IL1RL1 loci translates into increased susceptibility for asthma. We propose that genetic variation associated with asthma at the IL33 and IL1RL1 loci can be dissected into independent signals with distinct functional consequences for this pathway that is central to asthma pathogenesis. (J Allergy Clin Immunol 2013; 131:856-65.)	[Grotenboer, Neomi S.; Ketelaar, Maria E.; Nawijn, Martijn C.] Univ Groningen, Univ Med Ctr Groningen, Lab Allergol & Pulm Dis, Dept Pathol & Med Biol, NL-9700 RB Groningen, Netherlands; [Grotenboer, Neomi S.; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, Beatrix Childrens Hosp, NL-9700 RB Groningen, Netherlands; [Grotenboer, Neomi S.; Ketelaar, Maria E.; Koppelman, Gerard H.; Nawijn, Martijn C.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, NL-9700 RB Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Nawijn, MC (corresponding author), Univ Groningen, Lab Allergol & Pulm Dis Pathol & Med Biol, Univ Med Ctr Groningen, GRIAC Res Inst, IPC EA11,Hanzepl 1,POB 30-001, NL-9700 RB Groningen, Netherlands.	m.c.nawijn@umcg.nl	Koppelman, Gerard/AAG-9187-2020	Koppelman, Gerard/0000-0001-8567-3252; Nawijn, Martijn/0000-0003-3372-6521	Netherlands Asthma Foundation [3.2.09.081JU]; European Union; Stichting Astma Bestrijding	Netherlands Asthma Foundation; European Union(European Commission); Stichting Astma Bestrijding	Supported by a Netherlands Asthma Foundation grant (no. 3.2.09.081JU).; Disclosure of potential conflict of interest: G. H. Koppelman has been supported by one or more grants from or has one or more grants pending with the Netherlands Asthma Foundation, the European Union, and Stichting Astma Bestrijding and has received one or more payments for lecturing from or is on the speakers' bureau for GlaxoSmithKline. M. C. Nawijn has received one or more grants from or has one or more grants pending with the Netherlands Asthma Foundation, the European Union, and Stichting Astma Bestrijding, and has received support for travel from the European Respiratory Society. The rest of the authors declare that they have no relevant conflicts of interest.	Ali S, 2011, J IMMUNOL, V187, P1609, DOI 10.4049/jimmunol.1003080; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298; [Anonymous], DAT SINGL NUCL POL D; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Basith S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023989; Belpinati F, 2011, J ALLERGY CLIN IMMUN, V128, P667, DOI 10.1016/j.jaci.2011.05.004; Bonilla WV, 2012, SCIENCE, V335, P984, DOI 10.1126/science.1215418; Borish L, 2011, CURR ALLERGY ASTHM R, V11, P7, DOI 10.1007/s11882-010-0153-8; Bosse Y, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-98; Bousquet J, 2007, ALLERGY, V62, P102, DOI 10.1111/j.1398-9995.2006.01305.x; Brint EK, 2004, NAT IMMUNOL, V5, P373, DOI 10.1038/ni1050; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Cho KA, 2012, AM J PHYSIOL-LUNG C, V302, pL429, DOI 10.1152/ajplung.00252.2011; Choi YS, 2012, BIOCHEM BIOPH RES CO, V421, P305, DOI 10.1016/j.bbrc.2012.04.005; Dimas AS, 2009, SCIENCE, V325, P1246, DOI 10.1126/science.1174148; Enoksson M, 2011, J IMMUNOL, V186, P2523, DOI 10.4049/jimmunol.1003383; Ferreira MAR, 2011, EUR J HUM GENET, V19, P458, DOI 10.1038/ejhg.2010.191; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Ho LH, 2007, J LEUKOCYTE BIOL, V82, P1481, DOI 10.1189/jlb.0407200; Hueber AJ, 2011, EUR J IMMUNOL, V41, P2229, DOI 10.1002/eji.201041360; Iikura M, 2007, LAB INVEST, V87, P971, DOI 10.1038/labinvest.3700663; Kakkar R, 2008, NAT REV DRUG DISCOV, V7, P827, DOI 10.1038/nrd2660; Kim SH, 2009, CLIN EXP ALLERGY, V39, P203, DOI 10.1111/j.1365-2222.2008.03117.x; Komai-Koma M, 2012, ALLERGY, V67, P1118, DOI 10.1111/j.1398-9995.2012.02859.x; Komai-Koma M, 2007, EUR J IMMUNOL, V37, P2779, DOI 10.1002/eji.200737547; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kunisch E, 2012, INT J MOL MED, V29, P530, DOI 10.3892/ijmm.2012.883; Kurokawa M, 2011, INT ARCH ALLERGY IMM, V155, P12, DOI 10.1159/000327259; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Lingel A, 2009, STRUCTURE, V17, P1398, DOI 10.1016/j.str.2009.08.009; Liu JH, 2010, J IMMUNOL, V184, P5802, DOI 10.4049/jimmunol.0904127; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Melen E, 2010, J ALLERGY CLIN IMMUN, V126, P631, DOI 10.1016/j.jaci.2010.06.030; Mirchandani AS, 2012, TRENDS IMMUNOL, V33, P389, DOI 10.1016/j.it.2012.04.005; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Murphy A, 2010, HUM MOL GENET, V19, P4745, DOI 10.1093/hmg/ddq392; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nica AC, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002003; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Ramasamy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044008; Reijmerink NE, 2010, ALLERGY, V65, P199, DOI 10.1111/j.1398-9995.2009.02111.x; Reijmerink NE, 2008, J ALLERGY CLIN IMMUN, V122, P651, DOI 10.1016/j.jaci.2008.06.030; Reijmerink NE, 2010, EUR J HUM GENET, V18, P17, DOI 10.1038/ejhg.2009.128; Roussel L, 2008, EMBO REP, V9, P1006, DOI 10.1038/embor.2008.145; Sakashita M, 2008, CLIN EXP ALLERGY, V38, P1875, DOI 10.1111/j.1365-2222.2008.03114.x; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Savenije OEM, 2011, J ALLERGY CLIN IMMUN, V127, P750, DOI 10.1016/j.jaci.2010.12.014; Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Silver MR, 2010, INFLAMM RES, V59, P207, DOI 10.1007/s00011-009-0088-5; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Stranger BE, 2012, PLOS GENET, V8, P272, DOI 10.1371/journal.pgen.1002639; Suzukawa M, 2008, J IMMUNOL, V181, P5981, DOI 10.4049/jimmunol.181.9.5981; Torgerson DG, 2012, AM J HUM GENET, V90, P273, DOI 10.1016/j.ajhg.2012.01.008; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Wan YI, 2012, THORAX, V67, P762, DOI 10.1136/thoraxjnl-2011-201262; Watters TM, 2007, IMMUNOL CELL BIOL, V85, P411, DOI 10.1038/sj.icb.7100095; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Wu H, 2010, J ALLERGY CLIN IMMUN, V125, P321, DOI 10.1016/j.jaci.2009.09.007; Xia K, 2012, BIOINFORMATICS, V28, P451, DOI 10.1093/bioinformatics/btr678; Yagami A, 2010, J IMMUNOL, V185, P5743, DOI 10.4049/jimmunol.0903818; Yang TP, 2010, BIOINFORMATICS, V26, P2474, DOI 10.1093/bioinformatics/btq452; Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693	82	120	124	0	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					856	+		10.1016/j.jaci.2012.11.028	http://dx.doi.org/10.1016/j.jaci.2012.11.028			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23380221				2022-12-18	WOS:000315587800030
J	Vickery, BP; Lin, J; Kulis, M; Fu, ZY; Steele, PH; Jones, SM; Scurlock, AM; Gimenez, G; Bardina, L; Sampson, HA; Burks, AW				Vickery, Brian P.; Lin, Jing; Kulis, Michael; Fu, Zhiyan; Steele, Pamela H.; Jones, Stacie M.; Scurlock, Amy M.; Gimenez, Gustavo; Bardina, Ludmilla; Sampson, Hugh A.; Burks, A. Wesley			Peanut oral immunotherapy modifies IgE and IgG(4) responses to major peanut allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; oral immunotherapy; IgE; IgG(4); peptide microarray; epitope; B cell; antibody affinity	SEQUENTIAL EPITOPES; ARA H2; CHILDREN; IDENTIFICATION; INDUCTION; TOLERANCE; IGG4	Background: Patients with peanut allergy have highly stable pathologic antibody repertoires to the immunodominant B-cell epitopes of the major peanut allergens Ara h 1 to 3. Objective: We used a peptide microarray technique to analyze the effect of treatment with peanut oral immunotherapy (OIT) on such repertoires. Methods: Measurements of total peanut-specific IgE (psIgE) and peanut-specific IgG(4) (psIgG(4)) were made with CAP-FEIA. We analyzed sera from 22 patients with OIT and 6 control subjects and measured serum specific IgE and IgG(4) binding to epitopes of Ara h 1 to 3 using a high-throughput peptide microarray technique. Antibody affinity was measured by using a competitive peptide microarray, as previously described. Results: At baseline, psIgE and psIgG(4) diversity was similar between patients and control subjects, and there was broad variation in epitope recognition. After a median of 41 months of OIT, polyclonal psIgG(4) levels increased from a median of 0.3 mu g/mL (interquartile range [25% to 75%], 0.1-0.43 mu g/mL) at baseline to 10.5 mu g/mL (interquartile range [25% to 75%], 3.95-45.48 mu g/mL; P < .0001) and included de novo specificities. psIgE levels were reduced from a median baseline of 85.45 kU(A)/L (23.05-101.0 kU(A)/L) to 7.75 kU(A)/L (2.58-30.55 kU(A)/L, P < .0001). Affinity was unaffected. Although the psIgE repertoire contracted in most OIT-treated patients, several subjects generated new IgE specificities, even as the total psIgE level decreased. Global epitope-specific shifts from IgE to IgG(4) binding occurred, including at an informative epitope of Ara h 2. Conclusion: OIT differentially alters Ara h 1 to 3 binding patterns. These changes are variable between patients, are not observed in control subjects, and include a progressive polyclonal increase in IgG(4) levels, with concurrent reduction in IgE amount and diversity. (J Allergy Clin Immunol 2013;131:128-34.)	[Vickery, Brian P.; Kulis, Michael; Steele, Pamela H.; Burks, A. Wesley] Duke Univ, Div Pediat Allergy & Immunol, Sch Med, Durham, NC 27706 USA; [Lin, Jing; Fu, Zhiyan; Gimenez, Gustavo; Bardina, Ludmilla; Sampson, Hugh A.] Mt Sinai Sch Med, New York, NY USA; [Jones, Stacie M.; Scurlock, Amy M.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA	Duke University; Icahn School of Medicine at Mount Sinai; University of Arkansas System; University of Arkansas Medical Sciences	Vickery, BP (corresponding author), Univ N Carolina, Dept Pediat, CB 7231, Chapel Hill, NC 27599 USA.	bvickery@email.unc.edu		Vickery, Brian/0000-0002-7243-5543	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID); American Lung Association; Cephalon; Foundation of the American College of Allergy, Asthma & Immunology (ACAAI); Mead Johnson; NIH/NIAID; National Peanut Board; NIH; Food Allergy & Anaphylaxis Network; Abbott Nutrition International; Kentucky Society for Allergy, Asthma Immunology; New England Allergy Society; ACAAI, Indiana University Medical School; ACAAI, Riley Children's Hospital; Spanish Society of Allergy & Clinical Immunology (Madrid, Spain); Oregon Allergy Asthma & Immunology Society; NIAID; Allertein Therapeutics and Food Allergy Initiative; US Food and Drug Administration; Journal of Allergy and Clinical Immunology; NIH/HAI; Dannon Co Probiotics; Exploramed Development; Intelliject; McNeil Nutritionals; Merck Co; Novartis; Nutricia; Pfizer; Portola Pharmaceuticals; Schering-Plough; Food Allergy Initiative; National Peanut Board, Scientific Hospital Supplies (Nutricia North America); Wallace Research Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000030] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); American Lung Association; Cephalon; Foundation of the American College of Allergy, Asthma & Immunology (ACAAI); Mead Johnson; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Peanut Board; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy & Anaphylaxis Network; Abbott Nutrition International; Kentucky Society for Allergy, Asthma Immunology; New England Allergy Society; ACAAI, Indiana University Medical School; ACAAI, Riley Children's Hospital; Spanish Society of Allergy & Clinical Immunology (Madrid, Spain); Oregon Allergy Asthma & Immunology Society; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Allertein Therapeutics and Food Allergy Initiative; US Food and Drug Administration; Journal of Allergy and Clinical Immunology; NIH/HAI; Dannon Co Probiotics; Exploramed Development; Intelliject; McNeil Nutritionals; Merck Co(Merck & Company); Novartis(Novartis); Nutricia(Danone Nutricia); Pfizer(Pfizer); Portola Pharmaceuticals; Schering-Plough(Merck & CompanySchering Plough Corporation); Food Allergy Initiative; National Peanut Board, Scientific Hospital Supplies (Nutricia North America)(Danone Nutricia); Wallace Research Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by the National Institutes of Health/National Institute of Allergy and Infectious Diseases.; B. P. Vickery has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID); the American Lung Association; Cephalon; the Foundation of the American College of Allergy, Asthma & Immunology (ACAAI); and the Thrasher Research Fund and has received consultancy fees from Mead Johnson. M. Kulis has received research support from the NIH/NIAID. S. M. Jones has received research support from the National Peanut Board, the NIH, and the Food Allergy & Anaphylaxis Network; is on the Food Allergy & Anaphylaxis Network medical advisory board; has received lecture fees from Abbott Nutrition International, the Kentucky Society for Allergy, Asthma & Immunology, the New England Allergy Society, the ACAAI, Indiana University Medical School and Riley Children's Hospital, the Spanish Society of Allergy & Clinical Immunology (Madrid, Spain), and the Oregon Allergy Asthma & Immunology Society; is on the NIAID Safety Monitoring Committee and the Arkansas Medicaid Drug Review Committee; and participated in ad hoc review for the NIAID Study Section. H. A. Sampson has received research support and travel support from the NIAID; is on the Danone Scientific advisory board; has received consultancy fees from Allertein Therapeutics and Food Allergy Initiative; is employed by Mount Sinai Medical School; receives royalties from Elsevier-Wiley; and is a 42.5% owner of Herbs Springs, LLC. A. W. Burks has received research support and travel support from the NIH/NIAID; is on the board for the American Academy of Allergy, Asthma & Immunology (AAAAI), the Food Allergy & Anaphylaxis Network, the US Food and Drug Administration, the Journal of Allergy and Clinical Immunology, and the NIH/HAI; has received consultancy fees from Dannon Co Probiotics, Exploramed Development, Intelliject, McNeil Nutritionals, Merck & Co, Novartis, Nutricia, Pfizer, Portola Pharmaceuticals, and Schering-Plough; is employed by Duke University Medical Center and UNC North Carolina Children's Hospital; has received research support from the Food Allergy & Anaphylaxis Network, the Food Allergy Initiative, the NIH, the National Peanut Board, Scientific Hospital Supplies (Nutricia North America), and the Wallace Research Foundation; has received royalties from UpToDate; has received payment for developing educational presentations from Current Views; has stock/stock options in Allertein and MastCell; and has received travel support from the AAAAI, the European Academy of Allergy & Clinical Immunology, and the ACAAI. The rest of the authors declare that they have no relevant conflicts of interest.	Ayuso R, 2010, J ALLERGY CLIN IMMUN, V125, P1286, DOI 10.1016/j.jaci.2010.03.010; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P154, DOI 10.1067/mai.2002.125487; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Ji HK, 2005, BIOINFORMATICS, V21, P3629, DOI 10.1093/bioinformatics/bti593; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Lin J, 2008, J ALLERGY CLIN IMMUN, V121, pS246, DOI 10.1016/j.jaci.2007.12.974; Lin J, 2009, J ALLERGY CLIN IMMUN, V124, P315, DOI 10.1016/j.jaci.2009.05.024; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; Savilahti EM, 2010, J ALLERGY CLIN IMMUN, V125, P1315, DOI 10.1016/j.jaci.2010.03.025; Shamji MH, 2011, IMMUNOL ALLERGY CLIN, V31, P311, DOI 10.1016/j.iac.2011.03.005; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Uermosi C, 2010, J ALLERGY CLIN IMMUN, V126, P375, DOI 10.1016/j.jaci.2010.05.040; Vereda A, 2010, J ALLERGY CLIN IMMUN, V126, P596, DOI 10.1016/j.jaci.2010.06.023; Wachholz PA, 2004, CURR OPIN ALLERGY CL, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, P695, DOI 10.1016/j.jaci.2009.12.017	25	120	121	1	34	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					128	U194		10.1016/j.jaci.2012.10.048	http://dx.doi.org/10.1016/j.jaci.2012.10.048			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23199605	Green Accepted			2022-12-18	WOS:000312961200016
J	Akdis, M; Palomares, O; van de Veen, W; van Splunter, M; Akdis, CA				Akdis, Muebeccel; Palomares, Oscar; van de Veen, Willem; van Splunter, Marloes; Akdis, Cezmi A.			T(H)17 and T(H)22 cells: A confusion of antimicrobial response with tissue inflammation versus protection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; inflammation; T(H)17; T(H)22; epithelial cells; asthma; allergy	ROR-GAMMA-T; CHRONIC MUCOCUTANEOUS CANDIDIASIS; GROWTH-FACTOR-BETA; HYPER-IGE SYNDROME; SEASONAL ALLERGIC RHINITIS; ARYL-HYDROCARBON RECEPTOR; MUCOSAL HOST-DEFENSE; C VIRUS-INFECTION; CYTOKINE GM-CSF; TH17 CELLS	Substantial progress in understanding mechanisms of immune regulation in allergy, asthma, autoimmune diseases, tumors, organ transplantation, chronic infections, and pregnancy is in an exciting developmental phase that might lead to a variety of targeted therapeutic approaches. Recent progress in the interaction between immune/inflammatory cell subsets through cytokines, particularly the extension of the knowledge on reciprocal regulation and counterbalance between subsets of T(H)1, T(H)2, T(H)9, T(H)17, T(H)22, T follicular helper cells and different subsets of regulatory T cells, as well as corresponding and co-orchestrating B-cell, natural killer cell, dendritic cell, and innate lymphoid cell subsets, offers new possibilities for immune intervention. Studies on new subsets confirm the important role of T cells in the instruction of tissue cells and also demonstrate the important role of feedback regulation for the polarization toward distinct T-cell subsets. T(H)17 and T(H)22 cells are 2 emerging T-H cell subsets that link the immune response to tissue inflammation; IL-17A and IL-17F and IL-22 are their respective prototype cytokines. Although both cytokines play roles in immune defense to extracellular bacteria, IL-17 augments inflammation, whereas IL-22 plays a tissue-protective role. This review focuses on current knowledge on T(H)17 and T(H)22 cells and their role in inflammation, with special focus on the mechanisms of their generation and driving and effector cytokines, as well as their role in host defense, autoimmunity, and allergic diseases. (J Allergy Clin Immunol 2012;129:1438-49.)	[Akdis, Muebeccel; van de Veen, Willem; van Splunter, Marloes; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CH-7270 Davos, Switzerland; [Palomares, Oscar] Univ Complutense Madrid, Dept Biochem & Mol Biol, Sch Chem, Madrid, Spain	Swiss Institute of Allergy & Asthma Research; University of Zurich; Complutense University of Madrid	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22,Davos Pl, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020; Palomares, Oscar/ABG-5229-2020	Akdis, Cezmi/0000-0001-8020-019X; Palomares, Oscar/0000-0003-4516-0369	Swiss National Foundation [320030-132899, 320030-140772/1]; Christine Kuhne-Center for Allergy Research and Education (CK-CARE); European 7th Framework project MeDALL (Mechanisms of the Development of Allergy) [261357]; European 7th Framework project PREDICTA (Post-Infectious Immune Reprogramming and Its Association with Persistence and Chronicity of Respiratory Allergic Diseases) [260895]; MINECO; European Social Fund	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Christine Kuhne-Center for Allergy Research and Education (CK-CARE); European 7th Framework project MeDALL (Mechanisms of the Development of Allergy); European 7th Framework project PREDICTA (Post-Infectious Immune Reprogramming and Its Association with Persistence and Chronicity of Respiratory Allergic Diseases); MINECO(Spanish Government); European Social Fund(European Social Fund (ESF))	The authors' laboratories are supported by Swiss National Foundation grants 320030-132899 and 320030-140772/1; the Christine Kuhne-Center for Allergy Research and Education (CK-CARE); European 7th Framework projects MeDALL (Mechanisms of the Development of Allergy; no. 261357) and PREDICTA (Post-Infectious Immune Reprogramming and Its Association with Persistence and Chronicity of Respiratory Allergic Diseases; no. 260895). O.P. is a Ramon y Cajal Scholar funded by MINECO and the European Social Fund.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Ahern PP, 2010, IMMUNITY, V33, P279, DOI 10.1016/j.immuni.2010.08.010; Akdis CA, 2006, CURR OPIN IMMUNOL, V18, P718, DOI 10.1016/j.coi.2006.09.016; Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Akdis M, 2012, NAT IMMUNOL, V13, P312, DOI 10.1038/ni.2266; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Akkoc T, 2008, J ALLERGY CLIN IMMUN, V121, P652, DOI 10.1016/j.jaci.2007.12.1171; Al Khatib S, 2009, J ALLERGY CLIN IMMUN, V124, P342, DOI 10.1016/j.jaci.2009.05.004; Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Boniface K, 2007, CLIN EXP IMMUNOL, V150, P407, DOI 10.1111/j.1365-2249.2007.03511.x; Boyman O, 2012, J ALLERGY CLIN IMMUN, V129, P160, DOI 10.1016/j.jaci.2011.10.046; Brand S, 2006, AM J PHYSIOL-GASTR L, V290, pG827, DOI 10.1152/ajpgi.00513.2005; Burgler S, 2010, J IMMUNOL, V184, P6161, DOI 10.4049/jimmunol.0903243; Burgler S, 2009, J ALLERGY CLIN IMMUN, V123, P588, DOI 10.1016/j.jaci.2008.12.017; Burke SM, 2008, BLOOD, V111, P5467, DOI 10.1182/blood-2007-10-118547; Caproni M, 2009, J CLIN IMMUNOL, V29, P210, DOI 10.1007/s10875-008-9233-0; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Chang Y, 2011, J ALLERGY CLIN IMMUN, V127, P1046, DOI 10.1016/j.jaci.2010.12.1117; Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018; Chung YS, 2006, CELL RES, V16, P902, DOI 10.1038/sj.cr.7310106; Ciprandi G, 2009, ALLERGY, V64, P1375, DOI 10.1111/j.1398-9995.2009.02010.x; Codarri L, 2011, NAT IMMUNOL, V12, P560, DOI 10.1038/ni.2027; Coelho AL, 2005, CYTOKINE GROWTH F R, V16, P553, DOI 10.1016/j.cytogfr.2005.03.004; Conti HR, 2011, MUCOSAL IMMUNOL, V4, P448, DOI 10.1038/mi.2011.5; Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463; D'Addio F, 2011, J IMMUNOL, V187, P4530, DOI 10.4049/jimmunol.1002031; Dambacher J, 2008, CYTOKINE, V41, P209, DOI 10.1016/j.cyto.2007.11.016; Das J, 2009, J EXP MED, V206, P2407, DOI 10.1084/jem.20082286; Direskeneli H, 2011, J ALLERGY CLIN IMMUN, V128, P665, DOI 10.1016/j.jaci.2011.07.008; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; Dumoutier L, 2000, GENES IMMUN, V1, P488, DOI 10.1038/sj.gene.6363716; Dumoutier L, 2001, J IMMUNOL, V166, P7090, DOI 10.4049/jimmunol.166.12.7090; Dunne A, 2010, J IMMUNOL, V185, P1711, DOI 10.4049/jimmunol.1000105; Ehirchiou D, 2007, J EXP MED, V204, P1519, DOI 10.1084/jem.20062292; El-Behi M, 2011, NAT IMMUNOL, V12, P568, DOI 10.1038/ni.2031; Eyerich K, 2008, J INVEST DERMATOL, V128, P2640, DOI 10.1038/jid.2008.139; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Ferber IA, 1996, J IMMUNOL, V156, P5; Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Fujie H, 2012, INFLAMMATION, V35, P1119, DOI 10.1007/s10753-011-9419-0; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1010/J.JACL2011.05.016; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, P574, DOI 10.1016/j.jaci.2011.05.016; Ghoreschi K, 2011, TRENDS IMMUNOL, V32, P395, DOI 10.1016/j.it.2011.06.007; Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447; Gruenberg BH, 2001, GENES IMMUN, V2, P329, DOI 10.1038/sj.gene.6363786; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hansel A, 2011, J ALLERGY CLIN IMMUN, V127, P787, DOI 10.1016/j.jaci.2010.12.009; Hanabuchi S, 2011, IMMUNITY, V35, P851, DOI 10.1016/j.immuni.2011.12.005; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hashimoto M, 2010, J EXP MED, V207, P1135, DOI 10.1084/jem.20092301; Hayashida S, 2011, J DERMATOL SCI, V61, P180, DOI 10.1016/j.jdermsci.2010.10.013; He R, 2009, J ALLERGY CLIN IMMUN, V124, P761, DOI 10.1016/j.jaci.2009.07.040; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Hennig BJ, 2007, LIVER INT, V27, P1134, DOI 10.1111/j.1478-3231.2007.01518.x; Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993; Hoechst B, 2011, BLOOD, V117, P6532, DOI 10.1182/blood-2010-11-317321; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Huber S, 2011, IMMUNITY, V34, P554, DOI 10.1016/j.immuni.2011.01.020; Huh JR, 2011, NATURE, V472, P486, DOI 10.1038/nature09978; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kakkar R, 2008, NAT REV DRUG DISCOV, V7, P827, DOI 10.1038/nrd2660; Kang CM, 2005, AM J RESP CELL MOL, V33, P290, DOI 10.1165/rcmb.2005-0003OC; King C, 2008, ANNU REV IMMUNOL, V26, P741, DOI 10.1146/annurev.immunol.26.021607.090344; Kisand K, 2010, J EXP MED, V207, P299, DOI 10.1084/jem.20091669; Klotz L, 2009, J EXP MED, V206, P2079, DOI 10.1084/jem.20082771; Klunker S, 2009, J EXP MED, V206, P2701, DOI 10.1084/jem.20090596; Komine O, 2003, J EXP MED, V198, P51, DOI 10.1084/jem.20021200; Kotenko SV, 2001, J IMMUNOL, V166, P7096, DOI 10.4049/jimmunol.166.12.7096; Kotenko SV, 2001, J BIOL CHEM, V276, P2725, DOI 10.1074/jbc.M007837200; Krueger J, 2012, J ALLERGY C IN PRESS; Kullberg MC, 2006, J EXP MED, V203, P2485, DOI 10.1084/jem.20061082; Larsen JM, 2009, J ALLERGY CLIN IMMUN, V123, P486, DOI 10.1016/j.jaci.2008.09.036; Lazarevic V, 2011, NAT IMMUNOL, V12, P96, DOI 10.1038/ni.1969; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Li J, 2004, INT IMMUNOPHARMACOL, V4, P693, DOI 10.1016/j.intimp.2004.01.010; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Lluis A, 2011, J ALLERGY CLIN IMMUN, V127, P1587, DOI 10.1016/j.jaci.2011.03.015; Logsdon NJ, 2004, J MOL BIOL, V342, P503, DOI 10.1016/j.jmb.2004.07.069; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Ma HL, 2008, J CLIN INVEST, V118, P597, DOI 10.1172/JCI33263; Maddur MS, 2011, J ALLERGY CLIN IMMUN, V127, P823, DOI 10.1016/j.jaci.2010.12.1102; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Matsumoto Yuri, 2011, Allergology International, V60, P87, DOI 10.2332/allergolint.10-OA-0230; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Medvedev A, 1996, GENE, V181, P199, DOI 10.1016/S0378-1119(96)00504-5; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Melton AC, 2010, J CLIN INVEST, V120, P4436, DOI 10.1172/JCI43786; Meyer N, 2012, J ALLERGY CLIN IMMUN, V129, P964, DOI 10.1016/j.jaci.2011.12.1002; Milner JD, 2011, CURR OPIN IMMUNOL, V23, P784, DOI 10.1016/j.coi.2011.09.006; Milovanovic M, 2010, J INVEST DERMATOL, V130, P2621, DOI 10.1038/jid.2010.175; Minegishi Y, 2009, J EXP MED, V206, P1291, DOI 10.1084/jem.20082767; Misse D, 2007, J IMMUNOL, V178, P407, DOI 10.4049/jimmunol.178.1.407; Moreira AP, 2011, J CLIN INVEST, V121, P4420, DOI 10.1172/JCI44999; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Nagalakshmi ML, 2004, INT IMMUNOPHARMACOL, V4, P577, DOI 10.1016/j.intimp.2004.01.007; Nagem RAP, 2002, STRUCTURE, V10, P1051, DOI 10.1016/S0969-2126(02)00797-9; Nakae S, 2003, P NATL ACAD SCI USA, V100, P5986, DOI 10.1073/pnas.1035999100; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Ng WF, 2010, J ALLERGY CLIN IMMUN, V126, P1006, DOI 10.1016/j.jaci.2010.08.027; Niebuhr M, 2010, J ALLERGY CLIN IMMUN, V126, P1176, DOI 10.1016/j.jaci.2010.07.041; Nishimori H, 2012, BLOOD, V119, P285, DOI 10.1182/blood-2011-01-332478; Nograles KE, 2010, J ALLERGY CLIN IMMUN, V125, P744, DOI 10.1016/j.jaci.2009.12.934; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Ochs HD, 2009, J ALLERGY CLIN IMMUN, V123, P977, DOI 10.1016/j.jaci.2009.03.030; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Palomares O, 2010, EUR J IMMUNOL, V40, P1232, DOI 10.1002/eji.200940045; Passerini L, 2011, J ALLERGY CLIN IMMUN, V128, P1376, DOI 10.1016/j.jaci.2011.09.010; Peters A, 2011, CURR OPIN IMMUNOL, V23, P702, DOI 10.1016/j.coi.2011.08.007; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Pot C, 2011, SEMIN IMMUNOL, V23, P438, DOI 10.1016/j.smim.2011.08.003; Radaeva S, 2004, HEPATOLOGY, V39, P1332, DOI 10.1002/hep.20184; Rebane A, 2012, J ALLERGY CLIN IMMUN, V129, P1297, DOI 10.1016/j.jaci.2012.02.020; Robinson MJ, 2009, J EXP MED, V206, P2037, DOI 10.1084/jem.20082818; Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775; Schmidt-Weber CB, 2007, J ALLERGY CLIN IMMUN, V120, P247, DOI 10.1016/j.jaci.2007.06.039; Scriba TJ, 2008, J IMMUNOL, V180, P1962, DOI 10.4049/jimmunol.180.3.1962; Sergejeva S, 2005, AM J RESP CELL MOL, V33, P248, DOI 10.1165/rcmb.2004-0213OC; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Solt LA, 2011, NATURE, V472, P491, DOI 10.1038/nature10075; Sonderegger I, 2008, EUR J IMMUNOL, V38, P1833, DOI 10.1002/eji.200838511; Starnes T, 2002, J IMMUNOL, V169, P642, DOI 10.4049/jimmunol.169.2.642; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Sugimoto K, 2008, J CLIN INVEST, V118, P534, DOI [10.1172/JC133194, 10.1172/JCI33194]; Takahashi K, 2011, J ALLERGY CLIN IMMUN, V128, P1067, DOI 10.1016/j.jaci.2011.06.018; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Veldhoen M, 2009, J EXP MED, V206, P43, DOI 10.1084/jem.20081438; Wang H, 2010, CLIN EXP ALLERGY, V40, P1194, DOI 10.1111/j.1365-2222.2010.03542.x; Whitehead GS, 2012, J ALLERGY CLIN IMMUN, V129, P207, DOI 10.1016/j.jaci.2011.08.009; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2007, J IMMUNOL, V178, P5973, DOI 10.4049/jimmunol.178.9.5973; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Wong CK, 2000, LUPUS, V9, P589, DOI 10.1191/096120300678828703; Wu PW, 2008, J MOL BIOL, V382, P1168, DOI 10.1016/j.jmb.2008.07.046; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Yamaguchi Y, 2007, J IMMUNOL, V179, P7128, DOI 10.4049/jimmunol.179.10.7128; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Ying HY, 2010, J IMMUNOL, V185, P1375, DOI 10.4049/jimmunol.0903369; Zaba LC, 2010, J ALLERGY CLIN IMMUN, V125, P1261, DOI 10.1016/j.jaci.2010.03.018; Zenewicz LA, 2007, IMMUNITY, V27, P647, DOI 10.1016/j.immuni.2007.07.023; Zhang FP, 2008, NAT IMMUNOL, V9, P1297, DOI 10.1038/ni.1663; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zimmermann M, 2011, J ALLERGY CLIN IMMUN, V127, P200, DOI 10.1016/j.jaci.2010.11.005	171	120	129	0	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1438	1449		10.1016/j.jaci.2012.05.003	http://dx.doi.org/10.1016/j.jaci.2012.05.003			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22657405				2022-12-18	WOS:000304764600002
J	Granada, M; Wilk, JB; Tuzova, M; Strachan, DP; Weidinger, S; Albrecht, E; Gieger, C; Heinrich, J; Himes, BE; Hunninghake, GM; Celedon, JC; Weiss, ST; Cruikshank, WW; Farrer, LA; Center, DM; O'Connor, GT				Granada, Mark; Wilk, Jemma B.; Tuzova, Marina; Strachan, David P.; Weidinger, Stephan; Albrecht, Eva; Gieger, Christian; Heinrich, Joachim; Himes, Blanca E.; Hunninghake, Gary M.; Celedon, Juan C.; Weiss, Scott T.; Cruikshank, William W.; Farrer, Lindsay A.; Center, David M.; O'Connor, George T.			A genome-wide association study of plasma total IgE concentrations in the Framingham Heart Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Total IgE; atopy; asthma; genome-wide association study	IMMUNOGLOBULIN-E; ALLERGIC DISEASES; CHILDHOOD ASTHMA; HLA ANTIGENS; GENE; POPULATION; LINKAGE; STAT6; RISK; SUSCEPTIBILITY	Background: Atopy and plasma IgE concentration are genetically complex traits, and the specific genetic risk factors that lead to IgE dysregulation and clinical atopy are an area of active investigation. Objective: We sought to ascertain the genetic risk factors that lead to IgE dysregulation. Methods: A genome-wide association study (GWAS) was performed in 6819 participants from the Framingham Heart Study (FHS). Seventy of the top single nucleotide polymorphisms (SNPs) were selected based on P values and linkage disequilibrium among neighboring SNPs and evaluated in a meta-analysis with 5 independent populations from the Cooperative Health Research in the Region of Augsburg cohort, the British 1958 Birth Cohort, and the Childhood Asthma Management Program cohort. Results: Thirteen SNPs located in the region of 3 genes, FCER1A, signal transducer and activator of transcription 6 (STAT6), and IL13, were found to have genome-wide significance in the FHS cohort GWAS. The most significant SNPs from the 3 regions were rs2251746 (FCER1A, P = 2.11 x 10(-12)), rs1059513 (STAT6, P = 2.87 x 10(-8)), and rs1295686 (IL13, P = 3.55 x 10(-8)). Four additional gene regions, HLA-G, HLA-DQA2, HLA-A, and Duffy blood group, chemokine receptor (DARC), reached genome-wide statistical significance in a meta-analysis combining the FHS and replication cohorts, although the DARC association did not appear independent of SNPs in the nearby FCER1A gene. Conclusion: This GWAS of the FHS cohort has identified genetic loci in HLA genes that might have a role in the pathogenesis of IgE dysregulation and atopy. It also confirmed the association of the known susceptibility loci FCER1A, STAT6, and IL13 for the dysregulation of total IgE. (J Allergy Clin Immunol 2012;129:840-5.)	[Granada, Mark; Tuzova, Marina; Cruikshank, William W.; Center, David M.; O'Connor, George T.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; [Wilk, Jemma B.] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA; [Strachan, David P.] Univ London, Div Community Hlth Sci, London WC1E 7HU, England; [Weidinger, Stephan] Univ Kiel, Dept Dermatol, D-24098 Kiel, Germany; [Albrecht, Eva; Gieger, Christian] German Res Ctr Environm Hlth, Inst Genet Epidemiol, Helmholtz Zentrum Munchen, Neuherberg, Germany; [Heinrich, Joachim] German Res Ctr Environm Hlth, Inst Epidemiol 1, Helmholtz Zentrum Munchen, Neuherberg, Germany; [Himes, Blanca E.; Hunninghake, Gary M.; Weiss, Scott T.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Himes, Blanca E.; Hunninghake, Gary M.; Weiss, Scott T.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Celedon, Juan C.] Univ Pittsburgh, Div Pediat Pulm Med Allergy & Immunol, Childrens Hosp Pittsburgh, UPMC,Sch Med, Pittsburgh, PA 15260 USA; [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [O'Connor, George T.] NHLBI, Framingham Heart Study, Framingham, MA USA	Boston University; Harvard University; Brigham & Women's Hospital; University of London; University of Kiel; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	O'Connor, GT (corresponding author), Boston Univ, Sch Med, Ctr Pulm, 72 E Concord St R-304, Boston, MA 02118 USA.	goconnor@bu.edu	Weidinger, Stephan/C-8461-2011; Heinrich, Joachim/N-1720-2013; Farrer, Lindsay/AAS-1035-2020	Weidinger, Stephan/0000-0003-3944-252X; Heinrich, Joachim/0000-0002-9620-1629; Farrer, Lindsay/0000-0001-5533-4225; Center, David/0000-0002-5879-7978; O'Connor, George/0000-0002-6476-3926; Gieger, Christian/0000-0001-6986-9554	Flight Attendant Medical Research Institute; Medical Research Council [G0000934]; Wellcome Trust [068545/Z/02]; DFG [WE 2678/6-1]; German Ministry of Education and Research (BMBF) [01GS 0818]; Helmholtz Center Munich; German National Genome Research Network [01GS0823]; National Library of Medicine [K08 HL092222, 2T15LM007092-16]; National Institutes of Health/National Heart, Lung, and Blood Institute [U01 HL075419, U01 HL65899, P01 HL083069, N01 HR16049, T32 HL07427];  [N01 HC 25195];  [P01 AI 050516]; Medical Research Council [G1001799] Funding Source: researchfish; MRC [G1001799, G0000934] Funding Source: UKRI; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; DIVISION OF LUNG DISEASES [N01HR016049] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL083069, U01HL075419, U01HL065899, K99HL105663, T32HL007427, K08HL092222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050516] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007092] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); DFG(German Research Foundation (DFG)); German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Helmholtz Center Munich(Helmholtz Association); German National Genome Research Network; National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ; ; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	G.T.O. and J.B.W. were supported by N01 HC 25195 and P01 AI 050516. J.B.W. was supported by the Flight Attendant Medical Research Institute. D. P. S. was supported by Medical Research Council grant G0000934 and Wellcome Trust grant 068545/Z/02. S. W. was supported by the DFG (grant WE 2678/6-1) and the German Ministry of Education and Research (BMBF) as part of the National Genome Research Network (NGFN grant 01GS 0818). C. G., J.H., and E. A. were supported by Helmholtz Center Munich, German National Genome Research Network (NGFN-2 and NGFNPlus: 01GS0823) and MC Health as part of LMUinnovativ. G. M. H. was supported by K08 HL092222. B. E. H. was supported by 2T15LM007092-16 from the National Library of Medicine. The Childhood Asthma Management Program Genetics Ancillary Study is supported by U01 HL075419, U01 HL65899, P01 HL083069, N01 HR16049, and T32 HL07427 from the National Institutes of Health/National Heart, Lung, and Blood Institute.	Amoli MM, 2002, GENES IMMUN, V3, P220, DOI 10.1038/sj.gene.6363872; Aron Y, 1996, CLIN EXP ALLERGY, V26, P821, DOI 10.1111/j.1365-2222.1996.tb00614.x; Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Carosella ED, 2008, TRENDS IMMUNOL, V29, P125, DOI 10.1016/j.it.2007.11.005; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; Lara-Marquez ML, 1999, CLIN EXP ALLERGY, V29, P60, DOI 10.1046/j.1365-2222.1999.00461.x; Lee GR, 2003, IMMUNITY, V19, P145, DOI 10.1016/S1074-7613(03)00179-1; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; Li X, 2010, J ALLERGY CLIN IMMUN, V125, pe11; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Linehan LA, 1998, J IMMUNOL, V161, P302; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; MEYERS DA, 1983, AM J MED GENET, V16, P575, DOI 10.1002/ajmg.1320160414; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nejentsev S, 2007, NATURE, V450, P887, DOI 10.1038/nature06406; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Parapanissiou E, 2005, TISSUE ANTIGENS, V65, P481, DOI 10.1111/j.1399-0039.2005.00392.x; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902; Shao CC, 2004, J HUM GENET, V49, P115, DOI 10.1007/s10038-003-0118-z; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Strachan DP, 2007, INT J EPIDEMIOL, V36, P522, DOI 10.1093/ije/dyl309; Tamura K, 2003, INT ARCH ALLERGY IMM, V131, P33, DOI 10.1159/000070432; TURTON CWG, 1979, THORAX, V34, P670, DOI 10.1136/thx.34.5.670; Vergara C, 2008, AM J RESP CRIT CARE, V178, P1017, DOI 10.1164/rccm.200801-182OC; Weidinger S, 2004, J MED GENET, V41, P658, DOI 10.1136/jmg.2004.020263; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Wichmann HE, 2005, GESUNDHEITSWESEN, V67, pS26, DOI 10.1055/s-2005-858226; Woszczek G, 2002, EUR RESPIR J, V20, P79, DOI 10.1183/09031936.02.01002001; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Yunginger JW, 2000, J ALLERGY CLIN IMMUN, V105, P1077, DOI 10.1067/mai.2000.107041	38	120	124	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					840	U371		10.1016/j.jaci.2011.09.029	http://dx.doi.org/10.1016/j.jaci.2011.09.029			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22075330	Green Accepted, Green Published			2022-12-18	WOS:000301189300033
J	Roduit, C; Wohlgensinger, J; Frei, R; Bitter, S; Bieli, C; Loeliger, S; Buchele, G; Riedler, J; Dalphin, JC; Remes, S; Roponen, M; Pekkanen, J; Kabesch, M; Schaub, B; von Mutius, E; Braun-Fahrlander, C; Lauener, R				Roduit, Caroline; Wohlgensinger, Johanna; Frei, Remo; Bitter, Sondhja; Bieli, Christian; Loeliger, Susanne; Buechele, Gisela; Riedler, Josef; Dalphin, Jean-Charles; Remes, Sami; Roponen, Marjut; Pekkanen, Juha; Kabesch, Michael; Schaub, Bianca; von Mutius, Erika; Braun-Fahrlaender, Charlotte; Lauener, Roger		PASTURE Study Grp	Prenatal animal contact and gene expression of innate immunity receptors at birth are associated with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Prenatal; farm animal; Toll-like receptors; atopic dermatitis; gene-environment interaction	TOLL-LIKE RECEPTOR-2; SCHOOL-AGE-CHILDREN; HAY-FEVER; ALLERGIC SENSITIZATION; FARMING ENVIRONMENTS; ASTHMA; EXPOSURE; FARMERS; ECZEMA; PROTECT	Background: Cross-sectional studies have suggested that prenatal farm exposures might protect against allergic disease and increase the expression of receptors of the innate immune system. However, epidemiologic evidence supporting the association with atopic dermatitis remains inconsistent. Objective: To study the association between prenatal farm-related exposures and atopic dermatitis in a prospective study. We further analyzed the association between the expression of innate immune genes at birth and atopic dermatitis. Methods: A total of 1063 children who participated in a birth cohort study, Protection against Allergy-Study in Rural Environments, were included in this study. Doctor diagnosis of atopic dermatitis was reported by the parents from 1 to 2 years of age by questionnaire. Gene expression of Toll-like receptors (TLRs) and CD14 was assessed in cord blood leukocytes by quantitative PCR. Results: Maternal contact with farm animals and cats during pregnancy had a significantly protective effect on atopic dermatitis in the first 2 years of life. The risk of atopic dermatitis was reduced by more than half among children with mothers having contact with 3 or more farm animal species during pregnancy compared with children with mothers without contact (adjusted odds ratio, 0.43; 95% CI, 0.19-0.97). Elevated expression of TLR5 and TLR9 in cord blood was associated with decreased doctor diagnosis of atopic dermatitis. A significant interaction between polymorphism in TLR2 and prenatal cat exposure was observed in atopic dermatitis. Conclusion: Maternal contact with farm animals and cats during pregnancy has a protective effect on the development of atopic dermatitis in early life, which is associated with a lower expression of innate immune receptors at birth. (J Allergy Clin Immunol 2011;127:179-85.)	[Roduit, Caroline; Wohlgensinger, Johanna; Frei, Remo; Bieli, Christian; Loeliger, Susanne; Lauener, Roger] Univ Zurich, Childrens Hosp, CH-8006 Zurich, Switzerland; [Roduit, Caroline; Wohlgensinger, Johanna; Frei, Remo; Bieli, Christian; Loeliger, Susanne; Lauener, Roger] Christine Kuhne Ctr Allergy Res & Educ, Zurich, Switzerland; [Bitter, Sondhja; Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Bitter, Sondhja; Braun-Fahrlaender, Charlotte] Univ Basel, CH-4003 Basel, Switzerland; [Lauener, Roger] Childrens Allergy & Asthma Hosp, Hochgebirgsklin, Davos, Switzerland; [Lauener, Roger] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Buechele, Gisela] Univ Ulm, Inst Epidemiol, D-89069 Ulm, Germany; [Riedler, Josef] Childrens Hosp Schwarzach, Schwarzach, Austria; [Dalphin, Jean-Charles] Univ Hosp Besancon, Dept Resp Dis, Besancon, France; [Remes, Sami] Kuopio Univ Hosp, Dept Pediat, Kuopio, Finland; [Roponen, Marjut; Pekkanen, Juha] Natl Inst Hlth & Welf, Dept Environm Hlth, Kuopio, Finland; [Kabesch, Michael] Hannover Med Sch, Ctr Pediat, Clin Paediat Pneumol & Neonatol, Hannover, Germany; [Schaub, Bianca; von Mutius, Erika] Univ Childrens Hosp Munich, Munich, Germany	University Children's Hospital Zurich; University of Zurich; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Ulm University; Universite de Franche-Comte; CHU Besancon; Kuopio University Hospital; University of Eastern Finland; Finland National Institute for Health & Welfare; Hannover Medical School; University of Munich	Roduit, C (corresponding author), Kinderspital Zurich, Steinwiesstr 75, CH-8032 Zurich, Switzerland.	Caroline.Roduit@kispi.uzh.ch	Frei, Remo/AAI-9180-2020; Schaub, Bianca/B-9935-2019; Genuneit, Jon/I-9323-2012; Kabesch, Michael/GZM-1583-2022; Kabesch, Michael/AAB-5701-2020; Huttunen, Kati/D-8755-2012; Roduit, Caroline/S-4928-2017; Lauener, Roger P/O-8612-2016; Roponen, Marjut/C-2086-2017; riedler, josef/AAQ-4666-2020; Bieli, Christian/F-7209-2014	Schaub, Bianca/0000-0003-1652-8873; Genuneit, Jon/0000-0001-5764-1528; Huttunen, Kati/0000-0002-4888-9203; Lauener, Roger P/0000-0002-8412-606X; Roponen, Marjut/0000-0002-4442-9090; Gehring, Ulrike/0000-0003-3612-5780; Virtanen, Suvi/0000-0001-8928-0878; piarroux, renaud/0000-0002-4151-4134; Bieli, Christian/0000-0002-2128-6082; Reboux, Gabriel/0000-0002-7923-0858; Roduit, Caroline/0000-0002-5988-0570; von Mutius, Erika/0000-0002-8893-4515	European Union [QRLT4-CT 2001-00250, KBBE-2-2-06]; Kuhne-Foundation; European Union; Academy of Finland; TEKES; Farmers' Social Insurance Institution; EVO; Juho Vainio Foundation; Deutsche Forschungsgemeinschaft; Bundesministerium fur Bildung und Forschung; Airsonett AB; Kuhne Foundation	European Union(European Commission); Kuhne-Foundation; European Union(European Commission); Academy of Finland(Academy of Finland); TEKES(Finnish Funding Agency for Technology & Innovation (TEKES)); Farmers' Social Insurance Institution; EVO; Juho Vainio Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Airsonett AB(HOGANAS ABStatisticon AB); Kuhne Foundation	Supported by European Union research grants PASTURE/EFRAIM (QRLT4-CT 2001-00250, KBBE-2-2-06) and the Kuhne-Foundation.; J. Pekkanen has received research support from the European Union, Academy of Finland, TEKES, Farmers' Social Insurance Institution, EVO, and the Juho Vainio Foundation. M. Kabesch has received reimbursement for speaker activities from Roxall, Glaxo Wellcome, Novartis, and Allergopharma; has served on the scientific advisory board for Sanofi Aventis; and has received research support from Deutsche Forschungsgemeinschaft, Bundesministerium fur Bildung und Forschung, and the European Union. E. von Mutius has served as a consultant for GSK, UCB, Protectimmune, and Novartis and has received research support from Airsonett AB. R. Lauener has received research support from the European Union and the Kuhne Foundation. The rest of the authors have declared that they have no conflict of interest.	Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bieli C, 2008, ALLERGY, V63, P1633, DOI 10.1111/j.1398-9995.2008.01744.x; Bottcher MF, 2004, J ALLERGY CLIN IMMUN, V114, P561, DOI 10.1016/j.jaci.2004.04.050; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Douwes J, 2008, EUR RESPIR J, V32, P603, DOI 10.1183/09031936.00033707; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Fohr C, 2005, BRIT J DERMATOL, V152, P202, DOI [10.1111/J.1365-2133.2005.06436.X, 10.1111/j.1365-2133.2004.06436.x]; Gibbs S, 2004, INT J EPIDEMIOL, V33, P199, DOI 10.1093/ije/dyg267; Halkjaer LB, 2006, ARCH DERMATOL, V142, P561, DOI 10.1001/archderm.142.5.561; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Kormann MSD, 2008, J ALLERGY CLIN IMMUN, V122, P86, DOI 10.1016/j.jaci.2008.04.039; Kormann MS, 2008, J ALLERGY CLIN IMMUN, V122, pe1; Kormann MSD, 2005, AM J RESP CRIT CARE, V171, P1358, DOI 10.1164/rccm.200410-1312OC; Krauss-Etschmann S, 2006, CLIN IMMUNOL, V118, P292, DOI 10.1016/j.clim.2005.10.003; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; LUOMA R, 1983, ALLERGY, V38, P339, DOI 10.1111/j.1398-9995.1983.tb04128.x; Martin-Orozco E, 1999, INT IMMUNOL, V11, P1111, DOI 10.1093/intimm/11.7.1111; Novak N, 2007, ALLERGY, V62, P766, DOI 10.1111/j.1398-9995.2007.01358.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Smit LAM, 2009, AM J RESP CRIT CARE, V179, P363, DOI 10.1164/rccm.200810-1533OC; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Vicente-Suarez I, 2009, IMMUNOL LETT, V125, P114, DOI 10.1016/j.imlet.2009.06.007; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648	36	120	125	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					179	U281		10.1016/j.jaci.2010.10.010	http://dx.doi.org/10.1016/j.jaci.2010.10.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21112617				2022-12-18	WOS:000285917300026
J	Vu, AT; Baba, T; Chen, X; Le, TA; Kinoshita, H; Xie, Y; Kamijo, S; Hiramatsu, K; Ikeda, S; Ogawa, H; Okumura, K; Takai, T				Vu, Anh Tuan; Baba, Tadashi; Chen, Xue; Le, Tuan Anh; Kinoshita, Hirokazu; Xie, Yang; Kamijo, Seiji; Hiramatsu, Keiichi; Ikeda, Shigaku; Ogawa, Hideoki; Okumura, Ko; Takai, Toshiro			Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; keratinocyte; diacylated lipopeptide; Staphylococcus aureus; Toll-like receptor 2; Toll-like receptor 6; cytokine milieu; atopic dermatitis; vicious cycle	HUMAN EPITHELIAL-CELLS; ATOPIC-DERMATITIS; CUTTING EDGE; SKIN; EXPRESSION; INFLAMMATION; POLYMORPHISM; LIPOPROTEIN; FILAGGRIN; TLR2	Background: Staphylococcus aureus heavily colonizes the lesions of patients with atopic dermatitis (AD) and is known to trigger a worsening of AD. However, the exact mechanism by which S aureus promotes AD is unknown. Thymic stromal lymphopoietin (TSLP), which is highly expressed by keratinocytes in skin lesions of patients with AD and bronchial epithelial cells in asthmatic patients, represents a critical factor linking responses at interfaces between the body and the environment to allergic type 2 immune responses. Objectives: We sought to examine the ability of synthetic lipopeptides and S aureus to induce TSLP expression in human keratinocytes and identify the pathway of induction. Methods: We stimulated primary human keratinocytes with lipopeptides and S aureus-derived materials. The release and gene expression of TSLP were measured by means of ELISA and quantitative PCR, respectively. Results: Diacylated lipopeptide upregulated the expression of TSLP and other proinflammatory molecules. Heat-killed S aureus and the subcellular fractions of S aureus induced TSLP's release, with the membranous fraction having the greatest activity. Small interfering RNA-mediated knockdown of either Toll-like receptor (TLR) 2 or TLR6 inhibited the diacylated lipopeptide- and S aureus membrane-induced TSLP gene expression. S aureus membrane- and diacylated lipopeptide-induced release of TSLP was enhanced by T(H)2/TNF-alpha cytokines and partially suppressed by IFN-gamma and TGF-beta. Conclusions: The results suggest that ligands for the TLR2-TLR6 heterodimer in S aureus membranes, including diacylated lipoproteins, could promote T(H)2-type inflammation through TSLP production in keratinocytes, providing an overall picture of the vicious cycles between colonization by S aureus and AD in the T(H)2-skewed sensitization process, exacerbation of the disease, or both. (J Allergy Clin Immunol 2010;126:985-93.)	[Takai, Toshiro] Juntendo Univ, Grad Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan; [Vu, Anh Tuan; Le, Tuan Anh; Kinoshita, Hirokazu; Ikeda, Shigaku] Juntendo Univ, Grad Sch Med, Dept Dermatol & Allergol, Tokyo 1138421, Japan; [Baba, Tadashi; Hiramatsu, Keiichi] Juntendo Univ, Grad Sch Med, Dept Microbiol & Infect Control Sci, Tokyo 1138421, Japan; [Vu, Anh Tuan] Quyhoa Natl Leprosy Dermatol Hosp, Quynhon, Vietnam; [Chen, Xue] Peking Univ, Peoples Hosp, Dept Dermatol, Beijing 100871, Peoples R China; [Le, Tuan Anh] Inst Clin Med & Pharmaceut Sci 108, Dept Dermatol & Allergol, Hanoi, Vietnam	Juntendo University; Juntendo University; Juntendo University; Peking University	Takai, T (corresponding author), Juntendo Univ, Grad Sch Med, Atopy Allergy Res Ctr, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	t-takai@juntendo.ac.jp	Takai, Toshiro/K-5690-2013	Takai, Toshiro/0000-0001-8363-0355	Ministry of Education, Culture, Sports, Science and Technology, Japan	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to T. T.).	Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; ALY R, 1977, ARCH DERMATOL, V113, P780, DOI 10.1001/archderm.113.6.780; Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5; Baba T, 1996, EMBO J, V15, P4789, DOI 10.1002/j.1460-2075.1996.tb00859.x; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Cho JS, 2010, J CLIN INVEST, V120, P1762, DOI 10.1172/JCI40891; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; Fournier B, 2005, CLIN MICROBIOL REV, V18, P521, DOI 10.1128/CMR.18.3.521-540.2005; Gong JQ, 2006, BRIT J DERMATOL, V155, P680, DOI 10.1111/j.1365-2133.2006.07410.x; Hashimoto M, 2006, J IMMUNOL, V177, P3162, DOI 10.4049/jimmunol.177.5.3162; Hirasawa Y, 2010, J INVEST DERMATOL, V130, P614, DOI 10.1038/jid.2009.257; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008; Kang JY, 2009, IMMUNITY, V31, P873, DOI 10.1016/j.immuni.2009.09.018; Kinoshita H, 2009, J ALLERGY CLIN IMMUN, V123, P179, DOI 10.1016/j.jaci.2008.10.008; Kisich KO, 2008, J ALLERGY CLIN IMMUN, V122, P62, DOI 10.1016/j.jaci.2008.04.022; Koga C, 2008, J INVEST DERMATOL, V128, pS12; Kollisch G, 2005, IMMUNOLOGY, V114, P531, DOI 10.1111/j.1365-2567.2005.02122.x; Kolls JK, 2008, NAT REV IMMUNOL, V8, P829, DOI 10.1038/nri2433; Kurokawa K, 2009, J BIOL CHEM, V284, P8406, DOI 10.1074/jbc.M809618200; Le TA, 2009, ALLERGY, V64, P1231, DOI 10.1111/j.1398-9995.2009.02032.x; Le TA, 2010, INT ARCH ALLERGY IMM, V153, P27, DOI 10.1159/000301576; Leung AD, 2008, CLIN EXP ALLERGY, V38, P789, DOI 10.1111/j.1365-2222.2008.02964.x; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEYDEN JJ, 1977, BRIT J DERMATOL, V96, P179, DOI 10.1111/j.1365-2133.1977.tb12541.x; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Mrabet-Dahbi S, 2008, J ALLERGY CLIN IMMUN, V121, P1013, DOI 10.1016/j.jaci.2007.11.029; Niebuhr M, 2008, ALLERGY, V63, P728, DOI 10.1111/j.1398-9995.2008.01721.x; Oh DY, 2009, ALLERGY, V64, P1608, DOI 10.1111/j.1398-9995.2009.02066.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; Schenk M, 2009, IMMUNITY, V31, P847, DOI 10.1016/j.immuni.2009.11.008; Shibata K, 2000, J IMMUNOL, V165, P6538, DOI 10.4049/jimmunol.165.11.6538; Simon D, 2009, ALLERGY, V64, P1681, DOI 10.1111/j.1398-9995.2009.02097.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Takai T, 2009, J ALLERGY CLIN IMMUN, V124, P864, DOI 10.1016/j.jaci.2009.07.029; Tawaratsumida K, 2009, J BIOL CHEM, V284, P9147, DOI 10.1074/jbc.M900429200; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Travers JB, 2010, J ALLERGY CLIN IMMUN, V125, P146, DOI 10.1016/j.jaci.2009.09.052; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; Wong CK, 2010, AM J RESP CELL MOL, V43, P305, DOI 10.1165/rcmb.2009-0168OC; Wu WH, 2010, J ALLERGY CLIN IMMUN, V126, P290, DOI 10.1016/j.jaci.2010.05.024; Zahringer U, 2008, IMMUNOBIOLOGY, V213, P205, DOI 10.1016/j.imbio.2008.02.005	47	120	124	3	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					985	U145		10.1016/j.jaci.2010.09.002	http://dx.doi.org/10.1016/j.jaci.2010.09.002			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	21050945				2022-12-18	WOS:000283727100014
J	Whiteside, TL				Whiteside, Theresa L.			Immune responses to malignancies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cancer; immunity; tumor escape; immune suppression; effector T cells	SQUAMOUS-CELL CARCINOMA; REGULATORY T-CELLS; MYELOID SUPPRESSOR-CELLS; ZETA-CHAIN EXPRESSION; TUMOR MICROENVIRONMENT; PERIPHERAL-CIRCULATION; COLORECTAL-CANCER; DENDRITIC CELLS; TYPE-1 CELLS; HEAD	Immune responses to tumor-associated antigens (TAs) are often detectable in tumor-bearing hosts, but they fail to eliminate malignant cells or prevent the development of metastases. Patients with cancer generate robust immune responses to infectious agents (bacteria and viruses) perceived as a "danger signal'' but only ineffective weak responses to TAs, which are considered as "self.'' This fundamental difference in responses to self versus nonself is further magnified by the ability of tumors to subvert the host immune system. Tumors induce dysfunction and apoptosis in CD8(+) antitumor effector cells and promote expansion of regulatory T cells, myeloid-derived suppressor cells, or both, which downregulate antitumor immunity, allowing tumors to escape from the host immune system. The tumor escape is mediated by several distinct molecular mechanisms. Recent insights into these mechanisms encourage expectations that a more effective control of tumor-induced immune dysfunction will be developed in the near future. Novel strategies for immunotherapy of cancer are aimed at the protection and survival of antitumor effector cells and also of central memory T cells in the tumor microenvironment. (J Allergy Clin Immunol 2010;125:S272-83.)	[Whiteside, Theresa L.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; [Whiteside, Theresa L.] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA; [Whiteside, Theresa L.] Univ Pittsburgh, Dept Immunol, Sch Med, Pittsburgh, PA 15213 USA; [Whiteside, Theresa L.] Univ Pittsburgh, Dept Otolaryngol, Sch Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Whiteside, TL (corresponding author), Univ Pittsburgh, Inst Canc, 5171 Ctr Ave, Pittsburgh, PA 15213 USA.	whitesidetl@msx.upmc.edu			National Institutes of Health [PO1-CA109688]; NATIONAL CANCER INSTITUTE [P01CA109688] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported in part by National Institutes of Health grant PO1-CA109688 to Theresa L. Whiteside.	Albers AE, 2006, CLIN CANCER RES, V12, P2394, DOI 10.1158/1078-0432.CCR-05-1818; Aller MA, 2004, EXP BIOL MED, V229, P170, DOI 10.1177/153537020422900206; Azuma T, 2008, BLOOD, V111, P3635, DOI 10.1182/blood-2007-11-123141; Bergmann C, 2008, CLIN CANCER RES, V14, P3706, DOI 10.1158/1078-0432.CCR-07-5126; Bergmann C, 2007, CANCER RES, V67, P8865, DOI 10.1158/0008-5472.CAN-07-0767; Blank C, 2007, CANCER IMMUNOL IMMUN, V56, P739, DOI 10.1007/s00262-006-0272-1; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654; Cavallo F, 2006, ADV IMMUNOL, V90, P175, DOI 10.1016/S0065-2776(06)90005-4; Chang CC, 2005, ADV CANCER RES, V93, P189, DOI 10.1016/S0065-230X(05)93006-6; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; Coronella JA, 2002, J IMMUNOL, V169, P1829, DOI 10.4049/jimmunol.169.4.1829; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Diebold SS, 2008, IMMUNOL CELL BIOL, V86, P389, DOI 10.1038/icb.2008.26; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dworacki G, 2001, CLIN CANCER RES, V7, p947S; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Ferris RL, 2006, CLIN CANCER RES, V12, P3890, DOI 10.1158/1078-0432.CCR-05-2750; Ferrone S, 2007, SURG ONCOL CLIN N AM, V16, P755, DOI 10.1016/j.soc.2007.08.004; Filipazzi P, 2007, J CLIN ONCOL, V25, P2546, DOI 10.1200/JCO.2006.08.5829; Finke JH, 2001, CLIN CANCER RES, V7, p940S; Finn OJ, 2009, TUMOR ASS ANTIGENS I, P23; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2007, CANCER RES, V67, P1883, DOI 10.1158/0008-5472.CAN-06-4806; GERSHON RK, 1975, TRANSPLANT REV-DENMA, V26, P170; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Hansson M, 1996, J IMMUNOL, V156, P42; Hirano F, 2005, CANCER RES, V65, P1089; Hoffmann TK, 2002, CLIN CANCER RES, V8, P2553; Hoffmann TK, 2002, CANCER RES, V62, P3521; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; Jager E, 2006, P NATL ACAD SCI USA, V103, P14453, DOI 10.1073/pnas.0606512103; June CH, 2007, J CLIN INVEST, V117, P1466, DOI 10.1172/JCI32446; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kelly JM, 2002, NAT IMMUNOL, V3, P83, DOI 10.1038/ni746; Kim JW, 2005, CLIN CANCER RES, V11, P7901, DOI 10.1158/1078-0432.CCR-05-1346; Kim JW, 2004, CLIN CANCER RES, V10, P5101, DOI 10.1158/1078-0432.CCR-04-0309; KORNSTEIN MJ, 1983, CANCER RES, V43, P2749; Kryczek I, 2009, BLOOD, V114, P1141, DOI 10.1182/blood-2009-03-208249; Kuss I, 1999, CLIN CANCER RES, V5, P329; Kuss I, 2005, CLIN IMMUNOL, V116, P27, DOI 10.1016/j.clim.2004.12.011; Lanier LL, 2003, CURR OPIN IMMUNOL, V15, P308, DOI 10.1016/S0952-7915(03)00039-6; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Leek RD, 1996, CANCER RES, V56, P4625; Lollini Pier-Luigi, 2005, Future Oncol, V1, P57, DOI 10.1517/14796694.1.1.57; Mandapathil M, 2009, CLIN CANCER RES, V15, P6348, DOI 10.1158/1078-0432.CCR-09-1143; Martin-Orozco N, 2009, CURR OPIN INVEST DR, V10, P543; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; MURPHY GF, 1993, J INVEST DERMATOL, V100, pS335, DOI 10.1038/jid.1993.59; Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078-0432.CCR-06-2197; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pannellini Tania, 2004, Breast Dis, V20, P33; Parmiani G, 2007, J IMMUNOL, V178, P1975, DOI 10.4049/jimmunol.178.4.1975; Pittet MJ, 2001, CLIN CANCER RES, V7, p796S; Provinciali M, 2009, CANCER IMMUNOL IMMUN, V58, P1959, DOI 10.1007/s00262-009-0665-z; Reichert TE, 2001, CANCER, V91, P2136, DOI 10.1002/1097-0142(20010601)91:11<2136::AID-CNCR1242>3.0.CO;2-Q; Reichert TE, 1998, J IMMUNOTHER, V21, P295, DOI 10.1097/00002371-199807000-00007; Reichert TE, 2002, CLIN CANCER RES, V8, P3137; Romero P, 2006, ADV IMMUNOL, V92, P187, DOI 10.1016/S0065-2776(06)92005-7; Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005; Shurin GV, 2001, CANCER RES, V61, P363; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Smyth MJ, 2000, NAT IMMUNOL, V1, P459, DOI 10.1038/82698; Stickel JS, 2009, CANCER IMMUNOL IMMUN, V58, P1407, DOI 10.1007/s00262-008-0655-6; Strauss L, 2007, CLIN CANCER RES, V13, P4345, DOI 10.1158/1078-0432.CCR-07-0472; Szczepanski MJ, 2009, CANCER RES, V69, P3105, DOI 10.1158/0008-5472.CAN-08-3838; Uematsu S, 2006, J MOL MED-JMM, V84, P712, DOI 10.1007/s00109-006-0084-y; Uzzo RG, 1999, J NATL CANCER I, V91, P718, DOI 10.1093/jnci/91.8.718; VONKLEIST S, 1987, INT J CANCER, V40, P18, DOI 10.1002/ijc.2910400105; Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106; Vujanovic NL, 1996, J IMMUNOL, V157, P1117; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wang WS, 2009, INT IMMUNOL, V21, P1065, DOI 10.1093/intimm/dxp072; Whitehead A L, 1908, Proc R Soc Med, V1, P34; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Whiteside T. L., 1993, TUMOR INFILTRATING L; Whiteside Theresa L., 2007, P145, DOI 10.1007/978-1-4020-6087-8_7; Whiteside TL, 2007, IMMUNOL INVEST, V36, P25, DOI 10.1080/08820130600991893; Whiteside TL, 1998, CURR TOP MICROBIOL, V230, P221; Whiteside TL, 2002, SEMIN CANCER BIOL, V12, P43, DOI 10.1006/scbi.2001.0402; Whiteside TL, 2006, SEMIN CANCER BIOL, V16, P3, DOI 10.1016/j.semcancer.2005.07.008; Whiteside TL, 2002, VACCINE, V20, pA46, DOI 10.1016/S0264-410X(02)00387-0; WHITESIDE TL, 2006, EXPERT REV CLIN IMMU, V1, P369; Woo EY, 2001, CANCER RES, V61, P4766; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	96	120	126	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S272	S283		10.1016/j.jaci.2009.09.045	http://dx.doi.org/10.1016/j.jaci.2009.09.045			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20061007	Green Accepted			2022-12-18	WOS:000280170600025
J	Straumann, A; Bussmann, C; Conus, S; Beglinger, C; Simon, HU				Straumann, Alex; Bussmann, Christian; Conus, Sebastien; Beglinger, Christoph; Simon, Hans-Uwe			Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NECROSIS-FACTOR-ALPHA; CHIMERIC MONOCLONAL-ANTIBODY; CA2		[Straumann, Alex] Kantonsspital, Dept Gastroenterol, Olten, Switzerland; [Bussmann, Christian] Inst Clin Pathol Viollier, Basel, Switzerland; [Conus, Sebastien; Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Beglinger, Christoph] Univ Basel Hosp, Dept Gastroenterol, CH-4031 Basel, Switzerland	Kantonsspital Aarau AG (KSA); Kantonsspital Olten; University of Bern; University of Basel	Straumann, A (corresponding author), Kantonsspital, Dept Gastroenterol, Olten, Switzerland.	alex.straumann@hin.ch	Simon, Hans-Uwe/AAU-5079-2020; Simon, Hans-Uwe/AAU-7410-2020; Beglinger, Christoph/D-2247-2010; Yousefi, Shida/L-9689-2016	Simon, Hans-Uwe/0000-0002-9404-7736; Yousefi, Shida/0000-0002-9855-4305				Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Erin EM, 2006, AM J RESP CRIT CARE, V174, P753, DOI 10.1164/rccm.200601-072OC; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502	9	120	126	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					425	427		10.1016/j.jaci.2008.06.012	http://dx.doi.org/10.1016/j.jaci.2008.06.012			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18678345	Bronze			2022-12-18	WOS:000258426300038
J	Foley, SC; Mogas, AK; Olivenstein, R; Fiset, PO; Chakir, J; Bourbeau, J; Ernst, P; Lemiere, C; Martin, JG; Hamid, Q				Foley, Susan C.; Mogas, Andrea K.; Olivenstein, Ron; Fiset, Pierre O.; Chakir, Jamila; Bourbeau, Jean; Ernst, Pierre; Lemiere, Catherine; Martin, James G.; Hamid, Qutayba			Increased expression of ADAM33 and ADAM8 with disease progression in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADAM8; ADAM33; asthma severity; bronchial biopsies; immunohistochemistry; mRNA	BRONCHIAL HYPERRESPONSIVENESS; GENE; POLYMORPHISMS; DISINTEGRIN; ASSOCIATION; PROTEINS; FAMILY; CELL; IDENTIFICATION; MEMBRANE	Background: ADAM33, a disintegrin and metalloproteinase 33 gene, has been identified as a risk factor for asthma and bronchial hyperresponsiveness and has been postulated as a gene for airway remodeling. ADAM8 is strongly induced by allergens and T(H)2 cytokines; in the lung in experimental asthma. Objectives: To assess the importance of these genes in asthma pathogenesis and to investigate whether expression relates to disease severity or deterioration in lung function, we measured the mRNA and protein expression of both genes in bronchial biopsies of subjects with asthma and control subjects. Methods: RNA was extracted from frozen endobronchial biopsies of mild. moderate, and severe adults with asthma and controls. Subjects with moderate and severe asthma were taking corticosteroids. The mRNA transcript of both genes was measured by real time RT-PCR using specific primers. Protein expression was examined by immunohistochemistry on paraffin sections. Results: ADAM33 mRNA expression was significantly higher in both moderate and severe asthma compared with mild asthma (P <.05) and controls. Immunostaining for ADAM33 was increased in the epithelium, submucosal cells, and smooth muscle in severe asthma compared with mild disease and controls. ADAM8 mRNA expression was significantly increased in all asthma groups compared with controls. Increased inflammatory cells stained positive for ADAM8 in both moderate (P <.05) and severe asthma (P <.005) compared with mild disease. Conclusions: These results demonstrate increased expression of both ADAM genes as asthma severity increases. Clinical implications: These genes may contribute to the remodeling process that occurs with asthma progression and may have implications for future treatment in severe disease.	McGill Univ, Meakins Christie Labs, Montreal Chest Inst, Montreal, PQ H2X 2P2, Canada; McGill Univ, Div Resp, Ctr Hlth, Montreal, PQ H2X 2P2, Canada; Hop Sacre Coeur, Div Resp, Montreal, PQ H4J 1C5, Canada; Hop Laval, Ctr Rech, Ste Foy, PQ, Canada	McGill University; McGill University; Universite de Montreal; Laval University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, Montreal Chest Inst, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca		Martin, James/0000-0001-7574-5363				Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Chae SC, 2003, J HUM GENET, V48, P278, DOI 10.1007/s10038-003-0019-1; Chiappara G, 2001, CURR OPIN ALLERGY CL, V1, P85, DOI 10.1097/00130832-200102000-00015; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Fourie AM, 2003, J BIOL CHEM, V278, P30469, DOI 10.1074/jbc.M213157200; GIAID A, 1993, LANCET, V341, P1550; Goulet F, 1996, AM J RESP CELL MOL, V15, P312, DOI 10.1165/ajrcmb.15.3.8810634; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; Higuchi Yasunori, 1996, Tissue Antigens, V48, P423; Holgate ST, 2006, PULM PHARMACOL THER, V19, P3, DOI 10.1016/j.pupt.2005.02.008; Howard TD, 2003, J ALLERGY CLIN IMMUN, V112, P717, DOI 10.1016/S0091-6749(03)01939-0; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; King NE, 2004, AM J RESP CELL MOL, V31, P257, DOI 10.1165/rcmb.2004-0026OC; KLINKE DJ, 2001, AM J RESP CRIT CARE, V163, pA832; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Lee JH, 2004, CLIN EXP ALLERGY, V34, P860, DOI 10.1111/j.1365-2222.2004.01977.x; Lee JY, 2006, AM J RESP CRIT CARE, V173, P729, DOI 10.1164/rccm.200409-1175OC; Noguchi E, 2006, CLIN EXP ALLERGY, V36, P602, DOI 10.1111/j.1365-2222.2006.02471.x; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Powell RM, 2004, AM J RESP CELL MOL, V31, P13, DOI 10.1165/rcmb.2003-0330OC; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Schlomann U, 2000, J NEUROSCI, V20, P7964; Shapiro SD, 2002, NEW ENGL J MED, V347, P936, DOI 10.1056/NEJMcibr022144; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Umland SP, 2004, AM J RESP CELL MOL, V30, P530, DOI 10.1165/rcmb.2003-0220OC; Umland SP, 2003, AM J RESP CELL MOL, V29, P571, DOI 10.1165/rcmb.2003-0028OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Werner M, 2004, CLIN EXP ALLERGY, V34, P26, DOI 10.1111/j.1365-2222.2004.01846.x; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6; Yoshiyama K, 1997, GENOMICS, V41, P56, DOI 10.1006/geno.1997.4607; 1987, AM REV RESP DIS, V136, P225	35	120	131	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					863	871		10.1016/j.jaci.2006.12.665	http://dx.doi.org/10.1016/j.jaci.2006.12.665			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17339047	Bronze			2022-12-18	WOS:000245729500014
J	Zambelli-Weiner, A; Ehrlich, E; Stockton, ML; Grant, AV; Zhang, S; Levett, PN; Beaty, TH; Barnes, KC				Zambelli-Weiner, A; Ehrlich, E; Stockton, ML; Grant, AV; Zhang, S; Levett, PN; Beaty, TH; Barnes, KC			Evaluation of the CD14/-260 polymorphism and house dust endotoxin exposure in the Barbados Asthma Genetics Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD14; endotoxin; LPS; asthma; allergy; atopy; asthma severity; IgE; genetics; gene-environment interaction	CIRCULATING SOLUBLE CD14; INNATE IMMUNITY; VITAL CAPACITY; ASSOCIATION; TESTS	Background: Both a functional promoter polymorphism in the gene encoding CD14 (C-260T) and exposure to endotoxin are believed to play key roles in modulating the immune response and expression of atopic disease. Objective: We aimed to evaluate the role of the CD14 C-260T polymorphism in a population of African descent and to test for interaction between this genotype and house dust endotoxin (HDE) exposure on atopic phenotypes. Methods: Asthmatic probands and their families were recruited as part of the Barbados Asthma Genetics Study. The C-260T polymorphism and two additional CD14 promoter markers (G-1461T, C-1721T) were genotyped. Endotoxin was measured in house dust samples. Results: Using a Family-Based Association Test, the C-260T allele appeared to be protective against asthma (z = -2.444; P = .015) and asthma severity (z = -2.615; P = .009) under a recessive model. No significant associations were observed for the G-1461T and C-1721T markers both individually and in haplotypes. In a case-control analysis, the CD14 TT genotype was found to reduce risk of asthma compared with the CD 14 CC/CT genotypes (odds ratio [OR], 0.26; 95% CI, 0.14-0.49) and was associated with lower asthma severity scores (P < .002). The TT genotype might protect against asthma for individuals with low HDE (OR, 0.09; 95% CI, 0.03-0.24), but may be a risk factor for individuals with high HDE (OR, 11.66; 95% CI, 1.03-131.7), suggesting a gene-environment interaction. Conclusion: These data suggest that the CD14-260 polymorphism may play a role in controlling risk to atopic disease and underscore the importance of incorporating key environmental exposures into studies of genetic risk factors.	Johns Hopkins Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Univ W Indies, Fac Med, Sch Clin Med & Res, Bridgetown, Barbados	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University West Indies Mona Jamaica; University of the West Indies Open Campus	Barnes, KC (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 3A-62A,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	kbarnes@jhmi.edu			NIAID NIH HHS [AI 20059] Funding Source: Medline; NIEHS NIH HHS [T32 ES 07141] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007141] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akashi S, 2000, BIOCHEM BIOPH RES CO, V268, P172, DOI 10.1006/bbrc.2000.2089; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Barnes KC, 1999, J ALLERGY CLIN IMMUN, V104, P791, DOI 10.1016/S0091-6749(99)70289-7; Barnes KC, 1997, J MED ENTOMOL, V34, P212, DOI 10.1093/jmedent/34.2.212; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Chun DTW, 2002, ANN AGR ENV MED, V9, P49; GAENSLER EA, 1951, AM REV TUBERC PULM, V64, P256; Gao PS, 1999, CLIN GENET, V56, P164; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; Heinzmann A, 2003, EUR J IMMUNOGENET, V30, P345, DOI 10.1046/j.1365-2370.2003.00414.x; Horvath S, 2001, GENET EPIDEMIOL, V21, pS403; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; KORY RC, 1961, AM J MED, V30, P243, DOI 10.1016/0002-9343(61)90096-1; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; LANDMANN R, 1995, J INFECT DIS, V171, P639, DOI 10.1093/infdis/171.3.639; LEUALLEN EC, 1955, AM REV TUBERC PULM, V72, P783; LEWONTIN RC, 1988, GENETICS, V120, P849; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352, DOI 10.1164/ajrccm/146.2.352; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; Michel O, 2000, TOXICOLOGY, V152, P25, DOI 10.1016/S0300-483X(00)00288-2; MILLER WF, 1959, J APPL PHYSIOL, V14, P157, DOI 10.1152/jappl.1959.14.2.157; Nickel RG, 1999, HUM IMMUNOL, V60, P738, DOI 10.1016/S0198-8859(99)00039-7; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; PEMBERTON J, 1956, J APPL PHYSIOL, V9, P291, DOI 10.1152/jappl.1956.9.2.291; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; RIZZO MC, 1999, ACI INT, V11, P153; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981, DOI 10.1164/ajrccm/140.4.981; RYLANDER R, 1997, INT J OCCUP ENV HL S, V3, P32; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; *STAT, 2003, STAT STAT SOFTW REL; Togias A, 1997, INT ARCH ALLERGY IMM, V113, P87, DOI 10.1159/000237515; Vercelli D, 2001, J ENDOTOXIN RES, V7, P45, DOI 10.1179/096805101101532521; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634	39	120	122	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1203	1209		10.1016/j.jaci.2005.03.001	http://dx.doi.org/10.1016/j.jaci.2005.03.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940135				2022-12-18	WOS:000229815400015
J	Silkoff, PE; Carlson, M; Bourke, T; Katial, R; Ogren, E; Szefler, SJ				Silkoff, PE; Carlson, M; Bourke, T; Katial, R; Ogren, E; Szefler, SJ			The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						exhaled; nitric oxide; asthma; inflammation; monitoring	OBSTRUCTIVE PULMONARY-DISEASE; SINGLE-BREATH MEASUREMENTS; AIRWAY HYPERRESPONSIVENESS; ONLINE MEASUREMENT; HEALTHY-CHILDREN; LUNG-FUNCTION; MILD ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; INHALED CORTICOSTEROIDS; SPUTUM EOSINOPHILS	The Aerocrine exhaled nitric oxide (NO) monitoring system NIOX was cleared by the US Food and Drug Administration for clinical application in patients with asthma in May 2003. The fractional concentration of exhaled NO has been extensively researched as a marker of airway inflammation in asthma and other diseases and is now poised to enter clinical application. The American Thoracic and European Respiratory Societies' current guidelines recommend measurement at constant expiratory flow, which is difficult for some adults and children. The NIOX NO monitoring system was designed to facilitate standardized measurement according to guidelines. A clinical study was performed together with in vitro testing to obtain clearance. Exhaled NO levels were measured in unstable steroid-naive adult and pediatric asthmatic subjects and again after a 2-week treatment with inhaled corticosteroids. Exhaled NO levels decreased highly significantly, with 95% confidence limits for the decrease of -40% to -60% accompanied by clinical improvement. This trial, together with extensive in vitro testing, led to the clearance of NIOX by the US Food and Drug Administration. This article in the journal's "New products" feature section will describe background material regarding exhaled NO, special features of the NIOX NO monitoring system, and how this tool can be incorporated into clinical asthma management.	Natl Jewish Med & Res Ctr, Denver, CO USA; Aerocrine AB, Stockholm, Sweden; Aerocrine Inc, New York, NY USA	National Jewish Health	Silkoff, PE (corresponding author), 224 Spruce Tree Rd, Radnor, PA 19087 USA.	philsilkoff@hotmail.com	silkoff, philip/S-9037-2016	silkoff, philip/0000-0001-6018-5199				Agusti AGN, 1999, EUR RESPIR J, V14, P523, DOI 10.1034/j.1399-3003.1999.14c08.x; ALVING K, 1993, EUR RESPIR J, V6, P1368; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P1284, DOI 10.1164/ajrccm.159.4.9807084; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Baraldi E, 1997, J PEDIATR-US, V131, P381, DOI 10.1016/S0022-3476(97)80062-5; Baraldi E, 1999, PEDIATR PULM, V27, P54, DOI 10.1002/(SICI)1099-0496(199901)27:1<54::AID-PPUL10>3.0.CO;2-V; Baraldi E, 2000, AM J RESP CRIT CARE, V162, P1828, DOI 10.1164/ajrccm.162.5.2002014; Barnes PJ, 1996, THORAX, V51, P233, DOI 10.1136/thx.51.3.233; Bates CA, 2003, J ALLERGY CLIN IMMUN, V111, P256, DOI 10.1067/mai.2003.103; Beck-Ripp J, 2002, EUR RESPIR J, V19, P1015, DOI 10.1183/09031936.02.01582001; Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; Binding N, 2000, EUR RESPIR J, V16, P499, DOI 10.1034/j.1399-3003.2000.016003499.x; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227, DOI 10.1164/ajrccm.160.4.9903004; Bodini A, 2003, MEDIAT INFLAMM, V12, P47, DOI 10.1080/0962935031000096971; Bratton DL, 1999, PEDIATR PULM, V28, P402, DOI 10.1002/(SICI)1099-0496(199912)28:6<402::AID-PPUL3>3.0.CO;2-V; Brett SJ, 1998, AM J RESP CRIT CARE, V157, P993, DOI 10.1164/ajrccm.157.3.9705060; Buchvald F, 2003, ANN ALLERG ASTHMA IM, V91, P309, DOI 10.1016/S1081-1206(10)63536-3; Canady RG, 1999, AM J RESP CRIT CARE, V159, P311, DOI 10.1164/ajrccm.159.1.9803034; Chambers DC, 1998, THORAX, V53, P677, DOI 10.1136/thx.53.8.677; Chatkin JM, 1999, AM J RESP CRIT CARE, V159, P1810, DOI 10.1164/ajrccm.159.6.9809047; Condorelli P, 2004, J APPL PHYSIOL, V96, P1832, DOI 10.1152/japplphysiol.01157.2003; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; Delen FM, 2000, CHEST, V117, P695, DOI 10.1378/chest.117.3.695; Deykin A, 2002, AM J RESP CRIT CARE, V165, P1597, DOI 10.1164/rccm.2201081; Dupont LJ, 1998, AM J RESP CRIT CARE, V157, P894, DOI 10.1164/ajrccm.157.3.9709064; Fischer PH, 2002, INT ARCH OCC ENV HEA, V75, P348, DOI 10.1007/s00420-002-0320-x; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69, DOI 10.1164/ajrccm.159.1.9804134; Franklin PJ, 2003, THORAX, V58, P1048, DOI 10.1136/thorax.58.12.1048; Gabbay E, 2000, AM J RESP CRIT CARE, V162, P2182, DOI 10.1164/ajrccm.162.6.9911072; George SC, 2004, J APPL PHYSIOL, V96, P831, DOI 10.1152/japplphysiol.00950.2003; Grasemann H, 1999, HUM HERED, V49, P139, DOI 10.1159/000022861; Grasemann H, 1997, PEDIATR PULM, V24, P173, DOI 10.1002/(SICI)1099-0496(199709)24:3<173::AID-PPUL2>3.0.CO;2-O; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Guillen JBL, 1998, NATURE, V396, P614, DOI 10.1038/25215; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; Hogman M, 1997, ACTA PHYSIOL SCAND, V159, P345, DOI 10.1046/j.1365-201X.1997.00101.x; Hogman M, 2002, RESP MED, V96, P24, DOI 10.1053/rmed.2001.1204; Hsia CCW, 2002, CHEST, V122, P1774, DOI 10.1378/chest.122.5.1774; Hyde RW, 1997, J APPL PHYSIOL, V82, P1290, DOI 10.1152/jappl.1997.82.4.1290; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; JATAKANON A, EUR RESP J, DOI UNSP 121084-8; Jobsis Q, 2001, THORAX, V56, P285, DOI 10.1136/thorax.56.4.285; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Jouaville LF, 2003, CLIN EXP ALLERGY, V33, P1506, DOI 10.1046/j.1365-2222.2003.01800.x; Kanazawa H, 1998, CLIN EXP ALLERGY, V28, P1244; Karadag B, 1999, EUR RESPIR J, V13, P1402, DOI 10.1034/j.1399-3003.1999.13f28.x; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1889, DOI 10.1164/ajrccm.151.6.7767536; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Kissoon N, 2002, PEDIATR PULM, V33, P283, DOI 10.1002/ppul.10023; KOSHLAND DE, 1992, SCIENCE, V258, P1861, DOI 10.1126/science.1470903; Lehtimaki L, 2002, EUR RESPIR J, V20, P841, DOI 10.1183/09031936.02.00202002; Lehtimaki L, 2001, AM J RESP CRIT CARE, V163, P1557, DOI 10.1164/ajrccm.163.7.2010171; LEONE AM, 1994, BIOCHEM BIOPH RES CO, V201, P883, DOI 10.1006/bbrc.1994.1784; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Liu CY, 1998, BRIT J CANCER, V78, P534, DOI 10.1038/bjc.1998.528; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; Mahut B, 2004, J ALLERGY CLIN IMMUN, V113, P252, DOI 10.1016/j.jaci.2003.10.038; Malmberg LP, 2003, THORAX, V58, P494, DOI 10.1136/thorax.58.6.494; Martinez T, 2003, J APPL PHYSIOL, V94, P2384, DOI 10.1152/japplphysiol.00758.2002; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800, DOI 10.1164/ajrccm.152.2.7633745; Meijer RJ, 1996, EUR RESPIR J, V9, P1111, DOI 10.1183/09031936.96.09051111; Menzel L, 2001, APPL PHYS B-LASERS O, V72, P859, DOI 10.1007/s003400100562; National Institutes of Health, 1997, GUID DIAGN MAN ASTHM; Nogami H, 2003, J ASTHMA, V40, P653, DOI 10.1081/JAS-120019036; PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; Pietropaoli AP, 1999, J APPL PHYSIOL, V87, P1532, DOI 10.1152/jappl.1999.87.4.1532; Reid DW, 2003, RESPIROLOGY, V8, P479, DOI 10.1046/j.1440-1843.2003.00495.x; Robinson JK, 1999, ANAL CHEM, V71, P5131, DOI 10.1021/ac990646d; Shin HW, 2002, AM J RESP CRIT CARE, V165, P349, DOI 10.1164/ajrccm.165.3.2105098; Silkoff PE, 1999, CHEST, V116, P754, DOI 10.1378/chest.116.3.754; Silkoff PE, 1998, J ASTHMA, V35, P473, DOI 10.3109/02770909809071000; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; Silkoff PE, 1998, AM J RESP CRIT CARE, V157, P1822, DOI 10.1164/ajrccm.157.6.9707159; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218, DOI 10.1164/ajrccm.161.4.9903111; Silkoff PE, 1999, AM J RESP CRIT CARE, V159, P940, DOI 10.1164/ajrccm.159.3.9805044; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260, DOI 10.1164/ajrccm.155.1.9001322; Sippel JM, 2000, J ALLERGY CLIN IMMUN, V106, P645, DOI 10.1067/mai.2000.109618; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; Smith O, 1998, NAT MED, V4, P1215, DOI 10.1038/3182; Soderman C, 1997, SCAND J GASTROENTERO, V32, P591, DOI 10.3109/00365529709025105; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; SPRIESTERSBACH R, 1995, J APPL PHYSIOL, V78, P1502, DOI 10.1152/jappl.1995.78.4.1502; Steerenberg PA, 2003, THORAX, V58, P242, DOI 10.1136/thorax.58.3.242; Stirling RG, 1998, THORAX, V53, P1030, DOI 10.1136/thx.53.12.1030; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Tornberg DC, 2003, AM J RESP CRIT CARE, V168, P1210, DOI 10.1164/rccm.200306-784OC; Tsang KW, 2001, LUNG, V179, P83, DOI 10.1007/s004080000050; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653, DOI 10.1152/jappl.1998.85.2.653; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P642, DOI 10.1152/jappl.1998.85.2.642; Van Amsterdam JGC, 1999, ARCH ENVIRON HEALTH, V54, P331, DOI 10.1080/00039899909602496; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953, DOI 10.1164/ajrccm.162.3.9909033; van Rensen ELJ, 1999, THORAX, V54, P403, DOI 10.1136/thx.54.5.403; Wang CH, 1998, EUR RESPIR J, V11, P809, DOI 10.1183/09031936.98.11040809; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801; Yates DH, 1997, EUR RESPIR J, V10, P1483, DOI 10.1183/09031936.97.10071483; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247, DOI 10.1164/ajrccm.154.1.8680689; Yates DH, 1996, EUR RESPIR J, V9, P1130, DOI 10.1183/09031936.96.09061130; Zetterquist W, 1999, EUR RESPIR J, V13, P327, DOI 10.1034/j.1399-3003.1999.13b18.x	107	120	126	1	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1241	1256		10.1016/j.jaci.2004.08.042	http://dx.doi.org/10.1016/j.jaci.2004.08.042			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536442	Bronze			2022-12-18	WOS:000225047800040
J	Higa, S; Hirano, T; Kotani, M; Matsumoto, M; Fujita, A; Suemura, M; Kawase, I; Tanaka, T				Higa, S; Hirano, T; Kotani, M; Matsumoto, M; Fujita, A; Suemura, M; Kawase, I; Tanaka, T			Fisetin, a flavonol, inhibits T(H)2-type cytokine production by activated human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; basophils; cytokines; fisetin; nuclear factor of activated T cells	PERSIMMON LEAF EXTRACT; FC-EPSILON-RI; MAST-CELLS; T-CELLS; NUCLEAR FACTOR; HISTAMINE-RELEASE; PERIPHERAL-BLOOD; IL-4; LINE; EXPRESSION	Background: Activation of mast cells and basophils through allergen stimulation releases chemical mediators and synthesizes cytokines. Among these cytokines, IL-4, IL-13, and IL-5 have major roles in allergic inflammation. Objective: We sought to determine the potency of flavonoids (astragalin, fisetin, kaempferol, myricetin, quercetin, and rutin) for the inhibition of cytokine expression and synthesis by human basophils. Methods: The inhibitory effect of flavonoids on cytokine expression by stimulated KU812 cells, a human basophilic cell line, and freshly purified peripheral blood basophils was measured by means of semiquantitative RT-PCR and ELISA assays. The effects of flavonoids on transcriptional activation of the nuclear factor of activated T cells were assessed by means of electrophoretic mobility shift assays. Results: Fisetin suppressed the induction of IL-4, IL-13, and IL-5 mRNA expression by A23187-stimulated KU812 cells and basophils in response to cross-linkage of the IgE receptor. Fisetin reduced IL-4, IL-13, and IL-5 synthesis (inhibitory concentration of 50% [IC50] = 19.4, 17.7, and 17.4 mumol/L, respectively) but not IL-6 and IL-8 production by KU812 cells. In addition, fisetin inhibited IL-4 and IL-13 synthesis by anti-IgE antibody-stimulated human basophils (IC50 = 5.1 and 6.2 mumol/L, respectively) and IL-4 synthesis by allergen-stimulated basophils from allergic patients (IC50 = 4.8 mumol/L). Among the flavonoids examined, kaempferol and quercetin showed substantial inhibitory activities in cytokine expression but less so than those of fisetin. Fisetin inhibited nuclear localization of nuclear factor of activated T cells c2 by A23187-stimulated KU812 cells. Conclusion: These results provide evidence of a novel activity of the flavonoid fisetin that suppresses the expression of T(H)2-type cytokines (IL-4, IL-13, and IL-5) by basophils.	Osaka Univ, Dept Internal Med 3, Sch Med, Suita, Osaka 5650871, Japan; Sunstar Inc, Ctr Res & Dev, Osaka, Japan; Nissay Hosp, Osaka, Japan	Osaka University	Tanaka, T (corresponding author), Osaka Univ, Dept Internal Med 3, Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Ali H, 2000, J IMMUNOL, V165, P7215, DOI 10.4049/jimmunol.165.12.7215; BISSONNETTE EY, 1995, CLIN EXP IMMUNOL, V102, P78; Brown MA, 1997, CRIT REV IMMUNOL, V17, P1; CASOLARO V, 1993, J IMMUNOL, V151, P5563; Costa JJ, 1997, JAMA-J AM MED ASSOC, V278, P1815, DOI 10.1001/jama.278.22.1815; DEPAULIS A, 1991, J IMMUNOL, V146, P2374; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Escoubet-Lozach L, 2002, J ALLERGY CLIN IMMUN, V110, P553, DOI 10.1067/mai.2002.128076; Falcone FH, 2000, BLOOD, V96, P4028; FEWTRELL CMS, 1977, NATURE, V265, P635, DOI 10.1038/265635a0; Formica JV, 1995, FOOD CHEM TOXICOL, V33, P1061, DOI 10.1016/0278-6915(95)00077-1; Haisch K, 1999, J IMMUNOL METHODS, V226, P129, DOI 10.1016/S0022-1759(99)00059-9; Hollman PCH, 1996, FOOD CHEM, V57, P43, DOI 10.1016/0308-8146(96)00065-9; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; Kasaian MT, 1996, INT IMMUNOL, V8, P1287, DOI 10.1093/intimm/8.8.1287; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; Kotani M, 2000, J ALLERGY CLIN IMMUN, V106, P159, DOI 10.1067/mai.2000.107194; Kotani M., 1999, J JPN SOC NUTR FOOD, V52, P147; Marone G, 1997, INT ARCH ALLERGY IMM, V114, P207, DOI 10.1159/000237670; Marone G, 1998, INT J CLIN LAB RES, V28, P12, DOI 10.1007/s005990050012; Matsumoto M, 2002, BRIT J DERMATOL, V146, P221, DOI 10.1046/j.1365-2133.2002.04557.x; MIDDLETON E, 1984, BIOCHEM PHARMACOL, V33, P3333, DOI 10.1016/0006-2952(84)90102-3; Middleton E, 2000, PHARMACOL REV, V52, P673; Miller A L, 2001, Altern Med Rev, V6, P20; NISHINO H, 1984, JPN J CANCER RES, V75, P311; Ochi H, 1996, INT ARCH ALLERGY IMM, V111, P253, DOI 10.1159/000237375; Ranganath S, 1998, J IMMUNOL, V161, P3822; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; Schroeder JT, 2002, J ALLERGY CLIN IMMUN, V109, P507, DOI 10.1067/mai.2002.122460; Schroeder JT, 2001, ADV IMMUNOL, V77, P93, DOI 10.1016/S0065-2776(01)77015-0; Schwenger GTF, 1999, J ALLERGY CLIN IMMUN, V104, P820, DOI 10.1016/S0091-6749(99)70293-9; Shimizu Y, 1998, CLIN EXP ALLERGY, V28, P497, DOI 10.1046/j.1365-2222.1998.00267.x; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; Yanagihara Y, 1997, CLIN EXP IMMUNOL, V108, P295, DOI 10.1046/j.1365-2249.1997.d01-1001.x	36	120	129	2	13	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1299	1306		10.1067/mai.2003.1456	http://dx.doi.org/10.1067/mai.2003.1456			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789233	Bronze			2022-12-18	WOS:000183424700021
J	Arima, K; Umeshita-Suyama, R; Sakata, Y; Akaiwa, M; Mao, XQ; Enomoto, T; Dake, Y; Shimazu, S; Yamashita, T; Sugawara, N; Brodeur, S; Geha, R; Puri, RK; Sayegh, MH; Adra, CN; Hamasaki, N; Hopkin, JM; Shirakawa, T; Izuhara, K				Arima, K; Umeshita-Suyama, R; Sakata, Y; Akaiwa, M; Mao, XQ; Enomoto, T; Dake, Y; Shimazu, S; Yamashita, T; Sugawara, N; Brodeur, S; Geha, R; Puri, RK; Sayegh, MH; Adra, CN; Hamasaki, N; Hopkin, JM; Shirakawa, T; Izuhara, K			Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; polymorphism; IL-13 receptor alpha 2 chain; allergy; bronchial asthma	RECEPTOR-ALPHA-CHAIN; GENOME-WIDE SEARCH; SERUM IGE LEVELS; SIGNAL-TRANSDUCTION; INTERLEUKIN-4 RECEPTOR; GENETIC-VARIANTS; ILE50VAL VARIANT; ALLERGIC-ASTHMA; ATOPIC ASTHMA; T-CELLS	Background: A substantial body of evidence exists to support the pivotal role of IL-13 in the pathogenesis of bronchial asthma. We recently found that a variant of the IL13 gene (Arg110Gln) is genetically associated with bronchial asthma, which is concordant with animal experiments using IL-13 in the development of asthma. Objective: To address whether the Gln110 variant of IL13 influences IL-13 function, contributing to the pathogenesis of bronchial asthma, we studied the functional properties of the variant. Methods: We generated 2 types of recombinant IL-13 proteins, the amino acids of which at 110 were arginine or glutamine, and analyzed the binding affinities with the IL-13 receptors, as well as the stability of the proteins. We further compared the relationship between the genotype and serum levels of IL-13. Results: The variant showed a lower affinity with the IL-13 receptor alpha2 chain, a decoy receptor, causing less clearance. The variant also demonstrated an enhanced stability in both human and mouse plasma. We further identified that asthmatic patients homozygous for the Gln110 variant have higher serum levels of IL-13 than those without the variant. Conclusion: These results suggested that the variant might act as a functional genetic factor of bronchial asthma with a unique mechanism to upregulate local and systemic IL-13 concentration in vivo.	Saga Med Sch, Dept Biochem, Saga 8498501, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Fukuoka, Japan; Kyoto Univ, Grad Sch Publ Hlth, Dept Hlth Promot & Human Behav, Kyoto, Japan; Univ Coll Swansea, Expt Med Unit, Swansea, W Glam, Wales; Japanese Red Cross Soc, Wakayama Med Ctr, Dept Otolaryngol, Wakayama, Japan; Wakayama Natl Hosp, Dept Pediat, Wakayama, Japan; Mitsubishi Kagaku BCL, Tokyo, Japan; Harvard Univ, Children Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Dept Pediat, Boston, MA 02115 USA; US FDA, Ctr Biol Evaluat & Res, Lab Mol Tumor Biol, Div Cellular & Gene Therapies, Bethesda, MD USA; Brigham & Womens Hosp, Lab Immunogenet & Transplantat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA; RIKEN, SNP Res Ctr, Tokyo, Japan	Saga University; Kyushu University; Kyoto University; Swansea University; Mitsubishi Kagaku Bio-Clinical Laboratories; Harvard University; Boston Children's Hospital; Harvard University; US Food & Drug Administration (FDA); Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; RIKEN	Izuhara, K (corresponding author), Saga Med Sch, Dept Biochem, 5-1-1 Nabeshima, Saga 8498501, Japan.		SUYAMA, Ritsuko/J-3494-2013; Arima, Kazuhiko/I-8962-2014	Arima, Kazuhiko/0000-0002-0607-8787; SUYAMA, Ritsuko/0000-0001-6154-208X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043663] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43663] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Anderson GG, 1999, MOL MED TODAY, V5, P264, DOI 10.1016/S1357-4310(99)01479-3; Barnes KC, 1998, IMMUNOL TODAY, V19, P325, DOI 10.1016/S0167-5699(97)01241-3; BENNETT JP, 1985, NEUROTRANSMITTER REC, P62; Bodey KJ, 1999, ALLERGY, V54, P1083, DOI 10.1034/j.1398-9995.1999.00889.x; Cannon-Carlson S, 1998, PROTEIN EXPRES PURIF, V12, P239, DOI 10.1006/prep.1997.0835; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Cohn L, 1999, J IMMUNOL, V162, P6178; Corry DB, 1999, CURR OPIN IMMUNOL, V11, P610, DOI 10.1016/S0952-7915(99)00025-4; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Inoue R, 1997, INT ARCH ALLERGY IMM, V114, P354, DOI 10.1159/000237694; IZUHARA K, 1993, BIOCHEM BIOPH RES CO, V190, P992, DOI 10.1006/bbrc.1993.1147; Izuhara K, 1999, INT J MOL MED, V3, P3; Izuhara Kenji, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P505; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; Joshi BH, 2000, CANCER RES, V60, P1168; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; Kraan TCTMV, 1999, GENES IMMUN, V1, P61, DOI 10.1038/sj.gene.6363630; Laitinen T, 1997, HUM MOL GENET, V6, P2069, DOI 10.1093/hmg/6.12.2069; Leonard WJ, 2000, J ALLERGY CLIN IMMUN, V105, P877, DOI 10.1067/mai.2000.106899; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; Marsh DG, 1997, NAT GENET, V15, P389; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; Moffatt MF, 1999, CURR OPIN IMMUNOL, V11, P606, DOI 10.1016/S0952-7915(99)00024-2; Murata T, 1998, INT IMMUNOL, V10, P1103, DOI 10.1093/intimm/10.8.1103; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Obiri NI, 1997, J IMMUNOL, V158, P756; Ogata H, 1998, J BIOL CHEM, V273, P9864, DOI 10.1074/jbc.273.16.9864; Oshima Y, 2000, J BIOL CHEM, V275, P14375, DOI 10.1074/jbc.275.19.14375; Ott VL, 2000, J ALLERGY CLIN IMMUN, V106, P429, DOI 10.1067/mai.2000.109428; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Umeshita-Suyama R, 2000, INT IMMUNOL, V12, P1499, DOI 10.1093/intimm/12.11.1499; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	49	120	141	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					980	987		10.1067/mai.2002.124656	http://dx.doi.org/10.1067/mai.2002.124656			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063528				2022-12-18	WOS:000176442700014
J	Sabroe, RA; Poon, E; Orchard, GE; Lane, D; Francis, DM; Barr, RM; Black, MM; Black, AK; Greaves, MW				Sabroe, RA; Poon, E; Orchard, GE; Lane, D; Francis, DM; Barr, RM; Black, MM; Black, AK; Greaves, MW			Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: Comparison of patients with and without anti-Fc epsilon RI or anti-IgE autoantibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic idiopathic urticaria; anti-Fc epsilon RI antibodies; anti-IgE autoantibodies; immunohistochemistry; eosinophils; neutrophils; T lymphocytes	DELAYED PRESSURE URTICARIA; MAJOR BASIC-PROTEIN; HISTAMINE-RELEASING ACTIVITY; MAST-CELLS; SOLAR URTICARIA; DERMOGRAPHISM; LYMPHOCYTES; DEPOSITION; RECEPTOR; SKIN	Background: Previous studies defining the histopathologic features of patients with chronic idiopathic urticaria (CIU) were performed on wheals of uncertain duration and before the identification of functional autoantibodies against Fc epsilon RI and/or IgE, now known to be present in approximately 30% of patients with CIU. Objective: We sought to determine the timing of the inflammatory infiltrate in the wheals of patients with CIU and to detect differences between patients with and without autoantibodies. Methods: Immunohistochemistry was used to identify neutrophils (neutrophil elastase), T lymphocytes (CD3), and activated eosinophils (EG2) in biopsy specimens from uninvolved skin and wheals present for less than 4 hours and greater than 12 hours in 22 patients with CIU,as wed as in biopsy specimens from the skin of 12 healthy control subjects. Patients were identified as having functional autoantibodies on the basis of their serum-evoked histamine release in vitro from the basophils of 2 healthy donors Results: EG2(+), neutrophil elastase(+), and, to a lesser extent, CD3(+) cells were found in greater numbers in wheals undergoing biopsy at less than 4 and greater than IZ hours than in uninvolved skin (P < .05). Patients without autoantibodies (n = 12) had significantly more EG2(+) cells in wheals of greater than 12 hours' duration than patients with autoantibodies (n = 10; P = .02). There was no other difference between patients with and without autoantibodies in the cutaneous cellular infiltrate. Conclusion: Neutrophil and eosinophil accumulation occurs early in the evolution of a wheal in patients with CIU but eosinophil activation may occur later or be more persistent in patients without autoantibodies.	Guys Kings Coll & St Thomass Hosp Med & Dent Sch, Professorial Unit, St Johns Inst Dermatol, St Thomas Hosp, London SE1 7EH, England; Guys Kings Coll & St Thomass Hosp Med & Dent Sch, Dept Dermatopathol, St Johns Inst Dermatol, St Thomas Hosp, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Sabroe, RA (corresponding author), Guys Kings Coll & St Thomass Hosp Med & Dent Sch, Professorial Unit, St Johns Inst Dermatol, St Thomas Hosp, London SE1 7EH, England.							Barata LT, 1998, J ALLERGY CLIN IMMUN, V101, P222, DOI 10.1016/S0091-6749(98)70387-2; BARLOW RJ, 1993, J AM ACAD DERMATOL, V29, P954, DOI 10.1016/0190-9622(93)70273-V; BARLOW RJ, 1995, CLIN EXP ALLERGY, V25, P317, DOI 10.1111/j.1365-2222.1995.tb01049.x; BENYON RC, 1989, BRIT J PHARMACOL, V97, P898, DOI 10.1111/j.1476-5381.1989.tb12030.x; Black AK, 1996, CLIN EXP DERMATOL, V21, P424, DOI 10.1111/j.1365-2230.1996.tb00146.x; BOENISCH T, 1989, IMMUNOCHEMICAL STAIN, P13; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, pS154; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; HAAS N, 1995, ARCH DERMATOL RES, V287, P180, DOI 10.1007/BF01262329; Haas N, 1998, ARCH DERMATOL, V134, P41, DOI 10.1001/archderm.134.1.41; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; HIRSCHMANN JV, 1987, ARCH DERMATOL, V123, P462, DOI 10.1001/archderm.123.4.462; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KERMANI F, 1995, J INVEST DERMATOL, V105, P452; LAWLOR F, 1989, BRIT J DERMATOL, V120, P403, DOI 10.1111/j.1365-2133.1989.tb04167.x; LAWLOR F, 1989, CLIN EXP DERMATOL, V14, P416, DOI 10.1111/j.1365-2230.1989.tb02601.x; LEIFERMAN KM, 1989, J AM ACAD DERMATOL, V21, P75, DOI 10.1016/S0190-9622(89)70151-1; MASON DY, 1988, J CLIN PATHOL, V41, P121, DOI 10.1136/jcp.41.2.121; McEvoy MT, 1995, BRIT J DERMATOL, V133, P853, DOI 10.1111/j.1365-2133.1995.tb06916.x; MEKORI YA, 1983, J ALLERGY CLIN IMMUN, V72, P681, DOI 10.1016/0091-6749(83)90629-2; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; NORRIS PG, 1988, ARCH DERMATOL, V124, P80, DOI 10.1001/archderm.124.1.80; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; PETERS MS, 1985, BRIT J DERMATOL, V113, P25, DOI 10.1111/j.1365-2133.1985.tb02040.x; PETERS MS, 1987, J AM ACAD DERMATOL, V16, P513, DOI 10.1016/S0190-9622(87)70067-X; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Sabroe RA, 1998, J ALLERGY CLIN IMMUN, V102, P651, DOI 10.1016/S0091-6749(98)70283-0; SODHI N, 1990, Journal of Allergy and Clinical Immunology, V85, P204; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Toppe E, 1998, BRIT J DERMATOL, V138, P248; Toyoda M, 1996, AM J DERMATOPATH, V18, P49, DOI 10.1097/00000372-199602000-00008; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P767; WINKELMANN RK, 1985, ARCH DERMATOL RES, V278, P37, DOI 10.1007/BF00412493; WINKELMANN RK, 1985, J CUTAN PATHOL, V12, P486, DOI 10.1111/j.1600-0560.1985.tb00447.x; WINKELMANN RK, 1988, ACTA DERM-VENEREOL, V68, P129; WINKELMANN RK, 1988, HUM PATHOL, V19, P389, DOI 10.1016/S0046-8177(88)80486-6; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	44	120	124	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				484	493		10.1016/S0091-6749(99)70475-6	http://dx.doi.org/10.1016/S0091-6749(99)70475-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069884				2022-12-18	WOS:000079175700019
J	Bush, RK; Wood, RA; Eggleston, PA				Bush, RK; Wood, RA; Eggleston, PA			Laboratory animal allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							FEL-D-I; MOUSE ALLERGENS; AIRBORNE CONCENTRATIONS; SIZE DISTRIBUTION; CASCADE IMPACTOR; RAT ALLERGENS; CAT ALLERGEN; RISK-FACTORS; DOG; ASTHMA	Approximately one third of laboratory animal workers have occupational allergy to animal danders, and a third of these have symptomatic asthma. Sensitization generally occurs with the first 3 years of employment, and risk factors include atopic background, as well as job description as it relates to the intensity of exposure. A symptomatic worker can reduce allergen exposure with personal protective devices. A laboratory can further reduce exposure with generally available equipment. such as laminar flow caging, and procedures, such as frequent wet washing of vivaria and careful maintenance of ventilation systems. It is advisable to institute periodic medical screening of all laboratory animal workers with questionnaires and allergy skin testing in addition to providing them with training programs to reduce personal exposure.	William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA; Univ Wisconsin, Dept Med, Madison, WI USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University	Bush, RK (corresponding author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.							AGRUP G, 1986, BRIT J IND MED, V43, P192; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; ANDERSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P563, DOI 10.1016/0091-6749(85)90776-6; AOYAMA K, 1992, BRIT J IND MED, V49, P41; BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; Bayard C, 1996, BBA-GEN SUBJECTS, V1290, P129, DOI 10.1016/0304-4165(96)00006-2; BEESON MF, 1983, CLIN ALLERGY, V13, P433, DOI 10.1111/j.1365-2222.1983.tb02619.x; BLAND SM, 1987, OCCUP MED, V2, P525; BLAND SM, 1986, J OCCUP ENVIRON MED, V28, P1151; BOTHAM PA, 1987, BRIT J IND MED, V44, P627; BOUSQUET J, 1993, ALLERGY PRINCIPLES P, P573; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; CLARK AJ, 1984, EMBO J, V3, P1045, DOI 10.1002/j.1460-2075.1984.tb01925.x; Coca AF, 1923, J IMMUNOL, V8, P163; COCKCROFT A, 1981, LANCET, V1, P827; CORN M, 1988, ANN OCCUP HYG     S1, V32, P435; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589, DOI 10.1136/oem.51.9.589; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; EDWARDS RG, 1983, LAB ANIM, V17, P235, DOI 10.1258/002367783781070696; EGGLESTON PA, 1995, AM J RESP CRIT CARE, V151, P640; EGGLESTON PA, 1990, J ALLERGY CLIN IMMUN, V86, P63, DOI 10.1016/S0091-6749(05)80124-1; EGGLESTON PA, 1989, J ALLERGY CLIN IMMUN, V84, P347, DOI 10.1016/0091-6749(89)90419-3; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; GORDON S, 1992, BRIT J IND MED, V49, P416; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; Harber P, 1996, AM J RESP CRIT CARE, V154, P1153, DOI 10.1164/ajrccm.154.4.8887621; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562, DOI 10.1164/ajrccm.155.2.9032195; Hollander A, 1996, J ALLERGY CLIN IMMUN, V98, P545, DOI 10.1016/S0091-6749(96)70088-X; HUNSKAAR S, 1993, LAB ANIM, V27, P206, DOI 10.1258/002367793780745372; ISEN H, 1993, ALLERGY PRINCIPLES P, P529; JONES RB, 1995, AM IND HYG ASSOC J, V56, P398, DOI 10.1202/0002-8894(1995)056<0398:TEORHO>2.0.CO;2; KLEINETEBBE J, 1993, INT ARCH ALLERGY IMM, V100, P256, DOI 10.1159/000236421; LARSEN JN, 1988, J ALLERGY CLIN IMMUN, V82, P318, DOI 10.1016/0091-6749(88)90002-4; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; Lindqvist C, 1996, SCAND J LAB ANIM SCI, V23, P135; LONGBOTTOM JL, 1980, ADV ALLERGOLOGY APPL, P483; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MANCINI MA, 1989, J HISTOCHEM CYTOCHEM, V37, P149, DOI 10.1177/37.2.2463299; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; *NAT RES COUNC, 1996, I LAB AN RES COMM RE; NEWILL CA, 1992, AM REV RESPIR DIS, V146, P1494, DOI 10.1164/ajrccm/146.6.1494; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; OLFERT E, 1993, LAB ANIM, V22, P32; PETRY RW, 1985, J ALLERGY CLIN IMMUN, V75, P268, DOI 10.1016/0091-6749(85)90056-9; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; PRICE JA, 1988, CLIN ALLERGY, V18, P95, DOI 10.1111/j.1365-2222.1988.tb02848.x; PRICE JA, 1990, CLIN EXP ALLERGY, V20, P71, DOI 10.1111/j.1365-2222.1990.tb02778.x; RENSTROM A, 1994, ALLERGY, V49, P548, DOI 10.1111/j.1398-9995.1994.tb01127.x; ROTHMAN PA, 1995, OCCUP ENVIRON MED, V52, P129; SAKAGUCHI M, 1989, LAB ANIM SCI, V39, P63; SAKAGUCHI M, 1990, LAB ANIM SCI, V40, P613; SCHOU C, 1993, CLIN EXP ALLERGY, V23, P7, DOI 10.1111/j.1365-2222.1993.tb02477.x; SCHOU C, 1991, CLIN EXP ALLERGY, V21, P321, DOI 10.1111/j.1365-2222.1991.tb01663.x; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SCHUMACHER MJ, 1980, MOL IMMUNOL, V17, P1087, DOI 10.1016/0161-5890(80)90105-4; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V63, P435, DOI 10.1016/0091-6749(79)90219-7; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; SPITZAUER S, 1993, INT ARCH ALLERGY IMM, V100, P60, DOI 10.1159/000236389; SWANSON MC, 1990, AM REV RESPIR DIS, V141, P1578, DOI 10.1164/ajrccm/141.6.1578; SWANSON MC, 1984, AM REV RESPIR DIS, V129, P844, DOI 10.1164/arrd.1984.129.5.844; TAYLOR AN, 1977, LANCET, V2, P847; TEASDALE EL, 1993, BRIT MED J, V286, P1480; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VENABLES KM, 1988, BRIT J IND MED, V45, P660; VENABLES KM, 1988, BRIT J IND MED, V45, P667; WAHN U, 1980, J ALLERGY CLIN IMMUN, V65, P413, DOI 10.1016/0091-6749(80)90233-X; WALLS AF, 1985, J ALLERGY CLIN IMMUN, V75, P242, DOI 10.1016/0091-6749(85)90053-3; WALLS AF, 1985, CLIN ALLERGY, V15, P535, DOI 10.1111/j.1365-2222.1985.tb02307.x; WARNER JA, 1991, ALLERGY, V46, P481, DOI 10.1111/j.1398-9995.1991.tb00610.x; Watt AD, 1996, OCCUP ENVIRON MED, V53, P573, DOI 10.1136/oem.53.8.573; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x; ZIEMANN B, 1992, AM IND HYG ASSOC J, V53, P138, DOI 10.1202/0002-8894(1992)053<0138:TEOTDB>2.0.CO;2	79	120	125	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					99	112		10.1016/S0091-6749(98)70060-0	http://dx.doi.org/10.1016/S0091-6749(98)70060-0			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679853				2022-12-18	WOS:000074909500015
J	ISRAELBIET, D; LABROUSSE, F; TOURANI, JM; SORS, H; ANDRIEU, JM; EVEN, P				ISRAELBIET, D; LABROUSSE, F; TOURANI, JM; SORS, H; ANDRIEU, JM; EVEN, P			ELEVATION OF IGE IN HIV-INFECTED SUBJECTS - A MARKER OF POOR PROGNOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE; HIV	HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; IMMUNOGLOBULIN-E SYNTHESIS; B-CELL ACTIVATION; BINDING-FACTORS; MONOCLONAL-ANTIBODIES; HOMOSEXUAL MEN; HOST-DISEASE; ACUTE GRAFT; SERUM IGD	The IgE synthesis is tightly controlled by a complex network of T and B cells. Because human immunodeficiency virus (HIV) disease associates T cell activation and depletion, polyclonal B cell activation, atopic symptoms, drug hypersensitivity, and autoimmune activity, we have evaluated IgE, as well as IgA, IgG, and IgM, in 315 HIV-seropositive individuals with or without acquired immunodeficiency syndrome (AIDS) and compared the results to those of 100 HIV-seronegative subjects. IgE levels were higher in HIV-infected subjects as a whole, compared to levels in seronegative control subjects (p < 0.05). This difference was particularly marked between patients with AIDS and control subjects (p < 0.005). A strong relationship appeared between IgE and the immune status as assessed by CD4 cell counts (p < 0.001 between IgE values in patients with CD4 < 300 or > 300/mu-l). In addition, we assessed the predictive value of IgE elevation over disease progression: in subjects with a CD4 count < 300/mu-l, the survival analysis disclosed a 24-month occurrence rate of AIDS of 83% in individuals with IgE > 150 KIU/L versus 44% in individuals with IgE < 150 (p = 0.016). In subjects with an AIDS-related complex, IgE > 150 indicated a 100% rate of AIDS versus 9% in individuals with IgE < 150 (p = 0.003). Thus, IgE levels appear to be a very discriminative marker between patients in late stages of HIV infection. IgA, IgG, and IgM also significantly increased during HIV infection; the slope of their increase was, however, significantly less steep than that of IgE, suggesting different mechanisms of hyperproduction. Hypotheses regarding these mechanisms are discussed.	HOP LAENNEC,DEPT SPECIALIZED MED & IMMUNOPATHOL,F-75340 PARIS 07,FRANCE; HOP LAENNEC,DEPT BIOCHEM,F-75340 PARIS 07,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP				ISRAEL-BIET, Dominique/0000-0003-4308-4411				AMMANN AJ, 1983, CLIN IMMUNOL IMMUNOP, V27, P315, DOI 10.1016/0090-1229(83)90084-3; ANDRIEU JM, 1986, AIDS RES HUM RETROV, V2, P163, DOI 10.1089/aid.1.1986.2.163; AUCOUTURIER P, 1986, CLIN EXP IMMUNOL, V63, P234; BALL LM, 1987, LANCET, V2, P627; BONINI S, 1982, Folia Allergologica et Immunologica Clinica, V29, P63; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; CARINI C, 1988, P NATL ACAD SCI USA, V85, P9214, DOI 10.1073/pnas.85.23.9214; EVEN P, 1988, AUTOIMMUNE ASPECTS H, P79; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FLING JA, 1988, J ALLERGY CLIN IMMUN, V82, P965, DOI 10.1016/0091-6749(88)90132-7; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; HEYD J, 1988, BLOOD, V72, P442; ISHIZAKA K, 1988, ANNU REV IMMUNOL, V6, P513; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHALIFE J, 1988, AIDS RES HUM RETROV, V4, P3, DOI 10.1089/aid.1988.4.3; LABROUSSE F, 1989, 5 P INT AIDS C MONTR, P143; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LEUNG DYM, 1986, J CLIN INVEST, V77, P952, DOI 10.1172/JCI112395; LOWENSTEIN W, 1988, 4 P INT AIDS C STOCK, P2099; LUCEY D, 1989, 5 P INT AIDS C MONTR, P135; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MAZA OM, 1987, J IMMUNOL, V138, P3720; MIADONNA A, 1988, J ALLERGY CLIN IMMUN, V81, P235; MIZUMA H, 1987, CLIN EXP IMMUNOL, V68, P5; MOSS AR, 1988, BRIT MED J, V297, P1067, DOI 10.1136/bmj.297.6656.1067; NICHOLSON JKA, 1985, ANN INTERN MED, V103, P37, DOI 10.7326/0003-4819-103-1-37; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; PARRAVICINI CL, 1988, AIDS, V2, P171; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; REBHUN J, 1983, ANN ALLERGY, V50, P34; RING J, 1988, J ALLERGY CLIN IMMUN, V81, P191; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, pS13, DOI 10.1016/0090-1229(89)90110-4; ROSSOL S, 1989, J INFECT DIS, V159, P815, DOI 10.1093/infdis/159.5.815; SARYAN JA, 1983, J CLIN INVEST, V71, P556, DOI 10.1172/JCI110800; VENET A, 1990, CLIN EXP IMMUNOL, V80, P151, DOI 10.1111/j.1365-2249.1990.tb05224.x; VERCELLI D, 1989, J CLIN IMMUNOL, V9, P75, DOI 10.1007/BF00916934; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WIGNANTS H, 1989, LANCET, V2, P1455; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x	41	120	121	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				68	75		10.1016/S0091-6749(05)80042-9	http://dx.doi.org/10.1016/S0091-6749(05)80042-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1346148				2022-12-18	WOS:A1992GZ90800008
J	MULLER, U; BERCHTOLD, E; HELBLING, A				MULLER, U; BERCHTOLD, E; HELBLING, A			HONEYBEE VENOM ALLERGY - RESULTS OF A STING CHALLENGE 1 YEAR AFTER STOPPING SUCCESSFUL VENOM IMMUNOTHERAPY IN 86 PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BEE VENOM; PREDICTIVE VALUE; INSECT; IGE; ANTIBODIES; HYPERSENSITIVITY; SENSITIVITY	In 86 patients with a history of severe systemic reactions (SRs) to honeybee stings confirmed by a positive skin test and/or RAST to honeybee venom (HBV), immunotherapy (IT) with HBV was stopped after 3 to 10 years. All patients had tolerated well a honeybee sting during IT and were resubmitted to a sting 1 year after VIT was stopped. At the latter time, 15 patients (17%) developed an SR and 71 did not. There was no difference between the two groups regarding age, sex, IT duration, severity of the SR before treatment, as well as diagnostic tests with HBV (skin tests, RAST, and specific IgG) before the challenge. Patients with a relapse of their allergy had, however, developed allergic SRs to IT injections more frequently than patients with lasting protection (p < 0.001). SRs to the sting challenge (CH) after IT was stopped occurred more frequently in those patients in whom efficacy of IT had previously been confirmed by lacking responses to a field sting than in patients who had tolerated an intentional CH during the injection period (p < 0.025). Indeed, the incidence of relapse after venom IT was stopped was only 9.6% in patients who had previously tolerated an intentional CH. It is concluded that well-tolerated HBV IT may be stopped after at least 3 years, provided its efficacy has been documented by a CH without SR.			MULLER, U (corresponding author), ZIEGLERSPITAL BERN, DIV MED, CH-3007 BERN, SWITZERLAND.							BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; DAY JH, 1986, J ALLERGY CLIN IMMUN, V77, P142; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V83, P273; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; LANTNER R, 1989, J ALLERGY CLIN IMMUN, V84, P900, DOI 10.1016/0091-6749(89)90387-4; LAWRENCE ID, 1986, J ALLERGY CLIN IMMUN, V77, P178; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P247, DOI 10.1016/0091-6749(77)90158-0; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1977, CLIN ALLERGY, V7, P147, DOI 10.1111/j.1365-2222.1977.tb01435.x; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; MULLER U, 1987, J ALLERGY CLIN IMMUN, V80, P252, DOI 10.1016/0091-6749(87)90027-3; Muller UR., 1990, INSECT STING ALLERGY; PATRIZZI R, 1979, ALLERGY, V34, P249, DOI 10.1111/j.1398-9995.1979.tb01705.x; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; URBANEK R, 1981, EUR J PEDIATR, V136, P31, DOI 10.1007/BF00441707; URBANEK R, 1978, DEUT MED WOCHENSCHR, V103, P1656, DOI 10.1055/s-0028-1129317; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4; WUTHRICH B, 1981, PRAXIS, V70, P934; YUNGINGER JW, 1978, J ALLERGY CLIN IMMUN, V61, P93, DOI 10.1016/0091-6749(78)90231-2	28	120	120	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					702	709		10.1016/0091-6749(91)90392-2	http://dx.doi.org/10.1016/0091-6749(91)90392-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005323				2022-12-18	WOS:A1991FB80100016
J	IRANI, AMA; BUTRUS, SI; TABBARA, KF; SCHWARTZ, LB				IRANI, AMA; BUTRUS, SI; TABBARA, KF; SCHWARTZ, LB			HUMAN CONJUNCTIVAL MAST-CELLS - DISTRIBUTION OF MCT AND MCTC IN VERNAL CONJUNCTIVITIS AND GIANT PAPILLARY CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298; UNIV VIRGINIA,MED CTR,SCH MED,SALEM VET ADM MED CTR,DEPT OPHTHALMOL,CHARLOTTESVILLE,VA 22901; KING SAUD UNIV,COLL MED,DEPT OPHTHALMOL,RIYADH,SAUDI ARABIA	Virginia Commonwealth University; University of Virginia; US Department of Veterans Affairs; Veterans Health Administration (VHA); Salem Veterans Affairs Medical Center; King Saud University	IRANI, AMA (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PEDIAT,MCV STN BOX 225,RICHMOND,VA 23298, USA.				NIAID NIH HHS [AI-27517, AI-20487] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027517, R01AI020487, R37AI020487, R21AI020487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELSON MB, 1977, AM J OPHTHALMOL, V83, P417, DOI 10.1016/0002-9394(77)90743-7; ALLANSMITH M, 1963, J ALLERGY, V34, P535, DOI 10.1016/0021-8707(63)90095-9; ALLANSMITH MR, 1979, AM J OPHTHALMOL, V87, P544, DOI 10.1016/0002-9394(79)90247-2; ALLANSMITH MR, 1976, AM J OPHTHALMOL, V81, P506, DOI 10.1016/0002-9394(76)90310-X; BALLOW M, 1980, J ALLERGY CLIN IMMUN, V66, P112, DOI 10.1016/0091-6749(80)90057-3; BALLOW M, 1985, J ALLERGY CLIN IMMUN, V76, P473, DOI 10.1016/0091-6749(85)90729-8; BARNEY N P, 1988, Investigative Ophthalmology and Visual Science, V29, P66; BENYON RC, 1987, J IMMUNOL, V138, P861; BHAN AK, 1982, AM J OPHTHALMOL, V94, P205, DOI 10.1016/0002-9394(82)90076-9; BUTRUS SI, 1984, OPHTHALMOLOGY, V91, P1213; COLLIN HB, 1977, INVEST OPHTHALMOL VI, V16, P859; CRAIG SS, 1988, LAB INVEST, V58, P682; CRAIG SS, 1986, AM J PATHOL, V124, P427; EASTY DL, 1980, T OPHTHAL SOC UK, V100, P98; GRIENER JV, 1985, AM J OPHTHALMOL, V100, P45; HENRIQUEZ AS, 1981, ARCH OPHTHALMOL-CHIC, V99, P1266, DOI 10.1001/archopht.1981.03930020140019; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AA, 1990, CLIN EXP ALLERGY, V20, P53, DOI 10.1111/j.1365-2222.1990.tb02775.x; Irani AA, 1987, ARTHRITIS RHEUM, V30, P66; IRANI AMA, 1989, ALLERGY, V44, P31; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; IRANI AMA, 1987, J IMMUNOL, V138, P4381; LAVKER RM, 1985, J IMMUNOL, V135, P2368; MALONE DG, 1987, ARTHRITIS RHEUM, V30, P130, DOI 10.1002/art.1780300202; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; UDELL IJ, 1981, AM J OPHTHALMOL, V2, P226	26	120	129	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					34	39		10.1016/S0091-6749(05)80120-4	http://dx.doi.org/10.1016/S0091-6749(05)80120-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2196302				2022-12-18	WOS:A1990DQ68800006
J	DENBURG, JA; TELIZYN, S; BELDA, A; DOLOVICH, J; BIENENSTOCK, J				DENBURG, JA; TELIZYN, S; BELDA, A; DOLOVICH, J; BIENENSTOCK, J			INCREASED NUMBERS OF CIRCULATING BASOPHIL PROGENITORS IN ATOPIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT PATHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,PEDIAT,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University	DENBURG, JA (corresponding author), MCMASTER UNIV,DEPT MED,HOST RESISTANCE PROGRAMME,ROOM HSC-4H21,HAMILTON L8N 3Z5,ONTARIO,CANADA.							Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; ASKENASE PW, 1980, J EXP MED, V152, P1358, DOI 10.1084/jem.152.5.1358; ATKINS PC, 1982, J ALLERGY CLIN IMMUN, V69, P39, DOI 10.1016/0091-6749(82)90085-9; BENVENISTE J, 1976, CLIN EXP IMMUNOL, V26, P449; BJORNSON BH, 1982, BLOOD, V60, P721; CAPRON M, 1978, J IMMUNOL, V121, P2518; DENBURG JA, 1981, EXP HEMATOL, V9, P214; DENBURG JA, 1980, J CLIN INVEST, V65, P390, DOI 10.1172/JCI109682; DENBURG JA, 1983, BLOOD, V61, P775; DENBURG JA, 1985, EXP HEMATOL, V13, P185; DENBURG JA, 1984, CLIN RES, V32, pA145; DENBURG JA, BLOOD; DVORAK HF, 1971, J IMMUNOL, V107, P138; HASTIE R, 1979, LAB INVEST, V40, P554; HENOCQ E, 1981, CLIN ALLERGY, V11, P13, DOI 10.1111/j.1365-2222.1981.tb01560.x; HIRSCH SR, 1976, J ALLERGY CLIN IMMUN, V58, P676, DOI 10.1016/0091-6749(76)90179-2; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; LEONARD EJ, 1979, INT ARCH ALLER A IMM, V58, P460, DOI 10.1159/000232227; MITCHELL EB, 1982, LANCET, V1, P127; MITCHELL EB, 1982, J IMMUNOL, V128, P1662; OKUDA M, 1983, ANN ALLERGY, V50, P116; OKUDA M, 1977, ORL DIGEST, V39, P26; ROTHWELL TWL, 1975, J PATHOL, V16, P51; WARD PA, 1975, J IMMUNOL, V114, P1523	24	120	122	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					466	472		10.1016/0091-6749(85)90728-6	http://dx.doi.org/10.1016/0091-6749(85)90728-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	4031318				2022-12-18	WOS:A1985ARC0900008
J	BORGEAT, P; DELACLOS, BF; RABINOVITCH, H; PICARD, S; BRAQUET, P; HEBERT, J; LAVIOLETTE, M				BORGEAT, P; DELACLOS, BF; RABINOVITCH, H; PICARD, S; BRAQUET, P; HEBERT, J; LAVIOLETTE, M			EOSINOPHIL-RICH HUMAN POLYMORPHONUCLEAR LEUKOCYTE PREPARATIONS CHARACTERISTICALLY RELEASE LEUKOTRIENE-C4 ON IONOPHORE-A23187 CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LAVAL,CTR HOSP,CTR RECH IMMUNOL & RHEUMATOL,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; INST HENRI BEAUFOUR,F-92350 PLESSIS ROBINSON,FRANCE; HOP LAVAL,CTR PNEUMOL,QUEBEC CITY G1V 4G5,QUEBEC,CANADA	Laval University; Laval University	BORGEAT, P (corresponding author), UNIV LAVAL,CTR HOSP,ENDOCRINOL MOLEC LAB,RECH LEUCOTRIENES GRP,QUEBEC CITY G1V 4G2,QUEBEC,CANADA.							BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; BORGEAT P, 1979, J BIOL CHEM, V254, P2643; BOYLE W, 1968, TRANSPLANTATION, V6, P761, DOI 10.1097/00007890-196809000-00002; BOYUM A, 1976, SCAND J IMMUNOL   S5, V5, P9; DAHL R, 1982, EUR J RESPIR DIS, V63, P23; DELACLOS BF, 1984, PROSTA LEUKOTR MED, V13, P47, DOI 10.1016/0262-1746(84)90101-X; GOETZL EJ, 1982, BIOCHEM BIOPH RES CO, V106, P270, DOI 10.1016/0006-291X(82)91105-6; HENDERSON WR, 1982, J IMMUNOL, V128, P2609; JORG A, 1982, J EXP MED, V155, P390, DOI 10.1084/jem.155.2.390; LUNDBERG U, 1981, FEBS LETT, V126, P127, DOI 10.1016/0014-5793(81)81050-2; MAAS RL, 1981, P NATL ACAD SCI-BIOL, V78, P5523, DOI 10.1073/pnas.78.9.5523; SAMUELSSON B, 1982, ANGEW CHEM INT EDIT, V21, P902, DOI 10.1002/anie.198209021; SCHATZ M, 1982, ARCH INTERN MED, V142, P1515, DOI 10.1001/archinte.142.8.1515; SCUDAMORE HH, 1982, J ALLERGY CLIN IMMUN, V70, P129, DOI 10.1016/0091-6749(82)90241-X; SPRY CJF, 1982, ALLERGY, V37, P539, DOI 10.1111/j.1398-9995.1982.tb02339.x; TURK J, 1982, J BIOL CHEM, V257, P7068	16	120	120	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					310	315		10.1016/0091-6749(84)90122-2	http://dx.doi.org/10.1016/0091-6749(84)90122-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6432874				2022-12-18	WOS:A1984TQ63300002
J	WEBER, RW; SMITH, JA; NELSON, HS				WEBER, RW; SMITH, JA; NELSON, HS			AEROSOLIZED TERBUTALINE IN ASTHMATICS - DEVELOPMENT OF SUBSENSITIVITY WITH LONG-TERM ADMINISTRATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,AURORA,CO 80045									BENOY CJ, 1975, BRIT J PHARMACOL, V55, P547, DOI 10.1111/j.1476-5381.1975.tb07431.x; CAMPBELL RC, 1974, STATISTICS BIOL; Colton T., 1974, STAT MED, V1; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; ELLULMICALLEF R, 1975, LANCET, V2, P1269; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GIBSON GJ, 1978, BRIT J DIS CHEST, V72, P199, DOI 10.1016/0007-0971(78)90042-6; HOLGATE ST, 1977, LANCET, V2, P375; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; KALISKER A, 1977, J ALLERGY CLIN IMMUN, V60, P259, DOI 10.1016/0091-6749(77)90141-5; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LYONS HA, 1976, BRONCHIAL ASTHMA MEC, P727; MILLER J, 1977, ANN ALLERGY, V39, P418; MORRIS HG, 1980, J ALLERGY CLIN IMMUN, V65, P83, DOI 10.1016/0091-6749(80)90190-6; MORRIS HG, 1978, J ALLERGY CLIN IMMUN, V61, P294, DOI 10.1016/0091-6749(78)90050-7; NELSON HS, 1973, J ALLERGY CLIN IMMUN, V51, P191, DOI 10.1016/0091-6749(73)90138-3; NELSON HS, 1977, INT ARCH ALLER A IMM, V55, P362, DOI 10.1159/000231947; NELSON HS, 1977, AM REV RESPIR DIS, V116, P871; PLUMMER AL, 1978, CHEST, V73, pS949; SACKNER MA, 1977, AM REV RESPIR DIS, V115, P945; SANO Y, 1980, J ALLERGY CLIN IMMUN, V65, P223; STEPHAN WC, 1980, J ALLERGY CLIN IMMUN, V65, P105, DOI 10.1016/0091-6749(80)90193-1; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V63, P116, DOI 10.1016/0091-6749(79)90201-X	23	120	120	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	6					417	422		10.1016/0091-6749(82)90003-3	http://dx.doi.org/10.1016/0091-6749(82)90003-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PT744	6815252				2022-12-18	WOS:A1982PT74400003
J	JACOBS, RL; RAKE, GW; FOURNIER, DC; CHILTON, RJ; CULVER, WG; BECKMANN, CH				JACOBS, RL; RAKE, GW; FOURNIER, DC; CHILTON, RJ; CULVER, WG; BECKMANN, CH			POTENTIATED ANAPHYLAXIS IN PATIENTS WITH DRUG-INDUCED BETA-ADRENERGIC-BLOCKADE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									USAF,WILFORD HALL MED CTR,DEPT MED,CARDIOL SERV,LACKLAND AFB,TX 78236	United States Department of Defense; United States Air Force	JACOBS, RL (corresponding author), USAF,WILFORD HALL MED CTR,DEPT MED,ALLERGY IMMUNOL SERV,LACKLAND AFB,TX 78236, USA.			Jacobs, Robert/0000-0002-2831-9086				BRICK I, 1966, AM J CARDIOL, V18, P329, DOI 10.1016/0002-9149(66)90050-6; CHADDA KD, 1975, AM J MED, V59, P158, DOI 10.1016/0002-9343(75)90349-6; LUBBE WF, 1978, S AFR MED J, V54, P139; MATSUMURA Y, 1976, J ALLERGY CLIN IMMUN, V58, P387, DOI 10.1016/0091-6749(76)90119-6; NISAM MR, 1978, J APPL PHYSIOL, V44, P455, DOI 10.1152/jappl.1978.44.3.455; REED CE, 1967, J ALLERGY CLIN IMMUN, V39, P160; SHEREFF RH, 1973, J ALLERGY CLIN IMMUN, V52, P328, DOI 10.1016/0091-6749(73)90091-2; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P12; ZACEST R, 1972, PHARMACOLOGY, V7, P178, DOI 10.1159/000136287	9	120	121	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	2					125	127		10.1016/0091-6749(81)90170-6	http://dx.doi.org/10.1016/0091-6749(81)90170-6			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MD162	6114116				2022-12-18	WOS:A1981MD16200008
J	NORMAN, PS; LICHTENSTEIN, LM; TIGNALL, J				NORMAN, PS; LICHTENSTEIN, LM; TIGNALL, J			CLINICAL AND IMMUNOLOGICAL SPECIFICITY OF IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NORMAN, PS (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.							Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1972, INT ARCH ALLER A IMM, V42, P615, DOI 10.1159/000230642; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P572; LOWELL F, 1963, J ALLERGY, V34, P105; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MAY CD, 1972, J ALLERGY CLIN IMMUN, V50, P99, DOI 10.1016/0091-6749(72)90005-X; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P94, DOI 10.1016/0091-6749(73)90081-X; NORMAN PS, 1966, CLINICAL PHARMACOLOG, V2, P639; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8	17	120	121	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	6					370	377		10.1016/0091-6749(78)90116-1	http://dx.doi.org/10.1016/0091-6749(78)90116-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC593	77866	Bronze			2022-12-18	WOS:A1978FC59300005
J	CHAFEE, FH; SETTIPANE, GA				CHAFEE, FH; SETTIPANE, GA			ASPIRIN INTOLERANCE .1. FREQUENCY IN AN ALLERGIC POPULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RHODE ISLAND HOSP, DEPT MED, DIV ALLERGY, PROVIDENCE, RI USA; BROWN UNIV, DIV BIOL & MED SCI, PROVIDENCE, RI USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University								CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; Gardner E, 1940, AM J MED SCI, V200, P390, DOI 10.1097/00000441-194009000-00015; GIRALDO B, 1969, ANN INTERN MED, V71, P479, DOI 10.7326/0003-4819-71-3-479; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HIRSCHBERG, 1902, DEUT MED WOCHENSCHR, V28, P416; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; Miller F F, 1967, J Okla State Med Assoc, V60, P122; PEARSON RSB, 1963, SALICYLATES INT S, P170; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; WALTON C H, 1957, Can Med Assoc J, V76, P1016	13	120	121	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	4					193	199		10.1016/0091-6749(74)90080-3	http://dx.doi.org/10.1016/0091-6749(74)90080-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S6732					2022-12-18	WOS:A1974S673200001
J	Olivera, A; Beaven, MA; Metcalfe, DD				Olivera, Ana; Beaven, Michael A.; Metcalfe, Dean D.			Mast cells signal their importance in health and disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						mast cells; degranulation; Mas-related G protein-coupled receptor X2; IL-33; adhesion G protein-coupled receptor E2; tryptase; allergy; mastocytosis	INNATE LYMPHOID-CELLS; HUMANIZED MOUSE MODEL; HOST-DEFENSE; IN-VIVO; DIFFERENTIAL EXPRESSION; SYSTEMIC-ANAPHYLAXIS; CHEMOKINE PRODUCTION; IMMUNE-RESPONSES; IMMUNOGLOBULIN-E; ADHESION GPCRS	Fc epsilon RI is the primary receptor in mast cells that mediates allergic reactions by inducing rapid release of mediators, an adaptive immune response that might have evolved as a host defense against parasites and venoms. Yet it is apparent that mast cells are also activated through non-IgE receptors, the significance of which is just beginning to be understood. This includes the Mas-related G protein-coupled receptor X2, which might contribute to reactions to diverse antimicrobials and polybasic compounds, and the adhesion G protein-coupled receptor E2, variants of which are associated with familial vibratory urticaria and are activated by mechanical vibration. Similarly, mast cells have long been recognized as the main repository for histamine, heparin, and proteases. Recent evidence also points to new functions, modes of delivery, and mechanisms of action of mast cell proteases that add new dimensions to the roles of mast cells in human biology. In addition, exposure of mast cells to environmental cues can quantitatively and qualitatively modulate their responses and thus their effect on allergic inflammation. Illustrating this paradigm, we summarize a number of recent studies implicating the injury/tissue damage cytokine IL-33 as a modulator of allergen-induced mast cell responses. We also discuss the discovery of markers associated with transformed mast cells and new potential directions in suppressing mast cell activity.	[Olivera, Ana; Metcalfe, Dean D.] NIAID, Mast Cell Biol Sect, Lab Allerg Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Beaven, Michael A.] NHLBI, Lab Mol Immunol, NIH, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Olivera, A (corresponding author), NIAID, Mast Cell Biol Sect, Lab Allerg Dis, NIH, Bldg 10,Rm 11N240,10 Ctr Dr, Bethesda, MD 20892 USA.	ana.olivera@nih.gov			Division of Intramural Research Programs within the National Institute of Allergy and Infectious Diseases, National Institutes of Health; Division of Intramural Research Programs within National Heart, Lung, and Blood Institute, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000965, ZIAAI001206, ZIAAI000249] Funding Source: NIH RePORTER	Division of Intramural Research Programs within the National Institute of Allergy and Infectious Diseases, National Institutes of Health; Division of Intramural Research Programs within National Heart, Lung, and Blood Institute, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research Programs within the National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute, National Institutes of Health.	Abajian M, 2014, IMMUNOL ALLERGY CLIN, V34, P73, DOI 10.1016/j.iac.2013.09.010; Abebayehu D, 2016, J IMMUNOL, V197, P2909, DOI 10.4049/jimmunol.1600651; Akula S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096903; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Bandara G, 2015, EUR J IMMUNOL, V45, P3034, DOI 10.1002/eji.201545501; Bankova LG, 2015, MUCOSAL IMMUNOL, V8, P596, DOI 10.1038/mi.2014.91; Bibi S, 2016, ONCOTARGET, V7, P82985, DOI 10.18632/oncotarget.12824; Boyden SE, 2016, NEW ENGL J MED, V374, P656, DOI 10.1056/NEJMoa1500611; Bryce PJ, 2016, J ALLERGY CLIN IMMUN, V138, P769, DOI 10.1016/j.jaci.2016.01.049; Burton OT, 2017, J ALLERGY CLIN IMMUN, V139, P314, DOI 10.1016/j.jaci.2016.04.034; Cahill KN, 2017, NEW ENGL J MED, V376, P1911, DOI 10.1056/NEJMoa1613125; Caughey GH, 2016, EUR J PHARMACOL, V778, P44, DOI 10.1016/j.ejphar.2015.04.045; Cavalcante MCM, 2002, J STRUCT BIOL, V137, P313, DOI 10.1016/S1047-8477(02)00007-2; Cerny-Reiterer S, 2015, ONCOTARGET, V6, P3071, DOI 10.18632/oncotarget.3074; Chen CY, 2015, IMMUNITY, V43, P788, DOI 10.1016/j.immuni.2015.08.020; Chhiba KD, 2017, J IMMUNOL, V198, P4868, DOI 10.4049/jimmunol.1601825; Crivellato E, 2015, METHODS MOL BIOL, V1220, P11, DOI 10.1007/978-1-4939-1568-2_2; Cruse G, 2016, P NATL ACAD SCI USA, V113, P14115, DOI 10.1073/pnas.1608520113; Da'as S, 2011, DEV COMP IMMUNOL, V35, P125, DOI 10.1016/j.dci.2010.09.001; Dahdah A, 2014, J CLIN INVEST, V124, P4577, DOI 10.1172/JCI75212; Dahlin JS, 2013, ALLERGY, V68, P1333, DOI 10.1111/all.12223; Dahlin JS, 2016, BLOOD, V127, P383, DOI 10.1182/blood-2015-06-650648; Dawicki W, 2007, CURR OPIN IMMUNOL, V19, P31, DOI 10.1016/j.coi.2006.11.006; de Kleer IM, 2016, IMMUNITY, V45, P1285, DOI 10.1016/j.immuni.2016.10.031; Desai A, 2016, J ALLERGY CLIN IMMUN, V137, P1863, DOI 10.1016/j.jaci.2015.09.059; Drube S, 2016, J IMMUNOL, V197, P3662, DOI 10.4049/jimmunol.1600658; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Ferry X, 2002, PEPTIDES, V23, P1507, DOI 10.1016/S0196-9781(02)00090-6; Finkelman FD, 2016, J ALLERGY CLIN IMMUN, V137, P1674, DOI 10.1016/j.jaci.2016.02.015; Fitzsimmons CM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00061; Frossi B, 2017, J ALLERGY CLIN IMMUN, V139, P1266, DOI 10.1016/j.jaci.2016.08.011; Fujisawa D, 2014, J ALLERGY CLIN IMMUN, V134, P622, DOI 10.1016/j.jaci.2014.05.004; FUREDER W, 1995, J IMMUNOL, V155, P3152; Galand C, 2016, J ALLERGY CLIN IMMUN, V138, P1356, DOI 10.1016/j.jaci.2016.03.056; Galli SJ, 2016, AM J PATHOL, V186, P212, DOI 10.1016/j.ajpath.2015.07.025; Galli SJ, 2015, ADV IMMUNOL, V126, P45, DOI 10.1016/bs.ai.2014.11.002; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gaudenzio N, 2016, J CLIN INVEST, V126, P3981, DOI 10.1172/JCI85538; Gilfillan AM, 2011, CRIT REV IMMUNOL, V31, P475, DOI 10.1615/CritRevImmunol.v31.i6.30; Gordon ED, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87871; Gordon ED, 2016, P NATL ACAD SCI USA, V113, P8765, DOI 10.1073/pnas.1601914113; Graham AC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00238; Grujic M, 2017, ONCOTARGET, V8, P25066, DOI 10.18632/oncotarget.15339; Gupta K, 2017, INFECT IMMUN, V85, DOI [10.1128/IAI.00246-17, DOI 10.1128/IAI.00246-17.]; Haidl ID, 2015, METHODS MOL BIOL, V1220, P179, DOI 10.1007/978-1-4939-1568-2_12; Hartmann K, 2016, J ALLERGY CLIN IMMUN, V137, P35, DOI 10.1016/j.jaci.2015.08.034; Ho CCM, 2017, CELL, V168, P1041, DOI 10.1016/j.cell.2017.02.011; Hox V, 2016, J ALLERGY CLIN IMMUN, V138, P187, DOI 10.1016/j.jaci.2015.11.024; Huang YS, 2012, MOL CELL BIOL, V32, P1408, DOI 10.1128/MCB.06557-11; Ito R, 2013, J IMMUNOL, V191, P2890, DOI 10.4049/jimmunol.1203543; Johnzon CF, 2016, AM J PATHOL, V186, P4, DOI 10.1016/j.ajpath.2015.06.024; Joulia R, 2017, J ALLERGY CLIN IMMUN, V140, P497, DOI 10.1016/j.jaci.2016.09.049; Kamijo S, 2016, J IMMUNOL, V196, P3559, DOI 10.4049/jimmunol.1500717; Kaur D, 2015, ALLERGY, V70, P556, DOI 10.1111/all.12593; Kawauchi T, 2017, ALLERGOL INT, V66, P472, DOI 10.1016/j.alit.2017.02.004; Khodoun MV, 2018, J ALLERGY CLIN IMMUN, V141, P171, DOI 10.1016/j.jaci.2017.02.046; Kishore A, 2016, HANDB EXP PHARMACOL, V234, P127, DOI 10.1007/978-3-319-41523-9_7; Kormelink TG, 2016, J IMMUNOL, V197, P3382, DOI 10.4049/jimmunol.1600614; Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Lin HH, 2004, J BIOL CHEM, V279, P31823, DOI 10.1074/jbc.M402974200; Lind T, 2016, PLOS ONE, V11; Liu T, 2015, J IMMUNOL, V195, P3537, DOI 10.4049/jimmunol.1500905; Lyons JJ, 2017, GENET MED; Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696; Makrinioti H, 2014, LANCET RESP MED, V2, P226, DOI 10.1016/S2213-2600(13)70261-3; da Silva EZM, 2014, J HISTOCHEM CYTOCHEM, V62, P698, DOI 10.1369/0022155414545334; Marichal T, 2013, IMMUNITY, V39, P963, DOI 10.1016/j.immuni.2013.10.005; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Melo FR, 2017, J ALLERGY CLIN IMMUN, V140, P474, DOI 10.1016/j.jaci.2016.11.044; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Moritz DR, 1998, J IMMUNOL, V161, P4866; Motakis E, 2014, BLOOD, V123, pE58, DOI 10.1182/blood-2013-02-483792; Mukai K, 2016, SEMIN IMMUNOPATHOL, V38, P581, DOI 10.1007/s00281-016-0565-1; Nagarkar DR, 2015, J ALLERGY CLIN IMMUN, V136, P202, DOI 10.1016/j.jaci.2015.01.036; Ndaw VS, 2017, J IMMUNOL, V199, P866, DOI 10.4049/jimmunol.1601983; Niyonsaba F, 2010, J IMMUNOL, V184, P3526, DOI 10.4049/jimmunol.0900712; Noval Rivas M, 2016, J ALLERGY CLIN IMMUN, V138, P801; Oldford SA, 2015, MOL IMMUNOL, V63, P113, DOI 10.1016/j.molimm.2014.02.020; Oskeritzian CA, 2015, MOL IMMUNOL, V63, P104, DOI 10.1016/j.molimm.2014.03.018; Pagovich OE, 2016, J ALLERGY CLIN IMMUN, V138, P1652, DOI 10.1016/j.jaci.2016.03.053; Pardanani A, 2016, LEUKEMIA, V30, P914, DOI 10.1038/leu.2015.348; Rabenhorst A, 2016, J ALLERGY CLIN IMMUN, V137, P314, DOI 10.1016/j.jaci.2015.07.006; Reber LL, 2012, TRENDS IMMUNOL, V33, P613, DOI 10.1016/j.it.2012.09.008; Ribatti D, 2015, EXP CELL RES, V332, P157, DOI 10.1016/j.yexcr.2014.11.014; Rodewald HR, 2012, IMMUNITY, V37, P13, DOI 10.1016/j.immuni.2012.07.007; Russi A.E., 2016, CLIN IMMUNOL; Saluja R, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00146; Saluja R, 2016, EUR J PHARMACOL, V778, P68, DOI 10.1016/j.ejphar.2015.04.047; Savenije OE, 2014, J ALLERGY CLIN IMMUN, V134, P170, DOI 10.1016/j.jaci.2013.12.1080; Scholz N, 2016, HANDB EXP PHARMACOL, V234, P221, DOI 10.1007/978-3-319-41523-9_10; Shimokawa C, 2017, IMMUNITY, V46, P863, DOI 10.1016/j.immuni.2017.04.017; Shubin NJ, 2017, J ALLERGY CLIN IMMUN, V139, P323, DOI 10.1016/j.jaci.2016.03.051; Sjoberg LC, 2015, ALLERGY, V70, P514, DOI 10.1111/all.12590; St John AL, 2013, J IMMUNOL, V190, P4458, DOI 10.4049/jimmunol.1203420; Starkl P, 2016, J ALLERGY CLIN IMMUN, V137, P246, DOI 10.1016/j.jaci.2015.08.005; Stevens RL, 2017, J BIOL CHEM, V292, P5392, DOI 10.1074/jbc.M116.773416; Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051; Takagi S, 2012, BLOOD, V119, P2768, DOI 10.1182/blood-2011-05-353201; Tatemoto K, 2006, BIOCHEM BIOPH RES CO, V349, P1322, DOI 10.1016/j.bbrc.2006.08.177; Teufelberger AR, 2018, J ALLERGY CLIN IMMUN, V141, P549, DOI 10.1016/j.jaci.2017.05.004; Tsai M, 2015, CURR OPIN IMMUNOL, V36, P80, DOI 10.1016/j.coi.2015.07.001; Tsuzuki H, 2017, IMMUNOLOGY, V150, P64, DOI 10.1111/imm.12667; Wang ZP, 2017, J ALLERGY CLIN IMMUN, V139, P1205, DOI 10.1016/j.jaci.2016.09.019; Weigmann B, 2012, J ALLERGY CLIN IMMUN, V129, P1126, DOI 10.1016/j.jaci.2011.11.036; Wong GW, 2014, BIOCHEM BIOPH RES CO, V451, P314, DOI 10.1016/j.bbrc.2014.07.124; Xu Y, 2015, MEDIAT INFLAMM, V2015; Yu Y, 2015, ERU J PHARM, V778, P33; Zhang T, 2017, EUR J IMMUNOL, V47, P1949, DOI 10.1002/eji.201746951	111	119	121	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					381	393		10.1016/j.jaci.2018.01.034	http://dx.doi.org/10.1016/j.jaci.2018.01.034			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29454835	Bronze			2022-12-18	WOS:000440664400005
J	Croese, J; Giacomin, P; Navarro, S; Clouston, A; McCann, L; Dougall, A; Ferreira, I; Susianto, A; O'Rourke, P; Howlett, M; McCarthy, J; Engwerda, C; Jones, D; Loukas, A				Croese, John; Giacomin, Paul; Navarro, Severine; Clouston, Andrew; McCann, Leisa; Dougall, Annette; Ferreira, Ivana; Susianto, Atik; O'Rourke, Peter; Howlett, Mariko; McCarthy, James; Engwerda, Christian; Jones, Dianne; Loukas, Alex			Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Celiac disease; gluten; hookworm; autoimmunity; helminth therapy; desensitization; mucosal immunology; regulatory T cells; intra-epithelial lymphocytes	ANTIGEN-SPECIFIC IMMUNOTHERAPY; PLACEBO-CONTROLLED TRIAL; NECATOR-AMERICANUS; INTRAEPITHELIAL LYMPHOCYTES; COLITIS; POPULATION; AUTOIMMUNE; INTESTINE; RESPONSES; ALLERGY	Background: Celiac disease (CeD) is a common gluten-sensitive autoimmune enteropathy. A gluten-free diet is an effective treatment, but compliance is demanding; hence, new treatment strategies for CeD are required. Objective: Parasitic helminths hold promise for treating inflammatory disorders, so we examined the influence of experimental hookworm infection on the predicted outcomes of escalating gluten challenges in CeD subjects. Methods: A 52-week study was conducted involving 12 adults with diet-managed CeD. Subjects were inoculated with 20 Necator americanus larvae, and escalating gluten challenges consumed as pasta were subsequently administered: (1) 10 to 50 mg for 12 weeks (microchallenge); (2) 25 mg daily + 1 g twice weekly for 12 weeks (GC-1g); and (3) 3 g daily (60-75 straws of spaghetti) for 2 weeks (GC-3g). Symptomatic, serologic, and histological outcomes evaluated gluten toxicity. Regulatory and inflammatory T cell populations in blood and mucosa were examined. Results: Two gluten-intolerant subjects were withdrawn after microchallenge. Ten completed GC-1g, 8 of whom enrolled in and completed GC-3g. Primary outcomes: median villous height-to-crypt depth ratios (2.60-2.63; P = .98) did not decrease as predicted after GC-1g, and the mean IgA-tissue transglutaminase titers declined, contrary to the predicted rise after GC-3g. Secondary outcomes: quality of life scores improved (46.3-40.6; P = .05); celiac symptom indices (24.3-24.3; P = .53), intra-epithelial lymphocyte percentages (32.5-35.0; P = .47), and Marsh scores were unchanged by gluten challenge. Intestinal T cells expressing IFN gamma were reduced following hookworm infection (23.9%-11.5%; P = .04), with corresponding increases in CD4(+) Foxp3(+) regulatory T cells (0.19%-1.12%; P = .001). Conclusions: Necator americanus and gluten microchallenge promoted tolerance and stabilized or improved all tested indices of gluten toxicity in CeD subjects.	[Croese, John] Prince Charles Hosp, Dept Gastroenterol & Hepatol, Brisbane, Qld 4032, Australia; [Croese, John; Giacomin, Paul; Navarro, Severine; McCann, Leisa; Dougall, Annette; Ferreira, Ivana; Susianto, Atik; Loukas, Alex] James Cook Univ, Australian Inst Trop Hlth & Med, Ctr Biodiscovery & Mol Dev Therapeut, Cairns, Qld, Australia; [Clouston, Andrew] Envoi Specialist Pathologists, Brisbane, Qld, Australia; [O'Rourke, Peter; McCarthy, James; Engwerda, Christian] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Howlett, Mariko; McCarthy, James] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia; [Jones, Dianne] Logan Hosp, Brisbane, Qld, Australia	Prince Charles Hospital; James Cook University; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Croese, J (corresponding author), Prince Charles Hosp, Gastroenterol Unit, Rode Rd, Brisbane, Qld 4032, Australia.	mcroese@bigpond.net.au; alex.loukas@jcu.edu.au	Clouston, Andrew D/E-7199-2011; Navarro, Severine/B-7353-2014; Engwerda, Christian/I-3072-2015; Loukas, Alex/B-7355-2014	Clouston, Andrew D/0000-0002-9601-7952; Navarro, Severine/0000-0003-4568-9721; Giacomin, Paul/0000-0002-6326-6792; Loukas, Alex/0000-0002-0896-8441; Engwerda, Christian/0000-0003-2813-4804; Ferreira, Ivana/0000-0002-7309-3960; McCarthy, James/0000-0001-6596-9718	Australian National Health and Medical Research Council (NHMRC) Program Grant [1037304]; NHMRC Overseas Biomedical Fellowship [613718]; NHMRC Principal Research Fellowship [1020114]; NHMRC Senior Research Fellowship [1058685]; NHMRC Practitioner Fellowship; Government of Queensland Health Research Fellowship [1041802]; Far North Queensland Hospital Foundation Small Research Grant	Australian National Health and Medical Research Council (NHMRC) Program Grant(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Overseas Biomedical Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Government of Queensland Health Research Fellowship; Far North Queensland Hospital Foundation Small Research Grant	The work was funded by an Australian National Health and Medical Research Council (NHMRC) Program Grant (1037304 to A. L., C. E., and J.M.), NHMRC Overseas Biomedical Fellowship 613718 (to P. G.), NHMRC Principal Research Fellowship (1020114 to A. L.), NHMRC Senior Research Fellowship (1058685 to C. E.), NHMRC Practitioner Fellowship and Government of Queensland Health Research Fellowship (1041802 to J.M.) and a Far North Queensland Hospital Foundation Small Research Grant (P.G. and S.N.).	Abadie V, 2012, SEMIN IMMUNOPATHOL, V34, P551, DOI 10.1007/s00281-012-0316-x; Anderson RP, 2013, CURR OPIN IMMUNOL, V25, P410, DOI 10.1016/j.coi.2013.02.004; Bager P, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Bager P, 2010, J ALLERGY CLIN IMMUN, V125, P123, DOI 10.1016/j.jaci.2009.08.006; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Catassi C, 2007, AM J CLIN NUTR, V85, P160, DOI 10.1093/ajcn/85.1.160; Croese J, 2006, GUT, V55, P136, DOI 10.1136/gut.2005.079129; Croese J, 2006, GASTROENTEROLOGY, V131, P402, DOI 10.1053/j.gastro.2006.05.019; Daveson AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017366; Di Sabatino A, 2012, AUTOIMMUN REV, V11, P746, DOI 10.1016/j.autrev.2012.01.007; Dorn SD, 2010, ALIMENT PHARM THER, V31, P666, DOI 10.1111/j.1365-2036.2009.04220.x; Feary JR, 2010, CLIN EXP ALLERGY, V40, P299, DOI 10.1111/j.1365-2222.2009.03433.x; Ferreira I, 2013, INFECT IMMUN, V81, P2104, DOI 10.1128/IAI.00563-12; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Gaze S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002520; Geiger Stefan Michael, 2011, J Parasitol Res, V2011, P512154, DOI 10.1155/2011/512154; Holding S, 2014, J IMMUNOL METHODS, V405, P29, DOI 10.1016/j.jim.2014.01.002; Lambert SB, 2008, PEDIATRICS, V122, pE615, DOI 10.1542/peds.2008-0691; Leffler D, 2013, GUT, V62, P996, DOI 10.1136/gutjnl-2012-302196; Leffler DA, 2009, CLIN GASTROENTEROL H, V7, P1328, DOI 10.1016/j.cgh.2009.07.031; Ludvigsson JF, 2013, AM J GASTROENTEROL, V108, P818, DOI 10.1038/ajg.2013.60; LUNDQVIST C, 1992, J IMMUNOL METHODS, V152, P253, DOI 10.1016/0022-1759(92)90147-L; McSorley HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024092; Meresse B, 2012, IMMUNITY, V36, P907, DOI 10.1016/j.immuni.2012.06.006; Navarro S, 2013, INT J PARASITOL, V43, P225, DOI 10.1016/j.ijpara.2012.11.005; O'Mahony L, 2010, AUTOIMMUNITY, V43, P493, DOI 10.3109/08916931003674725; Qiao SW, 2012, SEMIN IMMUNOPATHOL, V34, P523, DOI 10.1007/s00281-012-0314-z; Ricci ND, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001383; Rubio-Tapia A, 2009, GASTROENTEROLOGY, V137, P88, DOI 10.1053/j.gastro.2009.03.059; Ruyssers NE, 2009, INFLAMM BOWEL DIS, V15, P491, DOI 10.1002/ibd.20787; Sabatos-Peyton CA, 2010, CURR OPIN IMMUNOL, V22, P609, DOI 10.1016/j.coi.2010.08.006; Spatola BN, 2014, ALIMENT PHARM THER, V39, P407, DOI 10.1111/apt.12603; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Taavela J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076163; Verweij JJ, 2007, AM J TROP MED HYG, V77, P685, DOI 10.4269/ajtmh.2007.77.685; Walker MM, 2011, HISTOPATHOLOGY, V59, P166, DOI 10.1111/j.1365-2559.2010.03680.x	37	119	119	1	53	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					508	U677		10.1016/j.jaci.2014.07.022	http://dx.doi.org/10.1016/j.jaci.2014.07.022			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25248819	Bronze			2022-12-18	WOS:000349372300025
J	Lopez-Guisa, JM; Powers, C; File, D; Cochrane, E; Jimenez, N; Debley, JS				Lopez-Guisa, Jesus M.; Powers, Claire; File, Daniele; Cochrane, Elizabeth; Jimenez, Nathalia; Debley, Jason S.			Airway epithelial cells from asthmatic children differentially express proremodeling factors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; children; airway remodeling; epithelial cells vascular endothelial growth factor; a disintegrin and metalloprotease 33; periostin; TGF-beta 2	ENDOTHELIAL GROWTH-FACTOR; BRONCHIAL-ASTHMA; LUNG-FUNCTION; SUBEPITHELIAL FIBROSIS; NONASTHMATIC SUBJECTS; ALLERGIC RHINITIS; BASEMENT-MEMBRANE; CHILDHOOD ASTHMA; INDUCED SPUTUM; ADAM33 GENE	Background: The airway epithelium can express factors that drive subepithelial airway remodeling. TGF-beta 2, vascular epithelial growth factor (VEGF), a disintegrin and metalloprotease 33 (ADAM33), and periostin are hypothesized to be involved in subepithelial remodeling and are overexpressed in adult asthmatic airways. Epidemiologic data suggest that lung function deficits in asthmatic patients are acquired in childhood. Objectives: We sought to determine whether airway epithelial cells (AECs) from asthmatic children differentially express TGF-beta 2, VEGF, ADAM33, or periostin compared with cells from atopic nonasthmatic and healthy children intrinsically or in response to IL-4/IL-13 stimulation. Methods: Bronchial and nasal epithelial cells were obtained from brushings from well-characterized asthmatic (n = 16), atopic nonasthmatic (n = 9), and healthy (n = 15) children after achievement of anesthesia for elective procedures. After differentiation at an air-liquid interface (ALI) for 3 weeks, conditioned media were sampled and RNA was extracted from unstimulated and IL-4/IL-13-stimulated cultures. TGF-beta 2 and VEGF levels were measured with ELISA. ADAM33 and periostin expression was assessed by using real-time PCR. Results: TGF-beta 2 and VEGF production was significantly greater in bronchial and nasal ALI cultures from asthmatic children than in cultures from atopic nonasthmatic and healthy children. TGF-beta 2 levels increased significantly in asthmatic cultures after IL-4/IL-13 stimulation. Within-subject correlation between nasal and bronchial ALI production of TGF-beta 2 (r = 0.64, P = .001) and VEGF (r = 0.73, P < .001) was good. Periostin expression was 3.7-fold higher in bronchial cells (P < .001) and 3.9-fold higher in nasal cells (P < .004) from asthmatic children than in cells from atopic nonasthmatic or healthy children. ADAM33 was not differentially expressed by AECs from asthmatic patients compared with that from cells from atopic nonasthmatic or healthy children. Conclusion: AECs from asthmatic children differentially express TGF-beta 2, VEGF, and periostin compared with cells from atopic nonasthmatic and healthy children. Nasal epithelial cells might be a suitable surrogate for bronchial cells that could facilitate investigation of the airway epithelium in future longitudinal pediatric studies. (J Allergy Clin Immunol 2012;129:990-7.)	[Lopez-Guisa, Jesus M.; Powers, Claire; File, Daniele; Debley, Jason S.] Univ Washington, Ctr Tissue & Cell Sci, Seattle Childrens Res Inst, Seattle, WA 98195 USA; [Cochrane, Elizabeth; Debley, Jason S.] Univ Washington, Seattle Childrens Hosp, Div Pulm Med, Seattle, WA 98195 USA; [Jimenez, Nathalia] Univ Washington, Seattle Childrens Hosp, Dept Anesthesia & Pain Management, Seattle, WA 98195 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of Washington; University of Washington Seattle	Debley, JS (corresponding author), Seattle Childrens Hosp, Div Pulm, A-5937,4800 Sand PointWay NE, Seattle, WA 98105 USA.	jason.debley@seattlechildrens.org		Jimenez, Nathalia/0000-0002-6785-8330	American Lung Association Biomedical [RG-71839-N]; National Heart, Lung, and Blood Institute [K23HL077626]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL077626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM086270] Funding Source: NIH RePORTER	American Lung Association Biomedical; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by American Lung Association Biomedical grant RG-71839-N (PI: J.S.D.) and National Heart, Lung, and Blood Institute grant K23HL077626 (PI: J.S.D.).	Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907, DOI 10.1164/ajrccm.157.6.9609040; Asai K, 2003, CLIN EXP ALLERGY, V33, P595, DOI 10.1046/j.1365-2222.2003.01576.x; Baluk P, 2004, AM J PATHOL, V165, P1071, DOI 10.1016/S0002-9440(10)63369-X; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Bhandari V, 2006, P NATL ACAD SCI USA, V103, P11021, DOI 10.1073/pnas.0601057103; Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x; Butcher JT, 2007, DEV BIOL, V302, P256, DOI 10.1016/j.ydbio.2006.09.048; Chakir J, 1996, LAB INVEST, V75, P735; Chetta A, 2005, CLIN EXP ALLERGY, V35, P1437, DOI 10.1111/j.1365-2222.2005.02360.x; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Debley JS, 2010, AM J RESP CRIT CARE, V181; Dorn GW, 2007, NEW ENGL J MED, V357, P1552, DOI 10.1056/NEJMcibr074816; E1. REST (Relative Expression Software Tool), REST RELATIVE EXPRES; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P863, DOI 10.1016/j.jaci.2006.12.665; Gillan L, 2002, CANCER RES, V62, P5358; Hackett TL, 2007, CURR OPIN ALLERGY CL, V7, P63, DOI 10.1097/ACI.0b013e328013d61b; Holgate Stephen T, 2009, Proc Am Thorac Soc, V6, P655, DOI 10.1513/pats.200907-072DP; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hossny E, 2009, PEDIAT ALLERG IMM-UK, V20, P89, DOI 10.1111/j.1399-3038.2008.00730.x; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kelly MM, 2005, AM J RESP CELL MOL, V32, P99, DOI 10.1165/rcmb.2004-0190OC; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; Kii I, 2006, BIOCHEM BIOPH RES CO, V342, P766, DOI 10.1016/j.bbrc.2006.02.016; Kikuchi Y, 2008, J HISTOCHEM CYTOCHEM, V56, P753, DOI 10.1369/jhc.2008.951061; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P567, DOI 10.1111/j.1365-2222.2004.1917.x; Lane C, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-53; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee JY, 2006, AM J RESP CRIT CARE, V173, P729, DOI 10.1164/rccm.200409-1175OC; Malavia NK, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-27; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Salvato G, 2001, THORAX, V56, P902, DOI 10.1136/thorax.56.12.902; Sharma S, 2009, EUR RESPIR J, V33, P1287, DOI 10.1183/09031936.00113008; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Thompson HGR, 2006, AM J PHYSIOL-LUNG C, V291, pL1277, DOI 10.1152/ajplung.00057.2006; Torrego A, 2007, THORAX, V62, P307, DOI 10.1136/thx.2006.063487; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Voelkel NF, 2006, AM J PHYSIOL-LUNG C, V290, pL209, DOI 10.1152/ajplung.00185.2005; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Yang Y, 2008, J ALLERGY CLIN IMMUN, V121, pe1; Yang YW, 2008, J ALLERGY CLIN IMMUN, V121, P1393, DOI 10.1016/j.jaci.2008.02.031	48	119	124	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					990	U496		10.1016/j.jaci.2011.11.035	http://dx.doi.org/10.1016/j.jaci.2011.11.035			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22227417	Green Accepted			2022-12-18	WOS:000302144600013
J	Melgert, BN; ten Hacken, NH; Rutgers, B; Timens, W; Postma, DS; Hylkema, MN				Melgert, Barbro N.; ten Hacken, Nick H.; Rutgers, Bea; Timens, Wim; Postma, Dirkje S.; Hylkema, Machteld N.			More alternative activation of macrophages in lungs of asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLAMMATION		[Melgert, Barbro N.] Univ Groningen, Groningen Res Inst Pharm, Dept Pharmacokinet Toxicol & Targeting, Groningen, Netherlands; [Melgert, Barbro N.; Rutgers, Bea; Timens, Wim; Hylkema, Machteld N.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands; [ten Hacken, Nick H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Melgert, BN (corresponding author), Univ Groningen, Groningen Res Inst Pharm, Dept Pharmacokinet Toxicol & Targeting, Groningen, Netherlands.	bnmelgert@mac.com	Timens, Wim/K-5570-2013	Timens, Wim/0000-0002-4146-6363; Hylkema, Machteld/0000-0002-6732-8903; Melgert, Barbro/0000-0001-7091-907X				Cochand L, 1999, AM J RESP CELL MOL, V21, P547, DOI 10.1165/ajrcmb.21.5.3785; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P963, DOI 10.1016/j.jaci.2010.02.011; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Melgert BN, 2010, AM J RESP CELL MOL, V42, P595, DOI 10.1165/rcmb.2009-0016OC; Peters-Golden M, 2004, AM J RESP CELL MOL, V31, P3, DOI 10.1165/rcmb.f279; ten Hacken NHT, 1998, EUR RESPIR J, V12, P546, DOI 10.1183/09031936.98.12030546; Vercelli D, 2003, J CLIN INVEST, V111, P1815, DOI 10.1172/JCI200318908; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	9	119	125	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					831	833		10.1016/j.jaci.2010.10.045	http://dx.doi.org/10.1016/j.jaci.2010.10.045			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21167569				2022-12-18	WOS:000288018400039
J	Sicherer, SH; Wood, RA; Stablein, D; Lindblad, R; Burks, AW; Liu, AH; Jones, SM; Fleischer, DM; Leung, DYM; Sampson, HA				Sicherer, Scott H.; Wood, Robert A.; Stablein, Donald; Lindblad, Robert; Burks, A. Wesley; Liu, Andrew H.; Jones, Stacie M.; Fleischer, David M.; Leung, Donald Y. M.; Sampson, Hugh A.			Maternal consumption of peanut during pregnancy is associated with peanut sensitization in atopic infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; sensitization; atopy; peanut allergy	FOOD ALLERGY; TREE NUT; ANAPHYLACTIC REACTIONS; IGE CONCENTRATIONS; GOVERNMENT ADVICE; RISK-FACTOR; SKIN PRICK; CHILDREN; PREVALENCE; DISEASES	Background: Peanut allergy is typically severe, lifelong, and prevalent. Objective: To identify factors associated with peanut sensitization. Methods: We evaluated 503 infants 3 to 15 months of age (mean, 9.4 months) with likely milk or egg allergy but no previous diagnosis of peanut allergy. A total of 308 had experienced an immediate allergic reaction to cow's milk and/or egg, and 204 had moderate to severe atopic dermatitis and a positive allergy test to milk and/or egg. A peanut IgE level >= 5 kU(A)/L was considered likely indicative of peanut allergy. Results: A total of 140 (27.8%) infants had peanut IgE levels >= 5 kU(A)/L. Multivariate analysis including clinical, laboratory, and demographic variables showed frequent peanut consumption during pregnancy (odds ratio, 2.9; 95% CI, 1.7-4.9; P < .001), IgE levels to milk (P = .001) and egg (P < .001), male sex (P = .02), and nonwhite race (P = .02) to be the primary factors associated with peanut IgE >= 5 kU(A)/L. Frequency of peanut consumption during pregnancy and breast-feeding showed a dose-response association with peanut IgE >= 5 kU(A)/L, but only consumption during pregnancy was a significant predictor. Among 71 infants never breast-fed, frequent consumption of peanut during pregnancy was strongly associated with peanut IgE >= 5 kU(A)/L (odds ratio, 4.99, 95% CI, 1.69-14.74; P < .004). Conclusion: In this cohort of infants with likely milk or egg allergy, maternal ingestion of peanut during pregnancy was strongly associated with a high level of peanut sensitization. (J Allergy Clin Immunol 2010; 126:1191-7.)	[Sicherer, Scott H.; Liu, Andrew H.; Sampson, Hugh A.] Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Stablein, Donald; Lindblad, Robert] EMMES Corp, Rockville, MD USA; [Burks, A. Wesley] Duke Univ, Med Ctr, Durham, NC USA; [Liu, Andrew H.; Fleischer, David M.; Leung, Donald Y. M.] Natl Jewish Hlth, Denver, CO USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA	Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Emmes Corporation; Duke University; National Jewish Health; University of Arkansas System; University of Arkansas Medical Sciences	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			NIH-NIAID [U19AI066738, U01AI066560]; National Center for Research Resources, National Institutes of Health [UL1 RR025780, UL1 RR 029887, UL 1 RR029884, UL 1 RR024128, UL1 RR 025005]; Food Allergy Initiative; NIH; Food Allergy& Anaphylaxis Network; Wallace Research Foundation; National Peanut Board; Dyax Corp; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071, UL1RR024128, UL1RR025780, UL1RR029884, UL1RR025005, UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066738, U01AI066560] Funding Source: NIH RePORTER	NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Food Allergy Initiative; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy& Anaphylaxis Network; Wallace Research Foundation; National Peanut Board; Dyax Corp; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by NIH-NIAID U19AI066738 and U01AI066560. The project was also supported by grant nos. UL1 RR025780 (National Jewish), UL1 RR 029887 (Mount Sinai), UL 1 RR029884 (Arkansas), UL 1 RR024128 (Duke), and UL1 RR 025005 (Johns Hopkins) from the National Center for Research Resources, a component of the National Institutes of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Center for Research Resources or National Institutes of Health.; Disclosure of potential conflict of interest: S. H. Sicherer is a consultant for the Food Allergy Initiative and an advisor for the Food Allergy & Anaphylaxis Network and receives research support from the NIH-NIAID and the Food Allergy Initiative. D. Stablein receives grant support from the NIH. R. A. Wood receives grant support from the NIH. A. W. Burks is a consultant for ActoGeniX NV, Intelliject, McNeil Nutritionals, Novartis, and Schering-Plough; is a minority stockholder in Allertein and MastCell, Inc; is on the advisory board for Dannon Co Probiotics; is on the expert panel for Nutricia; receives grant support from the National Institutes of Health, the Food Allergy& Anaphylaxis Network, and the Wallace Research Foundation; has provided legal consultation services/expert witness testimony in cases related to food allergy; is on the Medical Board of Directors for the Food Allergy& Anaphylaxis Network; is a Dermatological Allergy Committee member for ACAAI; is a Study Section member for the NIH-HAI; serves on the reviewer board for the Journal of Allergy and Clinical Immunology; and is a member of the FDA. S. M. Jones receives research support from the National Peanut Board, the NIH-NIAID, and Dyax Corp; serves on the Medical Advisory Board for the Food Allergy & Anaphylaxis Network; and is a steering committee member for Sanofi-Aventis. Donald Y. M. Leung is the medical director for the Food Allergy Initiative. H. A. Sampson is a consultant for Allertein, LLC; receives research support from the Food Allergy Initiative and the NIH-NIAID; is a consultant/scientific advisor for the Food Allergy Initiative; and is 45% owner of Herbal Springs, LLC. The rest of the authors have declared that they have no conflict of interest.	ARMITAGE P, 1998, ENCY BIOSTATISTICS, P3738; Baker SS, 2000, PEDIATRICS, V106, P346; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Busse PJ, 2002, NEW ENGL J MED, V347, P1535, DOI 10.1056/NEJM200211073471921; Dean T, 2007, J HUM NUTR DIET, V20, P95, DOI 10.1111/j.1365-277X.2007.00751.x; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Frank L, 1999, PEDIATR ALLERGY IMMU, V10, P27, DOI 10.1034/j.1399-3038.1999.101010.x; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Host A, 1999, ARCH DIS CHILD, V81, P80, DOI 10.1136/adc.81.1.80; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Klemola T, 2005, PEDIAT ALLERG IMM-UK, V16, P641, DOI 10.1111/j.1399-3038.2005.00326.x; Kmietowicz Z, 2007, BRIT MED J, V335, P633, DOI 10.1136/bmj.39349.377488.DB; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Koplin J, 2008, J ALLERGY CLIN IMMUN, V121, P1455, DOI 10.1016/j.jaci.2008.03.017; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Mullins RJ, 2009, J ALLERGY CLIN IMMUN, V123, P689, DOI 10.1016/j.jaci.2008.12.1116; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; Todd DG, 2007, PEDIATRICS, V120, P1304, DOI 10.1542/peds.2007-0350; Untersmayr E, 2008, J ALLERGY CLIN IMMUN, V121, P1301, DOI 10.1016/j.jaci.2008.04.025; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x	40	119	124	2	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1191	1197		10.1016/j.jaci.2010.08.036	http://dx.doi.org/10.1016/j.jaci.2010.08.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21035177	Green Accepted			2022-12-18	WOS:000284947800017
J	Bonagura, VR; Marchlewski, R; Cox, A; Rosenthal, DW				Bonagura, Vincent R.; Marchlewski, Robert; Cox, Amanda; Rosenthal, David W.			Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INTRAVENOUS IMMUNOGLOBULIN; THERAPY		[Bonagura, Vincent R.; Marchlewski, Robert; Cox, Amanda; Rosenthal, David W.] N Shore LIJ Hlth Syst, Schneider Childrens Hosp, Dept Pediat, Div Allergy Immunol, Great Neck, NY USA; [Bonagura, Vincent R.; Rosenthal, David W.] N Shore LIJ Hlth Syst, Feinstein Inst Med Research, Elmezzi Grad Sch Mol Med, Manhasset, NY USA	Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Northwell Health	Bonagura, VR (corresponding author), N Shore LIJ Hlth Syst, Schneider Childrens Hosp, Dept Pediat, Div Allergy Immunol, Great Neck, NY USA.	bonagura@lij.edu	Rosenthal, David W/E-2199-2011; Parker, Claire/AAW-8396-2020	Rosenthal, David W/0000-0003-2136-4287; Bonagura, Vincent/0000-0002-0681-2099				Berger M, 1999, J ALLERGY CLIN IMMUN, V104, P911, DOI 10.1016/S0091-6749(99)70067-9; BUCKLEY RH, 1982, J CLIN IMMUNOL, V2, P15; de Gracia J, 2004, INT IMMUNOPHARMACOL, V4, P745, DOI 10.1016/j.intimp.2004.02.011; *NAT GOVT SERV INC, INTR IMM GLOB IVIG; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; Quartier P, 1999, J PEDIATR-US, V134, P589, DOI 10.1016/S0022-3476(99)70246-5; Radinsky S, 2003, J ALLERGY CLIN IMMUN, V112, P630, DOI 10.1067/mai.2003.1688	7	119	124	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					210	212		10.1016/j.jaci.2008.04.044	http://dx.doi.org/10.1016/j.jaci.2008.04.044			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18602574				2022-12-18	WOS:000257605100034
J	Tavendale, R; Macgregor, DF; Mukhopadhyay, S; Palmer, CNA				Tavendale, Roger; Macgregor, Donald F.; Mukhopadhyay, Somnath; Palmer, Colin N. A.			A polymorphism controlling ORMDL3 expression is associated with asthma that is poorly controlled by current medications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; ORMDL3; genetics; single nucleotide polymorphism; susceptibility; exacerbation	GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY; RISK; EXACERBATIONS; FILAGGRIN; GENOTYPE; LOCUS; VARIANTS; GENETICS; ALLELES	Background: The specific genetic contributions to childhood asthma have been difficult to elucidate. A recent whole-genome association study suggested that single nucleotide polymorphisms at loci controlling the expression of the ORMDL3 gene and others in the neighborhood of the NRG1 and ERO1LB genes might be important. Objective: We sought to replicate the associations of these genetic markers with asthma in a large population of asthmatic patients from Scotland and to assess the effect of these variants on asthma outcomes. Methods: Using mouthwash-derived DNA and clinical interviews and measurements, we investigated the association of 3 single nucleotide polymorphisms in the candidate genes with susceptibility to asthma in a case-control study and also exacerbations in a group of 1054 patients aged 3 to 22 years. Results: A common C/T polymorphism at a locus controlling ORMDL3 gene expression (rs7216389) was significantly associated with the risk of childhood asthma (P = 1.73 x 10(-12)), with a single copy of the T allele conferring an odds ratio of 1.50 (95% CI, 1.24-1.81) and 2 copies of the T allele conferring an odds ratio of 2.11 (95% CI, 1.71-2.61), respectively. In asthmatic patients the T allele was associated with exacerbations of the condition (P = .008). Polymorphisms at the loci of nearby genes for NRG1 (rs4512342) and ERO1LB (rs10924993) were associated with neither the occurrence of nor exacerbations of asthma. Conclusion: A common genetic variation at a locus controlling the expression of the ORMDL3 locus increases the susceptibility to asthma and is associated with poor control of the condition in children and young adults.	[Tavendale, Roger; Palmer, Colin N. A.] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Populat Pharmacogenet Grp, Dundee DD1 9SY, Scotland; [Macgregor, Donald F.; Mukhopadhyay, Somnath] Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; [Mukhopadhyay, Somnath] Royal Alexandra Hosp Children, Brighton & Sussex Med Sch, Dundee, Scotland	University of Dundee; University of Dundee	Palmer, CNA (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Populat Pharmacogenet Grp, Dundee DD1 9SY, Scotland.	nuclear-receptor@dundee.ac.uk	Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560				Blakey J, 2005, THORAX, V60, P274, DOI 10.1136/thx.2004.027227; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cecil JE, 2005, DIABETOLOGIA, V48, P1496, DOI 10.1007/s00125-005-1817-0; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Haagerup A, 2002, ALLERGY, V57, P680, DOI 10.1034/j.1398-9995.2002.23523.x; Holgate ST, 2005, AM J RESP CRIT CARE, V172, P941, DOI 10.1164/rccm.2507007; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; Hunter DJ, 2007, NEW ENGL J MED, V357, P436, DOI 10.1056/NEJMp078120; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kimber CH, 2007, DIABETOLOGIA, V50, P1186, DOI 10.1007/s00125-007-0661-9; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Palmer CNA, 2007, CLIN PHARMACOL THER, V81, P713, DOI 10.1038/sj.clpt.6100119; Palmer CNA, 2006, THORAX, V61, P940, DOI 10.1136/thx.2006.059386; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Palmer CNA, 2006, PEDIATRICS, V118, P710, DOI 10.1542/peds.2005-3030; Pillai SG, 2006, EUR J HUM GENET, V14, P307, DOI 10.1038/sj.ejhg.5201532; Tamura M, 2007, GENOMICS, V89, P618, DOI 10.1016/j.ygeno.2007.01.003; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Wills-Karp M, 2004, NAT REV GENET, V5, P376, DOI 10.1038/nrg1326; Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022	26	119	133	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					860	863		10.1016/j.jaci.2008.01.015	http://dx.doi.org/10.1016/j.jaci.2008.01.015			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18395550	Bronze			2022-12-18	WOS:000254884000008
J	Kaiser, HB; Naclerio, RM; Given, J; Toler, TN; Ellsworth, A; Philpot, EE				Kaiser, Harold B.; Naclerio, Robert M.; Given, John; Toler, Tom N.; Ellsworth, Anna; Philpot, Edward E.			Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intranasal corticosteroids; fluticasone furoate; seasonal allergic rhinitis; ragweed pollen	QUALITY-OF-LIFE; OCULAR SYMPTOMS; PROPIONATE; EFFICACY; ASTERISK; SAFETY	Background: Fluticasone furoate (USAN-approved name) is a novel, enhanced-affinity glucocorticoid administered in a unique side-actuated device for the management of seasonal allergic rhinitis (SAR). Objective: We sought to evaluate the efficacy and safety of once-daily fluticasone furoate nasal spray, 110 mu g, in patients aged 12 years or older with fall SAR. Methods: Patients (n = 299) received fluticasone furoate or placebo for 2 weeks in this double-blind, parallel-group randomized study. Patients evaluated nasal and ocular symptoms using a 4-point categoric scale. Efficacy was assessed on the basis of the mean change from baseline in reflective and instantaneous total nasal symptom scores and reflective total ocular symptom scores. Results: Fluticasone furoate produced significantly greater improvements than placebo in daily reflective total nasal symptom score (-1.473, P < .001; primary end point), morning predose instantaneous total nasal symptom score (-1.375, P < .001), daily reflective total ocular symptom score (-0.600, P = .004), and patient-rated overall response to therapy (P < .001). The onset of therapeutic effect occurred at 8 hours after initial administration. Fluticasone furoate was well tolerated. Conclusion: Fluticasone furoate, 110 mu g once daily, was effective and well tolerated for the treatment of nasal symptoms of SAR in patients aged 12 years and older. Treatment also produced significant improvements in ocular symptoms. Fluticasone furoate was fast acting, as indicated by an 8-hour onset of action, and provided 24-hour symptom control. Clinical implications: New treatments for the bothersome symptoms of SAR are needed. One such treatment, fluticasone furoate nasal spray, provides effective relief of the symptom profile of SAR.	Clin Res Inst, Minneapolis, MN 55402 USA; Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; GlaxoSmithKline, Res Triangle Pk, NC USA	University of Chicago; GlaxoSmithKline	Kaiser, HB (corresponding author), Clin Res Inst, 825 Nicollet Mall,Suite 1135, Minneapolis, MN 55402 USA.	hbk@allergy-asthma-docs.com						Allen A, 2007, ANN ALLERG ASTHMA IM, V98, pA89; *AM AC ALL ASTH IM, 2000, TASK FORC ALL DIS AL, V1; ANDERSSON M, 1988, J ALLERGY CLIN IMMUN, V82, P1019, DOI 10.1016/0091-6749(88)90139-X; BANKEN R, 1992, Allergie et Immunologie (Paris), V24, P91; BARNEY NP, 2003, MIDDLETONS ALLERGY P, P1602; Baroody FM, 2003, OTOLARYNG HEAD NECK, V128, P616, DOI 10.1016/S0194-5998(03)00257-2; Bernstein DI, 2004, CLIN EXP ALLERGY, V34, P952, DOI 10.1111/j.1365-2222.2004.01952.x; BIGGADIKE K, 2006, EUR AC ALL CLIN IMM; Blaiss MS, 2000, ALLERGY ASTHMA PROC, V21, P7, DOI 10.2500/108854100778248953; Bousquet J, 2004, ALLERGY, V59, P4, DOI 10.1111/j.1398-9995.2004.00577.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; DeWester J, 2003, ALLERGY ASTHMA PROC, V24, P331; Dykema KJ, 1998, GEOM FUNCT ANAL, V8, P1, DOI 10.1007/s000390050046; Frenz DA, 1999, ANN ALLERG ASTHMA IM, V82, P41, DOI 10.1016/S1081-1206(10)62658-0; Frieri M, 2005, ALLERGY ASTHMA PROC, V26, P163; Gadermaier G, 2004, CURR ALLERGY ASTHM R, V4, P391, DOI 10.1007/s11882-004-0090-5; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; MARTIN B, 2006, EUR AC ALL CLIN IMM; MELTZER EO, 2005, ALLERGY CLIN IMMU S1, V17, pA709; Mygind N, 2001, J ALLERGY CLIN IMMUN, V108, pS16, DOI 10.1067/mai.2001.115561; PHILPOT E, 2006, EUR AC ALL CLIN IMM; SALTER M, 2006, EUR AC ALL CLIN IMM; Schoenwetter WF, 2004, CURR MED RES OPIN, V20, P305, DOI 10.1185/030079903125003053; Spangler DL, 2003, CLIN THER, V25, P2245, DOI 10.1016/S0149-2918(03)80217-5; Thompson AK, 2000, ANN ALLERG ASTHMA IM, V85, P338, DOI 10.1016/S1081-1206(10)62543-4; VALOTIS A, 2006, EUR AC ALL CLIN IMM; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; Wilken JA, 2002, ANN ALLERG ASTHMA IM, V89, P372, DOI 10.1016/S1081-1206(10)62038-8; Wjst M, 2005, PLOS MED, V2, P977, DOI 10.1371/journal.pmed.0020294; 2006, ALLERGIES AM EXECUTI	32	119	126	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1430	1437		10.1016/j.jaci.2007.02.022	http://dx.doi.org/10.1016/j.jaci.2007.02.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17418384				2022-12-18	WOS:000247232800019
J	Charles, T; Quinn, D; Weatherall, M; Aldington, S; Beasley, R; Holt, S				Charles, Thomas; Quinn, Dean; Weatherall, Mark; Aldington, Sarah; Beasley, Richard; Holt, Shaun			An audiovisual reminder function improves adherence with inhaled corticosteroid therapy in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adherence; adults; asthma; compliance; inhaled corticosteroids; reminder function	FLUTICASONE PROPIONATE; CLINICAL-TRIALS; MEDICATION; ADULTS; SCHIZOPHRENIA; INTERVENTIONS	Background: Adherence to medication regimens is poor in the management of chronic diseases, including asthma. Objective: To determine whether an audiovisual reminder device improves adherence with inhaled corticosteroid (ICS) therapy in adult asthma. Methods: A randomized open-label parallel group study of I 10 adult or adolescent subjects with asthma was undertaken. Subjects were randomized to receive 24 weeks of fluticasone propionate 250 mu g, 1 actuation twice daily via a metered dose inhaler (MDI) with or without an audiovisual reminder function (AVRF). All MDIs had electronic covert adherence monitors. The primary outcome variable was adherence, defined as the proportion of medication taken as prescribed over the final 12 weeks of the study. Adherence was also assessed as the proportion of subjects who took > 50%, > 80%, or > 90% of prescribed medication. Results: The proportion of medication taken in the last 12 weeks was greater in the AVRF group (93%) compared with the control group (74%), with a difference of 18% (95% confidence interval [CI] 10-26%; P <.0001). The proportion of subjects taking > 50%, > 80%, or > 90% of their medication was greater in the AVRF group, with a ratio of proportions adherent of 1.33 (95% Cl, 1.10-1.61; P =.003), 2.27 (95% CI, 1.56-3.3; P <.0001), and 3.25 (95% CI, 1.74-6.1%; P <.0001), respectively. Conclusion: An audiovisual reminder function can significantly improve adherence with ICS therapy in adult asthma. Clinical implications: An audiovisual reminder function has potential to improve adherence with medication regimens across a wide spectrum of diseases, in both research and clinical practice.	Med Res Inst New Zealand, Wellington 6036, New Zealand	Medical Research Institute Of New Zealand	Beasley, R (corresponding author), Med Res Inst New Zealand, POB 10055, Wellington 6036, New Zealand.	Richard.Beasley@mrinz.ac.nz	Weatherall, Mark/Y-6824-2019; Beasley, Richard/AAH-3908-2019	Weatherall, Mark/0000-0002-0051-9107; Beasley, Richard/0000-0003-0337-406X				Bauman LJ, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e6; COCHRANE GM, 1992, EUR RESPIR J, V5, P122; Cramer JA, 2004, DIABETES CARE, V27, P1218, DOI 10.2337/diacare.27.5.1218; Frick PA, 2001, INT J STD AIDS, V12, P329, DOI 10.1258/0956462011923048; Goldsmith C.H., 1979, COMPLIANCE HLTH CARE, P297; Holt S, 2001, BRIT MED J, V323, P253, DOI 10.1136/bmj.323.7307.253; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; Lask B, 1998, BRIT J PSYCHIAT, V173, P271, DOI 10.1192/bjp.173.3.271c; Laster S F, 1996, J Am Optom Assoc, V67, P654; Masoli M, 2004, THORAX, V59, P16; MAWHINNEY H, 1991, ANN ALLERGY, V66, P294; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Ruskin PE, 2003, DRUG INF J, V37, P283, DOI 10.1177/009286150303700304; Solomon DH, 2005, ARCH INTERN MED, V165, P2414, DOI 10.1001/archinte.165.20.2414; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Tilson HH, 2004, ANN PHARMACOTHER, V38, P161, DOI 10.1345/aph.1D207; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; YEUNG M, 1994, RESP MED, V88, P31, DOI 10.1016/0954-6111(94)90171-6; Zygmunt A, 2002, AM J PSYCHIAT, V159, P1653, DOI 10.1176/appi.ajp.159.10.1653	22	119	122	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					811	816		10.1016/j.jaci.2006.11.700	http://dx.doi.org/10.1016/j.jaci.2006.11.700			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17320942				2022-12-18	WOS:000245729500007
J	Alessandrini, F; Schulz, H; Takenaka, S; Lentner, B; Karg, E; Behrendt, H; Jakob, T				Alessandrini, F; Schulz, H; Takenaka, S; Lentner, B; Karg, E; Behrendt, H; Jakob, T			Effects of ultrafine carbon particle inhalation on allergic inflammation of the lung	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						particulate matter; elemental carbon ultrafine particles; allergic inflammation	PARTICULATE AIR-POLLUTION; EMERGENCY-ROOM VISITS; DIESEL EXHAUST PARTICLES; FINE PARTICLES; IN-VIVO; RESPIRATORY HEALTH; ADJUVANT ACTIVITY; OXIDATIVE STRESS; ASTHMA; MICE	Background: Epidemiologic studies show that exposure to particulate air pollution is associated with asthma exacerbation. Ultrafine particles (diameter <100 nm) may contribute to these adverse effects. Objective: To investigate potential adjuvant activity of inhaled elemental carbon ultrafine particles (EC-UFPs) on allergic airway inflammation. Methods: The effects of ultrafine particle inhalation on allergic airway inflammation was analyzed in ovalbumin-sensitized mice and nonsensitized controls. Particle exposure (526 mu g/m(3), 24 hours) was performed 24, 96, or 168 hours before or 24 or 72 hours after ovalbumin aerosol challenge. Allergic inflammation was analyzed at different time points after allergen challenge by means of bronchoalveolar lavage cell count and cytokine/total protein assays, lung histology, and airway hyperresponsiveness. Results: In sensitized mice, inhalation of ultrafine particles 24 hours before allergen challenge caused a significant increase of bronchoalveolar lavage inflammatory cell infiltrate, protein, IL-4, IL-5, and IL-13 compared with relevant controls. These adjuvant effects were dose- and time-dependent and were still present when particle exposure was performed 4 days before allergen challenge. The adjuvant effect of ultrafine particles was also documented by increased mucus production, peribronchiolar and perivascular inflammation, and enhanced airway hyperresponsiveness. In contrast, particle exposure in sensitized mice after allergen challenge caused only moderate effects, such as a delay of inflammatory infiltrate and a reduction of cytokines in bronchoalveolar lavage fluid. Conclusion: Exposure to ultrafine carbon particles before allergen challenge exerts strong adjuvant effects on the manifestation of allergic airway inflammation. Allergen-sensitized individuals may therefore be more susceptible to detrimental health effects of ultrafine particles.	GSF, Div Environm Dermatol Allergy, Natl Res Ctr Environm Hlth, TUM,ZAUM Ctr Allergy Environm, D-85764 Neuherberg, Germany; GSF, Div Environm Dermatol Allergy, Natl Res Ctr Environm Hlth, TUM,ZAUM Ctr Allergy Environm, Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Focus Network Aerosols & Hlth, Neuherberg, Germany; Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-8000 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Alessandrini, F (corresponding author), GSF, Div Environm Dermatol Allergy, Natl Res Ctr Environm Hlth, TUM,ZAUM Ctr Allergy Environm, Bldg 34,Room 0340, D-85764 Neuherberg, Germany.	Franci@gsf.de	Schulz, Holger/J-5643-2015; Jakob, Thilo/J-1621-2012	Schulz, Holger/0000-0002-1157-200X; 				Anjilvel S, 1999, MULTIPLE PATH PARTIC; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860, DOI 10.1164/ajrccm.164.10.2010138; Barrett EG, 2003, INHAL TOXICOL, V15, P151, DOI 10.1080/08958370304474; Birch M.E., 1999, ELEMENTAL CARBON DIE; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; Cyrys J, 2003, SCI TOTAL ENVIRON, V305, P143, DOI 10.1016/S0048-9697(02)00494-1; de Haar C, 2005, TOXICOL SCI, V87, P409, DOI 10.1093/toxsci/kfi255; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dick CAJ, 2003, INHAL TOXICOL, V15, P39, DOI 10.1080/08958370304454; DOCKERY DW, 1996, AM J RESP CRIT CAR S, V154, P250; DRORBAUGH JE, 1955, PEDIATRICS, V16, P81; FERIN J, 1992, AM J RESP CELL MOL, V6, P535, DOI 10.1165/ajrcmb/6.5.535; FUJIMAKI H, 1994, TOXICOLOGY, V92, P261, DOI 10.1016/0300-483X(94)90182-1; Gavett SH, 2003, ENVIRON HEALTH PERSP, V111, P1471, DOI 10.1289/ehp.6300; Goldsmith CAW, 1999, INHAL TOXICOL, V11, P981; Granum B, 2001, TOXICOL LETT, V118, P171, DOI 10.1016/S0378-4274(00)00292-7; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; HILDEMANN LM, 1994, ENVIRON SCI TECHNOL, V28, P1565, DOI 10.1021/es00058a006; Hiltermann TJN, 1998, EUR RESPIR J, V11, P686; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; KITTELSON DB, 2001, MNRC200112 MINN DEP; Lambert AL, 1999, TOXICOL APPL PHARM, V158, P269, DOI 10.1006/taap.1999.8709; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.2307/3433245; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Maejima K, 1997, J TOXICOL ENV HEALTH, V52, P231, DOI 10.1080/009841097159674; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; Oberdorster G, 2000, Res Rep Health Eff Inst, P5; Peden DB, 1997, ALLERGY, V52, P37, DOI 10.1111/j.1398-9995.1997.tb04869.x; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; Pope C. Arden III, 2000, Environmental Health Perspectives, V108, P713, DOI 10.2307/3454408; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123, DOI 10.1164/ajrccm/145.5.1123; POPE CA, 1995, ENVIRON HEALTH PERSP, V103, P472, DOI 10.2307/3432586; Roth C, 2004, AEROSOL SCI TECH, V38, P228, DOI 10.1080/02786820490247632; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.05.014; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; Takano H, 1998, TOXICOL APPL PHARM, V150, P328, DOI 10.1006/taap.1998.8437; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; Timonen KL, 2004, OCCUP ENVIRON MED, V61, P908, DOI 10.1136/oem.2004.012849; Timonen KL, 1997, AM J RESP CRIT CARE, V156, P546, DOI 10.1164/ajrccm.156.2.9608044; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798, DOI 10.1093/oxfordjournals.aje.a010280; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802, DOI 10.1136/oem.56.12.802; van Zijverden M, 2000, TOXICOL APPL PHARM, V168, P131, DOI 10.1006/taap.2000.9013; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032, DOI 10.1080/10473289.2002.10470842	50	119	121	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					824	830		10.1016/j.jaci.2005.11.046	http://dx.doi.org/10.1016/j.jaci.2005.11.046			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630940				2022-12-18	WOS:000236862800016
J	Allmers, H; Schmengler, J; Skudlik, C				Allmers, H; Schmengler, J; Skudlik, C			Primary prevention of natural rubber latex allergy in the German health care system through education and intervention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; natural rubber latex allergy; powder free latex gloves; latex allergens; primary prevention	IGE ANTIBODIES; GLOVES; SENSITIZATION; PREVALENCE; WORKERS; NURSES	Background: The development of occupational asthma and allergic skin reactions caused by natural rubber latex (NRL) allergy are risks for health care workers. There are few published studies to suggest that intervention programs to reduce exposure will lead to primary prevention of sensitization. Objective: This study assesses the effects of intervention to reduce the incidence of NRL allergy in personnel working in health care facilities insured by the German statutory accident insurance company for health care workers, Berufsgenossenschaft fur Gesundheitsdienst und Wohlfahrtspflege, with approximately 3 million insured employees, by switching to powder-free NRL gloves. Methods: The timing of introduction of intervention strategies, such as education of both physicians and administrators, together with regulations demanding that health care facilities only purchase low-protein, powder-free NRL gloves are reported. We reviewed the annual numbers of reported suspected cases of NRL-caused occupational allergies and the amount and type of gloves used in German acute-care hospitals since 1986. Results: The purchase of powder-free NRL examination gloves exceeded that of powdered gloves for the first time in 1998. This only became true for powder-free NRL sterile gloves 2 years later in 2000. The incidence of suspected occupational NRL allergy cases rose until 1998 and has declined steadily since. There was a 2-year lag between the beginning of the decline in the purchase of powdered NRL examination gloves and the beginning of a decline in suspected NRL-caused occupational asthma cases. Conclusions: Despite the effect of increased recognition of NRL allergies, education about NRL allergies in health care facilities combined with the introduction of powder-free gloves with reduced protein levels has been associated with a decline in the number of suspected cases of occupational allergies caused by NRL in Germany on a nationwide scale. These results clearly indicate that primary prevention of occupational NRL allergies can be achieved if these straightforward and practical interventions are properly carried out and maintained.	Univ Osnabruck, Dept Dermatol Environm Med & Hlth Sci, D-49090 Osnabruck, Germany; Harvard Sch Publ Hlth, Boston, MA USA; Berufsgenossenschaft & Gesundheitsdienst & Wohlfa, Delmenhorst, Germany	University Osnabruck; Harvard University; Harvard T.H. Chan School of Public Health	Allmers, H (corresponding author), Univ Osnabruck, Dept Dermatol Environm Med & Hlth Sci, Sedanstr 115, D-49090 Osnabruck, Germany.		Skudlik, Christoph/W-7963-2018					Allmers H, 1997, DEUT MED WOCHENSCHR, V122, P1308, DOI 10.1055/s-2008-1047764; Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; Allmers H, 1996, DEUT MED WOCHENSCHR, V121, P823, DOI 10.1055/s-2008-1043073; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; Baur X, 1996, ANAESTHESIST, V45, P653, DOI 10.1007/s001010050299; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; HAAMANN F, 2001, ERFOLGREICHE PRAVENT; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Levy DA, 1999, JAMA-J AM MED ASSOC, V281, P988, DOI 10.1001/jama.281.11.988; Liss GM, 2001, AM J IND MED, V40, P347, DOI 10.1002/ajim.1108; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; Roy A, 1997, J Can Dent Assoc, V63, P297; SAARY J, 2001, AM J RESP CRIT CARE, V163, pA809; Shoup A J, 1997, AORN J, V66, P729, DOI 10.1016/S0001-2092(06)62931-1; Shoup AJ, 1997, AORN J, V66, P729; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V102, P333, DOI 10.1016/S0091-6749(98)70110-1; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; Tarlo SM, 2001, J ALLERGY CLIN IMMUN, V108, P628, DOI 10.1067/mai.2001.118792; TUJANMAA K, 2000, J ALLERGY CLIN IMMUN, V104; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; WITT S, 1999, TECHNICAL INFORMATIO; YASSIN MS, 1994, ANN ALLERGY, V85, P626	24	119	122	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					318	323	UNSP 1/87/126461	10.1067/mai.2002.126461	http://dx.doi.org/10.1067/mai.2002.126461			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	585DY	12170275				2022-12-18	WOS:000177509800019
J	Wang, F; Robotham, JM; Teuber, SS; Tawde, P; Sathe, SK; Roux, KH				Wang, F; Robotham, JM; Teuber, SS; Tawde, P; Sathe, SK; Roux, KH			Ana o 1, a cashew (Anacardium occidental) allergen of the vicilin seed storage protein family	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ana o 1; Anacardium occidental; food allergy; cashew allergy; tree nut allergy; vicilin; 7S globulin; sucrose-binding protein; seed storage proteins; linear epitope; epitope map	IGE-BINDING EPITOPES; PISTACHIO NUT ALLERGENS; MUTATIONAL ANALYSIS; MAJOR ALLERGEN; GRASS-POLLEN; JUGLANS-REGIA; I ALLERGY; PEANUT; IDENTIFICATION; HYPERSENSITIVITY	Background: The allergens responsible for cashew food allergy have not been well characterized. Objectives: We initiated a study to clone cDNAs encoding cashew food allergens. Methods: A cashew cDNA library was screened with human serum for IgE-reactive clones and rabbit IgG anti-cashew extract antisera. Reactive clones were sequenced and Expressed, and linear epitopes were identified by means of solid-phase overlapping peptide analysis. Immunoblot inhibition was used to identify the native peptide in cashew extract. Results: Four closely related clones reactive with both human and rabbit antisera were sequenced. Sequence analysis showed that these encode members of the vicilin/sucrose-binding protein family of plant seed storage proteins. Screening of the recombinant protein with sera from 20 patients with cashew allergy and 8 cashew-tolerant patients with allergies to other tree nuts showed that 50% and 25% of sera from patients with cashew allergy and cashew-tolerant subjects, respectively, bound the recombinant protein. The corresponding native allergen protein, designated Ana o 1, was located at approximately 50 kd. Epitope mapping revealed 11 linear IgE-binding epitopes, of which 3 appear to be immunodominant. None of the epitopes were shared in common with those of the peanut vicilin allergen Ara h 1. Conclusion: Ana o 1, a vicilin-like protein, is a major food allergen in cashews. Cashew and peanut vicilins do not share linear epitopes.	Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA; Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA; Vet Affairs No Calif Hlth Care Syst, Pleasant Hill, CA USA; Florida State Univ, Dept Nutr Food & Exercise Sci, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University; University of California System; University of California Davis; State University System of Florida; Florida State University	Roux, KH (corresponding author), Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA.							Aas K, 1975, Dev Biol Stand, V29, P90; BALL G, 1994, CLIN EXP ALLERGY, V24, P758, DOI 10.1111/j.1365-2222.1994.tb00987.x; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; Beezhold DH, 2001, J ALLERGY CLIN IMMUN, V107, P1069, DOI 10.1067/mai.2001.115482; Bhalla PL, 2001, INT ARCH ALLERGY IMM, V124, P51, DOI 10.1159/000053666; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; Bredehorst R, 2001, J CHROMATOGR B, V756, P33, DOI 10.1016/S0378-4347(01)00069-X; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; ELSAYED S, 1989, INT ARCH ALLER A IMM, V89, P410, DOI 10.1159/000234984; Fernandez C, 1995, CLIN EXP ALLERGY, V25, P1254, DOI 10.1111/j.1365-2222.1995.tb03050.x; Garcia F, 2000, J INVEST ALLERG CLIN, V10, P173; GRIMES HD, 1992, PLANT CELL, V4, P1561, DOI 10.1105/tpc.4.12.1561; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; Helm RM, 2000, J ALLERGY CLIN IMMUN, V105, P378, DOI 10.1016/S0091-6749(00)90091-5; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193, DOI 10.1159/000235213; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; MARCUS JP, 1991, PLANT J, V19, P699; MARKS JG, 1984, J AM ACAD DERMATOL, V10, P627, DOI 10.1016/S0190-9622(84)80269-8; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; PARRA FM, 1993, CLIN EXP ALLERGY, V23, P996, DOI 10.1111/j.1365-2222.1993.tb00290.x; PELIKAN Z, 1983, ANN ALLERGY, V51, P395; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; RASANEN L, 1994, ALLERGY, V49, P342, DOI 10.1111/j.1398-9995.1994.tb02279.x; Robotham JM, 2002, J ALLERGY CLIN IMMUN, V109, P143, DOI 10.1067/mai.2002.120558; Schramm G, 2001, CLIN EXP ALLERGY, V31, P331, DOI 10.1046/j.1365-2222.2001.01049.x; SHANTI KN, 1993, J IMMUNOL, V151, P5354; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Sze-Tao KWC, 2001, J SCI FOOD AGR, V81, P1215, DOI 10.1002/jsfa.932; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; Teuber SS, 1999, J ALLERGY CLIN IMMUN, V104, P1311, DOI 10.1016/S0091-6749(99)70029-1; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; VANKAMPEN V, 1994, MOL IMMUNOL, V31, P1133, DOI 10.1016/0161-5890(94)90027-2; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x	38	119	135	3	24	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					160	166		10.1067/mai.2002.125208	http://dx.doi.org/10.1067/mai.2002.125208			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110836	Bronze			2022-12-18	WOS:000176870300028
J	Wollenberg, A; Sharma, S; von Bubnoff, D; Geiger, E; Haberstok, J; Bieber, T				Wollenberg, A; Sharma, S; von Bubnoff, D; Geiger, E; Haberstok, J; Bieber, T			Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; Langerhans cells; inflammatory dendritic epidermal cells; dendritic cells; IgE receptor	FC-EPSILON-RI; HUMAN LANGERHANS CELLS; IGE RECEPTOR; SKIN; OINTMENT; ECZEMA; PATHOGENESIS; TRIAL; CYCLOSPORINE; CHILDREN	Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease in which antigen-presenting epidermal dendritic cells (DCs), ie, Langerhans cells and the so-called inflammatory dendritic epidermal cells (IDECs) expressing the high-affinity receptor for IgE (Fc epsilon RI) may play a significant pathophysiologic role. Therapeutic efficacy of the immunosuppressive macrolide tacrolimus (FK506) in AD has been demonstrated in clinical trials, but little is known of its mode of action. Objective: The present study focused on the effects of topical tacrolimus treatment on epidermal CD1a(+)/Fc epsilon RI(+) DC populations in lesional AD. Methods: Immunohistological analysis, epidermal DC phenotyping, and functional studies were performed on skin biopsy specimens from treated and untreated lesional skin of 10 patients with AD participating in a clinical trial with tacrolimus. Results: Untreated lesional skin was characterized by a high proportion of CD1a(+) cells, which was largely due to a high proportion of IDECs strongly expressing Fc epsilon RI. Epidermal DCs isolated from untreated lesional skin exhibited high stimulatory activity toward autologous T cells, which was strongly reduced while clinical improvement was seen during application of tacrolimus. Concomitantly, a decreased Fc epsilon RI expression was observed in both Langerhans cells and IDECs. Finally, topical tacrolimus led to a progressive decrease in the IDEC population within the pool of CD1a(+) epidermal DCs and also to a decrease in their CD36 expression, which is indicative of lower local inflammation. Conclusion: Epidermal CD1a(+) DCs may represent a target for topical tacrolimus in the treatment of AD.	Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany; Univ Munich, Dept Dermatol, D-8000 Munich, Germany	University of Bonn; University of Munich	Bieber, T (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.							Alaiti S, 1998, J AM ACAD DERMATOL, V38, P69, DOI 10.1016/S0190-9622(98)70541-9; Bieber T, 1997, IMMUNOL TODAY, V18, P311, DOI 10.1016/S0167-5699(97)01046-3; BIEBER T, 1989, J INVEST DERMATOL, V93, P215, DOI 10.1111/1523-1747.ep12277574; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; BOS JD, 1994, LANCET, V343, P1338, DOI 10.1016/S0140-6736(94)92473-2; BOS JD, 1993, IMMUNOL TODAY, V14, P75, DOI 10.1016/0167-5699(93)90062-P; BRUIJNZEELKOOME.C, 1986, ARCH DERMATOL RES, V278, P199; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; COOPER KD, 1991, PHARM SKIN, V4, P119; DUPUY P, 1991, J INVEST DERMATOL, V96, P408, DOI 10.1111/1523-1747.ep12469772; FURUE M, 1988, J IMMUNOL, V140, P4139; GRABBE J, 1993, BRIT J DERMATOL, V129, P120, DOI 10.1111/j.1365-2133.1993.tb03512.x; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Hanifin JM, 1999, J AM ACAD DERMATOL, V41, P72, DOI 10.1016/S0190-9622(99)70410-X; JOHNSON JK, 1993, J INFECT DIS, V167, P698, DOI 10.1093/infdis/167.3.698; LAUERMA AI, 1992, LANCET, V340, P556, DOI 10.1016/0140-6736(92)91757-Y; LAUERMA AI, 1994, ARCH DERMATOL RES, V286, P337, DOI 10.1007/BF00402225; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; LEUNG DYM, 1987, CLIN IMMUNOL IMMUNOP, V42, P328, DOI 10.1016/0090-1229(87)90021-3; PANHANSGROSS A, IN PRESS J ALLERGY C; Reitamo S, 2000, ARCH DERMATOL, V136, P999, DOI 10.1001/archderm.136.8.999; Reitamo S, 1998, J INVEST DERMATOL, V111, P396, DOI 10.1046/j.1523-1747.1998.00323.x; RISKE F, 1991, J BIOL CHEM, V266, P11245; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; TAYLOR RS, 1991, J IMMUNOL, V147, P3794; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; Wollenberg A, 2000, ALLERGY, V55, P205, DOI 10.1034/j.1398-9995.2000.00115.x; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596	31	119	129	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					519	525		10.1067/mai.2001.112942	http://dx.doi.org/10.1067/mai.2001.112942			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240954				2022-12-18	WOS:000167793300015
J	Allen, DB				Allen, DB			Systemic effects of intranasal steroids: An endocrinologist's perspective	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intranasal steroids; systemic effects; allergic rhinitis; children; HPA axis; growth; bone metabolism	AQUEOUS NASAL SPRAY; SEASONAL ALLERGIC RHINITIS; PITUITARY-ADRENAL-AXIS; SHORT-TERM GROWTH; DAILY BECLOMETHASONE DIPROPIONATE; FLUTICASONE PROPIONATE; INHALED CORTICOSTEROIDS; ASTHMATIC-CHILDREN; LONG-TERM; ADRENOCORTICAL FUNCTION	Intranasal steroids (INSs) are established its first-line treatment for allergic rhinitis, Extensive use of INSs with few reported adverse events supports the safety of these medications. Nevertheless, the prescription of more potent LNSs for consistent and more prolonged use to younger and older patients, often in combination with inhaled corticosteroids, justifies the careful examination of their potential adverse systemic effects. Systemic bioavailability of INSs, by way of nasal and intestinal absorption, can be substantial; but current INSs vary significantly in their degree of first-pass hepatic inactivation and clearance from the body of the swallowed drug. For safety studies of INSs, distinguishing detectable physiologic perturbations from important adverse events is aided by an understanding of normal endocrine physiology and the methods used to test these systems. A review of available information indicates that (1) sensitive tests can measure the effects of INSs on biologic feedback systems, but they do not accurately predict clinically relevant adverse effects; (2) the primary factors that influence the relationship between therapeutic and adverse systemic effects of INSs are dosing frequency and efficiency of hepatic inactivation of swallowed drug; (3) INS treatment in recommended doses does not cause clinically significant hypothalamic-pituitary-adrenal axis suppression; (4) growth suppression can occur with twice-daily administration of certain INSs but does not appear to occur with once-daily dosing or with agents with more complete first-pass hepatic inactivation; (5) harmful effects of INSs on bone metabolism have not yet been adequately studied but would not be expected with the use of an INS dose and dosing frequency that do not suppress basal hypothalamic-pituitary-adrenal axis function or growth; and (6) these conclusions apply to INS treatment alone and in recommended doses-the risk of adverse effects in individual patients who are treated with LNSs is increased by excessive dosing or concomitant inhaled cortico-steroid or other topical corticosteroid therapy.	Univ Wisconsin, Childrens Hosp, Dept Pediat, Div Endocrinol, Madison, WI 53706 USA	Children's Hospital of Wisconsin; University of Wisconsin System; University of Wisconsin Madison	Allen, DB (corresponding author), H4-448 CSC Pediat,600 Highland Ave, Madison, WI 53792 USA.							Agertoft L, 1999, J ALLERGY CLIN IMMUN, V104, P948, DOI 10.1016/S0091-6749(99)70073-4; Allen DB, 1999, ALLERGY, V54, P29, DOI 10.1111/j.1398-9995.1999.tb04385.x; Allen DB, 1998, J CLIN ENDOCR METAB, V83, P2824, DOI 10.1210/jc.83.8.2824; Allen DB, 1996, ENDOCRIN METAB CLIN, V25, P699, DOI 10.1016/S0889-8529(05)70348-0; Allen DB, 1998, J PEDIATR-US, V132, P472, DOI 10.1016/S0022-3476(98)70023-X; Bachert C, 1999, J ALLERGY CLIN IMMUN, V103, P353, DOI 10.1016/S0091-6749(99)70514-2; Bernstein DI, 1996, J ALLERGY CLIN IMMUN, V97, P749, DOI 10.1016/S0091-6749(96)80151-5; BRANNAN MD, 1995, CLIN THER, V17, P637, DOI 10.1016/0149-2918(95)80040-9; BROIDE J, 1995, J CLIN ENDOCR METAB, V80, P1243, DOI 10.1210/jc.80.4.1243; Bronsky EA, 1996, J ALLERGY CLIN IMMUN, V97, P915, DOI 10.1016/S0091-6749(96)80065-0; Chervinsky P, 1996, CLIN THER, V18, P790, DOI 10.1016/S0149-2918(96)80039-7; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; Corren J, 1999, J ALLERGY CLIN IMMUN, V104, pS144, DOI 10.1016/S0091-6749(99)70310-6; Daley-Yates Peter T., 1998, Allergy (Copenhagen), V53, P158; Daley-Yates PT, 2000, J ALLERGY CLIN IMMUN, V105, pS201, DOI 10.1016/S0091-6749(00)91031-5; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; EDSBACKER S, 1985, EUR J CLIN PHARMACOL, V29, P477, DOI 10.1007/BF00613465; *FDA CTR DRUG EV R, 1998, P FOOD DRUG ADM CTR; Finkelstein JS, 1996, J CLIN ENDOCR METAB, V81, P1152, DOI 10.1210/jc.81.3.1152; FIOCCHI A, 1999, EUR RESPIR J, V14, pA13; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; HERMANUSSEN M, 1988, ANN HUM BIOL, V15, P103, DOI 10.1080/03014468800009521; Howland WC, 1996, J ALLERGY CLIN IMMUN, V98, P32, DOI 10.1016/S0091-6749(96)70223-3; Johnson M, 1998, J ALLERGY CLIN IMMUN, V101, pS434, DOI 10.1016/S0091-6749(98)70155-1; KARLBERG J, 1994, EUR J CLIN NUTR, V48, pS25; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; Lumry WR, 1999, J ALLERGY CLIN IMMUN, V104, pS150, DOI 10.1016/S0091-6749(99)70311-8; McDowall JE, 1997, CLIN DRUG INVEST, V14, P44, DOI 10.2165/00044011-199714010-00006; MERKUS PJFM, 1993, PEDIATRICS, V91, P1121; *NAT ASTHM ED PREV, 1997, EXP PAN REP 2 GUID D; Nayak AS, 1998, J ALLERGY CLIN IMMUN, V101, P157, DOI 10.1016/S0091-6749(98)70379-3; PAKES GE, 1980, DRUGS, V19, P397, DOI 10.2165/00003495-198019060-00001; RICHARDS DH, 2000, ALLERGY S, V55, pA185; Schenkel EJ, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e22; Skoner DP, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e23; Smith CL, 1998, ARZNEIMITTEL-FORSCH, V48, P957; Storms WW, 1999, J ALLERGY CLIN IMMUN, V103, P177, DOI 10.1016/S0091-6749(99)70545-2; TURKELTAUB PC, 1982, ALLERGY, V37, P303, DOI 10.1111/j.1398-9995.1982.tb01916.x; Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1; Vargas R, 1998, J ALLERGY CLIN IMMUN, V102, P191, DOI 10.1016/S0091-6749(98)70085-5; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; WALES JKH, 1987, ARCH DIS CHILD, V62, P166, DOI 10.1136/adc.62.2.166; WASNICH R, 1993, AM J MED, V95, pS6, DOI 10.1016/0002-9343(93)90374-X; Wihl JA, 1997, ALLERGY, V52, P620, DOI 10.1111/j.1398-9995.1997.tb01040.x; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V102, P598, DOI 10.1016/S0091-6749(98)70275-1; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V101, P470, DOI 10.1016/S0091-6749(98)70354-9; Wolthers OD, 1996, EUR RESPIR J, V9, P821, DOI 10.1183/09031936.96.09040821; WOLTHERS OD, 1992, PEDIATRICS, V89, P839; WOLTHERS OD, 1992, ACTA PAEDIATR, V81, P902, DOI 10.1111/j.1651-2227.1992.tb12132.x; WOLTHERS OD, 1994, ALLERGY, V49, P96, DOI 10.1111/j.1398-9995.1994.tb00807.x; WOLTHERS OD, 1993, ACTA PAEDIATR, V82, P635, DOI 10.1111/j.1651-2227.1993.tb12780.x; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3	55	119	130	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4		S			S179	S190		10.1067/mai.2000.110038	http://dx.doi.org/10.1067/mai.2000.110038			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	366QM	11032642				2022-12-18	WOS:000090016100001
J	Wedi, B; Raap, U; Lewrick, H; Kapp, A				Wedi, B; Raap, U; Lewrick, H; Kapp, A			Delayed eosinophil programmed cell death in vitro: A common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic diseases; atopic dermatitis; eosinophils; programmed cell death cytokines	COLONY-STIMULATING FACTOR; PERIPHERAL-BLOOD EOSINOPHILS; CATIONIC PROTEIN; IN-VITRO; GRANULE PROTEINS; DISEASE-ACTIVITY; MESSENGER-RNA; GM-CSF; APOPTOSIS; SURVIVAL	The present studies were undertaken to characterize the potential role of eosinophil programmed cell death (PCD) in atopic diseases. Peripheral blood eosinophil PCD was found to be delayed in inhalant allergy (p < 0.05) and delayed to an even greater extent in atopic dermatitis (AD) (p < 0.0001) when compared to nonatopic subjects, There was no difference in the occurrence of PCD between the extrinsic and the intrinsic type of AD, pointing to a secondary role of specific sensitization, Blockade of eosinophil PCD was not responsible for peripheral blood eosinophilia, because we found no obvious relationship of eosinophil survival to blood eosinophil count, Eosinophil supernatants of more patients with AD than of patients with inhalant allergy dose-dependently inhibited PCD in nonatopic eosinophils, and it was shown that this effect was possibly due to autocrine production of granulocyte-macrophage-colony stimulating factor, probably IL-5, Eosinophil expression of CD95 (Fas antigen) did not change over time in culture and was not modulated by cytokines prolonging eosinophil survival, In contrast, IL-3, IL-5, and granulocyte-macrophage-colony stimulating factor caused an upregulated expression of CD69. However, in AD, CD69 on eosinophils was upregulated without the need of exogenous growth factor or factors over time in culture, thus confirming an autocrine production of proeosinophilic cytokines, In conclusion, our data clearly indicate that eosinophil PCD is markedly delayed in the so-called atopic diseases irrespective of allergen sensitization and suggest that this effect is mediated by the autocrine production of growth factors by eosinophils.			Wedi, B (corresponding author), HANNOVER MED SCH, DEPT DERMATOL, RICKLINGER STR 5, D-30449 HANNOVER, GERMANY.		Wedi, Bettina/ABE-3636-2021	Wedi, Bettina/0000-0002-9868-6308; Kapp, Alexander/0000-0002-1748-6276				ALAM R, 1994, J EXP MED, V179, P1041, DOI 10.1084/jem.179.3.1041; BORRES MP, 1995, J ALLERGY CLIN IMMUN, V95, P694, DOI 10.1016/S0091-6749(95)70174-5; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BRUIJNZEELKOOMEN C, 1992, J ALLERGY CLIN IMMUN, V89, P52, DOI 10.1016/S0091-6749(05)80040-5; Calbi M, 1993, Pediatr Allergy Immunol, V4, P86, DOI 10.1111/j.1399-3038.1993.tb00072.x; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; Druilhe A, 1996, BLOOD, V87, P2822, DOI 10.1182/blood.V87.7.2822.bloodjournal8772822; ELSNER J, 1994, EUR J IMMUNOL, V24, P518, DOI 10.1002/eji.1830240304; HALBERT AR, 1995, J AM ACAD DERMATOL, V33, P1008, DOI 10.1016/0190-9622(95)90295-3; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; Humbert M, 1996, CLIN EXP ALLERGY, V26, P123, DOI 10.1111/j.1365-2222.1996.tb00069.x; KAGI MK, 1992, DERMATOLOGY, V185, P88, DOI 10.1159/000247419; KAPP A, 1995, CLIN EXP ALLERGY, V25, P210, DOI 10.1111/j.1365-2222.1995.tb01031.x; KAPP A, 1991, J AM ACAD DERMATOL, V24, P555, DOI 10.1016/0190-9622(91)70081-C; KAPP A, 1994, J INVEST DERMATOL, V102, P906, DOI 10.1111/1523-1747.ep12383399; KAPP A, 1993, ALLERGY, V48, P1, DOI 10.1111/j.1398-9995.1993.tb02167.x; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; KRUTMANN J, 1992, J AM ACAD DERMATOL, V26, P225, DOI 10.1016/0190-9622(92)70031-A; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEIFERMAN KM, 1994, J ALLERGY CLIN IMMUN, V94, P1310, DOI 10.1016/0091-6749(94)90347-6; LEIST M, 1994, J IMMUNOL, V153, P1778; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; MOSER R, 1992, J IMMUNOL, V149, P1432; NISHIKAWA K, 1992, J ALLERGY CLIN IMMUN, V90, P169, DOI 10.1016/0091-6749(92)90068-D; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; PAGANELLI R, 1991, INT ARCH ALLER A IMM, V96, P175, DOI 10.1159/000235490; Rothe MJ, 1996, J AM ACAD DERMATOL, V35, P1, DOI 10.1016/S0190-9622(96)90486-7; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SEHMI R, 1993, CLIN EXP ALLERGY, V23, P1027, DOI 10.1111/j.1365-2222.1993.tb00295.x; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; SPRY CJF, 1992, IMMUNOL TODAY, V13, P384, DOI 10.1016/0167-5699(92)90085-L; SUGAI T, 1992, CLIN EXP ALLERGY, V22, P275, DOI 10.1111/j.1365-2222.1992.tb03083.x; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; TANAKA Y, 1994, J INVEST DERMATOL, V103, P589, DOI 10.1111/1523-1747.ep12396899; TERADA N, 1994, J ALLERGY CLIN IMMUN, V94, P629, DOI 10.1016/0091-6749(94)90140-6; VENGE P, 1991, CLIN EXP ALLERGY, V21, P31, DOI 10.1111/j.1365-2222.1991.tb01761.x; WALKER C, 1993, CLIN EXP ALLERGY, V23, P145, DOI 10.1111/j.1365-2222.1993.tb00310.x; WALLEN N, 1991, J IMMUNOL, V147, P3490; Walsh GM, 1996, BLOOD, V87, P2815, DOI 10.1182/blood.V87.7.2815.bloodjournal8772815; Wedi B, 1996, ALLERGY, V51, P676; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; ZECKKAPP G, 1995, ALLERGY, V50, P34, DOI 10.1111/j.1398-9995.1995.tb02481.x	55	119	119	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					536	543		10.1016/S0091-6749(97)70147-7	http://dx.doi.org/10.1016/S0091-6749(97)70147-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338549				2022-12-18	WOS:A1997YA52900018
J	Tarlo, SM; Sussman, GL; Holness, DL				Tarlo, SM; Sussman, GL; Holness, DL			Latex sensitivity in dental students and staff: A cross-sectional study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; dermatitis; occupational asthma	DISPOSABLE MEDICAL GLOVES; OCCUPATIONAL ASTHMA; HOSPITAL PERSONNEL; CONTACT URTICARIA; SKIN PROBLEMS; RISK-FACTORS; ALLERGY; RUBBER; HYPERSENSITIVITY; TECHNICIANS	Background: Dental practitioners, like other health care providers who regularly use latex gloves, are at increased risk for latex sensitivity, They are also at risk for irritant or allergic contact dermatitis. Objective: This study was carried out to determine the prevalence of latex sensitivity and possible risk factors in staff and students of a Faculty of Dentistry, Methods: A cross-sectional study was performed by using a questionnaire and allergy skin prick testing, Results: Two hundred three students and staff members completed the questionnaire, Five percent reported asthma symptoms on exposure to rubber products, 13% reported symptoms of rhinitis or conjunctivitis, and 17% reported pruritus or urticaria within minutes of exposure to rubber, Overall, 10% of 131 subjects who underwent skin prick tests had a positive response to natural rubber latex. Among the students tested, there were increasing percentages of positive skin test responses to latex with increasing years of study (0% of Year 1 and 2 students tested; 6% of Year 3; and 10% of Year 4). Positive responses were seen as early as Year 3 in students (in their second year of clinical activity and glove use), Positive skin prick test responses to latex were related to a personal history of atopy (p = 0.005), positive prick test responses to common allergens (p < 0.005), latex-attributed immediate pruritus or urticaria (p < 0.05), rhinoconjunctivitis (p < 0.001), and asthma symptoms (p < 0.001). Conclusion: Dental school students and faculty are at high risk for latex sensitization, This occurs as early as the second year of glove use, Overall prevalence of skin sensitization was 10% of those tested. Preventive strategies in this group merit further investigation.	UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA	University of Toronto	Tarlo, SM (corresponding author), GAGE OCCUPAT & ENVIRONM HLTH UNIT, 223 COLL ST, TORONTO, ON M5T 1R4, CANADA.			Tarlo, Susan/0000-0002-4746-5310				BEAUDOUIN E, 1990, REV FR ALLERGOL, V30, P157, DOI 10.1016/S0335-7457(05)80230-8; BERKY ZT, 1992, JAMA-J AM MED ASSOC, V268, P2695; BRADLEY J, 1991, CAN J ANAESTH, V38, pA100; CHAROUS BL, 1994, J ALLERGY CLIN IMMUN, V94, P12, DOI 10.1016/0091-6749(94)90065-5; ESTLANDER T, 1984, CONTACT DERMATITIS, V10, P201, DOI 10.1111/j.1600-0536.1984.tb00100.x; Hadjiliadis D, 1996, J ALLERGY CLIN IMMUN, V97, P1202, DOI 10.1016/S0091-6749(96)70185-9; HOLNESS DL, 1995, CONTACT DERMATITIS, V32, P352, DOI 10.1111/j.1600-0536.1995.tb00624.x; JONES RT, 1994, ANN ALLERGY, V73, P321; KAVLI G, 1987, CONTACT DERMATITIS, V17, P156, DOI 10.1111/j.1600-0536.1987.tb02697.x; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Lammintausta K, 1982, Derm Beruf Umwelt, V30, P184; LAMMINTAUSTA K, 1982, CONTACT DERMATITIS, V8, P84, DOI 10.1111/j.1600-0536.1982.tb04151.x; MALO JL, 1991, AM REV RESPIR DIS, V143, P528, DOI 10.1164/ajrccm/143.3.528; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; MURER AJL, 1995, CONTACT DERMATITIS, V33, P42, DOI 10.1111/j.1600-0536.1995.tb00446.x; NILSSON E, 1986, ACTA DERM-VENEREOL, P1; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; PATTERSON P, 1995, ALLERGY ISSUES CONIP, V11; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TURJANMAA K, 1988, DERMATOL CLIN, V6, P47, DOI 10.1016/S0733-8635(18)30688-0; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3	28	119	125	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					396	401		10.1016/S0091-6749(97)70058-7	http://dx.doi.org/10.1016/S0091-6749(97)70058-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058696				2022-12-18	WOS:A1997WM42200017
J	TOMAZIC, VJ; SHAMPAINE, EL; LAMANNA, A; WITHROW, TJ; ADKINSON, NF; HAMILTON, RG				TOMAZIC, VJ; SHAMPAINE, EL; LAMANNA, A; WITHROW, TJ; ADKINSON, NF; HAMILTON, RG			CORNSTARCH POWDER ON LATEX PRODUCTS IS AN ALLERGEN CARRIER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX; NATURAL RUBBER; CORNSTARCH; ALLERGEN; TYPE I ALLERGIC REACTION; IGE ANTIBODIES	SURGICAL GLOVE POWDER; CONTACT URTICARIA; ANAPHYLACTOID REACTION; OCCUPATIONAL ASTHMA; RUBBER; HYPERSENSITIVITY; ANTIGENS; SURGERY	Allergic reactions of the upper respiratory tract during use of powdered latex rubber gloves have been recently associated with sensitivity to latex. We have studied the ability of cornstarch powder to bind latex proteins and evaluated allergenic properties of the bound protein. Allergenicity was determined by competitive inhibition of human anti-latex IgE binding to solid-phase latex antigen. Cornstarch extracted from powdered latex products and clean cornstarch exposed to latex protein extracts were evaluated in comparison with clean unexposed cornstarch. Both exposed cornstarch preparations inhibited specific binding of anti-latex IgE antibodies to latex proteins in a dose-response manner. Latex-exposed cornstarch diluted 50% vol/vol produced complete inhibition, whereas greater dilutions exhibited variable levels of inhibition, depending on the source of cornstarch-bound proteins, insolubilized latex proteins, and IgE antibody-containing human serum used. Cornstarch not exposed to latex had no inhibitory activity. The study demonstrates that cornstarch indeed binds allergenic latex proteins and supports the causative relationship between allergic reactions in individuals with latex sensitivity and the exposure to airborne particles from powdered latex products.	JOHNS HOPKINS UNIV,CTR ASTHMA & ALLERGY,BALTIMORE,MD 21224	Johns Hopkins University	TOMAZIC, VJ (corresponding author), US FDA,CTR DEVICES & RADIOL HLTH,DIV LIFE SCI,HLTH SCI BRANCH,12709 TWINBROOK PKWY,ROCKVILLE,MD 20852, USA.							ASSALVE D, 1988, CONTACT DERMATITIS, V19, P61, DOI 10.1111/j.1600-0536.1988.tb02870.x; BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; CHARPIN D, 1991, Journal of Allergy and Clinical Immunology, V87, P269, DOI 10.1016/0091-6749(91)91801-Y; FISHER AA, 1987, CONTACT DERMATITIS, V16, P224, DOI 10.1111/j.1600-0536.1987.tb01430.x; FISHER AA, 1986, CUTIS, V38, P307; GOLD M, 1991, Journal of Allergy and Clinical Immunology, V87, P268, DOI 10.1016/0091-6749(91)91797-W; HAMILTON RG, 1992, MANUAL CLIN IMMUNOLO, P689; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; LEYNADIER F, 1989, ANAESTHESIA, V44, P547, DOI 10.1111/j.1365-2044.1989.tb11438.x; MARCOS C, 1991, ANN ALLERGY, V67, P319; MEEROPOL E, 1990, NEW ENGL J MED, V323, P1072; MONERETVAUTRIN DA, 1990, LANCET, V335, P865, DOI 10.1016/0140-6736(90)90989-I; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; SEATON A, 1990, LANCET, V336, P808, DOI 10.1016/0140-6736(90)93268-T; SEATON A, 1988, BRIT MED J, V296, P531, DOI 10.1136/bmj.296.6621.531-a; SEGGEV JS, 1990, ANN ALLERGY, V65, P152; SLATER J E, 1990, Journal of Allergy and Clinical Immunology, V85, P293; SLATER JE, 1990, ANN ALLERGY, V65, P411; SLATER JE, 1992, ANN ALLERGY, V68, P203; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUSSMAN GL, 1992, ALLERGY PROC, V13, P67, DOI 10.2500/108854192778878890; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; TURJANMAA K, 1988, DERMATOL CLIN, V6, P47, DOI 10.1016/S0733-8635(18)30688-0; TURJANMAA K, 1990, LANCET, V336, P1588, DOI 10.1016/0140-6736(90)93372-V; VANDERMEEREN HLM, 1986, CONTACT DERMATITIS, V14, P190, DOI 10.1111/j.1600-0536.1986.tb01213.x	26	119	122	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					751	758		10.1016/0091-6749(94)90255-0	http://dx.doi.org/10.1016/0091-6749(94)90255-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	8163784				2022-12-18	WOS:A1994NH49700008
J	BLANCA, M; FERNANDEZ, J; MIRANDA, A; TERRADOS, S; TORRES, MJ; VEGA, JM; AVILA, MJ; PEREZ, E; GARCIA, JJ; SUAU, R				BLANCA, M; FERNANDEZ, J; MIRANDA, A; TERRADOS, S; TORRES, MJ; VEGA, JM; AVILA, MJ; PEREZ, E; GARCIA, JJ; SUAU, R			CROSS-REACTIVITY BETWEEN PENICILLINS AND CEPHALOSPORINS - CLINICAL AND IMMUNOLOGICAL STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TORRE CARDENAS HOSP,ALLERGY SECT,ALMERIA,SPAIN; FAC SCI MALAGA,DEPT ORGAN CHEM,MALAGA,SPAIN	Universidad de Malaga	BLANCA, M (corresponding author), CARLOS HAYA HOSP,RES UNIT ALLERG DIS,ALLERGY SECT,MALAGA,SPAIN.		Fernandez, Javier/B-6425-2018; Torres, María José/T-3518-2017; Torres, Maria/GVU-3391-2022; Perez-Inestrosa, Ezequiel/H-9801-2015	Fernandez, Javier/0000-0003-1065-7199; Torres, María José/0000-0001-5228-471X; Perez-Inestrosa, Ezequiel/0000-0001-7546-5273				BATCHELOR FR, 1966, IMMUNOLOGY, V10, P21; BLANCA M, IN PRESS ALLERGY; EBATA M, 1976, J ANTIBIOT TOKYO, V29, P656; GONZALEZ J, 1988, J ALLERGY CLIN IMMUN, V81, P222; HAMILTONMILLER JM, 1971, BIOCHEM J, V123, P183, DOI 10.1042/bj1230183; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; LEVINE BB, 1961, J EXP MED, V114, P875, DOI 10.1084/jem.114.6.875; MUNRO AC, 1978, J PHARM SCI, V67, P1977; PETZ LD, 1978, J INFECT DIS       S, V137, P74; SCHNEIDER CH, 1981, BETA LACTAM ANTIBIOT, P299; SHIBATA K, 1966, NATURE, V212, P419, DOI 10.1038/212419a0; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; THOBURN R, 1966, J AMER MED ASSOC, V198, P345, DOI 10.1001/jama.198.4.345; TSE SK, 1978, IMMEDIATE HYPERSENSI, P749; Yman L, 1975, Dev Biol Stand, V29, P151	15	119	121	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				381	385		10.1016/0091-6749(89)90122-X	http://dx.doi.org/10.1016/0091-6749(89)90122-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2918183				2022-12-18	WOS:A1989T448900003
J	DYER, J; WARREN, K; MERLIN, S; METCALFE, DD; KALINER, M				DYER, J; WARREN, K; MERLIN, S; METCALFE, DD; KALINER, M			MEASUREMENT OF PLASMA HISTAMINE - DESCRIPTION OF AN IMPROVED METHOD AND NORMAL VALUES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,ALLERG DIS SECT,CLIN INVEST LAB,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								AUSTEN KF, 1979, METHODS IMMUNOLOGY I, V5, P126; Beaven M A, 1978, Monogr Allergy, V13, P1; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BROWN MJ, 1980, ANAL BIOCHEM, V109, P142, DOI 10.1016/0003-2697(80)90022-6; DENT C, 1979, AGENTS ACTIONS, V9, P34, DOI 10.1007/BF02024097; GRAHAM H, 1968, BIOCHEM PHARMACOL, V17, P2271, DOI 10.1016/0006-2952(68)90034-8; HORAKOVA Z, 1977, CLIN CHIM ACTA, V79, P447, DOI 10.1016/0009-8981(77)90441-7; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; LORENZ W, 1972, H-S Z PHYSIOL CHEM, V353, P911, DOI 10.1515/bchm2.1972.353.1.911; MOSS J, 1981, ANESTHESIOLOGY, V55, P19, DOI 10.1097/00000542-198107000-00006; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544; SUBRAMANIAN N, 1978, ACTA HEPATO-GASTRO, V25, P456; SUMMERS R, 1981, J ALLERGY CLIN IMMUN, V67, P456, DOI 10.1016/0091-6749(81)90099-3	15	119	122	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	2					82	87		10.1016/0091-6749(82)90233-0	http://dx.doi.org/10.1016/0091-6749(82)90233-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PB591	7096824				2022-12-18	WOS:A1982PB59100002
J	MEURS, H; KOETER, GH; DEVRIES, K; KAUFFMAN, HF				MEURS, H; KOETER, GH; DEVRIES, K; KAUFFMAN, HF			THE BETA-ADRENERGIC SYSTEM AND ALLERGIC BRONCHIAL-ASTHMA - CHANGES IN LYMPHOCYTE BETA-ADRENERGIC-RECEPTOR NUMBER AND ADENYLATE-CYCLASE ACTIVITY AFTER AN ALLERGEN-INDUCED ASTHMATIC ATTACK	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GRONINGEN HOSP,DEPT PULMONOL,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen	MEURS, H (corresponding author), STATE UNIV GRONINGEN HOSP,DEPT ALLERGOL,INTERNAL MED CLIN,9713 EZ GRONINGEN,NETHERLANDS.							ALBANO J D M, 1973, Biochemical Society Transactions, V1, P477; ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BOOYNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROOKS SM, 1979, J ALLERGY CLIN IMMUN, V63, P401, DOI 10.1016/0091-6749(79)90213-6; BRUYNZEEL PLB, 1979, ANN ALLERGY, V43, P105; BUSSE WW, 1977, J CLIN INVEST, V59, P1080, DOI 10.1172/JCI108731; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DEVRIES K, 1982, EUR J RESPIR DIS, V63, P60; DOWNS RW, 1980, J BIOL CHEM, V255, P949; FRASER J, 1981, J CLIN INVEST, V67, P1777, DOI 10.1172/JCI110217; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GALANT SP, 1980, J CLIN INVEST, V65, P577, DOI 10.1172/JCI109702; GOKEMEYER JDM, 1976, THESIS; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; JOHNSON GL, 1978, J BIOL CHEM, V253, P1472; KARIMAN K, 1980, LUNG, V158, P41, DOI 10.1007/BF02713701; KENT RS, 1980, MOL PHARMACOL, V17, P14; KOETER GH, 1982, EUR J RESPIR DIS, V63, P72; KOETER GH, AGENTS ACTIONS; KRALL JF, 1980, J PHARMACOL EXP THER, V214, P554; KRALL JF, 1981, J CLIN ENDOCR METAB, V52, P863, DOI 10.1210/jcem-52-5-863; LICHTENSTEIN LM, 1976, ROLE IMMUNOLOGICAL F, P339; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCNEILL RS, 1966, AM J CARDIOL, V18, P473, DOI 10.1016/0002-9149(66)90072-5; MEURS H, 1980, CLIN CHIM ACTA, V106, P91, DOI 10.1016/0009-8981(80)90378-2; MEURS H, 1981, PROTIDES BIOL FLUIDS, V29, P163; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MORRIS HG, 1977, CLIN PHARMACOL THER, V22, P352; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; Rodbell M, 1975, Adv Cyclic Nucleotide Res, V5, P3; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SAFKO MJ, 1981, J ALLERGY CLIN IMMUN, V68, P218, DOI 10.1016/0091-6749(81)90187-1; STADEL JM, 1981, J CYCLIC NUCL PROT, V7, P37; SU YF, 1979, J BIOL CHEM, V254, P38; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; Terasaki W L, 1978, Adv Cyclic Nucleotide Res, V9, P33; TOHMEH JF, 1980, J CLIN INVEST, V65, P836, DOI 10.1172/JCI109735; WESSELS MR, 1979, MOL PHARMACOL, V16, P10; WIEMER G, 1981, N-S ARCH PHARMACOL, V317, P294, DOI 10.1007/BF00501309; WILLIAMS LT, 1978, RECEPTOR BINDING STU, P127	53	119	119	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	4					272	280		10.1016/0091-6749(82)90063-X	http://dx.doi.org/10.1016/0091-6749(82)90063-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PL151	6288790				2022-12-18	WOS:A1982PL15100007
J	WARREN, CPW; HOLFORDSTREVENS, V; WONG, C; MANFREDA, J				WARREN, CPW; HOLFORDSTREVENS, V; WONG, C; MANFREDA, J			THE RELATIONSHIP BETWEEN SMOKING AND TOTAL IMMUNOGLOBULIN-E LEVELS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,DEPT MED,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT IMMUNOL,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT SOCIAL & PREVENT MED,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba; University of Manitoba								BAHNA SL, 1980, J ALLERGY CLIN IMMUN, V65, P231; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; DALES LG, 1974, J CHRON DIS, V27, P293, DOI 10.1016/0021-9681(74)90093-9; DELESPESSE G, 1977, CLIN ALLERGY, V7, P155, DOI 10.1111/j.1365-2222.1977.tb01436.x; GERRARD JW, 1980, ANN ALLERGY, V44, P261; GULSVIK A, 1979, LANCET, V1, P449; HALGREN R, 1981, J ALLERGY CLIN IMMUN, V67, P398; HOLT PG, 1977, BACTERIOL REV, V41, P205, DOI 10.1128/MMBR.41.1.205-216.1977; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; JACOB CV, 1980, IMMUNOLOGY, V40, P621; Johansson S G, 1972, Prog Clin Immunol, V1, P157; JONES JG, 1980, LANCET, V1, P66; LEHRER SB, 1980, AM REV RESPIR DIS, V121, P168; MILLER RG, 1966, SIMULTANEOUS STATIST; NYE L, 1975, Clinical Allergy, V5, P13, DOI 10.1111/j.1365-2222.1975.tb01832.x; PAGANELLI R, 1979, CLIN EXP IMMUNOL, V36, P256; PEPYS J, 1975, CLIN ASPECTS IMMUNOL; STRANNEGARD O, 1978, IMMUNOL REV, V41, P149, DOI 10.1111/j.1600-065X.1978.tb01463.x; WALTON CHA, 1945, CAN MED ASSOC J, V53, P529; Walton CHA, 1940, CAN MED ASSOC J, V42, P430; WINGERD J, 1977, CLIN CHEM, V23, P1310; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215; 1971, 1ST P NHLI EP WORKSH; [No title captured]	28	119	119	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	4					370	375		10.1016/0091-6749(82)90148-8	http://dx.doi.org/10.1016/0091-6749(82)90148-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL280	7069072				2022-12-18	WOS:A1982NL28000007
J	KALINER, M; SIGLER, R; SUMMERS, R; SHELHAMER, JH				KALINER, M; SIGLER, R; SUMMERS, R; SHELHAMER, JH			EFFECTS OF INFUSED HISTAMINE - ANALYSIS OF THE EFFECTS OF H-1-HISTAMINE AND H-2-HISTAMINE RECEPTOR ANTAGONISTS ON CARDIOVASCULAR AND PULMONARY RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WALTER REED ARMY MED CTR,DEPT ALLERGY,WASHINGTON,DC 20012	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	KALINER, M (corresponding author), NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20205, USA.							ALBINUS M, 1974, AGENTS ACTIONS, V4, P222, DOI 10.1007/BF01965223; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; BACAL E, 1978, CLIN ALLERGY, V8, P295, DOI 10.1111/j.1365-2222.1978.tb03227.x; Beaven M A, 1978, Monogr Allergy, V13, P1; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BROWN R, 1977, J APPL PHYSIOL, V42, P221, DOI 10.1152/jappl.1977.42.2.221; CARROLL PR, 1974, AUST J EXP BIOL MED, V52, P577, DOI 10.1038/icb.1974.55; CASTERLINE CL, 1977, J ALLERGY CLIN IMMUN, V59, P420, DOI 10.1016/0091-6749(77)90004-5; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; Douglas W. W., 1980, PHARMACOL BASIS THER, P609; HIRSCHOWITZ BI, 1979, ANNU REV PHARMACOL, V19, P203, DOI 10.1146/annurev.pa.19.040179.001223; LIEBERMAN P, 1979, ARCH INTERN MED, V139, P1032, DOI 10.1001/archinte.139.9.1032; PLOYSONGSANG Y, 1978, J APPL PHYSIOL, V44, P690, DOI 10.1152/jappl.1978.44.5.690; ROBERTS LJ, 1979, NEW ENGL J MED, V300, P236, DOI 10.1056/NEJM197902013000506; ROWLEYJONES D, 1978, CIMETIDINE, P72; SHELHAMER JH, 1980, J ALLERGY CLIN IMMUN, V66, P52, DOI 10.1016/0091-6749(80)90138-4; Weiss S, 1929, AM HEART J, V4, P664, DOI 10.1016/S0002-8703(29)90550-0; WYLLIE JH, 1972, LANCET, V1, P1117	19	119	120	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	5					365	371		10.1016/0091-6749(81)90134-2	http://dx.doi.org/10.1016/0091-6749(81)90134-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MQ454	7299000				2022-12-18	WOS:A1981MQ45400004
J	ATKINS, P; GREEN, GR; ZWEIMAN, B				ATKINS, P; GREEN, GR; ZWEIMAN, B			HISTOLOGIC STUDIES OF HUMAN SKIN-TEST RESPONSES TO RAGWEED, COMPOUND 48-80, AND HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN, SCH MED, DEPT MED, ALLERGY & IMMUNOL SECT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania								CALLERAME ML, 1972, J ALLERGY CLIN IMMUN, V49, P116; CARLSSON SA, 1969, ACTA PHYSIOL SCAND, V77, P449, DOI 10.1111/j.1748-1716.1969.tb04589.x; CONNELL JT, 1971, J AMER MED ASSOC, V215, P769, DOI 10.1001/jama.215.5.769; EIDINGER D, 1964, J ALLERGY, V35, P77, DOI 10.1016/0021-8707(64)90052-8; FELARCA AB, 1971, J ALLERGY CLIN IMMUN, V48, P125, DOI 10.1016/0091-6749(71)90007-8; FELARCA AB, 1968, J ALLERGY, V41, P82, DOI 10.1016/0021-8707(68)90016-6; FOWLER JW, 1966, J ALLERGY, V37, P19, DOI 10.1016/0021-8707(66)90106-7; GREEN GR, 1967, J ALLERGY, V40, P224, DOI 10.1016/0021-8707(67)90085-8; HUBSCHER T, 1971, INT ARCH ALLER A IMM, V41, P689, DOI 10.1159/000230561; HUBSCHER T, 1972, J ALLERGY CLIN IMMUN, V49, P91; HUBSCHER T, 1970, J IMMUNOL, V104, P1187; ISHIZAKA K, 1971, J ALLERGY, V47, P89; ISHIZAKA T, 1972, J IMMUNOL, V108, P513; KAY AB, 1971, J IMMUNOL, V107, P899; KAY AB, 1970, CLIN EXP IMMUNOL, V6, P75; KLINE B. S., 1932, JOUR ALLERGY, V3, P531, DOI 10.1016/S0021-8707(32)90148-8; LITT M, 1964, ANN NY ACAD SCI, V116, P964, DOI 10.1111/j.1749-6632.1964.tb52562.x; PATTERSON R, 1971, INT ARCH ALLER A IMM, V40, P361, DOI 10.1159/000230419; PATTERSON R, 1971, J IMMUNOL, V106, P1274; RILEY JF, 1955, PHARMACOL REV, V7, P267; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; TAICHMAN NS, 1971, INT ARCH ALLER A IMM, V40, P934, DOI 10.1159/000230475; WARD PA, 1969, AM J PATHOL, V54, P121; WICHER K, 1972, J ALLERGY CLIN IMMUN, V49, P104	24	119	119	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	5					263	273		10.1016/0091-6749(73)90128-0	http://dx.doi.org/10.1016/0091-6749(73)90128-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P5931	4697356				2022-12-18	WOS:A1973P593100002
J	Isabwe, GAC; Neuer, MG; Sanchez, LD; Lynch, DM; Marquis, K; Castells, M				Isabwe, Ghislaine Annie C.; Neuer, Marlene Garcia; de las Vecillas Sanchez, Leticia; Lynch, Donna-Marie; Marquis, Kathleen; Castells, Mariana			Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Monoclonal antibody; hypersensitivity reaction; phenotype; endotype; biomarkers; tryptase; IL-6; skin testing; desensitization; precision medicine	RAPID DESENSITIZATION; DRUG ALLERGY; ANAPHYLAXIS; MANAGEMENT; RITUXIMAB; GLYCOSYLATION; DIAGNOSIS; SAFETY; RISK	Background: The increasing use of mAbs has led to a rise in hypersensitivity reactions (HSRs), which prevent their use as first-line therapy. HSRs' symptoms, diagnostic tools, and directed management approaches have not been standardized. Objective: We propose a novel evidence-based classification of HSRs to mAbs, based on the clinical phenotypes, underlying endotypes and biomarkers, as well as their management with desensitization. Methods: Phenotypes, endotypes, and biomarkers of HSRs to 16 mAbs for 104 patients were described and compared with the outcomes of 526 subcutaneous and intravenous desensitizations. Results: Initial reactions presented with 4 patterns: type I-like reactions (63%), cytokine-release reactions (13%), mixed reactions (21%), and delayed type IV reactions (3%). In contrast, of the 23% breakthrough HSRs during desensitization, 52% were cytokine-release reactions, 32% were type 1, 12% were mixed, and 4% were type I with delayed type IV. Skin testing to 10 mAbs in 58 patients was positive in 41% of patients. Serum tryptase was elevated in 1 patient and IL-6 was elevated in 8 patients during desensitization and was associated with a cytokine-release phenotype. Conclusions: HSRs to mAbs can be defined as type I, cytokinerelease, mixed (type I/cytokine-release), and type IV reactions, which are identified by biomarkers such as skin test, tryptase, and IL-6. These phenotypes can be used to improve personalized and precision medicine when diagnosing HSRs to mAbs and providing management recommendations with desensitization. Desensitization provides a safe and effective retreatment option to remain on culprit mAbs as first-line therapy.	[Isabwe, Ghislaine Annie C.; Neuer, Marlene Garcia; de las Vecillas Sanchez, Leticia; Lynch, Donna-Marie; Marquis, Kathleen; Castells, Mariana] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA USA; [Isabwe, Ghislaine Annie C.] Univ Sherbrooke, Ctr Hosp Univ Sherbrooke, Dept Pediat, Div Allergy & Immunol, Sherbrooke, PQ, Canada; [de las Vecillas Sanchez, Leticia] Marques de Valdecilla Univ Hosp, Inst Invest Marques de Valdecilla, Dept Allergy, Santander, Spain	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Sherbrooke; Hospital Universitario Marques de Valdecilla (HUMV)	Castells, M (corresponding author), 60 Fenwood Rd, Boston, MA 02115 USA.	mcastells@bwh.harvard.edu	de las Vecillas Sanchez, Leticia/ABF-5180-2021	de las Vecillas Sanchez, Leticia/0000-0003-4969-5678	Instituto de Investigacion Marques de Valdecilla (Santander, Spain)	Instituto de Investigacion Marques de Valdecilla (Santander, Spain)	L.d.l.V.S. is funded by a postresidency contract ''Wenceslao Lopez-Albo'' provided by Instituto de Investigacion Marques de Valdecilla (Santander, Spain).	Ang WXG, 2016, J CLIN INVEST, V126, P4103, DOI 10.1172/JCI87492; Arnold DF, 2008, NEW ENGL J MED, V358, P2735, DOI 10.1056/NEJMc080834; Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; Baldo BA, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26333; Bavbek S, 2015, J ALLER CL IMM-PRACT, V3, P629, DOI 10.1016/j.jaip.2015.01.009; Brennan PJ, 2009, J ALLERGY CLIN IMMUN, V124, P1259, DOI 10.1016/j.jaci.2009.09.009; Brockow K, 2013, ALLERGY, V68, P702, DOI 10.1111/all.12142; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Caiado J, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0515-3; Calogiuri G, 2008, CURR PHARM DESIGN, V14, P2883, DOI 10.2174/138161208786369786; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Chung CH, 2008, ONCOLOGIST, V13, P725, DOI 10.1634/theoncologist.2008-0012; Sanchez LD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061316; Demoly P, 2014, ALLERGY, V69, P420, DOI 10.1111/all.12350; Doessegger L, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2015.14; Fu M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045516; Galvao VR, 2015, J ALLER CL IMM-PRACT, V3, P175, DOI 10.1016/j.jaip.2014.12.006; Gonzalez-de-Olano D, 2016, J ALLER CL IMM-PRACT, V4, P338, DOI 10.1016/j.jaip.2015.10.007; Hong DI, 2012, EXPERT REV CLIN IMMU, V8, P43, DOI [10.1586/eci.11.75, 10.1586/ECI.11.75]; Kimby E, 2005, CANCER TREAT REV, V31, P456, DOI 10.1016/j.ctrv.2005.05.007; Levin AS, 2017, J ALLER CL IMM-PRACT, V5, P107, DOI 10.1016/j.jaip.2016.06.022; Limsuwan T, 2010, EXPERT OPIN DRUG SAF, V9, P39, DOI 10.1517/14740330903446936; Lowndes S, 2002, ANN ONCOL, V13, P1948, DOI 10.1093/annonc/mdf350; Muraro A, 2017, ALLERGY, V72, P1006, DOI 10.1111/all.13132; O'Meara S, 2014, INFLAMM BOWEL DIS, V20, P1, DOI 10.1097/01.MIB.0000436951.80898.6d; O'Neil BH, 2007, J CLIN ONCOL, V25, P3644, DOI 10.1200/JCO.2007.11.7812; Picard M, 2017, J ALLER CL IMM-PRACT, V5, P600, DOI 10.1016/j.jaip.2016.12.001; Picard M, 2016, J ALLERGY CLIN IMMUN, V137, P1154, DOI 10.1016/j.jaci.2015.10.039; Sancho-Serra MD, 2011, EUR J IMMUNOL, V41, P1004, DOI 10.1002/eji.201040810; Scheinfeld Noah, 2006, Dermatol Online J, V12, P3; SCHMIDT D, 1983, EPILEPSIA, V24, P440, DOI 10.1111/j.1528-1157.1983.tb04914.x; Sheeley DM, 1997, ANAL BIOCHEM, V247, P102, DOI 10.1006/abio.1997.2036; Sloane D, 2016, J ALLER CL IMM-PRACT, V4, P497, DOI 10.1016/j.jaip.2015.12.019; Thompson LM, 2014, ONCOLOGIST, V19, P228, DOI 10.1634/theoncologist.2013-0286; Vultaggio A, 2012, INT ARCH ALLERGY IMM, V159, P321, DOI 10.1159/000336839	36	118	121	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					159	+		10.1016/j.jaci.2018.02.018	http://dx.doi.org/10.1016/j.jaci.2018.02.018			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29518427	Bronze			2022-12-18	WOS:000437837500020
J	Durham, SR; Penagos, M				Durham, Stephen R.; Penagos, Martin			Sublingual or subcutaneous immunotherapy for allergic rhinitis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergic rhinitis; immunotherapy; sublingual immunotherapy; subcutaneous immunotherapy	HOUSE-DUST MITE; TERM CLINICAL-EFFICACY; DOUBLE-BLIND; FOLLOW-UP; RESPIRATORY ALLERGY; HAY-FEVER; ASTHMA; CHILDREN; SAFETY; TABLET	Allergen immunotherapy is effective in patients with allergic rhinitis (AR) and, unlike antiallergic drugs, has been shown to modify the underlying cause of the disease, with proved long-term benefits. Subcutaneous immunotherapy (SCIT) has been the gold standard, whereas sublingual immunotherapy (SLIT) has emerged as an effective and safe alternative. Previous Cochrane systematic reviews and meta-analyses have confirmed that both SLIT and SCIT are effective in patients with seasonal AR, whereas evidence for their efficacy in patients with perennial disease has been less convincing. Recent large, adequately powered trials have demonstrated reductions in both symptoms and use of rescue medication in patients with seasonal and those with perennial AR. Here we appraise evidence for SCIT versus SLIT based on indirect evidence from Cochrane reviews and recent well-powered double-blind, randomized controlled trials versus placebo and the limited direct evidence available from randomized blind head-to-head comparisons. At present, based on an overall balance of efficacy and side effects, the patient is in equipoise. Pending definitive comparative trials, choice might be determined largely by the local availability of SCIT and SLIT products of proved value and personal (patient) preference.	[Durham, Stephen R.; Penagos, Martin] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Div Resp Sci, Allergy & Clin Immunol, Dovehouse St, London SW3 6LY, England	Imperial College London	Durham, SR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Div Resp Sci, Allergy & Clin Immunol, Dovehouse St, London SW3 6LY, England.	s.durham@imperial.ac.uk		Penagos, Martin/0000-0002-9488-194X	Merck through Imperial College London; Circassia through Imperial College London; Leti Spain through Imperial College London; Stallergenes through Imperial College London; Biomay Austria through Imperial College London; Anergic Switzerland through Imperial College London; Regeneron USA; Biotech Tools Belgium; ALK-Abello; Merck; Pneumo Update Europe	Merck through Imperial College London; Circassia through Imperial College London; Leti Spain through Imperial College London; Stallergenes through Imperial College London; Biomay Austria through Imperial College London; Anergic Switzerland through Imperial College London; Regeneron USA(Regeneron); Biotech Tools Belgium; ALK-Abello; Merck(Merck & Company); Pneumo Update Europe	S. R. Durham has received consultancy fees from Merck, Circassia, Leti Spain, Stallergenes, Biomay Austria, and Anergic Switzerland, all through Imperial College London; has provided expert witness testimony for Merck; has received research support from Regeneron USA, Biotech Tools Belgium, ALK-Abello, and Merck; and has received payment for development of educational presentations from Pneumo Update Europe. M. Penagos has received payment for educational presentations and travel support from Stallergenes and ALK-Abello.	Aasbjerg K, 2015, BASIC CLIN PHARMACOL, V117, P73, DOI 10.1111/bcpt.12416; Antunez C, 2008, PEDIAT ALLERG IMM-UK, V19, P210, DOI 10.1111/j.1399-3038.2007.00604.x; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bergmann KC, 2014, J ALLERGY CLIN IMMUN, V133, P1608, DOI 10.1016/j.jaci.2013.11.012; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet PJ, 2009, ALLERGY, V64, P1737, DOI 10.1111/j.1398-9995.2009.02232.x; Calderon MA, 2012, ALLERGY, V67, P302, DOI 10.1111/j.1398-9995.2011.02761.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Calderon MA, 2016, COCHRANE DA IN PRESS; Calderon MA, 2013, J ALLERGY CLIN IMMUN, V132, P1322, DOI 10.1016/j.jaci.2013.09.004; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-6; Chelladurai Y, 2013, J ALLER CL IMM-PRACT, V1, P361, DOI 10.1016/j.jaip.2013.04.005; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Bona D, 2015, JAMA INTERN MED, V175, P1301, DOI 10.1001/jamainternmed.2015.2840; Di Bona D, 2012, J ALLERGY CLIN IMMUN, V130, P1097, DOI 10.1016/j.jaci.2012.08.012; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Didier A, 2013, CLIN EXP ALLERGY, V43, P568, DOI 10.1111/cea.12100; Didier A, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0057-8; Didier A, 2011, J ALLERGY CLIN IMMUN, V128, P559, DOI 10.1016/j.jaci.2011.06.022; Dretzke J, 2013, J ALLERGY CLIN IMMUN, V131, P1361, DOI 10.1016/j.jaci.2013.02.013; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Eifan AO, 2010, CLIN EXP ALLERGY, V40, P922, DOI 10.1111/j.1365-2222.2009.03448.x; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Greiner AN, 2011, LANCET, V378, P2112, DOI 10.1016/S0140-6736(11)60130-X; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Karakoc-Aydiner E, 2015, J INVEST ALLERG CLIN, V25, P334; Keles S, 2011, J ALLERGY CLIN IMMUN, V128, P808, DOI 10.1016/j.jaci.2011.04.033; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kim JM, 2013, PEDIATRICS, V131, P1155, DOI 10.1542/peds.2013-0343; Lee E, 2015, ALLERGY ASTHMA RESPI, V3, P180, DOI 10.4168/aard.2015.3.3.180; Lin SY, 2013, COMP EFFECTIVENESS R; Makatsori M, 2014, ALLERGY, V69, P571, DOI 10.1111/all.12385; Malling HJ, 2014, ALLERGENS AND ALLERGEN IMMUNOTHERAPY: SUBCUTANEOUS, SUBLINGUAL,AND ORAL, 5TH EDITION, P349; Maloney J, 2015, ANN ALLERGY ASTHMA I; Maloney J, 2014, ANN ALLERG ASTHMA IM, V112, P146, DOI 10.1016/j.anai.2013.11.018; Mauro M, 2007, Eur Ann Allergy Clin Immunol, V39, P119; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Mills EJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2914; Mosbech H, 2015, ANN ALLERG ASTHMA IM, V114, P134, DOI 10.1016/j.anai.2014.11.015; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P293, DOI 10.1016/S0091-6749(97)70240-9; Nelson H, 2015, J ALLER CL IMM-PRACT, V3, P256, DOI 10.1016/j.jaip.2014.09.018; Nelson HS, 2014, J ALLER CL IMM-PRACT, V2, P144, DOI 10.1016/j.jaip.2013.11.018; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Okamoto Y, 2015, INT ARCH ALLERGY IMM, V166, P177, DOI 10.1159/000381059; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2008.01875.x, 10.1111/j.1398-9995.2009.02194.x]; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Passalacqua G, 2013, J ALLERGY CLIN IMMUN, V132, P93, DOI 10.1016/j.jaci.2013.03.039; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; PIAZZA I, 1993, ANN ALLERGY, V71, P461; Pokladnikova J, 2008, ANN ALLERG ASTHMA IM, V100, P482, DOI 10.1016/S1081-1206(10)60475-9; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Radulovic S, 2011, ALLERGY, V66, P740, DOI 10.1111/j.1398-9995.2011.02583.x; Radulovic S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002893.pub2; Rossi RE, 2007, VACCINE, V25, P957, DOI 10.1016/j.vaccine.2006.08.040; Saporta D, 2007, ENT-EAR NOSE THROAT, V86, P493, DOI 10.1177/014556130708600816; Saporta D, 2012, J ENVIRON PUBLIC HEA, V2012, DOI 10.1155/2012/492405; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Stanaland BE, 1996, J ALLERGY CLIN IMMUN, V97, P1045, DOI 10.1016/S0091-6749(96)70256-7; Tahamiler R, 2008, ORL-J OTO-RHIN-LARYN, V70, P144, DOI 10.1159/000124286; Tiwari Ruby, 2009, Allergology International, V58, P557, DOI 10.2332/allergolint.09-OA-0094; Valovirta E, 2011, CLIN THER, V33, P1537, DOI 10.1016/j.clinthera.2011.09.013; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Ventura MT, 2009, INT J IMMUNOPATH PH, V22, P403, DOI 10.1177/039463200902200217; Vita D, 2010, ALLERGY, V65, P668, DOI 10.1111/j.1398-9995.2009.02223.x; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; Wheatley LM, 2015, NEW ENGL J MED, V372, P456, DOI 10.1056/NEJMcp1412282; White P, 1998, CLIN EXP ALLERGY, V28, P266; Yukselen A, 2012, INT ARCH ALLERGY IMM, V157, P288, DOI 10.1159/000327566	79	118	123	1	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					339	+		10.1016/j.jaci.2015.12.1298	http://dx.doi.org/10.1016/j.jaci.2015.12.1298			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26853126				2022-12-18	WOS:000369235500001
J	Barnes, PJ				Barnes, Peter J.			Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Corticosteroids; bronchodilator; cytokine; chemokine; IgE; kinase; p38 mitogen-activated protein kinase; bronchial thermoplasty; corticosteroid resistance; macrolide	REVERSES CORTICOSTEROID INSENSITIVITY; NLRP3 INFLAMMASOME ACTIVATION; THYMIC STROMAL LYMPHOPOIETIN; HISTONE DEACETYLASE ACTIVITY; MIGRATION INHIBITORY FACTOR; INDUCED AIRWAY INFLAMMATION; BLOOD MONONUCLEAR-CELLS; P38 MAPK INHIBITION; FACTOR-KAPPA-B; DOUBLE-BLIND	The recognition that there are some patients with features of asthma and chronic obstructive pulmonary disease (COPD) has highlighted the need to develop more specific treatments for these clinical phenotypes. Some patients with COPD have predominantly eosinophilic inflammation and might respond to high doses of inhaled corticosteroids and newly developed specific antieosinophil therapies, including blocking antibodies against IL-5, IL-13, IL-33, and thymic stromal lymphopoietin, as well as oral chemoattractant receptor-homologous molecule expressed on T(H)2 cells antagonists. Other patients have severe asthma or are asthmatic patients who smoke with features of COPD-induced inflammation and might benefit from treatments targeting neutrophils, including macrolides, CXCR2 antagonists, phosphodiesterase 4 inhibitors, p38 mitogenactivating protein kinase inhibitors, and antibodies against IL-1 and IL-17. Other patients appear to have largely fixed obstruction with little inflammation and might respond to long-acting bronchodilators, including long-acting muscarinic antagonists, to reduce hyperinflation. Highly selected patients with severe asthma might benefit from bronchial thermoplasty. Some patients with overlap syndromes can be conveniently treated with triple fixed-dose combination inhaler therapy with an inhaled corticosteroid, long-acting b2-agonist, and long-acting muscarinic antagonist, several of which are now in development. Corticosteroid resistance is a feature of asthma-COPD overlap syndrome, and understanding the various molecular mechanisms of this resistance has identified novel therapeutic targets and presented the prospect of therapies that can restore corticosteroid responsiveness.	[Barnes, Peter J.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	p.j.barnes@imperial.ac.uk		Barnes, Peter/0000-0002-5122-4018	NIHR Respiratory Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London, United Kingdom; National Institute for Health Research [NF-SI-0611-10148] Funding Source: researchfish	NIHR Respiratory Biomedical Research Unit at the Royal Brompton; Harefield NHS Foundation Trust; Imperial College London, United Kingdom; National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the NIHR Respiratory Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, United Kingdom.	Aaron SD, 2007, ANN INTERN MED, V146, P545, DOI 10.7326/0003-4819-146-8-200704170-00152; Abraham SM, 2006, J EXP MED, V203, P1883, DOI 10.1084/jem.20060336; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Al-Samri MT, 2010, J ALLERGY CLIN IMMUN, V125, P1161, DOI 10.1016/j.jaci.2010.02.005; Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Ameriks MK, 2009, CURR TOP MED CHEM, V9, P738, DOI 10.2174/156802609789044434; Azam Mohammed Afzal, 2014, Sci Pharm, V82, P453, DOI 10.3797/scipharm.1404-08; Bafadhel M, 2012, RESPIRATION, V83, P36, DOI 10.1159/000330667; Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC; Balloy V, 2014, BRIT J PHARMACOL, V171, P1783, DOI 10.1111/bph.12574; Banner KH, 2009, BRIT J PHARMACOL, V157, P892, DOI 10.1111/j.1476-5381.2009.00170.x; Barczyk A, 2006, J ALLERGY CLIN IMMUN, V117, P1484, DOI 10.1016/j.jaci.2006.02.013; Barnes PJ, 2009, CLIN EXP ALLERGY, V39, P1145, DOI 10.1111/j.1365-2222.2009.03298.x; Barnes PJ, 2008, CURR MOL MED, V8, P330, DOI 10.2174/156652408785160952; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1055, DOI 10.1016/j.jaci.2007.01.015; Barnes PJ, 2013, NAT REV DRUG DISCOV, V12, P543, DOI 10.1038/nrd4025; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Barnes PJ, 2012, J ALLERGY CLIN IMMUN, V129, P48, DOI 10.1016/j.jaci.2011.11.006; Barnes PJ, 2011, EXPERT REV RESP MED, V5, P297, DOI [10.1586/ERS.11.26, 10.1586/ers.11.26]; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barnes PJ, 2009, ANNU REV PHYSIOL, V71, P451, DOI 10.1146/annurev.physiol.010908.163257; Barrecheguren M, 2015, CURR OPIN PULM MED, V21, P74, DOI 10.1097/MCP.0000000000000118; Bateman ED, 2009, PULM PHARMACOL THER, V22, P533, DOI 10.1016/j.pupt.2009.06.002; Bateman ED, 2014, EXPERT REV RESP MED, V8, P357, DOI 10.1586/17476348.2014.910457; Beghe B, 2013, AM J RESP CRIT CARE, V188, P271, DOI 10.1164/rccm.201301-0021PP; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Benson JM, 2011, NAT BIOTECHNOL, V29, P615, DOI 10.1038/nbt.1903; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Bhavsar P, 2010, EUR RESPIR J, V35, P750, DOI 10.1183/09031936.00071309; Birrell MA, 2006, MOL PHARMACOL, V69, P1791, DOI 10.1124/mol.105.019521; Birrell MA, 2011, PHARMACOL THERAPEUT, V130, P364, DOI 10.1016/j.pharmthera.2011.03.007; Bousquet J, 2006, ALLERGY, V61, P72, DOI 10.1111/j.1398-9995.2005.00931.x; Brightling CE, 2005, THORAX, V60, P193, DOI 10.1136/thx.2004.032516; Brightling CE, 2014, LANCET RESP MED, V2, P891, DOI 10.1016/S2213-2600(14)70187-0; Brusselle GG, 2014, CHEST, V145, P1121, DOI 10.1378/chest.13-1885; Brusselle GG, 2013, THORAX, V68, P322, DOI 10.1136/thoraxjnl-2012-202698; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Byers DE, 2013, J CLIN INVEST, V123, P3967, DOI 10.1172/JCI65570; Calverley PMA, 2009, LANCET, V374, P685, DOI 10.1016/S0140-6736(09)61255-1; Caramori G, 2003, THORAX, V58, P348, DOI 10.1136/thorax.58.4.348; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Castro M, 2014, LANCET RESP MED, V2, P879, DOI 10.1016/S2213-2600(14)70201-2; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Cazzola M, 2012, PHARMACOL REV, V64, P450, DOI 10.1124/pr.111.004580; Chesne J, 2014, AM J RESP CRIT CARE, V190, P1094, DOI 10.1164/rccm.201405-0859PP; Chung KF, 2006, EUR J PHARMACOL, V533, P110, DOI 10.1016/j.ejphar.2005.12.059; Chung KF, 2011, CHEST, V139, P1470, DOI 10.1378/chest.10-1914; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; Cosio BG, 2004, J EXP MED, V200, P689, DOI 10.1084/jem.20040416; Dentener MA, 2008, RESPIRATION, V76, P275, DOI 10.1159/000117386; Di Stefano A, 2009, CLIN EXP IMMUNOL, V157, P316, DOI 10.1111/j.1365-2249.2009.03965.x; Di Stefano A, 2014, THORAX, V69, P516, DOI 10.1136/thoraxjnl-2012-203062; Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058; Donnelly LE, 2011, DRUG FUTURE, V36, P465, DOI 10.1358/dof.2011.036.06.1622072; Duan W, 2005, AM J RESP CRIT CARE, V171, P571, DOI 10.1164/rccm.200408-1006OC; Essilfie AT, 2015, THORAX, V70, P458, DOI 10.1136/thoraxjnl-2014-206067; Fan HP, 2014, ARTHRITIS RHEUMATOL, V66, P2059, DOI 10.1002/art.38689; Footitt J, 2015, CHEST; Ford PA, 2010, CHEST, V137, P1338, DOI 10.1378/chest.09-2363; Franciosi LG, 2013, LANCET RESP MED, V1, P714, DOI 10.1016/S2213-2600(13)70187-5; Friedlander AL, 2010, CHEST, V138, P1202, DOI 10.1378/chest.10-0196; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Grootendorst DC, 2007, THORAX, V62, P1081, DOI 10.1136/thx.2006.075937; Grubek-Jaworska H, 2012, RESPIRATION, V84, P101, DOI 10.1159/000334900; Guenette JA, 2012, EUR RESPIR J, V40, P322, DOI 10.1183/09031936.00157711; Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004; Hammaker D, 2010, ANN RHEUM DIS, V69, P77, DOI 10.1136/ard.2009.119479; Han MLK, 2014, AM J RESP CRIT CARE, V189, P1503, DOI 10.1164/rccm.201402-0207OC; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Hawkins PT, 2015, BBA-MOL CELL BIOL L, V1851, P882, DOI 10.1016/j.bbalip.2014.12.006; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Hodge S, 2006, EUR RESPIR J, V28, P486, DOI 10.1183/09031936.06.00001506; Hoi Alberta Y., 2007, Inflammation & Allergy Drug Targets, V6, P183, DOI 10.2174/187152807781696455; Holz O, 2010, EUR RESPIR J, V35, P564, DOI 10.1183/09031936.00048509; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Ismaili N, 2004, ANN NY ACAD SCI, V1024, P86, DOI 10.1196/annals.1321.007; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Ivanov S, 2009, TRENDS PHARMACOL SCI, V30, P95, DOI 10.1016/j.tips.2008.11.004; Iyer VN, 2014, CHEST, V146, P17, DOI 10.1378/chest.14-0536; Jiang ZY, 2014, J MED CHEM, V57, P2736, DOI 10.1021/jm5000529; Kagami S, 2009, INT IMMUNOL, V21, P679, DOI 10.1093/intimm/dxp037; Kanemitsu Y, 2014, AM J RESP CRIT CARE, V190, P472, DOI 10.1164/rccm.201403-0562LE; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kearley J, 2015, IMMUNITY, V42, P566, DOI 10.1016/j.immuni.2015.02.011; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; Kerstjens HAM, 2015, LANCET RESP MED, V3, P367, DOI 10.1016/S2213-2600(15)00031-4; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; Kerstjens HAM, 2011, J ALLERGY CLIN IMMUN, V128, P308, DOI 10.1016/j.jaci.2011.04.039; Khorasani N, 2015, INT J CHRONIC OBSTR, V10, P283, DOI 10.2147/COPD.S72403; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; KIRSTEN DK, 1993, CHEST, V104, P1101, DOI 10.1378/chest.104.4.1101; Koarai A, 2012, EUR RESPIR J, V39, P698, DOI 10.1183/09031936.00136710; Kobayashi Y, 2013, BRIT J PHARMACOL, V169, P1024, DOI 10.1111/bph.12187; Kobayashi Y, 2014, CHEST, V145, P305, DOI 10.1378/chest.13-0835; Kobayashi Y, 2013, J PHARMACOL EXP THER, V345, P76, DOI 10.1124/jpet.112.200733; Kobayashi Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027627; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Lazaar AL, 2011, BRIT J CLIN PHARMACO, V72, P282, DOI 10.1111/j.1365-2125.2011.03968.x; Leaker BR, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-137; Lee YC, 2008, AM J PHYSIOL-LUNG C, V294, pL921, DOI 10.1152/ajplung.00250.2007; Li LB, 2004, J ALLERGY CLIN IMMUN, V114, P1059, DOI 10.1016/j.jaci.2004.08.005; Lomas DA, 2012, J CLIN PHARMACOL, V52, P416, DOI 10.1177/0091270010397050; MacNee W, 2013, THORAX, V68, P738, DOI 10.1136/thoraxjnl-2012-202744; MAGNUSSEN H, 2010, EUR RESPIR J, V36, pS38; Malhotra D, 2008, AM J RESP CRIT CARE, V178, P592, DOI 10.1164/rccm.200803-380OC; Malhotra D, 2011, J CLIN INVEST, V121, P4289, DOI 10.1172/JCI45144; Maneechotesuwan K, 2013, CLIN EXP ALLERGY, V43, P212, DOI 10.1111/cea.12067; Maneechotesuwan K, 2015, CHEST; Maneechotesuwan K, 2008, J ALLERGY CLIN IMMUN, V121, P43, DOI 10.1016/j.jaci.2007.10.011; Maneechotesuwan K, 2013, THORAX, V68, P330, DOI 10.1136/thoraxjnl-2012-202127; Manetsch M, 2012, BRIT J PHARMACOL, V166, P2049, DOI 10.1111/j.1476-5381.2012.01923.x; Martinez FJ, 2015, LANCET, V385, P857, DOI 10.1016/S0140-6736(14)62410-7; Martinez-Gonzalez I, 2015, TRENDS IMMUNOL, V36, P189, DOI 10.1016/j.it.2015.01.005; Marwick JA, 2009, AM J RESP CRIT CARE, V179, P542, DOI 10.1164/rccm.200810-1570OC; Matera MG, 2011, TRENDS PHARMACOL SCI, V32, P495, DOI 10.1016/j.tips.2011.04.003; Matsusaka M, 2015, ALLERGOL INT, V64, P175, DOI 10.1016/j.alit.2014.07.003; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; Meja KK, 2008, AM J RESP CELL MOL, V39, P312, DOI 10.1165/rcmb.2008-0012OC; Menet CJ, 2013, PROGR MED CHEM, V52, P153, DOI 10.1016/B978-0-444-62652-3.00004-1; Mercado N, 2011, MOL PHARMACOL, V80, P1128, DOI 10.1124/mol.111.071993; Mercado N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041582; Mercado N, 2011, BIOCHEM BIOPH RES CO, V406, P292, DOI 10.1016/j.bbrc.2011.02.035; Mercado N, 2011, J PHARMACOL EXP THER, V337, P465, DOI 10.1124/jpet.110.175950; Millan DS, 2011, J MED CHEM, V54, P7797, DOI 10.1021/jm200677b; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; Ni WT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121257; Ohta S, 2010, CLIN EXP ALLERGY, V40, P1266, DOI 10.1111/j.1365-2222.2010.03478.x; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Page C, 2014, EUR RESPIR J, V44, P475, DOI 10.1183/09031936.00003814; Papi A, 2000, AM J RESP CRIT CARE, V162, P1773, DOI 10.1164/ajrccm.162.5.9910112; Papi A, 2013, J ALLERGY CLIN IMMUN, V132, P1075, DOI 10.1016/j.jaci.2013.05.028; Parnham MJ, 2014, PHARMACOL THERAPEUT, V143, P225, DOI 10.1016/j.pharmthera.2014.03.003; Pera T, 2011, EUR RESPIR J, V38, P789, DOI 10.1183/09031936.00146610; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Pettipher R, 2014, ALLERGY, V69, P1223, DOI 10.1111/all.12451; Pridgeon C, 2011, CLIN SCI, V120, P515, DOI 10.1042/CS20100417; Renda T, 2008, EUR RESPIR J, V31, P62, DOI 10.1183/09031936.00036707; Rennard SI, 2007, AM J RESP CRIT CARE, V175, P926, DOI 10.1164/rccm.200607-995OC; Rennard SI, 2015, AM J RESP CRIT CARE, V191, P1001, DOI 10.1164/rccm.201405-0992OC; Rodgers W, 2013, ANTIMICROB AGENTS CH, V57, P1632, DOI 10.1128/AAC.02316-12; Rogliani P, 2015, PULM PHARMACOL THER, V31, P15, DOI 10.1016/j.pupt.2015.01.005; Salminen A, 2012, CELL MOL LIFE SCI, V69, P2999, DOI 10.1007/s00018-012-0962-0; Scanlon ST, 2012, CURR OPIN IMMUNOL, V24, P707, DOI 10.1016/j.coi.2012.08.009; Seemungal TAR, 2008, AM J RESP CRIT CARE, V178, P1139, DOI 10.1164/rccm.200801-145OC; Sel S, 2008, J ALLERGY CLIN IMMUN, V121, P910, DOI 10.1016/j.jaci.2007.12.1175; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Simpson JL, 2014, EUR RESPIR J, V43, P1067, DOI 10.1183/09031936.00105013; Singh D, 2015, BRIT J CLIN PHARMACO, V79, P695, DOI 10.1111/bcp.12545; Siva R, 2007, EUR RESPIR J, V29, P906, DOI 10.1183/09031936.00146306; Snell N, 2013, RESP MED, V107, P1722, DOI 10.1016/j.rmed.2013.06.006; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Spears M, 2009, EUR RESPIR J, V33, P1010, DOI 10.1183/09031936.00158208; Sugawara A, 2011, BIOORG MED CHEM LETT, V21, P3373, DOI 10.1016/j.bmcl.2011.04.004; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; To Y, 2010, AM J RESP CRIT CARE, V182, P897, DOI 10.1164/rccm.200906-0937OC; Townley RG, 2012, ANN ALLERG ASTHMA IM, V109, P365, DOI 10.1016/j.anai.2012.04.004; Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725; Uzun S, 2014, LANCET RESP MED, V2, P361, DOI 10.1016/S2213-2600(14)70019-0; van Noord JA, 2010, THORAX, V65, P1086, DOI 10.1136/thx.2010.139113; Vanaudenaerde BM, 2011, AM J RESP CRIT CARE, V183, P977, DOI 10.1164/rccm.201007-1196PP; Wang YY, 2014, DRUG DES DEV THER, V8, P2075, DOI 10.2147/DDDT.S68872; Wedzicha JA, 2013, LANCET RESP MED, V1, P199, DOI 10.1016/S2213-2600(13)70052-3; Welte T, 2009, AM J RESP CRIT CARE, V180, P741, DOI 10.1164/rccm.200904-0492OC; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Xia J, 2015, AM J PHYSIOL-LUNG C, V308, pL619, DOI 10.1152/ajplung.00305.2014; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Zhang X, 2008, J IMMUNOL, V180, P6988, DOI 10.4049/jimmunol.180.10.6988	177	118	121	3	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					531	545		10.1016/j.jaci.2015.05.052	http://dx.doi.org/10.1016/j.jaci.2015.05.052			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	26343937				2022-12-18	WOS:000360913300002
J	Brockow, K; Kneissl, D; Valentini, L; Zelger, O; Grosber, M; Kugler, C; Werich, M; Darsow, U; Matsuo, H; Morita, E; Ring, J				Brockow, Knut; Kneissl, Daniel; Valentini, Luzia; Zelger, Otto; Grosber, Martine; Kugler, Claudia; Werich, Martina; Darsow, Ulf; Matsuo, Hiroaki; Morita, Eishin; Ring, Johannes			Using a gluten oral food challenge protocol to improve diagnosis of wheat-dependent exercise-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wheat-dependent exercise-induced anaphylaxis; omega-5-gliadin; gluten; anaphylaxis; cofactors; plasma gliadin levels; threshold levels; oral challenge test	RECOMBINANT OMEGA-5 GLIADIN; INTESTINAL PERMEABILITY; ALLERGY; INTENSITY; PEPTIDES; ANTIGENS; TESTS	Background: Oral wheat plus cofactors challenge tests in patients with wheat-dependent exercise-induced anaphylaxis (WDEIA) produce unreliable results. Objective: We sought to confirm WDEIA diagnosis by using oral gluten flour plus cofactors challenge, to determine the amount of gluten required to elicit symptoms, and to correlate these results with plasma gliadin levels, gastrointestinal permeability, and allergologic parameters. Methods: Sixteen of 34 patients with a history of WDEIA and omega 5-gliadin IgE underwent prospective oral challenge tests with gluten with or without cofactors until objective symptoms developed. Gluten reaction threshold levels, plasma gliadin concentrations, gastrointestinal permeability, sensitivities and specificities for skin prick tests, and specific IgE levels were ascertained in patients and 38 control subjects. Results: In 16 of 16 patients (8 female and 8 male patients; age, 23-76 years), WDEIA was confirmed by challenges with gluten alone (n = 4) or gluten plus cofactors (n = 12), including 4 patients with previous negative wheat challenge results. Higher gluten doses or acetylsalicylic acid (ASA) plus alcohol instead of physical exercise were cofactors in 2 retested patients. The cofactors ASA plus alcohol and exercise increased plasma gliadin levels (P < .03). Positive challenge results developed after a variable period of time at peak or when the plateau plasma gliadin level was attained. Positive plasma gliadin threshold levels differed by greater than 100-fold and ranged from 15 to 2111 pg/mL (median, 628 pg/mL). The clinical history, IgE gliadin level, and baseline gastrointestinal level were not predictive of the outcomes of the challenge tests. The challenge-confirmed sensitivity and specificity of gluten skin prick tests was 100% and 96%, respectively. Conclusion: Oral challenge with gluten alone or along with ASA and alcohol is a sensitive and specific test for the diagnosis of WDEIA. Exercise is not an essential trigger for the onset of symptoms in patients with WDEIA.	[Brockow, Knut; Kneissl, Daniel; Grosber, Martine; Kugler, Claudia; Darsow, Ulf; Ring, Johannes] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-80802 Munich, Germany; [Valentini, Luzia; Werich, Martina] Charite Univ Med Berlin, Sect Nutr Med, Dept Gastroenterol & Hepatol, Berlin, Germany; [Zelger, Otto] Tech Univ Munich, Dept Prevent Rehabil & Sports Med, D-80802 Munich, Germany; [Matsuo, Hiroaki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pathophysiol & Therapeut, Hiroshima 730, Japan; [Morita, Eishin] Shimane Univ, Fac Med, Dept Dermatol, Izumo, Shimane, Japan	Technical University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Munich; Hiroshima University; Shimane University	Brockow, K (corresponding author), Tech Univ Munich, Klinikums Rechts Isar, Klin & Poliklin Dermatol & Allergol Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.	knut.brockow@lrz.tu-muenchen.de	Matsuo, Hiroaki/B-4290-2008; Ring, Johannes/GLN-4341-2022; Valentini, Luzia/L-8859-2016	Matsuo, Hiroaki/0000-0002-8730-5389; Ring, Johannes/0000-0001-8236-3152; Valentini, Luzia/0000-0002-4313-0441; Morita, Eishin/0000-0002-5427-8468	Grants-in-Aid for Scientific Research [26461488] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Aihara M, 2002, BRIT J DERMATOL, V146, P466, DOI 10.1046/j.1365-2133.2002.04601.x; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Buhner S, 2004, ALLERGY, V59, P1118, DOI 10.1111/j.1398-9995.2004.00631.x; Choo KJL, 2010, ALLERGY, V65, P1205, DOI 10.1111/j.1398-9995.2010.02424.x; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; Fiedler EM, 2002, ALLERGY, V57, P1090, DOI 10.1034/j.1398-9995.2002.23836_12.x; Fukunaga A, 2012, ACTA DERM-VENEREOL, V92, P480, DOI 10.2340/00015555-1210; Gordins P, 2011, INT ARCH ALLERGY IMM, V155, P93, DOI 10.1159/000318740; Hanakawa Y, 1998, BRIT J DERMATOL, V138, P898; Hofmann SC, 2012, ALLERGY, V67, P1457, DOI 10.1111/all.12020; Inoue Naoyuki, 2011, Arerugi, V60, P1560; Jacquenet S, 2009, INT ARCH ALLERGY IMM, V149, P74, DOI 10.1159/000176309; Kohno K, 2013, ALLERGOL INT, V62, P229, DOI 10.2332/allergolint.12-OA-0495; Lamprecht M, 2012, MED SPORT SCI, V59, P47, DOI 10.1159/000342169; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Loibl M, 2009, ALLERGY, V64, P1560, DOI 10.1111/j.1398-9995.2009.02103.x; Matsukura S, 2010, CLIN EXP DERMATOL, V35, P233, DOI 10.1111/j.1365-2230.2009.03709.x; Matsuo H, 2008, ALLERGY, V63, P233, DOI 10.1111/j.1398-9995.2007.01504.x; Matsuo H, 2005, J IMMUNOL, V175, P8116, DOI 10.4049/jimmunol.175.12.8116; Matsuo H, 2005, CLIN EXP ALLERGY, V35, P461, DOI 10.1111/j.1365-2222.2005.02213.x; Menard S, 2010, MUCOSAL IMMUNOL, V3, P247, DOI 10.1038/mi.2010.5; Morisset M, 2003, CLIN EXP ALLERGY, V33, P1046, DOI 10.1046/j.1365-2222.2003.01734.x; Morita Eishin, 2009, Allergology International, V58, P493, DOI 10.2332/allergolint.09-RAI-0125; Norman K, 2012, EUR J CLIN NUTR, V66, P1116, DOI 10.1038/ejcn.2012.104; OKAZAKI M, 1992, INTERNAL MED, V31, P1052, DOI 10.2169/internalmedicine.31.1052; Palosuo K, 1999, J ALLERGY CLIN IMMUN, V103, P912, DOI 10.1016/S0091-6749(99)70438-0; Pals KL, 1997, J APPL PHYSIOL, V82, P571, DOI 10.1152/jappl.1997.82.2.571; ROMANO A, 1995, ALLERGY, V50, P817, DOI 10.1111/j.1398-9995.1995.tb05055.x; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1; Yano H, 2002, EUR J APPL PHYSIOL, V87, P358, DOI 10.1007/s00421-002-0653-x	31	118	121	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					977	+		10.1016/j.jaci.2014.08.024	http://dx.doi.org/10.1016/j.jaci.2014.08.024			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25269870				2022-12-18	WOS:000352238600020
J	Namazy, J; Cabana, MD; Scheuerle, AE; Thorp, JM; Chen, H; Carrigan, G; Wang, Y; Veith, J; Andrews, EB				Namazy, Jennifer; Cabana, Michael D.; Scheuerle, Angela E.; Thorp, John M., Jr.; Chen, Hubert; Carrigan, Gillis; Wang, Yan; Veith, Joachim; Andrews, Elizabeth B.			The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Omalizumab; pregnancy; moderate-to-severe persistent allergic asthma	ASTHMA MEDICATION USE; CONGENITAL-MALFORMATIONS; MATERNAL ASTHMA; INHALED CORTICOSTEROIDS; PERINATAL OUTCOMES; UNITED-STATES; WOMEN; RISK; EXACERBATIONS; METAANALYSIS	Background: For many asthma medications, pregnancy safety data remains insufficient. Objective: The omalizumab pregnancy registry, EXPECT, evaluates maternal, pregnancy, and infant outcomes after exposure to omalizumab, including incidence of congenital anomalies. Methods: EXPECT is a prospective, observational study of pregnant women exposed to >= 1 dose of omalizumab within 8 weeks prior to conception or at any time during pregnancy. Primary outcome measures include rates of live births, elective terminations, stillbirths, and congenital anomalies. Data were collected at enrollment, each trimester, birth, and every 6 months up to 18 months post-delivery. Results: As of November 2012, 188 of 191 pregnant women were exposed to omalizumab during their first trimester. Of 169 pregnancies with known outcomes (median exposure during pregnancy, 8.8 months), there were 156 live births of 160 infants (4 twin pairs), 1 fetal death/stillbirth, 11 spontaneous abortions, and 1 elective termination. Among 152 singleton infants, 22 (14.5%) were born prematurely. Of 147 singleton infants with weight data, 16 (10.9%) were small for gestational age. Among 125 singleton full-term infants, 4 (3.2%) had low birth weights. Overall, 20 infants had congenital anomalies confirmed, 7 (4.4%) of whom had 1 major defect. No pattern of anomalies was observed. Conclusions: To date, proportions of major congenital anomalies, prematurity, low birth weight, and small size for gestational age observed in the EXPECT registry are not inconsistent with findings from other studies in this asthma population. Recognizing the small sample size available, no apparent increased birth prevalence of major anomalies or patterns of major anomalies has been observed.	[Namazy, Jennifer] Scripps Clin, La Jolla, CA USA; [Cabana, Michael D.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Scheuerle, Angela E.] Tesserae Genet, Dallas, TX USA; [Thorp, John M., Jr.] Univ N Carolina, Sch Med, Chapel Hill, NC USA; [Chen, Hubert; Carrigan, Gillis; Wang, Yan; Veith, Joachim] Genentech Inc, San Francisco, CA USA; [Andrews, Elizabeth B.] RTI Hlth Solut, Res Triangle Pk, NC USA	Scripps Research Institute; University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Roche Holding; Genentech; Research Triangle Institute	Namazy, J (corresponding author), 7565 Mission Valley Rd, San Diego, CA 92108 USA.	janamazy@me.com		Andrews, Elizabeth B./0000-0003-1131-5983; Chen, Hubert/0000-0002-6630-239X; Wang, Yan/0000-0003-3430-2210	Genentech, Inc.	Genentech, Inc.(Roche HoldingGenentech)	We would like to acknowledge Katie Miller for her contribution to study design, study conduct, and data review. Editorial support was provided by professional medical writers Lisa Quinn and Christine Arris of CircleScience and was funded by Genentech, Inc.	Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X; Avalos LA, 2012, BIRTH DEFECTS RES A, V94, P417, DOI 10.1002/bdra.23014; Bakhireva LN, 2007, J ALLERGY CLIN IMMUN, V119, P618, DOI 10.1016/j.jaci.2006.12.618; Blais L, 2007, THORAX, V62, P320, DOI 10.1136/thx.2006.062950; Blais L, 2010, BIRTH DEFECTS RES A, V88, P216, DOI 10.1002/bdra.20651; Blais L, 2009, J ALLERGY CLIN IMMUN, V124, P1229, DOI 10.1016/j.jaci.2009.09.025; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; California Birth Defects Monitoring Program, 1994, BIRTH DEF CAL 1983 1; Centers for Disease Control and Prevention (CDC), 2008, MMWR MORB MORTAL WKL, V57, P1359; Congenital Malformation Registry, 2013, STAT SUMM CHILDR BOR; Correa Adolfo, 2007, Birth Defects Res A Clin Mol Teratol, V79, P65; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; European Medicines Agency, 2013, XOL EUR PUBL ASS REP; Genentech Inc, 2010, XOLAIR OM FULL PRESC; Kwon HL, 2006, IMMUNOL ALLERGY CLIN, V26, P29, DOI 10.1016/j.iac.2005.11.002; Lim A, 2011, ANN PHARMACOTHER, V45, P931, DOI 10.1345/aph.1P764; Lin S, 2012, PEDIATRICS, V129, pE317, DOI 10.1542/peds.2010-2660; MacDorman Marian F, 2012, Natl Vital Stat Rep, V60, P1; Martin Joyce A, 2013, Natl Vital Stat Rep, V62, P1; Murphy VE, 2011, BJOG-INT J OBSTET GY, V118, P1314, DOI 10.1111/j.1471-0528.2011.03055.x; Murphy VE, 2005, OBSTET GYNECOL, V106, P1046, DOI 10.1097/01.AOG.0000185281.21716.02; Namazy JA, 2013, EUR RESPIR J, V41, P1082, DOI 10.1183/09031936.00195111; Parker SE, 2010, BIRTH DEFECTS RES A, V88, P1008, DOI 10.1002/bdra.20735; Pasternak B, 2013, NEW ENGL J MED, V368, P814, DOI 10.1056/NEJMoa1211035; Rahimi R, 2006, HUM EXP TOXICOL, V25, P447, DOI 10.1191/0960327106het647oa; Rynn L., 2008, Morbidity and Mortality Weekly Report, V57, P1; Sarkar M, 2009, EUR J CLIN PHARMACOL, V65, P1259, DOI 10.1007/s00228-009-0713-9; SCHATZ M, 1990, CHEST, V98, P389, DOI 10.1378/chest.98.2.389; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Scheuerle A, 2002, PHARMACOEPIDEM DR S, V11, P465, DOI 10.1002/pds.726; Sheiner E, 2005, J MATERN-FETAL NEO M, V18, P237, DOI 10.1080/14767050500260616; Tata LJ, 2008, THORAX, V63, P981, DOI 10.1136/thx.2008.098244; Tata LJ, 2007, AM J RESP CRIT CARE, V175, P991, DOI 10.1164/rccm.200611-1641OC; Texas Birth Defects Registry, 2012, REP BIRTH DEF 2000 2	35	118	124	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					407	412		10.1016/j.jaci.2014.08.025	http://dx.doi.org/10.1016/j.jaci.2014.08.025			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25441639				2022-12-18	WOS:000349372300012
J	Hong, JY; Bentley, JK; Chung, YT; Lei, J; Steenrod, JM; Chen, Q; Sajjan, US; Hershenson, MB				Hong, Jun Young; Bentley, J. Kelley; Chung, Yutein; Lei, Jing; Steenrod, Jessica M.; Chen, Qiang; Sajjan, Uma S.; Hershenson, Marc B.			Neonatal rhinovirus induces mucous metaplasia and airways hyperresponsiveness through IL-25 and type 2 innate lymphoid cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; IL-25; mouse; neonatal; rhinovirus; type 2 innate lymphoid cells	RESPIRATORY-SYNCYTIAL-VIRUS; EARLY-LIFE; ALLERGIC INFLAMMATION; VIRAL-INFECTIONS; DENDRITIC CELLS; ASTHMA; IMMUNITY; MICE; RISK; TH2	Background: Early-life human rhinovirus infection has been linked to asthma development in high-risk infants and children. Nevertheless, the role of rhinovirus infection in the initiation of asthma remains unclear. Objective: We hypothesized that, in contrast to infection of mature BALB/c mice, neonatal infection with rhinovirus promotes an IL-25-driven type 2 response, which causes persistent mucous metaplasia and airways hyperresponsiveness. Methods: Six-day-old and 8-week-old BALB/c mice were inoculated with sham HeLa cell lysate or rhinovirus. Airway responses from 1 to 28 days after infection were assessed by using quantitative PCR, ELISA, histology, immunofluorescence microscopy, flow cytometry, and methacholine responsiveness. Selected mice were treated with a neutralizing antibody to IL-25. Results: Compared with mature mice, rhinovirus infection in neonatal mice increased lung IL-13 and IL-25 production, whereas IFN-gamma, IL-12p40, and TNF-alpha expression was suppressed. In addition, the population of IL-13-secreting type 2 innate lymphoid cells (ILC2s) was expanded with rhinovirus infection in neonatal but not mature mice. ILC2s were the major cell type secreting IL-13 in neonates. Finally, anti-IL-25 neutralizing antibody attenuated ILC2 expansion, mucous hypersecretion, and airways responsiveness. Conclusions: These findings suggest that early-life viral infection could contribute to asthma development by provoking age-dependent, IL-25-driven type 2 immune responses.	[Hong, Jun Young; Hershenson, Marc B.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Bentley, J. Kelley; Chung, Yutein; Lei, Jing; Steenrod, Jessica M.; Chen, Qiang; Sajjan, Uma S.; Hershenson, Marc B.] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hershenson, MB (corresponding author), Med Sci Res Bldg 2,1150 W Med Ctr Dr, Ann Arbor, MI 48019 USA.	mhershen@umich.edu		Hong, Jun Young/0000-0002-4963-7147; Bentley, John Kelley/0000-0001-8865-7979	National Institutes of Health [HL081420]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081420] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the National Institutes of Health HL081420 (to M.B.H.).	Al-Garawi A, 2011, MUCOSAL IMMUNOL, V4, P682, DOI 10.1038/mi.2011.35; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P91, DOI 10.1016/j.jaci.2012.02.010; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Brickshawana A, 2011, J IMMUNOL, V187, P5795, DOI 10.4049/jimmunol.1102242; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P964, DOI 10.1016/j.jaci.2008.12.011; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chelvarajan RL, 2004, J LEUKOCYTE BIOL, V75, P982, DOI 10.1189/jlb.0403179; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Goriely S, 2004, J EXP MED, V199, P1011, DOI 10.1084/jem.20031272; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Janssen R, 2007, J INFECT DIS, V196, P826, DOI 10.1086/520886; Johnston SL., 1997, DIAGNOSTIC PROCEDURE, P553; Kaiko GE, 2013, J ALLERGY CLIN IMMUN, V131, P1331, DOI 10.1016/j.jaci.2013.02.041; Kaiko GE, 2010, J IMMUNOL, V185, P4681, DOI 10.4049/jimmunol.1001758; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Langrish CL, 2002, CLIN EXP IMMUNOL, V128, P118, DOI 10.1046/j.1365-2249.2002.01817.x; Lee HH, 2008, J EXP MED, V205, P2269, DOI 10.1084/jem.20071371; Levy O, 2004, J IMMUNOL, V173, P4627, DOI 10.4049/jimmunol.173.7.4627; Li LQ, 2004, IMMUNITY, V20, P429, DOI 10.1016/S1074-7613(04)00072-X; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Miller EK, 2011, J ALLERGY CLIN IMMUN, V127, P883, DOI 10.1016/j.jaci.2010.11.041; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Newcomb DC, 2008, AM J RESP CRIT CARE, V177, P1111, DOI 10.1164/rccm.200708-1243OC; Newcomb DC, 2005, J BIOL CHEM, V280, P36952, DOI 10.1074/jbc.M502449200; Potaczek DP, 2013, PEDIAT ALLERG IMM-UK, V24, P441, DOI 10.1111/pai.12083; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Rickel EA, 2008, J IMMUNOL, V181, P4299, DOI 10.4049/jimmunol.181.6.4299; Rose S, 2007, J IMMUNOL, V178, P2667, DOI 10.4049/jimmunol.178.5.2667; Sadeghi K, 2007, J INFECT DIS, V195, P296, DOI 10.1086/509892; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Schneider D, 2013, AM J PHYSIOL-LUNG C, V304, pL162, DOI 10.1152/ajplung.00182.2012; Schneider D, 2012, J IMMUNOL, V188, P2894, DOI 10.4049/jimmunol.1101391; Siegle JS, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-14; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, P131, DOI 10.1016/j.jaci.2008.10.042; Webster RB, 2007, J BIOL CHEM, V282, P700, DOI 10.1074/jbc.M609501200; You DH, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-107	53	118	125	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					429	+		10.1016/j.jaci.2014.04.020	http://dx.doi.org/10.1016/j.jaci.2014.04.020			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24910174	Green Accepted			2022-12-18	WOS:000341370800024
J	Roufosse, FE; Kahn, JE; Gleich, GJ; Schwartz, LB; Singh, AD; Rosenwasser, LJ; Denburg, JA; Ring, J; Rothenberg, ME; Sheikh, J; Haig, AE; Mallett, SA; Templeton, DN; Ortega, HG; Klion, AD				Roufosse, Florence E.; Kahn, Jean-Emmanuel; Gleich, Gerald J.; Schwartz, Lawrence B.; Singh, Anish D.; Rosenwasser, Lanny J.; Denburg, Judah A.; Ring, Johannes; Rothenberg, Marc E.; Sheikh, Javed; Haig, Ann E.; Mallett, Stephen A.; Templeton, Deborah N.; Ortega, Hector G.; Klion, Amy D.			Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; monoclonal antibody; interleukin-5; corticosteroid	ASTHMA; EOSINOPHILIA	Background: Hypereosinophilic syndromes (HESs) are chronic disorders that require long-term therapy to suppress eosinophilia and clinical manifestations. Corticosteroids are usually effective, yet many patients become corticosteroid refractory or develop corticosteroid toxicity. Mepolizumab, a humanized monoclonal anti-IL-5 antibody, showed corticosteroid-sparing effects in a double-blind, placebo-controlled study of FIP1L1/PDGFRA-negative, corticosteroid-responsive subjects with HESs. Objective: We evaluated long-term safety and efficacy of mepolizumab (750 mg) in HES. Methods: MHE100901 is an open-label extension study. The primary end point was the frequency of adverse events (AEs). Optimal dosing frequency, corticosteroid-sparing effect of mepolizumab, and development of antimepolizumab antibodies were also explored. Results: Seventy-eight subjects received 1 to 66 mepolizumab infusions each (including mepolizumab infusions received in the placebo-controlled trial). Mean exposure was 251 weeks (range, 4-302 weeks). The most common dosing interval was 9 to 12 weeks. The incidence of AEs was 932 events per 100 subject-years in the first year, declining to 461 events per 100 subject-years after 48 months. Serious AEs, including 1 death, were reported by the investigator as possibly due to mepolizumab in 3 subjects. The median daily prednisone dose decreased from 20.0 to 0 mg in the first 24 weeks. The median average daily dose for all subjects over the course of the study was 1.8 mg. Sixty-two percent of subjects were prednisone free without other HES medications for >= 12 consecutive weeks. No neutralizing antibodies were detected. Twenty-four subjects withdrew before study completion for death (n = 4), lack of efficacy (n = 6), or other reasons. Conclusion: Mepolizumab was well tolerated and effective as a long-term corticosteroid-sparing agent in PDGFRA-negative HES. (J Allergy Clin Immunol 2013;131:461-7.)	[Roufosse, Florence E.] Univ Libre Brussels, Inst Med Immunol, Hop Erasme, Dept Internal Med, Gosselies, Belgium; [Kahn, Jean-Emmanuel] CHRU Lille, Hop Foch Suresnes & Reseau Eosinophile, Immunol Lab, Serv Med Interne, Lille, France; [Gleich, Gerald J.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Richmond, VA USA; [Singh, Anish D.] Sir Charles Gairdner Hosp, Dept Haematol, Perth, WA, Australia; [Rosenwasser, Lanny J.] Childrens Mercy Hosp, Kansas City, MO 64108 USA; [Rosenwasser, Lanny J.] Univ Missouri, Kansas City, MO 64110 USA; [Denburg, Judah A.] McMaster Univ, Hamilton, ON, Canada; [Ring, Johannes] Tech Univ Munich, Dept Dermatol & Allergy, CK CARE, D-80290 Munich, Germany; [Rothenberg, Marc E.] Cincinnati Childrens Hosp & Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH USA; [Sheikh, Javed] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Haig, Ann E.] GlaxoSmithKline, King Of Prussia, PA USA; [Mallett, Stephen A.] GlaxoSmithKline, Stockley Pk, Middx, England; [Templeton, Deborah N.; Ortega, Hector G.] GlaxoSmithKline, Res Triangle Pk, NC USA; [Klion, Amy D.] NIAID, NIH, Bethesda, MD 20892 USA	Hospital Foch; Universite de Lille - ISITE; CHU Lille; Utah System of Higher Education; University of Utah; Virginia Commonwealth University; University of Western Australia; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City; McMaster University; Technical University of Munich; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Harvard University; Beth Israel Deaconess Medical Center; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Klion, AD (corresponding author), NIAID, Parasit Dis Lab, NIH, Bldg 4,Rm B1-28, Bethesda, MD 20892 USA.	aklion@niaid.nih.gov	Ring, Johannes/GLN-4341-2022; KAHN, Jean-Emmanuel/S-8509-2018	Ring, Johannes/0000-0001-8236-3152; KAHN, Jean-Emmanuel/0000-0002-9565-6074; Mallett, Stephen/0000-0003-1053-958X; Klion, Amy/0000-0002-4986-5326	GlaxoSmithKline; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Belgian National Fund for Scientific Research (FNRS) [3.4545.11]; TRIA Bioscience Corp; ImmViz; Genentech; Carolus; NeilMed; Marshall Edwards Inc; Sanofi-Aventis; ALK-Abello; Allergopharma; Almirall-Herman; Astellas; Bavarian Nordic; Bencard; Galderma; Leo; Novartis; PLS Design; Stallergenes; Biogen-Idec; MSD; Phadia; Proctor Gamble; Sanofi Aventis; ImmunePharm; National Institutes of Health; Department of Defense; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001130] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Belgian National Fund for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS); TRIA Bioscience Corp; ImmViz; Genentech(Roche HoldingGenentech); Carolus; NeilMed; Marshall Edwards Inc; Sanofi-Aventis(Sanofi-Aventis); ALK-Abello; Allergopharma; Almirall-Herman(Almirall); Astellas(Astellas Pharmaceuticals); Bavarian Nordic; Bencard; Galderma; Leo(LEO Pharma); Novartis(Novartis); PLS Design; Stallergenes; Biogen-Idec(Biogen); MSD; Phadia(Phadia); Proctor Gamble(Procter & Gamble); Sanofi Aventis(Sanofi-Aventis); ImmunePharm; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by GlaxoSmithKline, the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (A. D. K.), and the Belgian National Fund for Scientific Research (FNRS; grant no. 3.4545.11 to F.E.R.).; F. E. Roufosse has received consultancy fees from GlaxoSmithKline for advisory board meetings and for revision of clinical study report. J.-E. Kahn has received grants and travel expenses from GlaxoSmithKline. G. J. Gleich has received research support from GlaxoSmithKline, TRIA Bioscience Corp, and ImmViz; is on the APFED Board; has received consultancy fees from GlaxoSmithKline; has patents from ImmViz; received royalties from Teva for the sales of reslizumab; and has stock/stock options in Immune Design Corp. L. B. Schwartz has received research support from GlaxoSmithKline, Genentech, Carolus, and NeilMed; is president of the Clinical Immunology Society; is a board member of the Asthma & Allergy Foundation of America; has received consultancy fees from Genentech, Marshall Edwards Inc, and Sanofi-Aventis; and has received royalties from Thermo-Fisher, Hycult & BioLegend, and Millipore Santa Cruz. L. J. Rosenwasser has consultant arrangements with Regeneron and Sanofi-Aventis and has received payment for lectures from Genentech. J. A. Denburg has received grants from GlaxoSmithKline. J. Ring has participated in clinical trials sponsored by ALK-Abello, Allergopharma, Almirall-Herman, Astellas, Bavarian Nordic, Bencard, Galderma, GlaxoSmithKline, Leo, Novartis, PLS Design, and Stallergenes; and has received research support from Biogen-Idec, MSD, Phadia, Proctor & Gamble, and Sanofi Aventis. M. E. Rothenberg is on the boards of the International Eosinophil Society and the American Partnership for Eosinophilic Disorders; has received consultancy fees from ImmunePharm; has received research support from the National Institutes of Health and the Department of Defense; has many patents all of which are owned by CCHMC; has received royalties from Teva Pharmaceuticals; has stock/stock options and has received travel expenses from ImmunePharm. J. Sheikh has received grants and travel support from and has consultant arrangements with GlaxoSmithKline. D. N. Templeton is employed by and has stock/stock options in GlaxoSmithKline. A. E. Haig is employed by and has stock/stock options in GlaxoSmithKline. A. D. Klion has received research support from GlaxoSmithKline. H. G. Ortega is an employee of GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.	Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Howlander N, 2012, SEER CANC STAT REV 1; Joppi R, 2006, BRIT J CLIN PHARMACO, V61, P355, DOI 10.1111/j.1365-2125.2006.02579.x; Lilly CM, 2002, J ALLERGY CLIN IMMUN, V109, pS1, DOI 10.1067/mai.2002.120854; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Fernandez ER, 2011, LEUKEMIA RES, V35, pE97, DOI 10.1016/j.leukres.2010.12.020; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Roufosse F, 2007, IMMUNOL ALLERGY CLIN, V27, P389, DOI 10.1016/j.iac.2007.07.002; Roufosse F, 2010, J ALLERGY CLIN IMMUN, V126, P828, DOI 10.1016/j.jaci.2010.06.049; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Stolk P, 2006, B WORLD HEALTH ORGAN, V84, P745, DOI 10.2471/BLT.06.031518; Valent P, 2012, J ALLERGY CLIN IMMUN	14	118	137	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					461	+		10.1016/j.jaci.2012.07.055	http://dx.doi.org/10.1016/j.jaci.2012.07.055			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23040887	Green Accepted			2022-12-18	WOS:000314661500025
J	Amar, SM; Harbeck, RJ; Sills, M; Silveira, LJ; O'Brien, H; Nelson, HS				Amar, Sheila M.; Harbeck, Ronald J.; Sills, Michael; Silveira, Lori J.; O'Brien, Holly; Nelson, Harold S.			Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sublingual immunotherapy; timothy grass extract; multiple allergen immunotherapy; Phl p 5; cytokine; skin prick tests; nasal challenge; allergen-specific IgE; allergen-specific IgG(4)	DOUBLE-BLIND; ANAPHYLAXIS; MULTIPLE; THERAPY; ASTHMA	Background: To date, there have been no randomized, double-blind studies showing the effectiveness of sublingual immunotherapy with multiple allergens. Objective: The purpose of this study was to examine whether the efficacy of sublingual immunotherapy (SLIT) with standardized timothy extract was reduced by combination with other allergen extracts. Methods: A single-center, randomized, double-blind, placebo-controlled trial with SLIT was conducted. After an observational grass season, SLIT was administered for 10 months to 54 patients randomized to 1 of 3 treatment arms: placebo, timothy extract (19 mu g Phl p 5 daily) as monotherapy, or the same dose of timothy extract plus 9 additional pollen extracts. Symptom and medication scores were collected and titrated nasal challenges, titrated skin prick tests, specific IgE, IgG(4) and cytokines release by timothy-stimulated lymphocyte proliferation were performed. Results: Perhaps because of a very low grass pollen season in 2008, there were no significant differences in medication or symptom scores in either treatment group compared with placebo. Compared with placebo, in the timothy monotherapy group, thresholds for titrated nasal challenge and skin prick tests (P = .03 and P = .001, respectively), and serum-specific IgG4 levels (P = .005) significantly increased, and IFN- gamma levels decreased (P = .02), whereas in the multiallergen group, there was significant improvement only in the titrated skin prick tests (P = .04) which was less than in the monotherapy group. There were no significant differences between the 2 active groups in any outcome measure, and both active groups experienced more adverse events than placebo. There were no systemic reactions. Conclusion: Improvement in multiple relevant outcomes strongly suggests that SLIT with timothy extract alone was effective; however, the results for symptom and medication scores were not significant. The differences between multiple allergen SLIT and placebo only in skin sensitivity to timothy suggest a reduction in SLIT efficacy in this group. However, further studies are required to confirm these observations. (J Allergy Clin Immunol 2009;124:150-6.)	[Amar, Sheila M.; Harbeck, Ronald J.; Sills, Michael; Silveira, Lori J.; O'Brien, Holly; Nelson, Harold S.] Natl Jewish Hlth, Denver, CO 80206 USA; [Amar, Sheila M.; Harbeck, Ronald J.; Nelson, Harold S.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nelson, HS (corresponding author), Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA.	nelsonh@njc.org						Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bordignon V, 2003, J INVEST ALLERG CLIN, V13, P170; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; Busse WW, 2007, J ALLERGY CLIN IMMUN, V120, P1012, DOI 10.1016/j.jaci.2007.09.016; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Esch RE, 2003, ARB P EHRLICH I BUND, V94, P17; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; JOHNSTONE D, 1961, PEDIATRICS, V27, P39; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; LOWELL FC, 1967, JAMA-J AM MED ASSOC, V201, P915; Marogna M, 2007, ANN ALLERG ASTHMA IM, V98, P274, DOI 10.1016/S1081-1206(10)60718-1; Schatz M, 2007, ALLERGY, V62, P9, DOI 10.1111/j.1398-9995.2007.01548.x; WILSON DR, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD002893, 10.1002/14651858]	17	118	120	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					150	156		10.1016/j.jaci.2009.04.037	http://dx.doi.org/10.1016/j.jaci.2009.04.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19523672				2022-12-18	WOS:000267909700019
J	Pistiner, M; Gold, DR; Abdulkerim, H; Hoffman, E; Celedon, JC				Pistiner, Michael; Gold, Diane R.; Abdulkerim, Hassen; Hoffman, Elaine; Celedon, Juan C.			Birth by cesarean section, allergic rhinitis, and allergic sensitization among children with a parental history of atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cesarean delivery; allergic rhinitis; atopy; childhood	ENVIRONMENTAL ENDOTOXIN MEASUREMENT; BLOOD MONONUCLEAR-CELLS; DAY-CARE ATTENDANCE; 1ST YEAR; EARLY-LIFE; INTESTINAL MICROFLORA; CHILDHOOD ASTHMA; GUT MICROBIOTA; LIMULUS ASSAY; DELIVERY	Background: Cesarean delivery can alter neonatal immune responses and increase the risk of atopy. Studies of the relation between cesarean delivery and allergic diseases in children not selected on the basis of a family history of atopy have yielded inconsistent findings. Objective: We sought to examine the relation between birth by cesarean delivery and atopy and allergic diseases in children at risk for atopy. Methods: We examined the relation between mode of delivery and the development of atopy and allergic diseases among 432 children with a parental history of atopy followed from birth to age 9 years. Asthma was defined as physician-diagnosed. asthma and wheeze in the previous year, and allergic rhinitis was defined as physician-diagnosed allergic rhinitis and naso-ocular symptoms apart from colds in the previous year. Atopy was considered present at school,age if there was 1 or more positive skin test response or specific IgE to common allergens. Stepwise logistic regression was used to study the relation between cesarean delivery and the outcomes of interest. Results: After adjustment for other covariates, children born by cesarean section had 2-fold higher odds of atopy than those born by vaginal delivery (odds ratio, 2.1; 95% CI, 1.1-3.9). In multivariate analyses birth by cesarean section was significantly associated with increased odds of allergic rhinitis (odds ratio, 1.8; 95% CI, 1.0-3.1) but not with asthma. Conclusions: Our findings suggest that cesarean delivery is associated with allergic rhinitis and atopy among children with a parental history of asthma or allergies. This could be explained by lack of contact with the maternal vaginal/fecal flora or reduced/absent labor during cesarean delivery.	[Pistiner, Michael; Gold, Diane R.; Abdulkerim, Hassen; Celedon, Juan C.] Channing Labs, Boston, MA 02115 USA; [Pistiner, Michael] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Celedon, Juan C.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Pistiner, Michael] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Gold, Diane R.; Celedon, Juan C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Hoffman, Elaine] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Celedon, JC (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079966, R01HL073373, R01HL066289, R37HL066289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786, R56AI035786] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL073373, R37 HL066289, R01 HL066289, R01 HL073373, HL66289, R01 HL079966, HL079966] Funding Source: Medline; NIAID NIH HHS [R01 AI035786, AI/EHS35786] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Annesi-Maesano I, 2001, ALLERGY, V56, P491, DOI 10.1034/j.1398-9995.2001.056006491.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P51, DOI 10.1067/mai.2003.34; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Celedon JC, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e77; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Eggesbo M, 2005, ALLERGY, V60, P1172, DOI 10.1111/j.1398-9995.2005.00857.x; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Hakansson S, 2003, CLIN EXP ALLERGY, V33, P757, DOI 10.1046/j.1365-2222.2003.01667.x; HTERNEAU TM, 2000, EXTENDING COX MODEL, P185; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kero J, 2002, PEDIATR RES, V52, P6, DOI 10.1023/01.PDR.0000017263.01840.F0; Lange J, 2003, CLIN EXP ALLERGY, V33, P1537, DOI 10.1046/j.1365-2222.2003.01789.x; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Lotz M, 2006, J EXP MED, V203, P973, DOI 10.1084/jem.20050625; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Ly Ngoc P, 2006, Clin Mol Allergy, V4, P13; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Maitra A, 2004, CLIN EXP ALLERGY, V34, P1349, DOI 10.1111/j.1365-2222.2004.02048.x; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P800, DOI 10.1067/mai.2002.124046; Menacker Fay, 2005, Natl Vital Stat Rep, V54, P1; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; MILTON DK, 1992, ENVIRON RES, V57, P212, DOI 10.1016/S0013-9351(05)80081-7; Nafstad P, 2000, J ALLERGY CLIN IMMUN, V106, P867, DOI 10.1067/mai.2000.110558; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Negele K, 2004, PEDIAT ALLERG IMM-UK, V15, P48, DOI 10.1046/j.0905-6157.2003.00101.x; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; PITTARD WB, 1989, AM J OBSTET GYNECOL, V160, P151, DOI 10.1016/0002-9378(89)90109-9; Raby BA, 2004, PEDIATRICS, V114, pE327, DOI 10.1542/peds.2003-0838-L; Ramsey CD, 2007, J ALLERGY CLIN IMMUN, V119, P150, DOI 10.1016/j.jaci.2006.09.012; Renz-Polster H, 2005, CLIN EXP ALLERGY, V35, P1466, DOI 10.1111/j.1365-2222.2005.02356.x; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Salam MT, 2006, ANN EPIDEMIOL, V16, P341, DOI 10.1016/j.annepidem.2005.06.054; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Sharp MJ, 2003, CLIN EXP ALLERGY, V33, P435, DOI 10.1046/j.1365-2222.2003.01627.x; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; Weston S, 2005, ARCH DIS CHILD, V90, P892, DOI 10.1136/adc.2004.060673; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	51	118	124	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					274	279		10.1016/j.jaci.2008.05.007	http://dx.doi.org/10.1016/j.jaci.2008.05.007			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18571710	Green Accepted			2022-12-18	WOS:000258426300009
J	Blok, BMJF; DunnGalvin, A; Viieg-Boerstra, BJ; Elberink, JNGO; Duiverman, EJ; Hourihane, JO; Dubois, AEJ				Blok, Bertine M. J. Flokstra-de; DunnGalvin, Audrey; Viieg-Boerstra, Berber J.; Elberink, Joanne N. G. Oude; Duiverman, Eric J.; Hourihane, Jonathan O'Brien; Dubois, Anthony E. J.			Development and validation of the self-administered Food Allergy Quality of Life Questionnaire for adolescents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adolescents; EuroPrevall; food allergy; health-related quality of life; teenagers	ANAPHYLACTIC REACTIONS; PSYCHOLOGICAL BURDEN; YOUNG-ADULTS; IMPACT; CHILDREN; FATALITIES; FAMILIES; PARENTS	Background: Food allergy can affect health-related quality of life (HRQL). Currently, no validated, self-administered, disease-specific HRQL questionnaire for adolescents with food allergy exists. Objective: We sought to develop and validate the Food Allergy Quality of Life Questionnaire-Teenager Form (FAQLQ-TF) in the Dutch language. Methods: Ten adolescents (13-17 years) with food allergy were interviewed and generated 166 HRQL items. The most important items were identified by 51 adolescents with food allergy by using the clinical impact method, resulting in the FAQLQ-TF containing 28 items (score range: 1 "no impairment" to 7 "maximal impairment"). The FAQLQ-TF, the Food Allergy Independent Measure, and a generic HRQL questionnaire (CHQ-CF87) were sent to 98 adolescents with food allergy for cross-sectional validation of the FAQLQ-TF. Results: Construct validity was assessed based on the correlation between the FAQLQ-TF and the Food Allergy Independent Measure (rho = 0.57, P <.001). The FAQLQ-TF had excellent internal consistency (Cronbach alpha =.92) and discriminated between adolescents who differed in number of food allergies (1 vs >2 food allergies: total FAQLQ-TF score, 4.3 vs 3.5; P = 0.037) but did not discriminate between those who did or did not have reported anaphylaxis. The FAQLQ-TF correlated weakly with 6 of the 11 CHQ-CF87 scales, demonstrating convergent/discriminant validity. Conclusion: The FAQLQ-TF is the first self-administered, disease-specific HRQL questionnaire for adolescents with food allergy. It has good construct validity and excellent internal consistency and discriminates between adolescents who differ in the number of food allergies. The FAQLQ-TF is short: and easy to use and might therefore be a useful tool in clinical research.	[Elberink, Joanne N. G. Oude] Univ Groningen, Univ Med Ctr Groningen, Div Allergy, Dept Internal Med, NL-9700 RB Groningen, Netherlands; [Blok, Bertine M. J. Flokstra-de; Viieg-Boerstra, Berber J.; Duiverman, Eric J.; Dubois, Anthony E. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Paediat, Div Paediat Allergy & Paediat Pulmonol, NL-9700 RB Groningen, Netherlands; [DunnGalvin, Audrey; Hourihane, Jonathan O'Brien] Univ Coll, Dept Paediat & Child Health, Cork, Ireland	University of Groningen; University of Groningen; University College Cork	Blok, BMJF (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Paediat, Div Paediat Allergy & Paediat Pulmonol, PO Box 30 001, NL-9700 RB Groningen, Netherlands.	b.mj.flokstra.de.blok@bkk.umcg.nl	DunnGalvin, Audrey/G-1741-2012; Vlieg-Boerstra, Berber/O-1922-2019	Vlieg-Boerstra, Berber/0000-0001-7962-5406				Akeson N, 2007, CLIN EXP ALLERGY, V37, P1213, DOI 10.1111/j.1365-2222.2007.02758.x; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415, DOI 10.1016/S1081-1206(10)60908-8; Calsbeek H, 2006, INT J BEHAV MED, V13, P121, DOI 10.1207/s15327558ijbm1302_3; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; Connolly MA, 1999, PHARMACOECONOMICS, V16, P605, DOI 10.2165/00019053-199916060-00002; CRONBACH LJ, 2001, PSYCHOMETRIKA, V16, P297; DunnGalvin A, 2008, CLIN EXP ALLERGY, V38, P977, DOI 10.1111/j.1365-2222.2008.02978.x; DunnGalvin A, 2006, ALLERGY, V61, P1336, DOI 10.1111/j.1398-9995.2006.01181.x; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V109, P162, DOI 10.1067/mai.2002.120552; GUYATT GH, 1992, J CLIN EPIDEMIOL, V45, P1341, DOI 10.1016/0895-4356(92)90194-R; Jaeschke R, 1990, QUALITY LIFE ASSESSM, P47; Juniper EF, 2003, J ALLERGY CLIN IMMUN, V111, P484, DOI 10.1067/mai.2003.137; Juniper EF, 1997, J CLIN EPIDEMIOL, V50, P233, DOI 10.1016/S0895-4356(96)00377-0; Juniper EF, QUALITY LIFE PHARMAC, V2nd; Kline P., 1994, EASY GUIDE FACTOR AN; Landgraf JM, 1999, CHILD HLTH QUESTIONN; LeBovidge JS, 2006, ANN ALLERG ASTHMA IM, V96, P472, DOI 10.1016/S1081-1206(10)60916-7; Marklund B, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-48; Marklund Birgitta, 2004, Health Qual Life Outcomes, V2, P65, DOI 10.1186/1477-7525-2-65; Muris P, 1996, BEHAV RES THER, V34, P265, DOI 10.1016/0005-7967(95)00067-4; Noone S. A., 2003, Journal of Allergy and Clinical Immunology, V111, pS133, DOI 10.1016/S0091-6749(03)80417-7; Elberink JNG, 2006, CURR OPIN ALLERGY CL, V6, P298, DOI 10.1097/01.all.0000235906.95300.3e; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Raat H, 2002, QUAL LIFE RES, V11, P575, DOI 10.1023/A:1016393311799; Ravens-Sieberer U, 2006, PHARMACOECONOMICS, V24, P1199, DOI 10.2165/00019053-200624120-00005; Rutishauser C, 2001, EUR RESPIR J, V17, P52, DOI 10.1183/09031936.01.17100520; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson MA, 2006, J ALLERGY CLIN IMMUN, V117, P1440, DOI 10.1016/j.jaci.2006.03.009; Schuck P, 2004, QUAL LIFE RES, V13, P571, DOI 10.1023/B:QURE.0000021318.92272.2a; Sicherer SH, 2002, LANCET, V360, P701, DOI 10.1016/S0140-6736(02)09831-8; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Teufel M, 2007, WORLD J GASTROENTERO, V13, P3456, DOI 10.3748/wjg.v13.i25.3456; Wiebe S, 2003, J CLIN EPIDEMIOL, V56, P52, DOI 10.1016/S0895-4356(02)00537-1; World Health Organization, 2008, PROCESS TRANSLATION	37	118	118	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					139	144		10.1016/j.jaci.2008.05.008	http://dx.doi.org/10.1016/j.jaci.2008.05.008			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	325RD	18602570				2022-12-18	WOS:000257605100023
J	Krauss-Etschmann, S; Hard, D; Rzehak, P; Heinrich, J; Shadid, R; Ramirez-Tortosa, MDC; Campoy, C; Pardillo, S; Schendel, DJ; Decsi, T; Dernmelmair, H; Koletzko, BV				Krauss-Etschmann, Susanne; Hard, Dominik; Rzehak, Peter; Heinrich, Joachim; Shadid, Rania; Ramirez-Tortosa, Maria Del Carmen; Campoy, Cristina; Pardillo, Susana; Schendel, Dolores J.; Decsi, Tamas; Dernmelmair, Hans; Koletzko, Berthold V.			Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-beta levels after fish oil supplementation of pregnant women	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pregnancy; trial; fish oil; folate; cytokine; cord blood; allergy; neonate	POLYUNSATURATED FATTY-ACIDS; DOCOSAHEXAENOIC ACID; FOLIC-ACID; CYTOKINE PRODUCTION; CONTROLLED-TRIAL; DENDRITIC CELLS; HIGH-RISK; IN-VITRO; PLASMA; FOLATE	Background: Altered intakes of n-3 and n-6 polyunsaturated fatty acids were suggested to modulate allergic disease, but intervention trials yielded inconclusive results. Because allergies are primed in early infancy and in utero, the fetus might be more accessible to nutritional intervention strategies. Objective: We sought to investigate how supplementation of pregnant women with a fish oil (FO) preparation modulates allergy-related immune parameters in mothers and offspring. Methods: We performed a multicenter, randomized, double-blind, placebo-controlled trial. Three hundred eleven pregnant women received daily either FO with 0.5 g of docosahexaenoic acid and 0.15 g of eicosapentaenoic acid, 400 mu g of methyl-tetrahydrofolic acid, both, or placebo from the 22nd gestational week. T(H)1/T(H)2-related molecules were quantified in 197 maternal and 195 cord blood samples by using real-time RT-PCR. Data are given as geometric means [95% CIs]. Results: FO supplementation was associated with increased TGF-beta mRNA in maternal (0.85 [0.8-0.89]; placebo: 0.68 [0.64-0.72]) and cord blood (0.85 [0.81-0.9]; placebo: 0.75 [0.71-0.79]). IL-1 (0.69 [0.66-0.73]; placebo: 0.83 [0.79-0.88]) and IFN-gamma (0.54 [0.51-0.57]; placebo: 0.65 [0.61-0.69]) were decreased in mothers only (P<.001). Cord blood mRNA levels of IL-4 (0.54 [0.52-0.57]; placebo: 0.64 [0.61-0.68]), IL-13 (0.61 [0.58-0.65]; placebo: 0.85 [0.80-0.89]), CCR4 (0.70 [0.67-0.73]; placebo: 0.88 [0.84-0.92]; all P<.001), and natural killer (P<.001) and CCR3(+)CD8(+) T cells (P<.04) were decreased in the FO group. Conclusion: Supplementation with FO during pregnancy is associated with decreased mRNA levels of T(H)2-related molecules in the fetus and decreased maternal inflammatory cytokines. We speculate that both effects are mediated by TGF-beta.	[Krauss-Etschmann, Susanne; Hard, Dominik; Shadid, Rania] Univ Munich, Childrens Hosp, GSF, Natl Res Ctr Environm & Hlth,Clin Cooperat Grp, Neuherberg, Germany; [Rzehak, Peter; Heinrich, Joachim] GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; [Rzehak, Peter] Univ Munich, Inst Med Data Management Biometr & Epidemiol, Munich, Germany; [Ramirez-Tortosa, Maria Del Carmen] Univ Granada, Dept Biochem, E-18071 Granada, Spain; [Campoy, Cristina; Pardillo, Susana] Univ Granada, Dept Mol Biol, E-18071 Granada, Spain; [Schendel, Dolores J.] Univ Granada, Dept Pediat, E-18071 Granada, Spain; [Schendel, Dolores J.] Nat Res Ctr Environm & Hlth, GSF, Inst Mol Immunol, Grosshadern, Germany; [Schendel, Dolores J.] Nat Res Ctr Environm & Hlth, GSF, Clin Coop Grp, Grosshadern, Germany; [Decsi, Tamas] Univ Pecs, Dept Pediat, Pecs, Hungary; [Dernmelmair, Hans; Koletzko, Berthold V.] Univ Munich, Dr Von Hauner Childrens Hosp, Div Met Dis & Nutr, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Granada; University of Granada; University of Granada; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Pecs; University of Munich	Krauss-Etschmann, S (corresponding author), Univ Munich, Childrens Hosp, GSF, Natl Res Ctr Environm & Hlth,Dept Pediat, Lindwurmstr 2a, D-80337 Munich, Germany.	susanne.krauss-etschmann@med.uni-muenchen.de	Robles-Sardin, Alma E/M-7714-2015; Heinrich, Joachim/N-1720-2013; Campoy, Cristina/F-4946-2017; Krauss-Etschmann, Susanne/H-5198-2018	Robles-Sardin, Alma E/0000-0003-2044-7793; Heinrich, Joachim/0000-0002-9620-1629; Campoy, Cristina/0000-0002-9860-6785; Krauss-Etschmann, Susanne/0000-0001-5945-5702				AGREN JJ, 1992, J LIPID RES, V33, P1871; Almqvist C, 2007, J ALLERGY CLIN IMMUN, V119, P1438, DOI 10.1016/j.jaci.2007.01.046; BETZ M, 1991, J IMMUNOL, V146, P108; Bohles H, 1999, EUR J PEDIATR, V158, P243, DOI 10.1007/s004310051059; Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S; Courtemanche C, 2004, J IMMUNOL, V173, P3186, DOI 10.4049/jimmunol.173.5.3186; Di Simone N, 2004, MOL HUM REPROD, V10, P665, DOI 10.1093/molehr/gah091; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Durand P, 1996, ATHEROSCLEROSIS, V121, P231, DOI 10.1016/0021-9150(95)06724-8; Field CJ, 2006, J NUTR BIOCHEM, V17, P37, DOI 10.1016/j.jnutbio.2005.04.010; Gosset P, 2003, J IMMUNOL, V170, P4943, DOI 10.4049/jimmunol.170.10.4943; Hauer AC, 2003, CLIN EXP ALLERGY, V33, P615, DOI 10.1046/j.1365-2222.2003.01646.x; Hirose S, 1998, Nihon Jinzo Gakkai Shi, V40, P8; Husemoen LLN, 2006, INT J EPIDEMIOL, V35, P954, DOI 10.1093/ije/dyl094; Kalinski P, 1997, J IMMUNOL, V159, P28; KOLAROVIC L, 1986, ANAL BIOCHEM, V156, P244, DOI 10.1016/0003-2697(86)90179-X; Kompauer I, 2004, EUR J MED RES, V9, P378; Krauss-Etschmann S, 2007, AM J CLIN NUTR, V85, P1392; Larque E, 2002, ANN NY ACAD SCI, V967, P299; LEPAGE G, 1989, J LIPID RES, V30, P1483; MANKU MS, 1984, BRIT J DERMATOL, V110, P643, DOI 10.1111/j.1365-2133.1984.tb04698.x; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Maxwell S. E., 2018, DESIGNING EXPT ANAL, DOI 10.4324/9781315642956; Miles EA, 2004, BRIT J NUTR, V91, P893, DOI 10.1079/BJN20041131; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Pita ML, 2000, THROMB HAEMOSTASIS, V84, P420; Power LL, 2002, J REPROD IMMUNOL, V56, P19, DOI 10.1016/S0165-0378(01)00146-2; Reisman J, 2006, BMC Complement Altern Med, V6, P26, DOI 10.1186/1472-6882-6-26; Sausenthaler S, 2007, AM J CLIN NUTR, V85, P530; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; Szajewska H, 2006, AM J CLIN NUTR, V83, P1337, DOI 10.1093/ajcn/83.6.1337; Troen AM, 2006, J NUTR, V136, P189, DOI 10.1093/jn/136.1.189; Umhau JC, 2006, EUR J CLIN NUTR, V60, P352, DOI 10.1038/sj.ejcn.1602321; WOODS RK, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; Yu G, 1998, PEDIAT ALLERG IMM-UK, V9, P133, DOI 10.1111/j.1399-3038.1998.tb00359.x	37	118	122	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					464	470		10.1016/j.jaci.2007.09.018	http://dx.doi.org/10.1016/j.jaci.2007.09.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	17980419	Bronze			2022-12-18	WOS:000253337800028
J	Yokoi, H; Hubbard, W; Lee, HS; Canning, BJ; Lee, HH; Ryu, SD; Von Gunten, S; Bickel, CA; Hudson, SA; MacGlashan, DW; Bochner, BS				Yokoi, Hidenori; Hubbard, Walter; Lee, Hyun-Sil; Canning, Brendan J.; Lee, Hyun H.; Ryu, Seung-Duk; Von Gunten, Stephan; Bickel, Carol A.; Hudson, Sherry A.; MacGlashan, Donald W., Jr.; Bochner, Bruce S.			Inhibition of Fc epsilon RI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Siglec; mast cell; immunoreceptor tyrosine-based inhibitory motif; histamine; prostaglandin D-2; IgE receptor	TYROSINE-BASED MOTIFS; RBL-2H3 CELLS; IN-VITRO; SIGLECS; ANTIGEN; IGE; MECHANISM; SIGNALS; AIRWAYS	Background: Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a family of glycan-binding inhibitory receptors, and among them, Siglec-8 is selectively expressed on human eosinophils, basophils, and mast cells. On eosinophils, Siglec-8 engagement induces apoptosis, but its function on mast cells is unknown. Objective: We sought to study the effect of Siglec-8 engagement on human mast cell survival and mediator release responses. Methods: Human mast cells were generated from CD34(+) precursors. Apoptosis was studied by using flow cytometry. Mast cell mediator release or human lung airway smooth muscle contraction was initiated by Fc epsilon RI cross-linking with or without preincubation with Siglec-8 or control antibodies, and release of mediators was analyzed along with Ca++ flux. RBL-2H3 cells transfected with normal and mutated forms of Siglec-8 were used to study how Siglec-8 engagement alters mediator release. Results: Siglec-8 engagement failed to induce human mast cell apoptosis. However, preincubation with Siglec-8 mAbs significantly (P<.05) inhibited Fc epsilon RI-dependent histamine and prostaglandin D-2 release, Ca++ flux, and anti-IgE-evoked contractions of human bronchial rings. In contrast, release of IL-8 was not inhibited. Siglec-8 ligation was also shown to inhibit beta-hexosaminidase release and Ca++ flux triggered through Fc epsilon RI in RBL-2H3 cells transfected with full-length human Siglec-8 but not in cells transfected with Siglec-8 containing a tyrosine to phenylalanine point mutation in the membrane-proximal immunoreceptor tyrosine-based inhibitory motif domain. Conclusion: These data represent the first reported inhibitory effects of Siglec engagement on human mast cells.	[Yokoi, Hidenori; Hubbard, Walter; Lee, Hyun-Sil; Canning, Brendan J.; Lee, Hyun H.; Ryu, Seung-Duk; Von Gunten, Stephan; Bickel, Carol A.; Hudson, Sherry A.; MacGlashan, Donald W., Jr.; Bochner, Bruce S.] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Dept Med,Div Allergy & Clin Immunol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine	Bochner, BS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	bbochner@jhmi.edu	Canning, Brendan/ABE-5261-2020; Canning, Brendan/AAM-9404-2021	Canning, Brendan/0000-0003-4197-5560; von Gunten, Stephan/0000-0002-2753-8738	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041472, R21AI041472, R01AI072265] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI072265, AI41472] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GK, 1979, J IMMUNOL, V122, P555; Avril T, 2004, J IMMUNOL, V173, P6841, DOI 10.4049/jimmunol.173.11.6841; BJORCK T, 1993, PULM PHARMACOL, V6, P87, DOI 10.1006/pulp.1993.1012; Blank U, 2004, TRENDS IMMUNOL, V25, P266, DOI 10.1016/j.it.2004.03.005; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; CHOI OH, 1993, J IMMUNOL, V151, P5586; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; Crocker PR, 2005, CURR OPIN PHARMACOL, V5, P431, DOI 10.1016/j.coph.2005.03.003; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Foussias G, 2000, BIOCHEM BIOPH RES CO, V278, P775, DOI 10.1006/bbrc.2000.3866; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Isnardi I, 2004, J BIOL CHEM, V279, P51931, DOI 10.1074/jbc.M410261200; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; Katz HR, 2002, CURR OPIN IMMUNOL, V14, P698, DOI 10.1016/S0952-7915(02)00400-4; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; Kovarova M, 2004, CURR MED CHEM, V11, P2083, DOI 10.2174/0929867043364801; Lee HS, 2005, CELL CALCIUM, V38, P581, DOI 10.1016/j.ceca.2005.08.002; Li LX, 2004, CELL MOL IMMUNOL, V1, P408; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MacGlashan D, 2005, CLIN REV ALLERG IMMU, V29, P49, DOI 10.1385/CRIAI:29:1:049; Marone G, 2005, ADV IMMUNOL, V88, P97, DOI 10.1016/S0065-2776(05)88004-6; Nutku E, 2005, BIOCHEM BIOPH RES CO, V336, P918, DOI 10.1016/j.bbrc.2005.08.202; Nutku E, 2003, ALLERGY FRONTIERS AND FUTURES, P130; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; NUTKUBILIR E, 2007, AM J RESP CELL MOL B; Saxon A, 2004, CURR OPIN ALLERGY CL, V4, P563, DOI 10.1097/00130832-200412000-00015; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SOTO EO, 1988, J IMMUNOL, V141, P4324; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112; Yokoi H, 2006, ALLERGY, V61, P769, DOI 10.1111/j.1398-9995.2006.01133.x; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219	34	118	125	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					499	505		10.1016/j.jaci.2007.10.004	http://dx.doi.org/10.1016/j.jaci.2007.10.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18036650				2022-12-18	WOS:000253337800033
J	Tantisira, KG; Silverman, ES; Mariani, TJ; Xu, JS; Richter, BG; Klanderman, BJ; Litonjua, AA; Lazarus, R; Rosenwasser, LJ; Fuhlbrigge, AL; Weiss, ST				Tantisira, Kelan G.; Silverman, Eric S.; Mariani, Thomas J.; Xu, Jingsong; Richter, Brent G.; Klanderman, Barbara J.; Litonjua, Augusto A.; Lazarus, Ross; Rosenwasser, Lanny J.; Fuhlbrigge, Anne L.; Weiss, Scott T.			FCER2: A pharmacogenetic basis for severe exacerbations in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; CD23; FCER2; exacerbation; corticosteroid; pharmacogenetic; hospitalization	CD23 EXPRESSION; RISK-FACTORS; ALLERGIC SENSITIZATION; CHILDHOOD ASTHMA; IMMUNOGLOBULIN-E; IGE ANTIBODIES; GLUCOCORTICOIDS; HOSPITALIZATIONS; POLYMORPHISMS; EPIDEMIOLOGY	Background: Although inhaled corticosteroids (ICSs) generally protect against severe exacerbations in asthma, they may result in elevated IgE levels, which are associated with exacerbations. Objective: To determine whether variation in the low-affinity IgE receptor gene, FCER2, is associated with severe exacerbations defined as emergency department visits and/or hospitalizations in patients with asthma on ICSs. Methods: We resequenced, then genotyped 10 FCER2 single nucleotide polymorphisms (SNPs) in 311 children randomized to inhaled budesonide as part of the Childhood Asthma Management Program. We evaluated the association of FCER2 variants with IgE levels and presence or absence of severe exacerbations over the 4-year clinical trial. We also evaluated differences in cellular expression of the novel FCER2 SNP, T2206C. Results: In white subjects, 3 FCER2 SNPs were significantly associated (P < .05) with elevated 4-year IgE level; each was also associated with increased severe exacerbations. Final multivariable models demonstrated associations between T2206C and severe exacerbations in both white and African American children (hazard ratio, 3.95; 95% CI, 1.64-9.51; and hazard ratio, 3.08; 95% CI, 1.00-9.47), despite ICS use. Interaction models supported a true gene-environment effect in white subjects (interaction P = .004). T2206C was also associated with decreased FCER2 expression (P = .02). Conclusion: FCER2 predicts the likelihood of treatment protocol success in asthma. The associations of T2206C with IgE level, severe exacerbations, and FCER2 expression may provide a mechanistic basis for the observed findings. Clinical implications: Genetic variation in FCER2 may help form a prognostic model for ICS response in asthma.	[Tantisira, Kelan G.; Richter, Brent G.; Klanderman, Barbara J.; Litonjua, Augusto A.; Lazarus, Ross; Fuhlbrigge, Anne L.; Weiss, Scott T.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Tantisira, Kelan G.; Mariani, Thomas J.; Xu, Jingsong; Fuhlbrigge, Anne L.] Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; [Tantisira, Kelan G.; Mariani, Thomas J.; Xu, Jingsong; Klanderman, Barbara J.; Litonjua, Augusto A.; Lazarus, Ross; Fuhlbrigge, Anne L.; Weiss, Scott T.] Harvard Univ, Sch Med, Boston, MA USA; [Silverman, Eric S.] MetroWest Med Ctr, Natick, MA USA; [Rosenwasser, Lanny J.] Univ Missouri, Sch Med, Kansas City, MO 64110 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Missouri System; University of Missouri Kansas City	Tantisira, KG (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	kelan.tantisira@channing.harvard.edu		Litonjua, Augusto/0000-0003-0422-5875; lazarus, ross/0000-0003-3939-1961	DIVISION OF LUNG DISEASES [N01HR016045, N01HR016046, N01HR016052, N01HR016050, N01HR016051, N01HR016044, N01HR016048, N01HR016047, N01HR016049] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065899] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K23HG003983] Funding Source: NIH RePORTER	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bacharier LB, 2003, PEDIATRICS, V112, pE85, DOI 10.1542/peds.112.2.e85; Belessis Y, 2004, PEDIATR PULM, V37, P201, DOI 10.1002/ppul.10443; Bousquet J, 2004, CHEST, V125, P1378, DOI 10.1378/chest.125.4.1378; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; CEMADAS M, 1999, AM J RESP CELL MOL B, V20, P1; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; CHUNG KF, 2003, ASTHMA, P339; Cloutier MM, 2005, J PEDIATR-US, V146, P591, DOI 10.1016/j.jpeds.2004.12.017; Dahl M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-113; DUFF AL, 1993, PEDIATRICS, V92, P535; FISCHER A, 1990, IMMUNOLOGY, V71, P473; Genty V, 2004, LEUKEMIA RES, V28, P307, DOI 10.1016/j.leukres.2003.08.009; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Haczku A, 2000, AM J RESP CRIT CARE, V161, P952, DOI 10.1164/ajrccm.161.3.9905046; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V120, P84, DOI 10.1016/j.jaci.2007.04.032; Laitinen T, 2000, AM J RESP CRIT CARE, V161, P700, DOI 10.1164/ajrccm.161.3.9810056; Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Netuveli G, 2005, LANCET, V365, P312, DOI 10.1016/S0140-6736(05)17785-X; PATERSON RLK, 1994, J IMMUNOL, V152, P2139; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449; Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention, 1998, MMWR RECOMMENDATIONS, V47, P1; Riffo-Vasquez Y, 2000, CLIN EXP ALLERGY, V30, P728; Roblot P, 1996, IMMUNOL LETT, V53, P41, DOI 10.1016/0165-2478(96)02612-0; Rodriguez RG, 2000, PULM PHARMACOL THER, V13, P31, DOI 10.1006/pupt.2000.0228; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Siroux V, 2003, CLIN EXP ALLERGY, V33, P746, DOI 10.1046/j.1365-2222.2003.01674.x; Sun XY, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e68; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; Wever-Hess J, 2000, PEDIATR PULM, V29, P250, DOI 10.1002/(SICI)1099-0496(200004)29:4<250::AID-PPUL3>3.0.CO;2-4; WILLIAMS J, 1992, J IMMUNOL, V149, P2823; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092; ZIEG G, 1994, J ALLERGY CLIN IMMUN, V94, P222, DOI 10.1016/0091-6749(94)90044-2	41	118	128	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1285	1291		10.1016/j.jaci.2007.09.005	http://dx.doi.org/10.1016/j.jaci.2007.09.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17980418				2022-12-18	WOS:000251653800007
J	Yang, Z; Yan, WX; Tedla, N; Armishaw, C; Di Girolamo, N; Wang, HW; Hampartzoumian, T; Simpson, JL; Gibson, PG; Hunt, J; Hart, P; Hughes, JM; Perry, MA; Alewood, PF; Geczy, CL				Yang, Zheng; Yan, Wei Xing; Tedla, Nicodemus; Armishaw, Chris; Di Girolamo, Nick; Wang, Hong Wei; Hampartzoumian, Taline; Simpson, Jodie L.; Gibson, Peter G.; Hunt, John; Hart, Prue; Hughes, J. Margaret; Perry, Michael A.; Alewood, Paul F.; Geczy, Carolyn L.			S100A12 provokes mast cell activation: A potential amplification pathway in asthma and innate immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						S100A12; inflammation; mast cell activation; leukocyte migration; asthma; eosinophils; sputum; receptor for advanced glycation end products	GLYCATION END-PRODUCTS; DELAYED-TYPE HYPERSENSITIVITY; TOLL-LIKE RECEPTOR-4; IN-VITRO; SURFACE RECEPTOR; PROTEIN S100A12; GENE-EXPRESSION; BONE-MARROW; RAGE; DISEASE	Background: The calcium-binding protein S100A12 might provoke inflammation and monocyte recruitment through the receptor for advanced glycation end products. Objective: Because inflammation elicited by S100A12 in vivo had characteristics of mast cell (MC) activation, we aimed to define the mechanism. Methods: Various MC populations were used to test S100A12 activation assessed on the basis of morphology, histamine release, leukotriene production, and cytokine induction. MC dependence of S100A12-provoked inflammation was tested in mice and on the rat microcirculation by means of intravital microscopy. Immunohistochemistry localized S100A12 in the asthmatic lung, and levels in sputum from asthmatic patients were quantitated by means of ELISA. Expression of the receptor for advanced glycation end products was evaluated by means of RT-PCR and Western blotting. Results: S100A12 provoked degranulation of mucosal and tissue MCs in vitro and in vivo and amplified IgE-mediated responses. It induced a cytokine profile indicating a role in innate/T(H)1-mediated responses. S100A12-induced edema and leukocyte rolling, adhesion, and transmigration in the microcirculation were MC dependent. Eosinophils in airway tissue from asthmatic patients were S100A12 positive, and levels were increased in sputum. S100A12 responses were partially blocked by an antagonist to the receptor for advanced glycation end products, but MCs did not express mRNA or protein, suggesting an alternate receptor. Conclusion: This novel pathway highlights the potential importance of S100A12 in allergic responses and in infectious and chronic inflammatory diseases. Clinical implications: MC activation by S100A12 might exacerbate allergic inflammation and asthma. S100A12 might provide a novel marker for eosinophilic asthma.	Univ New S Wales, Sch Med Sci, Sydney, NSW 2052, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; John Hunter Hosp, Hunter Med Res Inst, Dept Resp & Sleep Med, New Lambton, Australia; Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; Univ Sydney, Fac Pharm, Resp Res Grp, Sydney, NSW 2006, Australia	University of New South Wales Sydney; University of Queensland; Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle; Telethon Kids Institute; University of Western Australia; University of Sydney	Geczy, CL (corresponding author), Univ New S Wales, Sch Med Sci, Sydney, NSW 2052, Australia.	c.geczy@unsw.edu.au	SIMPSON, JODIE LOUISE/G-7639-2013; Alewood, Paul F/J-2412-2014; gibson, peter/G-6194-2014	SIMPSON, JODIE LOUISE/0000-0002-3626-680X; Yang, Zheng/0000-0003-4275-0590; Hart, Prue/0000-0001-7207-6467; gibson, peter/0000-0001-5865-489X				ASKENASE PW, 1980, J EXP MED, V152, P1358, DOI 10.1084/jem.152.5.1358; Basta G, 2002, CIRCULATION, V105, P816, DOI 10.1161/hc0702.104183; Befus AD, 1999, J IMMUNOL, V163, P947; Brody D, 1998, CLIN EXP ALLERGY, V28, P1167; Cai Y, 1998, EUR RESPIR J, V11, P848, DOI 10.1183/09031936.98.11040848; DEVERY JM, 1994, J IMMUNOL, V152, P1888; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Foell D, 2004, ARTHRITIS RHEUM-US, V50, P3762, DOI 10.1002/art.20631; Foell D, 2003, GUT, V52, P847, DOI 10.1136/gut.52.6.847; Fu WY, 2002, ATHEROSCLEROSIS, V161, P177, DOI 10.1016/S0021-9150(01)00643-8; Gaboury JP, 1996, CIRCULATION, V93, P318, DOI 10.1161/01.CIR.93.2.318; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gottsch JD, 1999, INFECT IMMUN, V67, P6631; Gurish MF, 2001, J EXP MED, V194, pF1, DOI 10.1084/jem.194.1.F1; HART PH, 1999, J IMMUNOL, V98, P1; Hasegawa T, 2003, ATHEROSCLEROSIS, V171, P211, DOI 10.1016/j.atherosclerosis.2003.08.021; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Kosaki A, 2004, J CLIN ENDOCR METAB, V89, P5423, DOI 10.1210/jc.2003-032223; Kubes P, 1996, CARDIOVASC RES, V32, P699, DOI 10.1016/S0008-6363(96)00118-6; LAU W, 1995, J CLIN INVEST, V95, P1957, DOI 10.1172/JCI117879; LI L, 1994, J IMMUNOL, V153, P3967; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Marshall JS, 2003, INT ARCH ALLERGY IMM, V132, P87, DOI 10.1159/000073709; McDonald DR, 1998, J NEUROSCI, V18, P4451; Metso T, 2002, THORAX, V57, P449, DOI 10.1136/thorax.57.5.449; MOLLER A, 1993, J IMMUNOL, V151, P3261; Nagy N, 2001, LAB INVEST, V81, P599, DOI 10.1038/labinvest.3780269; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Okumura S, 2003, BLOOD, V102, P2547, DOI 10.1182/blood-2002-12-3929; Ravasi T, 2004, GENOMICS, V84, P10, DOI 10.1016/j.ygeno.2004.02.002; Robbie-Ryan M, 2002, CURR OPIN IMMUNOL, V14, P728, DOI 10.1016/S0952-7915(02)00394-1; Rottem M, 2005, AUTOIMMUN REV, V4, P21, DOI 10.1016/j.autrev.2004.05.001; Rouleau P, 2003, CLIN IMMUNOL, V107, P46, DOI 10.1016/S1521-6616(02)00043-8; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Shishibori T, 1999, BIOCHEM J, V338, P583, DOI 10.1042/0264-6021:3380583; Sorci G, 2003, MOL CELL BIOL, V23, P4870, DOI 10.1128/MCB.23.14.4870-4881.2003; Supajatura V, 2001, J IMMUNOL, V167, P2250, DOI 10.4049/jimmunol.167.4.2250; Tanji N, 2000, J AM SOC NEPHROL, V11, P1656, DOI 10.1681/ASN.V1191656; TAUB D, 1995, J IMMUNOL, V154, P2393; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Yang Z, 2001, J LEUKOCYTE BIOL, V69, P986	44	118	125	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					106	114		10.1016/j.jaci.2006.08.021	http://dx.doi.org/10.1016/j.jaci.2006.08.021			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208591				2022-12-18	WOS:000243622200016
J	Bleecker, ER; Yancey, SW; Baitinger, LA; Edwards, LD; Klotsman, M; Anderson, WH; Dorinsky, PM				Bleecker, Eugene R.; Yancey, Steven W.; Baitinger, Leslie A.; Edwards, Lisa D.; Klotsman, Michael; Anderson, Wayne H.; Dorinsky, Paul M.			Salmeterol response is not affected by beta(2)-adrenergic receptor genotype in subjects with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; salmeterol xinafoate; genotype; polymorphism (genetics); receptors; beta(2); adrenergic; fluticasone propionate	BETA-2-ADRENERGIC RECEPTOR; MONTELUKAST; POLYMORPHISMS; ASSOCIATION; PROPIONATE; ALBUTEROL; THERAPY; PROTEIN; GENE	Background: Recent studies suggest that there might be an association between albuterol use and worsening asthma in patients homozygous for arginine (Arg/Arg) at codon 16 of the beta-receptor. However, it is not known whether similar responses occur in Arg/Arg patients receiving long-acting beta(2)-agonists. Objective: We sought to evaluate the effects of variation in the beta(2)-adrenergic receptor gene (ADRB2) on clinical response to salmeterol administered with fluticasone propionate. Methods: Subjects (n=183) currently receiving short-acting beta(2)-agonists were randomized to twice-daily therapy with salmeterol, 50 mu g, administered with fluticason propionate, 100 mu g, in a single inhaler or daily therapy with montelukast for 12 weeks, followed by a 2- to 4-day run-out period. Results: There was sustained and significant improvement (P <.001) over baseline in all measures of asthma control in subjects receiving salmeterol, regardless of Arg16Gly genotype. Morning peak expiratory flow in subjects with the Arg/Arg genotype showed 89.0 +/- 16.1 L/min improvement over baseline compared with 93.7 +/- 12.7 L/min for Gly/Gly subjects and 92.5 +/- 11.9 L/min for Arg/Gly subjects. Pairwise changes were similar for Arg/Arg compared with Gly/Gly or Arg/Gly genotypes (estimated differences, 4.7 L/min and 3.5 L/min, respectively). Responses did not appear to be modified by haplotype pairs. During the run-out period, all subjects had predictable and similar decreases in measures of asthma control, with no differences between genotypes. Conclusion: Response to salmeterol does not vary between ADRB2 genotypes after chronic dosing with an inhaled corticosteroid. Clinical implications: Analyses from this study indicate that genetic polymorphisms leading to Arg16Gly sequence changes within the beta(2)-adrenergic receptor do not affect patients' responses to recommended asthma therapy with salmeterol and fluticasone propionate.	Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; GlaxoSmithKline, Res Triangle Pk, NC USA	Wake Forest University; Wake Forest Baptist Medical Center; GlaxoSmithKline	Bleecker, ER (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	ebleeck@wfubmc.edu		Edwards, Lisa/0000-0002-4867-2151				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Calhoun WJ, 2001, AM J RESP CRIT CARE, V164, P759, DOI 10.1164/ajrccm.164.5.2012124; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Hancox RJ, 1998, EUR RESPIR J, V11, P589; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Jewell-Motz EA, 2000, J BIOL CHEM, V275, P28989, DOI 10.1074/jbc.M005381200; Joos L, 2001, Curr Opin Pulm Med, V7, P69, DOI 10.1097/00063198-200103000-00003; KLOTSMAN M, 2004, AM J RESP CRIT CARE, V169, pA582; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; Liggett SB, 2000, AM J RESP CRIT CARE, V161, pS197, DOI 10.1164/ajrccm.161.supplement_2.a1q4-10; Liggett Stephen B., 2002, Journal of Allergy and Clinical Immunology, V110, pS223, DOI 10.1067/mai.2002.129945; McGraw DW, 2003, J CLIN INVEST, V112, P619, DOI 10.1172/JCI200318193; Moore RH, 1998, CHEST, V113, P1095, DOI 10.1378/chest.113.4.1095; *NIH NAT HEART LUN, 2002, NHLBI WHO WORKSH; *NIH NAT HEART LUN, 1997, NIH PUBL; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Connor RD, 2002, CHEST, V121, P1028, DOI 10.1378/chest.121.4.1028; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P861, DOI 10.1164/ajrccm.165.7.2109096; Panettieri Reynold A. Jr., 2002, Journal of Allergy and Clinical Immunology, V110, pS269, DOI 10.1067/mai.2002.129429; Pearlman DS, 2002, ANN ALLERG ASTHMA IM, V88, P227, DOI 10.1016/S1081-1206(10)62001-7; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Sheth K, 2002, PHARMACOECONOMICS, V20, P909, DOI 10.2165/00019053-200220130-00004; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Silverman EK, 2003, J ALLERGY CLIN IMMUN, V112, P870, DOI 10.1016/S0091-6749(03)02023-2; Stempel DA, 2002, J ALLERGY CLIN IMMUN, V109, P433, DOI 10.1067/mai.2002.121953; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Yancey S., 2004, Journal of Allergy and Clinical Immunology, V113, pS34, DOI 10.1016/j.jaci.2003.12.079	36	118	124	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					809	816		10.1016/j.jaci.2006.06.036	http://dx.doi.org/10.1016/j.jaci.2006.06.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030231				2022-12-18	WOS:000241434200005
J	Marceau, C; Lemiere, C; Berbiche, D; Perreault, S; Blais, L				Marceau, Claudine; Lemiere, Catherine; Berbiche, Djamal; Perreault, Sylvie; Blais, Lucie			Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; combination therapy; concurrent therapy; persistence; adherence; effectiveness	LONG-ACTING BETA(2)-AGONISTS; SMOOTH-MUSCLE-CELLS; FLUTICASONE PROPIONATE; INHALED CORTICOSTEROIDS; SINGLE INHALER; SALMETEROL; MEDICATION; GLUCOCORTICOIDS; MONTELUKAST	Background: Limited evidence exists on adherence and effectiveness of combination therapy (inhaled corticosteroids and long-acting beta(2)-agonists in the same inhaler) in asthma. Objective: To compare persistence, adherence, and effectiveness between patients with asthma 16 to 44 years old starting combination or concurrent therapies (inhaled corticosteroids and long-acting beta(2)-agonists in 2 different inhalers). Methods: This retrospective 1-to-1 matched cohort included newly treated asthmatics with either a combination or concurrent therapy selected from the Regie de l'assurance maladie du Quebec database between 1999 and 2002. Persistence was determined by Kaplan-Meier and Cox regression analyses. Adherence was estimated by the number of prescriptions filled during the first year and compared between the 2 drug regimens using a linear regression model. Treatment effectiveness to reduce the rate of moderate to severe asthma exacerbations was estimated with Poisson regression models. Results: Persistence fell to 10% and 5% after 12 months for combination and concurrent users, respectively. Combination users were found to be 17% less likely to stop their treatment (adjusted hazard ratio, 0.83; 95% CI, 0.78, 0.88) and filled on average 0.9 more prescription per year than concurrent users (P = .0001). Combination users were also found to be 17% less likely to have a moderate to severe asthma exacerbation (adjusted rate ratio, 0.83; 95% CI, 0.75, 0.91). Conclusion: The observed differences in treatment persistence and adherence were found to be associated with a reduction in the rate of moderate to severe asthma exacerbations among combination users. Clinical implications: Combination therapy might be preferred to concurrent therapy for patients with asthma with low adherence to controller therapies.	Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada; Hop Sacre Coeur Res Ctr, Montreal, PQ, Canada; AstraZeneca, Pharmaceut Chair Resp Hlth, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; AstraZeneca	Blais, L (corresponding author), Univ Montreal, Fac Pharm, POB 6128 Ctr Ville Stn, Montreal, PQ H3C 3J7, Canada.	lucie.blais@umontreal.ca	Perreault, Sylvie/AAM-8009-2020	Perreault, Sylvie/0000-0002-0066-0127				Barnes PJ, 2002, EUR RESPIR J, V19, P182, DOI 10.1183/09031936.02.00283202; Blais L, 2004, THORAX, V59, P943, DOI 10.1136/thx.2004.022475; Boulet L P, 2001, Can Respir J, V8 Suppl A, p5A; Bukstein DA, 2001, CLIN THER, V23, P1589, DOI 10.1016/S0149-2918(01)80130-2; Campbell Debbie A, 2004, Treat Respir Med, V3, P133, DOI 10.2165/00151829-200403030-00001; Chapman KR, 2000, RESP MED, V94, P2, DOI 10.1053/rmed.1999.0667; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; Garcia-Marcos L, 2003, EXPERT OPIN PHARMACO, V4, P23, DOI 10.1517/eoph.4.1.23.21097; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; *HLTH MIN, 1997, REG ASS MAL QUEB; Holt S, 2004, J ALLERGY CLIN IMMUN, V113, P219, DOI 10.1016/j.jaci.2003.11.022; Kalbfleisch J.D., 2011, STAT ANAL FAILURE TI, V360; Kelloway JS, 2000, ANN ALLERG ASTHMA IM, V84, P324, DOI 10.1016/S1081-1206(10)62781-0; Kuna P, 2002, INT J CLIN PRACT, V56, P797; Lee E, 2013, STAT METHODS SURVIVA; Lemiere Catherine, 2004, Can Respir J, V11 Suppl A, p9A; Lotvall J, 2004, CURR MED RES OPIN, V20, P1711, DOI 10.1185/030079904X3104; Lynd LD, 2002, CHEST, V122, P1973, DOI 10.1378/chest.122.6.1973; Mak JCW, 2002, BRIT J PHARMACOL, V135, P987, DOI 10.1038/sj.bjp.0704545; Myo S, 2004, EUR RESPIR J, V23, P511, DOI 10.1183/09031936.04.00065904; *NAEPP COORD COMM, 2002, J ALLERGY CLIN IMMUN, V11, pS141; Nelson HS, 2003, J ALLERGY CLIN IMMUN, V112, P29, DOI 10.1067/mai.2003.1558; Nelson HS, 2001, J ALLERGY CLIN IMMUN, V107, P397, DOI 10.1067/mai.2001.112939; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; Remington TL, 2005, CURR OPIN PULM MED, V11, P74, DOI 10.1097/01.mcp.0000146784.56834.ff; Ringdal N, 2002, RESP MED, V96, P851, DOI 10.1053/rmed.2002.1416; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; Stempel DA, 2005, RESP MED, V99, P1263, DOI 10.1016/j.rmed.2005.03.002; Stempel DA, 2001, RESP MED, V95, P227, DOI 10.1053/rmed.2000.1027; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; *WHO, 1977, PUBL PHS; *WHO, 2003, GLOB IN ASTHM	35	118	119	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					574	581		10.1016/j.jaci.2006.06.034	http://dx.doi.org/10.1016/j.jaci.2006.06.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950273	Bronze			2022-12-18	WOS:000240649000007
J	Hales, BJ; Martin, AC; Pearce, LJ; Laing, IA; Hayden, CM; Goldblatt, J; Le Souef, PN; Thomas, WR				Hales, Belinda J.; Martin, Andrew C.; Pearce, Leigh J.; Laing, Ingrid A.; Hayden, Catherine M.; Goldblatt, Jack; Le Souef, Peter N.; Thomas, Wayne R.			IgE and IgG anti-house dust mite specificities in allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mite allergens; IgE; IgG(4); IgG(1); asthma	MODIFIED TH2 RESPONSE; DERMATOPHAGOIDES-PTERONYSSINUS; CHILDREN; ASTHMA; ANTIBODIES; EXTRACT; DER-P-2; BINDING; POPULATION; CHILDHOOD	Background: There are few studies that quantitatively compare IgE and IgG antibody binding to the major and minor house dust mite allergens. Objective: To measure the IgE and IgG antibody specificities produced by adults and children, including children admitted to an emergency department for asthma. Methods: Antibodies were measured by solid-phase microliter assays. Results: Children recruited from the emergency department had similar titers and patterns of IgE antibody binding compared with children without acute disease. Der p 1 and 2 bound 50 % to 65 % of the IgE antibody, and most of the remaining binding was to Der p 4, 5, and 7. Der p 3, 8, 10, and 20 induced low titers. The pattern was similar across a wide range of antibouse.dust mite titers. IgG(1) and IgG(4) antibodies predominantly bound the major and midrange allergens and were mainly found in children with allergy. Children recruited in the emergency department had lower titers. Conclusion: The same IgE antibody-binding pattern and predominant contribution of Der p 1 and 2 was found across a wide range of total IgE antibody titers and for children admitted to an emergency department. IgG, and IgG(4) antibodies bound to the more allergenic specificities and were largely found in children with allergy. The IgG antibody titers were lower in sera from children admitted to the emergency department for asthma exacerbations. Clinical implications: Der p 1 and 2 and possibly Der p 4, 5, and 7 provide a formulation suitable for immunotherapy and diagnosis. Low IgG antibodies were a feature of acute disease.	Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Div Mol Biotechnol, Subiaco, WA 6008, Australia; Univ Western Australia, Sch Paediat & Child Hlth, Nedlands, WA 6009, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Hales, BJ (corresponding author), Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Div Mol Biotechnol, 100 Roberts Rd, Subiaco, WA 6008, Australia.	belinda@ichr.uwa.edu.au	Laing, Ingrid/I-7092-2013; Hales, Belinda J/C-3858-2013; Le Souef, Peter N/H-5256-2014	Laing, Ingrid/0000-0002-1641-9899; Hales, Belinda J/0000-0003-2193-3996; Le Souef, Peter/0000-0003-0930-1654				Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Hales BJ, 2004, INT ARCH ALLERGY IMM, V135, P101, DOI 10.1159/000080652; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; O'Brien RM, 2000, CLIN EXP ALLERGY, V30, P333; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; Satinover SM, 2005, J ALLERGY CLIN IMMUN, V115, P803, DOI 10.1016/j.jaci.2005.01.018; Schuurman J, 1997, CLIN EXP ALLERGY, V27, P1095, DOI 10.1111/j.1365-2222.1997.tb01262.x; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Smith AM, 1998, CLIN IMMUNOL IMMUNOP, V86, P102, DOI 10.1006/clin.1997.4454; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Trombone APF, 2002, CLIN EXP ALLERGY, V32, P1323, DOI 10.1046/j.1365-2745.2002.01455.x; Van Der Veen MJ, 2001, CLIN EXP ALLERGY, V31, P705, DOI 10.1046/j.1365-2222.2001.01120.x; VANDERHEIJDEN FL, 1995, CLIN EXP IMMUNOL, V99, P289; Weghofer M, 2005, CLIN EXP ALLERGY, V35, P1384, DOI 10.1111/j.1365-2222.2005.02345.x	23	118	131	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					361	367		10.1016/j.jaci.2006.04.001	http://dx.doi.org/10.1016/j.jaci.2006.04.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890759				2022-12-18	WOS:000239877700010
J	Honda, K; Marquillies, P; Capron, M; Dombrowicz, D				Honda, K; Marquillies, P; Capron, M; Dombrowicz, D			Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peroxisome proliferator activated receptors; asthma; airway remodeling; airway hyperresponsiveness; IgE; eosinophils; trachea; TGF-beta	SMOOTH-MUSCLE-CELLS; PPAR-GAMMA; ALLERGIC INFLAMMATION; BRONCHIAL-ASTHMA; KAPPA-B; HYPERREACTIVITY; DIFFERENTIATION; APOPTOSIS; DISEASE; IL-13	Background: Allergic asthma is associated with persistent functional and structural changes in the airways and involves many different cell types. Peroxisome proliferator-activated receptor gamma (PPAR-gamma), a member of the nuclear hormone receptor superfamilly, is predominantly expressed in adipose tissue and plays a major role in regulating adipocyte differentiation and glucose metabolism. Recently, PPAR-gamma has been shown to play an important role in the control of inflammatory responses, including within the lung, acting on both immune and nonimmune cells. Objective: Our aim was to assess the anti-inflammatory potential of a PPAR-gamma agonist locally delivered by means of nebulization. Methods: We used a mouse model of asthma induced by sensitization and airway challenge with ovalbumin. Ciglitazone, a PPAR-gamma agonist, was administered by means of nebulization alone at the time of antigen challenge or by means of gavage and nebulization. Treatments with both ciglitazone and GW9662, a specific antagonist, were also performed to verify that ciglitazone's effects were mediated through PPAR-gamma activation. Results: Our results show that PPAR-gamma is mainly expressed in airway epithelium on antigen sensitization. Treatment with ciglitazone reduced PPAR-gamma levels in the lung, whereas combined treatment with GW9662 abrogated this inhibition. Importantly, nebulization with ciglitazone decreased airway hyperresponsiveness, basement membrane thickness, mucus production, collagen deposition, and TGF-beta synthesis. A significant correlation was also found between airway hyperresponsiveness, basement membrane thickness, and TGF-beta levels. Conclusion: These results demonstrate that inhaled agonistic ligands of PPAR-gamma might have new therapeutic potential for airway asthmatic inflammation.	Inst Pasteur, INSERM, U547, IFR17, F-59019 Lille, France; Inst Pasteur, INSERM, U416, IFR17, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Dombrowicz, D (corresponding author), Inst Pasteur, INSERM, U547, IFR17, 1 Rue Professeur Calmette,BP 245, F-59019 Lille, France.		Dombrowicz, David/F-7044-2013; Capron, monique/Z-2207-2019	Dombrowicz, David/0000-0002-0485-8923; Capron, monique/0000-0001-5625-5158				Adcock IM, 1996, AM J RESP CRIT CARE, V154, pS58, DOI 10.1164/ajrccm/154.2_Pt_2.S58; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487, DOI 10.1164/ajrccm.164.8.2101070; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Clark RB, 2002, J LEUKOCYTE BIOL, V71, P388; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; Cover RA, 2000, J ALLERGY CLIN IMMUN, V106, P651; Cunard R, 2002, J IMMUNOL, V168, P2795, DOI 10.4049/jimmunol.168.6.2795; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Escoubet-Lozach L, 2002, J ALLERGY CLIN IMMUN, V110, P553, DOI 10.1067/mai.2002.128076; Faveeuw C, 2000, FEBS LETT, V486, P261, DOI 10.1016/S0014-5793(00)02319-X; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fu MG, 2001, J BIOL CHEM, V276, P45888, DOI 10.1074/jbc.M105490200; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Harris SG, 2001, EUR J IMMUNOL, V31, P1098, DOI 10.1002/1521-4141(200104)31:4<1098::AID-IMMU1098>3.0.CO;2-I; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Patel HJ, 2003, J IMMUNOL, V170, P2663, DOI 10.4049/jimmunol.170.5.2663; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Setoguchi K, 2001, J CLIN INVEST, V108, P1667; Sugiyama H, 2000, FEBS LETT, V467, P259, DOI 10.1016/S0014-5793(00)01169-8; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wang ACC, 2001, AM J RESP CELL MOL, V24, P688, DOI 10.1165/ajrcmb.24.6.4376; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Zhang X, 2002, INT IMMUNOPHARMACOL, V2, P1029, DOI 10.1016/S1567-5769(02)00057-7; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	43	118	133	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					882	888		10.1016/j.jaci.2004.02.036	http://dx.doi.org/10.1016/j.jaci.2004.02.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131570	Bronze			2022-12-18	WOS:000221269000010
J	Beyer, K; Ellman-Grunther, L; Jarvinen, KM; Wood, RA; Hourihane, J; Sampson, HA				Beyer, K; Ellman-Grunther, L; Jarvinen, KM; Wood, RA; Hourihane, J; Sampson, HA			Measurement of peptide-specific IgE as an additional tool in identifying patients with clinical reactivity to peanuts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut; Ara h 1; Ara h 2; Ara h 3; epitope; tolerant; outgrown; IgE	COWS MILK ALLERGY; TREE NUT ALLERGY; ARA-H-I; BINDING EPITOPES; MUTATIONAL ANALYSIS; ATOPIC-DERMATITIS; FOOD CHALLENGES; IDENTIFICATION; HYPERSENSITIVITY; PERSISTENT	Background: Peanut allergy is one of the most common food allergies, often resulting in severe reactions. Diagnostic decision levels of food-specific IgE antibody concentrations have been described. However, many patients still need to undergo oral peanut challenges because their IgE levels are in the non-diagnostic level. Objective: The aim of this study was to determine whether differences exist in IgE-binding epitope recognition between sensitized children with and without symptomatic peanut allergy. Methods: Eight peptides representing the immunodominant sequential epitopes on Ara h 1, 2, and 3 were synthesized on SPOTs membranes. Individual patient labeling was performed with sera from 15 patients with symptomatic peanut allergy and 16 patients who were sensitized but tolerant. Ten of these 16 patients had "outgrown" their allergy. Results: Regardless of their peanut-specific IgE levels, most patients with symptomatic peanut allergy showed IgE binding to the 3 immunodominant epitopes on Ara h 2. In contrast, each of these epitopes was recognized by < 10% of the tolerant patients. In addition, tolerant patients did not recognize 2 immunodominant epitopes on Ara h 1. At least 93% of symptomatic, but only 12.5% of tolerant patients, recognized 1 of these "predictive" epitopes on Ara h 1 or 2. Moreover, the cumulative IgE binding to the peanut peptides was significantly higher in patients with peanut allergy than in tolerant patients. With up to 50% of patients with peanut-specific IgE levels below diagnostic decision levels still being clinically reactive, oral food challenges could be avoided in &SIM;90% of these patients through determination of peptide-specific IgE. Conclusions: Determination of epitope recognition provides an additional tool to diagnose symptomatic peanut allergy, especially in children with peanut-specific IgE below diagnostic decision levels.	Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY 10029 USA; Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY 10029 USA; Johns Hopkins Univ, Div Pediat Allergy, Baltimore, MD USA; Southampton Univ Hosp NHS Trust, Div Infect Inflammat & Repair, Southampton, Hants, England	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; University of Southampton; University Hospital Southampton NHS Foundation Trust	Beyer, K (corresponding author), Mt Sinai Sch Med, Div Pediat Allergy & Immunol, Box 1198,1 Gustave L levy Pl, New York, NY 10029 USA.							BEYER K, 2003, IN PRESS CURR OPIN A; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Clarke MCA, 1998, CLIN EXP ALLERGY, V28, P1251, DOI 10.1046/j.1365-2222.1998.00386.x; Cooke SK, 1997, J IMMUNOL, V159, P2026; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Hourihane JO, 2002, CURR OPIN ALLERGY CL, V2, P227, DOI 10.1097/00130832-200206000-00012; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; Maleki SJ, 2003, J ALLERGY CLIN IMMUN, V112, P190, DOI 10.1067/mai.2003.1551; Monneaux F, 2002, ARTHRITIS RHEUM, V46, P1430, DOI 10.1002/art.10263; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 2000, BRIT MED BULL, V56, P925, DOI 10.1258/0007142001903607; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x	31	118	122	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					202	207		10.1067/mai.2003.1621	http://dx.doi.org/10.1067/mai.2003.1621			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847500				2022-12-18	WOS:000184010600031
J	Medeiros, M; Figueiredo, JP; Almeida, MC; Matos, MA; Araujo, MI; Cruz, AA; Atta, AM; Rego, MAV; de Jesus, AR; Taketomi, EA; Carvalho, EM				Medeiros, M; Figueiredo, JP; Almeida, MC; Matos, MA; Araujo, MI; Cruz, AA; Atta, AM; Rego, MAV; de Jesus, AR; Taketomi, EA; Carvalho, EM			Schistosoma mansoni infection is associated with a reduced course of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; skin prick test; dust mites; helminths; Schistosoma mansoni; IL-10; IgE	HOUSE-DUST MITE; INVERSE ASSOCIATION; ATOPY; EXPOSURE; REACTIVITY; ACTIVATION; CHILDREN	Background: Helminthic infections decrease skin reactivity to indoor allergens, but data on whether they influence asthma severity are lacking. Objective: This study evaluated the course of asthma in patients with and without Schistosoma mansoni infection. Methods: Asthmatic subjects were enrolled from 3 low-socioeconomic areas: a rural area endemic for schistosomiasis (group 1) in addition to a rural area (group 2) and a slum area (group 3), both of which were not endemic for schistosomiasis. A questionnaire on the basis of the International Study of Asthma and Allergies in Childhood study was applied in these 3 areas, and from each area, 21 age- and sex-matched asthmatic subjects were selected for a prospective 1-year study. Pulmonary function tests, skin prick tests with indoor allergens, stool examinations, and serum evaluations were performed in these subjects. Every 3 months, the subjects were evaluated for asthma exacerbation through physical examination, and a questionnaire regarding asthma symptoms and use of antiasthma medicine was administered. Results: The prevalence of S mansoni infection was greater in group I compared with in groups 2 and 3 (P < .0001), whereas the frequency of other helminth and protozoa infections was similar among the 3 groups. The frequency of positive skin test responses to indoor allergens was less (19.0%) in group I subjects relative to those in group 2 (76.2%) and group 3 (57.1%; P < .001). The frequencies of symptoms, use of antiasthma drugs, and pulmonary abnormal findings at physical examination were less in group 1 subjects than in group 2 and 3 subjects (P = .0001). Conclusion: Our results suggest that S mansoni infection is associated with a milder course of asthma.	Hosp Univ Prof Edgar Santos, Serv Imunol, BR-40110160 Salvador, BA, Brazil; Inst Saude Coletiva, Salvador, BA, Brazil; Univ Fed Bahia, Dept Anal Clin & Toxicol, Salvador, BA, Brazil; Escola Baiana Med & Saude Publ, Salvador, BA, Brazil; Univ Fed Uberlandia, Dept Microbiol Immunol & Parasitol, BR-38400 Uberlandia, MG, Brazil	Universidade Federal da Bahia; Escola Bahiana de Medicina e Saude Publica; Universidade Federal de Uberlandia	Medeiros, M (corresponding author), Hosp Univ Prof Edgar Santos, Serv Imunol, Rua Joao Botas S-N,5 Andar, BR-40110160 Salvador, BA, Brazil.		Cruz, Alvaro A/I-1676-2012	Cruz, Alvaro A/0000-0002-7403-3871				Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Araujo MI, 1996, EUR J IMMUNOL, V26, P1399, DOI 10.1002/eji.1830260633; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Catapani WR, 1997, J ALLERGY CLIN IMMUN, V100, P142; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Cooper PJ, 2002, CLIN EXP IMMUNOL, V128, P398, DOI 10.1046/j.1365-2249.2002.01908.x; Howard TD, 2000, J ALLERGY CLIN IMMUN, V105, pS477, DOI 10.1016/S0091-6749(00)90046-0; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; KATZ N, 1968, Revista do Instituto de Medicina Tropical de Sao Paulo, V10, P295; KATZ N, 1970, J PARASITOL, V56, P1032, DOI 10.2307/3277532; King CL, 1996, J IMMUNOL, V156, P4715; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217, DOI 10.1016/S0091-6749(98)70386-0; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Medeiros M, 2002, J ALLERGY CLIN IMMUN, V109, pS139, DOI 10.1016/S0091-6749(02)81542-1; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Velupillai P, 2000, HUM IMMUNOL, V61, P225, DOI 10.1016/S0198-8859(99)00136-6; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; Weiss ST, 2000, J ALLERGY CLIN IMMUN, V105, P205, DOI 10.1016/S0091-6749(00)90067-8	28	118	127	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					947	951		10.1067/mai.2003.1381	http://dx.doi.org/10.1067/mai.2003.1381			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743556				2022-12-18	WOS:000182904500006
J	Sander, I; Flagge, A; Merget, R; Halder, TM; Meyer, HE; Baur, X				Sander, I; Flagge, A; Merget, R; Halder, TM; Meyer, HE; Baur, X			Identification of wheat floor allergens by means of 2-dimensional immunoblotting	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Baker's asthma; wheat flour allergens; triosephosphate isomerase; glycerinaldehyde-3-phosphate dehydrogenase; serpin	ALPHA-AMYLASE-INHIBITOR; BAKERS ASTHMA; SEQUENCE-ANALYSIS; GRAIN ALLERGENS; MAJOR ALLERGEN; PROTEINS; BINDING; FLOUR; IGE; ELECTROPHORESIS	Background: Wheat flour proteins are allergens for 60% to 70% of bakers with workplace-related respiratory symptoms. Objective: The aim of the study was to investigate the variability of IgE antibody patterns of wheat flour-sensitized bakers and to identify the most frequently recognized allergens. Methods: Water/salt-soluble wheat flour proteins from the cultivar Bussard were separated by using 2-dimensional gel electrophoresis with immobilized pH gradients. IgE-reactive proteins were identified by means of immunoblotting with sera of 10 subjects with baker's asthma. Mass spectrometric fingerprinting was used to identify the proteins most frequently recognized by IgE. Results: The IgE immunoblots obtained with 10 different sera exhibited a remarkable heterogeneity. Each patient showed an individual IgE-binding pattern with 4 to 50 different allergen spots. Altogether, more than 100 IgE-binding protein spots were detected. Nine of the predominant IgE-binding protein spots were identified by using mass spectrometric fingerprinting. The obtained masses matched 2 different isoforms of glycerinaldehyde-3-phosphate dehydrogenase from Hordeum vulgare, triosephosphate isomerase from H vulgare, and serpin, a serine proteinase inhibitor from Triticum aestivum. Conclusions: The results show a great interindividual variation of IgE-binding patterns of wheat flour proteins in baker's asthma, The clinical relevance of the identified 4 new allergens will be further investigated in the near future.	Res Inst Occupat Med, Bochum, Germany; Ruhr Univ Bochum, Dept Immunol, D-4630 Bochum, Germany	Ruhr University Bochum; Ruhr University Bochum	Sander, I (corresponding author), Burkle de la Camp Pl 1, D-44789 Bochum, Germany.		Sander, Ingrid/R-8940-2017	Sander, Ingrid/0000-0002-5014-4112				Amano M, 1998, BIOCHEM J, V330, P1229, DOI 10.1042/bj3301229; ARMENTIA A, 1993, CLIN EXP ALLERGY, V23, P410, DOI 10.1111/j.1365-2222.1993.tb00347.x; Baur X, 1998, ALLERGY, V53, P562, DOI 10.1111/j.1398-9995.1998.tb03931.x; BLANDS J, 1976, INT ARCH ALLER A IMM, V52, P392, DOI 10.1159/000231706; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; FRANKEN J, 1994, INT ARCH ALLERGY IMM, V104, P171, DOI 10.1159/000236726; Gevaert K, 1996, ELECTROPHORESIS, V17, P918, DOI 10.1002/elps.1150170513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maruyama N, 1998, EUR J BIOCHEM, V255, P739, DOI 10.1046/j.1432-1327.1998.2550739.x; *NAT ASTHM ED PREV, 1997, NIH PUBLIC; POSCH A, 1995, ELECTROPHORESIS, V16, P1115, DOI 10.1002/elps.11501601188; SANCHEZMONGE R, 1992, BIOCHEM J, V281, P401, DOI 10.1042/bj2810401; SanchezMonge R, 1997, CLIN EXP ALLERGY, V27, P1130, DOI 10.1046/j.1365-2222.1997.1340945.x; Sander I, 1999, ALLERGY, V54, P50; Sandiford CP, 1997, CLIN EXP ALLERGY, V27, P1120, DOI 10.1046/j.1365-2222.1997.1310936.x; SUTTON R, 1984, CLIN ALLERGY, V14, P93, DOI 10.1111/j.1365-2222.1984.tb02196.x; WALSH BJ, 1985, J ALLERGY CLIN IMMUN, V76, P23, DOI 10.1016/0091-6749(85)90799-7; WALSH BJ, 1989, J IMMUNOL METHODS, V121, P275, DOI 10.1016/0022-1759(89)90171-3; WEISS W, 1993, ELECTROPHORESIS, V14, P805, DOI 10.1002/elps.11501401126; Weiss W, 1997, ELECTROPHORESIS, V18, P826, DOI 10.1002/elps.1150180529	23	118	122	1	13	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					907	913						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344361	Bronze			2022-12-18	WOS:000168812300022
J	Oyama, N; Sudo, N; Sogawa, H; Kubo, C				Oyama, N; Sudo, N; Sogawa, H; Kubo, C			Antibiotic use during infancy promotes a shift in the T(H)1/T(H)2 balance toward T(H)2-dominant immunity in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antibiotics; IFN-gamma; IgE; IL-4; IL-12; intestinal microflora; kanamycin	DENDRITIC CELLS; EARLY-CHILDHOOD; ORAL TOLERANCE; CYTOKINE; ATOPY; EXPRESSION; RESPONSES; SYSTEM	Background: Recent epidemiologic studies indicate that antibiotic use in infancy may be associated with an increased risk of development of atopy; however, its precise mechanism remains to be elucidated. Objective: The purpose of this study is to clarify whether one such antibiotic, kanamycin, affects the T(H)1/T(H)2 balance. Methods: BALB/c mice at 3 and 52 weeks of age were orally administered 600 mg/d kanamycin sulfate for 7 consecutive days. Blood samples were collected on weeks 0, 10, 18, and 26 after the cessation of kanamycin treatment, and the effect of the kanamycin treatment on the T(H)1/T(H)2 balance was evaluated on the basis of both the in vivo antibody levels and the in vitro splenocyte cytokine secretion pattern. Results: The administration of kanamycin increased the serum levels of total IgG 1 and IgE while decreasing the serum IgG2a levels. Moreover, when spleen cells were stimulated with immobilized anti-CD3 antibody in vitro, such kanamycin treatment enhanced the in vitro IL-4 secretion while reducing the in vitro IFN-gamma secretion. The basal IL-12 p70 secretion levels of splenic dendritic cells in the kanamycin-treated mice were lower than those In the control mice, although no significant difference was seen in IL-12 p40 levels between either group of mice. Conclusion: These results suggested that antibiotic use during infancy may indeed quantitatively disturb, qualitatively disturb, or both the intestinal microflora and thereby prevent postnatal T(H)1 cell maturation, thus resulting in a T(H)2-polarized immune deviation.	Kyushu Univ, Grad Sch Med Sci, Dept Psychosomat Med, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Sudo, N (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Psychosomat Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.			Sudo, Nobuyuki/0000-0002-7935-878X				Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BENNO Y, 1992, MICROBIOL IMMUNOL, V36, P683, DOI 10.1111/j.1348-0421.1992.tb02071.x; Bjorksten B, 1999, J ALLERGY CLIN IMMUN, V104, P1119; BRUNDA MJ, 1994, J LEUKOCYTE BIOL, V55, P280; Chen NX, 1995, TRANSPLANTATION, V60, P1187; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Fukui Y, 1997, J NEUROIMMUNOL, V79, P211, DOI 10.1016/S0165-5728(97)00126-4; GARSIDE P, 1995, J IMMUNOL, V154, P5649; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; GILLESSEN S, 1995, EUR J IMMUNOL, V25, P200, DOI 10.1002/eji.1830250133; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; KRUSZEWSKA B, 1995, J IMMUNOL, V155, P4613; LIN H, 1993, J IMMUNOL, V151, P4562; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Marriott I, 1999, EUR J IMMUNOL, V29, P1107, DOI 10.1002/(SICI)1521-4141(199904)29:04<1107::AID-IMMU1107>3.0.CO;2-0; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; Prescott SL, 1998, J IMMUNOL, V160, P4730; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STERN AS, 1990, P NATL ACAD SCI USA, V87, P6808, DOI 10.1073/pnas.87.17.6808; Sudo N, 1997, J IMMUNOL, V159, P1739; Tada T, 1996, CELL IMMUNOL, V173, P155, DOI 10.1006/cimm.1996.0261; TINCKE CTM, 1997, J IMMUNOL, V158, P5560; Verhasselt V, 1997, J IMMUNOL, V158, P2919; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766	28	118	130	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					153	159		10.1067/mai.2001.111142	http://dx.doi.org/10.1067/mai.2001.111142			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11150005				2022-12-18	WOS:000166533300025
J	Golden, DBK; Kagey-Sobotka, A; Lichtenstein, LM				Golden, DBK; Kagey-Sobotka, A; Lichtenstein, LM			Survey of patients after discontinuing venom immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						venom immunotherapy; insect sting; Hymenoptera; anaphylaxis; immunotherapy	YELLOW JACKET VENOM; STING CHALLENGE; HONEYBEE VENOM; FOLLOW-UP; SENSITIVITY; STOP; HYPERSENSITIVITY; ANAPHYLAXIS; CRITERIA; SEVERITY	Background: Venom immunotherapy rapidly reduces the risk of a systemic sting reaction in adults from 30% to 70% to less than 2%, When venom immunotherapy is stopped after 5 years or longer, the risk of a systemic sting reaction is 5% to 15% during the first few years after stopping treatment. It is uncertain whether systemic sting reactions will occur more than 5 years after discontinuing venom immunotherapy and whether treatment can be safely stopped in some patients after less than 5 years. Objective: The purpose of this study is to estimate the risk of systemic reaction to a sting 10 years after discontinuing treatment and the relative risk after 3 years of treatment compared with that after 5 years or more of treatment. Methods: Among all patients who had venom immunotherapy at our center, we identified 395 patients who stopped treatment: some had dropped out of therapy early (6-24 months), some stopped after 3 to 4 years, and most completed 5 years or more of venom immunotherapy and were advised to stop by the allergist (many as part of our reported studies of discontinuing venom immunotherapy). Results: Contact was made with 191 patients, including telephone interviews for sting history and requests to visit the office for skin testing and blood sampling. Of these patients, 74 had been included in our original study of patients who had 5 years or more of venom immunotherapy and had sting challenges after 1 to 5 years off venom immunotherapy, as previously reported. Of the 74 in that original study, 61 were reached for this survey, and 30 reported recent stings, with 5 systemic sting reactions. Another 133 patients who had stopped venom immunotherapy were reached: 82 had 5 or more years of venom immunotherapy, 20 had 3 to 4 years of venom immunotherapy, and 31 had less than 2 years of venom immunotherapy, Of 51 patients stung from this group, 27 had 5 or more years of venom immunotherapy (no systemic sting reactions), and 24 had less than 5 years of venom immunotherapy (3 systemic sting reactions). We have now observed a total of 113 patients who had 5 or more years of venom immunotherapy and were stung after stopping. Sixteen (14%) had systemic sting reactions; most were mild, but 4 were severe, Systemic sting reactions occurred in 12 (10.7%) of 112 patients stung in the first 4 years off venom immunotherapy and 5 (10%) of 50 stung more than 5 years off venom immunotherapy. In 4 of 8 patients with current systemic sting reactions, the skin test response was negative, although the venom-IgE response was positive at the previous encounter. All systemic sting reactions were similar in pattern and severity to prevenom immunotherapy reactions in the same patient. Conclusions: We conclude that the risk of systemic sting reactions when venom immunotherapy is stopped after 5 years or longer remains in the reported range of 5% to 15% in the 5 to 10 years after stopping venom immunotherapy. This risk of systemic sting reactions does not seem to decrease over time, unlike the progressive decline in immunologic markers (skin test and venom-IgE responses). To prospectively assess the risk of recurrent systemic sting reactions, there is a need for sting challenge studies of patients who have been off venom immunotherapy for 5 to 10 years and patients who have stopped venom immunotherapy after just 3 to 4 years treatment.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Golden, DBK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Blvd, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08270] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		FRANKEN HH, 1994, J ALLERGY CLIN IMMUN, V93, P431, DOI 10.1016/0091-6749(94)90351-4; GALATAS ID, 1994, J ALLERGY CLIN IMMUN, V94, P272, DOI 10.1016/0091-6749(94)90055-8; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P727, DOI 10.1016/0091-6749(86)90418-5; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P435, DOI 10.1016/0091-6749(86)90177-6; GOLDEN DBK, 1987, J ALLERGY CLIN IMMUN, V79, P126; GOLDEN DBK, 1985, J ALLERGY CLIN IMMUN, V75, P208, DOI 10.1016/0091-6749(85)90550-0; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GOLDEN DBK, 1981, JAMA-J AM MED ASSOC, V246, P2460, DOI 10.1001/jama.246.21.2460; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Graft DF, 1998, J ALLERGY CLIN IMMUN, V101, P573, DOI 10.1016/S0091-6749(98)70161-7; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; MACGLASHAN D, 1987, J IMMUNOL, V139, P501; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1991, J ALLERGY CLIN IMMUN, V87, P618, DOI 10.1016/0091-6749(91)90378-2; van Halteren HK, 1997, J ALLERGY CLIN IMMUN, V100, P767, DOI 10.1016/S0091-6749(97)70271-9; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889	23	118	119	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				385	390		10.1016/S0091-6749(00)90092-7	http://dx.doi.org/10.1016/S0091-6749(00)90092-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669863	Bronze			2022-12-18	WOS:000085402200027
J	Tupker, RA; DeMonchy, JGR; Coenraads, PJ; Homan, A; vanderMeer, JB				Tupker, RA; DeMonchy, JGR; Coenraads, PJ; Homan, A; vanderMeer, JB			Induction of atopic dermatitis by inhalation of house dust mite	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; house dust mite; bronchial challenge; early bronchial reaction; total IgE	ALLERGENS; CHALLENGE; PEPTIDE; ASTHMA	Background: The pathogenetic role of house dust mite in atopic dermatitis remains controversial. Recent studies have shown that intensive epicutaneous contact of house dust mite allergen with premanipulated skin may induce dematitis. It is, however, uncertain whether such conditions are met during natural contact with house dust mite. In the past, allergen inhalation has been suggested to induce exacerbation of atopic dermatitis. The aim of this study was to investigate whether dermatitis could be induced in patients with atopic dermatitis by inhalation of house dust mite. Methods: Twenty patients with atopic dermatitis underwent bronchial provocations with house dust mite. Challenge tests were performed with four concentrations of a standardized house dust mite extract in a double-blind randomized, placebo-controlled fashion. Spirometry was performed, and FEV, runs measured before and after each challenge dose. Changes in severity or localization of itching or erythema were recorded. Results: In nine of 20 patients with atopic dermatitis bronchial challenge with house dust mite induced unequivocal skin symptoms after 1.5 to 17 hours. Pruritic erythematous lesions on noninvolved sites together with exacerbations of existing lesions were seen in three patients. Three patients had an exacerbation only, and three other patients had new lesions only. In eight of nine patients with house dust mite inhalation-induced dermatitis, skin symptoms were preceded by an early bronchial reaction. All patients with house dust mite-induced dermatitis had a history of asthma, and as a group they had a higher mean blood total IgE la el compared with the ''negative skirt responders.'' One patient had pruritic erythema on the placebo challenge day, without a preceding bronchoconstrictive reaction. The number of patients who had a skin response on the house dust mite challenge day was significantly higher than the number of patients who had a skin response on the placebo day (p = 0.011 [Prescott's test]). Conclusions: The respiratory route may be relevant in the induction and exacerbation of dermatitis in a subset of patients with atopic dermatitis who have early bronchial reactions after house dust mite inhalation, a history of asthma, and an elevated blood total IgE level. Furthermore, these findings suggest a possible causal relationship between bronchial reactions and skirt reactions.	UNIV GRONINGEN HOSP,DEPT ALLERGOL,NL-9700 RB GRONINGEN,NETHERLANDS	University of Groningen	Tupker, RA (corresponding author), UNIV GRONINGEN HOSP,DEPT DERMATOL,POB 300001,NL-9700 RB GRONINGEN,NETHERLANDS.							ADINOFF AD, 1988, J ALLERGY CLIN IMMUN, V81, P736, DOI 10.1016/0091-6749(88)91047-0; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; CZARNETZKI BM, 1991, HDB ATOPIC ECZEMA, P186; GONDO A, 1986, BRIT J DERMATOL, V115, P485, DOI 10.1111/j.1365-2133.1986.tb06243.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HEGARTY JM, 1995, J ALLERGY CLIN IMMUN, V95, P249; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; KONTOUKARAKITSOS K, 1975, J ALLERGY CLIN IMMUN, V55, P241, DOI 10.1016/0091-6749(75)90143-8; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; MITCHELL EB, 1982, LANCET, V1, P127; NORRIS PG, 1988, BRIT J DERMATOL, V118, P435, DOI 10.1111/j.1365-2133.1988.tb02440.x; Prescott R. J., 1981, Applied Statistics, V30, P9, DOI 10.2307/2346652; RAJKA G, 1963, ACTA DERM VENERE S54, V43, P109; ROBERTS DLL, 1984, BRIT J DERMATOL, V110, P735, DOI 10.1111/j.1365-2133.1984.tb04714.x; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; STORCK H, 1961, Arch Belg Dermatol Syphiligr, V17, P95; STORCK H, 1960, DERMATOLOGICA, V121, P150; TANAKA Y, 1989, ACTA DERM-VENEREOL S, V144, P93; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; TUFT L, 1950, J INVEST DERMATOL, V15, P333, DOI 10.1038/jid.1950.107; TUFT L, 1950, J ALLERGY, V21, P181, DOI 10.1016/0021-8707(50)90125-0; TUFT L, 1952, J ALLERGY, V23, P528, DOI 10.1016/0021-8707(52)90040-3; VADER PCV, 1991, ACTA DERM-VENEREOL, V71, P301; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VANLOVEREN H, 1990, SKIN IMMUNE SYSTEM S, P307; VANREIJSEN FC, 1995, THESIS U UTRECHT THE; WARRINGA RAJ, 1993, J ALLERGY CLIN IMMUN, V91, P1198, DOI 10.1016/0091-6749(93)90323-8; WEERSINK EJM, 1994, AM J RESP CRIT CARE, V150, P1262, DOI 10.1164/ajrccm.150.5.7952550	30	118	122	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1064	1070		10.1016/S0091-6749(96)70259-2	http://dx.doi.org/10.1016/S0091-6749(96)70259-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626983				2022-12-18	WOS:A1996UL26100006
J	Droste, JHJ; Kerkhof, M; deMonchy, JGR; Schouten, JP; Rijcken, B				Droste, JHJ; Kerkhof, M; deMonchy, JGR; Schouten, JP; Rijcken, B			Association of skin test reactivity, specific IgE, total IgE, and eosinophils with nasal symptoms in a community-based population study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						general population; nasal allergy; skin test reactivity; specific IgE positivity; total serum IgE; eosinophil count	NUTRITION EXAMINATION SURVEY; 2ND NATIONAL-HEALTH; HOUSE DUST MITE; FEL-D-I; RESPIRATORY-DISEASE; HAY-FEVER; ALLERGEN; ASTHMA; ASSAY	Background: Skin prick tests and measurement of specific IgE are important markers possible allergic causes of disorders of the upper respiratory tract. Objective: In this study we investigated the association of skin test reactivity and specific IgE positivity to five common aeroallergens separately and of total serum IgE and eosinophil count with nasal allergy symptoms in a random sample of the adult population in The Netherlands. Methods: A cross-sectional study was carried out in a sample of 2167 subjects, aged 20 to 70 years, stratified by age and gender. Nasal allergy symptoms were differentiated into three categories: symptoms after exposure to indoor allergens only, symptoms after exposure to outdoor allergens only, and symptoms after exposure to both indoor and outdoor allergens. Associations were investigated by multiple logistic regression analyses with adjustment for area of residence, gender, age, and smoking status. Results: Skin test and specific IgE reactivity to indoor and outdoor allergens were significantly related to their corresponding nasal symptom groups. Odds ratios increased with increasing number of positive skin test results or increasing levels of specific IgE to allergens in all three nasal symptom groups. For each allergen, a positive skin test result together with a positive specific IgE measurement were the strongest predictors of nasal symptoms. Sensitization to house dust mite was the most prevalent in our study population, whereas the association of skin test reactivity and specific IgE positivity with nasal symptoms was strongest for cat allergen. Skin test and specific IgE reactivity to Cladosporium species were not significantly related to the prevalence of nasal symptoms. Total serum IgE was related to nasal symptoms only in subjects who reported symptoms in response to both indoor and outdoor allergens and only at high levels of IgE. Eosinophil count was associated with nasal symptoms in all nasal symptom groups. Conclusions: Our findings confirm the close relationship of skin test positivity with reported symptoms of nasal allergy in a general population. Specific IgE positivity also shows a close relationship with nasal symptoms in response to allergen exposure in a general population. Skin testing and specific IgE measurement may be considered complementary to one another in diagnosing allergic rhinitis. Total IgE may be considered an indicator of greater dysregulation of the immune system in atopic allergy. Eosinophil count is associated with nasal symptoms, regardless of type and extent of nasal symptoms.	UNIV GRONINGEN,DEPT EPIDEMIOL & STAT,9713 AV GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT ALLERGOL,GRONINGEN,NETHERLANDS; GGD GRONINGEN STAD & OMMELANDEN,GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen			Kerkhof, Marjan/A-8846-2008					BAKKE P, 1990, ALLERGY, V45, P515, DOI 10.1111/j.1398-9995.1990.tb00527.x; BARBEE RA, 1991, CHEST, V99, P20, DOI 10.1378/chest.99.1.20; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; BRAND PLP, 1993, J ALLERGY CLIN IMMUN, V91, P560, DOI 10.1016/0091-6749(93)90262-E; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; GERGEN PJ, 1991, ARCH INTERN MED, V151, P487, DOI 10.1001/archinte.151.3.487; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1992, EXP APPL ACAROL, V16, P141, DOI 10.1007/BF01201497; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P776, DOI 10.1164/ajrccm/144.4.776; Vervloet D, 1991, Allerg Immunol (Paris), V23, P281	14	118	124	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					922	932		10.1016/S0091-6749(96)80066-2	http://dx.doi.org/10.1016/S0091-6749(96)80066-2			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655887				2022-12-18	WOS:A1996UG08600006
J	CIPRANDI, G; BUSCAGLIA, S; PESCE, G; VILLAGGIO, B; BAGNASCO, M; CANONICA, GW				CIPRANDI, G; BUSCAGLIA, S; PESCE, G; VILLAGGIO, B; BAGNASCO, M; CANONICA, GW			ALLERGIC SUBJECTS EXPRESS INTERCELLULAR-ADHESION MOLECULE - 1 (ICAM-1 OR CD54) ON EPITHELIAL-CELLS OF CONJUNCTIVA AFTER ALLERGEN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SEASONAL RHINOCONJUNCTIVITIS; OFF-POLLEN SEASON; CONJUNCTIVAL PROVOCATION TEST; PARIETARIA-JUDAICA; ALLERGIC INFLAMMATION; ADHESION MOLECULES; CONJUNCTIVAL EPITHELIAL CELLS	PROVOCATION TEST; OCULAR ALLERGY; ASTHMA; INFLAMMATION; LFA-1; REJECTION; HUMANS; LIGAND; SYSTEM; MODEL	Background: Allergic inflammation can be experimentally reproduced in vivo in humans, by means of the conjunctival provocation test with allergen. The allergen stimulation triggers an early clinical response and an almost simultaneous cellular infiltrate. Among the factors that can contribute to the local cellular recruitment, we postulate a possible early involvement of CD54 in the development of inflammation caused by the allergic reaction. Methods: We used a sensitive immunocytochemical immunoenzymatic alkaline phosphatase-monoclonal antialkaline phosphatase technique to detect the possible expression of CD54 molecule on epithelial cells of conjunctiva in 15 allergic subjects and in 15 healthy individuals in basal conditions and after allergen challenge (Parietaria judaica) during the off-pollen season. Results: At baseline all studied individuals did not evidence CD54 expression on epithelial cells; 30 minutes after allergen challenge, all the allergic individuals showed a marked expression of CD54 on conjunctival epithelium, whereas none of healthy subjects showed any CD54 expression. First, CD54 expression on conjunctival epithelium after specific provocation test appeared as a specific phenomenon occurring only in sensitized subjects; moreover, it is an immediate event concomitant with the local inflammatory infiltrate. Therefore conjunctival epithelium unexpectedly appeared to be more than a bystander in the allergic reaction; it may be perceived as an active participant interacting with the inflammatory infiltrate. Conclusions: These findings indicate that CD54 may play a central role in the allergic inflammation and strongly support the concept that maneuvers designed to interact with the adhesion machinery expressed on inflammatory cells and epithelium may be a helpful therapeutic approach.			CIPRANDI, G (corresponding author), UNIV GENOA,DEPT INTERNAL MED,ALLERGY & CLIN IMMUNOL SERV,DI ML,V BENEDETTO XV 6,I-16132 GENOA,ITALY.		canonica, giorgio walter/ABF-2037-2020; Ciprandi, Giorgio/G-7462-2012	canonica, giorgio walter/0000-0001-8467-2557; Ciprandi, Giorgio/0000-0001-7016-8421; Pesce, Giampaola/0000-0002-6294-9110				ADAMS DH, 1989, LANCET, V2, P1122; BAGNASCO M, 1991, CLIN EXP IMMUNOL, V83, P309; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; Barnes P J, 1991, Clin Exp Allergy, V21 Suppl 1, P80, DOI 10.1111/j.1365-2222.1991.tb01710.x; BIERER BE, 1988, FASEB J, V2, P2584, DOI 10.1096/fasebj.2.10.2838364; BONINI S, 1990, J ALLERGY CLIN IMMUN, V86, P869, DOI 10.1016/S0091-6749(05)80148-4; BONINI S, 1988, J ALLERGY CLIN IMMUN, V82, P462, DOI 10.1016/0091-6749(88)90020-6; BONINI S, 1989, INT ARCH ALLER A IMM, V88, P144, DOI 10.1159/000234769; BROWN PH, 1991, LANCET, V338, P590, DOI 10.1016/0140-6736(91)90605-O; CAMPBELL AM, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P215; CANONICA GW, 1991, ALLERGY CLIN IMMUN S, V1, P28; CIPRANDI G, 1991, ALLERGY, V46, P393, DOI 10.1111/j.1398-9995.1991.tb00604.x; CIPRANDI G, 1992, DRUGS, V43, P154, DOI 10.2165/00003495-199243020-00003; CIPRANDI G, 1991, INT ARCH ALLER A IMM, V96, P344, DOI 10.1159/000235519; CIPRANDI G, 1992, ALLERGY, V47, P309, DOI 10.1111/j.1398-9995.1992.tb02059.x; COCKCROFT DW, 1991, J ALLERGY CLIN IMMUN, V87, P914, DOI 10.1016/0091-6749(91)90412-H; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DOUGHERTY GJ, 1988, EUR J IMMUNOL, V18, P35, DOI 10.1002/eji.1830180107; DURHAMSR, 1991, CLIN EXP ALLERGY, V21, P3; DUSTIN ML, 1986, J IMMUNOL, V137, P245; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FAULL RJ, 1989, TRANSPLANTATION, V48, P226, DOI 10.1097/00007890-198908000-00009; FRIEDLAENDER MH, 1991, ANN ALLERGY, V67, P5; FRIEDLAENDER MH, 1990, T AM OPHTHAL SOC, V87, P577; HOWARTH PH, 1990, CLIN EXP ALLERGY, V20, P31, DOI 10.1111/j.1365-2222.1990.tb02459.x; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KRENSKY AM, 1983, J IMMUNOL, V131, P64; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEMANSKE RF, 1988, ALLERGY PRINCIPLES P, P224; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; MACHADO L, 1986, CLIN ALLERGY, V16, P111, DOI 10.1111/j.1365-2222.1986.tb00754.x; MAKGOBA MW, 1989, IMMUNOL TODAY, V10, P417, DOI 10.1016/0167-5699(89)90039-X; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MENTZER SJ, 1986, J CELL PHYSIOL, V126, P285, DOI 10.1002/jcp.1041260219; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OFOSUAPPIAH W, 1989, SCAND J IMMUNOL, V29, P1517; OLIVE D, 1986, HUMAN T CELL CLONES, P173; PROUD D, 1990, J ALLERGY CLIN IMMUN, V85, P896, DOI 10.1016/0091-6749(90)90075-F; SCHOENEICH M, 1990, CLIN EXP ALLERGY, V20, P171, DOI 10.1111/j.1365-2222.1990.tb02663.x; SOBEL RA, 1990, AM J PATHOL, V136, P1309; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TUFT L, 1959, J ALLERGY, V30, P492, DOI 10.1016/0021-8707(59)90003-6; VOLPES R, 1990, HEPATOLOGY, V12, P59, DOI 10.1002/hep.1840120110; WEETMAN AP, 1990, EUR J IMMUNOL, V20, P271, DOI 10.1002/eji.1830200207; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WILCOXON F, 1909, SOME RAPID APPROXIMA, P13; 1990, LANCET, V336, P1351	50	118	120	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					783	792		10.1016/0091-6749(93)90198-O	http://dx.doi.org/10.1016/0091-6749(93)90198-O			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8095941				2022-12-18	WOS:A1993KU20300011
J	HORAN, RF; SHEFFER, AL; AUSTEN, KF				HORAN, RF; SHEFFER, AL; AUSTEN, KF			CROMOLYN SODIUM IN THE MANAGEMENT OF SYSTEMIC MASTOCYTOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NIAID NIH HHS [AI-23401, AI-22531] Funding Source: Medline; NIAMS NIH HHS [AR-35907] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI023401, R01AI022531, R37AI022531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR035907] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CZARNETZKI BM, 1983, DERMATOLOGICA, V166, P44, DOI 10.1159/000249832; CZARNETZKI BM, 1981, BRIT J DERMATOL, V105, P563, DOI 10.1111/j.1365-2133.1981.tb00800.x; FRIERI M, 1985, AM J MED, V78, P9, DOI 10.1016/0002-9343(85)90454-1; GUINOT P, 1988, LANCET, V2, P114; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; SOTER NA, 1979, NEW ENGL J MED, V301, P465, DOI 10.1056/NEJM197908303010903; VANDOORMAAL JJ, 1986, AGENTS ACTIONS, V18, P269	7	118	125	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					852	855		10.1016/0091-6749(90)90067-E	http://dx.doi.org/10.1016/0091-6749(90)90067-E			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2110198				2022-12-18	WOS:A1990DD95900005
J	VANDERZEE, JS; VANSWIETEN, P; JANSEN, HM; AALBERSE, RC				VANDERZEE, JS; VANSWIETEN, P; JANSEN, HM; AALBERSE, RC			SKIN-TESTS AND HISTAMINE-RELEASE WITH P-1-DEPLETED DERMATOPHAGOIDES-PTERONYSSINUS BODY EXTRACTS AND PURIFIED P-1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT PULMONOL,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	VANDERZEE, JS (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PUBLICAT SECRETARIAT,POB 9406,1006 AK AMSTERDAM,NETHERLANDS.		van der Zee, Jaring/HGU-9235-2022; van der Zee, Jaring/AAQ-6669-2021; van der Zee, Jaring S/M-8462-2013	van der Zee, Jaring S/0000-0002-8698-6039				AALBERSE RC, 1983, REGULATORY CONTROL S, P137; ASTALDI GCB, 1980, J IMMUNOL, V125, P1411; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KOWAL R, 1980, ANAL BIOCHEM, V102, P72, DOI 10.1016/0003-2697(80)90319-X; KRILIS S, 1981, INT ARCH ALLER A IMM, V66, P252, DOI 10.1159/000232912; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P142, DOI 10.1016/0091-6749(84)90277-X; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P132, DOI 10.1016/0091-6749(84)90275-6; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LIND P, 1986, INT ARCH ALLER A IMM, V79, P60, DOI 10.1159/000233943; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; OHMAN JL, 1974, J IMMUNOL, V113, P1668; RAWLE FC, 1984, J IMMUNOL, V133, P195; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; STALLMAN PJ, 1977, INT ARCH ALLER A IMM, V54, P9, DOI 10.1159/000231803; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; TOVEY ER, 1985, INT ARCH ALLER A IMM, V76, P82, DOI 10.1159/000233667; VANMOURIK P, 1984, J IMMUNOL METHODS, V68, P45, DOI 10.1016/0022-1759(84)90135-2; VANTOORENENBERGEN AW, 1981, INT ARCH ALLER A IMM, V65, P432, DOI 10.1159/000232784; WAHN U, 1985, ALLERGY, V40, P389, DOI 10.1111/j.1398-9995.1985.tb02676.x	26	118	123	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				884	896		10.1016/0091-6749(88)90946-3	http://dx.doi.org/10.1016/0091-6749(88)90946-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	2453544				2022-12-18	WOS:A1988N703600018
J	LAM, S; LERICHE, J; PHILLIPS, D; CHANYEUNG, M				LAM, S; LERICHE, J; PHILLIPS, D; CHANYEUNG, M			CELLULAR AND PROTEIN-CHANGES IN BRONCHIAL LAVAGE FLUID AFTER LATE ASTHMATIC REACTION IN PATIENTS WITH RED CEDAR ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LAM, S (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DIV RES,2775 HEATHER ST,VANCOUVER V5Z 3J5,BC,CANADA.							ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DUNNILL MS, 1978, ALLERGY PRINCIPLES P, V2, P678; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; FRIGAS E, 1980, LAB INVEST, V42, P35; LAM S, 1985, CHEST, V88, P856, DOI 10.1378/chest.88.6.856; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LAM S, 1985, CHEST, V87, P740, DOI 10.1378/chest.87.6.740; LEMANSKE RF, 1982, IMMUNOLOGY, V45, P561; METZGER WJ, 1985, CHEST, V87, pS155, DOI 10.1378/chest.87.5_Supplement.155S; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TONNEL AB, 1983, LANCET, V1, P1406; WELLER PF, 1984, J ALLERGY CLIN IMMUN, V73, P1, DOI 10.1016/0091-6749(84)90474-3	17	118	118	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					44	50		10.1016/S0091-6749(87)80189-6	http://dx.doi.org/10.1016/S0091-6749(87)80189-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	3598029				2022-12-18	WOS:A1987J219400007
J	SMITH, CM; ANDERSON, SD				SMITH, CM; ANDERSON, SD			HYPEROSMOLARITY AS THE STIMULUS TO ASTHMA INDUCED BY HYPERVENTILATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL PRINCE ALFRED HOSP,DEPT THORAC MED,CAMPERDOWN,NSW 2050,AUSTRALIA	University of Sydney				Anderson, Sandra/0000-0002-6308-8770				AITKEN ML, 1985, AM REV RESPIR DIS, V131, P357; ANDERSON SD, 1985, EUR J RESPIR DIS, V67, P20; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; ANDERSON SD, 1985, J ALLERGY CLIN IMMUN, V76, P763, DOI 10.1016/0091-6749(85)90745-6; AQUILINA AT, 1983, THORAX, V38, P766, DOI 10.1136/thx.38.10.766; BOUCHER RC, 1981, J APPL PHYSIOL, V50, P613, DOI 10.1152/jappl.1981.50.3.613; CHEN WY, 1977, RESPIRATION, V34, P305, DOI 10.1159/000193842; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; ESCHENBACHER WL, 1985, AM REV RESPIR DIS, V131, P894; FABBRI LM, 1984, ANN ALLERGY, V53, P172; Ferron G. A., 1977, Journal of Aerosol Science, V8, P251, DOI 10.1016/0021-8502(77)90045-3; FINNEY MJB, CLIN EXP PHARM PHYSL; HAHN A, 1984, AM REV RESPIR DIS, V130, P575; INGELSTEDT S, 1956, Acta Otolaryngol Suppl, V131, P1; KILBURN KH, 1968, AM REV RESPIR DIS, V98, P449; KILHAM H, 1979, THORAX, V34, P582, DOI 10.1136/thx.34.5.582; LOPATA M, 1974, AM REV RESPIR DIS, V110, P730; MAN SFP, 1979, J APPL PHYSIOL, V46, P205, DOI 10.1152/jappl.1979.46.2.205; MARIN MG, 1976, AM J PHYSIOL, V231, P1546, DOI 10.1152/ajplegacy.1976.231.5.1546; MARTONEN TB, 1982, ANN OCCUP HYG, V26, P93, DOI 10.1093/annhyg/26.1.93; MCFADDEN ER, 1982, J CLIN INVEST, V69, P700, DOI 10.1172/JCI110498; MCFADDEN ER, 1979, NEW ENGL J MED, V301, P763; MITCHELL JW, 1972, J APPL PHYSIOL, V32, P474, DOI 10.1152/jappl.1972.32.4.474; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; PHILLIPS YY, 1985, AM REV RESPIR DIS, V131, P31; POTTER JL, 1967, AM REV RESPIR DIS, V96, P83; RICHARDSON PS, 1978, PHARMACOL THER PT B, V3, P441, DOI 10.1016/S0306-039X(78)90010-7; Snedecor G. W., 1967, STATISTICAL METHODS, P432; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; Weibel ER, 1964, HDB PHYSIOLOGY RES 3, V1, P285	34	118	119	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					729	736		10.1016/0091-6749(86)90419-7	http://dx.doi.org/10.1016/0091-6749(86)90419-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3700898				2022-12-18	WOS:A1986C390300017
J	BLAAUW, PJ; SMITHUIS, LOMJ				BLAAUW, PJ; SMITHUIS, LOMJ			THE EVALUATION OF THE COMMON DIAGNOSTIC METHODS OF HYPERSENSITIVITY FOR BEE AND YELLOW JACKET VENOM BY MEANS OF AN IN-HOSPITAL INSECT STING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST LAMBERTUS HOSP, WESSELMANLAAN 25, 5707 HA HELMOND, NETHERLANDS									BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BLAAUW PJ, 1981, PHARM WEEKBLAD, V116, P1215; CHAFEE FH, 1970, ACTA ALLERGOL, V25, P292, DOI 10.1111/j.1398-9995.1970.tb01265.x; CHARPIN J, 1983, REV FR ALLERGOL, V23, P51, DOI 10.1016/S0335-7457(83)80030-6; CHIPPS BE, 1980, J PEDIATR-US, V97, P177, DOI 10.1016/S0022-3476(80)80470-7; FRAZIER CA, 1976, JAMA-J AM MED ASSOC, V235, P2410, DOI 10.1001/jama.235.22.2410; GERVAIS P, 1971, CONCOURS MED, V93, P4848; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GRANT JA, 1983, REV FR ALLERGOL, V23, P59, DOI 10.1016/S0335-7457(83)80033-1; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; Levine M. I., 1981, MONOGRAPH INSECT ALL; MOSBECH H, 1983, ALLERGY, V38, P195, DOI 10.1111/j.1398-9995.1983.tb01606.x; Mueller H L, 1966, J Asthma Res, V3, P331; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V67, P290, DOI 10.1016/0091-6749(81)90024-5; MULLER U, 1981, SCHWEIZ MED WSCHR, V111, P106; NEUMAN I, 1983, ANN ALLERGY, V50, P410; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; PARRISH HM, 1963, AM J MED SCI, V245, P129; REISMAN RE, 1983, REV FR ALLERGOL, V23, P53, DOI 10.1016/S0335-7457(83)80031-8; REISMAN RE, 1982, 11 P INT C ALL CLIN, P459; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; Snelling R.R., 1981, P369; Somerville R, 1975, Rev Med Liege, V30, P76; URBANEK R, 1978, DEUT MED WOCHENSCHR, V103, P1656, DOI 10.1055/s-0028-1129317; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0	27	118	118	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					556	562		10.1016/0091-6749(85)90029-6	http://dx.doi.org/10.1016/0091-6749(85)90029-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	3989140				2022-12-18	WOS:A1985AHV0700003
J	BERNSTEIN, M; DAY, JH; WELSH, A				BERNSTEIN, M; DAY, JH; WELSH, A			DOUBLE-BLIND FOOD CHALLENGE IN THE DIAGNOSIS OF FOOD SENSITIVITY IN THE ADULT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KINGSTON GEN HOSP,DIV ALLERGY,KINGSTON K7L 2V7,ONTARIO,CANADA	Queens University - Canada								BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P294; GALANT SP, 1973, CLIN ALLERGY, V3, P363, DOI 10.1111/j.1365-2222.1973.tb01343.x; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; May C D, 1972, Clin Allergy, V2, P335, DOI 10.1111/j.1365-2222.1972.tb01298.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MAY CD, 1979, PAEDIATRICIAN, V8, P141; PLATTS TAE, 1976, J HUM NUTR, V3, P141; SIRAGANIAN RP, 1977, J ALLERGY CLIN IMMUN, V59, P214, DOI 10.1016/0091-6749(77)90152-X; SIRAGANIAN RP, 1976, J ALLERGY CLIN IMMUN, V57, P525, DOI 10.1016/0091-6749(76)90003-8; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; VLAGOPOULOS P, 1980, J ALLERGY CLIN IMMUN, V65, P212; WRAITH DG, 1979, CLIN ALLERGY, V9, P25, DOI 10.1111/j.1365-2222.1979.tb01519.x	14	118	120	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	3					205	210		10.1016/0091-6749(82)90043-4	http://dx.doi.org/10.1016/0091-6749(82)90043-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG384	6179975				2022-12-18	WOS:A1982PG38400008
J	EGGLESTON, PA; GUERRANT, JL				EGGLESTON, PA; GUERRANT, JL			STANDARDIZED METHOD OF EVALUATING EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV VIRGINIA,SCH MED,DEPT PEDIAT,CHARLOTTESVILLE,VA 22901; UNIV VIRGINIA,SCH MED,DEPT INTERN MED,CHARLOTTESVILLE,VA 22901	University of Virginia; University of Virginia								ASMUSSEN E, 1965, HDB PHYSIOLOGY; ASTRAND PO, 1954, J APPL PHYSIOL, V7, P218, DOI 10.1152/jappl.1954.7.2.218; ASTRAND PO, 1970, TXB WORK PHYSIOLOGY; BANG O, 1936, SCAND ARCH PHYSL S, V10, P51; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V50, P235, DOI 10.1016/0091-6749(72)90017-6; BLACKHALL MI, 1970, DISODIUM CROMOGLYCAT, P63; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; CHANYEUNG MM, 1971, AM REV RESPIR DIS, V104, P915; CORPE RF, 1965, AM REV RESPIR DIS, V92, P513; DAVIES SE, 1970, DISODIUM CROMOGLYCAT, P55; EGGLESTON PA, 1975, PEDIATRICS, V56, P856; ENGSTROM I, 1960, Acta Paediatr, V49, P850, DOI 10.1111/j.1651-2227.1960.tb16095.x; FISHER HK, 1970, AM REV RESPIR DIS, V101, P885; FITCH KD, 1971, BRIT MED J, V4, P577, DOI 10.1136/bmj.4.5787.577; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P199, DOI 10.1016/0091-6749(73)90058-4; GODFREY S, 1974, EXERCISE TESTING CHI, P74; GRIFFITHS J, 1972, Chest, V62, P527; HERMANSE.L, 1969, J APPL PHYSIOL, V26, P31, DOI 10.1152/jappl.1969.26.1.31; IRNELL L, 1966, SCAND J RESPIR DIS, V47, P103; KATZ RM, 1971, J ALLERGY, V47, P148, DOI 10.1016/S0091-6749(71)80293-2; LANGEANDERSEN K, 1971, FUNDAMENTALS EXERCIS, P78; LANGEANDERSEN K, 1971, FUNDAMENTALS EXERCIS, P22; MCFADDEN ER, 1975, NEW ENGL J MED, V292, P555, DOI 10.1056/NEJM197503132921103; MCNEILL RS, 1966, Q J MED, V35, P55; MILDON A, 1974, AM REV RESPIR DIS, V110, P409; PIERSON WE, 1969, J ALLERGY, V43, P136, DOI 10.1016/S0021-8707(69)80004-3; SHEPHARD RJ, 1968, B WORLD HEALTH ORGAN, V38, P765; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SLY RM, 1972, ANN ALLERGY, V30, P688; VASSALLO CL, 1972, AM REV RESPIR DIS, V105, P42	30	118	118	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	3					414	425		10.1016/0091-6749(76)90122-6	http://dx.doi.org/10.1016/0091-6749(76)90122-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD454	987088				2022-12-18	WOS:A1976CD45400008
J	HARGREAVE, FE; PEPYS, J				HARGREAVE, FE; PEPYS, J			ALLERGIC RESPIRATORY REACTIONS IN BIRD FANCIERS PROVOKED BY ALLERGEN INHALATION PROVOCATION TESTS - RELATION TO CLINICAL FEATURES AND ALLERGIC MECHANISMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ALTOUNYAN R. E. C., 1964, THORAX, V19, P406, DOI 10.1136/thx.19.5.406; ARNER BENGT, 1950, ACTA ALLERGOL, V3, P156, DOI 10.1111/j.1398-9995.1950.tb03382.x; AVILA R, 1971, Clinical Allergy, V1, P343, DOI 10.1111/j.1365-2222.1971.tb00784.x; BACH C, 1971, PRESSE MED, V79, P383; BARBEE RA, 1965, P SOC EXP BIOL MED, V118, P546, DOI 10.3181/00379727-118-29901; BARROWCLIFF DF, 1968, THORAX, V23, P490, DOI 10.1136/thx.23.5.490; BATES D V, 1962, Med Serv J Can, V18, P211; BATES DV, 1955, J PHYSIOL-LONDON, V129, P237, DOI 10.1113/jphysiol.1955.sp005350; BERSTEIN L, 1954, THORAX, V9, P63; BIER OG, 1968, IMMUNOLOGY, V14, P291; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BURTIN P, 1962, INT ARCH ALLER A IMM, V21, P8, DOI 10.1159/000229311; CALLERAME ML, 1971, J ALLERGY, V47, P187, DOI 10.1016/S0091-6749(71)80464-5; CALLERAME ML, 1971, NEW ENGL J MED, V284, P459, DOI 10.1056/NEJM197103042840902; CHANNELL S, 1969, Q J MED, V38, P351; CHANYEUNG M, 1971, CAN MED ASSOC J, V105, P56; CITRON K M, 1958, Thorax, V13, P229, DOI 10.1136/thx.13.3.229; CITRON KM, 1967, ACTA ALLERGOL, VS 22, P17; COCHRANE CG, 1968, IMMUNOPATHOLOGY, P32; COLLDAHL H, 1964, ACTA ALLERGOL, V19, P325, DOI 10.1111/j.1398-9995.1964.tb03254.x; COLLDAHL HELGE, 1952, ACTA ALLERGOL, V5, P143, DOI 10.1111/j.1398-9995.1952.tb03445.x; COLLDAHL HELGE, 1952, ACTA ALLERGOL, V5, P154, DOI 10.1111/j.1398-9995.1952.tb03446.x; COLLDAHL HELGE, 1952, ACTA ALLERGOL, V5, P133, DOI 10.1111/j.1398-9995.1952.tb03444.x; COMROE JH, 1959, J APPL PHYSIOL, V14, P439, DOI 10.1152/jappl.1959.14.3.439; Coombs, 1968, CLIN ASPECTS IMMUNOL, P575; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; ENGSTROM I, 1958, Acta Paediatr, V47, P441, DOI 10.1111/j.1651-2227.1958.tb07656.x; FAUX J A, 1971, Clinical Allergy, V1, P149, DOI 10.1111/j.1365-2222.1971.tb03014.x; FEINBERG SM, 1952, J ALLERGY, V23, P387, DOI 10.1016/0021-8707(52)90001-4; GERBER MA, 1971, AM J PATHOL, V62, P339; GODFREY S, 1967, P ROY SOC MED, V60, P1088, DOI 10.1177/003591576706011P112; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; GRABAR P, 1955, BIOCHIM BIOPHYS ACTA, V17, P67, DOI 10.1016/0006-3002(55)90320-6; GRONEMEYER W, 1959, INT ARCH ALLER A IMM, V14, P217, DOI 10.1159/000228514; HARGREAV.FE, 1966, LANCET, V1, P445; HARGREAVE F, 1972, Clinical Radiology, V23, P1, DOI 10.1016/S0009-9260(72)80126-0; HARGREAVE FE, 1968, LANCET, V1, P619; HARGREAVE FE, IN PRESS; HEARN CED, 1968, BRIT J IND MED, V25, P283; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P189, DOI 10.1159/000227963; ITKIN IH, 1963, J ALLERGY, V34, P97, DOI 10.1016/0021-8707(63)90062-5; JACKSON E, 1970, THORAX, V25, P25, DOI 10.1136/thx.25.1.25; JUHLINDANNFELT C, 1950, ACTA MED SCAND  S239, P320; KIM CJ, 1965, J ALLERGY, V36, P353, DOI 10.1016/0021-8707(65)90042-0; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; LOWELL FC, 1948, J ALLERGY, V19, P100, DOI 10.1016/0021-8707(48)90096-3; MacNAMARA J., 1959, THORAX, V14, P166, DOI 10.1136/thx.14.2.166; McALLEN MONICA K., 1961, THORAX, V16, P30, DOI 10.1136/thx.16.1.30; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; McMichael J, 1939, CLIN SCI, V4, P167; OUCHTERLONY O, 1949, ACTA PATHOL MIC SC, V26, P516; OUCHTERLONY O, 1948, ACTA PATHOL MIC SC, V25, P186; PARISH WE, 1970, LANCET, V2, P591; PEPYS J, 1959, AM REV RESPIR DIS, V80, P167; PEPYS J, 1968, LANCET, V2, P134; PEPYS J, 1969, LANCET, V1, P1181; PEPYS J, 1968, ALLERGOLOGIE, P221; REED CE, 1965, J AMER MED ASSOC, V193, P261, DOI 10.1001/jama.1965.03090040005001; RIDDLE HFV, 1968, THORAX, V23, P271, DOI 10.1136/thx.23.3.271; SCHLUETER DP, 1969, ANN INTERN MED, V70, P457, DOI 10.7326/0003-4819-70-3-457; SEAL RME, 1968, THORAX, V23, P469, DOI 10.1136/thx.23.5.469; SIQUEIRA M, 1961, P SOC EXP BIOL MED, V107, P779; SOSMAN AJ, 1969, NEW ENGL J MED, V281, P977, DOI 10.1056/NEJM196910302811802; SPECTOR WG, 1969, J PATHOL, V98, P31, DOI 10.1002/path.1710980105; STERLING GM, 1967, THORAX, V22, P533, DOI 10.1136/thx.22.6.533; TAYLOR G, 1971, BRIT J IND MED, V28, P143; TENCATE HJ, 1954, THESIS GRONINGEN; TSE KS, 1972, J ALLERGY CLIN IMMUN, V49, P130; VANGEUNS HA, 1956, INT ARCH ALLER A IMM, V8, P218, DOI 10.1159/000228287; VANLOOKERENCAMP.JG, 1969, SCAND J RESPIR DIS, V50, P76; WENZEL FJ, 1971, J ALLERGY CLIN IMMUN, V48, P224, DOI 10.1016/0091-6749(71)90069-8; WIDE L, 1967, LANCET, V2, P1105; WILLIAMS J. V., 1963, THORAX, V18, P182, DOI 10.1136/thx.18.2.182; WILSON AF, 1971, J ALLERGY, V47, P107	75	118	118	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	3					157	+		10.1016/0091-6749(72)90047-4	http://dx.doi.org/10.1016/0091-6749(72)90047-4			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N4708	4626166				2022-12-18	WOS:A1972N470800005
J	Bousquet, J; Schunemann, HJ; Togias, A; Bachert, C; Erhola, M; Hellings, PW; Klimek, L; Pfaar, O; Wallace, D; Ansotegui, I; Agache, I; Bedbrook, A; Bergmann, KC; Bewick, M; Bonniaud, P; Bosnic-Anticevich, S; Bosse, I; Bouchard, J; Boulet, LP; Brozek, J; Brusselle, G; Calderon, MA; Canonica, WG; Caraballo, L; Cardona, V; Casale, T; Cecchi, L; Chu, DK; Costa, EM; Cruz, AA; Czarlewski, W; D'Amato, G; Devillier, P; Dykewicz, M; Ebisawa, M; Fauquert, JL; Fokkens, WJ; Fonseca, JA; Fontaine, JF; Gemicioglu, B; van Wijk, RG; Haahtela, T; Halken, S; Ierodiakonou, D; Iinuma, T; Ivancevich, JC; Jutel, M; Kaidashev, I; Khaitov, M; Kalayci, O; Tebbe, JK; Kowalski, ML; Kuna, P; Kvedariene, V; La Grutta, S; Larenas-Linemann, D; Lau, S; Laune, D; Le, L; Lieberman, P; Carlsen, KCL; Lourenco, O; Marien, G; Carreiro-Martins, P; Melen, E; Menditto, E; Neffen, H; Mercier, G; Mosgues, R; Mullol, J; Muraro, A; Namazova, L; Novellino, E; O'Hehir, R; Okamoto, Y; Ohta, K; Park, HS; Panzner, P; Passalacqua, G; Nhan, PT; Price, D; Roberts, G; Roche, N; Rolland, C; Rosario, N; Ryan, D; Samolinski, B; Sanchez-Borges, M; Scadding, GK; Shamji, MH; Sheikh, A; Bom, AMT; Toppila-Salmi, S; Tsiligianni, I; Valentin-Rostan, M; Valiulis, A; Valovirta, E; Ventura, MT; Walker, S; Waserman, S; Yorgancioglu, A; Zuberbier, T				Bousquet, Jean; Schunemann, Holger J.; Togias, Akdis; Bachert, Claus; Erhola, Martina; Hellings, Peter W.; Klimek, Ludger; Pfaar, Oliver; Wallace, Dana; Ansotegui, Ignacio; Agache, Ioana; Bedbrook, Anna; Bergmann, Karl-Christian; Bewick, Mike; Bonniaud, Philippe; Bosnic-Anticevich, Sinthia; Bosse, Isabelle; Bouchard, Jacques; Boulet, Louis-Philippe; Brozek, Jan; Brusselle, Guy; Calderon, Moises A.; Canonica, Walter G.; Caraballo, Luis; Cardona, Vicky; Casale, Thomas; Cecchi, Lorenzo; Chu, Derek K.; Costa, Elisio M.; Cruz, Alvaro A.; Czarlewski, Wienczyslawa; D'Amato, Gennaro; Devillier, Philippe; Dykewicz, Mark; Ebisawa, Motohiro; Fauquert, Jean-Louis; Fokkens, Wytske J.; Fonseca, Joao A.; Fontaine, Jean-Francois; Gemicioglu, Bilun; van Wijk, Roy Gerth; Haahtela, Tari; Halken, Susanne; Ierodiakonou, Despo; Iinuma, Tomohisa; Ivancevich, Juan-Carlos; Jutel, Marek; Kaidashev, Igor; Khaitov, Musa; Kalayci, Omer; Tebbe, Jorg Kleine; Kowalski, Marek L.; Kuna, Piotr; Kvedariene, Violeta; La Grutta, Stefania; Larenas-Linemann, Desiree; Lau, Susanne; Laune, Daniel; Le, Lan; Lieberman, Philipp; Carlsen, Karin C. Lodrup; Lourenco, Olga; Marien, Gert; Carreiro-Martins, Pedro; Melen, Erik; Menditto, Enrica; Neffen, Hugo; Mercier, Gregoire; Mosgues, Ralph; Mullol, Joaquim; Muraro, Antonella; Namazova, Leyla; Novellino, Ettore; O'Hehir, Robyn; Okamoto, Yoshitaka; Ohta, Ken; Park, Hae Sim; Panzner, Petr; Passalacqua, Giovanni; Nhan Pham-Thi; Price, David; Roberts, Graham; Roche, Nicolas; Rolland, Christine; Rosario, Nelson; Ryan, Dermot; Samolinski, Boleslaw; Sanchez-Borges, Mario; Scadding, Glenis K.; Shamji, Mohamed H.; Sheikh, Aziz; Bom, Ana-Maria Todo; Toppila-Salmi, Sanna; Tsiligianni, Ioana; Valentin-Rostan, Marylin; Valiulis, Arunas; Valovirta, Erkka; Ventura, Maria-Teresa; Walker, Samantha; Waserman, Susan; Yorgancioglu, Arzu; Zuberbier, Torsten		Allergic Rhinitis Its Impact Asthm	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Allergic rhinitis; Allergic Rhinitis and Its Impact on Asthma; Grading of Recommendations Assessment; Development and Evaluation; guidelines; real-world evidence	AZELASTINE NASAL SPRAY; MOBILE TECHNOLOGY; HEALTH LITERACY; MASK-RHINITIS; MACVIA-ARIA; PLACEBO; ONSET; EFFICACY; LORATADINE; QUALITY	The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on many factors. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines have considerably improved the treatment of allergic rhinitis. However, there is an increasing trend toward use of real-world evidence to inform clinical practice, especially because randomized controlled trials are often limited with regard to the applicability of results. The Contre les Maladies Chroniques pour un Vieillissement Actif (MACVIA) algorithm has proposed an allergic rhinitis treatment by a consensus group. This simple algorithm can be used to step up or step down allergic rhinitis treatment. Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for the disease, real-world evidence provided by mobile technology, and additive studies (allergen chamber studies) to refine the MACVIA algorithm.	[Bousquet, Jean; Bedbrook, Anna] Fdn Partenariale FMC VIA LR, MACVIA France, Montpellier, France; [Bousquet, Jean] VIMA, INSERM U1168, VIMA Ageing & Chron Dis Epidemiol & Publ Hlth App, Villejuif, France; [Bousquet, Jean] Univ Versailles St Quentin En Yvelines, UMR S 1168, Montigny Le Bretonneux, France; [Bousquet, Jean; Hellings, Peter W.; Marien, Gert] Euforea, Brussels, Belgium; [Bousquet, Jean] Univ Med Berlin, Charite, Berlin, Germany; [Bousquet, Jean; Bergmann, Karl-Christian; Zuberbier, Torsten] Humboldt Univ, Berlin, Germany; [Bousquet, Jean; Bergmann, Karl-Christian; Zuberbier, Torsten] Berlin Inst Hlth, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Berlin, Germany; [Schunemann, Holger J.; Brozek, Jan; Chu, Derek K.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Div Immunol & Allergy, Hamilton, ON, Canada; [Togias, Akdis] Natl Inst Allergy & Infect Dis, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD USA; [Bachert, Claus] Ghent Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium; [Erhola, Martina] Natl Inst Hlth AndWelf, Helsinki, Finland; [Hellings, Peter W.] Univ Hosp Leuven, Dept Otorhinolaryngol, Leuven, Belgium; [Hellings, Peter W.] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Klimek, Ludger] Ctr Rhinol & Allergol, Wiesbaden, Germany; [Pfaar, Oliver] Philipps Univ Marburg, Dept Otorhinolaryngol Head & Neck Surg, Sect Rhinol & Allergy, Univ Hosp Marburg, Marburg, Germany; [Wallace, Dana] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA; [Ansotegui, Ignacio] Hosp Quironsalud Bizkaia, Dept Allergy & Immunol, Erandio, Spain; [Agache, Ioana] Transylvania Univ, Fac Med, Brasov, Romania; [Bergmann, Karl-Christian; Zuberbier, Torsten] Charite Univ Med Berlin, Berlin, Germany; [Bergmann, Karl-Christian; Zuberbier, Torsten] Free Univ Berlin, Berlin, Germany; [Bergmann, Karl-Christian; Zuberbier, Torsten] GA2LEN, Berlin, Germany; [Bewick, Mike] iQ4U Consultants, London, England; [Bonniaud, Philippe] CHU Dijon, Dijon, France; [Bosnic-Anticevich, Sinthia] Univ Sydney, Woolcock Inst Med Res, Glebe, NSW, Australia; [Bosnic-Anticevich, Sinthia] Woolcock Emphysema Ctr, Glebe, NSW, Australia; [Bosnic-Anticevich, Sinthia] Sydney Local Hlth Dist, Glebe, NSW, Australia; [Bouchard, Jacques] Laval Univ, Quebec City, PQ, Canada; [Boulet, Louis-Philippe] Laval Univ, Quebec Heart & Lung Inst, Quebec City, PQ, Canada; [Brusselle, Guy] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium; [Calderon, Moises A.] Imperial Coll London, Royal Brompton Hosp NHS, Natl Heart & Lung Inst, London, England; [Canonica, Walter G.] Humanitas Univ, Humanitas Res Hosp, Personalized Med Clin Asthma & Allergy, Milan, Italy; [Caraballo, Luis] Univ Cartagena, Inst Immunol Res, Campus Zaragocilla, Cartagena, Colombia; [Caraballo, Luis] Fdn Dev Med & Biol Sci Fundemeb, Cartagena, Colombia; [Cardona, Vicky] Hosp Valle De Hebron, Dept Internal Med, Allergy Sect, Barcelona, Spain; [Cardona, Vicky] ARADyAL Res Network, Barcelona, Spain; [Casale, Thomas] Univ S Florida, Div Allergy Immunol, Tampa, FL 33620 USA; [Cecchi, Lorenzo] USL Toscana Ctr, SOS Allergol & Clin Immunol, Prato, Italy; [Costa, Elisio M.] Univ Porto, Fac Pharm, REQUIMTE, UCIBIO, Porto, Portugal; [Costa, Elisio M.] Univ Porto, AgeUPNetWork, Competence Ctr Act & Hlth Ageing, Porto, Portugal; [Cruz, Alvaro A.] Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil; [Cruz, Alvaro A.] WHO GARD Planning Grp, Salvador, BA, Brazil; [Czarlewski, Wienczyslawa] Med Consulting Czarlewski, Levallois Perret, France; [D'Amato, Gennaro] Univ Naples Federico II, Hosp A Cardarelli, Div Resp & Allerg Dis, Naples, Italy; [Devillier, Philippe] Univ Paris Saclay, Hop Foch, Pole Malad Voies Resp, UPRES EA220, Suresnes, France; [Devillier, Philippe] Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England; [Dykewicz, Mark] St Louis Univ, Sch Med, Sect Allergy & Immunol, St Louis, MO 63103 USA; [Ebisawa, Motohiro] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan; [Fauquert, Jean-Louis] CHU Clermont Ferrand Estaing, Unite Pneumoallergol Enfant, Pole Pediat Pr Labbe, Clermont Ferrand, France; [Fokkens, Wytske J.] Amsterdam Univ Med Ctr, Dept Otorhinolaryngol, AMC, Amsterdam, Netherlands; [Fonseca, Joao A.] Univ Porto, Fac Med, Ctr Res Hlth Technol & Informat Syst, CINTESIS, Porto, Portugal; [Fonseca, Joao A.] Medida, Porto, Portugal; [Gemicioglu, Bilun] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Pulm Dis, Istanbul, Turkey; [van Wijk, Roy Gerth] Erasmus MC, Sect Allergol, Dept Internal Med, Rotterdam, Netherlands; [Haahtela, Tari; Toppila-Salmi, Sanna] Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland; [Haahtela, Tari; Toppila-Salmi, Sanna] Univ Helsinki, Helsinki, Finland; [Halken, Susanne] Odense Univ Hosp, Hans Christian Andersen Childrens Hosp, Odense, Denmark; [Ierodiakonou, Despo; Tsiligianni, Ioana] Univ Crete, Fac Med, Dept Social Med, Iraklion, Greece; [Ierodiakonou, Despo; Tsiligianni, Ioana] Int Primary Care Resp Grp, Iraklion, Greece; [Iinuma, Tomohisa; Okamoto, Yoshitaka] Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan; [Ivancevich, Juan-Carlos] Clin Santa Isabel, Serv Alergia & Immunol, Buenos Aires, DF, Argentina; [Jutel, Marek] Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland; [Kaidashev, Igor] Ukrainina Med Stomatol Acad, Poltava, Ukraine; [Khaitov, Musa] Natl Res Ctr, Inst Immunol, Lab Mol Immunol, Fed Medicobiol Agcy, Moscow, Russia; [Kalayci, Omer] Hacettepe Univ, Pediat Allergy & Asthma Unit, Sch Med, Ankara, Turkey; [Kowalski, Marek L.] Med Univ Lodz, Hlth Ageing Res Ctr, Dept Immunol & Allergy, Lodz, Poland; [Kuna, Piotr] Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland; [Kvedariene, Violeta] Vilnius Univ, Fac Med, Inst Biomed Sci, Dept Pathol, Vilnius, Lithuania; [Kvedariene, Violeta] Vilnius Univ, Fac Med, Inst Clin Med, Clin Chest Dis & Allergol, Vilnius, Lithuania; [La Grutta, Stefania] Natl Res Council CNR, Inst Biomed & Mol Immunol IBIM, Palermo, Italy; [Larenas-Linemann, Desiree] Med Sur Clin Fdn & Hosp, Ctr Excellence Asthma & Allergy, Mexico City, DF, Mexico; [Lau, Susanne] Charite, Dept Paediat Pneumol Immunol & Intens Care, Berlin, Germany; [Laune, Daniel] KYomed INNOV, Montpellier, France; [Le, Lan] Univ Med & Pharm, Ho Chi Minh City, Vietnam; [Lieberman, Philipp] Univ Tennessee, Coll Med, Dept Internal Med, Div Allergy, Germantown, MD USA; [Lieberman, Philipp] Univ Tennessee, Coll Med, Dept Internal Med, Div Immunol, Germantown, MD USA; [Lieberman, Philipp] Univ Tennessee, Coll Med, Dept Pediat, Div Allergy, Germantown, MD USA; [Lieberman, Philipp] Univ Tennessee, Coll Med, Dept Pediat, Div Immunol, Germantown, MD USA; [Carlsen, Karin C. Lodrup] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Carlsen, Karin C. Lodrup] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Lourenco, Olga] Univ Beira Interior, Fac Hlth Sci, Covilha, Portugal; [Lourenco, Olga] Univ Beira Interior, Hlth Sci Res Ctr, CICS UBI, Covilha, Portugal; [Carreiro-Martins, Pedro] EPE, Ctr Hosp Lisboa Cent, Hosp Dona Estefania, Lisbon, Portugal; [Carreiro-Martins, Pedro] Nova Med Sch, Integrated Pathophysiol Mech Res Grp, CEDOC, Lisbon, Portugal; [Melen, Erik] Soder Sjukhuset, Sachs Children & Youth Hosp, Stockholm, Sweden; [Melen, Erik] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Menditto, Enrica] Univ Naples Federico II, Ctr Pharmacoecon, CIRFF, Naples, Italy; [Neffen, Hugo] Ctr Allergy Immunol & Resp Dis, Santa Fe, Argentina; [Neffen, Hugo] Ctr Allergy & Immunol, Santa Fe, Argentina; [Mercier, Gregoire] Univ Hosp, Dept Informat Med, Unite Medicoecon, Montpellier, France; [Mosgues, Ralph] Univ Cologne, Med Fac, Inst Med Stat & Computat Biol, Cologne, Germany; [Mosgues, Ralph] Clin Res Int, Cologne, Germany; [Mullol, Joaquim] Hosp Clin Barcelona, ENT Dept, Rhinol Unit, Barcelona, Spain; [Mullol, Joaquim] Hosp Clin Barcelona, ENT Dept, Smell Clin, Barcelona, Spain; [Mullol, Joaquim] Univ Barcelona, CIBERES, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain; [Muraro, Antonella] Padua Gen Univ Hosp, Food Allergy Referral Ctr Veneto Reg, Dept Women & Child Hlth, Padua, Italy; [Namazova, Leyla] Sci Ctr Childrens Hlth MoH, Moscow, Russia; [Namazova, Leyla] Russian Natl Res Med Univ Named Pirogov, Moscow, Russia; [Novellino, Ettore] Univ Naples Federico II, Dept Pharm, Naples, Italy; [O'Hehir, Robyn] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia; [O'Hehir, Robyn] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia; [O'Hehir, Robyn] Monash Univ, Dept Immunol, Melbourne, Vic, Australia; [Park, Hae Sim] Ajou Univ, Dept Allergy & Clin Immunol, Sch Med, Suwon, South Korea; [Panzner, Petr] Charles Univ Prague, Fac Med Pilsen, Dept Immunol & Allergol, Plzen, Czech Republic; [Passalacqua, Giovanni] Univ Genoa, Allergy & Resp Dis, Osped Policlino San Martino, Genoa, Italy; [Nhan Pham-Thi] Pasteur Inst, Allergy Dept, Paris, France; [Price, David] Observat & Pragmat Res Inst, Singapore, Singapore; [Roberts, Graham] St Marys Hosp, David Hide Ctr, Newport, Wight, England; [Roberts, Graham] Univ Southampton, Southampton, Hants, England; [Roche, Nicolas] Hop Univ Paris, Pneumol & Soins Intensifs Resp, Paris, France; [Roche, Nicolas] Hop Cochin, Paris, France; [Rolland, Christine] Assoc Asthme & Allergie, Paris, France; [Rosario, Nelson] Univ Parana, Hosp Clin, Curitiba, Parana, Brazil; [Ryan, Dermot] Univ Edinburgh, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland; [Samolinski, Boleslaw] Med Univ Warsaw, Dept Prevent Envinronmental Hazards & Allergol, Warsaw, Poland; [Sanchez-Borges, Mario] Ctr Medicodocente La Trinidad, Allergy & Clin Immunol Dept, Caracas, Venezuela; [Scadding, Glenis K.] UCL, Royal Natl TNE Hosp, London, England; [Shamji, Mohamed H.] Imperial Coll London, Immunomodulat & Tolerance Grp, London, England; [Shamji, Mohamed H.] Imperial Coll London, Allergy & Clin Immunol, London, England; [Sheikh, Aziz] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Bom, Ana-Maria Todo] Ctr Hosp Univ Coimbra, Imunoalergol, Coimbra, Portugal; [Bom, Ana-Maria Todo] Univ Coimbra, Fac Med, Coimbra, Portugal; [Valiulis, Arunas] Vilnius Univ, Inst Clin Med, Clin Childrens Dis, Vilnius, Lithuania; [Valiulis, Arunas] Inst Hlth Sci, Dept Publ Hlth, Vilnius, Lithuania; [Valiulis, Arunas] European Acad Paediat EAP UEMS SP, Brussels, Belgium; [Valovirta, Erkka] Univ Turku, Dept Lung Dis & Clin Immunol, Turku, Finland; [Valovirta, Erkka] Terveystalo Allergy Clin, Turku, Finland; [Ventura, Maria-Teresa] Univ Bari, Unit Geriatr Immunoallergol, Med Sch, Bari, Italy; [Walker, Samantha] Asthma UK, London, England; [Waserman, Susan] McMaster Univ, Dept Med Clin Immunol & Allergy, Hamilton, ON, Canada; [Yorgancioglu, Arzu] Celal Bayar Univ, Fac Med, Dept Pulm Dis, Manisa, Turkey; [Tebbe, Jorg Kleine] Allergy & Asthma Ctr Westend, Outpatient & Clin Res Ctr, Berlin, Germany; [Ohta, Ken] Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan	Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Berlin Institute of Health; McMaster University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Ghent University; Ghent University Hospital; KU Leuven; University Hospital Leuven; University of Amsterdam; Academic Medical Center Amsterdam; Philipps University Marburg; University Hospital of Giessen & Marburg; Nova Southeastern University; quironsalud Group; Transylvania University of Brasov; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; CHU Dijon Bourgogne; University of Sydney; Woolcock Institute of Medical Research; University of Sydney; Woolcock Institute of Medical Research; Laval University; Laval University; Quebec Heart & Lung Institute; Ghent University; Ghent University Hospital; Imperial College London; Royal Brompton Hospital; Humanitas University; Universidad de Cartagena; Hospital Universitari Vall d'Hebron; State University System of Florida; University of South Florida; Universidade do Porto; Universidade do Porto; Universidade Federal da Bahia; Antonio Cardarelli Hospital; University of Naples Federico II; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay; Imperial College London; Saint Louis University; CHU Clermont Ferrand; University of Amsterdam; Academic Medical Center Amsterdam; Universidade do Porto; Istanbul University - Cerrahpasa; Erasmus University Rotterdam; Erasmus MC; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Southern Denmark; Odense University Hospital; University of Crete; Chiba University; Wroclaw Medical University; Poltava State Medical University; NRC Institute of Immunology FMBA of Russia; Hacettepe University; Medical University Lodz; Medical University Lodz; Vilnius University; Vilnius University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hochiminh City University of Medicine & Pharmacy; University of Oslo; University of Oslo; Universidade da Beira Interior; Universidade da Beira Interior; Centro Hospitalar de Lisboa Central, EPE; Universidade de Lisboa; Sodersjukhuset Hospital; Karolinska Institutet; University of Naples Federico II; Universite de Montpellier; CHU de Montpellier; University of Cologne; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Naples Federico II; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; Ajou University; Charles University Prague; University of Genoa; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Southampton; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Edinburgh; Medical University of Warsaw; University of London; University College London; Imperial College London; Imperial College London; University of Edinburgh; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra; Vilnius University; University of Turku; Universita degli Studi di Bari Aldo Moro; McMaster University; Celal Bayar University	Bousquet, J (corresponding author), CHU Arnaud de Villeneuve, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France.	jean.bousquet@orange.fr	Bachert, Claus/J-8825-2012; Agache, Ioana/AAP-7403-2020; Gemicioglu, Bilun/AAH-6927-2019; Ryan, Dermot/AAJ-2329-2021; Kaidashev, Igor/L-2606-2019; Khaitov, Musa/AAC-1516-2021; Roche, Nicolas/AAP-4445-2021; Lourenço, Olga/S-6233-2016; Martins, Pedro/A-1433-2011; Roche, Nicolas/AAE-9206-2021; canonica, giorgio walter/ABF-2037-2020; Shamji, Mohamed/AAD-1788-2019; Namazova-Baranova, Leyla/C-9485-2019; Bosnic-Anticevich, Sinthia/AAD-2526-2021; Namazova-Baranova, Leyla/HDN-1442-2022; Cardona, Victoria/GRX-4196-2022; Fokkens, Wytske WJ/ABF-2185-2020; La Grutta, Stefania/N-3615-2014; Price, David/H-2837-2019; Todo Bom, Ana/AHD-3630-2022; Toppila-Salmi, Sanna/ABF-5840-2020; Kvedarienė, Violeta/GON-7937-2022; Shamji, Mohamed/AAU-8811-2020; Fonseca, João A./B-7562-2008; Panzner, Petr/I-7034-2017; O'Hehir, Robyn/H-3627-2011; Costa, Elisio/K-1990-2013	Gemicioglu, Bilun/0000-0001-5953-4881; Ryan, Dermot/0000-0002-4115-7376; Kaidashev, Igor/0000-0002-4708-0859; Khaitov, Musa/0000-0003-4961-9640; Lourenço, Olga/0000-0002-8401-5976; Martins, Pedro/0000-0002-4129-133X; canonica, giorgio walter/0000-0001-8467-2557; Namazova-Baranova, Leyla/0000-0002-2209-7531; Bosnic-Anticevich, Sinthia/0000-0001-5077-8329; La Grutta, Stefania/0000-0001-8026-0715; Price, David/0000-0002-9728-9992; Toppila-Salmi, Sanna/0000-0003-0890-6686; Kvedarienė, Violeta/0000-0002-6119-211X; Shamji, Mohamed/0000-0003-3425-3463; Fonseca, João A./0000-0002-0887-8796; Brusselle, Guy/0000-0001-7021-8505; Iinuma, Tomohisa/0000-0002-9940-5520; Bergmann, Karl-Christian/0000-0002-0306-9922; Panzner, Petr/0000-0002-1291-450X; Ebisawa, Motohiro/0000-0003-4117-558X; Cecchi, Lorenzo/0000-0002-0658-2449; VENTURA, Maria Teresa/0000-0002-2637-4583; Kuna, Piotr/0000-0003-2401-0070; O'Hehir, Robyn/0000-0002-3489-7595; Ierodiakonou, Despo/0000-0002-7862-2016; Zuberbier, Torsten/0000-0002-1466-8875; Costa, Elisio/0000-0003-1158-1480; Roberts, Graham/0000-0003-2252-1248; JUTEL, MAREK/0000-0003-1555-9379; Bousquet, Jean/0000-0002-4061-4766; Park, Hae-Sim/0000-0003-2614-0303; Cardona, Victoria/0000-0003-2197-9767; orlando, valentina/0000-0002-8209-8878; Schunemann, Holger/0000-0003-3211-8479; Halken, Susanne/0000-0003-0161-8278; yorgancioglu, arzu/0000-0002-4032-0944; Chu, Derek/0000-0001-8269-4496; Todo-Bom, Ana/0000-0002-1850-6689; menditto, enrica/0000-0001-8633-5650; Ivancevich, Juan Carlos/0000-0001-8713-6258	Medical Research Council [G1000758] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Batterham RW, 2016, PUBLIC HEALTH, V132, P3, DOI 10.1016/j.puhe.2016.01.001; Bedard A, 2019, J ALLERGY CLIN IMMUN, V144, P135, DOI 10.1016/j.jaci.2019.01.053; Bonini M, 2017, CURR OPIN PULM MED, V23, P21, DOI 10.1097/MCP.0000000000000336; Bourret Rodolphe, 2015, World Hosp Health Serv, V51, P36; Bousquet J, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0252-0; Bousquet J, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0227-6; Bousquet J, 2018, ALLERGY, V73, P1622, DOI 10.1111/all.13448; Bousquet J, 2018, ALLERGY, V73, P1763, DOI 10.1111/all.13406; Bousquet J, 2018, J INVEST ALLERG CLIN, V28, P42, DOI 10.18176/jiaci.0197; Bousquet J, 2018, ALLERGY, V73, P505, DOI 10.1111/all.13307; Bousquet J, 2018, ALLERGY, V73, P77, DOI 10.1111/all.13218; Bousquet J, 2017, ALLERGY, V72, P857, DOI 10.1111/all.13125; Bousquet J, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0137-4; Bousquet J, 2015, ALLERGY, V70, P1372, DOI 10.1111/all.12686; Bousquet J, 2003, ALLERGY, V58, P733, DOI 10.1034/j.1398-9995.2003.00076.x; Bousquet J, 2017, EUR RESP J, V49; Bousquet J, 2019, J ALLERGY CLIN IMMUN, V143, P864, DOI 10.1016/j.jaci.2018.08.049; Bousquet J, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0221-z; Bousquet J, 2018, ANN ALLERG ASTHMA IM, V121, P741, DOI 10.1016/j.anai.2018.07.034; Bousquet J, 2018, J ALLER CL IMM-PRACT, V6, P1726, DOI 10.1016/j.jaip.2018.01.031; Bousquet J, 2016, J ALLERGY CLIN IMMUN, V138, P367, DOI 10.1016/j.jaci.2016.03.025; Bousquet J, 2009, J ALLERGY CLIN IMMUN, V124, P428, DOI 10.1016/j.jaci.2009.06.027; Bousquet J, 2009, INT ARCH ALLERGY IMM, V150, P75, DOI 10.1159/000210383; Briere JB, 2018, CURR MED RES OPIN, V34, P2125, DOI 10.1080/03007995.2018.1524751; Brozek JL, 2011, ALLERGY, V66, P588, DOI 10.1111/j.1398-9995.2010.02530.x; Brozek JL, 2009, ALLERGY, V64, P1109, DOI 10.1111/j.1398-9995.2009.02083.x; Brozek JL, 2009, ALLERGY, V64, P669, DOI 10.1111/j.1398-9995.2009.01973.x; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Caimmi D, 2017, CLIN EXP ALLERGY, V47, P1526, DOI 10.1111/cea.13025; Carr W, 2012, J ALLERGY CLIN IMMUN, V129, P1282, DOI 10.1016/j.jaci.2012.01.077; Courbis AL, 2018, CLIN EXP ALLERGY, V48, P1640, DOI 10.1111/cea.13230; Dykewicz MS, 2017, ANN ALLERG ASTHMA IM, V119, P489, DOI 10.1016/j.anai.2017.08.012; Ellis AK, 2019, ANN ALLERG ASTHMA IM, V122, P639, DOI 10.1016/j.anai.2019.03.007; European Medicines Agency, GUID CLIN DEV MED PR; Glacy J, 2013, TREATMENTS SEASONAL; Hampel FC, 2010, ANN ALLERG ASTHMA IM, V105, P168, DOI 10.1016/j.anai.2010.06.008; Hellings PW, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0186-3; Horak F, 2006, CURR MED RES OPIN, V22, P151, DOI 10.1185/030079906X80305; Horak F, 1996, ARZNEIMITTEL-FORSCH, V46, P1077; Horak F, 2002, J ALLERGY CLIN IMMUN, V109, P956, DOI 10.1067/mai.2002.124657; HORAK F, 1992, J INT MED RES, V20, P422, DOI 10.1177/030006059202000507; HORAK F, 1988, ARZNEIMITTEL-FORSCH, V38-1, P124; Horak F, 2010, INFLAMM RES, V59, P391, DOI 10.1007/s00011-009-0117-4; Kaszuba SM, 2001, ARCH INTERN MED, V161, P2581, DOI 10.1001/archinte.161.21.2581; Katial RK, 2009, ALLERGY ASTHMA PROC, V30, P595, DOI 10.2500/aap.2009.30.3291; Meltzer EO, 2016, J ALLER CL IMM-PRACT, V4, P682, DOI 10.1016/j.jaip.2016.02.006; Meltzer EO, 2013, ALLERGY ASTHMA PROC, V34, P301, DOI 10.2500/aap.2013.34.3676; Menditto E, 2019, CLIN EXP ALLERGY, V49, P442, DOI 10.1111/cea.13333; mHealth, GLOBAL OBSERVATORY E, V3; Miller TA, 2016, PATIENT EDUC COUNS, V99, P1079, DOI 10.1016/j.pec.2016.01.020; Munoz-Cano R, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0212-0; Murdoch RD, 2015, CLIN EXP ALLERGY, V45, P1346, DOI 10.1111/cea.12556; Nagarajan N, 2019, ADV CHRONIC KIDNEY D, V26, P99, DOI 10.1053/j.ackd.2019.03.002; Oyinlola JO, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1562-8; Patel P, 2008, ANN ALLERG ASTHMA IM, V101, P287, DOI 10.1016/S1081-1206(10)60494-2; Patel P, 2007, OTOLARYNG HEAD NECK, V137, P918, DOI 10.1016/j.otohns.2007.08.005; Patel P, 2007, AM J RHINOL, V21, P499, DOI 10.2500/ajr.2007.21.3058; Patel P, 2008, ENT-EAR NOSE THROAT, V87, P340, DOI 10.1177/014556130808700612; Pfaar O, 2017, ALLERGY, V72, P1035, DOI 10.1111/all.13133; Pizzulli A, 2014, CLIN EXP ALLERGY, V44, P1246, DOI 10.1111/cea.12386; Salapatek AM, 2011, ALLERGY ASTHMA PROC, V32, P221, DOI 10.2500/aap.2011.32.3444; Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216; Sleurs K, 2019, ALLERGY, V74, P1292, DOI 10.1111/all.13720; Stubner P, 2004, CURR MED RES OPIN, V20, P891, DOI 10.1185/030079904125003700; Stubner UP, 2001, ARZNEIMITTEL-FORSCH, V51, P904; Stuebner P, 2006, ANN ALLERG ASTHMA IM, V96, P37, DOI 10.1016/S1081-1206(10)61038-1; United States Food and Drug Administration, 2017, US REAL WORLD EV SUP; US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2018, ALL RHIN DEV DRUG PR; Vandenplas Olivier, 2018, J Allergy Clin Immunol Pract, V6, P1274, DOI 10.1016/j.jaip.2017.09.002; Wustenberg E, 2017, ALLERGO J, V26, P14; Zieglmayer Ursula P, 2005, Treat Respir Med, V4, P283, DOI 10.2165/00151829-200504040-00006	72	117	130	7	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					70	+		10.1016/j.jaci.2019.06.049	http://dx.doi.org/10.1016/j.jaci.2019.06.049			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31627910	Green Published, Bronze			2022-12-18	WOS:000505590800007
J	de Maat, S; Bjorkqvist, J; Suffritti, C; Wiesenekker, CP; Nagtegaal, W; Koekman, A; van Dooremalen, S; Pasterkamp, G; de Groot, PG; Cicardi, M; Renne, T; Maas, C				de Maat, Steven; Bjorkqvist, Jenny; Suffritti, Chiara; Wiesenekker, Chantal P.; Nagtegaal, Willem; Koekman, Arnold; van Dooremalen, Sanne; Pasterkamp, Gerard; de Groot, Philip G.; Cicardi, Marco; Renne, Thomas; Maas, Coen			Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Angioedema; bradykinin; Factor XII; plasma kallikrein; kininogen; C1 esterase inhibitor; plasmin	CONTACT SYSTEM ACTIVATION; HAGEMAN-FACTOR; NORMAL C1-INHIBITOR; KALLIKREIN CLEAVAGE; FIBRINOLYTIC SYSTEM; ALTEPLASE TREATMENT; C1 INHIBITOR; F12 GENE; COAGULATION; DEFICIENCY	Background: Patients with angioedema experience unpredictable attacks of tissue swelling in which bradykinin is implicated. Several distinct mutations in Factor XII (FXII) are associated with hereditary angioedema(HAE) inthe presence of normal C1 esterase inhibitor activity (FXII-HAE). The underlying disease mechanisms are unclear, which complicates diagnosis and treatment. Objective: We sought to identify the natural trigger for FXII activation, which causes uncontrolled bradykinin production in patients with FXII-HAE. Methods: We generated recombinant variants of FXII, representing health and disease, and studied their behavior in functional studies. We investigated bradykinin-forming pathways in blood plasma with newly developed nanobody-based analytic methods. Results: We here report that FXII-HAE mutations collectively introduce new sites that are sensitive to enzymatic cleavage by plasmin. These FXII mutants rapidly activate after cleavage by plasmin, escape from inhibition through C1 esterase inhibitor, and elicit excessive bradykinin formation. Furthermore, our findings indicate that plasmin modulates disease activity in patients with FXII-HAE. Finally, we show that soluble lysine analogs attenuate this mechanism, explaining their therapeutic value in patients with HAE. Conclusion: Our findings indicate a new pathway for bradykinin formation in patients with HAE, in which FXII is cleaved and activated by plasmin. This should lead to the identification of new markers for diagnosis and targets for treatment.	[de Maat, Steven; Wiesenekker, Chantal P.; Nagtegaal, Willem; Koekman, Arnold; van Dooremalen, Sanne; Pasterkamp, Gerard; de Groot, Philip G.; Maas, Coen] Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, Heidelberglaan 100,Room G-03-550, NL-3584 CX Utrecht, Netherlands; [de Maat, Steven; Renne, Thomas] Karolinska Inst & Univ Hosp, Dept Mol Med & Surg, Solna, Sweden; [Bjorkqvist, Jenny; Renne, Thomas] Univ Med Ctr Hamburg Eppendorf, Inst Clin Chem & Lab Med, Hamburg, Germany; [Suffritti, Chiara] Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, I-20122 Milan, Italy; [Suffritti, Chiara] Luigi Sacco Hosp, Milan, Italy	Utrecht University; Utrecht University Medical Center; Karolinska Institutet; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Milan; Luigi Sacco Hospital; University of Milan; Luigi Sacco Hospital	Maas, C (corresponding author), Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, Heidelberglaan 100,Room G-03-550, NL-3584 CX Utrecht, Netherlands.	cmaas4@umcutrecht.nl	Suffritti, Chiara/AAE-2940-2020; cicardi, marco/K-9219-2016	Suffritti, Chiara/0000-0002-8872-8842; Maas, Coen/0000-0003-4593-0976; de Maat, Steven/0000-0003-1179-374X; Koekman, Arnold/0000-0002-7374-847X; cicardi, marco/0000-0003-1251-225X; Renne, Thomas/0000-0003-4594-5975	International Patient Organization; Veni Fellowship, Netherlands Organization for Scientific Research (NWO) [016-126-159]; Technology Foundation STW [10714]; Hjart Lungfonden [20140741]; Stockholms lans landsting (ALF) [20140464]; Vetenskapsradet [K2013-65X-21462-04-5]; German Research Society [SFB877, TP A11, SFB841, TP B8]; European Research Council [ERC-StG-2012-311575_F-12]; Telethon [GGP08223]; ERA-Net E-RARE-1 Research Programme Within the European 24 Framework 7 entitled "Genetics, Pathophysiology, and Therapy of Hereditary Angioedema Type III" (HAEIII)	International Patient Organization; Veni Fellowship, Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Technology Foundation STW(Technologiestichting STW); Hjart Lungfonden; Stockholms lans landsting (ALF); Vetenskapsradet(Swedish Research Council); German Research Society(German Research Foundation (DFG)); European Research Council(European Research Council (ERC)European Commission); Telethon(Fondazione Telethon); ERA-Net E-RARE-1 Research Programme Within the European 24 Framework 7 entitled "Genetics, Pathophysiology, and Therapy of Hereditary Angioedema Type III" (HAEIII)	Supported by a research grant from the International Patient Organization for C1-Inhibitor Deficiencies (HAEi). The work of C.M. is supported by a Veni Fellowship (016-126-159), provided by the Netherlands Organization for Scientific Research (NWO). The work of P.G.d.G. and S.d.M. is supported by Technology Foundation STW (project 10714). T.R. acknowledges support from Hjart Lungfonden (20140741), Stockholms lans landsting (ALF, 20140464), Vetenskapsradet (K2013-65X-21462-04-5), the German Research Society (SFB877, TP A11 and SFB841, TP B8), and a European Research Council grant (ERC-StG-2012-311575_F-12). C.S. and M.C. were supported by Telethon (no. GGP08223) and the ERA-Net E-RARE-1 Research Programme Within the European 24 Framework 7 entitled "Genetics, Pathophysiology, and Therapy of Hereditary Angioedema Type III" (HAEIII; coordinated by S.C.).	Apweiler R, 2014, NUCLEIC ACIDS RES, V42, pD191, DOI 10.1093/nar/gkt1140; Asmis LM, 2002, THROMB RES, V105, P463, DOI 10.1016/S0049-3848(02)00045-2; Benson DA, 2005, NUCLEIC ACIDS RES, V33, pD34, DOI 10.1093/nar/gki063; Bjorkqvist J, 2015, J CLIN INVEST, V125, P3132, DOI 10.1172/JCI77139; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Bork K, 2014, HAEMOPHILIA, V20, pe372, DOI 10.1111/hae.12519; Bork K, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2013.05.017; Bork K, 2011, CLIN IMMUNOL, V141, P31, DOI 10.1016/j.clim.2011.07.002; Bouma B, 2007, J THROMB HAEMOST, V5, P1139, DOI 10.1111/j.1538-7836.2007.02457.x; Bygum A, 2015, ACTA DERM-VENEREOL, V95, P706, DOI 10.2340/00015555-2014; Cicardi M, 2014, ALLERGY, V69, P602, DOI 10.1111/all.12380; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; Citarella F, 1997, BRIT J HAEMATOL, V99, P197, DOI 10.1046/j.1365-2141.1997.3513165.x; Correia AS, 2015, J STROKE CEREBROVASC, V24, P31, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.045; Csuka D, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0351-5; de Maat S, 2014, SEMIN THROMB HEMOST, V40, P887, DOI 10.1055/s-0034-1395159; de Maat S, 2013, THROMB HAEMOSTASIS, V110, P458, DOI 10.1160/TH12-11-0792; Defendi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070140; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; DORS DM, 1992, THROMB HAEMOSTASIS, V67, P644; EWALD GA, 1995, CIRCULATION, V91, P28, DOI 10.1161/01.CIR.91.1.28; Firinu D, 2015, CLIN IMMUNOL, V157, P239, DOI 10.1016/j.clim.2015.02.013; Gelincik A, 2015, ANN ALLERG ASTHMA IM, V114, P154, DOI 10.1016/j.anai.2014.11.018; Hill MD, 2003, NEUROLOGY, V60, P1525, DOI 10.1212/01.WNL.0000058840.66596.1A; HOVINGA JK, 1994, BLOOD, V84, P1173, DOI 10.1182/blood.V84.4.1173.bloodjournal8441173; Joseph K, 2015, J ALLERGY CLIN IMMUN; Kaplan AP, 2010, J ALLERGY CLIN IMMUN, V126, P918, DOI 10.1016/j.jaci.2010.08.012; KAPLAN AP, 1971, J EXP MED, V133, P696, DOI 10.1084/jem.133.4.696; Kiss N, 2013, CLIN IMMUNOL, V149, P142, DOI 10.1016/j.clim.2013.08.001; KLENIEWSKI J, 1992, J LAB CLIN MED, V120, P129; Li JN, 2005, AM J PATHOL, V166, P783, DOI 10.1016/S0002-9440(10)62299-7; Maas C, 2008, J CLIN INVEST, V118, P3208, DOI [10.1172/JC135424, 10.1172/JCI35424]; Mansi M, 2015, J INTERN MED, V277, P585, DOI 10.1111/joim.12304; McLaren M, 2002, RHEUMATOL INT, V22, P182, DOI 10.1007/s00296-002-0219-6; Nielsen EW, 1996, SCAND J IMMUNOL, V44, P185; NILSSON T, 1985, THROMB RES, V40, P817, DOI 10.1016/0049-3848(85)90318-4; NUIJENS JH, 1988, BLOOD, V72, P1841; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Nussberger J, 1999, J ALLERGY CLIN IMMUN, V104, P1321, DOI 10.1016/S0091-6749(99)70030-8; Reshef A, 2015, ALLERGY, V70, P506, DOI 10.1111/all.12587; REVAK SD, 1978, J EXP MED, V147, P719, DOI 10.1084/jem.147.3.719; Roovers RC, 1998, BRIT J CANCER, V78, P1407, DOI 10.1038/bjc.1998.700; Roovers RC, 2007, CANCER IMMUNOL IMMUN, V56, P303, DOI 10.1007/s00262-006-0180-4; Sainz IM, 2004, FASEB J, V18, P887, DOI 10.1096/fj.03-0835fje; Steentoft C, 2013, EMBO J, V32, P1478, DOI 10.1038/emboj.2013.79; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Tersteeg C, 2014, CIRCULATION, V129, P1320, DOI 10.1161/CIRCULATIONAHA.113.006727; VANDERLINDEN PWG, 1993, BLOOD, V82, P1740; VANDERLINDEN PWG, 1993, BLOOD, V82, P1732, DOI 10.1182/blood.V82.6.1732.bloodjournal8261732; Werner R, 2014, CEREBROVASC DIS, V38, P101, DOI 10.1159/000365205; Wilkins MR, 1999, METH MOL B, V112, P531; Wintenberger C, 2014, CLIN EXP IMMUNOL, V178, P112, DOI 10.1111/cei.12379	52	117	119	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1414	+		10.1016/j.jaci.2016.02.021	http://dx.doi.org/10.1016/j.jaci.2016.02.021			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27130860	Bronze			2022-12-18	WOS:000389542700021
J	Mashiko, S; Bouguermouh, S; Rubio, M; Baba, N; Bissonnette, R; Sarfati, M				Mashiko, Shunya; Bouguermouh, Salim; Rubio, Manuel; Baba, Nobuyasu; Bissonnette, Robert; Sarfati, Marika			Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; T cells; IL-22; IL-17; psoriasis; atopic dermatitis	INNATE LYMPHOID-CELLS; SKIN INFLAMMATION; T-CELLS; POTENTIAL ROLE; GAMMA; CYTOKINE; DISEASE; MEMORY; GENES; IL-17	Background: Psoriasis is a systemic inflammatory disease in which IL-17 and IL-22 levels are markedly increased in the skin and blood. The prevalent concept, using skin cells that are isolated from psoriatic plaques and examined after cell expansion and in vitro stimulation, is that IL-17 and IL-22 production essentially results from T cells and the rare type 3 innate lymphoid cells. Objective: We sought to examine the cellular source of IL-17A and IL-22 at the protein and transcriptional single-cell level immediately after ex vivo skin cell isolation from psoriatic plaques. Methods: Skin biopsy specimens were collected from patients with psoriasis, as well as from patients with atopic dermatitis. Cell suspensions were prepared by combining mild enzymatic digestion and mechanical dissociation and analyzed for cytokine expression without prior in vitro culture and stimulation. Expression of IL-17 and IL-22 was quantified at the protein and mRNA single-cell level by using flow cytometry. Results: IL-22 is predominantly expressed by CD3(-)c-Kit(+) cells relative to CD3(+) T cells in lesional skin of patients with psoriasis and patients with atopic dermatitis. Strikingly, we identified c-Kit(+) FceRI(+) mast cells as major IL-22 producers. The proportion of mast cells that produce IL-22 ranges from 20% to 80% in patients with psoriasis or those with atopic dermatitis. Skin mast cells express IL-22 and IL-17 mRNA. Conversely, IL-17-producing T cells outnumber IL-17-producing mast cells, which also express IL-17 receptor. Conclusion: Human skin mast cells are previously unrecognized IL-22 producers. We further established that skin mast cells express IL-17. Thus mast cells might play an important role in the physiopathology of chronic inflammatory skin disorders.	[Mashiko, Shunya; Bouguermouh, Salim; Rubio, Manuel; Sarfati, Marika] Ctr Hosp Univ Montreal CRCHUM, Ctr Rech, Immunoregulat Lab, Montreal, PQ, Canada; [Baba, Nobuyasu] Kochi Univ, Sch Med, Ctr Innovat & Translat Med, Nankoku, Kochi, Japan; [Bissonnette, Robert] Innovaderm Res, Montreal, PQ, Canada	Universite de Montreal; Kochi University; Innovaderm Research Inc.	Sarfati, M (corresponding author), Ctr Hosp Univ Montreal, Ctr Rech, Immunoregulat Lab, Tour Viger R-12-424-204,900 St Denis St East, Montreal, PQ H2X 0A9, Canada.	m.sarfati@umontreal.ca	Baba, Nobuyasu/AAF-8593-2019	Baba, Nobuyasu/0000-0001-9945-080X	Innovaderm Research	Innovaderm Research	Supported by Innovaderm Research.	Ackermann L, 1999, BRIT J DERMATOL, V140, P624; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Boniface K, 2007, CLIN EXP IMMUNOL, V150, P407, DOI 10.1111/j.1365-2249.2007.03511.x; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Capon F, 2007, HUM GENET, V122, P201, DOI 10.1007/s00439-007-0397-0; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; Chapuy L, 2014, J ALLERGY CLIN IMMUN, V134, P978, DOI 10.1016/j.jaci.2014.05.025; Chen L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085226; Cheuk S, 2014, J IMMUNOL, V192, P3111, DOI 10.4049/jimmunol.1302313; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Dumoutier L, 2000, J IMMUNOL, V164, P1814, DOI 10.4049/jimmunol.164.4.1814; Elder JT, 2010, J INVEST DERMATOL, V130, P1213, DOI 10.1038/jid.2009.319; Gaudenzio N, 2013, J ALLERGY CLIN IMMUN, V131, P1400, DOI 10.1016/j.jaci.2013.01.029; Gottlieb AB, 2005, J IMMUNOL, V175, P2721, DOI 10.4049/jimmunol.175.4.2721; Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503; Gurish MF, 2012, IMMUNITY, V37, P25, DOI 10.1016/j.immuni.2012.07.003; Hueber AJ, 2010, J IMMUNOL, V184, P3336, DOI 10.4049/jimmunol.0903566; Jiang WY, 2001, INT J DERMATOL, V40, P699, DOI 10.1046/j.1365-4362.2001.01262.x; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Keijsers RRMC, 2014, J INVEST DERMATOL, V134, P1276, DOI 10.1038/jid.2013.526; Kumari S, 2013, IMMUNITY, V39, P899, DOI 10.1016/j.immuni.2013.10.009; Laggner U, 2011, J IMMUNOL, V187, P2783, DOI 10.4049/jimmunol.1100804; Lai YP, 2012, IMMUNITY, V37, P74, DOI 10.1016/j.immuni.2012.04.010; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; LEE FI, 1990, AM J GASTROENTEROL, V85, P962; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Meephansan J, 2011, EUR J DERMATOL, V21, P501, DOI 10.1684/ejd.2011.1335; Noordenbos T, 2012, ARTHRITIS RHEUM-US, V64, P99, DOI 10.1002/art.33396; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Perera GK, 2012, ANNU REV PATHOL-MECH, V7, P385, DOI 10.1146/annurev-pathol-011811-132448; Pfizer, SINGL DOS STUD SAF T; Rodewald HR, 2012, IMMUNITY, V37, P13, DOI 10.1016/j.immuni.2012.07.007; Rutz S, 2013, IMMUNOL REV, V252, P116, DOI 10.1111/imr.12027; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Shefler I, 2014, J ALLERGY CLIN IMMUN, V133, P217, DOI 10.1016/j.jaci.2013.04.035; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Suurmond J, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3466; Takaishi M, 2014, J DERMATOL SCI, V73, P261, DOI 10.1016/j.jdermsci.2013.11.008; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2351, DOI 10.1038/jid.2014.146; TORUNIOWA B, 1988, ARCH DERMATOL RES, V280, P189, DOI 10.1007/BF00513956; TOYRY S, 1988, ARCH DERMATOL RES, V280, P282, DOI 10.1007/BF00440601; Van Belle AB, 2012, J IMMUNOL, V188, P462, DOI 10.4049/jimmunol.1102224; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Wang B, 2013, CANCER IMMUNOL IMMUN, V62, P1575, DOI 10.1007/s00262-013-1460-4; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Wolk K, 2009, J MOL MED, V87, P523, DOI 10.1007/s00109-009-0457-0; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	51	117	123	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					351	+		10.1016/j.jaci.2015.01.033	http://dx.doi.org/10.1016/j.jaci.2015.01.033			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25792465				2022-12-18	WOS:000359004900016
J	Khalid, S; Murdoch, R; Newlands, A; Smart, K; Kelsall, A; Holt, K; Dockry, R; Woodcock, A; Smith, JA				Khalid, Saifudin; Murdoch, Robert; Newlands, Amy; Smart, Kevin; Kelsall, Angela; Holt, Kimberley; Dockry, Rachel; Woodcock, Ashley; Smith, Jaclyn A.			Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cough; transient receptor potential vanilloid 1; capsaicin; cough sounds; sensory nerves	YOUNG GUINEA-PIGS; REFLEX SENSITIVITY; CAPSAICIN COUGH; PAIN RELIEF; SB-705498; ACTIVATION; BRADYKININ; NEURONS; HUMANS; INHALATION	Background: Inhalation of capsaicin, the extract of hot chili peppers, induces coughing in both animals and human subjects through activation of transient receptor potential vanilloid 1 (TRPV1) on airway sensory nerves. Therefore the TRPV1 receptor is an attractive target for the development of antitussive agents. Objective: We sought to assess the antitussive effect of TRPV1 antagonism in patients with refractory chronic cough. Methods: Twenty-one subjects with refractory chronic cough (> 8 weeks) attending a specialist clinic were recruited to a randomized, double-blind, placebo-controlled crossover trial assessing a TRPV1 antagonist (SB-705498). Cough reflex sensitivity to capsaicin (concentration of capsaicin inducing at least 5 coughs) and 24-hour cough frequency were coprimary end points assessed after a single dose of SB-705498 (600 mg) and matched placebo. Cough severity and urge to cough were reported on visual analog scales, and cough-specific quality of life data were also collected. Results: Treatment with SB-705498 produced a significant improvement in cough reflex sensitivity to capsaicin at 2 hours and a borderline significant improvement at 24 hours compared with placebo (adjusted mean difference of +1.3 doubling doses at 2 hours [95% CI, +0.3 to +2.2; P=.0049] and +0.7doubling doses at 24 hours [95% CI, +0.0 to +1.5; P =.0259]). However, 24-hour objective cough frequency was not improved compared with placebo. Patient-reported cough severity, urge to cough, and cough-specific quality of life similarly suggested no effect of SB-705498. Conclusion: This study raises important questions about both the role of TRVP1-mediated mechanisms in patients with refractory chronic cough and also the predictive value of capsaicin challenge testing in the assessment of novel antitussive agents.	[Khalid, Saifudin; Kelsall, Angela; Holt, Kimberley; Dockry, Rachel; Woodcock, Ashley; Smith, Jaclyn A.] Univ Manchester, Univ S Manchester Hosp, Ctr Resp & Allergy, Manchester, Lancs, England; [Murdoch, Robert; Newlands, Amy; Smart, Kevin] GlaxoSmithKline, Stevenage, Herts, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; GlaxoSmithKline	Smith, JA (corresponding author), Univ S Manchester Hosp, Educ & Res Ctr, 2nd Floor,Southmoor Rd, Manchester M23 9LT, Lancs, England.	jacky.smith@manchester.ac.uk		Smith, Jaclyn/0000-0001-8837-4928; Khalid, Saifudin/0000-0001-9503-2803; Woodcock, Ashley/0000-0002-5428-8578; Holt, Kimberley/0000-0003-0413-8085; Dockry, Rachel/0000-0002-0908-3362	GlaxoSmithKline; MRC [G0701918]; Medical Research Council [G0701918] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10249, NF-SI-0513-10040] Funding Source: researchfish	GlaxoSmithKline(GlaxoSmithKline); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by GlaxoSmithKline. J.A.S. was funded by an MRC Clinician Scientist award (G0701918).	Bareille P, 2013, INT J CLIN PHARM TH, V51, P576, DOI 10.5414/CP201890; Birrell MA, 2009, AM J RESP CRIT CARE, V180, P1042, DOI 10.1164/rccm.200905-0665OC; Blanc FX, 2009, RESP MED, V103, P786, DOI 10.1016/j.rmed.2008.11.010; Carr MJ, 2003, J PHARMACOL EXP THER, V304, P1275, DOI 10.1124/jpet.102.043422; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chizh BA, 2007, PAIN, V132, P132, DOI 10.1016/j.pain.2007.06.006; CHOUDRY NB, 1992, EUR RESPIR J, V5, P296; Decalmer SC, 2007, THORAX, V62, P329, DOI 10.1136/thx.2006.067413; Dicpinigaitis PV, 2008, LUNG, V186, P369, DOI 10.1007/s00408-008-9114-6; Dicpinigaitis Peter V, 2012, Cough, V8, P10, DOI 10.1186/1745-9974-8-10; Dicpinigaitis PV, 1997, CLIN DRUG INVEST, V14, P326, DOI 10.2165/00044011-199714040-00012; Eccles R, 2010, LUNG, V188, pS53, DOI 10.1007/s00408-009-9173-3; Eid SR, 2011, CURR TOP MED CHEM, V11, P2118; Faruqi S, 2011, RESPIROLOGY, V16, P314, DOI 10.1111/j.1440-1843.2010.01893.x; FORSBERG K, 1986, ACTA PHYSIOL SCAND, V128, P319, DOI 10.1111/j.1748-1716.1986.tb07981.x; French CT, 2002, CHEST, V121, P1123, DOI 10.1378/chest.121.4.1123; FUJIMURA M, 1995, EUR RESPIR J, V8, P1499; FULLER RW, 1988, J APPL PHYSIOL, V65, P1125, DOI 10.1152/jappl.1988.65.3.1125; Gavva NR, 2008, PAIN, V136, P202, DOI 10.1016/j.pain.2008.01.024; Grace M, 2012, THORAX, V67, P891, DOI 10.1136/thoraxjnl-2011-201443; Groneberg DA, 2004, AM J RESP CRIT CARE, V170, P1276, DOI 10.1164/rccm.200402-174OC; Gunthorpe MJ, 2007, J PHARMACOL EXP THER, V321, P1183, DOI 10.1124/jpet.106.116657; Hilton EC, 2013, J ALLERGY CLIN IMMUN, V132, pe1; Hilton ECY, 2013, J ALLERGY CLIN IMMUN, V132, P847, DOI 10.1016/j.jaci.2013.04.042; HOLLANDERJANSEN M, 1989, PHARM RES-DORDR, V6, P585, DOI 10.1023/A:1015901414495; Hope-Gill BDM, 2003, AM J RESP CRIT CARE, V168, P995, DOI 10.1164/rccm.200304-597OC; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Joad JP, 2004, AM J RESP CRIT CARE, V169, P499, DOI 10.1164/rccm.200308-1139OC; Kelsall A, 2011, CHEST, V139, P569, DOI 10.1378/chest.10-0438; Kollarik M, 2004, J PHYSIOL-LONDON, V555, P115, DOI 10.1113/jphysiol.2003.054890; Krarup AL, 2011, ALIMENT PHARM THER, V33, P1113, DOI 10.1111/j.1365-2036.2011.04629.x; Lieu TM, 2012, AM J PHYSIOL-LUNG C, V302, pL941, DOI 10.1152/ajplung.00366.2011; MATHISEN LC, 1995, PAIN, V61, P215, DOI 10.1016/0304-3959(94)00170-J; McGarvey L, 2009, PULM PHARMACOL THER, V22, P59, DOI 10.1016/j.pupt.2008.11.003; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; MOHAMMED SP, 1993, J PHYSIOL-LONDON, V469, P51, DOI 10.1113/jphysiol.1993.sp019804; Morice AH, 2007, EUR RESPIR J, V29, P1256, DOI 10.1183/09031936.00101006; Morice AH, 2007, AM J RESP CRIT CARE, V175, P312, DOI 10.1164/rccm.200607-892OC; Murdoch RD, 2012, THORAX, V67, pA129, DOI 10.1136/thoraxjnl-2012-202678.215; OCONNELL F, 1994, AM J RESP CRIT CARE, V150, P374, DOI 10.1164/ajrccm.150.2.8049818; OConnell F, 1996, RESP MED, V90, P279, DOI 10.1016/S0954-6111(96)90099-2; Prudon B, 2005, CHEST, V127, P550, DOI 10.1378/chest.127.2.550; Qiu ZH, 2011, RESPIROLOGY, V16, P645, DOI 10.1111/j.1440-1843.2011.01952.x; Rami HK, 2006, BIOORG MED CHEM LETT, V16, P3287, DOI 10.1016/j.bmcl.2006.03.030; Ryan NM, 2012, LANCET, V380, P1583, DOI 10.1016/S0140-6736(12)60776-4; Sanchez JF, 2001, NEUROSCIENCE, V107, P373, DOI 10.1016/S0306-4522(01)00373-6; Sekizawa SI, 2008, EUR J NEUROSCI, V28, P771, DOI 10.1111/j.1460-9568.2008.06378.x; Singapuri Amisha, 2008, Cough, V4, P10, DOI 10.1186/1745-9974-4-10; Smith JA, 2006, THORAX, V61, P425, DOI 10.1136/thx.2005.050963; Smith JA, 2010, GASTROENTEROLOGY, V139, P754, DOI 10.1053/j.gastro.2010.06.050; Smith JA, 2010, OTOLARYNG CLIN N AM, V43, P157, DOI 10.1016/j.otc.2009.11.014; Smith JK, 2012, PSYCHOL AESTHET CREA, V6, P1, DOI 10.1037/a0027241; Sumner H, 2010, AM J RESP CRIT CARE, V181, pA5555; Szallasi A, 2012, EXPERT OPIN INV DRUG, V21, P1351, DOI 10.1517/13543784.2012.704021; Ternesten-Hasseus E, 2006, PULM PHARMACOL THER, V19, P172, DOI 10.1016/j.pupt.2005.04.010; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4	56	117	126	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					56	+		10.1016/j.jaci.2014.01.038	http://dx.doi.org/10.1016/j.jaci.2014.01.038			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24666696				2022-12-18	WOS:000338930300008
J	Wendell, SG; Baffi, C; Holguin, F				Wendell, Stacy Gelhaus; Baffi, Cindy; Holguin, Fernando			Fatty acids, inflammation, and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; diet; obesity; fatty acids; n-6; n-3; inflammation; resolution	CONJUGATED LINOLEIC-ACID; EXERCISE-INDUCED BRONCHOCONSTRICTION; ALLERGIC AIRWAY INFLAMMATION; FISH-OIL SUPPLEMENTATION; DIETARY-INTAKE; LUNG-FUNCTION; OMEGA-3; SEVERITY; PREGNANCY; DISEASE	Fatty acids and consequently diet play an essential role in the formation of inflammatory mediators involved in the pathogenesis of asthma. Because intake variations of omega-6 (n-6) and omega-3 (n-3) fatty acids ultimately determine cell membrane incorporation, changes in diet have the potential to modify downstream production of inflammatory mediators derived from these compounds. It has long been hypothesized that decreasing the n-6/n-3 ratio could reduce the production of more proinflammatory mediators while increasing the formation of downstream metabolites that can serve to limit or resolve inflammation. In turn, these changes would result in improved asthma outcomes or would lower the risk for asthma incidence. This review will focus on the role of fatty acid inflammatory and resolving mediators and will summarize the clinical and epidemiologic data on how diet and obesity alter fatty acid profiles that can contribute to asthma.	[Wendell, Stacy Gelhaus; Baffi, Cindy; Holguin, Fernando] UPMC, Dept Med, Asthma Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Holguin, F (corresponding author), UPMC, Dept Med, Asthma Inst, MONF NW628, Pittsburgh, PA 15213 USA.	feh9@pitt.edu	Gelhaus, Stacy/AAF-2570-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098177] Funding Source: NIH RePORTER; NHLBI NIH HHS [U10 HL098177] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Almqvist C, 2007, J ALLERGY CLIN IMMUN, V119, P1438, DOI 10.1016/j.jaci.2007.01.046; Aoki H, 2008, BIOCHEM BIOPH RES CO, V367, P509, DOI 10.1016/j.bbrc.2008.01.012; Barros R, 2011, BRIT J NUTR, V106, P441, DOI 10.1017/S0007114511000328; Batthyany C, 2006, J BIOL CHEM, V281, P20450, DOI 10.1074/jbc.M602814200; Bilal S, 2011, BBA-MOL BASIS DIS, V1812, P1164, DOI 10.1016/j.bbadis.2011.05.002; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Bolte G, 2006, CLIN EXP ALLERGY, V36, P293, DOI 10.1111/j.1365-2222.2006.02441.x; Broadfield EC, 2004, CLIN EXP ALLERGY, V34, P1232, DOI 10.1111/j.1365-2222.2004.02032.x; Burns JS, 2007, CHEST, V132, P238, DOI 10.1378/chest.07-0038; Celik GE, 2007, CLIN EXP ALLERGY, V37, P1494, DOI 10.1111/j.1365-2222.2007.02806.x; Churruca I, 2009, BIOFACTORS, V35, P105, DOI 10.1002/biof.13; Covar R, 2010, CLIN EXP ALLERGY, V40, P1163, DOI 10.1111/j.1365-2222.2010.03523.x; de Vries A, 2009, PHARMACOL THERAPEUT, V122, P78, DOI 10.1016/j.pharmthera.2009.02.001; Emelyanov A, 2002, EUR RESPIR J, V20, P596, DOI 10.1183/09031936.02.02632001; Emmanouil E, 2010, PEDIAT ALLERG IMM-UK, V21, P90, DOI 10.1111/j.1399-3038.2009.00876.x; Fajt ML, 2013, J ALLERGY CLIN IMMUN, V131, P1504, DOI 10.1016/j.jaci.2013.01.035; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Groeger AL, 2010, NAT CHEM BIOL, V6, P433, DOI 10.1038/nchembio.367; Hodge L, 1998, EUR RESPIR J, V11, P361, DOI 10.1183/09031936.98.11020361; HORROBIN DF, 1987, MED HYPOTHESES, V22, P421, DOI 10.1016/0306-9877(87)90037-5; Hoyos C, 2008, ASIA PAC J CLIN NUTR, V17, P552; Kitz R, 2010, RESP MED, V104, P1793, DOI 10.1016/j.rmed.2010.06.019; Kompauer I, 2008, EUR J EPIDEMIOL, V23, P175, DOI 10.1007/s10654-007-9218-y; Kremmyda LS, 2011, CLIN REV ALLERG IMMU, V41, P36, DOI 10.1007/s12016-009-8186-2; Levy BD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00390; Li JJ, 2013, AM J CLIN NUTR, V97, P173, DOI 10.3945/ajcn.112.041145; Lin D, 2008, CHEM RES TOXICOL, V21, P2361, DOI 10.1021/tx800248x; Lumia M, 2011, PEDIAT ALLERG IMM-UK, V22, P827, DOI 10.1111/j.1399-3038.2011.01202.x; Lundstrom SL, 2013, MOL NUTR FOOD RES, V57, P1378, DOI 10.1002/mnfr.201200827; MacRedmond R, 2010, CLIN EXP ALLERGY, V40, P1071, DOI 10.1111/j.1365-2222.2010.03531.x; MacRedmond R, 2011, PULM PHARMACOL THER, V24, P540, DOI 10.1016/j.pupt.2011.03.005; McKeever TM, 2008, THORAX, V63, P208, DOI 10.1136/thx.2007.090399; Mickleborough TD, 2006, CHEST, V129, P39, DOI 10.1378/chest.129.1.39; Mickleborough TD, 2003, AM J RESP CRIT CARE, V168, P1181, DOI 10.1164/rccm.200303-373OC; Mickleborough TD, 2008, PHYSICIAN SPORTSMED, V36, P11, DOI 10.3810/psm.2008.12.7; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Misso NL, 2012, PROSTAGLANDINS LEUKO; Miyake Y, 2008, CLIN EXP ALLERGY, V38, P1644, DOI 10.1111/j.1365-2222.2008.03074.x; Moreira A, 2007, J INVEST ALLERG CLIN, V17, P309; Nakamura K, 2013, PUBLIC HEALTH NUTR, V16, P2040, DOI 10.1017/S1368980012004363; Nwaru BI, 2012, BRIT J NUTR, V108, P720, DOI 10.1017/S0007114511005940; Olsen SF, 2008, AM J CLIN NUTR, V88, P167, DOI 10.1093/ajcn/88.1.167; PARM J, 1988, THORAX, V43, P84, DOI 10.1136/thx.43.2.84; Reddy AT, 2013, J IMMUNOL, V191, P2053, DOI 10.4049/jimmunol.1300730; Rodriguez-Rodriguez E, 2010, EUR J CLIN NUTR, V64, P1065, DOI 10.1038/ejcn.2010.127; Rudolph TK, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.290re7; Rudolph V, 2009, J BIOL CHEM, V284, P1461, DOI 10.1074/jbc.M802298200; Sanak M, 2000, EUR RESPIR J, V16, P44, DOI 10.1034/j.1399-3003.2000.16a08.x; Sastre B, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/645383; Schopfer FJ, 2011, CHEM REV, V111, P5997, DOI 10.1021/cr200131e; Schubert R, 2009, INT ARCH ALLERGY IMM, V148, P321, DOI 10.1159/000170386; Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c; Serhan CN, 2011, CHEM BIOL, V18, P976, DOI 10.1016/j.chembiol.2011.06.008; Standl M, 2011, CLIN EXP ALLERGY, V41, P1757, DOI 10.1111/j.1365-2222.2011.03833.x; Tricon S, 2004, AM J CLIN NUTR, V80, P614; Uddin M, 2011, PROG LIPID RES, V50, P75, DOI 10.1016/j.plipres.2010.09.002; Velazquez JR, 2013, CLIN REV ALLERG IMMU, V45, P75, DOI 10.1007/s12016-012-8340-0; Wenzel SE, 1997, PHARMACOTHERAPY, V17, pS3; Wood LG, 2009, PHARMACOL THERAPEUT, V123, P37, DOI 10.1016/j.pharmthera.2009.03.015; Woods RK, 2004, THORAX, V59, P105, DOI 10.1136/thorax.2003.009498; WOODS RK, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; Zulet MA, 2005, J PHYSIOL BIOCHEM, V61, P483, DOI 10.1007/BF03168454	62	117	126	0	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1255	1264		10.1016/j.jaci.2013.12.1087	http://dx.doi.org/10.1016/j.jaci.2013.12.1087			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24613565	Green Accepted, Bronze			2022-12-18	WOS:000335450700003
J	van der Wiel, E; ten Hacken, NHT; Postma, DS; van den Berge, M				van der Wiel, Erica; ten Hacken, Nick H. T.; Postma, Dirkje S.; van den Berge, Maarten			Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: A systematic review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Small-airways disease; asthma; phenotypes; asthma control	ALVEOLAR NITRIC-OXIDE; EXERCISE-INDUCED BRONCHOCONSTRICTION; BRONCHOALVEOLAR LAVAGE FLUID; PARTICULATE AIR-POLLUTION; ULTRAFINE PARTICLES; LUNG-FUNCTION; DISTAL LUNG; VENTILATION HETEROGENEITY; DYNAMIC HYPERINFLATION; IMPULSE OSCILLOMETRY	Traditionally, asthma has been considered a disease that predominantly involves the large airways. Today, this concept is being challenged, and increasing evidence has become available showing that abnormalities in the small airways also contribute to the clinical expression of asthma. The small airways can be affected by inflammation, remodeling, and changes in the surrounding tissue, all contributing to small-airways dysfunction. In this article we have performed a systematic review of the literature on the association between small-airways dysfunction and clinical signs and symptoms of asthma. This review shows that small-airways dysfunction associates with worse control of asthma, higher numbers of exacerbations, the presence of nocturnal asthma, more severe bronchial hyperresponsiveness, exercise-induced asthma, and the late-phase allergic response. Importantly, small-airways dysfunction can already be present in patients with mild asthma. Our review provides suggestive evidence that a better response of the small airways to inhaled steroids or montelukast associates with better asthma control. For this reason, an early recognition of small-airways dysfunction is important because it enables the physician to start timely treatment to target the small airways. It is important to develop simpler and more reliable tools (eg, questionnaires or bronchial provocation tests with small-particle stimuli) to assess the presence and extent of small-airways dysfunction in daily clinical practice. (J Allergy Clin Immunol 2013;131:646-57.)	[van den Berge, Maarten] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Med & TB, NL-9700 RB Groningen, Netherlands; Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, NL-9700 RB Groningen, Netherlands	University of Groningen; University of Groningen	van den Berge, M (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Med & TB, POB 30-001, NL-9700 RB Groningen, Netherlands.	m.van.den.berge@umcg.nl			Dutch Asthma Foundation; NWO; ZonMw; SAB; AstraZeneca; Chiesi	Dutch Asthma Foundation; NWO(Netherlands Organization for Scientific Research (NWO)); ZonMw(Netherlands Organization for Health Research and Development); SAB; AstraZeneca(AstraZeneca); Chiesi(Chiesi Pharmaceuticals Inc)	D. S. Postma has received grants from the Dutch Asthma Foundation, NWO, ZonMw, SAB, AstraZeneca, and Chiesi and has received travel support from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Nycomed/Takeda. M. van den Berge has consulted for GlaxoSmithKline and Novartis and has received payment for a lecture for Nycomed.	AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; AHMED T, 1980, CLIN RES PROC, V16, P721; Alessandrini F, 2006, J ALLERGY CLIN IMMUN, V117, P824, DOI 10.1016/j.jaci.2005.11.046; Allegra L, 2012, RESP MED, V106, P205, DOI 10.1016/j.rmed.2011.10.001; Andersen ZJ, 2008, OCCUP ENVIRON MED, V65, P458, DOI 10.1136/oem.2007.033290; Aronsson D, 2011, CLIN RESPIR J, V5, P10, DOI 10.1111/j.1752-699X.2009.00183.x; BACKER V, 1992, CLIN PHYSIOL, V12, P575, DOI 10.1111/j.1475-097X.1992.tb00360.x; Bacsi A, 2006, J ALLERGY CLIN IMMUN, V118, P844, DOI 10.1016/j.jaci.2006.07.006; Barnes N, 2011, CLIN EXP ALLERGY, V41, P1521, DOI 10.1111/j.1365-2222.2011.03820.x; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834, DOI 10.5694/j.1326-5377.1992.tb136994.x; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Berry M, 2005, EUR RESPIR J, V25, P986, DOI 10.1183/09031936.05.00132404; Blomberg A, 2000, CLIN EXP ALLERGY, V30, P310; Boulet LP, 2007, RESP MED, V101, P1677, DOI 10.1016/j.rmed.2007.03.001; Bourdin A, 2006, ALLERGY, V61, P85, DOI 10.1111/j.1398-9995.2006.00970.x; Brindicci C, 2007, CHEST, V131, P1353, DOI 10.1378/chest.06-2531; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; Carvalho TC, 2011, INT J PHARMACEUT, V406, P1, DOI 10.1016/j.ijpharm.2010.12.040; Contoli M, 2010, ALLERGY, V65, P141, DOI 10.1111/j.1398-9995.2009.02242.x; CRAWFORD ABH, 1985, J APPL PHYSIOL, V59, P838, DOI 10.1152/jappl.1985.59.3.838; Currie GP, 2003, ANN ALLERG ASTHMA IM, V90, P560, DOI 10.1016/S1081-1206(10)61851-0; D'Amato G, 2007, ALLERGY, V62, P11, DOI 10.1111/j.1398-9995.2006.01271.x; Daigle CC, 2003, INHAL TOXICOL, V15, P539, DOI 10.1080/08958370304468; Davidson AC, 1996, BRIT MED J, V312, P601; DECRAMER M, 1984, B EUR PHYSIOPATH RES, V20, P237; Downie SR, 2007, THORAX, V62, P684, DOI 10.1136/thx.2006.069682; Drewek R, 2009, J ASTHMA, V46, P375, DOI 10.1080/02770900802492079; Farah CS, 2012, J ALLERGY CLIN IMMUN, V130, P61, DOI 10.1016/j.jaci.2012.02.015; Farah CS, 2012, J ALLERGY CLIN IMMUN, V129, P381, DOI 10.1016/j.jaci.2011.11.017; Filippelli M, 2003, CHEST, V124, P2164, DOI 10.1378/chest.124.6.2164; Fonseca-Guedes CHF, 2003, PEDIATR PULM, V36, P49, DOI 10.1002/ppul.10309; Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492; Gelb AF, 2010, THORAX, V65, P619, DOI 10.1136/thx.2009.132696; Gustafsson PM, 2003, EUR RESPIR J, V21, P1033, DOI 10.1183/09031936.03.00049302; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hoek G, 1998, EUR RESPIR J, V11, P1307, DOI 10.1183/09031936.98.11061307; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Holzer K, 2003, AM J RESP CRIT CARE, V167, P534, DOI 10.1164/rccm.200208-916OC; Huchon G, 2009, RESP MED, V103, P41, DOI 10.1016/j.rmed.2008.09.002; Iskandar A, 2012, THORAX, V67, P252, DOI 10.1136/thoraxjnl-2011-200324; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905, DOI 10.1164/ajrccm/146.4.905; KAMINSKY DA, 1995, AM J RESP CRIT CARE, V152, P1784, DOI 10.1164/ajrccm.152.6.8520737; Kaminsky DA, 2000, AM J RESP CRIT CARE, V162, P179, DOI 10.1164/ajrccm.162.1.9806079; Keen C, 2011, RESP MED, V105, P1476, DOI 10.1016/j.rmed.2011.04.004; KIERS A, 1981, CLIN RES PROC, V17, P869; Kosmas EN, 2004, EUR RESPIR J, V24, P378, DOI 10.1183/09031936.04.00113003; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1551, DOI 10.1164/ajrccm.163.7.2008013; Kraft M, 1999, EUR RESPIR J, V14, P1403, DOI 10.1183/09031936.99.14614039; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Kraft M, 2006, CHEST, V130, P1726, DOI 10.1378/chest.130.6.1726; Kreyling WG, 2004, J AEROSOL MED, V17, P140, DOI 10.1089/0894268041457147; Lang A, 2008, ALLERGY, V63, P1054, DOI 10.1111/j.1398-9995.2008.01672.x; Laveneziana P, 2006, EUR RESPIR J, V27, P742, DOI 10.1183/09031936.06.00080505; Leach CL, 2002, CHEST, V122, P510, DOI 10.1378/chest.122.2.510; Leach CL, 1998, RESP MED, V92, P3, DOI 10.1016/S0954-6111(98)90211-6; Lee JH, 2010, J INVEST ALLERG CLIN, V20, P575; Lehtimaki L, 2005, J ASTHMA, V42, P605, DOI 10.1080/02770900500294678; Lehtimaki L, 2002, EUR RESPIR J, V20, P841, DOI 10.1183/09031936.02.00202002; Lieutier-Colas F, 2003, AM J RESP CRIT CARE, V167, P1077, DOI 10.1164/rccm.2204037; Ljungberg HK, 2003, PEDIATR PULM, V36, P339, DOI 10.1002/ppul.10356; Lougheed MD, 2006, CHEST, V130, P1072, DOI 10.1378/chest.130.4.1072; LOUGHEED MD, 1993, AM REV RESPIR DIS, V148, P1452, DOI 10.1164/ajrccm/148.6_Pt_1.1452; Lougheed MD, 2002, AM J RESP CRIT CARE, V166, P370, DOI 10.1164/rccm.2109003; MACHADO L, 1986, CLIN ALLERGY, V16, P111, DOI 10.1111/j.1365-2222.1986.tb00754.x; MACKLEM PT, 1967, J APPL PHYSIOL, V22, P395, DOI 10.1152/jappl.1967.22.3.395; Maestrelli P, 2011, J INVEST ALLERG CLIN, V21, P120; Mahut B, 2004, CHEST, V125, P1012, DOI 10.1378/chest.125.3.1012; Mahut B, 2010, ALLERGY, V65, P636, DOI 10.1111/j.1398-9995.2009.02221.x; Mahut B, 2010, RESP MED, V104, P1230, DOI 10.1016/j.rmed.2010.05.005; Mansur AH, 2008, RESP MED, V102, P42, DOI 10.1016/j.rmed.2007.08.007; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; Martin RJ, 2002, J ALLERGY CLIN IMMUN, V109, pS447, DOI 10.1067/mai.2002.121409; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; MEAD J, 1970, NEW ENGL J MED, V282, P1318, DOI 10.1056/NEJM197006042822311; METZER WJ, 1985, CHEST, V88, P369, DOI 10.1378/chest.88.3.369; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; Muller V, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-40; Newson R, 1997, THORAX, V52, P680, DOI 10.1136/thx.52.8.680; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Ohbayashi Hiroyuki, 2008, Allergol Int, V57, P231, DOI 10.2332/allergolint.O-07-522; OOSTERHOFF Y, 1995, J ALLERGY CLIN IMMUN, V96, P219, DOI 10.1016/S0091-6749(95)70011-0; Paraskakis E, 2006, AM J RESP CRIT CARE, V174, P260, DOI 10.1164/rccm.200506-962OC; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Peroni DG, 2002, CLIN EXP ALLERGY, V32, P850, DOI 10.1046/j.1365-2222.2002.01372.x; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; Platts-Mills TA, 2009, AM J RESP CRIT CARE, V180, P120; Platts-Mills TAE, 2009, AM J RESP CRIT CARE, V180, P109, DOI 10.1164/rccm.200811-1756PR; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLISS LB, 1989, J APPL PHYSIOL, V66, P2298, DOI 10.1152/jappl.1989.66.5.2298; Pope C. Arden III, 2000, Environmental Health Perspectives, V108, P713, DOI 10.2307/3454408; Price D, 2010, J ALLERGY CLIN IMMUN, V126, P511, DOI 10.1016/j.jaci.2010.06.040; Puckett JL, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-47; Riediker M, 2000, CLIN EXP ALLERGY, V30, P867; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118, DOI 10.1164/ajrccm/147.1.118; Rundell KW, 2004, MED SCI SPORT EXER, V36, P405, DOI 10.1249/01.MSS.0000117118.77267.BF; Scichilone N, 2009, ALLERGY, V64, P1563, DOI 10.1111/j.1398-9995.2009.02139.x; Segal LN, 2011, COPD, V8, P145, DOI 10.3109/15412555.2011.560127; Shi YX, 2012, J ALLERGY CLIN IMMUN, V129, P671, DOI 10.1016/j.jaci.2011.11.002; Shorter JH, 2011, J BREATH RES, V5, DOI 10.1088/1752-7155/5/3/037108; Spahn JD, 2006, ANN ALLERG ASTHMA IM, V96, P541, DOI 10.1016/S1081-1206(10)63548-X; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Takeda T, 2010, RESPIRATION, V80, P120, DOI 10.1159/000242113; Tantucci C, 1999, EUR RESPIR J, V14, P295; Taylor PE, 2007, INT ARCH ALLERGY IMM, V144, P162, DOI 10.1159/000103230; Trenga CA, 2006, CHEST, V129, P1614, DOI 10.1378/chest.129.6.1614; Tufvesson E, 2011, PROSTAG LEUKOTR ESS, V85, P67, DOI 10.1016/j.plefa.2011.04.025; van den Berge M, 2011, CHEST, V139, P412, DOI 10.1378/chest.10-1210; van Veen IH, 2006, EUR RESPIR J, V27, P951, DOI 10.1183/09031936.06.00087905; VANVYVE T, 1992, CHEST, V102, P356, DOI 10.1378/chest.102.2.356; Verbanck S, 2003, J APPL PHYSIOL, V94, P1380, DOI 10.1152/japplphysiol.00588.2002; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Wagner EM, 1998, AM J RESP CRIT CARE, V157, P447, DOI 10.1164/ajrccm.157.2.9611043; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WANNER A, 1974, J CLIN INVEST, V54, P1200, DOI 10.1172/JCI107863; Weibel E.R., 1963, MORPHOMETRY HUMAN LU, DOI DOI 10.1007/978-3-642-87553-3; Zeidler MR, 2006, J ALLERGY CLIN IMMUN, V118, P1075, DOI 10.1016/j.jaci.2006.06.042; Zeidler MR, 2006, EUR RESPIR J, V27, P307, DOI 10.1183/09031936.06.00005605	121	117	118	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					646	657		10.1016/j.jaci.2012.12.1567	http://dx.doi.org/10.1016/j.jaci.2012.12.1567			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23380222				2022-12-18	WOS:000315587800003
J	Tripodi, S; Frediani, T; Lucarelli, S; Macri, F; Pingitore, G; Businco, AD; Dondi, A; Pansa, P; Ragusa, G; Asero, R; Faggian, D; Plebani, M; Matricardi, PM				Tripodi, Salvatore; Frediani, Tullio; Lucarelli, Sandra; Macri, Francesco; Pingitore, Giuseppe; Businco, Andrea Di Rienzo; Dondi, Arianna; Pansa, Paola; Ragusa, Giovanni; Asero, Riccardo; Faggian, Diego; Plebani, Mario; Matricardi, Paolo Maria			Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: Implications for specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergenic molecules; atopy; children; classification; combinatorial analysis; component-resolved diagnosis; component-resolved therapy; epidemiology; grass pollen; hay fever; molecular profiles; Phleum pratense; specific IgE	SKIN-TEST; ASTHMA; DIAGNOSIS; EXTRACTS; RHINITIS; RHINOCONJUNCTIVITIS; PREVENTION	Background: The so-called component-resolved immunotherapy of allergies proposes an immunization tailored to the molecular sensitization profiles of individual patients. Objectives: We sought (1) to investigate the profiles of IgE sensitization to Phleum pratense in children with grass pollen allergy and (2) to define the compatibility of these profiles with a mixture of recombinant allergenic molecules of P pratense previously proposed for specific immunotherapy. Methods: We examined 200 children (age, 4-18 years; 126 boys) with allergic rhinitis, asthma, or both ascertained through validated questionnaires. Each child underwent skin prick testing (ALK-Abello) and serum IgE assays (ImmunoCAP, Phadia) with 9 pollen extracts. Sera reacting against P pratense were tested for the individual molecules (rPhl p 1, rPhl p 2, rPhl p 4, nPhl p 4, rPhl p 5b, rPhl p 6, rPhl p 7, rPhl p 11, and Phl p 12). Through a combinatorial approach, the IgE individual sensitization profiles were matched against an experimental allergen-specific immunotherapy (SIT) preparation containing Phl p 1, Phl p 2, Phl p 5, and Phl p 6. Results: Among the 176 of 200 children with IgE sensitization to P pratense extract, 39 profiles of sensitization to the 8 allergenic molecules tested (cutoff, 0.35 kU/L) were identified. This high heterogeneity was reduced by considering only 6 or 4 P pratense molecules but not by increasing the cutoff levels of IgE positivity. The molecular profile of the experimental SIT preparation matched that of 7 (4%) of 176 patients only; the remaining 169 patients were classified in 4 mismatch categories: underpowered (29%), overpowered (32%), underpowered/overpowered (32%), and unrelated (3%). Conclusions: IgE sensitization profiles to P pratense are highly heterogeneous. Molecularly designed SIT preparations tailored to patients' needs should consider this high heterogeneity and be driven by locally performed population studies. (J Allergy Clin Immunol 2012;129:834-9.)	[Matricardi, Paolo Maria] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Tripodi, Salvatore; Businco, Andrea Di Rienzo] Sandro Pertini Hosp, Pediat Allergol Unit, Rome, Italy; [Frediani, Tullio; Lucarelli, Sandra; Macri, Francesco; Pansa, Paola; Ragusa, Giovanni] Univ Roma La Sapienza, Dept Pediat, Rome, Italy; [Pingitore, Giuseppe] GB Grassi Hosp, Dept Pediat, Rome, Italy; [Dondi, Arianna] Univ Bologna, Pediat Unit, Dept Obstet Gynecol & Pediat Sci, I-40126 Bologna, Italy; [Asero, Riccardo] Clin San Carlo, Allergy Serv, Paderno Dugnano, Italy; [Faggian, Diego; Plebani, Mario] Univ Padua, Dept Lab Med, I-35100 Padua, Italy	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ospedale Sandro Pertini; Sapienza University Rome; University of Bologna; University of Padua	Matricardi, PM (corresponding author), Charite, Dept Pediat Pneumol & Immunol, Augustenburgerpl 1, D-13353 Berlin, Germany.	paolo.matricardi@charite.de	Plebani, Mario/AAF-4953-2020; PANSA, PAOLA/AAA-6142-2020; Dondi, Arianna/E-4269-2012; pingitore, Giuseppe/ABG-8047-2020	Dondi, Arianna/0000-0002-7516-243X; 	Allergopharma; Phadia-Thermo Fisher; DFG Germany	Allergopharma; Phadia-Thermo Fisher; DFG Germany(German Research Foundation (DFG))	S. Tripodi is a shareholder in TPS Production. A. Dondi has received honoraria from TPS Production. P. M. Matricardi has received research support from Allergopharma, Phadia-Thermo Fisher, and DFG Germany.	Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Asero R, 2005, INT ARCH ALLERGY IMM, V137, P62, DOI 10.1159/000085105; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bousquet J, 2010, ALLERGY, V65, P1212, DOI [10.1111/j.1398-9995.2010.02439.x, 10.1111/j.1398-9995.2010.02480.x]; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Canonica GW, 2007, RESP MED, V101, P1885, DOI 10.1016/j.rmed.2007.05.003; DREBORG S, 1989, J AM ACAD DERMATOL, V21, P820, DOI 10.1016/S0190-9622(89)70256-5; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Fahlbusch B, 1998, CLIN EXP ALLERGY, V28, P799; Jauregui I, 2011, PEDIAT ALLERG IMM-UK, V22, P388, DOI 10.1111/j.1399-3038.2010.01108.x; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kaul S, 2010, CURR OPIN ALLERGY CL, V10, P594, DOI 10.1097/ACI.0b013e32833fd5d2; Larsen Jorgen Nedergaard, 2008, Clin Allergy Immunol, V21, P283; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Metz-Favre C, 2007, J ALLERGY CLIN IMMUN, V120, P315, DOI 10.1016/j.jaci.2007.03.046; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Rossi R, 2010, EUR ANN ALLERGY CLIN, V42, P112; Rossi RE, 2001, ALLERGY, V56, P1180, DOI 10.1034/j.1398-9995.2001.00258.x; Scala E, 2010, CLIN EXP ALLERGY, V40, P911, DOI 10.1111/j.1365-2222.2010.03470.x; Schmidt H, 2010, PROTEOMICS, V10, P4352, DOI 10.1002/pmic.201000451; Suphioglu C, 2000, CLIN EXP ALLERGY, V30, P1335, DOI 10.1046/j.1365-2222.2000.00955.x; Tozzi AE, 2011, PEDIAT ALLERG IMM-UK, V22, P267, DOI 10.1111/j.1399-3038.2011.01157.x; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824	28	117	117	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					834	U344		10.1016/j.jaci.2011.10.045	http://dx.doi.org/10.1016/j.jaci.2011.10.045			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22206774				2022-12-18	WOS:000301189300032
J	Wambre, E; DeLong, JH; James, EA; LaFond, RE; Robinson, D; Kwok, WW				Wambre, Erik; DeLong, Jonathan H.; James, Eddie A.; LaFond, Rebecca E.; Robinson, David; Kwok, William W.			Differentiation stage determines pathologic and protective allergen-specific CD4(+) T-cell outcomes during specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; allergy; pollen; T cells; CD4; peptide-MHC class II tetramer; peripheral tolerance; differentiation stage; ex vivo	RESPONSES; EXPRESSION; INDIVIDUALS; MECHANISMS; INDUCTION; EFFECTOR; PROGRAMS; CD8	Background: The main obstacle to elucidating the role of CD4(+) T cells in allergen-specific immunotherapy (SIT) has been the absence of an adequately sensitive approach to directly characterize rare allergen-specific T cells without introducing substantial phenotypic modifications by means of in vitro amplification. Objective: We sought to monitor, in physiological conditions, the allergen-specific CD4(+) T cells generated during natural pollen exposure and during allergy vaccination. Methods: Alder pollen allergy was used as a model for studying seasonal allergies. Allergen-specific CD4(+) T cells were tracked and characterized in 12 subjects with alder pollen allergy, 6 nonallergic subjects, and 9 allergy vaccine-treated subjects by using peptide-MHC class II tetramers. Results: Allergen-specific CD4(+) T cells were detected in all of the subjects with alder pollen allergy and nonallergic subjects tested. Pathogenic responses-chemoattractant receptor homologous molecule expressed on TH- lymphocytes (CRTH2) expression and T(H)2 cytokine production- are specifically associated with terminally differentiated (CD27(-)) allergen-specific CD4(+) T cells, which dominate in allergic subjects but are absent in nonallergic subjects. In contrast, CD27(+) allergen-specific CD4(+) T cells are present at low frequencies in both allergic and nonallergic subjects and reflect classical features of the protective immune response with high expression of IL-10 and IFN-gamma. Restoration of a protective response during SIT appears to be due to the preferential deletion of pathogenic (CD27(-)) allergen-specific CD4(+) T cells accompanied by IL-10 induction in surviving CD27(+) allergen-specific CD4(+) T cells. Conclusions: Differentiation stage divides allergen-specific CD4(+) T cells into 2 distinct subpopulations with unique functional properties and different fates during SIT. (J Allergy Clin Immunol 2012;129:544-51.)	[Wambre, Erik; DeLong, Jonathan H.; James, Eddie A.; LaFond, Rebecca E.; Kwok, William W.] Univ Washington, Benaroya Res Inst Virginia Mason, Seattle, WA 98101 USA; [Robinson, David] Univ Washington, Virginia Mason Med Ctr, Seattle, WA 98101 USA; [Kwok, William W.] Univ Washington, Dept Immunol, Seattle, WA 98101 USA	Benaroya Research Institute; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Washington; University of Washington Seattle	Kwok, WW (corresponding author), Univ Washington, Benaroya Res Inst Virginia Mason, 1201 9th Ave, Seattle, WA 98101 USA.	bkwok@benaroyaresearch.org	James, Eddie/V-4929-2019	James, Eddie/0000-0002-7217-5729	National Institutes of Health [HHSN272200700046C]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by National Institutes of Health contract HHSN272200700046C.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akkoc T, 2011, ALLERGY ASTHMA IMMUN, V3, P11, DOI 10.4168/aair.2011.3.1.11; Aslam A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011028; BAARS PA, 1995, J IMMUNOL, V154, P17; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EBNER C, 1993, MOL IMMUNOL, V30, P1323, DOI 10.1016/0161-5890(93)90093-Q; Fritsch RD, 2005, J IMMUNOL, V175, P6489, DOI 10.4049/jimmunol.175.10.6489; Fuller MJ, 2003, J IMMUNOL, V170, P477, DOI 10.4049/jimmunol.170.1.477; Gabrysova L, 2009, J EXP MED, V206, P1755, DOI 10.1084/jem.20082118; GERDES J, 1984, J IMMUNOL, V133, P1710; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hadjur S, 2009, IMMUNOL LETT, V122, P37, DOI 10.1016/j.imlet.2008.11.001; Hendricks J, 2003, J EXP MED, V198, P1369, DOI 10.1084/jem.20030916; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kwok WW, 2010, J ALLERGY CLIN IMMUN, V125, P1407, DOI 10.1016/j.jaci.2010.03.037; Kwok WW, 2001, TRENDS IMMUNOL, V22, P583, DOI 10.1016/S1471-4906(01)02038-5; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Mack DG, 2009, J IMMUNOL, V182, P7317, DOI 10.4049/jimmunol.0804305; Maggi E, 2010, CLIN EXP IMMUNOL, V161, P10, DOI 10.1111/j.1365-2249.2010.04148.x; MALAVASI F, 1992, INT J CLIN LAB RES, V22, P73, DOI 10.1007/BF02591400; Mantel PY, 2007, PLOS BIOL, V5, P2847, DOI 10.1371/journal.pbio.0050329; Mobs C, 2010, J IMMUNOL, V184, P2194, DOI 10.4049/jimmunol.0901379; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Novak EJ, 1999, J CLIN INVEST, V104, pR63, DOI 10.1172/JCI8476; Pepper M, 2010, NAT IMMUNOL, V11, P83, DOI 10.1038/ni.1826; Pillemer BBL, 2009, J IMMUNOL, V183, P155, DOI 10.4049/jimmunol.0803733; Rappl G, 2008, REJUV RES, V11, P543, DOI 10.1089/rej.2007.0612; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Saraiva M, 2009, IMMUNITY, V31, P209, DOI 10.1016/j.immuni.2009.05.012; Scriba TJ, 2005, J IMMUNOL, V175, P6334, DOI 10.4049/jimmunol.175.10.6334; Snyder CM, 2008, IMMUNITY, V29, P650, DOI 10.1016/j.immuni.2008.07.017; Trinchieri G, 2001, J EXP MED, V194, pF53, DOI 10.1084/jem.194.10.f53; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; Wei J, 2007, P NATL ACAD SCI USA, V104, P18169, DOI 10.1073/pnas.0703642104; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	42	117	118	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					544	U411		10.1016/j.jaci.2011.08.034	http://dx.doi.org/10.1016/j.jaci.2011.08.034			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	21975176	Green Accepted			2022-12-18	WOS:000299951700035
J	Ganeshan, K; Neilsen, CV; Hadsaitong, A; Schleimer, RP; Luo, XR; Bryce, PJ				Ganeshan, Kirthana; Neilsen, Colleen V.; Hadsaitong, April; Schleimer, Robert P.; Luo, Xunrong; Bryce, Paul J.			Impairing oral tolerance promotes allergy and anaphylaxis: A new murine food allergy model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; Staphylococcus aureus enterotoxin B; T(H)2; anaphylaxis; murine; peanut; ovalbumin; tolerance; mast cells; eosinophils	STAPHYLOCOCCAL-ENTEROTOXIN-B; T-CELL RESPONSES; ATOPIC-DERMATITIS; CHOLERA-TOXIN; HYPERSENSITIVITY RESPONSES; CHRONIC RHINOSINUSITIS; ACTIVE SUPPRESSION; IPEX SYNDROME; BALB/C MICE; SENSITIZATION	Background: Food allergy is a disorder in which antigenic food proteins elicit immune responses. Animal models of food allergy have several limitations that influence their utility, including failure to recapitulate several key immunologic hallmarks. Consequently, little is known regarding the pathogenesis and mechanisms leading to food allergy. Staphylococcus aureus-derived enterotoxins, a common cause of food contamination, are associated with antigen responses in atopic dermatitis. Objective: We hypothesized that S aureus-derived enterotoxins might influence the development of food allergy. We examined the influence of administration of staphylococcal enterotoxin B (SEB) with food allergens on immunologic responses and compared these responses with those elicited by a cholera toxin-driven food allergy model. Methods: Oral administration of ovalbumin or whole peanut extract with or without SEB was performed once weekly. After 8 weeks, mice were challenged with oral antigen alone, and the physiologic and immunologic responses to antigen were studied. Results: SEB administered with antigen resulted in immune responses to the antigen. Responses were highly T(H)2 polarized, and oral challenge with antigen triggered anaphylaxis and local and systemic mast cell degranulation. SEB-driven sensitization induced eosinophilia in the blood and intestinal tissues not observed with cholera toxin sensitization. SEB impaired tolerance specifically by impairing expression of TGF-beta and regulatory T cells, and tolerance was restored with high-dose antigen. Conclusions: We demonstrate a new model of food allergy to oral antigen in common laboratory strains of mice that recapitulates many features of clinical food allergy that are not seen in other models. We demonstrate that SEB impairs oral tolerance and permits allergic responses. (J Allergy Clin Immunol 2009;123:231-8.)	[Ganeshan, Kirthana; Neilsen, Colleen V.; Hadsaitong, April; Schleimer, Robert P.; Bryce, Paul J.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60610 USA; [Luo, Xunrong] Northwestern Univ, Feinberg Sch Med, Div Nephrol Hypertens, Chicago, IL 60610 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Bryce, PJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60610 USA.	p-bryce@northwestern.edu	Eckhardt, Erik/G-1567-2010		National Institutes of Health (NIH) [ROI HL068546, HL078860, AI072570, ROI AI076456, R2I AI079525]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025741] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078860, R01HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI078525, R01AI072570, R01AI076456] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Food Allergy Project. R.P.S. was supported by National Institutes of Health (NIH) grants ROI HL068546, HL078860, and AI072570. P.J.B. was supported by NIH grants ROI AI076456 and R2I AI079525.	Adel-Patient K, 2005, CLIN EXP ALLERGY, V35, P539, DOI 10.1111/j.1365-2222.2005.02225.x; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Bashir MEH, 2004, J IMMUNOL, V172, P6978, DOI 10.4049/jimmunol.172.11.6978; Breiteneder H, 2005, J ALLERGY CLIN IMMUN, V115, P14, DOI 10.1016/j.jaci.2004.10.022; Breuer K, 2000, ALLERGY, V55, P551, DOI 10.1034/j.1398-9995.2000.00432.x; Bryce PJ, 2006, J CLIN INVEST, V116, P1624, DOI 10.1172/JCI26150; Bryce PJ, 2003, J ALLERGY CLIN IMMUN, V112, P149, DOI 10.1067/mai.2003.1616; Campbell DE, 1998, ARCH DIS CHILD, V79, P400, DOI 10.1136/adc.79.5.400; Cardona ID, 2006, J ALLERGY CLIN IMMUN, V117, P688, DOI 10.1016/j.jaci.2005.11.037; Cecilia M, 2008, J ALLERGY CLIN IMMUN, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Conley DB, 2006, AM J RHINOL, V20, P534, DOI 10.2500/ajr.2006.20.2941; Cox E, 2006, VET RES, V37, P511, DOI 10.1051/vetres:2006014; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Grdic D, 1999, EUR J IMMUNOL, V29, P1774, DOI 10.1002/(SICI)1521-4141(199906)29:06<1774::AID-IMMU1774>3.0.CO;2-1; Hamad ARA, 1997, J EXP MED, V185, P1447, DOI 10.1084/jem.185.8.1447; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1595, DOI 10.1046/j.1365-2222.2003.01790.x; Jacobsen EA, 2008, J EXP MED, V205, P699, DOI 10.1084/jem.20071840; Knippels LMJ, 2004, CURR OPIN ALLERGY CL, V4, P205, DOI 10.1097/01.all.0000129452.96597.c1; Kobayashi N, 2007, IMMUNITY, V27, P927, DOI 10.1016/j.immuni.2007.11.011; Koppelman SJ, 2003, ALLERGY, V58, P1144, DOI 10.1034/j.1398-9995.2003.00259.x; Kroghsbo S, 2003, INT ARCH ALLERGY IMM, V131, P256, DOI 10.1159/000072137; Langer K, 2007, EXP DERMATOL, V16, P124, DOI 10.1111/j.1600-0625.2006.00523.x; Laouini D, 2003, J ALLERGY CLIN IMMUN, V112, P981, DOI 10.1016/j.jaci.2003.07.007; Le Loir Yves, 2003, Genet Mol Res, V2, P63; Lee SY, 2001, CLIN IMMUNOL, V101, P220, DOI 10.1006/clim.2001.5122; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; Liu T, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-24; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; Miyanishi M, 2007, NATURE, V450, P435, DOI 10.1038/nature06307; MONERETVAUTRIN DA, 2004, ALLERG IMMUNOL PARIS, V36, P46; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Perez-Machado MA, 2003, EUR J IMMUNOL, V33, P2307, DOI 10.1002/eji.200323308; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rao A, 2007, BLOOD, V109, P383, DOI 10.1182/blood-2006-05-025072; RENZ H, 1993, J IMMUNOL, V151, P7206; Rodriguez-Manzanet R, 2008, J IMMUNOL, V180, P4706, DOI 10.4049/jimmunol.180.7.4706; Savinko T, 2005, J IMMUNOL, V175, P8320, DOI 10.4049/jimmunol.175.12.8320; Scott-Taylor TH, 2005, CLIN EXP ALLERGY, V35, P1473, DOI 10.1111/j.1365-2222.2005.02355.x; Seiberling KA, 2005, LARYNGOSCOPE, V115, P1580, DOI 10.1097/01.mlg.0000168111.11802.9c; Shupp JW, 2002, INFECT IMMUN, V70, P2178, DOI 10.1128/IAI.70.4.2178-2186.2002; SNIDER DP, 1994, J IMMUNOL, V153, P647; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; Strange P, 1996, ARCH DERMATOL, V132, P27, DOI 10.1001/archderm.132.1.27; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Strid Jessica, 2005, Current Drug Targets - Inflammation and Allergy, V4, P531, DOI 10.2174/156801005774322199; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Tsuji NM, 2001, IMMUNOLOGY, V103, P458, DOI 10.1046/j.1365-2567.2001.01265.x; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; van Wijk F, 2007, CLIN EXP ALLERGY, V37, P572, DOI 10.1111/j.1365-2222.2007.02681.x; van Wijk F, 2005, J IMMUNOL, V174, P174, DOI 10.4049/jimmunol.174.1.174; van Wijk F, 2004, CLIN EXP ALLERGY, V34, P1422, DOI 10.1111/j.1365-2222.2004.02062.x; Yang PC, 2007, GASTROENTEROLOGY, V133, P1522, DOI 10.1053/j.gastro.2007.08.006	60	117	122	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					231	238		10.1016/j.jaci.2008.10.011	http://dx.doi.org/10.1016/j.jaci.2008.10.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19022495	Green Accepted			2022-12-18	WOS:000262793900037
J	Kormann, MSD; Depner, M; Harti, D; Klopp, N; Illig, T; Adamski, J; Vogelberg, C; Weiland, SK; von Mutius, E; Kabesch, M				Kormann, Michael S. D.; Depner, Martin; Harti, Dominik; Klopp, Norman; Illig, Thomas; Adamski, Jerzy; Vogelberg, Christian; Weiland, Stephan K.; von Mutius, Erika; Kabesch, Michael			Toll-like receptor heterodimer variants protect from childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopic asthma; toll-like receptor; heterodimer; polymorphism	HAY-FEVER; CHILDREN; CELLS; ATOPY; POLYMORPHISMS; POPULATION; PREVALENCE; MECHANISMS; EXPRESSION; HAPLOTYPES	Background: Early exposure to microbes reduces the risk for asthma. Toll-like receptors (TLRs) represent a major group of receptors for the specific recognition of pathogen-associated molecular patterns of microbes capable of activating innate and adaptive immunity. Objective: Because TLRs can influence key events in the induction and perpetuation of asthma and atopy, we sought to determine whether genetic alterations in TLR genes affect asthma risk. Methods: We systematically evaluated putatively functional genetic variants in all 10 human TLR genes for their association with different asthma phenotypes in a case-control study (n = 1872) by using matrix-assisted laser desorption/ionization time-of-flight genotyping. For polymorphisms showing association with atopic asthma, effects on gene and protein expression were studied by means of RT-PCR and flow cytometry ex vivo. T-cell cytokine production was evaluated by means of ELISA after stimulation of the respective TLRs with specific ligands. Results: Protective effects on atopic asthma were identified for single nucleotide polymorphisms in TLR1 (odds ratio [OR], 0.54; 95% CI, 0.37-0.81; P =.002), TLR6 (OR, 0.54; 95% CI, 0.37-0.79; P =.003), and TLR10 (OR, 0.58; 95% CI, 0.39-0.86; P =.006), all capable of forming heterodimers with TLR2. Effects remained significant after correction for multiple comparisons. PBMCs of minor allele carriers showed increased levels of the respective TLR mRNA and proteins, augmented inflammatory responses, increased T(H)1 cytokine expression, and reduced T(H)2-associated IL-4 production after specific stimulation. Conclusion: These results suggest that functional relevant TLR1 and TLR6 variants are directly involved in asthma development.	[Kormann, Michael S. D.; Depner, Martin; Harti, Dominik; Klopp, Norman; Illig, Thomas; von Mutius, Erika; Kabesch, Michael] Univ Munich, Univ Childrens Hosp, D-80337 Munich, Germany; [Weiland, Stephan K.] Univ Ulm, Inst Epidemiol, D-89069 Ulm, Germany; [Vogelberg, Christian] Univ Childrens Hosp, Dresden, Germany; [Adamski, Jerzy] GSF Natl Res Ctr Environm & Hlth, Inst Expt Genet, Neuherberg, Germany; [Klopp, Norman; Illig, Thomas] GSF Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Ulm University; Technische Universitat Dresden; University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Kabesch, M (corresponding author), Univ Munich, Univ Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Michael.Kabesch@med.uni-muenchen.de	Kormann, Michael SD/C-7723-2014; Kabesch, Michael/AAB-5701-2020; Kabesch, Michael/GZM-1583-2022	von Mutius, Erika/0000-0002-8893-4515; Adamski, Jerzy/0000-0001-9259-0199				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bourke E, 2003, BLOOD, V102, P956, DOI 10.1182/blood-2002-11-3355; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cohn L, 1998, J IMMUNOL, V161, P3813; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Hasan U, 2005, J IMMUNOL, V174, P2942, DOI 10.4049/jimmunol.174.5.2942; HOMUNG V, 2002, J IMMUNOL, V168, P4531; Ishii KJ, 2005, J CLIN IMMUNOL, V25, P511, DOI 10.1007/s10875-005-7829-1; Kormann MSD, 2005, AM J RESP CRIT CARE, V171, P1358, DOI 10.1164/rccm.200410-1312OC; Lazarus R, 2004, AM J RESP CRIT CARE, V170, P594, DOI 10.1164/rccm.200404-491OC; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rccm.200207-634OC; Renner ED, 2005, J CLIN IMMUNOL, V25, P321, DOI 10.1007/s10875-005-4183-2; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Vaidya SA, 2003, CURR OPIN IMMUNOL, V15, P402, DOI 10.1016/S0952-7915(03)00070-0; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Yuan HY, 2006, NUCLEIC ACIDS RES, V34, pW635, DOI 10.1093/nar/gkl236; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986; INNATE IMMUNITY PGA	29	117	124	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					86	92		10.1016/j.jaci.2008.04.039	http://dx.doi.org/10.1016/j.jaci.2008.04.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18547625	Bronze			2022-12-18	WOS:000257605100014
J	Quint, JK; Wedzicha, JA				Quint, Jennifer Kathleen; Wedzicha, Jadwiga Anna			The neutrophil in chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						neutrophil; COPD; exacerhation	NECROSIS-FACTOR-ALPHA; PERIPHERAL-BLOOD NEUTROPHILS; AIRWAY BACTERIAL LOAD; ACUTE EXACERBATIONS; COPD EXACERBATIONS; INDUCED SPUTUM; LUNG-FUNCTION; SYSTEMIC INFLAMMATION; RESPIRATORY VIRUSES; ADHESION MOLECULES	Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous collection of conditions characterized by irreversible expiratory airflow limitation. The disease involves a multifaceted progressive inflammatory process leading to the development of mucus hypersecretion, tissue destruction, and disruption to the normal repair and defense mechanisms. The result is increased resistance to airflow in small conducting airways, change in lung compliance, and the premature collapse of airways during expiration that leads to air trapping. Neutrophils are necessary in healthy lungs; they are an important component of innate immunity, protecting healthy individuals against infection. However, in COPD, they play a role in the destructive processes that characterize the disease. They can be responsible for significant damage when they accumulate at sites of inflammation and are harmful to healthy tissue. In recent years, increased understanding of the role of neutrophils has led to improved knowledge of the pathogenesis of COPD and allowed new avenues of treatment to be investigated.	UCL, Royal Free & Univ Coll Med Sch, Acad Unit Resp Med, London NW3 2PF, England	University of London; University College London	Wedzicha, JA (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Acad Unit Resp Med, Rowland Hill St, London NW3 2PF, England.	j.a.wedzicha@medsch.ucl.ac.uk	quint, jennifer/ABE-3384-2020	Quint, Jennifer/0000-0003-0149-4869				Baraldo S, 2004, THORAX, V59, P308, DOI 10.1136/thx.2003.012146; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; BATTAGLIA S, 2006, J CLIN PATHOL   0817; Berger P, 2003, RADIOLOGY, V228, P85, DOI 10.1148/radiol.2281020187; Bhowmik A, 2000, THORAX, V55, P114, DOI 10.1136/thorax.55.2.114; BOSKEN CH, 1992, AM REV RESPIR DIS, V145, P911, DOI 10.1164/ajrccm/145.4_Pt_1.911; Chung K.F., 2001, EUR RESPIR J, V34, P50, DOI DOI 10.1183/09031936.01.00229701; Di Stefano A, 1998, AM J RESP CRIT CARE, V158, P1277, DOI 10.1164/ajrccm.158.4.9802078; Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002; Di Stefano A, 2001, CLIN EXP ALLERGY, V31, P893, DOI 10.1046/j.1365-2222.2001.01098.x; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DISTEFANO A, 1994, AM J RESP CRIT CARE, V149, P803, DOI 10.1164/ajrccm.149.3.7509705; Donaldson GC, 2006, THORAX, V61, P164, DOI 10.1136/thx.2005.041806; Donaldson GC, 2005, CHEST, V128, P1995, DOI 10.1378/chest.128.4.1995; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Drost EM, 2005, THORAX, V60, P293, DOI 10.1136/thx.2004.027946; Fujimoto K, 2005, EUR RESPIR J, V25, P640, DOI 10.1183/09031936.05.00047504; Global Initiative for Chronic Obstructive Lung Disease, 2006, GLOB STRAT DIAGN MAN; Gompertz S, 2001, EUR RESPIR J, V17, P1112, DOI 10.1183/09031936.01.99114901; Gustafsson A, 2000, INT J CLIN LAB RES, V30, P187, DOI 10.1007/s005990070005; Hacievliyagil SS, 2006, RESP MED, V100, P846, DOI 10.1016/j.rmed.2005.08.022; Haslett C, 1999, AM J RESP CRIT CARE, V160, pS5, DOI 10.1164/ajrccm.160.supplement_1.4; Hill AT, 2000, AM J MED, V109, P288, DOI 10.1016/S0002-9343(00)00507-6; HOGG JC, 1995, THORAX, V50, P819, DOI 10.1136/thx.50.8.819; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; HUBBARD RC, 1991, J CLIN INVEST, V88, P891, DOI 10.1172/JCI115391; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Hurst JR, 2006, AM J RESP CRIT CARE, V173, P71, DOI 10.1164/rccm.200505-704OC; Hurst JR, 2005, EUR RESPIR J, V26, P846, DOI 10.1183/09031936.05.00043405; Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Koenderman L, 2000, J LEUKOCYTE BIOL, V68, P58; Nadel JA, 2000, CHEST, V117, p386S, DOI 10.1378/chest.117.5_suppl_2.386S; Noguera A, 1998, AM J RESP CRIT CARE, V158, P1664, DOI 10.1164/ajrccm.158.5.9712092; Noguera A, 2001, THORAX, V56, P432, DOI 10.1136/thorax.56.6.432; O'Donnell RA, 2004, THORAX, V59, P837, DOI 10.1136/thx.2003.019349; Pabst R, 2002, J ALLERGY CLIN IMMUN, V110, P209, DOI 10.1067/mai.2002.126836; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Patel IS, 2002, THORAX, V57, P759, DOI 10.1136/thorax.57.9.759; Pesci A, 1998, RESP MED, V92, P863, DOI 10.1016/S0954-6111(98)90389-4; Pletz MWR, 2004, EUR RESPIR J, V23, P532, DOI 10.1183/09031936.04.00089004; Rahman I, 1997, THORAX, V52, P565, DOI 10.1136/thx.52.6.565; Rohde G, 2003, THORAX, V58, P37, DOI 10.1136/thorax.58.1.37; Rytila P, 2006, EUR RESPIR J, V28, P1163, DOI 10.1183/09031936.00149005; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646, DOI 10.1164/ajrccm.150.6.7952628; Sapey E, 2006, THORAX, V61, P250, DOI 10.1136/thx.2005.041822; Schmidt-Ioanas M, 2006, RESP MED, V100, P639, DOI 10.1016/j.rmed.2005.08.011; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; Seemungal TAR, 2000, EUR RESPIR J, V16, P677, DOI 10.1034/j.1399-3003.2000.16d19.x; Sethi S, 2006, AM J RESP CRIT CARE, V173, P991, DOI 10.1164/rccm.200509-1525OC; Sethi S, 2000, CHEST, V118, P1557, DOI 10.1378/chest.118.6.1557; Soler N, 1999, EUR RESPIR J, V14, P1015, DOI 10.1183/09031936.99.14510159; Spencer S, 2003, THORAX, V58, P589, DOI 10.1136/thorax.58.7.589; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; Takeyama K, 2000, J IMMUNOL, V164, P1546, DOI 10.4049/jimmunol.164.3.1546; Tanino M, 2002, THORAX, V57, P405, DOI 10.1136/thorax.57.5.405; Tetley TD, 2002, CHEST, V121, p156S, DOI 10.1378/chest.121.5_suppl.156S; Traves SL, 2002, THORAX, V57, P590, DOI 10.1136/thorax.57.7.590; TUMKAYA M, 2006, RESP MED        0923; Vernooy JH, 2002, AM J RESP CRIT CARE, V166, P1218, DOI 10.1164/rccm.2202023; Wilkinson TMA, 2003, AM J RESP CRIT CARE, V167, P1090, DOI 10.1164/rccm.200210-1179OC; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200; Woolhouse IS, 2005, EUR RESPIR J, V25, P612, DOI 10.1183/09031936.05.00086304; Zhu J, 2001, AM J RESP CRIT CARE, V164, P109, DOI 10.1164/ajrccm.164.1.2007050	64	117	125	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1065	1071		10.1016/j.jaci.2006.12.640	http://dx.doi.org/10.1016/j.jaci.2006.12.640			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17270263				2022-12-18	WOS:000246427200003
J	Hunninghake, GM; Soto-Quiros, ME; Avila, L; Ly, NP; Liang, C; Sylvia, JS; Klanderman, BJ; Silverman, EK; Celedon, JC				Hunninghake, Gary M.; Soto-Quiros, Manuel E.; Avila, Lydiana; Ly, Ngoc P.; Liang, Catherine; Sylvia, Jody S.; Klanderman, Barbara J.; Silverman, Edwin K.; Celedon, Juan C.			Sensitization to Ascaris lumbricoides and severity of childhood asthma in Costa Rica	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ascaris; helminth; atopy; exacerbation; severity; asthma; Costa Rica	IMMUNOGLOBULIN-E; GEOHELMINTH INFECTIONS; ALLERGIC SENSITIZATION; ANTHELMINTIC TREATMENT; IGE ANTIBODIES; RURAL AREA; CHILDREN; ATOPY; REACTIVITY; PARASITES	Background: Little is known about sensitization (defined as a positive IgE) to helminths and disease severity in patients with asthma. Objectives: To examine the relationship between sensitization (defined as a positive IgE) to Ascaris lumbricoides and measures of asthma morbidity and severity in a Costa Rican population with low prevalence of parasitic infection but high prevalence of parasitic exposure. Methods: Cross-sectional study of 439 children (ages 6 to 14 years) with asthma. Linear regression and logistic regression were used for the multivariate statistical analysis. Results: After adjustment for parental education and other covariates, sensitization to Ascaris lumbricoides was associated with having at least 1 positive skin test to allergens (odds ratio, 5.15; 95% CI, 2.36-11.21; P < .001), increased total serum IgE and eosinophils in peripheral blood, reductions in FEV1 and FEV1/forced vital capacity, increased airway responsiveness and bronchodilator responsiveness, and hospitalizations for asthma in the previous year (odds ratio, 3.08; 95% Cl, 1.23-7.68; P = .02). Conclusion: Sensitization to Ascaris lumbricoides is associated with increased severity and morbidity of asthma among children in Costa Rica. This association is likely mediated by an increased degree of atopy among children with asthma who are sensitized to Asearis. Clinical implications: In areas with a low prevalence of helminthiasis such as Costa Rica, Ascaris sensitization may be an important marker of severe atopy and disease morbidity in children with asthma.	Channing Labs, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Hosp Nacl Ninos Dr Carlos Saenz Herrera, Div Pediat Pulmonol, San Jose, Costa Rica; Massachusetts Gen Hosp, Pediat Pulm Div, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Celedon, JC (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu	Avila, Lydiana/D-5638-2015	Avila, Lydiana/0000-0002-9579-1591	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL066289, R01HL066289, F32HL083634, K01HL004370] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL083634, F32 HL083634-01, HL04370, HL66289] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; [Anonymous], 1995, NORM AT INT SAL PRIM, P13; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bernardini R, 2005, INT J IMMUNOPATH PH, V18, P671, DOI 10.1177/039463200501800408; BLUMENTHAL MN, 1995, CLIN EXP ALLERGY, V25, P29, DOI 10.1111/j.1365-2222.1995.tb00416.x; Camara AA, 2004, J ALLERGY CLIN IMMUN, V113, P551, DOI 10.1016/j.jaci.2003.11.027; Carroll WD, 2006, ARCH DIS CHILD, V91, P405, DOI 10.1136/adc.2005.088278; CHAN MS, 1994, PARASITOLOGY, V109, P373, DOI 10.1017/S0031182000078410; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; COOPER E, 1999, TROPICAL INFECT DIS; Cooper PJ, 2004, PARASITE IMMUNOL, V26, P455, DOI 10.1111/j.0141-9838.2004.00728.x; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; Cooper PJ, 2004, J INFECT DIS, V190, P1338, DOI 10.1086/423944; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 2004, CLIN REV ALLERG IMMU, V26, P5, DOI 10.1385/CRIAI:26:1:5; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Dold S, 1998, J ALLERGY CLIN IMMUN, V102, P414, DOI 10.1016/S0091-6749(98)70129-0; Escamilla MA, 1996, AM J MED GENET, V67, P244, DOI 10.1002/(SICI)1096-8628(19960531)67:3<244::AID-AJMG2>3.3.CO;2-8; Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x; GYORKOS TW, 1989, AM J EPIDEMIOL, V130, P976, DOI 10.1093/oxfordjournals.aje.a115430; Karadag B, 2006, ALLERGY, V61, P996, DOI 10.1111/j.1398-9995.2006.01107.x; Khuroo MS, 1996, GASTROENTEROL CLIN N, V25, P553, DOI 10.1016/S0889-8553(05)70263-6; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217, DOI 10.1016/S0091-6749(98)70386-0; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50, DOI 10.1164/ajrccm.156.1.9606081; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; *MIN SAL, 1997, ENC NAC NUTR 1996; MORALES MT, 1997, ACTA PEDIATR COSTARR, V11, P106; MORRIS AJ, 1992, J CLIN MICROBIOL, V30, P3213, DOI 10.1128/JCM.30.12.3213-3216.1992; Obihara CC, 2006, CLIN EXP ALLERGY, V36, P640, DOI 10.1111/j.1365-2222.2006.02479.x; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Ponsonby AL, 2002, CHEST, V121, P135, DOI 10.1378/chest.121.1.135; Ramsay CE, 1999, HUM GENET, V104, P269, DOI 10.1007/s004390050947; REVOLTELLA R, 1980, INT ARCH ALLER A IMM, V62, P23, DOI 10.1159/000232480; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Siroux V, 2003, CLIN EXP ALLERGY, V33, P746, DOI 10.1046/j.1365-2222.2003.01674.x; Soto-Quiros ME, 1998, ALLERGY, V53, P499, DOI 10.1111/j.1398-9995.1998.tb04087.x; TURNER KJ, 1980, AUST J EXP BIOL MED, V58, P249, DOI 10.1038/icb.1980.25; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303	41	117	121	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					654	661		10.1016/j.jaci.2006.12.609	http://dx.doi.org/10.1016/j.jaci.2006.12.609			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336615				2022-12-18	WOS:000244925000019
J	McLachlan, CR; Poulton, R; Car, G; Cowan, J; Filsell, S; Greene, JM; Taylor, DR; Welch, D; Williamson, A; Sears, MR; Hancox, RJ				McLachlan, Christene R.; Poulton, Richie; Car, George; Cowan, Jan; Filsell, Susan; Greene, Justina M.; Taylor, D. Robin; Welch, David; Williamson, Avis; Sears, Malcolm R.; Hancox, Robert J.			Adiposity, asthma, and airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; obesity; exhaled nitric oxide; body mass index; airway inflammation	BODY-MASS INDEX; EXHALED NITRIC-OXIDE; OBESITY; ATOPY; FAT; SEX; ASSOCIATION; WEIGHT; HEALTH; RISK	Background: Several studies have found obesity to be associated with an increased prevalence of asthma. For reasons that remain unclear, this association has often been reported to be stronger in women than in men. One possible explanation might be that these studies have used body mass index to identify adiposity, which might be a less reliable measure of body fat in men than in women. Objective: We sought to explore the association between body fat percentage measured by means of bioelectrical impedance analysis and asthma, airflow obstruction, and airway inflammation in men and women. Methods: Respiratory questionnaires, spirometry, bronchodilator response, exhaled nitric oxide level, and percentage of body fat were measured in a population-based cohort of approximately 1000 individuals at age 32 years. Results: There was a significant association between the percentage of body fat and asthma in women (P = .043) but not in men (P = .75). Airflow obstruction was associated with percentage of body fat in women (P = .046), but there was an inverse association in men (P = .010). Bronchodilator responsiveness was also associated with lower body fat in men (P = .004). Airway inflammation, measured by means of exhaled nitric oxide, was not associated with body fat in either women (P = .17) or men (P = .25). Conclusion: Adiposity is associated with asthma and airflow obstruction in women. This does not appear to be mediated by airway inflammation. In men airflow obstruction and bronchodilator responsiveness are associated with a lower percentage of body fat. Clinical implications: In women, but not in men, obesity is associated with asthma and airflow obstruction, but there was no association with airway inflammation.	Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin Multidisciplinary Hlth & Dev Res Unit, Dunedin, New Zealand; Charles Sturt Univ, Dept Biomed Sci, Wagga Wagga, NSW, Australia; Univ Otago, Dunedin Sch Med, Dept Resp Med, Dunedin, New Zealand; McMaster Univ, Dept Med, Firestone Inst Resp Hlth, Hamilton, ON L8S 4L8, Canada	University of Otago; Charles Sturt University; University of Otago; McMaster University	Hancox, RJ (corresponding author), Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin Multidisciplinary Hlth & Dev Res Unit, POB 913, Dunedin, New Zealand.	bob.hancox@otago.ac.nz	Hancox, Robert/G-4746-2011					[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1999, Am J Respir Crit Care Med, V160, P2104; Beckett WS, 2001, AM J RESP CRIT CARE, V164, P2045, DOI 10.1164/ajrccm.164.11.2004235; Celedon JC, 2001, AM J RESP CRIT CARE, V164, P1835, DOI 10.1164/ajrccm.164.10.2105033; Chen Y, 2005, CHEST, V128, P3048, DOI 10.1378/chest.128.4.3048; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; de Winter-de Groot KM, 2005, J ALLERGY CLIN IMMUN, V115, P419, DOI 10.1016/j.jaci.2004.11.025; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Gallagher D, 1996, AM J EPIDEMIOL, V143, P228, DOI 10.1093/oxfordjournals.aje.a008733; Gallagher D, 2000, AM J CLIN NUTR, V72, P694, DOI 10.1093/ajcn/72.3.694; Guerra S, 2002, CHEST, V122, P1256, DOI 10.1378/chest.122.4.1256; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323, DOI 10.1046/j.1365-2222.1999.00455.x; Jarvis D, 2002, CLIN EXP ALLERGY, V32, P831, DOI 10.1046/j.1365-2222.2002.01380.x; Kazaks A, 2005, J ALLERGY CLIN IMMUN, V116, P929, DOI 10.1016/j.jaci.2005.06.005; Leung TF, 2004, PEDIAT ALLERG IMM-UK, V15, P344, DOI 10.1111/j.1399-3038.2004.00164.x; Luder E, 2004, RESP MED, V98, P29, DOI 10.1016/j.rmed.2003.08.004; NEGRI E, 1988, J EPIDEMIOL COMMUN H, V42, P24, DOI 10.1136/jech.42.1.24; Roubenoff R, 1996, AM J CLIN NUTR, V64, P459; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Silva P., 1996, CHILD ADULT DUNEDIN; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sun SS, 2003, AM J CLIN NUTR, V77, P331, DOI 10.1093/ajcn/77.2.331; Sung RYT, 2001, ARCH DIS CHILD, V85, P263, DOI 10.1136/adc.85.3.263; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Wattanapenpaiboon N, 1998, INT J OBESITY, V22, P854, DOI 10.1038/sj.ijo.0800672; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; *WHO, GLOB STRAG DIET PHYS	31	117	123	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					634	639		10.1016/j.jaci.2006.10.029	http://dx.doi.org/10.1016/j.jaci.2006.10.029			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17141852	Bronze			2022-12-18	WOS:000244925000016
J	Pichavant, M; Charbonnier, AS; Taront, S; Brichet, AB; Wallaert, B; Pestel, J; Tonnel, AB; Gosset, P				Pichavant, M; Charbonnier, AS; Taront, S; Brichet, AB; Wallaert, B; Pestel, J; Tonnel, AB; Gosset, P			Asthmatic bronchial epithelium activated by the proteolytic allergen Der p 1 increases selective dendritic cell recruitment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epithelial cells; dendritic cells; chemokines; allergy; lung	INFLAMMATORY PROTEIN 3-ALPHA; BRONCHOALVEOLAR LAVAGE FLUID; NECROSIS-FACTOR-ALPHA; ATOPIC ASTHMA; PROINFLAMMATORY CYTOKINES; INTESTINAL EPITHELIUM; RESPIRATORY-TRACT; AIRWAY EPITHELIUM; ANATOMIC SITES; UP-REGULATION	Background: Airway dendritic cells (DCs) are crucial for allergen-induced sensitization and inflammation in allergic asthma. After allergen challenge, an increased number of DCs is observed in airway epithelium from patients with allergy. Objective: Because Der p 1, a cysteine protease allergen from Dermatophagoides pteronyssinus, induces chemokine production by bronchial epithelial cells (BECs), the purpose of this investigation was to evaluate the capacity of BEC exposed to Der p 1 to recruit DCs. Methods: Chemotactic activity of BEAS-2B, a bronchial epithelial cell line, and BECs from nonatopic controls and patients with allergic asthma was evaluated on the migration of precursors, immature and mature monocyte-derived DCs (MDDCs), and CD34(+)-derived Langerhans cells (LCs). Results: C-C chemokine ligand (CCL)-2, CCL5, and C-X-C chemokine ligand 10 production by BEAS-2B and BEC was increased after Der p 1 exposure, whereas the proenzyme proDer p 1 devoid of enzymatic activity had no effect. Der p I stimulation of BEAS-2B and BEC from both groups increased significantly the recruitment of MDDC precursors, depending on CCL2, CCL5, and C-X-C chemokine ligand 10 production. In a reconstituted polarized epithelium, apical application of Der p I enhanced MDDC precursor migration into the epithelial layer. Moreover, Der p 1 stimulation of BEC from patients with asthma but not from controls increased the migration of LC precursors, mainly dependent on CCL20 secretion. No migration of immature and mature DCs was observed. Conclusion: These data confirmed that BECs participate in the homeostasis of the DC network present within the bronchial epithelium through the secretion of chemokines. In allergic asthma, upregulation of CCL20 production induced LC recruitment, the role of which remains to be determined.	Inst Pasteur, INSERM, U416, IFR 17, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Gosset, P (corresponding author), Inst Pasteur, INSERM, U416, IFR 17, 1 Rue Prof Calmette,BP 245, F-59019 Lille, France.	Philippe.Gosset@pasteur-lille.fr	Gosset, Philippe/C-6174-2018; Pichavant, Muriel/B-9036-2018; DEZITTER, Solenne/N-5219-2018	Gosset, Philippe/0000-0002-4043-6429; Pichavant, Muriel/0000-0002-1315-4397; DEZITTER, Solenne/0000-0001-5850-7291				Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; BELLINI A, 1993, CHEST, V103, P997, DOI 10.1378/chest.103.4.997; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Caux C, 2000, SPRINGER SEMIN IMMUN, V22, P345, DOI 10.1007/s002810000053; Caux C, 1997, BLOOD, V90, P1458, DOI 10.1182/blood.V90.4.1458.1458_1458_1470; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; Gosset P, 1999, J ALLERGY CLIN IMMUN, V103, P289, DOI 10.1016/S0091-6749(99)70504-X; Grassi F, 1998, J LEUKOCYTE BIOL, V64, P484, DOI 10.1002/jlb.64.4.484; Hammad H, 2002, J IMMUNOL, V169, P1524, DOI 10.4049/jimmunol.169.3.1524; Hammad H, 2000, LAB INVEST, V80, P605, DOI 10.1038/labinvest.3780065; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113, DOI 10.1164/ajrccm.162.supplement_2.ras-12; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P255, DOI 10.1111/j.1365-2222.1989.tb02380.x; Holt PG, 2000, J AEROSOL MED, V13, P361, DOI 10.1089/jam.2000.13.361; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Izadpanah A, 2001, AM J PHYSIOL-GASTR L, V280, pG710, DOI 10.1152/ajpgi.2001.280.4.G710; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; King C, 1998, J IMMUNOL, V161, P3645; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Lukacs NW, 2001, J EXP MED, V194, P551, DOI 10.1084/jem.194.4.551; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; Novak N, 2004, ALLERGY, V59, P5, DOI 10.1046/j.1398-9995.2003.00337.x; Pichavant M, 2003, J IMMUNOL, V171, P6697, DOI 10.4049/jimmunol.171.12.6697; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-0095OC; Rozyk KJ, 1997, IMMUNOL LETT, V58, P47; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Stumbles PA, 2001, J IMMUNOL, V167, P228, DOI 10.4049/jimmunol.167.1.228; Tanaka Y, 1999, EUR J IMMUNOL, V29, P633, DOI 10.1002/(SICI)1521-4141(199902)29:02<633::AID-IMMU633>3.0.CO;2-I; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; Vanbervliet A, 2002, EUR J IMMUNOL, V32, P231, DOI 10.1002/1521-4141(200201)32:1<231::AID-IMMU231>3.0.CO;2-8; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844	42	117	119	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					771	778		10.1016/j.jaci.2004.11.043	http://dx.doi.org/10.1016/j.jaci.2004.11.043			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805997	Bronze			2022-12-18	WOS:000228373400016
J	Muller, UR; Haeberli, G				Muller, UR; Haeberli, G			Use of beta-blockers during immunotherapy for Hymenoptera venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; beta-blockers; hymenoptera venom immunotherapy	FATAL ANAPHYLACTIC REACTIONS; ADRENERGIC-BLOCKADE; HEART-FAILURE; RISK; HISTAMINE; EFFICACY; THERAPY; SAFETY; DRUGS	Background: B-Blockers may aggravate anaphylactic reactions and interfere with treatment. There is therefore concern about their use in patients who have a history of anaphylaxis or are on allergen immunotherapy. Immunotherapy is the best available treatment for prevention of life-threatening anaphylaxis to Hymenoptera stings, which is often observed in elderly patients who have cardiovascular disease and therefore are on beta-blocker treatment. Objective: To analyze the risk of beta-blocker treatment during venom immunotherapy. Methods: We screened all 1682 patients with Hymenoptera venom allergy seen during a period of 34 months for immunotherapy, cardiovascular disease, and treatment with beta-blockers. Results: Of the 1389 patients in whom immunotherapy was recommended, 11.2% had cardiovascular disease, and 44 of these were on beta-blockers before immunotherapy. In 31 of those, the drug was replaced before starting treatment. In 3 with coronary heart disease and I with severe ventricular arrhythmia, the drug was continued throughout immunotherapy. In 9, it was reintroduced after reaching the maintenance dose. In an additional 12 patients, beta-blockers were newly started during immunotherapy. Of 25 patients on beta-blockers during immunotherapy, 3 (12%) developed allergic side effects, compared with 23 (16.7%) of 117 with cardiovascular disease but without beta-blockers. Systemic allergic symptoms after re-exposure by sting challenge or field sting were observed in 1 of 7 (14.3%) with and 4 of 29 (13.8%) without beta-blockade. No severe reactions to treatment or sting reexposure were observed in patients with beta-blockade. Conclusion: Combination of beta-blockers with venom immunotherapy may be indicated in heavily exposed patients with severe cardiovascular disease.	Spital Bern Ziegler, Dept Med, CH-3007 Bern, Switzerland		Muller, UR (corresponding author), Spital Bern Ziegler, Dept Med, Morillonstr 75-91, CH-3007 Bern, Switzerland.	ulrich.mueller@spitalbern.ch						ASSEM ESK, 1971, BRIT J PHARMACOL, V42, P620, DOI 10.1111/j.1476-5381.1971.tb07146.x; AWAI LE, 1984, ANN ALLERGY, V53, P48; BERKELMAN RL, 1986, ANN INTERN MED, V104, P134, DOI 10.7326/0003-4819-104-1-134_1; Foody JM, 2002, JAMA-J AM MED ASSOC, V287, P883, DOI 10.1001/jama.287.7.883; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; Haeberli G, 2003, CLIN EXP ALLERGY, V33, P1216, DOI 10.1046/j.1365-2222.2003.01755.x; HANNAWAY PJ, 1983, NEW ENGL J MED, V308, P1536; Helbling A, 2004, CLIN EXP ALLERGY, V34, P285, DOI 10.1111/j.1365-2222.2004.01882.x; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; INGALL M, 1984, JAMA-J AM MED ASSOC, V251, P1432, DOI 10.1001/jama.1984.03340350026019; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KAPLAN AP, 1989, J ALLERGY CLIN IMMUN, V84, P129, DOI 10.1016/0091-6749(89)90186-3; LANG DM, 1995, DRUG SAFETY, V12, P299, DOI 10.2165/00002018-199512050-00002; LAXENAIRE M C, 1984, Annales Francaises d'Anesthesie et de Reanimation, V3, P453, DOI 10.1016/S0750-7658(84)80146-X; Locke M, 1998, J INSECT PHYSIOL, V44, P1, DOI 10.1016/S0022-1910(97)00088-7; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; MALLING HJ, 1993, ALLERGY, V48, P9; MATSUMURA Y, 1976, J ALLERGY CLIN IMMUN, V58, P387, DOI 10.1016/0091-6749(76)90119-6; Mosbech H, 2000, ALLERGY, V55, P1005, DOI 10.1034/j.1398-9995.2000.00587.x; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1993, ALLERGY, V48, P37; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller UR, 2003, ALLERGY S74, V58, P99; Muller UR., 1990, INSECT STING ALLERGY; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; PARRISH HM, 1963, AM J MED SCI, V245, P129; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1111/j.1365-2222.1996.tb00537.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SASVARY T, 1994, SCHWEIZ MED WSCHR, V124, P1887; *SCHW BUND STAT, 1998, SEKT GES TOD SCHWEIZ; Skrbic D, 1996, ALLERGOLOGIE, V19, P123; TenBrook JA, 2004, J ALLERGY CLIN IMMUN, V113, P977, DOI 10.1016/j.jaci.2004.02.043; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TOOGOOD JH, 1987, CAN MED ASSOC J, V136, P929	37	117	118	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					606	610		10.1016/j.jsci.2004.11.012	http://dx.doi.org/10.1016/j.jsci.2004.11.012			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753911				2022-12-18	WOS:000227687000026
J	Bender, B; Milgrom, H; Apter, A				Bender, B; Milgrom, H; Apter, A			Adherence intervention research: What have we learned and what do we do next?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adherence; intervention; asthma	ASTHMA SELF-MANAGEMENT; PEAK EXPIRATORY FLOW; INNER-CITY CHILDREN; RANDOMIZED-TRIAL; MEDICATION ADHERENCE; TREATMENT GUIDELINES; PATIENT-EDUCATION; PROGRAM; CARE; ATTENDANCE	Although there is general agreement from studies demonstrating that adherence to inhaled corticosteroid therapy is often inadequate to establish consistent control, relatively little concurrence exists in reports of interventions to correct the problem. Half of the studies reviewed found that the experimental intervention did not change adherence, and behavior change reported by patients was often not accompanied by changes in treatment success. Studies used a variety of methods that differed in quality with findings that were often contradictory. Key limitations in many studies included reliance on inadequate adherence measures, inclusion of convenience samples of well-motivated patients, and assessments of intervention outcomes artificially boosted by attrition of least adherent participants. Research is encouraged into innovative interventions that are brief, easily implemented, and can be tailored to individual patients and diverse clinical settings. Of particular importance is inclusion of hard-to-reach patients, including urban and rural poor and the use of valid measures of adherence at intervals sufficient to establish enduring benefit.	Hosp Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Med, Natl Jewish Med & Res Ctr, Philadelphia, PA 19104 USA; Hosp Univ Penn, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; National Jewish Health; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Bender, B (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.							ALLEN RM, 1995, THORAX, V50, P731, DOI 10.1136/thx.50.7.731; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Bailey WC, 1999, ARCH INTERN MED, V159, P2422, DOI 10.1001/archinte.159.20.2422; Bartlett SJ, 2002, J ASTHMA, V39, P47, DOI 10.1081/JAS-120000806; Beasley R, 2002, J ALLERGY CLIN IMMUN, V109, pS482, DOI 10.1067/mai.2002.122716; Bender B, 2000, ANN ALLERG ASTHMA IM, V85, P416, DOI 10.1016/S1081-1206(10)62557-4; Bonner S, 2002, J ASTHMA, V39, P167, DOI 10.1081/JAS-120002198; Burkhart Patricia V, 2002, Pediatr Nurs, V28, P409; Burkhart PV, 2001, J NURS SCHOLARSHIP, V33, P27, DOI 10.1111/j.1547-5069.2001.00027.x; Carnrike CLM, 1996, J CLIN PSYCHOL MED S, V3, P57, DOI 10.1007/BF01989289; Clark NM, 2000, EUR RESPIR J, V16, P15, DOI 10.1034/j.1399-3003.2000.16a04.x; Clark NM, 1998, PEDIATRICS, V101, P831, DOI 10.1542/peds.101.5.831; Cote J, 1997, AM J RESP CRIT CARE, V155, P1509, DOI 10.1164/ajrccm.155.5.9154850; Cote J, 2001, AM J RESP CRIT CARE, V163, P1415, DOI 10.1164/ajrccm.163.6.2006069; Couturaud F, 2002, J ASTHMA, V39, P493, DOI 10.1081/JAS-120004913; CRAMER JA, 1990, ARCH INTERN MED, V150, P1509, DOI 10.1001/archinte.150.7.1509; Creer TL, 1993, PSYCHOPHYSIOLOGICAL, P151; Diamond S A, 2001, Can Respir J, V8, P261; Evans D, 1997, PEDIATRICS, V99, P157, DOI 10.1542/peds.99.2.157; FINKELSTEIN J, 2001, PATIENT CARE ASPECTS, V9, P810; Gallefoss F, 1999, AM J RESP CRIT CARE, V160, P2000, DOI 10.1164/ajrccm.160.6.9901028; GARRETT J, 1994, THORAX, V49, P976, DOI 10.1136/thx.49.10.976; George M, 2003, J ALLERGY CLIN IMMUN, V111, P967, DOI 10.1067/mai.2003.1459; Guendelman S, 2002, ARCH PEDIAT ADOL MED, V156, P114, DOI 10.1001/archpedi.156.2.114; Hardy KJ, 2001, BRIT MED J, V323, P1298, DOI 10.1136/bmj.323.7324.1298; HAYNES RB, 2002, COCHRANE DATABASE SY, P4; Julius SM, 2002, CHEST, V121, P871, DOI 10.1378/chest.121.3.871; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KOTSES H, 1995, J ALLERGY CLIN IMMUN, V95, P529, DOI 10.1016/S0091-6749(95)70315-2; Levy ML, 2000, RESP MED, V94, P900, DOI 10.1053/rmed.2000.0861; Lopez-Vina A, 2000, RESP MED, V94, P760, DOI 10.1053/rmed.2000.0815; Marosi A, 2001, J ASTHMA, V38, P681, DOI 10.1081/JAS-100107546; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; PROBSTFIELD JL, 1986, AM J MED, V80, P777, DOI 10.1016/0002-9343(86)90615-7; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Riekert KA, 1999, J PEDIATR PSYCHOL, V24, P253, DOI 10.1093/jpepsy/24.3.253; Strunk Robert C., 2002, Journal of Allergy and Clinical Immunology, V109, P229, DOI 10.1067/mai.2002.120950; TASHKIN DP, 1991, AM J MED S4A, V91, P33; Turner MO, 1998, AM J RESP CRIT CARE, V157, P540, DOI 10.1164/ajrccm.157.2.9703060; van Es SM, 2001, PATIENT EDUC COUNS, V44, P193, DOI 10.1016/S0738-3991(00)00195-6; Weinberger M, 2002, JAMA-J AM MED ASSOC, V288, P1594, DOI 10.1001/jama.288.13.1594; Wilson SR, 2001, CHEST, V120, P1709, DOI 10.1378/chest.120.5.1709; Zuckerman IH, 2000, CURR THER RES CLIN E, V61, P912, DOI 10.1016/S0011-393X(00)90018-3	45	117	122	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					489	494		10.1067/mai.2003.1680	http://dx.doi.org/10.1067/mai.2003.1680			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679805				2022-12-18	WOS:000185231200005
J	Kelly, HW				Kelly, HW			Potential adverse effects of the inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						inhaled corticosteroids; adverse effects; growth; hypothalamic-pituitary-adrenal axis; bone mineral density	BONE-MINERAL DENSITY; FLUTICASONE PROPIONATE; ASTHMA; STEROIDS; BUDESONIDE; CHILDREN; EFFICACY; THERAPY; GROWTH; SAFETY	The purpose of this review is to provide the clinician with an update on the potential adverse effects caused by the inhaled corticosteroids (ICSs). The systemic effects of ICSs are a result of that portion swallowed and absorbed through the gastrointestinal tract and not eliminated by first-pass metabolism and that portion delivered to the lung and absorbed. If administered in high enough doses, any of the ICSs will produce clinically significant systemic activity. This review will explore the risks for clinically significant adverse effects from sustained use of ICSs, as recommended by the current guidelines. The standard method for assessing systemic activity in short-term studies is measurement of hypothalamic-pituitary-adrenal axis function. The ICSs provided in the medium dose range can produce measurable effects on the hypothalamic-pituitary-adrenal axis. However, clinically significant suppression is unlikely to occur except at high doses. The effect on growth in children over 1 to 4 years occurs at low to medium doses, might be dependent on the specific ICS, and is small (1-2 cm). The data are insufficient to determine whether there is an effect on attainment of predicted adult height. The ICSs affect bone mineral density and risk of fractures in a dose-dependent fashion that appears significant at high doses.	Univ New Mexico, Childrens Hosp, Dept Pediat, Albuquerque, NM 87131 USA	University of New Mexico	Kelly, HW (corresponding author), Univ New Mexico, Childrens Hosp, Dept Pediat, ACC Bldg 3rd Floor,2211 Lomas Blvd,NE, Albuquerque, NM 87131 USA.							Abdu TAM, 1999, J CLIN ENDOCR METAB, V84, P838, DOI 10.1210/jc.84.3.838; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; Agency for Healthcare Research and Quality, 2003, AHRQ PUBL; Allen DB, 1998, J PEDIATR-US, V132, P472, DOI 10.1016/S0022-3476(98)70023-X; Asmus MJ, 2002, ANN ALLERG ASTHMA IM, V88, P204, DOI 10.1016/S1081-1206(10)61997-7; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BROIDE J, 1995, J CLIN ENDOCR METAB, V80, P1243, DOI 10.1210/jc.80.4.1243; BROWN PH, 1993, THORAX, V48, P967, DOI 10.1136/thx.48.10.967; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Dempsey OJ, 1999, CHEST, V116, P935, DOI 10.1378/chest.116.4.935; DERENDORF H, 1993, J CLIN PHARMACOL, V33, P115, DOI 10.1002/j.1552-4604.1993.tb03930.x; DeRijk RH, 2002, J STEROID BIOCHEM, V81, P103, DOI 10.1016/S0960-0760(02)00062-6; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Elmstahl S, 2003, J ALLERGY CLIN IMMUN, V111, P91, DOI 10.1067/mai.2003.4; Ferguson AC, 1999, J PEDIATR-US, V134, P422, DOI 10.1016/S0022-3476(99)70198-8; Henzen C, 2000, LANCET, V355, P542, DOI 10.1016/S0140-6736(99)06290-X; Hubbard RB, 2002, AM J RESP CRIT CARE, V166, P1563, DOI 10.1164/rccm.200206-606OC; Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P144, DOI 10.1210/jc.83.1.144; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Kelly H W, 1999, Respir Care Clin N Am, V5, P537; Kelly HW, 1998, ANN PHARMACOTHER, V32, P220, DOI 10.1345/aph.17014; KELLY HW, 2003, IN PRESS ANN ALLERGY; KELLY HW, 2002, NHLBI CLIN RES ASTHM; KOZOWER M, 1974, J CLIN ENDOCR METAB, V38, P407, DOI 10.1210/jcem-38-3-407; Krasner AS, 1999, JAMA-J AM MED ASSOC, V282, P671, DOI 10.1001/jama.282.7.671; Lane NE, 1998, ENDOCRIN METAB CLIN, V27, P465, DOI 10.1016/S0889-8529(05)70017-7; LARSEN PR, 2003, WILLIAMS TXB ENCRINO; Leach CL, 2002, CHEST, V122, P510, DOI 10.1378/chest.122.2.510; LIPWORTH BJ, 1995, THORAX, V50, P105, DOI 10.1136/thx.50.2.105; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Lipworth BJ, 1998, SEMIN RESP CRIT CARE, V19, P625, DOI 10.1055/s-2007-1009437; LUENGO M, 1991, THORAX, V46, P803, DOI 10.1136/thx.46.11.803; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Miller PD, 2003, ENDOCRIN METAB CLIN, V32, P159, DOI 10.1016/S0889-8529(02)00086-5; Nielsen LP, 2000, AM J RESP CRIT CARE, V162, P2053, DOI 10.1164/ajrccm.162.6.9912072; *NIH, 2002, J ALLERGY CLIN IMMUN, V110, pS142; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; Panarelli M, 1998, J CLIN ENDOCR METAB, V83, P1846, DOI 10.1210/jc.83.6.1846; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; Pedersen S, 2001, AM J RESP CRIT CARE, V164, P521, DOI 10.1164/ajrccm.164.4.2101050; Saag KG, 2003, ENDOCRIN METAB CLIN, V32, P135, DOI 10.1016/S0889-8529(02)00064-6; Sharek PJ, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.1.e8; Sharma PK, 2003, J CLIN PHARMACOL, V43, P193, DOI 10.1177/0091270002239829; Sivri A, 2001, Respirology, V6, P131, DOI 10.1046/j.1440-1843.2001.00323.x; SPAHN JD, 1995, AM J RESP CRIT CARE, V151, P1709, DOI 10.1164/ajrccm.151.6.7767511; SZEFLER SJ, 1991, J ALLERGY CLIN IMMUN, V88, P147, DOI 10.1016/0091-6749(91)90323-G; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Todd GRG, 2002, ARCH DIS CHILD, V87, P457, DOI 10.1136/adc.87.6.457; Toogood JH, 1999, J ALLERGY CLIN IMMUN, V104, P769, DOI 10.1016/S0091-6749(99)70286-1; Toogood JH, 1998, J ALLERGY CLIN IMMUN, V102, P705, DOI 10.1016/S0091-6749(98)70007-7; Walsh LJ, 2002, AM J RESP CRIT CARE, V166, P691, DOI 10.1164/rccm.2110047; Wilson AM, 1999, LANCET, V353, P2128, DOI 10.1016/S0140-6736(99)01443-9; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3; 1998, P FDA CTR DRUG EV RE; 2003, NIH PUBLICATON	57	117	127	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					469	478		10.1067/mai.2003.1718	http://dx.doi.org/10.1067/mai.2003.1718			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679801				2022-12-18	WOS:000185231200001
J	Morafo, V; Srivastava, K; Huang, CK; Kleiner, G; Lee, SY; Sampson, HA; Li, XM				Morafo, V; Srivastava, K; Huang, CK; Kleiner, G; Lee, SY; Sampson, HA; Li, XM			Genetic susceptibility to food allergy is linked to differential T(H)2-T(H)1 responses in C3H/HeJ and BALB/c mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						marine strains; food allergy susceptibility; T(H)2-T(H)1 cytokines	MAJOR PEANUT ALLERGEN; HOUSE-DUST ENDOTOXIN; T-CELL; IFN-GAMMA; MURINE MODEL; ATOPIC-DERMATITIS; IMMUNE-RESPONSES; INTERFERON-GAMMA; ORAL TOLERANCE; IL-10	Background: Although food allergy is a serious health problem in westernized countries, factors influencing the development of food allergy are largely unknown. Appropriate marine models of food allergy would be useful in understanding the mechanisms underlying food allergy in human subjects. Objective: We sought to determine the susceptibility of different strains of mice to food hypersensitivity. Methods: C3H/HeJ and BALB/c mice were sensitized to cow's milk (CM) or peanut by means of intragastric administration, with cholera toxin as a mucosal adjuvant. Mice were then challenged with CM or peanut Antigen-specific IgE levels, anaphylactic symptoms, plasma histamine levels, and splenocyte cytokine profiles of these 2 strains were compared. Results: CM-specific IgE levels were significantly increased only in the C3HMeJ strain, 87% of which exhibited systemic anaphylactic reactions accompanied by significantly increased plasma histamine levels in response to challenge. BALB/c mice exhibited no significant CM-specific IgE response, increased plasma histamine levels, or anaphylactic symptoms. After peanut challenge, 100% of peanut-sensitized C3H/HeJ mice exhibited high levels of peanut-specific IgE and anaphylactic symptoms. In contrast, no hypersensitivity reactions were detected in BALB/c mice, despite the presence of significant serum peanut-specific IgE levels. Splenocytes from CM- and peanut-sensitized C3H/HeJ mice exhibited significantly increased IL-4 and IL-10 secretion, whereas splenocytes from BALB/c mice exhibited significantly increased IFN-gamma secretion. Conclusion: induction of food-induced hypersensitivity reactions in mice is strain dependent, with C3H/HeJ mice being susceptible and BALB/c mice being resistant. This strain-dependent susceptibility to food allergy is associated with differential T(H)2-T(H)1 responses after intragastric food allergen sensitization.	CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Morafo, V (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044236] Funding Source: NIH RePORTER; NIAID NIH HHS [P01-AI44236-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atherton KT, 2002, ANN NY ACAD SCI, V964, P163; Barnes PJ, 2001, CLIN EXP ALLERGY, V31, P667, DOI 10.1046/j.1365-2222.2001.01118.x; Bashir MEH, 2002, J IMMUNOL, V169, P3284, DOI 10.4049/jimmunol.169.6.3284; BISSONNETTE EY, 1990, J IMMUNOL, V145, P3385; Bjorksten B, 2001, CURR OPIN ALLERGY CL, V1, P225, DOI 10.1097/01.all.0000011018.32315.1d; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; Dabbagh K, 2002, J IMMUNOL, V168, P4524, DOI 10.4049/jimmunol.168.9.4524; Daser A, 1998, INT ARCH ALLERGY IMM, V117, P239, DOI 10.1159/000024017; De Jong EC, 1998, CLIN EXP ALLERGY, V28, P743, DOI 10.1046/j.1365-2222.1998.00301.x; DONON BJ, 1994, J ALLERGY CLIN IMMUN, V93, P93; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; HEINZEL FP, 1994, INFECT IMMUN, V62, P4244, DOI 10.1128/IAI.62.10.4244-4249.1994; Helm RM, 2002, ANN NY ACAD SCI, V964, P139; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; HSU DH, 1992, INT IMMUNOL, V4, P563, DOI 10.1093/intimm/4.5.563; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN; JOHANSSON SGO, 1984, ANN ALLERGY, V53, P665; Lee HO, 2000, GASTROENTEROLOGY, V119, P129, DOI 10.1053/gast.2000.8542; Lee SY, 2001, CLIN IMMUNOL, V101, P220, DOI 10.1006/clim.2001.5122; Lewkowich IP, 2002, EUR J IMMUNOL, V32, P3536, DOI 10.1002/1521-4141(200212)32:12<3536::AID-IMMU3536>3.0.CO;2-U; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 1999, J IMMUNOL, V162, P3045; Lin CC, 2000, IMMUNOL LETT, V73, P57, DOI 10.1016/S0165-2478(00)00200-5; MacDonald TT, 2000, INFLAMM BOWEL DIS, V6, P116, DOI 10.1097/00054725-200005000-00008; Maitland AL, 2001, J ALLERGY CLIN IMMUN, V107, pS140; Morafo V, 2002, J ALLERGY CLIN IMMUN, V109, pS287, DOI 10.1016/S0091-6749(02)82014-0; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOWAT AM, 1986, IMMUNOLOGY, V58, P677; Nilsen EM, 1998, GASTROENTEROLOGY, V115, P551, DOI 10.1016/S0016-5085(98)70134-9; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Ruffilli A, 1997, ALLERGY, V52, P256, DOI 10.1111/j.1398-9995.1997.tb00990.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; Sicherer SH, 2002, ANN ALLERG ASTHMA IM, V88, P350, DOI 10.1016/S1081-1206(10)62363-0; Strobel S, 2002, ANN NY ACAD SCI, V958, P47; VANNIER E, 1991, J CLIN INVEST, V87, P1936, DOI 10.1172/JCI115219; VOGEL SN, 1994, INFECT IMMUN, V62, P4454, DOI 10.1128/IAI.62.10.4454-4459.1994; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x	47	117	126	1	20	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1122	1128		10.1067/mai.2003.1463	http://dx.doi.org/10.1067/mai.2003.1463			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743580				2022-12-18	WOS:000182904500030
J	Kepley, CL; Cambier, JC; Morel, PA; Lujan, D; Ortega, E; Wilson, BS; Oliver, JM				Kepley, CL; Cambier, JC; Morel, PA; Lujan, D; Ortega, E; Wilson, BS; Oliver, JM			Negative regulation of Fc epsilon RI signaling by Fc gamma RII costimulation in human blood basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; mast cell; basophil; signal transduction; Fc receptors; allergy; Fc epsilon RI	MAST-CELL ACTIVATION; TYROSINE-PHOSPHATASE SHP-1; INHIBITORY RECEPTOR; B-CELLS; IGE; ANTIGEN; KINASE; SYK; ASSOCIATION; RECRUITMENT	Background: Signaling through the antigen receptors of human B and T cells and the high-affinity IgE receptor Fc epsilon RI of rodent mast cells is decreased by cross-linking these receptors to the low-affinity Ige receptor Fc gamma RII, The inhibition is thought to involve the tyrosine phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in the Fc gamma RIIB cytoplasmic tail, creating binding sites For SH2-containing protein (Src homology domain containing protein tyrosine phosphatase 1 and 2 [SHP-1, SHP-2]) and/or lipid (SH2 domain-containing polyphosphatidylinositol 5-phosphatase) phosphatases that oppose activating signals from the costimulated antigen receptors, Objective: In human basophils and mast cells Fc epsilon RI signaling generates mediators and cytokines responsible for allergic inflammation. We proposed to determine whether Fc epsilon RI signaling is inhibited by Fc gamma RII costimulation in human basophils and to explore the underlying mechanism as an approach to improving the treatment of allergic inflammation. Methods: Fc gamma R expression on human basophils was examined using flow cytometry and RT-PCR analysis. Fc gamma RII/Fc epsilon RI costimulation was typically accomplished by priming cells with anti-dinitrophenol (DNP) IgE and anti-DNP Ige and stimulating with DNP-BSA. Phosphatases were identified by Western blotting, and their partitioning between membrane and cytosol was determined by cell fractionation, Biotinylated synthetic peptides and phosphopeptides corresponding to the Fc gamma RIIB ITIM sequence were used for adsorption assays. Results: We report that peripheral blood basophils express Fc gamma RII (in both the ITIM-containing Fc gamma RIIB and the immunoreceptor tyrosine-based activation motif-containing Fc gamma RIIA forms) and that costimulating Fc gamma RII and Fc epsilon RI inhibits basophil Fc epsilon RI-mediated histamine release, IL-4 production, and Ca2+ mobilization, The inhibition of basophil Fc epsilon RI signaling by Fc gamma RII/Fc epsilon RI costimulation is linked to a significant decrease in Syk tyrosine phosphorylation, Human basophils express all 3 SH2-containing phosphatases. Conclusions: Evidence that Fc gamma RII/Fc epsilon RI costimulation induces SHP-1 translocation from the cytosolic to membrane fractions of basophils and that biotinylated synthetic peptides corresponding to the phosphorylated Fc gamma RIIB ITIM sequence specifically recruit SHP-1 from basophil Lysates particularly implicates this protein phosphatase in the negative regulation of Fc epsilon RI signaling by costimulated Fc gamma RII.	Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Immunol, Mexico City, DF, Mexico	University of New Mexico; University of New Mexico's Health Sciences Center; National Jewish Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Universidad Nacional Autonoma de Mexico	Kepley, CL (corresponding author), Cell Pathol Labs, CRF 203,2325 Camino Salud, Albuquerque, NM 87131 USA.		Morel, Penelope Anne/AAI-6239-2020	Morel, Penelope Anne/0000-0002-1743-3676; Cambier, John/0000-0002-7803-242X	FIC NIH HHS [R03 TW00440] Funding Source: Medline; NHLBI NIH HHS [P50 HL56384] Funding Source: Medline; NIGMS NIH HHS [R01 GM49814] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW000440] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049814] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSELMINO LM, 1989, J ALLERGY CLIN IMMUN, V84, P907, DOI 10.1016/0091-6749(89)90388-6; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; BUDDE P, 1994, J BIOL CHEM, V269, P30636; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; Capel P J, 1994, Immunomethods, V4, P25, DOI 10.1006/immu.1994.1004; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Dustin LB, 1999, J IMMUNOL, V162, P2717; Fleming TJ, 1997, J EXP MED, V186, P1307, DOI 10.1084/jem.186.8.1307; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Galfre G, 1981, Methods Enzymol, V73, P3; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; ISHIZAKA T, 1979, J IMMUNOL, V123, P578; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; KEPLEY C, 1994, J IMMUNOL METHODS, V175, P1, DOI 10.1016/0022-1759(94)90326-3; Kepley CL, 1998, J ALLERGY CLIN IMMUN, V102, P304, DOI 10.1016/S0091-6749(98)70100-9; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; LEE RJ, 1995, MOL BIOL CELL, V6, P825, DOI 10.1091/mbc.6.7.825; Lu-Kuo JM, 1999, J BIOL CHEM, V274, P5791, DOI 10.1074/jbc.274.9.5791; MACGLASHAN DW, 1995, CHEM IMMUNOL, V61, P88; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Malbec O, 1998, J IMMUNOL, V160, P1647; Metes D, 1998, BLOOD, V91, P2369, DOI 10.1182/blood.V91.7.2369.2369_2369_2380; Miura K, 1998, BLOOD, V92, P1206, DOI 10.1182/blood.V92.4.1206.416k01_1206_1218; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Perez-Villar JJ, 1999, MOL CELL BIOL, V19, P2903; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RISKE F, 1991, J BIOL CHEM, V266, P11245; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; SOTO EO, 1988, J IMMUNOL, V141, P4324; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Wang LL, 1999, J IMMUNOL, V162, P1318; Yamashita Y, 1998, J IMMUNOL, V161, P4042	51	117	123	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					337	348		10.1067/mai.2000.107931	http://dx.doi.org/10.1067/mai.2000.107931			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932079				2022-12-18	WOS:000088708100018
J	Reed, CE				Reed, CE			The natural history of asthma in adults: The problem of irreversibility	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; adults; natural history; cause of death; treatment; smoking; lung function; airway remodeling; bronchiectasis; emphysema	RESOLUTION COMPUTED-TOMOGRAPHY; OBSTRUCTIVE PULMONARY-DISEASE; TOTAL SERUM IGE; CHRONIC RESPIRATORY SYMPTOMS; GENERAL-POPULATION SAMPLE; AIR-FLOW OBSTRUCTION; SELF-REPORTED ASTHMA; OCCUPATIONAL ASTHMA; CHRONIC-BRONCHITIS; YOUNG-ADULTS	Asthma is common, affecting 5% to 10% of adults; asthma is progressive, leading to irreversible obstruction in 80% of elderly patients; and asthma is complex, often complicated by coexisting lung diseases. This loss of lung function results from 4 independent pathologic conditions: (1) airway remodeling, especially in the small airways, from the lymphocytic-eosinophilic inflammation that characterizes asthma; (2) bronchiectasis; (3) postinfectious pulmonary fibrosis; and (4) emphysema and chronic bronchitis from tobacco smoke. Deterioration in lung function develops faster in nonallergic patients with intrinsic asthma during the period shortly after onset of asthma and in older patients, About 4% of patients die of asthma, and most are elderly Death most often results from complications of irreversible obstruction or cardiotoxicity of bronchodilator therapy. More research is needed to improve therapy for preventing remodeling of small airways, to confirm the frequency of bronchiectasis and postinfectious fibrosis and to determine their causes, and to develop diagnostic criteria to identify these complications. Meanwhile, clinicians treating adult asthmatic patients need to be aggressive in preventing the damage from cigarette smoke; in immunizing for influenza and pneumococcus infection and identifying and treating respiratory infections, particularly at times of acute exacerbations; in diagnosing and managing bronchiectasis; and in objectively confirming the efficacy of asthma therapy to prevent illness from overtreatment with glucocorticoids and bronchodilators.	Mayo Clin, Allerg Dis Res Lab, Rochester, MN 55905 USA	Mayo Clinic	Reed, CE (corresponding author), Mayo Clin, Allerg Dis Res Lab, Plummer 10,200 1st St SW, Rochester, MN 55905 USA.							ALMIND M, 1992, DAN MED BULL, V39, P561; ANNESI I, 1992, CHEST, V101, P642, DOI 10.1378/chest.101.3.642; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Barbee RA, 1997, ASTHMA ELDERLY, P1; Bauer BA, 1997, CHEST, V111, P303, DOI 10.1378/chest.111.2.303; BEASLEY R, 1993, J ALLERGY CLIN IMMUN, V92, P148, DOI 10.1016/0091-6749(93)90097-Y; BECKETT WS, 1994, EUR RESPIR J, V7, P161, DOI 10.1183/09031936.94.07010161; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; BOULET LP, 1994, CLIN INVEST MED, V17, P432; Bousquet J, 1996, AM J RESP CRIT CARE, V153, P1648, DOI 10.1164/ajrccm.153.5.8630616; BREMNER P, 1992, THORAX, V47, P814, DOI 10.1136/thx.47.10.814; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; BRUGNAMI G, 1995, J ALLERGY CLIN IMMUN, V96, P457, DOI 10.1016/S0091-6749(95)70287-3; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; BURROWS B, 1991, J ALLERGY CLIN IMMUN, V88, P870, DOI 10.1016/0091-6749(91)90243-H; CAMPBELL DA, 1992, MED J AUSTRALIA, V156, P860, DOI 10.5694/j.1326-5377.1992.tb137000.x; CAMPBELL K, 1993, NEW ZEAL MED J, V106, P282; CASTELLSAGUE J, 1995, THORAX, V50, P1051, DOI 10.1136/thx.50.10.1051; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; CLINE MG, 1994, CHEST, V106, P1089, DOI 10.1378/chest.106.4.1089; DODGE R, 1994, J ALLERGY CLIN IMMUN, V94, P831, DOI 10.1016/0091-6749(94)90150-3; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; Ertle AR, 1998, J ASTHMA, V35, P281, DOI 10.3109/02770909809068219; ESCHENBACHER WL, 1995, ENVIRON HEALTH PERSP, V103, P209, DOI 10.2307/3432375; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; Fleming JS, 1996, J NUCL MED, V37, P873; Forastiere F, 1998, AM J RESP CRIT CARE, V157, P1864, DOI 10.1164/ajrccm.157.6.9712081; FRETTE C, 1991, AM REV RESPIR DIS, V143, P987, DOI 10.1164/ajrccm/143.5_Pt_1.987; Gassert TH, 1998, J OCCUP ENVIRON MED, V40, P481, DOI 10.1097/00043764-199805000-00011; GERRITSEN J, 1990, J ALLERGY CLIN IMMUN, V85, P116, DOI 10.1016/0091-6749(90)90232-S; GODFREY RWA, 1995, EUR RESPIR J, V8, P922; HUNT LW, 1993, JAMA-J AM MED ASSOC, V269, P1947, DOI 10.1001/jama.269.15.1947; JEFFERY PK, 1998, ALLERGY PRINCIPLES P, P867; JENKINS MA, 1988, MED J AUSTRALIA, V149, P620, DOI 10.5694/j.1326-5377.1988.tb120805.x; JENKINS MA, 1992, AUST J PUBLIC HEALTH, V16, P427; Kaplan BA, 1997, J ASTHMA, V34, P219, DOI 10.3109/02770909709068192; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137, DOI 10.1164/ajrccm.154.1.8680669; KONDOH Y, 1990, CHEST, V97, P845, DOI 10.1378/chest.97.4.845; KRZYZANOWSKI M, 1992, EUR RESPIR J, V5, P12; LAM S, 1987, OCCUP MED, V2, P373; Lange P, 1996, LANCET, V347, P1285, DOI 10.1016/S0140-6736(96)90937-X; LANGE P, 1995, EUR RESPIR J, V8, P1694, DOI 10.1183/09031936.95.08101694; LEBOWITZ MD, 1995, CHEST, V108, P55, DOI 10.1378/chest.108.1.55; LEBOWITZ MD, 1995, EUR J EPIDEMIOL, V11, P541, DOI 10.1007/BF01719306; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; MANFREDA J, 1993, CHEST, V103, P151, DOI 10.1378/chest.103.1.151; MATSUSE T, 1992, AM REV RESPIR DIS, V146, P177, DOI 10.1164/ajrccm/146.1.177; MEREDITH S, 1993, J EPIDEMIOL COMMUN H, V47, P459, DOI 10.1136/jech.47.6.459; Mochizuki T, 1997, CHEST, V112, P1522, DOI 10.1378/chest.112.6.1522; MODEL D, 1995, RESP MED, V89, P21, DOI 10.1016/0954-6111(95)90066-7; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P1520, DOI 10.1164/ajrccm/140.6.1520; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; Okazawa M, 1996, AM J RESP CRIT CARE, V154, P1557, DOI 10.1164/ajrccm.154.5.8912780; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110, DOI 10.1164/ajrccm.153.1.8542102; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084, DOI 10.1164/ajrccm/146.4.1084; PAOLETTI P, 1989, EUR RESPIR J, V2, P428; Park JW, 1997, J INVEST ALLERG CLIN, V7, P186; PATTERSON R, 1986, ARCH INTERN MED, V146, P916, DOI 10.1001/archinte.146.5.916; Peat JK, 1996, ALLERGY, V51, P804, DOI 10.1111/j.1398-9995.1996.tb00026.x; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; PISATI G, 1993, BRIT J IND MED, V50, P60; POSTMA DS, 1995, ARCH INTERN MED, V155, P1393, DOI 10.1001/archinte.155.13.1393; Prescott E, 1997, THORAX, V52, P287, DOI 10.1136/thx.52.3.287; RACKEMANN FM, 1958, J ALLERGY, V29, P528, DOI 10.1016/0021-8707(58)90025-X; RIMPELA AH, 1995, SCAND J SOC MED, V23, P60, DOI 10.1177/140349489502300111; Ronmark E, 1997, ALLERGY, V52, P1071, DOI 10.1111/j.1398-9995.1997.tb00178.x; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SCHENKER MB, 1993, AM REV RESPIR DIS, V147, P1454, DOI 10.1164/ajrccm/147.6_Pt_1.1454; SHERRILL DL, 1994, J ALLERGY CLIN IMMUN, V94, P954, DOI 10.1016/0091-6749(94)90113-9; SHERRILL DL, 1995, AM J RESP CRIT CARE, V152, P98, DOI 10.1164/ajrccm.152.1.7599870; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; SLUITER HJ, 1991, EUR RESPIR J, V4, P479; Smyth ET, 1996, THORAX, V51, P293, DOI 10.1136/thx.51.3.293; SOBONYA RE, 1984, AM REV RESPIR DIS, V130, P289; SPARROW D, 1993, AM REV RESPIR DIS, V147, P367, DOI 10.1164/ajrccm/147.2.367; Strachan DP, 1996, BRIT MED J, V312, P1195; SUNYER J, 1992, AM REV RESPIR DIS, V145, P1098, DOI 10.1164/ajrccm/145.5.1098; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; Sunyer J, 1997, THORAX, V52, P235, DOI 10.1136/thx.52.3.235; SUNYER J, 1995, J ALLERGY CLIN IMMUN, V95, P699, DOI 10.1016/S0091-6749(95)70175-3; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527, DOI 10.1164/ajrccm/140.6.1527; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P776, DOI 10.1164/ajrccm/144.4.776; Toren K, 1996, INT J EPIDEMIOL, V25, P617, DOI 10.1093/ije/25.3.617; ULRIK CS, 1995, CHEST, V108, P10, DOI 10.1378/chest.108.1.10; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; US Department of Health and Human Services, 1997, NIH PUBL, V01-3680; VENABLES KM, 1993, THORAX, V48, P214, DOI 10.1136/thx.48.3.214; Vergnenegre A, 1992, Allergol Immunopathol (Madr), V20, P190; Vignola AM, 1998, J ALLERGY CLIN IMMUN, V101, P149, DOI 10.1016/S0091-6749(98)70378-1; WEICH DG, 1998, ALLERGY PRINCIPLES P, P769; Weiss ST, 1998, J ALLERGY CLIN IMMUN, V101, P720, DOI 10.1016/S0091-6749(98)70300-8; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WRIGHT SC, 1994, THORAX, V49, P141, DOI 10.1136/thx.49.2.141; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	99	117	118	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					539	547		10.1016/S0091-6749(99)70221-6	http://dx.doi.org/10.1016/S0091-6749(99)70221-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10199998				2022-12-18	WOS:000079723900001
J	Greineder, DK; Loane, KC; Parks, P				Greineder, DK; Loane, KC; Parks, P			A randomized controlled trial of a pediatric asthma outreach program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; child; case management; health education; cost; risk; managed care; allergy; outreach	UNITED-STATES; CHILDHOOD ASTHMA; CHILDREN; HOSPITALIZATION; PREVALENCE; EDUCATION; IMPACT; HEALTH; TRENDS	Background: Previous studies have shown that asthma education and case management may reduce asthma emergency care, hospitalizations, and expenditures. Objective: We sought to study the effect of an asthma outreaeh program (AOP), a team-based, case-management intervention, on emergency ward (EW) and hospital use. Methods: Fifty-seven patients aged 1 to 15 years with the diagnosis of asthma based on the usual clinical practice criteria who ere continuously enrolled in a staff-model health maintenance organization for a period of at least 2 consecutive years were randomized into 2 intervention groups. The control group received a single intensive asthma education intervention, and the BOP group received the same initial education hut then was followed-up by an asthma case management nurse throughout the intervention period. Results: EW visits, hospitalizations, and total outside-of-health-plan expenditures (consisting of EW and hospital expenses, as well as miscellaneous costs, such as ambulance, durable medical equipment, tertiary referrals, and home care) were assessed from claims pled for a year before and after enrollment. Control group patients experienced significant reductions in EW visits (39%), hospitalizations (43%), and outside-of-health-plan costs (28%), possibly as a result of the baseline educational intervention received by all enrolled patients, in conjunction with regression to the mean. AOP group patients experienced significant reductions in EW visits, (73 %, P = .0002), hospitalizations (84% p = .0012), and outside-of-health-plan use (82%, P < .0001), When compared with the control group, AOP group patients demonstrated additional significant reductions in EW visits (57%, P < .05), hospitalizations (75%, P < .05), and outside-of-health-plan use (71%, P < .001). Estimates of direct savings to the health plan ranged from $7.69 to $11.67 for every dollar spent on the AOP nurse's salary, depending on assumptions, Conclusions: Asthma patients in a staff-model health maintenance organization decreased their resource use between 57% to 75% by participation in an AOP as compared with a randomized control group receiving only an educational intervention. Substantial savings were achieved compared with the cost of the AOP nurse.	Harvard Pilgrim Hlth Care, Dept Allergy, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA	Harvard Pilgrim Health Care; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Greineder, DK (corresponding author), Harvard Pilgrim Hlth Care, Dept Allergy, 133 Brookline Ave, Boston, MA 02215 USA.							*CDCP, 1995, MMWR-MORBID MORTAL W, V43, P952; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FIREMAN P, 1981, PEDIATRICS, V68, P341; GARRETT J, 1994, THORAX, V49, P976, DOI 10.1136/thx.49.10.976; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; Greineder DK, 1998, AM J MANAG CARE, V4, P196; GREINEDER DK, 1995, ARCH PEDIAT ADOL MED, V149, P415, DOI 10.1001/archpedi.1995.02170160069010; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HUGHES PC, 1987, PINEAL RES REV, V5, P1; MITCHELL EA, 1987, ARCH DIS CHILD, V62, P414; *NAT ASTHM ED PROG, 1991, NIH PUBL; Siegel S, 1956, NONPARAMETRIC STAT B; Swinscow TDV, 1978, STAT SQUARE ONE, V4th; TAYLOR WR, 1992, PEDIATRICS, V90, P657; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEISS KB, 1991, SPECIAL REPORT NIAID	19	117	123	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				436	440		10.1016/S0091-6749(99)70468-9	http://dx.doi.org/10.1016/S0091-6749(99)70468-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069877				2022-12-18	WOS:000079175700012
J	Milewski, M; Mastalerz, L; Nizankowska, E; Szczeklik, A				Milewski, M; Mastalerz, L; Nizankowska, E; Szczeklik, A			Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin-sensitive asthma; bronchial asthma; nasal provocation test; rhinitis	CHALLENGE; HISTAMINE; ACETYLSALICYLATE; RHINOSINUSITIS; SECRETIONS; ALLERGEN; RELEASE	Nasal provocation tests (NPTs) with lysine-aspirin (L-ASA) have been recently introduced for assessment of aspirin-induced asthma (AIA). They differ in dose and means of aspirin instillation, duration of observation period, and criteria for positivity. Thus far they have not become a routine part of clinical diagnosis. Fifty-one patients with AIA, confirmed by oral challenge test, were recruited to undergo diagnostic NPTs with L-ASA. In 10 of these patients (19.6%), NPTs could not be performed because of total obstruction of at least one nostril or marked fluctuations in nasal hows, leaving 41 patients with AIA for the study. Control groups consisted of 13 aspirin-tolerant asthmatic patients and 10 healthy subjects. L-ASA at a total dose of 16 mg of acetylsalicylic acid applied bilaterally into the inferior nasal conchae caused significant fall in inspiratory nasal how in at least one nostril (>40%), which nas measured by anterior rhinomanometry, and clinical Symptoms of watery discharge and nasal blockage in 35 of 41 patients with AIA, one of 10 healthy subjects, and none of 13 aspirin-tolerant asthmatic patients. No relationship was found between the baseline nasal flow values and the intensity of response to L-ASA. No systemic: reactions, including bronchospasm, were noticed, even in patients whose initial FEV1 was lower than 70% of predicted value. This test is highly specific (95.7%) and sensitive (86.7%), but negative results do not exclude possible intolerance to aspirin (predictive value of a negative result 78.6%). In conclusion, the NPT described is a simple, safe, and quick test for diagnosis of AIA. It can be used in patients with unstable asthma. It may be a method of choice to confirm hypersensitivity to aspirin manifested only by symptoms from the upper respiratory tract. Patients suspected of aspirin intolerance who have negative NPT results should undergo bronchial or oral challenge tests with aspirin.	Jagiellonian Univ, Sch Med, Dept Med, PL-31066 Cracow, Poland	Jagiellonian University; Collegium Medicum Jagiellonian University	Szczeklik, A (corresponding author), Jagiellonian Univ, Sch Med, Dept Med, Skawinska 8 St, PL-31066 Cracow, Poland.		Mastalerz, Lucyna/U-5974-2018	Mastalerz, Lucyna/0000-0002-8994-0036				BIANCO S, 1977, IRCS (International Research Communications System) Medical Science Library Compendium, V5, P129; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; DAHLEN B, 1990, EUR RESPIR J, V3, P527; ECCLES R, 1989, RHINITIS MECH MANAGE, P53; EGGLESTON PA, 1988, J ALLERGY CLIN IMMUN, V81, P1036, DOI 10.1016/0091-6749(88)90176-5; FIREMAN P, 1988, J ALLERGY CLIN IMMUN, V81, P953, DOI 10.1016/0091-6749(88)90159-5; Kowalski ML, 1996, CLIN EXP ALLERGY, V26, P807, DOI 10.1046/j.1365-2222.1996.d01-371.x; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; MANNING ME, 1991, IMMUNOL ALLERGY CLIN, V11, P659; MENELLA JA, 1992, ACTA OTOLARYNGOL STO, V112, P1025; MILEWSKI M, 1996, VALUE NASAL PROVOCAT; MYGIND N, 1986, EUR J RESPIR DIS, V68, P31; NASSER SMS, IN PRESS EICOSANOIDS; NIZANKOWSKA E, 1989, ANN ALLERGY, V63, P157; ORTOLANI C, 1987, ANN ALLERGY, V59, P106; PATRIARCA G, 1991, ANN ALLERGY, V67, P60; PAWLOWICZ A, 1991, ALLERGY, V46, P405, DOI 10.1111/j.1398-9995.1991.tb04218.x; PERSSON CGA, 1992, THORAX, V47, P993, DOI 10.1136/thx.47.12.993; PHILLIPS GD, 1989, J ALLERGY CLIN IMMUN, V84, P232, DOI 10.1016/0091-6749(89)90330-8; PICADO C, 1992, AM REV RESPIR DIS, V145, P65, DOI 10.1164/ajrccm/145.1.65; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; SCHAPOWAL A, 1990, Atemwegs-und Lungenkrankheiten, V16, pS1; STEVENSON DD, 1976, CLIN ALLERGY, V6, P493, DOI 10.1111/j.1365-2222.1976.tb01934.x; Stevenson DD, 1993, ALLERGY PRINCIPLES P, V4th, P1747; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; Szczeklik A., 1992, P548; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608, DOI 10.1164/ajrccm.154.6.8970343; Szczeklik A, 1997, ALLERGY, V52, P613, DOI 10.1111/j.1398-9995.1997.tb01039.x; SZCZEKLIK A, 1993, METHODS ASTHMOLOGY, P253; VANDEHEYNING PH, 1989, ALLERGY, V44, P482; Wagenmann M, 1996, CLIN EXP ALLERGY, V26, P371, DOI 10.1046/j.1365-2222.1996.d01-324.x; WAGENMANN M, 1994, J ALLERGY CLIN IMMUN, V93, P594, DOI 10.1016/S0091-6749(94)70071-0; Wagenmann M, 1997, AM J RESP CRIT CARE, V155, P426, DOI 10.1164/ajrccm.155.2.9032173; WELLBROCK M, 1993, HNO, V41, P577	34	117	121	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					581	586		10.1016/S0091-6749(98)70163-0	http://dx.doi.org/10.1016/S0091-6749(98)70163-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600492				2022-12-18	WOS:000073697400003
J	Ballow, M				Ballow, M			Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						intravenous immune serum globulin (IVIG); gamma-globulin; immune therapy; autoimmune disease; immune modulation; cytokines; complement; Fc receptors	IDIOPATHIC THROMBOCYTOPENIC PURPURA; ACUTE KAWASAKI-DISEASE; NECROSIS-FACTOR-ALPHA; T-CELL PROLIFERATION; FC-GAMMA RECEPTOR; IMMUNOGLOBULIN PREPARATIONS; ANTIHEMOPHILIC-FACTOR; CROSS-LINKING; SUPPRESSION; INVITRO	Intravenous immune serum globulin (IVIG) is primarily used as replacement therapy in patients with hypogammaglobulinemia. It has been over 15 years since IVIG was first shown to be effective in the treatment of patients with autoimmune thrombocytopenic purpura. Over the past decade, IVIG has been used in the treatment of a number of autoimmune and systemic inflammatory disorders. Although the use of IVIG in many of these immune-mediated disorders was purely speculative initially, we now have a much better understanding of the mechanisms by which IVIG exerts its effects in these autoimmune diseases, IVIG exhibits a number of immune modulatory activities that are mediated by the Fc portion of IgG through the Fc gamma receptor on a variety of cell types, Although the major component in IVIG is IgG, other minor components such as solubilized lymphocyte surface membrane determinants and specific antibodies to lymphocyte surface molecules may have important immunoregulatory effects on T-and B-cell immune responses, This review discusses the proposed mechanisms of action of IVIG in autoimmune and inflammatory disorders.	SUNY BUFFALO, CHILDRENS HOSP BUFFALO, DIV ALLERGY IMMUNOL & PEDIAT RHEUMATOL, SCH MED & BIOMED SCI, BUFFALO, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ballow, M (corresponding author), CHILDRENS HOSP, DEPT PEDIAT, DIV ALLERGY IMMUNOL & PEDIAT RHEUMATOL, 219 BRYANT ST, BUFFALO, NY 14222 USA.							ABE J, 1993, J EXP MED, V177, P791, DOI 10.1084/jem.177.3.791; ABE J, 1992, P NATL ACAD SCI USA, V89, P4066, DOI 10.1073/pnas.89.9.4066; ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ACHIRON A, 1992, ARCH NEUROL-CHICAGO, V49, P1233, DOI 10.1001/archneur.1992.00530360031013; ACHIRON A, 1994, J CLIN INVEST, V93, P600, DOI 10.1172/JCI117012; Achiron A, 1996, CLIN EXP IMMUNOL, V104, P67, DOI 10.1111/cei.1996.104.s1.67; AMRAN D, 1994, CLIN IMMUNOL IMMUNOP, V73, P180, DOI 10.1006/clin.1994.1186; Andersson J, 1996, CLIN EXP IMMUNOL, V104, P10, DOI 10.1111/cei.1996.104.s1.10; ANDERSSON JP, 1990, IMMUNOLOGY, V71, P372; ANTEL JP, 1981, CLIN EXP IMMUNOL, V43, P351; Ashman RF, 1996, J IMMUNOL, V157, P5; AUKRUST P, 1994, BLOOD, V84, P2136; BALLOW M, 1997, INTRAVENOUS IMMUNOGL, P123; BARNES PJ, 1994, AM J RESP CRIT CARE, V150, pS42, DOI 10.1164/ajrccm/150.5_Pt_2.S42; BASTA M, 1991, BLOOD, V77, P376; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BLASCZYK R, 1993, LANCET, V341, P789, DOI 10.1016/0140-6736(93)90563-V; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; BUSSEL J, 1986, J CLIN IMMUNOL, V6, P50, DOI 10.1007/BF00915364; BUSSEL JB, 1989, J ALLERGY CLIN IMMUN, V84, P566, DOI 10.1016/0091-6749(89)90193-0; Chacko GW, 1996, J IMMUNOL, V157, P2234; COUSER WG, 1995, J AM SOC NEPHROL, V5, P1888; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; DESOUZA VR, 1995, EUR J IMMUNOL, V25, P1267, DOI 10.1002/eji.1830250521; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; DIETRICH G, 1990, J CLIN INVEST, V85, P620, DOI 10.1172/JCI114483; DRUCKER NA, 1994, CIRCULATION, V89, P252, DOI 10.1161/01.CIR.89.1.252; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; FRIDMAN WH, 1993, CURR OPIN IMMUNOL, V5, P355, DOI 10.1016/0952-7915(93)90053-U; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P3189; HASHIMOTO F, 1986, CLIN EXP IMMUNOL, V65, P409; HEYMAN B, 1990, SCAND J IMMUNOL, V31, P601, DOI 10.1111/j.1365-3083.1990.tb02811.x; Hurez V, 1994, Ther Immunol, V1, P269; IMBACH P, 1981, LANCET, V1, P1228; JAYNE DRW, 1993, ADV EXP MED BIOL, V336, P469; JENNETTE JC, 1993, ADV EXP MED BIOL, V336, P7; Kaveri S, 1996, J CLIN INVEST, V97, P865, DOI 10.1172/JCI118488; KIMBERLY RP, 1984, J IMMUNOL, V132, P745; KONDO N, 1991, J CLIN IMMUNOL, V11, P152, DOI 10.1007/BF00918683; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; LAM L, 1993, LANCET, V342, P678, DOI 10.1016/0140-6736(93)91784-J; LEUNG DY, 1992, IVIG THERAPY TODAY, P93; Leung DYM, 1996, CLIN EXP IMMUNOL, V104, P49, DOI 10.1111/cei.1996.104.s1.49; LEUNG DYM, 1989, LANCET, V2, P1298; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; Lockwood CM, 1996, CLIN EXP IMMUNOL, V104, P77, DOI 10.1111/cei.1996.104.s1.77; Mannhalter J W, 1989, Int Rev Immunol, V5, P173, DOI 10.3109/08830188909061984; MANNHALTER JW, 1987, INT ARCH ALLER A IMM, V82, P159, DOI 10.1159/000234182; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1988, J IMMUNOL, V141, P4243; RATKO TA, 1995, JAMA-J AM MED ASSOC, V273, P1865, DOI 10.1001/jama.273.23.1865; Rose NR, 1996, CLIN IMMUNOL IMMUNOP, V80, pS92, DOI 10.1006/clin.1996.0146; ROSSI F, 1989, J IMMUNOL, V143, P4104; SAOUDI A, 1993, TRANSPLANT P, V25, P2838; SHIMOZATO T, 1991, IMMUNOLOGY, V72, P497; SHOENFELD Y, 1994, FASEB J, V8, P1296, DOI 10.1096/fasebj.8.15.8001742; STOHL W, 1986, J IMMUNOL, V136, P4407; Sullivan KM, 1996, CLIN EXP IMMUNOL, V104, P43, DOI 10.1111/cei.1996.104.s1.43; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; SULTAN Y, 1987, P NATL ACAD SCI USA, V84, P828, DOI 10.1073/pnas.84.3.828; SULTAN Y, 1984, LANCET, V2, P765; SWIFT AJ, 1994, CLIN DIAGN LAB IMMUN, V1, P585, DOI 10.1128/CDLI.1.5.585-589.1994; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; VASSILEV T, 1993, CLIN EXP IMMUNOL, V92, P369; WHITE WB, 1987, AM J MED, V83, P431, DOI 10.1016/0002-9343(87)90752-2	70	117	121	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					151	157		10.1016/S0091-6749(97)70217-3	http://dx.doi.org/10.1016/S0091-6749(97)70217-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275133				2022-12-18	WOS:A1997XR35100002
J	SUBIZA, J; JEREZ, M; JIMENEZ, JA; NARGANES, MJ; CABRERA, M; VARELA, S; SUBIZA, E				SUBIZA, J; JEREZ, M; JIMENEZ, JA; NARGANES, MJ; CABRERA, M; VARELA, S; SUBIZA, E			ALLERGENIC POLLEN AND POLLINOSIS IN MADRID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						POLLEN CALENDAR; AIRBORNE POLLEN; ALLERGENIC POLLEN; POLLINOSIS	MOUNTAIN CEDAR POLLINOSIS; MEDITERRANEAN AREA; ATMOSPHERE	Objective: A 15-year pollen count was performed in the atmosphere of Madrid, Spain, to determine the months in which the highest concentrations of allergenic pollens occur. Methods: Pollen counts were done with a Burkard spore trap (Burkard Manufacturing, Rickmansworth, Herst., U.K.). The results were subsequently compared with results of skin tests in patients with pollinosis born and living in and around Madrid. Results: The highest airborne presence (percent of total yearly pollen counts, mean of counts from 1979 to 1993) was for Quercus spp. (17%); followed by Platanus spp. (15%), Poaceae (15%), Cupressaceae (11%) Olea spp. (9%), Pinus spp. (7%), Populus spp. (4%), and Plantago spp. (4%). The most predominant pollens from January to April are tree pollens (Cupressaceae, Alnus, Fraxinus, Ulmus, Populus, Platanus, and Morus), although these are also abundant in May and June (Quercus, Olea, and Pinus spp.). The grass pollination period shows a double curve: the first peak occurs from February to April (8% of yearly grasses), and the second peak occurs from May to July (90% of yearly grasses). Among allergenically significant weeds, the most notable is Plantago; in contrast, Rumex, Urticaceae, Cheno-Amaranthaceae, and Artemisia spp. have very low concentrations (less than or equal to 2% yearly total pollens). The most significant allergenic pollen is that of grasses, with a prevalence of positive prick test results of 94%, followed by Olea europaea (61%), Plantago lagopus (53%), Platanus hybrida (52%), and Cupressus arizonica (20%). Conclusion: The population of Madrid is exposed to high concentrations of allergenic pollen from February to July, although the most intense period is from May to June. Grass pollens are the most important cause of pollinosis in this area.	GEN PARDINAS CTR ALLERGY & CLIN IMMUNOL, E-28006 MADRID, SPAIN; ROYAL BOT GARDENS, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Real Jardin Botanico de Madrid								BELMONTE J, 1991, GRANA, V30, P364, DOI 10.1080/00173139109431992; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; CAIAFFA MF, 1993, ANN ALLERGY, V71, P45; CHAPARRO A, 1984, 14 C NAC SEA, P44; COSENTINO S, 1990, ANN ALLERGY, V65, P393; DAMATO G, 1989, J ALLERGY CLIN IMMUN, V83, P116, DOI 10.1016/0091-6749(89)90485-5; DAMATO G, 1992, ANN ALLERGY, V68, P433; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P210, DOI 10.1111/j.1365-2222.1994.tb00222.x; DASILVA QGP, 1974, ATLAS EUROPEAN ALLER, P171; DAVIES RR, 1973, CLIN ALLERGY, V3, P477, DOI 10.1111/j.1365-2222.1973.tb01332.x; DELAGUARDIA CD, 1993, J INVEST ALLERG CLIN, V3, P251; FEIN BT, 1962, J ALLERGY, V33, P141; FERREIRO M, 1984, 14 C NAC SEA, P51; FLORIDO JF, 1994, REV ESP AKERGOL IMMU, V9, P1; Font Tullot I, 1983, CLIMATOLOGIA ESPANA; FRANKLAND AW, 1974, ATLAS EUROPEAN ALLER, P131; FREEMAN GL, 1993, ANN ALLERGY, V70, P491; GOLDBERG C, 1988, GRANA, V27, P209, DOI 10.1080/00173138809428928; Gonzalez F., 1986, GRAMINEAS PRATENSES; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; Hyde HA, 1958, ATLAS AIRBORNE POLLE; ICKOVIC MR, 1988, FRANCE POLLENS; KEYNAN N, 1991, GRANA, V30, P477, DOI 10.1080/00173139109432013; Lewis W. H., 1983, AIRBORNE ALLERGENIC, P105; Macchia L, 1991, ALLERGENIC POLLEN PO, P87; NARDI G, 1986, ANN ALLERGY, V57, P193; NEGRINI AC, 1992, ALLERGY, V47, P371, DOI 10.1111/j.1398-9995.1992.tb02074.x; PANZANI R, 1986, ANN ALLERGY, V56, P460; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; PERALTA V, 1994, REV ESP ALERGOL IMMU, V9, P33; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; Solomon W. R., 1988, ALLERGY PRINCIPLES P, P312; Spieksma F., 1991, ALLERGENIC POLLEN PO, P49; SPIEKSMA FTM, 1985, GRANA, V24, P99, DOI 10.1080/00173138509429920; SPIEKSMA FTM, 1989, AEROBIOLOGIA, V5, P38, DOI DOI 10.1007/BF02446486; SPIEKSMA FTM, 1993, POLEN ATMOSFERICO EU, P54; SUBIZA E, 1986, TRATADO ALERGOLOGIA, V4, P257; SUBIZA E, 1980, ALLERGOL IMMUNOPAT S, V6, P261; SUBIZA E, 1989, REV ESP ALERGOL INMU, V4, P45; SUBIZA J, 1992, CLIN EXP ALLERGY, V22, P540, DOI 10.1111/j.1365-2222.1992.tb00163.x; SUBIZA J, 1989, J ALLERGY CLIN IMMUN, V84, P353, DOI 10.1016/0091-6749(89)90420-X; SUBIZA J, 1994, CLIN EXP ALLERGY, V24, P1123, DOI 10.1111/j.1365-2222.1994.tb03317.x; SUBIZA J, 1987, REV ESP ALERGOL IMMU, V2, P11; SURINYACH R, 1974, ATLAS EUROPEAN ALLER, P111; VILCHES ED, 1993, J INVEST ALLERG CLIN, V3, P121; WHEELER AW, 1992, CLIN EXP ALLERGY, V22, P1052, DOI 10.1111/j.1365-2222.1992.tb00129.x; Wodehouse RP, 1971, HAY FEVER PLANTS, V2nd	47	117	123	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					15	23		10.1016/S0091-6749(95)70028-5	http://dx.doi.org/10.1016/S0091-6749(95)70028-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622759				2022-12-18	WOS:A1995RK38300003
J	CUSHLEY, MJ; HOLGATE, ST				CUSHLEY, MJ; HOLGATE, ST			ADENOSINE-INDUCED BRONCHOCONSTRICTION IN ASTHMA - ROLE OF MAST-CELL MEDIATOR RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CUSHLEY, MJ (corresponding author), SOUTHAMPTON GEN HOSP, DEPT MED 1, LEVEL D, CTR BLOCK, TREMONA RD, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.							ALTOUNYAN REC, 1980, CLIN ALLERGY, V10, P481, DOI 10.1111/j.1365-2222.1980.tb02162.x; Arch J R, 1978, Essays Biochem, V14, P82; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BASOMBA A, 1976, CLIN ALLERGY, V6, P269, DOI 10.1111/j.1365-2222.1976.tb01907.x; BRESLIN FJ, 1980, AM REV RESPIR DIS, V122, P11; BROWN CM, 1982, BRIT J PHARMACOL, V76, P381, DOI 10.1111/j.1476-5381.1982.tb09231.x; CHURCH MK, 1983, BRIT J PHARMACOL, V80, P719, DOI 10.1111/j.1476-5381.1983.tb10063.x; CHURCH MK, 1982, J IMMUNOL, V129, P2116; CHURCH MK, 1983, FED PROC, V42, P1342; Cushley M J, 1983, Agents Actions Suppl, V13, P109; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; FREDHOLM BB, 1981, ACTA PHYSIOL SCAND, V111, P507, DOI 10.1111/j.1748-1716.1981.tb06772.x; GOTO K, 1982, INT ARCH ALLER A IMM, V68, P332, DOI 10.1159/000233122; GRIFFIN MP, 1983, J ALLERGY CLIN IMMUN, V71, P331, DOI 10.1016/0091-6749(83)90088-X; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HARRIES MG, 1981, LANCET, V1, P5; HOLGATE ST, 1980, P NATL ACAD SCI-BIOL, V77, P6800, DOI 10.1073/pnas.77.11.6800; HOLGATE ST, 1984, ASTHMA PHYSL IMMUNOP, P391; HOWARTH PH, 1983, THORAX, V38, P705; KARLBERG BE, 1974, J CLIN ENDOCR METAB, V39, P96, DOI 10.1210/jcem-39-1-96; KARLSSON JA, 1982, J PHARM PHARMACOL, V34, P788, DOI 10.1111/j.2042-7158.1982.tb06226.x; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MANN JS, 1983, CLIN SCI, V65, pP22; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; MENTZER RM, 1975, AM J PHYSIOL, V229, P1625; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; PAUWELS RAR, 1983, J ALLERGY CLIN IMMUN, V71, P103, DOI 10.1016/0091-6749(83)90182-3; RICHARDSON PS, 1969, BMJ-BRIT MED J, V3, P143, DOI 10.1136/bmj.3.5663.143; SHAH J, 1980, CLIN SCI, V59, pP29; VANCALKER D, 1979, J NEUROCHEM, V33, P999, DOI 10.1111/j.1471-4159.1979.tb05236.x; WOENNE R, 1979, AM REV RESPIR DIS, V119, P927; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199	34	117	119	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					272	278		10.1016/0091-6749(85)90057-0	http://dx.doi.org/10.1016/0091-6749(85)90057-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	2981912				2022-12-18	WOS:A1985ABZ0500007
J	GROSS, NJ				GROSS, NJ			ALLERGY TO LABORATORY-ANIMALS - EPIDEMIOLOGIC, CLINICAL, AND PHYSIOLOGIC ASPECTS, AND A TRIAL OF CROMOLYN IN ITS MANAGEMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM HOSP,DEPT MED,HINES,IL 60141; LOYOLA UNIV,CHICAGO,IL 60611	Loyola University Chicago								CARROLL K B, 1975, Clinical Allergy, V5, P443, DOI 10.1111/j.1365-2222.1975.tb01883.x; GELL PGH, 1968, CLINICAL ASPECTS IMM, P580; Goldstein A, 1964, BIOSTATISTICS INTRO; LINCOLN TA, 1974, J OCCUP ENVIRON MED, V16, P465; LUTSKY II, 1975, ANN ALLERGY, V35, P201; NEUMAN I, 1976, ANN ALLERGY, V36, P23; PATTERSON R, 1964, LAB ANIM CARE, V14, P466; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RAJKA G, 1961, ACTA ALLERGOL, V16, P168, DOI 10.1111/j.1398-9995.1961.tb02891.x; SORRELL A H, 1957, Ann Allergy, V15, P662; TENNENBAUM JI, 1970, GENETICS DISORDERS M, P1009; WALLENSTEIN S, 1977, BIOMETRICS, V33, P261, DOI 10.2307/2529321	12	117	118	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	2					158	165		10.1016/0091-6749(80)90064-0	http://dx.doi.org/10.1016/0091-6749(80)90064-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD119	6772703				2022-12-18	WOS:A1980KD11900011
J	EGGLESTON, PA; ROSENTHAL, RR; ANDERSON, SA; ANDERTON, R; BIERMAN, CW; BLEECKER, ER; CHAI, H; CROPP, GJA; JOHNSON, JD; KONIG, P; MORSE, J; SMITH, LJ; SUMMERS, RJ; TRAUTLEIN, JJ				EGGLESTON, PA; ROSENTHAL, RR; ANDERSON, SA; ANDERTON, R; BIERMAN, CW; BLEECKER, ER; CHAI, H; CROPP, GJA; JOHNSON, JD; KONIG, P; MORSE, J; SMITH, LJ; SUMMERS, RJ; TRAUTLEIN, JJ			GUIDELINES FOR THE METHODOLOGY OF EXERCISE CHALLENGE TESTING OF ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											EGGLESTON, PA (corresponding author), UNIV VIRGINIA,CTR MED,CHARLOTTESVILLE,VA 22908, USA.			Anderson, Sandra/0000-0002-6308-8770					0	117	121	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					642	645		10.1016/0091-6749(79)90028-9	http://dx.doi.org/10.1016/0091-6749(79)90028-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	512260				2022-12-18	WOS:A1979HX84300016
J	Depner, M; Ege, MJ; Cox, MJ; Dwyer, S; Walker, AW; Birzele, LT; Genuneit, J; Horak, E; Braun-Fahrlander, C; Danielewicz, H; Maier, RM; Moffatt, MF; Cookson, WO; Heederik, D; von Mutius, E; Legatzki, A				Depner, Martin; Ege, Markus J.; Cox, Michael J.; Dwyer, Sarah; Walker, Alan W.; Birzele, Lena T.; Genuneit, Jon; Horak, Elisabeth; Braun-Fahrlaender, Charlotte; Danielewicz, Hanna; Maier, Raina M.; Moffatt, Miriam F.; Cookson, William O.; Heederik, Dick; von Mutius, Erika; Legatzki, Antje			Bacterial microbiota of the upper respiratory tract and childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; childhood; upper respiratory tract; throat; nose; microbiota; 16S rRNA gene	AIRWAY MICROBIOME; COLONIZATION; ASSOCIATIONS; MICROFLORA; CHILDREN; IMMUNITY; DISEASE; HEALTH	Background: Patients with asthma and healthy controls differ in bacterial colonization of the respiratory tract. The upper airways have been shown to reflect colonization of the lower airways, the actual site of inflammation in asthma, which is hardly accessible in population studies. Objective: We sought to characterize the bacterial communities at 2 sites of the upper respiratory tract obtained from children from a rural area and to relate these to asthma. Methods: The microbiota of 327 throat and 68 nasal samples from school-age farm and nonfarm children were analyzed by 454-pyrosequencing of the bacterial 16S ribosomal RNA gene. Results: Alterations in nasal microbiota but not of throat microbiota were associated with asthma. Children with asthma had lower alpha- and beta-diversity of the nasal microbiota as compared with healthy control children. Furthermore, asthma presence was positively associated with a specific operational taxonomic unit from the genus Moraxella in children not exposed to farming, whereas in farm children Moraxella colonization was unrelated to asthma. In nonfarm children, Moraxella colonization explained the association between bacterial diversity and asthma to a large extent. Conclusions: Asthma was mainly associated with an altered nasal microbiota characterized by lower diversity and Moraxella abundance. Children living on farms might not be susceptible to the disadvantageous effect of Moraxella. Prospective studies may clarify whether Moraxella outgrowth is a cause or a consequence of loss in diversity.	[Depner, Martin; Ege, Markus J.; Birzele, Lena T.; von Mutius, Erika; Legatzki, Antje] Ludwig Maximilians Univ Munchen, Dr von Hauner Childrens Hosp, Munich, Germany; [Ege, Markus J.; von Mutius, Erika] German Ctr Lung Res DZL, Munich, Germany; [Cox, Michael J.; Dwyer, Sarah; Moffatt, Miriam F.; Cookson, William O.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Walker, Alan W.] Wellcome Trust Sanger Inst, Pathogen Genom Grp, Hinxton, Cambs, England; [Genuneit, Jon] Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany; [Horak, Elisabeth] Med Univ Innsbruck, Div Cardiol & Pulmonol, Dept Pediat & Adolescents, Innsbruck, Austria; [Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Braun-Fahrlaender, Charlotte] Univ Basel, Basel, Switzerland; [Danielewicz, Hanna] Wroclaw Med Univ, Dept Pediat Allergol & Cardiol, Wroclaw, Poland; [Maier, Raina M.] Univ Arizona, Dept Soil Water & Environm Sci, Tucson, AZ USA; [Heederik, Dick] Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, Utrecht, Netherlands	University of Munich; Imperial College London; Wellcome Trust Sanger Institute; Ulm University; Medical University of Innsbruck; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Wroclaw Medical University; University of Arizona; Utrecht University	Depner, M (corresponding author), Dr von Hauner Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	martin.depner@med.uni-muenchen.de	Cookson, William/HHC-1790-2022; Ege, Markus/C-1962-2012; Danielewicz, Hanna/AAY-6014-2020; Genuneit, Jon/I-9323-2012; Walker, Alan W./AAE-8102-2019	Ege, Markus/0000-0001-6643-3923; Danielewicz, Hanna/0000-0001-7999-8923; Genuneit, Jon/0000-0001-5764-1528; Walker, Alan W./0000-0001-5099-8495; Heederik, Dick/0000-0002-4550-1437; Cox, Michael/0000-0002-4002-1506; Maier, Raina/0000-0002-0421-4677; von Mutius, Erika/0000-0002-8893-4515	European Research Council [250268]; Wellcome Trust [098051]; Medical Research Council [G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10126] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish	European Research Council(European Research Council (ERC)European Commission); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	This study was supported by the European Research Council (grant no. 250268) and the Wellcome Trust (grant no. 098051).	Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Abreu NA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003783; Bassis CM, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-27; Biesbroek G, 2014, AM J RESP CRIT CARE, V190, P1283, DOI 10.1164/rccm.201407-1240OC; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Blaser M, 2013, NAT REV MICROBIOL, V11, P213, DOI 10.1038/nrmicro2973; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cardenas PA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046803; Castro-Nallar E, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0121-1; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Chen J., 2012, GUNIFRAC GEN UNIFRAC; Claesson MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006669; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; de Vries SPW, 2009, MICROBIOL MOL BIOL R, V73, P389, DOI 10.1128/MMBR.00007-09; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Fierer N, 2008, P NATL ACAD SCI USA, V105, P17994, DOI 10.1073/pnas.0807920105; Frank DN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010598; Genuneit J, 2011, PAEDIATR PERINAT EP, V25, P436, DOI 10.1111/j.1365-3016.2011.01223.x; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hoen AG, 2015, J PEDIAT, V167, pe1; Hoen AG, 2015, J PEDIATR-US, V167, P138, DOI 10.1016/j.jpeds.2015.02.049; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Huang YJ, 2013, AM J RESP CRIT CARE, V187, P1382, DOI 10.1164/rccm.201303-0488WS; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Jervis-Bardy J, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0083-8; Lemon KP, 2010, MBIO, V1, DOI 10.1128/mBio.00129-10; Lozupone C, 2011, ISME J, V5, P169, DOI 10.1038/ismej.2010.133; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Normand AC, 2011, OCCUP ENVIRON MED, V68, P849, DOI 10.1136/oem.2010.061879; Oh J, 2012, GENOME MED, V4, DOI 10.1186/gm378; Oksanen J, 2020, VEGAN COMMUNITY ECOL; Park HM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109479; Petersen C, 2014, CELL MICROBIOL, V16, P1024, DOI 10.1111/cmi.12308; Quince C, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-38; R Development Core Team, 2018, R LANG ENV STAT COMP; Segata N, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r42; Sim K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032543; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Tlaskalova-Hogenova H, 2004, IMMUNOL LETT, V93, P97, DOI 10.1016/j.imlet.2004.02.005; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; von Hertzen L, 2011, EMBO REP, V12, P1089, DOI 10.1038/embor.2011.195; Yan ML, 2013, CELL HOST MICROBE, V14, P631, DOI 10.1016/j.chom.2013.11.005	47	116	119	0	47	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					826	+		10.1016/j.jaci.2016.05.050	http://dx.doi.org/10.1016/j.jaci.2016.05.050			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27576124	Green Published, Bronze			2022-12-18	WOS:000397295800015
J	den Dekker, HT; Voort, AMMSVD; de Jongste, JC; Anessi-Maesano, I; Arshad, SH; Barros, H; Beardsmore, CS; Bisgaard, H; Phar, SC; Craig, L; Devereux, G; van der Ent, CK; Esplugues, A; Fantini, MP; Flexeder, C; Frey, U; Forastiere, F; Gehring, U; Gori, D; van der Gugten, AC; Henderson, AJ; Heude, B; Ibarluzea, J; Inskip, HM; Keil, T; Kogevinas, M; Kreiner-Moller, E; Kuehni, CE; Lau, S; Melen, E; Mommers, M; Morales, E; Penders, J; Pike, KC; Porta, D; Reiss, IK; Roberts, G; Schmidt, A; Schultz, ES; Schulz, H; Sunyer, J; Torrent, M; Vassilaki, M; Wijga, AH; Zabaleta, C; Jaddoe, VWV; Duijts, L				den Dekker, Herman T.; Voort, Agnes M. M. Sonnenschein-van der; de Jongste, Johan C.; Anessi-Maesano, Isabella; Arshad, S. Hasan; Barros, Henrique; Beardsmore, Caroline S.; Bisgaard, Hans; Phar, Sofia Correia; Craig, Leone; Devereux, Graham; van der Ent, C. Kors; Esplugues, Ana; Fantini, Maria P.; Flexeder, Claudia; Frey, Urs; Forastiere, Francesco; Gehring, Ulrike; Gori, Davide; van der Gugten, Anne C.; Henderson, A. John; Heude, Barbara; Ibarluzea, Jesus; Inskip, Hazel M.; Keil, Thomas; Kogevinas, Manolis; Kreiner-Moller, Eskil; Kuehni, Claudia E.; Lau, Susanne; Melen, Erik; Mommers, Monique; Morales, Eva; Penders, John; Pike, Katy C.; Porta, Daniela; Reiss, Irwin K.; Roberts, Graham; Schmidt, Anne; Schultz, Erica S.; Schulz, Holger; Sunyer, Jordi; Torrent, Matias; Vassilaki, Maria; Wijga, Alet H.; Zabaleta, Carlos; Jaddoe, Vincent W. V.; Duijts, Liesbeth			Early growth characteristics and the risk of reduced lung function and asthma: A meta-analysis of 25,000 children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Preterm birth; low birth weight; infant growth; asthma; lung function; children; meta-analysis	BIRTH-WEIGHT; PRETERM BIRTH; RESPIRATORY-FUNCTION; AIRWAY FUNCTION; CHILDHOOD; AGE; ADOLESCENCE; STANDARDIZATION; ASSOCIATION; SPIROMETRY	Background: Children born preterm or with a small size for gestational age are at increased risk for childhood asthma. Objective: We sought to assess the hypothesis that these associations are explained by reduced airway patency. Methods: We used individual participant data of 24,938 children from 24 birth cohorts to examine and meta-analyze the associations of gestational age, size for gestational age, and infant weight gain with childhood lung function and asthma (age range, 3.9-19.1 years). Second, we explored whether these lung function outcomes mediated the associations of early growth characteristics with childhood asthma. Results: Children born with a younger gestational age had a lower FEV1, FEV1/forced vital capacity (FVC) ratio, and forced expiratory volume after exhaling 75% of vital capacity (FEF75), whereas those born with a smaller size for gestational age at birth had a lower FEV1 but higher FEV1/FVC ratio (P < .05). Greater infant weight gain was associated with higher FEV1 but lower FEV1/FVC ratio and FEF75 in childhood (P < .05). All associations were present across the full range and independent of other early-life growth characteristics. Preterm birth, low birth weight, and greater infant weight gain were associated with an increased risk of childhood asthma (pooled odds ratio, 1.34 [95% CI, 1.15-1.57], 1.32 [95% CI, 1.07-1.62], and 1.27 [95% CI, 1.21-1.34], respectively). Mediation analyses suggested that FEV1, FEV1/FVC ratio, and FEF75 might explain 7% (95% CI, 2% to 10%) to 45% (95% CI, 15% to 81%) of the associations between early growth characteristics and asthma. Conclusions: Younger gestational age, smaller size for gestational age, and greater infant weight gain were across the full ranges associated with childhood lung function. These associations explain the risk of childhood asthma to a substantial extent.	[den Dekker, Herman T.; Voort, Agnes M. M. Sonnenschein-van der; de Jongste, Johan C.; Duijts, Liesbeth] Erasmus Univ, Med Ctr, Dept Pediat, Div Resp Med, Sp 3435,POB 2060, NL-3000 CB Rotterdam, Netherlands; [den Dekker, Herman T.; Voort, Agnes M. M. Sonnenschein-van der; Jaddoe, Vincent W. V.; Duijts, Liesbeth] Erasmus Univ, Med Ctr, Dept Epidemiol, Sp 3435,POB 2060, NL-3000 CB Rotterdam, Netherlands; [den Dekker, Herman T.; Voort, Agnes M. M. Sonnenschein-van der; Jaddoe, Vincent W. V.] Erasmus Univ, Med Ctr, Generat Study Grp R, Sp 3435,POB 2060, NL-3000 CB Rotterdam, Netherlands; [Reiss, Irwin K.; Duijts, Liesbeth] Erasmus Univ, Med Ctr, Dept Pediat, Div Neonatol, Sp 3435,POB 2060, NL-3000 CB Rotterdam, Netherlands; [Jaddoe, Vincent W. V.] Erasmus Univ, Med Ctr, Dept Pediat, Sp 3435,POB 2060, NL-3000 CB Rotterdam, Netherlands; [Anessi-Maesano, Isabella] UMR S 707 INSERM Paris, EPAR, Paris, France; [Anessi-Maesano, Isabella] Univ Paris 06, UMR S 707, EPAR, Paris, France; [Anessi-Maesano, Isabella] Univ Paris 06, UMR S 707, EPAR, Paris, France; [Arshad, S. Hasan; Roberts, Graham] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Wight, England; [Arshad, S. Hasan; Pike, Katy C.; Roberts, Graham] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England; [Arshad, S. Hasan; Roberts, Graham] Univ Hosp Southampton NHS Fdn Trust, NIHR Resp Biomed Res Unit, Southampton, Hants, England; [Barros, Henrique; Phar, Sofia Correia] Univ Porto, Sch Med, Dept Clin Epidemiol Predict Med & Publ Hlth, Rua Campo Alegre 823, P-4100 Oporto, Portugal; [Beardsmore, Caroline S.] Univ Leicester, Div Child Hlth, Dept Infect Immun & Inflammat, Leicester, Leics, England; [Beardsmore, Caroline S.] Inst Lung Hlth, Leicester, Leics, England; [Kreiner-Moller, Eskil] Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood COPS, Fac Hlth Sci, DK-1168 Copenhagen, Denmark; [Kreiner-Moller, Eskil; Morales, Eva] Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Gentofte, Denmark; [Craig, Leone] Univ Aberdeen, Publ Hlth Nutr Res Grp, Aberdeen AB9 1FX, Scotland; [Craig, Leone; Devereux, Graham] Univ Aberdeen, Appl Hlth Sci, Aberdeen AB9 1FX, Scotland; [van der Ent, C. Kors] Univ Med Ctr Utrecht, Dept Pediat Pulmonol, Wilhelmina Childrens Hosp, Utrecht, Netherlands; [Esplugues, Ana] Fac Nursing & Chiropody, Valencia, Spain; [Esplugues, Ana] FISABIO, Valencia, Spain; [Esplugues, Ana; Ibarluzea, Jesus] CIBERESP, Madrid, Spain; [Fantini, Maria P.; Gori, Davide] Univ Bologna, Dept Biomed & Neuromotor Sci, I-40126 Bologna, Italy; [Flexeder, Claudia] Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany; [Frey, Urs] Univ Basel, Univ Childrens Hosp Basel UKBB, CH-4003 Basel, Switzerland; [Forastiere, Francesco] Lazio Reg Hlth Serv, Dept Epidemiol, Rome, Italy; [Gehring, Ulrike] Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; [Henderson, A. John] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England; [Heude, Barbara] CESP Inserm, UMRS 1018, Team 10, Villejuif, France; [Heude, Barbara] Univ Paris 11, UMRS 1018, Team 10, Villejuif, France; [Ibarluzea, Jesus] Publ Hlth Div Gipuzkoa, San Sebastian, Spain; [Inskip, Hazel M.] Univ Southampton, MRC Life Course Epidemiol Unit, Southampton Gen Hosp, Southampton SO9 5NH, Hants, England; [Keil, Thomas] Charite, Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Kogevinas, Manolis] Natl Sch Publ Hlth, Athens, GA USA; [Kogevinas, Manolis; Sunyer, Jordi] CREAL, Barcelona, Spain; [Kogevinas, Manolis] Hosp Mar Med Res Inst IMIM, Barcelona, Spain; [Kuehni, Claudia E.] Univ Bern, Inst Social & Prevent Med ISPM, CH-3012 Bern, Switzerland; [Lau, Susanne] Charite, Dept Pediat Pneumol & Immunol, Med Ctr, D-13353 Berlin, Germany; [Schultz, Erica S.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Melen, Erik; Schultz, Erica S.] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden; [Mommers, Monique; Penders, John] Maastricht Univ, Dept Epidemiol, CAPHRI Sch Publ Hlth & Primary Care, NL-6200 MD Maastricht, Netherlands; [Morales, Eva; Sunyer, Jordi] Univ Pompeu Fabra, Barcelona, Spain; [Schmidt, Anne] Univ Bern, Div Resp Med, Dept Pediat, Inselspital, CH-3012 Bern, Switzerland; [Torrent, Matias] IB SALUT Area Salut Menorca, Balearic Isl, Spain; [Vassilaki, Maria] Univ Crete, Dept Social Med, Sch Med, Crete, France; [Wijga, Alet H.] Natl Inst Publ Hlth & Environm RIVM, Ctr Nutr Prevent & Hlth Serv, Bilthoven, Netherlands; [Zabaleta, Carlos] Nuestra Senora Antigua Hosp, OSAKIDETZA Basque Hlth Serv, San Sebastian, Spain	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Universidade do Porto; University of Leicester; University of Leicester; University of Copenhagen; University of Copenhagen; University of Aberdeen; University of Aberdeen; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Bologna; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Basel; Utrecht University; University of Bristol; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; University of Southampton; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University of Bern; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Karolinska Institutet; Karolinska Institutet; Maastricht University; Pompeu Fabra University; University of Bern; Atencio Primaria de Menorca; Universite de Franche-Comte; Netherlands National Institute for Public Health & the Environment			Barros, Henrique/Q-8609-2019; Forastiere, Francesco/J-9067-2016; Porta, Daniela/J-9042-2016; Schulz, Holger/J-5643-2015; Penders, John/A-1280-2011; Bisgaard, Hans/N-4761-2016; Esplugues, Ana/AAX-5393-2021; Gori, Davide/AAC-3486-2022; Morales, Eva/HHS-0651-2022; Íbarluzea, Jesus/ACJ-5440-2022; pike, katy/GPX-8105-2022; Heude, Barbara/G-3095-2016; Esplugues, Ana/AAX-5245-2021; Barros, Henrique/A-5488-2008; Kogevinas, Manolis/C-3918-2017; Heude, Barbara/GLU-9626-2022; Sunyer, Jordi/G-6909-2014; Inskip, Hazel/L-5467-2018	Barros, Henrique/0000-0003-4699-6571; Forastiere, Francesco/0000-0002-9162-5684; Porta, Daniela/0000-0002-3431-2729; Schulz, Holger/0000-0002-1157-200X; Penders, John/0000-0001-9146-5919; Bisgaard, Hans/0000-0003-4131-7592; Esplugues, Ana/0000-0002-7647-7900; Gori, Davide/0000-0003-4954-9419; Morales, Eva/0000-0003-3145-7022; Íbarluzea, Jesus/0000-0002-6933-5373; Heude, Barbara/0000-0002-1565-1629; Kogevinas, Manolis/0000-0002-9605-0461; Heude, Barbara/0000-0002-1565-1629; Sunyer, Jordi/0000-0002-2602-4110; Gehring, Ulrike/0000-0003-3612-5780; Kreiner, Eskil/0000-0003-1204-2438; Van der Ent, Cornelis/0000-0002-2501-4121; Roberts, Graham/0000-0003-2252-1248; Frey, Urs/0000-0003-3773-2822; Kuehni, Claudia E./0000-0001-8957-2002; Lau, Susanne/0000-0002-5189-4265; Inskip, Hazel/0000-0001-8897-1749	FP7 MeDALL project (Mechanisms of the Development of ALLergy) [261357]; National Institutes of Health (NIH); Medical Research Council; Swiss National Science Foundation; Wellcome Trust; UK Medical Research Council; British Heart Foundation; Asthma Research UK; British Lung Foundation; Food Standards Agency; Dunhill Medical Trust; German Research Foundation; Allergopharma; Symbiopharma; Medical Research Council [MC_PC_15018, MC_UU_12011/4, G9815508, G0900453, G0401540, MC_UP_A620_1017] Funding Source: researchfish; MRC [G0401540, MC_UU_12011/4, MC_UP_A620_1017, G0900453] Funding Source: UKRI	FP7 MeDALL project (Mechanisms of the Development of ALLergy); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Wellcome Trust(Wellcome Trust); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Asthma Research UK; British Lung Foundation; Food Standards Agency; Dunhill Medical Trust(Dunhill Medical Trust); German Research Foundation(German Research Foundation (DFG)); Allergopharma; Symbiopharma; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	I. Anessi-Maesano has received a grant from the FP7 MeDALL project (Mechanisms of the Development of ALLergy, FP7 no. 261357) and has board memberships with the European Respiratory Journal, Clinical and Experimental Allergy, the International Journal of Tuberculosis and Lung Disease, BMC Public Health, the European Respiratory Review, Multidisciplinary Respiratory Medicine, Therapeutic Advances in Respiratory Disease, Multidisciplinary Review Frontiers in Medicine, and La lettre du pneumologue. S. H. Arshad has received grants from the National Institutes of Health (NIH) and the Medical Research Council and has consultant arrangements with Merck & Co. U. Frey and A. Schmidt have received grants from the Swiss National Science Foundation. A. J. Henderson has received grants from the Medical Research Council and the Wellcome Trust. H. M. Inskip has received grants from the UK Medical Research Council, the British Heart Foundation, Asthma Research UK, the British Lung Foundation, the Food Standards Agency, and the Dunhill Medical Trust; is deputy chair of a grant-funding board for the UK Medical Research Council; and has her employment funded by the Medical Research Council. S. Lau has received grants from the German Research Foundation, Allergopharma, and Symbiopharma and has consultant arrangements with Merck. K. C. Pike has received grants from the Food Standards Agency and the British Lung Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Been JV, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001596; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Bjermer L, 2014, CURR OPIN PULM MED, V20, P23, DOI 10.1097/MCP.0000000000000018; Bland JM, 1996, BRIT MED J, V312, P1654, DOI 10.1136/bmj.312.7047.1654; Boezen HM, 2002, EUR RESPIR J, V20, P383, DOI 10.1183/09031936.02.00234102; Brostrom EB, 2013, EUR J EPIDEMIOL, V28, P79, DOI 10.1007/s10654-013-9761-7; Canoy D, 2007, THORAX, V62, P396, DOI 10.1136/thx.2006.066241; Cerin E, 2009, PUBLIC HEALTH NUTR, V12, P1182, DOI 10.1017/S1368980008003649; Cole DA, 2014, PSYCHOL METHODS, V19, P300, DOI 10.1037/a0033805; Costeloe KL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7976; Debray TPA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060650; Dixon Anne E, 2010, Proc Am Thorac Soc, V7, P325, DOI 10.1513/pats.200903-013ST; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Hancox RJ, 2009, THORAX, V64, P228, DOI 10.1136/thx.2008.103978; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Hsia CCW, 2004, AM J RESP CRIT CARE, V170, P319, DOI 10.1164/rccm.200209-1062ST; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kotecha S, 2000, Paediatr Respir Rev, V1, P308, DOI 10.1053/prrv.2000.0069; Kotecha SJ, 2013, THORAX, V68, P760, DOI 10.1136/thoraxjnl-2012-203079; Kotecha SJ, 2012, THORAX, V67, P54, DOI 10.1136/thoraxjnl-2011-200329; Lawlor DA, 2005, THORAX, V60, P851, DOI 10.1136/thx.2005.042408; Lima RD, 2005, CHEST, V128, P2400, DOI 10.1378/chest.128.4.2400; Lipworth B, 2014, LANCET RESP MED, V2, P497, DOI 10.1016/S2213-2600(14)70103-1; Lum S, 2001, AM J RESP CRIT CARE, V164, P2078, DOI 10.1164/ajrccm.164.11.2104053; MacKinnon DP, 2009, CURR DIR PSYCHOL SCI, V18, P16, DOI 10.1111/j.1467-8721.2009.01598.x; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; MILLER MR, 1988, THORAX, V43, P265, DOI 10.1136/thx.43.4.265; Narang I, 2008, AM J RESP CRIT CARE, V178, P74, DOI 10.1164/rccm.200705-701OC; Narayanan M, 2012, AM J RESP CRIT CARE, V185, P186, DOI 10.1164/rccm.201107-1348OC; NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P; Quanjer PH, 2010, EUR RESPIR J, V36, P1391, DOI 10.1183/09031936.00164109; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Rzehak P, 2013, J ALLERGY CLIN IMMUN, V131, P1528, DOI 10.1016/j.jaci.2013.01.001; Scholtens S, 2009, J ALLERGY CLIN IMMUN, V123, P1312, DOI 10.1016/j.jaci.2009.02.029; Sherrill DL, 2011, PEDIATR PULM, V46, P956, DOI 10.1002/ppul.21470; Stocks J, 2013, THER ADV RESPIR DIS, V7, P161, DOI 10.1177/1753465813479428; Suresh S, 2012, CHEST, V142, P1603, DOI 10.1378/chest.11-2976; van der Gugten AC, 2012, EUR RESPIR J, V39, P403, DOI 10.1183/09031936.00188310; van der Gugten AD, 2011, AM J RESP CRIT CARE, V183, P553, DOI 10.1164/ajrccm.183.4.553; van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040; Vollsaeter M, 2013, THORAX, V68, P767, DOI 10.1136/thoraxjnl-2012-202980; Voort AMMSVD, 2014, J ALLERGY CLIN IMMUN, V133, P1317, DOI 10.1016/j.jaci.2013.12.1082; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005	51	116	118	1	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1026	1035		10.1016/j.jaci.2015.08.050	http://dx.doi.org/10.1016/j.jaci.2015.08.050			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26548843	Bronze, Green Submitted, Green Published			2022-12-18	WOS:000373351200008
J	Creticos, PS; Maloney, J; Bernstein, DI; Casale, T; Kaur, A; Fisher, R; Liu, N; Murphy, K; Nekam, K; Nolte, H				Creticos, Peter S.; Maloney, Jennifer; Bernstein, David I.; Casale, Thomas; Kaur, Amarjot; Fisher, Robert; Liu, Nancy; Murphy, Kevin; Nekam, Kristof; Nolte, Hendrik			Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy immunotherapy tablet; allergic conjunctivitis; allergic rhinitis; allergic rhinoconjunctivitis; specific immunotherapy; ragweed pollen; sublingual immunotherapy	SUBLINGUAL IMMUNOTHERAPY; DOSE-RESPONSE; EFFICACY; SAFETY; RHINITIS; SENSITIZATION; ORGANIZATION; ANTIBODIES; INJECTIONS; CHILDREN	Background: In North America and Europe, millions of patients experience symptoms of allergic rhinitis with or without conjunctivitis (AR/C) on exposure to ragweed pollen. The disease burden can be significant, with most patients relying on symptomatic medications without disease-modifying potential. However, novel sublingual immunomodulatory treatment options may potentially play an important role if efficacy and side effect profiles allow the convenience of self-administration. Objectives: This study evaluated an allergy immunotherapy tablet (AIT; SCH 39641/MK-3641) for treatment of ragweed-induced AR/C in the first large randomized, double-blind multinational trial of this therapeutic modality for ragweed allergy. Methods: Adults (n = 784) with short ragweed-induced AR/C were randomly assigned to approximately 52 weeks of daily self-administered ragweed AIT of 1.5, 6, or 12 units of Ambrosia artemisiifolia major allergen 1 (Amb a 1-U) or placebo. Subjects could use as-needed allergy rescue medication. Symptoms and medications were recorded daily. The primary efficacy end point was total combined daily symptom/medication score (TCS) during peak ragweed season. Safety was monitored through adverse event diaries maintained through study duration. Results: During peak ragweed season, ragweed AIT of 1.5, 6, and 12 Amb a 1-U reduced TCS by 9% (-0.76; P =.22), 19% (-1.58; P =.01), and 24% (-2.04; = -.002) compared with placebo. During the entire season, ragweed AIT of 1.5, 6, and 12 Amb a 1-U reduced TCS by 12% (-0.88; P = .09), 18% (-1.28; P =.01), and 27% (-1.92; P <.001) compared with placebo. Treatment was well tolerated; no systemic allergic reactions occurred. Conclusions: In this trial, ragweed AIT of 12 Amb a 1-U was effective and tolerable with a safety profile that permitted daily self-administration of ragweed allergen immunotherapy.	[Creticos, Peter S.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD 21224 USA; [Maloney, Jennifer; Kaur, Amarjot; Liu, Nancy; Nolte, Hendrik] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA; [Bernstein, David I.] Bernstein Clin Res Ctr, Cincinnati, OH USA; [Bernstein, David I.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Casale, Thomas] Creighton Univ, Omaha, NE 68178 USA; [Fisher, Robert] Allergy Res & Care, Milwaukee, WI USA; [Murphy, Kevin] Boys Town Natl Res Hosp, Boys Town, IL USA; [Nekam, Kristof] Bros St John God, Hosp Hospitaller, Budapest, Hungary	Johns Hopkins University; Merck & Company; University System of Ohio; University of Cincinnati; Creighton University	Creticos, PS (corresponding author), Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	psocrates@comcast.net	Fisher, Robert Anthony/H-6779-2019		Merck Sharp & Dohme Corp, Whitehouse Station, NJ; Bernstein Clinical Research Center	Merck Sharp & Dohme Corp, Whitehouse Station, NJ; Bernstein Clinical Research Center	Supported by Merck Sharp & Dohme Corp, Whitehouse Station, NJ.; Disclosure of potential conflict of interest: D. I. Bernstein has been supported by one or more grants from the Bernstein Clinical Research Center; has received one or more consulting fees or honoraria and received one or more fees for participation from Merck and ALK-Abello; has received support for travel from Merck; has consultancy arrangements with Proctor and Gamble and Sanofi Aventis; has provided expert testimony for a number of law firms; and has received one or more grants from or has one or more grants pending with NIOSH/CDC, NIAID, and NIEHS. T. Casale has been supported by one or more grants from Merck, has consultancy arrangements with and has received one or more grants from or has one or more grants pending with Stallergenes, and has received one or more payments for lecturing from or is on the speakers' bureau for ALK-Abello. P. S. Creticos has been supported by one or more grants from Johns Hopkins School of Medicine; has consultancy arrangements with Merck, Greer Labs, Stallergenes, and Circassia; and has received one or more grants from or has one or more grants pending with Merck/Schering-Plough, Greer Labs, Stallergenes, Circassia, and UpToDate/AHRQ. A. Kaur, N. Liu, J. Maloney, and H. Nolte are employed by Merck Sharp& Dohme Corp, a subsidiary of Merck& Co, Inc, Whitehouse Station, NJ. K. Murphy is an Advisory Board member for, has consultancy arrangements with, and has received one or more payments for lecturing from or is on the speakers' bureau for Merck. The rest of the authors declare that they have no relevant conflicts of interest.	Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; [Anonymous], 2009, GUID CLIN DEV PROD S; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Asero R, 2006, CLIN EXP ALLERGY, V36, P658, DOI 10.1111/j.1365-2222.2006.02477.x; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2011, ALLERGY, V66, P765, DOI 10.1111/j.1398-9995.2011.02590.x; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425, DOI 10.1016/S1081-1206(10)61408-1; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Burbach GJ, 2009, ALLERGY, V64, P664, DOI 10.1111/j.1398-9995.2009.01975.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Creticos PS, 2007, J ALLERGY CLIN IMMUN, V119, P1031, DOI 10.1016/j.jaci.2007.02.035; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Didier A, 2011, J ALLERGY CLIN IMMUN, V128, P559, DOI 10.1016/j.jaci.2011.06.022; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Epstein TG, 2011, ANN ALLERG ASTHMA IM, V107, P426, DOI 10.1016/j.anai.2011.05.020; Esch RE, 2008, ANN ALLERG ASTHMA IM, V100, P475, DOI 10.1016/S1081-1206(10)60474-7; Gadermaier G, 2008, ALLERGY, V63, P1543, DOI 10.1111/j.1398-9995.2008.01780.x; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Hsu NM, 2012, INT FORUM ALLERGY RH, V2, P280, DOI 10.1002/alr.21037; Kette F, 2011, J ALLERGY CLIN IMMUN, V128, P430, DOI 10.1016/j.jaci.2011.04.048; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; Nayak AS, 2012, ALLERGY ASTHMA PROC, V33, P404, DOI 10.2500/aap.2012.33.3605; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Oberhuber C, 2008, INT ARCH ALLERGY IMM, V145, P94, DOI 10.1159/000108134; Skoner D, 2010, J ALLERGY CLIN IMMUN, V125, P660, DOI 10.1016/j.jaci.2009.12.931; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425, DOI 10.1016/S1081-1206(10)61509-8; Ziska L, 2011, P NATL ACAD SCI USA, V108, P4248, DOI 10.1073/pnas.1014107108	38	116	120	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1342	U148		10.1016/j.jaci.2013.03.019	http://dx.doi.org/10.1016/j.jaci.2013.03.019			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23622121				2022-12-18	WOS:000318912200011
J	Di Bona, D; Plaia, A; Leto-Barone, MS; La Piana, S; Di Lorenzo, G				Di Bona, Danilo; Plaia, Antonella; Leto-Barone, Maria Stefania; La Piana, Simona; Di Lorenzo, Gabriele			Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis-based comparison	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sublingual immunotherapy; subcutaneous immunotherapy; allergic rhinitis; grass; meta-analysis	PLACEBO-CONTROLLED IMMUNOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; 5-GRASS POLLEN TABLET; HIGH-MOLECULAR-WEIGHT; DOUBLE-BLIND; SWALLOW IMMUNOTHERAPY; STANDARDIZED GRASS; CONTROLLED MULTICENTER; CLINICAL-EFFICACY; SAFETY	Background: Subcutaneous (SCIT) and sublingual (SLIT) immunotherapy are the 2 most prescribed routes for administering allergen-specific immunotherapy. They were shown to be effective in control of symptoms and in reducing rescue medication use in patients with allergic diseases, but their effectiveness has to be balanced against side effects. In recent years, SLIT has been increasingly prescribed, instead of SCIT, because of improved safety and easy administration. Objective: We assessed which route is the most effective in the treatment of patients with seasonal allergic rhinitis to grass pollen. Methods: An indirect meta-analysis-based comparison between SCIT and SLIT was performed. Treatment efficacy was determined as the standardized mean difference (SMD) in symptom and medication scores obtained with active treatment, SCIT or SLIT, compared with placebo. Studies were included if they were double-blind randomized controlled trials comparing SCIT or SLIT with placebo. Thirty-six randomized controlled trials (3014 patients; 2768 controls) were analyzed. Results: The overall effect size of SCIT for symptom score (SMD, 20.92; 95% CI, 21.26 to 20.58) was significantly higher than SLIT, both administered via drops (SMD, 20.25; 95% CI, 20.45 to 20.05) and tablets (SMD, 20.40; 95% CI, 20.54 to 20.27). Similar results were reported for medication score (SCIT: SMD, 20.58; 95% CI, 20.86 to 20.30. SLIT drops: SMD, 20.37; 95% CI, 20.74 to 20.00. SLIT tablets SMD, 20.30; 95% CI, 20.44 to 20.16). Conclusions: Our results provide indirect but solid evidence that SCIT is more effective than SLIT in controlling symptoms and in reducing the use of antiallergic medications in seasonal allergic rhinoconjuntivitis to grass pollen. (J Allergy Clin Immunol 2012;130:1097-107.)	[Di Bona, Danilo; La Piana, Simona] Univ Palermo, Dipartimento Biopatol & Biotecnol Med & Forensi, I-90133 Palermo, Italy; [Di Bona, Danilo] CNR, IBIM, Palermo, Italy; [Di Bona, Danilo] Azienda Osped Univ Policlin Palermo, Unita Operativa Immunoematol & Med Trasfus, Palermo, Italy; [Leto-Barone, Maria Stefania; Di Lorenzo, Gabriele] Univ Palermo, Dipartimento Med Interna & Specialist DIMIS, I-90133 Palermo, Italy; [Plaia, Antonella] Univ Palermo, Dipartimento Sci Stat & Matemat, I-90133 Palermo, Italy	University of Palermo; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR); University of Palermo; Policlinico Paolo Giaccone; University of Palermo; University of Palermo	Di Lorenzo, G (corresponding author), Dipartimento Med Clin & Patol Emergenti, Via Vespro 141, I-90127 Palermo, Italy.	gabriele.dilorenzo@unipa.it	Plaia, Antonella/K-2462-2015	Plaia, Antonella/0000-0001-7811-2430; Di Lorenzo, Gabriele/0000-0002-0197-5665				Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; BOUSQUET J, 1987, INT ARCH ALLER A IMM, V82, P550, DOI 10.1159/000234277; Bousquet J, 2010, ALLERGY, V65, P1212, DOI [10.1111/j.1398-9995.2010.02439.x, 10.1111/j.1398-9995.2010.02480.x]; Bousquet PJ, 2011, J ALLERGY CLIN IMMUN, V127, P49, DOI 10.1016/j.jaci.2010.09.017; Brewczynski PZ, 1999, ALLERGOLOGIE, V22, P411; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Calderon MA, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001936.PUB2; Calderon MA, 2011, J ALLERGY CLIN IMMUN, V127, P30, DOI 10.1016/j.jaci.2010.08.024; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cox L, 2011, IMMUNOL ALLERGY CLIN, V31, P561, DOI 10.1016/j.iac.2011.05.001; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; De Blay F, 2007, ANN ALLERG ASTHMA IM, V99, P453, DOI 10.1016/S1081-1206(10)60571-6; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Di Bona D, 2010, J ALLERGY CLIN IMMUN, V126, P558, DOI 10.1016/j.jaci.2010.06.013; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; DuBuske LH, 2011, ALLERGY ASTHMA PROC, V32, P239, DOI 10.2500/aap.2011.32.3453; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT, 2008, INT J EPIDEMIOL, V37, P1158, DOI 10.1093/ije/dyn204; Horak F, 2009, CLIN EXP ALLERGY, V39, P394, DOI 10.1111/j.1365-2222.2008.03153.x; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Mosges R, 2007, ACTA DERMATOVEN ALP, V16, P143; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2008.01875.x, 10.1111/j.1398-9995.2009.02194.x]; Palma-Carlos A G, 2006, Allergol Immunopathol (Madr), V34, P194, DOI 10.1157/13094026; PASTORELLO EA, 1992, ALLERGY, V47, P281, DOI 10.1111/j.1398-9995.1992.tb02054.x; Pfaar O, 2012, ALLERGY, V67, P272, DOI 10.1111/j.1398-9995.2011.02736.x; Pfaar O, 2008, ANN ALLERG ASTHMA IM, V100, P256, DOI 10.1016/S1081-1206(10)60451-6; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; R Core Team, 2017, R LANGUAGE ENVIRONME; Radulovic S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002893.pub2; Roder E, 2007, J ALLERGY CLIN IMMUN, V119, P892, DOI 10.1016/j.jaci.2006.12.651; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Schwarzer G., 2010, META METAANALYSIS R; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Viechtbauer W., 2010, METAFOR METAANALYSIS; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Zenner HP, 1997, J ALLERGY CLIN IMMUN, V100, P23, DOI 10.1016/S0091-6749(97)70190-8	57	116	118	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1097	+		10.1016/j.jaci.2012.08.012	http://dx.doi.org/10.1016/j.jaci.2012.08.012			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	23021885				2022-12-18	WOS:000310571400010
J	Darrow, LA; Hess, J; Rogers, CA; Tolbert, PE; Klein, M; Sarnat, SE				Darrow, Lyndsey A.; Hess, Jeremy; Rogers, Christine A.; Tolbert, Paige E.; Klein, Mitchel; Sarnat, Stefanie E.			Ambient pollen concentrations and emergency department visits for asthma and wheeze	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pollen; asthma exacerbation; wheeze; pollinosis; aeroallergens; bioaerosols; ozone; climate change; epidemiology	AMBROSIA-ARTEMISIIFOLIA L.; CLIMATE-CHANGE; TIME-SERIES; OUTDOOR AEROALLERGENS; SPATIAL VARIABILITY; AIRBORNE POLLEN; OZONE EXPOSURE; CASE-CROSSOVER; AIR-POLLUTION; TREE POLLEN	Background: Previous studies report associations between aeroallergen exposure and asthma exacerbations. Aeroallergen burdens and asthma prevalence are increasing worldwide and are projected to increase further with climate change, highlighting the importance of understanding population-level relationships between ambient pollen concentrations and asthma. Objective: We sought to examine short-term associations between ambient concentrations of various pollen taxa and emergency department (ED) visits for asthma and wheeze in the Atlanta metropolitan area between 1993 and 2004. Methods: We assessed associations between the 3-day moving average (lag 0-1-2) of Betulaceae (except Alnus species), Cupressaceae, Quercus species, Pinaceae (except Tsuga species), Poaceae, and Ambrosia species pollen concentrations and daily asthma and wheeze ED visit counts, controlling for covarying pollen taxa and ambient pollutant concentrations. Results: We observed a 2% to 3% increase in asthma-and wheeze-related ED visits per SD increase in Quercus species and Poaceae pollen and a 10% to 15% increased risk on days with the highest concentrations (comparing the top 5% of days with the lowest 50% of days). An SD increase in Cupressaceae concentrations was associated with a 1% decrease in ED visits. The association for Quercus species pollen was strongest for children aged 5 to 17 years. Effects of Ambrosia species pollen on asthma exacerbations were difficult to assess in this large-scale temporal analysis because of possible confounding by the steep increase in circulating rhinoviruses every September. Conclusion: Poaceae and Quercus species pollen contribute to asthma morbidity in Atlanta. Altered Quercus species and Poaceae pollen production caused by climate change could affect allergen-induced asthma morbidity in the southeastern United States. (J Allergy Clin Immunol 2012;130:630-8.)	[Darrow, Lyndsey A.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; [Hess, Jeremy; Tolbert, Paige E.; Klein, Mitchel; Sarnat, Stefanie E.] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA; [Hess, Jeremy] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA; [Rogers, Christine A.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Publ Hlth, Amherst, MA 01003 USA	Emory University; Rollins School Public Health; Emory University; Rollins School Public Health; Emory University; University of Massachusetts System; University of Massachusetts Amherst	Darrow, LA (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd NE,CNR 3037, Atlanta, GA 30322 USA.	ldarrow@emory.edu	Rogers, Christine A/A-2189-2008; Rogers, Christine A/M-6007-2017; Tolbert, Paige E/A-5676-2015	Rogers, Christine A/0000-0003-0887-9606; Rogers, Christine A/0000-0003-0887-9606; 	Centers for Disease Control and Prevention (TKC Global Solutions, LLC) [JR5000139]; US Environmental Protection Agency (USEPA) [RD834799, RD833626]; National Institute of Environmental Health Sciences (NIEHS) [R03ES018963, R01ES11294]; Electric Power Research Institute [EP-P277231/C13172]; Centers for Disease Control and Prevention (CDC); CDC; EPA; National Institutes of Health; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES018963, R01ES011294] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention (TKC Global Solutions, LLC); US Environmental Protection Agency (USEPA)(United States Environmental Protection Agency); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Electric Power Research Institute; Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); CDC(Centre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); EPA(United States Environmental Protection Agency); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Centers for Disease Control and Prevention (TKC Global Solutions, LLC: JR5000139), the US Environmental Protection Agency (USEPA; RD834799), and the National Institute of Environmental Health Sciences (NIEHS; R03ES018963). Creation of the emergency department database was supported by the USEPA (RD833626), the NIEHS (R01ES11294), and the Electric Power Research Institute (EP-P277231/C13172). The content of this publication is solely the responsibility of the grantee and does not necessarily represent the official views of the USEPA. Furthermore, USEPA does not endorse the purchase of any commercial products or services mentioned in the publication.; L. A. Darrow and M. Klein have received research support from the National Institute of Environmental Health Sciences, the US Environmental Protection Agency (EPA), the Electric Power Research Institute, and the Centers for Disease Control and Prevention (CDC). J. Hess has received research support from the CDC. P. E. Tolbert has received research support from the EPA, the Electric Power Research Institute, the National Institutes of Health, and the CDC. S. E. Sarnat has received research support from the EPA and the Electric Power Research Institute. C. A. Rogers declares that she has no relevant conflicts of interest.	Atkinson RW, 2004, THORAX, V59, P277, DOI 10.1136/thx.2003.019133; Beggs PJ, 2010, INT J ENV RES PUB HE, V7, P3006, DOI 10.3390/ijerph7083006; Behrendt H, 2001, CURR OPIN IMMUNOL, V13, P709, DOI 10.1016/S0952-7915(01)00283-7; D'Amato G, 2010, J INVEST ALLERG CLIN, V20, P95; Dales RE, 2004, J ALLERGY CLIN IMMUN, V113, P303, DOI 10.1016/j.jaci.2003.11.016; Dales RE, 2008, INT ARCH ALLERGY IMM, V146, P241, DOI 10.1159/000116360; Frenz D., 1996, AEROBIOLOGIA, V12, P51; Frenz DA, 2001, ANN ALLERG ASTHMA IM, V86, P150, DOI 10.1016/S1081-1206(10)62683-X; Galan I, 2010, THORAX, V65, P398, DOI 10.1136/thx.2009.118992; Garcia-Mozo H, 2006, ANN AGR ENV MED, V13, P209; Heguy L, 2008, ENVIRON RES, V106, P203, DOI 10.1016/j.envres.2007.10.005; Ivy D, 2008, J AIR WASTE MANAGE, V58, P711, DOI 10.3155/1047-3289.58.5.711; Janes H, 2005, EPIDEMIOLOGY, V16, P717, DOI 10.1097/01.ede.0000181315.18836.9d; Jariwala SP, 2011, J ASTHMA, V48, P442, DOI 10.3109/02770903.2011.567427; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Katelaris CH, 2004, ANN ALLERG ASTHMA IM, V93, P131, DOI 10.1016/S1081-1206(10)61464-0; Lewis WH VP, 1983, AIRBORNE ALLERGENIC; Lierl MB, 2003, ANN ALLERG ASTHMA IM, V90, P28, DOI 10.1016/S1081-1206(10)63610-1; Lu Y, 2007, BIOSTATISTICS, V8, P337, DOI 10.1093/biostatistics/kxl013; National Heart Lung and Blood Institute, 2007, NIH PUBL; Pashley CH, 2009, AEROBIOLOGIA, V25, P249, DOI 10.1007/s10453-009-9130-x; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336, DOI 10.1164/ajrccm.151.5.7735583; Rogers CA, 2006, ENVIRON HEALTH PERSP, V114, P865, DOI 10.1289/ehp.8549; Sarnat SE, 2010, J EXPO SCI ENV EPID, V20, P135, DOI 10.1038/jes.2009.10; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; Strickland MJ, 2010, AM J RESP CRIT CARE, V182, P307, DOI 10.1164/rccm.200908-1201OC; Tobias A, 2003, THORAX, V58, P708, DOI 10.1136/thorax.58.8.708; Vagaggini B, 2002, AM J RESP CRIT CARE, V166, P1073, DOI 10.1164/rccm.2201013; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279, DOI 10.1016/S1081-1206(10)62009-1; Wright AL, 2002, CLIN REV ALLERG IMMU, V22, P33, DOI 10.1385/CRIAI:22:1:033; Ziska LH, 2000, GLOB WARM INT CTR M, P449	31	116	117	1	53	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					630	+		10.1016/j.jaci.2012.06.020	http://dx.doi.org/10.1016/j.jaci.2012.06.020			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22840851	Green Accepted			2022-12-18	WOS:000308463500009
J	Senti, G; von Moos, S; Tay, F; Graf, N; Sonderegger, T; Johansen, P; Kundig, TM				Senti, Gabriela; von Moos, Seraina; Tay, Fabian; Graf, Nicole; Sonderegger, Theodor; Johansen, Pal; Kuendig, Thomas M.			Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epicutaneous allergen-specific immunotherapy; epicutaneous immunotherapy; patch immunization	ATOPY PATCH TEST; T-CELL RESPONSE; SUBLINGUAL IMMUNOTHERAPY; POSITION PAPER; RHINITIS; TOLERANCE	Background: Epicutaneous allergen administration using a patch may be an alternative to subcutaneous or sublingual immunotherapy. Objective: To optimize treatment dose and to demonstrate the efficacy and safety of epicutaneous immunotherapy. Methods: This monocentric, placebo-controlled, double-blind trial included 132 patients with grass pollen-induced rhinoconjunctivitis. In February 2008, patients were randomly allocated to receive placebo or 3 different doses of allergen. Before and during the pollen season 2008, patients received 6 weekly patches. Efficacy was assessed 4 to 5 months later (n = 110) and during the pollen season of the treatment-free followup year in 2009 (n = 93). The primary outcome was patientreported changes in hay fever symptoms assessed by a visual analog scale. Secondary outcome measures were weekly visual analog scale symptom scores during pollen season, use of rescue medication, changes in conjunctival and skin reactivity, as well as safety. Results: Hay fever symptoms during the pollen season were reduced by more than 30% in 2008 and by 24% in 2009 in the high-dose group as compared with that in the placebo group, and the alleviation of symptoms in the follow-up year was dependent on the treatment dose. Higher allergen doses were associated with drug-related adverse events (AEs), predominantly manifested by pruritus, erythema, wheal, or eczema. Eleven systemic AEs of grades 1 to 2 required treatment and led to study exclusion. The dropout rate due to AEs was 8.3%. No drug-related serious AE was recorded. Conclusion: Epicutaneous immunotherapy is safe and efficacious in a dose-dependent manner after 6 patches only. (J Allergy Clin Immunol 2012; 129: 128-35.)	[Johansen, Pal; Kuendig, Thomas M.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; [Senti, Gabriela; von Moos, Seraina; Tay, Fabian; Graf, Nicole] Univ Zurich Hosp, Clin Trials Ctr, CH-8091 Zurich, Switzerland; [Sonderegger, Theodor] Cantonal Pharm, Galen Dept, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Kundig, TM (corresponding author), Univ Zurich Hosp, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland.	thomas.kuendig@usz.ch	Johansen, Pål/A-1403-2013; Senti, Gabriela/Y-1019-2019	Johansen, Pål/0000-0002-5055-6299; Senti, Gabriela/0000-0002-9066-8383	Swiss National Science Foundation (SNSF); University of Zurich; Medanz Medical GmbH (Starnberg, Germany); Allergy Innovations (Munich, Germany)	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); University of Zurich; Medanz Medical GmbH (Starnberg, Germany); Allergy Innovations (Munich, Germany)	This academic investigator-initiated study was financially supported by the Swiss National Science Foundation (SNSF), the University of Zurich, Medanz Medical GmbH (Starnberg, Germany), and Allergy Innovations (Munich, Germany).	ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P84, DOI 10.1001/archopht.1990.01070030090035; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Combadiere B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010818; Cox L, 2009, ANN ALLERG ASTHMA IM, V103, P9; Cox L, 2010, CURR MED RES OPIN, V26, P2723, DOI 10.1185/03007995.2010.528647; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Cox L, 2009, ANN ALLERG ASTHMA IM, V103, P451, DOI 10.1016/S1081-1206(10)60259-1; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; Frech SA, 2008, LANCET, V371, P2019, DOI 10.1016/S0140-6736(08)60839-9; Frerichs DM, 2008, VACCINE, V26, P2782, DOI 10.1016/j.vaccine.2008.02.070; Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064; Hankin CS, 2010, ANN ALLERG ASTHMA IM, V104, P79, DOI 10.1016/j.anai.2009.11.010; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Johansson C, 2009, INT ARCH ALLERGY IMM, V150, P51, DOI 10.1159/000210380; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; Maggi E, 2010, CLIN EXP IMMUNOL, V161, P10, DOI 10.1111/j.1365-2249.2010.04148.x; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Passalacqua G, 2009, CURR DRUG TARGETS, V10, P1255, DOI 10.2174/138945009789753237; Pfaar O, 2009, CURR OPIN ALLERGY CL, V9, P208, DOI 10.1097/ACI.0b013e32832aef57; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; RAGUSA VF, 2004, ALLERGY IMMUNOL PARI, V36, P52; Senna G, 2010, J ALLERGY CLIN IMMUN, V126, P668, DOI 10.1016/j.jaci.2010.06.045; Senti G, 2011, ALLERGY, V66, P798, DOI 10.1111/j.1398-9995.2011.02560.x; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019; Turjanmaa K, 2006, ALLERGY, V61, P1377, DOI 10.1111/j.1398-9995.2006.01136.x	35	116	119	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					128	135		10.1016/j.jaci.2011.08.036	http://dx.doi.org/10.1016/j.jaci.2011.08.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	21996342	Green Accepted			2022-12-18	WOS:000298634000016
J	Rothers, J; Wright, AL; Stern, DA; Halonen, M; Camargo, CA				Rothers, Janet; Wright, Anne L.; Stern, Debra A.; Halonen, Marilyn; Camargo, Carlos A., Jr.			Cord blood 25-hydroxyvitamin D levels are associated with aeroallergen sensitization in children from Tucson, Arizona	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; IgE; aeroallergen; allergic rhinitis; asthma; children	VITAMIN-D INTAKE; CHILDHOOD ASTHMA; D SUPPLEMENTATION; PREGNANCY; RISK; IGE; DISEASES; WHEEZE	Background: The association between vitamin D status at birth and childhood allergic outcomes is uncertain. The desert climate of Tucson offers a unique setting for studying the health effects of higher exposure to vitamin D. Objective: To assess the relationship between cord blood 25-hydroxyvitamin D (25[OH]D) levels and allergic outcomes through age 5 years. Methods: Cord blood 25(OH)D levels were measured in 219 participants in the Tucson Infant Immune Study, a population-based birth cohort. Plasma total IgE and specific IgE levels to 6 aeroallergens were measured at 1, 2, 3, and 5 years. Skin prick test (SPT) positivity (wheal diameter >= 3 mm) and physician-diagnosed active allergic rhinitis and asthma were assessed at age 5 years. Longitudinal models were used to assess the relationship between 25(OH)D and IgE levels. Logistic regression models were used to assess the relationship of 25(OH)D level with SPT positivity, allergic rhinitis, and asthma. Results: The median cord blood 25(OH)D level was 64 nmol/L (interquartile range, 49-81 nmol/L). Relative to the reference group (50-74.9 nmol/L), both low (<50 nmol/L) and high (>= 100 nmol/L) levels were associated with increased total IgE (coefficient = 0.27, P = .006 and coefficient = 0.27, P = .04, respectively) and detectable inhalant allergen-specific IgE (odds ratio = 2.4, P = .03 and odds ratio = 4.0, P = .01, respectively) through age 5 years. High 25(OH)D levels were also associated with increased SPT positivity (odds ratio = 4.0, P = .02). By contrast, the 25(OH)D level was not significantly associated with allergic rhinitis or asthma. Conclusion: Both low and high levels of cord blood 25(OH)D were associated with increased aeroallergen sensitization. The association between vitamin D status and actual allergic diseases merits further study. (J Allergy Clin Immunol 2011;128:1093-9.)	[Wright, Anne L.] Univ Arizona, Arizona Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85724 USA; [Rothers, Janet] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ 85724 USA; [Wright, Anne L.] Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA; [Halonen, Marilyn] Univ Arizona, Dept Pharmacol, Tucson, AZ 85724 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona; University of Arizona; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Wright, AL (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Arizona Resp Ctr, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	awright@arc.arizona.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; Halonen, Marilyn/0000-0001-9606-935X	National Institutes of Health [AI 42268, AI 61811]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042268, R01AI061811] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded by National Institutes of Health grants AI 42268 and AI 61811 and the Massachusetts General Hospital Center for D-receptor Activation Research.; Disclosure of potential conflict of interest: J. Rothers, A.L. Wright, and M. Halonen receive research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Back O, 2009, ACTA DERM-VENEREOL, V89, P28, DOI 10.2340/00015555-0541; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Brockow I, 2009, J INVEST ALLERG CLIN, V19, P180; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Camargo CA, 2010, BRIT J NUTR, V104, P1051, DOI 10.1017/S0007114510001674; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Erkkola M, 2009, CLIN EXP ALLERGY, V39, P875, DOI 10.1111/j.1365-2222.2009.03234.x; Freishtat RJ, 2010, J PEDIATR-US, V156, P948, DOI 10.1016/j.jpeds.2009.12.033; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; Godel JC, 2007, PAED CHILD HEALT-CAN, V12, P583, DOI 10.1093/pch/12.7.583; Hypponen E, 2009, ALLERGY, V64, P613, DOI 10.1111/j.1398-9995.2008.01865.x; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Kull I, 2006, J ALLERGY CLIN IMMUN, V118, P1299, DOI 10.1016/j.jaci.2006.08.022; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Litonjua AA, 2009, CURR OPIN ALLERGY CL, V9, P202, DOI 10.1097/ACI.0b013e32832b36cd; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matheu V, 2003, J ALLERGY CLIN IMMUN, V112, P585, DOI [10.1016/S0091-6749(03)01855-4, 10.1037/mai.2003.1703]; Miyake Y, 2010, EUR RESPIR J, V35, P1228, DOI 10.1183/09031936.00100609; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Roth HJ, 2008, ANN CLIN BIOCHEM, V45, P153, DOI 10.1258/acb.2007.007091; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Singh RJ, 2006, J CLIN ENDOCR METAB, V91, P3055, DOI 10.1210/jc.2006-0710; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094; Weiss ST, 2008, CLIN EXP ALLERGY, V38, P385, DOI 10.1111/j.1365-2222.2007.02920.x; Wintergerst ES, 2007, ANN NUTR METAB, V51, P301, DOI 10.1159/000107673; Wittke A, 2004, J IMMUNOL, V173, P3432, DOI 10.4049/jimmunol.173.5.3432; Wjst M, 2007, ALLERGY, V62, P1085, DOI 10.1111/j.1398-9995.2007.01437.x; Wjst M, 1999, ALLERGY, V54, P757, DOI 10.1034/j.1398-9995.1999.00193.x	33	116	120	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1093	U275		10.1016/j.jaci.2011.07.015	http://dx.doi.org/10.1016/j.jaci.2011.07.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21855975	Green Accepted, Bronze			2022-12-18	WOS:000296578200024
J	Lowe, AJ; Hosking, CS; Bennett, CM; Allen, KJ; Axelrad, C; Carlin, JB; Abramson, MJ; Dharmage, SC; Hill, DJ				Lowe, Adrian J.; Hosking, Clifford S.; Bennett, Catherine M.; Allen, Katrina J.; Axelrad, Christine; Carlin, John B.; Abramson, Michael J.; Dharmage, Shyamali C.; Hill, David J.			Effect of a partially hydrolyzed whey infant formula at weaning on risk of allergic disease in high-risk children: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy prevention; infant formulas; partially hydrolyzed whey formula; conventional cow's milk formulas; eczema; asthma; allergic rhinitis; randomized control trial	NUTRITIONAL INTERVENTION; BETA-LACTOGLOBULIN; ATOPIC-DERMATITIS; FOOD ALLERGY; MILK FORMULA; PREVENTION; ASTHMA; TOLERANCE; MANIFESTATIONS; LIFE	Background: Partially hydrolyzed whey formula (pHWF) has been recommended for infants with a family history of allergic disease at the cessation of exclusive breast-feeding to promote oral tolerance and prevent allergic diseases. Objective: To determine whether feeding infants pHWF reduces their risk of allergic disease. Methods: A single-blind (participant) randomized controlled trial was conducted to compare allergic outcomes between infants fed a conventional cow's milk formula, a pHWF, or a soy formula. Before birth, 620 infants with a family history of allergic disease were recruited and randomized to receive the allocated formula at cessation of breast-feeding. Skin prick tests to 6 common allergens (milk, egg, peanut, dust mite, rye grass, and cat dander) were performed at 6, 12, and 24 months. The primary outcome was development of allergic manifestations (eczema and food reactions) measured 18 times in the first 2 years of life. Results: Follow-up was complete for 93% (575/620) at 2 years and 80% (495/620) at 6 or 7 years of age. There was no evidence that infants allocated to the pHWF (odds ratio, 1.21; 95% CI, 0.81-1.80) or the soy formula (odds ratio, 1.26; 95% CI, 0.84-1.88) were at a lower risk of allergic manifestations in infancy compared with conventional formula. There was also no evidence of reduced risk of skin prick test reactivity or childhood allergic disease. Conclusion: Despite current dietary guidelines, we found no evidence to support recommending the use of pHWF at weaning for the prevention of allergic disease in high-risk infants. (J Allergy Clin Immunol 2011;128:360-5.)	[Lowe, Adrian J.; Allen, Katrina J.; Axelrad, Christine; Carlin, John B.; Hill, David J.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic 3053, Australia; [Lowe, Adrian J.; Bennett, Catherine M.; Carlin, John B.; Dharmage, Shyamali C.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Sch Populat Hlth, Melbourne, Vic, Australia; [Hosking, Clifford S.] John Hunter Childrens Hosp, Dept Paediat, Newcastle, NSW, Australia; [Abramson, Michael J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Monash University	Hill, DJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic 3053, Australia.	davidjlhill@bigpond.com	Carlin, John B/B-3492-2012; Carlin, John/AAG-4332-2020; Abramson, Michael/AAQ-2671-2020; Allen, Katrina/I-4361-2018	Carlin, John B/0000-0002-2694-9463; Carlin, John/0000-0002-2694-9463; Abramson, Michael/0000-0002-9954-0538; Allen, Katrina/0000-0002-1921-4493; Dharmage, Shyamali/0000-0001-6063-1937; Lowe, Adrian/0000-0002-4691-8162; Bennett, Catherine/0000-0001-9581-1612	Nestec Ltd, a subsidiary of Nestle Australia; Dairy Australia; Nestle Australia; SHS International; Nutricia	Nestec Ltd, a subsidiary of Nestle Australia(Nestle SA); Dairy Australia(Dairy Australia); Nestle Australia(Nestle SA); SHS International; Nutricia(Danone Nutricia)	Nestec Ltd, a subsidiary of Nestle Australia, provided the study formula and staff funding for the first 6 years of the study.; A. J. Lowe has received research support from Dairy Australia. K. J. Allen has received speaker's honoraria from Wyeth and Nutricia. D. J. Hill has received research support from Nestle Australia, SHS International, and Nutricia. The rest of the authors have declared that they have no conflict of interest.	AAS K, 1973, INT ARCH ALLER A IMM, V45, P57, DOI 10.1159/000231002; de Seta L, 1994, Pediatr Med Chir, V16, P251; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Field CJ, 2005, J NUTR, V135, P1; Fritsche R, 1997, J ALLERGY CLIN IMMUN, V100, P266, DOI 10.1016/S0091-6749(97)70235-5; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Grimshaw KEC, 2009, ALLERGY, V64, P1407, DOI 10.1111/j.1398-9995.2009.02172.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hays T, 2005, ARCH PEDIAT ADOL MED, V159, P810, DOI 10.1001/archpedi.159.9.810; Heine RG, 2008, CURR OPIN CLIN NUTR, V11, P320, DOI 10.1097/MCO.0b013e3282fbf589; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; Host A, 2005, CURR OPIN ALLERGY CL, V5, P255, DOI 10.1097/01.all.0000168791.89829.2a; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; LAM BCC, 1992, 6 ANN SCI M HONG KON; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P1624, DOI 10.1111/j.1365-2222.2007.02822.x; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P536, DOI 10.1111/j.1365-2222.2007.02691.x; MAKINENKILJUNEN S, 1993, CLIN EXP ALLERGY, V23, P287, DOI 10.1111/j.1365-2222.1993.tb00324.x; Marini A, 1996, ACTA PAEDIATR, V85, P1, DOI 10.1111/j.1651-2227.1996.tb14267.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McMillan J, 2000, J SOCIOL, V36, P64, DOI 10.1177/144078330003600105; Miniello V L, 2008, Minerva Pediatr, V60, P1437; Nieto A, 2009, J ALLERGY CLIN IMMUN, V124, P157, DOI 10.1016/j.jaci.2009.04.015; OSBORN DA, 2006, COCHRANE DB SYST REV, P4; Pali-Scholl I, 2009, J ALLERGY CLIN IMMUN, V123, P1012, DOI 10.1016/j.jaci.2009.01.045; Pecquet S, 2000, J ALLERGY CLIN IMMUN, V105, P514, DOI 10.1067/mai.2000.103049; PIANTADOSI S, 1997, CLIN TRIALS METHODOL; Prescott SL, 2005, MED J AUSTRALIA, V182, P464, DOI 10.5694/j.1326-5377.2005.tb06787.x; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/BF02029362; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; WHO (World Health Organization), 2002, COMPL FEED REP GLOB; WILLEMS R, 1993, ANN ALLERGY, V71, P147; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x	37	116	119	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					360	U373		10.1016/j.jaci.2010.05.006	http://dx.doi.org/10.1016/j.jaci.2010.05.006			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21696814				2022-12-18	WOS:000293280800017
J	Gatto, D; Brink, R				Gatto, Dominique; Brink, Robert			The germinal center reaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Germinal center; antibody response; B-cell differentiation; somatic hypermutation; affinity maturation; B-cell migration	MEMORY B-CELLS; FOLLICULAR DENDRITIC CELLS; CLASS-SWITCH RECOMBINATION; PRIMARY IMMUNE-RESPONSE; HELPER T-CELLS; PLASMA-CELL; SOMATIC HYPERMUTATION; IN-VIVO; AUTOIMMUNE-DISEASE; IGE PRODUCTION	The germinal center (GC) reaction is the basis of T-dependent humoral immunity against foreign pathogens and the ultimate expression of the adaptive immune response. GCs represent a unique collaboration between proliferating antigen-specific B cells, T follicular helper cells, and the specialized follicular dendritic cells that constitutively occupy the central follicular zones of secondary lymphoid organs. The primary function of GCs is to produce the high-affinity antibody-secreting plasma cells and memory B cells that ensure sustained immune protection and rapid recall responses against previously encountered foreign antigens. However, the process of somatic mutation of antibody variable region genes that underpins GC function also carries significant risks in the form of unintended oncogenic mutations and generation of potentially pathogenic autoantibody specificities. Here we review the current knowledge on the recruitment, selection, and differentiation of B cells during GC responses and the implication of defects in GC physiology for autoimmune, inflammatory, and malignant diseases. Recent advances in documenting cellular movement within GCs and some of the key migratory signals responsible for GC formation are also discussed. (J Allergy Clin Immunol 2010; 126:898-907.)	[Brink, Robert] Univ New S Wales, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia; Univ New S Wales, St Vincents Clin Sch, Darlinghurst, NSW 2010, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney; University of New South Wales Sydney	Brink, R (corresponding author), Univ New S Wales, Garvan Inst Med Res, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	r.brink@garvan.org.au	Brink, Robert/B-7910-2010	Brink, Robert/0000-0002-9586-3655	Alliance for Lupus Research; National Health and Medical Research Council of Australia	Alliance for Lupus Research; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	D. Gatto has received research support from the Alliance for Lupus Research and the National Health and Medical Research Council of Australia. R. Brink has received research support from the National Health and Medical Research Council of Australia.	Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100; Allen CDC, 2007, SCIENCE, V315, P528, DOI 10.1126/science.1136736; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Aloisi F, 2006, NAT REV IMMUNOL, V6, P205, DOI 10.1038/nri1786; Armengol MP, 2001, AM J PATHOL, V159, P861, DOI 10.1016/S0002-9440(10)61762-2; Arnold CN, 2007, EUR J IMMUNOL, V37, P100, DOI 10.1002/eji.200636486; ARPIN C, 1995, SCIENCE, V268, P720, DOI 10.1126/science.7537388; Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; Bachmann MF, 1996, J EXP MED, V183, P2259, DOI 10.1084/jem.183.5.2259; Bende RJ, 2007, J EXP MED, V204, P2655, DOI 10.1084/jem.20071006; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chan TD, 2009, J IMMUNOL, V183, P3139, DOI 10.4049/jimmunol.0901690; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; Cunningham-Rundles C, 2005, NAT REV IMMUNOL, V5, P880, DOI 10.1038/nri1713; Cyster JG, 2000, IMMUNOL REV, V176, P181; de Vinuesa CG, 2000, J EXP MED, V191, P485, DOI 10.1084/jem.191.3.485; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; Flemming W., 1985, ARCH MIKROSK ANAT, V24, P355; Flemming W., 1885, ARCH MIKROSK ANAT, V24, P50; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; FOY TM, 1994, J EXP MED, V180, P157, DOI 10.1084/jem.180.1.157; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; Gatto D, 2005, J EXP MED, V201, P993, DOI 10.1084/jem.20042239; Gatto D, 2007, J IMMUNOL, V178, P67, DOI 10.4049/jimmunol.178.1.67; Gatto D, 2009, IMMUNITY, V31, P259, DOI 10.1016/j.immuni.2009.06.016; Gearhart PJ, 2001, NAT REV IMMUNOL, V1, P187, DOI 10.1038/35105009; Good-Jacobson KL, 2010, NAT IMMUNOL, V11, P535, DOI 10.1038/ni.1877; Goodnow CC, 2010, NAT IMMUNOL, V11, P681, DOI 10.1038/ni.1900; HAN SH, 1995, J IMMUNOL, V155, P556; Hao ZY, 2008, IMMUNITY, V29, P615, DOI 10.1016/j.immuni.2008.07.016; Hargreaves DC, 2001, J EXP MED, V194, P45, DOI 10.1084/jem.194.1.45; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Hauser AE, 2007, IMMUNITY, V26, P655, DOI 10.1016/j.immuni.2007.04.008; Haynes NM, 2007, J IMMUNOL, V179, P5099, DOI 10.4049/jimmunol.179.8.5099; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1992, J EXP MED, V176, P679, DOI 10.1084/jem.176.3.679; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Kim HJ, 1999, J IMMUNOL, V162, P3053; Klein U, 2003, P NATL ACAD SCI USA, V100, P2639, DOI 10.1073/pnas.0437996100; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; KOOPMAN G, 1991, J EXP MED, V173, P1297, DOI 10.1084/jem.173.6.1297; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Lin KI, 2003, IMMUNOL REV, V194, P19, DOI 10.1034/j.1600-065X.2003.00040.x; Lindhout E, 1999, J IMMUNOL, V162, P5949; Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; Luo ZH, 2004, J ALLERGY CLIN IMMUN, V114, P726, DOI 10.1016/j.jaci.2004.07.049; MacLennan ICM, 2003, IMMUNOL REV, V194, P8, DOI 10.1034/j.1600-065X.2003.00058.x; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; McIntosh RS, 1996, J IMMUNOL, V157, P927; NIEUWENHUIS P, 1984, AM J ANAT, V170, P421, DOI 10.1002/aja.1001700315; Notarangelo LD, 2006, J ALLERGY CLIN IMMUN, V117, P855, DOI 10.1016/j.jaci.2006.01.043; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; O'Connor BP, 2006, J IMMUNOL, V177, P7723, DOI 10.4049/jimmunol.177.11.7723; Okamoto T, 2003, J RHEUMATOL, V30, P1157; OLEE TW, 1992, J EXP MED, V175, P831, DOI 10.1084/jem.175.3.831; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Pape KA, 2003, J EXP MED, V197, P1677, DOI 10.1084/jem.20012065; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Paus D, 2006, J EXP MED, V203, P1081, DOI 10.1084/jem.20060087; Pereira JP, 2009, NATURE, V460, P1122, DOI 10.1038/nature08226; Phan TG, 2006, J EXP MED, V203, P2419, DOI 10.1084/jem.20061254; Phan TG, 2009, NAT IMMUNOL, V10, P786, DOI 10.1038/ni.1745; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; Qin YF, 1998, J CLIN INVEST, V102, P1045, DOI 10.1172/JCI3568; Reif K, 2002, NATURE, V416, P94, DOI 10.1038/416094a; REYNES M, 1985, J IMMUNOL, V135, P2687; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Salomonsson S, 2003, ARTHRITIS RHEUM-US, V48, P3187, DOI 10.1002/art.11311; SCHITTEK B, 1990, NATURE, V346, P749, DOI 10.1038/346749a0; Schwickert TA, 2007, NATURE, V446, P83, DOI 10.1038/nature05573; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Shang XZ, 2006, CELL IMMUNOL, V241, P66, DOI 10.1016/j.cellimm.2006.07.011; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; Simpson N, 2010, ARTHRITIS RHEUM-US, V62, P234, DOI 10.1002/art.25032; Sims GP, 2001, J IMMUNOL, V167, P1935, DOI 10.4049/jimmunol.167.4.1935; Smith KGC, 2000, J EXP MED, V191, P475, DOI 10.1084/jem.191.3.475; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; Stevenson F, 1998, IMMUNOL REV, V162, P247, DOI 10.1111/j.1600-065X.1998.tb01446.x; Stott DI, 1998, J CLIN INVEST, V102, P938, DOI 10.1172/JCI3234; Subramanian S, 2006, P NATL ACAD SCI USA, V103, P9970, DOI 10.1073/pnas.0603912103; Suto A, 2002, BLOOD, V100, P4565, DOI 10.1182/blood-2002-04-1115; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Thaunat O, 2006, CURR OPIN IMMUNOL, V18, P576, DOI 10.1016/j.coi.2006.07.006; Vinuesa CG, 2009, NAT REV IMMUNOL, V9, P845, DOI 10.1038/nri2637; Vinuesa CG, 2005, NATURE, V435, P452, DOI 10.1038/nature03555; Wagner SD, 1996, ANNU REV IMMUNOL, V14, P441, DOI 10.1146/annurev.immunol.14.1.441; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Zotos D, 2010, J EXP MED, V207, P365, DOI 10.1084/jem.20091777	104	116	119	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					898	907		10.1016/j.jaci.2010.09.007	http://dx.doi.org/10.1016/j.jaci.2010.09.007			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	21050940	Bronze			2022-12-18	WOS:000283727100002
J	Di Lorenzo, G; Mansueto, P; Pacor, ML; Rizzo, M; Castello, F; Martinelli, N; Ditta, V; Lo Bianco, C; Leto-Barone, MS; D'Alcamo, A; Di Fede, G; Rini, G; Ditto, AM				Di Lorenzo, Gabriele; Mansueto, Pasquale; Pacor, Maria Luisa; Rizzo, Manfredi; Castello, Francesco; Martinelli, Nicola; Ditta, Vito; Lo Bianco, Claudia; Leto-Barone, Maria Stefania; D'Alcamo, Alberto; Di Fede, Gaetana; Rini, GiovarnBattista; Ditto, Anne Marie			Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen-specific immunotherapy; total IgE; specific IgE; blood eosinophil counts; serum-specific IgE/serum total IgE ratio; receiver operating characteristic curve	DOSE SUBLINGUAL THERAPY; HOUSE DUST MITE; POLLEN SEASON; RHINITIS; ASTHMA; SENSITIZATION; EOSINOPHILS; EXPRESSION; MEDICINE; CELL	Background: To date, no predictive tests for the clinical response to allergen-specific immunotherapy (ASI) are available. Therefore an in vivo or in vitro test would be of great value. Objective: We sought to evaluate pretreatment parameters used in diagnosing allergic rhinitis and determining serum specific IgE (s-IgE) levels, serum total IgE (t-IgE) levels, and blood eosinophil counts and to identify whether can be used to predict clinical improvement in monosensitized patients with allergic rhinitis with or without asthma treated with immunotherapy. Methods: We analyzed 279 patients who had undergone 4 years of ASI administered either by means of the subcutaneous immunotherapy (76 patients) or sublingual immunotherapy (203 patients) routes. Serum t-IgE and s-IgE levels, blood eosinophil counts, and serum s-IgE/t-IgE ratios were calculated and tested for correlation with clinical response to ASI. Receiver operating characteristic curves were determined. Predicted probabilities and predictive areas under the curve were calculated. Results: The clinical response to ASI was effective in 145 (52.0%) of 279 total patients, 42 (55.2%) of 76 patients treated with subcutaneous immunotherapy, and 103 (50.7%) of 203 patients treated with sublingual immunotherapy. A significant correlation was found between the serum s-IgE/t-IgE ratio and the clinical response to ASI, with high ratios (>16.2) associated with an effective response. The sensitivity and specificity of the area under the curve of the ratio were higher than those of serum s-IgE and t-IgE alone. Conclusion: The calculation of the serum s-IgE/t-IgE ratio for predicting the clinical response to ASI offers an advantage over measuring t-IgE and s-IgE levels in monosensitized patients for the following allergens: grass, Parietaria judaica, Olea europea, and house dust mite. (J Allergy Clin Immunol 2009;123:1103-10.)	[Di Lorenzo, Gabriele; Mansueto, Pasquale; Rizzo, Manfredi; Castello, Francesco; Ditta, Vito; Lo Bianco, Claudia; Leto-Barone, Maria Stefania; D'Alcamo, Alberto; Rini, GiovarnBattista] Univ Palermo, Dipartimento Med Clin & Patol Emergenti, I-90127 Palermo, Italy; [Pacor, Maria Luisa; Martinelli, Nicola] Univ Verona, Dipartimento Med Clin & Sperimentale, I-37100 Verona, Italy; [Di Fede, Gaetana] Univ Palermo, Dipartimento Discipline Chirurg & Oncol, I-90127 Palermo, Italy; [Ditto, Anne Marie] Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA	University of Palermo; University of Verona; University of Palermo; Northwestern University; Feinberg School of Medicine	Di Lorenzo, G (corresponding author), Univ Palermo, Dipartimento Med Clin & Patol Emergenti, Via Vespro 141, I-90127 Palermo, Italy.	dilo601@unipa.it	Martinelli, Nicola/J-5622-2016; Mansueto, Pasquale/K-3458-2016	Martinelli, Nicola/0000-0001-6465-5119; Di Lorenzo, Gabriele/0000-0002-0197-5665; RIZZO, Manfredi/0000-0002-9549-8504; Mansueto, Pasquale/0000-0002-0406-0583	Ministero Italiano dell'Universita e della Ricerca; Ernest S. Bazley	Ministero Italiano dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Ernest S. Bazley	Supported by grants from the Ministero Italiano dell'Universita e della Ricerca (MIUR; fondi ex 60%) to Gabriele Di Lorenzo. Anne Marie Ditto is supported by the Ernest S. Bazley Grant.	Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; Abramson MJ, 2000, COCHRANE DB SYST REV; Adkinson NF, 2001, AM J RESP CRIT CARE, V164, P2140; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Bousquet J, 2004, ALLERGY, V59, P12, DOI 10.1111/j.1398-9995.2004.00654.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Di Lorenzo G, 1997, J ALLERGY CLIN IMMUN, V100, P832, DOI 10.1016/S0091-6749(97)70281-1; DiLorenzo G, 1997, CLIN EXP ALLERGY, V27, P1052; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; Jackola DR, 2004, HUM IMMUNOL, V65, P20, DOI 10.1016/j.humimm.2003.10.012; Kerkhof M, 2003, ALLERGY, V58, P905, DOI 10.1034/j.1398-9995.2003.00230.x; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Noon L, 1911, LANCET, V1, P1572; Ortolani C, 1999, ALLERGY, V54, P1173, DOI 10.1034/j.1398-9995.1999.00200.x; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; WARNER JO, 1986, CLIN ALLERGY, V16, P387, DOI 10.1111/j.1365-2222.1986.tb01973.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Xystrakis E, 2007, CURR OPIN ALLERGY CL, V7, P535, DOI 10.1097/ACI.0b013e3282f14d7c	21	116	119	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1103	1110		10.1016/j.jaci.2009.02.012	http://dx.doi.org/10.1016/j.jaci.2009.02.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19356792	Green Submitted			2022-12-18	WOS:000266309400019
J	Visness, CM; London, SJ; Daniels, JL; Kaufman, JS; Yeatts, KB; Siega-Riz, AM; Liu, AH; Calatroni, A; Zeldin, DC				Visness, Cynthia M.; London, Stephanie J.; Daniels, Julie L.; Kaufman, Jay S.; Yeatts, Karin B.; Siega-Riz, Anna-Maria; Liu, Andrew H.; Calatroni, Agustin; Zeldin, Darryl C.			Association of obesity with IgE levels and allergy symptoms in children and adolescents: Results from the National Health and Nutrition Examination Survey 2005-2006	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; allergen-specific IgE; total IgE; body mass index; obesity; overweight; allergic disease; inflammation	BODY-MASS INDEX; ASTHMA; ATOPY; OVERWEIGHT; CONSUMPTION; FATNESS; DRINKS	Background: The prevalence of both obesity and allergic disease has increased among children over the last several decades. Previous literature on the relationship between obesity and allergic disease has been inconsistent. It is not known whether systemic inflammation could be a factor in this relationship. Objective: We sought to examine the association of obesity with total and allergen-specific IgE levels and allergy symptoms in US children and adolescents and to assess the role of C-reactive protein. Methods: National Health and Nutrition Examination Survey data from 2005-2006 included measurement of total and allergen-specific IgE levels and allergy questions. Overweight was defined as the 85th or greater to less than the 95th percentile of body mass index for age, and obesity was defined as the 95th percentile or greater. Linear and logistic regression models were used to examine the association of weight categories with total IgE levels, atopy, allergen-specific IgE levels, and allergy symptoms among youth aged 2 to 19 years. Results: Geometric mean total IgE levels were higher among obese (geometric mean ratio, 1.31; 95% CI, 1.10-1.57) and overweight (ratio, 1.25; 95% CI, 1.02-1.54) children than among normal-weight children. The odds ratio (OR) for atopy (any positive specific IgE measurement) was increased in the obese children compared with that seen in those of normal weight; this association was driven largely by allergic sensitization to foods (OR for atopy, 1.26 [95% CI, 1.03-1.55]; OR for food sensitization, 1.59 [95% CI, 1.28-1.98]). C-reactive protein levels were associated with total IgE levels, atopy, and food sensitization. Conclusions: Obesity might be a contributor to the increased prevalence of allergic disease in children, particularly food allergy. Systemic inflammation might play a role in the development of allergic disease. (J Allergy Clin Immunol 2009;123:1163-9.)	[Visness, Cynthia M.; Calatroni, Agustin] Rho Fed Syst Div Inc, Chapel Hill, NC 27517 USA; [Visness, Cynthia M.; Daniels, Julie L.; Kaufman, Jay S.; Yeatts, Karin B.; Siega-Riz, Anna-Maria] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [London, Stephanie J.; Zeldin, Darryl C.] Natl Inst Environm Hlth Sci, Div Intramural Res, Res Triangle Pk, NC USA; [Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA; [Liu, Andrew H.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Visness, CM (corresponding author), Rho Fed Syst Div Inc, 6330 Quadrangle Dr,Suite 500, Chapel Hill, NC 27517 USA.	cindy_visness@rhoworld.com	Zeldin, Darryl C/Y-7091-2018; Eckhardt, Erik/G-1567-2010	Zeldin, Darryl C/0000-0002-2087-7307; 	National Institutes of Health; National Institute of Environmental Health Sciences [Z01 ES025041-10]; National Institute of Allergy and Infections Diseases; National Institutes of Health [NO1-A1-25482]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD050924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES049019, ZIAES025041, Z01ES025041] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Allergy and Infections Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences(Z01 ES025041-10), and by the National Institute of Allergy and Infections Diseases, National Institutes of Health (NO1-A1-25482).	Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Braback L, 2005, RESP MED, V99, P1010, DOI 10.1016/j.rmed.2005.02.004; Burkhauser RV, 2008, J HEALTH ECON, V27, P519, DOI 10.1016/j.jhealeco.2007.05.005; Butland BK, 2008, EUR RESPIR J, V32, P77, DOI 10.1183/09031936.00077207; Centers for Disease Control, 2007, CLIN GROWTH CHARTS; Chen Y, 2006, CHEST, V130, P890, DOI 10.1378/chest.130.3.890; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323, DOI 10.1046/j.1365-2222.1999.00455.x; Jarvis D, 2002, CLIN EXP ALLERGY, V32, P831, DOI 10.1046/j.1365-2222.2002.01380.x; Kalliomaki M, 2008, AM J CLIN NUTR, V87, P534, DOI 10.1093/ajcn/87.3.534; Krebs NF, 2007, PEDIATRICS, V120, pS193, DOI 10.1542/peds.2007-2329D; Law M, 2005, BRIT MED J, V330, P1187, DOI 10.1136/bmj.38435.582975.AE; Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1; Mei ZG, 2002, AM J CLIN NUTR, V75, P978, DOI 10.1093/ajcn/75.6.978; National Center for Health Statistics, 2007, LETS IMPR OUR HLTH N; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; RCore Team, 2022, R LANG ENV STAT COMP; Rothman K., 1998, MODERN EPIDEMIOLOGY; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Schernhammer ES, 2008, PEDIAT ALLERG IMM-UK, V19, P125, DOI 10.1111/j.1399-3038.2007.00597.x; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; *US BUR CENS, 2007, CENS BUR MEAS POV; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Von Mutius E., 1998, CLIN EXP ALLERGY, V28, pS45; Welsh JA, 2005, PEDIATRICS, V115, pE223, DOI 10.1542/peds.2004-1148; Xu BZ, 2000, J ALLERGY CLIN IMMUN, V105, P393, DOI 10.1016/S0091-6749(00)90095-2	25	116	121	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1163	1169		10.1016/j.jaci.2008.12.1126	http://dx.doi.org/10.1016/j.jaci.2008.12.1126			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW		Green Accepted			2022-12-18	WOS:000266309400027
J	Goleva, E; Hauk, PJ; Hall, CF; Liu, AH; Riches, DWH; Martin, RJ; Leung, DYM				Goleva, Elena; Hauk, Pia J.; Hall, Clifton F.; Liu, Andrew H.; Riches, David W. H.; Martin, Richard J.; Leung, Donald Y. M.			Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						corticosteroids; asthma; resistance; genes; endotoxin	NECROSIS-FACTOR-ALPHA; GLUCOCORTICOID-RECEPTOR-BETA; HUMAN MONOCYTIC CELLS; ENDOTOXIN EXPOSURE; LIPOPOLYSACCHARIDE; EXPRESSION; UPDATE; INDUCTION; SEVERITY; EGR-1	Background: The cause of corticosteroid-resistant (CR) asthma is unknown. Objective: We sought to perform gene microarray analyses by using bronchoalveolar lavage (BAL) cells from well-characterized subjects with CR asthma and subject with corticosteroid-sensitive (CS) asthma to elucidate the differential expression of genes that contribute to the development of corticosteroid resistance. Methods: The patients were characterized as having CR or CS asthma based on FEV1 percent predicted improvement after a I-week course of oral prednisone. Expression of selected gene targets was verified by means of real-time PCR and ELISA. Results: Microarray analyses demonstrated significantly higher levels (>3-fold increase, P <.05) of transcripts for TNF-alpha, IL-1 alpha, IL-1 beta, IL-6, CXCL1, CXCL2, CXCL3, CXCL8 (IL-8), CCL3, CCL4, and CCl20 in BAL cells of subjects with CR asthma. These findings, confirmed by means of RT-PCR in additional BAL samples, were consistent with classical macrophage activation by bacterial products. In contrast, markers of alternatively activated macrophages, arginase I and CCL24, were decreased. Genes associated with activation of the LPS signaling pathway (early growth response 1, dual-specificity phosphatase 2, molecule possessing ankyrin repeats induced by LPS, and TNF-alpha-induced protein 3) were significantly increased in BAL samples from subjects with CR asthma (P <.05). These patients had significantly higher amounts (1444.0 +/- 457.3 pg/mg total protein) of LPS in BAL fluid than seen in subjects with CS asthma (270.5 +/- 216.0 pg, P <.05), as detected by using the LAL assay and confirmed by means of gas chromatographic/mass spectrometric analysis. Prolonged exposure to LPS induced functional steroid resistance to dexamethasone in normal human monocytes, as demonstrated by persistently increased IL-6 levels in the presence of dexamethasone. Conclusions: Classical macrophage activation and induction of LPS signaling pathways along with high endotoxin levels detected in BAL fluid from subjects with CR asthma suggest that LPS exposure might contribute to CR asthma.	[Goleva, Elena; Hauk, Pia J.; Hall, Clifton F.; Liu, Andrew H.; Riches, David W. H.; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Martin, Richard J.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA; [Liu, Andrew H.; Riches, David W. H.; Leung, Donald Y. M.] Univ Colorado, Dept Pediat, Denver, CO 80202 USA; [Martin, Richard J.] Univ Colorado, Dept Med, Denver, CO 80202 USA; Hlth Sci Ctr, Aurora, CO USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St Room K926i, Denver, CO 80206 USA.	leungd@njc.org			National Institutes of Health [A1070140, HL37260]; General Clinical Research Center [MOI RR00051]; Division of Research Resources; Edelstein Family Chair in Pediatric Allergy and Immunology; University of Colorado Cancer Center; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI070140, R01AI070140] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Division of Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Edelstein Family Chair in Pediatric Allergy and Immunology; University of Colorado Cancer Center; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants A1070140 and HL37260, General Clinical Research Center grant MOI RR00051 from the Division of Research Resources, the Edelstein Family Chair in Pediatric Allergy and Immunology and the University of Colorado Cancer Center.	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alwis KU, 2006, AM J IND MED, V49, P296, DOI 10.1002/ajim.20264; [Anonymous], 1987, Am Rev Respir Dis, V136, P1066; Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Chen ZT, 2003, J CELL BIOCHEM, V89, P1206, DOI 10.1002/jcb.10590; DOHERTY DE, 1989, J IMMUNOL, V143, P3673; Drazen JM, 2000, BRIT MED BULL, V56, P1054, DOI 10.1258/0007142001903535; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Goleva E, 2007, J ALLERGY CLIN IMMUN, V119, pS155, DOI 10.1016/j.jaci.2006.11.544; Goleva E, 2006, AM J RESP CRIT CARE, V173, P607, DOI 10.1164/rccm.200507-1046OC; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gotfried MH, 2004, CHEST, V125, p52S, DOI 10.1378/chest.125.2_suppl.52S; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Ito T, 2004, GENE, V342, P137, DOI 10.1016/j.gene.2004.07.032; Kiley J, 2007, CURR OPIN PULM MED, V13, P19; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Locati M, 2002, J IMMUNOL, V168, P3557, DOI 10.4049/jimmunol.168.7.3557; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Moore WC, 2007, AM J RESP CRIT CARE, V175, P649, DOI 10.1164/rccm.200701-099UP; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; O'Reilly SM, 2003, BIOCHEM BIOPH RES CO, V303, P586, DOI 10.1016/S0006-291X(03)00389-9; Platts-Mills JA, 2005, J ALLERGY CLIN IMMUN, V116, P384, DOI 10.1016/j.jaci.2005.05.012; Reynolds SJ, 2005, J ENVIRON MONITOR, V7, P1371, DOI 10.1039/b509256f; Rizzo MC, 1997, PEDIAT ALLERG IMM-UK, V8, P121; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Spahn JD, 2001, ANN ALLERG ASTHMA IM, V87, P501, DOI 10.1016/S1081-1206(10)62264-8; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Sutherland ER, 2007, CHEST, V132, P1962, DOI 10.1378/chest.06-2415; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	51	116	124	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					550	559		10.1016/j.jaci.2008.07.007	http://dx.doi.org/10.1016/j.jaci.2008.07.007			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18774390	Green Accepted, Bronze			2022-12-18	WOS:000259234000017
J	Ercan, H; Birben, E; Dizdar, EA; Keskin, O; Karaaslan, C; Soyer, OU; Dut, R; Sackesen, C; Besler, T; Kalayci, O				Ercan, Hulya; Birben, Esra; Dizdar, Evrim A.; Keskin, Ozlem; Karaaslan, Cagatay; Soyer, Ozge U.; Dut, Raziye; Sackesen, Cansin; Besler, Tanju; Kalayci, Omer			Oxidative stress and genetic and epidemiologic determinants of oxidant injury in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; genotype; glutathione; glutathione S transferase; malondialdehyde; oxidation; severity	GLUTATHIONE-S-TRANSFERASE; SUPEROXIDE-DISMUTASE; AIRWAY INFLAMMATION; BRONCHIAL HYPERRESPONSIVENESS; LIPID-PEROXIDATION; ALLERGIC SUBJECTS; SUPERGENE FAMILY; RISK-FACTORS; GSTP1 LOCUS; IN-VITRO	Background: The factors contributing to the oxidant! antioxidant imbalance in asthma are incompletely understood. Objective: To determine the factors associated with oxidative stress including asthma severity and the genotype of the antioxidant enzymes. Methods: A total of 196 children with mild asthma, 116 children with moderate-severe asthma, and 2 healthy control groups (187 and 68 children) were included in the study. Plasma levels of malondialdehyde were measured as the indicator of oxidative stress, and reduced glutathione levels as the indicator of antioxidant defense. Children were genotyped for null variants of glutathione S transferase (GST) T1 and GSTMl, and ile105val variant of GSTP1. Risk factors were analyzed with multivariate logistic regression. Results: Systemic levels of malondialdehyde increased and reduced glutathione levels decreased significantly from healthy controls to patients with mild asthma and then to patients with moderate-severe asthma (P <.001 for each). Multivariate logistic regression identified asthma and asthma severity as independent factors associated with oxidative stress (odds ratio between 17 and 56; P <.001). Children with asthma with GSTP1 val/val genotype had higher malondialdehyde and lower glutathione levels compared with other genotypes (P =.023 and P =.014, respectively). GSTPI vaUval genotype was independently associated with asthma severity (odds ratio, 4.210; 95% CI, 1.581-11.214; P =.004). Conclusion: Our study indicates the presence of a strong oxidative stress in children with asthma that increases with the severity of the disease. In this population, val/val genotype at GSTPI ile105vaI locus may be an important factor in determining the degree of oxidant injury. Clinical implications: Children with asthma with val/val genotype at GSTPI ile105val locus may be good candidates for supplemental antioxidant therapy.	Hacettepe Univ, Sch Med, Pediat Allergy & Asthma Unit, TR-06100 Ankara, Turkey; Hacettepe Univ, Fac Sci, Dept Biol Mol, TR-06100 Ankara, Turkey; Hacettepe Univ, Dept Dietet, Sch Hlth Technol, TR-06100 Ankara, Turkey	Hacettepe University; Hacettepe University; Hacettepe University	Kalayci, O (corresponding author), Hacettepe Univ, Sch Med, Pediat Allergy & Asthma Unit, TR-06100 Ankara, Turkey.	okalayci@hacettepe.edu.tr	KARAASLAN, Cagatay/AAA-1621-2021; Besler, Halit Tanju/I-9965-2013	KARAASLAN, Cagatay/0000-0003-4857-0857; BIRBEN, ESRA/0000-0003-1192-309X; Ercan, Hulya/0000-0002-9754-7429; Besler, Halit Tanju/0000-0002-6523-7995				Andreadis AA, 2003, FREE RADICAL BIO MED, V35, P213, DOI 10.1016/S0891-5849(03)00278-8; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; Balta G, 2003, AM J HEMATOL, V73, P154, DOI 10.1002/ajh.10339; BARNES PJ, 1995, MOL MED TODAY, V1, P149, DOI 10.1016/S1357-4310(95)80093-X; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; Besler HT, 2003, NUTR NEUROSCI, V6, P189, DOI 10.1080/1028415031000115945; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317, DOI 10.1164/ajrccm/145.2_Pt_1.317; Campo S, 2005, MUTAT RES-FUND MOL M, V578, P143, DOI 10.1016/j.mrfmmm.2005.04.001; Chen CR, 2001, BIOREMED SER, V6, P187; CRAPO JD, 1974, AM J PHYSIOL, V226, P1401, DOI 10.1152/ajplegacy.1974.226.6.1401; Dauletbaev N, 2001, THORAX, V56, P13, DOI 10.1136/thorax.56.1.13; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V93, P108, DOI 10.1016/0091-6749(94)90239-9; DEMOLY P, 1995, ANN ALLERG ASTHMA IM, V75, P162; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Evans DJ, 1996, EUR RESPIR J, V9, P703, DOI 10.1183/09031936.96.09040703; FOLZ RJ, 1994, HUM MOL GENET, V3, P2251, DOI 10.1093/hmg/3.12.2251; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437, DOI 10.1164/ajrccm.161.5.9903006; Ganas K, 2001, RESP MED, V95, P649, DOI 10.1053/rmed.2001.1117; Gilliland FD, 1999, ENVIRON HEALTH PERSP, V107, P403, DOI 10.1289/ehp.99107s3403; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Global Initiative for Asthma, 2002, GLOB STRAT ASTHM MAN; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Holla LI, 2006, ALLERGY, V61, P265, DOI 10.1111/j.1398-9995.2006.01000.x; Hu X, 1997, BIOCHEM BIOPH RES CO, V238, P397, DOI 10.1006/bbrc.1997.7311; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; ISAAC Steering Committee, 1998, PHAS 2 MOD INT STUD; Ivaschenko TE, 2002, J MOL MED, V80, P39, DOI 10.1007/s001090100274; Juul K, 2006, AM J RESP CRIT CARE, V173, P858, DOI 10.1164/rccm.200509-1387OC; Kalayci O, 2006, ALLERGY, V61, P97, DOI 10.1111/j.1398-9995.2006.00979.x; Kalayci O, 2000, TURKISH J PEDIATR, V42, P9; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; Kinnula VL, 2004, THORAX, V59, P116, DOI 10.1136/thorax.2003.005611; LI XY, 1994, AM J RESP CRIT CARE, V149, P1518, DOI 10.1164/ajrccm.149.6.8004308; Mak JCW, 2004, J ALLERGY CLIN IMMUN, V114, P260, DOI 10.1016/j.jaci.2004.05.013; Mattey DL, 1999, ANN RHEUM DIS, V58, P164, DOI 10.1136/ard.58.3.164; Mylonas C, 1999, IN VIVO, V13, P295; Nadeem A, 2003, J ALLERGY CLIN IMMUN, V111, P72, DOI 10.1067/mai.2003.17; OWEN S, 1991, NEW ENGL J MED, V325, P586; Ozaras R, 2000, Respirology, V5, P289, DOI 10.1046/j.1440-1843.2000.00260.x; PRYOR WA, 1991, FREE RADICAL BIO MED, V11, P41, DOI 10.1016/0891-5849(91)90186-7; Saadat M, 2004, J ALLERGY CLIN IMMUN, V113, P996, DOI 10.1016/j.jaci.2004.02.007; Sackesen C, 2005, ALLERGY, V60, P1485, DOI 10.1111/j.1398-9995.2005.00874.x; SANDERS SP, 1995, AM J RESP CRIT CARE, V151, P1725, DOI 10.1164/ajrccm.151.6.7767513; SANDSTROM J, 1994, J BIOL CHEM, V269, P19163; Saraclar Y, 2003, ANN ALLERG ASTHMA IM, V91, P477, DOI 10.1016/S1081-1206(10)61517-7; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8; Tamer L, 2004, RESPIROLOGY, V9, P493, DOI 10.1111/j.1440-1843.2004.00657.x; VACHIER I, 1994, EUR RESPIR J, V7, P1585, DOI 10.1183/09031936.94.07091585; vanKlaveren RJ, 1997, EUR RESPIR J, V10, P1392, DOI 10.1183/09031936.97.10061392; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040	54	116	121	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1097	1104		10.1016/j.jaci.2006.08.012	http://dx.doi.org/10.1016/j.jaci.2006.08.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088135				2022-12-18	WOS:000244282300015
J	Borish, L				Borish, L			Allergic rhinitis: Systemic inflammation and implications for management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergic rhinitis; asthma; chronic hyperplastic eosinophilic sinusitis; eosinophils; leukotrienes; cytokines; inflammation	PLACEBO-CONTROLLED TRIAL; CHRONIC HYPERPLASTIC SINUSITIS; ADHESION MOLECULE EXPRESSION; MESSENGER-RNA EXPRESSION; BONE-MARROW; DOUBLE-BLIND; BRONCHIAL RESPONSIVENESS; FLUTICASONE PROPIONATE; NASAL SECRETIONS; INTRANASAL CORTICOSTEROIDS	Allergic rhinitis triggers a systemic increase of inflammation. Within minutes of allergen exposure, immune cells release histamine, proteases, cysteinyl leukotrienes, prostaglandins, and cytokines. Some produce the early symptoms, while others augment the production, systemic circulation, and subsequent infiltration of the nasal mucosa with inflammatory cells that sustain the symptoms. Systemic circulation of inflammatory cells permits their infiltration into other tissues where chemoattractant and adhesion molecules already exist. Consequently, allergic rhinitis is linked to comorbid conditions: asthma, chronic hyperplastic eosinophilic sinusitis, nasal pollyposis, and serous otitis media. Effective therapy should be directed at underlying inflammation and its systemic manifestations. It should improve the rhinitis and the comorbid conditions. Antihistamines relieve early symptoms by blocking basophil- and mast cell-generated histamine, but they do not significantly influence the pro-inflammatory loop. They are often little better than placebo. Oral corticosteroids provide the systemic anti-inflammatory efficacy, but their toxicity precludes such an approach. Intranasal corticosteroids effectively target the local inflammatory processes of rhinitis, reducing local inflammatory cells within the nares, but they do not directly access tissues involved in the comorbid conditions. Leukotriene modifiers have both systemic anti-inflammatory effects and an acceptable safety profile.	Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA	University of Virginia	Borish, L (corresponding author), Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Beirne Carter Ctr Immunol Res, MR-4 Bldg,Room 5041,Lane Rd, Charlottesville, VA 22908 USA.							Abdelaziz MM, 1998, J ALLERGY CLIN IMMUN, V101, P410, DOI 10.1016/S0091-6749(98)70256-8; ADAMS PF, 1999, VITAL HLTH STAT, V10, P200; Adams RJ, 2002, J ALLERGY CLIN IMMUN, V109, P636, DOI 10.1067/mai.2002.123237; Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Amin K, 1999, INFLAMM RES, V48, P626, DOI 10.1007/s000110050513; ARRIGHI HM, 1995, J ALLERGY CLIN IMMUN, V95, P192; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Baraniuk JN, 1998, ANN ALLERG ASTHMA IM, V81, P359, DOI 10.1016/S1081-1206(10)63129-8; Baraniuk JN, 1998, AM J RHINOL, V12, P435, DOI 10.2500/105065898780707964; BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; Baroody FM, 1999, J APPL PHYSIOL, V86, P659, DOI 10.1152/jappl.1999.86.2.659; Baroody FM, 2000, J ALLERGY CLIN IMMUN, V105, pS70, DOI 10.1016/S0091-6749(00)90647-X; Baroody FM, 2002, J ALLERGY CLIN IMMUN, V109, pS84, DOI 10.1016/S0091-6749(02)81352-5; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; Bensch GW, 2002, ANN ALLERG ASTHMA IM, V88, P457, DOI 10.1016/S1081-1206(10)62382-4; Bernstein DI, 1997, ANN ALLERG ASTHMA IM, V79, P443, DOI 10.1016/S1081-1206(10)63041-4; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; Bjornsdottir US, 1999, ALLERGY, V54, P55, DOI 10.1111/j.1398-9995.1999.tb04389.x; Borish L, 2002, J ALLERGY CLIN IMMUN, V109, P606, DOI 10.1067/mai.2002.123024; Borish L, 1998, J ALLERGY CLIN IMMUN, V102, P222, DOI 10.1016/S0091-6749(98)70090-9; BORTS MR, 1989, J ALLERGY CLIN IMMUN, V83, P302; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Boyce JA, 2003, J ALLERGY CLIN IMMUN, V111, P24, DOI 10.1067/mai.2003.60; Braccioni F, 2002, J ALLERGY CLIN IMMUN, V110, P96, DOI 10.1067/mai.2002.125000; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Caffarelli C, 1996, OTOLARYNG HEAD NECK, V115, P454, DOI 10.1016/S0194-5998(96)70083-9; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; Cuffel B, 1999, PSYCHOSOMATICS, V40, P491, DOI 10.1016/S0033-3182(99)71187-4; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; Denburg Judah A., 2000, Journal of Allergy and Clinical Immunology, V106, pS242; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; Elsas MICG, 1997, AM J RESP CELL MOL, V17, P404, DOI 10.1165/ajrcmb.17.4.2691; Emanuel IA, 2000, OTOLARYNG HEAD NECK, V123, P687, DOI 10.1067/mhn.2000.110961; Ferguson BJ, 2000, LARYNGOSCOPE, V110, P799, DOI 10.1097/00005537-200005000-00010; Figueroa DJ, 2003, CLIN EXP ALLERGY, V33, P1380, DOI 10.1046/j.1365-2222.2003.01786.x; FINOTTO S, 1994, J IMMUNOL, V153, P2278; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Fontanari P, 1996, J APPL PHYSIOL, V81, P1739, DOI 10.1152/jappl.1996.81.4.1739; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Gleeson K, 1997, CHEST, V111, P1266, DOI 10.1378/chest.111.5.1266; Golden S, 2000, ANN ALLERG ASTHMA IM, V85, P53, DOI 10.1016/S1081-1206(10)62434-9; GRIFFIN MP, 1982, J ALLERGY CLIN IMMUN, V69, P354, DOI 10.1016/0091-6749(82)90145-2; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Howarth PH, 1997, ALLERGY, V52, P12, DOI 10.1111/j.1398-9995.1997.tb04878.x; Inman MD, 1999, AM J RESP CELL MOL, V21, P473, DOI 10.1165/ajrcmb.21.4.3622; Jen A, 2000, J ALLERGY CLIN IMMUN, V105, P732, DOI 10.1067/mai.2000.105225; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; Kaliner MA, 1997, J ALLERGY CLIN IMMUN, V99, pS829, DOI 10.1016/S0091-6749(97)70041-1; Karaman O, 2001, Allergol Immunopathol (Madr), V29, P55; KEMP JP, 1985, ANN ALLERGY, V54, P502; KNANI J, 1992, J ALLERGY CLIN IMMUN, V90, P880, DOI 10.1016/0091-6749(92)90460-J; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Ledford DK, 1998, J RESP DIS, V19, P576; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; MA X, 2000, AM J RESP CRIT CARE, V161, pA325; Marshall PS, 2000, ANN ALLERG ASTHMA IM, V84, P403, DOI 10.1016/S1081-1206(10)62273-9; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357, DOI 10.1164/ajrccm/136.2.357; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Murris-Espin M, 1998, ANN ALLERG ASTHMA IM, V80, P399, DOI 10.1016/S1081-1206(10)62991-2; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592, DOI 10.1016/S1081-1206(10)61891-1; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; Nielsen LP, 2001, DRUGS, V61, P1563, DOI 10.2165/00003495-200161110-00004; Nouri-Aria KT, 2000, CLIN EXP ALLERGY, V30, P1709, DOI 10.1046/j.1365-2222.2000.00998.x; Numata T, 1999, ANN OTO RHINOL LARYN, V108, P467, DOI 10.1177/000348949910800509; OKUDA M, 1988, ANN ALLERGY, V60, P537; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; Parikh A, 2001, RHINOLOGY, V39, P75; Parnes S M, 2000, Ear Nose Throat J, V79, P18; Pedersen KE, 1997, J PHARMACOL EXP THER, V281, P655; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; Peters EJ, 2003, ANN ALLERG ASTHMA IM, V90, P316, DOI 10.1016/S1081-1206(10)61800-5; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RASP G, 1994, CLIN EXP ALLERGY, V24, P1151, DOI 10.1111/j.1365-2222.1994.tb03321.x; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Saito H, 2001, IMMUNOLOGY, V104, P226, DOI 10.1046/j.1365-2567.2001.01253.x; Sarti W, 1995, Sao Paulo Med J, V113, P968; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, pS55, DOI 10.1097/00006454-198511001-00003; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Spada CS, 1997, ADV EXP MED BIOL, V400, P699; SPADA CS, 1986, PROSTAGLANDINS, V31, P795, DOI 10.1016/0090-6980(86)90181-4; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Thio BJ, 2000, THORAX, V55, P826, DOI 10.1136/thorax.55.10.826; Togias A, 2002, J ALLERGY CLIN IMMUN, V109, pS262, DOI 10.1016/S0091-6749(02)81934-0; Togias A, 2000, J ALLERGY CLIN IMMUN, V105, pS599, DOI 10.1067/mai.2000.106885; TOGIAS AG, 1989, ANN ALLERGY, V63, P465; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; VIEGAS M, 1987, BRIT MED J, V294, P414, DOI 10.1136/bmj.294.6569.414; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WANG DY, 1995, INT ARCH ALLERGY IMM, V106, P278, DOI 10.1159/000236855; WANG DY, 1994, ACTA OTO-LARYNGOL, V114, P552, DOI 10.3109/00016489409126103; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; WHITE MV, 1992, J ALLERGY CLIN IMMUN, V90, P699, DOI 10.1016/0091-6749(92)90155-U; Wood JJ, 1998, AM J RESP CRIT CARE, V157, P99, DOI 10.1164/ajrccm.157.1.9704125; Wood LJ, 1998, AM J RESP CELL MOL, V18, P759, DOI 10.1165/ajrcmb.18.6.3006; Wood LJ, 2002, AM J RESP CRIT CARE, V166, P883, DOI 10.1164/rccm.2108015; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Young MC, 1998, ALLERGY ASTHMA PROC, V19, P211, DOI 10.2500/108854198778557890	131	116	132	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1021	1031		10.1016/j.jaci.2003.09.015	http://dx.doi.org/10.1016/j.jaci.2003.09.015			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657851				2022-12-18	WOS:000187154200001
J	Verlato, G; Corsico, A; Villani, S; Cerveri, I; Migliore, E; Accordini, S; Carolei, A; Piccioni, P; Bugiani, M; Lo Cascio, V; Marinoni, A; Poli, A; de Marco, R				Verlato, G; Corsico, A; Villani, S; Cerveri, I; Migliore, E; Accordini, S; Carolei, A; Piccioni, P; Bugiani, M; Lo Cascio, V; Marinoni, A; Poli, A; de Marco, R			Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergic rhinitis; temporal trend; epidemiology	RESPIRATORY-HEALTH-SURVEY; NONRESPONSE BIAS; SURVEY ECRHS; SYMPTOMS; MORTALITY; YOUNG; ATOPY; HYPERRESPONSIVENESS; SCHOOLCHILDREN; EPIDEMIOLOGY	Background: The prevalence of asthma and allergic rhinitis has increased worldwide during the 1970s and 1980s. Objective: This study was aimed at evaluating whether the increasing trend in prevalence persisted during the 1990s in the young adult Italian population. Methods: In 1998 to 2000 a screening questionnaire was sent by mail to a general population sample aged 20 to 44 years; nonresponders were contacted again first by mail and then by phone, achieving a final response rate of 78.1% (6876 of 8800). Prevalence estimates, adjusted to correct for nonresponse bias, were compared with those recorded in Italy in 1991 to 1993 during the European Community Respiratory Health Survey, when response rate had been slightly higher (87.6%). Temporal variations in symptom prevalence were analyzed by a logistic regression model, controlling for sex, age, site of residence (urban vs suburban areas), season of response, response rate, and type of contact (mail vs phone). Results: The prevalence of asthma attacks did not vary significantly from 1991 to 1993 (3.6%) to 1998 to 2000 (3.2%) (P = .188). The prevalence of asthma-like symptoms (wheezing, chest tightness, shortness of breath) tended to decrease in the age classes of 32.5 to 45 years, while increasing in the youngest age class (20 to 26 years). A clear-cut increase from 15.4% to 18.3% was observed for the prevalence of allergic rhinitis (P < .001), whereas the proportion of people under antiasthmatic treatment increased in suburban areas but not in urban areas (interaction time-site of residence, P < .001). Conclusion: Asthma prevalence has not increased during the last decade in Italy. The persistence of an increasing trend in allergic rhinitis prevalence deserves attention.	Univ Verona, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, I-37100 Verona, Italy; Univ Pavia, Hosp San Matteo, IRCCS, Clin Resp Dis, I-27100 Pavia, Italy; Univ Pavia, Fac Med, Dept Appl Hlth Sci, I-27100 Pavia, Italy; CPA, Unit Pneumol, Turin, Italy; Univ Verona, Dept Biomed & Surg Sci, Unit Internal Med & Pneumol, I-37100 Verona, Italy; Univ Verona, Dept Med & Publ Hlth, Unit Hyg & Prevent Environm & Occupat Med, I-37100 Verona, Italy	University of Verona; University of Pavia; University of Pavia; University of Verona; University of Verona	Verlato, G (corresponding author), Inst Biol 2, Sez Epidemiol & Stat Med, Str Grazie 8, I-37134 Verona, Italy.		Corsico, Angelo Guido/AAC-8138-2019; SESM, SESM/C-1440-2008; de Marco, Roberto/A-5470-2008; Carolei, Adriana/AAQ-7656-2021; Bucca, Caterina/C-9886-2009	Corsico, Angelo Guido/0000-0002-8716-4694; Carolei, Adriana/0000-0002-5254-8532; Bucca, Caterina/0000-0002-9941-9236; /0000-0003-2517-6515; Cerveri, Isa/0000-0003-0337-043X				Asher MI, 1998, EUR RESPIR J, V12, P315; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Campello C, 1998, Monaldi Arch Chest Dis, V53, P505; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; de Marco R, 1999, EUR RESPIR J, V14, P1044, DOI 10.1183/09031936.99.14510449; de Marco R, 1998, EUR RESPIR J, V11, P599; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; DEMARCO R, 1995, ALLERGY, V50, P755; DEMARCO R, 1994, EUR RESPIR J, V7, P2139, DOI 10.1183/09031936.94.07122139; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; Dubois P, 1998, THORAX, V53, P101, DOI 10.1136/thx.53.2.101; Fleming DM, 2000, THORAX, V55, P657, DOI 10.1136/thorax.55.8.657; Goldman M, 2000, J ALLERGY CLIN IMMUN, V105, P71, DOI 10.1016/S0091-6749(00)90180-5; Hansen EF, 2000, THORAX, V55, P833, DOI 10.1136/thorax.55.10.833; HOWARTH PH, 1995, ALLERGY, V50, P4, DOI 10.1111/j.1398-9995.1995.tb02733.x; Kalyoncu AF, 1999, PEDIATR ALLERGY IMMU, V10, P261, DOI 10.1034/j.1399-3038.1999.00031.x; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; Kumana CR, 2001, J ASTHMA, V38, P161, DOI 10.1081/JAS-100000035; Lang DM, 2001, ANN ALLERG ASTHMA IM, V87, P91, DOI 10.1016/S1081-1206(10)62200-4; Linneberg A, 1999, ALLERGY, V54, P1194, DOI 10.1034/j.1398-9995.1999.00180.x; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Olivieri M, 2002, ALLERGY, V57, P600, DOI 10.1034/j.1398-9995.2002.23537.x; PEAT JK, 1992, BMJ-BRIT MED J, V305, P1326, DOI 10.1136/bmj.305.6865.1326; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810; TENNANT A, 1991, J EPIDEMIOL COMMUN H, V45, P81, DOI 10.1136/jech.45.1.81; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; TURNER KJ, 1988, CLIN ALLERGY, V18, P331, DOI 10.1111/j.1365-2222.1988.tb02880.x; VERLATO G, 2001, SALUTE INFORMAZIONE, P190; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; Wieringa MH, 2001, CLIN EXP ALLERGY, V31, P1553, DOI 10.1046/j.1365-2222.2001.01188.x; Woods RK, 2001, ANN ALLERG ASTHMA IM, V87, P117, DOI 10.1016/S1081-1206(10)62204-1; Woolcock AJ, 1997, CIBA F SYMP, V206, P122	36	116	118	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1232	1238		10.1067/mai.2003.1484	http://dx.doi.org/10.1067/mai.2003.1484			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789222				2022-12-18	WOS:000183424700010
J	Halken, S; Host, A; Niklassen, U; Hansen, LG; Nielsen, F; Pedersen, S; Osterballe, O; Veggerby, C; Poulsen, LK				Halken, S; Host, A; Niklassen, U; Hansen, LG; Nielsen, F; Pedersen, S; Osterballe, O; Veggerby, C; Poulsen, LK			Effect of mattress and pillow encasings on children with asthma and house dust mite allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mattress encasing; house dust mite allergy; childhood asthma; inhaled steroids	CHILDHOOD ASTHMA; AIRBORNE ALLERGENS; AVOIDANCE MEASURES; EXPOSURE; SENSITIZATION; MANAGEMENT; ANTIGEN	Background: House dust mite (HDM) allergy is a frequent cause of allergic asthma in children. Reduction of exposure seems to be the most logical way to treat these patients. Objective: Our aim was to investigate whether mattress and pillow encasings resulted in an effective long-term control of HDM allergen levels, thereby reducing the need for asthma medication in children with asthma and HDM allergy. Methods: In a prospective, double-blind, placebo-controlled study 60 children (age range, 6-15 years) with asthma and HDM allergy were randomized to active (allergy control) or placebo mattress and pillow encasings. After a 2-week baseline period, follow-up was performed every 3 months for I year. During the entire study period, the dose of inhaled steroids was tapered off to the lowest effective dose according to well-defined criteria. Results: Fifty-two patients completed the trial, and 5 were excluded, leaving data from 47 children (26 in the active treatment group and 21 in the placebo group) for analysis. A significant perennial reduction in HDM allergen concentrations was seen only for the active treatment group. Also, a significant decrease in the dose of inhaled steroids (mean, 408 to 227 mug/d; P <.001) was found for the active treatment group only, with significant differences between groups after 9 and 12 months. After 1 year, the dose of inhaled steroids was reduced by at least 50% in significantly more children in the active treatment group than in the placebo group (73% vs 24%, P <.01). Conclusion: Encasing of mattresses and pillows resulted in a significant long-term reduction in HDM allergen concentrations in mattresses and in the need for inhaled steroids in children with asthma and HDM allergy.	Sonderborg Hosp, Dept Pediat, DK-6400 Sonderberg, Denmark; Lab Med Allergol, Copenhagen, Denmark; Viborg Hosp, Dept Pediat, Viborg, Denmark; Kolding Cty Hosp, Dept Pediat, Kolding, Denmark; Odense Univ Hosp, Dept Pediat, Odense, Denmark	Aarhus University; Kolding Hospital; University of Southern Denmark; University of Southern Denmark; Odense University Hospital	Halken, S (corresponding author), Sonderborg Hosp, Dept Pediat, DK-6400 Sonderberg, Denmark.		Poulsen, Lars K/J-3065-2019	Poulsen, Lars K/0000-0002-1730-847X; Halken, Susanne/0000-0003-0161-8278				Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; Carswell F, 1999, CLIN EXP ALLERGY, V29, P193, DOI 10.1046/j.1365-2222.1999.00499.x; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Custovic A, 2000, CLIN REV ALLERG IMMU, V18, P397, DOI 10.1385/CRIAI:18:3:397; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Gotzsche PC, 1998, BRIT MED J, V317, P1105, DOI 10.1136/bmj.317.7166.1105; Host A, 2000, ALLERGY, V55, P600, DOI 10.1034/j.1398-9995.2000.00122.x; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Jirapongsananuruk O, 2000, ANN ALLERG ASTHMA IM, V84, P305, DOI 10.1016/S1081-1206(10)62778-0; MATTHYS H, 1993, RESPIRATION, V60, P343; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; Silvestri M, 1996, ANN ALLERG ASTHMA IM, V76, P239, DOI 10.1016/S1081-1206(10)63433-3; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; Vanlaar CH, 2000, J ALLERGY CLIN IMMUN, V105, P1130, DOI 10.1067/mai.2000.106213; VERVLOET D, 1991, ALLERGY, V46, P554, DOI 10.1111/j.1398-9995.1991.tb00620.x; Weeks J, 1995, CLIN EXP ALLERGY, V25, P1179, DOI 10.1111/j.1365-2222.1995.tb03041.x; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8	22	116	119	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					169	176		10.1067/mai.2003.5	http://dx.doi.org/10.1067/mai.2003.5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532114				2022-12-18	WOS:000180465500026
J	Trautmann, A; Akdis, M; Schmid-Grendelmeier, P; Disch, R; Brocker, EB; Blaser, K; Akdis, CA				Trautmann, A; Akdis, M; Schmid-Grendelmeier, P; Disch, R; Brocker, EB; Blaser, K; Akdis, CA			Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; atopic dermatitis; allergic contact dermatitis; cyclosporine A; dexamethasone; intravenous immunoglobulin; keratinocyte; rapamycine; tacrolimus/FK506; T cell	INTRAVENOUS IMMUNOGLOBULIN; DNA FRAGMENTATION; CYCLOSPORINE-A; DOUBLE-BLIND; MECHANISMS; HYPERSENSITIVITY; PERSPECTIVES; INHIBITION; DISEASES; FK506	Background: Activation and skin-selective homing of T cells and effector functions in the skin represent sequential events in the pathogenesis of atopic dermatitis and allergic contact dermatitis. Objective: T cell-mediated keratinocyte apoptosis plays a key pathogenetic role in the formation of eczematous dermatitis. IFN-gamma released from activated T cells upregulates Fas on keratinocytes, which renders them susceptible to apoptosis. The lethal hit is given to keratinocytes by means of Fas ligand expressed on the T-cell surface or released to the inflammatory microenvironment. We sought to investigate whether drugs used for the treatment of eczematous disorders interfere with this pathogenic pathway. Methods: T cell-mediated, Fas-induced keratinocyte apoptosis in a keratinocyte-T cell coculture system serves as an in vitro model of eczematous dermatitis. We tested, in this model, whether immunomodulatory agents (dexamethasone, cyclosporine A, rapamycine, tacrolimus/FK506, intravenous immunoglobulin [IVIG], and theophylline) are able to inhibit apoptosis of keratinocytes. Additionally, skin biopsy specimens from patients with untreated and successfully treated eczematous dermatitis were evaluated for keratinocyte apoptosis. Results: Dexamethasone, cyclosporine A, FK506, rapamycine, and IVIG are inhibitors of keratinocyte apoptosis induced by activated T cells. This effect is mediated by 2 major mechanisms directed on T cells or keratinocytes. T-cell activation was mainly inhibited by dexamethasone, FK506, cyclosporine A, and rapamycine. Interestingly, high-dose dexamethasone and IVIG directly inhibited Fas-mediated keratinocyte apoptosis. In vivo keratinocyte apoptosis was significantly reduced after successful topical treatment of eczematous lesions. Conclusion: These results demonstrate mechanisms of action of current treatment approaches and provide a future for more focused therapeutic applications.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Univ Wurzburg, Dept Dermatol, D-8700 Wurzburg, Germany	Swiss Institute of Allergy & Asthma Research; University of Wurzburg	Trautmann, A (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.		Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X				Akdis CA, 2000, CURR OPIN IMMUNOL, V12, P641, DOI 10.1016/S0952-7915(00)00156-4; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; AMRAN D, 1994, CLIN IMMUNOL IMMUNOP, V73, P180, DOI 10.1006/clin.1994.1186; Aragane Y, 1997, P NATL ACAD SCI USA, V94, P11490, DOI 10.1073/pnas.94.21.11490; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Bekersky I, 2001, J AM ACAD DERMATOL, V44, pS17, DOI 10.1067/mjd.2001.109816; BERARDESCA E, 1995, CURR PROBL DERMATOL, V22, P86; Brazelton TR, 1996, CURR OPIN IMMUNOL, V8, P710, DOI 10.1016/S0952-7915(96)80090-2; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; Fleischer AB, 1999, J ALLERGY CLIN IMMUN, V104, pS126, DOI 10.1016/S0091-6749(99)70055-2; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Granlund H, 1996, ACTA DERM-VENEREOL, V76, P371; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; HANIFIN JM, 1982, J AM ACAD DERMATOL, V6, P1, DOI 10.1016/S0190-9622(82)70001-5; Jolles S, 2000, BRIT J DERMATOL, V142, P551, DOI 10.1046/j.1365-2133.2000.03377.x; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; Leung DYM, 1999, ALLERGY, V54, P39, DOI 10.1111/j.1398-9995.1999.tb04748.x; Levin C, 2000, CONTACT DERMATITIS, V43, P317, DOI 10.1034/j.1600-0536.2000.043006317.x; Michel G, 1996, IMMUNOL TODAY, V17, P106, DOI 10.1016/0167-5699(96)80599-8; Modiano JF, 1997, CLIN IMMUNOL IMMUNOP, V83, P77, DOI 10.1006/clin.1997.4329; Mouthon L, 1996, CLIN EXP IMMUNOL, V104, P3, DOI 10.1111/cei.1996.104.s1.3; Norris DA, 1997, APOPTOSIS, V2, P136, DOI 10.1023/A:1026456229688; Rabe KF, 1998, CLIN EXP ALLERGY, V28, P35; Robert C, 1999, NEW ENGL J MED, V341, P1817, DOI 10.1056/NEJM199912093412407; SHARPE GR, 1990, BRIT J DERMATOL, V123, P207, DOI 10.1111/j.1365-2133.1990.tb01848.x; Staley K, 1997, CELL DEATH DIFFER, V4, P66, DOI 10.1038/sj.cdd.4400207; Traidl C, 2000, J IMMUNOL, V165, P3058, DOI 10.4049/jimmunol.165.6.3058; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; TRAUTMANN A, IN PRESS J INVEST DE; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Wen LP, 1997, AM J PHYSIOL-LUNG C, V273, pL921, DOI 10.1152/ajplung.1997.273.5.L921; Zaki I, 1996, BRIT J DERMATOL, V135, P21, DOI 10.1111/j.1365-2133.1996.tb00705.x; Zurbriggen B, 1999, DERMATOLOGY, V198, P56, DOI 10.1159/000018065	36	116	122	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					839	846		10.1067/mai.2001.118796	http://dx.doi.org/10.1067/mai.2001.118796			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692113	Bronze			2022-12-18	WOS:000172523800028
J	Tanaka, H; Miyazaki, N; Oashi, K; Teramoto, S; Shiratori, M; Hashimoto, M; Ohmichi, M; Abe, S				Tanaka, H; Miyazaki, N; Oashi, K; Teramoto, S; Shiratori, M; Hashimoto, M; Ohmichi, M; Abe, S			IL-18 might reflect disease activity in mild and moderate asthma exacerbation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-18; IFN-gamma; IL-2 receptor; acute asthma; sarcoidosis	INTERFERON-GAMMA PRODUCTION; IFN-GAMMA; ESCHERICHIA-COLI; PERIPHERAL-BLOOD; CYTOKINE; INTERLEUKIN-18; EXPRESSION; HISTAMINE; RECEPTOR; RELEASE	Background: IL-18, identified as an IFN-gamma -inducing factor, is a proinflammatory cytokine that plays an important role in T(H)1 cell activation. Recently, it was reported that histamine induced IL-18 and that IL-18 might act as a coinducer of T(H)1 and T(H)2 cytokines. Objective: The aim was to evaluate the contribution of IL-18 to asthma exacerbation. Methods: Serum IL-18, soluble IL-2 receptor, eosinophil cationic protein, and plasma IFN-gamma levels, as well as peak expiratory flow were measured in patients with stable asthma (n = 28), acute mild or moderate asthma (n = 23), or pulmonary sarcoidosis (n = 35) and in healthy subjects (n = 26). We compared the serum IL-18 levels between patients with acute asthma and those in remission and examined the time course in acute exacerbation after asthma therapy. Results: Significantly higher serum IL-18 levels were found in patients with acute asthma (215 +/- 33 pg/mL, mean +/- SE; P = .02) and pulmonary sarcoidosis (239 +/- 27 pg/mL, P = .008) than in control subjects (127 +/- 11 pg/mL), but the plasma IFN-gamma level was significantly elevated in only pulmonary sarcoidosis (P < .001). In pulmonary sarcoidosis the IL-18 values significantly correlated with the IFN-<gamma> levels (r = 0.61, P < .001), but in acute asthma they did not. The IL-18 levels during acute asthma exacerbation were significantly higher (P = .01) than on remission days. In acute asthma, circulating IL-18 levels significantly correlated with serum soluble IL-2 receptor levels (r = 0.77, P < .0001) but not with serum eosinophil cationic protein levels. The IL-18 level had a tendency to inversely correlate with peak expiratory flow. The elevated IL-18 levels in acute asthma quickly decreased on day 3 (P = .02) and day 3 (P = .002) after therapy. Conclusion: It was suggested that IL-18 may play a potential role to activate immunologic responses and may reflect disease activity in mild and moderate asthma exacerbation.	Sapporo Med Univ, Sch Med, Dept Internal Med 3, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Hokkaido Railway, Sapporo Hosp, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo City General Hospital	Tanaka, H (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 3, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BERTLEY AM, 1996, AM J RESP CRIT CARE, V153, P551; CORBRIDGE TC, 1995, AM J RESP CRIT CARE, V151, P1296, DOI 10.1164/ajrccm.151.5.7735578; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Fukao T, 2000, J IMMUNOL, V164, P64, DOI 10.4049/jimmunol.164.1.64; Gracie JA, 1999, J CLIN INVEST, V104, P1393, DOI 10.1172/JCI7317; HASHIMOTO S, 1993, ANN ALLERGY, V71, P455; Hoshino T, 1999, J IMMUNOL, V162, P5070; Kodama T, 2000, J ALLERGY CLIN IMMUN, V105, P45, DOI 10.1016/S0091-6749(00)90176-3; KOHDA H, 1998, J LEUKOCYTE BIOL, V64, P519; Kohka H, 2000, J IMMUNOL, V164, P6640, DOI 10.4049/jimmunol.164.12.6640; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Krug N, 1996, AM J RESP CELL MOL, V14, P319, DOI 10.1165/ajrcmb.14.4.8600935; Kumano K, 1999, AM J RESP CRIT CARE, V160, P873, DOI 10.1164/ajrccm.160.3.9805026; Lauw FN, 1999, J INFECT DIS, V180, P1878, DOI 10.1086/315155; Moller DR, 1996, J IMMUNOL, V156, P4952; Netea MG, 2000, J IMMUNOL, V164, P2644, DOI 10.4049/jimmunol.164.5.2644; *NIH, 1995, GLOB STRAT ASTHM MAN, P77; Okamura H, 1998, CURR OPIN IMMUNOL, V10, P259, DOI 10.1016/S0952-7915(98)80163-5; Okamura H, 1998, ADV IMMUNOL, V70, P281, DOI 10.1016/S0065-2776(08)60389-2; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Pizarro TT, 1999, J IMMUNOL, V162, P6829; Purello-D'Ambrosio F, 1999, J INVEST ALLERG CLIN, V9, P262; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Setsuda J, 1999, AM J PATHOL, V155, P257, DOI 10.1016/S0002-9440(10)65119-X; Shi HZ, 1999, J ALLERGY CLIN IMMUN, V103, P388, DOI 10.1016/S0091-6749(99)70461-6; Takada H, 1999, BRIT J HAEMATOL, V106, P182, DOI 10.1046/j.1365-2141.1999.01504.x; Ushio S, 1996, J IMMUNOL, V156, P4274; van Schaik SM, 1999, J ALLERGY CLIN IMMUN, V103, P630, DOI 10.1016/S0091-6749(99)70235-6; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Yoshimoto T, 1997, P NATL ACAD SCI USA, V94, P3948, DOI 10.1073/pnas.94.8.3948	31	116	123	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					331	336		10.1067/mai.2001.112275	http://dx.doi.org/10.1067/mai.2001.112275			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174201				2022-12-18	WOS:000167071400021
J	Yoshizawa, Y; Ohtani, Y; Hayakawa, H; Sato, A; Suga, M; Ando, M				Yoshizawa, Y; Ohtani, Y; Hayakawa, H; Sato, A; Suga, M; Ando, M			Chronic hypersensitivity pneumonitis in Japan: A nationwide epidemiologic survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic hypersensitivity pneumonitis; nationwide survey; antigen-induced lymphocyte proliferation; upper lung field; honeycombing; pulmonary fibrosis	EXTRINSIC ALLERGIC ALVEOLITIS; BIRD FANCIERS LUNG; BRONCHOALVEOLAR LAVAGE; CIGARETTE-SMOKING; FUNCTION TESTS; FARMERS LUNG; FOLLOW-UP; DISEASE; PREVALENCE; RESPONSES	Background: Pulmonary fibrosis inevitably develops in patients with chronic hypersensitivity pneumonitis (HP). Objective: We conducted a nationwide epidemiologic study in Japan to evaluate the frequency and clinical characteristics of chronic HP. Methods: This report is on 36 cases of chronic HP, including 10 patients with summer-type HP, 5 patients with home-related HP, 7 patients with bird fancier's lung, 5 patients with isocyanate-induced HP, 4 patients with farmer's lung, and 5 patients with other types of chronic HP, Chronic HP was further subgrouped into 2 types: one type of patients were first seen with chronic disease (9 patients), and the other type became chronic with fibrosis after repeated acute episodes (27 patients). Results: The upper lung field was frequently involved in chronic HP (17%). Ground-glass opacities were observed in 57% and air space consolidation in 30% of the patients, Honeycombing was apparent in 37%. Twenty-six of 28 patients had antibodies to the presumptive antigens, Five of 8 patients with chronic HP were positive for antigen-induced lymphocyte proliferation. In 2 cases patients did not have detectable antibodies to causative antigens, although antigen-induced lymphocyte proliferation was detectable, The ratio of CD4 to CD8 in BAL lymphocytes was lowest in isocyanate-induced HP (mean 0.22) and tended to be high in farmer's lung and bird fancier's lung. Granulomas were observed in 39% and Masson bodies in 42% of specimens on histologic examination. Administration of prednisolone was effective in 58% of patients. Conclusions: The insidious form of chronic HP has probably been misdiagnosed as idiopathic pulmonary fibrosis when a good history was not taken and immunologic (especially antigen-induced lymphocyte proliferation) and BAL testing were not counted.	Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo 1138519, Japan; Tenryu Hosp, Natl Sanat, Dept Internal Med, Hamakita, Japan; Kyoto Prevent Med Ctr, Kyoto, Japan; Kumamoto Univ, Sch Med, Dept Internal Med 1, Kumamoto 860, Japan	Tokyo Medical & Dental University (TMDU); Kumamoto University	Yoshizawa, Y (corresponding author), Tokyo Med & Dent Univ, Bunkyo Ku, 5-45 Yushima 1 Chome, Tokyo 1138519, Japan.							ADLER BD, 1992, RADIOLOGY, V185, P91, DOI 10.1148/radiology.185.1.1523340; ANDO M, 1991, J ALLERGY CLIN IMMUN, V87, P1002, DOI 10.1016/0091-6749(91)90423-L; ANDO M, 1991, AM REV RESPIR DIS, V144, P765, DOI 10.1164/ajrccm/144.4.765; ARIMA K, 1992, ARCH ENVIRON HEALTH, V47, P274, DOI 10.1080/00039896.1992.9938361; BARBEE RA, 1968, AM REV RESPIR DIS, V97, P223; BAUR X, 1995, J ALLERGY CLIN IMMUN, V95, P1004, DOI 10.1016/S0091-6749(95)70101-X; BOURKE SJ, 1989, CLIN EXP ALLERGY, V19, P629, DOI 10.1111/j.1365-2222.1989.tb02758.x; DYKEWICZ MS, 1988, J ALLERGY CLIN IMMUN, V81, P455, DOI 10.1016/0091-6749(88)90917-7; HENDRICK DJ, 1980, THORAX, V35, P415, DOI 10.1136/thx.35.6.415; HUBBARD RB, 1995, AM J RESP CRIT CARE, V151, pA198; IWAI K, 1994, AM J RESP CRIT CARE, V150, P670, DOI 10.1164/ajrccm.150.3.8087336; KALTREIDER HB, 1993, WESTERN J MED, V159, P570; KUSAKA H, 1989, AM REV RESPIR DIS, V140, P695, DOI 10.1164/ajrccm/140.3.695; LALANCETTE M, 1993, AM REV RESPIR DIS, V148, P216, DOI 10.1164/ajrccm/148.1.216; MURAYAMA J, 1993, CHEST, V101, P47; PEREZPADILLA R, 1993, AM REV RESPIR DIS, V148, P49, DOI 10.1164/ajrccm/148.1.49; REMYJARDIN M, 1993, RADIOLOGY, V189, P111, DOI 10.1148/radiology.189.1.8372179; SALVAGGIO JE, 1993, RESP MED, V87, P495, DOI 10.1016/0954-6111(93)90004-J; SANSORES R, 1990, ARCH INTERN MED, V150, P1849, DOI 10.1001/archinte.150.9.1849; THOMAS W, 1973, NATURE, V243, P240, DOI 10.1038/243240a0; WARREN CPW, 1977, THORAX, V32, P567, DOI 10.1136/thx.32.5.567; YOSHIZAWA Y, 1995, J ALLERGY CLIN IMMUN, V96, P122, DOI 10.1016/S0091-6749(95)70041-2	22	116	122	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				315	320		10.1016/S0091-6749(99)70507-5	http://dx.doi.org/10.1016/S0091-6749(99)70507-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949324				2022-12-18	WOS:000078630100020
J	Shapiro, G; Mendelson, L; Kraemer, MJ; Cruz-Rivera, M; Walton-Bowen, K; Smith, JA				Shapiro, G; Mendelson, L; Kraemer, MJ; Cruz-Rivera, M; Walton-Bowen, K; Smith, JA			Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						budesonide; budesonide inhalation suspension; asthma; inhaled corticosteroid; children; pediatric; pulmonary function; steroid-dependent asthma; clinical trial	SEVERE INFANTILE ASTHMA; NEBULIZED BUDESONIDE; MODERATE	Background: Inhaled glucocorticosteroids are indicated for the treatment of persistent asthma: however, many young children are unable to effectively use currently available inhalers. Objective: We sought to evaluate the efficacy and safety of 3 different tn icr daily doses of budesonide inhalation suspension (Pulmicort Respules) in inhaled steroid-dependent asthmatic children, Methods: This was a 12-week, randomized, double-blind, placebo-controlled, parallel-group study involving 178 children (age range, 4 to 8 years) at 17 centers in the United States. Budesonide inhalation suspension doses of 0.25 mg, 0.50 mg, or 1.0 mg twice daily were administered by means of a jet nebulizer and air compressor system. Efficacy nas assessed by recording at home nighttime and day time asthma symptom scores, use of rescue medication, pulmonary function tests, and treatment discontinuation because of worsening symptoms. Safety was assessed by reported adverse events and changes in baseline and adrenocorticotrophic hormone-stimulated plasma cortisol levels in a subset of patients. Results: Baseline demographics, symptom scores, and pulmonary function data were similar across treatment groups. All doses of budesonide inhalation suspension were superior to placebo in improving nighttime and daytime asthma symptom scores (P less than or equal to .026), reducing use of breakthrough medication (P less than or equal to .032), and improving morning peak expiratory flow (P less than or equal to .030). The number of dropouts because of worsening asthma was also significantly fewer in the budesonide groups (P less than or equal to .015), There were no differences between doses of budesonide, Adverse events and basal and adrenocorticotrophic hormone-stimulated cortisol responses were not different between budesonide and placebo groups. Conclusion: Budesonide inhalation suspension, 0.25 mg, 0.50 mg, and 1.0 mg twice daily, is an effective and safe treatment for young children with inhaled steroid-dependent, persistent asthma.	Asthma Inc, Seattle, WA 98105 USA; Connecticut Asthma & Allergy Ctr, W Hartford, CT USA; Spokane Allergy & Asthma Res Unit, Spokane, WA USA; Astra USA Inc, Westborough, MA USA		Shapiro, G (corresponding author), Asthma Inc, Suite 200,4540 Sand Point Way NE, Seattle, WA 98105 USA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Agertoft L, 1998, AM J RESP CRIT CARE, V157, P178, DOI 10.1164/ajrccm.157.1.9707072; BISGAARD H, 1990, LANCET, V336, P649, DOI 10.1016/0140-6736(90)92147-A; Bisgaard H, 1998, RESP MED, V92, P44, DOI 10.1016/S0954-6111(98)90031-2; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; *CDCP, 1995, MMWR-MORBID MORTAL W, V43, P952; deBlic J, 1996, J ALLERGY CLIN IMMUN, V98, P14, DOI 10.1016/S0091-6749(96)70221-X; Eseverri J L, 1995, Allerg Immunol (Paris), V27, P129; GEORGITIS J, 1997, CHEST, V112, pS37; GODFREY S, 1987, LANCET, V2, P851; Grimfeld A., 1994, European Respiratory Journal, V7, p27S; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HAATHELA T, 1997, CLIN EXP ALLERGY, V27, P351; HULTQUIST C, 1989, LANCET, V1, P380; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356, DOI 10.1136/adc.68.3.356; Jagoda A, 1997, ANN EMERG MED, V29, P262, DOI 10.1016/S0196-0644(97)70278-6; *NIH, 1997, NIH PUBL; *NIH, 1991, J ALLERGY CLIN IMMUN, V88, P427; NOBLE V, 1992, ARCH DIS CHILD, V67, P285, DOI 10.1136/adc.67.3.285; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; PEDERSEN S, 1989, EUR RESP J S8, V2, pS647; Pedersen S, 1997, AM J RESP CRIT CARE, V155, pA268; SELROOS O, 1994, ALLERGY, V49, P833, DOI 10.1111/j.1398-9995.1994.tb00783.x; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VikreJorgensen J, 1997, PEDIATR PULM, V23, P270, DOI 10.1002/(SICI)1099-0496(199704)23:4<270::AID-PPUL4>3.0.CO;2-Q; Wennergren G, 1996, ACTA PAEDIATR, V85, P183, DOI 10.1111/j.1651-2227.1996.tb13989.x	27	116	125	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					789	796		10.1016/S0091-6749(98)70019-3	http://dx.doi.org/10.1016/S0091-6749(98)70019-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819296				2022-12-18	WOS:000077033400013
J	Reiss, TF; Altman, LC; Chervinsky, P; Bewtra, A; Stricker, WE; Noonan, GP; Kundu, S; Zhang, J				Reiss, TF; Altman, LC; Chervinsky, P; Bewtra, A; Stricker, WE; Noonan, GP; Kundu, S; Zhang, J			Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LDT(4)) receptor antagonist, in patients with chronic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						montelukast (MK-0476); bronchodilation; cysteinyl leukotriene receptor antagonist	INHIBITION; BRONCHODILATION; RELEASE; MK-571	Background: Cysteinyl leukotrienes mediate signs and symptoms of asthma. In a double-blind, placebo-controlled, crossover study, a new potent and specific cysteinyl leukotriene (LTD(4)) receptor antagonist, montelukast (MK-0476), was evaluated for tolerability and clinical efficacy in patients with chronic asthma (receiving and not receiving inhaled corticosteroids). Methods: Twenty-nine nonsmoking patients with asthma (15 treated concomitantly with inhaled corticosteroids) with FEV(1) percent predicted values between 50% to 80% received MK-0476, 200 mg, or placebo three times daily for 10 1/3 days (31 doses) in a random, crossover manner, after a 2-week, open, baseline period. Comparisons in FEV(1) (mean percent change from baseline after the first and last dose), mean daily daytime asthma and nocturnal awakening scores, and mean daily beta-agonist use were made between treatment periods. Results: Montelukast, compared with placebo, caused improvements in FEV(1) (mean percentage point difference of the percentage change from baseline) 3 and 4 hours after dosing on day 1 (hour 3, 9.0%; 95% confidence interval [CI] 0.53, 18.72; hour four, 10.9%; 95% CI -0.25, 20.20) and day 11 (hour 3, 14.0%; 95% CI 0.76, 31.43; hour 4, 13.4%; 95% CI 1.24, 28.83). Reductions were observed in mean daily beta-agonist use (1.0 puff/day [95% CI -1.61, -0.26]), mean daytime symptom scores, and nocturnal awakenings over the 10 1/3 day treatment period. There were no important differences between the groups receiving and those not receiving inhaled corticosteroids. Montelukast was well tolerated with no serious clinical adverse events reported. Conclusions: In this study Montelukast, 200 mg, administered three times daily for 10 1/3 days, compared with placebo, was generally well tolerated and resulted in significant improvement in chronic asthma, irrespective of the presence of inhaled corticosteroids.	MERCK RES LABS, DEPT BIOSTAT, RAHWAY, NJ 07065 USA; PACIFIC MED CTR, SEATTLE, WA USA; CTR ASTHMA & ALLERGY, N DARTMOUTH, MA USA; CREIGHTON UNIV, SCH MED, DEPT ALLERGY & IMMUNOL, OMAHA, NE USA; CLIN RES OZARKS INC, ROLLA, MO USA	Merck & Company; Creighton University	Reiss, TF (corresponding author), MERCK RES LABS, DEPT PULM IMMUNOL, POB 2000, RY 33-648, RAHWAY, NJ 07065 USA.							BOTTO A, 1994, AM J RESP CRIT CARE, V149, pA465; DAHLEN B, 1992, American Review of Respiratory Disease, V145, pA15; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358, DOI 10.1164/ajrccm/146.2.358; HONG SL, 1976, P NATL ACAD SCI USA, V73, P1730, DOI 10.1073/pnas.73.5.1730; IMPENS N, 1993, AM REV RESPIR DIS, V147, P1442, DOI 10.1164/ajrccm/147.6_Pt_1.1442; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MARGOLSKEE D, 1991, Journal of Allergy and Clinical Immunology, V87, P309, DOI 10.1016/0091-6749(91)91959-W; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; PARKER SR, 1989, AM REV RESPIR DIS, V140, P848, DOI 10.1164/ajrccm/140.3.848; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; SANTANELLO NC, 1994, AM REV RESP CRIT CAR, V149, pA917; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; WOODWARD DF, 1983, PROSTAGLANDINS, V25, P131, DOI 10.1016/0090-6980(83)90142-9	17	116	121	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					528	534		10.1016/S0091-6749(96)70086-6	http://dx.doi.org/10.1016/S0091-6749(96)70086-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828530				2022-12-18	WOS:A1996VJ42800009
J	APTER, A; BRACKER, A; HODGSON, M; SIDMAN, J; LEUNG, WY				APTER, A; BRACKER, A; HODGSON, M; SIDMAN, J; LEUNG, WY			EPIDEMIOLOGY OF THE SICK BUILDING SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INDOOR AIR; EPIDEMIOLOGY; OCCUPATIONAL HEALTH; SICK BUILDING SYNDROME	INDOOR AIR-QUALITY; VOLATILE ORGANIC-COMPOUNDS; OFFICE WORKERS; OCCUPATIONAL STRESS; SYMPTOMS; HEALTH; ILLNESS; POLLUTION; PREVALENCE; TRIAL	The sick building syndrome (SBS) has been the subject of serious scientific inquiry only in the past 10 years. It is commonly accepted to represent eye, nose, and throat irritation; headaches, lethargy difficulty concentrating, and sometimes dizziness; nausea, chest tightness; and other symptoms. Evidence suggests that what is called the SBS is at least three separate entities, each of which has at least one cause. This review will summarize the epidemiologic investigations of the SBS and present an overview of etiologic hypotheses.	UNIV CONNECTICUT, SCH MED, DIV GEN MED, SECT ALLERGY & IMMUNOL, FARMINGTON, CT 06030 USA; UNIV CONNECTICUT, SCH MED, DIV GEN MED, ENVIRONM & OCCUPAT MED SECT, FARMINGTON, CT USA	University of Connecticut; University of Connecticut								ANDERSSEN K, 1992, INDOOR AIR QUALITY 9, P25; BAUER RM, 1992, J CONSULT CLIN PSYCH, V60, P213, DOI 10.1037/0022-006X.60.2.213; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; CAIN WS, 1983, ATMOS ENVIRON, V17, P1183, DOI 10.1016/0004-6981(83)90341-4; COLLIGAN MJ, 1981, B NEW YORK ACAD MED, V57, P1014; DALES RE, 1989, AM REV RESPIR DIS, V139, P1459, DOI 10.1164/ajrccm/139.6.1459; DANIELL W, 1991, J OCCUP ENVIRON MED, V33, P681, DOI 10.1097/00043764-199106000-00007; FANGER PO, 1988, ENERG BUILDINGS, V12, P7, DOI 10.1016/0378-7788(88)90052-7; FANGER PO, 1988, ENERG BUILDINGS, V12, P1, DOI 10.1016/0378-7788(88)90051-5; FINNEGAN MJ, 1986, CLIN ALLERGY, V16, P389, DOI 10.1111/j.1365-2222.1986.tb01974.x; FINNEGAN MJ, 1984, BRIT MED J, V289, P1573, DOI 10.1136/bmj.289.6458.1573; GIRMAN JR, 1989, OCCUP MED, V4, P695; GUIDOTTI TL, 1987, J OCCUP ENVIRON MED, V29, P148; HARRISON J, 1992, RESP MED, V86, P225, DOI 10.1016/S0954-6111(06)80060-0; HEDGE A, 1992, INDOOR AIR QUALITY 9, P151; HODGSON M, 1994, J ALLERGY CLIN IMMUN, V94, P296, DOI 10.1053/ai.1994.v94.a56008; HODGSON M, 1992, ANN NY ACAD SCI, V641, P21, DOI 10.1111/j.1749-6632.1992.tb16529.x; HODGSON MJ, 1991, J OCCUP ENVIRON MED, V33, P527; HODGSON MJ, 1991, ALLERGY PROC, V12, P371, DOI 10.2500/108854191779114266; HODGSON MJ, 1992, INDOOR AIR QUALITY 9, P33; HODGSON MJ, 1987, INDOOR AIR 87, P459; HODGSON MJ, 1989, P INDOOR AIR QUALITY, P8; HODGSON MJ, 1993, P INDOOR AIR QUALITY; HOESEIN HR, 1990, P INDOOR AIR, V2, P423; HOFFMAN RE, 1993, AM J PUBLIC HEALTH, V83, P89, DOI 10.2105/AJPH.83.1.89; HOUSE JS, 1986, J HEALTH SOC BEHAV, V27, P62, DOI 10.2307/2136503; HOUSE JS, 1979, J HEALTH SOC BEHAV, V20, P139, DOI 10.2307/2136435; JANNSEN J, 1986, INDOOR AIR QUALITY 8, P161; JANTUNEN MJ, 1990, P INDOOR AIR, V2, P73; KREISS K, 1989, OCCUP MED, V4, P575; KROELING P, 1987, GESUNDHEITS INGENIEU, V108, P121; LEVIN H, 1989, OCCUP MED, V4, P667; LEVIN H, 1993, INDOOR AIR B, V2, P7; Melius J., 1984, ANN AM C GOVT IND HY, V10, P3; MENDELL M, 1992, CALIFORNIA HLTH BUIL; MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193; MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201; MENZIES R, 1991, INDOOR AIR QUALITY 9, P90; MENZIES R, 1993, INDOOR AIR QUALITY 9, P119; MOLHAVE L, 1987, INDOOR AIR 87, V2, P469; NAGDA NL, 1991, INDOOR AIR QUALITY 9, P101; NORBACK D, 1990, SCAND J WORK ENV HEA, V16, P121, DOI 10.5271/sjweh.1808; NORBACK D, 1990, BRIT J IND MED, V47, P733; OLSEN JH, 1982, AM IND HYG ASSOC J, V43, P366, DOI 10.1080/15298668291409866; REINIKAINEN LM, 1992, ARCH ENVIRON HEALTH, V47, P8, DOI 10.1080/00039896.1992.9935938; ROBERTSON AS, 1985, BRIT MED J, V291, P373, DOI 10.1136/bmj.291.6492.373; ROBERTSON AS, 1988, THORAX, V43, pP263; Rodes C. E., 1991, INDOOR AIR, V1, P123; ROHLES RH, AM SOC HEATING REFRI; RYAN CM, 1992, J CONSULT CLIN PSYCH, V60, P220, DOI 10.1037/0022-006X.60.2.220; SAMET JM, 1988, AM REV RESPIR DIS, V137, P221, DOI 10.1164/ajrccm/137.1.221; SAMET JM, 1987, AM REV RESPIR DIS, V136, P1486, DOI 10.1164/ajrccm/136.6.1486; SKOV P, 1987, ENVIRON INT, V13, P339, DOI 10.1016/0160-4120(87)90190-5; SKOV P, 1989, SCAND J WORK ENV HEA, V15, P286, DOI 10.5271/sjweh.1851; STELLMAN JM, 1985, AM IND HYG ASSOC J, V46, P286, DOI 10.1080/15298668591394824; STERLING E, 1983, CAN J PUBLIC HEALTH, V74, P385; SUNDELL J, 1991, IAQ 91 HLTH BUILDING, P85; WOODS JE, 1989, OCCUP MED, V4, P753; WOODS JE, 1987, INDOOR AIR 87, P464; WYON DP, 1992, ENVIRON TECHNOL, V13, P313, DOI 10.1080/09593339209385159; Zweers T, 1992, INDOOR AIR, V2, P127, DOI DOI 10.1111/J.1600-0668.1992.00001.X; [No title captured]; 1992, GUIDELINES VENTILATI; 1987, INDOOR AIR GUIDELINE	64	116	120	3	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2	2				277	288		10.1016/0091-6749(94)90087-6	http://dx.doi.org/10.1016/0091-6749(94)90087-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG770	8077580				2022-12-18	WOS:A1994PG77000002
J	MELTZER, EO; ORGEL, HA; BACKHAUS, JW; BUSSE, WW; DRUCE, HM; METZGER, WJ; MITCHELL, DQ; SELNER, JC; SHAPIRO, GG; VANBAVEL, JH; BASCH, C				MELTZER, EO; ORGEL, HA; BACKHAUS, JW; BUSSE, WW; DRUCE, HM; METZGER, WJ; MITCHELL, DQ; SELNER, JC; SHAPIRO, GG; VANBAVEL, JH; BASCH, C			INTRANASAL FLUNISOLIDE SPRAY AS AN ADJUNCT TO ORAL ANTIBIOTIC-THERAPY FOR SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ACUTE MAXILLARY SINUSITIS; AQUEOUS NASAL SPRAY; ALLERGIC RHINITIS; MANAGEMENT; CHILDREN; CYTOLOGY	Background: The diagnosis of sinusitis is difficult and there are few controlled studies Of customary therapies. In particular, the possible role of topical intranasal steroid as an adjunct to antibiotic treatment has not been evaluated Methods: The study was a multicenter, double-blind, randomized, parallel trial in which patients aged 14 years or older were recruited from allergy practices. All patients had maxillary sinusitis documented by radiographs. Treatment consisted of amoxicillin/clavulanate postassium 500 mg combined with nasal spray of either 100 mug fl or placebo 10 each nostril three times a day for 3 weeks (phase I) followed by administration of flunisolide or placebo nasal spray alone three times a day for 4 weeks (phase II). Results: Clinical symptoms and signs decreased significantly in both treatment groups during phase I (p < 0.01). There was a trend to greater improvement in the patients treated with flunisolide, but only the decrease in turbinate swelling/obstruction was statistically significant at the end of phase I when compared with placebo (p = 0.041). Patients' global assessment of overall effectiveness of treatment was higher for flunisolide than placebo after phase I (p = 0.007) and after phase II (p = 0.08). Maxillary sinus radiographs showed improvement in both treatment groups during phase I (p < 0.004) with somewhat greater regression of abnormal findings in patients treated with flunisolide after phase II (p = 0.066). However, 80% of radiographs were still abnormal at the end of phase L All types of inflammatory cells were significantly decreased in nasal cytograms in patients treated with flunisolide in comparison with those treated with placebo. Flare-up of sinusitis during phase II occurred in 26% of patients treated with flunisolide and 35% of those treated with placebo and tended to be more severe in the latter, although these differences were not statistically significant. Adverse events, mainly gastrointestinal symptoms and headache, were similar in both groups and more frequent in phase I than in phase II, (42 vs 15 patients); these side effects were probably due to the antibiotic. Conclusion: The addition of flunisolide topical nasal spray as an adjunct to antibiotic was most effective in global evaluations, tended to improve symptoms, to decrease inflammatory cells in nasal cytograms, to normalize ultrasound scans, and to aid regression of abnormalities compared with placebo spray.	APC, ALLERGY & ASTHMA MED GRP & RES CTR, 9610 GRANITE RIDGE DR, SUITE B, SAN DIEGO, CA 92123 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA; SAN DIEGO DIAGNOST RADIOL MED GRP, SAN DIEGO, CA USA; UNIV WISCONSIN, SCH MED, MADISON, WI 53706 USA; ST LOUIS UNIV, SCH MED, ST LOUIS, MO 63104 USA; E CAROLINA UNIV, SCH MED, GREENVILLE, NC 27834 USA; MISSISSIPPI ASTHMA & ALLERGY CLIN, JACKSON, MS USA; ALLERGY RESP INST COLORADO, DENVER, CO USA; UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; AUSTIN DIAGNOST CLIN, AUSTIN, TX USA; SYNTEX LABS INC, PALO ALTO, CA USA	University of California System; University of California San Diego; University of Wisconsin System; University of Wisconsin Madison; Saint Louis University; University of North Carolina; East Carolina University; University of Washington; University of Washington Seattle; Syntex Corporation								AXELSSON A, 1973, LARYNGOSCOPE, V83, P2003, DOI 10.1288/00005537-197312000-00011; AXELSSON A, 1972, ACTA OTO-LARYNGOL, V74, P118, DOI 10.3109/00016487209128430; BUSINCO L, 1981, INT J PEDIATR OTORHI, V3, P287, DOI 10.1016/0165-5876(81)90053-7; CABLE HR, 1981, J LARYNGOL OTOL, V95, P775, DOI 10.1017/S0022215100091428; CARTER BL, 1983, RADIOLOGY, V147, P739, DOI 10.1148/radiology.147.3.6844609; CUENANT G, 1986, ORL J OTO-RHINO-LARY, V48, P226, DOI 10.1159/000275873; DRUCE HM, 1990, OTOLARYNG HEAD NECK, V103, P880, DOI 10.1177/01945998901030S508; DRUCE HM, 1991, J ALLERGY CLIN IMMUN, V88, P675, DOI 10.1016/0091-6749(91)90161-G; DRUCE HM, 1987, IMMUNOL ALLERGY CLIN, V7, P117; DRUCE HM, 1988, N ENGL REG ALLERGY P, V9, P5; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FINNEY DJ, 1978, STATISTICAL METHODS; GILL FF, 1989, AM J RHINOL, V3, P13; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; KALINER MA, 1992, J ALLERGY CLIN IMMUN, V90, P424, DOI 10.1016/0091-6749(92)90162-U; KENNEDY DW, 1990, OTOLARYNG HEAD NECK, V103, P847, DOI 10.1177/01945998901030S502; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; MELTZER EO, 1990, ANN ALLERGY, V64, P536; Meltzer EO, 1988, AM J RHINOL, V2, P47, DOI DOI 10.2500/105065888781693212; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; Qvarnberg Yrjo, 1992, Rhinology (Utrecht), V30, P103; RACHELEFSKY GS, 1982, J ALLERGY CLIN IMMUN, V69, P382, DOI 10.1016/0091-6749(82)90150-6; SAHAY JN, 1980, CLIN ALLERGY, V10, P451, DOI 10.1111/j.1365-2222.1980.tb02128.x; SAVOLAINEN S, 1989, ALLERGY, V44, P116, DOI 10.1111/j.1398-9995.1989.tb02234.x; SHAPIRO GG, 1986, J ALLERGY CLIN IMMUN, V77, P59, DOI 10.1016/0091-6749(86)90324-6; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, pS55, DOI 10.1097/00006454-198511001-00003; SLAVIN RG, 1988, ALLERGY PRINCIPLES P, P1291; SPECTOR SL, 1982, CLIN ALLERGY, V12, P187, DOI 10.1111/j.1365-2222.1982.tb01638.x; SYKES DA, 1986, LANCET, V2, P359; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; WILSON NW, 1988, AM J RHINOL, V2, P55; ZEIGER RS, 1992, J ALLERGY CLIN IMMUN, V90, P478, DOI 10.1016/0091-6749(92)90173-Y; 1984, NIH DATA BOOK, P57; 1988, NATIONAL DISEASE THE, P487; 1988, SAS PROCEDURES GUIDE	38	116	119	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					812	823		10.1016/0091-6749(93)90058-N	http://dx.doi.org/10.1016/0091-6749(93)90058-N			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258615				2022-12-18	WOS:A1993ML89300006
J	BERNHISELBROADBENT, J; STRAUSE, D; SAMPSON, HA				BERNHISELBROADBENT, J; STRAUSE, D; SAMPSON, HA			FISH HYPERSENSITIVITY .2. CLINICAL RELEVANCE OF ALTERED FISH ALLERGENICITY CAUSED BY VARIOUS PREPARATION METHODS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FISH ALLERGY; FOOD HYPERSENSITIVITY; DOUBLE-BLIND; PLACEBO-CONTROLLED ORAL FOOD CHALLENGES; LYOPHILIZATION; ELISA INHIBITION ASSAY; IMMUNOBLOTTING	FOOD HYPERSENSITIVITY; CHILDREN; ALLERGY	In double-blind, placebo-controlled, oral food challenges with fish, a 12-fold higher false-negative rate was found compared with other food antigens. In an effort to elucidate this discrepancy, cooked lyophilized fish extracts (used in double-blind, placebo-controlled, oral food challenges) were compared with cooked, nonlyophilized fish extracts (used in open challenges) by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, immunoblot, and ELISA-inhibition assays. Altered fish allergenicity as a result of food processing was examined with canned tuna and salmon. Forty-five children and young adults with food allergies, including 18 patients with IgE-mediated hypersensitivity to fish, were challenged with canned tuna. All 45 challenges with canned tuna were negative. Two of these patients are allergic to salmon and also have negative reactions to challenges with canned salmon. In vitro investigation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of tuna and salmon extracts revealed a striking loss of definable protein fractions in the canned fish extract when compared with raw and cooked fish extracts, and immunoblot analyses demonstrated minimal IgE-specific binding to the canned fish extracts. In addition, decreased allergenicity of the canned tuna and salmon was demonstrated by ELISA-inhibition assay and by negative oral challenges with canned salmon in two patients allergic to salmon. Collectively, these findings suggest that some of the major allergens responsible for IgE-mediated food allergy to fish are more labile than previously recognized.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,DIV ALLERGY IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA016754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16754] Funding Source: Medline; NCRR NIH HHS [RR00052] Funding Source: Medline; NIAID NIH HHS [AI24439] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1967, INT ARCH ALLER A IMM, V32, P1, DOI 10.1159/000229911; Aas K., 1987, FOOD ALLERGY INTOLER, P356; BERNHISELBROADB.J, IN PRESS J ALLERGY C; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V87, pA175; EBBELING W, 1989, J ALLERGY CLIN IMMUN, V83, pA238; ELSAYED S, 1983, ALLERGY, V38, P449, DOI 10.1111/j.1398-9995.1983.tb02353.x; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; LIFSCHITZ CH, 1988, J PEDIATR GASTR NUTR, V7, P141, DOI 10.1097/00005176-198801000-00026; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1991, J PEDIATR-US, V118, P520, DOI 10.1016/S0022-3476(05)90001-2; SAMPSON HA, 1992, IN PRESS PEDIATRICS; TAYLOR SL, 1987, ANN ALLERGY, V59, P93; TAYLOR SL, 1986, CRC CR REV TOXICOL, V17, P91, DOI 10.3109/10408448609023767; 1989, PEDIATRICS, V83, P1068	16	116	122	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				622	629		10.1016/0091-6749(92)90135-O	http://dx.doi.org/10.1016/0091-6749(92)90135-O			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1401644				2022-12-18	WOS:A1992JT99500008
J	LEUNG, DYM; HIRSCH, RL; SCHNEIDER, L; MOODY, C; TAKAOKA, R; LI, SH; MEYERSON, LA; MARIAM, SG; GOLDSTEIN, G; HANIFIN, JM				LEUNG, DYM; HIRSCH, RL; SCHNEIDER, L; MOODY, C; TAKAOKA, R; LI, SH; MEYERSON, LA; MARIAM, SG; GOLDSTEIN, G; HANIFIN, JM			THYMOPENTIN THERAPY REDUCES THE CLINICAL SEVERITY OF ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									IMMUNOBIOL RES INST,ANNANDALE,NJ; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DIV ALLERGY,BOSTON,MA 02115; OREGON HLTH SCI UNIV,DEPT DERMATOL,PORTLAND,OR 97201	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Oregon Health & Science University					NHLBI NIH HHS [HL37260] Funding Source: Medline; NIAID NIH HHS [AI 18615, AI 22058] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022058, R01AI018615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKIN RM, 1987, CURRENT PEDIATRIC DI, P207; BOLLA K, 1985, SURV IMMUNOL RES, V4, P37; BROWN MA, 1989, CLIN RES, V37, pA229; Cooper K D, 1983, Diagn Immunol, V1, P211; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DIEZEL W, 1984, BIOMED BIOCHIM ACTA, V43, P9; GERSHWIN ME, 1979, J RHEUMATOL, V6, P610; GOLDBERG EH, 1984, TRANSPLANTATION, V38, P52, DOI 10.1097/00007890-198407000-00013; GOLDSTEIN G, 1979, SCIENCE, V204, P1309, DOI 10.1126/science.451537; GRIFFIN DE, 1985, J ALLERGY CLIN IMMUN, V76, P206, DOI 10.1016/0091-6749(85)90703-1; HANIFIN JM, 1982, J AM ACAD DERMATOL, V6, P1, DOI 10.1016/S0190-9622(82)70001-5; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; JABARA HH, 1988, J CLIN IMMUNOL, V8, P437, DOI 10.1007/BF00916948; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; KANG K, 1983, J AM ACAD DERMATOL, V8, P372, DOI 10.1016/S0190-9622(83)70042-3; LEUNG DYM, 1986, CLIN REV ALLERG, V4, P67; LEUNG DYM, 1986, DERMATOLOGY GENERAL, P1385; MACK GA, 1980, J AM STAT ASSOC, V75, P947, DOI 10.2307/2287186; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MERONI PL, 1987, CLIN IMMUNOL IMMUNOP, V42, P151, DOI 10.1016/0090-1229(87)90002-X; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; PAVONI D, 1987, Bollettino dell'Istituto Sieroterapico Milanese, V66, P308; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; REINHOLD U, 1988, INT ARCH ALLER A IMM, V87, P120, DOI 10.1159/000234661; SAURAT JH, 1985, ACTA DERM-VENER    S, V114, P125; SCHEID MP, 1978, J EXP MED, V147, P1727, DOI 10.1084/jem.147.6.1727; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; SHULTZLARSEN F, 1986, J AM ACAD DERMATOL, V15, P487; SILVESTRIS F, 1989, J LAB CLIN MED, V113, P139; SUNSHINE GH, 1978, J IMMUNOL, V120, P1594; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8	31	116	120	0	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					927	933		10.1016/0091-6749(90)90079-J	http://dx.doi.org/10.1016/0091-6749(90)90079-J			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2185294				2022-12-18	WOS:A1990DD95900017
J	BOUSQUET, J; HEJJAOUI, A; CLAUZEL, AM; GUERIN, B; DHIVERT, H; SKASSABROCIEK, W; MICHEL, FB				BOUSQUET, J; HEJJAOUI, A; CLAUZEL, AM; GUERIN, B; DHIVERT, H; SKASSABROCIEK, W; MICHEL, FB			SPECIFIC IMMUNOTHERAPY WITH A STANDARDIZED DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT .2. PREDICTION OF EFFICACY OF IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LABS STALLERGENES,FRESNES,FRANCE	Stallergenes Greer	BOUSQUET, J (corresponding author), CHU MONTPELLIER,HOP AIGUELONGUE,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					AAS K, 1972, ACTA ALLERGOL, V27, P439; AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1987, HIGHLIGHTS ASTHMOLOG, P394; BROWN HM, 1968, BRIT MED J, V3, P647; BUSSE WW, 1987, HIGHLIGHTS ASTHMOLOG, P58; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; FARREL MK, 1985, BRONCHIAL ASTHMA MEC, P494; KNUDSON RJ, 1977, AM REV RESPIR DIS, V115, P195; LANNER A, 1984, Journal of Allergy and Clinical Immunology, V73, P141; MAUNSELL K, 1971, LANCET, V1, P967; MICHEL FB, 1987, J ALLERGY CLIN IMMUN, V79, P247; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; PEPYS J, 1975, BR J HOSP MED, V14, P912; PLATTSMILLS TAE, IN PRESS J ALLERGY C; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; PUTTONEN E, 1981, INT ARCH ALLER A IMM, V64, P157, DOI 10.1159/000232687; RACHELEFSKY GS, 1982, J ALLERGY CLIN IMMUN, V69, P382, DOI 10.1016/0091-6749(82)90150-6; SLAVIN RG, 1984, J ALLERGY CLIN IMMUN, V73, P712, DOI 10.1016/0091-6749(84)90312-9; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; SPECTOR SL, 1983, ALLERGY PRINCIPLES P, P1249; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; VANARSDEL PP, 1985, BRONCHIAL ASTHMA MEC, P303; Voorhorst R., 1964, Allergie Asthma, V10, P329; WARNER JO, 1978, LANCET, V2, P912; 1962, AM REV RESPIR DIS, V85, P762	31	116	117	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					971	977		10.1016/0091-6749(88)90133-9	http://dx.doi.org/10.1016/0091-6749(88)90133-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	3204255				2022-12-18	WOS:A1988R631100004
J	ZIMMERMAN, B; FEANNY, S; REISMAN, J; HAK, H; RASHED, N; MCLAUGHLIN, FJ; LEVISON, H				ZIMMERMAN, B; FEANNY, S; REISMAN, J; HAK, H; RASHED, N; MCLAUGHLIN, FJ; LEVISON, H			ALLERGY IN ASTHMA .1. THE DOSE RELATIONSHIP OF ALLERGY TO SEVERITY OF CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,DEPT PEDIAT,DIV CHEST,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	ZIMMERMAN, B (corresponding author), HOSP SICK CHILDREN,DEPT PEDIAT,DIV ALLERGY,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.							BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; CARTIER A, 1980, American Review of Respiratory Disease, V121, P61; Coca AF, 1923, J IMMUNOL, V8, P163; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; Cooke RA, 1916, J IMMUNOL, V1, P201; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; DOLOVICH J, 1983, ASTHMA, P132; EISENBREY AB, 1985, J ALLERGY CLIN IMMUN, V75, P84; GALDESSEBALDT M, 1985, J PEDIATR-US, V107, P526, DOI 10.1016/S0022-3476(85)80009-3; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GODFREY S, 1983, ASTHMA, P415; GREGG I, 1983, ASTHMA, P242; GREGG I, 1983, ASTHMA, P160; HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587; KEMP A, 1984, AUST PAEDIATR J, V20, P161; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; Matthews D.E., 2016, ACTA HAEMATOL-BASEL, V135, P194; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; MCNICOL KN, 1983, BRIT MED J, V4, P7; METZGER WJ, 1985, CHEST, V87, P1555; Pepys J., 1975, BR J HOSP MED, V14, P412; RICCI M, 1985, INT ARCH ALLER A IMM, V77, P32, DOI 10.1159/000233749; RIEDEL F, 1986, PEDIATR PULM, V2, P15, DOI 10.1002/ppul.1950020107; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SIBBALD B, 1980, CLIN ALLERGY, V10, P313, DOI 10.1111/j.1365-2222.1980.tb02113.x; SIBBALD B, 1980, ARCH DIS CHILD, V55, P354, DOI 10.1136/adc.55.5.354; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6	32	116	116	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					63	70		10.1016/0091-6749(88)90221-7	http://dx.doi.org/10.1016/0091-6749(88)90221-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3339192				2022-12-18	WOS:A1988M027400010
J	SHEFFER, AL; SOTER, NA; MCFADDEN, ER; AUSTEN, KF				SHEFFER, AL; SOTER, NA; MCFADDEN, ER; AUSTEN, KF			EXERCISE-INDUCED ANAPHYLAXIS - A DISTINCT FORM OF PHYSICAL ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL IMMUNOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital				Soter, Nicholas/0000-0003-3518-3209	NIAID NIH HHS [AI-18139, AI-10356, AI-07722] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BRISCOE WA, 1958, J CLIN INVEST, V37, P1279, DOI 10.1172/JCI103715; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; Duke WW, 1924, J AMER MED ASSOC, V83, P3, DOI 10.1001/jama.1924.02660010007002; FAHEY JL, 1965, J IMMUNOL, V94, P84; GRANT J A, 1982, Journal of Allergy and Clinical Immunology, V69, P103; HARRIES MG, 1979, CLIN ALLERGY, V9, P437, DOI 10.1111/j.1365-2222.1979.tb02506.x; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P319, DOI 10.1016/0091-6749(81)90158-5; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KENT JF, 1963, AM J TROP MED HYG, V12, P103, DOI 10.4269/ajtmh.1963.12.103; KIDD J, 1982, Journal of Allergy and Clinical Immunology, V69, P103; LEWIS J, 1981, J ALLERGY CLIN IMMUN, V68, P432, DOI 10.1016/0091-6749(81)90197-4; LONGLEY A, 1982, J ALLERGY CLIN IMMUN, V69, P103; MATHEWS K P, 1970, Algerie Medicale, V72, P241; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MCNEILL RS, 1966, Q J MED, V35, P55; MOOREROBINSON M, 1968, BRIT J DERMATOL, V80, P794, DOI 10.1111/j.1365-2133.1968.tb11948.x; RUDDY S, 1971, J EXP MED, V134, pS259; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; Siegel S., 1956, NONPARAMETRIC STAT, P116; SIGLER RW, 1979, J ALLERGY CLIN IMMUN, V63, P35, DOI 10.1016/0091-6749(79)90159-3; SOTER N A, 1982, Journal of Allergy and Clinical Immunology, V69, P103; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; SYKES TW, 1977, AM REV RESPIR DIS, V115, P581; TSE KS, 1980, J ALLERGY CLIN IMMUN, V65, P227; WARIN RP, 1974, URTICARIA, P136	30	116	116	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	3					311	316		10.1016/0091-6749(83)90085-4	http://dx.doi.org/10.1016/0091-6749(83)90085-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH188	6826991				2022-12-18	WOS:A1983QH18800007
J	HOGG, JC				HOGG, JC			BRONCHIAL MUCOSAL PERMEABILITY AND ITS RELATIONSHIP TO AIRWAYS HYPER-REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HOGG, JC (corresponding author), UNIV BRITISH COLUMBIA,ST PAULS HOSP,PULM RES LAB,VANCOUVER V6Z 1Y6,BC,CANADA.							BOUCHER RC, 1979, J ALLERGY CLIN IMMUN, V64, P197, DOI 10.1016/0091-6749(79)90095-2; BOUCHER RC, 1977, J ALLERGY CLIN IMMUN, V60, P134, DOI 10.1016/0091-6749(77)90039-2; BOUCHER RC, 1978, J APPL PHYSIOL, V45, P939, DOI 10.1152/jappl.1978.45.6.939; BOUCHER RC, 1980, LAB INVEST, V43, P94; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FLOREY HW, 1962, GENERAL PATHOLOGY; GERRARD JW, 1980, AM REV RESPIR DIS, V122, P577; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GUERZON GM, 1979, AM REV RESPIR DIS, V119, P59; HOGG JC, 1977, ASTHMA, V2, P1; HOLTZMAN MJ, 1980, AM REV RESPIR DIS, V122, P17; HULBERT WC, 1981, AM REV RESPIR DIS, V123, P320; INOUE S, 1977, J ULTRA MOL STRUCT R, V61, P89, DOI 10.1016/S0022-5320(77)90008-9; JONES JG, 1980, LANCET, V1, P66; MICHOUD MC, 1978, J APPL PHYSIOL, V45, P846, DOI 10.1152/jappl.1978.45.6.846; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; PATERSON R, 1974, CLIN EXP IMMUNOL, V16, P223; REID L, 1979, FED PROC, V38, P191; SIMANI AS, 1974, LAB INVEST, V31, P75; VIDRUK EH, 1977, J APPL PHYSIOL, V43, P397, DOI 10.1152/jappl.1977.43.3.397; VRACKO R, 1974, AM J PATHOL, V75, P204; VRACKO R, 1974, DIABETES, V23, P94; WIDDICOMBE JG, 1977, ASTHMA PHYSL IMMUNOP, V2, P225	25	116	117	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	6					421	425		10.1016/0091-6749(81)90094-4	http://dx.doi.org/10.1016/0091-6749(81)90094-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LU068	7346527	Bronze			2022-12-18	WOS:A1981LU06800002
J	BUTCHER, BT; ONEIL, CE; REED, MA; SALVAGGIO, JE				BUTCHER, BT; ONEIL, CE; REED, MA; SALVAGGIO, JE			RADIOALLERGOSORBENT TESTING OF TOLUENE DIISOCYANATE-REACTIVE INDIVIDUALS USING PARA-TOLYL ISOCYANATE ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BUTCHER, BT (corresponding author), TULANE UNIV,MED CTR,DEPT MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015092] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-15092-06] Funding Source: Medline; PHS HHS [120-75-0006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P655, DOI 10.1016/0091-6749(79)90031-9; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P233; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; KAROL MH, 1979, J OCCUP MED, V21, P383; KARR RM, 1978, J ALLERGY CLIN IMMUN, V61, P54, DOI 10.1016/0091-6749(78)90474-8; OBRIEN IM, 1979, CLIN ALLERGY, V9, P7, DOI 10.1111/j.1365-2222.1979.tb01517.x; PEPYS J, 1972, Clinical Allergy, V2, P225, DOI 10.1111/j.1365-2222.1972.tb01287.x; Weill H, 1975, Environ Health Perspect, V11, P101	12	116	116	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	3					213	216		10.1016/0091-6749(80)90041-X	http://dx.doi.org/10.1016/0091-6749(80)90041-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KH358	6251126				2022-12-18	WOS:A1980KH35800007
J	VAZ, NM; MAIA, LCS; HANSON, DG; LYNCH, JM				VAZ, NM; MAIA, LCS; HANSON, DG; LYNCH, JM			INHIBITION OF HOMOCYTOTROPIC ANTIBODY-RESPONSES IN ADULT INBRED MICE BY PREVIOUS FEEDING OF SPECIFIC ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL ASTHMA CTR,DENVER,CO 80204									ANDRE C, 1975, J EXP MED, V142, P1509, DOI 10.1084/jem.142.6.1509; AUERBACH R, 1975, SCIENCE, V189, P811, DOI 10.1126/science.1162355; AVRAMEAS S, 1969, IMMUNOCHEMISTRY, V6, P67, DOI 10.1016/0019-2791(69)90179-7; BATTISTO JR, 1965, J EXP MED, V121, P591, DOI 10.1084/jem.121.4.591; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; Claman H N, 1976, Contemp Top Immunobiol, V5, P211; CLARK SL, 1959, J BIOPHYS BIOCHEM CY, V5, P41, DOI 10.1083/jcb.5.1.41; DAVID MF, 1975, J ALLERGY CLIN IMMUN, V55, P135; DUNHAM EK, 1973, J IMMUNOL, V111, P1621; FILLIPP G, 1967, J ALLERGY, V39, P167; HALSEY JF, 1976, J IMMUNOL, V116, P1204; HANSON D, IN PRESS; HILL K. J., 1956, QUART JOUR EXPTL PHYSIOL, V41, P421; ISHIZAKA K, 1976, ADV IMMUNOL, V23, P1, DOI 10.1016/S0065-2776(08)60318-1; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; McDevitt H O, 1969, Adv Immunol, V11, P31, DOI 10.1016/S0065-2776(08)60477-0; MILLER SD, 1976, J IMMUNOL, V117, P1519; Morris I G, 1974, Biomembranes, V4A, P483; POMERANZ JR, 1966, J EXP MED, V124, P69, DOI 10.1084/jem.124.1.69; Sulzberger MB, 1929, ARCH DERMATOL SYPH, V20, P669, DOI 10.1001/archderm.1929.01440050079007; THOMAS HC, 1974, IMMUNOLOGY, V27, P631; VAZ NM, 1976, FED PROC, V35, P788; VAZ NM, 1971, J EXP MED, V134, P1335, DOI 10.1084/jem.134.5.1335; VAZ NM, 1974, INT ARCH ALLER A IMM, V46, P275, DOI 10.1159/000231130; Wells HG, 1911, J INFECT DIS, V8, P66, DOI 10.1093/infdis/8.1.66	25	116	119	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	2					110	115		10.1016/0091-6749(77)90035-5	http://dx.doi.org/10.1016/0091-6749(77)90035-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR448	874210				2022-12-18	WOS:A1977DR44800004
J	TAYLOR, G; FREED, DLJ				TAYLOR, G; FREED, DLJ			ASSESSING DEGREE OF NASAL PATENCY BY MEASURING PEAK EXPIRATORY FLOW-RATE THROUGH NOSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANCHESTER,DEPT BACTERIOL & VIROL,IMMUNOL LABS,STOPFORD BLDG 1,MANCHESTER M13 9PT,ENGLAND	University of Manchester								CONNELL JT, 1966, J ALLERGY, V37, P127, DOI 10.1016/0021-8707(66)90087-6; INGELSTE.S, 1969, ACTA OTO-LARYNGOL, V68, P189, DOI 10.3109/00016486909121557; PROETZ AW, 1951, ANN OTO RHINOL LARYN, V60, P439, DOI 10.1177/000348945106000216; SOLOMON WR, 1965, ANN OTO RHINOL LARYN, V74, P978, DOI 10.1177/000348946507400406; SOLOMON WR, 1965, J ALLERGY, V36, P63; TAYLOR G, 1971, Clinical Allergy, V1, P63, DOI 10.1111/j.1365-2222.1971.tb02448.x	6	116	115	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	4					193	198		10.1016/0091-6749(73)90057-2	http://dx.doi.org/10.1016/0091-6749(73)90057-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q9817	4270244	Bronze			2022-12-18	WOS:A1973Q981700001
J	Lovinsky-Desir, S; Deshpande, DR; De, A; Murray, L; Stingone, JA; Chan, A; Patel, N; Rai, N; DiMango, E; Milner, J; Kattan, M				Lovinsky-Desir, Stephanie; Deshpande, Deepti R.; De, Aliva; Murray, Laurie; Stingone, Jeanette A.; Chan, Angela; Patel, Neha; Rai, Nooralam; DiMango, Emily; Milner, Joshua; Kattan, Meyer			Asthma among hospitalized patients with COVID-19 and related outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SARS-CoV-2; coronavirus; New York City; respiratory disease	CORONAVIRUS; PREVALENCE; VIRUSES; ACE2	Background: Several underlying conditions have been associated with severe acute respiratory syndrome coronavirus 2 illness, but it remains unclear whether underlying asthma is associated with worse coronavirus disease 2019 (COVID-19) outcomes. Objective: Given the high prevalence of asthma in the New York City area, our objective was to determine whether underlying asthma was associated with poor outcomes among hospitalized patients with severe COVID-19 compared with patients without asthma. Methods: Electronic heath records were reviewed for 1298 sequential patients 65 years or younger without chronic obstructive pulmonary disease who were admitted to our hospital system with a confirmed positive severe acute respiratory syndrome coronavirus 2 test result. Results: The overall prevalence of asthma among all hospitalized patients with COVID-19 was 12.6%, yet a higher prevalence (23.6%) was observed in the subset of 55 patients younger than 21 years. There was no significant difference in hospital length of stay, need for intubation, length of intubation, tracheostomy tube placement, hospital readmission, or mortality between patients with and without asthma. Observations between patients with and without asthma were similar when stratified by obesity, other comorbid conditions (ie, hypertension, hyperlipidemia, and diabetes), use of controller asthma medication, and absolute eosinophil count. Conclusions: Among hospitalized patients 65 years or younger with severe COVID-19, asthma diagnosis was not associated with worse outcomes, regardless of age, obesity, or other high-risk comorbidities. Future population-based studies are needed to investigate the risk of developing COVID-19 among patients with asthma once universal testing becomes readily available.	[Lovinsky-Desir, Stephanie; De, Aliva; Patel, Neha; Rai, Nooralam; Kattan, Meyer] Columbia Univ, Vagelos Coll Phys & Surg, Div Pediat Pulmonol, Irving Med Ctr, New York, NY 10032 USA; [Deshpande, Deepti R.; Chan, Angela; Milner, Joshua] Columbia Univ, Vagelos Coll Phys & Surg, Div Allergy Immunol & Rheumatol, Irving Med Ctr, New York, NY 10032 USA; [Murray, Laurie] New York Presbyterian Morgan Stanley Childrens Ho, Dept Pediat, New York, NY USA; [Stingone, Jeanette A.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA; [DiMango, Emily] Columbia Univ, Vagelos Coll Phys & Surg, Div Pulm Allergy & Crit Care Med, Irving Med Ctr, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; NewYork-Presbyterian Hospital; Morgan Stanley Children's Hospital; Columbia University; Columbia University; NewYork-Presbyterian Hospital	Lovinsky-Desir, S (corresponding author), Columbia Univ, Med Ctr, 3959 Broadway,CHC 701, New York, NY 10032 USA.	sl3230@cumc.columbia.edu		Lovinsky-Desir, Stephanie/0000-0003-2272-4387	RobertWood Johnson Foundation -Amos Medical Faculty Development Award Program [K01 HL140216]	RobertWood Johnson Foundation -Amos Medical Faculty Development Award Program	We disclose the following funding sources that played no role in the writing of the manuscript or in the decision to submit it for publication: National Institutes of Health K01 HL140216, RobertWood Johnson Foundation -Amos Medical Faculty Development Award Program.	Abrams EM, 2020, J PEDIATR-US, V222, P221, DOI 10.1016/j.jpeds.2020.04.049; Avdeev S, 2020, ALLERGY, V75, P2703, DOI 10.1111/all.14420; BODE BW, 2020, MMWR-MORBID MORTAL W, V69, DOI DOI 10.2337/DB20-111-LB; Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841; Caussy C, 2020, OBESITY, V28, P1175, DOI 10.1002/oby.22842; Centers for Disease Control and Prevention, 2020, ASTHM EFF NAT; Centers for Disease Control and Prevention, 2020, CORONAVIRUS DIS 2019; Chao JY, 2020, J PEDIATR-US, V223, P14, DOI 10.1016/j.jpeds.2020.05.006; Chhiba KD, 2020, J ALLERGY CLIN IMMUN, V146, P307, DOI 10.1016/j.jaci.2020.06.010; Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2; Docherty A. B., 2020, JS NGUYEN VAN TAM, DOI [10.1101/2020.04.23.20076042v1, DOI 10.1101/2020.04.23.20076042, 10.1136/bmj.m1985]; Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3; Han MY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120682; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang KW, 2019, LANCET, V394, P407, DOI 10.1016/S0140-6736(19)31147-X; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Kalligeros M, 2020, OBESITY, V28, P1200, DOI 10.1002/oby.22859; Kimes D, 2004, ENVIRON RES, V94, P7, DOI 10.1016/S0013-9351(03)00046-X; Kimura H, 2020, J ALLERGY CLIN IMMUN, V146, P80, DOI 10.1016/j.jaci.2020.05.004; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; Kurai D, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00293; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Li YW, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104833; Lieberman-Cribbin W, 2020, CHEST, V158, P2290, DOI 10.1016/j.chest.2020.05.575; Lindsley AW, 2020, J ALLERGY CLIN IMMUN, V146, P1, DOI 10.1016/j.jaci.2020.04.021; Maes T, 2020, AM J RESP CRIT CARE, V202, P8, DOI 10.1164/rccm.202005-1651ED; Mahdavinia M, 2020, J ALLER CL IMM-PRACT, V8, P2388, DOI 10.1016/j.jaip.2020.05.006; Matsuyama S, 2020, BIORXIV, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]; Mendy A, 2018, CLIN RESPIR J, V12, P2369, DOI 10.1111/crj.12917; Michalakis K, 2020, DIABETES METAB SYND, V14, P469, DOI 10.1016/j.dsx.2020.04.033; Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262; Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831; Tibirica E, 2020, OBESITY, V28, P1374, DOI 10.1002/oby.22887; Van Bever HP, 2004, PEDIAT ALLERG IMM-UK, V15, P206, DOI 10.1111/j.1399-3038.2004.00137.x; WALLEN N, 1991, J IMMUNOL, V147, P3490; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; Xu X, 2020, EUR J NUCL MED MOL I, V47, P1275, DOI 10.1007/s00259-020-04735-9; Yamaya M, 2020, RESPIR INVESTIG, V58, P155, DOI 10.1016/j.resinv.2019.12.005; Yan TT, 2020, FASEB J, V34, P6017, DOI 10.1096/fj.202000782; Yang X, 2020, LANCET RESP MED, V8, pE26; Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zheng XY, 2018, ARCH VIROL, V163, P845, DOI 10.1007/s00705-017-3700-y; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	49	115	117	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					1027	+		10.1016/j.jaci.2020.07.026	http://dx.doi.org/10.1016/j.jaci.2020.07.026			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32771560	Green Published, Bronze			2022-12-18	WOS:000588153700007
J	Schmitt, J; Schwarz, K; Baurecht, H; Hotze, M; Folster-Holst, R; Rodriguez, E; Lee, YAE; Franke, A; Degenhardt, F; Lieb, W; Gieger, C; Kabesch, M; Nothen, MM; Irvine, AD; McLean, WHI; Deckert, S; Stephan, V; Schwarz, P; Aringer, M; Novak, N; Weidinger, S				Schmitt, Jochen; Schwarz, Kristin; Baurecht, Hansjoerg; Hotze, Melanie; Foelster-Holst, Regina; Rodriguez, Elke; Lee, Young A. E.; Franke, Andre; Degenhardt, Frauke; Lieb, Wolfgang; Gieger, Christian; Kabesch, Michael; Noethen, Markus M.; Irvine, Alan D.; McLean, W. H. Irwin; Deckert, Stefanie; Stephan, Victoria; Schwarz, Peter; Aringer, Martin; Novak, Natalija; Weidinger, Stephan			Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; cohort study; epidemiology; inflammatory bowel disease; rheumatoid arthritis; type 1 diabetes	GENOME-WIDE ASSOCIATION; GERMAN HEALTH INTERVIEW; SECONDARY DATA-ANALYSIS; SUSCEPTIBILITY LOCI; ULCERATIVE-COLITIS; SOCIOECONOMIC-STATUS; CROHNS-DISEASE; MENTAL-HEALTH; ADULTS DEGS1; BIRTH COHORT	Background: Atopic dermatitis (AD) is characterized by epidermal barrier failure and immune-mediated inflammation. Evidence on AD as a potential risk factor for inflammatory comorbidities is scarce. Objectives: We sought to test the hypothesis that prevalent AD is a risk factor for incident rheumatoid arthritis (RA) and inflammatory bowel disease (IBD; Crohn disease [CD], ulcerative colitis [UC]) and is inversely related to type 1 diabetes (T1D) and to investigate established RA, IBD, and T1D susceptibility loci in AD. Methods: This cohort study used data from German National Health Insurance beneficiaries aged 40 years or younger (n = 655,815) from 2005 through 2011. Prevalent AD in the period 2005 to 2006 was defined as primary exposure, and incident RA, IBD, and T1D in the period 2007 to 2011 were defined as primary outcomes. Risk ratios were calculated with generalized linear models. Established RA, IBD, and T1D loci were explored in high-density genotyping data from 2,425 cases with AD and 5,449 controls. Results: Patients with AD (n = 49,847) were at increased risk for incident RA (risk ratio [RR], 1.72; 95% CI, 1.25-2.37) and/or IBD (CD: RR, 1.34; 95% CI, 1.11-1.61; UC: RR, 1.25; 95% CI, 1.03-1.53). After adjusting for health care utilization, there was a nominally significant inverse effect on T1D risk (RR, 0.72; 95% CI, 0.53-0.998). There was no disproportionate occurrence of known RA, CD, UC, or T1D risk alleles in AD. Conclusions: AD is a risk factor for the development of RA and IBD. This excess comorbidity cannot be attributed to major known IBD and RA genetic risk factors.	[Schmitt, Jochen; Schwarz, Kristin; Deckert, Stefanie; Stephan, Victoria] Tech Univ Dresden, Ctr Evidence Based Healthcare, Med Fak Carl Gustav Carus, D-01307 Dresden, Germany; [Schmitt, Jochen] Tech Univ Dresden, Univ Allergy Ctr, D-01307 Dresden, Germany; [Baurecht, Hansjoerg; Hotze, Melanie; Foelster-Holst, Regina; Rodriguez, Elke; Degenhardt, Frauke; Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol Venereol & Allergy, Kiel, Germany; [Lee, Young A. E.] Max Delbruck Ctr Mol Med, Berlin, Germany; [Lee, Young A. E.] Charite, Pediat Allergy Expt & Clin Res Ctr, D-13353 Berlin, Germany; [Franke, Andre; Degenhardt, Frauke] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Lieb, Wolfgang] Univ Hosp Schleswig Holstein, Inst Epidemiol, Kiel, Germany; [Lieb, Wolfgang] Univ Hosp Schleswig Holstein, PopGen Biobank, Kiel, Germany; [Gieger, Christian] German Res Ctr Environm Hlth, Inst Genet Epidemiol, Helmholtz Zentrum Munchen, Neuherberg, Germany; [Kabesch, Michael] Univ Childrens Hosp Regensburg KUNO, Dept Pediat Pneumol & Allergy, Regensburg, Germany; [Noethen, Markus M.] Univ Bonn, Inst Human Genet, Bonn, Germany; [Noethen, Markus M.] Univ Bonn, Dept Genom, Life & Brain Ctr, Bonn, Germany; [Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Paediat Dermatol, Dublin, Ireland; [Irvine, Alan D.] Natl Childrens Res Ctr, Dublin, Ireland; [Irvine, Alan D.] Univ Dublin Trinity Coll, Dept Clin Med, Dublin 2, Ireland; [McLean, W. H. Irwin] Univ Dundee, Dermatol & Genet Med, Div Mol Med, Coll Life Sci, Dundee, Scotland; [McLean, W. H. Irwin] Univ Dundee, Coll Med Dent & Nursing, Dundee, Scotland; [Schwarz, Peter; Aringer, Martin] Tech Univ Dresden, Dept Med 3, Med Fak Carl Gustav Carus, D-01307 Dresden, Germany; [Novak, Natalija] Univ Bonn, Med Ctr, Dept Dermatol & Allergy, Bonn, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; University of Kiel; Schleswig Holstein University Hospital; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Bonn; University of Bonn; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; National Children's Research Centre (NCRC); Trinity College Dublin; Trinity College Dublin; University of Dundee; University of Dundee; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Bonn	Schmitt, J (corresponding author), Tech Univ Dresden, Ctr Evidence Based Healthcare, Med Fak Carl Gustav Carus, Fetscherstr 74, D-01307 Dresden, Germany.	jochen.schmitt@uniklinikum-dresden.de	Franke, Andre/B-2151-2010; Irvine, Alan D/A-3982-2008; Rodríguez, Elke/C-4259-2013; Schwarz, Peter/AAF-1558-2020; Kabesch, Michael/GZM-1583-2022; Kabesch, Michael/AAB-5701-2020; Lieb, Wolfgang/AAC-7650-2022; Aringer, Martin/AAJ-7641-2020; Weidinger, Stephan/C-8461-2011; Baurecht, Hansjorg/C-4035-2013	Franke, Andre/0000-0003-1530-5811; Irvine, Alan D/0000-0002-9048-2044; Rodríguez, Elke/0000-0003-3692-3950; Aringer, Martin/0000-0003-4471-8375; Weidinger, Stephan/0000-0003-3944-252X; Stephan, Victoria/0000-0002-7966-6539; Deckert, MPH, Stefanie/0000-0002-4889-3632; Baurecht, Hansjorg/0000-0002-9265-5594; Nothen, Markus/0000-0002-8770-2464; Degenhardt, Frauke/0000-0001-7516-3179; Gieger, Christian/0000-0001-6986-9554	DFG [EXC306, EXC306/2]; German Federal Ministry of Education and Research (BMBF) [01ZX1306A]; PopGen 2.0 network [01EY1103]; German National Research Council (DFG) [SFB704]; Cluster of Excellence "ImmunoSensation''; Christine Kuhne Stiftung Center for Allergy Research and Education; MRC [G0700314, G0802780] Funding Source: UKRI; Medical Research Council [G0802780, G0700314] Funding Source: researchfish	DFG(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); PopGen 2.0 network; German National Research Council (DFG)(German Research Foundation (DFG)); Cluster of Excellence "ImmunoSensation''; Christine Kuhne Stiftung Center for Allergy Research and Education; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The project received infrastructure support through the DFG Clusters of Excellence "Inflammation at Interfaces'' (grant nos EXC306 and EXC306/2), and was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept (sysINFLAME, grant no. 01ZX1306A), and the PopGen 2.0 network (grant no. 01EY1103). N.N. was supported by the German National Research Council (DFG) through SFB704, the Cluster of Excellence "ImmunoSensation,'' and the Christine Kuhne Stiftung Center for Allergy Research and Education.	Augurzky B, 2013, EUR J HEALTH ECON, V14, P615, DOI 10.1007/s10198-012-0407-6; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Baron S, 2005, GUT, V54, P357, DOI 10.1136/gut.2004.054353; Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9; Baurecht H, 2015, AM J HUM GENET, V96, P104, DOI 10.1016/j.ajhg.2014.12.004; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bradfield JP, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002293; Daha NA, 2009, ARTHRITIS RHEUM-US, V60, P1255, DOI 10.1002/art.24503; Davidovici BB, 2010, J INVEST DERMATOL, V130, P1785, DOI 10.1038/jid.2010.103; Deckert S, 2014, ALLERGY, V69, P37, DOI 10.1111/all.12246; Ellinghaus D, 2013, NAT GENET, V45, P808, DOI 10.1038/ng.2642; Esparza-Gordillo J, 2013, J ALLERGY CLIN IMMUN, V132, P371, DOI 10.1016/j.jaci.2013.01.057; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Feeney MA, 2002, EUR J GASTROEN HEPAT, V14, P529, DOI 10.1097/00042737-200205000-00010; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Festen EAM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001283; Flohr C, 2011, CURR PROBL DERMATOL, V41, P1, DOI 10.1159/000323290; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Franke A, 2010, NAT GENET, V42, P292, DOI 10.1038/ng.553; Fsadni P, 2012, CLIN RESPIR J, V6, P18, DOI 10.1111/j.1752-699X.2011.00239.x; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Ihle P, 2008, GESUNDHEITSWESEN, V70, P54, DOI 10.1055/s-2007-1022529; Jakobsen C, 2013, J CROHNS COLITIS, V7, P79, DOI 10.1016/j.crohns.2012.05.024; Karatay S, 2013, MOD RHEUMATOL, V23, P351, DOI 10.1007/s10165-012-0653-6; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Lampert T, 2013, BUNDESGESUNDHEITSBLA, V56, P814, DOI 10.1007/s00103-013-1695-4; Lampert T, 2013, BUNDESGESUNDHEITSBLA, V56, P631, DOI 10.1007/s00103-012-1663-4; Langan SM, 2007, ARCH DERMATOL, V143, P1570, DOI 10.1001/archderm.143.12.1570; Lieb W, 2013, HYPERTENSION, V61, P995, DOI 10.1161/HYPERTENSIONAHA.111.00275; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; Meerwaldt R, 2002, CLIN EXP ALLERGY, V32, P254, DOI 10.1046/j.1365-2222.2002.01311.x; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Niwa Y, 2004, J INVEST DERMATOL, V123, P999, DOI 10.1111/j.0022-202X.2004.23462.x; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Olesen AB, 2001, LANCET, V357, P1749, DOI 10.1016/S0140-6736(00)04896-0; Ordas I, 2012, LANCET, V380, P1606, DOI 10.1016/S0140-6736(12)60150-0; Parkes M, 2013, NAT REV GENET, V14, P661, DOI 10.1038/nrg3502; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Pelucchi C, 2013, J ALLERGY CLIN IMMUN, V132, P616, DOI 10.1016/j.jaci.2013.04.009; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Roberson EDO, 2012, J INVEST DERMATOL, V132, P583, DOI 10.1038/jid.2011.348; Rodriguez E, 2014, J INVEST DERMATOL, V134, P1873, DOI 10.1038/jid.2014.87; Rudwaleit M, 2002, ANN RHEUM DIS, V61, P968, DOI 10.1136/ard.61.11.968; Saleh NM, 2011, DIABETES-METAB RES, V27, P838, DOI 10.1002/dmrr.1259; Schmitt J, 2011, ALLERGY, V66, P404, DOI 10.1111/j.1398-9995.2010.02487.x; Schmitt J, 2009, BRIT J DERMATOL, V161, P878, DOI 10.1111/j.1365-2133.2009.09309.x; Schmitt J, 2008, ITAL J PUBLIC HLTH, V5, P187; Schmitt J, 2009, JAMA-J AM MED ASSOC, V301, P724, DOI 10.1001/jama.2009.136; Schmitt J, 2009, J DTSCH DERMATOL GES, V7, P345, DOI 10.1111/j.1610-0387.2008.06967.x; Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4; Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851; Swart E, 2005, GESUNDHEITSWESEN, V67, P416, DOI 10.1055/s-2005-858356; Tang TS, 2012, J ALLERGY CLIN IMMUN, V129, P1209, DOI 10.1016/j.jaci.2012.02.002; Tsakok T, 2013, BRIT J DERMATOL, V169, P983, DOI 10.1111/bjd.12476; van der Hulst AE, 2007, J ALLERGY CLIN IMMUN, V120, P565, DOI 10.1016/j.jaci.2007.05.042; Weidinger S, 2013, HUM MOL GENET, V22, P4841, DOI 10.1093/hmg/ddt317; Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229; Wilke CM, 2011, TRENDS IMMUNOL, V32, P603, DOI 10.1016/j.it.2011.08.003; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Yaghmaie P, 2013, J ALLERGY CLIN IMMUN, V131, P428, DOI 10.1016/j.jaci.2012.10.041; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	64	115	117	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					130	136		10.1016/j.jaci.2015.06.029	http://dx.doi.org/10.1016/j.jaci.2015.06.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26253344				2022-12-18	WOS:000367724300003
J	Ueki, S; Konno, Y; Takeda, M; Moritoki, Y; Hirokawa, M; Matsuwaki, Y; Honda, K; Ohta, N; Yamamoto, S; Takagi, Y; Wada, A; Weller, PF				Ueki, Shigeharu; Konno, Yasunori; Takeda, Masahide; Moritoki, Yuki; Hirokawa, Makoto; Matsuwaki, Yoshinori; Honda, Kohei; Ohta, Nobuo; Yamamoto, Shiori; Takagi, Yuri; Wada, Atsushi; Weller, Peter F.			Eosinophil extracellular trap cell death-derived DNA traps: Their presence in secretions and functional attributes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic chronic rhinosinusitis; eosinophils; extracellular trap cell death; extra-cellular DNA traps; neutrophils	GRANULES; DEFENSE; NUCLEOSOME; MOLECULES; SINUSITIS; RELEASE	Background: Activated human eosinophils, as well as neutrophils, can release extracellular chromatin to form DNA traps through cytolytic extracellular trap cell death (ETosis). Although formations of neutrophil DNA traps are recognized in patients with various inflammatory conditions, neither the presence of ETosis-derived eosinophil DNA traps in human allergic diseases nor the characteristics of these DNA traps have been studied. Objective: We investigated the presence of ETosis-derived DNA traps in eosinophil-rich sinus and ear secretions and the functional attributes of ETosis DNA traps. Methods: Eosinophil-rich secretions obtained from patients with eosinophilic chronic rhinosinusitis and eosinophilic otitis media were studied microscopically. In vitro studies of ETosis and DNA trap formation used blood-derived eosinophils and neutrophils, and studies of the binding capacities of DNA traps used labeled bacteria and fluorescent microbeads. Stabilities of DNA traps were evaluated by using fluorescence microscopy. Results: Abundant nuclear histone H1-bearing DNA traps formed in vivo in the eosinophilic secretions and contributed to their increased viscosity. In vitro, after brief shear flow, eosinophil ETosis-elicited DNA traps assembled to form stable aggregates. Eosinophil DNA traps entrapped bacteria and fungi and, through hydrophobic interactions, microbeads. In comparison with neutrophil-derived DNA traps, eosinophil DNA traps ultrastructurally exhibited thicker fibers with globular structures and were less susceptible to leukocyte-derived proteolytic degradation, likely because of the lesser protease activities of eosinophils. Conclusions: In human allergic diseases local cytolysis of eosinophils not only releases free eosinophil granules but also generates nuclear-derived DNA traps that are major extracellular structural components within eosinophil-rich secretions.	[Ueki, Shigeharu; Konno, Yasunori; Takeda, Masahide; Moritoki, Yuki; Hirokawa, Makoto] Akita Univ, Grad Sch Med, Dept Gen Internal Med & Clin Lab Med, Akita 0108543, Japan; [Honda, Kohei] Akita Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Akita 0108543, Japan; [Ueki, Shigeharu; Weller, Peter F.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Allergy & Inflammat,Dept Med, Boston, MA 02215 USA; [Ueki, Shigeharu; Weller, Peter F.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Infect Dis,Dept Med, Boston, MA 02215 USA; [Matsuwaki, Yoshinori] Jikei Univ, Sch Med, Dept Otorhinolaryngol, Tokyo, Japan; [Ohta, Nobuo] Yamagata Univ, Dept Otorhinolaryngol, Sch Med, Yamagata 990, Japan; [Yamamoto, Shiori; Takagi, Yuri; Wada, Atsushi] Sysmex Corp, Cell Anal Ctr, Sci Affairs, Kobe, Hyogo, Japan	Akita University; Akita University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Jikei University; Yamagata University; Sysmex Corporation	Ueki, S (corresponding author), Akita Univ, Grad Sch Med, Dept Gen Internal Med & Clin Lab Med, 1-1-1 Hondo, Akita 0108543, Japan.	ueki-shige@nifty.com	Ueki, Shigeharu/I-3566-2019	Ueki, Shigeharu/0000-0002-3537-7735	Uehara Memorial Foundation; NIH [R37-AI020241];  [13383320];  [25462675];  [R01-AI051645]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051645, R37AI020241] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [25460670] Funding Source: KAKEN	Uehara Memorial Foundation(Uehara Memorial Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in part by Uehara Memorial Foundation and Grant-in-Aid for Scientific Research 13383320 (to S.U.), 25462675 (to N.O.), NIH R37-AI020241 (to P.F.W.), and R01-AI051645 (to P.F.W.).	Baumann CG, 1997, P NATL ACAD SCI USA, V94, P6185, DOI 10.1073/pnas.94.12.6185; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710; Cheng OZ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00001; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; Granville L, 2004, HUM PATHOL, V35, P474, DOI 10.1016/j.humpath.2003.10.024; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Iino Y, 2011, AURIS NASUS LARYNX, V38, P456, DOI 10.1016/j.anl.2010.11.016; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; Kono M, 2014, TRANSFUSION, V54, P2811, DOI 10.1111/trf.12700; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Manzenreiter R, 2012, J CYST FIBROS, V11, P84, DOI 10.1016/j.jcf.2011.09.008; Matsuwaki Y, 2008, INT ARCH ALLERGY IMM, V146, P77, DOI 10.1159/000126066; Neves JS, 2010, J ALLERGY CLIN IMMUN, V125, P477, DOI 10.1016/j.jaci.2009.11.029; Neves JS, 2008, P NATL ACAD SCI USA, V105, P18478, DOI 10.1073/pnas.0804547105; Papayannopoulos V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028526; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Remijsen Q, 2011, CELL DEATH DIFFER, V18, P581, DOI 10.1038/cdd.2011.1; Robinson PJJ, 2006, CURR OPIN STRUC BIOL, V16, P336, DOI 10.1016/j.sbi.2006.05.007; Saitoh T, 2012, CELL HOST MICROBE, V12, P109, DOI 10.1016/j.chom.2012.05.015; Ueki S, 2009, ALLERGY, V64, P718, DOI 10.1111/j.1398-9995.2008.01871.x; Ueki S, 2013, BLOOD, V121, P2074, DOI 10.1182/blood-2012-05-432088; Ueki S, 2008, J IMMUNOL, V181, P7689, DOI 10.4049/jimmunol.181.11.7689; Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x; Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639; von Kockritz-Blickwede M, 2009, J MOL MED, V87, P775, DOI 10.1007/s00109-009-0481-0; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855	29	115	117	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					258	267		10.1016/j.jaci.2015.04.041	http://dx.doi.org/10.1016/j.jaci.2015.04.041			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26070883	Green Accepted, Bronze			2022-12-18	WOS:000367724300017
J	Sehra, S; Yao, WG; Nguyen, ET; Glosson-Byers, NL; Akhtar, N; Zhou, BH; Kaplan, MH				Sehra, Sarita; Yao, Weiguo; Nguyen, Evelyn T.; Glosson-Byers, Nicole L.; Akhtar, Nahid; Zhou, Baohua; Kaplan, Mark H.			T(H)9 cells are required for tissue mast cell accumulation during allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)9 cells; T(H)2 cells; mast cells; allergic inflammation; PU.1	TRANSCRIPTION FACTOR PU.1; AFFINITY IGE RECEPTOR; AIRWAY HYPERRESPONSIVENESS; IL-9 EXPRESSION; MURINE MODEL; INTERLEUKIN-9; ASTHMA; GROWTH; LUNG; IMMUNITY	Background: IL-9 is important for the growth and survival of mast cells. IL-9 is produced by T cells, natural killer T cells, mast cells, eosinophils, and innate lymphoid cells, although the cells required for mast cell accumulation during allergic inflammation remain undefined. Objective: We sought to elucidate the role of T(H)9 cells in promoting mast cell accumulation in models of allergic lung inflammation. Methods: Adoptive transfer of ovalbumin-specific T(H)2 and T(H)9 cells was used to assess the ability of each subset to mediate mast cell accumulation in tissues. Mast cell accumulation was assessed in wild-type mice and mice with PU.1-deficient T cells subjected to acute and chronic models of allergic inflammation. Results: Adoptive transfer experiments demonstrated that recipients of T(H)9 cells had significantly higher mast cell accumulation and expression of mast cell proteases compared with control or T(H)2 recipients. Mast cell accumulation was dependent on IL-9, but not IL-13, a cytokine required for many aspects of allergic inflammation. In models of acute and chronic allergic inflammation, decreased IL-9 levels in mice with PU.1-deficient T cells corresponded to diminished tissue mast cell numbers and expression of mast cell proteases. Mice with PU.1-deficient T cells have defects in IL-9 production from CD4(+) T cells, but not natural killer T cells or innate lymphoid cells, suggesting a TH cell-dependent phenotype. Rag1(-/-) mice subjected to a chronic model of allergic inflammation displayed reduced mast cell infiltration comparable with accumulation in mice with PU.1-deficient T cells, emphasizing the importance of IL-9 produced by T cells in mast cell recruitment. Conclusion: T(H)9 cells are a major source of IL-9 in models of allergic inflammation and play an important role in mast cell accumulation and activation.	[Sehra, Sarita; Yao, Weiguo; Nguyen, Evelyn T.; Akhtar, Nahid; Zhou, Baohua; Kaplan, Mark H.] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN 46202 USA; [Glosson-Byers, Nicole L.; Zhou, Baohua; Kaplan, Mark H.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Kaplan, MH (corresponding author), Indiana Univ Sch Med, Indianapolis, IN 46202 USA.	mkaplan2@iupui.edu		Kaplan, Mark/0000-0002-2923-8245	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI085046]; NIH/NIAID [AI057459]; NATIONAL CANCER INSTITUTE [P30CA082709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI085046, R01AI057459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519, U54DK106846] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	B. Zhou has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (grant no. AI085046). M. H. Kaplan has received research support from the NIH/NIAID (grant no. AI057459). The rest of the authors declare that they have no relevant conflicts of interest.	Becker M, 2011, J IMMUNOL, V186, P7225, DOI 10.4049/jimmunol.1100676; Chang HC, 2010, NAT IMMUNOL, V11, P527, DOI 10.1038/ni.1867; Chang HC, 2009, J IMMUNOL, V183, P4887, DOI 10.4049/jimmunol.0900363; Dakic A, 2005, J EXP MED, V201, P1487, DOI 10.1084/jem.20050075; Dodd JS, 2009, J IMMUNOL, V183, P7006, DOI 10.4049/jimmunol.0900085; Erpenbeck VJ, 2003, J ALLERGY CLIN IMMUN, V111, P1319, DOI 10.1067/mai.2003.1485; Fallon PG, 2002, IMMUNITY, V17, P7, DOI 10.1016/S1074-7613(02)00332-1; Faulkner H, 1997, EUR J IMMUNOL, V27, P2536, DOI 10.1002/eji.1830271011; Faulkner H, 1998, INFECT IMMUN, V66, P3832, DOI 10.1128/IAI.66.8.3832-3840.1998; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Gerlach K, 2014, NAT IMMUNOL, V15, P676, DOI 10.1038/ni.2920; Godfraind C, 1998, J IMMUNOL, V160, P3989; Goswami R, 2011, J IMMUNOL, V186, P3283, DOI 10.4049/jimmunol.1003049; Gounni AS, 2000, J ALLERGY CLIN IMMUN, V106, P460, DOI 10.1067/mai.2000.109172; HULTNER L, 1990, EXP HEMATOL, V18, P873; HUNTLEY JF, 1990, PARASITE IMMUNOL, V12, P85, DOI 10.1111/j.1365-3024.1990.tb00938.x; Jabeen R, 2013, J CLIN INVEST, V123, P4641, DOI 10.1172/JCI69489; Jager A, 2009, J IMMUNOL, V183, P7169, DOI 10.4049/jimmunol.0901906; Jones CP, 2012, J ALLERGY CLIN IMMUN, V129, P1000, DOI 10.1016/j.jaci.2011.12.965; Jones TG, 2009, J IMMUNOL, V183, P5251, DOI 10.4049/jimmunol.0901471; Kambayashi T, 2014, NAT REV IMMUNOL, V14, P719, DOI 10.1038/nri3754; Kaplan MH, 2013, IMMUNOL REV, V252, P104, DOI 10.1111/imr.12028; Kearley J, 2011, AM J RESP CRIT CARE, V183, P865, DOI 10.1164/rccm.200909-1462OC; Kim YS, 2007, EUR J IMMUNOL, V37, P1107, DOI 10.1002/eji.200636612; Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855; Licona-Limon P, 2013, IMMUNITY, V39, P744, DOI 10.1016/j.immuni.2013.07.020; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; LOUAHED J, 1995, J IMMUNOL, V154, P5061; Masuda T, 2003, CLIN EXP ALLERGY, V33, P705, DOI 10.1046/j.1365-2222.2003.01588.x; Matsuzawa S, 2003, J IMMUNOL, V170, P3461, DOI 10.4049/jimmunol.170.7.3461; Noelle RJ, 2010, NAT REV IMMUNOL, V10, P683, DOI 10.1038/nri2848; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Pae S, 2010, IMMUNOGENETICS, V62, P499, DOI 10.1007/s00251-010-0452-1; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; Purwar R, 2012, NAT MED, V18, P1248, DOI 10.1038/nm.2856; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; Stassen M, 2000, J IMMUNOL, V164, P5549, DOI 10.4049/jimmunol.164.11.5549; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Taube C, 2004, J IMMUNOL, V172, P6398, DOI 10.4049/jimmunol.172.10.6398; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; VANSNICK J, 1989, J EXP MED, V169, P363, DOI 10.1084/jem.169.1.363; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Yao WG, 2013, IMMUNITY, V38, P360, DOI 10.1016/j.immuni.2013.01.007; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702	51	115	121	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					433	+		10.1016/j.jaci.2015.01.021	http://dx.doi.org/10.1016/j.jaci.2015.01.021			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25746972	Green Submitted, Green Accepted			2022-12-18	WOS:000359004900025
J	Fyhrquist, N; Ruokolainen, L; Suomalainen, A; Lehtimaki, S; Veckman, V; Vendelin, J; Karisola, P; Lehto, M; Savinko, T; Jarva, H; Kosunen, TU; Corander, J; Auvinen, P; Paulin, L; von Hertzen, L; Laatikainen, T; Makela, M; Haahtela, T; Greco, D; Hanski, I; Alenius, H				Fyhrquist, Nanna; Ruokolainen, Lasse; Suomalainen, Alina; Lehtimaki, Sari; Veckman, Ville; Vendelin, Johanna; Karisola, Piia; Lehto, Maili; Savinko, Terhi; Jarva, Hanna; Kosunen, Timo U.; Corander, Jukka; Auvinen, Petri; Paulin, Lars; von Hertzen, Leena; Laatikainen, Tiina; Makela, Mika; Haahtela, Tari; Greco, Dario; Hanski, Ilkka; Alenius, Harri			Acinetobacter species in the skin microbiota protect against allergic sensitization and inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; Gammaproteobacteria; Acinetobacter species; PBMC; anti-inflammatory gene expression; dendritic cells; keratinocytes; mouse asthma model	HYGIENE HYPOTHESIS; CHILDHOOD ASTHMA; IMMUNE-SYSTEM; OLD FRIENDS; DISEASE; BIODIVERSITY; PREVALENCE; INDUCTION; MECHANISM; BACTERIA	Background: The human commensal microbiota interacts in a complex manner with the immune system, and the outcome of these interactions might depend on the immune status of the subject. Objective: Previous studies have suggested a strong allergy-protective effect for Gammaproteobacteria. Here we analyze the skin microbiota, allergic sensitization (atopy), and immune function in a cohort of adolescents, as well as the influence of Acinetobacter species on immune responses in vitro and in vivo. Methods: The skin microbiota of the study subjects was identified by using 16S rRNA sequencing. PBMCs were analyzed for baseline and allergen-stimulated mRNA expression. In in vitro assays human monocyte-derived dendritic cells and primary keratinocytes were incubated with Acinetobacter lwoffii. Finally, in in vivo experiments mice were injected intradermally with A lwoffii during the sensitization phase of the asthma protocol, followed by readout of inflammatory parameters. Results: In healthy subjects, but not in atopic ones, the relative abundance of Acinetobacter species was associated with the expression of anti-inflammatory molecules by PBMCs. Moreover, healthy subjects exhibited a robust balance between anti-inflammatory and T(H)1/T(H)2 gene expression, which was related to the composition of the skin microbiota. In cell assays and in a mouse model, Acinetobacter species induced strong T(H)1 and anti-inflammatory responses by immune cells and skin cells and protected against allergic sensitization and lung inflammation through the skin. Conclusion: These results support the hypothesis that skin commensals play an important role in tuning the balance of T(H)1, T(H)2, and anti-inflammatory responses to environmental allergens.	[Fyhrquist, Nanna; Suomalainen, Alina; Veckman, Ville; Vendelin, Johanna; Karisola, Piia; Lehto, Maili; Greco, Dario; Alenius, Harri] Finnish Inst Occupat Hlth, Unit Syst Toxicol, FIN-00250 Helsinki, Finland; [Ruokolainen, Lasse] Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; [Lehtimaki, Sari] Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; [Jarva, Hanna; Kosunen, Timo U.] Turku Ctr Biotechnol, Mol Immunol Grp, Turku, Finland; [Jarva, Hanna; Kosunen, Timo U.] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland; [Jarva, Hanna; Kosunen, Timo U.] Univ Helsinki, Res Programs Unit, FIN-00014 Helsinki, Finland; [Jarva, Hanna; Kosunen, Timo U.] Univ Helsinki, Cent Hosp Lab HUSLAB, FIN-00014 Helsinki, Finland; [Corander, Jukka] Univ Helsinki, Dept Math & Stat, FIN-00014 Helsinki, Finland; [von Hertzen, Leena; Makela, Mika; Haahtela, Tari] Helsinki Univ Hosp, Skin & Allergy Hosp, Dept Allergy, Helsinki, Finland; [Laatikainen, Tiina] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland; [Laatikainen, Tiina] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland	Finnish Institute of Occupational Health; University of Helsinki; University of Helsinki; University of Turku; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; University of Eastern Finland	Alenius, H (corresponding author), Finnish Inst Occupat Hlth, Unit Syst Toxicol, Topeliuksenkatu 41 B, FIN-00250 Helsinki, Finland.	harri.alenius@ttl.fi	Auvinen, Petri/D-5044-2009; Laatikainen, Tiina/ABD-6622-2021; Auvinen, Petri/AAP-8117-2021; Greco, Dario/T-7113-2019	Auvinen, Petri/0000-0002-3947-4778; Laatikainen, Tiina/0000-0002-6614-4782; Greco, Dario/0000-0001-9195-9003; Jarva, Hanna/0000-0002-9154-354X; Suomalainen, Alina/0000-0003-1531-6932; Makela, Mika/0000-0002-2933-3111; Karisola, Piia/0000-0003-0635-2704; Fyhrquist, Nanna Theresia/0000-0002-5408-0005; Savinko, Terhi/0000-0003-4483-7235; Alenius, Harri/0000-0003-0106-8923; Ruokolainen, Lasse/0000-0003-0951-9100	Academy of Finland [138695, 255350, 121025, 251170]; European Research Council [239784]; Jane and Aatos Erkko Foundation, Helsinki University Hospital (HUS) [8361]; European Union's Seventh Framework Programme FP7 [261366, 261357]	Academy of Finland(Academy of Finland); European Research Council(European Research Council (ERC)European Commission); Jane and Aatos Erkko Foundation, Helsinki University Hospital (HUS); European Union's Seventh Framework Programme FP7	The research leading to these results has received funding from the Academy of Finland (grants nos. 138695, 255350, 121025, and 251170), the European Research Council (grant no. 239784), the Jane and Aatos Erkko Foundation, Helsinki University Hospital (HUS) (grant no. 8361), and by the European Union's Seventh Framework Programme FP7/2007-2013 under grant agreements 261366 (MAARS) and 261357 (MeDALL).	Abreu GCG, 2010, J STAT SOFTW, V37, P1; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Chen X, 2007, J IMMUNOL, V179, P154, DOI 10.4049/jimmunol.179.1.154; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Ege MJ, 2012, ALLERGY, V67, P1565, DOI 10.1111/all.12028; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Friedman J., 2011, GLASSO GRAPHICAL LAS; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Haapakoski R, 2011, AM J RESP CELL MOL, V44, P639, DOI 10.1165/rcmb.2009-0355OC; Halonen M, 2009, J IMMUNOL, V182, P3285, DOI 10.4049/jimmunol.0711996; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Hessle C, 2000, INFECT IMMUN, V68, P3581, DOI 10.1128/IAI.68.6.3581-3586.2000; Hojsgaard S, 2012, USE R, P1, DOI 10.1007/978-1-4614-2299-0; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Leyva-Castillo JM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3847; Margolin AA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S1-S7; Meyer PE, 2008, MINET OPEN SOURCE R; Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152; Nakatsuji T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2441; Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312; Romagnani S, 2007, J ALLERGY CLIN IMMUN, V119, P1511, DOI 10.1016/j.jaci.2007.04.005; Rook GAW, 2014, CLIN EXP IMMUNOL, V177, P1, DOI 10.1111/cei.12269; Rook GAW, 2010, CLIN EXP IMMUNOL, V160, P70, DOI 10.1111/j.1365-2249.2010.04133.x; Rook GA, 2013, P NATL ACAD SCI USA, V110, P18360, DOI 10.1073/pnas.1313731110; Rook GAW, 2009, IMMUNOLOGY, V126, P3, DOI 10.1111/j.1365-2567.2008.03007.x; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schram ME, 2010, BRIT J DERMATOL, V162, P964, DOI 10.1111/j.1365-2133.2010.09689.x; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; von Hertzen L, 2006, J ALLERGY CLIN IMMUN, V117, P151, DOI 10.1016/j.jaci.2005.07.028; von Hertzen L, 2011, EMBO REP, V12, P1089, DOI 10.1038/embor.2011.195; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Zhang M, 2010, GUT MICROBES, V1, P325, DOI 10.4161/gmic.1.5.13052	37	115	118	0	50	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1301	+		10.1016/j.jaci.2014.07.059	http://dx.doi.org/10.1016/j.jaci.2014.07.059			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25262465				2022-12-18	WOS:000346075400012
J	Hirahara, K; Poholek, A; Vahedi, G; Laurence, A; Kanno, Y; Milner, JD; O'Shea, JJ				Hirahara, Kiyoshi; Poholek, Amanda; Vahedi, Golnaz; Laurence, Arian; Kanno, Yuka; Milner, Joshua D.; O'Shea, John J.			Mechanisms underlying helper T-cell plasticity: Implications for immune-mediated disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-cell plasticity; asthma; allergic disease; epigenetics; histone modification; therapy	GENOME-WIDE ASSOCIATION; ANTI-INTERLEUKIN-17 MONOCLONAL-ANTIBODY; TRANSCRIPTION FACTOR GATA-3; IFN-GAMMA PROMOTER; TH17 CELLS; ALLERGIC-ASTHMA; IN-VIVO; AIRWAY HYPERRESPONSIVENESS; MOLECULAR-MECHANISMS; LINEAGE COMMITMENT	CD4 helper T cells are critical for proper immune cell homeostasis and host defense but are also major contributors to immune and inflammatory disease. Arising from a simple biphasic model of differentiation (ie, T(H)1 and T(H)2 cells). A bewildering number of fates seem possible for helper T cells. To what extent different helper cell subsets maintain their characteristic gene expression profiles or exhibit functional plasticity is a hotly debated topic. In this review we will discuss how the expression of "signature cytokines'' and "master regulator'' transcription factors do not neatly conform to a simple helper T-cell paradigm. Although this might seem confusing, the good news is that the newly recognized complexity fits better with our understanding of immunopathogenesis. Finally, we will discuss factors, including epigenetic regulation and metabolic alterations, that contribute to helper cell specificity and plasticity.	[Hirahara, Kiyoshi; Poholek, Amanda; Vahedi, Golnaz; Laurence, Arian; Kanno, Yuka; O'Shea, John J.] NIAMSD, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA; [Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	O'Shea, JJ (corresponding author), 10 Ctr Dr,Bldg 10,Rm 13C103, Bethesda, MD 20892 USA.	osheajo@mail.nih.gov	Kanno, Yuka/B-5802-2013; Hirahara, Kiyoshi/E-2460-2017; Laurence, Arian/A-8770-2009	Kanno, Yuka/0000-0001-5668-9319; Hirahara, Kiyoshi/0000-0002-9128-9449; Laurence, Arian/0000-0003-0942-8292	National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); JSPS; NIH; PRAT; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001098, ZIAAI001099, ZIAAI001183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041159] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PRAT; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Intramural Research Program, the JSPS Research Fellowship for Japanese Biomedical and Behavioral Researchers at the NIH (to K.H.), and PRAT (to A.P.).	Ahyi ANN, 2009, J IMMUNOL, V183, P1598, DOI 10.4049/jimmunol.0803302; Akdis M, 2012, J ALLERGY CLIN IMMUN, V129, P1438, DOI 10.1016/j.jaci.2012.05.003; Akiba H, 2005, J IMMUNOL, V175, P2340, DOI 10.4049/jimmunol.175.4.2340; Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Allan RS, 2012, NATURE, V487, P249, DOI 10.1038/nature11173; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Awasthi A, 2007, NAT IMMUNOL, V8, P1380, DOI 10.1038/ni1541; Bauquet AT, 2009, NAT IMMUNOL, V10, P167, DOI 10.1038/ni.1690; Bending D, 2009, J CLIN INVEST, V119, P565, DOI 10.1172/JCI37865; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213; Brustle A, 2007, NAT IMMUNOL, V8, P958, DOI 10.1038/ni1500; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chang HC, 2010, NAT IMMUNOL, V11, P527, DOI 10.1038/ni.1867; Chen K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020333; Chen Y, 2011, IMMUNITY, V34, P409, DOI 10.1016/j.immuni.2011.02.011; Cho JY, 2003, INT IMMUNOL, V15, P1149, DOI 10.1093/intimm/dxg113; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016; Cipolletta D, 2012, NATURE, V486, P549, DOI 10.1038/nature11132; Ciprandi G, 2013, PEDIATR DERMATOL, V30, P222, DOI 10.1111/j.1525-1470.2012.01766.x; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Crotty S, 2012, IMMUNOL REV, V247, P133, DOI 10.1111/j.1600-065X.2012.01117.x; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Crotty S, 2010, NAT IMMUNOL, V11, P114, DOI 10.1038/ni.1837; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Delgoffe GM, 2011, NAT IMMUNOL, V12, P295, DOI 10.1038/ni.2005; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Endo Y, 2011, IMMUNITY, V35, P733, DOI 10.1016/j.immuni.2011.08.017; Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906; Eyerich S, 2011, NEW ENGL J MED, V365, P231, DOI 10.1056/NEJMoa1104200; Feng T, 2011, GASTROENTEROLOGY, V140, P2031, DOI 10.1053/j.gastro.2011.03.009; Finkelman FD, 2010, J IMMUNOL, V184, P1663, DOI 10.4049/jimmunol.0902185; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Gallo E, 2012, EUR J IMMUNOL, V42, P2322, DOI 10.1002/eji.201142227; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Genovese MC, 2010, ARTHRITIS RHEUM-US, V62, P929, DOI 10.1002/art.27334; Genovese MC, 2012, ANN RHEUM DIS; Ghoreschi K, 2011, TRENDS IMMUNOL, V32, P395, DOI 10.1016/j.it.2011.06.007; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Glasmacher E, 2012, SCIENCE, V338, P975, DOI 10.1126/science.1228309; Gold DR, 2006, NEW ENGL J MED, V354, P2058, DOI 10.1056/NEJMe068058; Gor DO, 2003, NAT IMMUNOL, V4, P503, DOI 10.1038/ni0603-503; Grenningloh K, 2005, J EXP MED, V201, P615, DOI 10.1084/jem.20041330; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Hadjur S, 2009, NATURE, V460, P410, DOI 10.1038/nature08079; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hansen W, 2012, J EXP MED, V209, P2001, DOI 10.1084/jem.20111497; Harismendy O, 2011, NATURE, V470, P264, DOI 10.1038/nature09753; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Hegazy AN, 2010, IMMUNITY, V32, P116, DOI 10.1016/j.immuni.2009.12.004; Hill JA, 2008, IMMUNITY, V29, P758, DOI 10.1016/j.immuni.2008.09.018; Hirahara K, 2008, J ALLERGY CLIN IMMUN, V122, P512, DOI 10.1016/j.jaci.2008.06.004; Hirahara K, 2012, IMMUNITY, V36, P1017, DOI 10.1016/j.immuni.2012.03.024; Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hsu HC, 2008, NAT IMMUNOL, V9, P166, DOI 10.1038/ni1552; Huber M, 2008, P NATL ACAD SCI USA, V105, P20846, DOI 10.1073/pnas.0809077106; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Johnston RJ, 2012, J EXP MED, V209, P243, DOI 10.1084/jem.20111174; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Jones RG, 2007, IMMUNITY, V27, P173, DOI 10.1016/j.immuni.2007.07.008; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Kashiwada M, 2011, EMBO J, V30, P2071, DOI 10.1038/emboj.2011.111; Kerdiles YM, 2010, IMMUNITY, V33, P890, DOI 10.1016/j.immuni.2010.12.002; Koch MA, 2012, IMMUNITY, V37, P501, DOI 10.1016/j.immuni.2012.05.031; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Komatsu N, 2009, P NATL ACAD SCI USA, V106, P1903, DOI 10.1073/pnas.0811556106; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Kurebayashi Y, 2012, CELL REP, V1, P360, DOI 10.1016/j.celrep.2012.02.007; Kwon H, 2009, IMMUNITY, V31, P941, DOI 10.1016/j.immuni.2009.10.008; Laan M, 2002, EUR RESPIR J, V19, P534, DOI 10.1183/09031936.02.00280902; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Laurence A, 2012, IMMUNITY, V37, P209, DOI 10.1016/j.immuni.2012.05.027; Lazarevic V, 2011, NAT IMMUNOL, V12, P96, DOI 10.1038/ni.1969; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Lee YK, 2009, IMMUNITY, V30, P92, DOI 10.1016/j.immuni.2008.11.005; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Li P, 2012, NATURE, V490, P543, DOI 10.1038/nature11530; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Ma CS, 2012, BLOOD, V119, P3997, DOI 10.1182/blood-2011-11-392985; Makar KW, 2003, NAT IMMUNOL, V4, P1183, DOI 10.1038/ni1004; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Milner JD, 2011, CURR OPIN IMMUNOL, V23, P784, DOI 10.1016/j.coi.2011.09.006; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Miyao T, 2012, IMMUNITY, V36, P262, DOI 10.1016/j.immuni.2011.12.012; Miyazaki Y, 2005, J IMMUNOL, V175, P2401, DOI 10.4049/jimmunol.175.4.2401; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Motomura Y, 2011, NAT IMMUNOL, V12, P450, DOI 10.1038/ni.2020; Mullen AC, 2002, NAT IMMUNOL, V3, P652, DOI 10.1038/ni807; Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Naito T, 2012, IMMUNOLOGY; Nakayamada S, 2011, IMMUNITY, V35, P919, DOI 10.1016/j.immuni.2011.11.012; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097; O'Shea JJ, 2013, NAT REV RHEUMATOL, V9, P173, DOI 10.1038/nrrheum.2013.7; O'Shea JJ, 2013, NEW ENGL J MED, V368, P161, DOI 10.1056/NEJMra1202117; Oestreich KJ, 2012, NAT IMMUNOL, V13, P405, DOI 10.1038/ni.2242; Oestreich KJ, 2011, J EXP MED, V208, P1001, DOI 10.1084/jem.20102144; Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010; Oldenhove G, 2009, IMMUNITY, V31, P772, DOI 10.1016/j.immuni.2009.10.001; Onodera A, 2010, J EXP MED, V207, P2493, DOI 10.1084/jem.20100760; Ouyang WM, 2012, NATURE, V491, P554, DOI 10.1038/nature11581; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Oyoshi MK, 2009, P NATL ACAD SCI USA, V106, P14954, DOI 10.1073/pnas.0904021106; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Pandiyan P, 2011, IMMUNITY, V34, P422, DOI 10.1016/j.immuni.2011.03.002; Parelho V, 2008, CELL, V132, P422, DOI 10.1016/j.cell.2008.01.011; Patel DR, 2010, CURR OPIN RHEUMATOL, V22, P478, DOI 10.1097/BOR.0b013e32833ae915; Pepper M, 2011, IMMUNITY, V35, P583, DOI 10.1016/j.immuni.2011.09.009; Prussin C, 2010, J ALLERGY CLIN IMMUN, V126, P1094, DOI 10.1016/j.jaci.2010.08.031; Pulendran B, 2012, SCIENCE, V337, P431, DOI 10.1126/science.1221064; Qi H, 2008, NATURE, V455, P764, DOI 10.1038/nature07345; Quintana FJ, 2012, NAT IMMUNOL, V13, P770, DOI 10.1038/ni.2363; Ramming A, 2012, BLOOD, V119, P4665, DOI 10.1182/blood-2011-11-392589; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Reinhardt RL, 2009, NAT IMMUNOL, V10, P385, DOI 10.1038/ni.1715; Robinson DS, 2010, J ALLERGY CLIN IMMUN, V126, P1081, DOI 10.1016/j.jaci.2010.06.025; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996; Ruiz-Esquide V, 2012, REUMATOL CLIN, V8, P342, DOI [10.1016/j.reuma.2012.02.011, 10.1016/j.reumae.2012.06.007]; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Samstein RM, 2012, CELL, V151, P153, DOI 10.1016/j.cell.2012.06.053; Schmitt E, 2012, J CLIN INVEST, V122, P3857, DOI 10.1172/JCI65929; Schnyder B, 2010, CYTOKINE, V50, P220, DOI 10.1016/j.cyto.2010.02.003; Schuster M, 2012, IMMUNITY, V37, P998, DOI 10.1016/j.immuni.2012.08.023; Sekimata M, 2009, IMMUNITY, V31, P551, DOI 10.1016/j.immuni.2009.08.021; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shi GP, 2008, J IMMUNOL, V181, P7205, DOI 10.4049/jimmunol.181.10.7205; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Stockinger B, 2007, SEMIN IMMUNOL, V19, P353, DOI 10.1016/j.smim.2007.10.008; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Stumhofer JS, 2007, NAT IMMUNOL, V8, P1363, DOI 10.1038/ni1537; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Takatori H, 2009, J EXP MED, V206, P35, DOI 10.1084/jem.20072713; Tan C, 2012, CRIT REV IMMUNOL, V32, P1; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tsuji M, 2009, SCIENCE, V323, P1488, DOI 10.1126/science.1169152; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; Upadhyaya B, 2011, J IMMUNOL, V187, P3111, DOI 10.4049/jimmunol.1101283; Vahedi G, 2012, CELL, V151, P981, DOI 10.1016/j.cell.2012.09.044; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Vermeer PD, 2003, AM J RESP CELL MOL, V28, P286, DOI 10.1165/rcmb.4887; Villarino A, 2003, IMMUNITY, V19, P645, DOI 10.1016/S1074-7613(03)00300-5; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wang YQ, 2011, IMMUNITY, V35, P337, DOI 10.1016/j.immuni.2011.08.012; Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009; Wei L, 2007, J BIOL CHEM, V282, P34605, DOI 10.1074/jbc.M705100200; Weinreich MA, 2009, IMMUNITY, V31, P122, DOI 10.1016/j.immuni.2009.05.011; Weiss JM, 2012, J EXP MED, V209, P1723, DOI 10.1084/jem.20120914; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson CB, 2009, NAT REV IMMUNOL, V9, P91, DOI 10.1038/nri2487; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Wohlfert EA, 2011, J CLIN INVEST, V121, P4503, DOI 10.1172/JCI57456; Xiong YM, 2012, CURR OPIN IMMUNOL, V24, P139, DOI 10.1016/j.coi.2012.02.002; Yadav M, 2012, J EXP MED, V209, P1713, DOI 10.1084/jem.20120822; Yamashita M, 2006, IMMUNITY, V24, P611, DOI 10.1016/j.immuni.2006.03.017; Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Yoshida H, 2001, IMMUNITY, V15, P569, DOI 10.1016/S1074-7613(01)00206-0; Yu D, 2009, IMMUNITY, V31, P457, DOI 10.1016/j.immuni.2009.07.002; Zhang FP, 2006, J EXP MED, V203, P1493, DOI 10.1084/jem.20060066; Zhang JLA, 2012, CELL, V149, P467, DOI 10.1016/j.cell.2012.01.056; Zhao Y, 2010, INT ARCH ALLERGY IMM, V151, P297, DOI 10.1159/000250438; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074-7613(02)00317-5	201	115	115	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1276	1287		10.1016/j.jaci.2013.03.015	http://dx.doi.org/10.1016/j.jaci.2013.03.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23622118	Green Accepted			2022-12-18	WOS:000318912200002
J	Savage, JH; Courneya, JP; Sterba, PM; MacGlashan, DW; Saini, SS; Wood, RA				Savage, Jessica H.; Courneya, Jean-Paul; Sterba, Patricia M.; MacGlashan, Donald W.; Saini, Sarbjit S.; Wood, Robert A.			Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Omalizumab; peanut allergy; oral food challenge; basophil; mast cell	ANTI-IGE; EXPRESSION; HISTAMINE; RELEASE; ASTHMA	Background: Monoclonal antibodies directed at IgE demonstrate clinical efficacy in subjects with peanut allergy, but previous studies have not addressed the kinetics of the clinical response or the role of mast cells and basophils in the food-induced allergic response. Objective: We sought to determine the kinetics of the clinical response to omalizumab and whether clinical improvement is associated with either mast cell or basophil suppression. Methods: Subjects with peanut allergy were treated with omalizumab for 6 months and assessed for clinical and cellular responses. At baseline, subjects had a double-blind, placebo-controlled oral food challenge (OFC), skin prick test titration (SPTT), and basophil histamine release (BHR) to peanut. BHR was repeated at week 2 and then weekly until it decreased to less than 20% of baseline values. The OFCs and SPTTs were repeated after the BHR reduction (or at week 8 if BHR did not decrease) and again at 6 months. Results: Fourteen subjects enrolled in the study. At the second food challenge, there was a significant increase in the threshold dose of peanut inducing allergic symptoms (80 to 6500 mg, P < .01). Peanut-induced BHR was either completely suppressed (n = 5) or 10-fold more allergen was required to induce maximal BHR (n = 9), and SPTT responses were not significantly changed from baseline. After 6 months of omalizumab, further changes in the OFC threshold dose or BHR were not observed, but a significant suppression in SPTTs was identified. Conclusions: The clinical response to omalizumab occurs early in treatment when the basophil, but not the mast cell, is suppressed, supporting a role for the basophil in acute food reactions. (J Allergy Clin Immunol 2012;130:1123-9.)	[Wood, Robert A.] Johns Hopkins Univ Hosp, Div Pediat Allergy & Immunol, Baltimore, MD 21287 USA; [Savage, Jessica H.; Courneya, Jean-Paul; Sterba, Patricia M.; MacGlashan, Donald W.; Saini, Sarbjit S.] Johns Hopkins Univ Hosp, Div Allergy & Clin Immunol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Wood, RA (corresponding author), Johns Hopkins Univ Hosp, Div Pediat Allergy & Immunol, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	rwood@jhmi.edu			National Institutes of Health [AI070345, T32AI007056-31]; National Institutes of Health (NIH); National Institute of Allergic and Infectious Diseases; Genentech; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070345, T32AI007056] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergic and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Genentech(Roche HoldingGenentech); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI070345 and T32AI007056-31.; Disclosure of potential conflict of interest: D. W. MacGlashan has received research support from the National Institutes of Health (NIH). S. S. Saini has consultant arrangements with Genentech, Novartis, Pharmacyclics, and Medimmune; has received research support from the National Institute of Allergic and Infectious Diseases and Genentech; received the drug for this study from Genentech; and receives royalties from UpToDate. R. A. Wood has consulted for the Asthma and Allergy Foundation of America and has provided expert testimony for the NIH. The rest of the authors declare that they have no relevant conflicts of interest.	Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Bousquet J, 2004, CHEST, V125, P1378, DOI 10.1378/chest.125.4.1378; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Eckman JA, 2010, J ALLERGY CLIN IMMUN, V125, P889, DOI 10.1016/j.jaci.2009.09.012; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; MacGlashan DW, 2012, J ALLERGY CLIN IMMUN, V130, P1130, DOI 10.1016/j.jaci.2012.05.038; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Saini SS, 2001, J ALLERGY CLIN IMMUN, V107, P832, DOI 10.1067/mai.2001.114653; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Sussman H, 1928, ARCH INTERN MED, V42, P409, DOI 10.1001/archinte.1928.00020020097011; Vonakis BM, 2007, J ALLERGY CLIN IMMUN, V119, P441, DOI 10.1016/j.jaci.2006.09.035	13	115	120	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1123	+		10.1016/j.jaci.2012.05.039	http://dx.doi.org/10.1016/j.jaci.2012.05.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22800401	Green Accepted			2022-12-18	WOS:000310571400013
J	Palomares, O; Ruckert, B; Jartti, T; Kucuksezer, UC; Puhakka, T; Gomez, E; Fahrner, HB; Speiser, A; Jung, A; Kwok, WW; Kalogjera, L; Akdis, M; Akdis, CA				Palomares, Oscar; Rueckert, Beate; Jartti, Tuomas; Kuecueksezer, Umut Can; Puhakka, Tuomo; Gomez, Enrique; Fahrner, Heinz B.; Speiser, Andreas; Jung, Andreas; Kwok, William W.; Kalogjera, Livije; Akdis, Muebeccel; Akdis, Cezmi A.			Induction and maintenance of allergen-specific FOXP31 Treg cells in human tonsils as potential first-line organs of oral tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immune tolerance; tonsils; allergen-specific Treg cells; plasmacytoid dendritic cells; myeloid dendritic cells	REGULATORY T-CELLS; BIRCH POLLEN ALLERGEN; DENDRITIC CELLS; PARTIAL PROTECTION; HUMAN THYMUS; RESPONSES; SUBSETS; IDENTIFICATION; IMMUNOTHERAPY; INDIVIDUALS	Background: Tonsils are strategically located in the gateway of both alimentary and respiratory tracts representing the first contact point of food and aeroallergens with the immune system. Tonsillectomy removes only the palatine tonsils and sometimes adenoids. Lingual tonsil is anatomically big and remains lifelong intact. Objective: The aim of this study was to demonstrate cellular and molecular mechanisms of oral tolerance induction to food and aeroallergens in human tonsils. Methods: Tonsil allergen-specific FOXP3(+) regulatory T (Treg) cells, plasmacytoid dendritic cells (pDCs), and myeloid dendritic cells were characterized by flow cytometry and suppressive assays. Intracellular staining, [H-3]-thymidine incorporation, and carboxy-fluorescein succinimidyl ester dilution experiments were performed. Tonsil biopsies were analyzed by confocal microscopy. Results: CD4(+)FOXP3(+) Treg cells and pDCs constitute important T-and dendritic cell-compartments in palatine and lingual tonsils. Tonsil pDCs have the ability to generate functional CD4(+)CD25(+)CD127(-)FOXP3(+) Treg cells with suppressive property from naive T cells. CD4(+)FOXP3(+) Treg cells proliferate and colocalize with pDCs in vivo in T-cell areas of lingual and palatine tonsils. Tonsil T cells did not proliferate to common food and aeroallergens. Depletion of FOXP3(+) Treg cells enables the allergen-induced proliferation of tonsil T cells, indicating an active role of Treg cells in allergen-specific T-cell unresponsiveness. High numbers of major birch pollen allergen, Bet v 1-specific CD4(+)FOXP3(+) Treg cells, are identified in human tonsils compared with peripheral blood. A positive correlation between the percentages of FOXP3(+) Treg cells and pDCs is observed in tonsils from nonatopic individuals. Conclusion: Functional allergen-specific Treg cells are identified both in lingual and in palatine tonsils. (J Allergy Clin Immunol 2012;129:510-20.)	[Palomares, Oscar; Rueckert, Beate; Kuecueksezer, Umut Can; Gomez, Enrique; Jung, Andreas; Akdis, Muebeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; [Jartti, Tuomas] Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland; [Puhakka, Tuomo] Turku Univ Hosp, Dept Otorhinolaryngol, FIN-20520 Turku, Finland; [Kuecueksezer, Umut Can] Istanbul Univ, Dept Immunol, Inst Expt Med DETAE, Istanbul, Turkey; [Puhakka, Tuomo] Satakunta Cent Hosp, Dept Otorhinolaryngol, Pori, Finland; [Fahrner, Heinz B.] Kantonsspital Graubunden, Dept ENT, Chur, Switzerland; [Speiser, Andreas] Spital Davos, Davos, Switzerland; [Jung, Andreas] Hochgebirgsklin Davos Wolfgang, Davos, Switzerland; [Kwok, William W.] Benaroya Res Inst Virginia Mason, Seattle, WA USA; [Kalogjera, Livije] Univ Hosp Ctr Sestre Milosrdnice, Dept ORL, Zagreb Sch Med, Zagreb, Croatia	Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Turku; University of Turku; Istanbul University; Satakunta Central Hospital; Kantonsspital Graubunden; Benaroya Research Institute; Virginia Mason Medical Center; University of Zagreb	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Obere Str 22,Davos Platz, CH-7270 Davos, Switzerland.	oscar.palomares@quim.ucm.es; akdisac@siaf.uzh.ch	Palomares, Oscar/ABG-5229-2020; kucuksezer, umut/AAD-5168-2020; Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X; Palomares, Oscar/0000-0003-4516-0369; Gomez Alcaide, Enrique/0000-0003-0542-303X	Swiss National Foundation [32-125249, 320030-132899]; Christine Kuhne-Center for Allergy Research and Education (CK-CARE); Ministerio de Educacion y Ciencia; FECYT (Spain); NIH [HHSN272200700046C]; European Commission [261357]; Predicta; Novartis; Stallergenes; Global Allergy and Asthma European Network; Christine Kuhne-Center for Allergy Research and Education	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Christine Kuhne-Center for Allergy Research and Education (CK-CARE); Ministerio de Educacion y Ciencia(Spanish Government); FECYT (Spain); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Commission(European CommissionEuropean Commission Joint Research Centre); Predicta; Novartis(Novartis); Stallergenes; Global Allergy and Asthma European Network; Christine Kuhne-Center for Allergy Research and Education	The authors' laboratories are supported by Swiss National Foundation grants 32-125249 and 320030-132899 and Christine Kuhne-Center for Allergy Research and Education (CK-CARE). O.P. was supported by a postdoctoral fellowship from Ministerio de Educacion y Ciencia and FECYT (Spain) and W.W.K by NIH contract HHSN272200700046C.; This work was supported by the European Commission's Seventh Framework Programme under grant agreement no. 261357.; M. Akdis has received research support from the Swiss National Foundation, European Commission FP7 (MeDALL), and Predicta. C. A. Akdis has received research support from Novartis, Stallergenes, the Swiss National Science Foundation, Global Allergy and Asthma European Network, and Christine Kuhne-Center for Allergy Research and Education; is a Fellow and interest group member of the American Academy of Allergy, Asthma & Immunology; is Vice President of the European Academy of Allergy and Clinical Immunology; and was a committee member for GA<SUP>2</SUP>LEN. The rest of the authors declare that they have no relevant conflicts of interest.	Akbar AN, 2007, NAT REV IMMUNOL, V7, P231, DOI 10.1038/nri2037; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Bonasio R, 2006, CURR OPIN IMMUNOL, V18, P503, DOI 10.1016/j.coi.2006.05.011; Brandtzaeg P, 1984, IMMUNOLOGY LUNG UPPE; Chen W, 2008, J IMMUNOL, V181, P5396, DOI 10.4049/jimmunol.181.8.5396; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Clarke TB, 2010, NAT MED, V16, P228, DOI 10.1038/nm.2087; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Crameri R, 2009, CURR OPIN ALLERGY CL, V9, P568, DOI 10.1097/ACI.0b013e3283310fdf; EBNER C, 1993, J IMMUNOL, V150, P1047; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Fehervari Z, 2004, J CLIN INVEST, V114, P1209, DOI 10.1172/JCI200434495; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; HART DNJ, 1988, J EXP MED, V168, P157, DOI 10.1084/jem.168.1.157; Ito T, 2006, BLOOD, V107, P2423, DOI 10.1182/blood-2005-07-2709; Ito T, 2008, IMMUNITY, V28, P870, DOI 10.1016/j.immuni.2008.03.018; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Klunker S, 2009, J EXP MED, V206, P2701, DOI 10.1084/jem.20090596; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martin-Gayo E, 2010, BLOOD, V115, P5366, DOI 10.1182/blood-2009-10-248260; McCartney SA, 2009, IMMUNOL REV, V227, P87, DOI 10.1111/j.1600-065X.2008.00726.x; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Nave H, 2001, ANAT EMBRYOL, V204, P367, DOI 10.1007/s004290100210; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Ogra PL, 2000, PEDIATR INFECT DIS J, V19, pS4, DOI 10.1097/00006454-200005001-00002; Perry M, 1998, IMMUNOL TODAY, V19, P414, DOI 10.1016/S0167-5699(98)01307-3; Phillips J, 2009, NAT REV CLIN ONCOL, V6, P439, DOI 10.1038/nrclinonc.2009.105; Piqueras B, 2006, BLOOD, V107, P2613, DOI 10.1182/blood-2005-07-2965; Polak ME, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-10; Pulendran B, 2008, CURR OPIN IMMUNOL, V20, P61, DOI 10.1016/j.coi.2007.10.009; Rescigno M, 2009, J CLIN INVEST, V119, P2441, DOI 10.1172/JCI39134; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Scholl I, 2007, FASEB J, V21, P1264, DOI 10.1096/fj.06-7223com; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Stahl-Hennig C, 2007, FRONT BIOSCI, V12, P2107, DOI 10.2741/2215; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Stent G, 2002, CYTOMETRY, V48, P167, DOI 10.1002/cyto.10118; Summers KL, 2001, AM J PATHOL, V159, P285, DOI 10.1016/S0002-9440(10)61694-X; Vagenas P, 2009, JAIDS-J ACQ IMM DEF, V52, P433, DOI 10.1097/QAI.0b013e3181b880f3; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106	51	115	125	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					510	U361		10.1016/j.jaci.2011.09.031	http://dx.doi.org/10.1016/j.jaci.2011.09.031			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22051696				2022-12-18	WOS:000299951700031
J	Maddur, MS; Vani, J; Hegde, P; Lacroix-Desmazes, S; Kaveri, SV; Bayry, J				Maddur, Mohan S.; Vani, Janakiraman; Hegde, Pushpa; Lacroix-Desmazes, Sebastien; Kaveri, Srini V.; Bayry, Jagadeesh			Inhibition of differentiation, amplification, and function of human T(H)17 cells by intravenous immunoglobulin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Intravenous immunoglobulin; allergy; autoimmunity; inflammation; T(H)17 cells; IL-17; regulatory T cells; retinoic-acid-related orphan receptor C; forkhead box protein 3	REGULATORY T-CELLS; TH17 CELLS; ALLERGIC DISEASES; IMMUNE GLOBULIN; DENDRITIC CELLS; IL-17; AUTOIMMUNE; THERAPY; ASTHMA; INTERLEUKIN-17	Background: T(H)17 cells play a critical role in the pathogenesis of several autoimmune and allergic diseases. Intravenous immunoglobulin (IVIg), a therapeutic preparation of polyclonal IgG that is increasingly used in the treatment of diverse autoimmune and allergic diseases, might target T(H)17 cells to exert therapeutic effects. Objective: We sought to examine whether IVIg interferes with the development and function of human T(H)17 cells. Methods: T(H)17 cells were differentiated from naive human CD4(+) T cells in the presence of TGF-beta and IL-21. T(H)17 cells were amplified by stimulating memory CD4(+) T cells in the presence of IL-1 beta and IL-6. The effect of IVIg was examined on the differentiation and amplification of T(H)17 cells, expression of the T(H)17 lineage-specific transcription factor retinoic acid-related orphan receptor C, secretion of T(H)17 effector cytokines, and phosphorylation of signal transducer and activator of transcription 3, a transcription factor that plays an important role in T(H)17 cell development and function. Results: IVIg inhibits the differentiation and amplification of human T(H)17 cells, as well as the production of their effector cytokines IL-17A, IL-17F, IL-21, and CCL20. The inhibitory effects of IVIg on T(H)17 cells are F(ab')(2) dependent and involve interference with the expression of retinoic acid-related orphan receptor C and activation of signal transducer and activator of transcription 3. Also, IVIg significantly enhanced forkhead box protein 3-positive regulatory T cells among the memory CD4(+) T cells. Conclusion: These results reveal a novel mechanism of action of IVIg in achieving a therapeutic effect in autoimmune and allergic diseases, in which T(H)17 cells play a key modulatory role in sustaining the chronic inflammatory response. Our results also suggest a reciprocal regulation of T(H)17 and regulatory T-cell populations by IVIg. (J Allergy Clin Immunol 2011;127:823-30.)	[Bayry, Jagadeesh] INSERM, U872, Equipe Ctr Rech Cordeliers 16, F-75006 Paris, France; [Maddur, Mohan S.; Vani, Janakiraman; Lacroix-Desmazes, Sebastien; Kaveri, Srini V.; Bayry, Jagadeesh] Univ Paris 06, Ctr Rech Cordeliers, Equipe Immunopathol & Therapeut Immunointervent 1, Paris, France; [Maddur, Mohan S.; Vani, Janakiraman; Lacroix-Desmazes, Sebastien; Kaveri, Srini V.; Bayry, Jagadeesh] Univ Paris 05, Paris, France; [Hegde, Pushpa] Univ Technol Compiegne, F-60206 Compiegne, France; [Lacroix-Desmazes, Sebastien; Kaveri, Srini V.; Bayry, Jagadeesh] INSERM, Int Associated Lab IMPACT, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Picardie Universites; Universite de Technologie de Compiegne; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bayry, J (corresponding author), INSERM, U872, Equipe Ctr Rech Cordeliers 16, 15 Rue Ecole Med, F-75006 Paris, France.	srini.kaveri@crc.jussieu.fr; jagadeesh.bayry@crc.jussieu.fr	Bayry, Jagadeesh/A-6589-2011; J, Vani/B-4882-2013; Maddur, Mohan/E-4763-2015	Bayry, Jagadeesh/0000-0003-0498-9808; Kaveri, Srini/0000-0002-0837-4053; Maddur, Mohan/0000-0002-7085-1762; Lacroix-Desmazes, Sebastien/0000-0001-5625-8447; Hegde, Pushpa/0000-0002-2376-8659	Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique (CNRS); Universite Pierre et Marie Curie; Universite Paris Descartes; European Community [HEALTH-F2-2010-260338-ALLFUN]; Octapharma; Lachen, Switzerland	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Universite Pierre et Marie Curie; Universite Paris Descartes; European Community(European Commission); Octapharma; Lachen, Switzerland	Supported by grants from Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite Pierre et Marie Curie, Universite Paris Descartes, the European Community's Seventh Framework Programme (FP7-2007-2013) under Grant Agreement no. HEALTH-F2-2010-260338-ALLFUN, and Octapharma, Lachen, Switzerland.	Andersson J, 1996, CLIN EXP IMMUNOL, V104, P10, DOI 10.1111/cei.1996.104.s1.10; Annunziato F, 2009, NAT REV RHEUMATOL, V5, P325, DOI 10.1038/nrrheum.2009.80; Aubin E, 2010, BLOOD, V115, P1727, DOI 10.1182/blood-2009-06-225417; Bayry J, 2003, BLOOD, V101, P758, DOI 10.1182/blood-2002-05-1447; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Ciprandi G, 2010, INT IMMUNOPHARMACOL, V10, P226, DOI 10.1016/j.intimp.2009.11.004; Colin EM, 2010, ARTHRITIS RHEUM-US, V62, P132, DOI 10.1002/art.25043; Crome SQ, 2010, J IMMUNOL, V185, P3199, DOI 10.4049/jimmunol.1000557; De Groot AS, 2008, BLOOD, V112, P3303, DOI 10.1182/blood-2008-02-138073; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Ephrem A, 2008, BLOOD, V111, P715, DOI 10.1182/blood-2007-03-079947; Fletcher JM, 2009, J IMMUNOL, V183, P7602, DOI 10.4049/jimmunol.0901881; Gelfand EW, 1996, CLIN EXP IMMUNOL, V104, P61, DOI 10.1111/cei.1996.104.s1.61; Gold R, 2007, NAT CLIN PRACT NEURO, V3, P36, DOI 10.1038/ncpneuro0376; Hashimoto T, 2005, INT ARCH ALLERGY IMM, V137, P51, DOI 10.1159/000085432; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Kessel A, 2007, J IMMUNOL, V179, P5571, DOI 10.4049/jimmunol.179.8.5571; Klotz L, 2009, J EXP MED, V206, P2079, DOI 10.1084/jem.20082771; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Larsen JM, 2009, J ALLERGY CLIN IMMUN, V123, P486, DOI 10.1016/j.jaci.2008.09.036; Lemieux W, 2005, MOL IMMUNOL, V42, P839, DOI 10.1016/j.molimm.2004.07.046; LEUNG DYM, 1992, CLIN REV ALLERG, V10, P93; Louten J, 2009, J ALLERGY CLIN IMMUN, V123, P1004, DOI 10.1016/j.jaci.2009.04.003; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; MAZER BD, 1989, CLIN IMMUNOL IMMUNOP, V53, pS156, DOI 10.1016/0090-1229(89)90081-0; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Nimmerjahn F, 2008, ANNU REV IMMUNOL, V26, P513, DOI 10.1146/annurev.immunol.26.021607.090232; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; Prins C, 2007, ACTA DERM-VENEREOL, V87, P206, DOI 10.2340/00015555-0249; Rabinovitch N, 1999, ALLERGY, V54, P662, DOI 10.1034/j.1398-9995.1999.00094.x; Ramgolam VS, 2009, J IMMUNOL, V183, P5418, DOI 10.4049/jimmunol.0803227; Seite JF, 2008, AUTOIMMUN REV, V7, P435, DOI 10.1016/j.autrev.2008.04.012; Sundrud MS, 2009, SCIENCE, V324, P1334, DOI 10.1126/science.1172638; Tha-In T, 2006, TRANSPLANTATION, V81, P1725, DOI 10.1097/01.tp.0000226073.20185.b1; Tha-In T, 2010, TRANSPLANTATION, V89, P1446, DOI 10.1097/TP.0b013e3181dd6bf1; Tha-In T, 2008, TRENDS IMMUNOL, V29, P608, DOI 10.1016/j.it.2008.08.004; van Beelen AJ, 2007, CURR OPIN ALLERGY CL, V7, P374, DOI 10.1097/ACI.0b013e3282ef869e; Wang YH, 2008, CURR OPIN IMMUNOL, V20, P697, DOI 10.1016/j.coi.2008.09.004; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Zhang X, 2008, J IMMUNOL, V180, P6988, DOI 10.4049/jimmunol.180.10.6988; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001	41	115	122	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					823	U514		10.1016/j.jaci.2010.12.1102	http://dx.doi.org/10.1016/j.jaci.2010.12.1102			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21281961				2022-12-18	WOS:000288018400038
J	Haselkorn, T; Fish, JE; Zeiger, RS; Szefler, SJ; Miller, DP; Chipps, BE; Simons, FER; Weiss, ST; Wenzel, SE; Borish, L; Bleecker, ER				Haselkorn, Tmirah; Fish, James E.; Zeiger, Robert S.; Szefler, Stanley J.; Miller, Dave P.; Chipps, Bradley E.; Simons, F. Estelle R.; Weiss, Scott T.; Wenzel, Sally E.; Borish, Larry; Bleecker, Eugene R.		TENOR Study Grp	Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma guidelines; impairment domain; risk; exacerbations; health care use; asthma control; The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens study	QUALITY-OF-LIFE; HEALTH-CARE UTILIZATION; GLOBAL BURDEN; CHILDREN; ASSOCIATION; VALIDATION; EMERGENCY; QUESTIONNAIRE; PREVALENCE; ADULTS	Background: Identification of patients at risk for asthma exacerbations can assist physicians in addressing disease management and improve asthma-related health outcomes. Objective: We sought to evaluate whether level of impairment, as defined by the 2007 asthma guidelines, predicts risk for future asthma exacerbations. Methods: The study included children aged 6 to 11 years (n = 82) and adolescent/adult patients aged 12 years and older (n = 725) from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens study with data representing all components of the impairment domain of the asthma guidelines at baseline, month 12, and month 24. Patients were categorized into 2 cohorts: (1) consistently very poorly controlled (VPC) asthma from baseline through 2 years of follow-up and (2) improved from VPC asthma at baseline (including patients who improved to not well-controlled or well-controlled asthma), with improvement maintained through 2 years of follow-up. Odds ratios (ORs) and 95% CIs for risk of asthma exacerbations at month 30 were generated by using multivariable logistic regression by age group. Results: After adjustment, children with consistently VPC asthma over the 2-year period demonstrated a 6-fold increased risk of hospitalization, emergency department visit, or corticosteroid burst (OR, 6.4; 95% CI, 1.2-34.5) compared with the improved group. Adolescent/adult patients with consistently VPC asthma were more likely to have a corticosteroid burst (OR, 2.8; 95% CI, 1.7-4.8) or have a hospitalization, emergency department visit, or corticosteroid burst (OR, 3.2; 95% CI, 1.9-5.3). Conclusions: Consistently VPC asthma, as defined by the impairment domain of the 2007 asthma guidelines, is strongly predictive of future asthma exacerbations. (J Allergy Clin Immunol 2009;124:895-902.)	[Haselkorn, Tmirah; Fish, James E.] Genentech Inc, San Francisco, CA 94080 USA; [Zeiger, Robert S.] Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA; [Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Miller, Dave P.] ICON Clin Res, San Francisco, CA USA; [Chipps, Bradley E.] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA; [Simons, F. Estelle R.] Univ Manitoba, Winnipeg, MB, Canada; [Weiss, Scott T.] Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA; [Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Asthma Inst, Pittsburgh, PA USA; [Borish, Larry] Univ Virginia Hlth Syst, Charlottesville, VA USA; [Bleecker, Eugene R.] Wake Forest Univ Hlth Sci, Winston Salem, NC USA	Roche Holding; Genentech; Kaiser Permanente; National Jewish Health; ICON plc; University of Manitoba; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Virginia; Wake Forest University; Wake Forest University School of Medicine	Haselkorn, T (corresponding author), Genentech Inc, 1 DNA Way,MS 58B, San Francisco, CA 94080 USA.	haselkorn.tmirah@gene.com			Genentech, Inc; Novartis Pharmaceuticals Corporation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076285] Funding Source: NIH RePORTER	Genentech, Inc(Roche HoldingGenentech); Novartis Pharmaceuticals Corporation(Novartis); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by Genentech, Inc, and Novartis Pharmaceuticals Corporation.	Accordini S, 2006, INT ARCH ALLERGY IMM, V141, P189, DOI 10.1159/000094898; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904; Apter AJ, 2008, J ALLERGY CLIN IMMUN, V121, P839, DOI 10.1016/j.jaci.2007.12.1176; Arnold DH, 2008, AM J EMERG MED, V26, P473, DOI 10.1016/j.ajem.2007.05.026; Belessis Y, 2004, PEDIATR PULM, V37, P201, DOI 10.1002/ppul.10443; Bender BG, 2002, J ALLERGY CLIN IMMUN, V109, pS554, DOI 10.1067/mai.2002.124570; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Breekveldt-Postma NS, 2008, CURR MED RES OPIN, V24, P975, DOI [10.1185/030079908X280518, 10.1185/030079908X280518 ]; Castro M, 2003, AM J RESP CRIT CARE, V168, P1095, DOI 10.1164/rccm.200208-877OC; Chen H, 2008, MAYO CLIN PROC, V83, P786, DOI 10.4065/83.7.786; Chen H, 2007, J ALLERGY CLIN IMMUN, V120, P396, DOI 10.1016/j.jaci.2007.04.040; Chipps BE, 2007, J ALLERGY CLIN IMMUN, V119, P1156, DOI 10.1016/j.jaci.2006.12.668; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Janson SL, 2008, HEART LUNG, V37, P211, DOI 10.1016/j.hrtlng.2007.05.014; JESSOP DJ, 1995, ARCH PEDIAT ADOL MED, V149, P1105, DOI 10.1001/archpedi.1995.02170230059008; Joseph CLM, 1996, J PEDIATR-US, V129, P735, DOI 10.1016/S0022-3476(96)70158-0; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; Lafata JE, 2002, AMBUL PEDIATR, V2, P268, DOI 10.1367/1539-4409(2002)002<0268:RFFEDU>2.0.CO;2; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; *MERCK CO INC, 2008, ASTHM THER ASS QUEST; Miller J E, 2001, Vital Health Stat 2, P1; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; *NAT CTR HLTH STAT, ASTHM; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; National Heart Lung and Blood Institute, 2007, NIH PUBL; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Randler C, 2007, WILSON J ORNITHOL, V119, P23, DOI 10.1676/04-014.1; Schatz M, 2008, J ALLERGY CLIN IMMUN, V121, pS69, DOI 10.1016/j.jaci.2007.12.275; Schatz M, 2003, AM J MANAG CARE, V9, P538; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P564, DOI 10.1016/j.jaci.2004.12.005; Schatz M, 2008, AM J MANAG CARE, V14, P206; Schatz M, 2006, AM J MANAG CARE, V12, P478; Sears MR, 2008, J ALLERGY CLIN IMMUN, V122, P662, DOI 10.1016/j.jaci.2008.08.003; Sharma HP, 2007, PEDIATRICS, V120, pE1174, DOI 10.1542/peds.2007-0206; Sullivan SD, 2007, ALLERGY, V62, P655, DOI 10.1111/j.1398-9995.2007.01383.x; U.S. Department of Agriculture, 2000 RUR URB COMM AR; US Census Bureau, US CENS 2000; *USDA, USDA RUR URB COMM AR; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; *WHO, 2008, ASTHM; Yoo KH, 2007, J ALLERGY CLIN IMMUN, V120, P1468, DOI 10.1016/j.jaci.2007.09.008; Zeiger RS, 2008, J ALLERGY CLIN IMMUN, V121, P885, DOI 10.1016/j.jaci.2007.12.1178	52	115	115	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					895	902		10.1016/j.jaci.2009.07.035	http://dx.doi.org/10.1016/j.jaci.2009.07.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI		Bronze			2022-12-18	WOS:000272108000003
J	Larsen, JM; Bonefeld, CM; Poulsen, SS; Geisler, C; Skov, L				Larsen, Jeppe Madura; Bonefeld, Charlotte Menne; Poulsen, Steen Seier; Geisler, Carsten; Skov, Lone			IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic contact dermatitis; contact hypersensitivity; inflammation; keratinocytes; T(H)17 cells; IL-23	T-CELLS; HUMAN KERATINOCYTES; TH17 CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; SKIN INFLAMMATION; TRANSGENIC MICE; HYPERSENSITIVITY; EXPRESSION; IL-17; INTERLEUKIN-17	Background: IL-17-producing T-H (T(H)17) cells are key mediators of chronic inflammation in mice. Recent studies have implicated T(H)17-mediated inflammation in the pathogenesis of human autoimmune diseases; however, the involvement of T(H)17 cells in allergic disorders remains largely elusive. Objective: To investigate T(H)17-mediated inflammation in human beings with allergic contact dermatitis; in particular, the innate response of keratinocytes to contact allergen, the induction of allergen-specific T(H)17 cells, and the presence of T(H)17-related effector cells in inflamed skin. Methods: Human keratinocytes were stimulated with nickel in vitro followed by measurements of IL-23 and IL-12 production by quantitative PCR and ELISA. Allergen-specific memory T cells from the blood of individuals with nickel allergy and healthy controls were identified and characterized by using a short-term ex vivo assay. Nickel patch test lesions and normal skin were analyzed for the expression of T(H)17-related cells and molecules by using immunohistochemistry. Results: Keratinocytes were found to produce IL-23, but no detectable IL-12, in a response to nickel stimulation. Memory T cells isolated from peripheral blood of individuals with nickel allergy, but not healthy controls, contained T(H)17 and T(H)1 cells proliferating in response to nickel-pulsed DCs. Inflamed skin of nickel-challenged allergic individuals contained infiltrating neutrophils and cells expressing IL-17, IL-22, CCR6, and IL-22R. Conclusion: Our results demonstrate the involvement of T(H)17-mediated immunopathology in human allergic contact dermatitis, including both innate and adaptive immune responses to contact allergens. (J Allergy Clin Immunol 2009;123:486-92.)	[Larsen, Jeppe Madura] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Sect Expt Immunol, DK-2200 Copenhagen N, Denmark; [Poulsen, Steen Seier] Univ Copenhagen, Dept Biomed Sci, DK-2200 Copenhagen N, Denmark; [Skov, Lone] Gentofte Univ Hosp, Dept Dermatol, Hellerup, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital	Larsen, JM (corresponding author), Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Sect Expt Immunol, Blegdamsvej 3C 22-5, DK-2200 Copenhagen N, Denmark.	jml@sund.ku.dk	Geisler, Carsten/A-7056-2012; Larsen, Jeppe Madura/K-6518-2019; Skov, Lone/W-3575-2018	Geisler, Carsten/0000-0002-8472-0771; Larsen, Jeppe Madura/0000-0003-1492-0708; Skov, Lone/0000-0002-4784-9680; Poulsen, Steen Seier/0000-0003-4419-4911; Bonefeld, Charlotte Menne/0000-0002-0523-6229	LEO Pharma Research Foundation; Copenhagen County Research Foundation; Aage Bangs Foundation; Danish Asthma-Allergy Association	LEO Pharma Research Foundation(LEO Pharma); Copenhagen County Research Foundation; Aage Bangs Foundation; Danish Asthma-Allergy Association	Supported by the LEO Pharma Research Foundation, the Copenhagen County Research Foundation, the Aage Bangs Foundation, and the Danish Asthma-Allergy Association.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Akiba H, 2002, J IMMUNOL, V168, P3079, DOI 10.4049/jimmunol.168.6.3079; Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Albanesi C, 1999, J IMMUNOL, V162, P494; Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Banerjee G, 2004, SCAND J IMMUNOL, V59, P385, DOI 10.1111/j.0300-9475.2004.01394.x; Burns R, 2005, J ALLERGY CLIN IMMUN, V115, P383, DOI 10.1016/j.jaci.2004.11.019; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; GASPARI AA, 1988, J IMMUNOL, V140, P2956; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; He DG, 2006, J IMMUNOL, V177, P6852, DOI 10.4049/jimmunol.177.10.6852; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; KAPSENBERG ML, 1992, J INVEST DERMATOL, V98, P59, DOI 10.1111/1523-1747.ep12494841; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Koenders MI, 2005, AM J PATHOL, V167, P141, DOI 10.1016/S0002-9440(10)62961-6; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Kopp T, 2003, J IMMUNOL, V170, P5438, DOI 10.4049/jimmunol.170.11.5438; Kopp T, 2001, J INVEST DERMATOL, V117, P618, DOI 10.1046/j.1523-1747.2001.01441.x; Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lebre MC, 2007, J INVEST DERMATOL, V127, P331, DOI 10.1038/sj.jid.5700530; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liao F, 1999, J IMMUNOL, V162, P186; Lushniak BD, 2003, INT ARCH OCC ENV HEA, V76, P325, DOI 10.1007/s00420-002-0417-2; Ma HL, 2008, J CLIN INVEST, V118, P597, DOI 10.1172/JCI33263; Meding B, 2005, J INVEST DERMATOL, V124, P893, DOI 10.1111/j.0022-202X.2005.23723.x; Mitsui G, 2003, IMMUNOL LETT, V86, P191, DOI 10.1016/S0165-2478(03)00017-8; Moed H, 2004, BRIT J DERMATOL, V151, P32, DOI 10.1111/j.1365-2133.2004.05975.x; Moed H, 2004, J PATHOL, V204, P39, DOI 10.1002/path.1619; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Paradis TJ, 2008, J INVEST DERMATOL, V128, P628, DOI 10.1038/sj.jid.5701055; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Piskin G, 2006, J IMMUNOL, V176, P1908, DOI 10.4049/jimmunol.176.3.1908; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; WILKINSON DS, 1970, ACTA DERM-VENEREOL, V50, P287; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505	47	115	123	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					486	492		10.1016/j.jaci.2008.09.036	http://dx.doi.org/10.1016/j.jaci.2008.09.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	18986691				2022-12-18	WOS:000263495000030
J	Sackesen, C; Ercan, H; Dizdar, E; Soyer, O; Gumus, P; Tosun, BN; Buyuktuncer, Z; Karabulut, E; Besler, T; Kalayci, O				Sackesen, Cansin; Ercan, Hulya; Dizdar, Evrim; Soyer, Ozge; Gumus, Pinar; Tosun, Berat Nursal; Bueyuektuncer, Zebra; Karabulut, Erdem; Besler, Tanju; Kalayci, Omer			A comprehensive evaluation of the enzymatic and nonenzymatic antioxidant systems in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						amino acid; antioxidant; ascorbic acid; asthma; glutathione; glutathione peroxidase; lycopene; malondialdehyde; oxidative stress; superoxide dismutase; alpha-tocopherol; beta-carotene	EXTRACELLULAR-SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; PROTEIN OXIDATION; CYSTEINE KINETICS; PLASMA LYCOPENE; FREE-RADICALS; AMINO-ACIDS; GLUTATHIONE; AIRWAY; PREVALENCE	Background: Even though there is ample evidence on the oxidative stress in asthma, there is limited information on the antioxidant defense systems. Objectives: To conduct a comprehensive evaluation of various components of both enzymatic and nonenzymatic antioxidants in a large group of children with asthma. Methods: A total of 164 children with mild asthma and 173 healthy children were included in the study. Levels of the enzymes glutathione peroxidase and superoxide dismutase were measured by using ELISA, whereas reduced glutathione, ascorbic acid, alpha-tocopherol, lycopene, beta-carotene, amino acids participating in glutathione synthesis, and amino acids susceptible to oxidation were measured by HPLC. All comparisons were adjusted for atopy, body mass index, smoke exposure, and pet ownership. Results: Levels of the enzymes glutathione peroxidase and superoxide dismutase and of the nonenzymatic components of the antioxidant system including reduced glutathione, ascorbic acid, alpha-tocopherol, lycopene, and beta-carotene were significantly lower in children with asthma compared with healthy controls (P <.001 for each). Of the amino acids contributing to glutathione synthesis, glycine and glutamine were significantly lower in children with asthma (P <.001). The majority of the amino acid susceptible to oxidative stress displayed lower levels in children with asthma (P <.05). Conclusion: Childhood asthma is associated with significant decreases in various components of both enzymatic and nonenzymatic antioxidant defenses.	[Karabulut, Erdem] Hacettepe Univ, Sch Med, Dept Biostat, TR-06100 Ankara, Turkey; [Sackesen, Cansin; Ercan, Hulya; Dizdar, Evrim; Soyer, Ozge; Gumus, Pinar; Kalayci, Omer] Hacettepe Univ, Sch Med, Pediat Allergy & Asthma Unit, TR-06100 Ankara, Turkey; [Tosun, Berat Nursal; Bueyuektuncer, Zebra; Besler, Tanju] Hacettepe Univ, Sch Hlth Technol, Dept Nutr & Dietet, TR-06100 Ankara, Turkey	Hacettepe University; Hacettepe University; Hacettepe University	Sackesen, C (corresponding author), Hacettepe Univ, Sch Med, Pediat Allergy & Asthma Unit, TR-06100 Ankara, Turkey.	csackesen@yahoo.com	Karabulut, Erdem/E-9242-2013; Besler, Halit Tanju/I-9965-2013	Besler, Halit Tanju/0000-0002-6523-7995; Ercan, Hulya/0000-0002-9754-7429				Andreadis AA, 2003, FREE RADICAL BIO MED, V35, P213, DOI 10.1016/S0891-5849(03)00278-8; ARNAUD J, 2001, J CHROMATOGR, V572, P103; Atmaca G, 2004, YONSEI MED J, V45, P776, DOI 10.3349/ymj.2004.45.5.776; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Besler HT, 2003, NUTR NEUROSCI, V6, P189, DOI 10.1080/1028415031000115945; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; CEBALLOSPICOT I, 1992, CLIN CHEM, V38, P66; COMMITTEE IS, 1998, PHASE 2 MODULES INT, P11; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; Ercan H, 2006, J ALLERGY CLIN IMMUN, V118, P1097, DOI 10.1016/j.jaci.2006.08.012; Fang YZ, 2002, NUTRITION, V18, P872, DOI 10.1016/S0899-9007(02)00916-4; Fogarty A, 2004, EUR RESPIR J, V23, P565, DOI 10.1183/09031936.04.00090404; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; Ford ES, 2004, J ASTHMA, V41, P179, DOI 10.1081/JAS-120026075; Fukagawa NK, 1996, AM J PHYSIOL-ENDOC M, V270, pE209, DOI 10.1152/ajpendo.1996.270.2.E209; HALLIWELL B, 1988, HUM TOXICOL, V7, P7, DOI 10.1177/096032718800700102; Harik-Khan RI, 2004, AM J EPIDEMIOL, V159, P351, DOI 10.1093/aje/kwh053; Heber D, 2002, EXP BIOL MED, V227, P920, DOI 10.1177/153537020222701013; HIRAMATSU T, 1994, AM J CLIN NUTR, V60, P525, DOI 10.1093/ajcn/60.4.525; JONES DP, 2000, DETOXIFICATION PROTE; Kalayci O, 2006, ALLERGY, V61, P97, DOI 10.1111/j.1398-9995.2006.00979.x; Kim YG, 2003, LIFE SCI, V72, P1171, DOI 10.1016/S0024-3205(02)02366-4; KINNULA VL, 1995, LAB INVEST, V73, P3; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; Maier CM, 2002, NEUROSCIENTIST, V8, P323, DOI 10.1177/107385840200800408; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Misso NLA, 2005, EUR RESPIR J, V26, P257, DOI 10.1183/09031936.05.00006705; Mizuno Y, 2006, PEDIATR INT, V48, P261, DOI 10.1111/j.1442-200X.2006.02200.x; Nadeem A, 2003, J ALLERGY CLIN IMMUN, V111, P72, DOI 10.1067/mai.2003.17; OBLED C, 2004, SULFUR CONTAINING AM; OWEN S, 1991, NEW ENGL J MED, V325, P586; Park EM, 1998, FREE RADICAL BIO MED, V25, P79, DOI 10.1016/S0891-5849(98)00041-0; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman I, 1999, AM J PHYSIOL-LUNG C, V277, pL1067, DOI 10.1152/ajplung.1999.277.6.L1067; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Riccioni G, 2007, J ASTHMA, V44, P429, DOI 10.1080/02770900701421880; Riccioni G, 2006, ALLERGY, V61, P1371, DOI 10.1111/j.1398-9995.2006.01100.x; Rubin RN, 2004, AM J RESP CRIT CARE, V169, P393, DOI 10.1164/rccm.200301-055OC; Sackesen C, 2005, ALLERGY, V60, P1485, DOI 10.1111/j.1398-9995.2005.00874.x; Saraclar Y, 2003, ANN ALLERG ASTHMA IM, V91, P477, DOI 10.1016/S1081-1206(10)61517-7; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Stadtman ER, 2003, AMINO ACIDS, V25, P207, DOI 10.1007/s00726-003-0011-2; STIPANUK MH, 1992, J NUTR, V122, P420, DOI 10.1093/jn/122.3.420; van der Vliet A, 1999, AM J PHYSIOL-LUNG C, V276, pL289, DOI 10.1152/ajplung.1999.276.2.L289; Wood LG, 2005, J AM COLL NUTR, V24, P448, DOI 10.1080/07315724.2005.10719490; Yilmaz T, 2004, OTOLARYNG HEAD NECK, V131, P797, DOI 10.1016/j.otohns.2004.07.001; Yilmaz T, 2004, INT J PEDIATR OTORHI, V68, P1053, DOI 10.1016/j.ijporl.2004.04.003	50	115	117	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					78	85		10.1016/j.jaci.2008.03.035	http://dx.doi.org/10.1016/j.jaci.2008.03.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18485467				2022-12-18	WOS:000257605100013
J	Sukkar, MB; Xie, SP; Khorasani, NM; Kon, OM; Stanbridge, R; Issa, R; Chung, KF				Sukkar, Maria B.; Xie, Shaoping; Khorasani, Nadia M.; Kon, Onn Min; Stanbridge, Rex; Issa, Razao; Chung, Kian Fan			Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						toll-like receptor; human airway smooth muscle; double-stranded RNA; pepticloglycan; lipopolysaccharide; IFN-gamma; TNF-alpha; eotaxin; IL-8; corticosteroid	DOUBLE-STRANDED-RNA; TOLL-LIKE RECEPTOR-3; EPITHELIAL-CELLS; SYNOVIAL FIBROBLASTS; IMMUNE-RESPONSES; DENDRITIC CELLS; INDUCTION; LIGANDS; INNATE; GAMMA	Background: Host defense against microbial pathogens is elicited through the innate immune system by means of Toll-like receptors (TLRs). Airway smooth muscle cells (ASMCs) display proinflammatory and immunomodulatory functions. ASMCs might participate in airway inflammatory responses associated with innate immune activation. Objectives: We determined the effects of cytokines, TLR ligands, and corticosteroids on TLR expression and function in human ASMCs. Methods: Real-time PCR and flow cytometry were used to assess TLR mRNA and protein expression, respectively. ASMCs were stimulated with TLR ligands, and chemokine release was measured by means of ELISA. Results: ASMCs expressed TLR1 to TLR10 mRNA, and TLR2 and TLR3 protein expression was demonstrated. TNF-alpha and double-stranded RNA (dsRNA; TLR3 ligand) were potent inducers of TLR2 and TLR3 mRNA expression, and both stimuli had additive or synergistic effects with IFN-gamma on TLR2 and TLR4, but not TLR3, mRNA expression. Peptidoglycan (TLR2 ligand) and LPS (TLR4 ligand) weakly enhanced TLR2 mRNA expression. Peotidoglycan, dsRNA, and LPS induced IL-8 and eotaxin release, with dsRNA being most potent. dsRNA also modulated cytokine-induced chemokine release in a differential manner. Dexamethasone inhibited cytokine- and ligand-induced TLR2, TLR3, and TLR4 expression and chemokine release. However, dexamethasone potentiated TLR2 expression induced by combined IFN-gamma and TNF-alpha stimulation. Conclusion: Expression of TLR2, TLR3, and TLR4 is regulated by cytokines and TLR ligands, and their activation mediates chemokine release in ASMCs. Clinical implications: Proinflammatory responses mediated by activation of pathogen-recognition receptors in ASMCs might contribute to infectious exacerbations of airway inflammatory conditions, such as asthma and chronic obstructive pulmonary disease.	Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, Expt Studies Grp, London SW3 6LY, England; St Marys Hosp, London, England	Imperial College London; Imperial College London	Chung, KF (corresponding author), Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, Expt Studies Grp, Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk	Sukkar, Maria B/L-6917-2013; Chung, Kian Fan/B-1872-2012; Chung, Kian Fan/I-8456-2019	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Sukkar, Maria/0000-0003-4591-2399; Kon, Onn Min/0000-0003-2647-4688	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Armstrong L, 2004, AM J RESP CELL MOL, V31, P241, DOI 10.1165/rcmb.2004-0078OC; Bachar O, 2004, EUR J IMMUNOL, V34, P1196, DOI 10.1002/eji.200324569; Chaudhuri N, 2005, CLIN SCI, V109, P125, DOI 10.1042/CS20050044; Gern JE, 2003, AM J RESP CELL MOL, V28, P731, DOI 10.1165/rcmb.2002-0055OC; Gounni AS, 2005, J IMMUNOL, V175, P2613, DOI 10.4049/jimmunol.175.4.2613; Greene CM, 2005, J IMMUNOL, V174, P1638, DOI 10.4049/jimmunol.174.3.1638; Groskreutz DJ, 2006, J IMMUNOL, V176, P1733, DOI 10.4049/jimmunol.176.3.1733; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Hermoso MA, 2004, MOL CELL BIOL, V24, P4743, DOI 10.1128/MCB.24.11.4743-4756.2004; Hirst SJ, 2003, RESP PHYSIOL NEUROBI, V137, P309, DOI 10.1016/S1569-9048(03)00155-1; Homma T, 2004, AM J RESP CELL MOL, V31, P463, DOI 10.1165/rcmb.2004-0161OC; Jack CS, 2005, J IMMUNOL, V175, P4320, DOI 10.4049/jimmunol.175.7.4320; Kyburz D, 2003, ARTHRITIS RHEUM-US, V48, P642, DOI 10.1002/art.10848; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; McDonald C, 2005, J BIOL CHEM, V280, P20177, DOI 10.1074/jbc.R500001200; Morris GE, 2005, AM J RESP CRIT CARE, V171, P814, DOI 10.1164/rccm.200403-406OC; Netea MG, 2005, J IMMUNOL, V174, P6518, DOI 10.4049/jimmunol.174.10.6518; Pierer M, 2004, J IMMUNOL, V172, P1256, DOI 10.4049/jimmunol.172.2.1256; Pivarcsi A, 2005, MICROBES INFECT, V7, P1117, DOI 10.1016/j.micinf.2005.03.016; Proost P, 2004, J LEUKOCYTE BIOL, V75, P777, DOI 10.1189/jlb.1003524; Sakai A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-2; Schaefer TM, 2004, IMMUNOLOGY, V112, P428, DOI 10.1111/j.1365-2567.2004.01898.x; Schleimer Robert P, 2004, Proc Am Thorac Soc, V1, P222, DOI 10.1513/pats.200402-018MS; Schneeman TA, 2005, J IMMUNOL, V175, P376, DOI 10.4049/jimmunol.175.1.376; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; Sukkar MB, 2004, AM J PHYSIOL-LUNG C, V287, pL1230, DOI 10.1152/ajplung.00014.2004; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Ueta M, 2004, J IMMUNOL, V173, P3337, DOI 10.4049/jimmunol.173.5.3337; van Rijt LS, 2005, J CLIN VIROL, V34, P161, DOI 10.1016/j.jcv.2005.07.002; Wesch D, 2006, J IMMUNOL, V176, P1348, DOI 10.4049/jimmunol.176.3.1348	34	115	129	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					641	648		10.1016/j.jaci.2006.05.013	http://dx.doi.org/10.1016/j.jaci.2006.05.013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950283				2022-12-18	WOS:000240649000017
J	Hogan, SP; Seidu, L; Blanchard, C; Groschwitz, K; Mishra, A; Karow, ML; Ahrens, R; Ards, D; Murphy, AJ; Valenzuela, DM; Yancopoulos, GD; Rothenberg, ME				Hogan, Simon P.; Seidu, Luqman; Blanchard, Carine; Groschwitz, Katherine; Mishra, Anil; Karow, Margaret L.; Ahrens, Richard; Ards, David; Murphy, Andrew J.; Valenzuela, David M.; Yancopoulos, George D.; Rothenberg, Marc E.			Resistin-like molecule beta regulates innate colonic function: Barrier integrity and inflammation susceptibility	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; colitis; gastrointestinal; inflammatory; innate; IL-13; mucosal; resistin	INDUCIBLE FACTOR-I; INTESTINAL PERMEABILITY; BOWEL-DISEASE; GENETIC-BASIS; DEFICIENT; COLITIS; ASTHMA; OBESITY; MICE; EXPRESSION	Background: Resistin-like molecule (RELM) P is a cysteine-rich cytokine expressed in the gastrointestinal tract and implicated in insulin resistance and gastrointestinal nematode immunity; however, its function primarily remains an enigma. Objective: We sought to elucidate the function of RELM-beta in the gastrointestinal tract. Methods: We generated RELM-beta gene-targeted mice and examined colonic epithelial barrier function, gene expression profiles, and susceptibility to acute colonic inflammation. Results: We show that RELM-P is constitutively expressed in the colon by goblet cells and enterocytes and has a role in homeostasis, as assessed by alterations in colon mRNA transcripts and epithelial barrier function in the absence of RELM-P. Using acute colonic inflammatory models, we demonstrate that RELM-beta has a central role in the regulation of susceptibility to colonic inflammation. Mechanistic studies identify that RELM-beta regulates expression of type III regenerating gene (REG) (REG3 beta and gamma), molecules known to influence nuclear factor kappa B signaling. Conclusions: These data define a critical role for RELM-P in the maintenance of colonic barrier function and gastrointestinal innate immunity. Clinical implications: These findings identify RFLM-beta as an important molecule in homeostatic gastrointestinal function and colonic inflammation, and as such, these results have implications for a variety of human inflammatory gastrointestinal conditions, including allergic gastroenteropathies.	Univ Cincinnati, Div Allergy & Immunol, Cincinnati Childrens Hosp Med Ctr, Coll Med,Dept Pediat, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Immunobiol, Cincinnati, OH USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Regeneron; University of Pennsylvania	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,ML7028, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org	MISHRA, ANIL/S-7983-2017	MISHRA, ANIL/0000-0003-4266-4684; Murphy, Andrew/0000-0003-4152-4081; Artis, David/0000-0002-1753-4100	NIAID NIH HHS [T32 AI 060515, T32 AI060515, AI 45898, R01 AI 61570, R01 AI053479, AI 53479, R37 AI045898, R01 AI045898, R01 AI 42242, R01 AI061570] Funding Source: Medline; NIAMS NIH HHS [R01 AR042242] Funding Source: Medline; NIDDK NIH HHS [R24 DK 64403, R24 DK064403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053479, R01AI061570, R37AI045898, R01AI042242, T32AI060515, R01AI045898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abelson P, 2004, SCIENCE, V304, P1413, DOI 10.1126/science.304.5676.1413; Artis D, 2004, P NATL ACAD SCI USA, V101, P13596, DOI 10.1073/pnas.0404034101; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Blumberg RS, 1999, CURR OPIN IMMUNOL, V11, P648, DOI 10.1016/S0952-7915(99)00032-1; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Brasch-Andersen C, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.035519; Buhner S, 2006, GUT, V55, P342, DOI 10.1136/gut.2005.065557; Camoglio L, 2000, EUR J IMMUNOL, V30, P1486, DOI 10.1002/(SICI)1521-4141(200005)30:5<1486::AID-IMMU1486>3.0.CO;2-8; DIELEMAN LA, 1994, GASTROENTEROLOGY, V107, P1643, DOI 10.1016/0016-5085(94)90803-6; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Fichtner-Feigl S, 2005, J CLIN INVEST, V115, P3057, DOI 10.1172/JCI24792; Flier JS, 2001, NATURE, V409, P292, DOI 10.1038/35053251; Forbes E, 2004, J IMMUNOL, V172, P5664, DOI 10.4049/jimmunol.172.9.5664; Gironella M, 2005, GUT, V54, P1244, DOI 10.1136/gut.2004.056309; Hendrickson BA, 2002, CLIN MICROBIOL REV, V15, P79, DOI 10.1128/CMR.15.1.79-94.2002; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Karhausen J, 2004, J CLIN INVEST, V114, P1098, DOI 10.1172/JCI200421086; MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442; Marcus RC, 2000, DEV BIOL, V221, P132, DOI 10.1006/dbio.2000.9660; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; Okamoto H, 1999, J Hepatobiliary Pancreat Surg, V6, P254, DOI 10.1007/s005340050115; Panwala CM, 1998, J IMMUNOL, V161, P5733; Patel SD, 2004, SCIENCE, V304, P1154, DOI 10.1126/science.1093466; Peeters M, 1997, GASTROENTEROLOGY, V113, P802, DOI 10.1016/S0016-5085(97)70174-4; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; ROTHENBERG ME, 1995, J EXP MED, V181, P1211, DOI 10.1084/jem.181.3.1211; Schinke T, 2004, BIOCHEM BIOPH RES CO, V314, P356, DOI 10.1016/j.bbrc.2003.12.100; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Stevceva L, 2000, GENES IMMUN, V1, P213, DOI 10.1038/sj.gene.6363654; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Ten Hove T, 2002, DIGEST DIS SCI, V47, P2056, DOI 10.1023/A:1019629013945; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Wang ML, 2005, AM J PHYSIOL-GASTR L, V288, pG1074, DOI 10.1152/ajpgi.00442.2004; Weiss ST, 2004, AM J RESP CRIT CARE, V169, P963, DOI 10.1164/rccm.200303-403WS; WYATT J, 1993, LANCET, V341, P1437, DOI 10.1016/0140-6736(93)90882-H; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	40	115	118	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					257	268		10.1016/j.jaci.2006.04.039	http://dx.doi.org/10.1016/j.jaci.2006.04.039			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815164	Green Accepted, Bronze			2022-12-18	WOS:000239184800032
J	Perzanowski, MS; Miller, RL; Thorne, PS; Barr, RG; Divjan, A; Sheares, BJ; Garfinkel, RS; Perera, FP; Goldstein, IF; Chew, GL				Perzanowski, Matthew S.; Miller, Rachel L.; Thorne, Peter S.; Barr, R. Graham; Divjan, Adnan; Sheares, Beverley J.; Garfinkel, Robin S.; Perera, Frederica P.; Goldstein, Inge F.; Chew, Ginger L.			Endotoxin in inner-city homes: Associations with wheeze and eczema in early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; asthma; allergy; hygiene hypothesis; wheeze; inner-city; eczema	HOUSE-DUST ENDOTOXIN; INDOOR ALLERGENS; NATIONAL-SURVEY; HIGH-RISK; EXPOSURE; ASTHMA; SENSITIZATION; HYGIENE; INFANTS; CHILDREN	Background: An inverse association between domestic exposure to endotoxin and atopy in childhood has been observed. The relevance of this aspect of the hygiene hypothesis to US inner-city communities that have disproportionately high asthma prevalence has not been determined. Objectives: To measure endotoxin in the dust from inner-city homes, evaluate associations between endotoxin and housing/lifestyle characteristics, and determine whether endotoxin exposure predicted wheeze, allergic rhinitis, and eczema over the first 3 years of life. Methods: As part of an ongoing prospective birth cohort study, children of Dominican and African-American mothers living in New York City underwent repeated questionnaire measures. Dust samples collected from bedroom floors at age 12 or 36 months were assayed for endotoxin. Results: Among the samples collected from 301 participants' homes, the geometric mean endotoxin concentration (95% CI) was 75.9 EU/mg (66-87), and load was 3892 EU/m(2) (3351-4522). Lower endotoxin concentrations were associated with wet mop cleaning and certain neighborhoods. Endotoxin concentration correlated weakly with cockroach (Bla g 2: r = 0.22, P < .001) and mouse (mouse urinary protein: r = 0.28; P < .001) allergens in the dust. Children in homes with higher endotoxin concentration were less likely to have eczema at age 1 year (odds ratio, 0.70 [0.53-0.93]) and more likely to wheeze at age 2 years (odds ratio, 1.34 [1.01-1.78]). These associations were stronger among children with a maternal history of asthma. Conclusion: Endotoxin levels in this inner-city community are similar to those in nonfarm homes elsewhere. In this community, domestic endotoxin exposure was inversely associated with eczema at age 1 year, but positively associated with wheeze at age 2 years. Clinical implications: Endotoxin exposure in the inner-city community may be related to wheeze in the early life; however, given the inverse association seen with eczema, the long-term development of allergic disease is still in question.	Columbia Univ, Mailman Sch Publ Hlth, Columbias Ctr Childrens Environm Hlth, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Data Coordinating Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Div Pulm Allergy & Crit Care Med, New York, NY USA; Columbia Univ, Coll Phys & Surg, Div Gen Med, Dept Med, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY USA; Univ Iowa, Dept Environm & Occupat Hlth, Iowa City, IA USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; University of Iowa	Chew, GL (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Columbias Ctr Childrens Environm Hlth, 60 Haven Ave,B-1, New York, NY 10032 USA.	cg2gg@columbia.edu		Thorne, Peter/0000-0002-5045-0929; Divjan, Adnan/0000-0002-8895-5965	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009600, P50ES009600, P30ES009089, R01ES011158, R01ES012468, R01ES008977, P30ES005605] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000645, RR00645] Funding Source: Medline; NIEHS NIH HHS [5 P30 ES009089, R01ES111158, R01 ES011158, P30 ES05605, P50 ES009600, R01 ES012468, R01 ES012468-03, P50 ES09600, P01 ES009600-09, P30 ES005605-17, 5 R01 ES08977, P01 ES009600, R01 ES008977-10, P30 ES009089-09, P30 ES005605, R01 ES008977, P30 ES009089, R01 ES011158-03] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bischof W, 2002, INDOOR AIR, V12, P2, DOI 10.1034/j.1600-0668.2002.120102.x; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; *CIT NEW YORK DEP, 2003, ASTHM FACTS; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348, DOI 10.1164/ajrccm.162.4.9909118; Douwes J, 1998, INDOOR AIR, V8, P255, DOI 10.1111/j.1600-0668.1998.00006.x; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763, DOI 10.1128/AEM.61.5.1763-1769.1995; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Meyer IH, 2003, J ASTHMA, V40, P545, DOI 10.1081/JAS-120018789; Miller RL, 2004, CHEST, V126, P1071, DOI 10.1378/chest.126.4.1071; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Mueller-Anneling L, 2004, ENVIRON HEALTH PERSP, V112, P583, DOI 10.1289/ehp.6552; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Phipatanakul W, 2004, PEDIATRICS, V114, P13, DOI 10.1542/peds.114.1.13; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323, DOI 10.1289/ehp.02110s2323; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Thorne PS, 2000, TOXICOLOGY, V152, P13, DOI 10.1016/S0300-483X(00)00287-0; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527, DOI 10.1289/ehp.02110527; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Weiss ST, 2002, NEW ENGL J MED, V347, P930, DOI 10.1056/NEJMe020092; Wickens K, 2004, INDOOR AIR, V14, P217, DOI 10.1111/j.1600-0668.2004.00253.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	39	115	117	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1082	1089		10.1016/j.jaci.2005.12.1348	http://dx.doi.org/10.1016/j.jaci.2005.12.1348			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675336	Green Accepted			2022-12-18	WOS:000237436300016
J	Bochner, BS; Hudson, SA; Xiao, HQ; Liu, MC				Bochner, BS; Hudson, SA; Xiao, HQ; Liu, MC			Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemokines; pulmonary late-phase response; segmental allergen challenge; MDC; TARC; I-309; IP-10	ACTIVATION-REGULATED CHEMOKINE; T-CELLS; DIFFERENTIAL EXPRESSION; BRONCHOALVEOLAR LAVAGE; RECEPTORS CCR4; CUTTING EDGE; CHALLENGE; EOTAXIN; IMMUNOLOGY; THYMUS	Background: Segmental antigen bronchoprovocation has long been used as a model to study allergic pulmonary inflammatory responses. Among the characteristics of the resulting cellular infiltrate is the preferential recruitment of T(H)2 lymphocytes. The mechanisms responsible for their selective recruitment remain unknown, but T(H)2 cells preferentially express the chemokine receptors CCR4 and CCR8. Objectives: We tested the hypothesis that the chemokines thymus- and activation-regulated chemokine (TARC) (CCL17) and macrophage-derived chemokine (MDC) (CCL22), whose receptor is CCR4, and I-309 (CCL1), whose receptor is CCR8, would be released at sites of segmental allergen challenge. Methods: Segmental allergen challenge with saline or allergen Was performed in 10 adult allergic subjects with asthma, who were off medications. Bronchoalveolar lavage (BAL) was performed at both the saline- and allergen-challenged sites 20 hours after challenge. BAL fluids were analyzed for total cell counts and differentials, and supernatants were assayed by ELISA for levels of TARC, MDC, and I-309. As a control, the BAL fluids were also analyzed for levels of interferon-inducible protein 10 (IP-10) (CXCL10), an IFN-gamma-induced cbemokine active on CXCR3, a chemokine receptor that is preferentially expressed on T(H)1 lymphocytes. Results: Allergen challenge led to an approximately 6-fold increase in total leukocytes, including lymphocytes, compared with those seen at saline-challenged sites. At antigen-challenged sites, eosinophils predominated. Chemokine levels at control, saline-challenged sites were either below the detectable limit or low, with the predominant chemokine detected being IP-10. At antigen-challenged sites, levels of MDC, TARC, and IP-10 were all significantly increased compared with saline sites, each with a median of 486 to 1130 pg/mL detected. On the basis of a comparison with serum values, BAL chemokine levels at most antigen-challenged sites could not be accounted for by transudation from plasma. In contrast, levels of I-309 were extremely low or undetectable in all BAL and serum samples tested. Finally, BAL levels of MDC significantly correlated with those for TARC, but no significant correlations were found between levels of chemokine and any cell type. Conclusions: These data suggest that among the chemokines measured in this study, IP-10 is the predominant chemokine detected 20 hours after saline challenge, likely representing baseline production of a chemokine that favors T(H)1 Cell recruitment. At antigen-challenged sites, levels of both CCR4 and CXCR3 active chemokines, but not CCR8 active chemokines, are markedly increased and are produced at levels that are likely to have biologic significance. Given the preferential accumulation of T(H)2 cells at these antigen-challenged sites, the increased production of CCR4-active chemokines might contribute to this response.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Bochner, BS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NIAID NIH HHS [AI41425] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belperio JA, 2002, J IMMUNOL, V169, P1037, DOI 10.4049/jimmunol.169.2.1037; Berin MC, 2001, AM J RESP CELL MOL, V24, P382, DOI 10.1165/ajrcmb.24.4.4360; Bochner BS, 1999, J ALLERGY CLIN IMMUN, V103, P527, DOI 10.1016/S0091-6749(99)70481-1; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P817, DOI 10.1067/mai.2000.110813; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bonecchi R, 1998, BLOOD, V92, P2668, DOI 10.1182/blood.V92.8.2668.420k39_2668_2671; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Hasday JD, 2000, AM J RESP CRIT CARE, V161, P1229, DOI 10.1164/ajrccm.161.4.9904026; HUANG SK, 1995, J IMMUNOL, V155, P2688; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; KELLY CA, 1988, AM REV RESPIR DIS, V138, P81, DOI 10.1164/ajrccm/138.1.81; Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI200113543; Lilly CM, 2001, AM J RESP CRIT CARE, V163, P1669, DOI 10.1164/ajrccm.163.7.9812044; Liu MC, 2001, J ALLERGY CLIN IMMUN, V108, P29; Miotto D, 2001, J ALLERGY CLIN IMMUN, V107, P664, DOI 10.1067/mai.2001.113524; Miyazaki E, 2002, AM J RESP CRIT CARE, V165, P1125, DOI 10.1164/ajrccm.165.8.2106110; Murphy PM, 2000, CHEMOKINES IN ALLERGIC DISEASE, P53; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Romagnani S, 2002, MOL IMMUNOL, V38, P881, DOI 10.1016/S0161-5890(02)00013-5; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sauty A, 1999, J IMMUNOL, V162, P3549; Sekiya T, 2000, J IMMUNOL, V165, P2205, DOI 10.4049/jimmunol.165.4.2205; Yamamoto J, 2000, J LEUKOCYTE BIOL, V68, P568; Ying S, 1999, J IMMUNOL, V163, P6321; Zingoni A, 1998, J IMMUNOL, V161, P547	31	115	119	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					930	934		10.1016/j.jaci.2003.08.012	http://dx.doi.org/10.1016/j.jaci.2003.08.012			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610482				2022-12-18	WOS:000186553300015
J	Liu, CA; Wang, CL; Chuang, H; Ou, CY; Hsu, TY; Yang, KD				Liu, CA; Wang, CL; Chuang, H; Ou, CY; Hsu, TY; Yang, KD			Prenatal prediction of infant atopy by maternal but not paternal total IgE levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cord blood; infant eczema; maternal atopy; specific IgE; total IgE	CORD-BLOOD IGE; SERUM IGE; PARENTAL SMOKING; FAMILY HISTORY; FOLLOW-UP; RISK; DETERMINANTS; ALLERGY; DISEASE; ASTHMA	Background: The atopic history of parents has long been used to predict infant atopy. However, bias from questionnaires of allergic history are also frequently suspected, because a large number of vasomotor rhinitis, intrinsic asthma, and seborrheic dermatitis cases are probably misinterpreted to be atopic diseases. Objective: We attempted to identify a risk factor other than parental atopic history to predict elevated infant IgE levels and infant atopy. Methods: A total of 655 core families were prenatally recruited, and finally 545 families completed the study for the prospective analysis of infant atopy at 6 months of age. Atopic history and blood samples of parents were collected in the third trimester during pregnancy. Cord blood (CB) was collected immediately after birth. Infant blood samples and history of infant eczema were collected in the 6-month physical checkup clinic. Blood total IgE and specific IgE levels were determined by use of the Pharmacia CAP system. Results: In univariate analysis, maternal, but not paternal, atopic history correlated with elevated CB IgE levels and the occurrence of infant eczema. Elevated maternal, but not paternal, total IgE levels (>150 KU/L) significantly correlated with increases of CB IgE levels (median, 0.54 vs 0.17 KU/L, P < .001), infant IgE levels (log-transformed mean values, 1.32 +/- 0.51 vs 1.13 +/- 0.51 KU/L, P < .001), and infant eczema (P = .008). Multivariate logistical regression analysis, however, showed that only maternal total IgE levels correlated with CB and infant IgE levels and the development of infant eczema. Conclusions: The maternal, but not paternal, total IgE level correlates with elevated infant IgE levels and infant atopy. This provides a high specificity (83%) and a sensitivity of 34% for prediction of infant atopy. This suggests that maternal factors, placental factors, or both have an impact on perinatal allergic sensitization.	Chang Gung Childrens Hosp Kaohsiung, Kaohsiung 833, Taiwan; Chang Gung Mem Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital	Yang, KD (corresponding author), Chang Gung Childrens Hosp Kaohsiung, 123 Ta Pei Rd, Kaohsiung 833, Taiwan.							Atici A, 1995, PEDIATR ALLERGY IMMU, V6, P213, DOI 10.1111/j.1399-3038.1995.tb00288.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; BERGMANN RL, 1995, ALLERGY, V50, P65, DOI 10.1111/j.1398-9995.1995.tb02484.x; Bjerke T, 1994, Pediatr Allergy Immunol, V5, P88, DOI 10.1111/j.1399-3038.1994.tb00223.x; BRADLEY M, 2002, ACTA DERM-VENEREOL, V80, P106; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; ETZEL RA, 1995, ENVIRON HEALTH PERSP, V103, P55, DOI 10.2307/3432346; GERRARD JW, 1980, ANN ALLERGY, V44, P261; Golding J, 1997, EARLY HUM DEV, V49, pS121, DOI 10.1016/S0378-3782(97)00058-3; Hansen LG, 1996, PEDIATR ALLERGY IMMU, V7, P95, DOI 10.1111/j.1399-3038.1996.tb00405.x; HANSEN LG, 1992, ALLERGY, V47, P391, DOI 10.1111/j.1398-9995.1992.tb02078.x; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; Johnson CC, 1998, AM J EPIDEMIOL, V147, P1145; Kaan A, 2000, ANN ALLERG ASTHMA IM, V84, P37, DOI 10.1016/S1081-1206(10)62738-X; KJELLMAN NIM, 1981, LANCET, V1, P993; Kulig M, 1999, J PEDIATR-US, V134, P453, DOI 10.1016/S0022-3476(99)70203-9; LUBS ML, 1972, J PEDIATR-US, V80, P26, DOI 10.1016/S0022-3476(72)80448-7; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; ORYSZCZYN MP, 1991, J ALLERGY CLIN IMMUN, V87, P1169, DOI 10.1016/0091-6749(91)92163-U; OWNBY DR, 1990, J ALLERGY CLIN IMMUN, V86, P279, DOI 10.1016/S0091-6749(05)80088-0; OWNBY DR, 1991, J ALLERGY CLIN IMMUN, V88, P555, DOI 10.1016/0091-6749(91)90148-H; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; Sugiura H, 1997, ACTA DERM-VENEREOL, V77, P52; Warner JA, 1996, ALLERGY, V51, P447, DOI 10.1111/j.1398-9995.1996.tb04650.x; Yang K D, 2000, Chang Gung Med J, V23, P641; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	32	115	119	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					899	904		10.1016/j.jaci.2003.08.030	http://dx.doi.org/10.1016/j.jaci.2003.08.030			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610477				2022-12-18	WOS:000186553300011
J	Ma, SH; Sicherer, SH; Nowak-Wegrzyn, A				Ma, SH; Sicherer, SH; Nowak-Wegrzyn, A			A survey on the management of pollen-food allergy syndrome in allergy practices	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pollen-food allergy syndrome; oral allergy syndrome; allergy to fruits and vegetables; pollen food cross-reactivity	BIRCH POLLEN; CROSS-REACTIVITY; IGE; ROSACEAE; MELON; HYPERSENSITIVITY; SENSITIZATION; SYMPTOMS	Background: There is no consensus on the diagnosis and therapy of oral allergy syndrome (OAS; also known as pollen-food allergy syndrome), a disorder caused by IgE antibody-mediated reactions to homologous proteins in pollens and fruits and vegetables. Objective: We sought to determine how practicing allergists define and treat OAS. Methods: A questionnaire was mailed to 226 randomly selected US allergists from the American Academy of Allergy, Asthma and Immunology directory. Results: One hundred twenty-two (54%) returned surveys were analyzed. Median estimates of the prevalence of OAS among the patients with pollen allergy were 5% among children and 8% among adults. Twenty percent of allergists reported that some patients progressed to systemic symptoms. Fifty-three percent of allergists recommended complete avoidance of causal foods to all patients, whereas 9% did not advocate any restrictions. Thirty percent never prescribed epinephrine for OAS, 3% always did, and the remainder did so on the basis of symptoms. When presented with clinical cases, 20% diagnosed systemic reactions to peach as OAS, 13% believed peanut could cause OAS, and 25% did not prescribe epinephrine for peanut allergy manifested by oral symptoms. Conclusion: Allergists' estimates of the prevalence of OAS in patients with pollen allergy (5%-8%) are lower than the prevalence reported (approximately 50%) in the published studies of these patients, perhaps reflecting a low index of suspicion, underdiagnosis, or both. The wide range of responses regarding diagnosis and management indicates the need for a better definition for the disorder and standard therapeutic guidelines. Discrepancies might be related to the term OAS, and therefore use of the more specific term "pollen-food allergy syndrome" is suggested.	Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Nowak-Wegrzyn, A (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.			Nowak-Wegrzyn, Anna/0000-0002-0960-9854	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001709] Funding Source: NIH RePORTER; NIAID NIH HHS [K23 AI 01709-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; Asero R, 1999, ANN ALLERG ASTHMA IM, V83, P377, DOI 10.1016/S1081-1206(10)62834-7; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; Crespo JF, 2002, ALLERGY, V57, P946, DOI 10.1034/j.1398-9995.2002.23626.x; Cuesta-Herranz J, 1999, J ALLERGY CLIN IMMUN, V104, P688, DOI 10.1016/S0091-6749(99)70343-X; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V111, P628, DOI 10.1067/mai.2003.75; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; ERIKSSON NE, 1983, ALLERGY, V38, P353, DOI 10.1111/j.1398-9995.1983.tb04130.x; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Rodriguez J, 2000, J ALLERGY CLIN IMMUN, V106, P183, DOI 10.1067/mai.2000.106927; Rodriguez J, 2000, J ALLERGY CLIN IMMUN, V106, P968, DOI 10.1067/mai.2000.110467; Rodriguez-Perez R, 2003, J ALLERGY CLIN IMMUN, V111, P634, DOI 10.1067/mai.2003.74; Schocker F, 2000, EUR J NUTR, V39, P172, DOI 10.1007/s003940070021; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5	22	115	120	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					784	788		10.1016/S0091-6749(03)02008-6	http://dx.doi.org/10.1016/S0091-6749(03)02008-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564362				2022-12-18	WOS:000185831200020
J	Simonte, SJ; Ma, SH; Mofidi, S; Sicherer, SH				Simonte, SJ; Ma, SH; Mofidi, S; Sicherer, SH			Relevance of casual contact with peanut butter in children with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; inhalation; skin contact	TREE-NUT-ALLERGY; NATURAL-HISTORY; FOOD ALLERGIES; IGE; IMMUNOTHERAPY; REGISTRY; TESTS	Background: Casual skin contact or inhalation of peanut butter fumes is reported and feared to cause allergic reactions in highly sensitive children with peanut allergy but has not been systematically studied. Objective: We sought to determine the clinical relevance of exposure to peanut butter by means of inhalation and skin contact in children with peanut allergy. Methods: Children with significant peanut allergy (recent peanut-specific IgE antibody concentration >50 kIU/L or evidence of peanut-specific IgE antibody and one of the following: clinical anaphylaxis, a reported inhalation-contact reaction, or positive double-blind, placebo-controlled oral challenge result to peanut) underwent double-blind, placebo-controlled, randomized exposures to peanut butter by means of contact with intact skin (0.2 mL pressed flat for 1 minute) and inhalation (surface area of 6.3 square inches 12 inches from the face for 10 minutes). Placebo challenges were performed by using soy butter mixed with histamine (contact), and scent was masked with soy butter, tuna, and mint (inhalation). Results: Thirty children underwent the challenges (median age, 7.7 years; median peanut IgE level, >100 kIU/L; 13 with prior history of contact and 11 with inhalation reactions). None experienced a systemic or respiratory reaction. Erythema (3 subjects), pruritus without erythema (5 subjects), and wheat-and-flare reactions (2 subjects) developed only at the site of skin contact with peanut butter. From this number of participants, it can be stated with 96% confidence that at least 90% of highly sensitive children with peanut allergy would not experience a systemic-respiratory reaction from casual exposure to peanut butter. Conclusions: Casual exposure to peanut butter is unlikely to elicit significant allergic reactions. The results cannot be generalized to larger exposures or to contact with peanut in other forms (flour and roasted peanuts).	Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY USA	Icahn School of Medicine at Mount Sinai	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001709] Funding Source: NIH RePORTER; NIAID NIH HHS [K23 AI01709] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baker SS, 2000, PEDIATRICS, V106, P346; CARLSTON JA, 1988, ANN ALLERGY, V61, P80; CRESPO JF, 1995, ALLERGY, V50, P257, DOI 10.1111/j.1398-9995.1995.tb01143.x; Devenney I, 2000, ANN ALLERG ASTHMA IM, V85, P455, DOI 10.1016/S1081-1206(10)62571-9; Hallett R, 2002, NEW ENGL J MED, V346, P1833, DOI 10.1056/NEJM200206063462320; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Jones R. T., 1996, Journal of Allergy and Clinical Immunology, V97, P423, DOI 10.1016/S0091-6749(96)81179-1; Kalogeromitros D, 1996, ANN ALLERG ASTHMA IM, V77, P480, DOI 10.1016/S1081-1206(10)63354-6; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Polasani R, 1997, ANN ALLERG ASTHMA IM, V78, P35, DOI 10.1016/S1081-1206(10)63368-6; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Roberts G, 2002, ALLERGY, V57, P713, DOI 10.1034/j.1398-9995.2002.03366.x; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Tan BM, 2001, ANN ALLERG ASTHMA IM, V86, P583, DOI 10.1016/S1081-1206(10)62908-0; Valyasevi MA, 1999, ANN ALLERG ASTHMA IM, V83, P132, DOI 10.1016/S1081-1206(10)62624-5; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235	21	115	118	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					180	182		10.1067/mai.2003.1486	http://dx.doi.org/10.1067/mai.2003.1486			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847496				2022-12-18	WOS:000184010600027
J	Fellrath, JM; Kettner, A; Dufour, N; Frigerio, C; Schneeberger, D; Leimgruber, A; Corradin, G; Spertini, F				Fellrath, JM; Kettner, A; Dufour, N; Frigerio, C; Schneeberger, D; Leimgruber, A; Corradin, G; Spertini, F			Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: Results of a phase I trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)1/T(H)2; allergy; immunotherapy; bee venom; phospholipase A2; long synthetic peptides; tolerance; anergy; IL-10	BEE-VENOM IMMUNOTHERAPY; LATE ASTHMATIC REACTIONS; PHOSPHOLIPASE A(2); HONEYBEE VENOM; SUBCUTANEOUS INJECTION; ANTIBODY-RESPONSES; EPITOPE PEPTIDES; TH1 CELLS; ANTIGEN; MICE	Background: There is a need to improve the safety and efficacy of allergen-specific immunotherapy. Long synthetic peptide-based immunotherapy was proven safe, immunogenic, and protective in preclinical trials. Objective: To evaluate the safety and immunogenicity of an allergen-derived long synthetic overlapping peptide (LSP) immunotherapy, we designed a double-blind, placebo-controlled phase I clinical trial in patients hypersensitive to bee venom. Methods: Patients from the active group were injected at day 0 with a mixture of 3 LSPs mapping the entire PLA2 molecule, a major bee venom allergen, in a dose-escalating protocol to a maintenance dose of 100 mug per peptide repeated at days 4, 7, 14, 42, and 70. The control group was injected with human albumin. Results: Whereas specific T-cell proliferation in the peptide group increased up to day 14, a sharp decline was observed thereafter, ending in specific T-cell hyporesponsiveness at day 80. Serum-specific IgG4 response was enhanced, in contrast to anti-PLA2 IgE. Specific T-cell cytokine modulation was marked by increased IL-10 and IFN-gamma secretion. LSP injections were well tolerated in all patients except for mild, late allergic reactions in 2 patients at day 70. Conclusions: The results of this short-term study demonstrate that LSP-based allergen immunotherapy was safe and able to induce T(H)1-type immune deviation, allergen-specific IL-10 production, and T-cell hyporesponsiveness. LSPs, which offer the advantage of covering all possible T-cell epitopes for any HLA genotype, can be considered candidates for a novel and safe approach of specific immunotherapy.	CHU Vaudois, Div Immunol & Allergy, CH-1011 Lausanne, Switzerland; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne	Spertini, F (corresponding author), CHU Vaudois, Div Immunol & Allergy, Rue Bugnon, CH-1011 Lausanne, Switzerland.							Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1999, FASEB J, V13, P603, DOI 10.1096/fasebj.13.6.603; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Astori M, 2000, J IMMUNOL, V165, P3497, DOI 10.4049/jimmunol.165.6.3497; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hoyne GF, 1996, INT IMMUNOL, V8, P335, DOI 10.1093/intimm/8.3.335; JUTEL M, 1995, J IMMUNOL, V154, P4187; JUTEL M, 1995, CLIN EXP ALLERGY, V25, P1108, DOI 10.1111/j.1365-2222.1995.tb03258.x; Kammerer R, 1997, J ALLERGY CLIN IMMUN, V100, P96, DOI 10.1016/S0091-6749(97)70200-8; Kammerer R, 1997, CLIN EXP ALLERGY, V27, P1016, DOI 10.1111/j.1365-2222.1997.tb01253.x; Kettner A, 1999, CLIN EXP ALLERGY, V29, P394, DOI 10.1046/j.1365-2222.1999.00492.x; King TP, 1998, J ALLERGY CLIN IMMUN, V101, P397, DOI 10.1016/S0091-6749(98)70254-4; LESOURD B, 1989, J ALLERGY CLIN IMMUN, V83, P563, DOI 10.1016/0091-6749(89)90067-5; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; Malvey EN, 1998, J IMMUNOL, V161, P2168; MULLER HL, 1966, J ASTHMA RES, V3, P331; MULLER U, 1993, ALLERGY, V48, P37; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; MULLER UR, 1995, J ALLERGY CLIN IMMUN, V96, P395, DOI 10.1016/S0091-6749(95)70059-5; Muller UR., 1990, INSECT STING ALLERGY; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Ollert MW, 2000, J ALLERGY CLIN IMMUN, V105, pS59, DOI 10.1016/S0091-6749(00)90609-2; Pape KA, 1998, J IMMUNOL, V160, P4719; Roggero MA, 1997, FEBS LETT, V408, P285, DOI 10.1016/S0014-5793(97)00441-9; Rueff F, 2001, J ALLERGY CLIN IMMUN, V107, P928; SCHNEIDER T, 1994, J ALLERGY CLIN IMMUN, V94, P61, DOI 10.1016/0091-6749(94)90072-8; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; von Garnier C, 2000, EUR J IMMUNOL, V30, P1638, DOI 10.1002/1521-4141(200006)30:6<1638::AID-IMMU1638>3.0.CO;2-R	38	115	131	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					854	861		10.1067/mai.2003.1337	http://dx.doi.org/10.1067/mai.2003.1337			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704369				2022-12-18	WOS:000182258500029
J	Bender, BG; Leung, SB; Leung, DYM				Bender, BG; Leung, SB; Leung, DYM			Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: An objective life quality measure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; sleep; actigraph	WAKE IDENTIFICATION; WRIST ACTIVITY; CHILDREN	Background: Patients with atopic dermatitis (AD) frequently report compromised quality of life because of disturbed sleep and daytime fatigue secondary to their skin disease, but few studies provide objective measurement of sleep change in this population. Objective: The purpose of this investigation was to contrast subjective and objective measures of sleep quality in patients with AD. Methods: Fourteen adult patients with AD and 14 adult control subjects with no skin disease wore actigraphs; for 1 week and completed questionnaires about sleep, itch, and quality of life. Results: As measured by self-report and actigraphy, the AD group slept more poorly and reported more daytime fatigue than the control group. Actigraphy alone was correlated with itch and quality of life and was able to discriminate movement during sleep, number of awakenings, minutes asleep, and minutes awake. Conclusions: Results from this study demonstrate that sleep is significantly compromised in patients with AD. Patients' perception of their sleep provides less detail and accuracy than actigraphy. The actigraph is an objective, unobtrusive measure of sleep at home in patients with skin disease and can provide an important outcome measure in clinical trials.	Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, 1400 Jackson St,Room K926I, Denver, CO 80206 USA.							Bender BG, 2002, IMMUNOL ALLERGY CLIN, V22, P43, DOI 10.1016/S0889-8561(03)00068-7; COLE RJ, 1992, SLEEP, V15, P461, DOI 10.1093/sleep/15.5.461; Corkum P, 2001, SLEEP, V24, P303, DOI 10.1093/sleep/24.3.303; DAHL RE, 1995, ARCH PEDIAT ADOL MED, V149, P856, DOI 10.1001/archpedi.1995.02170210030005; Ebata T, 2001, BRIT J DERMATOL, V144, P305, DOI 10.1046/j.1365-2133.2001.04019.x; Ebata Toshiya, 1996, Journal of Dermatology (Tokyo), V23, P153; Eissa MAH, 2001, BLOOD PRESS MONIT, V6, P21, DOI 10.1097/00126097-200102000-00004; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; FITZPATRICK MF, 1991, THORAX, V46, P569, DOI 10.1136/thx.46.8.569; Jean-Louis G, 2001, PHYSIOL BEHAV, V72, P21, DOI 10.1016/S0031-9384(00)00355-3; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Reuveni H, 1999, ARCH PEDIAT ADOL MED, V153, P249; SADEH A, 1994, SLEEP, V17, P201, DOI 10.1093/sleep/17.3.201; Stores G, 1998, PEDIATR DERMATOL, V15, P264, DOI 10.1046/j.1525-1470.1998.1998015264.x; THORPY M, 1995, SLEEP, V18, P285	15	115	117	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					598	602		10.1067/mai.2003.174	http://dx.doi.org/10.1067/mai.2003.174			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642843				2022-12-18	WOS:000181639500024
J	Simons, FER; Peterson, S; Black, CD				Simons, FER; Peterson, S; Black, CD			Epinephrine dispensing patterns for an out-of-hospital population: A novel approach to studying the epidemiology of anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epinephrine; adrenaline; anaphylaxis; severe acute allergic reactions; general population; EpiPen; EpiPen Jr; Ana-Kit; food allergy; Hymenoptera venom allergy; latex allergy; drug allergy	PEANUT ALLERGY; EMERGENCY; CHILDREN; PRESCRIPTION; ADMISSIONS	Background: The underlying rate of occurrence of anaphylaxis from all potential triggers in the general population is unknown. Objective: We sought to obtain a perspective on the epidemiology of anaphylaxis in a defined general population by studying epinephrine dispensing patterns in an out-of-hospital setting. Methods: Using an administrative claims pharmaceutical database, we analyzed dispensing data for all epinephrine formulations prescribed for out-of-hospital treatment over 5 consecutive fiscal years in a population of 1.15 million persons in the province of Manitoba, Canada. We identified the number and percentage of individuals in the general population for whom epinephrine was dispensed on one or more occasions, their age and sex, and the type of formulation dispensed. In addition to performing these analyses for the entire population of children, adults, and elderly individuals, we also performed analyses by 5-year age groupings; furthermore, for individuals younger than 5 years of age, we performed a detailed analysis by 6-month age groupings. Results: During the 5-year period, 0.95% of this defined general population had injectable epinephrine dispensed for out-of-hospital treatment. There were substantial variations in epinephrine dispensing rates across subsets of the population, ranging from 1.44% for individuals younger than 17 years of age, to 0.9% for individuals 17 to 64 years of age (inclusive), to 0.32% for those age 65 years or older. In infancy, childhood, and early adolescence boys were more likely to have epinephrine dispensed than girls. Beginning at age 15 years and continuing into adulthood, girls and women were more likely to have epinephrine dispensed than boys and men. In the elderly there were no differences in dispensing patterns between the sexes. The highest epinephrine dispensing rate (5.3%) was found for boys age 12 to 17 months. Conclusions: Epinephrine dispensing data provide a novel and practical approach for studying and monitoring the epidemiology of anaphylaxis in a community. Using this approach, we provide evidence that anaphylaxis from all triggers peaks in early childhood and then gradually declines into old age.	Univ Manitoba, Manitoba Ctr Hlth Policy, Winnipeg, MB, Canada; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; University of Manitoba; University of Manitoba								Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Coghlan-Johnston M, 2001, J ALLERGY CLIN IMMUN, V107, pS57; Dibs S D, 1997, Pediatrics, V99, pE7, DOI 10.1542/peds.99.1.e7; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; Kozyrskyj AL, 1998, ANN PHARMACOTHER, V32, P1152, DOI 10.1345/aph.18117; Laporte JR, 1998, EPIDEMIOLOGY, V9, P141, DOI 10.1097/00001648-199803000-00007; Metge C, 1999, MED CARE, V37, pJS42, DOI 10.1097/00005650-199906001-00008; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; NICKLAS RA, 1998, J ALLERGY CLIN IMMUN, V101, pS465; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; Pastorello EA, 2001, J CHROMATOGR B, V756, P11, DOI 10.1016/S0378-4347(01)00067-6; Pumphrey RSH, 2000, J CLIN PATHOL, V53, P273, DOI 10.1136/jcp.53.4.273; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1111/j.1365-2222.1996.tb00537.x; Sheikh A, 2000, BRIT MED J, V320, P1441, DOI 10.1136/bmj.320.7247.1441; Sheikh A, 2001, CLIN EXP ALLERGY, V31, P1571, DOI 10.1046/j.1365-2222.2001.01203.x; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Simons FER, 2002, J ALLERGY CLIN IMMUN, V109, pS181; Simons FER, 2001, ANN ALLERG ASTHMA IM, V86, P622, DOI 10.1016/S1081-1206(10)62289-2; SORENSEN HT, 1989, ALLERGY, V44, P288, DOI 10.1111/j.1398-9995.1989.tb01071.x; Stewart AG, 1996, QJM-MON J ASSOC PHYS, V89, P859, DOI 10.1093/qjmed/89.11.859; Straand J, 1998, ACTA PAEDIATR, V87, P218, DOI 10.1080/08035259850157705; Unsworth DJ, 2001, ARCH DIS CHILD, V84, P410, DOI 10.1136/adc.84.5.410; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1	28	115	119	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					647	651		10.1067/mai.2002.127860	http://dx.doi.org/10.1067/mai.2002.127860			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373275				2022-12-18	WOS:000178501900017
J	Bjorksten, B				Bjorksten, B			The intrauterine and postnatal environments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; immunology; maturation; gestation; infants	BLOOD MONONUCLEAR-CELLS; INTERFERON-GAMMA PRODUCTION; SKIN-TEST REACTIVITY; T-CELLS; ATOPIC DISEASE; IGG SUBCLASS; IFN-GAMMA; COWS MILK; NEONATAL LYMPHOCYTES; DECREASED PRODUCTION	Pregnancy is associated with a strong skewing toward T(H)2 cytokine pattern, which enables the survival of the fetus, including fetal allergen-specific immune responses, The postnatal maturation of the immune system which is characterized by the development of a balanced T(H)1/T(H)2 immunity is genetically determined and modified by the environment. The process seems to proceed at a slower rate in atopic than in nonatopic infants. There is a close immunologic interaction between the mother and her offspring through the breast milk. Individual variations in the composition of human milk may el;plain the controversy with regard to the possible allergy-preventive effects of breast-feeding. Recurrent respiratory infections have been suggested to enhance immune deviation. The microbial flora are a more likely source, however, because they are a major driving force in the maturation of the immune system. Changes in its composition, as a consequence of an altered lifestyle and diet, may play a role in the higher prevalence of allergy. So far, primary prevention of allergy has failed. Future studies should therefore focus on factors enhancing immune deviation (ie, "success" factors) rather than on "risk" factors. The intestinal microflora is one of these factors that deserves closer analysis.	Linkoping Univ, Dept Hlth & Environm, Div Paediat, Linkoping, Sweden	Linkoping University	Bjorksten, B (corresponding author), Linkoping Univ Hosp, Dept Paediat, Floor 14, Linkoping, Sweden.							AALBERSE RC, 1992, CLIN EXP ALLERGY, V22, P1003, DOI 10.1111/j.1365-2222.1992.tb03028.x; ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ALLARDYCE RA, 1984, CLIN ALLERGY, V14, P259, DOI 10.1111/j.1365-2222.1984.tb02205.x; Aniansson Zdolsek H, 1999, Int Arch Allergy Immunol, V119, P6, DOI 10.1159/000024169; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bjorksten B, 1997, PEDIAT ALLERG IMM-UK, V8, P32; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BORRES MP, 1995, CLIN EXP ALLERGY, V25, P543, DOI 10.1111/j.1365-2222.1995.tb01092.x; BOTTCHER M, 1999, IN PRESS CLIN EXP AL; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; Braback Lennart, 1995, Archives of Disease in Childhood, V72, P487; BRYSON YJ, 1980, CELL IMMUNOL, V55, P191, DOI 10.1016/0008-8749(80)90150-1; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CASIMIR GJA, 1989, ANN ALLERGY, V63, P517; Chalmers IMH, 1998, BLOOD, V92, P11, DOI 10.1182/blood.V92.1.11.413a39_11_18; Chheda S, 1996, PEDIATR RES, V40, P475, DOI 10.1203/00006450-199609000-00018; CLEMENT LT, 1990, J IMMUNOL, V145, P102; De Simone C., 1991, European Journal of Clinical Nutrition, V45, P32; Duchen K, 1998, PEDIATR RES, V44, P478, DOI 10.1203/00006450-199810000-00003; DUCHEN K, 1999, THESIS LINKOPIN U LI; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; ENGLISH BK, 1992, PEDIATR RES, V31, P211, DOI 10.1203/00006450-199203000-00004; FALTHMAGNUSSON K, 1988, J ALLERGY CLIN IMMUN, V81, P743, DOI 10.1016/0091-6749(88)91048-2; FRENKEL L, 1987, J PEDIATR-US, V111, P97, DOI 10.1016/S0022-3476(87)80353-0; Friedman MG, 1996, CLIN EXP IMMUNOL, V103, P206, DOI 10.1046/j.1365-2249.1996.d01-620.x; FULEIHAN R, 1994, EUR J IMMUNOL, V24, P1925, DOI 10.1002/eji.1830240832; GLOVSKY MM, 1991, ANN ALLERGY, V67, P21; GOLLOB JA, 1995, J EXP MED, V182, P721, DOI 10.1084/jem.182.3.721; Gollob JA, 1996, J IMMUNOL, V157, P1886; HACSEK G, 1995, J PEDIAT GASTROENTER, V22, P307; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; HATTEVIG G, 1990, J ALLERGY CLIN IMMUN, V85, P108, DOI 10.1016/0091-6749(90)90231-R; Hayward A R, 1983, Birth Defects Orig Artic Ser, V19, P289; HAYWARD AR, 1989, EUR J IMMUNOL, V19, P771, DOI 10.1002/eji.1830190430; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P80, DOI 10.1111/j.1399-3038.1995.tb00263.x; HUISINTVELD JHJ, 1994, TRENDS BIOTECHNOL, V12, P6, DOI 10.1016/0167-7799(94)90004-3; IIKURA Y, 1989, INT ARCH ALLER A IMM, V88, P250, DOI 10.1159/000234800; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; JENMALM M, 1999, IN PRESS CLIN EXP AL; Jenmalm MC, 1998, J ALLERGY CLIN IMMUN, V102, P671, DOI 10.1016/S0091-6749(98)70286-6; Jenmalm MC, 1999, INT ARCH ALLERGY IMM, V118, P395, DOI 10.1159/000024146; Jenmalm MC, 1999, PEDIATR ALLERGY IMMU, V10, P112, DOI 10.1034/j.1399-3038.1999.00015.x; JUVONEN P, 1999, IN PRESS PEDIAT ALLE, P10; KEMENY DM, 1989, CLIN EXP ALLERGY, V19, P545, DOI 10.1111/j.1365-2222.1989.tb02431.x; KEMENY DM, 1991, J ALLERGY CLIN IMMUN, V87, P920, DOI 10.1016/0091-6749(91)90413-I; Lewis SA, 1998, CLIN EXP ALLERGY, V28, P1493; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; LILJA G, 1991, PEDIATR ALLERGY IMMU, V2, P6; LING ZD, 1993, J CLIN IMMUNOL, V13, P302, DOI 10.1007/BF00920238; LUDVIKSSON BR, 1992, J PEDIATR-US, V121, P23, DOI 10.1016/S0022-3476(05)82535-1; MACHTINGER S, 1986, J ALLERGY CLIN IMMUN, V77, P341, DOI 10.1016/S0091-6749(86)80115-4; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Matsuzaki T, 1998, J DAIRY SCI, V81, P48, DOI 10.3168/jds.S0022-0302(98)75549-3; MELVIN AJ, 1995, EUR J IMMUNOL, V25, P426, DOI 10.1002/eji.1830250218; Metchnikoff E., 1907, PROLONGATION LIFE; Midtvedt T., 1985, MICROECOL THER, V15, P295; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1111/j.1365-2222.1996.tb00608.x; MIYAGAWA Y, 1980, PEDIATRICS, V65, P497; MIYAWAKI T, 1985, CLIN EXP IMMUNOL, V59, P505; Nilssen L, 1997, PEDIATR ALLERGY IMMU, V8, P134, DOI 10.1111/j.1399-3038.1997.tb00166.x; Nilsson L, 1998, ARCH PEDIAT ADOL MED, V152, P734; Okamoto Y, 1991, Adv Exp Med Biol, V310, P215; PAYETTE K, 1977, ANN ALLERGY, V39, P328; PIRENNE H, 1992, PEDIATR RES, V32, P81, DOI 10.1203/00006450-199207000-00016; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Seeger M, 1998, EUR J IMMUNOL, V28, P2124, DOI 10.1002/(SICI)1521-4141(199807)28:07<2124::AID-IMMU2124>3.0.CO;2-A; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; SEPP E, 1999, IN PRESS MICROBIAL E; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shida K, 1998, INT ARCH ALLERGY IMM, V115, P278, DOI 10.1159/000069458; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIDERAS P, 1992, J IMMUNOL, V149, P244; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; SPLAWSKI JB, 1991, J CLIN INVEST, V87, P545, DOI 10.1172/JCI115029; Splawski JB, 1998, EUR J IMMUNOL, V28, P4248, DOI 10.1002/(SICI)1521-4141(199812)28:12<4248::AID-IMMU4248>3.0.CO;2-D; SPLAWSKI JB, 1994, J IMMUNOL, V152, P5259; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P151; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; STRANNEGARD O, 1979, CLIN ALLERGY, V9, P637, DOI 10.1111/j.1365-2222.1979.tb00490.x; Sudo N, 1997, J IMMUNOL, V159, P1739; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TANG MLK, 1995, PEDIATR ALLERGY IMMU, V6, P11, DOI 10.1111/j.1399-3038.1995.tb00251.x; TAYLOR B, 1973, LANCET, V2, P111; Trivedi HN, 1997, HUM IMMUNOL, V57, P69, DOI 10.1016/S0198-8859(97)00202-4; VANASPEREN PP, 1985, CLIN EXP IMMUNOL, V62, P753; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Warner JA, 1996, ALLERGY, V51, P447, DOI 10.1111/j.1398-9995.1996.tb04650.x; WATSON W, 1991, CLIN EXP IMMUNOL, V83, P169; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WINGREN AG, 1993, J IMMUNOL, V151, P1328; Wold AE, 1998, ACTA PAEDIATR, V87, P19, DOI 10.1080/08035259850157804; YACHIE A, 1995, CLIN EXP IMMUNOL, V102, P204; Yu G, 1998, ACTA PAEDIATR, V87, P729, DOI 10.1080/080352598750013798	103	115	116	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1119	1127						9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588990				2022-12-18	WOS:000084289200001
J	Rosa-Rosa, L; Zimmermann, N; Bernstein, JA; Rothenberg, ME; Hershey, GKK				Rosa-Rosa, L; Zimmermann, N; Bernstein, JA; Rothenberg, ME; Hershey, GKK			The R576 IL-4 receptor alpha allele correlates with asthma severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopic hypersensitivity; genetic predisposition to disease; IL-4; IL-13; bronchial hyperreactivity	STEROID-RESISTANT ASTHMA; HUMAN B-CELLS; INTERLEUKIN-4 RECEPTOR; IGE SYNTHESIS; IL4-RECEPTOR GENE; EXPRESSION; ATOPY; ASSOCIATION; RESPONSES; POLYMORPHISMS	Background: Atopic disorders, including asthma, are very prevalent affecting up to 40% of populations, and their incidence is on the rise Although environmental factors are important in the development of atopy, there is a strong genetic predisposition. Several genes and chromosomal regions have been linked to atopy and asthma, supporting the polygenic nature of these disorders. IL-4 and IL-13 are T(H)2 cytokines with numerous activities that contribute to allergic inflammation and asthma, Both IL-4 and IL-13 use the IL-4 receptor a chain (IL-4R alpha) as a component of their respective receptor systems. Allelic variants of IL-4R alpha have been reported, and the R576IL-4R alpha allele was recently shown to be a risk factor for atopy: Objective: We sought to determine whether the R576 allele was associated with the prevalence or clinical severity of asthma. Methods: We developed a rapid, reliable, PCR-based assay to screen individuals for the R576IL-4R alpha allele and used this assay to genotype prospectively recruited individuals with asthma (n = 149) and control subjects (n = 57), Results: There was a strong association of R576IL-4R alpha with the prevalence and clinical severity of asthma. in a prospective cohort, homozygosity for R576 was significantly increased in individuals nith asthma (0 = 149, P = .03; relative risk 8.2) compared with controls (n = 57). Furthermore, 1 or 2 copies R576IL-4R alpha correlated with asthma severity establishing a genotype-phenotype relationship and suggesting a gene dosage effect Conclusions: Thus R576IL-4R alpha acts as an allergic asthma susceptibility and disease-modifying gene and may serve as a clinically useful marker of asthma severity.	Childrens Hosp, Med Ctr, Div Pulm Med Allergy & Clin Immunol, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Med Ctr, Dept Internal Med, Div Immunol, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Med Allergy & Clin Immunol, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Bernstein, Jonathan/0000-0002-3476-1196; Khurana Hershey, Gurjit/0000-0001-6663-977X	NICHD NIH HHS [P30HD2887] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ADAMS PF, 1994, SERIES NIH, V10; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; Bonnefoy JY, 1996, ANN NY ACAD SCI, V796, P59, DOI 10.1111/j.1749-6632.1996.tb32567.x; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BRODER I, 1962, J ALLERGY, V33, P524, DOI 10.1016/0021-8707(62)90020-5; BRODER I, 1962, J ALLERGY, V33, P513, DOI 10.1016/0021-8707(62)90019-9; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; Glantz SA., 1997, PRIMER BIOSTATISTICS; Grimbacher B, 1998, NEW ENGL J MED, V338, P1073; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Harris JR, 1997, AM J RESP CRIT CARE, V156, P43, DOI 10.1164/ajrccm.156.1.9609094; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Laitinen T, 1998, AM J RESP CRIT CARE, V157, P1073, DOI 10.1164/ajrccm.157.4.9704041; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; Leung DYM, 1998, ANN NY ACAD SCI, V840, P735, DOI 10.1111/j.1749-6632.1998.tb09612.x; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARTINEZ FD, 1995, AM J RESP CRIT CARE, V151, P1644, DOI 10.1164/ajrccm.151.5.7735627; Matthews DJ, 1997, EUR J IMMUNOL, V27, P116, DOI 10.1002/eji.1830270118; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; Neddenriep D, 1989, Curr Probl Pediatr, V19, P325; *NIH NAT HEART LUN, 1997, PUBL NIH NAT HEART L; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; Noguchi E, 1999, AM J RESP CRIT CARE, V160, P342, DOI 10.1164/ajrccm.160.1.9807130; Pan PY, 1998, FASEB J, V12, pA1084; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; ROEHM NW, 1984, J EXP MED, V160, P679, DOI 10.1084/jem.160.3.679; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; Wang HY, 1999, J IMMUNOL, V162, P4385; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x	52	115	131	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1008	1014		10.1016/S0091-6749(99)70082-5	http://dx.doi.org/10.1016/S0091-6749(99)70082-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550746				2022-12-18	WOS:000083778400024
J	Ownby, DR; Ownby, HE; McCullough, J; Shafer, AW				Ownby, DR; Ownby, HE; McCullough, J; Shafer, AW			The prevalence of anti-latex IgE antibodies in 1000 volunteer blood donors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; anti-latex IgE antibodies; prevalance; volunteer blood donors	OCCUPATIONAL ASTHMA; ALLERGY; CHILDREN; HYPERSENSITIVITY; SENSITIVITY	Background: Latex allergy has been recognized as a medical problem with increasing frequency since the mid 1980s. Although certain groups of individuals, such as health care workers, have been recognized as having increased risk for latex allergy, little is known about the prevalence of latex allergy in the general population. Methods: To estimate the prevalence of latex allergy among healthy adults, we measured anti-latex IgE antibodies in residual serum samples from 1000 volunteer Red Cross blood donors. The 1000 samples were from a sample of blood units collected from workplace mobile sites throughout Southeastern Michigan. Samples collected from mobile sites operating at health care institutions were excluded to minimize sampling of health care workers. Anti-latex IgE antibodies were measured by using the AlaSTAT assay (Diagnostic Products Corp., Los Angeles, Calif.) according to the manufacturer's directions. Samples with anti-latex IgE concentrations of 0.35 IU/ml or greater were classified as positive and samples with IgE concentrations of 1.50 IU/ml or greater were classified as strongly positive. All positive samples wee assayed a second time to confirm the result. All positive samples were also measured with the CAP assay (Pharmacia Diagnostics, Dublin, Ohio). Results: The samples tested were from donors with a mean age of 37.8 years, and 47% were women. Sixty-four (6.4%, 95% confidence interval = 4.9-8.1%) of the samples were confirmed as repeatedly positive for anti-latex IgE, and 23 of the 64 positive samples were strongly positive (2.3% of the 1000). Sixty-one percent of the samples positive as determined by the AlaSTAT assay were also positive as determined by the CAP assay. Samples from male donors were more likely to be positive than those from female donors (8.7% vs 4.1%, p = 0.003). Prevalence of positive samples was not related to age or race. Conclusions: We conclude that the prevalence of detectable anti-latex IgE antibodies, in a large and relatively unselected adult population, is higher than previous estimates have suggested. Although the clinical significance of these observations needs further evaluation, the data suggest that latex allergy is not confined to individuals in previously recognized high-risk groups.	AMER RED CROSS BLOOD SERV SE MICHIGAN REG,DETROIT,MI	American Red Cross	Ownby, DR (corresponding author), HENRY FORD HOSP,DIV ALLERGY,ALLERGY RES LAB,2799 W GRAND BLVD,DETROIT,MI 48202, USA.							BERKY ZT, 1992, JAMA-J AM MED ASSOC, V268, P2695; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GRZYBOWSKI MK, 1994, THESIS U MICHIGAN AN; KLEINETEBBE J, 1992, CLIN EXP ALLERGY, V22, P475, DOI 10.1111/j.1365-2222.1992.tb00150.x; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; MEEROPOL E, 1993, J PEDIATR ORTHOPED, V13, P1, DOI 10.1097/01241398-199301000-00001; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; OWNBY DR, 1993, J CLIN IMMUNOASSAY, V16, P109; REINHEIMER G, 1995, ANN ALLERG ASTHMA IM, V74, P184; SHIELD SW, 1992, ALLERGY PROC, V13, P129, DOI 10.2500/108854192778878827; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; STUCKEY M, 1982, LANCET, V2, P41; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35	19	115	121	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1188	1192		10.1016/S0091-6749(96)70183-5	http://dx.doi.org/10.1016/S0091-6749(96)70183-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648011				2022-12-18	WOS:A1996VD60700003
J	LAVAUD, F; PREVOST, A; COSSART, C; GUERIN, L; BERNARD, J; KOCHMAN, S				LAVAUD, F; PREVOST, A; COSSART, C; GUERIN, L; BERNARD, J; KOCHMAN, S			ALLERGY TO LATEX, AVOCADO PEAR, AND BANANA - EVIDENCE FOR A 30-KD ANTIGEN IN IMMUNOBLOTTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LATEX; IMMEDIATE HYPERSENSITIVITY; FRUIT; IMMUNOBLOT; CROSS-REACTIVITY; ALLERGENS	CONTACT URTICARIA; CROSS-REACTIVITY; IGE ANTIBODIES; RUBBER; ANAPHYLAXIS; PROTEINS; HYPERSENSITIVITY; IDENTIFICATION; INHIBITION; CHILDREN	Allergens of natural latex, latex gloves, avocado pear, and banana extracts were investigated by an immunoblotting technique in saa of patients experiencing associated latex and fruit allergies. Extracts were separated by sodium dodecyl-sulfate-polyacrylamide gel electrophoresis and electroblotted onto nitrocellulose. After incubation with patients' sera, IgE antibodies were revealed by a goat anti-human IgE alkaline-phosphatase conjugate. Seventeen serum samples fr om patients with well-documented latex allergy were studied. Among these patients, 10 demonstrated an allergy to avocado pear sometimes associated with banana. In sera from patients with latex and fruit allergy, prominent IgE binding was revealed at about 30 kd with latex and fruit extracts. Serum controls remained negative. Cross-inhibition of immunoblotting confirmed that this main allergen is linked to a common epitope present in latex and fruits. This must be related to clinical findings and previous observations of cross-reactivity.	UNIV & REG MED CTR,DEPT RESP DIS & ALLERGOL,REIMS,FRANCE; ALLERBIO LAB,VARENNES,FRANCE									ALENIUS H, 1991, INT ARCH ALLER A IMM, V96, P376, DOI 10.1159/000235525; ALENIUS H, 1993, J ALLERGY CLIN IMMUN, V91, P240; ARCHER BL, 1960, BIOCHEM J, V75, P236, DOI 10.1042/bj0750236; AXELSSON IGK, 1988, ACTA PAEDIATR SCAND, V77, P314, DOI 10.1111/j.1651-2227.1988.tb10652.x; BORRIES M, 1992, ALLERGY, V47, P57; CARILLO T, 1986, CONTACT DERMATITIS, V15, P69; CEUPPENS JL, 1992, LANCET, V339, P492; DAUZAC J, 1989, PHYSL RUBER TREE LAT; DECORRES LF, 1993, ANN ALLERGY, V70, P35; FABRO L, 1989, HAUTARZT, V40, P208; Gaignon I, 1991, Acta Anaesthesiol Belg, V42, P219; GLAZER AN, 1969, J BIOL CHEM, V244, P3583; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; JOHANSSON E, 1991, CLIN EXP ALLERGY, V21, P511, DOI 10.1111/j.1365-2222.1991.tb01693.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; LEYNADIER F, 1989, ANAESTHESIA, V44, P547, DOI 10.1111/j.1365-2044.1989.tb11438.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINENKILJUNEN S, 1993, J ALLERGY CLIN IMMUN, V91, P242; MAKINENKILJUNEN S, 1992, ALLERGY S, V47, P56; MATHEW SN, 1992, J ALLERGY CLIN IMMUN, V89, P225; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; RODRIGUEZ M, 1993, ANN ALLERGY, V70, P31; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SOUTHORN WA, 1964, J EXP BOT, V15, P616, DOI 10.1093/jxb/15.3.616; TATA S J, 1976, Journal of the Rubber Research Institute of Malaysia, V24, P233; TATA SJ, 1976, MALAYSIAN RUBBER PRO, P441; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1990, LANCET, V337, P1588; WADEE AA, 1990, J ALLERGY CLIN IMMUN, V85, P801, DOI 10.1016/0091-6749(90)90202-F; ZACHARISEN MC, 1992, J ALLERGY CLIN IMMUN, V89, P225	35	115	118	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					557	564		10.1016/S0091-6749(95)70318-7	http://dx.doi.org/10.1016/S0091-6749(95)70318-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7852672				2022-12-18	WOS:A1995QH69700008
J	ROORDA, RJ; GERRITSEN, J; VANAALDEREN, WMC; SCHOUTEN, JP; VELTMAN, JC; WEISS, ST; KNOL, K				ROORDA, RJ; GERRITSEN, J; VANAALDEREN, WMC; SCHOUTEN, JP; VELTMAN, JC; WEISS, ST; KNOL, K			FOLLOW-UP OF ASTHMA FROM CHILDHOOD TO ADULTHOOD - INFLUENCE OF POTENTIAL CHILDHOOD RISK-FACTORS ON THE OUTCOME OF PULMONARY-FUNCTION AND BRONCHIAL RESPONSIVENESS IN ADULTHOOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; PROGNOSIS; PULMONARY FUNCTION; BRONCHIAL RESPONSIVENESS	LUNG-FUNCTION; AIRWAY RESPONSIVENESS; POPULATION-SAMPLE; NATURAL-HISTORY; CHILDREN; HISTAMINE; HYPERRESPONSIVENESS; METHACHOLINE; REACTIVITY; SEVERITY	The outcome of asthma in 406 children, aged 8 to 12 years, was studied. Follow-up in adulthood was 86%, with a mean age of 24.7 years and a mean interval of follow-up of 14.8 years. The predictive value of gender and various childhood variables on the adult level of pulmonary function (forced expiratory volume in 1 second [FEV1]) and bronchial responsiveness in adulthood was assessed. An increase in mean percent predicted FEV1 from childhood to adulthood was found, both in subjects with (76%) and without (24%) current respiratory symptoms. The only childhood variable predictive of adult level of FEV1 was the level of percent predicted FEV1 (p < 0.01). The proportion of subjects with a histamine provocative concentration causing a 10% decrease in FEV1 less than or equal to 16 mg/ml decreased significantly in adulthood. The degree of bronchial responsiveness had increased slightly in adults with symptoms (p = 0.87), whereas it had decreased significantly in subjects without symptoms (p < 0.01). Female subjects were significantly mom responsive in adulthood than male subjects (p = 0.047). The childhood degree of bronchial responsiveness significantly predicted the presence of bronchial responsiveness in adulthood (p = 0.02). We conclude that childhood percent predicted FEV1 is relevant to predict the outcome of the adult pulmonary function level, whereas female gender and the childhood degree of bronchial responsiveness are important for the prediction of adult degree of bronchial responsiveness among children with asthma.	UNIV GRONINGEN HOSP,DEPT PEDIAT,DIV PEDIAT PULMONOL,9700 RB GRONINGEN,NETHERLANDS; UNIV GRONINGEN,DEPT EPIDEMIOL,9700 AB GRONINGEN,NETHERLANDS; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV PULM & CRIT CARE,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115	University of Groningen; University of Groningen; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School								AVITAL A, 1991, AM REV RESPIR DIS, V144, P36, DOI 10.1164/ajrccm/144.1.36; BLACKHALL MI, 1970, ARCH DIS CHILD, V45, P363, DOI 10.1136/adc.45.241.363; COCKCROFT DW, 1977, CLIN ALLERGY, V72, P35; CONNELLAN SJ, 1982, THORAX, V37, P232; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; FOUCARD T, 1984, ACTA PAEDIATR SCAND, V73, P577, DOI 10.1111/j.1651-2227.1984.tb09977.x; FRIBERG S, 1989, J ALLERGY CLIN IMMUN, V84, P183, DOI 10.1016/0091-6749(89)90323-0; FRIBERG S, 1988, ACTA PAEDIATR SCAND, V77, P424, DOI 10.1111/j.1651-2227.1988.tb10671.x; GERRARD JW, 1980, AM REV RESPIR DIS, V122, P577; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; JONES RHT, 1966, BMJ-BRIT MED J, V2, P976, DOI 10.1136/bmj.2.5520.976; KELLY WJW, 1990, J ALLERGY CLIN IMMUN, V85, P548, DOI 10.1016/0091-6749(90)90092-I; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KNOL K, 1965, THESIS U GRONINGEN N; MARTIN AJ, 1981, MED J AUSTRALIA, V2, P470, DOI 10.5694/j.1326-5377.1981.tb112942.x; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MARTIN AJ, 1982, AUST PAEDIATR J, V81, P84; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; Nishima S, 1987, Acta Paediatr Jpn, V29, P639; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; RIJCKEN B, 1989, AM REV RESPIR DIS, V140, P615, DOI 10.1164/ajrccm/140.3.615; TAMMELING GJ, 1969, SELECTED PAPERS, V1, P65; VANAALDEREN WMC, 1989, PEDIATR PULM, V6, P113, DOI 10.1002/ppul.1950060211; VANDERLENDE R, 1972, SCAND J RESPIR DIS, V53, P218; VANSCHAYCK CP, 1991, AM REV RESPIR DIS, V144, P197; WEISS ST, 1984, AM REV RESPIR DIS, V129, P898; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; WOOLCOCK AJ, 1991, AM REV RESPIR DIS, V143, pS75, DOI 10.1164/ajrccm/143.3_Pt_2.S75	34	115	115	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1994	93	3					575	584		10.1016/S0091-6749(94)70069-9	http://dx.doi.org/10.1016/S0091-6749(94)70069-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ND140	8151060				2022-12-18	WOS:A1994ND14000004
J	MCDONALD, LG; TOVEY, E				MCDONALD, LG; TOVEY, E			THE ROLE OF WATER TEMPERATURE AND LAUNDRY PROCEDURES IN REDUCING HOUSE DUST MITE POPULATIONS AND ALLERGEN CONTENT OF BEDDING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HOUSE DUST MITES; MORTALITY; WATER TEMPERATURE; DETERGENTS; LAUNDRY PROCEDURES	DERMATOPHAGOIDES-PTERONYSSINUS; ASTHMA; PYROGLYPHIDAE; TRIAL	The effects of various laundry procedures on house dust mites and their allergens have been established. All mites were killed by water temperatures 55-degrees-C or greater. Killing at lower temperatures was not enhanced by any of the pure detergents or laundry products tested. A cold cycle of laundry washing with or without laundry powder did not remove most live mites from bedding, however, the allergen concentration (Der p I/gm fine dust) was reduced by more than 90%. Dry cleaning did not reduce the allergen concentration of the dust, although most, if not all, mites were killed.	UNIV SYDNEY, DEPT MED DO6, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney			Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				ANDERSEN A, 1989, ALLERGY, V44, P396, DOI 10.1111/j.1398-9995.1989.tb04170.x; BISCHOFF E, 1988, REV FR ALLERGOL, V28, P115, DOI 10.1016/S0335-7457(88)80061-3; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; COLLOFF MJ, 1987, EXP APPL ACAROL, V3, P279, DOI 10.1007/BF01193165; DEBOER R, 1990, J ALLERGY CLIN IMMUN, V86, P808, DOI 10.1016/S0091-6749(05)80187-3; KINNAIRD C H, 1974, Acarologia (Paris), V16, P340; KNIEST F, 1989, J ALLERGY CLIN IMMUN, V83, P262; KNULLE W, 1984, ACAROLOGY, V6, P71; LEYSEN MT, 1974, ACTA ALLERGOL, V29, P455, DOI 10.1111/j.1398-9995.1974.tb01665.x; MARKS G, 1991, AUST NZ J MED, V21, P660; MURRAY AB, 1983, PEDIATRICS, V71, P418; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART S, 1988, CLIN REV ALLERG, V6, P23; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P716, DOI 10.1136/adc.49.9.716; SCHOBER G, 1987, EXP APPL ACAROL, V3, P179, DOI 10.1007/BF01270453; SELINGER B, 1989, CHEM MARKETPLACE, P34; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; WATANABE F, 1989, Shoyakugaku Zasshi, V43, P163; ZAR JH, 1984, BIOSTAT ANAL, P369	22	115	122	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				599	608		10.1016/0091-6749(92)90132-L	http://dx.doi.org/10.1016/0091-6749(92)90132-L			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1401643				2022-12-18	WOS:A1992JT99500005
J	MCHUGH, SM; LAVELLE, B; KEMENY, DM; PATEL, S; EWAN, PW				MCHUGH, SM; LAVELLE, B; KEMENY, DM; PATEL, S; EWAN, PW			A PLACEBO-CONTROLLED TRIAL OF IMMUNOTHERAPY WITH 2 EXTRACTS OF DERMATOPHAGOIDES PTERONYSSINUS IN ALLERGIC RHINITIS, COMPARING CLINICAL OUTCOME WITH CHANGES IN ANTIGEN-SPECIFIC IGE, IGG, AND IGG SUBCLASSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CAMBRIDGE, SCH CLIN,CTR MRC,MOLEC IMMUNOPATHOL UNIT,HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND; GUYS & ST THOMAS HOSP, SCH MED, DEPT MED, LONDON SE1 9RT, ENGLAND	University of Cambridge; Guy's & St Thomas' NHS Foundation Trust								AALBERSE RC, 1983, J IMMUNOL, V130, P722; AALBERSE RC, 1983, CLIN REV ALLERG, V1, P289; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; ARMITAGE P, 1987, STATISTICAL METHODS; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; CAMPBELL RC, 1974, STATISTICS BIOL; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CLINTON PM, 1989, INT ARCH ALLER A IMM, V89, P43, DOI 10.1159/000234921; CORRADO OJ, 1989, ALLERGY, V44, P108, DOI 10.1111/j.1398-9995.1989.tb02233.x; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DEVEY ME, 1989, J ALLERGY CLIN IMMUN, V84, P326, DOI 10.1016/0091-6749(89)90416-8; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; DSOUZA MF, 1983, CLIN ALLERGY, V13, P329, DOI 10.1111/j.1365-2222.1983.tb02608.x; ETIEVANT M, 1979, ANN ALLERGY, V43, P169; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; FAGAN DL, 1982, J ALLERGY CLIN IMMUN, V70, P399, DOI 10.1016/0091-6749(82)90031-8; Fisher R, 1954, BIOL MONOGRAPHS MANU; GIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625; GWYNN CM, 1982, LANCET, V2, P1339; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; KEMENY DM, 1987, J IMMUNOL METHODS, V96, P47, DOI 10.1016/0022-1759(87)90366-8; KEMENY DM, 1987, INT ARCH ALLER A IMM, V83, P113, DOI 10.1159/000234343; MAASCH HJ, 1987, INT ARCH ALLER A IMM, V84, P363, DOI 10.1159/000234451; MORRISONSMITH J, 1975, CLIN ASPECTS IMMUNOL, P903; NAKAGAWA T, 1987, INT ARCH ALLER A IMM, V82, P95, DOI 10.1159/000234297; NAKAGAWA T, 1983, INT ARCH ALLER A IMM, V71, P122, DOI 10.1159/000233374; NEWTON DAG, 1978, BRIT J DIS CHEST, V72, P21, DOI 10.1016/0007-0971(78)90004-9; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; PARISH WE, 1981, BRIT J DERMATOL, V105, P223, DOI 10.1111/j.1365-2133.1981.tb01210.x; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; ROWNTREE S, 1986, INT ARCH ALLER A IMM, V79, P132, DOI 10.1159/000233960; STANWORTH DR, 1986, MONOGR ALLERGY, V19, P227; WAHL R, 1988, INT ARCH ALLER A IMM, V87, P109, DOI 10.1159/000234659; 1979, BR J DIS CHEST, V73, P260; 1988, ALLERGY S6, V43, P1	36	115	118	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				521	531		10.1016/S0091-6749(05)80208-8	http://dx.doi.org/10.1016/S0091-6749(05)80208-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	1699985				2022-12-18	WOS:A1990EG45400012
J	BUSSE, WW				BUSSE, WW			RESPIRATORY-INFECTIONS - THEIR ROLE IN AIRWAY RESPONSIVENESS AND THE PATHOGENESIS OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BUSSE, WW (corresponding author), UNIV WISCONSIN,CTR CLIN SCI,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,H6-360,600 HIGHLAND AVE,MADISON,WI 53792, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015685, P50AI010404] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15685, AI 10404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERMAN SZ, 1975, J ALLERGY CLIN IMMUN, V56, P206, DOI 10.1016/0091-6749(75)90091-3; BLAIR HT, 1976, AM REV RESPIR DIS, V114, P95; BUCKNER CK, 1981, J CLIN INVEST, V67, P376, DOI 10.1172/JCI110045; BUCKNER CK, 1985, AM REV RESPIR DIS, V132, P305; BUSSE WW, 1979, AM REV RESPIR DIS, V119, P561; BUSSE WW, 1980, AM REV RESPIR DIS, V122, P641; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; BUSSE WW, 1983, J ALLERGY CLIN IMMUN, V71, P382, DOI 10.1016/0091-6749(83)90066-0; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GADDY JN, 1986, AM REV RESPIR DIS, V134, P969, DOI 10.1164/arrd.1986.134.5.969; GURWITZ D, 1981, J PEDIATR-US, V98, P551, DOI 10.1016/S0022-3476(81)80758-5; HALL WJ, 1978, ANN INTERN MED, V88, P203, DOI 10.7326/0003-4819-88-2-203; HALL WJ, 1976, AM REV RESPIR DIS, V113, P141; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; JACOBY DB, 1988, J APPL PHYSIOL, V64, P2653, DOI 10.1152/jappl.1988.64.6.2653; KIMMURA I, 1975, CLIN ALLERGY, V1, P95; LEBOWITZ MD, 1977, AM J EPIDEMIOL, V105, P544, DOI 10.1093/oxfordjournals.aje.a112418; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LETTBROWN MA, 1981, J CLIN INVEST, V67, P547, DOI 10.1172/JCI110065; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P112; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PICKEN JJ, 1972, AM J MED, V52, P738, DOI 10.1016/0002-9343(72)90079-4; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; SABAN R, 1987, AM REV RESPIR DIS, V136, P586, DOI 10.1164/ajrccm/136.3.586; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573; WELLIVER RC, 1979, J PEDIATR-US, V94, P370, DOI 10.1016/S0022-3476(79)80573-9; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; ZWEIMAN B, 1971, J ALLERGY CLIN IMMUN, V48, P283, DOI 10.1016/0091-6749(71)90029-7	41	115	120	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					671	683		10.1016/0091-6749(90)90181-3	http://dx.doi.org/10.1016/0091-6749(90)90181-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	2182693				2022-12-18	WOS:A1990DA43700001
J	GREENBERGER, PA; PATTERSON, R				GREENBERGER, PA; PATTERSON, R			ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS AND THE EVALUATION OF THE PATIENT WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											GREENBERGER, PA (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NIAID NIH HHS [AI 11403, AI 23071] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403, R01AI023071] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERKIN KE, 1982, BRIT MED J, V285, P552, DOI 10.1136/bmj.285.6341.552; CHANYEUN.M, 1971, CHEST, V59, P33, DOI 10.1378/chest.59.1.33; FISHER MR, 1985, CHEST, V87, P499, DOI 10.1378/chest.87.4.499; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GRAMMER LC, 1986, INT ARCH ALLER A IMM, V76, P246; GRAVES TS, 1979, ANN INTERN MED, V91, P378, DOI 10.7326/0003-4819-91-3-378; GREENBERGER PA, 1987, CHEST, V91, pS165, DOI 10.1378/chest.91.6.165S; GREENBERGER PA, 1980, J ALLERGY CLIN IMMUN, V66, P327, DOI 10.1016/0091-6749(80)90029-9; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; GREENBERGER PA, 1984, IMMUNOL ALLERGY PRAC, V6, P65; GUTT L, 1986, J ALLERGY CLIN IMMUN, V78, P98, DOI 10.1016/0091-6749(86)90120-X; HALWIG JM, 1984, J ALLERGY CLIN IMMUN, V74, P738, DOI 10.1016/0091-6749(84)90238-0; HALWIG JM, 1985, J ALLERGY CLIN IMMUN, V76, P55, DOI 10.1016/0091-6749(85)90804-8; IMBEAU SA, 1977, AM J DIS CHILD, V131, P1127, DOI 10.1001/archpedi.1977.02120230073013; KIEFER TA, 1986, ANN ALLERGY, V56, P233; LAUFER P, 1984, J ALLERGY CLIN IMMUN, V73, P44, DOI 10.1016/0091-6749(84)90482-2; LEE TM, 1987, ARCH INTERN MED, V147, P319, DOI 10.1001/archinte.147.2.319; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; PALMER RH, 1983, MED DECIS MAKING, V2, P299; PATTERSON R, 1986, ARCH INTERN MED, V146, P916, DOI 10.1001/archinte.146.5.916; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PATTERSON R, 1978, J IMMUNOL, V120, P66; PATTERSON R, 1977, AM J MED, V63, P257, DOI 10.1016/0002-9343(77)90240-6; PATTERSON R, 1983, ANN INTERN MED, V99, P18, DOI 10.7326/0003-4819-99-1-18; RICKETTI AJ, 1984, J ALLERGY CLIN IMMUN, V74, P68, DOI 10.1016/0091-6749(84)90089-7; RICKETTI AJ, 1983, J ALLERGY CLIN IMMUN, V71, P541, DOI 10.1016/0091-6749(83)90434-7; RICKETTI AJ, 1984, INT ARCH ALLER A IMM, V73, P283, DOI 10.1159/000233483; ROSENBERG M, 1977, CHEST, V72, P597, DOI 10.1378/chest.72.5.597; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SCADDING JG, 1967, SCAND J RESPIR DIS, V48, P372; SCHWARTZ HJ, 1978, J ALLERGY CLIN IMMUN, V62, P9, DOI 10.1016/0091-6749(78)90065-9; SLAVIN R G, 1970, Journal of Pediatrics, V76, P416, DOI 10.1016/S0022-3476(70)80482-6; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P718, DOI 10.1016/0091-6749(88)91044-5	34	115	117	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					646	650		10.1016/0091-6749(88)91034-2	http://dx.doi.org/10.1016/0091-6749(88)91034-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3356845				2022-12-18	WOS:A1988N065000003
J	SKASSABROCIEK, W; MANDERSCHEID, JC; MICHEL, FB; BOUSQUET, J				SKASSABROCIEK, W; MANDERSCHEID, JC; MICHEL, FB; BOUSQUET, J			SKIN-TEST REACTIVITY TO HISTAMINE FROM INFANCY TO OLD-AGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP AIGUELONGUE,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE; HOP LA PEYRONIE,DEPT INFORMAT MED,UNITE RECH CLIN,MONTPELLIER,FRANCE	Universite de Montpellier; CHU de Montpellier			Bousquet, Jean/O-4221-2019					BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; DELESPESSE G, 1977, CLIN ALLERGY, V7, P155, DOI 10.1111/j.1365-2222.1977.tb01436.x; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; LEE RE, 1977, ANN ALLERGY, V38, P231; LESSOF MH, 1980, CLIN ALLERGY, V10, P115, DOI 10.1111/j.1365-2222.1980.tb02088.x; MENARDO JL, 1983, ANN ALLERGY, V51, P535; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P646, DOI 10.1016/0091-6749(85)90088-0; MENARDO JL, 1987, HIGHLIGHTS ASTHMOLOG, P399; MICHEL FB, 1986, J ALLERGY CLIN IMMUN, V77, P222; OSTERBALLE O, 1981, Ugeskrift for Laeger, V143, P3211; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; Pepys J., 1975, BR J HOSP MED, V14, P412; PUPIL P, 1976, ANN ANESTHESIOL, V27, P199; REINBERG A, 1969, J ALLERGY, V44, P292, DOI 10.1016/0021-8707(69)90034-3; SCHWARZENBACH HR, 1982, CLIN ALLERGY, V12, P465, DOI 10.1111/j.1365-2222.1982.tb01645.x; TUFT L, 1955, J ALLERGY, V26, P359, DOI 10.1016/0021-8707(55)90064-2; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; VORHOORST R, 1980, ALLERGY, V39, P247; 1982, NLN PUBLICATION, V7, P1	23	115	115	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					711	716		10.1016/0091-6749(87)90292-2	http://dx.doi.org/10.1016/0091-6749(87)90292-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K9930	3680814	Bronze			2022-12-18	WOS:A1987K993000012
J	PLESKOW, WW; STEVENSON, DD; MATHISON, DA; SIMON, RA; SCHATZ, M; ZEIGER, RS				PLESKOW, WW; STEVENSON, DD; MATHISON, DA; SIMON, RA; SCHATZ, M; ZEIGER, RS			ASPIRIN-SENSITIVE RHINOSINUSITIS ASTHMA - SPECTRUM OF ADVERSE REACTIONS TO ASPIRIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,DEPT BASIC & CLIN RES,10666 N TORREY PINES RD,LA JOLLA,CA 92037; KAISER PERMANENTE MED CTR,DEPT ALLERGY & CLIN IMMUNOL,SAN DIEGO,CA	Scripps Research Institute; Kaiser Permanente				Zeiger, Robert/0000-0001-5788-5063	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00833] Funding Source: Medline; NIAID NIH HHS [AI-10386] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASOMBA A, 1976, CLIN ALLERGY, V6, P269, DOI 10.1111/j.1365-2222.1976.tb01907.x; CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; Dysart BR, 1933, J AMER MED ASSOC, V101, P446, DOI 10.1001/jama.1933.27430310002009a; FARR RS, 1978, ANN INTERN MED, V89, P577, DOI 10.7326/0003-4819-89-4-577_2; Francis N, 1935, J ALLERGY, V6, P504; GIRALDO B, 1969, ANN INTERN MED, V7, P479; HARNETT JC, 1978, ALLERGY PRINCIPLES P, P1002; HIRSCHBERG, 1902, DEUT MED WOCHENSCHR, V1, P416; Lamson RW, 1932, J AMER MED ASSOC, V99, P107, DOI 10.1001/jama.1932.02740540015005; MARTELLI NA, 1977, THORAX, V32, P684, DOI 10.1136/thx.32.6.684; MARTELLI NA, 1979, AM REV RESPIR DIS, V120, P1073; MATHISON DA, 1979, J ALLERGY CLIN IMMUN, V64, P669, DOI 10.1016/0091-6749(79)90036-8; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MOOREROB.M, 1967, BRIT MED J, V4, P262, DOI 10.1136/bmj.4.5574.262; PARKER CW, 1976, ASTHMA PHYSL IMMUNOP, P301; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; Prickman LE, 1937, J AMER MED ASSOC, V108, P445, DOI 10.1001/jama.1937.02780060011004; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SAMTER M, 1973, HOSP PRACT, V8, P85; SCHLUMBERGER HD, 1974, ACTA MED SCAND, V196, P451; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STENIUS BSM, 1976, CLIN ALLERGY, V6, P119, DOI 10.1111/j.1365-2222.1976.tb01889.x; SZCZEKLIK A, 1979, THORAX, V34, P654, DOI 10.1136/thx.34.5.654; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1976, J ALLERGY CLIN IMMUN, V58, P10, DOI 10.1016/0091-6749(76)90102-0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VEDANTHAN PK, 1977, J ALLERGY CLIN IMMUN, V60, P8, DOI 10.1016/0091-6749(77)90077-X; Widal M, 1922, PRESSE MED, V30, P189; WIJNJA L, 1966, LANCET, V2, P768; WUTHRICH B, 1979, RESPIRATION, V37, P224; YURCHAK AM, 1970, J ALLERGY, V46, P245, DOI 10.1016/0021-8707(70)90028-6	33	115	116	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	6					574	579		10.1016/0091-6749(83)90439-6	http://dx.doi.org/10.1016/0091-6749(83)90439-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QV139	6853926				2022-12-18	WOS:A1983QV13900009
J	SLAVIN, RG; CANNON, RE; FRIEDMAN, WH; PALITANG, E; SUNDARAM, M				SLAVIN, RG; CANNON, RE; FRIEDMAN, WH; PALITANG, E; SUNDARAM, M			SINUSITIS AND BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Discussion									ST LOUIS UNIV,SCH MED,DEPT OTOLARYNGOL,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT RADIOL,ST LOUIS,MO 63104	Saint Louis University; Saint Louis University	SLAVIN, RG (corresponding author), ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63104, USA.							AXELSSON A, 1973, LARYNGOSCOPE, V83, P2003, DOI 10.1288/00005537-197312000-00011; BERMAN SZ, 1974, J ALLERGY CLIN IMMUN, V53, P311, DOI 10.1016/0091-6749(74)90111-0; Blumgart HL, 1924, ARCH INTERN MED, V33, P415, DOI 10.1001/archinte.1924.00110280011002; BULLEN SS, 1932, J ALLERGY, V4, P402; CARENFELT C, 1978, ACTA OTO-LARYNGOL, V86, P298, DOI 10.3109/00016487809124750; ENGLISH GM, 1978, ALLERGY PRINCIPLES P; EVANS RO, 1974, N ENGL J MED, V290, P735; FEINBERG SM, 1946, ALLERGY PRACTICE, P401; FINLAND M, 1976, ANTIMICROB AGENTS CH, V9, P274, DOI 10.1128/AAC.9.2.274; FREDERICK J, 1974, NEW ENGL J MED, V290, P135, DOI 10.1056/NEJM197401172900304; FREEDMAN S, 1976, CLIN IMMUNOLOGY; FRIEDMAN WH, 1975, LARYNGOSCOPE, V85, P1999, DOI 10.1288/00005537-197512000-00005; Gottlieb MJ, 1925, J AMER MED ASSOC, V85, P105, DOI 10.1001/jama.1925.02670020025013; KATZ R, 1978, J ALLERGY CLIN IMMUN, V61, P190, DOI 10.1016/0091-6749(78)90446-3; MOSHER HP, 1912, T AM LARYNGEAL ASSN, V34, P25; PHIPATAN.CS, 1974, ARCH OTOLARYNGOL, V100, P109; Rackemann FM, 1929, ARCHIV OTOLARYNGOL, V9, P612; SAMTER M, 1971, IMMUNOLOGIC DISEASES; Sheldon J. M., 1967, MANUAL CLIN ALLERGY; Sluder G, 1919, J AMER MED ASSOC, V73, P589, DOI 10.1001/jama.1919.02610340021006; SUTTER VL, 1976, ANTIMICROB AGENTS CH, V10, P736, DOI 10.1128/AAC.10.4.736; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; Weille FL, 1936, NEW ENGL J MED, V215, P235, DOI 10.1056/NEJM193608062150602; YANKAUER S, 1930, LARYNGOSCOPE, V40, P642; Zizmor J, 1973, Otolaryngol Clin North Am, V6, P459	25	115	116	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	3					250	257		10.1016/0091-6749(80)90048-2	http://dx.doi.org/10.1016/0091-6749(80)90048-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KH358	7410747				2022-12-18	WOS:A1980KH35800014
J	Meyts, I; Bosch, B; Bolze, A; Boisson, B; Itan, Y; Belkadi, A; Pedergnana, V; Moens, L; Picard, C; Cobat, A; Bossuyt, X; Abel, L; Casanova, JL				Meyts, Isabelle; Bosch, Barbara; Bolze, Alexandre; Boisson, Bertrand; Itan, Yuval; Belkadi, Aziz; Pedergnana, Vincent; Moens, Leen; Picard, Capucine; Cobat, Aurelie; Bossuyt, Xavier; Abel, Laurent; Casanova, Jean-Laurent			Exome and genome sequencing for inborn errors of immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Next-generation sequencing; whole-exome sequencing; whole-genome sequencing; targeted sequencing; primary immunodeficiency	GAIN-OF-FUNCTION; COMBINED IMMUNODEFICIENCY; HYPOMORPHIC MUTATION; INNATE IMMUNITY; DEFICIENCY; DISEASE; DIAGNOSIS; VARIANTS; TOOL; CLASSIFICATION	The advent of next-generation sequencing (NGS) in 2010 has transformed medicine, particularly the growing field of inborn errors of immunity. NGS has facilitated the discovery of novel disease-causing genes and the genetic diagnosis of patients with monogenic inborn errors of immunity. Whole-exome sequencing (WES) is presently the most cost-effective approach for research and diagnostics, although whole-genome sequencing offers several advantages. The scientific or diagnostic challenge consists in selecting 1 or 2 candidate variants among thousands of NGS calls. Variant-and genelevel computational methods, as well as immunologic hypotheses, can help narrow down this genome-wide search. The key to success is a well-informed genetic hypothesis on 3 key aspects: mode of inheritance, clinical penetrance, and genetic heterogeneity of the condition. This determines the search strategy and selection criteria for candidate alleles. Subsequent functional validation of the disease-causing effect of the candidate variant is critical. Even the most up-to-date dry lab cannot clinch this validation without a seasoned wet lab. The multifariousness of variations entails an experimental rigor even greater than traditional Sanger sequencing-based approaches in order not to assign a condition to an irrelevant variant. Finding the needle in the haystack takes patience, prudence, and discernment.	[Meyts, Isabelle] Univ Hosp Leuven, Dept Immunol & Microbiol, Dept Pediat, Childhood Immunol, Leuven, Belgium; [Meyts, Isabelle; Bosch, Barbara] Univ Hosp Leuven, Dept Pediat, Herestr 49, B-3000 Leuven, Belgium; [Bosch, Barbara; Bolze, Alexandre; Boisson, Bertrand; Itan, Yuval; Abel, Laurent; Casanova, Jean-Laurent] Univ Hosp Leuven, Lab Med, Expt Immunol Lab, Dept Lab Med, Leuven, Belgium; [Bosch, Barbara; Bolze, Alexandre; Boisson, Bertrand; Itan, Yuval; Abel, Laurent; Casanova, Jean-Laurent] Katholieke Univ Leuven, Leuven, Belgium; [Bolze, Alexandre] Rockefeller Univ, Rockefeller Branch, St Giles Lab Human Genet Infect Dis, 1230 York Ave, New York, NY 10021 USA; [Boisson, Bertrand; Belkadi, Aziz; Pedergnana, Vincent; Picard, Capucine; Cobat, Aurelie; Abel, Laurent] Helix, San Carlos, CA USA; [Boisson, Bertrand; Belkadi, Aziz; Pedergnana, Vincent; Picard, Capucine; Cobat, Aurelie; Abel, Laurent; Casanova, Jean-Laurent] Necker Hosp Sick Children, INSERM, U1163, Lab Human Genet Infect Dis, Paris, France; [Pedergnana, Vincent] Paris Descartes Univ, Imagine Inst, Paris, France; [Moens, Leen; Bossuyt, Xavier] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England; [Picard, Capucine] Paris Descartes Univ, Sorbonne Paris Cite, Paris, France; [Picard, Capucine] Necker Enfants Malades Hosp, AP HP, Study Ctr Immunodeficiency, Paris, France; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA; [Casanova, Jean-Laurent] Necker Hosp Sick Children, AP HP, Pediat Hematol & Immunol Unit, Paris, France	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; Rockefeller University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Oxford; Wellcome Centre for Human Genetics; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Meyts, I (corresponding author), Univ Hosp Leuven, Dept Pediat, Herestr 49, B-3000 Leuven, Belgium.	Isabelle.Meyts@uzleuven.be	Bossuyt, Xavier/B-2085-2019; Boisson, Bertrand/AAC-6058-2019; Abel, Laurent/H-8888-2017; Casanova, Jean-Laurent/I-3418-2017; Meyts, Isabelle/Z-3295-2019; Boisson, Bertrand/I-2485-2017; Cobat, Aurélie/H-4722-2017	Bossuyt, Xavier/0000-0001-6856-8485; Boisson, Bertrand/0000-0001-5240-3555; Abel, Laurent/0000-0001-7016-6493; Boisson, Bertrand/0000-0001-5240-3555; Cobat, Aurélie/0000-0001-7209-6257; Bolze, Alexandre/0000-0001-7399-2766; Casanova, Jean-Laurent/0000-0002-7782-4169; Pedergnana, Vincent/0000-0002-7852-5339	KOF mandate of the KU Leuven; Jeffrey Modell Foundation; Research Mandate of the FWO Vlaanderen; Research Council of the Catholic University of Leuven; Institut National de la Sante et de la Recherche Medicale (INSERM); University Paris Descartes; Rockefeller University; St. Giles Foundation; European Research Council [ERC-2010-AdG-268777]; French National Research Agency (ANR) under the "Investments for the future'' program [ANR-10-IAHU-01]; National Institute of Allergy and Infectious Diseases [R37AI095983]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI095983] Funding Source: NIH RePORTER	KOF mandate of the KU Leuven; Jeffrey Modell Foundation; Research Mandate of the FWO Vlaanderen; Research Council of the Catholic University of Leuven(KU Leuven); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University Paris Descartes; Rockefeller University; St. Giles Foundation; European Research Council(European Research Council (ERC)European Commission); French National Research Agency (ANR) under the "Investments for the future'' program(French National Research Agency (ANR)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	I.M. is funded by a KOF mandate of the KU Leuven and by the Jeffrey Modell Foundation. B.B. is funded by a Research Mandate of the FWO Vlaanderen. X.B. is funded by a research grant from the Research Council of the Catholic University of Leuven. The Laboratory of Human Genetics of Infectious Diseases (J.-L.C., A.B., B.B., and Y. I.) was supported in part by grants from the Institut National de la Sante et de la Recherche Medicale (INSERM), University Paris Descartes, the Rockefeller University, the St. Giles Foundation, the European Research Council (grant no. ERC-2010-AdG-268777; to L.A.), the French National Research Agency (ANR) under the "Investments for the future'' program (grant no. ANR-10-IAHU-01), and the National Institute of Allergy and Infectious Diseases (grant no. R37AI095983).	Adam R, 2016, AM J HUM GENET, V99, P337, DOI 10.1016/j.ajhg.2016.06.015; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Aguilar C, 2014, J ALLERGY CLIN IMMUN, V134, P1131, DOI 10.1016/j.jaci.2014.04.031; Alcais A, 2010, ANN NY ACAD SCI, V1214, P18, DOI 10.1111/j.1749-6632.2010.05834.x; Alsina L, 2013, J ALLERGY CLIN IMMUN, V132, P741, DOI 10.1016/j.jaci.2013.03.038; Bousfiha AA, 2013, J CLIN IMMUNOL, V33, P1078, DOI 10.1007/s10875-013-9901-6; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Ban SA, 2014, J CLIN IMMUNOL, V34, P941, DOI 10.1007/s10875-014-0088-2; Belkadi A, 2016, P NATL ACAD SCI USA, V113, P6713, DOI 10.1073/pnas.1606460113; Belkadi A, 2015, P NATL ACAD SCI USA, V112, P5473, DOI 10.1073/pnas.1418631112; Boisson B, 2015, CURR OPIN IMMUNOL, V32, P90, DOI 10.1016/j.coi.2015.01.005; Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Bolze A, 2013, SCIENCE, V340, P976, DOI 10.1126/science.1234864; Bolze A, 2010, AM J HUM GENET, V87, P873, DOI 10.1016/j.ajhg.2010.10.028; Bousfiha A, 2015, J CLIN IMMUNOL, V35, P727, DOI 10.1007/s10875-015-0198-5; Buckley RH, 2004, J CLIN INVEST, V114, P1409, DOI 10.1172/JCI200423571; Butte MJ, 2007, CLIN IMMUNOL, V125, P159, DOI 10.1016/j.clim.2007.06.007; Casanova JL, 2014, J EXP MED, V211, P2137, DOI 10.1084/jem.20140520; Casanova JL, 2004, NAT REV IMMUNOL, V4, P55, DOI 10.1038/nri1264; Chandrasekaran P, 2016, J ALLERGY CLIN IMMUN; Ciancanelli MJ, 2015, SCIENCE, V348, P448, DOI 10.1126/science.aaa1578; Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975; Conley ME, 2014, CURR OPIN IMMUNOL, V30, P17, DOI 10.1016/j.coi.2014.05.004; Cooper DN, 2013, HUM GENET, V132, P1077, DOI 10.1007/s00439-013-1331-2; Cooper GM, 2011, NAT REV GENET, V12, P628, DOI 10.1038/nrg3046; Crow YJ, 2015, NAT REV IMMUNOL, V15, P429, DOI 10.1038/nri3850; de Diego RP, 2010, IMMUNITY, V33, P400, DOI 10.1016/j.immuni.2010.08.014; de Koning HD, 2015, J ALLERGY CLIN IMMUN, V135, P561, DOI 10.1016/j.jaci.2014.07.050; Deschamps M, 2016, AM J HUM GENET, V98, P5, DOI 10.1016/j.ajhg.2015.11.014; Fang MY, 2016, J CLIN IMMUNOL, V36, pS68, DOI 10.1007/s10875-016-0260-y; Fischer A, 2016, CR BIOL, V339, P314, DOI 10.1016/j.crvi.2016.04.011; Gilad Y, 2009, TRENDS GENET, V25, P463, DOI 10.1016/j.tig.2009.09.003; Goldstein DB, 2013, NAT REV GENET, V14, P460, DOI 10.1038/nrg3455; Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73; Guo YQ, 2011, J EXP MED, V208, P2083, DOI 10.1084/jem.20101568; Hanna S, 2015, J ALLERGY CLIN IMMUN, V136, P1113, DOI 10.1016/j.jaci.2015.04.021; Hodges E, 2007, NAT GENET, V39, P1522, DOI 10.1038/ng.2007.42; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Holzelova E, 2004, NEW ENGL J MED, V351, P1409, DOI 10.1056/NEJMoa040036; Hubbard N, 2016, BLOOD, V127, P2513, DOI 10.1182/blood-2015-11-683235; International MS Genetics Consortium CC, 2016, BIORXIV; Itan Y, 2016, NAT METHODS, V13, P109, DOI 10.1038/nmeth.3739; Itan Y, 2015, P NATL ACAD SCI USA, V112, P13615, DOI 10.1073/pnas.1518646112; Itan Y, 2015, P NATL ACAD SCI USA, V112, P11426, DOI 10.1073/pnas.1515057112; Itan Y, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00142; Itan Y, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-256; Itan Y, 2013, P NATL ACAD SCI USA, V110, P5558, DOI [10.1073/pnas.1218167110, 10.1073/PNAS.1218167110]; Kane A, 2016, J ALLERGY CLIN IMMUN; Kebschull JM, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv717; Khan S, 2016, J ALLERGY CLIN IMMUN, V138, P289, DOI 10.1016/j.jaci.2015.11.033; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Krumm N, 2012, GENOME RES, V22, P1525, DOI 10.1101/gr.138115.112; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lee S, 2014, AM J HUM GENET, V95, P5, DOI 10.1016/j.ajhg.2014.06.009; Lee YN, 2014, J ALLERGY CLIN IMMUN, V133, P1099, DOI 10.1016/j.jaci.2013.10.007; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lenardo M, 2016, ANNU REV IMMUNOL, V34, P121, DOI 10.1146/annurev-immunol-041015-055620; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Maffucci P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00220; Meienberg J, 2015, NUCLEIC ACIDS RES, V43, pE76, DOI 10.1093/nar/gkv216; Meuwissen MEC, 2016, J EXP MED, V213, P1163, DOI 10.1084/jem.20151529; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Miosge LA, 2015, P NATL ACAD SCI USA, V112, pE5189, DOI 10.1073/pnas.1511585112; Narasimhan VM, 2016, SCIENCE, V352, P474, DOI 10.1126/science.aac8624; Netter P, 2016, J ALLERGY CLIN IMMUN, V138, P599, DOI 10.1016/j.jaci.2015.12.1337; Nijman IJ, 2014, J ALLERGY CLIN IMMUN, V133, P529, DOI 10.1016/j.jaci.2013.08.032; Notarangelo LD, 2016, NAT REV IMMUNOL, V16, P234, DOI 10.1038/nri.2016.28; Notarangelo LD, 2008, J ALLERGY CLIN IMMUN, V122, P1069, DOI 10.1016/j.jaci.2008.08.038; Pessach IM, 2011, J ALLERGY CLIN IMMUN, V127, P1400, DOI 10.1016/j.jaci.2010.11.008; Picard C, 2014, EUR J IMMUNOL, V44, P2854, DOI 10.1002/eji.201444669; Picard C, 2009, EUR J IMMUNOL, V39, P1966, DOI 10.1002/eji.200939385; Quintana-Murci L, 2013, NAT REV IMMUNOL, V13, P280, DOI 10.1038/nri3421; Raje N, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0468-y; Savic S, 2015, J ALLERGY CLIN IMMUN, V136, P502, DOI 10.1016/j.jaci.2015.02.002; Scott EM, 2016, NAT GENET; Shendure J, 2016, GENETICS, V203, P617, DOI 10.1534/genetics.115.180562; Sims D, 2014, NAT REV GENET, V15, P121, DOI 10.1038/nrg3642; Starokadomskyy P, 2016, NAT IMMUNOL, V17, P495, DOI 10.1038/ni.3409; Stenson PD, 2014, HUM GENET, V133, P1, DOI 10.1007/s00439-013-1358-4; Stoddard JL, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00531; TASSARA C, 1995, HUM MOL GENET, V4, P1693, DOI 10.1093/hmg/4.9.1693; Veltman JA, 2012, NAT REV GENET, V13, P565, DOI 10.1038/nrg3241; Vogel TP, 2015, J CLIN IMMUNOL, V35, P615, DOI 10.1007/s10875-015-0187-8; Walter JE, 2015, J CLIN INVEST, V125, P4135, DOI 10.1172/JCI80477; Wang Z, 2016, NEURON, V90, P948, DOI 10.1016/j.neuron.2016.04.039; Woutsas S, 2015, BLOOD, V125, P1674, DOI 10.1182/blood-2014-08-595397; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506; Zhang XQ, 2015, NATURE, V517, P89, DOI 10.1038/nature13801; Zhang Y, 2015, NAT IMMUNOL, V16, P1001, DOI 10.1038/ni.3275	89	114	117	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					957	969		10.1016/j.jaci.2016.08.003	http://dx.doi.org/10.1016/j.jaci.2016.08.003			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27720020	Bronze, Green Accepted			2022-12-18	WOS:000385499400002
J	Jones, SM; Burks, AW; Keet, C; Vickery, BP; Scurlock, AM; Wood, RA; Liu, AH; Sicherer, SH; Henning, AK; Lindblad, RW; Dawson, P; Berin, C; Fleischer, DM; Leung, DYM; Plaut, M; Sampson, HA				Jones, Stacie M.; Burks, A. Wesley; Keet, Corinne; Vickery, Brian P.; Scurlock, Amy M.; Wood, Robert A.; Liu, Andrew H.; Sicherer, Scott H.; Henning, Alice K.; Lindblad, Robert W.; Dawson, Peter; Berin, Cecilia; Fleischer, David M.; Leung, Donald Y. M.; Plaut, Marshall; Sampson, Hugh A.		CoFAR	Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Egg allergy; food allergy; oral immunotherapy; desensitization; sustained unresponsiveness; immune tolerance; IgE; follow-up	DOUBLE-BLIND; NATURAL-HISTORY; PEANUT ALLERGY; FOOD ALLERGY; PREVALENCE; CHILDREN; DESENSITIZATION	Background: We previously reported the results of a randomized placebo-controlled study of egg oral immunotherapy (eOIT) in which 27.5% of subjects achieved sustained unresponsiveness (SU) after 2 years. Here we report the results of treatment through 4 years and long-term follow-up. Objective: We sought to evaluate the efficacy and safety of eOIT in participants treated up to 4 years. Methods: Children with egg allergy (5-18 years old) received eOIT (n = 40) for up to 4 years or placebo (n = 15) for 1 year or less. The key outcome was the percentage of subjects achieving SU by year 4. Safety and immunologic assessments were performed, and long-term follow-up questionnaires (LFQs) were administered after study conclusion (LFQ-1) and 1 year later (LFQ-2). Results: Of 40 eOIT-treated subjects, 20 (50.0%) of 40 demonstrated SU by year 4. For those subjects still dosing during years 3 and 4, mild symptoms were present in 12 (54.5%) of 22 subjects. At the time of the LFQ, more subjects receiving eOIT (LFQ-1, 23/34 [68%]; LFQ-2, 21/33 [64%]) were consuming unbaked and baked egg versus placebo (LFQ-1, 2/11 [18%], P = .006; LFQ-2, 3/12 [25%], P = .04). Of subjects achieving SU, 18 (90%) of 20 completed the LFQ, with 18 (100%) of 18 reporting consumption of all forms of egg. When compared with subjects not achieving SU, subjects achieving SU had higher IgG4 values (P = .001) and lower egg skin prick test scores (P = .0002) over time and a lower median baseline ratio of egg-specific IgE to total IgE (1.1% vs 2.7%, P = .04). Conclusions: SU after eOIT is enhanced with longer duration of therapy and increases the likelihood of tolerating unbaked egg in the diet.	[Jones, Stacie M.; Scurlock, Amy M.] Univ Arkansas Med Sci, Dept Pediat, 13 Childrens Way,Slot 512-13, Little Rock, AR 72202 USA; [Jones, Stacie M.; Scurlock, Amy M.] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA; [Burks, A. Wesley; Vickery, Brian P.] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Keet, Corinne; Wood, Robert A.] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA; [Liu, Andrew H.; Fleischer, David M.; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Sicherer, Scott H.; Berin, Cecilia; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Henning, Alice K.; Lindblad, Robert W.; Dawson, Peter] EMMES Corp, Rockville, MD USA; [Plaut, Marshall] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University; Johns Hopkins Medicine; National Jewish Health; Icahn School of Medicine at Mount Sinai; Emmes Corporation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jones, SM (corresponding author), Univ Arkansas Med Sci, Dept Pediat, 13 Childrens Way,Slot 512-13, Little Rock, AR 72202 USA.	JonesStacieM@uams.edu		berin, cecilia/0000-0002-9051-9249; Vickery, Brian/0000-0002-7243-5543	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [U19AI066738, U01AI066560]; National Center for Research Resources (NCRR), a component of the NIH [UL1 TR000154, UL1 TR000067, UL1 TR000039, UL1 TR000083, UL1 TR000424]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082, UL1TR000039, UL1TR000424, UL1TR000154, UL1TR000067, UL1TR001433, UL1TR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI103187, U19AI066738, U01AI066560] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources (NCRR), a component of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grants U19AI066738 and U01AI066560. The project was also supported by grants UL1 TR000154 (National Jewish), UL1 TR000067 (Mount Sinai), UL1 TR000039 (Arkansas), UL1 TR000083 (North Carolina), and UL1 TR000424 (Johns Hopkins) from the National Center for Research Resources (NCRR), a component of the NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NCRR or NIH.	Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Begin P, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-7; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Caminiti L, 2015, J ALLER CL IMM-PRACT, V3, P532, DOI 10.1016/j.jaip.2015.01.017; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Fleischer DM, 2013, J ALLERGY CLIN IMMUN, V131, P119, DOI 10.1016/j.jaci.2012.11.011; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Gorelik M, 2015, J ALLERGY CLIN IMMUN, V135, P1283, DOI 10.1016/j.jaci.2014.11.010; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Jones SM, 2014, J ALLERGY CLIN IMMUN, V133, P318, DOI 10.1016/j.jaci.2013.12.1040; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Keet CA, 2013, J ALLERGY CLIN IMMUN, V132, P737, DOI 10.1016/j.jaci.2013.05.006; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Martorell A, 2011, CLIN EXP ALLERGY, V41, P1297, DOI 10.1111/j.1365-2222.2011.03749.x; Narisety SD, 2015, J ALLERGY CLIN IMMUN, V135, P1275, DOI 10.1016/j.jaci.2014.11.005; Pajno GB, 2010, ANN ALLERG ASTHMA IM, V105, P376, DOI 10.1016/j.anai.2010.03.015; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Salmivesi S, 2013, ACTA PAEDIATR, V102, P172, DOI 10.1111/j.1651-2227.2012.02815.x; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P492, DOI 10.1016/j.jaci.2013.12.1041; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wood RA, 2014, J ALLER CL IMM-PRACT, V2, P97, DOI 10.1016/j.jaip.2013.11.010; Wright BL, 2015, J ALLERGY CLIN IMMUN, V135, pAB38, DOI 10.1016/j.jaci.2014.12.1055	29	114	115	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1117	+		10.1016/j.jaci.2015.12.1316	http://dx.doi.org/10.1016/j.jaci.2015.12.1316			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26924470	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000373351200018
J	Valenta, R; Campana, R; Focke-Tejkl, M; Niederberger, V				Valenta, Rudolf; Campana, Raffaela; Focke-Tejkl, Margit; Niederberger, Verena			Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergen; allergen-specific immunotherapy; allergy vaccine; preventive allergy vaccine	BET V 1; BIRCH POLLEN ALLERGEN; VIRUS-LIKE PARTICLES; GRASS-POLLEN; COMBINATION VACCINES; IMMUNOGLOBULIN-E; INTRALYMPHATIC IMMUNOTHERAPY; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; THERAPEUTIC VACCINES	In the past, the development of more effective, safe, convenient, broadly applicable, and easy to manufacture vaccines for allergen-specific immunotherapy (AIT) has been limited by the poor quality of natural allergen extracts. Progress made in the field of molecular allergen characterization has now made it possible to produce defined vaccines for AIT and eventually for preventive allergy vaccination based on recombinant DNA technology and synthetic peptide chemistry. Here we review the characteristics of recombinant and synthetic allergy vaccines that have reached clinical evaluation and discuss how molecular vaccine approaches can make AIT more safe and effective and thus more convenient. Furthermore, we discuss how new technologies can facilitate the reproducible manufacturing of vaccines of pharmaceutical grade for inhalant, food, and venom allergens. Allergy vaccines in clinical trials based on recombinant allergens, recombinant allergen derivatives, and synthetic peptides allow us to target selectively different immune mechanisms, and certain of those show features that might make them applicable not only for therapeutic but also for prophylactic vaccination.	[Valenta, Rudolf; Campana, Raffaela; Focke-Tejkl, Margit] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Waehringer Guertel 18-20, A-1090 Vienna, Austria; [Niederberger, Verena] Med Univ Vienna, Dept ENT, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Valenta, R (corresponding author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at		Valenta, Rudolf/0000-0001-5944-3365; Campana, Raffaela/0000-0001-9309-9908	Austrian Science Fund (FWF) [F4605, F4613]; BIOMAY AG, Vienna, Austria	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); BIOMAY AG, Vienna, Austria	This study was supported by research grants F4605 and F4613 from the Austrian Science Fund (FWF) and by a research grant from BIOMAY AG, Vienna, Austria.	Asarnoj A, 2015, J ALLERGY CLIN IMMUN; Banerjee S, 2014, J IMMUNOL, V192, P4867, DOI 10.4049/jimmunol.1400064; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2013, INT ARCH ALLERGY IMM, V161, P1, DOI 10.1159/000343018; Campana R, 2016, J ALLERGY CLIN IMMUN, V137, P601, DOI 10.1016/j.jaci.2015.08.042; Campana R, 2010, J ALLERGY CLIN IMMUN, V126, P1024, DOI 10.1016/j.jaci.2010.05.023; Canonica GW, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-17; Casset A, 2013, INT ARCH ALLERGY IMM, V161, P287, DOI 10.1159/000347047; Casset A, 2012, INT ARCH ALLERGY IMM, V159, P253, DOI 10.1159/000337654; Chen KW, 2012, J ALLERGY CLIN IMMUN, V130, P435, DOI 10.1016/j.jaci.2012.05.035; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Couroux P, 2015, CLIN EXP ALLERGY, V45, P974, DOI 10.1111/cea.12488; Cox L, 2012, IMMUNOTHERAPY-UK, V4, P601, DOI [10.2217/IMT.12.36, 10.2217/imt.12.36]; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Custovic A, 2015, J ALLERGY CLIN IMMUN, V136, P1645, DOI 10.1016/j.jaci.2015.03.041; Douladiris N, 2015, J ALLERGY CLIN IMMUN, V136, P493, DOI 10.1016/j.jaci.2015.01.015; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Dunbar WP, 1903, BERLINER KLIN WOCHEN, P24; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Edlmayr J, 2011, CURR TOP MICROBIOL, V352, P121, DOI 10.1007/82_2011_130; Edlmayr J, 2009, J IMMUNOL, V182, P6298, DOI 10.4049/jimmunol.0713622; Focke M, 2008, CLIN EXP ALLERGY, V38, P1400, DOI 10.1111/j.1365-2222.2008.03031.x; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Focke-Tejkl M, 2015, J ALLERGY CLIN IMMUN, V135, P1207, DOI 10.1016/j.jaci.2014.09.012; Gadermaier E, 2011, ALLERGY, V66, P1174, DOI 10.1111/j.1398-9995.2011.02592.x; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Kahlert H, 2000, J IMMUNOL, V165, P1807, DOI 10.4049/jimmunol.165.4.1807; Kiel MA, 2013, J ALLERGY CLIN IMMUN, V132, P353, DOI 10.1016/j.jaci.2013.03.013; Klimek L, 2012, CLIN EXP ALLERGY, V42, P936, DOI 10.1111/j.1365-2222.2012.03971.x; Klimek L, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0071-x; Kundig TM, 2006, J ALLERGY CLIN IMMUN, V117, P1470, DOI 10.1016/j.jaci.2006.01.040; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Linhart B, 2005, J ALLERGY CLIN IMMUN, V115, P1010, DOI 10.1016/j.jaci.2004.12.1142; Linhart B, 2014, CLIN EXP ALLERGY, V44, P278, DOI 10.1111/cea.12216; Linhart B, 2002, FASEB J, V16, P1301, DOI 10.1096/fj.01-1012fje; Linhart B, 2015, J IMMUNOL, V194, P4008, DOI 10.4049/jimmunol.1400402; Linhart B, 2012, VACCINE, V30, P4328, DOI 10.1016/j.vaccine.2011.11.011; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; MARSH DG, 1970, IMMUNOLOGY, V18, P705; Marth K, 2013, J IMMUNOL, V190, P3068, DOI 10.4049/jimmunol.1202441; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 2015, J ALLERGY CLIN IMMUN, V136, P1101, DOI 10.1016/j.jaci.2015.03.034; Niespodziana K, 2011, J ALLERGY CLIN IMMUN, V127, P1562, DOI 10.1016/j.jaci.2011.02.004; Nony E, 2015, ALLERGY, V70, P795, DOI 10.1111/all.12622; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; Sastre J, 2012, ALLERGY, V67, P709, DOI 10.1111/j.1398-9995.2012.02808.x; Sato S, 2014, INT ARCH ALLERGY IMM, V164, P1, DOI 10.1159/000361025; Schmitz N, 2009, J EXP MED, V206, P1941, DOI 10.1084/jem.20090199; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P1290, DOI 10.1016/j.jaci.2012.02.026; Sledge RF, 1938, US NAVAL MED B, V36, P18; Spertini F, 2014, J ALLERGY CLIN IMMUN, V134, P239, DOI 10.1016/j.jaci.2014.04.001; Spina L, 2015, INT ARCH ALLERGY IMM, V167, P103, DOI 10.1159/000434681; Swoboda I, 2007, J IMMUNOL, V178, P6290, DOI 10.4049/jimmunol.178.10.6290; Szepfalusi Z, 2014, PEDIAT ALLERG IMM-UK, V25, P788, DOI 10.1111/pai.12310; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 2012, J INTERN MED, V272, P144, DOI 10.1111/j.1365-2796.2012.02556.x; Valovirta E, 2011, ALLERGY, V66, P53, DOI 10.1111/j.1398-9995.2011.02640.x; von Moos S, 2014, J ALLERGY CLIN IMMUN, V134, P965, DOI 10.1016/j.jaci.2014.07.037; Westman M, 2015, J ALLERGY CLIN IMMUN, V135, P1199, DOI 10.1016/j.jaci.2014.10.042; Winther L, 2006, CLIN EXP ALLERGY, V36, P254, DOI 10.1111/j.1365-2222.2006.02340.x; Wollmann E, 2015, J ALLERGY CLIN IMMUN, V136, P806, DOI 10.1016/j.jaci.2015.02.034; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029; Zaleska A, 2014, ALLERGY, V69, P1162, DOI 10.1111/all.12461; Zolkipli Z, 2015, J ALLERGY CLIN IMMUN, V136, P1541, DOI 10.1016/j.jaci.2015.04.045; Zuidmeer-Jongejan L, 2015, INT ARCH ALLERGY IMM, V166, P41, DOI 10.1159/000371657	79	114	117	3	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					351	357		10.1016/j.jaci.2015.12.1299	http://dx.doi.org/10.1016/j.jaci.2015.12.1299			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26853127	Green Accepted, hybrid			2022-12-18	WOS:000369235500002
J	Caulley, L; Thavorn, K; Rudmik, L; Cameron, C; Kilty, SJ				Caulley, Lisa; Thavorn, Kednapa; Rudmik, Luke; Cameron, Chris; Kilty, Shaun J.			Direct costs of adult chronic rhinosinusitis by using 4 methods of estimation: Results of the US Medical Expenditure Panel Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; cost; direct medical expenditures; rhinosinusitis treatment; Medical Expenditure Panel Survey	CANADIAN GUIDELINES; HEALTH; EPIDEMIOLOGY; SINUSITIS	Background: Chronic rhinosinusitis (CRS) is an inflammatory disease that affects 2% to 16% of the US population. Despite its increasing prevalence, there are currently limited data in the literature evaluating the economic burden of this disease. Objective: This study aimed to determine the direct health care costs of CRS from the perspective of the US government. Methods: A prevalence-based approach was used to estimate cost of illness for CRS from the 2011 Medical Expenditure Panel Survey database by using a 4-part model: (1) an estimated sum of all health care expenditures, (2) an attribution model for disease-specific estimation of expenditures, (3) an estimation based on a propensity score model, and (4) estimated disease-specific expenditure by using a linear regression-based approach. A disease prevalence of 3.5% was used. Results: The mean CRS-specific annual expenditure was $5955 (95% CI, $5087-$6823) by using method 1 compared with $5560 (95% CI, $4689-$6431) by using method 2 and $5560 (95% CI, $4653-$6467) by using method 3. The annual expenditure, as estimated by using method 4, was $5589 (95% CI, $4986-$6192). Ambulatory expenses accounted for the largest proportion of expenditures, followed by prescription and in-hospital expenses. Conclusions: This study provided a range of estimates of the direct medical expenditures associated with CRS. We demonstrated that the economic burden attributable to this disease was an estimated $60.2 to $64.5 billion US dollars in 2011, with a wide variation in the total and incremental direct expenditures depending on the type of estimation model used and the prevalence assumed.	[Caulley, Lisa; Kilty, Shaun J.] Univ Ottawa, Dept Otolaryngol Head & Neck Surg, Ottawa, ON K1Y 1J8, Canada; [Thavorn, Kednapa; Cameron, Chris] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON K1Y 1J8, Canada; [Thavorn, Kednapa; Cameron, Chris; Kilty, Shaun J.] Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Rudmik, Luke] Univ Calgary, Div Otolaryngol Head & Neck Surg, Calgary, AB T2N 1N4, Canada; [Rudmik, Luke] Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Calgary; University of Calgary	Kilty, SJ (corresponding author), Univ Ottawa, Ottawa Hosp, Dept Otolaryngol Head & Neck Surg, 737 Parkdale Ave,Rm 459, Ottawa, ON K1Y 1J8, Canada.	kiltysj@gmail.com		Thavorn, Kednapa/0000-0003-4738-8447; Caulley, Lisa/0000-0002-9661-4634; Kilty, Shaun/0000-0003-1857-7628	ICER - National Pharmaceutical Council; Novartis; Baxter; Merck	ICER - National Pharmaceutical Council; Novartis(Novartis); Baxter; Merck(Merck & Company)	C. Cameron is Director of the Cornerstone Research Group and has received payment for manuscript preparation as a contractor for ICER on a grant funded by the National Pharmaceutical Council. S. J. Kilty has received consultancy fees from Novartis, research support from Baxter, and lecture fees from Merck and Novartis. The rest of the authors declare that they have no relevant conflicts of interest.	Akobundu E, 2006, PHARMACOECONOMICS, V24, P869, DOI 10.2165/00019053-200624090-00005; Baser O, 2006, VALUE HEALTH, V9, P377, DOI 10.1111/j.1524-4733.2006.00130.x; Bhattacharyya N, 2011, ANN OTO RHINOL LARYN, V120, P423, DOI 10.1177/000348941112000701; Chen Y, 2003, LARYNGOSCOPE, V113, P1199, DOI 10.1097/00005537-200307000-00016; Cohen JW, 2009, MED CARE, V47, pS44, DOI 10.1097/MLR.0b013e3181a23e3a; Coughlan D, 2014, VALUE HEALTH, V17, P90, DOI 10.1016/j.jval.2013.10.004; Desrosiers M, 2011, ALLERGY ASTHMA CL IM, V7, DOI 10.1186/1710-1492-7-2; DHoore W, 1996, J CLIN EPIDEMIOL, V49, P1429, DOI 10.1016/S0895-4356(96)00271-5; Goetzel RZ, 2003, J OCCUP ENVIRON MED, V45, P5, DOI 10.1097/00043764-200301000-00007; Halawi AM, 2013, ALLERGY ASTHMA PROC, V34, P328, DOI 10.2500/aap.2013.34.3675; Howard DH, 2004, CANCER-AM CANCER SOC, V100, P883, DOI 10.1002/cncr.20063; Hsu J, 2014, AM J RHINOL ALLERGY, V28, P140, DOI 10.2500/ajra.2014.28.4012; Kaliner MA, 1997, OTOLARYNG HEAD NECK, V116, pS1; Kaplan A, 2013, CAN FAM PHYSICIAN, V59, pE528; Kaplan A, 2013, CAN FAM PHYSICIAN, V59, P1275; Kilty S, 2012, BMC EAR NOSE THROAT, V12, DOI 10.1186/1472-6815-12-1; Kilty SJ, 2011, RHINOLOGY, V49, P533, DOI 10.4193/Rhino10.298; Lipscomb J, 2009, MED CARE, V47, pS1, DOI 10.1097/MLR.0b013e3181a7e401; Macdonald KI, 2009, LARYNGOSCOPE, V119, P184, DOI 10.1002/lary.20034; MEPS, 2014, MED EXP PAN SURV DAT; Rappaport H, 2012, J ALLERGY, V3, P1, DOI DOI 10.4172/2155-6121.1000118; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P408, DOI 10.1016/S0091-6749(99)70464-1; Rudmik L, 2014, LARYNGOSCOPE, V124, P2007, DOI 10.1002/lary.24630; Rudmik L, 2013, LARYNGOSCOPE, V123, P1341, DOI 10.1002/lary.23943; Rudmik L, 2011, CURR ALLERGY ASTHM R, V11, P247, DOI 10.1007/s11882-010-0175-2; Short PF, 2011, CANCER-AM CANCER SOC, V117, P2791, DOI 10.1002/cncr.25835; Smith KA, 2015, LARYNGOSCOPE, V125, P1547, DOI 10.1002/lary.25180; Soler ZM, 2011, LARYNGOSCOPE, V121, P2672, DOI 10.1002/lary.21847; Van Cauwenberge P, 2000, THORAX, V55, pS20, DOI 10.1136/thorax.55.suppl_2.S20	29	114	115	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1517	1522		10.1016/j.jaci.2015.08.037	http://dx.doi.org/10.1016/j.jaci.2015.08.037			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26483176	Bronze			2022-12-18	WOS:000366044300012
J	McGowan, EC; Keet, CA				McGowan, Emily C.; Keet, Corinne A.			Prevalence of self-reported food allergy in the National Health and Nutrition Examination Survey (NHANES) 2007-2010	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[McGowan, Emily C.; Keet, Corinne A.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD 21218 USA	Johns Hopkins University	McGowan, EC (corresponding author), Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD 21218 USA.	ckeet1@jhmi.edu		Keet, Corinne/0000-0002-6585-239X	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001077, UL1TR001079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI103187] Funding Source: NIH RePORTER; NCATS NIH HHS [KL2 TR001077, UL1 TR001079] Funding Source: Medline; NIAID NIH HHS [K23 AI103187, 1K23AI103187] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Ben-Shoshan M, 2010, J ALLERGY CLIN IMMUN, V125, P1327, DOI 10.1016/j.jaci.2010.03.015; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Jackson K. D., 2013, NCHS DATA BRIEF; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Soller L, 2012, J ALLERGY CLIN IMMUN, V130, P986, DOI 10.1016/j.jaci.2012.06.029; Woods RK, 2002, EUR J CLIN NUTR, V56, P31, DOI 10.1038/sj.ejcn.1601306; Zuidmeer L, 2008, J ALLERGY CLIN IMMUN, V121, P1210, DOI 10.1016/j.jaci.2008.02.019	11	114	118	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1216	1219		10.1016/j.jaci.2013.07.018	http://dx.doi.org/10.1016/j.jaci.2013.07.018			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23992749	Green Accepted, Bronze			2022-12-18	WOS:000326235600025
J	Kim, J; Kim, EH; Oh, I; Jung, K; Han, Y; Cheong, HK; Ahn, K				Kim, Jihyun; Kim, Eun-Hye; Oh, Inbo; Jung, Kweon; Han, Youngshin; Cheong, Hae-Kwan; Ahn, Kangmo			Symptoms of atopic dermatitis are influenced by outdoor air pollution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PARTICLES; EXPOSURE; CHILDREN; FINE; INFLAMMATION; ECZEMA		[Kim, Jihyun; Ahn, Kangmo] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea; [Kim, Jihyun; Kim, Eun-Hye; Han, Youngshin; Cheong, Hae-Kwan; Ahn, Kangmo] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Environm Hlth Ctr Atop Dis, Seoul, South Korea; [Kim, Eun-Hye; Cheong, Hae-Kwan] Sungkyunkwan Univ, Sch Med, Dept Social & Prevent Med, Suwon, South Korea; [Kim, Eun-Hye; Cheong, Hae-Kwan] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Suwon, South Korea; [Oh, Inbo] Univ Ulsan, Coll Med, Ctr Environm Hlth, Ulsan 680749, South Korea; [Jung, Kweon] Seoul Res Inst Publ Hlth & Environm, Gwacheon, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); University of Ulsan	Kim, J (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea.	kmaped@skku.edu	Ahn, Kangmo/F-4609-2014	Cheong, Hae-Kwan/0000-0003-2758-9399				DiazSanchez D, 1997, ALLERGY, V52, P52; Eberlein-Konig B, 1998, J ALLERGY CLIN IMMUN, V101, P141, DOI 10.1016/S0091-6749(98)70212-X; Happo MS, 2010, INHAL TOXICOL, V22, P402, DOI 10.3109/08958370903527908; Huss-Marp J, 2006, CLIN EXP ALLERGY, V36, P338, DOI 10.1111/j.1365-2222.2006.02448.x; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Nikasinovic L, 2006, J ALLERGY CLIN IMMUN, V117, P1382, DOI 10.1016/j.jaci.2006.03.023; Plummer LE, 2012, J TOXICOL ENV HEAL A, V75, P253, DOI 10.1080/15287394.2012.640102; Song S, 2011, ENVIRON RES, V111, P394, DOI 10.1016/j.envres.2010.10.010	9	114	118	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					495	498		10.1016/j.jaci.2013.04.019	http://dx.doi.org/10.1016/j.jaci.2013.04.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23763977				2022-12-18	WOS:000322631700036
J	Rzehak, P; Wijga, AH; Keil, T; Eller, E; Bindslev-Jensen, C; Smit, HA; Weyler, J; Dom, S; Sunyer, J; Mendez, M; Torrent, M; Vall, O; Bauer, CP; Berdel, D; Schaaf, B; Chen, CM; Bergstrom, A; Fantini, MP; Mommers, M; Wahn, U; Lau, S; Heinrich, J				Rzehak, Peter; Wijga, Alet H.; Keil, Thomas; Eller, Esben; Bindslev-Jensen, Carsten; Smit, Henriette A.; Weyler, Joost; Dom, Sandra; Sunyer, Jordi; Mendez, Michelle; Torrent, Maties; Vall, Oriol; Bauer, Carl-Peter; Berdel, Dietrich; Schaaf, Beate; Chen, Chih-Mei; Bergstroem, Anna; Fantini, Maria P.; Mommers, Monique; Wahn, Ulrich; Lau, Susanne; Heinrich, Joachim		Working Grp GA2LEN-WP 1 5 Birth	Body mass index trajectory classes and incident asthma in childhood: Results from 8 European Birth Cohorts-a Global Allergy and Asthma European Network initiative	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Body mass index; rapid growth; asthma; child; latent growth mixture model; European birth cohorts; Global Allergy and Asthma European Network	ATOPIC DISEASES; LUNG-FUNCTION; OBESITY; RISK; ASSOCIATION; OVERWEIGHT; ADIPOSITY; CHILDREN; WEIGHT; GROWTH	Background: The causal link between body mass index (BMI) or obesity and asthma in children is still being debated. Analyses of large longitudinal studies with a sufficient number of incident cases and in which the time-dependent processes of both excess weight and asthma development can be validly analyzed are lacking. Objective: We sought to investigate whether the course of BMI predicts incident asthma in childhood. Methods: Data from 12,050 subjects of 8 European birth cohorts on asthma and allergies were combined. BMI and doctor-diagnosed asthma were modeled during the first 6 years of life with latent growth mixture modeling and discrete time hazard models. Subpopulations of children were identified with similar standardized BMI trajectories according to age-and sex-specific "World Health Organization (WHO) child growth standards" and "WHO growth standards for school aged children and adolescents" for children up to age 5 years and older than 5 years, respectively (BMI-SDS). These types of growth profiles were analyzed as predictors for incident asthma. Results: Children with a rapid BMI-SDS gain in the first 2 years of life had a higher risk for incident asthma up to age 6 years than children with a less pronounced weight gain slope in early childhood. The hazard ratio was 1.3 (95% CI, 1.1-1.5) after adjustment for birth weight, weight-for-length at birth, gestational age, sex, maternal smoking in pregnancy, breastfeeding, and family history of asthma or allergies. A rapid BMI gain at 2 to 6 years of age in addition to rapid gain in the first 2 years of life did not significantly enhance the risk of asthma. Conclusion: Rapid growth in BMI during the first 2 years of life increases the risk of asthma up to age 6 years.	[Rzehak, Peter; Chen, Chih-Mei; Heinrich, Joachim] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol 1, Neuherberg, Germany; [Rzehak, Peter] Univ Munich, Inst Med Data Management Biometr & Epidemiol, Chair Epidemiol, D-80337 Munich, Germany; [Rzehak, Peter] Univ Munich, Med Ctr, Dr von Hauner Childrens Hosp, Div Metab & Nutr Med, D-80337 Munich, Germany; [Wijga, Alet H.] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; [Keil, Thomas; Chen, Chih-Mei] Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Eller, Esben; Bindslev-Jensen, Carsten] Odense Univ Hosp, Dept Dermatol, Odense, Denmark; [Eller, Esben; Bindslev-Jensen, Carsten] Odense Univ Hosp, Allergy Ctr, Odense, Denmark; [Smit, Henriette A.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Weyler, Joost; Dom, Sandra] Univ Antwerp, Antwerp, Belgium; [Weyler, Joost] Univ Antwerp, StatUA Stat Ctr, Antwerp, Belgium; [Sunyer, Jordi] Res Ctr Environm Epidemiol CREAL, Barcelona, Spain; [Mendez, Michelle] Univ Pompeu Fabra, CIBERESP, Inst Municipal Salut IMIM, Barcelona, Spain; [Torrent, Maties] Ib Salut, Area Salut Menorca, Menorca, Spain; [Vall, Oriol] IMIM Hosp del Mar, URIE, Barcelona, Spain; [Vall, Oriol] Univ Autonoma Barcelona, E-08193 Barcelona, Spain; [Bauer, Carl-Peter] Tech Univ Munich, Dept Pediat, D-80290 Munich, Germany; [Berdel, Dietrich] Marien Hosp Wesel, Dept Pediat, Wesel, Germany; [Schaaf, Beate] Med Practice Pediat, Bad Honnef, Germany; [Bergstroem, Anna] Karolinska Inst, Inst Environm Med, Dept Environm Epidemiol, S-10401 Stockholm, Sweden; [Fantini, Maria P.] Univ Bologna, Dept Publ Hlth, Alma Mater Studiorum, I-40126 Bologna, Italy; [Mommers, Monique] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Epidemiol, Maastricht, Netherlands; [Wahn, Ulrich; Lau, Susanne] Charite Univ Med Ctr, Dept Pediat Allergol & Immunol, Berlin, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; Netherlands National Institute for Public Health & the Environment; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; Utrecht University; Utrecht University Medical Center; University of Antwerp; University of Antwerp; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Pompeu Fabra University; Atencio Primaria de Menorca; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; Technical University of Munich; St. Marien Hospital; Karolinska Institutet; University of Bologna; Maastricht University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Rzehak, P (corresponding author), Univ Munich, Med Ctr, Dr von Hauner Childrens Hosp, Div Metab & Nutr Med, Lindwurmstr 4, D-80337 Munich, Germany.	Peter.Rzehak@med.uni-muenchen.de	Heinrich, Joachim/N-1720-2013; Weyler, Joost JJ/O-8594-2016; Sunyer, Jordi/G-6909-2014; Bindslev-Jensen, Carsten/H-1877-2011	Heinrich, Joachim/0000-0002-9620-1629; Weyler, Joost JJ/0000-0001-7271-5492; Sunyer, Jordi/0000-0002-2602-4110; Bindslev-Jensen, Carsten/0000-0002-8940-038X	Global Allergy and Asthma European Network (GA2LEN) under the Sixth Framework Programme for Research of the European Union [FOOD-CT-2004-506378]; "Kompetenznetz Adipositas (Competence Network Obesity)"; Federal Ministry of Education and Research of Germany [FKZ: 01GI0826]; Munich Center of Health Sciences (MCHEALTH) as part of the Munich Ludwigs-Maximilians-Universitat LMU innovative; Federal Ministry for Education, Science, Research, and Technology [01 EE 9401-4, 01 EG 9705/2, 01EG9732]; Federal Ministry of Environment (IUF) [FKZ 20462296, FKS 20462296]; German Federal Ministry of Education and Research (BMBF) [07015633, 07 ALE 27, 01EE9405/5, 01EE9406]; German Research Foundation (DFG) [KE 1462/2-1]; Danish National Ministry of Health; Netherlands Organization for Health Research and Development; Netherlands Organization for Scientific Research; Netherlands Asthma Fund; Netherlands Ministry of Spatial Planning Housing, and the Environment; Netherlands Ministry of Health, Welfare, and Sport; Research Foundation Flanders (FWO, Fonds Wetenschappelijk Onderzoek Vlaanderen); Ministry of Health of the Flemish Community; Fondo de Investigacion Sanitaria, ISCIII, Ministero de Sanidad y Servicios Sociales, Spain [FIS 95/0314, FIS 96/0799, FIS 00/0021, FIS 03/0296]; Istituto Superiore di Sanita [CIRT-1999 SGR 00241]; COLT Foundation; Fifth European Program [QLK4-CT-2000-00263]; Fondo de Investigacion Sanitaria, ISCIII, Ministerio de Sanidad y Servicios Sociales, Spain [G03/176, CB06/02/0041, 97/0588, 00/0021-2, PI061756, PS0901958]; EC [QLK4 CT 2000 00263]; Fundacion Roger Torne; Charite Berlin	Global Allergy and Asthma European Network (GA2LEN) under the Sixth Framework Programme for Research of the European Union; "Kompetenznetz Adipositas (Competence Network Obesity)"; Federal Ministry of Education and Research of Germany(Federal Ministry of Education & Research (BMBF)); Munich Center of Health Sciences (MCHEALTH) as part of the Munich Ludwigs-Maximilians-Universitat LMU innovative; Federal Ministry for Education, Science, Research, and Technology; Federal Ministry of Environment (IUF); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Research Foundation (DFG)(German Research Foundation (DFG)); Danish National Ministry of Health; Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Netherlands Asthma Fund; Netherlands Ministry of Spatial Planning Housing, and the Environment; Netherlands Ministry of Health, Welfare, and Sport; Research Foundation Flanders (FWO, Fonds Wetenschappelijk Onderzoek Vlaanderen)(FWO); Ministry of Health of the Flemish Community; Fondo de Investigacion Sanitaria, ISCIII, Ministero de Sanidad y Servicios Sociales, Spain; Istituto Superiore di Sanita; COLT Foundation; Fifth European Program; Fondo de Investigacion Sanitaria, ISCIII, Ministerio de Sanidad y Servicios Sociales, Spain; EC(European CommissionEuropean Commission Joint Research Centre); Fundacion Roger Torne; Charite Berlin	Supported by the Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN) under the Sixth Framework Programme for Research of the European Union (project no. FOOD-CT-2004-506378) and the "Kompetenznetz Adipositas (Competence Network Obesity)" funded by the Federal Ministry of Education and Research of Germany (FKZ: 01GI0826). Personal and financial support was provided by the Munich Center of Health Sciences (MCHEALTH) as part of the Munich Ludwigs-Maximilians-Universitat LMU innovative is gratefully acknowledged. Each of the 8 analyzed birth cohorts had their own funding. The GINIplus study was funded for 3 years by grants of the Federal Ministry for Education, Science, Research, and Technology (Grant No. 01 EE 9401-4), and the 6-year follow-up of the GINIplus study was partly funded by the Federal Ministry of Environment (IUF, FKZ 20462296). The LISAplus study was funded by grants of the Federal Ministry for Education, Science, Research, and Technology (Grant No. 01 EG 9705/2 and 01EG9732), and the 6-year follow-up of the LISAplus study was partly funded by the Federal Ministry of Environment (IUF, FKS 20462296). The MAS study was funded by grants from the German Federal Ministry of Education and Research (BMBF; reference nos. 07015633, 07 ALE 27, 01EE9405/5, 01EE9406) and the German Research Foundation (DFG; reference no. KE 1462/2-1). The DARC study was funded by Danish National Ministry of Health. The PIAMA-NHS study received funding from The Netherlands Organization for Health Research and Development; The Netherlands Organization for Scientific Research; The Netherlands Asthma Fund, The Netherlands Ministry of Spatial Planning Housing, and the Environment; and The Netherlands Ministry of Health, Welfare, and Sport. PIPO was funded by the Research Foundation Flanders (FWO, Fonds Wetenschappelijk Onderzoek Vlaanderen) and by the Ministry of Health of the Flemish Community. The AMICS-Barcelona study was funded by Fondo de Investigacion Sanitaria, ISCIII, Ministero de Sanidad y Servicios Sociales, Spain (FIS 95/0314, FIS 96/0799, FIS 00/0021, FIS 03/0296), Istituto Superiore di Sanita, CIRT-1999 SGR 00241, COLT Foundation and the Fifth European Program (QLK4 CT 2000 00263). The AMICS-Menorca study was funded by Fondo de Investigacion Sanitaria, ISCIII, Ministerio de Sanidad y Servicios Sociales, Spain (grants G03/176, CB06/02/0041, 97/0588, 00/0021-2, PI061756 and PS0901958), EC contract no. QLK4-CT-2000-00263 and Fundacion Roger Torne.; Disclosure of potential conflict of interest: T. Keil has received grants from and is employed by Charite Berlin. The rest of the authors declare that they have no relevant conflicts of interest.	BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; Burgess JA, 2007, EUR RESPIR J, V29, P668, DOI 10.1183/09031936.00080906; Castro-Rodriguez JA, 2008, ALLERGOL IMMUNOPATH, V36, P280, DOI 10.1016/S0301-0546(08)75224-8; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Chen CM, 2007, J ALLERGY CLIN IMMUN, V119, P1148, DOI 10.1016/j.jaci.2007.02.017; Chinn S, 2006, PAEDIATR RESPIR REV, V7, P223, DOI 10.1016/j.prrv.2006.04.007; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497; Delgado J, 2008, J INVEST ALLERG CLIN, V18, P420; Flaherman V, 2006, ARCH DIS CHILD, V91, P334, DOI 10.1136/adc.2005.080390; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Hagendorens MM, 2005, CLIN EXP ALLERGY, V35, P733, DOI 10.1111/j.1365-2222.2005.02254.x; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Hersoug LG, 2007, ALLERGY, V62, P1205, DOI 10.1111/j.1398-9995.2007.01506.x; Host A, 2002, PEDIATR ALLERGY IMMU, V13, P23, DOI 10.1034/j.1399-3038.13.s.15.7.x; Hyvarinen M, 2009, J ALLERGY CLIN IMMUN, V124, P1119, DOI 10.1016/j.jaci.2009.06.050; Jensen ME, 2012, CURR OPIN ALLERGY CL, V12, P186, DOI 10.1097/ACI.0b013e3283508df5; Keil T, 2006, ALLERGY, V61, P1104, DOI 10.1111/j.1398-9995.2006.01167.x; Keil T, 2006, ALLERGY, V61, P221, DOI 10.1111/j.1398-9995.2006.00989.x; Koletzko B, 2012, P NUTR SOC, V71, P371, DOI 10.1017/S0029665112000596; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P1075, DOI 10.1016/j.jaci.2008.03.005; Lucas SR, 2006, PAEDIATR RESPIR REV, V7, P233, DOI 10.1016/j.prrv.2006.08.001; Mamun AA, 2007, INT J OBESITY, V31, P578, DOI 10.1038/sj.ijo.0803571; Mannino DM, 2006, INT J OBESITY, V30, P6, DOI 10.1038/sj.ijo.0803145; McLachlan CR, 2007, J ALLERGY CLIN IMMUN, V119, P634, DOI 10.1016/j.jaci.2006.10.029; Muthen B, 2002, BIOSTATISTICS, V3, P459, DOI 10.1093/biostatistics/3.4.459; Ong KKL, 2000, BRIT MED J, V320, P967, DOI 10.1136/bmj.320.7240.967; Rzehak P, 2009, EUR J EPIDEMIOL, V24, P449, DOI 10.1007/s10654-009-9356-5; SAS Institute, 2004, SAS STAT 9 1 US GUID; Scholtens S, 2009, J ALLERGY CLIN IMMUN, V123, P1312, DOI 10.1016/j.jaci.2009.02.029; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Singer J. D., 2003, APPL LONGITUDINAL DA; Sunyer J, 2001, CLIN EXP ALLERGY, V31, P1352, DOI 10.1046/j.1365-2222.2001.01187.x; Sutherland TJT, 2009, ANN ALLERG ASTHMA IM, V103, P101, DOI 10.1016/S1081-1206(10)60161-5; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Tantisira KG, 2001, THORAX, V56, P64; Taveras EM, 2008, J ALLERGY CLIN IMMUN, V121, P1161, DOI 10.1016/j.jaci.2008.03.021; Thyagarajan B, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-31; Visser M, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.1.e13; von Berg A, 2010, CLIN EXP ALLERGY, V40, P627, DOI 10.1111/j.1365-2222.2009.03444.x; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Wang WH, 2012, EUR RESPIR J, V39, P1213, DOI 10.1183/09031936.00091311; WHO Multicentre Growth Reference Study Group, 2013, WHO CHILD GROWTH STA; Wijga A, 2001, CLIN EXP ALLERGY, V31, P576, DOI 10.1046/j.1365-2222.2001.01072.x; Yuksel H, 2012, ALLERGY ASTHMA IMMUN, V4, P98, DOI 10.4168/aair.2012.4.2.98; Zhang ZM, 2010, J ALLERGY CLIN IMMUN, V126, P1157, DOI 10.1016/j.jaci.2010.09.011	50	114	114	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1528	+		10.1016/j.jaci.2013.01.001	http://dx.doi.org/10.1016/j.jaci.2013.01.001			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23403049				2022-12-18	WOS:000320532800010
J	Diemert, DJ; Pinto, AG; Freire, J; Jariwala, A; Santiago, H; Hamilton, RG; Periago, MV; Loukas, A; Tribolet, L; Mulvenna, J; Correa-Oliveira, R; Hotez, PJ; Bethony, JM				Diemert, David J.; Pinto, Antonio G.; Freire, Janaina; Jariwala, Amar; Santiago, Helton; Hamilton, Robert G.; Periago, Maria Victoria; Loukas, Alex; Tribolet, Leon; Mulvenna, Jason; Correa-Oliveira, Rodrigo; Hotez, Peter J.; Bethony, Jeffrey M.			Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: Implications for the development of vaccines against helminths	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hookworm; Necator americanus; urticaria; vaccine; Na-ASP-2; IgE; Brazil	NECATOR-AMERICANUS; IMMUNE-RESPONSES; SECRETED PROTEIN; IMMUNOGLOBULIN-E; INFECTION; ANTIGEN; IGE; PARASITES; TRICHURIASIS; ASSOCIATIONS	Background: Necator americanus Ancylostoma-secreted protein 2 (Na-ASP-2) is secreted by infective hookworm larvae on entry into human hosts. Vaccination of laboratory animals with recombinant Na-ASP-2 provides significant protection against challenge infections. In endemic areas antibodies to Na-ASP-2 are associated with reduced risk of heavy N americanus infections. Objective: To assess the safety and immunogenicity of recombinant Na-ASP-2 adjuvanted with Alhydrogel in healthy Brazilian adults previously infected with N americanus. Methods: Participants were randomized to receive Na-ASP-2 or hepatitis B vaccine. Major IgG and IgE epitopes of the Na-ASP-2 molecule were mapped by using sera from these same subjects. Seroepidemiologic studies in adults and children residing in hookworm-endemic areas were conducted to assess the prevalence of IgE responses to Na-ASP-2. Results: Vaccination with a single dose of Na-ASP-2 resulted in generalized urticarial reactions in several volunteers. These reactions were associated with pre-existing Na-ASP-2-specific IgE likely induced by previous hookworm infection. Surveys revealed that a significant proportion of the population in hookworm-endemic areas had increased levels of IgE to Na-ASP-2. Epitope mapping demonstrated sites on the Na-ASP-2 molecule that are uniquely or jointly recognized by IgG and IgE antibodies. Conclusion: Infection with N americanus induces increased levels of total and specific IgE to Na-ASP-2 that result in generalized urticaria on vaccination with recombinant Na-ASP-2. These data advance knowledge of vaccine development for helminths given their propensity to induce strong T(H)2 responses. Study data highlight the important differences between the immune responses to natural helminth infection and to vaccination with a recombinant helminth antigen. (J Allergy Clin Immunol 2012;130:169-76.)	[Diemert, David J.; Jariwala, Amar; Hotez, Peter J.] Albert B Sabin Vaccine Inst, Washington, DC 20037 USA; [Diemert, David J.; Santiago, Helton; Bethony, Jeffrey M.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA; [Diemert, David J.; Pinto, Antonio G.; Freire, Janaina; Santiago, Helton; Periago, Maria Victoria; Correa-Oliveira, Rodrigo; Bethony, Jeffrey M.] Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil; [Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Loukas, Alex; Tribolet, Leon; Mulvenna, Jason] James Cook Univ, Queensland Trop Hlth Alliance, Cairns, Australia; [Mulvenna, Jason] Queensland Inst Med Res, Brisbane, Qld 4006, Australia; [Hotez, Peter J.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Hotez, Peter J.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	George Washington University; Fundacao Oswaldo Cruz; Johns Hopkins University; James Cook University; QIMR Berghofer Medical Research Institute; Baylor College of Medicine; Baylor College of Medicine	Diemert, DJ (corresponding author), Albert B Sabin Vaccine Inst, 2300 1St NW,Ross Hall 723-D, Washington, DC 20037 USA.	david.diemert@sabin.org; jbethony@gwu.edu	Mulvenna, Jason/H-7110-2014; Periago, Maria/H-1054-2013; Santiago, Helton/F-8704-2012; Periago, Maria Victoria/ABE-6384-2020; Loukas, Alex/B-7355-2014; Santiago, Helton/AAA-8558-2021; Periago, Maria Victoria/AAO-7914-2020; Diemert, David/AAQ-3353-2020	Mulvenna, Jason/0000-0003-3521-8061; Santiago, Helton/0000-0002-5695-8256; Periago, Maria Victoria/0000-0002-1470-5146; Loukas, Alex/0000-0002-0896-8441; Correa-Oliveira, Rodrigo/0000-0001-6419-9459; Tribolet, Leon/0000-0002-2093-9678; Diemert, David/0000-0002-2789-0512; Hotez, Peter/0000-0001-8770-1042	Albert B. Sabin Vaccine Institute through Bill & Melinda Gates Foundation; Johns Hopkins Dermatology, Allergy, and Clinical Immunology Reference Laboratory; Albert B. Sabin Vaccine Institute	Albert B. Sabin Vaccine Institute through Bill & Melinda Gates Foundation; Johns Hopkins Dermatology, Allergy, and Clinical Immunology Reference Laboratory; Albert B. Sabin Vaccine Institute	The Albert B. Sabin Vaccine Institute funded this work through a grant from the Bill & Melinda Gates Foundation. Additional funding was provided by the Johns Hopkins Dermatology, Allergy, and Clinical Immunology Reference Laboratory.; Disclosure of potential conflict of interest: D. J. Diemert, A. G. Pinto, J. Freire, A. Jariwala, H. Santiago, M. V. Periago, A. Loukas, L. Tribolet, J. Mulvenna, R. Correa-Oliveira, and J. M. Bethony have received research support from the Albert B. Sabin Vaccine Institute. P. J. Hotez has received research support from and is President of the Albert B. Sabin Vaccine Institute. R. G. Hamilton declares that he has no relevant conflicts of interest.	Abraham D, 2004, INFECT IMMUN, V72, P810, DOI 10.1128/IAI.72.2.810-817.2004; Asojo OA, 2005, J MOL BIOL, V346, P801, DOI 10.1016/j.jmb.2004.12.023; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Bethony J, 2005, FASEB J, V19, P1743, DOI 10.1096/fj.05-3936fje; Bethony JM, 2008, VACCINE, V26, P2408, DOI 10.1016/j.vaccine.2008.02.049; Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815; Brooker S, 2007, T ROY SOC TROP MED H, V101, P146, DOI 10.1016/j.trstmh.2006.05.012; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Deen JL, 2006, NAT REV DRUG DISCOV, V5, P932, DOI 10.1038/nrd2159; Diemert DJ, 2008, CLIN INFECT DIS, V46, P282, DOI 10.1086/524070; Edelman R, 2002, VACCINE, V21, P269, DOI 10.1016/S0264-410X(02)00468-1; Erb KJ, 2007, EUR J IMMUNOL, V37, P1170, DOI 10.1002/eji.200737314; Faulkner H, 2002, J INFECT DIS, V185, P665, DOI 10.1086/339005; Fitzsimmons CM, 2009, TRENDS PARASITOL, V25, P447, DOI 10.1016/j.pt.2009.07.004; Fleming FM, 2006, TROP MED INT HEALTH, V11, P56, DOI 10.1111/j.1365-3156.2005.01541.x; Fujiwara RT, 2006, VACCINE, V24, P501, DOI 10.1016/j.vaccine.2005.07.091; Goud GN, 2005, VACCINE, V23, P4754, DOI 10.1016/j.vaccine.2005.04.040; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; Hawdon JM, 1996, J BIOL CHEM, V271, P6672, DOI 10.1074/jbc.271.12.6672; Hawdon JM, 1999, MOL BIOCHEM PARASIT, V99, P149, DOI 10.1016/S0166-6851(99)00011-0; Hotez PJ, 2005, PLOS MED, V2, P187, DOI 10.1371/journal.pmed.0020067; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jardim-Botelho A, 2008, TROP MED INT HEALTH, V13, P994, DOI 10.1111/j.1365-3156.2008.02103.x; Jardim-Botelho A, 2008, TROP MED INT HEALTH, V13, P458, DOI 10.1111/j.1365-3156.2008.02022.x; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Kooyman FNJ, 2000, PARASITE IMMUNOL, V22, P13; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; Loukas A, 2006, LANCET INFECT DIS, V6, P733, DOI 10.1016/S1473-3099(06)70630-2; Madaan A, 2003, IMMUNOL ALLERGY CLIN, V23, P555, DOI 10.1016/S0889-8561(03)00099-7; Maizels RM, 2004, IMMUNOL REV, V201, P89, DOI 10.1111/j.0105-2896.2004.00191.x; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Moreno M, 2004, VET PARASITOL, V119, P37, DOI 10.1016/j.vetpar.2003.10.020; Parkinson J, 2004, NAT GENET, V36, P1259, DOI 10.1038/ng1472; Pearson MS, 2009, FASEB J, V23, P3007, DOI 10.1096/fj.09-131433; Pullan RL, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000352; Traidl-Hoffmann C, 2009, J ALLERGY CLIN IMMUN, V123, P558, DOI 10.1016/j.jaci.2008.12.003; Turner JD, 2005, MICROBES INFECT, V7, P990, DOI 10.1016/j.micinf.2005.03.036; Webster M, 1996, INFECT IMMUN, V64, P4042, DOI 10.1128/IAI.64.10.4042-4046.1996; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	39	114	114	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					169	+		10.1016/j.jaci.2012.04.027	http://dx.doi.org/10.1016/j.jaci.2012.04.027			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22633322				2022-12-18	WOS:000306644800025
J	Yildirim-Toruner, C; Diamond, B				Yildirim-Toruner, Cagri; Diamond, Betty			Current and novel therapeutics in the treatment of systemic lupus erythematosus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Systemic lupus erythematosus; treatment	INTRAVENOUS IMMUNOGLOBULIN TREATMENT; PLACEBO-CONTROLLED TRIAL; SPLEEN TYROSINE KINASE; TUMOR-NECROSIS-FACTOR; MURINE LUPUS; DOUBLE-BLIND; B-CELLS; MONOCLONAL-ANTIBODY; DISEASE-ACTIVITY; GENE VACCINATION	Systemic lupus erythematosus (SLE) is a complex autoimmune disease with significant clinical heterogeneity. Recent advances in our understanding of the genetic, molecular, and cellular bases of autoimmune diseases and especially SLE have led to the application of novel and targeted treatments. Although many treatment modalities are effective in lupus-prone mice, the situation is more complex in human subjects. This article reviews the general approach to the therapy of SLE, focusing on current approved therapies and novel approaches that might be used in the future. (J Allergy Clin Immunol 2011;127:303-12.)	[Yildirim-Toruner, Cagri; Diamond, Betty] Ctr Autoimmune & Musculoskeletal Dis, Feinstein Inst Med Res, Manhasset, NY USA; [Yildirim-Toruner, Cagri] Columbia Univ, Dept Pediat, Div Pediat Rheumatol, Morgan Stanley Childrens Hosp New York Presbyteri, New York, NY 10027 USA	Northwell Health; Columbia University; NewYork-Presbyterian Hospital; Morgan Stanley Children's Hospital	Diamond, B (corresponding author), Feinstein Inst Med Res Autoimmune & Musucloskelet, 350 Community Dr, Manhasset, NY 11030 USA.	bdiamond@nshs.edu			National Institues of Health; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049126] Funding Source: NIH RePORTER	National Institues of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	B. Diamond has received research support from the National Institues of Health and has provided expert testimony on the subjects of anti-TNF and anti-BNFF. C. Yildirim-Toruner has declared no conflict of interest.	Aharon A, 1997, LUPUS, V6, P408, DOI 10.1177/096120339700600412; Anolik JH, 2004, ARTHRITIS RHEUM, V50, pS460; [Anonymous], 2010, STUDY EVALUATE EFFIC; [Anonymous], 2010, ATACICEPT PHASE 2 3; [Anonymous], 2009, EFFICACY SAFETY ATAC; Aringer M, 2004, LUPUS, V13, P344, DOI 10.1191/0961203303lu1024oa; Aringer M, 2009, LUPUS, V18, P5, DOI 10.1177/0961203308098190; Aringer M, 2001, RHEUMATOLOGY, V40, P876, DOI 10.1093/rheumatology/40.8.876; Aringer M, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2341; Arnal C, 2002, J RHEUMATOL, V29, P75; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Bahjat FR, 2008, ARTHRITIS RHEUM-US, V58, P1433, DOI 10.1002/art.23428; Ballow M, 1997, J ALLERGY CLIN IMMUN, V100, P151, DOI 10.1016/S0091-6749(97)70217-3; BECKER BN, 1995, J AM SOC NEPHROL, V5, P1746; Bianchi S, 2003, AM J KIDNEY DIS, V41, P565, DOI 10.1053/ajkd.2003.50140; Borba EF, 2001, J RHEUMATOL, V28, P780; Bossu P, 2003, P NATL ACAD SCI USA, V100, P14181, DOI 10.1073/pnas.2336094100; Boumpas DT, 2003, ARTHRITIS RHEUM-US, V48, P719, DOI 10.1002/art.10856; Cardiel MH, 2008, ARTHRITIS RHEUM, V58, P2470, DOI 10.1002/art.23673; Carneiro JRM, 1999, J RHEUMATOL, V26, P1275; Chetan G, 2007, INDIAN J PEDIATR, V74, P1032, DOI 10.1007/s12098-007-0190-z; Contreras G, 2004, NEW ENGL J MED, V350, P971, DOI 10.1056/NEJMoa031855; Costedoat-Chalumeau N, 2003, ARTHRITIS RHEUM, V48, P3207, DOI 10.1002/art.11304; Daikh DI, 2001, J IMMUNOL, V166, P2913, DOI 10.4049/jimmunol.166.5.2913; Dall'Era M, 2007, ARTHRITIS RHEUM, V56, P4142, DOI 10.1002/art.23047; Daridon C, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3179; Deng GM, 2010, ARTHRITIS RHEUM-US, V62, P2086, DOI 10.1002/art.27452; DEPAULIS A, 1991, ARTHRITIS RHEUM-US, V34, P1289, DOI 10.1002/art.1780341013; Doria A, 2008, LUPUS, V17, P166, DOI 10.1177/0961203307087612; Dunn SE, 2006, J EXP MED, V203, P401, DOI 10.1084/jem.20051129; Ferreira GA, 2007, RHEUMATOLOGY, V46, P1560, DOI 10.1093/rheumatology/kem186; Ferrera F, 2007, ANN NY ACAD SCI, V1110, P99, DOI 10.1196/annals.1423.012; Ferrera F, 2007, ARTHRITIS RHEUM-US, V56, P1945, DOI 10.1002/art.22700; FINCK BK, 1994, J CLIN INVEST, V94, P585, DOI 10.1172/JCI117373; FRANCIONI C, 1994, CLIN EXP RHEUMATOL, V12, P163; Furtado PB, 2002, J CLIN PATHOL-MOL PA, V55, P315, DOI 10.1136/mp.55.5.315; Gao C, 2009, J CLIN INVEST, V119, P504, DOI 10.1172/JCI36745; Ginzler EM, 2005, NEW ENGL J MED, V353, P2219, DOI 10.1056/NEJMoa043731; Grenader T, 2004, CLIN RHEUMATOL, V23, P530, DOI 10.1007/s10067-004-0931-6; Grillo-Lopez AJ, 1999, SEMIN ONCOL, V26, P66; GRUBER BL, 1988, ARTHRITIS RHEUM-US, V31, P1000, DOI 10.1002/art.1780310810; Guiducci C, 2010, NATURE, V465, P937, DOI 10.1038/nature09102; Hayat Sawsan Johar, 2007, Mod Rheumatol, V17, P174, DOI 10.1007/s10165-006-0561-8; Houssiau FA, 2010, ANN RHEUM DIS, V69, P61, DOI 10.1136/ard.2008.102533; Illei GG, 2010, ARTHRITIS RHEUM-US, V62, P542, DOI 10.1002/art.27221; Iwai H, 2003, J IMMUNOL, V171, P2848, DOI 10.4049/jimmunol.171.6.2848; Jacobi AM, 2010, ARTHRITIS RHEUM-US, V62, P201, DOI 10.1002/art.27189; KALUNIAN K, 2010, BILAG MEASURED IMPRO; Kalunian KC, 2002, ARTHRITIS RHEUM, V46, P3251, DOI 10.1002/art.10681; Kotyla PJ, 2006, J RHEUMATOL, V33, P2361; Kowal C, 2004, IMMUNITY, V21, P179, DOI 10.1016/j.immuni.2004.07.011; Lazurova I, 2007, CLIN RHEUMATOL, V26, P2145, DOI 10.1007/s10067-007-0627-9; Lesprit P, 1996, SCAND J RHEUMATOL, V25, P177, DOI 10.3109/03009749609080011; Levy Y, 1999, LUPUS, V8, P705, DOI 10.1191/096120399678841007; Levy Y, 2000, SEMIN ARTHRITIS RHEU, V29, P321, DOI 10.1016/S0049-0172(00)80018-9; Llorente L, 2000, ARTHRITIS RHEUM, V43, P1790, DOI 10.1002/1529-0131(200008)43:8<1790::AID-ANR15>3.0.CO;2-2; LLORENTE L, 1995, J EXP MED, V181, P839, DOI 10.1084/jem.181.3.839; Looney RJ, 2004, ARTHRITIS RHEUM, V50, P2580, DOI 10.1002/art.20430; Lopez-Pedrera C., 2009, ANN RHEUM DIS     S3, V3, P245; Merrill JT, 2010, ARTHRITIS RHEUM-US, V62, P222, DOI 10.1002/art.27233; Micheloud D, 2007, ANN RHEUM DIS, V66, P986, DOI 10.1136/ard.2006.058784; Milstone AM, 2005, CLIN RHEUMATOL, V24, P394, DOI 10.1007/s10067-004-1046-9; Moosig F, 2004, LUPUS, V13, P605, DOI 10.1191/0961203304lu1047cr; Mosser DM, 2008, IMMUNOL REV, V226, P205, DOI 10.1111/j.1600-065X.2008.00706.x; Norby GE, 2009, ARTHRITIS RHEUM, V60, P1060, DOI 10.1002/art.24379; Ostendorf B, 2005, ANN RHEUM DIS, V64, P630, DOI 10.1136/ard.2004.025858; Park MC, 2004, CLIN RHEUMATOL, V23, P225, DOI 10.1007/s10067-004-0867-x; Park YB, 1998, CLIN EXP RHEUMATOL, V16, P283; Patschan S, 2006, CLIN EXP IMMUNOL, V145, P235, DOI 10.1111/j.1365-2249.2006.03141.x; Rother RP, 2004, LUPUS, V13, P328, DOI 10.1191/0961203303lu1021oa; Sturfelt G, 1997, BRIT J RHEUMATOL, V36, P1283; Suwannaroj S, 2001, LUPUS, V10, P258, DOI 10.1191/096120301680416940; Tackey E, 2004, LUPUS, V13, P339, DOI 10.1191/0961203304lu1023oa; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; Wallace DJ, 2009, ARTHRIT RHEUM-ARTHR, V61, P1168, DOI 10.1002/art.24699; Wallace DJ, 2001, LUPUS, V10, P385, DOI 10.1191/096120301678646092; Wallace DJ, 2001, LUPUS, V10, P193, DOI 10.1191/096120301671920760; Wang XB, 2003, ARTHRITIS RHEUM, V48, P495, DOI 10.1002/art.10929; Wang XB, 2002, J IMMUNOL, V168, P2046, DOI 10.4049/jimmunol.168.4.2046; Weinblatt ME, 2008, ARTHRITIS RHEUM-US, V58, P3309, DOI 10.1002/art.23992; Yao YH, 2009, ARTHRITIS RHEUM, V60, P1785, DOI 10.1002/art.24557; Zandman-Goddard G, 2009, LUPUS, V18, P884, DOI 10.1177/0961203309106921; 2010, PHASE 2B RANDOMIZED; 2009, STUDY LJP 394 LUPUS; 2009, RESULTS 1 INTERIM EF	85	114	127	2	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					303	312		10.1016/j.jaci.2010.12.1087	http://dx.doi.org/10.1016/j.jaci.2010.12.1087			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21281862	Green Accepted			2022-12-18	WOS:000286808000001
J	Vassallo, MF; Camargo, CA				Vassallo, Milo F.; Camargo, Carlos A., Jr.			Potential mechanisms for the hypothesized link between sunshine, vitamin D, and food allergy in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; vitamin D; vitamin D deficiency; mucosal immunity; epithelial barrier; microbial ecology; infections; sensitization; atopy	REGULATORY T-CELLS; BODY-MASS INDEX; ATOPIC-DERMATITIS; 1,25-DIHYDROXYVITAMIN D-3; D DEFICIENCY; ORAL TOLERANCE; IMMUNE-SYSTEM; US CHILDREN; D-RECEPTOR; PREGNANCY	Epidemiologic data suggest that the incidence of food allergy (FA) is increasing among children, yet a satisfactory model of its pathogenesis remains elusive. FA is the consequence of maladaptive immune responses to common and otherwise innocuous food antigens. Concurrent with the increase in FA is an epidemic of vitamin D deficiency (VDD) caused by several factors, especially decreased sunlight/UVB exposure. There is growing appreciation of the importance of the pleiotropic hormone vitamin D in the development of tolerance, immune system defenses, and epithelial barrier integrity. We propose a "multiplehit'' model in which VDD in a developmentally critical period increases susceptibility to colonization with abnormal intestinal microbial flora and gastrointestinal infections, contributing to abnormal intestinal barrier permeability and excess and inappropriate exposure of the immune system to dietary allergens. A compounding effect (and additional "hit'') of VDD is the promotion of a pro-sensitization immune imbalance that might compromise immunologic tolerance and contribute to FA. We propose that early correction of VDD might promote mucosal immunity, healthy microbial ecology, and allergen tolerance and thereby blunt the FA epidemic in children. (J Allergy Clin Immunol 2010;126:217-22.)	[Vassallo, Milo F.; Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA 02114 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Camargo, CA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol,Dept Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.	ccamargo@partners.org	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	National Institutes of Health (Bethesda, Md) [T32 AI-060548]; Massachusetts General Hospital Center for D-receptor Activation Research (Boston, Mass); Food Allergy and Anaphylaxis Network (Fairfax, Va); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060548] Funding Source: NIH RePORTER	National Institutes of Health (Bethesda, Md)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Massachusetts General Hospital Center for D-receptor Activation Research (Boston, Mass); Food Allergy and Anaphylaxis Network (Fairfax, Va); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	M. F. V. was supported by T32 AI-060548 from the National Institutes of Health (Bethesda, Md). C. A. C. was supported, in part, by the Massachusetts General Hospital Center for D-receptor Activation Research (Boston, Mass) and the Food Allergy and Anaphylaxis Network (Fairfax, Va).	Adorini L, 2003, J CELL BIOCHEM, V88, P227, DOI 10.1002/jcb.10340; Ali FN, 2009, PEDIATRICS, V123, P791, DOI 10.1542/peds.2008-0634; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Burks AW, 2008, J ALLERGY CLIN IMMUN, V121, P1344, DOI 10.1016/j.jaci.2008.02.037; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Cecilia M, 2008, J ALLERGY CLIN IMMUN, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Cochrane S, 2009, ALLERGY, V64, P1246, DOI 10.1111/j.1398-9995.2009.02128.x; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Dimeloe S, 2010, J STEROID BIOCHEM, V120, P86, DOI 10.1016/j.jsbmb.2010.02.029; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; Frank DN, 2008, CURR OPIN GASTROEN, V24, P4, DOI 10.1097/MOG.0b013e3282f2b0e8; Gartner LM, 2003, PEDIATRICS, V111, P908, DOI 10.1542/peds.111.4.908; Ginde AA, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.11.036; Ginde AA, 2009, CURR ALLERGY ASTHM R, V9, P81, DOI 10.1007/s11882-009-0012-7; Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; GRUSKAY FL, 1955, PEDIATRICS, V16, P763; HARVEY L, 2010, J STEROID BIOCH MOL; Heaney RP, 2009, J AM COLL NUTR, V28, P252, DOI 10.1080/07315724.2009.10719779; Heine G, 2008, EUR J IMMUNOL, V38, P2210, DOI 10.1002/eji.200838216; Hewison M, 2010, MOL CELL ENDOCRINOL, V321, P103, DOI 10.1016/j.mce.2010.02.013; Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Holick MF, 2009, ANN EPIDEMIOL, V19, P73, DOI 10.1016/j.annepidem.2007.12.001; Hollis BW, 2008, AM J CLIN NUTR, V88, p507S, DOI 10.1093/ajcn/88.2.507S; Hollis BW, 2009, NAT REV ENDOCRINOL, V5, P534, DOI 10.1038/nrendo.2009.178; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Janzi M, 2009, CLIN IMMUNOL, V133, P78, DOI 10.1016/j.clim.2009.05.014; Kong J, 2008, AM J PHYSIOL-GASTR L, V294, pG208, DOI 10.1152/ajpgi.00398.2007; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Lagishetty V, 2010, ENDOCRINOLOGY, V151, P2423, DOI 10.1210/en.2010-0089; Lagunova Z, 2009, ANTICANCER RES, V29, P3713, DOI 10.14341/2071-8713-4886; Mansbach JM, 2009, PEDIATRICS, V124, P1404, DOI 10.1542/peds.2008-2041; Maverakis E, 2010, J AUTOIMMUN, V34, pJ247, DOI 10.1016/j.jaut.2009.11.011; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; Mullins RJ, 2009, ANN ALLERG ASTHMA IM, V103, P488, DOI 10.1016/S1081-1206(10)60265-7; Nwaru BI, 2010, PEDIAT ALLERG IMM-UK, V21, P29, DOI 10.1111/j.1399-3038.2009.00949.x; Ogden CL, 2010, JAMA-J AM MED ASSOC, V303, P242, DOI 10.1001/jama.2009.2012; Rautava Samuli, 2007, Curr Gastroenterol Rep, V9, P385, DOI 10.1007/s11894-007-0047-7; Rochat MK, 2010, CLIN EXP ALLERGY, V40, P786, DOI 10.1111/j.1365-2222.2009.03428.x; Rudders SA, 2010, ANN ALLERG ASTHMA IM, V104, P413, DOI 10.1016/j.anai.2010.01.022; Salzman NH, 2010, NAT IMMUNOL, V11, P76, DOI 10.1038/ni.1825; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Sheehan WJ, 2009, J ALLERGY CLIN IMMUN, V124, P850, DOI 10.1016/j.jaci.2009.06.044; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sidbury R, 2008, BRIT J DERMATOL, V159, P245, DOI 10.1111/j.1365-2133.2008.08601.x; Slack E, 2009, SCIENCE, V325, P617, DOI 10.1126/science.1172747; Sudo N, 1997, J IMMUNOL, V159, P1739; Szeles L, 2009, J IMMUNOL, V182, P2074, DOI 10.4049/jimmunol.0803345; Todd DG, 2007, PEDIATRICS, V120, P1304, DOI 10.1542/peds.2007-0350; Unger WWJ, 2009, EUR J IMMUNOL, V39, P3147, DOI 10.1002/eji.200839103; Vassallo MF, 2010, ANN ALLERG ASTHMA IM, V104, P307, DOI 10.1016/j.anai.2010.01.019; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, P1163, DOI 10.1016/j.jaci.2008.12.1126; von Essen MR, 2010, NAT IMMUNOL, V11, P344, DOI 10.1038/ni.1851; Wagner CL, 2008, PEDIATRICS, V122, P1142, DOI 10.1542/peds.2008-1862; Wang TT, 2010, J BIOL CHEM, V285, P2237, DOI 10.1074/jbc.C109.071225; Weisberg P, 2004, AM J CLIN NUTR, V80, p1697S, DOI 10.1093/ajcn/80.6.1697S; Wjst M, 2006, PEDIAT ALLERG IMM-UK, V17, P477, DOI 10.1111/j.1399-3038.2006.00456.x; Wortsman J, 2000, AM J CLIN NUTR, V72, P690, DOI 10.1093/ajcn/72.3.690	67	114	121	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					217	222		10.1016/j.jaci.2010.06.011	http://dx.doi.org/10.1016/j.jaci.2010.06.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624647				2022-12-18	WOS:000281203800004
J	Holt, PG; Rowe, J; Kusel, M; Parsons, F; Hollams, EM; Bosco, A; McKenna, K; Subrata, L; de Klerk, N; Serralha, M; Holt, BJ; Zhang, GC; Loh, R; Ahlstedt, S; Sly, PD				Holt, Patrick G.; Rowe, Julie; Kusel, Merci; Parsons, Faith; Hollams, Elysia M.; Bosco, Anthony; McKenna, Kathy; Subrata, Lily; de Klerk, Nicholas; Serralha, Michael; Holt, Barbara J.; Zhang, Guicheng; Loh, Richard; Ahlstedt, Staffan; Sly, Peter D.			Toward improved prediction of risk for atopy and asthma among preschoolers: A prospective cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; respiratory tract infection; wheeze; asthma; infancy	ENVIRONMENTAL ALLERGENS; PERTUSSIS VACCINE; 1ST YEAR; SENSITIZATION; RESPONSES; LIFE; IDENTIFICATION; MATURATION; MEMORY; INFECTIONS	Background: Atopy and asthma are commonly initiated during early life, and there is increasing interest in the development of preventive treatments for at-risk children. However, effective methods for assessing the level of risk in individual children are lacking. Objective: We sought to identify clinical and laboratory biomarkers in 2-year-olds that are predictive of the risk for persistent atopy and wheeze at age 5 years. Methods: We prospectively studied 198 atopic family history positive children to age 5 years. Clinical and laboratory assessments related to asthma history and atopy status were undertaken annually; episodes of acute respiratory illness were assessed and classified throughout and graded by severity. Results: Aeroallergen-specific IgE titers cycled continuously within the low range in nonatopic subjects. Atopic subjects displayed similar cycling in infancy but eventually locked into a stable pattern of upwardly trending antibody production and T(H)2-polarized cellular immunity. The latter was associated with stable expression of IL-4 receptor in allergen-specific T(H)2 memory responses, which was absent from responses during infancy. Risk for persistent wheeze was strongly linked to early sensitization and in turn to early infection. Integration of these data by means of logistic regression revealed that attaining mite-specific IgE titers of greater than 0.20 kU/L by age 2 years was associated with a 12.7% risk of persistent wheeze, increasing progressively to an 87.2% risk with increasing numbers of severe lower respiratory tract illnesses experienced. Conclusion: The risk for development of persistent wheeze in children can be quantified by means of integration of measures related to early sensitization and early infections. Follow-up studies along similar lines in larger unselected populations to refine this approach are warranted. (J Allergy Clin Immunol 2010;125:653-9.)	[Holt, Patrick G.; Rowe, Julie; Kusel, Merci; Parsons, Faith; Hollams, Elysia M.; Bosco, Anthony; McKenna, Kathy; Subrata, Lily; de Klerk, Nicholas; Serralha, Michael; Holt, Barbara J.; Sly, Peter D.] Univ Western Australia, Fac Med & Dent, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; [Holt, Patrick G.; Rowe, Julie; Kusel, Merci; Parsons, Faith; Hollams, Elysia M.; Bosco, Anthony; McKenna, Kathy; Subrata, Lily; de Klerk, Nicholas; Serralha, Michael; Holt, Barbara J.; Sly, Peter D.] Univ Western Australia, Fac Med & Dent, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Zhang, Guicheng] Univ Western Australia, Dept Pediat, Perth, WA 6009, Australia; [Ahlstedt, Staffan] Phadia AB, Uppsala, Sweden; [Ahlstedt, Staffan] Karolinska Inst, Natl Inst Environm Med, Ctr Allergy Res, Stockholm, Sweden; [Loh, Richard] Princess Margaret Hosp Children, Perth, WA, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia; Thermo Fisher Scientific; Phadia; Karolinska Institutet; University of Western Australia	Holt, PG (corresponding author), Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, Perth, WA 6872, Australia.	patrick@ichr.uwa.edu.au	Bosco, Anthony/AAC-6900-2022; Sly, Peter D/F-1486-2010; de Klerk, Nicholas H/D-8388-2016; Serralha, Michael/CAA-0940-2022; Zhang, Brad/AAF-8719-2021; Holt, Patrick/H-1548-2011	Sly, Peter D/0000-0001-6305-2201; de Klerk, Nicholas H/0000-0001-9223-0767; Serralha, Michael/0000-0002-0121-2879; Holt, Patrick/0000-0003-1193-0935; Bosco, Anthony/0000-0002-4335-615X; Zhang, Guicheng/0000-0001-9888-5385; Hollams, Elysia/0000-0002-3481-6396	National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the National Health and Medical Research Council of Australia. Reagents for antibody assays were provided by Phadia AB.	Bosco A, 2009, J IMMUNOL, V182, P6011, DOI 10.4049/jimmunol.0804125; CALHOUN W J, 1992, American Review of Respiratory Disease, V145, pA638; Gavin MA, 1995, IMMUNITY, V3, P793, DOI 10.1016/1074-7613(95)90068-3; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Hassan J, 2001, J IMMUNOL, V167, P1970, DOI 10.4049/jimmunol.167.4.1970; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Hayward A R, 1991, Adv Exp Med Biol, V310, P71; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Holt PG, 2007, CURR OPIN ALLERGY CL, V7, P547, DOI 10.1097/ACI.0b013e3282f14a17; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P1117, DOI 10.1067/mai.2000.105804; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P255, DOI 10.1111/j.1365-2222.1989.tb02380.x; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Liao W, 2008, NAT IMMUNOL, V9, P1288, DOI 10.1038/ni.1656; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790, DOI 10.1164/ajrccm.161.6.9906130; MARIANI F, 1992, CLIN EXP ALLERGY, V22, P29, DOI 10.1111/j.1365-2222.1992.tb00111.x; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Rowe J, 2001, J INFECT DIS, V184, P80, DOI 10.1086/320996; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Sherrill D, 1999, CLIN EXP ALLERGY, V29, P905; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Thornton CA, 2004, J IMMUNOL, V173, P3084, DOI 10.4049/jimmunol.173.5.3084; Zhang GC, 2009, AM J RESP CRIT CARE, V179, P205, DOI 10.1164/rccm.200803-438OC	31	114	116	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					653	659		10.1016/j.jaci.2009.12.018	http://dx.doi.org/10.1016/j.jaci.2009.12.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226300	Bronze			2022-12-18	WOS:000275883200022
J	Schaub, B; Liu, J; Hoppler, S; Haug, S; Sattler, C; Lluis, A; Illi, S; von Mutius, E				Schaub, Bianca; Liu, Jing; Hoeppler, Sabine; Haug, Severine; Sattler, Christine; Lluis, Anna; Illi, Sabina; von Mutius, Erika			Impairment of T-regulatory cells in cord blood of atopic mothers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adaptive; cord blood; cytokines; innate; IL; regulatory T cells; T(H)17 cells; Toll-like receptor	NEONATAL IMMUNE-RESPONSES; SCHOOL-AGE-CHILDREN; EXPRESSION; STIMULATION; EXPOSURE; ASTHMA; INFLAMMATION; RECEPTOR-2; ALLERGY; FOXP3	Background: Maternal atopy is a strong predictor for the development of childhood allergic diseases. The underlying mechanisms are ill defined, yet regulatory T (Treg) and T(H)17 cells may play a key role potentially shaping the early immune system toward a proallergic or antiallergic immune regulation. Objective: We examined T(H)1/T(H)2, Treg, and T(H)17 cell responses to innate (lipid A/peptidoglycan) and mitogen/adaptive (phytohemagglutinin/Dermatophagoides pteronyssinus 1) immune stimulation in cord blood from offspring of atopic/nonatopic mothers. Methods: Cord blood mononuclear cells from 161 healthy neonates (59% nonatopic, 41% atopic mothers) were investigated regarding Treg and T(H)17 cells (mRNA/surface markers), suppressive function, and proliferation/cytokine secretion. Results: Cord blood from offspring of atopic mothers showed fewer innate-induced Treg cells (CD4(+)CD25(+) high), lower mRNA expression of associated markers (glucocorticoid-induced tumor necrosis factor receptor-related protein/lymphocyte activation gene 3; P < .05), and a trend toward lower Forkhead box transcription factor 3 (Foxp3) expression. Treg cell function was impaired in mitogen-induced suppression of T effector cells in cord blood of offspring from atopic mothers (P = .03). Furthermore, IL-10 and IFN-gamma secretion were decreased in innate-stimulated cord blood of offspring from atopic mothers (P = .04/.05). Innate-induced IL-17 was independent of maternal atopy and highly correlated with IL-13 secretion. Conclusion: In offspring of atopic mothers, Treg cell numbers, expression, and function were impaired at birth. T(H)17 cells were correlated with T(H)2 cells, independently of maternal atopy.	[Schaub, Bianca; Liu, Jing; Hoeppler, Sabine; Haug, Severine; Lluis, Anna; Illi, Sabina; von Mutius, Erika] Univ Children Hosp Munich, Dr Von Haunerschen Kinderspital, Dept Pulm & Allergy, D-80337 Munich, Germany; [Sattler, Christine] Univ Munich, Univ Hosp, Dept Gynecol, Munich, Germany; [Liu, Jing] Jilin Univ, Hosp 2, Dept Resp Med, Changchun 130023, Peoples R China	University of Munich; University of Munich; Jilin University	Schaub, B (corresponding author), Univ Children Hosp Munich, Dr Von Haunerschen Kinderspital, Dept Pulm & Allergy, Lindwurmstr 4, D-80337 Munich, Germany.	Bianca.Schaub@med.uni-muenchen.de	Schaub, Bianca/B-9935-2019	Schaub, Bianca/0000-0003-1652-8873; von Mutius, Erika/0000-0002-8893-4515				Allakhverdi Z, 2006, J ALLERGY CLIN IMMUN, V118, P1342, DOI 10.1016/j.jaci.2006.07.034; Amoudruz P, 2005, J ALLERGY CLIN IMMUN, V115, P1304, DOI 10.1016/j.jaci.2005.02.036; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Crestani E, 2004, J ALLERGY CLIN IMMUN, V113, P284, DOI 10.1016/j.jaci.2003.11.009; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Gold DR, 2006, J ALLERGY CLIN IMMUN, V117, P931, DOI 10.1016/j.jaci.2005.12.1322; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Heinrich J, 2002, Pneumologie, V56, P297, DOI 10.1055/s-2002-30699; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Ivanov S, 2007, AM J RESP CELL MOL, V36, P442, DOI 10.1165/rcmb.2006-0020OC; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Patel M, 2005, EUR J IMMUNOL, V35, P3581, DOI 10.1002/eji.200535421; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schaub B, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-40; Schaub B, 2005, J CLIN IMMUNOL, V25, P329, DOI 10.1007/s10875-005-4180-5; Schaub B, 2004, J INTERF CYTOK RES, V24, P543, DOI 10.1089/jir.2004.24.543; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Velasco G, 2005, AM J RESP CELL MOL, V32, P218, DOI 10.1165/rcmb.2003-0435OC; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002	25	114	118	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1491	1499		10.1016/j.jaci.2008.04.010	http://dx.doi.org/10.1016/j.jaci.2008.04.010			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18539197				2022-12-18	WOS:000256771700028
J	Estelle, F; Simons, R				Estelle, F.; Simons, R.			Anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; allergic reaction; mast cell; basophil; IgE; Fc epsilon RI; histamine; tryptase; food allergy; venom allergy; medication allergy; epinephrine; adrenaline; H-1-antihistamine	HYMENOPTERA VENOM ALLERGY; INSECT STING ALLERGY; MAST-CELLS; FOOD ALLERGY; ANTI-IGE; IMMUNOTHERAPY; BASOPHILS; EPINEPHRINE; MECHANISMS; COMMUNITY	Anaphylaxis is an acute-onset, potentially fatal systemic allergic reaction. It is usually triggered by an agent such as an insect sting, food, or medication, through a mechanism involving IgE and the high-affinity IgE receptor on mast cells or basophils. Less commonly, it is triggered through other immunologic mechanisms, or through nonimmunologic mechanisms. It often occurs in community settings. Anaphylaxis episodes range in severity from those that are mild and resolve spontaneously to those that are fatal within minutes. The clinical diagnosis is based on a meticulous history and physical examination, sometimes, but not necessarily, supported by a laboratory test such as an elevated serum total tryptase level. Sensitization to allergen triggers suggested by the history needs to be confirmed by skin testing and measurement of allergen-specific IgE. In some sensitized individuals, additional tests are needed to assess the risk of future anaphylaxis episodes. Prompt injection of epinephrine is life-saving. H-1-antihistamines and inhaled beta(2)-adrenergic agonists cannot be depended on to prevent fatality. Long-term risk reduction is an integral part of management.	[Estelle, F.; Simons, R.] Univ Manitoba, Allergy & Clin Immunol Sect, Dept Pediat & Child Hlth, Dept Immunol, Winnipeg, MB R3T 2N2, Canada; [Estelle, F.; Simons, R.] Univ Manitoba, Canadian Inst Hlth Res, Natl Training Program Allergy & Asthma, Fac Med, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; Institute for Work & Health; University of Manitoba	Estelle, F (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca						Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Castells M, 2006, CURR OPIN ALLERGY CL, V6, P476, DOI 10.1097/ACI.0b013e3280108716; Chang TW, 2006, J ALLERGY CLIN IMMUN, V117, P1203, DOI 10.1016/j.jaci.2006.04.005; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Golden DBK, 2006, J ALLERGY CLIN IMMUN, V117, P670, DOI 10.1016/j.jaci.2005.12.1313; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Greenberger PA, 2006, J ALLERGY CLIN IMMUN, V117, pS464, DOI 10.1016/j.jaci.2005.11.002; Greenberger PA, 2007, ANN ALLERG ASTHMA IM, V98, P252, DOI 10.1016/S1081-1206(10)60714-4; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Jensen Bettina M., 2007, Inflammation & Allergy Drug Targets, V6, P57, DOI 10.2174/187152807780077255; *JOINT TASK FORC P, 2005, J ALLERGY CLIN IM S2, V0115, pS 483; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; Kounis NG, 2006, INT J CARDIOL, V110, P7, DOI 10.1016/j.ijcard.2005.08.007; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jaci.2004.11.012, 10.1016/j.jsci.2004.11.012]; Olivera A, 2007, IMMUNITY, V26, P287, DOI 10.1016/j.immuni.2007.02.008; Plager DA, 2006, J ALLERGY CLIN IMMUN, V117, P626, DOI 10.1016/j.jaci.2005.10.023; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Rawas-Qalaji MM, 2006, J ALLERGY CLIN IMMUN, V117, P398, DOI 10.1016/j.jaci.2005.12.1310; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; SHEIKH A, 2007, COCHRANE DB SYST REV, V1; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2007, IMMUNOL ALLERGY CLIN, V27, P231, DOI 10.1016/j.iac.2007.03.007; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Stumpf JL, 2006, ANN PHARMACOTHER, V40, P699, DOI 10.1345/aph.1G295; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Yokoi H, 2006, ALLERGY, V61, P769, DOI 10.1111/j.1398-9995.2006.01133.x	40	114	118	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		2			S402	S407		10.1016/j.jaci.2007.08.061	http://dx.doi.org/10.1016/j.jaci.2007.08.061			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266IB	18241691				2022-12-18	WOS:000253426600010
J	Kinaciyan, T; Jahn-Schmid, B; Radakovics, A; Zwolfer, B; Schreiber, C; Francis, JN; Ebner, C; Bohle, B				Kinaciyan, Tamar; Jahn-Schmid, Beatrice; Radakovics, Astrid; Zwoelfer, Bettina; Schreiber, Claudia; Francis, James N.; Ebner, Christof; Bohle, Barbara			Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						birch pollen allergy; Bet v 1; food allergy; oral allergy syndrome; sublingual immunotherapy; cross-reactivity	T-CELL EPITOPE; CROSS-REACTIVITY; MAJOR ALLERGEN; DOUBLE-BLIND; POLLINOSIS; BET-V-1; IGE; CHILDREN; HAZELNUT; EFFICACY	Background: Cross-reactivity between the major birch pollen allergen, Bet v 1. and the apple protein, Mal d 1, frequently causes food allergy. Objective: To investigate the effects of successful sublingual immunotherapy (SLIT) with birch pollen extract on apple allergy and the immune response to Bet v I and Mal d 1. Methods: Before and after 1 year of SLIT, Bet v 1-sensitized patients with oral allergy syndrome to apple underwent nasal challenges with birch pollen and double-blind placebo-controlled food challenges with apple. Bet v 1-specific and Mal d I-specific serum antibody levels and proliferation in PBMCs and allergen-specific T-cell lines (TCLs) were determined. Bet v I-specific TCLs were mapped for T-cell epitopes. Results: In 9 patients with improved nasal provocation scores to birch pollen, apple-induced oral allergy syndrome was not significantly, reduced. Bet v I-specific IgE and IgG(4) levels significantly increased. Bet v I-specific T-cell responses to all epitopes and those cross-reactive with Mal d I significantly decreased. However, neither Mal d I-specific IgE and IgG4 levels nor Mal d I-induced T-cell proliferation changed significantly. In contrast, Mal d I-specific TCLs showed increased responses to Mal d 1 after I year of SLIT. Conclusion: This longitudinal study indicates that pollen SLIT does not efficiently alter the immune response to pollen-related food allergens. which may explain why pollen-associated food allergy is frequently not ameliorated by pollen immunotherapy even if respiratory symptoms significantly improve. Clinical implications: SLIT with birch pollen may have no clinical effect on associated apple allergy.	Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna, Div Immunol Allergy & Infect Dis, Dept Dermatol, A-1090 Vienna, Austria; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	Medical University of Vienna; Medical University of Vienna; Imperial College London	Bohle, B (corresponding author), Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Waehringer Guertel 18-20,AKH-3Q, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at		Bohle, Barbara/0000-0002-5105-7985; Kinaciyan, Tamar/0000-0002-8238-2561				Asero R, 2004, ALLERGY, V59, P1269, DOI 10.1111/j.1398-9995.2004.00561.x; Asero R, 1998, CLIN EXP ALLERGY, V28, P1368, DOI 10.1046/j.1365-2222.1998.00399.x; Asero R, 2003, ALLERGY, V58, P435, DOI 10.1034/j.1398-9995.2003.00139.x; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122, DOI 10.1016/S0091-6749(97)70203-3; Bohle B, 2005, CLIN EXP ALLERGY, V35, P1392, DOI 10.1111/j.1365-2222.2005.02332.x; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Bohle B, 2006, J ALLERGY CLIN IMMUN, V118, P242, DOI 10.1016/j.jaci.2006.03.011; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI 10.1111/j.1365-2222.2004.1939.x; Bousquet J, 2005, ALLERGY, V60, P1, DOI 10.1111/j.1398-9995.2005.00700.x; Bousquet J, 2006, ALLERGY, V61, P5, DOI 10.1111/j.1398-9995.2006.01183.x; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; Canonica GW, 2006, ALLERGY, V61, P20, DOI 10.1111/j.1398-9995.2006.01161.x; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Hansen KS, 2004, MOL NUTR FOOD RES, V48, P441, DOI 10.1002/mnfr.200400037; HERRMANN D, 1995, J INVEST ALLERG CLIN, V5, P259; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Marogna M, 2005, J ALLERGY CLIN IMMUN, V115, P1184, DOI 10.1016/j.jaci.2005.02.031; Modrzynski Marek, 2002, Przegl Lek, V59, P1007; MOLLER C, 1989, ANN ALLERGY, V62, P343; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Potter PC, 2006, ANN ALLERG ASTHMA IM, V96, pS22, DOI 10.1016/S1081-1206(10)60898-8; Schimek EM, 2005, J ALLERGY CLIN IMMUN, V116, P1327, DOI 10.1016/j.jaci.2005.09.007; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836	33	114	114	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					937	943		10.1016/j.jaci.2006.11.010	http://dx.doi.org/10.1016/j.jaci.2006.11.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17204315	Bronze			2022-12-18	WOS:000245729500024
J	Niggemann, B; Reibel, S; Roehr, CC; Felger, D; Ziegert, M; Sommerfeld, C; Wahn, U				Niggemann, B; Reibel, S; Roehr, CC; Felger, D; Ziegert, M; Sommerfeld, C; Wahn, U			Predictors of positive food challenge outcome in non-Ige-mediated reactions to food in children with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; atopy patch test; children; cow's milk; double-blind placebo-controlled food challenge; food challenge; hen's egg; sensitization; skin prick test; specific IgE	COWS MILK ALLERGY; 1ST 3 YEARS; DOUBLE-BLIND; PATCH TESTS; SKIN PRICK; DIAGNOSTIC-ACCURACY; HYPERSENSITIVITY; INFANTS; RESPONSES; NEED	Background: Atopic dermatitis is frequently associated with food allergy. In general, clinically manifested food allergy is regarded as IgE mediated. However, there are some children with food allergy for whom IgE hypersensitivity cannot be proven. Objective: The aim was to evaluate the percentage of children with positive double-blind, placebo-controlled food challenge (DBPCFC) results but without any proof of IgE sensitization and to characterize this subgroup or children. Methods: Two hundred eight DBPCFCs were performed in 139 children (median age, 13 months) with atopic dermatitis and suspected food-related clinical symptoms. All children were subjected to skin prick tests (SPTs), determination or specific IgE, and atopy patch tests. Results: One hundred eleven (53%) of 208 oral food challenge results were assessed as positive. Positive challenge results were separated into 2 groups according to IgE positivity: negative SPT and negative specific IgE results in serum (group A, n=12) and positive SPT, specific IgE, or both results in serum (group B, n=99). The atopy patch test results; the distribution of early, late, or both clinical reactions; the age of the children; and the total IgE levels all showed no significant differences between the 2 groups. However, wheat challenge results were more often positive among the apparently non-IgE-sensitized children, and hen's egg challenge results were more often positive in the sensitized group (P<.05). Conclusion: Around 10% of positive DBPCFC results:are not IgE mediated. Therefore not the proof of specific IgE but the suspicion of food-related symptoms should be them indication to perform oral food challenges, especially in the case of wheat. Otherwise, some children will not receive diagnoses for food allergy and be denied the benefits of a specific diet.	Humboldt Univ, Univ Childrens Hosp Charite, Dept Pneumol & Immunol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Niggemann, B (corresponding author), Humboldt Univ, Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.			Roehr, Charles Christoph/0000-0001-7965-4637				AXEN RE, 1988, NEW ENG REG ALLERGY, V9, P503; Beyer K, 1997, J ALLERGY CLIN IMMUN, V99, P522, DOI 10.1016/S0091-6749(97)70080-0; BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hoffman KM, 1997, J ALLERGY CLIN IMMUN, V99, P360, DOI 10.1016/S0091-6749(97)70054-X; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; Majamaa H, 1999, ALLERGY, V54, P851, DOI 10.1034/j.1398-9995.1999.00081.x; Majamaa H, 1999, ALLERGY, V54, P346, DOI 10.1034/j.1398-9995.1999.00834.x; Nakajima H, 1996, J ALLERGY CLIN IMMUN, V97, P1342, DOI 10.1016/S0091-6749(96)70203-8; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91, DOI 10.1046/j.1365-2222.1999.00454.x; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Niggemann B, 2000, ALLERGY, V55, P281, DOI 10.1034/j.1398-9995.2000.00464.x; Reekers R, 1996, BRIT J DERMATOL, V135, P935, DOI 10.1046/j.1365-2133.1996.d01-1098.x; Reibel S, 2000, ALLERGY, V55, P940, DOI 10.1034/j.1398-9995.2000.00689.x; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Werfel T, 1997, J ALLERGY CLIN IMMUN, V99, P124, DOI 10.1016/S0091-6749(97)81053-6	32	114	114	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					1053	1058		10.1067/mai.2001.120192	http://dx.doi.org/10.1067/mai.2001.120192			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742288	Bronze			2022-12-18	WOS:000172938400026
J	Ballmer-Weber, BK; Wuthrich, B; Wangorsch, A; Fotisch, K; Altmann, F; Vieths, S				Ballmer-Weber, BK; Wuthrich, B; Wangorsch, A; Fotisch, K; Altmann, F; Vieths, S			Carrot allergy: Double-blinded, placebo-controlled food challenge and identification of allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; double-blinded; placebo-controlled food challenge; DBPCFC; carrot allergy; Dau c 1; carrot profilin; carbohydrate epitopes; cross-reactive carbohydrate determinants; immunoblotting	BIRCH POLLEN; CROSS-REACTIVITY; IGE-BINDING; MOLECULAR-CLONING; MINOR ALLERGEN; APPLE ALLERGEN; CELERY ROOT; PLANT FOODS; PROTEINS; SENSITIZATION	Background: Allergic reactions to carrot affect up to 25% of food-allergic subjects. Clinical manifestations of carrot allergy and IgE responses to carrot proteins, however, have never been studied in subjects with carrot allergy confirmed by means of double-blinded, placebo-controlled food challenge (DBPCFC). Objective: The purposes of this investigation were to confirm clinically relevant sensitizations to carrot by means of DBPCFC, to validate current diagnostic methods, and to identify IgE-reactive carrot proteins in patients with true allergy. Methods: DBPCFCs were performed in 26 subjects with histories of allergic reactions to carrot. Patients underwent skin prick tests with carrot extract, fresh carrot, and various pollen extracts. Specific IgE to carrot, celery, birch, and mugwort pollen and to rBet v 1, rBet v 2, and rBet v 6 were measured through use of the CAP method. Carrot allergens were identified by means of immunoblotting and blotting inhibition. Results: Twenty of 26 patients had positive DBPCFC results. The sensitivity of the determination of carrot-specific IgE antibodies through use of the CAP method (greater than or equal to0.7 kU/L) was 90%, the sensitivity for skin prick testing with commercial extracts was 26%, and the sensitivity for prick-to-prick tests with raw carrot was 100%. The Bet v 1-related major carrot allergen Dau c 1 was recognized by IgE from 85% of patients; 45% were sensitized to cross-reactive carbohydrate determinants and 20% to carrot profilin. In 1 subject, a Bet v 6-related carrot allergen was recognized. In 4 patients, IgE binding to Dau c I was not inhibited or was weakly inhibited by rBet v 1 or birch pollen extract. Conclusion: This study confirmed the allergenicity of carrot by means of DBPCFC. DBPCFC-positive patients had exclusively specific IgE antibodies to birch pollen-related carrot allergens, Dan c 1 being the major allergen. The lack of inhibition of IgE binding to Dau c 1 by birch allergens in a subgroup of patients might indicate an secondary immune response to new epitopes on the food allergen that are not cross-reactive with Bet v 1.	Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Paul Ehrlich Inst, Dept Allergol, D-6070 Langen, Germany; Univ Agr Vienna, Inst Chem, Vienna, Austria	University of Zurich; University Zurich Hospital; Paul Ehrlich Institute; University of Natural Resources & Life Sciences, Vienna	Ballmer-Weber, BK (corresponding author), Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Gloriastr 31, CH-8091 Zurich, Switzerland.			Altmann, Friedrich/0000-0002-0112-7877				Aalberse RC, 1998, ALLERGY, V53, P54, DOI 10.1111/j.1398-9995.1998.tb04940.x; ALTMANN F, 1992, ANAL BIOCHEM, V204, P215, DOI 10.1016/0003-2697(92)90164-3; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Etesamifar M, 1998, ALLERGOLOGIE, V21, P451; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Goldstein Laurence, 1987, PRINCIPLES INTERNAL, P5; Hoffmann-Sommergruber K, 1999, J ALLERGY CLIN IMMUN, V104, P478, DOI 10.1016/S0091-6749(99)70397-0; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; Jankiewicz A, 1996, INT ARCH ALLERGY IMM, V111, P268, DOI 10.1159/000237377; Karamloo F, 1999, J ALLERGY CLIN IMMUN, V104, P991, DOI 10.1016/S0091-6749(99)70080-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luttkopf D, 2000, J ALLERGY CLIN IMMUN, V106, P390, DOI 10.1067/mai.2000.108711; Moneo I, 1999, ANN ALLERG ASTHMA IM, V83, P71, DOI 10.1016/S1081-1206(10)63516-8; Muller U, 2000, EUR FOOD RES TECHNOL, V212, P2, DOI 10.1007/s002170000245; ROSEN JP, 1994, J ALLERGY CLIN IMMUN, V93, P1068, DOI 10.1016/S0091-6749(94)70056-7; RUDESCHKO O, 1995, ALLERGY, V50, P575, DOI 10.1111/j.1398-9995.1995.tb01202.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; Scheurer S, 2000, CLIN EXP ALLERGY, V30, P962, DOI 10.1046/j.1365-2222.2000.00821.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; Vieths S, 1998, SCAND J IMMUNOL, V47, P263; VIETHS S, 1995, ANN ALLERG ASTHMA IM, V75, P48; Wellhausen A, 1996, Z ERNAHRUNGSWISS, V35, P348, DOI 10.1007/BF01610553; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; WUTHRICH B, 1985, SCHWEIZ MED WSCHR, V115, P358; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x	36	114	118	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					301	307		10.1067/mai.2001.116430	http://dx.doi.org/10.1067/mai.2001.116430			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496252	Bronze			2022-12-18	WOS:000170584600024
J	ten Brinke, A; van Dissel, JT; Sterk, PJ; Zwinderman, AH; Rabe, KF; Bel, EH				ten Brinke, A; van Dissel, JT; Sterk, PJ; Zwinderman, AH; Rabe, KF; Bel, EH			Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; severity of illness index; airway obstruction; prognosis; chronic disease; phenotype; Chlamydia pneumoniae; infection; immunology; human	AIR-FLOW OBSTRUCTION; BRONCHOALVEOLAR LAVAGE; LUNG-FUNCTION; PULMONARY-DISEASE; INTRINSIC ASTHMA; PERIPHERAL-BLOOD; BRONCHIAL-ASTHMA; FOLLOW-UP; ANTIBODIES; IMMUNOPATHOLOGY	Background: Persistent airflow limitation may develop in patients with asthma, particularly in adults with nonatopic (intrinsic) disease. Although the underlying mechanisms are still unknown, respiratory infections might be involved. Objective: We investigated the annual loss of lung function in relation to seropositivity to Chlamydia pneumoniae in different subgroups of patients with severe asthma according to age at onset of asthma and atopic status. Methods: One hundred one nonsmoking outpatients with a pulmonologist's diagnosis of severe asthma (32 men and 69 women; mean age, 46.0 years; range, 18-75 years) were included in a cross-sectional study. C pneumoniae-specific serum IgG and IgA were measured by means of ELISA. The estimated decline in lung function was calculated from the relationship between postbronchodilator FEV1/vital capacity (percent predicted) and the duration of asthma and expressed as the slope of the regression line. Results: Patients with adult-onset nonatopic asthma and positive IgG antibodies to C pneumoniae had a significantly steeper slope of the regression line compared with the other subgroups of asthmatic patients (P = .001), being indicative of a 4-fold greater estimated decline in postbronchodilator FEV1/vital capacity (2.3% vs 0.5% predicted per year of asthma duration). Conclusion: These results suggest that C pneumoniae infection might promote the development of persistent airflow limitation in patients with nonatopic adult-onset asthma. It remains to be established whether viable pathogens that are accessible for therapeutic intervention are still present in the lower airways.	Leiden Univ, Med Ctr, Dept Pulm Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	ten Brinke, A (corresponding author), Leiden Univ, Med Ctr, Dept Pulm Dis, C3-P,POB 9600, NL-2300 RC Leiden, Netherlands.		Sterk, P.J./AAK-8175-2020; Rabe, Klaus F./AAW-6296-2021	Rabe, Klaus F./0000-0002-7020-1401				Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Black PN, 2000, EUR RESPIR J, V15, P254, DOI 10.1034/j.1399-3003.2000.15b06.x; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; Cook PJ, 1998, THORAX, V53, P254, DOI 10.1136/thx.53.4.254; Cunningham AF, 1998, EUR RESPIR J, V11, P345, DOI 10.1183/09031936.98.11020345; Hahn DL, 1996, EPIDEMIOL INFECT, V117, P513, DOI 10.1017/S0950268800059197; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; Hansen EF, 1999, AM J RESP CRIT CARE, V159, P1267, DOI 10.1164/ajrccm.159.4.9807121; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Kroegel C, 1997, EUR RESPIR J, V10, P513; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; MABEY DCW, 1987, LANCET, V2, P1491; MACEK V, 1994, AM J RESP CRIT CARE, V150, P7, DOI 10.1164/ajrccm.150.1.8025775; MCINTOSH JC, 1992, INFECT IMMUN, V60, P2936, DOI 10.1128/IAI.60.7.2936-2942.1992; Miyashita N, 1998, ANN ALLERG ASTHMA IM, V80, P405, DOI 10.1016/S1081-1206(10)62992-4; MOORE DE, 1982, LANCET, V2, P574; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; Reed CE, 1999, J ALLERGY CLIN IMMUN, V103, P539, DOI 10.1016/S0091-6749(99)70221-6; Tang C, 1997, EUR RESPIR J, V10, P624; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; Virchow JC, 1996, J ALLERGY CLIN IMMUN, V98, pS27; von Hertzen L, 1999, CLIN EXP ALLERGY, V29, P522; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; Ward ME, 1995, APMIS, V103, P769, DOI 10.1111/j.1699-0463.1995.tb01436.x; Wong YK, 1999, HEART, V81, P232, DOI 10.1136/hrt.81.3.232; Wu L, 2000, AM J RESP CRIT CARE, V162, P1148, DOI 10.1164/ajrccm.162.3.9912134; YAMADA K, 2000, AM J RESP CRIT CARE, V161, pA606	33	114	117	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					449	454		10.1067/mai.2001.113047	http://dx.doi.org/10.1067/mai.2001.113047			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240944	Bronze			2022-12-18	WOS:000167793300005
J	Litonjua, AA; Carey, VJ; Burge, HA; Weiss, ST; Gold, DR				Litonjua, AA; Carey, VJ; Burge, HA; Weiss, ST; Gold, DR			Exposure to cockroach allergen in the home is associated with incident doctor-diagnosed asthma and recurrent wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Thoracic-Society	APR 24-29, 1998	CHICAGO, IL	Amer Thorac Soc		cockroach; indoor allergens; asthma; wheeze	INNER-CITY CHILDREN; CHILDHOOD ASTHMA; RESPIRATORY ILLNESS; UNITED-STATES; RISK FACTOR; SENSITIZATION; SMOKING; RACE; RESPONSIVENESS; PREVALENCE	Background: Indoor inhaled allergens have been repeatedly demonstrated to worsen asthma In sensitized individual, but their role in incident asthma is more controversial, Objective: We investigated the relationship between exposure to allergens (dust mite, cat, and cockroach) measured in the home and incident doctor-diagnosed asthma and recurrent wheezing in children born to parents with asthma, allergies, or both. Methods: From an ongoing longitudinal family and birth cohort study, rye identified 222 siblings (median age, 2.87 years) of the index children. Allergen levels in the home were measured from dust samples obtained at the beginning of the study. Incident doctor-diagnosed asthma and recurrent wheezing were determined from questionnaires administered at 14 months and 22 months after the initial questionnaire, Results: Thirteen (5.9%) children were reported to have Incident asthma, twenty (9.0%) children had recurrent asthmatic wheezing, and 18 (8.1%) had recurrent wheezing without asthma, Compared with children living in homes with Bla g 1 or 2 levels of less than 0.05 U/g, children exposed to Bra g 1 or 2 levels of 0.05 to less than 2 U/g had a relative risk for incident asthma of 8.27 (95% confidence interval, 1.04-66.04), whereas children exposed to Bla g 1 or 2 levels of 2 U/g or greater bad a relative risk for incident asthma of 35.87 (95% confidence Interval, 4.49-286.62). Cockroach allergen exposure was likewise a significant predictor for recurrent asthmatic wheezing. Neither dust mite nor cat allergen levels were significantly associated with either outcome. These findings remained after control for several covariates, Conclusion: Exposure to cockroach allergen early in life may contribute to the development of asthma in susceptible children.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Litonjua, AA (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07427] Funding Source: Medline; NIAID NIH HHS [AI35786] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BJORKSTEN B, 1987, CLIN REV ALLERG, V5, P339; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536, DOI 10.1164/ajrccm.157.5.9708011; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10, DOI 10.1164/ajrccm/148.1.10; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; INFANTERIVARD C, 1995, EPIDEMIOLOGY, V6, P178, DOI 10.1097/00001648-199503000-00016; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1998, EUR RESPIR J, V12, p3S; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; OPENSHAW PJM, 1994, THORAX, V49, P101, DOI 10.1136/thx.49.2.101; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SHERMAN CB, 1993, AM REV RESPIR DIS, V148, P98, DOI 10.1164/ajrccm/148.1.98; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811, DOI 10.1164/ajrccm/147.4.811; TOLLERUD DJ, 1995, J CLIN LAB ANAL, V9, P37, DOI 10.1002/jcla.1860090107; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	29	114	114	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					41	47		10.1067/mai.2001.111143	http://dx.doi.org/10.1067/mai.2001.111143			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	394PW	11149989				2022-12-18	WOS:000166533300008
J	Sicherer, SH; Furlong, TJ; DeSimone, J; Sampson, HA				Sicherer, SH; Furlong, TJ; DeSimone, J; Sampson, HA			Self-reported allergic reactions to peanut on commercial airliners	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; peanut; tree nut; airplane	ANAPHYLAXIS; FOOD; IMMUNOTHERAPY	Background: Allergic reactions to food occurring on commercial airlines have not been systematically characterized. Objective: We sought to describe the clinical characteristics of allergic reactions to peanuts on airplanes. Methods: Participants in the National Registry of Peanut and Tree Nut Allergy who indicated an allergic reaction while on a commercial airliner were interviewed by telephone, Results: Sixty-two of 3704 National Registry of Peanut and Tree Nut Allergy participants indicated a reaction on an airplane; 42 of 48 patients or parental surrogates contacted confirmed the reaction began on the airplane (median age of affected subject, 2 years; range, 6 months to 50 years). Of these, 35 reacted to peanuts (4 were uncertain of exposure) and 7 to tree nuts, although 3 of these 7 reacted to substances that may have also contained peanut. Exposures occurred by ingestion (20 subjects), skin contact (8 subjects), and inhalation (14 subjects). Reactions generally occurred within 10 minutes of exposure (32 of 42 subjects), and reaction severity correlated with exposure route (ingestion > inhalation > skin). The causal food was generally served by the airline (37 of 32 subjects). Medications were given in flight to 19 patients (epinephrine to 5) and to an additional 14 at landing/gate return (including epinephrine to 1 and intravenous medication to 2), totaling 79% treated. Flight crews were notified in 33% of reactions, During inhalation reactions as a result of peanut allergy, greater than 25 passengers were estimated to be eating peanuts at the time of the reaction, Initial symptoms generally involved the upper airway, with progression to the skin or further lower respiratory reactions (no gastrointestinal symptoms), Conclusions: Allergic reactions to peanuts and tree nuts caused by accidental ingestion, skin contact, or inhalation occur during commercial flights, but airline personnel are usually not notified, Reactions can be severe, requiring medications, including epinephrine.	CUNY Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Pediat Allergy Immunol, New York, NY 10029 USA; Food Allergy Network, Fairfax, VA USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Sicherer, SH (corresponding author), CUNY Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Pediat Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.							BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; CARLSTON JA, 1988, ANN ALLERGY, V61, P80; Casimir G, 1997, PEDIATR ALLERGY IMMU, V8, P103, DOI 10.1111/j.1399-3038.1997.tb00152.x; CRESPO JF, 1995, ALLERGY, V50, P257, DOI 10.1111/j.1398-9995.1995.tb01143.x; Dawe RS, 1996, LANCET, V348, P1522, DOI 10.1016/S0140-6736(05)65946-6; DESJARDINS A, 1995, J ALLERGY CLIN IMMUN, V96, P608, DOI 10.1016/S0091-6749(95)70259-8; FRIES JH, 1982, ANN ALLERGY, V48, P220; Furlong TJ, 1998, J ALLERGY CLIN IMMUN, V101, pS104; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P1240, DOI [10.1111/j.1365-2222.1997.tb01167.x, 10.1046/j.1365-2222.1997.1520954.x]; HOURIHANE JO, 1998, BRIT MED J, V316, P271; IGEA JM, 1994, J ALLERGY CLIN IMMUN, V94, P33, DOI 10.1016/0091-6749(94)90068-X; Jones R. T., 1996, Journal of Allergy and Clinical Immunology, V97, P423, DOI 10.1016/S0091-6749(96)81179-1; Kalogeromitros D, 1996, ANN ALLERG ASTHMA IM, V77, P480, DOI 10.1016/S1081-1206(10)63354-6; Polasani R, 1997, ANN ALLERG ASTHMA IM, V78, P35, DOI 10.1016/S1081-1206(10)63368-6; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 1997, J ALLERGY CLIN IMMUN, V99, P798, DOI 10.1016/S0091-6749(97)80014-0; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	19	114	119	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					186	189		10.1016/S0091-6749(99)70133-8	http://dx.doi.org/10.1016/S0091-6749(99)70133-8			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400859				2022-12-18	WOS:000081738900029
J	Willheim, M; Ebner, C; Baier, K; Kern, W; Schrattbauer, K; Thien, R; Kraft, D; Breiteneder, H; Reinisch, W; Scheiner, O				Willheim, M; Ebner, C; Baier, K; Kern, W; Schrattbauer, K; Thien, R; Kraft, D; Breiteneder, H; Reinisch, W; Scheiner, O			Cell surface characterization of T lymphocytes and allergen-specific T cell clones: Correlation of CD26 expression with T-H1 subsets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T helper cell subsets; T cell clones; cell surface molecules; cytokine receptors; CD26; cytokine production	BIRCH POLLEN ALLERGEN; BET-V-I; INTERFERON-GAMMA; TH2 SUBSETS; OVERLAPPING PEPTIDES; FUNCTIONAL SUBSETS; STIMULATORY FACTOR; CYTOKINE PROFILES; ATOPIC PATIENTS; INTERLEUKIN-12	To evaluate the possibility of using surface molecules as markers for human T helper cell subsets, we studied the expression of surface molecules on T cell clones (TCCs) specific for the major birch pollen allergen, Bet v 1. No difference in the expression of the respective receptors for interferon-gamma (IFN-gamma), IL-4, IL-6, or IL-10 could be detected on T-H subsets, nor did CD25 expression (IL-ZR alpha-chain) differ significantly. However, high expression of CD26 antigen (dipeptidyl peptidase IV) correlated with a T-H1/T-H0-like phenotype, whereas T-H2-like clones displayed a lower expression of CD26 antigen. Comparing cytokine production and CD26 expression simultaneously, we found a correlation between the IL-4/IFN-gamma ratio and the density of CD26 per cell. We could show that the amount of IL-4 secretion, and not of IFN-gamma secretion, was responsible for this correlation. To evaluate whether CD26 antigen expression is regulated by stimuli inducing a T-H1- or T-H2-like phenotype, peripheral blood mononuclear cells (PBMC) were cultured in the presence of IL-4, IFN-gamma, and IL-12, respectively. Incubation with IL-4 led to T cells with a T-H2-like cytokine pattern and a significantly lower expression of CD26; IFN-gamma and IL-12 led to a T-H1 shift associated with an increased expression of CD26 on CD4(+) T cells. By means of intracellular cytokine detection we analyzed expression of CD26 on CD4(+) PBMC stimulated to produce IFN-gamma or IL-4 on a single cell level. All activated, cytokine-producing CD4(+) T cells expressed CD26, but the increase in CD26 expression was higher in cells producing IFN-gamma. These data suggest that regulation of CD26 cell surface expression correlates with the production of T-H1-like cytokines.	UNIV VIENNA,INST GEN & EXPT PATHOL,VIENNA,AUSTRIA; UNIV VIENNA,DEPT GASTROENTEROL & HEPATOL,CLIN INTERNAL MED 4,VIENNA,AUSTRIA	University of Vienna; University of Vienna								ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; DELPRETE G, 1995, J EXP MED, V182, P1655, DOI 10.1084/jem.182.6.1655; DELPRETE G, 1995, FASEB J, V9, P81, DOI 10.1096/fasebj.9.1.7821763; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FINKELMAN FD, 1994, J EXP MED, V179, P1563, DOI 10.1084/jem.179.5.1563; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; Hamann D, 1996, J IMMUNOL, V156, P1387; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; KEMENY DM, 1994, IMMUNOL TODAY, V15, P107, DOI 10.1016/0167-5699(94)90152-X; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.iy.11.040193.001333; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NOBLE A, 1995, J IMMUNOL, V155, P2928; OGARRA A, 1994, CURR OPIN IMMUNOL, V6, P458, DOI 10.1016/0952-7915(94)90128-7; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279, DOI 10.1159/000236199; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SCHEELTOELLNER D, 1995, LAB INVEST, V73, P685; SEDER RA, 1992, J IMMUNOL, V148, P1652; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; TRINCHIERI G, 1994, IMMUNOL TODAY, V15, P460, DOI 10.1016/0167-5699(94)90189-9; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	37	114	115	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					348	355		10.1016/S0091-6749(97)70248-3	http://dx.doi.org/10.1016/S0091-6749(97)70248-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314347				2022-12-18	WOS:A1997XX47900012
J	SCHWARTZ, LB				SCHWARTZ, LB			TRYPTASE, A MEDIATOR OF HUMAN MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	MEETING ON HISTAMINE AND DISEASE : A FORUM ON CURRENT AND FUTURE MANAGEMENT	AUG 25-26, 1989	CARLSBAD, CA	MERRELL DOW PHARM							SCHWARTZ, LB (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MED & MICROBIOL & IMMUNOL,BOX 263,RICHMOND,VA 23298, USA.							ALTER SC, 1987, BIOCHEM J, V248, P821, DOI 10.1042/bj2480821; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CRAIG SS, 1986, AM J PATHOL, V124, P427; CRISP AJ, 1984, ARTHRITIS RHEUM, V27, P845, DOI 10.1002/art.1780270802; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; GODFREY HP, 1984, ARTHRITIS RHEUM, V27, P852, DOI 10.1002/art.1780270803; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; GRUBER BL, 1988, J IMMUNOL, V140, P3936; MAIER M, 1983, J IMMUNOL, V130, P2352; MARQUARDT DL, 1984, P NATL ACAD SCI-BIOL, V81, P6192, DOI 10.1073/pnas.81.19.6192; PHILLIPS GD, 1989, AM REV RESPIR DIS, V139, P463, DOI 10.1164/ajrccm/139.2.463; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; SCHWARTZ LB, 1990, J IMMUNOL, V144, P2304; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2672; SCHWARTZ LB, 1988, IMMUNOLOGICAL DISEAS, P157; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002	26	114	116	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			594	598		10.1016/S0091-6749(05)80222-2	http://dx.doi.org/10.1016/S0091-6749(05)80222-2			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	2229822				2022-12-18	WOS:A1990EH09300003
J	OTSUKA, H; DENBURG, J; DOLOVICH, J; HITCH, D; LAPP, P; RAJAN, RS; BIENENSTOCK, J; BEFUS, D				OTSUKA, H; DENBURG, J; DOLOVICH, J; HITCH, D; LAPP, P; RAJAN, RS; BIENENSTOCK, J; BEFUS, D			HETEROGENEITY OF METACHROMATIC CELLS IN HUMAN NOSE - SIGNIFICANCE OF MUCOSAL MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT PATHOL,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University; McMaster University			Befus, Dean/C-5561-2009	Befus, Dean/0000-0002-1611-2897				BEFUS AD, 1982, ADV EXP MED BIOL, V149, P521; BEFUS AD, 1982, J IMMUNOL, V128, P2475; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; BRYAN W T, 1959, Trans Am Acad Ophthalmol Otolaryngol, V63, P613; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; Enerback L., 1981, MONOGR ALLERGY, V17, P222; GOTO T, 1984, AM REV RESPIR DIS, V130, P797; HANSEL FK, 1953, CLIN ALLERGY, P411; HASTIE R, 1979, LAB INVEST, V40, P554; KIMURA I, 1975, Clinical Allergy, V5, P95, DOI 10.1111/j.1365-2222.1975.tb01840.x; LANGE S, 1980, INFECT IMMUN, V28, P17, DOI 10.1128/IAI.28.1.17-23.1980; MILLER HRP, 1980, BIOL CELLULAIRE, V39, P229; OHTSUKA H, 1981, ARCH OTORHINOLARYNGO, V223, P227; OHTSUKA H, 1979, J ALLERGOL JPN, V28, P633; OKUDA M, 1983, ANN ALLERGY, V50, P116; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; OKUDA M, 1978, ARCH OHREN NASEN KEH, V221, P215, DOI 10.1007/BF01886298; OKUDA M, 1985, ANN ALLERGY, V54, P152; PATTERSON R, 1978, J CLIN INVEST, V62, P519, DOI 10.1172/JCI109155; PATTERSON R, 1974, CLIN EXP IMMUNOL, V16, P223; PEARCE FL, 1982, J IMMUNOL, V128, P2481; RAWLE FC, 1983, CLIN ALLERGY, V13, P409, DOI 10.1111/j.1365-2222.1983.tb02616.x; RUITENBERG EJ, 1982, INT ARCH ALLER A IMM, V67, P233, DOI 10.1159/000233024; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; SHANAHAN F, UNPUB AM REV RESPIR; SHIODA H, 1966, J ALLERGY, V37, P321, DOI 10.1016/0021-8707(66)90131-6; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; TSAO CH, 1977, J ALLERGY CLIN IMMUN, V59, P320, DOI 10.1016/0091-6749(77)90054-9; WINGREN U, 1983, HISTOCHEM J, V15, P571, DOI 10.1007/BF01954148	30	114	116	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					695	702		10.1016/0091-6749(85)90673-6	http://dx.doi.org/10.1016/0091-6749(85)90673-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	2414352	Bronze			2022-12-18	WOS:A1985AUU3400007
J	MURRAY, AB; FERGUSON, AC; MORRISON, B				MURRAY, AB; FERGUSON, AC; MORRISON, B			AIRWAY RESPONSIVENESS TO HISTAMINE AS A TEST FOR OVERALL SEVERITY OF ASTHMA IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA, DEPT PAEDIAT, DIV ALLERGY, VANCOUVER V6T 1W5, BC, CANADA; UNIV BRITISH COLUMBIA, DEPT HLTH CARE & EPIDEMIOL, VANCOUVER V6T 1W5, BC, CANADA	University of British Columbia; University of British Columbia				Ferguson, Alexander C./0000-0002-3143-5619				ABBOUD RT, 1975, AM REV RESPIR DIS, V111, P405; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CARTIER A, 1980, American Review of Respiratory Disease, V121, P61; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GLINDMEYER HW, 1978, CHEST, V73, P596, DOI 10.1378/chest.73.5.596; GLINDMEYER HW, 1980, AM REV RESPIR DIS, V121, P599, DOI 10.1164/arrd.1980.121.3.599; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; MURRAY AB, 1976, LANCET, V2, P197; MURRAY AB, 1977, LANCET, V1, P708; SLY RM, 1970, ANN ALLERGY, V28, P1; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; WARNER JO, 1978, LANCET, V2, P912	21	114	115	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	2					119	124		10.1016/0091-6749(81)90169-X	http://dx.doi.org/10.1016/0091-6749(81)90169-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MD162	7251999				2022-12-18	WOS:A1981MD16200007
J	BERNSTEIN, IL; PERERA, M; GALLAGHER, J; MICHAEL, JG; JOHANSSON, SGO				BERNSTEIN, IL; PERERA, M; GALLAGHER, J; MICHAEL, JG; JOHANSSON, SGO			INVITRO CROSS-ALLERGENICITY OF MAJOR AEROALLERGENIC POLLENS BY RADIOALLERGOSORBENT TECHNIQUE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT MICROBIOL,CINCINNATI,OH 45229; UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45229	University of Cincinnati; University of Cincinnati								AUGUSTIN R, 1957, INT ARCH ALLER A IMM, V11, P218, DOI 10.1159/000228418; Bernton HS, 1923, J AMER MED ASSOC, V80, P1301, DOI 10.1001/jama.1923.02640450021008; BERRENS L, 1971, CHEMISTRY ATOPIC ALL, V7, P5; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; Coca AF, 1925, J IMMUNOL, V10, P445; COCA AF, 1931, ASTHMA HAY FEVER THE, P599; Cooke RA, 1916, J IMMUNOL, V1, P201; COULSON EJ, 1946, J IMMUNOL, V52, P259; FOUCARD T, 1972, INT ARCH ALLER A IMM, V43, P360, DOI 10.1159/000230851; FRANKLAND AW, 1955, INT ARCH ALLER A IMM, V6, P45, DOI 10.1159/000228145; FRICK OL, 1960, J ALLERGY, V31, P216, DOI 10.1016/0021-8707(60)90050-2; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GRUBB GLENN D., 1938, JOUR ALLERGY, V9, P211, DOI 10.1016/S0021-8707(38)90213-8; HERBERTSON S, 1958, ACTA CHEM SCAND, V12, P737, DOI 10.3891/acta.chem.scand.12-0737; JOHNSON P, 1965, EUR POLYM J, V1, P63; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; LICHTENSTEIN LM, 1966, J ALLERGY, V38, P174, DOI 10.1016/0021-8707(66)90040-2; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; PARISH WE, 1967, NATURE, V215, P738, DOI 10.1038/215738a0; WODEHOUSE RP, 1954, INT ARCH ALLER A IMM, V5, P337, DOI 10.1159/000228113; WODEHOUSE RP, 1971, HAY FEVER PLANTS, P7	21	114	114	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	2					141	152		10.1016/0091-6749(76)90033-6	http://dx.doi.org/10.1016/0091-6749(76)90033-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BE952	1249348				2022-12-18	WOS:A1976BE95200006
J	BAZARAL, M; ORGEL, HA; HAMBURGER, RN				BAZARAL, M; ORGEL, HA; HAMBURGER, RN			GENETICS OF IGE AND ALLERGY - SERUM IGE LEVELS IN TWINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF, SAN DIEGO,SCH MED,PEDIAT DEPT, PEDIAT IMMUNOL & ALLERGY DIV,POB 109, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego								Adkinson J, 1920, GENETICS, V5, P363; ALLANSMITH M, 1969, J IMMUNOL, V102, P1504; ARBESMAN CE, 1972, J ALLERGY CLIN IMMUN, V49, P72, DOI 10.1016/0091-6749(72)90058-9; BAILEY NTJ, 1959, STATISTICAL METHODS, P91; BAZARAL M, 1971, J IMMUNOL, V107, P794; BAZARAL M, 1972, Clinical Research, V20, P258; BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; BERG T, 1969, ACTA PAEDIATR SCAND, V58, P513, DOI 10.1111/j.1651-2227.1969.tb04753.x; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; CAVALLISFORZA LL, 1971, GENETICS HUMAN POPUL, P573; Cooke RA, 1916, J IMMUNOL, V1, P201; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; FALLIERS CJ, 1971, J ALLERGY, V47, P207, DOI 10.1016/S0091-6749(71)80466-9; FEINLEIB M, 1970, ACTA GENET MED GEMEL, V19, P243, DOI 10.1017/S1120962300025592; FELARCA AB, 1966, J ALLERGY, V37, P223, DOI 10.1016/0021-8707(66)90117-1; FISHER RA, 1970, STATISTICAL METHODS, P217; FISHER RA, 1970, STATISTICAL METHODS, P200; FISHER RA, 1963, STATISTICAL TABLES B, P48; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HAMBURGER RN, 1973, MECHANISMS ALLERGY R, P131; HARRIS H, 1966, PROC R SOC SER B-BIO, V164, P298, DOI 10.1098/rspb.1966.0032; HELLSTROM B, 1950, ACTA ANAT, V10, P81; ISHIZAKA K, 1967, J IMMUNOL, V98, P490; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; JABLON S, 1967, AM J HUM GENET, V19, P133; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON SG, 1968, LANCET, V1, P1118; JOHANSSON SG, 1968, INT ARCH ALLER A IMM, V34, P1; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; KALFF MW, 1969, CLIN EXP IMMUNOL, V5, P469; KEMPTHORNE O, 1961, AM J HUM GENET, V13, P320; KISIL FT, 1971, J ALLERGY, V47, P1, DOI 10.1016/S0091-6749(71)80312-3; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; LEVY DA, 1966, J IMMUNOL, V97, P203; LICHTMAN MA, 1967, ARTHRITIS RHEUM, V10, P204, DOI 10.1002/art.1780100306; LICHTMAN MA, 1965, AM J CLIN NUTR, V16, P492, DOI 10.1093/ajcn/16.6.492; MARSH DG, 1973, SCIENCE, V179, P691, DOI 10.1126/science.179.4074.691; MURPHY EA, 1967, AM J HUM GENET, V19, P322; NEEL JV, 1954, HUM HERED, P274; OPREE W, 1972, ACTA ALLERGOL, V27, P247, DOI 10.1111/j.1398-9995.1972.tb01423.x; ORGEL HA, 1974, J ALLERGY CLIN IMMUN, V53, P213, DOI 10.1016/0091-6749(74)90083-9; OSBORNE RH, 1959, GENETIC BASIS MORPHO, P55; OSBORNE RH, 1959, GENETIC BASIS MORPHO, P15; PARTANEN J, 1966, INHERITANCE DRINKING, P55; PEARSON ES, 1966, BIOMETR TABLES ST, V1, P169; POLMAR SH, 1973, J IMMUNOL, V110, P1253; RATNER B, 1952, ANN ALLERGY, V9, P1; ROWE D. S., 1968, CLIN EXP IMMUNOL, V3, P233; ROWE D S, 1970, Bulletin of the World Health Organization, V43, P609; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SELL S, 1964, J IMMUNOL, V93, P81; SPITZ E, 1972, J ALLERGY CLIN IMMUN, V49, P337, DOI 10.1016/0091-6749(72)90132-7; STOKES CR, 1973, EUR J IMMUNOL, V3, P241, DOI 10.1002/eji.1830030412; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TIPS RL, 1954, AM J HUM GENET, V6, P328; VAN ARSDEL P P Jr, 1959, Acta Genet Stat Med, V9, P101; WIDE L, 1967, LANCET, V2, P1105; Wiener AS, 1936, ANN EUGENIC, V7, P141, DOI 10.1111/j.1469-1809.1936.tb02135.x; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5; ZACHARIAE H, 1964, ACTA DERM-VENEREOL, V44, P219	60	114	114	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	5					288	304		10.1016/0091-6749(74)90015-3	http://dx.doi.org/10.1016/0091-6749(74)90015-3			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U6412		Bronze			2022-12-18	WOS:A1974U641200005
J	He, HL; Suryawanshi, H; Morozov, P; Gay-Mimbrera, J; Del Duca, E; Kim, HJ; Kameyama, N; Estrada, Y; Der, E; Krueger, JG; Ruano, J; Tuschl, T; Guttman-Yassky, E				He, Helen; Suryawanshi, Hemant; Morozov, Pavel; Gay-Mimbrera, Jesus; Del Duca, Ester; Kim, Hyun Je; Kameyama, Naoya; Estrada, Yeriel; Der, Evan; Krueger, James G.; Ruano, Juan; Tuschl, Thomas; Guttman-Yassky, Emma			Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; single-cell RNA sequencing; fibroblasts; dendritic cells; T cells; cytokines	T-CELLS; DENDRITIC CELLS; DERMAL FIBROBLASTS; LESIONAL SKIN; PSORIASIS; EXPRESSION; PERIOSTIN; GENE; DIFFERENTIATION; ACTIVATION	Background: Atopic dermatitis (AD) is a prevalent inflammatory skin disease with a complex pathogenesis involving immune cell and epidermal abnormalities. Despite whole tissue biopsy studies that have advanced the mechanistic understanding of AD, single cell based molecular alterations are largely unknown. Objective: Our aims were to construct a detailed, high-resolution atlas of cell populations and assess variability in cell composition and cell-specific gene expression in the skin of patients with AD versus in controls. Methods: We performed single-cell RNA sequencing on skin biopsy specimens from 5 patients with AD (4 lesional samples and 5 nonlesional samples) and 7 healthy control subjects, using 10x Genomics. Results: We created transcriptomic profiles for 39,042 AD (lesional and nonlesional) and healthy skin cells. Fibroblasts demonstrated a novel COL6A5(+)COL18A1(+) subpopulation that was unique to lesional AD and expressed CCL2 and CCL19 cytokines. A corresponding LAMP3(+) dendritic cell (DC) population that expressed the CCL19 receptor CCR7 was also unique to AD lesions, illustrating a potential role for fibroblast signaling to immune cells. The lesional AD samples were characterized by expansion of inflammatory DCs (CD1A(+) FCER1A(+)) and tissue-resident memory T cells (CD69(+)CD103(+)). The frequencies of type 2 (IL1(3+))/type 22 (IL22(+)) T cells were higher than those of type 1 (IFNG(+)) in lesional AD, whereas this ratio was slightly diminished in nonlesional AD and further diminished in controls. Conclusion: AD lesions were characterized by expanded type 2/type 22 T cells and inflammatory DCs, and by a unique inflammatory fibroblast that may interact with immune cells to regulate lymphoid cell organization and type 2 inflammation.	[He, Helen; Del Duca, Ester; Kim, Hyun Je; Kameyama, Naoya; Estrada, Yeriel; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Suryawanshi, Hemant; Morozov, Pavel; Tuschl, Thomas] Rockefeller Univ, Lab RNA Mol Biol, 1230 York Ave, New York, NY 10065 USA; [Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, New York, NY 10065 USA; [Gay-Mimbrera, Jesus; Ruano, Juan] Reina Sofia Univ Hosp, Dept Dermatol, Cordoba, Spain; [Der, Evan] Albert Einstein Coll Med, Div Rheumatol, New York, NY USA; [Der, Evan] Albert Einstein Coll Med, Dept Microbiol & Immunol, New York, NY USA	Icahn School of Medicine at Mount Sinai; Rockefeller University; Rockefeller University; Hospital Universitario Reina Sofia - Cordoba; Yeshiva University; Yeshiva University	Suryawanshi, H; Tuschl, T (corresponding author), Rockefeller Univ, Lab RNA Mol Biol, 1230 York Ave, New York, NY 10065 USA.; Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.; Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Lab Inflammatory Skin Dis, 5 E 98th St, New York, NY 10029 USA.	hsuryawans@mail.rockefeller.edu; ttuschl@rockefeller.edu; emma.guttman@mountsinai.org	Morozov, Pavel/GQP-7206-2022; Del Duca, Ester/AAC-2711-2022; Gay-Mimbrera, Jesus/C-8376-2017; Ruano, Juan/T-1991-2018	Del Duca, Ester/0000-0001-7948-8536; Gay-Mimbrera, Jesus/0000-0001-7223-1922; Ruano, Juan/0000-0002-0286-4107	National Center for Advancing Translational Sciences, National Institutes of Health, Clinical and Translational Science Award program [UL1TR001866]	National Center for Advancing Translational Sciences, National Institutes of Health, Clinical and Translational Science Award program	We acknowledge expert support by the members of the Rockefeller University Genomics Resource Center and the Epigenomics Core facility of Weil Cornell Medicine. The authors thank Arlene Hurley, NP, and the Research Facilitation Office staff at Rockefeller University for regulatory and administrative assistance supported in part by grant UL1TR001866 from the National Center for Advancing Translational Sciences, National Institutes of Health, Clinical and Translational Science Award program. We also thank Qiaolin Deng (Karolinska Institutet) for editorial comments, and we thank Seulah Choi (Mount Sinai) for her assistance with editing figures.	Agrawal R, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0433-9; Brandt Eric B, 2011, J Clin Cell Immunol, V2; Castro-Giner F, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-128; Cheng JB, 2018, CELL REP, V25, P871, DOI 10.1016/j.celrep.2018.09.006; Cheuk S, 2014, J IMMUNOL, V192, P3111, DOI 10.4049/jimmunol.1302313; Choy DF, 2012, J ALLERGY CLIN IMMUN, V130, P1335, DOI 10.1016/j.jaci.2012.06.044; Chu CC, 2012, J EXP MED, V209, P935, DOI 10.1084/jem.20112583; Cui CY, 2015, EXP DERMATOL, V24, P644, DOI 10.1111/exd.12773; Dahlgren MW, 2019, IMMUNITY, V50, P707, DOI 10.1016/j.immuni.2019.02.002; Der E, 2019, NAT IMMUNOL; Der E, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93009; Diaz A, 2020, J EUR ACAD DERMATOL, V34, pE161, DOI 10.1111/jdv.16097; Esaki H, 2015, J ALLERGY CLIN IMMUN, V135, P153, DOI 10.1016/j.jaci.2014.10.037; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, P574, DOI 10.1016/j.jaci.2011.05.016; Fuxench ZCC, 2019, J INVEST DERMATOL, V139, P583, DOI 10.1016/j.jid.2018.08.028; Gao JX, 1996, IMMUNOLOGY, V89, P375, DOI 10.1046/j.1365-2567.1996.d01-750.x; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Greenblatt MB, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926-012-0297-8; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Guttman-Yassky E, 2007, J ALLERGY CLIN IMMUN, V119, P1210, DOI 10.1016/j.jaci.2007.03.006; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V144, P482, DOI 10.1016/j.jaci.2018.11.053; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Harazin M, 2010, J DERMATOL, V37, P740, DOI 10.1111/j.1346-8138.2010.00923.x; Hijnen D, 2013, J INVEST DERMATOL, V133, P973, DOI 10.1038/jid.2012.456; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Hotamisligil GS, 2015, NAT REV ENDOCRINOL, V11, P592, DOI 10.1038/nrendo.2015.122; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Joost S, 2016, CELL SYST, V3, P221, DOI 10.1016/j.cels.2016.08.010; Kim TG, 2017, INT J MOL SCI, V19; Lanningham-Foster L, 2002, AM J PHYSL ENDOCRINO; Lessard JC, 2013, P NATL ACAD SCI USA, V110, P19537, DOI 10.1073/pnas.1309576110; Lewinsky H, 2018, J CLIN INVEST, V128, P5465, DOI 10.1172/JCI96610; Mabbott NA, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-632; Maeda D, 2019, J PLAST SURG HAND SU, V53, P288, DOI 10.1080/2000656X.2019.1612752; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Nakahigashi K, 2011, J INVEST DERMATOL, V131, P865, DOI 10.1038/jid.2010.395; Naumann A, 2011, J ALLERGY CLIN IMMUN, V127, P1187, DOI 10.1016/j.jaci.2010.12.1123; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Ogawa K, 2005, J DERMATOL SCI, V40, P35, DOI 10.1016/j.jdermsci.2005.06.001; Park CO, 2015, NAT MED, V21, P688, DOI 10.1038/nm.3883; Philippeos C, 2018, J INVEST DERMATOL, V138, P811, DOI 10.1016/j.jid.2018.01.016; Pruenster M, 2009, NAT IMMUNOL, V10, P101, DOI 10.1038/ni.1675; Quaranta M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008946; Rana BMJ, 2019, J EXP MED, V216, P1999, DOI 10.1084/jem.20190689; Sabatelli P, 2011, J INVEST DERMATOL, V131, P99, DOI 10.1038/jid.2010.284; Sanyal RD, 2019, ANN ALLERG ASTHMA IM, V122, P99, DOI 10.1016/j.anai.2018.08.024; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Shiraishi H, 2012, ALLERGOL INT, V61, P563, DOI 10.2332/allergolint.10-OA-0297; Silverberg JI, 2013, PEDIAT ALLERG IMM-UK, V24, P476, DOI 10.1111/pai.12095; Soderhall C, 2007, PLOS BIOL, V5; Spallanzani RG, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw3658; Strafella C, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3457898; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V135, P1218, DOI 10.1016/j.jaci.2015.03.003; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Suzuki O, 2009, MOL VIS, V15, P801; Tabib T, 2018, J INVEST DERMATOL, V138, P802, DOI 10.1016/j.jid.2017.09.045; Takamura K, 2007, J IMMUNOL, V179, P5897, DOI 10.4049/jimmunol.179.9.5897; Tsoi LC, 2019, J INVEST DERMATOL, V139, P1480, DOI 10.1016/j.jid.2018.12.018; Veniaminova NA, 2013, DEVELOPMENT, V140, P4870, DOI 10.1242/dev.101725; Watanabe R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010302; Wollenberg A, 2002, J INVEST DERMATOL, V118, P327, DOI 10.1046/j.0022-202x.2001.01665.x; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wollenberg A, 2019, J ALLERGY CLIN IMMUN, V143, P135, DOI 10.1016/j.jaci.2018.05.029; Wu CC, 2012, BBA-MOL CELL RES, V1823, P2227, DOI 10.1016/j.bbamcr.2012.08.013; Yeo SY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05274-6; Zheng GXY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14049	70	113	117	6	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1615	1628		10.1016/j.jaci.2020.01.042	http://dx.doi.org/10.1016/j.jaci.2020.01.042			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32035984	Bronze			2022-12-18	WOS:000539157800017
J	Ledford, D; Busse, W; Trzaskoma, B; Omachi, TA; Rosen, K; Chipps, BE; Luskin, AT; Solari, PG				Ledford, Dennis; Busse, William; Trzaskoma, Benjamin; Omachi, Theodore A.; Rosen, Karin; Chipps, Bradley E.; Luskin, Allan T.; Solari, Paul G.			A randomized multicenter study evaluating Xolair persistence of response after long-term therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; omalizumab; persistence; eosinophilia; exacerbations; IgE; high-affinity IgE receptor; long-term treatment; fractional exhaled nitric oxide	ANTI-IGE ANTIBODY; DOWN-REGULATION; FUTURE ASTHMA; OMALIZUMAB; EXACERBATIONS; WITHDRAWAL	Background: Few data are available to assist clinicians with decisions regarding long-term use of asthma therapies, including omalizumab. Objective: We sought to evaluate the benefit and persistence of response in subjects continuing or withdrawing from long-term omalizumab treatment. Methods: Evaluating the Xolair Persistency Of Response After Long-Term Therapy (XPORT) was a randomized, double-blind, placebo-controlled withdrawal study that included subjects with moderate-to-severe persistent asthma receiving long-term omalizumab. Subjects were randomized by using a hierarchical dynamic randomization scheme to continue their same dose of omalizumab or withdraw to placebo and were then followed every 4 weeks for 1 year. The primary outcome was any protocol-defined severe asthma exacerbation. The secondary outcome was time to first protocol-defined severe asthma exacerbation. Exploratory outcomes included changes in Asthma Control Questionnaire and Asthma Control Test scores. Results: Significantly more subjects in the omalizumab group (67%) had no protocol-defined exacerbation than in the placebo group (47.7%); an absolute difference of 19.3% (95% CI, 5.0%, 33.6%) represents a 40.1% relative difference. Time to first protocol-defined exacerbation analysis revealed a significantly different between-group exacerbation pattern that was consistent with the primary analysis. Subjects continuing omalizumab had significantly better asthma control (mean [SD] change from baseline to week 52: Asthma Control Test score, -1.16 [4.14] vs placebo, -2.88 [5.38], P = .0188; Asthma Control Questionnaire score, 0.22 [0.66] vs placebo, 0.63 [1.13], P = .0039). Discontinuation of omalizumab was associated with an increase in free IgE levels and an increase in basophil expression of the high-affinity IgE receptor. No safety concerns were noted. Conclusion: Continuation of omalizumab after long-term treatment results in continued benefit, as evidenced by improved symptom control and reduced exacerbation risk.	[Ledford, Dennis] Univ S Florida, Morsani Coll Med, Tampa, FL USA; [Ledford, Dennis] Univ S Florida, James A Haley VA Hosp, Tampa, FL USA; [Busse, William] Univ Wisconsin, Madison, WI 53706 USA; [Trzaskoma, Benjamin; Omachi, Theodore A.; Rosen, Karin; Solari, Paul G.] Genentech Inc, San Francisco, CA 94080 USA; [Chipps, Bradley E.] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA; [Luskin, Allan T.] Dean Clin, Madison, WI USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Wisconsin System; University of Wisconsin Madison; Roche Holding; Genentech	Ledford, D (corresponding author), Univ S Florida, Div Allergy & Immunol, VA Hosp 11D, 1300 Bruce B Downs Blvd, Tampa, FL 33613 USA.	dledford@health.usf.edu		Omachi, Theodore/0000-0001-9167-768X; Busse, William/0000-0003-2591-4696	Genentech, Inc, South San Francisco, Calif; Novartis Pharma AG, Basel, Switzerland; Genentech; Novartis Pharmaceuticals Corporation	Genentech, Inc, South San Francisco, Calif(Roche HoldingGenentech); Novartis Pharma AG, Basel, Switzerland; Genentech(Roche HoldingGenentech); Novartis Pharmaceuticals Corporation(Novartis)	This study was funded by Genentech, Inc, South San Francisco, Calif, and Novartis Pharma AG, Basel, Switzerland. Employees of the study sponsor are named as authors on this manuscript and contributed to the design of the study, the collection and interpretation of the data, and the preparation of this manuscript for submission. Medical writing support for this manuscript was provided by Linda Wagner, PharmD, of Excel Scientific Solutions and funded by Genentech and Novartis Pharmaceuticals Corporation. ClinicalTrials.gov identifier: NCT00314574.	[Anonymous], 2014, XOL OM PRESCR INF; Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Chanez P, 2010, RESP MED, V104, P1608, DOI 10.1016/j.rmed.2010.07.011; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Long AA, 2009, ANN ALLERG ASTHMA IM, V103, P212, DOI 10.1016/S1081-1206(10)60184-6; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Malinovschi A, 2013, J ALLERGY CLIN IMMUN, V132, P821, DOI 10.1016/j.jaci.2013.06.007; National Asthma Education and Prevention Program, 2007, EXP PAN REP 3 GUID D; Nopp A, 2007, ALLERGY, V62, P1175, DOI 10.1111/j.1398-9995.2007.01476.x; Nopp A, 2010, ALLERGY, V65, P56, DOI 10.1111/j.1398-9995.2009.02144.x; Pelaia G, 2011, J ASTHMA ALLERGY, V4, P49, DOI 10.2147/JAA.S14520; Saini SS, 1999, J IMMUNOL, V162, P5624; Schleich FN, 2014, EUR RESPIR J, V44, P1098, DOI [10.1183/09031936.00201813, 10.1183/09031936.00118014]; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Zeiger RS, 2015, J ALLER CL IMM-PRACT, V3, P283, DOI 10.1016/j.jaip.2014.10.009; Zeiger RS, 2014, J ALLER CL IMM-PRACT, V2, P741, DOI 10.1016/j.jaip.2014.06.005	19	113	121	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					162	+		10.1016/j.jaci.2016.08.054	http://dx.doi.org/10.1016/j.jaci.2016.08.054			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27826098	hybrid			2022-12-18	WOS:000404542000016
J	Tan, JWL; Valerio, C; Barnes, EH; Turner, PJ; Van Asperen, PA; Kakakios, AM; Campbell, DE				Tan, John Wei-Liang; Valerio, Carolina; Barnes, Elizabeth H.; Turner, Paul J.; Van Asperen, Peter A.; Kakakios, Alyson M.; Campbell, Dianne E.		Beating Egg Allergy Trial BEAT Stu	A randomized trial of egg introduction from 4 months of age in infants at risk for egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary prevention; egg allergy; tolerance	FOOD ALLERGY; NATURAL-HISTORY; PEANUT; PREVALENCE; CHILDREN; ECZEMA; CONSUMPTION; CHALLENGES; CRITERIA	Background: Epidemiologic evidence suggests delayed introduction of egg might not protect against egg allergy in infants at risk of allergic disease. Objective: We sought to assess whether dietary introduction of egg between 4 and 6 months in infants at risk of allergy would reduce sensitization to egg. Methods: We conducted a randomized controlled trial in infants with at least 1 first-degree relative with allergic disease. Infants with a skin prick test (SPT) response to egg white (EW) of less than 2 mm were randomized at age 4 months to receive wholeegg powder or placebo (rice powder) until 8 months of age, with all other dietary egg excluded. Diets were liberalized at 8 months in both groups. The primary outcome was an EW SPT response of 3 mm or greater at age 12 months. Results: Three hundred nineteen infants were randomized: 165 to egg and 154 to placebo. Fourteen infants reacted to egg within 1 week of introduction (despite an EW SPT response <2 mm at entry) and were unsuitable for intervention. Two hundred fifty-four (83%) infants were assessed at 12 months of age. Loss to follow-up was similar between groups. Sensitization to EW at 12 months was 20% and 11% in infants randomized to placebo and egg, respectively (odds ratio, 0.46; 95% CI, 0.22-0.95; P = .03, chi(2) test). The absolute risk reduction was 9.8% (95% CI, 8.2% to 18.9%), with a number needed to treat of 11 (95% CI, 6-122). Levels of IgG4 to egg proteins and IgG4/IgE ratios were higher in those randomized to egg (P < .0001 for each) at 12 months. There was no effect on the proportion of children with probable egg allergy (placebo, 13; egg, 8). Conclusions: Introduction of whole-egg powder into the diets of high-risk infants reduced sensitization to EW and induced egg-specific IgG4 levels. However, 8.5% of infants randomized to egg were not amenable to this primary prevention.	[Tan, John Wei-Liang; Valerio, Carolina; Van Asperen, Peter A.; Kakakios, Alyson M.; Campbell, Dianne E.] Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW, Australia; [Barnes, Elizabeth H.] Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Sydney, NSW, Australia; [Tan, John Wei-Liang; Valerio, Carolina; Van Asperen, Peter A.; Kakakios, Alyson M.; Campbell, Dianne E.] Childrens Hosp Westmead, Dept Allergy & Immunol, Sydney, NSW, Australia; [Turner, Paul J.] Imperial Coll London, Sect Paediat Allergy & Infect Dis, London, England; [Turner, Paul J.] Imperial Coll London, MRC, London, England; [Turner, Paul J.] Imperial Coll London, Asthma UK Ctr Allerg Mech Asthma, London, England	University of Sydney; University of Sydney; University of Sydney; Imperial College London; Imperial College London; Imperial College London; University of London; King's College London	Campbell, DE (corresponding author), Childrens Hosp Westmead, Allergy & Immunol, Sydney, NSW 2145, Australia.	dianne.campbell1@health.nsw.gov.au		Campbell, Dianne/0000-0002-0907-6963; Turner, Paul/0000-0001-9862-5161	Ilhan Food Allergy Foundation; Children's Hospital at Westmead Allergy and Immunology research fund	Ilhan Food Allergy Foundation; Children's Hospital at Westmead Allergy and Immunology research fund	Supported by the Ilhan Food Allergy Foundation and the Children's Hospital at Westmead Allergy and Immunology research fund.	Blom WM, 2013, J ALLERGY CLIN IMMUN, V131, P172, DOI 10.1016/j.jaci.2012.10.034; de Silva D, 2014, ALLERGY, V69, P581, DOI 10.1111/all.12334; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; Ho MHK, 2006, J ALLERGY CLIN IMMUN, V117, P1506, DOI 10.1016/j.jaci.2006.03.029; Koplin JJ, 2014, ALLERGY, V69, P1639, DOI 10.1111/all.12487; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Martin PE, 2015, CLIN EXP ALLERGY, V45, P255, DOI 10.1111/cea.12406; Nwaru BI, 2010, PEDIATRICS, V125, P50, DOI 10.1542/peds.2009-0813; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002; Panjari M, 2016, CLIN EXP ALLERGY, V46, P602, DOI 10.1111/cea.12699; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Ward CE, 2015, ANN ALLERG ASTHMA IM, V114, P312, DOI 10.1016/j.anai.2014.12.022; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Xepapadaki P, 2016, ALLERGY, V71, P350, DOI 10.1111/all.12801	23	113	115	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1621	+		10.1016/j.jaci.2016.08.035	http://dx.doi.org/10.1016/j.jaci.2016.08.035			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27742394	Green Submitted, Bronze			2022-12-18	WOS:000400465300023
J	Galand, C; Leyva-Castillo, JM; Juhan, Y; Han, A; Lee, MS; McKenzie, ANJ; Stassen, M; Oyoshi, MK; Finkelman, FD; Geha, RS				Galand, Claire; Leyva-Castillo, Juan Manuel; Yoon, Juhan; Han, Alex; Lee, Margaret S.; McKenzie, Andrew N. J.; Stassen, Michael; Oyoshi, Michiko K.; Finkelman, Fred D.; Geha, Raif S.			IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-33; ST2; food allergy; atopic dermatitis; mast cells	ATOPIC-DERMATITIS; MURINE MODEL; NATIONAL-HEALTH; PEANUT ALLERGY; INFLAMMATION; CYTOKINES; EXPOSURE; ANTIGEN; MOUSE; ST2	Background: Cutaneous exposure to food allergens predisposes to food allergy, which is commonly associated with atopic dermatitis (AD). Levels of the epithelial cytokine IL-33 are increased in skin lesions and serum of patients with AD. Mast cells (MCs) play a critical role in food-induced anaphylaxis and express the IL-33 receptor ST2. The role of IL-33 in patients with MC-dependent food anaphylaxis is unknown. Objective: We sought to determine the role and mechanism of action of IL-33 in patients with food-induced anaphylaxis in a model of IgE-dependent food anaphylaxis elicited by oral challenge of epicutaneously sensitized mice. Methods: Wild-type, ST2-deficient, and MC-deficient Kit(W-sh/W-sh) mice were epicutaneously sensitized with ovalbumin (OVA) and then challenged orally with OVA. Body temperature was measured by means of telemetry, Il33 mRNA by means of quantitative PCR, and IL-33, OVA-specific IgE, and mouse mast cell protease 1 by means of ELISA. Bone marrow-derived mast cell(BMMC) degranulation was assessed by using flow cytometry. Results: Il33 mRNA expression was upregulated in tape-stripped mouse skin and scratched human skin. Tape stripping caused local and systemic IL-33 release in mice. ST2 deficiency, as well as ST2 blockade before oral challenge, significantly reduced the severity of oral anaphylaxis without affecting the systemic T(H)2 response to the allergen. Oral anaphylaxis was abrogated in Kit(W-sh/W-sh) mice and restored by means of reconstitution with wildtype but not ST2-deficient BMMCs. IL-33 significantly enhanced IgE-mediated degranulation of BMMCs in vitro. Conclusion: IL-33 is released after mechanical skin injury, enhances IgE-mediated MC degranulation, and promotes oral anaphylaxis after epicutaneous sensitization by targeting MCs. IL-33 neutralization might be useful in treating food-induced anaphylaxis in patients with AD.	[Galand, Claire; Leyva-Castillo, Juan Manuel; Yoon, Juhan; Han, Alex; Lee, Margaret S.; Oyoshi, Michiko K.; Geha, Raif S.] Boston Childrens Hosp, Harvard Med Sch, Dept Pediat, Div Immunol, Boston, MA USA; [McKenzie, Andrew N. J.] MRC, Mol Biol Lab, Cambridge, England; [Stassen, Michael] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Immunol, Mainz, Germany; [Finkelman, Fred D.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Cincinnati Vet Affairs Med Ctr, Dept Med,Div Immunol Allergy & Rhematol, Cincinnati, OH USA	Harvard University; Boston Children's Hospital; Harvard Medical School; MRC Laboratory Molecular Biology; Johannes Gutenberg University of Mainz; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Geha, RS (corresponding author), Boston Childrens Hosp, Div Immunol, Karp Bldg,10th Floor,One Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Han, Alex/AAW-6560-2020	Han, Alex/0000-0002-4690-318X; Leyva Castillo, Juan Manuel/0000-0001-7394-4457	Bunning Foundation; MRC [MC_U105178805] Funding Source: UKRI; Medical Research Council [MC_U105178805] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI117673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER	Bunning Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by a grant from the Bunning Foundation.	Ahrens R, 2012, AM J PATHOL, V180, P1535, DOI 10.1016/j.ajpath.2011.12.036; Bartemes KR, 2012, CLIN IMMUNOL, V143, P222, DOI 10.1016/j.clim.2012.03.001; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Becker M, 2011, J IMMUNOL, V186, P7225, DOI 10.4049/jimmunol.1100676; Berin MC, 2013, TRENDS IMMUNOL, V34, P390, DOI 10.1016/j.it.2013.04.003; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004; Chen CY, 2015, IMMUNITY, V43, P788, DOI 10.1016/j.immuni.2015.08.020; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Enoksson M, 2011, J IMMUNOL, V186, P2523, DOI 10.4049/jimmunol.1003383; Fallon PG, 2001, J IMMUNOL, V166, P2712, DOI 10.4049/jimmunol.166.4.2712; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Haenuki Y, 2012, J ALLERGY CLIN IMMUN, V130, P184, DOI 10.1016/j.jaci.2012.02.013; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Hogan SP, 2012, SEMIN IMMUNOPATHOL, V34, P643, DOI 10.1007/s00281-012-0320-1; Iikura M, 2007, LAB INVEST, V87, P971, DOI 10.1038/labinvest.3700663; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Jin HL, 2009, J CLIN INVEST, V119, P47, DOI 10.1172/JCI32310; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Jung MY, 2013, J IMMUNOL, V190, P531, DOI 10.4049/jimmunol.1201576; Katz HR, 2011, IMMUNITY, V35, P668, DOI 10.1016/j.immuni.2011.11.004; Komai-Koma M, 2012, ALLERGY, V67, P1118, DOI 10.1111/j.1398-9995.2012.02859.x; Kucuk ZY, 2012, J ALLERGY CLIN IMMUN, V129, P1343, DOI 10.1016/j.jaci.2012.03.004; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Leyva-Castillo JM, 2013, J INVEST DERMATOL, V133, P154, DOI 10.1038/jid.2012.239; McGowan EC, 2013, J ALLERGY CLIN IMMUN, V132, P1216, DOI 10.1016/j.jaci.2013.07.018; MOLOFSKY AB, 2015, IMMUNITY, V42, P1005, DOI [DOI 10.1016/j.immuni.2015.06.006, DOI 10.1016/J.IMMUNI.2015.06.006]; Morita H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134226; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; Muto T, 2014, INT IMMUNOL, V26, P539, DOI 10.1093/intimm/dxu058; Okayama Y, 2003, EUR J IMMUNOL, V33, P1450, DOI 10.1002/eji.200323563; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Rance F, 2008, PEDIATR ALLERGY IMMU, V19, P279, DOI 10.1111/j.1399-3038.2008.00719.x; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Savinko T, 2013, J INVEST DERMATOL, V133, P2522, DOI 10.1038/jid.2013.195; Savinko T, 2012, J INVEST DERMATOL, V132, P1392, DOI 10.1038/jid.2011.446; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Sugarman JL, 2003, ARCH DERMATOL, V139, P1417, DOI 10.1001/archderm.139.11.1417; Tamagawa-Mineoka R, 2014, J AM ACAD DERMATOL, V70, P882, DOI 10.1016/j.jaad.2014.01.867; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Vaali K, 2006, SCAND J GASTROENTERO, V41, P1405, DOI 10.1080/00365520600815639; Wurbel MA, 2014, INFLAMM BOWEL DIS, V20, P1165, DOI 10.1097/MIB.0000000000000059; Xing W, 2011, P NATL ACAD SCI USA, V108, P14210, DOI 10.1073/pnas.1111048108	51	113	117	3	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1356	1366		10.1016/j.jaci.2016.03.056	http://dx.doi.org/10.1016/j.jaci.2016.03.056			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27372570	Green Accepted, Bronze			2022-12-18	WOS:000389542700015
J	Ullah, MA; Loh, ZX; Gan, WJ; Zhang, V; Yang, H; Li, JH; Yamamoto, Y; Schmidt, AM; Armour, CL; Hughes, JM; Phipps, S; Sukkar, MB				Ullah, Md Ashik; Loh, Zhixuan; Gan, Wan Jun; Zhang, Vivian; Yang, Huan; Li, Jian Hua; Yamamoto, Yasuhiko; Schmidt, Ann Marie; Armour, Carol L.; Hughes, J. Margaret; Phipps, Simon; Sukkar, Maria B.			Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergic sensitization; epithelium; TLR4; RAGE; IL-1 alpha; HMGB1; IL-25; IL-33; TSLP	HOUSE-DUST MITE; DENDRITIC CELLS; ASTHMA PATHOGENESIS; URIC-ACID; HMGB1; IMMUNITY; PROMOTES; RELEASE; PATHWAY; DISEASE	Background: The receptor for advanced glycation end products (RAGE) shares common ligands and signaling pathways with TLR4, a key mediator of house dust mite (Dermatophagoides pteronyssinus) (HDM) sensitization. We hypothesized that RAGE and its ligand high-mobility group box-1 (HMGB1) cooperate with TLR4 to mediate HDM sensitization. Objectives: To determine the requirement for HMGB1 and RAGE, and their relationship with TLR4, in airway sensitization. Methods: TLR4(-/-), RAGE(-/-), and RAGE-TLR4(-/-) mice were intranasally exposed to HDM or cockroach (Blatella germanica) extracts, and features of allergic inflammation were measured during the sensitization or challenge phase. Anti-HMGB1 antibody and the IL-1 receptor antagonist Anakinra were used to inhibit HMGB1 and the IL-1 receptor, respectively. Results: The magnitude of allergic airway inflammation in response to either HDM or cockroach sensitization and/or challenge was significantly reduced in the absence of RAGE but not further diminished in the absence of both RAGE and TLR4. HDM sensitization induced the release of HMGB1 from the airway epithelium in a biphasic manner, which corresponded to the sequential activation of TLR4 then RAGE. Release of HMGB1 in response to cockroach sensitization also was RAGE dependent. Significantly, HMGB1 release occurred downstream of TLR4-induced IL-1 alpha, and upstream of IL-25 and IL-33 production. Adoptive transfer of HDM-pulsed RAGE(+/+) dendritic cells to RAGE(-/-) mice recapitulated the allergic responses after HDM challenge. Immunoneutralization of HMGB1 attenuated HDM-induced allergic airway inflammation. Conclusion: The HMGB1-RAGE axis mediates allergic airway sensitization and airway inflammation. Activation of this axis in response to different allergens acts to amplify the allergic inflammatory response, which exposes it as an attractive target for therapeutic intervention.	[Ullah, Md Ashik; Armour, Carol L.; Hughes, J. Margaret; Sukkar, Maria B.] Univ Sydney, Woolcock Inst Med Res, Sydney Med Sch, Sydney, NSW 2006, Australia; [Ullah, Md Ashik; Loh, Zhixuan; Gan, Wan Jun; Zhang, Vivian; Phipps, Simon] Univ Queensland, Sch Biomed Sci, Lab Resp Neurosci & Mucosal Immun, Brisbane, Qld, Australia; [Yang, Huan; Li, Jian Hua] Feinstein Inst Med Res, Lab Biomed Sci, New York, NY USA; [Yamamoto, Yasuhiko] Kanazawa Univ, Grad Sch Med Sci, Dept Biochem & Mol Vasc Biol, Kanazawa, Ishikawa 9201192, Japan; [Schmidt, Ann Marie] NYU, Langone Med Ctr, Dept Pathol, New York, NY 10003 USA; [Hughes, J. Margaret] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia; [Sukkar, Maria B.] Univ Technol, Grad Sch Hlth, Sch Pharm, Sydney, NSW, Australia	University of Sydney; Woolcock Institute of Medical Research; University of Queensland; Northwell Health; Kanazawa University; New York University; NYU Langone Medical Center; University of Sydney; University of Technology Sydney	Sukkar, MB (corresponding author), Univ Technol, Grad Sch Hlth, Sch Pharm, Broadway, NSW 2007, Australia.	s.phipps@uq.edu.au; maria.sukkar@uts.edu.au	Phipps, Simon/F-9170-2010; Ullah, Ashik/G-3852-2010; Sukkar, Maria B/L-6917-2013; Loh, Zhixuan/G-4104-2015; Ullah, Ashik/N-6465-2017	Phipps, Simon/0000-0002-7388-3612; Ullah, Ashik/0000-0002-0025-1796; Loh, Zhixuan/0000-0002-4124-9502; Ullah, Ashik/0000-0002-0025-1796; Sukkar, Maria/0000-0003-4591-2399; Gan, Wan Jun/0000-0003-0917-1300; Armour, Carol/0000-0002-2930-2227	University of Technology, Sydney; NHMRC Australia [1023756]; University of Sydney	University of Technology, Sydney; NHMRC Australia(National Health and Medical Research Council (NHMRC) of Australia); University of Sydney(University of Sydney)	This work was funded by a Deputy Vice Chancellor Bridging Grant (University of Sydney) and seed funding (University of Technology, Sydney) awarded to M.B.S., and an NHMRC Australia Project Grant (1023756) awarded to S.P.	Arizmendi NG, 2011, J IMMUNOL, V186, P3164, DOI 10.4049/jimmunol.0903812; Ather JL, 2011, J IMMUNOL, V187, P64, DOI 10.4049/jimmunol.1100500; Barry KC, 2013, J IMMUNOL, V190, P6329, DOI 10.4049/jimmunol.1300100; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603; Dumitriu IE, 2007, J LEUKOCYTE BIOL, V81, P84, DOI 10.1189/jlb.0306171; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Hou CC, 2011, MOL MED, V17, P807, DOI 10.2119/molmed.2010.00173; Iwamoto H, 2014, EUR RESPIR J, V43, P421, DOI 10.1183/09031936.00024313; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lee CC, 2013, BIOCHEM PHARMACOL, V86, P940, DOI 10.1016/j.bcp.2013.08.003; Lee PY, 2011, J IMMUNOL, V186, P1747, DOI 10.4049/jimmunol.1001328; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403; McCarthy DA, 2013, REDOX BIOL, V1, P218, DOI 10.1016/j.redox.2013.03.001; Milutinovic PS, 2012, AM J PATHOL, V181, P1215, DOI 10.1016/j.ajpath.2012.06.031; Page K, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-62; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Qin YH, 2009, J IMMUNOL, V183, P6244, DOI 10.4049/jimmunol.0900390; Rabadi MM, 2012, AM J PHYSIOL-RENAL, V302, pF730, DOI 10.1152/ajprenal.00520.2011; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Reijmerink NE, 2010, ALLERGY, V65, P199, DOI 10.1111/j.1398-9995.2009.02111.x; Rojas A, 2013, CELL SIGNAL, V25, P609, DOI 10.1016/j.cellsig.2012.11.022; Rouhiainen A, 2013, CALCIUM BINDING PROT, V963, P239; Ryu JH, 2013, J ALLERGY CLIN IMMUN, V131, P549, DOI 10.1016/j.jaci.2012.07.050; Sakaguchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023132; Sevin CM, 2013, AM J RESP CELL MOL, V49, P396, DOI 10.1165/rcmb.2012-0442OC; Shalaby KH, 2013, J IMMUNOL, V191, P922, DOI 10.4049/jimmunol.1103644; Shim EJ, 2012, CLIN EXP ALLERGY, V42, P958, DOI 10.1111/j.1365-2222.2012.03998.x; Strickland DH, 2010, CURR OPIN IMMUNOL, V22, P789, DOI 10.1016/j.coi.2010.10.019; Sukkar MB, 2012, EUR RESPIR J, V39, P721, DOI 10.1183/09031936.00022011; Sukkar MB, 2012, BRIT J PHARMACOL, V167, P1161, DOI 10.1111/j.1476-5381.2012.01984.x; Tang DL, 2011, ANTIOXID REDOX SIGN, V14, P1315, DOI 10.1089/ars.2010.3356; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Venereau E, 2012, J EXP MED, V209, P1519, DOI 10.1084/jem.20120189; Wahamaa H, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3450; Watanabe T, 2011, RESP MED, V105, P519, DOI 10.1016/j.rmed.2010.10.016; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Wills-Karp M, 2010, CURR OPIN IMMUNOL, V22, P777, DOI 10.1016/j.coi.2010.10.011; Wilson RH, 2012, NAT MED, V18, P1705, DOI 10.1038/nm.2920; Yamamoto Y, 2011, J IMMUNOL, V186, P3248, DOI 10.4049/jimmunol.1002253; Yanai H, 2012, TRENDS IMMUNOL, V33, P633, DOI 10.1016/j.it.2012.10.005; Yang D, 2007, J LEUKOCYTE BIOL, V81, P59, DOI 10.1189/jlb.0306180; Zhou Y, 2012, HUM IMMUNOL, V73, P1171, DOI 10.1016/j.humimm.2012.08.016	47	113	120	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					440	+		10.1016/j.jaci.2013.12.1035	http://dx.doi.org/10.1016/j.jaci.2013.12.1035			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24506934				2022-12-18	WOS:000341370800025
J	Tsai, CL; Lee, WY; Hanania, NA; Camargo, CA				Tsai, Chu-Lin; Lee, Wen-Ya; Hanania, Nicola A.; Camargo, Carlos A., Jr.			Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acute asthma; age; emergency department; outcomes	PROSPECTIVE MULTICENTER; OLDER-ADULTS; EMERGENCY-DEPARTMENT; HOSPITAL ADMISSION; SEX-DIFFERENCES; INNER-CITY; EXACERBATIONS; EPIDEMIOLOGY; MEDICATIONS; GUIDELINES	Background: Little is known about the effect of age on acute asthma outcomes. Objective: We sought to investigate age-related differences in the emergency department (ED) presentation and clinical outcomes for patients with acute asthma. Methods: We analyzed the 2006-2008 Nationwide Emergency Department Sample, the largest, all-payer, US ED and inpatient database. ED visits for acute asthma were identified with a principal diagnosis of International Classification of Disease, ninth revision, Clinical Modification code 493.xx. Patients were divided into 3 age groups: children (<18 years), younger adults (18-54 years), and older adults (>= 55 years). The outcome measures were in-hospital all-cause mortality, near-fatal asthma-related events (noninvasive or mechanical ventilation), hospital charges, admission rates, and hospital length of stay. Results: There were an estimated 1,813,000 visits annually for acute asthma from approximately 4,700 EDs. The estimated overall annual number of in-hospital asthma-related deaths was 1,144 (0.06%); 101 died in the ED, and 1,043 died as inpatients. By age group, there were 37 asthma-related deaths per year in children, 204 in younger adults, and 903 in older adults. Compared with younger adults, older adults had higher mortality, had higher rates of near-fatal asthma-related events, had higher hospital charges, were more likely to be hospitalized, and had a longer hospital length of stay (P < .001 for all). After adjusting for comorbidities, older asthmatic patients had a 5-fold increased risk of overall mortality (adjusted odds ratio, 5.2; 95% CI, 4.0-6.9), compared with younger adults. Conclusions: Older adults with acute asthma have a substantial burden of morbidity and mortality. With the US population aging, there is an urgent need for targeted interventions for this high-risk population. (J Allergy Clin Immunol 2012;129:1252-8.)	[Tsai, Chu-Lin; Lee, Wen-Ya] Univ Texas Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA; [Hanania, Nicola A.] Baylor Coll Med, Dept Med, Sect Pulm & Crit Care Med, Houston, TX 77030 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Baylor College of Medicine; Harvard University; Harvard Medical School; Massachusetts General Hospital	Tsai, CL (corresponding author), Univ Texas Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, 1200 Herman Pressler,Suite W610, Houston, TX 77030 USA.	cltsai@post.harvard.edu	Hanania, Nicola A/C-5875-2016; Camargo, Carlos A./C-2145-2008	Hanania, Nicola A/0000-0003-3087-9530; Camargo, Carlos A./0000-0002-5071-7654; TSAI, CHU-LIN/0000-0003-4639-1513	Agency for Healthcare Research and Quality [R03HS020722]; GlaxoSmithKline; Sanofi-Aventis; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS020722] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); GlaxoSmithKline(GlaxoSmithKline); Sanofi-Aventis(Sanofi-Aventis); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Supported by grant no. R03HS020722 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.; Disclosure of potential conflict of interest: C. A. Camargo, Jr, is a consultant for Dey, Genentech, Merck, Novartis, and Pfizer and has received research support from GlaxoSmithKline and Sanofi-Aventis. The rest of the authors declare that they have no relevant conflicts of interest.	Abramson MJ, 2001, AM J RESP CRIT CARE, V163, P12, DOI 10.1164/ajrccm.163.1.9910042; Agency for Healthcare Research and Quality, HCUP METH SER; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; *AM LUNG ASS, TRENDS ASTHM MORB MO; Banerji A, 2006, J AM GERIATR SOC, V54, P48, DOI 10.1111/j.1532-5415.2005.00563.x; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Bryant-Stephens T, 2009, J ALLERGY CLIN IMMUN, V123, P1199, DOI 10.1016/j.jaci.2009.04.030; Chotirmall SH, 2009, J AM GERIATR SOC, V57, P901, DOI 10.1111/j.1532-5415.2009.02216.x; CONNOLLY MJ, 1992, THORAX, V47, P410, DOI 10.1136/thx.47.6.410; CONNOLLY MJ, 1995, CHEST, V108, P401, DOI 10.1378/chest.108.2.401; Department of Health and Human Services, INT CLASS DIS CLIN M, V1; Dhuper S, 2003, CHEST, V124, P1880, DOI 10.1378/chest.124.5.1880; Diette GB, 2002, ARCH INTERN MED, V162, P1123, DOI 10.1001/archinte.162.10.1123; Drazen JM, 2009, NEW ENGL J MED, V360, P1671, DOI 10.1056/NEJMe0902057; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; Gibson PG, 2010, LANCET, V376, P803, DOI 10.1016/S0140-6736(10)61087-2; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; Griswold SK, 2005, CHEST, V127, P1579, DOI 10.1378/chest.127.5.1579; Hanania NA, 2011, J ALLERGY CLIN IMMUN, V128, pS4, DOI 10.1016/j.jaci.2011.06.048; Hartert TV, 2000, J AM GERIATR SOC, V48, P651, DOI 10.1111/j.1532-5415.2000.tb04723.x; HCUP Nationwide Emergency Department Sample (NEDS), HCUP NAT EM DEP SAMP; Huss K, 2001, ANN ALLERG ASTHMA IM, V86, P524, DOI 10.1016/S1081-1206(10)62900-6; Janssens JP, 1999, EUR RESPIR J, V13, P197, DOI 10.1034/j.1399-3003.1999.13a36.x; Krishnan V, 2006, AM J RESP CRIT CARE, V174, P633, DOI 10.1164/rccm.200601-007OC; KRONENBERG RS, 1973, J CLIN INVEST, V52, P1812, DOI 10.1172/JCI107363; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Moorman JE, 2001, J ASTHMA, V38, P65, DOI 10.1081/JAS-100000023; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Navaratnam P, 2008, J AM GERIATR SOC, V56, P1312, DOI 10.1111/j.1532-5415.2008.01767.x; Patel SN, 2009, ANN ALLERG ASTHMA IM, V103, P121, DOI 10.1016/S1081-1206(10)60164-0; Pollack CV, 2002, ARCH PEDIAT ADOL MED, V156, P934; Reed CE, 2010, J ALLERGY CLIN IMMUN, V126, P681, DOI 10.1016/j.jaci.2010.05.035; Schatz M, 2006, CHEST, V129, P50, DOI 10.1378/chest.129.1.50; Sharma G, 2006, CLIN INTERV AGING, V1, P253, DOI 10.2147/ciia.2006.1.3.253; Shaya FT, 2008, CHEST, V134, P14, DOI 10.1378/chest.07-2317; Sin DD, 2001, CHEST, V119, P720, DOI 10.1378/chest.119.3.720; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; Slavin RG, 2006, ANN ALLERG ASTHMA IM, V96, P406, DOI 10.1016/S1081-1206(10)60907-6; Szefler SJ, 2011, J ALLERGY CLIN IMMUN, V128, P485, DOI 10.1016/j.jaci.2011.07.010; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V126, P939, DOI 10.1016/j.jaci.2010.09.018; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P521, DOI 10.1016/j.jaci.2010.01.025; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Tsai CL, 2009, J CLIN EPIDEMIOL, V62, P982, DOI 10.1016/j.jclinepi.2008.10.005; Tsai CL, 2009, J ALLERGY CLIN IMMUN, V123, P354, DOI 10.1016/j.jaci.2008.10.051; ULLAH MI, 1981, THORAX, V36, P523, DOI 10.1136/thx.36.7.523; US Census Bureau, CENS REG DIV US; Weber EJ, 2002, AM J MED, V113, P371, DOI 10.1016/S0002-9343(02)01242-1	51	113	116	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1252	U363		10.1016/j.jaci.2012.01.061	http://dx.doi.org/10.1016/j.jaci.2012.01.061			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22385630	Bronze			2022-12-18	WOS:000303418000011
J	Lu, TX; Sherrill, JD; Wen, T; Plassard, AJ; Besse, JA; Abonia, JP; Franciosi, JP; Putnam, PE; Eby, M; Martin, LJ; Aronow, BJ; Rothenberg, ME				Lu, Thomas X.; Sherrill, Joseph D.; Wen, Ting; Plassard, Andrew J.; Besse, John A.; Abonia, Juan Pablo; Franciosi, James P.; Putnam, Philip E.; Eby, Michael; Martin, Lisa J.; Aronow, Bruce J.; Rothenberg, Marc E.			MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; microRNA; glucocorticoid; biomarkers	SQUAMOUS-CELL CARCINOMA; ALLERGIC AIRWAY INFLAMMATION; CIRCULATING MICRORNAS; MEDIATED REGULATION; EXPRESSION PROFILE; EPITHELIAL-CELLS; MAST-CELLS; RNA-SEQ; CANCER; DIFFERENTIATION	Background: The role of microRNAs (miRNAs), a key class of regulators of mRNA expression and translation, in patients with eosinophilic esophagitis (EoE) has not been explored. Objective: We aimed to identify miRNAs dysregulated in patients with EoE and assess the potential of these miRNAs as disease biomarkers. Methods: Esophageal miRNA expression was profiled in patients with active EoE and those with glucocorticoid-induced disease remission. Expression profiles were compared with those of healthy control subjects and patients with chronic (noneosinophilic) esophagitis. Expression levels of the top differentially expressed miRNAs from the plasma of patients with active EoE and patients with EoE remission were compared with those of healthy control subjects. Results: EoE was associated with 32 differentially regulated miRNAs and was distinguished from noneosinophilic forms of esophagitis. The expression levels of the most upregulated miRNAs (miR-21 and miR-223) and the most downregulated miRNA (miR-375) strongly correlated with esophageal eosinophil levels. Bioinformatic analysis predicted interplay of miR-21 and miR-223 with key roles in the polarization of adaptive immunity and regulation of eosinophilia, and indeed, these miRNAs correlated with key elements of the EoE transcriptome. The differentially expressed miRNAs were largely reversible in patients who responded to glucocorticoid treatment. EoE remission induced a single miRNA (miR-675) likely to be involved in DNA methylation. Plasma analysis of the most upregulated esophageal miRNAs identified miR-146a, miR-146b, and miR-223 as the most differentially expressed miRNAs in the plasma. Conclusions: We have identified a marked dysregulated expression of a select group of miRNAs in patients with EoE and defined their reversibility with glucocorticoid treatment and their potential value as invasive and noninvasive biomarkers. (J Allergy Clin Immunol 2012;129:1064-75.)	[Lu, Thomas X.; Sherrill, Joseph D.; Wen, Ting; Besse, John A.; Abonia, Juan Pablo; Eby, Michael; Rothenberg, Marc E.] Univ Cincinnati, Div Allergy & Immunol, Cincinnati Childrens Hosp Med Ctr, Coll Med, Cincinnati, OH 45229 USA; [Lu, Thomas X.] Univ Cincinnati, Grad Program Mol & Dev Biol, Cincinnati Childrens Hosp Med Ctr, Coll Med, Cincinnati, OH 45229 USA; [Lu, Thomas X.] Univ Cincinnati, Phys Scientist Training Program, Cincinnati Childrens Hosp Med Ctr, Coll Med, Cincinnati, OH 45229 USA; [Plassard, Andrew J.; Aronow, Bruce J.] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA; [Franciosi, James P.; Putnam, Philip E.] Cincinnati Childrens Hosp Med Ctr, Div Gastroenterol Hepatol & Nutr, Cincinnati, OH 45229 USA; [Martin, Lisa J.] Cincinnati Childrens Hosp Med Ctr, Div Epidemiol & Biostat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Rothenberg, ME (corresponding author), Univ Cincinnati, Div Allergy & Immunol, Cincinnati Childrens Hosp Med Ctr, Coll Med, 3333 Burnet Ave,ML7028, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org	Martin, Lisa/E-2425-2016; Sherrill, Joseph/B-6662-2014; Aronow, Bruce J/F-8438-2012	Martin, Lisa/0000-0001-8702-9946; Abonia, Juan/0000-0003-3788-6485; Lu, Thomas/0000-0001-9712-180X; Besse, John/0000-0002-9874-5822	National Heart, Lung, and Blood Institute's Ruth L. Kirschstein National Research Service [F30HL104892]; Albert J. Ryan Foundation; Organogenesis Training Grant (National Institutes of Health [NIH] [T32HD046387, R01DK076893, U19 AI070235, P30 DK078392]; Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Food Allergy Initiative; National Institutes of Health (NIH), Ception Therapeutics; Children's Digestive Health and Nutrition Foundation; Department of Defense (DOD); Food Allergy & Anaphylaxis Network; International Eosinophil Society's Executive Council; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD046387] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL104892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI045898, U19AI070235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076893, P30DK078392] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute's Ruth L. Kirschstein National Research Service; Albert J. Ryan Foundation; Organogenesis Training Grant (National Institutes of Health [NIH]; Campaign Urging Research for Eosinophilic Disease (CURED); Buckeye Foundation; Food Allergy Initiative; National Institutes of Health (NIH), Ception Therapeutics; Children's Digestive Health and Nutrition Foundation; Department of Defense (DOD)(United States Department of Defense); Food Allergy & Anaphylaxis Network; International Eosinophil Society's Executive Council; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the National Heart, Lung, and Blood Institute's Ruth L. Kirschstein National Research Service Award for individual predoctoral MD/PhD fellows F30HL104892 (T.X.L), the Ryan Fellowship from the Albert J. Ryan Foundation (T.X.L.), and the Organogenesis Training Grant (National Institutes of Health [NIH] grant T32HD046387 supporting T.X.L.). Additionally, this work was supported by NIH grants R01DK076893 (M.E.R), U19 AI070235 (M.E.R), and P30 DK078392; the Campaign Urging Research for Eosinophilic Disease (CURED); the Buckeye Foundation; and the Food Allergy Initiative.; J. P. Abonia has received research support from the National Institutes of Health (NIH), Ception Therapeutics, and the Children's Digestive Health and Nutrition Foundation. L. J. Martin has received research support from the NIH and the Department of Defense (DOD). M. E. Rothenberg has equity interest in reslizumab through Cephalon; is a consultant for and Chief Scientific Officer of Immune Pharmaceuticals; has received research support from the NIH, the Food Allergy & Anaphylaxis Network, and the DOD; is on the American Partnership for Eosinophilic Disorders Medical Advisory Board; and is on the International Eosinophil Society's Executive Council. The rest of the authors declare that they have no relevant conflicts of interest.	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; Assa'ad AH, 2011, GASTROENTEROLOGY, V141, P1593, DOI 10.1053/j.gastro.2011.07.044; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Blanchard C, 2010, J IMMUNOL, V184, P4033, DOI 10.4049/jimmunol.0903069; Cai XZ, 2007, RNA, V13, P313, DOI 10.1261/rna.351707; Caldwell JM, 2010, J ALLERGY CLIN IMMUN, V125, P879, DOI 10.1016/j.jaci.2010.01.038; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Cheverud JM, 2001, HEREDITY, V87, P52, DOI 10.1046/j.1365-2540.2001.00901.x; Collison A, 2011, J ALLERGY CLIN IMMUN, V128, P160, DOI 10.1016/j.jaci.2011.04.005; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; DeBrosse CW, 2011, J ALLERGY CLIN IMMUN, V128, P132, DOI 10.1016/j.jaci.2011.05.006; Dellon ES, 2011, AM J GASTROENTEROL, V106, P264, DOI 10.1038/ajg.2010.412; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Jiang XY, 2011, MOL CELL BIOCHEM, V353, P35, DOI 10.1007/s11010-011-0771-z; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Li SJ, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-24; Li XL, 2011, DIGEST DIS SCI, V56, P2849, DOI 10.1007/s10620-011-1711-1; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lim EJ, 2011, J BIOL CHEM, V286, P13193, DOI 10.1074/jbc.M110.210724; Lin RJ, 2012, J SURG ONCOL, V105, P175, DOI 10.1002/jso.22066; Liu Q, 2012, MOL BIOL REP, V39, P1239, DOI 10.1007/s11033-011-0854-7; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu LF, 2010, CELL, V142, P914, DOI 10.1016/j.cell.2010.08.012; Lu TX, 2011, J IMMUNOL, V187, P3362, DOI 10.4049/jimmunol.1101235; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Matsushima K, 2010, DIGESTION, V82, P138, DOI 10.1159/000310918; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Mayoral RJ, 2009, J IMMUNOL, V182, P433, DOI 10.4049/jimmunol.182.1.433; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Polikepahad S, 2010, J BIOL CHEM, V285, P30139, DOI 10.1074/jbc.M110.145698; Rabinowits G, 2009, CLIN LUNG CANCER, V10, P42, DOI 10.3816/CLC.2009.n.006; Saini HK, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-564; Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x; Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010; Shen J, 2011, LAB INVEST, V91, P579, DOI 10.1038/labinvest.2010.194; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Smith CM, 2010, WORLD J GASTROENTERO, V16, P531, DOI 10.3748/wjg.v16.i5.531; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2010, J ALLERGY CLIN IMMUN, V126, P581, DOI 10.1016/j.jaci.2010.05.045; Stansfield WE, 2009, ANN THORAC SURG, V88, P1916, DOI 10.1016/j.athoracsur.2009.07.038; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Tian TA, 2010, J CELL BIOCHEM, V111, P488, DOI 10.1002/jcb.22733; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Tsuchiya S, 2011, J BIOL CHEM, V286, P420, DOI 10.1074/jbc.M110.170852; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wu F, 2008, GASTROENTEROLOGY, V135, P1624, DOI 10.1053/j.gastro.2008.07.068; Xiang Y, 2008, J CELL BIOCHEM, V103, P920, DOI 10.1002/jcb.21461; Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642; Yuan Q, 2006, EUR J IMMUNOL, V36, P2700, DOI 10.1002/eji.200636112; Yuan Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-57; Zahm AM, 2011, J PEDIATR GASTR NUTR, V53, P26, DOI 10.1097/MPG.0b013e31822200cc	62	113	119	0	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1064	U593		10.1016/j.jaci.2012.01.060	http://dx.doi.org/10.1016/j.jaci.2012.01.060			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22391115	Green Accepted			2022-12-18	WOS:000302144600023
J	Vickery, BP; Scurlock, AM; Jones, SM; Burks, AW				Vickery, Brian P.; Scurlock, Amy M.; Jones, Stacie M.; Burks, A. Wesley			Mechanisms of immune tolerance relevant to food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral tolerance; regulatory T cell; forkhead box protein 3; dendritic cell; food allergy; microbiota; vitamin A; TGF-beta; CD103	REGULATORY T-CELLS; PLASMACYTOID DENDRITIC CELLS; GROWTH-FACTOR-BETA; ORAL TOLERANCE; VITAMIN-A; TGF-BETA; INDOLEAMINE 2,3-DIOXYGENASE; INTESTINAL PERMEABILITY; ATOPIC DISEASE; HUMAN-MILK	The intestine has an unenviable task: to identify and respond to a constant barrage of environmental stimuli that can be both dangerous and beneficial. The proper execution of this task is central to the homeostasis of the host, and as a result, the gastrointestinal tract contains more lymphocytes than any other tissue compartment in the body, as well as unique antigen-presenting cells with specialized functions. When antigen is initially encountered through the gut, this system generates a robust T cell-mediated hyporesponsiveness called oral tolerance. Although seminal observations of oral tolerance were made a century ago, the relevant mechanisms are only beginning to be unraveled with the use of modern investigational techniques. Food allergy is among the clinical disorders that occur from a failure of this system, and therapies that seek to re-establish tolerance are currently under investigation. (J Allergy Clin Immunol 2011;127:576-84.)	[Vickery, Brian P.; Burks, A. Wesley] Duke Univ, Sch Med, Div Pediat Allergy & Immunol, Durham, NC 27706 USA; [Scurlock, Amy M.; Jones, Stacie M.] Univ Arkansas Med Sci, Div Pediat Allergy & Immunol, Little Rock, AR 72205 USA	Duke University; University of Arkansas System; University of Arkansas Medical Sciences	Vickery, BP (corresponding author), DUMC Box 2644, Durham, NC 27710 USA.	brian.vickery@duke.edu		Vickery, Brian/0000-0002-7243-5543	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID); Thrasher Research Fund; Cephalon; NIH; National Peanut Board; NIH/NIAID; DYAX Corp; Food Allergy Initiative; FAAN; Wallace Research Foundation; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT002557] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004435] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI077932, R01AI068074] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Thrasher Research Fund; Cephalon; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Peanut Board; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); DYAX Corp; Food Allergy Initiative; FAAN; Wallace Research Foundation; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	B. P. Vickery has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID), the Thrasher Research Fund, and Cephalon. A. M. Scurlock has received research support from the NIH. S. M. Jones has received research support from the National Peanut Board, NIH/NIAID, DYAX Corp, and the Food Allergy Initiative and is on the medical advisory board of the Food Allergy and Anaphylaxis Network (FAAN) and the steering committee of Sanofi-Aventis. A. W. Burks has consulted for ActoGeniX NV, Intelliject, McNeil Nutritionals, Novartis, Pfizer, and Schering-Plough; is a minority stockholder in Allertein and MastCell, Inc; has served on an advisory board for Dannon Co Probiotics and an expert panel for Nutricia; has received research support from the NIH, FAAN, and theWallace Research Foundation; has provided legal consultation or expert witness testimony on the topic of food allergy; and has served on the medical board of directors of FAAN.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Ando T, 2007, J ALLERGY CLIN IMMUN, V120, P916, DOI 10.1016/j.jaci.2007.05.023; Appleman LJ, 2003, IMMUNOL REV, V192, P161, DOI 10.1034/j.1600-065X.2003.00009.x; Bamboat ZM, 2009, J IMMUNOL, V182, P1901, DOI 10.4049/jimmunol.0803404; Belkaid Y, 2008, IMMUNITY, V29, P362, DOI 10.1016/j.immuni.2008.08.005; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Berin MC, 2006, ALLERGY, V61, P64, DOI 10.1111/j.1398-9995.2006.01012.x; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Blanchard C, 2010, J IMMUNOL, V184, P4033, DOI 10.4049/jimmunol.0903069; Blazquez AB, 2008, J IMMUNOL, V180, P4441, DOI 10.4049/jimmunol.180.7.4441; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Brandtzaeg P, 2010, CURR OPIN GASTROEN, V26, P554, DOI 10.1097/MOG.0b013e32833dccf8; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Burks AW, 2008, J ALLERGY CLIN IMMUN, V121, P1344, DOI 10.1016/j.jaci.2008.02.037; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Chen W, 2008, J IMMUNOL, V181, P5396, DOI 10.4049/jimmunol.181.8.5396; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Coombes JL, 2008, NAT REV IMMUNOL, V8, P435, DOI 10.1038/nri2335; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Cummings AJ, 2010, ALLERGY, V65, P933, DOI 10.1111/j.1398-9995.2010.02342.x; Dahan S, 2007, IMMUNOL REV, V215, P243, DOI 10.1111/j.1600-065X.2006.00484.x; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Dubois B, 2009, GASTROENTEROLOGY, V137, P1019, DOI 10.1053/j.gastro.2009.03.055; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Fukaya T, 2010, BLOOD, V116, P2266, DOI 10.1182/blood-2009-10-250472; Goubier A, 2008, IMMUNITY, V29, P464, DOI 10.1016/j.immuni.2008.06.017; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Hawkes JS, 1999, PEDIATR RES, V46, P194, DOI 10.1203/00006450-199908000-00012; Hershberg RM, 1998, J CLIN INVEST, V102, P792, DOI 10.1172/JCI3201; Holt PG, 2008, J ALLERGY CLIN IMMUN, V122, P717, DOI 10.1016/j.jaci.2008.08.019; Holt PG, 2009, J EXP MED, V206, P2861, DOI 10.1084/jem.20092469; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Iliev ID, 2007, J EXP MED, V204, P2253, DOI 10.1084/jem.20062535; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Iwata M, 2009, SEMIN IMMUNOL, V21, P8, DOI 10.1016/j.smim.2008.09.002; Jaensson E, 2008, J EXP MED, V205, P2139, DOI 10.1084/jem.20080414; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kang SG, 2007, J IMMUNOL, V179, P3724, DOI 10.4049/jimmunol.179.6.3724; Karlsson MR, 2010, ALLERGY, V65, P561, DOI 10.1111/j.1398-9995.2009.02225.x; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kukkonen K, 2010, PEDIAT ALLERG IMM-UK, V21, P67, DOI 10.1111/j.1399-3038.2009.00907.x; Levy Y, 2009, PEDIATR TRANSPLANT, V13, P63, DOI 10.1111/j.1399-3046.2007.00883.x; Li MO, 2008, IMMUNITY, V28, P468, DOI 10.1016/j.immuni.2008.03.003; Lopez-Exposito I, 2009, J ALLERGY CLIN IMMUN, V124, P1039, DOI 10.1016/j.jaci.2009.08.024; Matteoli G, 2010, GUT, V59, P595, DOI 10.1136/gut.2009.185108; Medini D, 2008, NAT REV MICROBIOL, V6, P419, DOI 10.1038/nrmicro1901; Middendorp S, 2009, MUCOSAL IMMUNOL, V2, P393, DOI 10.1038/mi.2009.99; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; Mosconi E, 2010, MUCOSAL IMMUNOL, V3, P461, DOI 10.1038/mi.2010.23; Moseman EA, 2004, J IMMUNOL, V173, P4433, DOI 10.4049/jimmunol.173.7.4433; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Mowat AM, 2004, ANN NY ACAD SCI, V1029, P1, DOI 10.1196/annals.1309.001; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Mucida D, 2009, SEMIN IMMUNOL, V21, P14, DOI 10.1016/j.smim.2008.08.001; Penttila I, 2006, PEDIATR RES, V59, P650, DOI 10.1203/01.pdr.0000203149.75465.74; Penttila IA, 2010, J PEDIATR-US, V156, pS21, DOI 10.1016/j.jpeds.2009.11.016; Perez-Machado MA, 2003, EUR J IMMUNOL, V33, P2307, DOI 10.1002/eji.200323308; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Prescott SL, 2010, P NUTR SOC, V69, P366, DOI 10.1017/S0029665110001874; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Sharma MD, 2007, J CLIN INVEST, V117, P2570, DOI 10.1172/JCI31911; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; Strober W, 2008, MUCOSAL IMMUNOL, V1, P92, DOI 10.1038/mi.2007.22; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Uematsu S, 2008, NAT IMMUNOL, V9, P769, DOI 10.1038/ni.1622; Untersmayr E, 2008, J ALLERGY CLIN IMMUN, V121, P1301, DOI 10.1016/j.jaci.2008.04.025; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Venter C, 2010, ALLERGY, V65, P103, DOI 10.1111/j.1398-9995.2009.02176.x; Ventura MT, 2006, DIGEST LIVER DIS, V38, P732, DOI 10.1016/j.dld.2006.06.012; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Yao TC, 2010, PEDIAT ALLERG IMM-UK, V21, P900, DOI 10.1111/j.1399-3038.2009.00955.x; Zhou YF, 2010, NAT MED, V16, P1128, DOI 10.1038/nm.2201; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	95	113	115	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					576	586		10.1016/j.jaci.2010.12.1116	http://dx.doi.org/10.1016/j.jaci.2010.12.1116			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21277624	Green Accepted			2022-12-18	WOS:000288018400003
J	Tulic, MK; Hodder, M; Forsberg, A; McCarthy, S; Richman, T; D'Vaz, N; van den Biggelaar, AHJ; Thornton, CA; Prescott, SL				Tulic, Meri K.; Hodder, Megan; Forsberg, Anna; McCarthy, Suzi; Richman, Tara; D'Vaz, Nina; van den Biggelaar, Anita H. J.; Thornton, Catherine A.; Prescott, Susan L.			Differences in innate immune function between allergic and nonallergic children: New insights into immune ontogeny	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toll-like receptor; ontogeny; innate immunity; allergic disease; children	RESPONSES; MONOCYTES; SYSTEM	Background: Microbial products are of central interest in the modulation of allergic propensity. Objective: We sought to explore whether allergic children show differences in microbial Toll-like receptor (TLR)-mediated responses over their first 5 years of life. Methods: Mononuclear cells isolated from 35 allergic and 35 nonallergic children at birth and 1, 2.5, and 5 years of age were stimulated with TLR2-TLR9 ligands to study innate immune function and with allergens or mitogen to assess adaptive T-cell responses. Cytokine production was measured by using Luminex multiplexing technology. Results: Nonallergic children show progressive and significant age-related increases in innate cytokine responses (IL-1 beta, IL-6, TNF-alpha, and IL-10) to virtually all TLR ligands. This innate maturation corresponds with a parallel increase in adaptive T(H)1 (IFN-gamma) responses to allergens and mitogens. In contrast, allergic children show exaggerated innate responses at birth (P < .01) but a relative decrease with age thereafter, so that by age 5 years, TLR responses are attenuated compared with those seen in nonallergic subjects (P < .05). This early hyperresponsiveness in allergic subjects fails to translate to a corresponding maturation of T(H)1 function, which remains attenuated relative to that seen in nonallergic subjects but is associated with a characteristic age-dependent increase in allergen-specific T(H)2 responses (P < .01). Conclusion: Our findings suggest significant differences in the developmental trajectory of innate immune function in children with allergic disease that might contribute to the recognized differences in postnatal adaptive T-cell immunity. (J Allergy Clin Immunol 2011;127:470-8.)	[Tulic, Meri K.] Univ Western Australia, Sch Paediat & Child Hlth, Fac Med Dent & Hlth Sci, Perth, WA 6009, Australia; [Forsberg, Anna] Linkoping Univ, Dept Clin & Expt Med, Div Inflammat Med, Linkoping, Sweden; [van den Biggelaar, Anita H. J.] UWA, Div Cell Biol, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA, Australia; [Thornton, Catherine A.] Swansea Univ, Inst Life Sci, Sch Med, Swansea, W Glam, Wales	University of Western Australia; Linkoping University; Telethon Kids Institute; University of Western Australia; Swansea University	Tulic, MK (corresponding author), Univ Western Australia, Sch Paediat & Child Hlth, Fac Med Dent & Hlth Sci, Perth, WA 6009, Australia.	mtulic@meddent.uwa.edu.au	Tulic, Meri K/ABB-5138-2020; Forsberg, Anna/ABD-2423-2020; Prescott, Susan/H-5665-2014; Tulic, Meri/P-6613-2016	Tulic, Meri K/0000-0002-2661-2369; Forsberg, Anna/0000-0001-6896-4867; Tulic, Meri/0000-0002-2661-2369	National Health and Medical Research Council (NHMRC) of Australia [458502]; NHMRC; Welsh Office of Research and Development	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Welsh Office of Research and Development	Supported by the National Health and Medical Research Council (NHMRC) of Australia (grant ID 458502). S. L. P. is supported by an NHMRC Practitioner Fellowship, and M. K. T. is supported by an NHMRC Career Development Award.; M. K. Tulic receives research support from the National Health and Medical Research Council (NHMRC), Australia. C. A. Thornton has received research support from the Welsh Office of Research and Development. S. L. Prescott is on the advisory board for Nestle Nutrition, is a consultant for Fonterra, is a speaker for Nutricia, and receives research support from the National Health and Medical Research Council (NHMRC), Australia. The rest of the authors have declared that they have no conflict of interest.	Amoudruz P, 2009, CLIN EXP IMMUNOL, V155, P387, DOI 10.1111/j.1365-2249.2008.03792.x; Bacchetti P, 2002, BRIT MED J, V324, P1271, DOI 10.1136/bmj.324.7348.1271; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Benwell RK, 2010, CLIN IMMUNOL, V134, P178, DOI 10.1016/j.clim.2009.09.013; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Dominitzki S, 2007, J IMMUNOL, V179, P2041, DOI 10.4049/jimmunol.179.4.2041; FELDMAN HA, 1988, J APPL PHYSIOL, V64, P1721, DOI 10.1152/jappl.1988.64.4.1721; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hart PH, 1999, J LEUKOCYTE BIOL, V66, P575, DOI 10.1002/jlb.66.4.575; Martino DJ, 2010, ALLERGY, V65, P7, DOI 10.1111/j.1398-9995.2009.02186.x; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Prescott SL, 2008, J ALLERGY CLIN IMMUN, V122, P391, DOI 10.1016/j.jaci.2008.04.042; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P200, DOI 10.1016/j.jaci.2007.03.045; Prescott SL, 2009, CURR OPIN ALLERGY CL, V9, P417, DOI 10.1097/ACI.0b013e328330634f; Sudo N, 1997, J IMMUNOL, V159, P1739; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Tulic MK, 2002, INT ARCH ALLERGY IMM, V129, P119, DOI 10.1159/000065881; Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002	22	113	117	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					470	U1817		10.1016/j.jaci.2010.09.020	http://dx.doi.org/10.1016/j.jaci.2010.09.020			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21093030				2022-12-18	WOS:000286808000022
J	Razi, CH; Harmanci, K; Abaci, A; Ozdemir, O; Hizli, S; Renda, R; Keskin, F				Razi, Cem Hasan; Harmanci, Koray; Abaci, Ayhan; Ozdemir, Osman; Hizli, Samil; Renda, Rahime; Keskin, Fersin			The immunostimulant OM-85 BV prevents wheezing attacks in preschool children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wheezing; OM-85 BV; children	RESPIRATORY-TRACT INFECTIONS; IFN-GAMMA PRODUCTION; BACTERIAL EXTRACT; BRONCHO-VAXOM; DOUBLE-BLIND; INHALED CORTICOSTEROIDS; RECURRENT INFECTIONS; ASTHMA; EXACERBATIONS; 1ST-YEAR	Background: No reagents have been shown to be effective in preventing wheezing attacks provoked by acute respiratory tract illnesses (ARTIs) in preschool children. New therapeutic agents and preventive strategies are needed. Objectives: We assessed the effect of OM-85 BV (Broncho-Vaxom; OM Pharma, Geneva, Switzerland) in preventing ARTI-provoked wheezing attacks in preschool children with recurrent wheezing. Methods: A randomized, double-blind, placebo-controlled, parallel-group study was carried out between August 2007 and September 2008. The study included 75 children with recurrent wheezing who were 1 to 6 years old. Participants were randomly assigned to groups given either OM-85 BV or a placebo (1 capsule per day for 10 days each month for 3 consecutive months) at the start of the trial. Participants were followed for 12 months, which included the administration period of the test article. Results: Subjects given OM-85 BV had a lower rate of wheezing attacks. The cumulative difference in wheezing attacks between the 2 groups was 2.18 wheezing attacks per patient in 12 months; there was a 37.9% reduction in the group given OM-85 BV compared with the group given placebo (P < .001). Stepwise multiple (linear) regression analysis showed that the main difference between the OM-85 BV and placebo groups was a reduction the number of ARTIs (R = -0.805, P < .001). The duration of each wheezing attack was 2 days shorter in the group given OM-85 BV than in the group given placebo (P = .001). Conclusion: Administration of OM-85 BV significantly reduced the rate and duration of wheezing attacks in preschool children with ARTIs. (J Allergy Clin Immunol 2010;126:763-9.)	[Razi, Cem Hasan; Harmanci, Koray] Kecioren Educ & Res Hosp, Dept Pediat, Div Pediat Allergy, Ankara, Turkey; [Renda, Rahime] Sami Ulus Pediat & Gynecol Educ & Res Hosp, Dept Pediat, Ankara, Turkey; [Keskin, Fersin] Minist Agr & Rural Affairs, Dept Stat, Ankara, Turkey	Ankara Kecioren Training & Research Hospital; Dr. Sami Ulus Education & Research Hospital; Ministry of Food, Agriculture & Livestock - Turkey	Razi, CH (corresponding author), Kecioren Egitim Arastirma Hastanesi, Cocuk Allerji Bolumu, Pinabasi Mahallesi Ardahan Sokak 25, TR-06290 Ankara, Turkey.	cemrazi2@gmail.com	Keskin, Fersin/AAH-6775-2021; RAZİ, CEM/AAY-1772-2020; Abaci, Ayhan/A-4356-2016; Harmanci, Koray/AAQ-5412-2020	Abaci, Ayhan/0000-0002-1812-0321; Harmanci, Koray/0000-0002-8494-648X; RAZI, CEM/0000-0003-0005-1409				Arshad SH, 2005, J ALLERGY CLIN IMMUN, V116, P3, DOI 10.1016/j.jaci.2005.03.043; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Byl B, 1998, J INTERF CYTOK RES, V18, P817, DOI 10.1089/jir.1998.18.817; COLLET JP, 1993, PEDIATR INFECT DIS J, V12, P648, DOI 10.1097/00006454-199308000-00005; CONNETT G, 1993, ARCH DIS CHILD, V68, P85, DOI 10.1136/adc.68.1.85; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; CVORISCEC B, 1989, RESPIRATION, V55, P129; DJURIC O, 1989, INT J IMMUNOTHER, V5, P139; Doull IJM, 2003, J PEDIATR-US, V142, pS21, DOI 10.1067/mpd.2003.22; EMMERICH B, 1990, RESPIRATION, V57, P90; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; GIRARD JP, 1979, MED HYG, V37, P2519; Gomez Barreto D, 1998, Allergol Immunopathol (Madr), V26, P17; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Gutierrez-Tarango MD, 2001, CHEST, V119, P1742, DOI 10.1378/chest.119.6.1742; Huber M, 2005, EUR J MED RES, V10, P209; Jara-Perez JV, 2000, CLIN THER, V22, P748, DOI 10.1016/S0149-2918(00)90008-0; Johnston S., 1993, Thorax, V48, P1055; Johnston Sebastian L, 2007, Proc Am Thorac Soc, V4, P267, DOI 10.1513/pats.200701-030AW; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; LUSUARDI M, 1993, CHEST, V103, P1783, DOI 10.1378/chest.103.6.1783; MAESTRONI GJM, 1984, INT J IMMUNOPHARMACO, V6, P111, DOI 10.1016/0192-0561(84)90005-5; Martinez FD, 2002, PEDIATRICS, V109, P362; MAUEL J, 1994, RESPIRATION, V61, P8; McKean M, 2000, Cochrane Database Syst Rev, pCD001107, DOI 10.1002/14651858.CD001107; Message SD, 2002, BRIT MED BULL, V61, P29, DOI 10.1093/bmb/61.1.29; *NAT ASTHM ED PREV, 2007, 3 NIH NAT HEART LUNG; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; PAUPE J, 1991, RESPIRATION, V58, P150; PUIGDOLLERS JM, 1980, RESPIRATION, V40, P142, DOI 10.1159/000194264; Roth M, 2000, THORAX, V55, P678, DOI 10.1136/thorax.55.8.678; Schaad UB, 2005, EUR RESPIR REV, V14, P74, DOI 10.1183/09059180.05.00009506; Schaad UB, 2002, CHEST, V122, P2042, DOI 10.1378/chest.122.6.2042; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Svedmyr J, 1999, ACTA PAEDIATR, V88, P42; van Rossum AMC, 2005, INFECT IMMUN, V73, P7718, DOI 10.1128/IAI.73.11.7718-7726.2005; von Mutius E, 2007, NEW ENGL J MED, V357, P1545, DOI 10.1056/NEJMe078119; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Weinberger M, 2003, J PEDIATR-US, V142, pS34, DOI 10.1067/mpd.2003.24; WILSON N, 1995, ARCH DIS CHILD, V72, P317, DOI 10.1136/adc.72.4.317	44	113	127	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					763	769		10.1016/j.jaci.2010.07.038	http://dx.doi.org/10.1016/j.jaci.2010.07.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920766				2022-12-18	WOS:000282510000012
J	Bisgaard, H; Bonnelykke, K				Bisgaard, Hans; Bonnelykke, Klaus			Long-term studies of the natural history of asthma in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Birth cohort; asthma; natural history	RESPIRATORY-SYNCYTIAL-VIRUS; 1ST 6 YEARS; INDIVIDUAL GENETIC RISK; HOUSE-DUST MITE; LUNG-FUNCTION; EARLY-LIFE; AIRWAY RESPONSIVENESS; BRONCHIAL HYPERRESPONSIVENESS; INHALED CORTICOSTEROIDS; RHINOVIRUS ILLNESSES	Segmentation of children with asthma and other wheezy disorders remains the main research challenge today, as it was when described 2 centuries ago. Early childhood wheezy disorders follow different temporal trajectories, probably representing different underlying mechanisms (endophenotypes). Prospective identification of endophenotypes allowing accurate prediction of the clinical course is currently not possible. The variability of the clinical course remains an enigma and difficult to predict. Three of 4 school-aged children with asthma have outgrown disease by midadulthood. The risk of persistence increases with severity, sensitization, smoking, and female sex. Genetic risk variants might help disentangle the heterogeneity of asthma and other wheezy disorders. At early school age, children with asthma have reduced lung function. It is an important and unresolved question whether the airflow limitation associated with asthma already existed at birth or developed along with symptoms. Likewise, the association between the infant's bronchial responsiveness and development of asthma and other wheezy disorders is unclear. Neither primary prevention through manipulation of environmental factors nor secondary prevention through the use of inhaled corticosteroids can effectively halt the long-term disease progression in childhood. In conclusion, the natural history of asthma and the associated airway changes is still poorly understood, and we have not managed to translate findings from long-term studies into a deeper understanding of the underlying endophenotypes or improved disease management. We propose the need for a translational research approach based on long-term clinical studies of birth cohorts with comprehensive and objective assessments of intermediate phenotypes and environmental exposures combined with interdisciplinary basic research and a systems biology approach. (J Allergy Clin Immunol 2010;126:187-97.)	[Bisgaard, Hans; Bonnelykke, Klaus] Univ Copenhagen, Danish Pediat Asthma Ctr, Copenhagen Univ Hosp, Copenhagen, Denmark	University of Copenhagen	Bisgaard, H (corresponding author), Univ Copenhagen, Danish Pediat Asthma Ctr, Copenhagen Univ Hosp, Copenhagen, Denmark.	Bisgaard@copsac.com	Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Bonnelykke, Klaus/0000-0003-2003-1018	AstraZeneca; Merck; Chiesi; Lundbeck Foundation; Pharmacy Foundation of 1991; Augustinus Foundation; Danish Medical Research Council; Danish Pediatric Asthma Centre; GlaxoSmithKline; Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish	AstraZeneca(AstraZeneca); Merck(Merck & Company); Chiesi(Chiesi Pharmaceuticals Inc); Lundbeck Foundation(Lundbeckfonden); Pharmacy Foundation of 1991; Augustinus Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Pediatric Asthma Centre; GlaxoSmithKline(GlaxoSmithKline); Lundbeck Foundation(Lundbeckfonden)	H. Bisgaard has received lecturing fees from AstraZeneca; has received lecturing and consulting fees from Merck; has received consulting fees from Chiesi; has received research support from the Lundbeck Foundation, the Pharmacy Foundation of 1991, Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Centre; and has served as an expert witness for the Europena Medicines Agency on the topic of guidelines on pediatric studies for documenting asthma drugs. K. Bonnelykke is a consultant and paid lecturer for Merck and GlaxoSmithKline.	AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; [Anonymous], 2006, LANCET, V368, P705; [Anonymous], J ALLERGY CLIN IMMUN; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P651, DOI 10.1016/j.jaci.2008.11.036; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; BONNELYKKE K, 2010, PEDIAT ALLERGY IMMUN; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brynildsen MP, 2009, MOL CELL, V34, P137, DOI 10.1016/j.molcel.2009.04.004; Bush A, 2009, NEW ENGL J MED, V360, P409, DOI 10.1056/NEJMe0808951; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Cane RS, 2001, ARCH DIS CHILD, V84, P31, DOI 10.1136/adc.84.1.31; Castro-Rodriguez JA, 1999, AM J RESP CRIT CARE, V159, P1891, DOI 10.1164/ajrccm.159.6.9811035; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; CHAWES BL, 2010, AM J RESP CRIT CARE; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; CLARKE JR, 1995, AM J RESP CRIT CARE, V151, P1434, DOI 10.1164/ajrccm.151.5.7735597; Cook DG, 1998, THORAX, V53, P884, DOI 10.1136/thx.53.10.884; Corver K, 2006, PEDIAT ALLERG IMM-UK, V17, P329, DOI 10.1111/j.1399-3038.2006.00410.x; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Crane J, 2003, EUR RESPIR J, V21, P455, DOI 10.1183/09031936.03.00041403; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403, DOI 10.1164/ajrccm.159.2.9712029; Duncan JM, 2008, CURR OPIN ALLERGY CL, V8, P398, DOI 10.1097/ACI.0b013e32830d82ed; Giwercman C, 2010, J ALLERGY CLIN IMMUN, V125, P866, DOI 10.1016/j.jaci.2010.01.026; Goetghebuer T, 2004, PEDIATR PULM, V38, P321, DOI 10.1002/ppul.20069; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Lazaar AL, 2003, AM J MED, V115, P652, DOI 10.1016/j.amjmed.2003.07.010; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; Loscalzo J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100163; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Lowe L, 2004, ARCH DIS CHILD, V89, P540, DOI 10.1136/adc.2003.038539; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312, DOI 10.1164/ajrccm/143.2.312; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MARTINEZ SR, 1999, ITINERA GEOBOT, V12, P5; McBride JT, 1999, J PEDIATR-US, V135, pS28; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Murray CS, 2002, THORAX, V57, P388, DOI 10.1136/thorax.57.5.388; O'Byrne PM, 2006, CHEST, V129, P1478, DOI 10.1378/chest.129.6.1478; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37, DOI 10.1164/ajrccm.163.1.2005013; Panditi S, 2003, ARCH DIS CHILD, V88, P807, DOI 10.1136/adc.88.9.807; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schuttelaar MLA, 2009, ALLERGY, V64, P1758, DOI 10.1111/j.1398-9995.2009.02080.x; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Smith JA, 2008, AM J RESP CRIT CARE, V177, P1358, DOI 10.1164/rccm.200709-1419OC; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Stensballe LG, 2006, PEDIATRICS, V118, pE1360, DOI 10.1542/peds.2006-0907; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Strachan DP, 1996, BRIT MED J, V312, P1195; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Swern AS, 2008, ANN ALLERG ASTHMA IM, V101, P626, DOI 10.1016/S1081-1206(10)60226-8; Thomsen SF, 2008, PEDIATRICS, V121, P493, DOI 10.1542/peds.2007-1889; Trefny P, 2000, PEDIATR PULM, V30, P302, DOI 10.1002/1099-0496(200010)30:4<302::AID-PPUL5>3.0.CO;2-R; Turner SW, 2009, AM J RESP CRIT CARE, V179, P98, DOI 10.1164/rccm.200805-804OC; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Turner SW, 2002, AM J RESP CRIT CARE, V165, P1294, DOI 10.1164/rccm.200110-018OC; van Schayck OCP, 2007, J ALLERGY CLIN IMMUN, V119, P1323, DOI 10.1016/j.jaci.2007.02.024; Van Sickle D, 2005, EUR RESPIR J, V26, P829, DOI 10.1183/09031936.05.00027205; Warren P, 2006, LANCET, V368, P1416, DOI 10.1016/S0140-6736(06)69596-2; Weiss ST, 2009, CURR OPIN GENET DEV, V19, P279, DOI 10.1016/j.gde.2009.05.001; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wilson NM, 2004, PEDIATR PULM, V38, P75, DOI 10.1002/ppul.20049; Wolfe R, 2000, AM J RESP CRIT CARE, V162, P2177, DOI 10.1164/ajrccm.162.6.9812019; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Wray NR, 2008, CURR OPIN GENET DEV, V18, P257, DOI 10.1016/j.gde.2008.07.006; Wray NR, 2007, GENOME RES, V17, P1520, DOI 10.1101/gr.6665407; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; YOUNG S, 1994, J PEDIATR-US, V124, P681, DOI 10.1016/S0022-3476(05)81355-1; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; Zerhouni EA, 2005, NEW ENGL J MED, V353, P1621, DOI 10.1056/NEJMsb053723	108	113	117	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					187	199		10.1016/j.jaci.2010.07.011	http://dx.doi.org/10.1016/j.jaci.2010.07.011			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20688204				2022-12-18	WOS:000281203800001
J	Li, XY; Meng, J; Qiao, XM; Liu, YF; Liu, F; Zhang, N; Zhang, J; Holtappels, G; Luo, B; Zhou, P; Zheng, YB; Lin, P; Liu, SX; Bachert, C				Li, Xiaoyuan; Meng, Juan; Qiao, Xiaoming; Liu, Yafeng; Liu, Feng; Zhang, Nan; Zhang, Jie; Holtappels, Gabriele; Luo, Ba; Zhou, Peng; Zheng, Yongbo; Lin, Ping; Liu, Shixi; Bachert, Claus			Expression of TGF, matrix metalloproteinases, and tissue inhibitors in Chinese chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chinese patients; chronic rhinosinusitis; collagen; fork-head box P3 (FOXP3); matrix metalloproteinase; nasal polyposis; regulatory T cells; tissue remodeling; TGF-beta 1; tissue inhibitor of metalloproteinase	GROWTH-FACTOR-BETA; NASAL POLYPS; MMP-9; INFLAMMATION; TIMP-1	Background: To date there is no information on the expression of mediators associated with tissue remodeling in Asian patients with chronic rhinitis with (CRSwNP) or without (CRSsNP) nasal polyps. Objectives: To study the expression of TGF-beta 1, matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs), collagen, and regulatory T cells in Chinese patients with CRSwNP and CRSsNP. Methods: Thirty-six male and female subjects (12 patients with CRSwNP, 12 patients with CRSsNP, and 12 control subjects), age 17 to 60 years, were recruited into the study. Samples were collected from polyp and sinusoidal mucosal, ethmoidal mucosal, or inferior turbinate in the respective groups and assessed for TGF-beta 1, MMP-2, MMP-7, MMP-9, TIMP-1, TIMP-2, TIMP-3, and TIMP-4 by immunoassay; collagen by histochemistry; and forkhead box P3 (FOXP3) mRNA by real-time PCR. Results: Patients with CRSwNP showed significantly lower concentrations of TGF-beta 1, TIMP-1, TIMP-4, FOXP3, and collagen compared with patients with CRSsNP. Although there were no significant differences between the concentrations of MMP-7 and MMP-9 in patients with CRSwNP and CRSsNP, these were significantly increased compared with control patients. MMP-2 and TIMP-2 concentrations were not significantly different in any patient group, whereas TIMP-3 was not detectable. Conclusion: Chronic rhinosinusitis with nasal polyps is characterized by a relative lack of TGF-beta expression versus CRSsNP. This finding may be causal for decreased collagen, TIMP-1/4, and FOXP3 expression in CRSwNP versus CRSsNP. TGF-beta serves as a main switch for different remodeling patterns in sinus disease. (J Allergy Clin Immunol 2010;125:1061-8.)	[Li, Xiaoyuan; Meng, Juan; Qiao, Xiaoming; Liu, Yafeng; Liu, Feng; Luo, Ba; Zhou, Peng; Zheng, Yongbo; Liu, Shixi] Sichuan Univ, Dept Otorhinolaryngol, W China Hosp, W China Med Sch, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Jie; Lin, Ping] Sichuan Univ, Upper Airway Res Lab, W China Hosp, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Nan; Holtappels, Gabriele; Bachert, Claus] Ghent Univ Hosp, Upper Airway Res Lab, Dept Otorhinolaryngol, B-9000 Ghent, Belgium	Sichuan University; Sichuan University; Ghent University; Ghent University Hospital	Liu, SX (corresponding author), Sichuan Univ, Dept Otorhinolaryngol, W China Hosp, W China Med Sch, 37 Guo Xue Alley, Chengdu 610041, Sichuan, Peoples R China.	linping9@yahoo.com.cn; liusx999@163.com	Bachert, Claus/J-8825-2012; Zhang, Nan/AAQ-3944-2020		Program of Science and Technology Foundation of Sichuan Province [2009HH0027]; National Natural Science Foundation of China [30973291]	Program of Science and Technology Foundation of Sichuan Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Supported by the Program of Science and Technology Foundation of Sichuan Province (grant no. 2009HH0027) and the National Natural Science Foundation of China (grant no. 30973291) to Shixi Liu, by a collaboration between Ghent University and Sichuan University, and by the Interuniversity Attraction Poles Programme - Belgian State -29 Belgian Science Policy, Nr. IAP P6/35.	Can IH, 2008, OTOLARYNG HEAD NECK, V139, P211, DOI 10.1016/j.otohns.2008.04.032; Cao PP, 2009, J ALLERGY CLIN  0619; Chen Y, 2003, LARYNGOSCOPE, V113, P1199, DOI 10.1097/00005537-200307000-00016; Eisenberg G, 2008, ACTA OTORRINOLAR ESP, V59, P444, DOI 10.1016/S0001-6519(08)75116-1; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; FOKKENS W, 2007, RHINOL S, V20, P1; Kahveci OK, 2008, SWISS MED WKLY, V138, P684, DOI 2008/45/smw-12459; Kostamo K, 2007, LARYNGOSCOPE, V117, P638, DOI 10.1097/MLG.0b013e318030aca6; Lechapt-Zalcman E, 2001, J PATHOL, V193, P233, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH771>3.0.CO;2-W; Lee YM, 2003, J KOREAN MED SCI, V18, P97; Li HB, 2008, CLIN IMMUNOL, V129, P394, DOI 10.1016/j.clim.2008.07.031; Lund VJ, 1997, OTOLARYNG HEAD NECK, V117, pS35, DOI 10.1016/S0194-5998(97)70005-6; Pawankar R, 2007, CURR ALLERGY ASTHM R, V7, P202, DOI 10.1007/s11882-007-0073-4; Perez-Novo CA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-75; Polzehl D, 2006, ALLERGY, V61, P1275, DOI 10.1111/j.1398-9995.2006.01132.x; Raffetto JD, 2008, BIOCHEM PHARMACOL, V75, P346, DOI 10.1016/j.bcp.2007.07.004; Shi J, 2009, J INVEST ALLERG CLIN, V19, P276; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Bruaene N, 2009, J ALLERGY CLIN IMMUN, V124, P253, DOI 10.1016/j.jaci.2009.04.013; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Verrecchia F, 2007, WORLD J GASTROENTERO, V13, P3056, DOI 10.3748/wjg.v13.i22.3056; Watelet JB, 2004, AM J RHINOL, V18, P267, DOI 10.1177/194589240401800502; Watelet JB, 2004, ALLERGY, V59, P54, DOI 10.1046/j.1398-9995.2003.00364.x; Xu G, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-13; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zhang N, 2006, AM J RHINOL, V20, P445, DOI 10.2500/ajr.2006.20.2887	27	113	122	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1061	1068		10.1016/j.jaci.2010.02.023	http://dx.doi.org/10.1016/j.jaci.2010.02.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20392482				2022-12-18	WOS:000277686700015
J	Meyer, N; Zimmermann, M; Bugler, S; Bassin, C; Woehrl, S; Moritz, K; Rhyner, C; Indermitte, P; Schmid-Grendelmeier, P; Akdis, M; Menz, G; Akdis, CA				Meyer, Norbert; Zimmermann, Maya; Buegler, Simone; Bassin, Claudio; Woehrl, Stefan; Moritz, Katharina; Rhyner, Claudio; Indermitte, Philippe; Schmid-Grendelmeier, Peter; Akdis, Muebeccel; Menz, Guenter; Akdis, Cezmi A.			IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human primary keratinocytes; atopic dermatitis; IL-32; apoptosis	PROINFLAMMATORY CYTOKINE; NATURAL-KILLER; ECZEMATOUS DERMATITIS; IFN-GAMMA; IN-SITU; CELLS; SKIN; INTERFERON; FILAGGRIN; PIMECROLIMUS	Background: Keratinocyte (KC) apoptosis is an important mechanism of eczema and spongiosis in patients with atopic dermatitis (AD) and is mediated by IFN-gamma, which is secreted by T(H)1 cells. IL-32 is a proinflammatory cytokine that is involved in the inflammatory processes of rheumatoid arthritis, chronic obstructive pulmonary disease, and Crohn disease. Recently, it was shown that upregulation of IL-32 induces apoptosis. Objective: The aim of the study was to investigate the expression and function of IL-32 in patients with AD. Methods: The expression of IL-32 in KCs was analyzed by means of RT-PCR, ELISA, and flow cytometry. Transfections of small interfering RNA were performed in primary KCs, and apoptosis was analyzed by means of terminal deoxynucleotidyl transferase mediated dUTP nick end-labeling, annexin-V, and 7-amino actinomycin D stainings. Immunofluorescence stainings were used to detect IL-32 in skin biopsy specimens, and serum levels of IL-32 were analyzed by means of ELISA. Results: We report that IL-32 is expressed in human primary KCs on stimulation with IFN-gamma, TNE-alpha, and T(H)1 cells in contrast to T(H)2, regulatory T (Treg), or T(H)17 cells, which showed no effect. Transfection of primary KCs and artificial skin equivalents with small interfering RNA to IL-32, which resulted in a clear decrease in IL-32 expression, significantly reduced KC apoptosis. Immunofluorescence staining demonstrated that IL-32 was expressed in AD lesional skin, whereas it was present in neither skin biopsy specimens from healthy donors nor in lesional skin from patients with psoriasis. Serum levels of IL-32 from patients with AD correlated with disease severity, but increased serum levels of IL-32 were also detected in asthmatic patients. Conclusion: The present study demonstrates KCs as a source of IL-32, which modulates KC apoptosis and contributes to the pathophysiology of All. (J Allergy Clin Immunol 2010;125:85865.)	[Meyer, Norbert; Zimmermann, Maya; Buegler, Simone; Bassin, Claudio; Rhyner, Claudio; Indermitte, Philippe; Akdis, Muebeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CH-7270 Davos, Switzerland; [Meyer, Norbert; Menz, Guenter] High Altitude Clin Davos, Davos, Switzerland; [Woehrl, Stefan; Moritz, Katharina] Med Univ Vienna, Dept Dermatol, Vienna, Austria; [Schmid-Grendelmeier, Peter] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Medical University of Vienna; University of Zurich; University Zurich Hospital	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020; Wöhrl, Stefan/B-6954-2013	Akdis, Cezmi/0000-0001-8020-019X; Wöhrl, Stefan/0000-0002-6324-0007	European Asthma and Allergy Center Davos (EACD); Swiss National Science Foundation [32-188226]; Christine Kuhne Center for Allergy Research and Education (CK-CARE); ALK-Abello; Novartis Pharma Switzerland; Swiss National Science Foundation and Invision; Novartis; Stallargenes; Swiss National Science Foundation; Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research	European Asthma and Allergy Center Davos (EACD); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne Center for Allergy Research and Education (CK-CARE); ALK-Abello; Novartis Pharma Switzerland; Swiss National Science Foundation and Invision; Novartis(Novartis); Stallargenes; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research	The author's laboratory is supported by the European Asthma and Allergy Center Davos (EACD), Swiss National Science Foundation grant no. 32-188226, and the Christine Kuhne Center for Allergy Research and Education (CK-CARE).; Disclosure of potential conflict of interest: S. Woehrl receives research support from ALK-Abello and the GA<SUP>2</SUP>LEN Network of Excellence EU 6th Framework Program and receives speaker's fees from Bencard Allergic. C. Rhyner is an employee of SIAF. P. Schmid-Grendelmeier receives research support from Novartis Pharma Switzerland. M. Akdis receives research support from the Swiss National Science Foundation and Invision and is a council member of Collegium Internationale Allergologicum, C. A. Akdis receives research support from Novartis. Stallargenes, the Swiss National Science Foundation, the Global Allergy and Asthma European Network, and the Christine Kuhne Center for Allergy Research; is a fellow of the American Association of Allergy. Asthma & Immunology; is vice president of the European Academy of Allergy and Clinical Immunology; and is an ex-committee member WP leader for GA<SUP>2</SUP>LEN. The rest of the authors have declared that they have no conflict of interest.	Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Albanesi C, 2007, CLIN DERMATOL, V25, P581, DOI 10.1016/j.clindermatol.2007.08.013; Armbruster N, 2009, J INVEST DERMATOL, V129, P1696, DOI 10.1038/jid.2008.438; Ashcroft DM, 2005, BMJ-BRIT MED J, V330, P516, DOI 10.1136/bmj.38376.439653.D3; Basinski TM, 2009, J ALLERGY CLIN IMMUN, V124, P74, DOI 10.1016/j.jaci.2009.04.019; Buentke E, 2002, J INVEST DERMATOL, V119, P850, DOI 10.1046/j.1523-1747.2002.00132.x; Burgler S, 2009, J ALLERGY CLIN IMMUN, V123, P588, DOI 10.1016/j.jaci.2008.12.017; Calabrese F, 2008, AM J RESP CRIT CARE, V178, P894, DOI 10.1164/rccm.200804-646OC; DAHL CA, 1992, J IMMUNOL, V148, P597; Engelhart K, 2005, ARCH DERMATOL RES, V297, P1, DOI 10.1007/s00403-005-0575-7; Goda C, 2006, INT IMMUNOL, V18, P233, DOI 10.1093/intimm/dxh339; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANDA K, 1983, J IMMUNOL, V130, P988; HONG J, 2009, CYTOKINE; Jensen JM, 2009, J ALLERGY CLIN IMMUN, V123, P1124, DOI 10.1016/j.jaci.2009.03.032; Joosten LAB, 2006, P NATL ACAD SCI USA, V103, P3298, DOI 10.1073/pnas.0511233103; Kang JW, 2009, IMMUNOLOGY, V128, pe532, DOI 10.1111/j.1365-2567.2008.03025.x; Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003; Klunker S, 2003, J IMMUNOL, V171, P1078, DOI 10.4049/jimmunol.171.2.1078; Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213; Marcondes AM, 2008, P NATL ACAD SCI USA, V105, P2865, DOI 10.1073/pnas.0712391105; Netea MG, 2005, P NATL ACAD SCI USA, V102, P16309, DOI 10.1073/pnas.0508237102; Netea MG, 2006, PLOS MED, V3, P1310, DOI 10.1371/journal.pmed.0030277; Nishimoto KP, 2008, J IMMUNOL, V181, P4010, DOI 10.4049/jimmunol.181.6.4010; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nold MF, 2008, J IMMUNOL, V181, P557, DOI 10.4049/jimmunol.181.1.557; Nold-Petry CA, 2009, P NATL ACAD SCI USA, V106, P3883, DOI 10.1073/pnas.0813334106; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pastore S, 1998, J ALLERGY CLIN IMMUN, V101, P538, DOI 10.1016/S0091-6749(98)70361-6; ROBINSON BWS, 1985, J CLIN INVEST, V75, P1488, DOI 10.1172/JCI111852; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; SCHMIED C, 1993, DERMATOLOGY, V187, P263, DOI 10.1159/000247260; Shioya M, 2007, CLIN EXP IMMUNOL, V149, P480, DOI 10.1111/j.1365-2249.2007.03439.x; Stober D, 2001, J IMMUNOL, V167, P957, DOI 10.4049/jimmunol.167.2.957; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839, DOI 10.1067/mai.2001.118796; Trautmann A, 2002, J ALLERGY CLIN IMMUN, V109, P329, DOI 10.1067/mai.2002.121460; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630	40	113	115	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					858	865		10.1016/j.jaci.2010.01.016	http://dx.doi.org/10.1016/j.jaci.2010.01.016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20227751				2022-12-18	WOS:000276787900011
J	Fitzpatrick, AM; Holguin, F; Teague, WG; Brown, LAS				Fitzpatrick, Anne M.; Holguin, Fernando; Teague, W. Gerald; Brown, Lou Ann S.			Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; innate immunity; alveolar macrophage; respiratory infection	MEDIATED PHAGOCYTOSIS; CELL PHAGOCYTOSIS; VIRAL-INFECTIONS; GM-CSF; AIRWAY; RHINOVIRUS; CLEARANCE; PERSISTENCE; EXPRESSION; EXPOSURE	Background: Lower respiratory tract infection is a differentiating feature of children with poorly controlled asthma. Objective: Given the role of alveolar macrophages (AMs) in innate immunity, we hypothesized that AM phagocytosis might be impaired in poorly controlled asthma. Methods: Bronchoalveolar lavage fluid AMs were isolated from 28 asthmatic children (moderate asthma, n = 12; severe asthma, n = 16), 10 nonasthmatic children with chronic cough treated with inhaled corticosteroids, and 10 healthy adult control subjects. AMs were stimulated with LPS and exposed to fluorescein isothiocyanate-conjugated Staphylococcus aureus for 2 hours. Phagocytosis was quantified by using a phagocytic index (PI) calculated from the percentage of phagocytic cells multiplied by the relative fluorescence (RFU) units of S aureus per cell. Apoptosis was determined from the percentage of cells positive for poly (adenosine diphosphate-ribose) polymerase. Results: Phagocytosis as measured by using the unstimulated PI was decreased in subjects with poorly controlled asthma (healthy control subjects, 9330 3992 RFU; chronic cough, 9042 +/- 5976 RFU; moderate asthma, 4361 +/- 2536 RFU; severe asthma, 3153 +/- 1886 RFU; P<.001) and remained unchanged with LPS stimulation. Children with severe asthma also had increased AM apoptosis, both the unstimulated and LPS-simulated states (P<.001), which correlated with the PI. Conclusions: AM function is compromised in children with poorly controlled asthma and is characterized by decreased phagocytosis and increased apoptosis.	[Fitzpatrick, Anne M.; Teague, W. Gerald; Brown, Lou Ann S.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; [Holguin, Fernando] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA	Emory University; Emory University	Fitzpatrick, AM (corresponding author), 2015 Uppergate Dr, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu		Fitzpatrick, Anne/0000-0002-2933-5926	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454, KL2TR000455] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025009, K12RR017643] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR010548, K01NR010584] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000454, KL2 TR000455] Funding Source: Medline; NCRR NIH HHS [K12 RR017643, KL2 RR025009] Funding Source: Medline; NHLBI NIH HHS [R01 HL69170, R01 HL069170] Funding Source: Medline; NINR NIH HHS [K01 NR010584-02, R01 NR010548, K01 NR010584, K01 NR010584-01, K01 NR010548] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		ALDEREN A, 1999, ANNU REV IMMUNOL, V17, P593; Alexis NE, 2003, J ALLERGY CLIN IMMUN, V112, P353, DOI 10.1067/mai.2003.1651; Alexis NE, 2001, AM J PHYSIOL-LUNG C, V280, pL369; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Berclaz PY, 2002, J IMMUNOL, V169, P6332, DOI 10.4049/jimmunol.169.11.6332; Berclaz PY, 2002, BLOOD, V100, P4193, DOI 10.1182/blood-2002-04-1102; Berenson CS, 2006, J INFECT DIS, V194, P1375, DOI 10.1086/508428; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317, DOI 10.1164/ajrccm/145.2_Pt_1.317; COME JM, 2002, LANCET, V359, P831; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; Esposito S, 2000, EUR RESPIR J, V16, P1142, DOI 10.1034/j.1399-3003.2000.16f21.x; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Gauthier TW, 2005, PEDIATR RES, V57, P76, DOI 10.1203/01.PDR.0000149108.44152.D3; Gern JE, 1996, J IMMUNOL, V156, P621; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grissell TV, 2007, PEDIATR PULM, V42, P380, DOI 10.1002/ppul.20592; Guerrero-Plata A, 2001, VIRAL IMMUNOL, V14, P19, DOI 10.1089/08828240151061347; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hodge S, 2006, EUR RESPIR J, V28, P486, DOI 10.1183/09031936.06.00001506; Huber VC, 2001, J IMMUNOL, V166, P7381, DOI 10.4049/jimmunol.166.12.7381; Huynh MLN, 2005, AM J RESP CRIT CARE, V172, P972, DOI 10.1164/rccm.200501-035OC; Iles KE, 2002, IMMUNOL RES, V26, P95, DOI 10.1385/IR:26:1-3:095; JARJOUR NN, 1994, J LAB CLIN MED, V123, P131; Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Laza-Stanca V, 2006, J VIROL, V80, P8248, DOI 10.1128/JVI.00162-06; Morimoto K, 2006, J IMMUNOL, V176, P7657, DOI 10.4049/jimmunol.176.12.7657; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Vandivier RW, 2002, J CLIN INVEST, V109, P661, DOI 10.1172/JCI200213572; Yin XJJ, 2004, TOXICOL SCI, V77, P263, DOI 10.1093/toxsci/kfh035	36	113	122	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1372	1378		10.1016/j.jaci.2008.03.008	http://dx.doi.org/10.1016/j.jaci.2008.03.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18417198	Green Accepted			2022-12-18	WOS:000256771700011
J	Palacin, A; Quirce, S; Armentia, A; Fernandez-Nieto, M; Pacios, LF; Asensio, T; Sastre, J; Diaz-Perales, A; Salcedo, G				Palacin, Arantxa; Quirce, Santiago; Armentia, Alicia; Fernandez-Nieto, Mar; Pacios, Luis F.; Asensio, Teresa; Sastre, Joaquin; Diaz-Perales, Araceli; Salcedo, Gabriel			Wheat lipid transfer protein is a major allergen associated with baker's asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						baker's asthma; lipid transfer protein; wheat; cross-reactivity; inhalant allergen; IgE epitopes; 3-dimensional modeling; electrostatic potential	PEACH ALLERGEN; IDENTIFICATION; FAMILY; FOOD; SENSITIZATION; EXPRESSION; REACTIVITY; DIAGNOSIS; EPITOPES; PATTERN	Background: Baker's asthma is a frequent occupational allergic disorder mainly caused by inhalation of cereal flours. Lipid transfer proteins (LTPs) constitute a family of plant food panallergens, but their role as inhalant and wheat allergens is still unclear. Objective: We sought to explore the involvement of wheat LTPs in baker's asthma caused by wheat flour sensitization. Methods: Forty patients with occupational asthma caused by wheat flour inhalation were studied. Wheat UP, Tri a 14, was purified by using a 2-step chromatographic protocol and characterized by N-terminal amino acid sequencing and 3-dimensional modeling. Its reactivity was confirmed by means of IgE immunodetection, ELISA and ELISA-inhibition assays, and skin prick tests. Results: Specific IgE to Tri a 14 was found in 60% of 40 individual sera from patients with baker's asthma, and the purified allergen elicited positive skin prick test reactions in 62% of 24 of these patients. Tri a 14 and peach UP, Pru p 3, showed a sequence identity of 45%, but the low cross-reactivity between both allergens detected in several individual sera reflected great differences in their 3-dimensional IgE-binding regions. Conclusions: Wheat UP is a major inhalant allergen associated with baker's asthma caused by wheat flour sensitization. Poor cross-reactivity with its peach homolog was found in some patients. Clinical implications: LTPs can be considered relevant inhalant allergens linked to respiratory disorders. UP from wheat (Tri a 14) can be used as a helpful tool for the diagnosis of baker's asthma.	UPM, ETS Ingn Agron, Dept Biotecnol, Unidad Bioquim, Madrid 28040, Spain; Fdn Jimenez Diaz, Serv Alergia, E-28040 Madrid, Spain; Hosp Univ Rio Hortega, Secc Alergia, Valladolid, Spain; UPM, ETS Ingn Montes, Dept Biotecnol, Unidad Quim & Bioquim, Madrid, Spain	Universidad Politecnica de Madrid; Hospital del Rio Hortega; Universidad Politecnica de Madrid	Salcedo, G (corresponding author), UPM, ETS Ingn Agron, Dept Biotecnol, Unidad Bioquim, Ciudad Univ, Madrid 28040, Spain.	gabriel.salcedo@upm.es	Díaz-Perales, Araceli/D-8433-2016; Pacios, Luis F./AAL-6124-2021; Pacios, Luis F/I-5164-2015; s, q/AAD-7171-2020; Armentia, Alicia/GLS-3358-2022	Díaz-Perales, Araceli/0000-0002-1093-3627; Pacios, Luis F./0000-0002-0585-4289; Pacios, Luis F/0000-0002-0585-4289; ARMENTIA, ALICIA/0000-0002-4165-4305				ARMENTIA A, 1993, CLIN EXP ALLERGY, V23, P410, DOI 10.1111/j.1365-2222.1993.tb00347.x; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Baur X, 1998, J ALLERGY CLIN IMMUN, V102, P984, DOI 10.1016/S0091-6749(98)70337-9; Boutrot F, 2005, BBA-GENE STRUCT EXPR, V1730, P114, DOI 10.1016/j.bbaexp.2005.06.010; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brisman J, 2002, OCCUP ENVIRON MED, V59, P498, DOI 10.1136/oem.59.7.498; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V111, P628, DOI 10.1067/mai.2003.75; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P87, DOI 10.1046/j.0022-0477.2001.01257.x; Dolinsky TJ, 2004, NUCLEIC ACIDS RES, V32, pW665, DOI 10.1093/nar/gkh381; Douliez JP, 2000, J CEREAL SCI, V32, P1, DOI 10.1006/jcrs.2000.0315; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P926, DOI 10.1016/j.jaci.2005.05.041; Garcia-Casado G, 2003, J ALLERGY CLIN IMMUN, V112, P599, DOI 10.1037/mai.2003.1638; Garcia-Casado G, 2001, J ALLERGY CLIN IMMUN, V108, P647, DOI 10.1067/mai.2001.118793; GINCEL E, 1994, EUR J BIOCHEM, V226, P413, DOI 10.1111/j.1432-1033.1994.tb20066.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauer I, 2007, CLIN EXP ALLERGY, V37, P261, DOI 10.1111/j.1365-2222.2007.02653.x; Lombardero M, 2004, CLIN EXP ALLERGY, V34, P1415, DOI 10.1111/j.1365-2222.2004.02053.x; Pasquato N, 2006, J MOL BIOL, V356, P684, DOI 10.1016/j.jmb.2005.11.063; Pastorello EA, 2001, J ALLERGY CLIN IMMUN, V108, P145, DOI 10.1067/jmai.2001.114988; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; Quirce S, 2006, ALLERGY, V61, P1202, DOI 10.1111/j.1398-9995.2006.01189.x; QUIRCE S, 1992, J ALLERGY CLIN IMMUN, V90, P970, DOI 10.1016/0091-6749(92)90470-M; Salcedo G, 2007, BBA-MOL CELL BIOL L, V1771, P781, DOI 10.1016/j.bbalip.2007.01.001; Salcedo G, 2004, CLIN EXP ALLERGY, V34, P1336, DOI 10.1111/j.1365-2222.2004.02018.x; Salcedo G., 2004, PLANT FOOD ALLERGENS, P70, DOI DOI 10.1002/9780470995174.CH5; SANCHEZMADRID F, 1984, J IMMUNOL METHODS, V73, P367, DOI 10.1016/0022-1759(84)90412-5; SanchezMonge R, 1997, CLIN EXP ALLERGY, V27, P1130, DOI 10.1046/j.1365-2222.1997.1340945.x; Sander I, 2004, ALLERGY, V59, P95, DOI 10.1046/j.1398-9995.2003.00349.x; Sander I, 2001, J ALLERGY CLIN IMMUN, V107, P907, DOI 10.1067/mai.2001.113761; Sandiford CP, 1997, CLIN EXP ALLERGY, V27, P1120, DOI 10.1046/j.1365-2222.1997.1310936.x; van Ree R, 2002, BIOCHEM SOC T, V30, P910, DOI 10.1042/BST0300910; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Weichel M, 2006, J ALLERGY CLIN IMMUN, V117, P676, DOI 10.1016/j.jaci.2005.11.040	35	113	114	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1132	1138		10.1016/j.jaci.2007.07.008	http://dx.doi.org/10.1016/j.jaci.2007.07.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17716720				2022-12-18	WOS:000250973400023
J	Ueda, T; Niimi, A; Matsumoto, H; Takemura, M; Hirai, T; Yamaguchi, M; Matsuoka, H; Jinnai, M; Muro, S; Chin, K; Mishima, M				Ueda, Tetsuya; Niimi, Akio; Matsumoto, Hisako; Takemura, Masaya; Hirai, Toyohiro; Yamaguchi, Masafumi; Matsuoka, Hirofumi; Jinnai, Makiko; Muro, Shigeo; Chin, Kazuo; Mishima, Michiaki			Role of small airways in asthma: Investigation using high-resolution computed tomography	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; small airways; high-resolution computed tomography; lung density; airway responsiveness; airway inflammation; airway remodeling; air trapping	LOW-ATTENUATION AREAS; WALL THICKNESS; LUNG INFLAMMATION; SPUTUM INDUCTION; DISTAL LUNG; CT; HYDROFLUOROALKANE; COMPLEXITY; EMPHYSEMA; SAMPLES	Background: Small airways may have an important role in asthma but are more difficult to assess pathologically than central airways. Computed tomographic indices of lung density are assumed to reflect air trapping and may be a useful noninvasive measure of small airways disease, but their pathophysiological relevance remains undetermined. Objective: To evaluate lung density on high-resolution computed tomography and examine its correlations with clinical and physiologic variables in 29 patients with stable asthma. Methods: Both lungs were scanned at full-inspiratory and fullexpiratory phases to quantify percentage of lung field occupied by low attenuation area (LAA%; < -960 Hounsfield units) and mean lung density. Asthma severity, pulmonary function, methacholine airway sensitivity and reactivity, and sputum eosinophil counts were evaluated. Results: The mean lung density increased and LAA% decreased in all patients at expiratory phase compared with inspiratory phase. The inspiratory density indices and expiratory mean lung density correlated only with FEV1/forced vital capacity (FVC). Expiratory LAA% correlated more strongly than other variables with FEV1/FVC and with indices of peripheral airflow obstruction. Expiratory/inspiratory ratios of LAA% and mean lung density correlated, the former more strongly, with disease severity, residual volume/total lung capacity, and airway sensitivity, as well as with indices of global (FEV1 and FEV1/FVC) and peripheral airflow obstruction. Conclusion: Expiratory/inspiratory high-resolution computed tomography is useful for assessing small airways disease in asthma. Small airways involvement is associated with airflow obstruction, airway hypersensitivity, and more severe disease. Clinical implications: Small airways are an important therapeutic target in asthma.	Kyoto Univ, Dept Resp Med, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Phys Thearpy Resp Med, Kyoto, Japan	Kyoto University; Kyoto University	Niimi, A (corresponding author), Kyoto Univ, Dept Resp Med, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.	niimi@kuhp.kyoto-u.ac.jp		Matsuoka, Hirofumi/0000-0001-5219-7501				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Beigelman-Aubry C, 2002, RADIOLOGY, V223, P181, DOI 10.1148/radiol.2231010779; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Biernacki W, 1997, EUR RESPIR J, V10, P2455, DOI 10.1183/09031936.97.10112455; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; de Blic J, 2005, J ALLERGY CLIN IMMUN, V116, P750, DOI 10.1016/j.jaci.2005.07.009; Eda S, 1997, AM J RESP CRIT CARE, V155, P1290, DOI 10.1164/ajrccm.155.4.9105069; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53, DOI 10.1164/ajrccm.152.1.7599862; GELB AF, 1973, NEW ENGL J MED, V288, P395, DOI 10.1056/NEJM197302222880805; Gershman NH, 1999, J ALLERGY CLIN IMMUN, V104, P322, DOI 10.1016/S0091-6749(99)70374-X; Gevenois PA, 1996, AM J ROENTGENOL, V167, P1169, DOI 10.2214/ajr.167.5.8911175; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; Goldin JG, 1998, RADIOLOGY, V208, P321, DOI 10.1148/radiology.208.2.9680554; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; Guckel C, 1999, J APPL PHYSIOL, V86, P701, DOI 10.1152/jappl.1999.86.2.701; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hansell DM, 2001, EUR RESPIR J, V17, P1294, DOI 10.1183/09031936.01.00206101; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Ketai L, 2005, J ASTHMA, V42, P667, DOI 10.1080/02770900500264978; King GG, 1999, AM J RESP CRIT CARE, V159, P992, DOI 10.1164/ajrccm.159.3.9805064; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 1999, EUR RESPIR J, V14, P1403, DOI 10.1183/09031936.99.14614039; Kubo K, 1998, AM J RESP CRIT CARE, V158, P979, DOI 10.1164/ajrccm.158.3.9802042; Little SA, 2002, THORAX, V57, P247, DOI 10.1136/thorax.57.3.247; Matsumoto H, 2005, THORAX, V60, P277, DOI 10.1136/thx.2004.028936; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; MCFADDEN ER, 1972, AM J MED, V52, P725, DOI 10.1016/0002-9343(72)90078-2; McParland BE, 2003, J APPL PHYSIOL, V95, P426, DOI 10.1152/japplphysiol.00159.2003; Mishima M, 1999, J COMPUT ASSIST TOMO, V23, P380, DOI 10.1097/00004728-199905000-00011; Mishima M, 1999, P NATL ACAD SCI USA, V96, P8829, DOI 10.1073/pnas.96.16.8829; Mitsunobu F, 2003, AM J RESP CRIT CARE, V167, P411, DOI 10.1164/rccm.2112070; Mitsunobu F, 2001, J ASTHMA, V38, P413, DOI 10.1081/JAS-100001496; Mitsunobu F, 2001, THORAX, V56, P851, DOI 10.1136/thorax.56.11.851; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102, DOI 10.1164/ajrccm.162.3.9907120; NEWMAN KB, 1994, CHEST, V106, P105, DOI 10.1378/chest.106.1.105; Niimi A, 2004, CLIN REV ALLERG IMMU, V27, P45, DOI 10.1385/CRIAI:27:1:045; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518, DOI 10.1164/ajrccm.162.4.9909044; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211-1268OC; Niimi A, 2004, AM J MED, V116, P725, DOI 10.1016/j.amjmed.2003.11.026; SAKAI N, 1994, CHEST, V106, P1319, DOI 10.1378/chest.106.5.1319; Sutherland ER, 2004, J ALLERGY CLIN IMMUN, V113, P1046, DOI 10.1016/j.jaci.2004.03.016; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Takemura M, 2004, CHEST, V125, P1352, DOI 10.1378/chest.125.4.1352; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; Zeidler MR, 2006, EUR RESPIR J, V27, P307, DOI 10.1183/09031936.06.00005605; 2004, GLOBAL STRATEGY ASTH	52	113	117	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1019	1025		10.1016/j.jaci.2006.07.032	http://dx.doi.org/10.1016/j.jaci.2006.07.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088124	Green Submitted, Bronze			2022-12-18	WOS:000244282300004
J	Gern, JE; Rosenthal, LA; Sorkness, RL; Lemanske, RF				Gern, JE; Rosenthal, LA; Sorkness, RL; Lemanske, RF			Effects of viral respiratory infections on lung development and childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						viral injection; respiratory syncytial virus; rhinovirus; children; lung development; cytokines; asthina	SYNCYTIAL VIRUS BRONCHIOLITIS; HEPATOCYTE GROWTH-FACTOR; RHINOVIRUS INFECTION; AIRWAY HYPERRESPONSIVENESS; GENDER-DIFFERENCES; YOUNG-CHILDREN; TRACT DISEASE; RATS; AGE; INFANCY	Viral infections are closely linked to wheezing in infancy, and those children with recurrent virus-induced wheezing episodes are at great risk for chronic childhood asthma. Infancy is a time of increased susceptibility to viral infections, and this stage is also characterized by pulmonary alveolar multiplication and extensive remodeling of the airways to accommodate growth. This coincidence, together with the observation that children with asthma can have structural lung changes and functional deficits at an early age, suggests that viral infections could adversely affect lung development. Inflammatory mediators induced by viral infection are known to have effects on the remodeling process, suggesting a plausible mechanism to support this theory. Furthermore, animal models of viral infection during lung growth and development suggest that developmental factors are important in determining the consequences of infection on long-term lung function. Greater understanding of the effects of viral infections on lung development and growth in early childhood might lead to the discovery of additional strategies for the prevention of recurrent wheezing and chronic asthma.	Univ Wisconsin, Dept Pediat, Madison, WI USA; Univ Wisconsin, Dept Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gern, JE (corresponding author), Univ Wisconsin Hosp, 600 Highland Ave, Madison, WI 53792 USA.	gern@medicine.wisc.edu	Rosenthal, Louis/A-8868-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831, R01HL061879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 61879-01, P01 HL 70831-01] Funding Source: Medline; NIAID NIH HHS [N01 AI 25496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bartram U, 2004, CHEST, V125, P754, DOI 10.1378/chest.125.2.754; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; Boezen HA, 2004, CLIN CHEST MED, V25, P237, DOI 10.1016/j.ccm.2004.01.012; Cardell LO, 1999, AM J RESP CRIT CARE, V160, P411, DOI 10.1164/ajrccm.160.2.9808117; CASTLEMAN WL, 1988, LAB INVEST, V59, P387; Castro-Rodriguez JA, 1999, AM J RESP CRIT CARE, V159, P1891, DOI 10.1164/ajrccm.159.6.9811035; Dosanjh A, 2003, PEDIAT ALLERG IMM-UK, V14, P437, DOI 10.1046/j.0905-6157.2003.00090.x; Eriksson M, 2000, PEDIAT ALLERG IMM-UK, V11, P193, DOI 10.1034/j.1399-3038.2000.00076.x; FUJIMURA M, 1993, PEDIATRICS, V92, P564; GEM JE, 2002, PEDIATR ALLERGY IMMU, V13, P386; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gern JE, 1996, J IMMUNOL, V157, P1605; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Hendley JO, 1998, CLIN INFECT DIS, V26, P847, DOI 10.1086/513921; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Holtzman Michael J, 2004, Pediatr Infect Dis J, V23, pS235, DOI 10.1097/01.inf.0000144674.24802.c1; Hsia CCW, 2004, AM J RESP CRIT CARE, V170, P319, DOI 10.1164/rccm.200209-1062ST; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P722, DOI 10.1016/0091-6749(93)90016-9; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Jobe AH, 2001, RESP RES, V2, P27, DOI 10.1186/rr35; Johnston SL, 1997, J INFECT DIS, V175, P323, DOI 10.1093/infdis/175.2.323; Kaul P, 2000, J INFECT DIS, V181, P1885, DOI 10.1086/315504; Kneyber M, 2000, ACTA PAEDIATR, V89, P654, DOI 10.1080/080352500750043945; KORPPI M, 1993, AM J DIS CHILD, V147, P628, DOI 10.1001/archpedi.1993.02160300034017; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kumar A, 1997, AM J RESP CRIT CARE, V155, P130, DOI 10.1164/ajrccm.155.1.9001301; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Le Cras TD, 2004, AM J PHYSIOL-LUNG C, V287, pL718, DOI 10.1152/ajplung.00084.2004; Lee CG, 2000, AM J RESP CELL MOL, V23, P662, DOI 10.1165/ajrcmb.23.5.4188; Martinez FD, 2003, PEDIATR INFECT DIS J, V22, pS76, DOI 10.1097/00006454-200302001-00011; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mason RJ, 2002, AM J RESP CELL MOL, V26, P517, DOI 10.1165/ajrcmb.26.5.f239; Massaro D, 2004, AM J PHYSIOL-LUNG C, V287, pL715, DOI 10.1152/ajplung.00166.2004; McBride JT, 1999, J PEDIATR-US, V135, pS28; Message SD, 2004, J LEUKOCYTE BIOL, V75, P5, DOI 10.1189/jlb.0703315; Mikus LD, 2001, AM J RESP CELL MOL, V24, P74, DOI 10.1165/ajrcmb.24.1.4125; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; NIELSEN HC, 1990, EXP CELL RES, V188, P89, DOI 10.1016/0014-4827(90)90281-E; Ohrui T, 1998, AM J RESP CRIT CARE, V158, P241, DOI 10.1164/ajrccm.158.1.9607117; Openshaw PJM, 2004, J ALLERGY CLIN IMMUN, V114, P1275, DOI 10.1016/j.jaci.2004.08.024; Openshaw PJM, 2003, PEDIATR INFECT DIS J, V22, pS58, DOI 10.1097/00006454-200302001-00009; OPENSHAW PJM, 1995, SPRINGER SEMIN IMMUN, V17, P187; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37, DOI 10.1164/ajrccm.163.1.2005013; PANUSKA JR, 1995, J CLIN INVEST, V96, P2445, DOI 10.1172/JCI118302; Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Pierce RA, 2000, AM J RESP CELL MOL, V23, P137, DOI 10.1165/ajrcmb.23.2.f194; Reijonen TM, 2000, PEDIATRICS, V106, P1406, DOI 10.1542/peds.106.6.1406; Rosenthal LA, 2004, AM J RESP CELL MOL, V30, P702, DOI 10.1165/rcmb.2003-0181OC; Rosenthal LA, 2003, RESP INFECT ALLERGY, P365; Sakamaki Y, 2002, AM J RESP CELL MOL, V26, P525, DOI 10.1165/ajrcmb.26.5.4714; Sanders SP, 1999, P SOC EXP BIOL MED, V220, P123, DOI 10.1046/j.1525-1373.1999.d01-19.x; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sorkness RL, 1999, AM J RESP CRIT CARE, V160, P705, DOI 10.1164/ajrccm.160.2.9810002; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; THURLBECK WM, 1982, THORAX, V37, P564, DOI 10.1136/thx.37.8.564; Uhl EW, 1996, AM J RESP CRIT CARE, V154, P1834, DOI 10.1164/ajrccm.154.6.8970378; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; Walter MJ, 2002, J CLIN INVEST, V110, P165, DOI 10.1172/JCI200214345; Welliver RC, 2003, PEDIATR INFECT DIS J, V22, pS6, DOI 10.1097/00006454-200302001-00002; Wennergren G, 2001, EUR RESPIR J, V18, P1044, DOI 10.1183/09031936.01.00254101; Wennergren G, 1997, ACTA PAEDIATR, V86, P351, DOI 10.1111/j.1651-2227.1997.tb09021.x; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472; Xuan W, 2000, AM J RESP CRIT CARE, V161, P1820, DOI 10.1164/ajrccm.161.6.9809118	68	113	119	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					668	674		10.1016/j.jaci.2005.01.057	http://dx.doi.org/10.1016/j.jaci.2005.01.057			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805982				2022-12-18	WOS:000228373400002
J	Gilissen, LJWJ; Bolhaar, STH; Matos, CI; Rouwendal, GJA; Boone, MJ; Krens, FA; Zuidmeer, L; van Leeuwen, A; Akkerdaas, J; Hoffmann-Sommergruber, K; Knulst, AC; Bosch, D; van de Weg, WE; van Ree, R				Gilissen, LJWJ; Bolhaar, STH; Matos, CI; Rouwendal, GJA; Boone, MJ; Krens, FA; Zuidmeer, L; van Leeuwen, A; Akkerdaas, J; Hoffmann-Sommergruber, K; Knulst, AC; Bosch, D; van de Weg, WE; van Ree, R			Silencing the major apple allergen Mal d 1 by using the RNA interference approach	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						gene silencing; Mal d 1; RNA interference; genetic modification; apple (Malus domestica); skin prick test; hypoallergenic; immunoblotting	BIRCH POLLEN; IMMUNOLOGICAL RELATIONSHIP; POTATO; GENE; IDENTIFICATION; ARABIDOPSIS; EXTRACTS; EPITOPES; BET-V-1; CARROT	Background: Apple allergy is dominated by IgE antibodies against Mal d 1 in areas where birch pollen is endemic. Apples with significantly decreased levels of Mal d 1 would allow most patients in these areas to eat apples without allergic reactions. Objective: The aim of this study was to inhibit the expression of Mal d 1 in apple plants by RNA interference. Methods: In vitro-grown apple plantlets were transformed with a construct coding for an intron-spliced hairpin RNA containing a Mal d 1-specific inverted repeat sequence separated by a Mal d 1-specific intron sequence. The presence of the construct in transformants was checked by PCR. Expression of Mal d 1 in leaves was monitored by prick-to-prick skin testing in 3 patients allergic to apples and by immunoblotting with a Mal d I-reactive mAb and with IgE antibodies against Mal d 1. Results: After transformation, plantlets were selected on the basis of having a normal phenotype and growth rate. With PCR, in 6 of 9 selected plantlets, the presence of the gene-silencing construct was demonstrated. By skin prick test it was shown that a wild-type plantlet had significantly (P < .05) higher allergenicity than 5 of the transformants. Reduction of expression of Mal d 1 was confirmed by immunoblotting. In wild-type and unsuccessful transformants, a strong band was detected with Mal d 1-reactive mAb 5H8 at the expected apparent M-r of 17 kDa. This band was virtually absent in the transformants that carried the gene-silencing construct. With human IgE antibodies, the same observations were made. Conclusions: Mal d 1 expression was successfully reduced by RNA interference. This translated into significantly reduced in vivo allergenicity. These observations support the feasibility of the production by gene silencing of apples hypoallergenic for Mal d 1.	Univ Wageningen & Res Ctr, Allergy Consortium Wageningen, NL-6700 AA Wageningen, Netherlands; Univ Utrecht Hosp, Dept Dermatol, Utrecht, Netherlands; Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands; Med Univ, Dept Pathophysiol, Vienna, Austria	Wageningen University & Research; Utrecht University; Utrecht University Medical Center	Gilissen, LJWJ (corresponding author), Univ Wageningen & Res Ctr, Allergy Consortium Wageningen, POB 16, NL-6700 AA Wageningen, Netherlands.	luud.gilissen@wur.nl	Van de Weg, Eric W/G-3225-2011; gilisen, luud/F-5496-2017; Zuidmeer, Laurian/B-5494-2008	Van de Weg, Eric W/0000-0002-9443-5974; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Zuidmeer-Jongejan, Laurian/0000-0003-3245-5555				AKKERDAAS JH, 1995, ALLERGY, V50, P215, DOI 10.1111/j.1398-9995.1995.tb01136.x; ANDERSEN KE, 1978, CONTACT DERMATITIS, V4, P73, DOI 10.1111/j.1600-0536.1978.tb03739.x; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; Byzova M, 2004, PLANTA, V218, P379, DOI 10.1007/s00425-003-1117-1; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Ebner C, 1996, MONOGR ALLERGY, V32, P73; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; FOLCK A, 2003, ISPMB 7 INT C PLANT, P403; GREENE B, 1994, GENETICS, V138, P1275; Herman EM, 2003, J EXP BOT, V54, P1317, DOI 10.1093/jxb/erg164; Hsieh LS, 1995, J ALLERGY CLIN IMMUN, V96, P960, DOI 10.1016/S0091-6749(95)70234-2; Kusaba M, 2004, CURR OPIN BIOTECH, V15, P139, DOI 10.1016/j.copbio.2004.02.004; Mari A, 2003, CLIN EXP ALLERGY, V33, P1419, DOI 10.1046/j.1365-2222.2003.01773.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nakamura R, 1996, BIOSCI BIOTECH BIOCH, V60, P1215, DOI 10.1271/bbb.60.1215; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; POULSEN LK, 1993, CLIN EXP ALLERGY, V23, P61, DOI 10.1111/j.1365-2222.1993.tb02485.x; Puehringer HM, 2003, GENE, V321, P173, DOI 10.1016/S0378-1119(03)00822-9; Puhringer H, 2000, PLANT SCI, V152, P35, DOI 10.1016/S0168-9452(99)00222-8; Puite KJ, 1996, PLANT SCI, V119, P125, DOI 10.1016/0168-9452(96)04448-2; Son DY, 1999, EUR J NUTR, V38, P201, DOI 10.1007/s003940050063; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; van Ree R, 1997, CRC DERMAT, P289; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VANENGELEN FA, 1995, TRANSGENIC RES, V4, P288, DOI 10.1007/BF01969123; VIETHS S, 1994, ALLERGY, V49, P262, DOI 10.1111/j.1398-9995.1994.tb02659.x	30	113	130	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					364	369		10.1016/j.jaci.2004.10.014	http://dx.doi.org/10.1016/j.jaci.2004.10.014			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696096				2022-12-18	WOS:000227043600025
J	Asero, R; Mistrello, G; Roncarolo, D; Amato, S; Zanoni, D; Barocci, F; Caldironi, G				Asero, R; Mistrello, G; Roncarolo, D; Amato, S; Zanoni, D; Barocci, F; Caldironi, G			Detection of clinical markers of sensitization to profilin in patients allergic to plant-derived foods	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; profilin; pollen-food syndrome; cross-reactivity; melon; orange; tomato; banana	CROSS-REACTIVE ALLERGEN; BIRCH POLLEN; ADVERSE REACTIONS; CELERY ALLERGY; GRASS-POLLEN; IGE-BINDING; TREE POLLEN; IDENTIFICATION; PROTEIN; SENSITIVITY	Background: A proper classification of patients allergic to plant-derived foods is of pivotal importance because the clinical features of allergic reactions to fruits and vegetables depend on the nature and characteristics of proteins responsible for sensitization. However, in normal clinical settings this is presently impossible. Objective: We sought to detect clinical markers of sensitization to profilin. Methods: Seventy-one patients allergic to fruits and vegetables but not sensitized to lipid transfer protein or natural rubber latex were studied. Food allergy was ascertained on the basis of clinical history and positive skin prick test responses with fresh foods, commercial extracts, or both. Allergies to foods that had caused less than 2 adverse reactions were confirmed by means of open oral challenge. IgE reactivity to rBet v 1/rBet v 2 and to natural Phleum species profilin were detected. Moreover, IgE to the 30- to 40-kd and 60- to 90-kd birch pollen-enriched fractions, which also can be involved in cross-reactivity phenomena, were measured in sera from 52 patients by means of ELISA. Results: On the basis of in vitro tests, 24, 18, and 25 patients turned out to be sensitized to Bet v 1, Bet v 2, or both, respectively. Four patients had negative test results for both allergens. Hypersensitivity to Bet v 2 was strongly associated with clinical allergy to citrus fruits (39% in patients monosensitized to Bet v 2 vs 4% in patients monosensitized to Bet v 1, P < .025), melon or watermelon (67% vs 0%, P < .001), banana (66% vs 8%, P < .001), and tomato (33% vs 0%, P < .05), whereas Bet v 1 sensitivity was associated with clinical allergy to apple (100% vs 39%, P < .001) and hazelnut (56% vs 0%, P < .001). The sensitivity of a history of allergy to gourd fruits, citrus fruits, tomato, banana, or a combination thereof as a means to detect profilin-hypersensitive patients was 85% (41148). The specificity of an allergy to any of these fruits exceeded 85%, with positive predictive values ranging between 68% and 91%. Conclusion: In clinical settings in which laboratory investigations are not easily accessible, allergy to melon, watermelon, citrus fruits, tomato, and banana can be used as a marker of profilin hypersensitivity once a sensitization to natural rubber latex and lipid transfer protein is ruled out.	Clin San Carlo, Ambulatorio Allergologia, I-20037 Paderno Dugnano, MI, Italy; Lofarma SpA, Milan, Italy; Ospedale Rho, Ctr Trasfus, Rho, Italy		Asero, R (corresponding author), Clin San Carlo, Ambulatorio Allergologia, Via Ospedale 21, I-20037 Paderno Dugnano, MI, Italy.		Amato, Sandra/AAH-4430-2021	Amato, Sandra/0000-0002-3277-0662				ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; Anliker MD, 2001, J ALLERGY CLIN IMMUN, V107, P718, DOI 10.1067/mai.2001.113568; Asero R, 2000, ANN ALLERG ASTHMA IM, V84, P460, DOI 10.1016/S1081-1206(10)62281-8; Asero R, 1999, ANN ALLERG ASTHMA IM, V83, P377, DOI 10.1016/S1081-1206(10)62834-7; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Ballmer-Weber BK, 2002, ALLERGY, V57, P228, DOI 10.1034/j.1398-9995.2002.1o3319.x; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenna O, 2000, J AGR FOOD CHEM, V48, P493, DOI 10.1021/jf9906681; DEMARTINO M, 1988, ALLERGY, V43, P206; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Ebner C, 1998, ALLERGY, V53, P52, DOI 10.1111/j.1398-9995.1998.tb04961.x; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; FAH J, 1995, CLIN EXP ALLERGY, V25, P1018, DOI 10.1111/j.1365-2222.1995.tb00405.x; Fritsch R, 1997, ALLERGY, V52, P335, DOI 10.1111/j.1398-9995.1997.tb01000.x; Goldstein Laurence, 1987, PRINCIPLES INTERNAL, P5; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; JORDANWAGNER DL, 1993, ANN ALLERGY, V71, P70; Karamloo F, 2001, EUR J BIOCHEM, V268, P5310, DOI 10.1046/j.0014-2956.2001.02463.x; Karamloo F, 1999, J ALLERGY CLIN IMMUN, V104, P991, DOI 10.1016/S0091-6749(99)70080-1; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; Mahler V, 2001, INT ARCH ALLERGY IMM, V124, P64, DOI 10.1159/000053670; Mari A, 2001, INT ARCH ALLERGY IMM, V125, P57, DOI 10.1159/000053797; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; Reindl J, 2000, J ALLERGY CLIN IMMUN, V106, P379, DOI 10.1067/mai.2000.107602; Reindl J, 2002, INT ARCH ALLERGY IMM, V128, P105, DOI 10.1159/000059400; Rodriguez J, 2000, J ALLERGY CLIN IMMUN, V106, P968, DOI 10.1067/mai.2000.110467; SCIBOLA E, 1997, GIORN IT ALLERGOL IM, V7, P166; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; van Ree R, 1999, CLIN EXP ALLERGY, V29, P848, DOI 10.1046/j.1365-2222.1999.00521.x; Van Ree R, 2000, ALLERGY CLIN IMMUNOL, V12, P7; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; Vieths S, 1998, SCAND J IMMUNOL, V47, P263; VIETHS S, 1995, ANN ALLERG ASTHMA IM, V74, P48; Wellhausen A, 1996, Z ERNAHRUNGSWISS, V35, P348, DOI 10.1007/BF01610553; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; WUTHRICH B, 1985, SCHWEIZ MED WSCHR, V115, P358; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x	45	113	118	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					427	432		10.1067/mai.2003.1611	http://dx.doi.org/10.1067/mai.2003.1611			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897752	Bronze			2022-12-18	WOS:000184650600030
J	Svanes, C; Heinrich, J; Jarvis, D; Chinn, S; Omenaas, E; Gulsvik, A; Kunzli, N; Burney, P				Svanes, C; Heinrich, J; Jarvis, D; Chinn, S; Omenaas, E; Gulsvik, A; Kunzli, N; Burney, P			Pet-keeping in childhood and adult asthma and hay fever: European Community Respiratory Health Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cats; dogs; birds; asthma; hay fever; sensitization; tolerance; hygiene hypothesis; ECRHS	HOUSE-DUST ENDOTOXIN; ALLERGEN EXPOSURE; CAT ALLERGENS; SENSITIZATION; CHILDREN; SYMPTOMS; LIFE; ATOPY; RISK; ENVIRONMENT	Background: Whether pet-keeping early in life protects against or promotes allergy remains unclear. Objective: Our aim was to examine the effects of childhood pet-keeping on adult allergic disease in a large international population-based study, including information on sensitization, adult pet-keeping, and pet prevalence in the populations. Methods: We used information from structured interviews (n = 18,530) and specific IgE to common aeroallergens in blood samples (n = 13,932) from participants in the European Community Respiratory Health Survey (ECRHS) to analyze the associations between keeping pets and adult asthma and hay fever. Results: Keeping cats in childhood was associated with asthma only among atopic subjects, an association that varied between centers (P = .002) and was stronger where cats where less common (< 40% cats: odds ratio(wheeze) [ORwheeze] = 1.84, 95% CI = 1.31-2.57; 40%-60% cats: ORwheeze = 1.33, 95% CI = 1.10-1.61; greater than or equal to60% cats: ORwheeze = 0.98, 95% CI = 0.73-1.33). Dogs owned in childhood or adulthood were associated with asthma among nonatopic subjects (childhood: ORwheeze = 1.28, 95% CI = 1.13-1.46; adulthood: ORwheeze = 1.31, 95% CI = 1.14-1.51; both: ORwheeze = 1.69, 95% CI = 1.40-2.04). In atopic subjects, those who had owned dogs in childhood had less hay fever (OR = 0.85; 95% CI = 0.73-0.98) and no increased risk of asthma (ORwheeze = 1.01, 95 % CI = 0.87-1.17). Respiratory symptoms were more common in subjects who had owned birds during childhood (ORwheeze = 1.12; 95 % CI = 1.02-1.23) independent of sensitization. Conclusions: The effects of pet-keeping in childhood varied according to the type of pet, the allergic sensitization of the individual, and the wider environmental exposure to allergen. Cats owned in childhood were associated with more asthma in sensitized adults who grew up in areas with a low community prevalence of cats. Dogs owned in childhood seemed to protect against adult allergic disease but promote nonallergic asthma.	Haraldsplass Hosp, Dept Med, N-5009 Bergen, Norway; Univ Bergen, Inst Med, Sect Resp Med, N-5009 Bergen, Norway; GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Kings Coll London, Dept Publ Hlth Sci, London WC2R 2LS, England; Univ So Calif, Los Angeles, CA USA; Univ Basel, Basel, Switzerland	University of Bergen; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of London; King's College London; University of Southern California; University of Basel	Svanes, C (corresponding author), Haraldsplass Hosp, Dept Med, N-5009 Bergen, Norway.		Kuenzli, Nino/F-7195-2014; Svanes, Cecilie/N-7556-2017; Jarvis, Deborah/E-6494-2011; Heinrich, Joachim/N-1720-2013	Kuenzli, Nino/0000-0001-8360-080X; Svanes, Cecilie/0000-0001-8512-5192; Heinrich, Joachim/0000-0002-9620-1629; Burney, Peter/0000-0001-8635-5678; Jarvis, Deborah/0000-0002-1753-3896	NCRR NIH HHS [2 S07 RR05521-28] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005521] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], STAT STAT SOFTW REL; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; *AVMA COMM HUM AN, 1995, J AM VET MED ASSOC, V206, P961; Baldini M, 2002, ALLERGY, V57, P188, DOI 10.1034/j.1398-9995.2002.1r152.x; Braback L, 2001, PEDIAT ALLERG IMM-UK, V12, P4, DOI 10.1034/j.1399-3038.2001.012001004.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2001, CLIN EXP ALLERGY, V31, P1799, DOI 10.1046/j.1365-2222.2001.01269.x; BUIJS J, 1995, AM J RESP CRIT CARE, V151, P873, DOI 10.1164/ajrccm/151.3_Pt_1.873; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Chan PWK, 2001, PEDIATR INT, V43, P350, DOI 10.1046/j.1442-200X.2001.01421.x; COPPERMAN SM, 1982, NEW YORK STATE J MED, V82, P1685; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gehring U, 2001, EUR RESPIR J, V18, P555, DOI 10.1183/09031936.01.00096801; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Henriksen AH, 2001, RESP MED, V95, P122, DOI 10.1053/rmed.2000.1004; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hesselmar B, 2001, PEDIATR ALLERGY IMMU, V12, P208, DOI 10.1034/j.1399-3038.2001.012004208.x; HOLSCHER B, 2002, PEDIAT ALLERGY IMMUN, V13; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Melsom T, 2001, THORAX, V56, P477, DOI 10.1136/thorax.56.6.477; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Noertjojo K, 1999, J ALLERGY CLIN IMMUN, V103, P60, DOI 10.1016/S0091-6749(99)70526-9; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prescott SL, 2001, CLIN EXP ALLERGY, V31, P1653, DOI 10.1046/j.1365-2222.2001.01258.x; Radon K, 2001, EUR RESPIR J, V17, P747, DOI 10.1183/09031936.01.17407470; Rees D, 1998, S AFR MED J, V88, P1110; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Ronmark E, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e37; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Sporik R, 2001, THORAX, V56, P58; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sunyer Y, 1997, EUR RESPIR J, V10, P2490, DOI 10.1183/09031936.97.10112490; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tan JS, 1997, ARCH INTERN MED, V157, P1933, DOI 10.1001/archinte.157.17.1933; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352, DOI 10.1164/ajrccm.158.2.9705079; 1980, CLASS OCC LOND OFF P	51	113	116	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					289	300		10.1067/mai.2003.1596	http://dx.doi.org/10.1067/mai.2003.1596			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897734				2022-12-18	WOS:000184650600012
J	Jain, VV; Kitagaki, K; Businga, T; Hussain, I; George, C; O'Shaughnessy, P; Kline, JN				Jain, VV; Kitagaki, K; Businga, T; Hussain, I; George, C; O'Shaughnessy, P; Kline, JN			CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; murine; CpG oligodeoxynucleotides; airway remodeling; collagen; subepithelial fibrosis; transforming growth factor beta; regulatory T lymphocytes	SUBEPITHELIAL FIBROSIS; FLOW OBSTRUCTION; BRONCHIAL-ASTHMA; INFLAMMATION; RESPONSIVENESS; CELLS; METHACHOLINE; GENERATION; MODULATION; RESPONSES	Background: We have previously demonstrated that CpG oligodeoxymicleotides (CpG-ODNs) protect against eosinophilia and airway hyperresponsiveness in marine models of allergen-induced asthma. Acute inflammation is hypothesized to induce chronic airway responses, but no previous studies have evaluated the effects of CpG-ODNs on allergen-induced airway remodeling. Because remodeling is thought to be responsible for many of the long-term adverse effects on asthmatic patients, we evaluated whether CpG-ODNs might similarly prevent these changes using a murine model of recurrent allergen exposure. Objective: The purpose of this study was to evaluate the effect of CpG-ODNs on chronic inflammatory changes and airway remodeling by using a marine model of chronic allergen-induced asthma. Methods: C57BL/6 mice were sensitized to ovalbumin (OVA) and subsequently exposed to nebulized OVA by means of inhalation 3 times weekly for 6 weeks. Some mice received CpG-ODNs by means of intraperitoneal injection at the time of sensitization. At the end of the exposure period, mice were evaluated for the development of airway inflammation, airway hyperresponsiveness, and airway remodeling. Results: OVA-sensitized mice exposed to recurrent airway challenge with OVA have chronic inflammation, persistent airway hyperresponsiveness, and evidence of airway remodeling, including subepithelial collagen deposition and goblet cell hyperplasia-metaplasia. These changes are significantly reduced in mice treated with CpG-ODNs. Interestingly, mice treated with CpG-ODNs exhibit increased levels of bronchoalveolar lavage transforming growth factor P, suggesting that regulatory T cells might be responsible for some of these protective effects. Conclusion: CpG-ODNs are effective not only in preventing acute inflammation but also appear to reduce markers of airway remodeling that develop after chronic allergen exposure.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Med, Iowa City, IA USA	University of Iowa; University of Iowa; University of Iowa	Kline, JN (corresponding author), UIHC, 200 Newton Rd, Iowa City, IA 52242 USA.			kline, joel/0000-0002-5523-8855; George, Caroline/0000-0001-9291-4405; Jain, Vipul/0000-0001-5575-7869	NHLBI NIH HHS [HL59324] Funding Source: Medline; NIDDK NIH HHS [DK54759] Funding Source: Medline; NIEHS NIH HHS [ES05605] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; BOLENDER RP, 1993, AM J PHYSIOL, V265, pL521, DOI 10.1152/ajplung.1993.265.6.L521; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Broide D, 1998, J IMMUNOL, V161, P7054; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46, DOI 10.1164/ajrccm.164.supplement_2.2106066; Haneda K, 1997, J IMMUNOL, V159, P4484; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; JEFFERY PK, 1991, AM REV RESPIR DIS, V143, P1152, DOI 10.1164/ajrccm/143.5_Pt_1.1152; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258, DOI 10.1016/S0091-6749(99)70022-9; Kline JN, 2002, AM J PHYSIOL-LUNG C, V283, pL170, DOI 10.1152/ajplung.00402.2001; Kline JN, 1998, J IMMUNOL, V160, P2555; Krieg Arthur M., 2002, Trends in Immunology, V23, P64, DOI 10.1016/S1471-4906(01)02150-0; Okazawa M, 1996, AM J RESP CRIT CARE, V154, P1557, DOI 10.1164/ajrccm.154.5.8912780; ROCHE WR, 1989, LANCET, V1, P520; Russ J.C., 2001, PRACTICAL STEREOLOGY; Santeliz JV, 2002, J ALLERGY CLIN IMMUN, V109, P455, DOI 10.1067/mai.2002.122156; Serebrisky D, 2000, J IMMUNOL, V165, P5906, DOI 10.4049/jimmunol.165.10.5906; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; Sur S, 1999, J IMMUNOL, V162, P6284; Temelkovski J, 1998, THORAX, V53, P849, DOI 10.1136/thx.53.10.849; Terui T, 2001, J IMMUNOL, V167, P3661, DOI 10.4049/jimmunol.167.7.3661; Warshamana GS, 1998, AM J PHYSIOL-LUNG C, V274, pL499, DOI 10.1152/ajplung.1998.274.4.L499; WILSON JW, 1993, AM REV RESPIR DIS, V148, P806, DOI 10.1164/ajrccm/148.3.806; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245; ZuanyAmorim C, 1996, J IMMUNOL, V157, P377	33	113	134	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					867	872		10.1067/mai.2002.129371	http://dx.doi.org/10.1067/mai.2002.129371			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464952				2022-12-18	WOS:000179777400008
J	Beyer, K; Castro, R; Birnbaum, A; Benkov, K; Pittman, N; Sampson, HA				Beyer, K; Castro, R; Birnbaum, A; Benkov, K; Pittman, N; Sampson, HA			Human milk-specific mucosal lymphocytes of the gastrointestinal tract display a T(H)2 cytokine profile	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						gut; food allergy; IL-4; IL-5; IL-13; transforming growth factor beta; IL-10	T-CELLS; EOSINOPHILIC GASTROENTERITIS; ALLERGIC DISEASE; FOOD ALLERGY; TGF-BETA-1; INTERLEUKIN-10; PROLIFERATION; EXPRESSION; RESPONSES; ANTIGEN	Background: A number of gastrointestinal disorders, including allergic eosinophilic gastroenteritis and food protein-induced enteropathy, have been associated with milk hypersensitivity. The immunologic reactions appear to involve T cells that are activated by specific food proteins. Objective: The present study was performed to examine the cytokine profiles of milk-specific lymphocytes from the duodenal lamina propria from children with milk-induced gastrointestinal diseases. Methods: Duodenal biopsy specimens obtained from 10 patients with allergic eosinophilic gastroenteritis, food protein-induced enteropathy, or both and 12 control subjects were mechanically minced and cultured with either mitogens (ie, polyclonal T-cell expansion) or milk proteins (ie, milk-specific T-cell expansion). By using flow cytometry, expanded T cells were phenotyped with anti-CD4, anti-CD8, anti-IL-4, anti-IL-5, and anti-IFN-gamma mAbs. The milk specificity of the lines was evaluated by means of the lymphocyte proliferation assay. In addition, the release of T(H)1, T(H)2, and T(H)3 cytokines was determined after restimulation. Results: In patients and control subjects polyclonal expansion of mucosal lymphocytes resulted in predominantly T(H)1 cells. Milk-specific mucosal T-cell lines could be established in 60% of the patients but in none of the control subjects. In contrast to the polyclonal expansion of T cells, the milk-specific expansion of mucosal T cells showed a clear T(H)2 cytokine profile. On restimulation with milk protein, these cells showed a high proliferative response. They released T(H)2 cytokines, predominately IL-13, but failed to release T(H)3 cytokines important in the development of oral tolerance. Conclusion. The release of T(H)2 cytokines after stimulation of milk-specific mucosal T cells may play a pathogenic role in the inflammatory changes seen in milk-induced gastrointestinal disorders.	Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY 10029 USA; Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY 10029 USA; Mt Sinai Sch Med, Div Pediat Gastroenterol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Beyer, K (corresponding author), Mt Sinai Sch Med, Div Pediat Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NCRR NIH HHS [MO1 RR-0007] Funding Source: Medline; NIAID NIH HHS [AI44236] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akdis CA, 2001, IMMUNOLOGY, V103, P131, DOI 10.1046/j.1365-2567.2001.01235.x; Braunstein J, 1997, GUT, V41, P215, DOI 10.1136/gut.41.2.215; Cerwenka A, 1999, MICROBES INFECT, V1, P1291, DOI 10.1016/S1286-4579(99)00255-5; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Desreumaux P, 1996, GASTROENTEROLOGY, V110, P768, DOI 10.1053/gast.1996.v110.pm8608886; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V120, P8, DOI 10.1159/000024215; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; JAFFE JS, 1994, J CLIN IMMUNOL, V14, P299, DOI 10.1007/BF01540983; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Kuehn Ralf, 1993, Cell, V75, P263; LEE CM, 1993, AM J GASTROENTEROL, V88, P70; Ludviksson BR, 2000, EUR J IMMUNOL, V30, P2101, DOI 10.1002/1521-4141(200007)30:7<2101::AID-IMMU2101>3.0.CO;2-P; MALEFYT RD, 1991, J EXP MED, V174, P915; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; Nagata S, 2000, J IMMUNOL, V165, P5315, DOI 10.4049/jimmunol.165.9.5315; Prussin C, 1997, J CLIN IMMUNOL, V17, P195, DOI 10.1023/A:1027350226435; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Sampson HA, 2001, GASTROENTEROLOGY, V120, P1026, DOI 10.1053/gast.2001.23031; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; Strobl H, 1999, MICROBES INFECT, V1, P1283, DOI 10.1016/S1286-4579(99)00256-7; van Ginkel FW, 1999, J IMMUNOL, V163, P1951; Vandezande LM, 1999, CLIN EXP ALLERGY, V29, P652, DOI [10.1046/j.1365-2222.1999.00514.x, 10.1046/j.1365-2222.1999.00511.x]; Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2	27	113	127	0	13	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					707	713		10.1067/mai.2002.122503	http://dx.doi.org/10.1067/mai.2002.122503			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941323	Bronze			2022-12-18	WOS:000175132600022
J	Santeliz, JV; Van Nest, G; Traquina, P; Larsen, E; Wills-Karp, M				Santeliz, JV; Van Nest, G; Traquina, P; Larsen, E; Wills-Karp, M			Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; T cells; immunotherapy; cytokines; CpG	ALLERGIC LUNG INFLAMMATION; IFN-GAMMA PRODUCTION; IMMUNOSTIMULATORY DNA; BACTERIAL-DNA; T-CELLS; RESPONSES; ANTIGEN; ACTIVATION; MOTIFS; EXPRESSION	Background: Recently, it has been demonstrated that immunostimulatory DNA sequences (ISS) containing CpG motifs prevent the development of allergic airway responses in murine models of disease. However, few studies have addressed the issue of whether these agents will reverse established T(H)2-driven allergic airway responses. Objective: The aim of this study was to determine whether intradermal delivery of an immunogenic protein of ragweed pollen linked to an immunostimulatory DNA sequence could reverse an established allergic response in the mouse lung. Methods: Mice sensitized and challenged with ragweed pollen extract were treated intradermally twice at 1-week intervals with an ISS chemically linked to Amb a 1 (Amb a 1-ISS). One week after the Amb a 1-ISS treatment, mice were rechallenged intratracheally with ragweed extract, and airway responses were assessed. Results: Amb a 1-ISS treatment of ragweed-sensitized and ragweed-challenged mice significantly reversed allergen-induced airway hyperresponsiveness and suppressed the total number of eosinophils in bronchoalveolar lavage fluid. The inhibitory effect of Amb a 1-ISS was associated with a marked increase in IFN-gamma levels by Amb a 1-stimulated splenocytes and a shift in the antibody profile from a T(H)2-directed IgG1 response to a T(H)1-directed IgG2a response. Interestingly, the inhibitory effect of Amb a 1-ISS on allergen-driven airway hyperresponsiveness was independent of suppression of T(H)2 cytokine production. Conclusion: These results demonstrate that intradermal delivery of allergen-specific DNA conjugates can reverse established allergic responses in the murine lung, supporting their potential use in the treatment of human asthma.	Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; Dynavax Technol Corp, Berkeley, CA USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Johns Hopkins University	Wills-Karp, M (corresponding author), Childrens Hosp, Med Ctr, Div Immunobiol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NHLBI NIH HHS [HL10342] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL010342] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ballas ZK, 1996, J IMMUNOL, V157, P1840; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Brehler R, 1999, J ALLERGY CLIN IMMUN, V104, P1128, DOI 10.1016/S0091-6749(99)70003-5; Broide D, 1998, J IMMUNOL, V161, P7054; Chace JH, 1997, CLIN IMMUNOL IMMUNOP, V84, P185, DOI 10.1006/clin.1997.4380; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Howarth PH, 1998, CLIN EXP ALLERGY, V28, P2; Jahn-Schmid B, 1999, J ALLERGY CLIN IMMUN, V104, P1015, DOI 10.1016/S0091-6749(99)70083-7; Jakob T, 1998, J IMMUNOL, V161, P3042; Kline JN, 1998, J IMMUNOL, V160, P2555; Kovarik J, 1999, J IMMUNOL, V162, P1611; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; LEVITT RC, 1988, FASEB J, V2, P2605, DOI 10.1096/fasebj.2.10.3384240; Li XM, 1996, J IMMUNOL, V157, P3216; Liang H, 1996, J CLIN INVEST, V98, P1119, DOI 10.1172/JCI118894; Liang H, 2000, SPRINGER SEMIN IMMUN, V22, P63, DOI 10.1007/s002810000017; Parronchi P, 1999, J IMMUNOL, V163, P5946; Peng ZK, 2001, INT IMMUNOL, V13, P3, DOI 10.1093/intimm/13.1.3; PLATTSMILLS T, 1999, ASTHMA CAUSES MECH E; Serebrisky D, 2000, J IMMUNOL, V165, P5906, DOI 10.4049/jimmunol.165.10.5906; Shirota H, 2000, AM J RESP CELL MOL, V22, P176, DOI 10.1165/ajrcmb.22.2.3772; Shirota H, 2000, J IMMUNOL, V164, P5575, DOI 10.4049/jimmunol.164.11.5575; Shirota H, 2001, J IMMUNOL, V167, P66, DOI 10.4049/jimmunol.167.1.66; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Stacey KJ, 1996, J IMMUNOL, V157, P2116; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Sun SQ, 2000, SPRINGER SEMIN IMMUN, V22, P77, DOI 10.1007/s002810000028; Sun SQ, 1998, J EXP MED, V187, P1145, DOI 10.1084/jem.187.7.1145; Sun SQ, 1998, J EXP MED, V188, P2335, DOI 10.1084/jem.188.12.2335; Sur S, 1996, J IMMUNOL, V157, P4173; Sur S, 1999, J IMMUNOL, V162, P6284; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tokunaga T, 1999, JPN J INFECT DIS, V52, P1; Von Mutius E, 1998, CLIN EXP ALLERGY, V28, P45; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2000, IMMUNOPHARMACOLOGY, V48, P263, DOI 10.1016/S0162-3109(00)00223-X; YAMAMOTO S, 1988, JPN J CANCER RES, V79, P866, DOI 10.1111/j.1349-7006.1988.tb00049.x	42	113	123	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					455	462		10.1067/mai.2002.122156	http://dx.doi.org/10.1067/mai.2002.122156			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897991				2022-12-18	WOS:000174586400012
J	Krishna, MT; Chauhan, A; Little, L; Sampson, K; Hawksworth, R; Mant, T; Djukanovic, R; Lee, T; Holgate, S				Krishna, MT; Chauhan, A; Little, L; Sampson, K; Hawksworth, R; Mant, T; Djukanovic, R; Lee, T; Holgate, S			Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						APC 366; late asthmatic response; tryptase; asthma; mast cell; airway inflammation; bronchial hyperresponsiveness; early asthmatic response	INCREASED BRONCHIAL RESPONSIVENESS; IN-VIVO; HYPERRESPONSIVENESS; HISTAMINE; BRONCHOCONSTRICTION; ACTIVATION; EOSINOPHIL; RELEASE; ENHANCEMENT; RECRUITMENT	Background: APC 366, a selective inhibitor of mast cell tryptase, has been shown to inhibit antigen-induced early asthmatic response (EAR), late asthmatic response (LAR), and bronchial hyperresponsiveness (BHR) in a sheep model of allergic asthma, Objective: The purpose of this study was to investigate the effects of APC 366 on antigen-induced EAR, LAR, and BHR in mild atopic asthmatics not on any anti-inflammatory therapy Methods: Sixteen mild atopic asthmatics, each with a demonstrable antigen-induced EAR, LAR, and BHR to histamine, were recruited into this randomized, double-blinded, crossover study. APC 366 (5 mg)/placebo was administered by aerosol inhalation 3 times per day on treatment days 1 through 4, Allergen challenge was carried out on day 4. Histamine challenge was performed the following morning, 1 hour after Final dosing. Results: Subjects were shown to have a significantly smaller overall mean area under the curve for the LAR (P = .012) and mean maximum fall in FEV1 for the LAR (P = .007) after pretreatment with APC 366 in comparison with placebo. No significant effects on BHR were demonstrable. Although the EAR was reduced by 18% after treatment with APC 366 in comparison with placebo, this was not statistically significant. Conclusion: Short-term repeated administration of APC 366 significantly reduced the magnitude of antigen-induced LAR in atopic asthmatics, which supports the role of mast cell tryptase in the pathophysiology of the LAR.	Univ Southampton, Southampton Gen Hosp, RCMB Div, Southampton SO16 6YD, Hants, England; Guys Drug Res Unit, London, England; Guys Hosp, GKT Sch Med, Dept Resp Med & Allergy, London, England	University of Southampton; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Krishna, MT (corresponding author), Univ Southampton, Southampton Gen Hosp, RCMB Div, Mail Point 810,Level D,Ctr Block,Tremona Rd, Southampton SO16 6YD, Hants, England.		Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Djukanovic, Ratko/0000-0001-6039-5612				ARIMA M, 1995, CHEST, V108, P529, DOI 10.1378/chest.108.2.529; ARMITAGE P, STAT METHODS MED RES, P120; Bentley AM, 1997, CLIN EXP ALLERGY, V27, P71, DOI 10.1111/j.1365-2222.1997.tb01830.x; BERNSTEIN DI, 1992, CHEST, V101, P437, DOI 10.1378/chest.101.2.437; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; CAIMS J, 1997, J CLIN INVEST, V99, P1313; Cairns JA, 1996, J IMMUNOL, V156, P275; CHAI H, 1979, J ALLERGY CLIN IMMUN, V64, P575, DOI 10.1016/0091-6749(79)90015-0; Clark James M., 1996, Drugs of the Future, V21, P811; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; Compton SJ, 1998, J IMMUNOL, V161, P1939; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; DJUKANOVIC R, 1991, AM REV RESPIR DIS, V143, P772, DOI 10.1164/ajrccm/143.4_Pt_1.772; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; GALLI SJ, 1995, ALLERGY, V50, P851, DOI 10.1111/j.1398-9995.1995.tb02490.x; He SH, 1997, J IMMUNOL, V159, P6216; Imamura T, 1996, LAB INVEST, V74, P861; Johnson PRA, 1997, EUR RESPIR J, V10, P38, DOI 10.1183/09031936.97.10010038; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Molinari JF, 1996, AM J RESP CRIT CARE, V154, P649, DOI 10.1164/ajrccm.154.3.8810600; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; Pepys J., 1975, BR J HOSP MED, V14, P412; PERNG DW, 1998, IMMUNOLOGY, V95, pP21; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; THORPE JE, 1987, CHEST, V91, P21, DOI 10.1378/chest.91.1.21; TWENTYMAN OP, 1993, J ALLERGY CLIN IMMUN, V91, P1169, DOI 10.1016/0091-6749(93)90320-F; Walls AF, 1998, LUNG BIOL HEALTH DIS, V117, P89; WALLS AF, 1995, INT ARCH ALLERGY IMM, V107, P372, DOI 10.1159/000237039; WEERSINK EJM, 1994, AM J RESP CRIT CARE, V150, P1262, DOI 10.1164/ajrccm.150.5.7952550; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002	38	113	125	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1039	1045		10.1067/mai.2001.115631	http://dx.doi.org/10.1067/mai.2001.115631			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398082				2022-12-18	WOS:000169454800016
J	Pene, J; Desroches, A; Paradis, L; Lebel, B; Farce, M; Nicodemus, CF; Yssel, H; Bousquet, J				Pene, J; Desroches, A; Paradis, L; Lebel, B; Farce, M; Nicodemus, CF; Yssel, H; Bousquet, J			Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-H1/T-H2; allergy; T-cell cytokines; allergens; peptides; T-cell epitopes	BEE VENOM IMMUNOTHERAPY; GRASS-POLLEN IMMUNOTHERAPY; MESSENGER-RNA EXPRESSION; HUMAN IGE SYNTHESIS; HUMAN B-CELLS; INTERFERON-GAMMA; IFN-GAMMA; MONONUCLEAR-CELLS; ANTIBODY LEVEL; CYCLOSPORINE-A	Background: Cells producing a T-H2-cytokine profile play an important role in the onset and maintenance of atopic diseases, and therefore specific immunotherapy is aimed to induce a switch to cells producing a T-H1- or T-H0-cytokine profile. Recently, a novel form of immunotherapy making use of synthetic peptides from the major cat allergen Fel d 1 has been developed, but its mechanisms of action are unknown. Objectives: We examined the effects of immunotherapy with Fel dl peptides on the response to bronchial provocation tests (PD20FEV1) with a standardized Fel d 1 cat extract on Fel d 1-specific serum IgE and IgG Levels and in vitro IL-4 and IFN-gamma production. Methods: Patients allergic to cats received 6 weekly injections of 7.5 mu g (Low dose), 75 mu g (medium dose), or 750 mu g (high dose) of Fel d 1 peptides (25 patients) or a placebo (6 patients). Results: Six weeks after ending immunotherapy, posttreatment PD20FEV1 was not significantly different between the treated and placebo groups. However, in the medium- and high-dose groups there was a significant improvement between baseline and posttreatment days. IL-4 release was significantly reduced in the high dose-treated group (P < .005, Wilcoxon W test), whereas it was unchanged in the low or medium dose- and in the placebo-treated groups. In all groups, IFN-gamma, IgE, and IgG levels remained unchanged. Conclusion: There was no correlation between the improvement of PD20FEV1 and the decrease in IL-4 production, These data suggest that peptide immunotherapy may act by shifting, the Fel d 1-induced response of PBMCs in vitro from the T-H2-like to the T-H0-like phenotype.	Hop Arnaud Villeneuve, INSERM U454, F-34295 Montpellier 5, France; Hop Arnaud Villeneuve, Clin Malad Respiratoires, F-34295 Montpellier 5, France; ImmuLogic, Waltham, MA USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Pene, J (corresponding author), Hop Arnaud Villeneuve, INSERM U454, 375 Ave Du Doyen G Giraud, F-34295 Montpellier 5, France.		Yssel, Hans/C-6406-2009; Yssel, Hans/AFV-2907-2022; Bousquet, Jean/O-4221-2019	Yssel, Hans/0000-0001-7454-1836; Yssel, Hans/0000-0001-7454-1836; 				Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akoum H, 1996, IMMUNOLOGY, V87, P593, DOI 10.1046/j.1365-2567.1996.506585.x; BOND JF, 1993, MOL IMMUNOL, V30, P1529, DOI 10.1016/0161-5890(93)90461-J; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P1, DOI 10.1016/0091-6749(94)90064-7; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; BURASTERO SE, 1993, J ALLERGY CLIN IMMUN, V91, P1075, DOI 10.1016/0091-6749(93)90222-2; CHRETIEN I, 1990, EUR J IMMUNOL, V20, P243, DOI 10.1002/eji.1830200203; DEL PG, 1988, J IMMUNOL, V140, P4193; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; GASCAN H, 1991, J IMMUNOL, V147, P8; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; JUTEL M, 1995, J IMMUNOL, V154, P4187; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; Kasaian MT, 1996, INT IMMUNOL, V8, P1287, DOI 10.1093/intimm/8.8.1287; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; Lagier B, 1995, J ALLERGY CLIN IMMUN, V96, P932, DOI 10.1016/S0091-6749(95)70231-8; Li Y, 1996, INT IMMUNOL, V8, P897, DOI 10.1093/intimm/8.6.897; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; McHugh S, 1996, EUR J IMMUNOL, V26, P1260, DOI 10.1002/eji.1830260612; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUELLER R, 1994, EUR J IMMUNOL, V24, P2935, DOI 10.1002/eji.1830241203; NIEMINEN MM, 1988, THORAX, V43, P896, DOI 10.1136/thx.43.11.896; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Ohashi Y, 1996, SCAND J IMMUNOL, V43, P680, DOI 10.1046/j.1365-3083.1996.d01-269.x; PENE J, 1993, CELL BIOL INT, V17, P353, DOI 10.1006/cbir.1993.1072; PENE J, 1994, IMMUNOLOGY, V81, P58; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SCHMIDT J, 1994, IMMUNOPHARMACOLOGY, V27, P173, DOI 10.1016/0162-3109(94)90013-2; SCHMIDT J, 1994, EUR J PHARMACOL, V260, P247, DOI 10.1016/0014-2999(94)90345-X; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; 1995, PUBLICATION NATL I H	47	113	119	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				571	578		10.1016/S0091-6749(98)70294-5	http://dx.doi.org/10.1016/S0091-6749(98)70294-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802364	Bronze			2022-12-18	WOS:000076600400006
J	Fricker, M; Helbling, A; Schwartz, L; Muller, U				Fricker, M; Helbling, A; Schwartz, L; Muller, U			Hymenoptera sting anaphylaxis and urticaria pigmentosa: Clinical findings and results of venom immunotherapy in ten patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hymenoptera sting anaphylaxis; urticaria pigmentosa; mastocytosis; venom immunotherapy	MASTOCYTOSIS; ACTIVATION; TRYPTASE; SHOCK	Background: Occasional patients with urticaria pigmentosa and anaphylaxis after Hymenoptera stings have been described. In this situation the question arises: Is anaphylaxis IgE-mediated or induced by pharmacologic mediator release from mast cells? Methods: We investigated 10 patients with histologically confirmed urticaria pigmentosa and a history of anaphylaxis after honeybee or Vespula stings before and during immunotherapy with the respective venom. Results: In eight of 10 patients, an elevated serum tryptase level was found. In two of 10 patients, no venom-specific IgE could be detected by either skin tests or RAST. Five patients had no detectable venom-specific serum IgE, and in the remaining patients the level was low (<1 Phadebas RAST unit). Venom immunotherapy was well tolerated and caused only one mild systemic reaction in a patient during the dose increase phase. Six patients were re-stung while receiving venom immunotherapy: only one had a mild systemic reaction (angioedema:) after a Vespula sting. Conclusion: Anaphylactic symptoms after Hymenoptera stings in patients with urticaria pigmentosa are most often IgE-mediated but can occasionally be observed in the absence of IgE sensitization to venom allergens. Venom immunotherapy can be safely and successfully used in patients with urticaria pigmentosa and sting anaphylaxis.	ZIEGLERSPITAL BERN,DEPT MED,CH-3001 BERN,SWITZERLAND; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV RHEUMATOL ALLERGY & IMMUNOL,RICHMOND,VA 23298	Virginia Commonwealth University								Blaauw PJ, 1996, J ALLERGY CLIN IMMUN, V98, P39, DOI 10.1016/S0091-6749(96)70224-5; CAPLAN RM, 1963, ARCH DERMATOL, V87, P146, DOI 10.1001/archderm.1963.01590140008002; ENANDER I, 1991, J IMMUNOL METHODS, V138, P39, DOI 10.1016/0022-1759(91)90062-K; ENGLER RJM, 1994, J ALLERGY CLIN IMMUN, V94, P556, DOI 10.1016/0091-6749(94)90213-5; FRANKEN HH, 1994, J ALLERGY CLIN IMMUN, V93, P431, DOI 10.1016/0091-6749(94)90351-4; HERMANN K, 1990, CLIN EXP ALLERGY, V20, P569, DOI 10.1111/j.1365-2222.1990.tb03151.x; KORS JW, 1993, J INTERN MED, V233, P255, DOI 10.1111/j.1365-2796.1993.tb00984.x; LEWIS RA, 1984, J ALLERGY CLIN IMMUN, V74, P755, DOI 10.1016/0091-6749(84)90172-6; METCALFE DD, 1993, ALLERGY PRINCIPLES P, P1537; MULLER U, 1990, ALLERGY, V45, P597, DOI 10.1111/j.1398-9995.1990.tb00945.x; MULLER UR, 1983, J ALLERGY CLIN IMMUN, V72, P685, DOI 10.1016/0091-6749(83)90630-9; MULLER UR, 1990, INSECT STING ALLERGY, P87; PRICE LA, 1987, J ALLERGY CLIN IMMUN, V79, P407, DOI 10.1016/0091-6749(87)90162-X; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; TRAFIS WD, 1993, MAST CELL HLTH DIS, P723; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; VANDERLINDEN PWG, 1993, BLOOD, V82, P1732, DOI 10.1182/blood.V82.6.1732.bloodjournal8261732; vanHalteren HK, 1996, J ALLERGY CLIN IMMUN, V97, P1058, DOI 10.1016/S0091-6749(96)70258-0	20	113	116	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					11	15		10.1016/S0091-6749(97)70188-X	http://dx.doi.org/10.1016/S0091-6749(97)70188-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257781	Bronze			2022-12-18	WOS:A1997XP42800003
J	Petersen, A; Vieths, S; Aulepp, H; Schlaak, M; Becker, WM				Petersen, A; Vieths, S; Aulepp, H; Schlaak, M; Becker, WM			Ubiquitous structures responsible for IgE cross-reactivity between tomato fruit and grass pollen allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						carbohydrate structure; cross-reactivity; grass pollen allergens; IgE binding; immunoblotting; tomato allergens	PHL-P-I; BET-V-I; VEGETABLE FOODS; APPLE ALLERGEN; PROFILIN; PROTEINS; IDENTIFICATION; NITROCELLULOSE; EXPRESSION; GLYCANS	The simultaneous presence of IgE reactivity to tomato fruit and grass pollen allergens is evident in many patients with allergy and may be caused by cross-reactivity. Using sera from polysensitized patients with a positive enzyme allergosorbent rest (EAST) result (score >2), we tested reactivity to both allergen sources. IgE reactivity against both extracts was demonstrated in eight serum samples, and cross-reactivity was confirmed by the EAST inhibition assay. The structures responsible for this cross-reactivity were identified by Western blotting: five of the eight serum demonstrated a 16 kd protein in both extracts, which was identified as profilin. Additionally, seven of the eight sera showed IgE binding to epitopes on carbohydrate moieties, which contained alpha 1,3 fucosylations. To determine the allergens of tomato fruit extract, we performed two-dimensional polyacrylamide gel electrophoresis blotting. We were able to demonstrate one highly concentrated and about 20 weaker proteins possessing terminal fucose residues. These are similarly found in grass pollen extracts. It is therefore postulated that the cross-reactivity is affected by profilins and similar carbohydrate determinants. If carbohydrate structures can provoke IgE cross-reactivity between phylogenetically distant species, such structures may play an important role in sensitization and mediator release. The ubiquitous nature of the IgE-binding determinants was studied by additional EAST inhibition tests with tomato allergen disks and extract from birch pollen, mugwort pollen apple and celery, leading to significant inhibitions among all these allergen sources. Epitopes exclusive to grass pollen and tomato have not been detected.	BUNDESVERSICHERUNGSANSTALT ANGESTELLTE,HOSP BORKUM RIFF,BORKUM,GERMANY		Petersen, A (corresponding author), FORSCHUNGSZENTRUM BORSTEL,DIV ALLERGOL,PARKALLEE 22,D-23845 BORSTEL,GERMANY.							AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; BECKER WM, 1988, BIOCH ENG, P440; CEDERGRENZEPPEZAUER ES, 1994, J MOL BIOL, V240, P459, DOI 10.1006/jmbi.1994.1461; CLAMP JR, 1965, BIOCHEM J, V94, P17, DOI 10.1042/bj0940017; DEMARTINO M, 1988, ALLERGY, V43, P206; ELLIOTT KJ, 1993, PLANT MOL BIOL, V21, P515, DOI 10.1007/BF00028808; FAH J, 1995, CLIN EXP ALLERGY, V25, P1018, DOI 10.1111/j.1365-2222.1995.tb00405.x; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HINO K, 1995, J BIOCHEM-TOKYO, V117, P289, DOI 10.1093/jb/117.2.289; JANKIEWICZ A, IN PRESS INT ARCH AL; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NILSEN BM, 1991, J BIOL CHEM, V266, P2660; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; PETERSEN A, 1995, J ALLERGY CLIN IMMUN, V95, P987, DOI 10.1016/S0091-6749(95)70099-4; PETERSEN A, 1992, INT ARCH ALLERGY IMM, V98, P105, DOI 10.1159/000236172; PETERSEN A, 1995, ELECTROPHORESIS, V16, P869, DOI 10.1002/elps.11501601144; SCHONING B, 1995, J SCI FOOD AGR, V67, P431, DOI 10.1002/jsfa.2740670403; SCHRAMM G, 1995, THESIS U BAYREUTH BA; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; TWELL D, 1989, MOL GEN GENET, V217, P240, DOI 10.1007/BF02464887; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; Vieths S., 1994, Food and Agricultural Immunology, V6, P453, DOI 10.1080/09540109409354857; VIETHS S, 1995, ALLERGY, V50, P421, DOI 10.1111/j.1398-9995.1995.tb01172.x; VIETHS S, 1995, ANN ALLERG ASTHMA IM, V74, P48; VINSON VK, 1993, J CELL BIOL, V122, P1277, DOI 10.1083/jcb.122.6.1277; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56, DOI 10.1159/000236803; WUTHRICH B, 1993, ALLERGOLOGIE, V16, P280; YAMASHITA K, 1985, J BIOL CHEM, V260, P4688	41	113	115	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					805	815		10.1016/S0091-6749(96)70130-6	http://dx.doi.org/10.1016/S0091-6749(96)70130-6			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876557				2022-12-18	WOS:A1996VM66500014
J	MOQBEL, R; LEVISCHAFFER, F; KAY, AB				MOQBEL, R; LEVISCHAFFER, F; KAY, AB			CYTOKINE GENERATION BY EOSINOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR-ALPHA; INTERLEUKIN-5 MESSENGER-RNA; NECROSIS-FACTOR-ALPHA; FUNCTIONAL-PROPERTIES; GENE-EXPRESSION; T-CELLS; ASTHMA; SURVIVAL; DISEASE				MOQBEL, R (corresponding author), NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.							ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ANWAR ARE, 1994, IMMUNOLOGY, V82, P222; ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEIL WJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1611, DOI 10.1177/41.11.8409368; BRAUN RK, 1993, EUR J IMMUNOL, V23, P956, DOI 10.1002/eji.1830230429; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; CLUTTERBUCK EJ, 1988, BLOOD, V73, P1504; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; COSTA JJ, 1993, J CLIN INVEST, V91, P2673, DOI 10.1172/JCI116506; DELPOZO V, 1990, J IMMUNOL, V144, P3117; DESREUMAUX P, 1992, J EXP MED, V175, P293, DOI 10.1084/jem.175.1.293; DUBUCQUOI S, 1994, J EXP MED, V179, P703, DOI 10.1084/jem.179.2.703; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; HAMID Q, 1992, BLOOD, V80, P1496; KADIN M, 1993, AM J PATHOL, V142, P11; KAY AB, 1985, INT ARCH ALLER A IMM, V77, P69, DOI 10.1159/000233755; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KITA H, 1991, J EXP MED, V174, P743; LEVISCHAFFER F, 1994, J ALLERGY CLIN IMMUN, V93, P268; MELANI C, 1993, BLOOD, V81, P2744; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; MOQBEL R, 1994, AM J RESP CRIT CARE, V149, pA836; OHNO I, 1991, AM J RESP CELL MOL, V5, P505, DOI 10.1165/ajrcmb/5.6.505; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SILBERSTEIN DS, 1987, IMMUNOL TODAY, V8, P380, DOI 10.1016/0167-5699(87)90214-3; STERN M, 1992, J IMMUNOL, V148, P3543; TAN XD, 1993, AM J PATHOL, V142, P1858; TODD R, 1991, AM J PATHOL, V138, P1307; VALERIUS T, 1990, J IMMUNOL, V145, P2950; WARDLAW AJ, 1992, ALLERGY IMMUNITY HEL, P54; WELLER PF, 1993, J IMMUNOL, V150, P2554; WONG DTW, 1993, AM J PATHOL, V143, P130; WONG DTW, 1991, BLOOD, V78, P2702; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356	39	113	113	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1183	1188		10.1016/0091-6749(94)90330-1	http://dx.doi.org/10.1016/0091-6749(94)90330-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798558				2022-12-18	WOS:A1994QA02000010
J	COTE, J; KENNEDY, S; CHANYEUNG, M				COTE, J; KENNEDY, S; CHANYEUNG, M			SENSITIVITY AND SPECIFICITY OF PC20 AND PEAK EXPIRATORY FLOW-RATE IN CEDAR ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA, VANCOUVER GEN HOSP, DEPT MED, DIV RESP, VANCOUVER V5Z 1M9, BC, CANADA	University of British Columbia								BARDY JD, 1987, AM REV RESPIR DIS, V135, P1033; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BURGE PS, 1982, EUR J RESPIR DIS, V63, P47; BURGE PS, 1979, THORAX, V34, P308, DOI 10.1136/thx.34.3.308; BURGE PS, 1979, THORAX, V34, P317, DOI 10.1136/thx.34.3.317; CARTIER A, 1984, CLIN ALLERGY, V14, P193, DOI 10.1111/j.1365-2222.1984.tb02652.x; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; FABBRI LM, 1988, AM REV RESPIR DIS, V137, P1494, DOI 10.1164/ajrccm/137.6.1494; GHEYSENS B, 1985, CHEST, V88, P740, DOI 10.1378/chest.88.5.740; HARGREAVE FE, 1984, AM REV RESPIR DIS, V130, P513; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; MOLLER DR, 1986, SEMIN RESPIR MED, V7, P225, DOI 10.1055/s-2007-1012618; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; VENABLES KM, 1984, THORAX, V39, P828, DOI 10.1136/thx.39.11.828; Zar J.J., 2010, BIOSTAT ANAL, Vfifth	16	113	115	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					592	598		10.1016/0091-6749(90)90098-O	http://dx.doi.org/10.1016/0091-6749(90)90098-O			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2179365				2022-12-18	WOS:A1990CU66800009
J	LUNDGREN, JD; SHELHAMER, JH				LUNDGREN, JD; SHELHAMER, JH			PATHOGENESIS OF AIRWAY MUCUS HYPERSECRETION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									NIH,CTR CLIN,DEPT CRIT CARE MED,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	LUNDGREN, JD (corresponding author), UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT INFECT DIS 144,DK-2650 HVIDOVRE,DENMARK.		Lundgren, Jens/AAE-6876-2019	Lundgren, Jens/0000-0001-8901-7850				ADLER KB, 1981, LAB INVEST, V45, P372; ADLER KB, 1987, EXP LUNG RES, V13, P25, DOI 10.3109/01902148709064307; ANNESI I, 1986, AM REV RESPIR DIS, V134, P688; ARNOUX B, 1988, AM REV RESPIR DIS, V137, P855, DOI 10.1164/ajrccm/137.4.855; BALTER MS, 1988, AM REV RESPIR DIS, V138, P1134, DOI 10.1164/ajrccm/138.5.1134; BARBIERI EJ, 1984, BRIT J PHARMACOL, V82, P199, DOI 10.1111/j.1476-5381.1984.tb16459.x; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; BARNES PJ, 1986, LANCET, V1, P242; BARTHELSON RA, 1987, AM J PHYSIOL, V253, pC802, DOI 10.1152/ajpcell.1987.253.6.C802; BASBAUM CB, 1981, CELL TISSUE RES, V220, P481, DOI 10.1007/BF00216752; BASBAUM CB, 1988, EUR RESPIR J S1, V1, pS104; BEDROSSIAN CWM, 1976, HUM PATHOL, V7, P195, DOI 10.1016/S0046-8177(76)80023-8; BEREND N, 1979, AM REV RESPIR DIS, V119, P695; BJORKANDER J, 1984, EUR J RESPIR DIS, V65, P529; BLACK LF, 1978, AM REV RESPIR DIS, V117, P421; BOAT TF, 1982, PEDIATR RES, V16, P792, DOI 10.1203/00006450-198209000-00017; BOAT TF, 1975, CHEST S, V2, pS32; BOAT TF, 1988, RESPIRATORY MED, P1126; BORSON DB, 1984, J APPL PHYSIOL, V57, P457, DOI 10.1152/jappl.1984.57.2.457; BORSON DB, 1987, EXP LUNG RES, V12, P21, DOI 10.3109/01902148709068812; BOWES D, 1977, THORAX, V32, P163, DOI 10.1136/thx.32.2.163; BRANDTZAEG P, 1974, J IMMUNOL, V112, P1553; BRAUTIGAN DL, 1988, INT J BIOCHEM, V20, P745, DOI 10.1016/0020-711X(88)90059-6; BREUER R, 1985, EXP LUNG RES, V9, P167, DOI 10.3109/01902148509061535; BREUER R, 1985, J LAB CLIN MED, V105, P635; BRUIST AS, 1988, RESPIRATORY MED, P1001; CAMPBELL AH, 1988, AIRWAY CALIBRE HLTH; CARLSTEDTDUKE J, 1986, P NATL ACAD SCI USA, V83, P9202, DOI 10.1073/pnas.83.23.9202; CARSTAIRS JR, 1986, J PHARMACOL EXP THER, V239, P249; CHAPMAN RS, 1985, AM REV RESPIR DIS, V132, P261; CHENG PW, 1986, AM REV RESPIR DIS, V133, pA295; CHODOSH S, 1987, AM J MED, V82, P154; COLES SJ, 1981, CELL TISSUE RES, V214, P107; COLES SJ, 1981, AM REV RESPIR DIS, V124, P531; COLES SJ, 1984, J APPL PHYSIOL, V57, P1323, DOI 10.1152/jappl.1984.57.5.1323; COLES SJ, 1984, CIBA F SYMP, V109, P40, DOI 10.1002/9780470720905.ch4; COLES SJ, 1983, PROSTAGLANDINS, V25, P155, DOI 10.1016/0090-6980(83)90101-6; COLES SJ, 1984, AM J PHYSIOL, V246, pC495; DAVIS B, 1982, J APPL PHYSIOL, V53, P985, DOI 10.1152/jappl.1982.53.4.985; DOUGLAS AN, 1980, THORAX, V35, P198, DOI 10.1136/thx.35.3.198; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1988, PULMONARY PATHOLOGY, P41; ELING TE, 1986, J BIOL CHEM, V261, P2841; FIELD WINIFRED E. H., 1968, BRIT J PIS CHEST, V62, P11, DOI 10.1016/S0007-0971(68)80025-7; Florey H, 1932, BRIT J EXP PATHOL, V13, P269; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FRATES RC, 1983, PEDIATR RES, V17, P30, DOI 10.1203/00006450-198301000-00006; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GALLAGHER JT, 1986, BIOCHIM BIOPHYS ACTA, V886, P243, DOI 10.1016/0167-4889(86)90142-4; GASHI AA, 1986, AM J PHYSIOL, V251, pC223, DOI 10.1152/ajpcell.1986.251.2.C223; GASHI AA, 1987, EXP LUNG RES, V12, P83; GERMAN VF, 1982, J APPL PHYSIOL, V52, P1153, DOI 10.1152/jappl.1982.52.5.1153; GOSWAMI S K, 1987, American Review of Respiratory Disease, V135, pA159; HIRATA F, 1989, ANTIINFLAMMATORY STE, P67; HIRSCH SR, 1975, NEW DIRECTIONS ASTHM, P351; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; HUA XY, 1985, REGUL PEPTIDES, V13, P1, DOI 10.1016/0167-0115(85)90082-5; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; HUTSON PA, 1988, AM REV RESPIR DIS, V137, P548, DOI 10.1164/ajrccm/137.3.548; JACOBY DB, 1988, J APPL PHYSIOL, V64, P2653, DOI 10.1152/jappl.1988.64.6.2653; JANOFF A, 1979, SCIENCE, V206, P1313, DOI 10.1126/science.316187; JEANNERETGROSJEAN A, 1988, AM REV RESPIR DIS, V137, P707, DOI 10.1164/ajrccm/137.3.707; JOHNSON HG, 1985, AM REV RESPIR DIS, V131, P917; JOHNSON HG, 1983, INT J IMMUNOPHARMACO, V5, P391, DOI 10.1016/0192-0561(83)90013-9; KALINER M, 1984, J ALLERGY CLIN IMMUN, V73, P318, DOI 10.1016/0091-6749(84)90403-2; Kaliner M, 1988, IMMUNOLOGIC DISEASES, P1067; KIM KC, 1987, P NATL ACAD SCI USA, V84, P9304, DOI 10.1073/pnas.84.24.9304; KLINGER JD, 1984, J CLIN INVEST, V74, P1669, DOI 10.1172/JCI111583; KOLLBERG H, 1978, SCAND J RESPIR DIS, V59, P297; LAMB D, 1968, J PATHOL BACTERIOL, V96, P97, DOI 10.1002/path.1700960111; Lamb D, 1972, Br J Dis Chest, V66, P239, DOI 10.1016/0007-0971(72)90042-3; LARSELL O, 1923, J COMP NEUROL, V35, P97; LARSEN P, IN PRESS APMIS; LAZARUS SC, 1984, AM J PHYSIOL, V247, pC327, DOI 10.1152/ajpcell.1984.247.5.C327; LAZARUS SC, 1986, AM J PHYSIOL, V251, pC115, DOI 10.1152/ajpcell.1986.251.1.C115; LEIKAUF GD, 1988, AM REV RESPIR DIS, V137, P435, DOI 10.1164/ajrccm/137.2.435; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948, DOI 10.1164/ajrccm/137.4.948; LIEDTKE CM, 1983, AM J PHYSIOL, V244, pC391, DOI 10.1152/ajpcell.1983.244.5.C391; LOGUN C, 1988, AM REV RESPIR DIS, V137, pA14; LOPEZVIDRIERO MT, 1975, THORAX, V30, P543, DOI 10.1136/thx.30.5.543; LOPEZVIDRIERO MT, 1977, THORAX, V32, P734, DOI 10.1136/thx.32.6.734; LOPEZVIDRIERO MT, 1978, AM REV RESPIR DIS, V117, P465; LUMSDEN AB, 1984, THORAX, V39, P844, DOI 10.1136/thx.39.11.844; LUND J, 1989, ENDOCR RES, V15, P17, DOI 10.3109/01902148909069606; LUNDBERG JM, 1980, P NATL ACAD SCI-BIOL, V77, P1651, DOI 10.1073/pnas.77.3.1651; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0; LUNDBERG JM, 1984, CELL TISSUE RES, V119, P243; LUNDGREN J, 1987, EXP LUNG RES, V12, P303, DOI 10.3109/01902148709062842; LUNDGREN J D, 1989, FASEB Journal, V3, pA609; LUNDGREN JD, 1989, J ALLERGY CLIN IMMUN, V83, P274; LUNDGREN JD, 1989, CLIN RES, V37, pA239; LUNDGREN JD, 1988, EXP LUNG RES, V14, P853, DOI 10.3109/01902148809087849; LUNDGREN JD, 1985, ANN ALLERGY, V55, P5; LUNDGREN JD, 1988, AM REV RESPIR DIS, V137, P353, DOI 10.1164/ajrccm/137.2.353; LUNDGREN JD, IN PRESS AM REV RESP; LUNDGREN JD, 1988, AM REV RESPIR DIS, V137, pA11; LUNDGREN JD, IN PRESS AM J PHYSL; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MAROM Z, 1984, PROSTAGLANDINS, V28, P79, DOI 10.1016/0090-6980(84)90115-1; MAROM Z, 1984, J EXP MED, V159, P844, DOI 10.1084/jem.159.3.844; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; MAROM Z, 1985, J EXP MED, V161, P657, DOI 10.1084/jem.161.4.657; MAROM Z, 1984, AM REV RESPIR DIS, V129, P62; MAROM Z, 1985, J CLIN INVEST, V75, P191, DOI 10.1172/JCI111674; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MASSON PL, 1966, THORAX, V21, P538, DOI 10.1136/thx.21.6.538; MCDONALD DM, 1988, AM REV RESPIR DIS, V137, P1432, DOI 10.1164/ajrccm/137.6.1432; MIAN N, 1982, BIOCHEM J, V208, P425, DOI 10.1042/bj2080425; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; MULLEN JB, 1988, BRIT MED J, V291, P1235; MURLAS CG, 1985, AM REV RESPIR DIS, V131, P314; NADEL JA, 1977, AM REV RESPIR DIS, V115, P117; NAGAI A, 1985, AM REV RESPIR DIS, V132, P937; NILAS RM, 1986, J LAB CLIN MED, V108, P489; OLLERENSHAW S, 1989, NEW ENGL J MED, V320, P1244, DOI 10.1056/NEJM198905113201904; PACK RJ, 1984, J ANAT, V138, P493; PEATFIELD AC, 1982, AM REV RESPIR DIS, V125, P210; PEATFIELD AC, 1982, EUR J PHARMACOL, V81, P617, DOI 10.1016/0014-2999(82)90351-X; PEATFIELD AC, 1983, AM REV RESPIR DIS, V128, P89, DOI 10.1164/arrd.1983.128.1.89; PEATFIELD AC, 1983, J PHYSIOL-LONDON, V342, P335, DOI 10.1113/jphysiol.1983.sp014854; PEATFIELD AC, 1982, BRIT J PHARMACOL, V77, P391, DOI 10.1111/j.1476-5381.1982.tb09310.x; PEATFIELD AC, 1983, J PHYSIOL-LONDON, V342, P327, DOI 10.1113/jphysiol.1983.sp014853; PETERS SP, 1984, J IMMUNOL, V132, P1972; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; PHIPPS RJ, 1983, J APPL PHYSIOL, V55, P1593, DOI 10.1152/jappl.1983.55.5.1593; PHIPPS RJ, 1982, CLIN SCI, V63, P23, DOI 10.1042/cs0630023; PHIPPS RJ, 1986, J APPL PHYSIOL, V60, P918, DOI 10.1152/jappl.1986.60.3.918; PHIPPS RJ, 1976, J PHYSIOL-LONDON, V261, P563, DOI 10.1113/jphysiol.1976.sp011574; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; QUINTON PM, 1979, NATURE, V279, P551, DOI 10.1038/279551a0; REID LM, 1954, LANCET, V1, P275; REID LYNNE, 1960, THORAX, V15, P132, DOI 10.1136/thx.15.2.132; REYNOLDS HY, 1981, MED CLIN N AM, V65, P667, DOI 10.1016/S0025-7125(16)31518-8; RICH B, 1984, THORAX, V39, P420, DOI 10.1136/thx.39.6.420; ROGERS D F, 1989, American Review of Respiratory Disease, V139, pA411; ROGERS DF, 1986, EXP LUNG RES, V10, P285, DOI 10.3109/01902148609061498; ROGERS DF, 1988, AM REV RESPIR DIS, V137, pA12; RYDER RC, 1971, J PATHOL, V104, P59, DOI 10.1002/path.1711040108; SANERKIN NG, 1965, J PATHOL BACTERIOL, V89, P535, DOI 10.1002/path.1700890211; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330, DOI 10.1164/ajrccm/137.6.1330; SASAKI T, 1989, J APPL PHYSIOL, V66, P764, DOI 10.1152/jappl.1989.66.2.764; SCHULTZ HD, 1985, J APPL PHYSIOL, V58, P907, DOI 10.1152/jappl.1985.58.3.907; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; SHIMOSEGAWA T, 1988, AM REV RESPIR DIS, V137, pA195; SHIMURA S, 1988, J APPL PHYSIOL, V65, P2537, DOI 10.1152/jappl.1988.65.6.2537; SHIMURA S, 1987, J APPL PHYSIOL, V63, P646, DOI 10.1152/jappl.1987.63.2.646; SHIMURA S, 1988, AM REV RESPIR DIS, V137, pA6; SHIMURA S, 1988, AM REV RESPIR DIS, V137, pA14; SIEGEL MI, 1981, PROSTAGLANDINS, V21, P123, DOI 10.1016/0090-6980(81)90202-1; Silberberg A., 1988, METHODS BRONCHIAL MU, P51; SNIDER GL, 1984, AM REV RESPIR DIS, V129, P155; SNIDER GL, 1985, AM REV RESPIR DIS, V132, P1155; STURGESS J, 1972, CLIN SCI, V43, P533, DOI 10.1042/cs0430533; STURGESS J, 1982, AM J PATHOL, V106, P303; SUNDAY ME, 1988, LAB INVEST, V59, P5; TAYLOR RG, 1986, THORAX, V41, P295, DOI 10.1136/thx.41.4.295; THURLBECK WM, 1982, EUR J RESPIR DIS, V63, P9; THURLBECK WM, 1975, AM REV RESPIR DIS, V112, P65; THURLBECK WM, 1970, MEDICINE, V49, P81, DOI 10.1097/00005792-197003000-00001; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512; TOS M, 1983, ARCH OTOLARYNGOL, V109, P673; TURNERWARWICK M, 1987, POSTGRAD MED J, V63, P79; UDDMAN R, 1984, ARCH OTO-RHINO-LARYN, V239, P145, DOI 10.1007/BF00463555; UDDMAN R, 1978, ACTA OTO-LARYNGOL, V86, P443, DOI 10.3109/00016487809124767; VERGHESE A, 1988, EXP LUNG RES, V14, P797, DOI 10.3109/01902148809087845; WANNER A, 1988, METHODS BRONCHIAL MU, P279; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WEBBER SE, 1987, AGENTS ACTIONS, V22, P82, DOI 10.1007/BF01968821; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WELSH MJ, 1986, N ENGL REG ALLERGY P, V7, P37; YANG CM, 1988, J APPL PHYSIOL, V64, P200, DOI 10.1152/jappl.1988.64.1.200; 1965, LANCET, V1, P286	173	113	117	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					399	417		10.1016/0091-6749(90)90147-V	http://dx.doi.org/10.1016/0091-6749(90)90147-V			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	2406321				2022-12-18	WOS:A1990CP51100001
J	DURHAM, SR; CRADDOCK, CF; COOKSON, WO; BENSON, MK				DURHAM, SR; CRADDOCK, CF; COOKSON, WO; BENSON, MK			INCREASES IN AIRWAY RESPONSIVENESS TO HISTAMINE PRECEDE ALLERGEN-INDUCED LATE ASTHMATIC RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND	University of Oxford	DURHAM, SR (corresponding author), BROMPTON HOSP,INST CARDIOTHORAC,FULHAM RD,LONDON SW3 GHP,ENGLAND.		Cookson, William/HHC-1790-2022	Craddock, Charles/0000-0001-5041-6678				BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BIERMAN CW, 1984, J ALLERGY CLIN IMMUN, V74, P701, DOI 10.1016/0091-6749(84)90233-1; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BURGE PS, 1982, EUR J RESPIR DIS, V123, P65; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; COCKCROFT DW, 1987, THORAX, V42, P302, DOI 10.1136/thx.42.4.302; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CROMWELL O, 1986, HDB EXPT IMMUNOLOGY, V4, P1; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FABBRI LM, 1985, AM REV RESPIR DIS, V132, P1010; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; HERGARDT B, 1981, ALLERGY, V36, P407; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; IIKURA Y, 1985, J ALLERGY CLIN IMMUN, V75, P285, DOI 10.1016/0091-6749(85)90059-4; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PEPYS J, 1968, LANCET, V2, P134; PEPYS J, 1974, CLIN ALLERGY, V4, P13, DOI 10.1111/j.1365-2222.1974.tb01358.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PLATTSMILLS TAE, 1982, LANCET, V2, P675; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROCCHICCIOLI K, 1984, THORAX, V39, P706; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; TATTERSFIELD AE, 1981, THORAX, V36, P561, DOI 10.1136/thx.36.8.561; THORPE JE, 1987, CHEST, V91, P21, DOI 10.1378/chest.91.1.21; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905	37	113	113	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				764	770		10.1016/0091-6749(88)90077-2	http://dx.doi.org/10.1016/0091-6749(88)90077-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3192861				2022-12-18	WOS:A1988R170800009
J	SAXON, A; ADELMAN, DC; PATEL, A; HAJDU, R; CALANDRA, GB				SAXON, A; ADELMAN, DC; PATEL, A; HAJDU, R; CALANDRA, GB			IMIPENEM CROSS-REACTIVITY WITH PENICILLIN IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MERCK & CO INC,MERCK SHARPE & DOHME RES LABS,W POINT,PA	Merck & Company	SAXON, A (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,10833 LECONTE AVE,52-175 CHS,LOS ANGELES,CA 90024, USA.							ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; AHLSTEDT S, 1984, ALLERGY, V39, P151, DOI 10.1111/j.1398-9995.1984.tb02619.x; ASHTON WT, 1980, 20TH INT C ANT AG CH, P271; GEDDES AM, 1985, REV INFECT DIS, V7, pS353; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; KABINS SA, 1965, J AMER MED ASSOC, V193, P165, DOI 10.1001/jama.1965.03090020079028; KROPP H, 1982, ANTIMICROB AGENTS CH, V22, P62, DOI 10.1128/AAC.22.1.62; LEVINE BB, 1969, INT ARCH ALLER A IMM, V35, P445, DOI 10.1159/000230197; Ratcliffe R. W., 1982, CHEM BIOL BETA LACTA, V2, P227; REMINGTON JS, 1985, AM J MED, V78, P1, DOI 10.1016/0002-9343(85)90096-8; SAXON A, 1984, J INFECT DIS, V149, P16, DOI 10.1093/infdis/149.1.16; SAXON A, 1983, Reviews of Infectious Diseases, V5, pS368; SAXON A, IN PRESS ANN INTERN	13	113	117	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					213	217		10.1016/0091-6749(88)91001-9	http://dx.doi.org/10.1016/0091-6749(88)91001-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	2457043	Bronze			2022-12-18	WOS:A1988P874100011
J	NOVEMBRE, E; DEMARTINO, M; VIERUCCI, A				NOVEMBRE, E; DEMARTINO, M; VIERUCCI, A			FOODS AND RESPIRATORY ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORENCE,DEPT PEDIAT,DIV CLIN IMMUNOL,I-50121 FLORENCE,ITALY	University of Florence								ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BALLOW M, 1980, J ALLERGY CLIN IMMUN, V66, P112, DOI 10.1016/0091-6749(80)90057-3; BELLANTI JA, 1981, ANN ALLERGY, V47, P260; BESSOT JC, 1985, MED HYG, V43, P2704; BIENENSTOCK J, 1984, NUTR REV, V42, P105, DOI 10.1111/j.1753-4887.1984.tb02298.x; BJORKSTEIN F, 1984, NUTR REV, V42, P131; CANT AJ, 1984, BRIT MED J, V288, P755, DOI 10.1136/bmj.288.6419.755; DECHAMP C, 1984, PRESSE MED, V13, P147; DEMARTINO M, UNPUB ALLERGY; HEINER DC, 1984, ANN ALLERGY, V53, P657; HEINER DC, 1960, AM J DIS CHILD, V100, P500; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; Lessof M. H., 1983, Clinical reactions to food, P103; MARCUCCI F, 1985, CLIN ALLERGY, V15, P345, DOI 10.1111/j.1365-2222.1985.tb03002.x; MATHINSON DA, 1985, CHEST, V875, P50; METCALFE DD, 1984, J ALLERGY CLIN IMMUN, V73, P749, DOI 10.1016/0091-6749(84)90442-1; MIADONNA A, 1983, CLIN ALLERGY, V13, P155, DOI 10.1111/j.1365-2222.1983.tb02583.x; MINFORD AMB, 1982, ARCH DIS CHILD, V57, P742, DOI 10.1136/adc.57.10.742; MONNERETVAUTRIN DA, 1985, MED HYG, V43, P1118; MONNERETVAUTRIN DA, 1986, MED HYG, V44, P926; NOVEMBRE E, UNPUB PED MED CHIR; OEHLING A, 1981, RESPIRATION S, V42, P44; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; PAGANELLI R, 1979, LANCET, V1, P1270; PAPAGEORGIOU N, 1983, J ALLERGY CLIN IMMUN, V72, P75, DOI 10.1016/0091-6749(83)90055-6; PELIKAN Z, 1985, ANN ALLERGY, V55, P387; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; WILSON N, 1982, BRIT MED J, V284, P1226, DOI 10.1136/bmj.284.6324.1226; WILSON N, 1985, J ROY SOC MED, V78, P11; WILSON NM, 1985, EUR J RESPIR DIS, V66, P25	32	113	117	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			1059	1065		10.1016/0091-6749(88)90181-9	http://dx.doi.org/10.1016/0091-6749(88)90181-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3286733				2022-12-18	WOS:A1988N703700026
J	STEVENSON, DD; SIMON, RA; LUMRY, WR; MATHISON, DA				STEVENSON, DD; SIMON, RA; LUMRY, WR; MATHISON, DA			ADVERSE REACTIONS TO TARTRAZINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN, RES INST, DIV ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA; SCRIPPS CLIN & RES FDN, RES INST, DEPT CLIN RES, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR-00833] Funding Source: Medline; NIAID NIH HHS [AI-10386] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; DOEGLAS HMG, 1975, BRIT J DERMATOL, V93, P135, DOI 10.1111/j.1365-2133.1975.tb06732.x; FITZGERALD MX, 1973, NEW ENGL J MED, V289, P1283, DOI 10.1056/NEJM197312132892406; FREEDMAN BJ, 1977, CLIN ALLERGY, V7, P407, DOI 10.1111/j.1365-2222.1977.tb01471.x; GERBER JG, 1979, J ALLERGY CLIN IMMUN, V63, P289, DOI 10.1016/0091-6749(79)90115-5; GIBSON A, 1980, CLIN ALLERGY, V10, P699, DOI 10.1111/j.1365-2222.1980.tb02154.x; HARIPARSAD D, 1984, CLIN ALLERGY, V14, P81, DOI 10.1111/j.1365-2222.1984.tb02194.x; JUHLIN L, 1981, BRIT J DERMATOL, V104, P369, DOI 10.1111/j.1365-2133.1981.tb15306.x; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; KROY RC, 1963, AM REV RESPIR DIS, V87, P228; LOCKEY STEPHEN D., 1959, ANN ALLERGY, V17, P719; MATHISON DA, 1979, J ALLERGY CLIN IMMUN, V64, P669, DOI 10.1016/0091-6749(79)90036-8; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MICHAELSSON G, 1973, BRIT J DERMATOL, V88, P525, DOI 10.1111/j.1365-2133.1973.tb08014.x; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; ROS AM, 1976, BRIT J DERMATOL, V95, P19, DOI 10.1111/j.1365-2133.1976.tb15532.x; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; SETTIPANE GA, 1976, J ALLERGY CLIN IMMUN, V57, P541, DOI 10.1016/0091-6749(76)90004-X; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; Speer K., 1958, MANAGEMENT CHILDHOOD, P23; STENIUS BSM, 1976, CLIN ALLERGY, V6, P119, DOI 10.1111/j.1365-2222.1976.tb01889.x; TARLO SM, 1982, CLIN ALLERGY, V12, P303, DOI 10.1111/j.1365-2222.1982.tb02532.x; THUNE P, 1975, DERMATOLOGICA, V151, P360, DOI 10.1159/000251361; VEDANTHAN PK, 1977, J ALLERGY CLIN IMMUN, V60, P8, DOI 10.1016/0091-6749(77)90077-X; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0	27	113	114	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	2	S			182	191		10.1016/0091-6749(86)90011-4	http://dx.doi.org/10.1016/0091-6749(86)90011-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2997	3722646				2022-12-18	WOS:A1986D299700011
J	Blanco, E; Perez-Andres, M; Arriba-Mendez, S; Contreras-Sanfeliciano, T; Criado, I; Pelak, O; Serra-Caetano, A; Romero, A; Puig, N; Remesal, A; Canizales, JT; Lopez-Granados, E; Kalina, T; Sousa, AE; van Zelm, M; van der Burg, M; van Dongen, JJM; Orfao, A				Blanco, Elena; Perez-Andres, Martin; Arriba-Mendez, Sonia; Contreras-Sanfeliciano, Teresa; Criado, Ignacio; Pelak, Ondrej; Serra-Caetano, Ana; Romero, Alfonso; Puig, Noemi; Remesal, Ana; Canizales, Juan Torres; Lopez-Granados, Eduardo; Kalina, Tomas; Sousa, Ana E.; van Zelm, Menno; van der Burg, Mirjam; van Dongen, Jacques J. M.; Orfao, Alberto		EuroFlow PID Grp	Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunoglobulins; IgH isotype; subclass; memory B cells; plasma cells; flow cytometry; reference ranges; normal B cells; age-related values	IGG SUBCLASS CONCENTRATIONS; MINIMAL RESIDUAL DISEASE; REFERENCE VALUES; SERUM-LEVELS; HEALTHY-CHILDREN; REFERENCE RANGES; EARLY-CHILDHOOD; FLOW-CYTOMETRY; MEMORY; ADULTS	Background: Humoral immunocompetence develops stepwise throughout life and contributes to individual susceptibility to infection, immunodeficiency, autoimmunity, and neoplasia. Immunoglobulin heavy chain (IgH) isotype serum levels can partly explain such age-related differences, but their relationship with the IgH isotype distribution within memory Bcell (MBC) and plasma cell (PCs) compartments remains to be investigated. Objective: We studied the age-related distribution of MBCs and PCs expressing different IgH isotypes in addition to the immature/transitional and naive B-cell compartments. Methods: B-cell and PC subsets and plasma IgH isotype levels were studied in cord blood (n = 19) and peripheral blood (n = 215) from healthy donors aged 0 to 90 years by using flow cytometry and nephelometry, respectively. Results: IgH-switched MBCs expressing IgG(1), IgG(2), IgG(3), IgA(1), and IgA(2) were already detected in cord blood and newborns at very low counts, whereas CD27 1 IgM 11 IgD 1 MBCs only became detectable at 1 to 5 months and remained stable until 2 to 4 years, and IgD MBCs peaked at 2 to 4 years, with both populations decreasing thereafter. MBCs expressing IgH isotypes of the second immunoglobulin heavy chain constant region (IGHC) gene block (IgG(1), IgG(3), and IgA(1)) peaked later during childhood (2-4 years), whereas MBCs expressing third IGHC gene block immunoglobulin isotypes (IgG2, IgG4, and IgA2) reached maximum values during adulthood. PCs were already detected in newborns, increasing in number until 6 to 11 months for IgM, IgG(1), IgG(2), IgG(3), IgA(1), and IgA(2); until 2 to 4 years for IgD; and until 5 to 9 years for IgG(4) and decreasing thereafter. For most IgH isotypes (except IgD and IgG4), maximum plasma levels were reached after PC and MBC counts peaked. Conclusions: PC counts reach maximum values early in life, followed by MBC counts and plasma IgH isotypes. Importantly, IgH isotypes from different IGHC gene blocks show different patterns, probably reflecting consecutive cycles of IgH isotype switch recombination through life.	[Blanco, Elena; Perez-Andres, Martin; Criado, Ignacio; Orfao, Alberto] Univ Salamanca, Inst Biomed Res Salamanca IBSAL, Canc Res Ctr IBMCC, Dept Med,USAL CSIC,Cytometry Serv NUCLEUS, Salamanca, Spain; [Blanco, Elena; Perez-Andres, Martin; Criado, Ignacio; Orfao, Alberto] Inst Salud Carlos III, Biomed Res Networking Ctr Consortium Oncol CIBERO, Madrid, Spain; [Arriba-Mendez, Sonia; Remesal, Ana] Hosp Univ Salamanca, Serv Pediat, Salamanca, Spain; [Contreras-Sanfeliciano, Teresa] Hosp Univ Salamanca, Serv Bioquim Clin, Salamanca, Spain; [Puig, Noemi] Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain; [Pelak, Ondrej; Kalina, Tomas] Charles Univ Prague, Fac Med 2, Dept Haematol Oncol, CLIP, Prague, Czech Republic; [Serra-Caetano, Ana] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal; [Romero, Alfonso; Sousa, Ana E.] Sanidad Castilla & Leon SACYL, Ctr Salud Miguel Armijo, Salamanca, Spain; [Canizales, Juan Torres; Lopez-Granados, Eduardo] Hosp Univ La Paz, Dept Inmunol, Madrid, Spain; [van Zelm, Menno] Monash Univ, Dept Pathol & Immunol, Melbourne, Vic, Australia; [van Zelm, Menno] Alfred Hosp, Melbourne, Vic, Australia; [van Zelm, Menno; van der Burg, Mirjam] Erasmus Univ, Med Ctr Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [van Dongen, Jacques J. M.] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Instituto de Salud Carlos III; University of Salamanca; Charles University Prague; Universidade de Lisboa; Hospital Universitario La Paz; Monash University; Florey Institute of Neuroscience & Mental Health; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Orfao, A (corresponding author), Univ Salamanca, Dept Med, Canc Res Ctr, Paseo Univ Coimbra S-N, Salamanca 37007, Spain.	orfao@usal.es	Orfao, Alberto/B-5801-2017; Criado, Ignacio/ABF-7031-2020; Kalina, Tomas/AAC-6655-2019; Kalina, Tomas/AAE-5036-2019; Kalina, Tomas/C-1078-2009; De Arriba Méndez, Sonia/AAC-1234-2020; Perez-Andres, Martin/B-3692-2019; De Arriba Méndez, Sonia/B-4856-2019; van Zelm, Menno/O-4404-2015; Sousa, Ana E./L-2642-2014	Kalina, Tomas/0000-0003-4475-2872; Kalina, Tomas/0000-0003-4475-2872; Perez-Andres, Martin/0000-0003-4599-0776; De Arriba Méndez, Sonia/0000-0003-1990-4125; Torres Canizales, Juan/0000-0002-7138-5732; Blanco Alvarez, Elena/0000-0002-8150-5646; van Dongen, Jacques J.M./0000-0002-3650-7087; Criado, Ignacio/0000-0003-4120-343X; Pelak, Ondrej/0000-0002-5758-7135; van Zelm, Menno/0000-0003-4161-1919; Sousa, Ana E./0000-0002-4618-9799; Caetano, Ana/0000-0002-1626-4364	Junta de Castilla y Leon (Fondo Social Europeo, Valladolid, Spain) [ORDEN EDU/346/2013]; CIBERONC, Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid, Spain [CB16/12/00400]; FONDOS FEDER [CB16/12/00400]; Fondo de Investigaciones Sanitarias of Instituto de Salud Carlos III (Madrid, Spain) [FIS PI12/00905-FEDER]; Ministry of Education, Youth and Sports (NPU I) [LO1604, 15-28541A]	Junta de Castilla y Leon (Fondo Social Europeo, Valladolid, Spain); CIBERONC, Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid, Spain; FONDOS FEDER(European Commission); Fondo de Investigaciones Sanitarias of Instituto de Salud Carlos III (Madrid, Spain); Ministry of Education, Youth and Sports (NPU I)	E.B. was supported by a grant from Junta de Castilla y Leon (Fondo Social Europeo, ORDEN EDU/346/2013, Valladolid, Spain). This work was supported by the CB16/12/00400 grant (CIBERONC, Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid, Spain, and FONDOS FEDER) and the FIS PI12/00905-FEDER grant from the Fondo de Investigaciones Sanitarias of Instituto de Salud Carlos III (Madrid, Spain). O.P. and T.K. were supported by the Ministry of Education, Youth and Sports (NPU I no. LO1604 and 15-28541A). The coordination and innovation processes of this study were supported by the EuroFlow Consortium.	Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; ALLANSMITH M, 1968, J PEDIATR-US, V72, P276, DOI 10.1016/S0022-3476(68)80324-5; BAKE AWLV, 1988, CLIN EXP IMMUNOL, V74, P115; BARZANJI AJ, 1978, EARLY HUM DEV, V1, P363, DOI 10.1016/0378-3782(78)90044-0; Berkowska MA, 2014, J ALLERGY CLIN IMMUN, V134, P688, DOI 10.1016/j.jaci.2014.03.036; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Berth M, 1999, CLIN CHEM, V45, P309; BIRD D, 1985, ARCH DIS CHILD, V60, P204, DOI 10.1136/adc.60.3.204; Blanco E, 2017, J IMMUNOL METHODS; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; Caraux A, 2010, HAEMATOL-HEMATOL J, V95, P1016, DOI 10.3324/haematol.2009.018689; Carr EJ, 2016, NAT IMMUNOL, V17, P461, DOI 10.1038/ni.3371; CEROTTINI JC, 1969, J IMMUNOL, V102, P1008; Collins AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00235; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; CONLEY ME, 1983, MOL IMMUNOL, V20, P977, DOI 10.1016/0161-5890(83)90038-X; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P118, DOI 10.1016/j.jaci.2015.08.027; Fecteau JF, 2006, J IMMUNOL, V177, P3728, DOI 10.4049/jimmunol.177.6.3728; Flores-Montero J, 2017, LEUKEMIA, V31, P2094, DOI 10.1038/leu.2017.29; Freeman JA, 2013, LEUKEMIA LYMPHOMA, V54, P99, DOI 10.3109/10428194.2012.706285; Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105; GRIFFIOEN AW, 1991, INFECT IMMUN, V59, P1839, DOI 10.1128/IAI.59.5.1839-1845.1991; Grimbacher B, 2014, CLIN EXP IMMUNOL, V178, P18, DOI 10.1111/cei.12496; Gronlund MM, 2000, ARCH DIS CHILD-FETAL, V83, pF186, DOI 10.1136/fn.83.3.F186; Halista SM, 1998, PEDIATR RES, V43, P496, DOI 10.1203/00006450-199804000-00010; Hannoun C, 2004, VIRUS RES, V103, P133, DOI 10.1016/j.virusres.2004.02.025; Haraldsson A, 2000, SCAND J IMMUNOL, V51, P415; Jackson KJL, 2014, IMMUNOL CELL BIOL, V92, P729, DOI 10.1038/icb.2014.44; Jansen MAE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126019; Jensen K, 2010, PEDIATR HEMAT ONCOL, V27, P31, DOI 10.3109/08880010903420687; JOHNSTON RB, 1979, PEDIATRICS, V64, P781; Kalina T, 2012, LEUKEMIA, V26, P1986, DOI 10.1038/leu.2012.122; LUSCIETI P, 1980, J CLIN PATHOL, V33, P454, DOI 10.1136/jcp.33.5.454; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; Manz RA, 2005, ANNU REV IMMUNOL, V23, P367, DOI 10.1146/annurev.immunol.23.021704.115723; Martins TB, 2014, J ALLERGY CLIN IMMUN, V133, P589, DOI 10.1016/j.jaci.2013.08.037; Melegaro A, 2004, EUR J EPIDEMIOL, V19, P365, DOI 10.1023/B:EJEP.0000024752.48929.bd; Rudolf-Oliveira RCM, 2015, IMMUNOL LETT, V163, P96, DOI 10.1016/j.imlet.2014.11.003; MOLLER G, 1965, J EXP MED, V121, P969, DOI 10.1084/jem.121.6.969; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Naradikian MS, 2016, IMMUNOL REV, V269, P118, DOI 10.1111/imr.12380; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; OCHS HD, 1987, ANNU REV MED, V38, P325, DOI 10.1146/annurev.me.38.020187.001545; OZAWA N, 1986, TRANSFUSION, V26, P73, DOI 10.1046/j.1537-2995.1986.26186124037.x; PEDRAZ C, 1980, AN ESP PEDIATR, V13, P571; Perez-Andres M, 2010, CYTOM PART B-CLIN CY, V78B, pS47, DOI 10.1002/cyto.b.20547; Piatosa B, 2010, CYTOM PART B-CLIN CY, V78B, P372, DOI 10.1002/cyto.b.20536; Pihlgren M, 2006, J IMMUNOL, V176, P165, DOI 10.4049/jimmunol.176.1.165; PLEBANI A, 1989, EUR J PEDIATR, V149, P164, DOI 10.1007/BF01958271; Pupovac A, 2017, CURR OPIN IMMUNOL, V45, P89, DOI 10.1016/j.coi.2017.03.004; Rohner GB, 2008, J IMMUNOL, V180, P2165, DOI 10.4049/jimmunol.180.4.2165; Sanchez ML, 2002, LEUKEMIA, V16, P1460, DOI 10.1038/sj.leu.2402584; Sanoja-Flores L, 2015, BLOOD, V126; Schauer U, 2003, CLIN CHIM ACTA, V328, P129, DOI 10.1016/S0009-8981(02)00418-7; Schauer U, 2003, CLIN CHEM, V49, P1924, DOI 10.1373/clinchem.2003.022350; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Siegrist CA, 2008, VACCINE IMMUNOL, P17; Siegrist CA, 2009, NAT REV IMMUNOL, V9, P185, DOI 10.1038/nri2508; Sims GP, 2005, BLOOD, V105, P4390, DOI 10.1182/blood-2004-11-4284; STIEHM ER, 1966, PEDIATRICS, V37, P715; Thiel J, 2012, J ALLERGY CLIN IMMUN, V129, P801, DOI 10.1016/j.jaci.2011.09.027; van den Heuvel D, 2017, J ALLERGY CLIN IMMUN, V139, P1923, DOI 10.1016/j.jaci.2016.10.023; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; van Twillert I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085227; VANDERGIESSEN M, 1975, CLIN EXP IMMUNOL, V21, P501; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; VLUG A, 1994, ANN BIOL CLIN-PARIS, V52, P561; Weinberger B, 2008, CLIN INFECT DIS, V46, P1078, DOI 10.1086/529197; WESTERGA J, 1989, SCAND J IMMUNOL, V29, P103, DOI 10.1111/j.1365-3083.1989.tb01104.x; Wong KJ, 2015, ALLERGY, V70, P420, DOI 10.1111/all.12563; Woof JM, 2011, MUCOSAL IMMUNOL, V4, P590, DOI 10.1038/mi.2011.39; Zhang HZ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000387	72	112	113	3	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2208	+		10.1016/j.jaci.2018.02.017	http://dx.doi.org/10.1016/j.jaci.2018.02.017			28	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29505809	Green Published, hybrid			2022-12-18	WOS:000434701600025
J	Teach, SJ; Gergen, PJ; Szefler, SJ; Mitchell, HE; Calatroni, A; Wildfire, J; Bloomberg, GR; Kercsmar, CM; Liu, AH; Makhija, MM; Matsui, E; Morgan, W; O'Connor, G; Busse, WW				Teach, Stephen J.; Gergen, Peter J.; Szefler, Stanley J.; Mitchell, Herman E.; Calatroni, Agustin; Wildfire, Jeremy; Bloomberg, Gordon R.; Kercsmar, Carolyn M.; Liu, Andrew H.; Makhija, Melanie M.; Matsui, Elizabeth; Morgan, Wayne; O'Connor, George; Busse, William W.			Seasonal risk factors for asthma exacerbations among inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; seasons; biomarkers; asthma exacerbations; IgE; exhaled nitric oxide; allergy; eosinophils; pulmonary function	EXHALED NITRIC-OXIDE; CHILDHOOD ASTHMA; TRIAL; ADOLESCENTS; INFECTIONS; ADULTS; EPIDEMIOLOGY; OMALIZUMAB; EXPOSURE; ALLERGEN	Background: Asthma exacerbations remain common, even in children and adolescents, despite optimal medical management. Identification of host risk factors for exacerbations is incomplete, particularly for seasonal episodes. Objective: We sought to define host risk factors for asthma exacerbations unique to their season of occurrence. Methods: This is a retrospective analysis of patients aged 6 to 20 years who comprised the control groups of the Asthma Control Evaluation study and the Inner City Anti-IgE Therapy for Asthma study. Univariate and multivariate models were constructed to determine whether patients' demographic and historical factors, allergic sensitization, fraction of exhaled nitric oxide values, spirometric measurements, asthma control, and treatment requirements were associated with seasonal exacerbations. Results: The analysis included 400 patients (54.5% male; 59.0% African American; median age, 13 years). Exacerbations occurred in 37.5% of participants over the periods of observation and were most common in the fall (28.8% of participants). In univariate analysis impaired pulmonary function was significantly associated with greater odds of exacerbations for all seasons, as was an exacerbation in the previous season for all seasons except spring. In multivariate analysis exacerbation in the previous season was the strongest predictor in fall and winter, whereas a higher requirement for inhaled corticosteroids was the strongest predictor in spring and summer. The multivariate models had the best predictive power for fall exacerbations (30.5% variance attributed). Conclusions: Among a large cohort of inner-city children with asthma, patients' risk factors for exacerbation vary by season. Thus information on individual patients might be beneficial in strategies to prevent these seasonal events.	[Teach, Stephen J.] Childrens Natl Hlth Syst, Washington, DC 20010 USA; [Teach, Stephen J.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; [Gergen, Peter J.] NIAID, Bethesda, MD 20892 USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Aurora, CO USA; [Szefler, Stanley J.] Univ Colorado Denver, Sch Med, Aurora, CO USA; [Mitchell, Herman E.; Calatroni, Agustin; Wildfire, Jeremy] Rho Fed Syst Div, Chapel Hill, NC USA; [Bloomberg, Gordon R.] Washington Univ, Sch Med, St Louis, MO 63130 USA; [Kercsmar, Carolyn M.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Liu, Andrew H.] Natl Jewish Hlth, Denver, CO USA; [Liu, Andrew H.] Univ Colorado, Childrens Hosp Colorado, Sch Med, Aurora, CO USA; [Makhija, Melanie M.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Matsui, Elizabeth] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Morgan, Wayne] Univ Arizona, Coll Med, Tucson, AZ USA; [O'Connor, George] Boston Univ, Sch Med, Boston, MA 02118 USA; [Busse, William W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA	Children's National Health System; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Children's Hospital Colorado; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Washington University (WUSTL); Cincinnati Children's Hospital Medical Center; National Jewish Health; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Ann & Robert H. Lurie Children's Hospital of Chicago; Johns Hopkins University; University of Arizona; Boston University; University of Wisconsin System; University of Wisconsin Madison	Teach, SJ (corresponding author), Childrens Natl Hlth Syst, 111 Michigan Ave NW, Washington, DC 20010 USA.	steach@childrensnational.org		Szefler, Stanley/0000-0002-6911-3199; Matsui, Elizabeth/0000-0001-8134-5593	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, HHSN272201000052I]; National Center for Research Resources, National Institutes of Health [RR00052, M01RR00533, UL1 RR024982, M01RR00071, 5M01RR020359-04, 1UL1RR025771, 1UL1RR025780, 1UL1RR024156, UL1RR031988, UL1RR025741, UL1TR000451]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001105, UL1TR000451, UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025771, UL1RR031988, M01RR020359, M01RR000071, M01RR000533, UL1RR025741, UL1RR024982, UL1RR025780, UL1RR024156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract nos. NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, and HHSN272201000052I. Additional support was provided by the National Center for Research Resources, National Institutes of Health, under grants RR00052, M01RR00533, UL1 RR024982, M01RR00071, 5M01RR020359-04, 1UL1RR025771, 1UL1RR025780, 1UL1RR024156, UL1RR031988, UL1RR025741, and UL1TR000451. Lincoln Diagnostics provided the Multi-Test, and GlaxoSmithKline (GSK) provided study drug for Asthma Control Evaluation study participants. Novartis Pharmaceuticals provided study drug under a clinical trial agreement with the University of Wisconsin-Madison, Dey Pharma provided EpiPens, and SC Johnson provided household pest control for Inner City Anti-IgE Therapy for Asthma study participants. None of these companies had a role in the development or approval of the protocol, conduct of the trial, data analysis, manuscript preparation, or the decision to submit for publication.	Bateman ED, 2015, J ALLERGY CLIN IMMUN, V135, P1457, DOI 10.1016/j.jaci.2014.08.015; Bloomberg GR, 2003, AM J RESP CRIT CARE, V167, P1068, DOI 10.1164/rccm.2201015; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; CHEVAN A, 1991, AM STAT, V45, P90, DOI 10.2307/2684366; Cohen HA, 2014, PEDIATRICS, V133, pE923, DOI 10.1542/peds.2013-2022; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Forno E, 2012, CURR OPIN PULM MED, V18, P63, DOI 10.1097/MCP.0b013e32834db288; Forno E, 2010, CHEST, V138, P1156, DOI 10.1378/chest.09-2426; Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003; Gergen PJ, 2002, J PEDIATR-US, V141, P631, DOI 10.1067/mpd.2002.127510; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P921, DOI 10.1016/j.jaci.2009.09.006; Ivanova JI, 2012, J ALLERGY CLIN IMMUN, V129, P1229, DOI 10.1016/j.jaci.2012.01.039; Johnston NW, 2006, THORAX, V61, P722, DOI 10.1136/thx.2005.045161; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; McCormack MC, 2013, CHEST, V144, P923, DOI 10.1378/chest.12-3098; Moorman J.E., 2012, VITAL HEALTH STAT, V3, P1; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; National Heart Lung and Blood Institute, 2007, NIH PUBLICATION, V07-4051; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Schatz M, 2013, J ALLER CL IMM-PRACT, V1, P618, DOI 10.1016/j.jaip.2013.07.009; Sears MR, 2008, J ALLERGY CLIN IMMUN, V122, P662, DOI 10.1016/j.jaci.2008.08.003; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Tarlo SM, 2001, J ALLERGY CLIN IMMUN, V108, P52, DOI 10.1067/mai.2001.116574; Wang Li Yan, 2005, Prev Chronic Dis, V2, pA11; Wildfire JJ, 2012, J ALLERGY CLIN IMMUN, V129, P694, DOI 10.1016/j.jaci.2011.12.962; Williams JV, 2005, J INFECT DIS, V192, P1149, DOI 10.1086/444392	34	112	112	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1465	U116		10.1016/j.jaci.2014.12.1942	http://dx.doi.org/10.1016/j.jaci.2014.12.1942			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25794658	Green Accepted			2022-12-18	WOS:000355933400008
J	Burton, OT; Logsdon, SL; Zhou, JS; Medina-Tamayo, J; Abdel-Gadir, A; Rivas, MN; Koleoglou, KJ; Chatila, TA; Schneider, LC; Rachid, R; Umetsu, DT; Oettgen, HC				Burton, Oliver T.; Logsdon, Stephanie L.; Zhou, Joseph S.; Medina-Tamayo, Jaciel; Abdel-Gadir, Azza; Rivas, Magali Noval; Koleoglou, Kyle J.; Chatila, Talal A.; Schneider, Lynda C.; Rachid, Rima; Umetsu, Dale T.; Oettgen, Hans C.			Oral immunotherapy induces IgG antibodies that act through Fc gamma RIIb to suppress IgE-mediated hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; tolerance; anaphylaxis; IgE; desensitization; oral immunotherapy	SYSTEMIC-ANAPHYLAXIS; HISTAMINE-RELEASE; MURINE MODEL; MAST-CELLS; ALLERGY; RECEPTORS; DESENSITIZATION; IMMUNIZATION; INHIBITION; ACTIVATION	Background: Food-induced anaphylaxis is triggered by specific IgE antibodies. Paradoxically, some subjects with significant IgE levels can ingest allergenic foods without incident. Similarly, subjects completing oral immunotherapy (OIT) tolerate food challenges despite persistent high-titer food-specific IgE. Objective: We sought to test whether IgG antibodies induced by food immunotherapy prevent food-induced anaphylaxis and whether this occurs through the inhibitory receptor Fc gamma RIIb. Methods: Food allergy-susceptible Il4raF709 mice were enterally sensitized to ovalbumin (OVA). Similarly sensitized IgE-deficient (IgE(-/-)) Il4raF709 mice, which can ingest OVA without anaphylaxis, were subjected to a high-dose enteral OVA desensitization protocol (OIT). Sera from both groups were tested for the ability to activate or inhibit bone marrow mast cells (BMMCs) exposed to allergen or to passively transfer allergy to naive hosts. In parallel experiments sera obtained from patients with peanut allergy before and after undergoing OIT were interrogated for their ability to enhance or suppress peanut-induced activation in an indirect assay by using basophils from nonallergic donors. Results: Il4raF709 mice exhibited strong OVA-specific IgE responses. Their sera efficiently sensitized BMMCs for activation by antigen challenge. Sera from Il4raF709/IgE(-/-) mice subjected to OVA OIT suppressed BMMC responses. This inhibition was IgG mediated and Fc gamma RIIb dependent. Similarly, pre-OIT but not post-OIT sera from patients efficiently sensitized basophils for peanut-induced activation. IgG antibodies in post-OIT sera suppressed basophil activation by pre-OIT sera. This inhibition was blocked by antibodies against Fc gamma RII. Conclusion: Food-specific IgG antibodies, such as those induced during OIT, inhibit IgE-mediated reactions. Strategies that favor IgG responses might prove useful in the management of food allergy.	[Burton, Oliver T.; Logsdon, Stephanie L.; Zhou, Joseph S.; Medina-Tamayo, Jaciel; Abdel-Gadir, Azza; Rivas, Magali Noval; Koleoglou, Kyle J.; Chatila, Talal A.; Schneider, Lynda C.; Rachid, Rima; Umetsu, Dale T.; Oettgen, Hans C.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Burton, Oliver T.; Logsdon, Stephanie L.; Zhou, Joseph S.; Medina-Tamayo, Jaciel; Abdel-Gadir, Azza; Rivas, Magali Noval; Chatila, Talal A.; Schneider, Lynda C.; Rachid, Rima; Umetsu, Dale T.; Oettgen, Hans C.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University	Oettgen, HC (corresponding author), Boston Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	hans.oettgen@childrens.harvard.edu	Noval Rivas, Magali/R-4987-2016	Noval Rivas, Magali/0000-0001-5570-8928; Burton, Oliver/0000-0003-3884-7373; Oettgen, Hans/0000-0003-1199-1391; Chatila, Talal/0000-0001-7439-2762; Abdel-Gadir, Azza/0000-0003-4210-9445	National Institutes of Health [NIAID R56 AI100889, 5T32AI007512-24, UL1 RR 025758]; Thrasher Foundation; Bunning Food Allergy Project; Jasmine and Paul Mashikian Fund; Genentech; Consejo Nacional de Ciencia y Tecnologia (CONACyT) [207999]; Department of Defense: DOD [11-1-0553]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI100889, T32AI007512] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Thrasher Foundation; Bunning Food Allergy Project; Jasmine and Paul Mashikian Fund; Genentech(Roche HoldingGenentech); Consejo Nacional de Ciencia y Tecnologia (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Department of Defense: DOD(United States Department of Defense); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants NIAID R56 AI100889 (to H.C.O.), 5T32AI007512-24 (to O.T.B., S.L.L., and J.S.Z.), and UL1 RR 025758 (to D.T.U.) and by grants from the Thrasher Foundation (to D.T.U.), the Bunning Food Allergy Project (to D.T.U., H.C.O., and R.R.), the Jasmine and Paul Mashikian Fund (to D.T.U.), Genentech (to D.T.U.), Consejo Nacional de Ciencia y Tecnologia (CONACyT) grant 207999 (to J.M.-T.), and the Department of Defense: DOD 11-1-0553 (to T.A.C.).	AALBERSE RC, 1983, J IMMUNOL, V130, P722; Bedoret D, 2012, MUCOSAL IMMUNOL, V5, P267, DOI 10.1038/mi.2012.5; Begin P, 2013, PEDIATR ANN, V42, P102, DOI 10.3928/00904481-20130522-10; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; Burton OT, 2013, MUCOSAL IMMUNOL, V6, P740, DOI 10.1038/mi.2012.112; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; Caubet JC, 2012, J ALLERGY CLIN IMMUN, V129, P739, DOI 10.1016/j.jaci.2011.11.053; Caubet JC, 2012, IMMUNOL ALLERGY CLIN, V32, P97, DOI 10.1016/j.iac.2011.11.002; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Flicker S, 2011, CURR TOP MICROBIOL, V352, P141, DOI 10.1007/82_2011_143; Foger N, 2011, J EXP MED, V208, P1777, DOI 10.1084/jem.20101757; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Kucuk ZY, 2012, J ALLERGY CLIN IMMUN, V129, P1343, DOI 10.1016/j.jaci.2012.03.004; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V129, P1579, DOI 10.1016/j.jaci.2012.04.009; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; Liu Y, 2013, J ALLERGY CLIN IMMUN, V131, P213, DOI 10.1016/j.jaci.2012.10.018; MacGlashan DW, 2013, J ALLERGY CLIN IMMUN, V132, P777, DOI 10.1016/j.jaci.2013.06.038; Malbec O, 2007, IMMUNOL REV, V217, P206, DOI 10.1111/j.1600-065X.2007.00510.x; Mathias CB, 2011, J ALLERGY CLIN IMMUN, V127, P795, DOI 10.1016/j.jaci.2010.11.009; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Pemberton AD, 2006, J IMMUNOL, V176, P899, DOI 10.4049/jimmunol.176.2.899; Savilahti EM, 2010, J ALLERGY CLIN IMMUN, V125, P1315, DOI 10.1016/j.jaci.2010.03.025; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Smith KGC, 2010, NAT REV IMMUNOL, V10, P328, DOI 10.1038/nri2762; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Tam SW, 2004, ALLERGY, V59, P772, DOI 10.1111/j.1398-9995.2004.00332.x; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; Vickery BP, 2010, ANN ALLERG ASTHMA IM, V105, P444, DOI 10.1016/j.anai.2010.09.030; Watanabe T, 2004, AM J RESP CRIT CARE, V169, P105, DOI 10.1164/rccm.200302-239OC; Wisniewski J, 2013, CLIN EXP ALLERGY, V43, P164, DOI 10.1111/cea.12016	43	112	114	0	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1310	+		10.1016/j.jaci.2014.05.042	http://dx.doi.org/10.1016/j.jaci.2014.05.042			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25042981	Green Accepted			2022-12-18	WOS:000346075400013
J	Margolis, DJ; Gupta, J; Apter, AJ; Ganguly, T; Hoffstad, O; Papadopoulos, M; Rebbeck, TR; Mitra, N				Margolis, David J.; Gupta, Jayanta; Apter, Andrea J.; Ganguly, Tapan; Hoffstad, Ole; Papadopoulos, Maryte; Rebbeck, Tim R.; Mitra, Nandita			Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; filaggrin; epidemiology; genetic epidemiology; atopy	OF-FUNCTION MUTATIONS; ICHTHYOSIS VULGARIS; RARE MUTATIONS; FLG MUTATIONS; SKIN BARRIER; ECZEMA; DISEASE; CHILDREN; RISK; IDENTIFICATION	Background: Atopic dermatitis (AD) is a common skin disease characterized by recurrent episodes of itching. Genetic variation associated with the persistence of AD has not been described for African American subjects. Objective: We sought to evaluate genetic variation of filaggrin-2 (FLG2) in African American subjects with AD. Methods: We evaluated a multiyear prospective cohort study of African American children with AD with respect to FLG2 variation based on whole-exome sequencing, followed by a targeted analysis. We ultimately evaluated the association of rs12568784 and rs16833974 with respect to the persistence of AD symptoms over time. Results: Whole-exome analysis was conducted on 60 subjects, revealing a premature stop codon in exon 3 at S2377X(rs12568784) and X2392S (rs150529054) and a large exon 3 deletion mutation, Q2053del224. On the basis of a priori criteria, we then studied rs12568784, rs16833974 (H1249R), and Q2053del224. We noted that patients with S2377X (odds ratio [OR], 0.44; 95% CI, 0.25-0.46) and H1249R (OR, 0.23; 05% CI, 0.12-0.46) were significantly less likely to be free of symptoms of AD, and Q2053del224 (OR, 0.54; 95% CI, 0.16-1.80) trended toward this outcome. S2377X and H1249R were in high linkage disequilibrium (D' = 0.95). Conclusions: In an African American cohort with AD, FLG2 mutations were associated with more persistent AD. This is the first finding of genetic variation of a skin barrier protein in subjects of African ancestry with AD.	[Margolis, David J.; Gupta, Jayanta; Hoffstad, Ole; Papadopoulos, Maryte; Rebbeck, Tim R.; Mitra, Nandita] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Margolis, David J.] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Apter, Andrea J.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Ganguly, Tapan] Univ Penn, DNA Sequencing Facil, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Margolis, DJ (corresponding author), 901 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	margo@upenn.edu			National Institute of Arthritis Musculoskeletal and Skin Diseases [R01-AR0056755]; Valeant Pharmaceuticals; NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056755] Funding Source: NIH RePORTER	National Institute of Arthritis Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Valeant Pharmaceuticals; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by R01-AR0056755 from the National Institute of Arthritis Musculoskeletal and Skin Diseases and from a grant from Valeant Pharmaceuticals for the Pediatric Eczema Elective Registry study.	Akiyama M, 2010, BRIT J DERMATOL, V162, P472, DOI 10.1111/j.1365-2133.2009.09582.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Brandt Eric B, 2011, J Clin Cell Immunol, V2; Broccardo CJ, 2011, J ALLERGY CLIN IMMUN, V127, P186, DOI 10.1016/j.jaci.2010.10.033; Brown SJ, 2009, BRIT J DERMATOL, V161, P884, DOI 10.1111/j.1365-2133.2009.09339.x; Brown SJ, 2012, J INVEST DERMATOL, V132, P751, DOI 10.1038/jid.2011.393; Carlsen BC, 2011, BRIT J DERMATOL, V165, P931, DOI 10.1111/j.1365-2133.2011.10550.x; de Koning HD, 2012, BRIT J DERMATOL, V166, P1245, DOI 10.1111/j.1365-2133.2012.10885.x; Donovan M, 2013, J INVEST DERMATOL S, V133, pS109; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Harder J, 2013, EXP DERMATOL, V22, P1, DOI 10.1111/exd.12046; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Henry J, 2012, FRONT BIOSCI-LANDMRK, V17, P1517, DOI 10.2741/4001; Hsu C, 2013, J INVEST DERMATOL, V133, pS124; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564; Kapoor R, 2009, PEDIATR DERMATOL, V26, P682, DOI 10.1111/j.1525-1470.2009.01013.x; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Marenholz I, 2011, J INVEST DERMATOL, V131, P1644, DOI 10.1038/jid.2011.90; Margolis DJ, 2012, J ALLERGY CLIN IMMUN, V130, P912, DOI 10.1016/j.jaci.2012.07.008; Margolis DJ, 2011, J INVEST DERMATOL, V131, P1765, DOI 10.1038/jid.2011.102; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Natsuga K, 2013, J INVEST DERMATOL, V133, pS192; Nielsen R, 2005, ANNU REV GENET, V39, P197, DOI 10.1146/annurev.genet.39.073003.112420; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Rabe-Hesketh S, 2001, GLLAMM MANUAL, P1; Rabe-Hesketh S, 2002, STATA J, V2, P1, DOI 10.1177/1536867X0200200101; Rahman Saifur, 2011, Inflammation & Allergy Drug Targets, V10, P486; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2007, J INVEST DERMATOL, V127, P1282, DOI 10.1038/sj.jid.5700876; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Williams HC, 2000, CLIN EXP DERMATOL, V25, P522, DOI 10.1046/j.1365-2230.2000.00698.x; Winge MCG, 2011, BRIT J DERMATOL, V165, P1074, DOI 10.1111/j.1365-2133.2011.10475.x; Wu ZH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005227	45	112	114	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					784	789		10.1016/j.jaci.2013.09.015	http://dx.doi.org/10.1016/j.jaci.2013.09.015			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24184149	Green Accepted			2022-12-18	WOS:000332397600021
J	Passalacqua, G; Baena-Cagnani, CE; Bousquet, J; Canonica, GW; Casale, TB; Cox, L; Durham, SR; Larenas-Linnemann, D; Ledford, D; Pawankar, R; Potter, P; Rosario, N; Wallace, D; Lockey, RF				Passalacqua, Giovanni; Baena-Cagnani, Carlos E.; Bousquet, Jean; Canonica, Giorgio Walter; Casale, Thomas B.; Cox, Linda; Durham, Stephen R.; Larenas-Linnemann, Desiree; Ledford, Dennis; Pawankar, Ruby; Potter, Paul; Rosario, Nelson; Wallace, Dana; Lockey, Richard F.			Grading local side effects of sublingual immunotherapy for respiratory allergy: Speaking the same language	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sublingual immunotherapy; safety; local side effects; grading	SWALLOW IMMUNOTHERAPY; PEDIATRIC-PATIENTS; CONTROLLED-TRIAL; POLLEN TABLET; SAFETY; EFFICACY; CHILDREN; ANAPHYLAXIS; RHINITIS; ASTHMA	Sublingual immunotherapy (SLIT) is increasingly used worldwide. Despite its safety being well ascertained, there is no universally accepted system to grade and classify its adverse events (AEs). According to the literature, it seems reasonable to classify and grade systemic side effects by using the previously published World Allergy Organization recommendations. On the other hand, local side effects are the most frequent with SLIT, sometimes leading to its discontinuation. Therefore grading of the severity of local side effects was perceived as necessary for the purpose of uniform reporting, classification, and quantification of this aspect. A World Allergy Organization Taskforce, after examining the available literature and the postmarketing surveillance data, proposed a clinically based grading of the severity of local AEs caused by SLIT. The use of the Medical Dictionary for Regulatory Activities nomenclature for AEs was also included in this context. The proposed grading system for SLIT-induced local reactions is expected to improve and harmonize surveillance and reporting of the safety of SLIT.	[Passalacqua, Giovanni; Canonica, Giorgio Walter] Univ Genoa, I-16126 Genoa, Italy; [Baena-Cagnani, Carlos E.] Catholica Univ Cordoba, Cordoba, Spain; [Bousquet, Jean] Hop A de Villeneuve, Univ Hosp, Dept Resp Dis, Montpellier, France; [Casale, Thomas B.] Creighton Univ, Sch Med, Omaha, NE USA; [Cox, Linda] Nova SE Univ, Ft Lauderdale, FL 33314 USA; [Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Larenas-Linnemann, Desiree] Hosp Med Sur, Dept Allergy, Mexico City, DF, Mexico; [Ledford, Dennis; Lockey, Richard F.] Univ S Florida, Tampa, FL USA; [Pawankar, Ruby] Nippon Med Sch, Tokyo 113, Japan; [Potter, Paul] Univ Cape Town, Groote Schuur, South Africa; [Rosario, Nelson] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil; [Wallace, Dana] Amer Coll Allergy Asthma & Immunol, Arlington Hts, IL USA	University of Genoa; Universite de Montpellier; CHU de Montpellier; Creighton University; Nova Southeastern University; Imperial College London; State University System of Florida; University of South Florida; Nippon Medical School; University of Cape Town; Universidade Federal do Parana	Passalacqua, G (corresponding author), Dept Internal Med, Padigl Maragliano,Lgo R Benzi 10, I-16133 Genoa, Italy.	passalacqua@unige.it	canonica, giorgio walter/ABF-2037-2020; Casale, Thomas B/K-4334-2013; Cox, Linda/AAP-1697-2021; Bousquet, Jean/O-4221-2019	canonica, giorgio walter/0000-0001-8467-2557; Casale, Thomas B/0000-0002-3149-7377; Cox, Linda/0000-0002-5258-6870; Larenas Linnemann, Desiree/0000-0002-5713-5331	Stallergenes; Actelion; Almirall; AstraZeneca; Chiesi; GlaxoSmithKline; Merck; MSD; Novartis; OM Pharma; Sanofi-Aventis; Schering-Plough; Teva; Uriach; Meda; ALK-Abello; Circassia; American Academy of Allergy, Asthma Immunology; American Board of Allergy and Immunology; Sharp Dohme (Mexico); Diemsa; Danone; Takeda; Myland Laboratories; Sanofi; ALA; World Allergy Organization	Stallergenes; Actelion; Almirall(Almirall); AstraZeneca(AstraZeneca); Chiesi(Chiesi Pharmaceuticals Inc); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); MSD; Novartis(Novartis); OM Pharma; Sanofi-Aventis(Sanofi-Aventis); Schering-Plough(Merck & CompanySchering Plough Corporation); Teva(Teva Pharmaceutical Industries); Uriach; Meda; ALK-Abello; Circassia; American Academy of Allergy, Asthma Immunology; American Board of Allergy and Immunology; Sharp Dohme (Mexico); Diemsa; Danone(Danone Nutricia); Takeda(Takeda Pharmaceutical Company Ltd); Myland Laboratories(Randox Laboratories); Sanofi; ALA; World Allergy Organization	J. Bousquet is a Board member for and has received one or more payments for lecturing from or is on the speakers' bureau for Stallergenes, Actelion, Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Merck, MSD, Novartis, OM Pharma, Sanofi-Aventis, Schering-Plough, Teva, and Uriach. G. W. Canonica is a Board member for Stallergenes, GlaxoSmithKline, and Novartis; has consultancy arrangements with ALK-Abello, GlaxoSmithKline, and Novartis; and has received one or more payments for lecturing from or is on the speakers' bureau for Stallergenes and Meda. T. B. Casale has consultancy arrangements with Stallergenes; serves as Executive Vice President of the American Academy of Allergy, Asthma and Immunology; has received one or more grants from or has one or more grants pending with ALK-Abello, Merck, and Stallergenes; and has received one or more payments for lecturing from or is on the speakers' bureau for ALK-Abello. L. Cox has received one or more consulting fees or honoraria from and has received support for travel from Stallergenes; has received one or more fees for participation from Novartis and Circassia; is a Board member for and has received one or more payments for travel/accommodations/meeting expenses from the American Academy of Allergy, Asthma & Immunology and the American Board of Allergy and Immunology; and has consultancy arrangements with Genentech. S. R. Durham is a Board member for the Immune Tolerance Network/National Institute of Allergy and Infectious Diseases and has consultancy arrangements with ALK-Abello, Circassia, and Merck. D. Larenas-Linnemann has consultancy arrangements with Laboratories Leti and Hollister-Stier and has received one or more payments for lecturing from or is on the speakers' bureau for Merck, Sharp & Dohme (Mexico) and Diemsa. D. Ledford is a Board member for the American Academy of Allergy, Asthma & Immunology; has consultancy arrangements with AstraZeneca and Genentech; is employed by the Veterans Administration; has provided expert testimony in cases of asthma death; has received one or more payments for lecturing from or is on the speakers' bureau for AstraZeneca and for Teva; and has received royalties from UpToDate. N. Rosario is employed by the Federal University of Parana, Brazil; and has received one or more payments for lecturing from or is on the speakers' bureau for Danone, Takeda, Sanofi, Novartis, and GlaxoSmithKline. D. Wallace is a Board member for the World Allergy Organization Board of directors and the ACAAI Board of Regents; has received one or more payments for lecturing from or is on the speakers' bureau for TEVA, Myland Laboratories, and Sanofi; and has received one or more payments for travel/accommodations/meeting expenses for a World Allergy Association meeting, ACAAI BOR meetings, and International Ambassador meetings. R. F. Lockey is a Board member for the World Allergy Organization; has consultancy arrangements with Merck and ALK-Abello; is employed by the University of South Florida and a VA hospital; has provided expert testimony for Shook, Hardy and Bacon (a Miami, Florida, law firm) and Chamberlain and McHaney (an Austin, Texas, law firm); has received one or more grants from or has one or more grants pending with ALA; has received one or more payments for lecturing from or is on the speakers' bureau for Merck and AstraZeneca; has received royalties from Informa Publishing; and has received one or more payments for travel/accommodations/meeting expenses from the World Allergy Organization (international congresses for presentations).; The rest of the authors declare that they have no relevant conflicts of interest.	Agostinis F, 2008, ALLERGY, V63, P1637, DOI 10.1111/j.1398-9995.2008.01742.x; Agostinis F, 2005, ALLERGY, V60, P133, DOI 10.1111/j.1398-9995.2004.00616.x; American Medical Association, 2005, CURR PROC TERM CPT 2; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; [Anonymous], 1993, ALLERGY, V48, P7; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Blazowski L, 2008, ALLERGY, V63, P374, DOI 10.1111/j.1398-9995.2007.01563.x; Bousquet C, 2005, DRUG SAFETY, V28, P19, DOI 10.2165/00002018-200528010-00002; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Brown EG, 1999, DRUG SAFETY, V20, P109, DOI 10.2165/00002018-199920020-00002; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Calderon MA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007685.pub2; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Casale TB, 2011, J ALLERGY CLIN IMMUN, V127, P8, DOI 10.1016/j.jaci.2010.10.034; Cochard MM, 2009, J ALLERGY CLIN IMMUN, V124, P378, DOI 10.1016/j.jaci.2009.04.040; Compalati E, 2009, ALLERGY, V64, P1570, DOI 10.1111/j.1398-9995.2009.02129.x; Coop CA, 2008, ANN ALLERG ASTHMA IM, V101, P96, DOI 10.1016/S1081-1206(10)60841-1; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; de Groot H, 2009, ALLERGY, V64, P963, DOI 10.1111/j.1398-9995.2009.01998.x; Di Bona D, 2010, J ALLERGY CLIN IMMUN, V126, P558, DOI 10.1016/j.jaci.2010.06.013; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Didier A, 2011, J ALLERGY CLIN IMMUN, V128, P559, DOI 10.1016/j.jaci.2011.06.022; Drachenberg K J, 2004, Allergol Immunopathol (Madr), V32, P76; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Fiocchi A, 2005, ANN ALLERG ASTHMA IM, V95, P254, DOI 10.1016/S1081-1206(10)61222-7; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; Halken S, 2010, PEDIAT ALLERG IMM-UK, V21, P970, DOI 10.1111/j.1399-3038.2010.01050.x; Ibanez MD, 2007, PEDIAT ALLERG IMM-UK, V18, P516, DOI 10.1111/j.1399-3038.2007.00556.x; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; Larsen TH, 2006, ALLERGY, V61, P1173, DOI 10.1111/j.1398-9995.2006.01203.x; Lombardi C, 2008, ALLERGY, V63, P375, DOI 10.1111/j.1398-9995.2007.01608.x; Lombardi C, 2001, ALLERGY, V56, P989, DOI 10.1034/j.1398-9995.2001.00181.x; MedDRA, MED DICT REG ACT MED; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V128, P907, DOI 10.1016/j.jaci.2011.07.006; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2008.01875.x, 10.1111/j.1398-9995.2009.02194.x]; Pajno Giovanni B, 2003, Paediatr Drugs, V5, P777, DOI 10.2165/00148581-200305110-00006; Peden DB, 2011, J ALLERGY CLIN IMMUN, V127, P696, DOI 10.1016/j.jaci.2011.01.030; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Radulovic S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002893.pub2; Rodriguez F, 2006, INT ARCH ALLERGY IMM, V140, P321, DOI 10.1159/000093710; Rodriguez-Perez N, 2008, ANN ALLERG ASTHMA IM, V101, P304, DOI 10.1016/S1081-1206(10)60496-6; Sabin BR, 2011, J ALLERGY CLIN IMMUN, V127, P342, DOI 10.1016/j.jaci.2010.11.049; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Windom HH, 2008, CURR OPIN ALLERGY CL, V8, P571, DOI 10.1097/ACI.0b013e32831845fb	59	112	119	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					93	98		10.1016/j.jaci.2013.03.039	http://dx.doi.org/10.1016/j.jaci.2013.03.039			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23683513	Green Published			2022-12-18	WOS:000321052300012
J	Swamy, RS; Reshamwala, N; Hunter, T; Vissamsetti, S; Santos, CB; Baroody, FM; Hwang, PH; Hoyte, EG; Garcia, MA; Nadeau, KC				Swamy, Ravi S.; Reshamwala, Neha; Hunter, Tessa; Vissamsetti, Soujanya; Santos, Carah B.; Baroody, Fuad M.; Hwang, Peter H.; Hoyte, Elisabeth G.; Garcia, Marco A.; Nadeau, Kari C.			Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory allergies; sublingual immunotherapy; regulatory T cell; epigenetics	GRASS-POLLEN IMMUNOTHERAPY; ALLERGIC RHINITIS; EFFICACY; MECHANISMS; MUCOSAL; INDUCTION; HISTAMINE; RESPONSES; EXTRACT; CD203C	Background: Allergen-specific immunotherapy is the only mode of therapy that has been demonstrated to offer a cure in patients with IgE-mediated respiratory allergies. Objective: We sought to demonstrate the safety and efficacy of timothy grass (TG) and dust mite (DM) dual sublingual immunotherapy (SLIT) and to begin to investigate the immune mechanisms involved in successful immunotherapy with multiple allergens. Methods: The safety and efficacy of dual SLIT with TG and DM in children and adults with demonstrated allergies to TG and DM were investigated in a single-center, randomized, double-blind, controlled phase I study. Thirty subjects received either TG and DM dual SLIT (n = 20) or placebo (n = 10). Immune parameters were evaluated for differentiation of desensitized subjects from control subjects. Results: Subjects treated with dual SLIT had decreased rhinoconjunctivitis scores (P < .001) and medication use scores (P < .001) and reduced responses to TG and DM allergen based on results of skin prick tests or nasal disk challenges (P < .01 and P < .001, respectively) compared with placebo-treated control subjects. An increase in TG- and DM-specific IgG(4) levels, reduced allergen-specific IgE levels, and subsequent basophil activation were observed in the active treatment group. Dual SLIT promoted allergen-specific suppressive CD4(+)CD25(high)CD127(low)CD45RO(+) forkhead box protein 3 (Foxp3)(+) memory regulatory T cells with reduced DNA methylation of CpG sites within the Foxp3 locus. Conclusion: The results of this pilot study suggest that dual SLIT could be an effective means to treat subjects with sensitivities to a variety of allergens and that long-term tolerance might be induced by epigenetic modifications of Foxp3 in memory regulatory T cells. (J Allergy Clin Immunol 2012; 130: 215-24.)	[Hunter, Tessa; Vissamsetti, Soujanya; Santos, Carah B.; Hoyte, Elisabeth G.; Garcia, Marco A.; Nadeau, Kari C.] Stanford Univ, Div Immunol & Allergy, Stanford, CA 94305 USA; [Swamy, Ravi S.; Hwang, Peter H.] Stanford Univ, Dept Otolaryngol, Stanford, CA 94305 USA; [Reshamwala, Neha] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Baroody, Fuad M.] Univ Chicago, Med Ctr, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA	Stanford University; Stanford University; Stanford University; University of Chicago; University of Chicago Medical Center	Nadeau, KC (corresponding author), Stanford Univ, Div Immunol & Allergy, 269 Campus Dr,CCSR Bldg,Rm 3215, Stanford, CA 94305 USA.	knadeau@stanford.edu		Hwang, Peter/0000-0002-0786-4675	Stanford Institute for Immunity, Transplantation, and Infectious Diseases; Allergology Society; Lucile Packard Children's Hospital; National Institute of Allergy and Infectious Diseases [AI-095838]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI095838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES020926] Funding Source: NIH RePORTER	Stanford Institute for Immunity, Transplantation, and Infectious Diseases; Allergology Society; Lucile Packard Children's Hospital; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the Stanford Institute for Immunity, Transplantation, and Infectious Diseases, the Allergology Society, the CHRP fund at Lucile Packard Children's Hospital, and National Institute of Allergy and Infectious Diseases R21 (AI-095838).	Acquistapace F, 2009, PEDIAT ALLERG IMM-UK, V20, P660, DOI 10.1111/j.1399-3038.2009.00860.x; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Baroody FM, 1999, J APPL PHYSIOL, V86, P659, DOI 10.1152/jappl.1999.86.2.659; Buhring HJ, 2004, INT ARCH ALLERGY IMM, V133, P317, DOI 10.1159/000077351; Calderon MA, 2011, J ALLERGY CLIN IMMUN, V127, P30, DOI 10.1016/j.jaci.2010.08.024; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Durham SR, 2011, J ALLERGY CLIN IMMUN, V127, P3, DOI 10.1016/j.jaci.2010.11.032; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gernez Y, 2011, INT ARCH ALLERGY IMM, V154, P318, DOI 10.1159/000321824; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jin HT, 2011, CURR TOP MICROBIOL, V350, P17, DOI 10.1007/82_2010_116; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2011, ALLERGY, V66, P725, DOI 10.1111/j.1398-9995.2011.02589.x; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584; Marogna M, 2007, INT ARCH ALLERGY IMM, V142, P70, DOI 10.1159/000096001; Miyara M, 2011, IMMUNOL CELL BIOL, V89, P346, DOI 10.1038/icb.2010.137; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V128, P907, DOI 10.1016/j.jaci.2011.07.006; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Nelson HS, 2009, J ALLERGY CLIN IMMUN, V123, P763, DOI 10.1016/j.jaci.2008.12.013; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Pilette C, 2007, J IMMUNOL, V178, P4658, DOI 10.4049/jimmunol.178.7.4658; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Scadding G, 2009, J ASTHMA, V46, P322, DOI 10.1080/02770900902785729; TePas EC, 2004, ANN ALLERG ASTHMA IM, V92, P25, DOI 10.1016/S1081-1206(10)61706-1; Wachholz PA, 2003, CLIN EXP ALLERGY, V33, P1171, DOI 10.1046/j.1365-2222.2003.01765.x; Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	40	112	114	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					215	+		10.1016/j.jaci.2012.04.021	http://dx.doi.org/10.1016/j.jaci.2012.04.021			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22677046	Green Accepted			2022-12-18	WOS:000306644800030
J	Barnes, PJ				Barnes, Peter J.			Severe asthma: Advances in current management and future therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Corticosteroids; bronchodilator; cytokine; chemokine; IgE; kinase; p38 mitogen-activated protein kinase; bronchial thermoplasty; corticosteroid resistance; macrolide	MIGRATION INHIBITORY FACTOR; RELATIVE CORTICOSTEROID INSENSITIVITY; NECROSIS-FACTOR-ALPHA; ACTING BETA-AGONISTS; AIRWAY INFLAMMATION; LUNG-FUNCTION; DOUBLE-BLIND; BRONCHIAL THERMOPLASTY; ALVEOLAR MACROPHAGES; DEACETYLASE ACTIVITY	Effective treatment of severe asthma is a major unmet need because patients' symptoms are not controlled on maximum treatment with inhaled therapy. Asthma symptoms can be poorly controlled because of poor adherence to controller therapy, and this might be addressed by using combination inhalers that contain a corticosteroid and long-acting beta(2)-agonist as reliever therapy in addition to maintenance treatment. New bronchodilators with a longer duration of action are in development, and recent studies have demonstrated the benefit of a long-acting anticholinergic bronchodilator in addition to beta(2)-agonists in patients with severe asthma. Anti-IgE therapy is beneficial in selected patients with severe asthma. Several new blockers of specific mediators, including prostaglandin D-2, IL-5, IL-9, and IL-13, are also in clinical trials and might benefit patients with subtypes of severe asthma. Several broad-spectrum anti-inflammatory therapies that target neutrophilic inflammation are in clinical development for the treatment of severe asthma, but adverse effects after oral administration might necessitate inhaled delivery. Macrolides might benefit some patients with infection by atypical bacteria, but recent results are not encouraging, although there could be an effect in patients with predominant neutrophilic asthma. Corticosteroid resistance is a major problem in patients with severe asthma, and several molecular mechanisms have been described that might lead to novel therapeutic approaches, including drugs that could reverse this resistance, such as theophylline and nortriptyline. In selected patients with severe asthma, bronchial thermoplasty might be beneficial, but thus far, clinical studies have not been encouraging. Finally, several subtypes of severe asthma are now recognized, and in the future, it will be necessary to find biomarkers that predict responses to specific forms of therapy. (J Allergy Clin Immunol 2012; 129: 48-59.)	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	p.j.barnes@imperial.ac.uk		Barnes, Peter/0000-0002-5122-4018	GlaxoSmithKline; AstraZeneca; Novartis; Boehringer Ingelheim; Pfizer; National Institute for Health Research [NF-SI-0611-10148] Funding Source: researchfish	GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Novartis(Novartis); Boehringer Ingelheim(Boehringer Ingelheim); Pfizer(Pfizer); National Institute for Health Research(National Institute for Health Research (NIHR))	P. J. Barnes receives research support from GlaxoSmithKline, AstraZeneca, Novartis, Boehringer Ingelheim, and Pfizer.	Adcock IM, 2006, EUR J PHARMACOL, V533, P118, DOI 10.1016/j.ejphar.2005.12.054; Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Antoniu SA, 2010, CURR OPIN MOL THER, V12, P770; Ayoub S, 2008, NAT CLIN PRACT RHEUM, V4, P98, DOI 10.1038/ncprheum0701; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Banner KH, 2009, BRIT J PHARMACOL, V157, P892, DOI 10.1111/j.1476-5381.2009.00170.x; Barnes N, 2011, CLIN EXP ALLERGY; Barnes PJ, 2007, EUR RESPIR J, V29, P587, DOI 10.1183/09031936.00080306; Barnes PJ, 2006, THORAX, V61, P742, DOI 10.1136/thx.2006.061002; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1055, DOI 10.1016/j.jaci.2007.01.015; Barnes PJ, 2011, EXPERT REV RESP MED, V5, P297, DOI [10.1586/ERS.11.26, 10.1586/ers.11.26]; Barnes PJ, 2011, IMMUNOL REV, V242, P31, DOI 10.1111/j.1600-065X.2011.01020.x; Barnes PJ, 2011, BRIT J PHARMACOL, V163, P29, DOI 10.1111/j.1476-5381.2010.01199.x; Barnes PJ, 2010, TRENDS PHARMACOL SCI, V31, P335, DOI 10.1016/j.tips.2010.04.009; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barnes PJ, 2009, ANNU REV PHYSIOL, V71, P451, DOI 10.1146/annurev.physiol.010908.163257; Bateman ED, 2009, PULM PHARMACOL THER, V22, P533, DOI 10.1016/j.pupt.2009.06.002; Bateman ED, 2011, J ALLERGY CLIN IMMUN, V128, P315, DOI 10.1016/j.jaci.2011.06.004; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Bhavsar P, 2010, EUR RESPIR J, V35, P750, DOI 10.1183/09031936.00071309; Bos IST, 2007, EUR RESPIR J, V30, P653, DOI 10.1183/09031936.00004907; Bousquet J, 2006, ALLERGY, V61, P72, DOI 10.1111/j.1398-9995.2005.00931.x; Brasier AR, 2010, CTS-CLIN TRANSL SCI, V3, P147, DOI 10.1111/j.1752-8062.2010.00204.x; Buckley J, 2011, THORAX; Buhling F, 2007, RESP MED, V101, P2386, DOI 10.1016/j.rmed.2007.06.009; Buels KS, 2011, BR J PHARM; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Castro M, 2011, AM J RESP CRIT CARE; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Cates CJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007313.pub2; Cazzola M, 2011, BRIT J PHARMACOL, V163, P4, DOI 10.1111/j.1476-5381.2011.01216.x; Chapman KR, 2008, EUR RESPIR J, V31, P320, DOI 10.1183/09031936.00039707; CHARRON C, 2007, P AM THORAC SOC, V175, pA640; Chiba Y, 2009, AM J RESP CELL MOL, V41, P516, DOI 10.1165/rcmb.2008-0163OC; Cho KJ, 2010, J IMMUNOL, V185, P6329, DOI 10.4049/jimmunol.1001213; Cho KJ, 2010, AM J RESP CELL MOL, V42, P294, DOI 10.1165/rcmb.2008-0445OC; Contoli M, 2010, ALLERGY, V65, P141, DOI 10.1111/j.1398-9995.2009.02242.x; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; Cosio BG, 2004, J EXP MED, V200, P689, DOI 10.1084/jem.20040416; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010; De Bosscher K, 2010, J STEROID BIOCHEM, V120, P96, DOI 10.1016/j.jsbmb.2010.02.027; Denyer J, 2009, DRUG NEWS PERSPECT, V22, P146, DOI 10.1358/dnp.2009.22.3.1354124; Deshpande DA, 2010, NAT MED, V16, P1299, DOI 10.1038/nm.2237; Diamant Z, 2011, PULM PHARMACOL THER, V24, P353, DOI 10.1016/j.pupt.2010.12.011; Donnelly LE, 2011, DRUGS FUTURE; Duan W, 2005, AM J RESP CRIT CARE, V171, P571, DOI 10.1164/rccm.200408-1006OC; Erin EM, 2008, CHEST, V134, P740, DOI 10.1378/chest.07-2575; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; Evans DJ, 1996, THORAX, V51, P1178, DOI 10.1136/thx.51.12.1178; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Friedlander AL, 2010, CHEST, V138, P1202, DOI 10.1378/chest.10-0196; Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC; Gauvreau GM, 2008, AM J RESP CRIT CARE, V177, P952, DOI 10.1164/rccm.200708-1251OC; Gentile DA, 2010, CURR OPIN PHARMACOL, V10, P260, DOI 10.1016/j.coph.2010.06.001; Grant GE, 2009, PROSTAG OTH LIPID M, V89, P98, DOI 10.1016/j.prostaglandins.2009.05.002; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Hansbro PM, 2011, BRIT J PHARMACOL, V163, P81, DOI 10.1111/j.1476-5381.2011.01219.x; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Hoi Alberta Y., 2007, Inflammation & Allergy Drug Targets, V6, P183, DOI 10.2174/187152807781696455; Holgate ST, 2011, EUR RESPIR J, V37, P1352, DOI 10.1183/09031936.00063510; Holz O, 2010, EUR RESPIR J, V35, P564, DOI 10.1183/09031936.00048509; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Humbert M, 2009, ALLERGY, V64, P1194, DOI 10.1111/j.1398-9995.2009.02122.x; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Jaeschke R, 2008, AM J RESP CRIT CARE, V178, P1009, DOI 10.1164/rccm.200804-494OC; Joos GF, 2010, EXPERT OPIN INV DRUG, V19, P257, DOI 10.1517/13543780903505084; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kerstjens HAM, 2011, J ALLERGY CLIN IMMUN, V128, P308, DOI 10.1016/j.jaci.2011.04.039; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; Kim S, 2010, J ALLERGY CLIN IMMUN, V125, P1336, DOI 10.1016/j.jaci.2010.03.028; Kirkham P, 2006, PHARMACOL THERAPEUT, V111, P476, DOI 10.1016/j.pharmthera.2005.10.015; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Kraft M, 1996, J ALLERGY CLIN IMMUN, V97, P1242, DOI 10.1016/S0091-6749(96)70191-4; Kummer W, 2008, HISTOCHEM CELL BIOL, V130, P219, DOI 10.1007/s00418-008-0455-2; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Linden A, 2003, THORAX, V58, P217, DOI 10.1136/thorax.58.3.217; Magrioti V, 2010, EXPERT OPIN THER PAT, V20, P1, DOI 10.1517/13543770903463905; Makowska Joanna S, 2009, BMC Pulm Med, V9, P27, DOI 10.1186/1471-2466-9-27; Maneechotesuwan K, 2007, J IMMUNOL, V178, P2491, DOI 10.4049/jimmunol.178.4.2491; Maneechotesuwan K, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000076; Marwick JA, 2009, AM J RESP CRIT CARE, V179, P542, DOI 10.1164/rccm.200810-1570OC; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; McKinley L, 2008, J IMMUNOL, V181, P4089, DOI 10.4049/jimmunol.181.6.4089; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V115, P791, DOI 10.1016/j.jaci.2005.01.040; Mercado N, 2011, J PHARMACOL EXP THER, V337, P465, DOI 10.1124/jpet.110.175950; Metz G, 2010, IMMUNOL ALLERGY CLIN, V30, P575, DOI 10.1016/j.iac.2010.08.003; Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216, DOI 10.1164/ajrccm.160.1.9809140; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nave R, 2009, CLIN PHARMACOKINET, V48, P243, DOI 10.2165/00003088-200948040-00002; Nicholson GC, 2011, J ALLERGY CLIN IMMUN, V128, P800, DOI 10.1016/j.jaci.2011.05.013; Norris AA, 1996, CLIN EXP ALLERGY, V26, P5, DOI 10.1111/j.1365-2222.1996.tb00661.x; Oh SH, 2009, RESP MED, V103, P1020, DOI 10.1016/j.rmed.2009.01.015; Ohnishi Hiroshi, 2008, Allergol Int, V57, P291, DOI 10.2332/allergolint.08-RAI-0019; Ohta S, 2010, CLIN EXP ALLERGY, V40, P1266, DOI 10.1111/j.1365-2222.2010.03478.x; Papi A, 2009, CHEST, V135, P1628, DOI 10.1378/chest.08-2536; Park HW, 2009, ALLERGY, V64, P778, DOI 10.1111/j.1398-9995.2008.01876.x; Parker JM, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-14; Partridge Martyn R, 2006, BMC Pulm Med, V6, P13, DOI 10.1186/1471-2466-6-13; Pera T, 2011, EUR RESPIR J, V38, P789, DOI 10.1183/09031936.00146610; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; Proudfoot AEI, 2010, EXPERT OPIN INV DRUG, V19, P345, DOI 10.1517/13543780903535867; Raemdonck J, 2011, THORAX; Rao NL, 2010, AM J RESP CRIT CARE, V181, P899, DOI 10.1164/rccm.200807-1158OC; Ray NC, 2009, EXPERT OPIN THER PAT, V19, P1, DOI 10.1517/13543770802630331; Reber L, 2006, EUR J PHARMACOL, V533, P327, DOI 10.1016/j.ejphar.2005.12.067; Richards DB, 2010, RESP MED, V104, P668, DOI 10.1016/j.rmed.2009.11.006; Robinson DS, 2001, LANCET, V357, P2007, DOI 10.1016/S0140-6736(00)05113-8; Rodrigo GJ, 2011, CHEST, V139, P28, DOI 10.1378/chest.10-1194; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Rosenwasser LJ, 2005, CLIN REV ALLERG IMMU, V29, P61, DOI 10.1385/CRIAI:29:1:061; Schacke H, 2004, P NATL ACAD SCI USA, V101, P227, DOI 10.1073/pnas.0300372101; Sears MR, 2009, CHEST, V136, P604, DOI 10.1378/chest.09-1214; Shikotra A, 2011, J ALLERGY CLIN IMMUN; Siddiqui S, 2010, CHEST, V137, P797, DOI 10.1378/chest.09-1839; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; Spahn JD, 1996, J IMMUNOL, V157, P2654; Spears M, 2009, CLIN PHARMACOL THER, V86, P49, DOI 10.1038/clpt.2009.41; Spears M, 2009, EUR RESPIR J, V33, P1010, DOI 10.1183/09031936.00158208; Stenton GR, 2002, J IMMUNOL, V169, P1028, DOI 10.4049/jimmunol.169.2.1028; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Sugawara A, 2011, BIOORG MED CHEM LETT, V21, P3373, DOI 10.1016/j.bmcl.2011.04.004; Sussan TE, 2009, P NATL ACAD SCI USA, V106, P250, DOI 10.1073/pnas.0804333106; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; Thomson NC, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-8; To Y, 2010, AM J RESP CRIT CARE, V182, P897, DOI 10.1164/rccm.200906-0937OC; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Xing JC, 2011, J ASTHMA, V48, P115, DOI 10.3109/02770903.2011.554944; Yang YH, 2010, PHARMACOLOGY, V86, P1, DOI 10.1159/000314164; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	143	112	118	1	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					48	59		10.1016/j.jaci.2011.11.006	http://dx.doi.org/10.1016/j.jaci.2011.11.006			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22196524				2022-12-18	WOS:000298634000007
J	Pichler, WJ; Naisbitt, DJ; Park, BK				Pichler, Werner J.; Naisbitt, Dean J.; Park, B. Kevin			Immune pathomechanism of drug hypersensitivity reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	4th Drug Hypersensitivity Meeting (DHM4)	APR 22-25, 2010	Rome, ITALY	European Acad Allergy & Clinical Immunol (EAACI)		Drug hypersensitivity; hapten; prohapten; p-i concept; dendritic cells; T lymphocytes	STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; BETA-LACTAM ANTIBIOTICS; T-CELLS; NITROSO SULFAMETHOXAZOLE; DENDRITIC CELLS; ALLERGIC INDIVIDUALS; REDUCED GLUTATHIONE; PENICILLIN ALLERGY; CYSTIC-FIBROSIS	Drug hypersensitivity research has progressed enormously in recent years, and a greater understanding of mechanisms has contributed to improved drug safety. Progress has been made in genetics, enabling personalized medicine for certain drugs, and in understanding drug interactions with the immune system. In a recent meeting in Rome, the clinical, chemical, pharmacologic, immunologic, and genetic aspects of drug hypersensitivity were discussed, and certain aspects are briefly summarized here. Small chemicals, including drugs, can induce immune reactions by binding as a hapten to a carrier protein. Park (Liverpool, England) demonstrated (1) that drug haptens bind to protein in patients in a highly restricted manner and (2) that irreversibly modified carrier proteins are able to stimulate CD4(+) and CD8(+) T cells from hypersensitive patients. Drug haptens might also stimulate cells of the innate immune system, in particular dendritic cells, and thus give rise to a complex and complete immune reaction. Many drugs do not have hapten-like characteristics but might gain them on metabolism (so-called prohaptens). The group of Naisbitt found that the stimulation of dendritic cells and T cells can occur as a consequence of the transformation of a prohapten to a hapten in antigen-presenting cells and as such explain the immune-stimulatory capacity of prohaptens. The striking association between HLA-B alleles and the development of certain drug reactions was discussed in detail. Mallal (Perth, Australia) elegantly described a highly restricted HLA-B*5701-specific T-cell response in abacavir-hypersensitive patients and healthy volunteers expressing HLA-B*5701 but not closely related alleles. Expression of HLA-B*1502 is a marker known to be necessary but not sufficient to predict carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han Chinese. The group of Chen and Hong (Taiwan) described the possible "missing link" because they showed that the presence of certain T-cell receptor (TCR) clonotypes was necessary to elicit T-cell responses to carbamazepine. The role of TCRs in drug binding was also emphasized by Pichler (Bern, Switzerland). Following up on their "pharmacological interactions of drugs with immune receptors" concept (p-i concept), namely that drugs can bind directly to TCRs, MHC molecules, or both and thereby stimulate T cells, they looked for drug-binding sites for the drug sulfamethoxazole in drug-specific TCRs: modeling revealed up to 7 binding sites on the CDR3 and CDR2 regions of TCR V alpha and V beta. Among many other presentations, the important role of regulatory T cells in drug hypersensitivity was addressed. (J Allergy Clin Immunol 2011;127:S74-81.)	[Pichler, Werner J.] Univ Bern, Inselspital, Div Allergol, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland; [Naisbitt, Dean J.; Park, B. Kevin] Univ Liverpool, Dept Pharmacol, MRC Ctr Drug Safety Sci, Liverpool L69 3BX, Merseyside, England	University of Bern; University Hospital of Bern; University of Liverpool	Pichler, WJ (corresponding author), Univ Bern, Inselspital, Div Allergol, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland.	werner.pichler@insel.ch		Pichler, Werner J./0000-0002-8117-359X; Naisbitt, Dean/0000-0003-4107-7832	MRC [G0700654] Funding Source: UKRI; Medical Research Council [G0700654] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abe R, 2009, ANN INTERN MED, V151, P514, DOI 10.7326/0003-4819-151-7-200910060-00016; Alfirevic A, 2010, PHARMACOGENOMICS, V11, P497, DOI [10.2217/pgs.10.12, 10.2217/PGS.10.12]; Baron JM, 2008, CURR MED CHEM, V15, P2258, DOI 10.2174/092986708785747535; BATCHELO.FR, 1965, NATURE, V206, P362, DOI 10.1038/206362a0; Beeler A, 2006, J ALLERGY CLIN IMMUN, V117, P455, DOI 10.1016/j.jaci.2005.10.030; Bergstrom MA, 2007, J INVEST DERMATOL, V127, P1145, DOI 10.1038/sj.jid.5700638; BRANDER C, 1995, J IMMUNOL, V155, P2670; Burkhart C., 2002, Clinical and Experimental Allergy, V32, P1635, DOI 10.1046/j.1365-2222.2002.01513.x; Burkhart C, 2001, BRIT J PHARMACOL, V132, P623, DOI 10.1038/sj.bjp.0703845; Callan HE, 2009, CHEM RES TOXICOL, V22, P937, DOI 10.1021/tx900034r; Castrejon JL, 2010, J ALLERGY CLIN IMMUN, V125, P411, DOI 10.1016/j.jaci.2009.10.031; Chessman D, 2008, IMMUNITY, V28, P822, DOI 10.1016/j.immuni.2008.04.020; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; CRIBB AE, 1991, DRUG METAB DISPOS, V19, P900; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Doss GA, 2006, DRUG METAB REV, V38, P641, DOI 10.1080/03602530600959466; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Jenkins RE, 2009, PROTEOM CLIN APPL, V3, P720, DOI 10.1002/prca.200800222; Kano Y, 2009, IMMUNOL ALLERGY CLIN, V29, P481, DOI 10.1016/j.iac.2009.04.007; Kindmark A, 2008, PHARMACOGENOMICS J, V8, P186, DOI 10.1038/sj.tpj.6500458; KOCH C, 1991, REV INFECT DIS, V13, pS608; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; Lavergne SN, 2009, J PHARMACOL EXP THER, V331, P372, DOI 10.1124/jpet.109.155374; LEVINE BB, 1969, INT ARCH ALLER A IMM, V35, P445, DOI 10.1159/000230197; LEVINE BB, 1961, J EXP MED, V114, P875, DOI 10.1084/jem.114.6.875; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Man CBL, 2007, EPILEPSIA, V48, P1015, DOI 10.1111/j.1528-1167.2007.01022.x; Manchanda T, 2002, MOL PHARMACOL, V62, P1011, DOI 10.1124/mol.62.5.1011; Martin AM, 2007, AIDS, V21, P1233, DOI 10.1097/QAD.0b013e3280119579; Martin SF, 2008, CURR OPIN ALLERGY CL, V8, P289, DOI 10.1097/ACI.0b013e3283088cf9; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Megherbi R, 2009, TOXICOL APPL PHARM, V238, P120, DOI 10.1016/j.taap.2009.05.001; Mizuashi M, 2005, J INVEST DERMATOL, V124, P579, DOI 10.1111/j.0022-202X.2005.23624.x; Naisbitt DJ, 1996, BIOORG MED CHEM LETT, V6, P1511, DOI 10.1016/S0960-894X(96)00260-0; Naisbitt DJ, 1999, BRIT J PHARMACOL, V126, P1393, DOI 10.1038/sj.bjp.0702453; Naisbitt DJ, 2000, DRUG SAFETY, V23, P483, DOI 10.2165/00002018-200023060-00002; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Neis MM, 2010, SKIN PHARMACOL PHYS, V23, P29, DOI 10.1159/000257261; Pichler Werner J, 2006, Allergol Int, V55, P17, DOI 10.2332/allergolint.55.17; Pichler WJ, 2002, CURR OPIN ALLERGY CL, V2, P301, DOI 10.1097/00130832-200208000-00003; Pichler WJ, 2010, MED CLIN N AM, V94, P645, DOI 10.1016/j.mcna.2010.04.003; Pichler WJ, 2005, TOXICOLOGY, V209, P95, DOI 10.1016/j.tox.2004.12.014; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; PLEASANTS RA, 1994, CHEST, V106, P1124, DOI 10.1378/chest.106.4.1124; Rodriguez-Pena R, 2006, J ALLERGY CLIN IMMUN, V118, P949, DOI 10.1016/j.jaci.2006.07.013; Rozieres A, 2010, ALLERGY, V65, P996, DOI 10.1111/j.1398-9995.2009.02307.x; Sanderson JP, 2007, J IMMUNOL, V178, P5533, DOI 10.4049/jimmunol.178.9.5533; Schnyder B, 2000, J IMMUNOL, V164, P6647, DOI 10.4049/jimmunol.164.12.6647; Takahashi R, 2009, J IMMUNOL, V182, P8071, DOI 10.4049/jimmunol.0804002; Tang W, 2010, DRUG METAB REV, V42, P225, DOI 10.3109/03602530903401658; Tassaneeyakul W, 2009, PHARMACOGENET GENOM, V19, P704, DOI 10.1097/FPC.0b013e328330a3b8; von Greyerz S, 2001, INT IMMUNOL, V13, P877, DOI 10.1093/intimm/13.7.877; Weltzien HU, 1998, J INVEST DERMATOL, V110, P203, DOI 10.1046/j.1523-1747.1998.00122.x; Wermuth G, 1998, PURE APPL CHEM, V70, P1129, DOI 10.1351/pac199870051129; Yang CWO, 2007, J ALLERGY CLIN IMMUN, V120, P870, DOI 10.1016/j.jaci.2007.06.017	57	112	122	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3		S			S74	S81		10.1016/j.jaci.2010.11.048	http://dx.doi.org/10.1016/j.jaci.2010.11.048			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	743NJ	21354503				2022-12-18	WOS:000289024700004
J	Jarvinen, KM; Sicherer, SH; Sampson, HA; Nowak-Wegrzyn, A				Jaervinen, Kirsi M.; Sicherer, Scott H.; Sampson, Hugh A.; Nowak-Wegrzyn, Anna			Use of multiple doses of epinephrine in food-induced anaphylaxis in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; autoinjector; self-injectable; epinephrine; children; anaphylaxis; food-induced anaphylaxis; peanut allergy; tree nut allergy; cow's milk allergy; milk allergy	MANAGEMENT; ALLERGY; FATALITIES; EPIPEN	Background: Food allergy is the most common cause of anaphylaxis outside the hospital setting. Objective: We sought to determine the rate, circumstances, and risk factors for repeated doses of epinephrine in the treatment of food-induced anaphylaxis in children. Methods: Anonymous questionnaires were distributed to families of children with food allergies during allergy outpatient visits to a food allergy referral center. Demographic information, allergy and reaction history, and details regarding the last 2 anaphylactic reactions requiring epinephrine were collected. Results: A total of 413 questionnaires were analyzed. Seventy-eight children (median, 4.5 years of age; range, 0.5-17.5 years) reported 95 reactions for which epinephrine was administered. Two doses were administered in 12 (13%) and 3 doses in an additional 6 (6%) reactions treated with epinephrine. Peanut, tree nuts, and cow's milk were responsible for >75% of reactions requiring epinephrine. Patients receiving multiple doses of epinephrine more often had asthma (P =.027) than children receiving a single dose. The amount of food ingested or a delay in the initial administration of epinephrine were not risk factors for receiving multiple doses. The second dose of epinephrine was administered by a health care professional in 94% of reactions. Conclusion: In this referral population of children and adolescents with multiple food allergies, 19% of food-induced anaphylactic reactions were treated with more than 1 dose of epinephrine. Prospective studies are necessary to identify risk factors for severe anaphylaxis and to establish rational guidelines for prescribing multiple epinephrine autoinjectors for children with food allergy.	Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, New York, NY 10029 USA; Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Jarvinen, KM (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Pediat Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	kirsi.jarvinen@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI059318, U19AI066738] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44236, AI059318, AI066738] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Estelle F, 2005, J ALLERGY CLIN IMMUN, V115, P640, DOI 10.1016/j.jaci.2005.01.023; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Kelso JM, 2006, J ALLERGY CLIN IMMUN, V117, P464, DOI 10.1016/j.jaci.2005.11.015; Kemp AS, 2003, J PAEDIATR CHILD H, V39, P372, DOI 10.1046/j.1440-1754.2003.00157.x; Korenblat P, 1999, ALLERGY ASTHMA PROC, V20, P383, DOI 10.2500/108854199778251834; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; Oren E, 2007, ANN ALLERG ASTHMA IM, V99, P429, DOI 10.1016/S1081-1206(10)60568-6; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pumphrey Richard S H, 2004, Novartis Found Symp, V257, P116; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sampson HA, 2003, PEDIATRICS, V111, P1601; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sicherer SH, 2007, PEDIATRICS, V119, P638, DOI 10.1542/peds.2006-3689; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; SIMONS FER, 2004, ALLERGY CLIN IMMUN S, P242; Uguz A, 2005, CLIN EXP ALLERGY, V35, P746, DOI 10.1111/j.1365-2222.2005.02257.x; Varghese M, 2006, J ALLERGY CLIN IMMUN, V117, pS305, DOI 10.1016/j.jaci.2005.12.1205; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1; Wood RA, 2003, PEDIATRICS, V111, P1631	25	112	118	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					133	138		10.1016/j.jaci.2008.04.031	http://dx.doi.org/10.1016/j.jaci.2008.04.031			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18547626	Bronze			2022-12-18	WOS:000257605100022
J	Small, CB; Hernandez, J; Reyes, A; Schenkel, E; Damiano, A; Stryszak, P; Staudinger, H; Danzig, M				Small, CB; Hernandez, J; Reyes, A; Schenkel, E; Damiano, A; Stryszak, P; Staudinger, H; Danzig, M			Efficacy and safety of mometasone furoate nasal spray in nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						congestion; corticosteroid; clinical trial; intranasal; mometasone furoate; nasal polyps	SEASONAL ALLERGIC RHINITIS; INTRANASAL BUDESONIDE; TISSUE EOSINOPHILIA; FLUTICASONE; SINUSITIS; MECHANISM; PLACEBO; TRIAL	Background: Studies have suggested that topical corticosteroids are effective in the treatment of nasal polyps; however, this has yet to be confirmed in a large, robust clinical trial. Objective: To evaluate the efficacy and safety of mometasone furoate nasal spray (MFNS) for nasal polyposis. Methods: A total of 354 subjects with bilateral nasal polyps and clinically significant congestion/obstruction participated in this multinational, randomized, double-blind, placebo-controlled study. Subjects received MFNS 200 mu g once or twice daily or placebo for 4 months. Coprimary endpoints were (1) change from baseline to last assessment in physician-evaluated bilateral polyp grade score and (2) change from baseline averaged over month 1 in subject-assessed nasal congestion/obstruction. ANOVA was used for all efficacy endpoints, except for change in bilateral polyp grade score, for which baseline polyp grade was added as a covariate. Results: Compared with placebo, MFNS 200 mu g administered once or twice daily produced significantly greater reductions in bilateral polyp grade score (P <.001, P =.010, respectively) and congestion/obstruction (P =.001, P <.001), as well as improvement in loss of smell (P <.001, P =.036), anterior rhinorrhea (P <.001 for both), and postnasal drip (P <.001, P =.001) over month 1. MFNS 200 mu g twice daily was superior to MFNS 200 jig once daily in reducing congestion/obstruction (P =.039), and there were more improvers in the MFNS 200 mu g twice daily group (P =.035). MFNS was well tolerated in both groups. Conclusion: MFNS 200 mu g, once or twice daily, was safe and significantly superior to placebo in reducing polyp grade (size and extent) and improving congestion/obstruction and return of sense of smell. MFNS is an effective medical treatment for nasal polyposis and may reduce or delay the need for surgery.	New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA; Medellin Clin, Medellin, Colombia; Ctr Med Imbanaco, Cali, Colombia; Drexel Univ, Sch Med, Philadelphia, PA USA; Schering Plough Corp, Inst Res, Kenilworth, NJ 07033 USA	New York Medical College; Drexel University; Merck & Company; Schering Plough Corporation	Small, CB (corresponding author), New York Med Coll, Div Infect Dis, Munger Pavilion Rm 245, Valhalla, NY 10595 USA.	Catherine_Small@nymc.edu						Allen DB, 2000, J ALLERGY CLIN IMMUN, V106, pS179, DOI 10.1067/mai.2000.110038; Bachert C, 2003, CURR ALLERGY ASTHM R, V3, P523, DOI 10.1007/s11882-003-0065-y; Bachert C, 2003, ALLERGY, V58, P176, DOI 10.1034/j.1398-9995.2003.02172.x; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Badia L, 2001, DRUGS, V61, P573, DOI 10.2165/00003495-200161050-00003; Berkowitz RB, 1999, ALLERGY ASTHMA PROC, V20, P167, DOI 10.2500/108854199778553037; Blomqvist EH, 2001, J ALLERGY CLIN IMMUN, V107, P224, DOI 10.1067/mai.2001.112124; Davies RJ, 1997, CLIN THER, V19, P27; DELANK KW, 1994, HNO, V42, P619; EBISAWA M, 1994, J IMMUNOL, V152, P4590; Filiaci F, 2000, RHINOLOGY, V38, P185; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Holmberg K, 1997, ANN ALLERG ASTHMA IM, V78, P270, DOI 10.1016/S1081-1206(10)63180-8; Jankowski R, 2001, ARCH OTOLARYNGOL, V127, P447, DOI 10.1001/archotol.127.4.447; JOHANSEN LV, 1993, CLIN OTOLARYNGOL, V18, P524, DOI 10.1111/j.1365-2273.1993.tb00628.x; Johansson L, 2004, ACTA OTO-LARYNGOL, V124, P77, DOI 10.1080/00016480310016037; Lund VJ, 1998, ARCH OTOLARYNGOL, V124, P513, DOI 10.1001/archotol.124.5.513; LUND VJ, 1994, J ROY SOC MED, V87, P70; MYGIND N, 1997, NASAL POLYPS EPIDEMI, P147; ROWEJONES JM, 1998, CURR OPIN OTOLARYNGO, V6, P41; RUHNO J, 1990, J ALLERGY CLIN IMMUN, V86, P946, DOI 10.1016/S0091-6749(05)80158-7; Schenkel E, 2003, EXPERT OPIN PHARMACO, V4, P1579, DOI 10.1517/14656566.4.9.1579; Simon HU, 1997, J IMMUNOL, V158, P3902; Tos M, 1998, AM J RHINOL, V12, P183, DOI 10.2500/105065898781390217	26	112	127	1	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1275	1281		10.1016/j.jaci.2005.07.027	http://dx.doi.org/10.1016/j.jaci.2005.07.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337459				2022-12-18	WOS:000235687000018
J	Viljanen, M; Pohjavuori, E; Haahtela, T; Korpela, R; Kuitunen, M; Sarnesto, A; Vaarala, O; Savilahti, E				Viljanen, M; Pohjavuori, E; Haahtela, T; Korpela, R; Kuitunen, M; Sarnesto, A; Vaarala, O; Savilahti, E			Induction of inflammation as a possible mechanism of probiotic effect in atopic eczema-dermatitis syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; atopic eczema dermatitis syndrome; cytokines; human; inflammation; probiotics; tolerance	C-REACTIVE PROTEIN; INTERCELLULAR-ADHESION MOLECULE-1; REGULATORY T-CELLS; ECZEMA/DERMATITIS SYNDROME; ENDOTHELIAL-CELLS; E-SELECTIN; IL-6; INTERLEUKIN-6; MICROFLORA; CHILDREN	Background: The immunomodulating mechanisms of Lactobacillus GG (LGG) and other probiotics are poorly understood. Objective: We studied in vivo the immunologic effects of probiotics in infants with atopic eczema-dermatitis syndrome (AEDS) and cow's milk allergy (CMA). Methods: Two hundred thirty infants with AEDS and suspected CMA received, concomitant with elimination diet, either LGG, a mixture of 4 probiotic strains (MIX), or placebo for 4 weeks. All available paired pretreatment and posttreatment plasma samples (n = 132) were analyzed for concentrations of IL-2, 1L-4, IL-6, IL-10, TNF-alpha, IFN-gamma, soluble intercellular adhesion molecule 1, soluble E-selectin, TGF-beta 1, TGF-beta 2, and C-reactive protein. Results: In infants with IgE-associated AEDS, treatment with LGG induced higher C-reactive protein levels than in the placebo group (geometric mean, 0.83 mu g/mL [95% Cl, 0.560.81] vs 0.42 mu g/ml, [95% Cl, 0.27-0.65], P=.021). Concomitantly, IL-6 levels increased after treatment with LGG (P=.023) but not with MIX or placebo. Soluble E-selectin levels were higher after probiotic than after placebo treatment in infants with IgE-mediated CMA (LGG geometric mean, 86.7 ng/mL [95% Cl, 75.2-100]; MIX geometric mean, 91.6 ng/ml, [95% CI, 74.8-111.9]; and placebo geometric mean, 64.9 ng/ml, [95 % Cl, 53-79.3], analysis of covariance, P=.035; LGG vs placebo, P=.023; MIX vs placebo, P=.020). Use of MIX induced an increase in plasma IL-10 levels (P=.016). Conclusion: Probiotics induced systemically detectable low-grade inflammation, which might explain the clinical effects of probiotics in AEDS and CMA.	Univ Helsinki, Hosp Children & Adolescents, Inst Biomed Pharmacol & Res Lab, Helsinki, Finland; Valio Res & Dev, Helsinki, Finland; Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland	University of Helsinki; Valio; Finland National Institute for Health & Welfare	Viljanen, M (corresponding author), Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, Meilahdentie 2, SF-00250 Helsinki, Finland.	mirva.viljanen@hus.fi		Korpela, Riitta/0000-0003-0337-9186				Alander M, 1999, APPL ENVIRON MICROB, V65, P351; Asseman C, 2003, J IMMUNOL, V171, P971, DOI 10.4049/jimmunol.171.2.971; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Cesari M, 2003, AM J CARDIOL, V92, P522, DOI 10.1016/S0002-9149(03)00718-5; Faria AMC, 2003, J AUTOIMMUN, V20, P135, DOI 10.1016/S0896-8411(02)00112-9; FUJIHASHI K, 1991, J CLIN INVEST, V88, P248, DOI 10.1172/JCI115284; Fujii K, 2001, J DERMATOL, V28, P248, DOI 10.1111/j.1346-8138.2001.tb00126.x; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Laan MP, 1998, ALLERGY, V53, P51, DOI 10.1111/j.1398-9995.1998.tb03773.x; Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246; Lee YK, 2003, J MED MICROBIOL, V52, P925, DOI 10.1099/jmm.0.05009-0; LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; Li SP, 1996, BIOCHEMISTRY-US, V35, P9060, DOI 10.1021/bi953033d; Lin RY, 2001, ANN ALLERG ASTHMA IM, V87, P412, DOI 10.1016/S1081-1206(10)62923-7; Maeda Y, 2001, IMMUNOBIOLOGY, V204, P442, DOI 10.1078/0171-2985-00054; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Miettinen M, 2000, J IMMUNOL, V164, P3733, DOI 10.4049/jimmunol.164.7.3733; Miettinen M, 1998, INFECT IMMUN, V66, P6058, DOI 10.1128/IAI.66.12.6058-6062.1998; Morita H, 2002, MICROBIOL IMMUNOL, V46, P293, DOI 10.1111/j.1348-0421.2002.tb02698.x; Newberry RD, 1999, NAT MED, V5, P900, DOI 10.1038/11341; OHMEN JD, 1995, J IMMUNOL, V154, P1956; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Pohjavuori E, 2004, J ALLERGY CLIN IMMUN, V114, P131, DOI 10.1016/j.jaci.2004.03.036; Pritts T, 2002, AM J SURG, V183, P372, DOI 10.1016/S0002-9610(02)00812-7; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Sato A, 2003, J IMMUNOL, V171, P3684, DOI 10.4049/jimmunol.171.7.3684; SEPP E, 1993, MICROB ECOL HEALTH D, V6, P309, DOI 10.3109/08910609309141340; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Sudo N, 1997, J IMMUNOL, V159, P1739; Szalai AJ, 2002, J IMMUNOL, V168, P5792, DOI 10.4049/jimmunol.168.11.5792; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x; Viljanen M, 2005, PEDIAT ALLERG IMM-UK, V16, P65, DOI 10.1111/j.1399-3038.2005.00224.x; Volanakis JE, 2001, MOL IMMUNOL, V38, P189, DOI 10.1016/S0161-5890(01)00042-6; Wang XP, 2004, J INVEST DERMATOL, V123, P124, DOI 10.1111/j.0022-202X.2004.22736.x; Watanabe S, 2003, J ALLERGY CLIN IMMUN, V111, P587, DOI 10.1067/mai.2003.105; Watson C, 1996, CLIN EXP IMMUNOL, V105, P112, DOI 10.1046/j.1365-2249.1996.d01-717.x; Zemann B, 2003, J ALLERGY CLIN IMMUN, V111, P1069, DOI [10.1067/mai.2003.1411, 10.1067/mai.2003/1411]	41	112	121	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1254	1259		10.1016/j.jaci.2005.03.047	http://dx.doi.org/10.1016/j.jaci.2005.03.047			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940143	Bronze			2022-12-18	WOS:000229815400023
J	Poley, GE; Slater, JE				Poley, GE; Slater, JE			Latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						latex; rubber; immediate hypersensitivity; allergen; immunotherapy; skin testing	NATURAL-RUBBER LATEX; HEALTH-CARE WORKERS; DISPOSABLE MEDICAL GLOVES; HEVEA-BRASILIENSIS LATEX; AMINO-ACID-SEQUENCE; SPINA-BIFIDA; ELONGATION-FACTOR; RISK-FACTORS; CROSS-REACTIVITY; IGE ANTIBODIES	Latex allergy continues to be an important medical problem. In this review we re-examine the definition of latex allergy, the offending allergens, the factors that enhance sensitization, the threshold levels that sensitize and elicit reactions in sensitized individuals, current diagnostic techniques, avoidance measures, the barrier properties of nonlatex alternatives, and the roles of premedication and immunotherapy. Twenty years after its resurgence, later allergy is a well-defined condition with established diagnostic criteria and rational treatment and prevention strategies. However, in spite of advances associated with molecular studies of latex allergens and improved understanding of immunotherapy, avoidance remains the only effective treatment.	US FDA, Ctr Biol Evaluat & Res, DFA,Lab Immunobiochem, Div Bacterial Parasit & Allergen Prod, Rockville, MD 20852 USA; Childrens Natl Med Ctr, Childrens Res Inst, Dept Allergy Immunol & Pulm Med, Washington, DC 20010 USA	US Food & Drug Administration (FDA); Children's National Health System	Slater, JE (corresponding author), US FDA, Ctr Biol Evaluat & Res, DFA,Lab Immunobiochem, Div Bacterial Parasit & Allergen Prod, 1401 Rockville Pike,HFM-422, Rockville, MD 20852 USA.							AHLROTH M, 1995, J ALLERGY CLIN IMMUN, V96, P167, DOI 10.1016/S0091-6749(95)70004-8; Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; Alenius H, 1996, CLIN EXP ALLERGY, V26, P341, DOI 10.1046/j.1365-2222.1996.d01-312.x; ALENIUS H, 1994, J LAB CLIN MED, V123, P712; ALENIUS H, 1995, INT ARCH ALLERGY IMM, V106, P258, DOI 10.1159/000236851; Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; ATTANYAKA DPSTG, 1991, PLANT MOL BIOL, V16, P1079, DOI 10.1007/BF00016080; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; BAUR X, 1995, ALLERGY, V50, P604, DOI 10.1111/j.1398-9995.1995.tb01208.x; Baur X, 1998, CLIN EXP ALLERGY, V28, P537; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; Beezhold DH, 1997, CLIN EXP IMMUNOL, V108, P114, DOI 10.1046/j.1365-2249.1997.d01-983.x; BER DJ, 1992, ALLERGY PROC, V13, P71, DOI 10.2500/108854192778878908; BERKY ZT, 1992, JAMA-J AM MED ASSOC, V268, P2695; Bernardini R, 1999, CLIN EXP ALLERGY, V29, P681; Bernardini R, 1998, J ALLERGY CLIN IMMUN, V101, P621, DOI 10.1016/S0091-6749(98)70169-1; Bernstein M L, 1998, J Emerg Nurs, V24, P58, DOI 10.1016/S0099-1767(98)90174-X; BEUERS U, 1990, LANCET, V335, P1095, DOI 10.1016/0140-6736(90)92664-4; Bode CP, 1996, PEDIATR ALLERGY IMMU, V7, P157, DOI 10.1111/j.1399-3038.1996.tb00125.x; CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; CHAROUS BL, 1994, ANN ALLERGY, V73, P277; CHEN MD, 1992, AM J OBSTET GYNECOL, V166, P968, DOI 10.1016/0002-9378(92)91373-I; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; CHYE ML, 1995, PLANT MOL BIOL, V29, P397, DOI 10.1007/BF00043663; CORNISH K, 1993, EUR J BIOCHEM, V218, P267, DOI 10.1111/j.1432-1033.1993.tb18374.x; Cremer R, 1998, PEDIATR ALLERGY IMMU, V9, P40, DOI 10.1111/j.1399-3038.1998.tb00299.x; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589, DOI 10.1136/oem.51.9.589; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DECORRES LF, 1993, ANN ALLERGY, V70, P35; Delbourg MF, 1996, ANN ALLERG ASTHMA IM, V76, P321, DOI 10.1016/S1081-1206(10)60032-4; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; DeSwert LFA, 1997, CLIN EXP ALLERGY, V27, P1067; Diez-Gomez ML, 1999, ALLERGY, V54, P951, DOI 10.1034/j.1398-9995.1999.00145.x; DODDS RDA, 1988, BRIT J SURG, V75, P966; Fuchs T, 1997, J ALLERGY CLIN IMMUN, V100, P356, DOI 10.1016/S0091-6749(97)70249-5; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841, DOI 10.1164/ajrccm.155.6.9196084; GOYVAERTS E, 1991, PLANT PHYSIOL, V97, P317, DOI 10.1104/pp.97.1.317; HAMANN CP, 1993, AM J INFECT CONTROL, V21, P289, DOI 10.1016/0196-6553(93)90385-H; Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, P925, DOI 10.1016/S0091-6749(99)70440-9; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; Hamilton RG, 1996, J ALLERGY CLIN IMMUN, V98, P872, DOI 10.1016/S0091-6749(96)80003-0; Hamilton RG, 1997, ANN ALLERG ASTHMA IM, V79, P266, DOI 10.1016/S1081-1206(10)63013-X; Heilman DK, 1996, J ALLERGY CLIN IMMUN, V98, P325, DOI 10.1016/S0091-6749(96)70157-4; HOLZMAN RS, 1993, ANESTH ANALG, V76, P635; Houba R, 1996, AM J RESP CRIT CARE, V154, P130, DOI 10.1164/ajrccm.154.1.8680668; HUNT LW, 1993, ARCH PATHOL LAB MED, V117, P874; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; Jezierski M, 1997, J Emerg Nurs, V23, P191, DOI 10.1016/S0099-1767(97)90119-7; JONES RT, 1994, ANN ALLERGY, V73, P321; Kaczmarek RG, 1996, ANN ALLERG ASTHMA IM, V76, P51, DOI 10.1016/S1081-1206(10)63406-0; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; KORNIEWICZ DM, 1993, AM IND HYG ASSOC J, V54, P22, DOI 10.1080/15298669391354261; KORNIEWICZ DM, 1994, AM J INFECT CONTROL, V22, P12, DOI 10.1016/0196-6553(94)90085-X; Kostyal DA, 1998, CLIN EXP IMMUNOL, V112, P355; Kurtz KM, 1998, J ALLERGY CLIN IMMUN, V101, pS204; Kurtz KM, 1999, ANN ALLERG ASTHMA IM, V83, P634, DOI 10.1016/S1081-1206(10)62886-4; Kurup VP, 1996, INT ARCH ALLERGY IMM, V109, P58, DOI 10.1159/000237232; KWITTKEN PL, 1992, ALLERGY PROC, V13, P123, DOI 10.2500/108854192778878782; KWITTKEN PL, 1992, J ALLERGY CLIN IMMUN, V89, P225; LAGIER F, 1990, LANCET, V336, P516, DOI 10.1016/0140-6736(90)92076-T; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; LAURENT J, 1992, J ALLERGY CLIN IMMUN, V89, P779, DOI 10.1016/0091-6749(92)90389-J; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; LEE H, 1991, J BIOL CHEM, V266, P15944; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; LEYNADIER F, 1989, ANAESTHESIA, V44, P547, DOI 10.1111/j.1365-2044.1989.tb11438.x; LIGHT DR, 1989, J BIOL CHEM, V264, P18589; Liss GM, 1999, AM J IND MED, V35, P196, DOI 10.1002/(SICI)1097-0274(199902)35:2<196::AID-AJIM12>3.0.CO;2-Y; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; LLATSER R, 1994, PEDIATRICS, V94, P736; Lundberg M, 1997, ALLERGY, V52, P1057, DOI 10.1111/j.1398-9995.1997.tb00176.x; MAKINENKILJUNEN S, 1993, J ALLERGY CLIN IMMUN, V91, P242; Melton AL, 1997, CLEV CLIN J MED, V64, P76, DOI 10.3949/ccjm.64.2.76; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; MUSK AW, 1989, BRIT J IND MED, V46, P636; Newsom S W, 1998, Ann R Coll Surg Engl, V80, P288; Nieto A, 1998, J ALLERGY CLIN IMMUN, V101, pS207; Nieto A, 1996, J ALLERGY CLIN IMMUN, V98, P501, DOI 10.1016/S0091-6749(96)70082-9; Niggemann B, 1997, J ALLERGY CLIN IMMUN, V100, P849, DOI 10.1016/S0091-6749(97)70284-7; Niggemann B, 1998, J ALLERGY CLIN IMMUN, V102, P665, DOI 10.1016/S0091-6749(98)70285-4; Noertjojo HK, 1996, AM J RESP CRIT CARE, V154, P968, DOI 10.1164/ajrccm.154.4.8887593; Novembre E, 1997, ALLERGY, V52, P101, DOI 10.1111/j.1398-9995.1997.tb02553.x; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OEI HD, 1992, ALLERGY PROC, V13, P121, DOI 10.2500/108854192778878809; Oh SK, 1999, J BIOL CHEM, V274, P17132, DOI 10.1074/jbc.274.24.17132; OLSEN RJ, 1993, JAMA-J AM MED ASSOC, V270, P350, DOI 10.1001/jama.270.3.350; Palczynski C, 1997, Int J Occup Med Environ Health, V10, P297; Pereira C, 1999, ALLERGY, V54, P291, DOI 10.1034/j.1398-9995.1999.00954.x; Posch A, 1997, J ALLERGY CLIN IMMUN, V99, P385, DOI 10.1016/S0091-6749(97)70057-5; Posch A, 1997, ELECTROPHORESIS, V18, P2803, DOI 10.1002/elps.1150181515; Raulf-Heimsoth M, 1998, CLIN EXP ALLERGY, V28, P339; Rego A, 1999, AM J INFECT CONTROL, V27, P405, DOI 10.1016/S0196-6553(99)70006-4; RODRIGUEZ M, 1993, ANN ALLERGY, V70, P31; ROSS BD, 1992, J ALLERGY CLIN IMMUN, V90, P409, DOI 10.1016/S0091-6749(05)80023-5; Scheiner O, 1999, INT ARCH ALLERGY IMM, V118, P311, DOI 10.1159/000024113; SETLOCK MA, 1993, ANESTH ANALG, V76, P650; SETTIPANE GA, 1992, ALLERGY PROC, V13, P79, DOI 10.2500/108854192778878944; Slater JE, 1999, MOL IMMUNOL, V36, P135, DOI 10.1016/S0161-5890(99)00021-8; Slater JE, 1998, J ALLERGY CLIN IMMUN, V102, P469, DOI 10.1016/S0091-6749(98)70137-X; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; SLATER JE, 1999, ALLERGENS ALLERGEN I, P255; Slater JE, 1997, ARB P EHRLICH I BUND, V235; SOCKIN S M, 1991, Journal of Allergy and Clinical Immunology, V87, P269, DOI 10.1016/0091-6749(91)91803-2; Sowka S, 1998, EUR J BIOCHEM, V255, P213, DOI 10.1046/j.1432-1327.1998.2550213.x; Sowka S, 1999, J ALLERGY CLIN IMMUN, V104, P1302, DOI 10.1016/S0091-6749(99)70028-X; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUNDERASAN E, 1995, J RUBBER RES, V10, P82; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; SUSSMAN GL, 1992, ALLERGY PROC, V13, P67, DOI 10.2500/108854192778878890; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; TAYLOR JS, 1989, J AM ACAD DERMATOL, V21, P874, DOI 10.1016/S0190-9622(89)70271-1; Toci G, 1998, J ALLERGY CLIN IMMUN, V101, pS161; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332, DOI 10.1111/j.1365-2222.1995.tb01051.x; Valyasevi MA, 1999, ANN ALLERG ASTHMA IM, V83, P132, DOI 10.1016/S1081-1206(10)62624-5; Wagner B, 1999, J ALLERGY CLIN IMMUN, V104, P1084, DOI 10.1016/S0091-6749(99)70093-X; Wakelin SH, 1999, CONTACT DERMATITIS, V40, P89, DOI 10.1111/j.1600-0536.1999.tb05997.x; WRIGHT HT, 1985, J MOL EVOL, V21, P133, DOI 10.1007/BF02100087; YAGAMI T, 1995, J ALLERGY CLIN IMMUN, V96, P677, DOI 10.1016/S0091-6749(95)70267-9; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379, DOI 10.1016/S0091-6749(98)70251-9; YASSIN MS, 1992, J ALLERGY CLIN IMMUN, V89, P224; Yeang HY, 1998, ALLERGY, V53, P513, DOI 10.1111/j.1398-9995.1998.tb04089.x; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0; YOUNG MC, 1992, J ALLERGY CLIN IMMUN, V89, P226; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3; ZAZA S, 1992, REACTIONS LATEX CONT, P18	138	112	119	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1054	1062		10.1067/mai.2000.106925	http://dx.doi.org/10.1067/mai.2000.106925			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856135				2022-12-18	WOS:000087781800002
J	Platts-Mills, TAE; Rakes, G; Heymann, PW				Platts-Mills, TAE; Rakes, G; Heymann, PW			The relevance of allergen exposure to the development of asthma in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergens; viral infections; infancy	HOUSE-DUST MITE; T-CELL RESPONSES; INNER-CITY CHILDREN; SERUM-FREE MEDIUM; RISK-FACTORS; TRICHOPHYTON-TONSURANS; INHALANT ALLERGENS; VIRAL-INFECTIONS; MAJOR ALLERGEN; PARTICLE-SIZE	Sensitization to 1 or more of the common indoor allergens has been consistently associated with asthma among children and young adults (odds ratios for asthma, 3-18), For dust mite and cockroach allergens, there is a dose response relationship between domestic exposure and sensitization. Given that allergen provocation can induce many of the features of asthma, the findings strongly suggest that there Is a causal relationship between allergen exposure in the home and asthma, However, it remains unclear at what time the critical exposure occurs (ie, in infancy or later) and what role allergen exposure has played in the increasing prevalence and severity of asthma, Objective evidence of an immune response to allergens is generally not present until after 2 years of age. Viral infections play several different roles in asthma in childhood. In infancy, respiratory syncytial virus infection can induce bronchiolitis and set up recurrent wheezing over the next few years. However, the risk factors for this are maternal smoking and small Lungs at birth, rather than allergy. By contrast, the role of rhinovirus in precipitating attacks in children and young adults is strongly associated with allergy. Thus the likely scenario is that allergen exposure over the first few years of life induces sensitization (ie, T-H2 cells and IgE antibodies). Continuing exposure can maintain inflammation in the nose and lungs. However, many other factors contribute to wheezing such that there is no simple relationship between allergen exposure and asthma, Nonetheless, it is clear that the changes that have increased asthma have acted on allergic children.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, Box 225 HSC, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034607, R01AI020565, R37AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI020565, U19-AI34607, AI20565, R01 AI020565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Bjorksten B, 1996, CLIN EXP ALLERGY, V26, P775, DOI 10.1111/j.1365-2222.1996.tb00607.x; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARTER MC, 1998, ALLERGEN AVOIDANCE T, P101; CHAPMAN MD, 1998, ENCY IMMUNOLOGY, V1, P64; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983, DOI 10.1164/ajrccm/143.5_Pt_1.983; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; Crater Scott E., 1998, Current Opinion in Pediatrics, V10, P594; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; DALARCON A, 1999, J ALLERGY CLIN IMMUN, V102, pS415; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; DUFF AL, 1993, PEDIATRICS, V92, P535; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; INGRAM JM, 1995, J PEDIATR-US, V127, P558, DOI 10.1016/S0022-3476(95)70112-5; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1111/j.1365-2222.1996.tb00608.x; Mollet JA, 1997, J MED ENTOMOL, V34, P307, DOI 10.1093/jmedent/34.3.307; OHEHIR RE, 1993, J ALLERGY CLIN IMMUN, V92, P105, DOI 10.1016/0091-6749(93)90044-G; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PlattsMills TAE, 1997, CIBA F SYMP, V206, P173; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; RAWLE FC, 1984, J IMMUNOL, V133, P195; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Slunt JB, 1996, J IMMUNOL, V157, P5192; Slunt JB, 1997, CLIN EXP ALLERGY, V27, P1184, DOI 10.1111/j.1365-2222.1997.tb01156.x; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; Srikiatkhachorn A, 1997, J EXP MED, V186, P421, DOI 10.1084/jem.186.3.421; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; Wanner A, 1997, AM J RESP CRIT CARE, V156, pS67; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	51	112	118	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S503	S508		10.1016/S0091-6749(00)90051-4	http://dx.doi.org/10.1016/S0091-6749(00)90051-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669532	Bronze, Green Published			2022-12-18	WOS:000085439600009
J	Fish, JE; Peters, SP				Fish, JE; Peters, SP			Airway remodeling and persistent airway obstruction in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						airway remodeling; persistent airflow obstruction; irreversible airflow obstruction; asthma; airway inflammation	INHALED CORTICOSTEROIDS; BRONCHIAL-MUCOSA; MAST-CELLS; SUBEPITHELIAL FIBROSIS; SMOOTH-MUSCLE; LUNG-FUNCTION; PULMONARY-FUNCTION; BASEMENT-MEMBRANE; T-LYMPHOCYTES; MILD ASTHMA	There is growing recognition that some patients with longstanding asthma may possess a component of irreversible airflow obstruction despite optimal therapy. This persistent airflow obstruction is thought to be the result of structural changes in the airways that occur as a result of airway remodeling. The structural changes that lead to chronic obstruction are not known, nor are the intricacies of the remodeling process. Hence airway remodeling and its role in the evolution of irreversible airflow obstruction remain conceptual, Much work has been carried out to better define the histopathologic characteristics of asthma, including the characteristic features of airway inflammation. However, attempts to delineate the physiologic consequences of specific histologic findings are at an early stage of development, The thesis that airway remodeling is driven by chronic inflammatory processes has important implications for the way we make treatment decisions, especially in the patient with mild asthma. Abounding interest in airway remodeling has led to a growing literature on the subject, a literature that is largely speculative and perhaps too tautologic in the sense that remodeling is frequently defined by any observed histologic change, irrespective of its physiologic consequences, Careful attempts to link histologic observations with clinical, demographic, and physiologic findings will be necessary to unravel the causes of remodeling and identify who is at risk for development of irreversible airway obstruction.	Thomas Jefferson Univ, Jefferson Med Coll, Div Crit Care Pulm Allerg & Immunol Dis, Philadelphia, PA 19107 USA	Jefferson University	Fish, JE (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Div Crit Care Pulm Allerg & Immunol Dis, 805 Coll Bldg,1025 Walnut St, Philadelphia, PA 19107 USA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Backman KS, 1997, CHEST, V112, P1234, DOI 10.1378/chest.112.5.1234; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; BOOTH H, 1995, AM J RESP CRIT CARE, V152, P45, DOI 10.1164/ajrccm.152.1.7599861; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; Burke CM, 1996, THORAX, V51, P993, DOI 10.1136/thx.51.10.993; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; Carroll NG, 1997, AM J RESP CRIT CARE, V155, P689, DOI 10.1164/ajrccm.155.2.9032214; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Cho SH, 1996, CLIN EXP ALLERGY, V26, P1210, DOI 10.1111/j.1365-2222.1996.tb00510.x; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; CONNOLLY CK, 1988, POSTGRAD MED J, V64, P422, DOI 10.1136/pgmj.64.752.422; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; Djukanovic R, 1997, AM J RESP CRIT CARE, V155, P826, DOI 10.1164/ajrccm.155.3.9117012; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; EBINA M, 1990, AM REV RESPIR DIS, V141, P1327, DOI 10.1164/ajrccm/141.5_Pt_1.1327; FINUCANE KE, 1984, THORAX, V39, P131; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565, DOI 10.1164/ajrccm.158.2.9705036; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; HEARD BE, 1973, J PATHOL, V110, P319, DOI 10.1002/path.1711100406; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; Hoshino M, 1996, EUR RESPIR J, V9, P696, DOI 10.1183/09031936.96.09040696; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83, DOI 10.1164/ajrccm.153.1.8542167; MESSER JW, 1960, DIS CHEST, V38, P616, DOI 10.1378/chest.38.6.616; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; MOLINA C, 1977, CLIN ALLERGY, V7, P137, DOI 10.1111/j.1365-2222.1977.tb01434.x; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; *NIH, 1997, PUBL NIH; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; OLLERENSHAW SL, 1992, AM REV RESPIR DIS, V145, P922, DOI 10.1164/ajrccm/145.4_Pt_1.922; Overbeek SE, 1996, CHEST, V110, P35, DOI 10.1378/chest.110.1.35; PANETTIERI RA, 1990, AM J PHYSIOL, V259, pL365, DOI 10.1152/ajplung.1990.259.6.L365; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PESCI A, 1993, AM REV RESPIR DIS, V147, P684, DOI 10.1164/ajrccm/147.3.684; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; POSTMA DS, 1986, AM REV RESPIR DIS, V134, P276; RAEBURN D, 1994, EUR RESPIR J, V7, P2226, DOI 10.1183/09031936.94.07122226; REDLINE S, 1989, AM REV RESPIR DIS, V140, P179, DOI 10.1164/ajrccm/140.1.179; Richmond I, 1996, AM J RESP CRIT CARE, V153, P899, DOI 10.1164/ajrccm.153.3.8630570; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROCHE WR, 1989, LANCET, V1, P520; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442, DOI 10.1164/ajrccm.155.2.9032176; SOBONYA RE, 1984, AM REV RESPIR DIS, V130, P289; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; Synek M, 1996, AM J RESP CRIT CARE, V154, P224, DOI 10.1164/ajrccm.154.1.8680684; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; VANSCHAYCK CP, 1991, AM REV RESPIR DIS, V144, P1297, DOI 10.1164/ajrccm/144.6.1297; Vignola AM, 1998, J ALLERGY CLIN IMMUN, V101, P149, DOI 10.1016/S0091-6749(98)70378-1; Xing Z, 1996, J CLIN INVEST, V97, P1102, DOI 10.1172/JCI118503	76	112	117	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				509	516		10.1016/S0091-6749(99)70315-5	http://dx.doi.org/10.1016/S0091-6749(99)70315-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482819	Bronze			2022-12-18	WOS:000082870000007
J	Ferrer, M; Nakazawa, K; Kaplan, AP				Ferrer, M; Nakazawa, K; Kaplan, AP			Complement dependence of histamine release in chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic urticaria; complement; C5a; autoantibodies	FC-EPSILON-RI; CHRONIC IDIOPATHIC URTICARIA; AFFINITY IGE RECEPTOR; SKIN MAST-CELLS; C5A DES ARG; AUTOANTIBODIES; IDENTIFICATION; ACTIVATION; PEPTIDES; BASOPHIL	Background: IgG autoantibodies directed to the a-subunit of the IgE receptor have been identified in 30% to 45% of patients with chronic urticaria, However, the exact mechanism by which histamine secretion is initiated Is uncertain, Objective: Histamine release from cutaneous mast cells may occur by cross-linking the IgE receptor or by activation of complement. Our goal is to distinguish these 2 possibilities. Methods: We incubated human cutaneous mast cells with patient sera, decomplemented sera, or purified patient IgG, The IgG was also added to pooled normal serum or to sera deficient in either C2 or C5, and its ability to activate mast cells was assessed. Mast cells were incubated with human IgE myeloma to saturate alpha-subunits to determine the effect on histamine release, Results: Patient sera released histamine (18.26% +/- 4.39%), but purified Ige from patients (5.5% +/- 4.3%) did not. Addition of the patient IgG to normal sera rendered the sera positive for histamine-releasing activity (18.4% +/- 4.3%), whereas control IgG or patient IgG added to C2- or C5-deficient sera did not release histamine. Histamine release with decomplemented patient sera was also diminished (8.34% +/- 4.3%). Preincubation of mast cells with a C5-blocking peptide decreased histamine release but was not statistically significant; there was a significant decrease after preincubating mast cells with IgE myeloma, Conclusion: The degranulation of mast cells by IgG autoantibodies in patients with chronic urticaria requires binding to the IgE receptor and activation of the classical complement cascade. Saturation of the IgE receptor with IgE inhibits such degranulation, presumably by preventing binding of the requisite IgG.	Med Univ S Carolina, Dept Med, Div Pulm Dis Crit Care & Allergy & Immunol, Ctr Asthma & Allergy, Charleston, SC 29425 USA	Medical University of South Carolina	Kaplan, AP (corresponding author), Med Univ S Carolina, Dept Med Pulm Allergy, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA.		Ferrer, Marta/C-4319-2016	Ferrer, Marta/0000-0001-8495-1302				BENYON RC, 1986, INT ARCH ALLER A IMM, V79, P332; ELLATI SG, 1994, J INVEST DERMATOL, V102, P803, DOI 10.1111/1523-1747.ep12378589; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; FUREDER W, 1994, ALLERGY, V49, P861, DOI 10.1111/j.1398-9995.1994.tb00788.x; GOTZE O, 1971, J EXP MED, V134, pS90; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; PEREZ HD, 1988, J CLIN INVEST, V82, P360, DOI 10.1172/JCI113595; REIN G, 1992, INT ARCH ALLERGY IMM, V98, P211, DOI 10.1159/000236187; Sabroe RA, 1998, J ALLERGY CLIN IMMUN, V102, P651, DOI 10.1016/S0091-6749(98)70283-0; SCHULMAN ES, 1988, J CLIN INVEST, V81, P918, DOI 10.1172/JCI113403; SWERLICK RA, 1989, J INVEST DERMATOL, V93, P417, DOI 10.1111/1523-1747.ep12280306; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	19	112	119	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					169	172		10.1016/S0091-6749(99)70129-6	http://dx.doi.org/10.1016/S0091-6749(99)70129-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400855				2022-12-18	WOS:000081738900025
J	Douwes, J; van der Sluis, B; Doekes, G; van Leusden, F; Wijnands, L; van Strien, R; Verhoeff, A; Brunekreef, B				Douwes, J; van der Sluis, B; Doekes, G; van Leusden, F; Wijnands, L; van Strien, R; Verhoeff, A; Brunekreef, B			Fungal extracellular polysaccharides in house dust as a marker for exposure to fungi: Relations with culturable fungi, reported home dampness, and respiratory symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fungi; house dust; extracellular polysaccharides; home dampness; respiratory symptoms	SYNTHETIC LIQUID-MEDIUM; RESIDENTIAL CHARACTERISTICS; INDOOR AIR; CHILDREN; MOLDS; HEALTH; PROPAGULES; (1->3)-BETA-D-GLUCAN; DETERMINANTS; ASPERGILLUS	Background: Epidemiologic studies have demonstrated an association between indoor fungal growth and respiratory symptoms. However, in only a few studies was fungal exposure actually measured. Objective: The purpose of this study was to evaluate the measurement by enzyme immunoassay of extracellular polysaccharides of Aspergillus and Penicillium species (EPS-Asp/Pen) in house dust as a marker for fungal exposure and to study the relations between EPS-Asp/Pen levels and home dampness and respiratory symptoms in children. Methods: Extracts of house dust samples from bedroom and living room floors and mattresses from homes of 31 children with chronic respiratory symptoms and 29 children with no chronic respiratory symptoms were analyzed for EPS-Asp/Pen. Results: EPS-Asp/Pen were readily detectable (40 to 46,513 nanogram equivalent/g dust) in 161 house dust extracts, with highest concentrations in living room Boor dust. EPS-Asp/Pen levels were 2 to 3 times higher on carpeted floors than on smooth floors. EPS-Asp/Pen were significantly correlated with total culturable fungi (r = 0.3 to 0.5) and with house dust mite allergens (r = 0.3 to 0.5). EPS-Asp/Pen levels in living room floor dust were positively associated with occupant-reported home dampness. This was not observed for EPS-Asp/Pen in bedroom floor and mattress dust. EPS-Asp/Pen levels in living room Boor dust were positively associated with respiratory symptoms, EPS-Asp/Pen in bedroom floor and mattress dust showed a reversed association with respiratory symptoms, possibly because of allergen-avoidance measures taken in the bedroom. Conclusion: The enzyme immunoassay for fungal EPS-Asp/Pen may be a useful method for exposure assessment of indoor fungi.	Wageningen Univ Agr, Dept Environm Sci, Environm & Occupat Hlth Grp, NL-6700 AE Wageningen, Netherlands; Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; Municipal Hlth Serv, Dept Epidemiol, Amsterdam, Netherlands	Wageningen University & Research; Netherlands National Institute for Public Health & the Environment	Doekes, G (corresponding author), Wageningen Univ Agr, Dept Environm Sci, Environm & Occupat Hlth Grp, POB 238, NL-6700 AE Wageningen, Netherlands.		Verhoeff, Arnoud P/F-7924-2013	brunekreef, bert/0000-0001-9908-0060; Douwes, Jeroen/0000-0003-3599-4036				BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363, DOI 10.1164/ajrccm/140.5.1363; BURR ML, 1988, J ROY SOC HEALTH, V3, P99; Dales RE, 1997, INT J EPIDEMIOL, V26, P120, DOI 10.1093/ije/26.1.120; DALES RE, 1991, AM J EPIDEMIOL, V134, P196, DOI 10.1093/oxfordjournals.aje.a116072; DIJKSTRA L, 1990, AM REV RESPIR DIS, V142, P1172, DOI 10.1164/ajrccm/142.5.1172; Douwes J, 1996, APPL ENVIRON MICROB, V62, P3176, DOI 10.1128/AEM.62.9.3176-3182.1996; GRAVESEN S, 1978, ALLERGY, V33, P268, DOI 10.1111/j.1398-9995.1978.tb01547.x; JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129; KAMPHUIS HJ, 1992, ANTON LEEUW INT J G, V61, P323, DOI 10.1007/BF00713940; KAMPHUIS HJ, 1991, FUNGAL CELL WALL IMM, P157; Miller JD, 1997, AM IND HYG ASSOC J, V58, P39, DOI 10.1080/15428119791013062; NOTERMANS S, 1988, J MED VET MYCOL, V26, P41; NOTERMANS S, 1985, INT J FOOD MICROBIOL, V2, P247, DOI 10.1016/0168-1605(85)90015-7; NOTERMANS S, 1986, A VAN LEEUW J MICROB, V52, P393, DOI 10.1007/BF00393467; NOTERMANS S, 1988, MOL IMMUNOL, V25, P975, DOI 10.1016/0161-5890(88)90003-X; PLATT SD, 1989, BRIT MED J, V298, P1673, DOI 10.1136/bmj.298.6689.1673; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V11, P199; Rylander R, 1997, ARCH ENVIRON HEALTH, V52, P281, DOI 10.1080/00039899709602199; Rylander R., 1996, INDOOR BUILT ENVIRON, P106; Rylander R, 1992, INDOOR ENVIRON, V1, P263; SPENGLER J, 1994, INDOOR AIR, V4, P72, DOI 10.1111/j.1600-0668.1994.t01-2-00002.x; SPORIK RB, 1993, CLIN EXP ALLERGY, V23, P326, DOI 10.1111/j.1365-2222.1993.tb00330.x; STRACHAN DP, 1990, THORAX, V45, P382, DOI 10.1136/thx.45.5.382; STRACHAN DP, 1988, BMJ-BRIT MED J, V297, P1223, DOI 10.1136/bmj.297.6658.1223; VANDERHEIDE S, 1985, ALLERGY, V40, P586; VANDERHEIDE S, 1985, ALLERGY, V40, P592; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843, DOI 10.1111/j.1365-2222.1994.tb01807.x; VERHOEFF AP, 1994, ALLERGY, V49, P533, DOI 10.1111/j.1398-9995.1994.tb01125.x; VERHOEFF AP, 1994, CLIN EXP ALLERGY, V24, P1061, DOI 10.1111/j.1365-2222.1994.tb02744.x; VERHOEFF AP, 1994, ALLERGY, V49, P540, DOI 10.1111/j.1398-9995.1994.tb01126.x; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103, DOI 10.1093/oxfordjournals.aje.a117398; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	34	112	113	0	21	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				494	500		10.1016/S0091-6749(99)70476-8	http://dx.doi.org/10.1016/S0091-6749(99)70476-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069885	Bronze			2022-12-18	WOS:000079175700020
J	White, M				White, M			Mediators of inflammation and the inflammatory process	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ARACHIDONIC-ACID; MAST-CELLS; POLYMORPHONUCLEAR LEUKOCYTES; RELEASE; 5-LIPOXYGENASE; PREKALLIKREIN; ABNORMALITIES; DEFICIENCY; HISTAMINE; RESPONSES	A complex interplay of inflammatory cells and chemical mediators is responsible for allergic inflammation. It is now understood that the allergic reaction consists of an early-phase response involving mast cell degranulation with the release of histamine and a late-phase response characterized by the migration of inflammatory cells. This review provides a summary of the early- and late-phase events associated with allergic inflammation and an overview of the principal chemical mediators involved in the inflammatory process.	Washington Hosp Ctr, Inst Asthma & Allergy, Washington, DC 20010 USA	MedStar Washington Hospital Center	White, M (corresponding author), Washington Hosp Ctr, Inst Asthma & Allergy, 106 Irving St NW,Suite 108, Washington, DC 20010 USA.							ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; BARANIUK JN, 1990, AM REV RESPIR DIS, V141, P706, DOI 10.1164/ajrccm/141.3.706; BARBARO JF, 1966, P SOC EXP BIOL MED, V122, P1245; BARNES PJ, 1993, ALLERGY PRINCIPLES P, P255; Benson M, 1997, PEDIATR ALLERGY IMMU, V8, P143, DOI 10.1111/j.1399-3038.1997.tb00168.x; Bhattacharyya SP, 1998, J LEUKOCYTE BIOL, V63, P337, DOI 10.1002/jlb.63.3.337; BHOOLA KD, 1962, BRIT J PHARM CHEMOTH, V19, P190, DOI 10.1111/j.1476-5381.1962.tb01439.x; BORGEAT P, 1979, J BIOL CHEM, V254, P2643; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; Bradding P, 1996, ANN NY ACAD SCI, V796, P272, DOI 10.1111/j.1749-6632.1996.tb32589.x; Carswell H, 1985, FRONTIERS HISTAMINE, P27; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; COREY EJ, 1980, J AM CHEM SOC, V102, P1436, DOI 10.1021/ja00524a045; COREY EJ, 1980, J AM CHEM SOC, V102, P7984, DOI 10.1021/ja00547a051; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; Dvorak AM, 1997, INT ARCH ALLERGY IMM, V114, P1, DOI 10.1159/000237635; Fish JE, 1997, CLIN THER, V19, P675, DOI 10.1016/S0149-2918(97)80092-6; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HO PC, 1978, FED PROC, V37, P1667; KEELE CA, 1969, PROC R SOC SER B-BIO, V173, P361, DOI 10.1098/rspb.1969.0062; KENNERLY DA, 1979, J EXP MED, V150, P1039, DOI 10.1084/jem.150.4.1039; LEWIS RA, 1981, BIOCH ACUTE ALLERGIC, P239; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; NACLERIO RM, 1991, AM REV RESPIR DIS, V143, pS91, DOI 10.1164/ajrccm/143.5_Pt_2.S91; NEWBALL HH, 1979, J CLIN INVEST, V64, P457, DOI 10.1172/JCI109483; NUSTAD K, 1978, GEN PHARMACOL-VASC S, V9, P1, DOI 10.1016/0306-3623(78)90049-6; PEARCE FL, 1991, AGENTS ACTIONS, V33, P4, DOI 10.1007/BF01993112; PEARCE FL, 1990, IMMUNOL ALLERGY CLIN, V102, P251; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; PROUD D, 1985, AM REV RESPIR DIS, V132, P405; Rihoux JP, 1997, INT ARCH ALLERGY IMM, V113, P339, DOI 10.1159/000237595; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P150; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; SHIN MH, 1992, CLIN EXP ALLERGY, V22, P289, DOI 10.1111/j.1365-2222.1992.tb03085.x; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927, DOI 10.1164/ajrccm.152.3.7545059; SOBERMAN RJ, 1985, J BIOL CHEM, V260, P4508; UVNAS B, 1964, ANN NY ACAD SCI, V116, P880, DOI 10.1111/j.1749-6632.1964.tb52554.x; UVNAS B, 1970, ACTA PHYSL SCAND   S, V336, P3; WEISS AS, 1974, J CLIN INVEST, V53, P622, DOI 10.1172/JCI107597	42	112	114	1	46	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	2	S			S378	S381		10.1016/S0091-6749(99)70215-0	http://dx.doi.org/10.1016/S0091-6749(99)70215-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	179CL	10069896				2022-12-18	WOS:000079305900002
J	Diaz-Perales, A; Collada, C; Blanco, C; Sanchez-Monge, R; Carrillo, T; Aragoncillo, C; Salcedo, G				Diaz-Perales, A; Collada, C; Blanco, C; Sanchez-Monge, R; Carrillo, T; Aragoncillo, C; Salcedo, G			Class I chitinases with hevein-like domain, but not class II enzymes, are relevant chestnut and avocado allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						avocado fruit; chestnut seed; IgE; allergen; chitinases; hevein-like domain; latex-fruit syndrome	MAJOR LATEX ALLERGEN; BINDING; PROTEINS; LYSOZYME; HYPERSENSITIVITY; IDENTIFICATION; BRASILIENSIS; PROHEVEIN; FRUITS; BANANA	Background: Several foods associated with the latex-fruit syndrome present relevant allergens of around 30 kd, Neither these components nor any other responsible for the reported cross-reactions have been identified and purified. Objective: We sought to isolate and characterize the 30 kd allergens from avocado fruit and chestnut seed, two of the main allergenic foods linked with latex allergy. Methods: Sera from patients allergic to chestnut and avocado were selected according to clinical symptoms, specific IgE levels, and positive skin prick test responses, Class I and II chitinases were purified by affinity and cation-exchange chromatography and characterized by specific IgE and anti-chitinase immunodetection, immunoblot inhibition assays, enzymatic activity tests, and N-terminal sequencing. Results: Relevant 32 kd allergens were detected by specific IgE immunodetection in both avocado and chestnut crude extracts. The same hands, together with others of 25 kd, were revealed by a monospecific antiserum against class II chitinases. Purification and characterization of the 32 kd allergens from both plant sources allowed their identification as class I chitinases with an N-terminal hel ein-domain. The purified allergens fully inhibited IgE binding by the corresponding crude extract when tested in immunoblot inhibition assays. Highly related 25 kd class II chitinases that lack the hevein-like domain were also isolated from the same protein preparations, No IgE-binding capacity mas shown by these class II enzymes. Conclusion: Class I chitinases are relevant allergens of avocado and chestnut and could be the panallergens responsible for the later-fruit syndrome. The hevein-like domain seems to be involved in their allergenic reactivity.	ETS Ingenieros Agron, Dept Biotecnol, Unidad Bioquim, Madrid 28040, Spain; ETS Ingenieros Montes, Dept Biotecnol, Unidad Quim & Bioquim, Madrid, Spain; Hosp Nuestra Senora Pino, Secc Alergia, Las Palmas Gran Canaria, Spain		Salcedo, G (corresponding author), ETS Ingenieros Agron, Dept Biotecnol, Unidad Bioquim, Ciudad Univ, Madrid 28040, Spain.		Collada, Carmen/H-1529-2015; Díaz-Perales, Araceli/D-8433-2016; Blanco, Carlos/B-3895-2012	Collada, Carmen/0000-0003-0236-1312; Díaz-Perales, Araceli/0000-0002-1093-3627; Blanco, Carlos/0000-0002-2893-6594				AKASAWA A, 1997, J ALLERGY CLIN IMMUN, V97, P231; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; Alenius H, 1996, J IMMUNOL, V156, P1618; Allona I, 1996, PLANT MOL BIOL, V32, P1171, DOI 10.1007/BF00041402; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; Beezhold DH, 1997, CLIN EXP IMMUNOL, V108, P114, DOI 10.1046/j.1365-2249.1997.d01-983.x; BLANCO C, 1994, ANN ALLERGY, V73, P309; BLANCO C, 1994, ALLERGY, V49, P454, DOI 10.1111/j.1398-9995.1994.tb00839.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; COLLADA C, 1992, PLANT PHYSIOL, V100, P778, DOI 10.1104/pp.100.2.778; COLLINGE DB, 1993, PLANT J, V3, P31, DOI 10.1046/j.1365-313X.1993.t01-1-00999.x; Delbourg MF, 1996, ANN ALLERG ASTHMA IM, V76, P321, DOI 10.1016/S1081-1206(10)60032-4; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; MOLANO J, 1905, ANAL BIOCHEM, V48, P77; Posch A, 1997, J ALLERGY CLIN IMMUN, V99, P385, DOI 10.1016/S0091-6749(97)70057-5; RAIKHEL NV, 1993, ANNU REV PLANT PHYS, V44, P591, DOI 10.1146/annurev.pp.44.060193.003111; SANCHEZMONGE R, 1992, BIOCHEM J, V281, P401, DOI 10.1042/bj2810401; Scheiner O, 1997, INT ARCH ALLERGY IMM, V113, P105, DOI 10.1159/000237519; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WADEE AA, 1990, J ALLERGY CLIN IMMUN, V85, P801, DOI 10.1016/0091-6749(90)90202-F; WIRTH SJ, 1990, J MICROBIOL METH, V12, P197, DOI 10.1016/0167-7012(90)90031-Z; YAGAMI T, 1995, J ALLERGY CLIN IMMUN, V96, P677, DOI 10.1016/S0091-6749(95)70267-9	26	112	115	0	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					127	133		10.1016/S0091-6749(98)70063-6	http://dx.doi.org/10.1016/S0091-6749(98)70063-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679856				2022-12-18	WOS:000074909500018
J	Teuber, SS; Dandekar, AM; Peterson, WR; Sellers, CL				Teuber, SS; Dandekar, AM; Peterson, WR; Sellers, CL			Cloning and sequencing of a gene encoding a 2S albumin seed storage protein precursor from English walnut (Juglans regia), a major food allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						2S albumin seed storage protein; walnut; food allergy; nut allergy	SIN-A-I; ATOPIC-DERMATITIS; BRAZIL-NUT; PEANUT ALLERGEN; IDENTIFICATION; EXPRESSION; PURIFICATION; CHALLENGES; CDNA; ACID	Background: Walnuts rank third in per capita consumption of tree nuts in the United States and can be associated with systemic IgE-mediated reactions in some individuals. Objective: The objectives of the study were to clone a gene encoding one of the major food allergens in the walnut kernel and to characterize the recombinant allergen, Methods: A cDNA expression library in the lambda vector Uni-ZAP, which was prepared from walnut somatic embryos, was screened by using a patient's sera that reacted with multiple protein bands on immunoblotting. Results: A cDNA clone containing an insert of 663 bp was identified and named Jug r I. DNA sequence analysis of this clone revealed that it encoded a protein 142 amino acids in length, Comparison of the encoded protein sequences with protein databases revealed that this clone exhibits a 46.1% identity with the Brazil nut (Bertholletia excelsa) methionine-rich 2S albumin seed storage protein precursor, Ber e 1. Jug r 1 appears to be an important walnut food allergen; 12 of 16 sera from patients allergic to walnuts demonstrated IgE binding to the 2S albumin seed storage protein precursor fusion protein. An IgE-binding inhibition study suggests that the walnut 28 protein precursor undergoes posttranslational modification into a large and small subunit that is similar to castor seed, cottonseed, mustard seed, and Brazil nut 28 seed storage protein allergens, Interestingly, the gene encoding this allergenic protein in Brazil nuts has recently gained notoriety because of its experimental use as a transgene to enhance the nutritional quality of legumes. Conclusion: This is now the sixth definitive 28 albumin seed storage protein demonstrated to bind IgE, suggesting that this class of proteins is inherently allergenic.	Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA; Vet Affairs No Calif Hlth Care Syst, Pleasant Hill, CA USA; Univ Calif Davis, Dept Pomol, Davis, CA USA; Univ Calif Berkeley, Dept Plant Biol, Berkeley, CA 94720 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Berkeley	Teuber, SS (corresponding author), Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA.			Dandekar, Abhaya/0000-0001-7925-4086	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035747] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35747] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alday E, 1996, ALLERGY, V51, P69, DOI 10.1111/j.1398-9995.1996.tb00019.x; ALEXANDER LJ, 1989, NUCLEIC ACIDS RES, V17, P6739, DOI 10.1093/nar/17.16.6739; ATKINS FM, 1988, J ALLERGY CLIN IMMUN, V82, P242, DOI 10.1016/0091-6749(88)91006-8; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V1, P261; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERNTON HARRY S., 1940, JOUR ALLERGY, V11, P138, DOI 10.1016/S0021-8707(40)90828-0; BLEUMINK E, 1968, INT ARCH ALLER A IMM, V34, P521, DOI 10.1159/000230147; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5291; DECASTRO LAB, 1987, MOL GEN GENET, V206, P338, DOI 10.1007/BF00333592; DELAPENA MAG, 1993, BIOCHEM BIOPH RES CO, V190, P648, DOI 10.1006/bbrc.1993.1097; DHONDT K, 1993, PLANT PHYSIOL, V102, P425, DOI 10.1104/pp.102.2.425; DRIVER JA, 1984, HORTSCIENCE, V19, P507; ELSAYED S, 1975, SCAND J IMMUNOL, V4, P203, DOI 10.1111/j.1365-3083.1975.tb02618.x; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GALAU GA, 1992, PLANT PHYSIOL, V99, P779, DOI 10.1104/pp.99.2.779; GANDER ES, 1991, PLANT MOL BIOL, V16, P437, DOI 10.1007/BF00023994; GILLESPIE DN, 1976, J ALLERGY CLIN IMMUN, V57, P302, DOI 10.1016/0091-6749(76)90086-5; GOETZ DW, 1993, J ALLERGY CLIN IMMUN, V91, P360; HOLEN E, 1990, INT ARCH ALLER A IMM, V91, P136, DOI 10.1159/000235104; IRWIN SD, 1990, NUCLEIC ACIDS RES, V18, P5890, DOI 10.1093/nar/18.19.5890; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; KREBBERS E, 1988, PLANT PHYSIOL, V87, P859, DOI 10.1104/pp.87.4.859; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; McGranahan G.H., 1987, CELLS TISSUE CULT, VVolume 24-26, P261, DOI DOI 10.1007/978-94-017-0992-7_; MENENDEZARIAS L, 1988, EUR J BIOCHEM, V177, P159, DOI 10.1111/j.1432-1033.1988.tb14357.x; MONSALVE RI, 1993, BIOCHEM J, V293, P625, DOI 10.1042/bj2930625; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; ORDMAN D, 1955, INT ARCH ALLER A IMM, V7, P10, DOI 10.1159/000228201; Osborne T. B., 1924, VEGETABLE PROTEINS; PANZANI R, 1957, INT ARCH ALLER A IMM, V11, P224, DOI 10.1159/000228420; SCHREIBER RA, 1989, MAYO CLIN PROC, V64, P1381, DOI 10.1016/S0025-6196(12)65380-4; SPIES JOSEPH R., 1939, JOUR ALLERGY, V10, P113, DOI 10.1016/S0021-8707(39)90044-4; Spies JR, 1943, J AM CHEM SOC, V65, P1720, DOI 10.1021/ja01249a020; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; *WALN MARK BOARD, 1996, WALN MARK BOARD STAT; YOULE RJ, 1978, PLANT PHYSIOL, V61, P1040, DOI 10.1104/pp.61.6.1040; YOULE RJ, 1979, J AGR FOOD CHEM, V27, P500, DOI 10.1021/jf60223a017; YOULE RJ, 1981, AM J BOT, V68, P44, DOI 10.2307/2442990; ZEIGER RS, 1990, ANN ALLERGY, V65, P430	44	112	131	1	20	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				807	814		10.1016/S0091-6749(98)70308-2	http://dx.doi.org/10.1016/S0091-6749(98)70308-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648708	Bronze			2022-12-18	WOS:000074414200015
J	Majamaa, H; Isolauri, E				Majamaa, H; Isolauri, E			Evaluation of the gut mucosal barrier: Evidence for increased antigen transfer in children with atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						intestinal absorption; atopic eczema	COWS MILK ALLERGY; INTESTINAL PERMEABILITY; MACROMOLECULAR ABSORPTION; PEYER PATCHES; TRANSPORT; RAT; DERMATITIS; PROTEIN; INVITRO; ADULT	Background: Intestinal antigen handling determines subsequent immune response to the antigen. Antigens are absorbed across epithelium along two functional pathways. The main pathway is degradative, which reduces the immunogenicity of the antigen. A minor pathway allows the transport of intact proteins, which is crucial for antigen-specific immune responses. The ussing chamber method allows the quantitative measurement of protein transfer across the intestinal mucosa. Objective: This study was designed to explore the theory that altered antigen transfer across the intestinal mucosa is a factor in the pathogenesis of atopic eczema, characterized by hyperreactivity to environmental antigens. Methods: The adsorption and degradation of horseradish peroxidase (molecular weight, 40,000 d) were studied in vitro in Ussing chambers. Eighteen biopsy specimens of upper small intestinal mucosa from 14 patients (aged 0.5 to 8 years) with atopic eczema and 18 specimens from 15 age-matched control subjects were examined. Results: The mean (95% confidence interval) absorption of intact horseradish peroxidase was significantly higher in children with atopic eczema than in control subjects: 242 (81-404) pmol . hr(-1). cm(-2) versus 23 (12-33) pmol . hr(-1). cm(-2); t = 2.86, p = 0.007. The absorption of degraded horseradish peroxidase was 972 (732-1213) pmol . hr(-1). cm(-2) in patients with atopic eczema and 672 (532-811) pmol . hr(-1). cm(-2) in control subjects; t = 2.29, p = 0.03. Conclusions: Our results may reflect a primarily altered antigen transfer in patients who have atopic eczema, which may initiate and perpetuate prompt immune responses to common environmental antigens, including foods.	TAMPERE UNIV,SCH MED,SF-33101 TAMPERE,FINLAND; TAMPERE UNIV HOSP,DEPT PEDIAT,TAMPERE,FINLAND	Tampere University; Tampere University; Tampere University Hospital								ARMSTRONG WM, 1987, PHYSL GASTROINTESTIN, P1251; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; ARVOLA T, 1992, PEDIATR RES, V32, P301, DOI 10.1203/00006450-199209000-00011; ATHERTON DJ, 1978, LANCET, V1, P401; BARBA A, 1989, BRIT J DERMATOL, V120, P71, DOI 10.1111/j.1365-2133.1989.tb07767.x; BJARNASON I, 1985, BRIT J DERMATOL, V112, P291, DOI 10.1111/j.1365-2133.1985.tb04856.x; BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; BRUCE MG, 1986, IMMUNOLOGY, V59, P295; CAFFARELLI C, 1993, CLIN EXP ALLERGY, V23, P28, DOI 10.1111/j.1365-2222.1993.tb02480.x; CAILLARD I, 1992, J NUTR BIOCHEM, V3, P653, DOI 10.1016/0955-2863(92)90085-W; DUMONT GCL, 1984, CLIN ALLERGY, V14, P55; DUPONT C, 1989, J PEDIATR GASTR NUTR, V8, P459, DOI 10.1097/00005176-198905000-00007; HANIFIN JM, 1987, MONOGR ALLERGY, V21, P116; HEYMAN M, 1992, J PEDIATR GASTR NUTR, V15, P48, DOI 10.1097/00005176-199207000-00008; HEYMAN M, 1990, INT ARCH ALLER A IMM, V92, P242, DOI 10.1159/000235184; HEYMAN M, 1988, PEDIATR RES, V24, P197, DOI 10.1203/00006450-198808000-00012; HEYMAN M, 1982, AM J PHYSIOL, V242, pG558, DOI 10.1152/ajpgi.1982.242.6.G558; HUSBY S, 1988, APMIS, V96, P1; ISOLAURI E, 1990, DIGEST DIS SCI, V35, P360, DOI 10.1007/BF01537415; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; JACKSON PG, 1981, LANCET, V1, P1285; JALONEN T, 1991, PEDIATR RES, V30, P290, DOI 10.1203/00006450-199109000-00019; JALONEN T, 1991, J ALLERGY CLIN IMMUN, V88, P737, DOI 10.1016/0091-6749(91)90180-V; KELJO DJ, 1983, AM J PHYSIOL, V244, pG637, DOI 10.1152/ajpgi.1983.244.6.G637; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; METCALFE DD, 1985, CLIN REV ALLERG, V3, P331, DOI 10.1007/BF02992999; PERDUE MH, 1986, AM J PHYSIOL, V250, pG427, DOI 10.1152/ajpgi.1986.250.4.G427; PIKE MG, 1986, J INVEST DERMATOL, V86, P101, DOI 10.1111/1523-1747.ep12284035; SANDERSON IR, 1993, GASTROENTEROLOGY, V104, P622, DOI 10.1016/0016-5085(93)90436-G; STERN M, 1984, PEDIATR RES, V18, P1252, DOI 10.1203/00006450-198412000-00005; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; TEICHBERG S, 1990, PEDIATR RES, V28, P31, DOI 10.1203/00006450-199007000-00008; TURNER MW, 1988, IMMUNOLOGY, V63, P119; UKABAM SO, 1984, BRIT J DERMATOL, V110, P649, DOI 10.1111/j.1365-2133.1984.tb04699.x; WALKER WA, 1972, J CELL BIOL, V54, P195, DOI 10.1083/jcb.54.2.195; WALKER WA, 1988, FOOD ALLERGY, P15; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809	38	112	116	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					985	990		10.1016/S0091-6749(96)80074-1	http://dx.doi.org/10.1016/S0091-6749(96)80074-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655895				2022-12-18	WOS:A1996UG08600014
J	BIRKHEAD, G; ATTAWAY, NJ; STRUNK, RC; TOWNSEND, MC; TEUTSCH, S				BIRKHEAD, G; ATTAWAY, NJ; STRUNK, RC; TOWNSEND, MC; TEUTSCH, S			INVESTIGATION OF A CLUSTER OF DEATHS OF ADOLESCENTS FROM ASTHMA - EVIDENCE IMPLICATING INADEQUATE TREATMENT AND POOR PATIENT ADHERENCE WITH MEDICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR DIS CONTROL, EPIDEMIOL PROGRAM OFF, DIV SURVEILLANCE & EPIDEMIOL STUDIES, ATLANTA, GA 30333 USA; ST LOUIS CHILDRENS HOSP, DIV PULM, ST LOUIS, MO 63178 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; ST LOUIS CHILDRENS HOSP, DIV ALLERGY IMMUNOL, ST LOUIS, MO 63178 USA; NIOSH, DIV RESP STUDIES, CLIN INVEST BRANCH, MORGANTOWN, WV 26505 USA	Centers for Disease Control & Prevention - USA; St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)			Birkhead, Guthrie/AAG-9058-2019	Birkhead, Guthrie/0000-0002-6511-6560				ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; CARSWELL F, 1985, ARCH DIS CHILD, V60, P25, DOI 10.1136/adc.60.1.25; CUSHLEY MJ, 1983, J ROY SOC MED, V76, P662, DOI 10.1177/014107688307600808; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; KENLINE PA, 1963, ARCH ENVIRON HEALTH, V12, P295; KRAVIS LP, 1985, AM J DIS CHILD, V139, P558, DOI 10.1001/archpedi.1985.02140080028026; LITT IF, 1980, PEDIATR CLIN N AM, V27, P3; MILLER BD, 1987, J ALLERGY CLIN IMMUN, V80, P481, DOI 10.1016/0091-6749(87)90080-7; PACKE GE, 1985, LANCET, V2, P199; POYNTER D, 1987, J ALLERGY CLIN IMMUN, V80, P423, DOI 10.1016/0091-6749(87)90067-4; REA HH, 1987, NEW ZEAL MED J, V100, P10; ROSNER B, 1982, FUNDAMENTALS BIOSTAT, P308; RUBINSTEIN S, 1984, ANN ALLERGY, V53, P311; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SEARS MR, 1986, BRIT MED J, V293, P1342, DOI 10.1136/bmj.293.6558.1342; SEARS MR, 1985, NEW ZEAL MED J, V98, P271; SEARS MR, 1987, BRIT MED J, V294, P477, DOI 10.1136/bmj.294.6570.477; SEARS MR, 1986, ARCH DIS CHILD, V61, P6, DOI 10.1136/adc.61.1.6; STABLEFORTH DE, 1987, J ALLERGY CLIN IMMUN, V80, P463, DOI 10.1016/0091-6749(87)90076-5; STRUNK R C, 1985, Journal of the American Medical Association, V254, P1193, DOI 10.1001/jama.254.9.1193; STRUNK RC, 1987, J ALLERGY CLIN IMMUN, V80, P455, DOI 10.1016/0091-6749(87)90073-X; WALLENSTEIN S, 1980, AM J EPIDEMIOL, V111, P367, DOI 10.1093/oxfordjournals.aje.a112908; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1985, DHHS PHS871120 PUBL, V36; 1980, NIOSH81108 NAT I OCC; 1980, CURRENT POPULATION P, V25; 1986, MISSOURI HOSPITAL PR; 1986, AGE RACE SEX COUNTY; 1978, EPA600878004 PUBL	31	112	112	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	1				484	491		10.1016/0091-6749(89)90361-8	http://dx.doi.org/10.1016/0091-6749(89)90361-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW760	2794293	Bronze			2022-12-18	WOS:A1989AW76000009
J	BLUESTONE, CD; DOYLE, WJ				BLUESTONE, CD; DOYLE, WJ			ANATOMY AND PHYSIOLOGY OF EUSTACHIAN-TUBE AND MIDDLE-EAR RELATED TO OTITIS-MEDIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP,OTITIS MEDIA RES CTR,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ANSON B, 1967, MORRIS HUMAN ANATOMY, P1195; ANSON B, 1967, SURG ANATOMY TEMPORA, P29; BERRY QC, 1975, LARYNGOSCOPE, V85, P1976; Bluestone C D, 1972, Trans Am Acad Ophthalmol Otolaryngol, V76, P1325; BLUESTONE CD, 1972, LARYNGOSCOPE, V82, P1654, DOI 10.1288/00005537-197209000-00009; BLUESTONE CD, 1971, ANN OTO RHINOL LARYN, V80, P1; BLUESTONE CD, 1978, LARYNGOSCOPE, V88, P1155; BLUESTONE CD, 1976, ANN OTO RHINOL LARYN, V85, P182, DOI 10.1177/00034894760850S235; BYLANDER A, 1983, ACTA OTO-LARYNGOL, V96, P467, DOI 10.3109/00016488309132733; BYLANDER A, 1983, ACTA OTO-LARYNGOL, V96, P255, DOI 10.3109/00016488309132898; BYLANDER A, 1980, ANN OTO RHINOL LARYN, V89, P20, DOI 10.1177/00034894800890S308; CANTEKIN EI, 1979, ANN OTO RHINOL LARYN, V88, P40, DOI 10.1177/000348947908800108; CANTEKIN EI, 1983, ARCH OTOLARYNGOL, V109, P281; CANTEKIN EI, 1980, ANN OTOL RHINOL LA S, V68, P71; Doyle, 1977, THESIS U PITTSBURGH; DOYLE WJ, 1980, ANN OTO RHINOL LARYN, V89, P41, DOI 10.1177/00034894800890S312; ELNER A, 1972, ACTA OTO-LARYNGOL, V74, P191, DOI 10.3109/00016487209128440; ELNER A, 1977, ACTA OTO-LARYNGOL, V83, P25, DOI 10.3109/00016487709128807; ELNER A, 1971, ACTA OTO-LARYNGOL, V72, P320, DOI 10.3109/00016487109122489; FALK B, 1984, INT J PEDIATR OTORHI, V7, P97, DOI 10.1016/S0165-5876(84)80034-8; GOSS C, 1967, GRAYS ANATOMY HUMAN, P1087; Graves GO, 1944, ARCHIV OTOLARYNGOL, V39, P359; HONJO I, 1981, ARCH OTOLARYNGOL, V107, P350; HONJO I, 1985, AM J OTOLARYNG, V6, P241, DOI 10.1016/S0196-0709(85)80095-8; HONJO I, 1983, ACTA OTO-LARYNGOL, V95, P329, DOI 10.3109/00016488309130950; INGELSTEDT S, 1967, ACTA OTO-LARYNGOL, V228, P31; LUPIN AJ, 1969, ANN OTO RHINOL LARYN, V78, P792, DOI 10.1177/000348946907800412; PROCTOR B, 1967, ARCHIV OTOLARYNGOL, V86, P503; Rich AR, 1920, B JOHNS HOPKINS HOSP, V31, P305; RIU R, 1966, PHYSL TROMPE DTSCH; ROOD SR, 1978, ANN OTO RHINOL LARYN, V87, P202, DOI 10.1177/000348947808700210; ROOD SR, 1973, AM J ANAT, V138, P191, DOI 10.1002/aja.1001380205; ROOD SR, 1982, CLEFT PALATE J, V19, P119; ROSEN LM, 1970, THESIS U PITTSBURGH; ROSS MA, 1971, ARCHIV OTOLARYNGOL, V93, P1; SIEGEL MI, 1987, RECENT ADV OTITIS ME; TERRACOL A, 1949, TROMPE EUSTACHE; TOS M, 1984, CLIN REV ALLERG, V2, P267	38	112	116	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			997	1003		10.1016/0091-6749(88)90168-6	http://dx.doi.org/10.1016/0091-6749(88)90168-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3286738				2022-12-18	WOS:A1988N703700013
J	BROWN, WG; HALONEN, MJ; KALTENBORN, WT; BARBEE, RA				BROWN, WG; HALONEN, MJ; KALTENBORN, WT; BARBEE, RA			RELATIONSHIP OF RESPIRATORY ALLERGY, SKIN-TEST REACTIVITY, AND SERUM IGE IN A COMMUNITY POPULATION-SAMPLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ARIZONA, COLL MED, DIV RESPIRATORY SCI, TUCSON, AZ 85724 USA	University of Arizona				Halonen, Marilyn/0000-0001-9606-935X				AHLSTEDT S, 1974, CLIN ALLERGY, V4, P131, DOI 10.1111/j.1365-2222.1974.tb01370.x; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BERG TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209, DOI 10.1016/0091-6749(74)90063-3; BRODER I, 1974, J ALLERGY CLIN IMMUN, V53, P127, DOI 10.1016/0091-6749(74)90001-3; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; CAVANAUGH MJ, 1977, J ALLERGY CLIN IMMUN, V59, P41, DOI 10.1016/0091-6749(77)90175-0; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GROW MH, 1936, J ALLERGY, V7, P108; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HOURI M, 1972, Clinical Allergy, V2, P285, DOI 10.1111/j.1365-2222.1972.tb01292.x; INDRAJANA T, 1971, ANN ALLERGY, V29, P639; Johansson S G, 1972, Prog Clin Immunol, V1, P157; LEBOWITZ MD, 1976, AM REV RESPIR DIS, V113, P627; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; LINDBLAD JH, 1961, J ALLERGY, V32, P392, DOI 10.1016/0021-8707(61)90016-8; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; PEPYS J, 1975, Clinical Allergy, V5, P431, DOI 10.1111/j.1365-2222.1975.tb01882.x; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; PERERA MG, 1975, AM REV RESPIR DIS, V111, P605; RACHEMANN FM, 1935, J ALLERGY CLIN IMMUN, V6, P184; REDDY PM, 1978, J ALLERGY CLIN IMMUN, V61, P36, DOI 10.1016/0091-6749(78)90471-2; STENIUS B, 1971, Clinical Allergy, V1, P37, DOI 10.1111/j.1365-2222.1971.tb02446.x; STENIUS B, 1978, ACTA ALLERGOL, V26, P81; WARREN CPW, 1974, CAN MED ASSOC J, V110, P425; WIDE L, 1973, CLIN ALLERGY, V3, P583, DOI 10.1111/j.1365-2222.1973.tb03063.x; WIDE L, 1967, LANCET, V2, P1105	27	112	116	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	5					328	335		10.1016/0091-6749(79)90127-1	http://dx.doi.org/10.1016/0091-6749(79)90127-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GU943	429712				2022-12-18	WOS:A1979GU94300006
J	Gale, SC; Gao, L; Mikacenic, C; Coyle, SM; Rafaels, N; Dudenkov, TM; Madenspacher, JH; Draper, DW; Ge, W; Aloor, JJ; Azzam, KM; Lai, LH; Blackshear, PJ; Calvano, SE; Barnes, KC; Lowry, SF; Corbett, S; Wurfel, MM; Fessler, MB				Gale, Stephen C.; Gao, Li; Mikacenic, Carmen; Coyle, Susette M.; Rafaels, Nicholas; Dudenkov, Tanda Murray; Madenspacher, Jennifer H.; Draper, David W.; Ge, William; Aloor, Jim J.; Azzam, Kathleen M.; Lai, Lihua; Blackshear, Perry J.; Calvano, Steven E.; Barnes, Kathleen C.; Lowry, Stephen F.; Corbett, Siobhan; Wurfel, Mark M.; Fessler, Michael B.			APO epsilon 4 is associated with enhanced in vivo innate immune responses in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Apolipoprotein; Toll-like receptor; LPS	APOLIPOPROTEIN-E GENOTYPE; E-DEFICIENT MICE; PLATELET-AGGREGATION; CONSENSUS CONFERENCE; APOE GENOTYPE; DISEASE; SEPSIS; LIPOPOLYSACCHARIDE; POLYMORPHISMS; THROMBOSIS	Background: The genetic determinants of the human innate immune response are poorly understood. Apolipoprotein (Apo) E, a lipid-trafficking protein that affects inflammation, has well-described wild-type (epsilon 3) and disease-associated (epsilon 2 and epsilon 4) alleles, but its connection to human innate immunity is undefined. Objective: We sought to define the relationship of APO epsilon 4 to the human innate immune response. Methods: We evaluated APO epsilon 4 in several functional models of the human innate immune response, including intravenous LPS challenge in human subjects, and assessed APO epsilon 4 association to organ injury in patients with severe sepsis, a disease driven by dysregulated innate immunity. Results: Whole blood from healthy APO epsilon 3/APO epsilon 4 volunteers induced higher cytokine levels on ex vivo stimulation with Toll-like receptor (TLR) 2, TLR4, or TLR5 ligands than blood from APO epsilon 3/APO epsilon 3 patients, whereas TLR7/8 responses were similar. This was associated with increased lipid rafts in APO epsilon 3/APO epsilon 4 monocytes. By contrast, APO epsilon 3/APO epsilon 3 and APO epsilon 3/APO epsilon 4 serum neutralized LPS equivalently and supported similar LPS responses in Apoe-deficient macrophages, arguing against a differential role for secretory APOE4 protein. After intravenous LPS, APO epsilon 3/APO epsilon 4 patients had higher hyperthermia and plasma TNF-alpha levels and earlier plasma IL-6 than APO epsilon 3/APO epsilon 3 patients. APO epsilon 4-targeted replacement mice displayed enhanced hypothermia, plasma cytokines, and hepatic injury and altered splenic lymphocyte apoptosis after systemic LPS compared with APO epsilon 3 counterparts. In a cohort of 828 patients with severe sepsis, APO epsilon 4 was associated with increased coagulation system failure among European American patients. Conclusions: APO epsilon 4 is a determinant of the human innate immune response to multiple TLR ligands and associates with altered patterns of organ injury in human sepsis.	[Madenspacher, Jennifer H.; Draper, David W.; Ge, William; Aloor, Jim J.; Azzam, Kathleen M.; Lai, Lihua; Fessler, Michael B.] NIEHS, Lab Resp Biol, NIH, Res Triangle Pk, NC 27709 USA; [Blackshear, Perry J.] NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; [Gale, Stephen C.; Coyle, Susette M.; Calvano, Steven E.; Lowry, Stephen F.; Corbett, Siobhan] UMDNJ Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ USA; [Gao, Li; Rafaels, Nicholas; Dudenkov, Tanda Murray; Barnes, Kathleen C.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Mikacenic, Carmen; Wurfel, Mark M.] Univ Washington, Dept Med, Seattle, WA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Rutgers State University New Brunswick; Rutgers State University Medical Center; Johns Hopkins University; University of Washington; University of Washington Seattle	Fessler, MB (corresponding author), NIEHS, 111 TW Alexander Dr,POB 12233,MD D2-01, Res Triangle Pk, NC 27709 USA.	fesslerm@niehs.nih.gov	Fessler, Michael B/C-6323-2019; Blackshear, Perry J./C-6206-2019	Fessler, Michael B/0000-0002-8262-8613; Blackshear, Perry J./0000-0002-9561-8529; Ge, William/0000-0002-2278-8201; Gale, Stephen/0000-0002-6454-4686	U.S. PHS [R01 GM-34695]; Intramural Research Program of the NIH, National Institute of Environmental Health Sciences [Z01 ES102005-08]; Mary Beryl Patch Turnbull Scholar Program;  [R01 HL089807-01];  [HL 73994]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089807, P50HL073994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES102005, ZIAES090080, ZIAES102005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034695] Funding Source: NIH RePORTER	U.S. PHS(United States Department of Health & Human ServicesUnited States Public Health Service); Intramural Research Program of the NIH, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Mary Beryl Patch Turnbull Scholar Program; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by R01 GM-34695 (U.S. PHS), R01 HL089807-01 (to M. M. W.), HL 73994 (to K. C. B.), and the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01 ES102005-08). K. C. B. was supported in part by the Mary Beryl Patch Turnbull Scholar Program.	Baitsch D, 2011, ARTERIOSCL THROM VAS, V31, P1160, DOI 10.1161/ATVBAHA.111.222745; Baumann CL, 2010, J EXP MED, V207, P2689, DOI 10.1084/jem.20101111; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Buga GM, 2010, ARTERIOSCL THROM VAS, V30, P283, DOI 10.1161/ATVBAHA.109.200162; Chang MH, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-62; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Chulada PC, 2011, ENVIRON HEALTH PERSP, V119, P1523, DOI 10.1289/ehp.1003348; Cox D, 2011, J THROMB HAEMOST, V9, P1097, DOI 10.1111/j.1538-7836.2011.04264.x; de Bont N, 2000, EUR J CLIN INVEST, V30, P818; Deo RC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000342; Dole VS, 2008, ARTERIOSCL THROM VAS, V28, P1111, DOI 10.1161/ATVBAHA.108.162347; Dong AP, 2010, THROMB RES, V126, pE312, DOI 10.1016/j.thromres.2010.03.010; DONG LM, 1994, J BIOL CHEM, V269, P22358; Edelstein LC, 2013, NAT MED, V19, P1609, DOI 10.1038/nm.3385; Ewbank DC, 2007, J GERONTOL A-BIOL, V62, P899, DOI 10.1093/gerona/62.8.899; Fessler MB, 2011, J IMMUNOL, V187, P1529, DOI 10.4049/jimmunol.1100253; Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC; Grocott HP, 2001, J THORAC CARDIOV SUR, V122, P622, DOI 10.1067/mtc.2001.115152; Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; Janot L, 2008, J INFECT DIS, V198, P115, DOI 10.1086/588815; Jofro-Monseny L, 2007, BIOCHEM BIOPH RES CO, V357, P319, DOI 10.1016/j.bbrc.2007.03.150; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kuhlmann I, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-8; Lowry SF, 2005, SHOCK, V24, P94, DOI 10.1097/01.shk.0000191340.23907.a1; Ma Y, 2010, BLOOD, V116, P1932, DOI 10.1182/blood-2010-02-268508; Madenspacher JH, 2012, J BIOL CHEM, V287, P43730, DOI 10.1074/jbc.M112.377192; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Marcourakis T, 2008, CELL BIOCHEM FUNCT, V26, P852, DOI 10.1002/cbf.1516; Merrick BA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.006007; Murphy AJ, 2013, NAT MED, V19, P586, DOI 10.1038/nm.3150; Murphy AJ, 2011, J CLIN INVEST, V121, P4138, DOI 10.1172/JCI57559; Okoro EU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044430; Ozturk Z, 2010, METAB SYNDR RELAT D, V8, P531, DOI 10.1089/met.2010.0034; Pritchard JK, 2000, GENETICS, V155, P945; Qayyum R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002491; Rensen PCN, 1997, J CLIN INVEST, V99, P2438, DOI 10.1172/JCI119427; Riddell DR, 1997, J BIOL CHEM, V272, P89; Roselaar SE, 1998, J LIPID RES, V39, P1740; Segal JB, 2006, ANN EPIDEMIOL, V16, P123, DOI 10.1016/j.annepidem.2005.06.052; Semeraro N, 2012, THROMB RES, V129, P290, DOI 10.1016/j.thromres.2011.10.013; Singh K, 2011, J BIOL CHEM, V286, P3839, DOI 10.1074/jbc.M110.176719; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; Van Oosten MV, 2001, J BIOL CHEM, V276, P8820, DOI 10.1074/jbc.M009915200; VANDEVENTER SJH, 1988, LANCET, V1, P605; Vincent JL, 2005, J ORGAN DYSFUNCTION, V1, P18; Wang H, 2009, ANAESTH INTENS CARE, V37, P38, DOI 10.1177/0310057X0903700111; Wurfel MM, 2008, AM J RESP CRIT CARE, V178, P710, DOI 10.1164/rccm.200803-462OC	51	111	113	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					127	+		10.1016/j.jaci.2014.01.032	http://dx.doi.org/10.1016/j.jaci.2014.01.032			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24655576	Green Accepted			2022-12-18	WOS:000338930300017
J	Puck, JM				Puck, Jennifer M.			Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: The winner is T-cell receptor excision circles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; T-cell receptor excision circle; severe combined immunodeficiency; lymphocytopenia; dried bloodspot; newborn screening	ADENOSINE-DEAMINASE DEFICIENCY; COMBINED IMMUNE-DEFICIENCY; THYMIC FUNCTION; GENE-THERAPY; TRANSPLANTATION; MUTATION; RECONSTITUTION; DISEASE; INFANT; EXPRESSION	The most profound primary immunodeficiency disease, severe combined immunodeficiency (SCID), is fatal in infancy unless affected infants are provided with an adaptive immune system through allogeneic hematopoietic cell transplantation, enzyme replacement, or gene therapy. However, most infants with SCID lack a family history or any clinical clues before the onset of infections, making this serious but treatable disease a candidate for population-based newborn screening. Of several approaches considered for SCID screening, testing for T-cell receptor excision circles (TRECs), a DNA biomarker of normal T-cell development, has proved successful. TREC numbers can be measured in DNA isolated from the dried bloodspots already routinely collected for newborn screening. Infants with low or absent TRECs can thus be identified and referred for confirmatory testing and prompt intervention. TREC testing of newborns is now being performed in several states, indicating that this addition to the newborn screening panel can be successfully integrated into state public health programs. (J Allergy Clin Immunol 2012; 129: 607-16.)	[Puck, Jennifer M.] Univ Calif San Francisco, Div Allergy Immunol & Bone Marrow Transplantat, Dept Pediat, San Francisco, CA 94143 USA; [Puck, Jennifer M.] UCSF Benioff Childrens Hosp, San Francisco, CA USA	University of California System; University of California San Francisco	Puck, JM (corresponding author), Univ Calif San Francisco, Div Allergy Immunol & Bone Marrow Transplantat, Dept Pediat, Box 0519,513 Parnassus Ave,HSE 301-A, San Francisco, CA 94143 USA.	puckj@peds.ucsf.edu			National Institutes of Health; Jeffrey Modell Foundation; National Institutes of Health (National Human Genome Research Institute Division of Intramural Research, National Institute of Allergy and Infectious Diseases) [RO1 AI078248]; National Institutes of Health, Primary Immune Deficiency Treatment Consortium [U54 AI082973]; National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development [RO3 HD 060311]; National Institutes of Health, National Center for Research Resources NCRR UCSF CTSI [UL1 RR024131]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD060311] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973, R01AI078248] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jeffrey Modell Foundation; National Institutes of Health (National Human Genome Research Institute Division of Intramural Research, National Institute of Allergy and Infectious Diseases); National Institutes of Health, Primary Immune Deficiency Treatment Consortium; National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institutes of Health, National Center for Research Resources NCRR UCSF CTSI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	J. M. Puck has received research support from the National Institutes of Health and the Jeffrey Modell Foundation.; This work was made possible by funding from the National Institutes of Health (National Human Genome Research Institute Division of Intramural Research, National Institute of Allergy and Infectious Diseases for RO1 AI078248 and Primary Immune Deficiency Treatment Consortium U54 AI082973, the Eunice Kennedy Shriver National Institute of Child Health and Human Development for RO3 HD 060311 and National Center for Research Resources NCRR UCSF CTSI UL1 RR024131) and from the Jeffrey Modell Foundation.	Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; [Anonymous], NEWB SCREEN STAT REP; Baker MW, 2009, J ALLERGY CLIN IMMUN, V124, P522, DOI 10.1016/j.jaci.2009.04.007; Bertrand Y, 2002, BONE MARROW TRANSPL, V29, P759, DOI 10.1038/sj.bmt.1703531; Brown L, 2011, BLOOD, V117, P3243, DOI 10.1182/blood-2010-08-300384; Buckley R, 2007, PRIMARY IMMUNODEFICI, P669; Buckley RH, 2011, IMMUNOL RES, V49, P25, DOI 10.1007/s12026-010-8191-9; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Cavazzana-Calvo M, 2007, BLOOD, V109, P4575, DOI 10.1182/blood-2006-07-029090; Chan A, 2011, CLIN IMMUNOL, V138, P3, DOI 10.1016/j.clim.2010.09.010; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Chase NM, 2010, CURR OPIN ALLERGY CL, V10, P521, DOI 10.1097/ACI.0b013e32833fd6fe; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; Dasouki M, 2011, CLIN IMMUNOL, V141, P128, DOI 10.1016/j.clim.2011.06.003; De Villartay JP, 2007, PRIMARY IMMUNODEFICI, P153; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Fischer A, 2011, J ALLERGY CLIN IMMUN, V127, P1356, DOI 10.1016/j.jaci.2011.04.030; Gaspar HB, 2009, BLOOD, V114, P3524, DOI 10.1182/blood-2009-06-189209; GATTI RA, 1968, LANCET, V2, P1366; Gerstel-Thompson JL, 2010, CLIN CHEM, V56, P1466, DOI 10.1373/clinchem.2010.144915; Gilroy RK, 2004, BLOOD, V103, P1171, DOI 10.1182/blood-2003-04-1187; Goldman FD, 1998, J CLIN INVEST, V102, P421, DOI 10.1172/JCI3205; Griffith LM, 2009, J ALLERGY CLIN IMMUN, V124, P1152, DOI 10.1016/j.jaci.2009.10.022; Griffith LM, 2008, J ALLERGY CLIN IMMUN, V122, P1087, DOI 10.1016/j.jaci.2008.09.045; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Guthrie R., 1963, PEDIATRICS, V32, P318; Hale JE, 2010, J ALLERGY CLIN IMMUN, V126, P1073, DOI 10.1016/j.jaci.2010.08.043; Hazenberg MD, 2001, J MOL MED, V79, P631, DOI 10.1007/s001090100271; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; Janik DK, 2010, CLIN CHEM, V56, P1460, DOI 10.1373/clinchem.2010.144329; Knutsen AP, 2000, J CLIN IMMUNOL, V20, P466, DOI 10.1023/A:1026463900925; Kung C, 2000, NAT MED, V6, P343; Lebet T, 2008, GENET MED, V10, P575, DOI [10.1097/GIM.0b013e31818063bc, 10.1097GIM.0b013e31818063bc]; Li LY, 2002, J IMMUNOL, V168, P6323, DOI 10.4049/jimmunol.168.12.6323; Lindegren Mary Lou, 2004, Morbidity and Mortality Weekly Report, V53, P1; Markert ML, 2009, IMMUNOL RES, V44, P61, DOI 10.1007/s12026-008-8082-5; McGhee SA, 2005, MOL GENET METAB, V86, P427, DOI 10.1016/j.ymgme.2005.09.005; MERYASH DL, 1981, NEW ENGL J MED, V304, P294, DOI 10.1056/NEJM198101293040510; Morinishi Y, 2009, J PEDIATR-US, V155, P829, DOI 10.1016/j.jpeds.2009.05.026; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; O'Reilly RJ, 1994, BONE MARROW TRANSPL, P849; Patel DD, 2000, NEW ENGL J MED, V342, P1325, DOI 10.1056/NEJM200005043421804; Patel NC, 2010, NEW ENGL J MED, V362, P314, DOI 10.1056/NEJMoa0904485; Pignata C, 1996, AM J MED GENET, V65, P167, DOI 10.1002/(SICI)1096-8628(19961016)65:2<167::AID-AJMG17>3.0.CO;2-O; Primary Immune Deficiency Treatment Consortium, 2011, RAR DIS CLIN RES NET; Puck J M, 2007, PRIMARY IMMUNODEFICI, P123; Puck JM, 2007, J ALLERGY CLIN IMMUN, V120, P760, DOI 10.1016/j.jaci.2007.08.043; Puck JM, 2011, CURR OPIN PEDIATR, V23, P667, DOI 10.1097/MOP.0b013e32834cb9b0; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; Puck JM, 1997, HUM GENET, V99, P628, DOI 10.1007/s004390050418; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Ram G, 2011, CLIN EXP IMMUNOL, V164, P9, DOI 10.1111/j.1365-2249.2011.04335.x; Recio MJ, 2007, J IMMUNOL, V178, P2556, DOI 10.4049/jimmunol.178.4.2556; REGUEIRO JR, 2007, PRIMARY IMMUNODEFICI, P216; Roberts JL, 2004, BLOOD, V103, P2009, DOI 10.1182/blood-2003-06-2104; Routes JM, 2009, JAMA-J AM MED ASSOC, V302, P2465, DOI 10.1001/jama.2009.1806; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Smogorzewska Elzbieta M., 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P111; Tangsinmankong N, 1999, J ALLERGY CLIN IMMUN, V103, P1222, DOI 10.1016/S0091-6749(99)70207-1; Tarini BA, 2011, PEDIATRICS, V128, P715, DOI 10.1542/peds.2010-2448; Tchilian EZ, 2001, J IMMUNOL, V166, P1308, DOI 10.4049/jimmunol.166.2.1308; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121	65	111	120	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					607	618		10.1016/j.jaci.2012.01.032	http://dx.doi.org/10.1016/j.jaci.2012.01.032			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22285280	Green Accepted, Bronze			2022-12-18	WOS:000301189300002
J	Quinto, KB; Zuraw, BL; Poon, KYT; Chen, WS; Schatz, M; Christiansen, SC				Quinto, Kenneth B.; Zuraw, Bruce L.; Poon, Kwun-Yee T.; Chen, Wansu; Schatz, Michael; Christiansen, Sandra C.			The association of obesity and asthma severity and control in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; childhood obesity; risk for exacerbation; asthma control; beta-agonists dispensed; oral corticosteroid courses	BODY-MASS INDEX; INCIDENT ASTHMA; ADULTS; WEIGHT; RISK; COHORT; WOMEN; AGE; ADOLESCENTS; LEPTIN	Background: The association between obesity and asthma severity and control in children is not well understood. Objective: The objective of this study was to examine the association of childhood body mass index (BMI) percentile for age of 85% or greater with the number of beta-agonist canisters dispensed, corticosteroid courses, emergency department visits, and hospitalizations for asthma. Methods: A retrospective cohort of 32,321 children aged 5 to 17 years and given a diagnosis of asthma who received at least 1 asthma (controller or rescue) medication and were enrolled in Kaiser Permanente from 2004-2008 was identified. Outcomes from electronic medical records included beta-agonist canister and nebulizer units dispensed per year, hospitalizations and emergency department visits for asthma exacerbations, and oral corticosteroid courses. Potential confounding factors known to influence asthma outcomes were also collected: demographics, parental education level, asthma controller use, gastroesophageal reflux disease diagnosis, and diabetes mellitus diagnosis. Multiple logistic regression models were used to measure the independent association of BMI status with outcomes. Results: Even after adjusting for demographics, parental education level, asthma controller use, and gastroesophageal reflux disease and diabetes mellitus diagnoses, overweight (BMI percentile for age, 85% to 94%) and obese (BMI percentile for age, >= 95%) children were more likely to have increased beta-agonists dispensed (odds ratio of 1.15 [95% CI, 1.02-1.27] and odds ratio of 1.17 [95% CI, 1.06-1.29], respectively) and increased risk for oral corticosteroids dispensed (odds ratio of 1.21 [95% CI, 1.13-1.29] and odds ratio of 1.28 [95% CI, 1.21-1.36], respectively) compared with normal-weight (BMI percentile for age, 16% to 84%) children. Conclusions: Our findings suggest that childhood obesity is associated with an increased risk of worse asthma control and exacerbations. (J Allergy Clin Immunol 2011;128:964-9.)	[Schatz, Michael; Christiansen, Sandra C.] Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA; [Quinto, Kenneth B.; Zuraw, Bruce L.; Schatz, Michael; Christiansen, Sandra C.] Univ Calif San Diego, Dept Allergy & Immunol, La Jolla, CA 92093 USA; [Zuraw, Bruce L.] San Diego VA Healthcare, San Diego, CA USA; [Poon, Kwun-Yee T.; Chen, Wansu] Kaiser Permanente, Dept Res & Evaluat, Pasadena, CA USA	Kaiser Permanente; University of California System; University of California San Diego; Kaiser Permanente	Christiansen, SC (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	Sandra.C.Christiansen@kp.org		Zuraw, Bruce/0000-0003-0640-6768	National Institutes of Health [T32 AI 07469]; Kaiser Permanente; National Institutes of Health/National Institute of Allergy and Infectious Diseases; Merck; GlaxoSmithKline; Aercrine; Genentech; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007469] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kaiser Permanente; National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Merck(Merck & Company); GlaxoSmithKline(GlaxoSmithKline); Aercrine; Genentech(Roche HoldingGenentech); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant T32 AI 07469 and a grant from Kaiser Permanente.; Disclosure of potential conflict of interest: B. L. Zuraw has received grants and research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. M. Schatz is a research consultant for Merck, Amgen, and GlaxoSmithKline and has received research support from Merck, GlaxoSmithKline, Aercrine, and Genentech. The rest of the authors have declared that they have no conflict of interest.	Aaron SD, 2008, CAN MED ASSOC J, V179, P1121, DOI 10.1503/cmaj.081332; Beckett WS, 2001, AM J RESP CRIT CARE, V164, P2045, DOI 10.1164/ajrccm.164.11.2004235; Boulet LP, 2007, RESP MED, V101, P2240, DOI 10.1016/j.rmed.2007.06.031; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; Ford ES, 2004, EUR RESPIR J, V24, P740, DOI 10.1183/09031936.04.00088003; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Gunnbjomsdottir MI, 2004, EUR RESPIR J, V24, P116, DOI 10.1183/09031936.04.00042603; Kattan M, 2010, J ALLERGY CLIN IMMUN, V125, P584, DOI 10.1016/j.jaci.2010.01.053; Koebnick C, 2010, J PEDIATR-US, V157, P26, DOI 10.1016/j.jpeds.2010.01.025; Michelson PH, 2009, ANN ALLERG ASTHMA IM, V103, P381, DOI 10.1016/S1081-1206(10)60356-0; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; *NAT CTR HLTH STAT, 2006, CHARTB TRENDS HLTH A; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; Ogden CL, 2008, JAMA-J AM MED ASSOC, V299, P2401, DOI 10.1001/jama.299.20.2401; Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P995, DOI 10.1016/j.jaci.2006.01.053; Shaheen SO, 1999, THORAX, V54, P396, DOI 10.1136/thx.54.5.396; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Sin DD, 2002, ARCH INTERN MED, V162, P1477, DOI 10.1001/archinte.162.13.1477; Sood A, 2006, THORAX, V61, P300, DOI 10.1136/thx.2004.031468; Spivak H, 2005, AM J SURG, V189, P27, DOI 10.1016/j.amjsurg.2004.06.038; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Taylor B, 2008, THORAX, V63, P14, DOI 10.1136/thx.2007.082784; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; *WHO, 2007, GLOB STRAT DIET PHYS; Wright CM, 2001, BMJ-BRIT MED J, V323, P1280, DOI 10.1136/bmj.323.7324.1280	32	111	117	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					964	969		10.1016/j.jaci.2011.06.031	http://dx.doi.org/10.1016/j.jaci.2011.06.031			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21820711				2022-12-18	WOS:000296578200007
J	Ege, MJ; Strachan, DP; Cookson, WOCM; Moffatt, MF; Gut, I; Lathrop, M; Kabesch, M; Genuneit, J; Buchele, G; Sozanska, B; Boznanski, A; Cullinan, P; Horak, E; Bieli, C; Braun-Fahrlander, C; Heederik, D; von Mutius, E				Ege, Markus J.; Strachan, David P.; Cookson, William O. C. M.; Moffatt, Miriam F.; Gut, Ivo; Lathrop, Mark; Kabesch, Michael; Genuneit, Jon; Buechele, Gisela; Sozanska, Barbara; Boznanski, Andrzej; Cullinan, Paul; Horak, Elisabeth; Bieli, Christian; Braun-Fahrlaender, Charlotte; Heederik, Dick; von Mutius, Erika		GABRIELA Study Grp	Gene-environment interaction for childhood asthma and exposure to farming in Central Europe	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; atopy; GWAS; gene-by-environment interaction; candidate genes	GENOMEWIDE ASSOCIATION; GLUTAMATE; CHILDREN	Background: Asthma is a disease in which both genetic and environmental factors play important roles. The farming environment has consistently been associated with protection from childhood asthma and atopy, and interactions have been reported with polymorphisms in innate immunity genes. Objective: To detect gene-environment interactions for asthma and atopy in the farming environment. Methods: We performed a genome-wide interaction analysis for asthma and atopy by using 500,000 genotyped single nucleotide polymorphisms (SNPs) and farm-related exposures in 1708 children from 4 rural regions of Central Europe. We also tested selectively for interactions between farm exposures and 7 SNPs that emerged as genome-wide significant in a large meta-analysis of childhood asthma and 5 SNPs that had been reported previously as interacting with farm exposures for asthma or atopy. Results: Neither the asthma-associated SNPs nor the SNPs previously published for interactions with asthma showed significant interactions. The genome-wide interaction study did not reveal any significant interactions with SNPs within genes in the range of interacting allele frequencies from 30% to 70%, for which our study was well powered. Among rarer SNPs, we identified 15 genes with strong interactions for asthma or atopy in relation to farming, contact with cows and straw, or consumption of raw farm milk. Conclusion: Common genetic polymorphisms are unlikely to moderate the protective influence of the farming environment on childhood asthma and atopy, but rarer variants, particularly of the glutamate receptor, metabotropic 1 gene, may do so. Given the limited statistical power of our study, these findings should be interpreted with caution before being replicated in independent farm populations. (J Allergy Clin Immunol 2011;127:138-44.)	[Ege, Markus J.; von Mutius, Erika] Univ Childrens Hosp Munich, Munich, Germany; [Strachan, David P.] Univ London, Div Community Hlth Sci, London, England; [Cookson, William O. C. M.; Moffatt, Miriam F.; Cullinan, Paul] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Gut, Ivo; Lathrop, Mark] Ctr Natl Genotypage, Inst Genom, Evry, France; [Lathrop, Mark] Fdn Jean Dausset CEPH, Paris, France; [Kabesch, Michael] Hannover Med Sch, Clin Pediat Pneumol & Neonatol, D-3000 Hannover, Germany; [Genuneit, Jon; Buechele, Gisela] Univ Ulm, Inst Epidemiol, Ulm, Germany; [Sozanska, Barbara; Boznanski, Andrzej] Wroclaw Med Univ, Dept Paediat Allergol & Cardiol 1, Wroclaw, Poland; [Horak, Elisabeth] Innsbruck Med Univ, Div Cardiol & Pulmonol, Dept Pediat & Adolescents, Innsbruck, Austria; [Bieli, Christian; Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Bieli, Christian; Braun-Fahrlaender, Charlotte] Univ Basel, Basel, Switzerland; [Heederik, Dick] Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, Utrecht, Netherlands	University of Munich; University of London; Imperial College London; CEA; UDICE-French Research Universities; Universite Paris Saclay; Foundation Jean Dausset-CEPH; Hannover Medical School; Ulm University; Wroclaw Medical University; Medical University of Innsbruck; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Utrecht University	Ege, MJ (corresponding author), Dr von Haunersche Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.	markus.ege@med.uni-muenchen.de	Gut, Ivo/ABF-3188-2020; Ege, Markus/C-1962-2012; Normand, Anne-Cécile/V-4271-2018; Kabesch, Michael/GZM-1583-2022; Genuneit, Jon/I-9323-2012; Loss, Georg/F-1557-2013; Cookson, William/HHC-1790-2022; Kabesch, Michael/AAB-5701-2020; Latzin, Philipp/F-2206-2017; Bieli, Christian/F-7209-2014	Gut, Ivo/0000-0001-7219-632X; Ege, Markus/0000-0001-6643-3923; Normand, Anne-Cécile/0000-0002-9589-4603; Genuneit, Jon/0000-0001-5764-1528; Heederik, Dick/0000-0002-4550-1437; Latzin, Philipp/0000-0002-5239-1571; Bieli, Christian/0000-0002-2128-6082; Loss, Georg/0000-0003-1090-812X; piarroux, renaud/0000-0002-4151-4134; von Mutius, Erika/0000-0002-8893-4515; Wouters, Inge M./0000-0001-7834-9390	European Commission [018996, LSH-2004-1.2.5-1]; GABRIEL consortium; German Research Foundation (DFG); Behring-Rontgen Foundation; Wellcome Trust; Roxall; Glaxo Wellcome; Novartis; Sanofi-Aventis; MSD; Bundesministerium fur Bildung und Forschung; Airsonett; Kuhne Foundation; European Union; Medical Research Council [G1000758B, G0801056B, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	European Commission(European CommissionEuropean Commission Joint Research Centre); GABRIEL consortium; German Research Foundation (DFG)(German Research Foundation (DFG)); Behring-Rontgen Foundation; Wellcome Trust(Wellcome TrustEuropean Commission); Roxall; Glaxo Wellcome; Novartis(Novartis); Sanofi-Aventis(Sanofi-Aventis); MSD; Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Airsonett; Kuhne Foundation; European Union(European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the European Commission as part of GABRIEL (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community) contract number 018996 under the Integrated Program LSH-2004-1.2.5-1. M.J.E received the Stephan-Weiland Fellowship of the GABRIEL consortium.; M. J. Ege has received research support from the European Union, the German Research Foundation (DFG), and the Behring-Rontgen Foundation. I. Gut has received research support from the European Commission (through Project GABRIEL) and the Wellcome Trust. M. Kabesch has received remuneration in the form of grants, honoraria, or consulting fees from Roxall, Glaxo Wellcome, Novartis, Sanofi-Aventis, MSD, and Allergopharma and has received research support from the DFG, Bundesministerium fur Bildung und Forschung, and the European Union. D. Heederik has received research support from the European Union. E. von Mutius has consulted for Novartis, GlaxoSmithKline, Protectimmun, and UCB and has received research support from Airsonett AB. M. Depner has received research support from the European Commission. R. Lauener has received research support from the European Union and the Kuhne Foundation. J. Weber has received research support from the European Commission. The rest of the authors have declared that they have no conflict of interest.	Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Dudbridge F, 2008, GENET EPIDEMIOL, V32, P227, DOI 10.1002/gepi.20297; Eder W, 2006, ALLERGY, V61, P1117, DOI 10.1111/j.1398-9995.2006.01128.x; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Murcray CE, 2009, AM J EPIDEMIOL, V169, P219, DOI 10.1093/aje/kwn353; Pacheco R, 2004, J BIOL CHEM, V279, P33352, DOI 10.1074/jbc.M401761200; Pacheco R, 2007, J NEUROIMMUNOL, V185, P9, DOI 10.1016/j.jneuroim.2007.01.003; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; Weiss ST, 2009, CURR OPIN GENET DEV, V19, P279, DOI 10.1016/j.gde.2009.05.001	14	111	113	0	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					138	U226		10.1016/j.jaci.2010.09.041	http://dx.doi.org/10.1016/j.jaci.2010.09.041			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211648	Green Submitted			2022-12-18	WOS:000285917300020
J	Hansen, KS; Ballmer-Weber, BK; Sastre, J; Lidholm, J; Andersson, K; Oberhofer, H; Lluch-Bernal, M; Ostling, J; Mattsson, L; Schocker, F; Vieths, S; Poulsen, LK				Hansen, Kirsten Skamstrup; Ballmer-Weber, Barbara K.; Sastre, Joaquin; Lidholm, Jonas; Andersson, Kerstin; Oberhofer, Hubert; Lluch-Bernal, Magdalena; Ostling, Jonas; Mattsson, Lars; Schocker, Frauke; Vieths, Stefan; Poulsen, Lars K.			Component-resolved in vitro diagnosis of hazelnut allergy in Europe	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Birch pollen; Cor a 1; double-blind; placebo-controlled food challenge; food allergy; hazelnut; IgE; lipid transfer protein; recombinant allergens	CONTROLLED FOOD CHALLENGE; SKIN-PRICK TESTS; CORYLUS-AVELLANA; DOUBLE-BLIND; ROASTED HAZELNUTS; CARROT ALLERGY; BIRCH POLLEN; NUT ALLERGY; IDENTIFICATION; CHILDREN	Background: Food allergy to hazelnut occurs both with and without concomitant pollen allergy. Objective: We sought to evaluate a panel of hazelnut allergens for diagnosis of hazelnut allergy in Spain, Switzerland, and Denmark. Methods: Fifty-two patients with a positive double-blind, placebo-controlled food challenge result with hazelnuts; 5 patients with a history of anaphylaxis; 62 patients with pollen allergy but hazelnut tolerance; and 63 nonatopic control subjects were included. Serum IgE levels to hazelnut extract, recombinant hazelnut allergens (rCor a 1.04, rCor a 2, rCor a 8, rCor a 11), and native allergens (nCor a 9, nCor a Bd8K, nCor a Bd11K) were analyzed by means of ImmunoCAP. Results: Among patients with hazelnut allergy, 91% (Switzerland/Spain, 100%; Denmark, 75%) had IgE to hazelnut extract, 75% to rCor a 1.04, 42% to rCor a 2, 28% to rCor a 8, and 2% to rCor a 11. The highest rate of sensitization to Cor a 1.04 was found in the northern regions (Switzerland/Denmark, 100%; Spain, 18%), whereas IgE to the lipid transfer protein rCor a 8 prevailed in Spain (Spain, 71%; Switzerland, 15%; Denmark, 5%). IgE to profilin rCor a 2 was equally distributed (40% to 45%). Among control subjects with pollen allergy, 61% had IgE to hazelnut extract, 69% to rCor a 1.04, 34% to rCor a 2, 10% to rCor a 8, and 6% to rCor a 11. Conclusion: Component-resolved in vitro analyses. revealed substantial differences in IgE profiles of hazelnut allergic and hazelnut tolerant patients across Europe. (J Allergy Clin Immunol 2009;123:1134-41.)	[Hansen, Kirsten Skamstrup; Poulsen, Lars K.] Natl Univ Hosp, Allergy Clin, DK-2100 Copenhagen, Denmark; [Ballmer-Weber, Barbara K.; Oberhofer, Hubert] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; [Sastre, Joaquin; Lluch-Bernal, Magdalena] Fdn Jimenez Diaz, Serv Alergol, E-28040 Madrid, Spain; [Lidholm, Jonas; Andersson, Kerstin; Ostling, Jonas; Mattsson, Lars] Phadia AB, Uppsala, Sweden; [Schocker, Frauke] Res Ctr Borstel, Div Biochem & Mol Allergol, Borstel, Germany; [Vieths, Stefan] Paul Ehrlich Inst, Div Allergol, D-6070 Langen, Germany	University of Zurich; University Zurich Hospital; Thermo Fisher Scientific; Phadia; Forschungszentrum Borstel; Paul Ehrlich Institute	Hansen, KS (corresponding author), Natl Univ Hosp, Allergy Clin, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	ksh@dadlnet.dk	Poulsen, Lars K/J-3065-2019	Poulsen, Lars K/0000-0002-1730-847X; Lidholm, Jonas/0000-0002-7779-3411	Phadia AB, Uppsala, Sweden; ALK-Abello; Novo-Nordic; Schering-Plough; Nutricia; European Union; NIDHS; Spanish Ministry of Health; German Research Society; Research Fund of the German Food Industry; Monsanto Company; Pioneer Hi-Breed International, Inc; European Directorate for the Quality of Medicines and Health Care; Phadia	Phadia AB, Uppsala, Sweden(Phadia); ALK-Abello; Novo-Nordic; Schering-Plough(Merck & CompanySchering Plough Corporation); Nutricia(Danone Nutricia); European Union(European Commission); NIDHS; Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); German Research Society(German Research Foundation (DFG)); Research Fund of the German Food Industry; Monsanto Company; Pioneer Hi-Breed International, Inc; European Directorate for the Quality of Medicines and Health Care; Phadia(Phadia)	Supported by Phadia AB, Uppsala, Sweden.; Disclosure of potential conflict of interest: K. S. Hansen has received research support from ALK-Abello, Novo-Nordic, Schering-Plough, and Nutricia and has provided expert testimony on allergy prophylaxis, infant feeding, and allergy to fungi for the National Board of Health, Denmark. J. Sastre has served as a consultant for ALK-Abello, GlaxoSmithKline, Novartis, and Phadia; has received research funding from the European Union, NIDHS, and the Spanish Ministry of Health; and serves as an invest section chair for the European Academy of Allergology and Clinical Immunology (EAACI). F. Schocker has received an honorarium for the transfer recombinant protein from Phadia, Uppsala, Sweden, and has received research support from the German Research Society. S. Vieths is an associate of the Institute for Product Quality. Berlin, Germany; has received an honoraria from Phadia. Uppsala. Sweden, the Food Allergy Resource and Research Program, and Mars Chocolate UK Ltd and Mars Nederland BV; has received research support from European Union, the German Research Society, the Research Fund of the German Food Industry, Monsanto Company, Pioneer Hi-Breed International, Inc, and the European Directorate for the Quality of Medicines and Health Care; and has served as the Chairman of the Food Allergy Interest Group for the EAACI, Chairman of the Allergen Standardization Subcommittee and Secretary of the Allergen Nomenclature Subcommittee for the International Union of Immunological Societies, a registered expert for the European Agency for the for the Evaluation of Medicinal Products and the European Pharmacopoeia Commission, a scientific advisor for ILSI Health and Environmental Science Institution, the Protein Allergenicity Technical Committee. Chairman of the Technical Committee for the European Committee for Standardization, and a member of the Food Allergy working Group of the German Society for Allergy and Clinical Immunology. L. K. Poulsen has received research support from Phadia. The rest of the authors have declared that they have no conflict of interest.	Akkerdaas JH, 2006, MOL NUTR FOOD RES, V50, P18, DOI 10.1002/mnfr.200500147; Akkerdaas JH, 2003, INT ARCH ALLERGY IMM, V132, P132, DOI 10.1159/000073714; Andersson K, 2007, ALLERGY, V62, P897, DOI 10.1111/j.1398-9995.2007.01450.x; Armstrong D, 1999, ARCH DIS CHILD, V80, P175, DOI 10.1136/adc.80.2.175; Ballmer-Weber BK, 2005, CLIN EXP ALLERGY, V35, P970, DOI 10.1111/j.1365-2222.2005.02294.x; Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P517, DOI 10.1067/mai.2002.127434; Bohle B, 2004, METHODS, V32, P292, DOI 10.1016/j.ymeth.2003.08.008; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Elfman L, 1997, INT ARCH ALLERGY IMM, V113, P249, DOI 10.1159/000237561; Ewan PW, 1996, BRIT MED J, V312, P1074; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P423, DOI 10.1016/j.jaci.2007.10.009; Hansen KS, 2003, ALLERGY, V58, P132, DOI 10.1034/j.1398-9995.2003.23959.x; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; KOOMEN CB, 1995, ALLERGY, V50, P623; Lauer I, 2004, BIOCHEM J, V383, P327, DOI 10.1042/BJ20041062; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; Muller U, 2000, EUR FOOD RES TECHNOL, V212, P2, DOI 10.1007/s002170000245; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; POULSEN LK, 1993, CLIN EXP ALLERGY, V23, P61, DOI 10.1111/j.1365-2222.1993.tb02485.x; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1111/j.1365-2222.1996.tb00537.x; Reuter A, 2006, CLIN EXP ALLERGY, V36, P815, DOI 10.1111/j.1365-2222.2006.2492.x; ROSEN JP, 1994, J ALLERGY CLIN IMMUN, V93, P1068, DOI 10.1016/S0091-6749(94)70056-7; RUDESCHKO O, 1995, ALLERGY, V50, P575, DOI 10.1111/j.1398-9995.1995.tb01202.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Schocker F, 2004, J ALLERGY CLIN IMMUN, V113, P141, DOI 10.1016/j.jaci.2003.09.013; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; van Ree R, 1999, J ALLERGY CLIN IMMUN, V103, P1000, DOI 10.1016/S0091-6749(99)70169-7	36	111	113	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1134	1141		10.1016/j.jaci.2009.02.005	http://dx.doi.org/10.1016/j.jaci.2009.02.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19344939				2022-12-18	WOS:000266309400023
J	Moir, S; Fauci, AS				Moir, Susan; Fauci, Anthony S.			Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HIV; B cells; immunopathogenesis; immune activation; lymphopenia; apoptosis	ACTIVE ANTIRETROVIRAL THERAPY; T-CELL HOMEOSTASIS; IMMUNODEFICIENCY-VIRUS-INFECTION; NEUTRALIZING ANTIBODIES; HIV-1-INFECTED CHILDREN; PNEUMOCOCCAL DISEASE; RHESUS MACAQUES; NK CELLS; MEMORY; CD4(+)	HIV disease is associated with abnormalities in all major lymphocyte populations, including B cells. Aberrancies in the B-cell compartment can be divided into 3 broad categories: changes that arise as a result of HIV-induced immune activation, changes that arise as a result of HIV-induced lymphopenia, and changes that arise independently of these 2 parameters. We review recent developments in all 3 categories of abnormalities and highlight how observations made in the early years of the HIV epidemic are better understood today in large part because of the advent of effective antiretroviral therapy. Insight into the mechanisms of B-cell dysfunction in HIV disease has also been achieved as a result of increased knowledge of the B-cell subpopulations as they exist in healthy individuals, compared with their abnormalities in HIV-infected individuals. A better understanding of the pathogenic mechanisms of B-cell abnormalities in HIV disease can potentially lead to new strategies for improving antibody responses against opportunistic pathogens that afflict HIV-infected individuals and against HIV itself, in the context of both HIV infection and an antibody-based HIV vaccine.	[Moir, Susan; Fauci, Anthony S.] Natl Inst Allergy & Infect Dis, Immunoregulat Lab, Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Moir, S (corresponding author), Natl Inst Allergy & Infect Dis, Immunoregulat Lab, Natl Inst Hlth, 9000 Rockville Pike,Bldg 10,Room 6A02, Bethesda, MD 20892 USA.	smoir@niaid.nih.gov	Moir, Susan/AAC-3676-2020		Intramural NIH HHS [Z01 AI000825-10] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000825] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson SM, 2006, IMMUNOL REV, V211, P280, DOI 10.1111/j.0105-2896.2006.00398.x; Avery DT, 2005, J IMMUNOL, V174, P4034, DOI 10.4049/jimmunol.174.7.4034; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Bekker V, 2006, J INFECT DIS, V194, P1323, DOI 10.1086/508197; Bekker V, 2006, PEDIATRICS, V118, pE315, DOI 10.1542/peds.2005-2616; BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497; Bliss SJ, 2008, LANCET INFECT DIS, V8, P67, DOI 10.1016/S1473-3099(07)70242-6; Chong Y, 2004, J MED VIROL, V73, P362, DOI 10.1002/jmv.20099; Chong Y, 2004, AIDS RES HUM RETROV, V20, P219, DOI 10.1089/088922204773004941; Cuss AK, 2006, J IMMUNOL, V176, P1506, DOI 10.4049/jimmunol.176.3.1506; D'Orsogna LJ, 2007, AIDS, V21, P1747, DOI 10.1097/QAD.0b013e32828642c7; Dankner WM, 2001, PEDIATR INFECT DIS J, V20, P40, DOI 10.1097/00006454-200101000-00008; De Boer RJ, 2003, J IMMUNOL, V170, P2479, DOI 10.4049/jimmunol.170.5.2479; De Milito A, 2004, CURR HIV RES, V2, P11, DOI 10.2174/1570162043485068; De Milito A, 2001, AIDS, V15, P957, DOI 10.1097/00002030-200105250-00003; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DOMER T, 2007, IMMUNITY, V27, P384; Ehrhardt GRA, 2005, J EXP MED, V202, P783, DOI 10.1084/jem.20050879; Fauci AS, 2005, NAT REV IMMUNOL, V5, P835, DOI 10.1038/nri1711; Fournier AM, 2002, CLIN IMMUNOL, V103, P98, DOI 10.1006/clim.2001.5195; Fry TJ, 2001, BLOOD, V97, P2983, DOI 10.1182/blood.V97.10.2983; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380; Hart M, 2007, J IMMUNOL, V178, P8212, DOI 10.4049/jimmunol.178.12.8212; Hatherill Mark, 2005, Pediatr Crit Care Med, V6, pS92, DOI 10.1097/01.PCC.0000161579.39050.6B; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Hedestam GBK, 2008, NAT REV MICROBIOL, V6, P143, DOI 10.1038/nrmicro1819; Ho J, 2006, P NATL ACAD SCI USA, V103, P19436, DOI 10.1073/pnas.0609515103; Jacobson MA, 2002, JAIDS, V31, P472, DOI 10.1097/00126334-200212150-00003; Johnston MI, 2007, NEW ENGL J MED, V356, P2073, DOI 10.1056/NEJMra066267; Juompan L, 1998, APPL BIOCHEM BIOTECH, V75, P139, DOI 10.1007/BF02787714; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; Lempicki RA, 2000, P NATL ACAD SCI USA, V97, P13778, DOI 10.1073/pnas.250472097; Letvin NL, 2006, NAT REV IMMUNOL, V6, P930, DOI 10.1038/nri1959; Li YX, 2007, NAT MED, V13, P1032, DOI 10.1038/nm1624; Malaspina A, 2006, P NATL ACAD SCI USA, V103, P2262, DOI 10.1073/pnas.0511094103; Malaspina A, 2005, J INFECT DIS, V191, P1442, DOI 10.1086/429298; Malaspina A, 2003, J IMMUNOL, V170, P5965, DOI 10.4049/jimmunol.170.12.5965; Malaspina A, 2002, J VIROL, V76, P8855, DOI 10.1128/JVI.76.17.8855-8863.2002; Malaspina A, 2007, BLOOD, V109, P2086, DOI 10.1182/blood-2006-06-031385; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; Margolin DH, 1997, J VIROL, V71, P8582, DOI 10.1128/JVI.71.11.8582-8591.1997; Martinez-Maza O, 2002, CURR OPIN ONCOL, V14, P528, DOI 10.1097/00001622-200209000-00009; Mascola JR, 1999, J VIROL, V73, P4009, DOI 10.1128/JVI.73.5.4009-4018.1999; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; Miller CJ, 2007, J VIROL, V81, P5024, DOI 10.1128/JVI.02444-06; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Moir S, 2000, J EXP MED, V192, P637, DOI 10.1084/jem.192.5.637; Moir S, 2001, P NATL ACAD SCI USA, V98, P10362, DOI 10.1073/pnas.181347898; Moir S, 2003, P NATL ACAD SCI USA, V100, P6057, DOI 10.1073/pnas.0730819100; Moir S, 2004, J EXP MED, V200, P587, DOI 10.1084/jem.20032236; Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683; Moir S, 2008, J INFECT DIS, V197, P572, DOI 10.1086/526789; Montefiori D, 2007, PLOS MED, V4, P1867, DOI 10.1371/journal.pmed.0040348; Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Nagase H, 2001, CLIN IMMUNOL, V100, P250, DOI 10.1006/clim.2001.5054; Napolitano LA, 2001, NAT MED, V7, P73, DOI 10.1038/83381; Ng VL, 1996, CLIN REV ALLERG IMMU, V14, P367; Nilssen DE, 2004, GUT, V53, P487, DOI 10.1136/gut.2003.027854; Notermans DW, 2001, AIDS RES HUM RETROV, V17, P1003, DOI 10.1089/088922201300343681; Obaro SK, 2004, LANCET INFECT DIS, V4, P510, DOI 10.1016/S1473-3099(04)01106-5; PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x; Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020; RACZ P, 1990, LYMPHOLOGY, V23, P85; Rickert RC, 2005, CURR OPIN IMMUNOL, V17, P237, DOI 10.1016/j.coi.2005.03.001; Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295; Samuelsson A, 1997, AIDS RES HUM RETROV, V13, P1031, DOI 10.1089/aid.1997.13.1031; Scamurra RW, 2000, J IMMUNOL, V164, P5482, DOI 10.4049/jimmunol.164.10.5482; Shearer WT, 2000, J ALLERGY CLIN IMMUN, V106, P559, DOI 10.1067/mai.2000.109433; SHIRAI A, 1992, J CLIN INVEST, V89, P561, DOI 10.1172/JCI115621; Siegel RM, 2006, NAT REV IMMUNOL, V6, P308, DOI 10.1038/nri1809; Sims GP, 2005, BLOOD, V105, P4390, DOI 10.1182/blood-2004-11-4284; Soriano-Sarabia N, 2005, J CLIN IMMUNOL, V25, P296, DOI 10.1007/s10875-005-3864-1; Stoiber H, 2003, VACCINE, V21, pS77, DOI 10.1016/S0264-410X(03)00203-2; Titanji K, 2005, AIDS, V19, P1947, DOI 10.1097/01.aids.0000191231.54170.89; Titanji K, 2006, BLOOD, V108, P1580, DOI 10.1182/blood-2005-11-013383	80	111	119	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					12	19		10.1016/j.jaci.2008.04.034	http://dx.doi.org/10.1016/j.jaci.2008.04.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18547629	Green Accepted			2022-12-18	WOS:000257605100002
J	Freeman, AF; Kleiner, DE; Nadiminti, H; Davis, J; Quezado, M; Anderson, V; Puck, JM; Holland, SM				Freeman, Alexandra F.; Kleiner, David E.; Nadiminti, Hari; Davis, Joie; Quezado, Martha; Anderson, Victoria; Puck, Jennifer M.; Holland, Steven M.			Causes of death in hyper-IgE syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspergillus; hyper-IgE syndrome; immunodeficiency; pneumonia; Pseudomonas	HYPERIMMUNOGLOBULIN-E SYNDROME; AMPHOTERICIN B; JOBS-SYNDROME; NEPHROTOXICITY; INFECTIONS	Background: Hyper-IgE syndrome (HIES) is characterized by recurrent pyogenic infections, eczema, increased serum IgE levels, and a variety of connective tissue and skeletal system abnormalities. Little has been published regarding the causes of death in these patients or pathologic findings. Objective: To identify the cause of death in patients with HIES and to describe pathologic findings in fatal HIES. Methods: We reviewed the medical records and autopsy slides of 6 patients with HIES with autopsies performed at our institution. Results: All 6 patients with HIES were women and ranged in age from 24 to 40 years. All patients had a history of cystic lung disease and had pneumonia at the time of death, with Pseudomonas aeruginosa and fungal organisms predominating. Pulmonary fungal vascular invasion with fatal hemorrhage was observed in 3 patients, and metastatic fungal disease to the brain was observed in 2 patients caused by Aspergillus fumigatus and Scedosporium prolificans. Four patients had evidence of renal tubular injury, which was likely from amphotericin B toxicity; 3 patients had glomerulosclerosis; and I patient had 2 kidney angiomyolipomas. Conclusions: Our series highlights the important role Pseudomonas and Aspergillus species play in patients with HIES with cystic lung disease. Intensified antifungal and gram-negative bacterial prophylaxis need evaluation as possible strategies to prevent these infectious complications in patients with cystic lung disease. Clinical implications: Fungal and Pseudomonas infection of cystic lung disease in HIES may be life threatening, and the proper management and prevention of these infections need continued investigation.	NIAID, Bethesda, MD 20892 USA; NCI, Bethesda, MD 20892 USA; NHGRI, NIH, Bethesda, MD 20892 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of California System; University of California San Francisco	Holland, SM (corresponding author), NIAID, Bldg 10,CRC B3-4141,MSC 1684, Bethesda, MD 20892 USA.	smh@nih.gov	Kleiner, David E/N-2770-2013	Kleiner, David E/0000-0003-3442-4453	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZICBC010685, Z01BC010685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000646, ZIAAI000646] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bearz A, 2004, TUMORI, V90, P528, DOI 10.1177/030089160409000519; Bissler JJ, 2004, KIDNEY INT, V66, P924, DOI 10.1111/j.1523-1755.2004.00838.x; Buckley RH, 2001, CLIN REV ALLERG IMMU, V20, P139, DOI 10.1385/CRIAI:20:1:139; BUTLER WT, 1964, ANN INTERN MED, V61, P175, DOI 10.7326/0003-4819-61-2-175; Erlewyn-Lajeunesse MDS, 2000, PEDIATR ALLERGY IMMU, V11, P133, DOI 10.1034/j.1399-3038.2000.00091.x; Fanos V, 2000, J CHEMOTHERAPY, V12, P463, DOI 10.1179/joc.2000.12.6.463; GAHR M, 1978, EUR J PEDIATR, V127, P173, DOI 10.1007/BF00442058; Grimbacher B, 1999, AM J HUM GENET, V65, P735, DOI 10.1086/302547; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Leonard GD, 2004, LEUKEMIA LYMPHOMA, V45, P2521, DOI 10.1080/10428190400004463; MERTEN DF, 1979, RADIOLOGY, V132, P71, DOI 10.1148/132.1.71; SHAMBERGER RC, 1992, ANN THORAC SURG, V54, P1206, DOI 10.1016/0003-4975(92)90100-I; WERTLAKE PT, 1963, AM J PATHOL, V43, P449	13	111	120	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1234	1240		10.1016/j.jaci.2006.12.666	http://dx.doi.org/10.1016/j.jaci.2006.12.666			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17335882				2022-12-18	WOS:000246427200027
J	Lee, JY; Simon, RA; Stevenson, DD				Lee, Jennifer Y.; Simon, Ronald A.; Stevenson, Donald D.			Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin; nonsteroidal anti-inflammatory drugs; aspirin-exacerbated respiratory disease; aspirin desensitization; leukotriene receptor antagonist; 5-lipoxygenase inhibitor	RHINOSINUSITIS-ASTHMA; IMPROVEMENT; TRIAL	Background: Aspirin desensitization followed by daily aspirin therapy is effective add-on treatment for patients with aspirin-exacerbated respiratory disease. Prior studies used 650 mg of aspirin twice daily, but studies at lower dosages were inconclusive. Objective: We sought to determine the optimal daily dosage of aspirin treatment. Methods: We studied 137 patients who had undergone successful aspirin desensitization and randomized them into 2 groups, 650 mg twice daily versus 325 mg twice daily. After 1 month, patients either increased or decreased their dosage based on their symptom control and continued that dosage for the remainder of the year. Results: Patients taking either 650 mg twice daily or 325 mg twice daily showed significant improvements in number of sinus infections, sinus operations, and hospitalizations for asthma (all P <.0001). Anosmia, nasal/sinus symptoms, and asthma symptoms also improved in both groups (all P <.03). Systemic corticosteroid dosages decreased by 3- and 4-fold in the 325 mg twice daily and 650 mg twice daily groups, respectively. Of the 137 patients, 32 had adverse effects from or discontinued aspirin therapy: 14 (44%) of 32 from the group randomized to taking 650 mg twice daily and 18 (56%) of 32 from the group randomized to 325 mg twice daily. The most common adverse effect was dyspepsia. Conclusion: Both dosages were efficacious, and side effects occurred in both groups at similar frequencies. Some patients initially taking 325 mg twice daily required an increase to 650 mg twice daily for optimal symptom control. Clinical implications: We recommend that patients begin daily aspirin therapy with 650 mg twice daily and subsequently decrease to the lowest effective dosage (usually 325 mg twice daily).	Scripps Clin, Div Allergy Asthma & Immunol, Dept Med, La Jolla, CA 92037 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Stevenson, DD (corresponding author), Scripps Clin, Div Allergy Asthma & Immunol, Dept Med, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Stevenson.donald@Scrippshealth.org						Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Borish L, 2002, J ALLERGY CLIN IMMUN, V109, P606, DOI 10.1067/mai.2002.123024; CHIU JT, 1983, J ALLERGY CLIN IMMUN, V71, P560, DOI 10.1016/0091-6749(83)90437-2; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P159, DOI 10.1385/CRIAI:24:2:159; Stevenson DD, 1984, N ENGL REG ALLERGY P, V5, P111; Sweet JA, 1990, J ALLERGY CLIN IMMUN, V86, P59; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; WOLFE MM, 1999, NEW ENGL J MED, V340, P661	15	111	114	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					157	164		10.1016/j.jaci.2006.09.011	http://dx.doi.org/10.1016/j.jaci.2006.09.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208597				2022-12-18	WOS:000243622200022
J	Hahn, C; Islamian, AP; Renz, H; Nockher, WA				Hahn, C; Islamian, AP; Renz, H; Nockher, WA			Airway epithelial cells produce neurotrophins and promote the survival of eosinophils during allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; neurotrophin; nerve growth factor; brain-derived neutrotrophic factor; eosinophils; survival; airway epithelium	NERVE GROWTH-FACTOR; BRONCHOALVEOLAR LAVAGE; MESSENGER-RNA; MOUSE MODEL; T-CELLS; EXPRESSION; ACTIVATION; INHALATION; APOPTOSIS; RELEASE	Background: Eosinophil-epithelial cell interactions make a major contribution to asthmatic airway inflammation. Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and other members of the neurotrophin family, originally defined as a class of neuronal growth factors, are now recognized to support the survival and activation of immune cells. Neurotrophin levels are increased in bronchoalveolar lavage fluid during allergic asthma. Objective: We sought to investigate the role of neurotrophins as inflammatory mediators in eosinophil-epithelial cell interactions during the allergic immune response. Methods: Neurotrophin expression in the lung was investigated by means of immunohistochemistry and ELISA in a mouse model of chronic experimental asthma. Coculture experiments were performed with airway epithelial cells and bronchoalveolar lavage fluid eosinophils. Results: Neurotrophin levels increased continuously during chronic allergic airway inflammation, and airway epithelial cells were the major source of NGF and BDNF within the inflamed lung. Epithelial neurotrophin production was upregulated by IL-1 beta, TNF-alpha, and T(H)2 cytokines. Lung eosinophils expressed the BDNF and NGF receptors tropomyosin-related kinase (Trk) A and TrkB, and coculture with airway epithelial cells resulted in enhanced epithelial neurotrophin production, as well as in prolonged survival of eosinophils. Eosinophil survival was completely abolished in the presence of the neurotrophin receptor Trk antagonist K252a. Conclusion: During allergic inflammation, airway epithelial cells express increased amounts of NGF and BDNF that promote the survival of tissue eosinophils. Controlling epithelial neurotrophin production might be an important therapeutic target to prevent allergic airway eosinophilia. Clinical implications: Attenuating the release of inflammatory mediators from the activated airway epithelium will become an important strategy to disrupt the pathogenesis of chronic allergic asthma.	Univ Marburg, Univ Hosp, Dept Clin Chem & Mol Diagnost, D-35033 Marburg, Germany	Philipps University Marburg	Nockher, WA (corresponding author), Univ Marburg, Univ Hosp, Dept Clin Chem & Mol Diagnost, Baldingerstr, D-35033 Marburg, Germany.	nockher@med.uni-marburg.de						BERG MM, 1992, J BIOL CHEM, V267, P13; Bonini S, 2003, INT ARCH ALLERGY IMM, V131, P80, DOI 10.1159/000070922; Braun A, 1998, EUR J IMMUNOL, V28, P3240, DOI 10.1002/(SICI)1521-4141(199810)28:10<3240::AID-IMMU3240>3.0.CO;2-U; Braun A, 1999, AM J RESP CELL MOL, V21, P537, DOI 10.1165/ajrcmb.21.4.3670; BRAUN A, 2002, NEUROIMMUNE INTERACT, P311; Burgel PR, 2001, J IMMUNOL, V167, P5948, DOI 10.4049/jimmunol.167.10.5948; Carr M J, 2001, Curr Opin Pulm Med, V7, P1, DOI 10.1097/00063198-200101000-00001; Davidson DJ, 2000, AM J PHYSIOL-LUNG C, V279, pL766, DOI 10.1152/ajplung.2000.279.4.L766; Hamada A, 1996, BRIT J HAEMATOL, V93, P299, DOI 10.1046/j.1365-2141.1996.5151055.x; Kassel O, 2001, CLIN EXP ALLERGY, V31, P1432, DOI 10.1046/j.1365-2222.2001.01177.x; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Kerzel S, 2003, AM J RESP CELL MOL, V28, P170, DOI 10.1165/rcmb.4811; Lee NA, 2001, J ALLERGY CLIN IMMUN, V107, P945, DOI 10.1067/mai.2001.116002; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MOQBEL R, 1995, J IMMUNOL, V155, P4939; Nassenstein C, 2003, J EXP MED, V198, P455, DOI 10.1084/jem.20010897; Nockher WA, 2005, CLIN CHIM ACTA, V352, P49, DOI 10.1016/j.cccn.2004.10.002; Nockher WA, 2003, CYTOKINE GROWTH F R, V14, P559, DOI 10.1016/S1359-6101(03)00071-6; Path G, 2002, AM J RESP CRIT CARE, V166, P818, DOI 10.1164/rccm.200202-134OC; Pattarawarapan M, 2003, J MED CHEM, V46, P5277, DOI 10.1021/jm030221q; Pawankar R, 2002, CURR OPIN ALLERGY CL, V2, P1, DOI 10.1097/00130832-200202000-00001; Raap U, 2005, J ALLERGY CLIN IMMUN, V115, P1268, DOI 10.1016/j.jaci.2005.02.007; Ricci A, 2004, AM J RESP CELL MOL, V30, P12, DOI 10.1165/rcmb.2002-0110OC; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021, DOI 10.4049/jimmunol.169.2.1021; Schuhmann B, 2005, J NEUROIMMUNOL, V163, P15, DOI 10.1016/j.jneuroim.2005.01.023; Sousa AR, 1996, AM J RESP CRIT CARE, V154, P1061, DOI 10.1164/ajrccm.154.4.8887608; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; TAPLEY P, 1992, ONCOGENE, V7, P371; Tomee JFC, 1998, J ALLERGY CLIN IMMUN, V102, P75, DOI 10.1016/S0091-6749(98)70057-0; Virchow JC, 1998, AM J RESP CRIT CARE, V158, P2002, DOI 10.1164/ajrccm.158.6.9803023; Walsh GM, 2001, CLIN EXP ALLERGY, V31, P351, DOI 10.1046/j.1365-2222.2001.01032.x; Walsh GM, 2000, BRIT J HAEMATOL, V111, P61; Wegmann M, 2005, CLIN EXP ALLERGY, V35, P1263, DOI 10.1111/j.1365-2222.2005.02306.x; Wong CK, 2005, CLIN EXP IMMUNOL, V139, P90, DOI 10.1111/j.1365-2249.2005.02678.x; YAMAGUCHI Y, 1991, BLOOD, V78, P2542	37	111	130	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					787	794		10.1016/j.jaci.2005.12.1339	http://dx.doi.org/10.1016/j.jaci.2005.12.1339			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630935	Bronze			2022-12-18	WOS:000236862800011
J	van Doorn, MBA; Burggraaf, J; van Dam, T; Eerenberg, A; Levi, M; Hack, CE; Schoemaker, RC; Cohen, AF; Nuijens, J				van Doorn, MBA; Burggraaf, J; van Dam, T; Eerenberg, A; Levi, M; Hack, CE; Schoemaker, RC; Cohen, AF; Nuijens, J			A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hereditary angioedema; C1 inhibitor; C4; complement; pharmacodynamics; pharmacokinetics; human	ACQUIRED C1-INHIBITOR DEFICIENCY; ANGIONEUROTIC-EDEMA; INH CONCENTRATE; COMPLEMENT; DANAZOL; ACTIVATION; KALLIKREIN; THERAPY; QUANTIFICATION; COMPLEXES	Background: Hereditary angioedema (HAE) is a congenital disorder with recurrent attacks of localized swelling of submucosal tissue, subcutaneous tissue, or both caused by a deficiency of the plasma protein C1 inhibitor (C1 esterase inhibitor [C1INH]). Objective: We sought to evaluate the effects of recombinant human C1INH (rhC1INH) isolated from the milk of transgenic rabbits in 12 asymptomatic patients with HAE. Methods: rhC1INH was intravenously administered at doses of 6.25 to 100 U/kg on 2 occasions. Results: rhC1INH appeared safe and was well tolerated. The course of functional C1INH in plasma showed a full initial recovery (dose-normalized maximum concentration of about 0.02 U/mL/U/kg) and a dose-dependent clearance of rhC1INH. After infusion of rhC1INH at 100 U/kg, a clearance of approximately 13 mL/min, a half-life of approximately 3 hours, and a volume of distribution of approximately 3 L were observed. Infusion at this dose led to functional C1INH levels in plasma of at least twice the normal level for about 2 hours and greater than 0.4 U/mL for about 9 hours. rhC1INH displayed dose-dependent biologic activity by increasing the C4 level, which was about 2-fold at 12 hours after rhC1INH at 100 U/kg, and decreasing levels of cleaved C4. Conclusion: The observed safety profile and biologic activity of rhCIINH warrants further clinical studies to assess its efficacy in treating HAE attacks.	Ctr Human Drug Res, NL-2333 CL Leiden, Netherlands; Phaming Technol, Leiden, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Immunopathol, Sanquin Res, Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, Amsterdam, Netherlands; Acad Med Ctr, Dept Internal Med, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van Doorn, MBA (corresponding author), Ctr Human Drug Res, Zernikedreef 10, NL-2333 CL Leiden, Netherlands.	mdoorn@chdr.nl	Cohen, Adam/G-3756-2010; Levi, Marcel/AAZ-8559-2020	Schoemaker, Rik/0000-0002-7538-3005				AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; AGOSTONI A, 1980, ANN ALLERGY, V44, P299; AGOSTONI A, 1993, BEHRING I MITT, V93, P306; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; BERGAMASCHINI L, 1983, ALLERGY, V38, P81; Bork K, 1999, LANCET, V353, P1066, DOI 10.1016/S0140-6736(99)00110-5; BORK K, 1989, J ALLERGY CLIN IMMUN, V83, P677, DOI 10.1016/0091-6749(89)90082-1; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; Cicardi M, 1996, NEW ENGL J MED, V334, P1666, DOI 10.1056/NEJM199606203342510; Crampon D, 1998, J HEPATOL, V29, P1035, DOI 10.1016/S0168-8278(98)80140-2; CUGNO M, 1990, J CLIN INVEST, V85, P1215, DOI 10.1172/JCI114555; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; HACK CE, 1988, J IMMUNOL, V141, P1602; Koles K, 2004, GLYCOBIOLOGY, V14, P51, DOI 10.1093/glycob/cwh010; Kunschak M, 1998, TRANSFUSION, V38, P540, DOI 10.1046/j.1537-2995.1998.38698326333.x; LANDERMAN NS, 1962, J ALLERGY, V33, P330, DOI 10.1016/0021-8707(62)90032-1; MINTA JO, 1981, J IMMUNOL, V126, P245; Nielsen EW, 1996, SCAND J IMMUNOL, V44, P185; NUIJENS JH, 1988, BLOOD, V72, P1841; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; Schoemaker RC, 1996, BRIT J CLIN PHARMACO, V42, P283, DOI 10.1046/j.1365-2125.1996.04231.x; SPATH P J, 1984, Complement, V1, P147; Visentin DE, 1998, ANN ALLERG ASTHMA IM, V80, P457, DOI 10.1016/S1081-1206(10)63067-0; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503; WOLBINK GJ, 1993, J IMMUNOL METHODS, V163, P67, DOI 10.1016/0022-1759(93)90240-8; ZURAW BL, 1986, J CLIN INVEST, V78, P567, DOI 10.1172/JCI112610; ZURLO JJ, 1990, FERTIL STERIL, V54, P64	28	111	115	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					876	883		10.1016/j.jaci.2005.05.019	http://dx.doi.org/10.1016/j.jaci.2005.05.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210064				2022-12-18	WOS:000235686600024
J	Peden, DB				Peden, DB			The epidemiology and genetics of asthma risk associated with air pollution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						air pollution; asthma; genetics; antioxidants	S-TRANSFERASE M1; ENVIRONMENTAL TOBACCO-SMOKE; DIESEL EXHAUST PARTICLES; INDOOR NITROGEN-DIOXIDE; RESPIRATORY SYMPTOMS; ANTIOXIDANT SUPPLEMENTATION; CHILDHOOD ASTHMA; OZONE EXPOSURE; LUNG-FUNCTION; BRONCHITIC SYMPTOMS	The occurrence of asthma and allergic diseases has continued to increase in the United States and worldwide, despite general improvements in air quality over the past 40 years. This observation has led many to question whether air quality is truly a significant risk factor in the development and exacerbation of asthma and whether further improvement in air quality is likely to result in improved health outcomes. However, epidemiologic studies have shown that levels of pollutants of less than the current ambient air quality standards still result in exacerbations of asthma and are associated with other morbidities as well. Specific locations, such as living near a roadway, might pose a special exposure risk. Genetic factors almost certainly play a role in determining susceptibility to pollutants, such as including those involved with antioxidant defenses. The best studied of these in the context of air pollution risks are glutathione-S-transferase polymorphisms. Irrespective of whether pollutants contribute to the development of asthma or the well-documented increases in asthma results in more people having pollutant-induced disease, poor air quality in many places remains a significant problem for patients with asthma and allergic disease. A number of public health, pharmaceutical, and nutriceutical interventions might mitigate the effects of pollutant exposure and deserve further study.	Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Peden, DB (corresponding author), Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.	peden@mcd.unc.edu		Peden, David/0000-0003-4526-4627				Alexis NE, 2001, J ALLERGY CLIN IMMUN, V108, P577; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; Bastain TM, 2003, CLIN IMMUNOL, V109, P130, DOI 10.1016/S1521-6616(03)00168-2; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; BRUNEKREEF B, 1990, J AIR WASTE MANAGE, V40, P1252, DOI 10.1080/10473289.1990.10466779; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Clancy L, 2002, LANCET, V360, P1210, DOI 10.1016/S0140-6736(02)11281-5; David GL, 2003, AM J RESP CRIT CARE, V168, P1199, DOI 10.1164/rccm.200305-684OC; Davies RJ, 1997, ALLERGY, V52, P59, DOI 10.1111/j.1398-9995.1997.tb04873.x; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633, DOI 10.1164/ajrccm.154.3.8810598; Diaz-Sanchez D, 1999, CLIN IMMUNOL, V90, P313, DOI 10.1006/clim.1998.4676; DIJKSTRA L, 1990, AM REV RESPIR DIS, V142, P1172, DOI 10.1164/ajrccm/142.5.1172; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223, DOI 10.1080/00039896.1994.9937471; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Garshick E, 2003, EPIDEMIOLOGY, V14, P728, DOI 10.1097/01.ede.0000082045.50073.66; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; GERGEN PJ, 1992, AM REV RESPIR DIS, V146, P823, DOI 10.1164/ajrccm/146.4.823; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Gergen PJ, 2001, RESP PHYSIOL, V128, P39, DOI 10.1016/S0034-5687(01)00263-8; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P576, DOI 10.1093/aje/kwg181; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; HATCH GE, 1995, AM J CLIN NUTR, V61, p625S, DOI 10.1093/ajcn/61.3.625S; Kabesch M, 2004, THORAX, V59, P569, DOI 10.1136/thx.2003.016667; Kalayci O, 2000, TURKISH J PEDIATR, V42, P17; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; Kongerud J, 2003, INHAL TOXICOL, V15, P101, DOI [10.1080/08958370390168184, 10.1080/08958370304477]; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; Mudway IS, 1999, EUR RESPIR J, V13, P1429, DOI 10.1183/09031936.99.13614399; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204, DOI 10.1093/oxfordjournals.aje.a116073; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103a; Nightingale JA, 2000, AM J RESP CRIT CARE, V161, P479, DOI 10.1164/ajrccm.161.2.9905031; PEDEN DB, 2003, MIDDLETONS ALLERGY P, P515; Peters A, 1996, AM J EPIDEMIOL, V144, P570, DOI 10.1093/oxfordjournals.aje.a008967; Peters A, 2004, NEW ENGL J MED, V351, P1721, DOI 10.1056/NEJMoa040203; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376, DOI 10.1164/ajrccm.155.4.9105082; Pope C. Arden III, 2000, Environmental Health Perspectives, V108, P713, DOI 10.2307/3454408; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90, DOI 10.1080/00039896.1991.9937434; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055, DOI 10.1164/ajrccm.154.4.8887607; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368, DOI 10.1080/00039899709602213; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546, DOI 10.1093/oxfordjournals.aje.a117470; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300, DOI 10.1164/ajrccm.154.2.8756798; Romieu I, 1998, AM J RESP CRIT CARE, V158, P226, DOI 10.1164/ajrccm.158.1.9712053; Romieu I, 2004, THORAX, V59, P8; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Romieu I, 2001, EPIDEMIOL REV, V23, P268, DOI 10.1093/oxfordjournals.epirev.a000806; Samet JM, 2001, AM J RESP CRIT CARE, V164, P819, DOI 10.1164/ajrccm.164.5.2008003; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; Trapp JF, 1998, CHEST, V113, P505, DOI 10.1378/chest.113.2.505; Trenga CA, 2001, ARCH ENVIRON HEALTH, V56, P242, DOI 10.1080/00039890109604448; Vagaggini B, 2001, AM J RESP CRIT CARE, V164, P2172, DOI 10.1164/ajrccm.164.12.2009090; van Strien RT, 2004, EPIDEMIOLOGY, V15, P471, DOI 10.1097/01.ede.0000129511.61698.d8; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560	62	111	115	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					213	219		10.1016/j.jaci.2004.12.003	http://dx.doi.org/10.1016/j.jaci.2004.12.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696070				2022-12-18	WOS:000227043600001
J	Neaville, WA; Tisler, C; Bhattacharya, A; Anklam, K; Gilbertson-White, S; Hamilton, R; Adler, K; DaSilva, DF; Roberg, KA; Carlson-Dakes, KT; Anderson, E; Yoshihara, D; Gangnon, R; Mikus, LD; Rosenthal, LA; Gern, JE; Lemanske, RF				Neaville, WA; Tisler, C; Bhattacharya, A; Anklam, K; Gilbertson-White, S; Hamilton, R; Adler, K; DaSilva, DF; Roberg, KA; Carlson-Dakes, KT; Anderson, E; Yoshihara, D; Gangnon, R; Mikus, LD; Rosenthal, LA; Gern, JE; Lemanske, RF			Developmental cytokine response profiles and the clinical and immunologic expression of atopy during the first year of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; T(H)2; immune development; allergy; IgE	INTERFERON-GAMMA PRODUCTION; COMMON FOOD PROTEINS; SUBSEQUENT DEVELOPMENT; IGE RESPONSES; ALLERGEN; CHILDREN; CELLS; BLOOD; ASTHMA; INTERLEUKIN-13	Background: Allergic diseases have been linked to abnormal patterns of immune development, and this has stimulated efforts to define the precise patterns of cytokine dysregulation that are associated with specific atopic phenotypes. Objective: Cytokine-response profiles were prospectively analyzed over the first year of life and compared with the clinical and immunologic expressions of atopy. Methods: Umbilical cord and 1-year PBMCs were obtained from 285 subjects from allergic families. PHA-stimulated cytokine-response profiles (IL-5, IL-10, IL-13, and IFN-gamma) were compared with blood eosinophil counts and total and specific IgE levels (dust mites, cat, egg, Alternaria species, peanut, milk, and dog) at age 1 year and at the development of atopic dermatitis and food allergy. Results: For the cohort as a whole, cytokine responses did not evolve according to a strict T(H)1 or T(H)2 polarization pattern. PHA-stimulated cord blood cells secreted low levels of IL-5 (2.1 pg/mL), moderate levels of IFN-gamma (57.4 pg/mL), and greater amounts of IL-13 (281.8 pg/mL). From birth to 1 year, IL-5 responses dramatically increased, whereas IL-13 and IFN-gamma responses significantly decreased. Reduced cord blood secretion of IL-10 and IFN-gamma was associated with subsequent sensitization to egg. In addition, there was evidence of T(H)2 polarization (increased IL-5 and IL-13 levels) associated with blood eosinophilia and increased total IgE levels by age 1 year. Conclusion: These findings demonstrate that cytokine responses change markedly during the first year of life and provide further evidence of a close relationship between T(H)2 skewing of immune responses and the incidence of atopic manifestations in children.	Univ Wisconsin, Dept Pediat, Madison, WI USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; Univ Wisconsin, Gen Clin Res Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Neaville, WA (corresponding author), Univ Wisconsin Hosp, K4-916,600 Highland Ave, Madison, WI 53792 USA.		Rosenthal, Louis/A-8868-2008	Gilbertson-White, Stephanie/0000-0002-9718-3717	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061879, P01HL070831] Funding Source: NIH RePORTER; NCRR NIH HHS [2 M01 RR03186-16] Funding Source: Medline; NHLBI NIH HHS [1P01HL70831-01, 1R01HL61879-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Gern JE, 1999, J CLIN INVEST, V104, P837, DOI 10.1172/JCI8272; Halonen M, 1997, CLIN EXP ALLERGY, V27, P1234; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; Hoekstra MO, 1997, CLIN EXP ALLERGY, V27, P1254; Jeannin P, 1998, J IMMUNOL, V160, P3555; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Matsui E, 2000, CLIN EXP ALLERGY, V30, P1250, DOI 10.1046/j.1365-2222.2000.00931.x; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; Prescott SL, 1998, J IMMUNOL, V160, P4730; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P1313; SAMPSON HA, 1998, ALLERGY PRINCIPLES P, P1162; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Williams TJ, 2000, J ALLERGY CLIN IMMUN, V105, P951, DOI 10.1067/mai.2000.106211; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	27	111	114	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					740	746		10.1016/S0091-6749(03)01868-2	http://dx.doi.org/10.1016/S0091-6749(03)01868-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564354				2022-12-18	WOS:000185831200014
J	Kakinuma, T; Saeki, H; Tsunemi, Y; Fujita, H; Asano, N; Mitsui, H; Tada, Y; Wakugawa, M; Watanabe, T; Torii, H; Komine, M; Asahina, A; Nakamura, K; Tamaki, K				Kakinuma, T; Saeki, H; Tsunemi, Y; Fujita, H; Asano, N; Mitsui, H; Tada, Y; Wakugawa, M; Watanabe, T; Torii, H; Komine, M; Asahina, A; Nakamura, K; Tamaki, K			Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cutaneous T cell-attracting chemokine; CCL27; atopic dermatitis; psoriasis vulgaris; disease activity	SKIN-ASSOCIATED CHEMOKINE; DISEASE-ACTIVITY; CC-CHEMOKINE; RECEPTOR; KERATINOCYTES; CYTOKINES; CTACK	Both atopic dermatitis (AD) and psoriasis vulgaris (PsV) are characterized as chronic and relapsing inflammatory skin diseases associated with various immunologic abnormalities. Cutaneous T cell-attracting chemokine (CTACK; CCL27) is a member of the CC chemokine family and a functional ligand for CC chemokine receptor 10. It is selectively expressed in skin and attracts CC chemokine receptor 10-expressing skin-homing memory T cells. The epidermal keratinocyte is a main source of CTACK, suggesting the involvement of various inflammatory skin diseases. Objective: The purpose of this investigation was to clarify whether CTACK produced by keratinocytes is detected in the sera of patients with AD and PsV and to examine the correlation between the serum CTACK levels and disease activity of patients with AD and PsV. Methods: We measured the serum CTACK levels in 50 patients with AD, 30 patients with PsV, and 22 healthy control subjects. We also divided 50 patients with AD into 3 groups (ie, those with mild, moderate, and severe disease) and compared them among 3 categories. Moreover, we compared the serum CTACK levels of patients with AD and PsV with clinical or laboratory data. Immunohistochemical staining of CTACK and IFN-induced protein of 10 kd (IP-10; CXCL10) was performed on the lesional skin of patients with AD and PsV. Results: The serum CTACK levels in,patients with AD and PsV were significantly higher than those in healthy control subjects. The serum CTACK levels in patients with AD significantly correlated with scoring atopic dermatitis (SCORAD) scores, serum soluble IL-2 receptor levels, serum soluble E-selectin levels, serum thymus and activation-regulated chemokine levels, and serum macrophage-derived chemokine levels. Serum CTACK levels in patients with PsV significantly correlated with the serum IP-10 levels but not with the Psoriasis Area and Severity Index score. Immunohistochemical staining showed CTACK was strongly expressed in lesional keratinocytes of patients with AD and PsV, whereas IP-10 was strongly expressed in lesional keratinocytes of patients with PsV and focally in those with AD. Conclusion: These results suggest that CTACK might be one of the important chemokines for the pathogenesis of AD and PsV.	Univ Tokyo, Dept Dermatol, Bunkyo Ku, Tokyo 1138655, Japan; Fukushima Med Univ, Sch Med, Dept Dermatol, Fukushima, Japan	University of Tokyo; Fukushima Medical University	Kakinuma, T (corresponding author), Univ Tokyo, Dept Dermatol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.			Torii, Hideshi/0000-0003-2123-3033; Komine, Mayumi/0000-0002-1086-1803				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CHANG E, 1995, ARCH DERMATOL, V128, P1479; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Homey B, 2000, J IMMUNOL, V164, P3465, DOI 10.4049/jimmunol.164.7.3465; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Ishikawa-Mochizuki I, 1999, FEBS LETT, V460, P544, DOI 10.1016/S0014-5793(99)01406-4; Kakinuma T, 2002, CLIN EXP IMMUNOL, V127, P270, DOI 10.1046/j.1365-2249.2002.01727.x; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; KAPP A, 1988, BRIT J DERMATOL, V119, P707, DOI 10.1111/j.1365-2133.1988.tb03491.x; Kunkel EJ, 2002, IMMUNITY, V16, P1, DOI 10.1016/S1074-7613(01)00261-8; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Stoof TJ, 2001, BRIT J DERMATOL, V144, P1114, DOI 10.1046/j.1365-2133.2001.04220.x; VALDIMARSSON H, 1986, IMMUNOL TODAY, V7, P256, DOI 10.1016/0167-5699(86)90005-8; Yamashita N, 1997, J ALLERGY CLIN IMMUN, V99, P410, DOI 10.1016/S0091-6749(97)70060-5	20	111	117	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					592	597		10.1067/mai.2003.114	http://dx.doi.org/10.1067/mai.2003.114			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642842				2022-12-18	WOS:000181639500023
J	Kawagishi, Y; Mita, H; Taniguchi, M; Maruyama, M; Oosaki, R; Higashi, N; Kashii, T; Kobayashi, M; Akiyama, K				Kawagishi, Y; Mita, H; Taniguchi, M; Maruyama, M; Oosaki, R; Higashi, N; Kashii, T; Kobayashi, M; Akiyama, K			Leukotriene C-4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin-induced asthma; cysteinyl leukotrienes; leukotriene C-4 synthase; 5-lipoxygenase; polymorphism	INTOLERANT ASTHMA; 11-DEHYDROTHROMBOXANE B-2; URINARY LEUKOTRIENE-E4; SENSITIVE ASTHMA; GENE; TRANSCRIPTION; EOSINOPHILS; EXPRESSION; ANTAGONIST; EXCRETION	Background: The A to C transversion in the promoter region of the gene encoding leukotriene C-4 synthase (LTC4S) is proposed to be associated with the development of aspirin-induced asthma (AIA). Objective: We investigated the frequency of the polymorphism in Japanese population and its association with clinical characteristics and cysteinyl leukotriene production. Methods: Genotyping of LTC4S gene promoter was performed on 60 patients with AIA, 100 patients with aspirin-tolerant asthma (ATA), and 110 control subjects. We assessed the basal levels of urinary LTE4, the increment of urinary LTE4 on venous aspirin challenge, and LTC4S activity in peripheral blood eosinophils. Results: The frequency of the variant C allele was significantly higher in patients with AIA (frequency of allele [q] = 0.192) than in patients with ATA (q = 0.110, P = .042). Variant C-allelic carriers experienced asthma at a significantly younger age (31.8 +/- 2.9 years [mean +/- SEM]) than wild-type A homozygotes (41.3 +/- 2.2 years, P = .007). Basal levels of LTE4 and the increment of urinary LTE4 on venous aspirin challenge did not show a difference between wild-type A homozygotes and variant C-allelic carriers. There was no relationship between the polymorphism and the LTC4S activity in eosinophils, although LTC4S activities were significantly higher in patients with AIA than in patients with ATA. Conclusion: Our findings reveal the lack of functionality of the polymorphism in the LTC4S gene, whereas this polymorphism might have some effect on the development of AIA, probably in linkage disequilibrium with another causatively important mutation.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Internal Med 1, Toyama 9300194, Japan; Natl Sagamihara Hosp, Clin Res Ctr, Sagamihara, Kanagawa, Japan	University of Toyama	Maruyama, M (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Internal Med 1, 2630 Sugitani, Toyama 9300194, Japan.							Boyce JA, 1996, BLOOD, V88, P4338; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; LEE TH, 1992, AM REV RESPIR DIS, V145, P34; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Oosaki R, 1997, ALLERGY, V52, P470, DOI 10.1111/j.1398-9995.1997.tb01032.x; Oosaki R, 1998, CLIN EXP ALLERGY, V28, P1138; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; Sanak M, 1999, CLIN EXP ALLERGY, V29, P306; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; SMITH CM, 1992, EUR RESPIR J, V5, P693; Stafforini DM, 1999, J CLIN INVEST, V103, P989, DOI 10.1172/JCI5574; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Van Sambeek R, 2000, J ALLERGY CLIN IMMUN, V106, P72, DOI 10.1067/mai.2000.107603; YAMAMOTO H, 1994, AM J RESP CRIT CARE, V150, P254, DOI 10.1164/ajrccm.150.1.8025759	26	111	117	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					936	942		10.1067/mai.2002.124466	http://dx.doi.org/10.1067/mai.2002.124466			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063521				2022-12-18	WOS:000176442700007
J	Jones, CA; Holloway, JA; Popplewell, EJ; Diaper, ND; Holloway, JW; Vance, GHS; Warner, JA; Warner, JO				Jones, CA; Holloway, JA; Popplewell, EJ; Diaper, ND; Holloway, JW; Vance, GHS; Warner, JA; Warner, JO			Reduced soluble CD14 levels in amniotic fluid and breast milk are associated with the subsequent development of atopy, eczema, or both	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						soluble CD14; amniotic fluid; breast milk; eczema	EARLY-CHILDHOOD; IGE PRODUCTION; IMMUNE-SYSTEM; CUTTING EDGE; HAY-FEVER; LIPOPOLYSACCHARIDE; CHILDREN; ASTHMA; RECOGNITION; MICROFLORA	Background: Exposure to various microbial products in early life reduces the risk of atopy. Such exposure induces down-regulation of T(H)2 allergy-biased responses by means of pattern recognition molecules, such as CD14, an LPS receptor. Objective: We sought to determine whether infant and maternal levels of soluble CD14 (sCD14) are associated with the atopic outcomes of infants. Methods: Levels of sCD14 in plasma, amniotic fluid, and breast milk were measured with a specific ELISA in different cohorts. Expression of toll-like receptors in the fetal gut was examined by using RT-PCR. Results: Soluble CD14 levels increased during fetal development and postnatally, attaining adult levels by around 4 months of age, with an overshoot of adult levels from 6 months of age. There was no difference in plasma sCD14 levels at birth of children with a high compared with those with a low risk of development of atopy. Amniotic fluid sCD14 levels at midgestation (16-17 weeks) were significantly lower when the child was subsequently atopic (P < .05). Soluble CD14 levels in breast milk collected 3 months postpartum were significantly lower in children with eczema at 6 months of age, irrespective of whether they were atopic (P = .003). Transcripts for toll-like receptor 4, which would enable transmembrane signaling for LPS/sCD14 complexes, were expressed within fetal gut and skin. Conclusion: Exposure to reduced levels of sCD14 in the fetal and neonatal gastrointestinal tract is associated with the development of atopy, eczema, or both. Thus the exogenous supply of sCD14 might influence immunologic reactivity both locally and systemically in early life and thereby influence disease outcome.	Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England; Southampton Gen Hosp, Sch Med, Div Human Genet, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton	Jones, CA (corresponding author), Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair, Level G Mailpoint 803, Southampton SO16 6YD, Hants, England.		Warner, John/AAF-9587-2020; Holloway, John W/B-5424-2009; Holloway, Judith A/A-1757-2010	Holloway, John W/0000-0001-9998-0464; Holloway, Judith A/0000-0002-2268-3071	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061858] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61858] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arias MA, 2000, J IMMUNOL, V164, P3480, DOI 10.4049/jimmunol.164.7.3480; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; ETAC Study Group, 1998, ALLERGY IMMUNOL, V9, P116; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; HAZIOT A, 1988, J IMMUNOL, V141, P547; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Horrobin DF, 2000, AM J CLIN NUTR, V71, p367S, DOI 10.1093/ajcn/71.1.367s; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; Jones A C, 1994, Pediatr Allergy Immunol, V5, P230, DOI 10.1111/j.1399-3038.1994.tb00245.x; Jones CA, 2001, J ALLERGY CLIN IMMUN, V108, P235, DOI 10.1067/mai.2001.117178; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201, DOI 10.1046/j.1365-2222.2000.00800.x; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Labeta MO, 2000, J EXP MED, V191, P1807, DOI 10.1084/jem.191.10.1807; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Roos T, 1997, AM J OBSTET GYNECOL, V177, P1230, DOI 10.1016/S0002-9378(97)70044-9; SPENCER J, 1986, CLIN EXP IMMUNOL, V64, P536; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Sudo N, 1997, J IMMUNOL, V159, P1739; Sugiyama T, 2001, J IMMUNOL, V166, P826, DOI 10.4049/jimmunol.166.2.826; TALEUCHI O, 1999, IMMUNITY, V11, P443; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766	32	111	122	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					858	866		10.1067/mai.2002.123535	http://dx.doi.org/10.1067/mai.2002.123535			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994712				2022-12-18	WOS:000175687800018
J	Jarjour, NN; Gern, JE; Kelly, EAB; Swenson, CA; Dick, CR; Busse, WW				Jarjour, NN; Gern, JE; Kelly, EAB; Swenson, CA; Dick, CR; Busse, WW			The effect of an experimental rhinovirus 16 infection on bronchial lavage neutrophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						virus-induced asthma; rhinovirus; asthma; neutrophils	SUBJECTS IN-VIVO; ASTHMATIC SUBJECTS; ALLERGIC SUBJECTS; ANTIGEN BRONCHOPROVOCATION; AIRWAY HYPERRESPONSIVENESS; INTERLEUKIN-8; VIRUS; COLDS; EXACERBATIONS; INFLAMMATION	Background: Viral respiratory tract infections are the most frequent cause of asthma exacerbations. Of the respiratory viruses associated with these exacerbations, rhinovirus (RV) is the most common. It is proposed that these RV infections may enhance airway inflammation and thus provoke asthma. Objective: It is our hypothesis that RV infections generate nasal proinflammatory mediators that are associated with an initial increase in circulating leukocytes and may contribute to later development of neutrophilic airway inflammation. Methods: To evaluate this hypothesis, subjects with a history of allergic asthma were experimentally inoculated with strain 16 RV (RV16). The effect of this experimental infection was evaluated on circulating leukocytes, nasal-derived mediators, and markers of bronchial inflammation that were obtained by bronchoscopy and lavage. Results: RV16 inoculation was associated with an initial increase in circulating neutrophils. paralleling these acute changes in circulating neutrophils was an increase in nasal concentrations of IL-8 and granulocyte-colony-stimulating factor (G-CSF). The RV16-associated changes in circulating and nasal G-CSF correlated with increases in peripheral blood neutrophils (r(s) = 0.874, P < .001 and r(s) = 0.898, P < .001, respectively). Bronchial lavage samples showed no increase in neutrophils 48 hours after RV16 inoculation; however, 96 hours after RV inoculation there was a significant increase in bronchial neutrophils compared with preinoculation values. Conclusions: These results suggest that the production of nasal mediators associated with the RV infection, particularly G-CSF, may be important to the eventual development of neutrophilic bronchial inflammation and thus contribute to asthma exacerbations.	Univ Wisconsin Hosp, Sch Med, Dept Med, Clin Sci Ctr H6367, Madison, WI 53792 USA; Univ Wisconsin Hosp, Sch Med, Dept Pediat, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin Hosp, Sch Med, Dept Med, Clin Sci Ctr H6367, 600 Highland Ave, Madison, WI 53792 USA.			Kelly, Elizabeth/0000-0001-7335-6698	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034891, R01AI026609, U01AI034891] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34891, AI 26609] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CALHOUN WJ, 1991, AM REV RESPIR DIS, V144, P1267, DOI 10.1164/ajrccm/144.6.1267; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282; DALESSIO DJ, 1976, J INFECT DIS, V133, P28, DOI 10.1093/infdis/133.1.28; DALESSIO DJ, 1984, J INFECT DIS, V150, P195; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; Jarjour NN, 1997, AM J RESP CRIT CARE, V155, P1515, DOI 10.1164/ajrccm.155.5.9154851; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kelly EAB, 1997, AM J RESP CRIT CARE, V156, P1421, DOI 10.1164/ajrccm.156.5.9703054; Khwaja A, 1994, Curr Opin Hematol, V1, P216; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LEVANDOWSKI RA, 1988, J MED VIROL, V25, P423, DOI 10.1002/jmv.1890250406; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P324; SCHMITZ S, 1993, EXP HEMATOL, V21, P755; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; Teran LM, 1996, AM J RESP CRIT CARE, V154, P469, DOI 10.1164/ajrccm.154.2.8756824; Teran LM, 1997, AM J RESP CRIT CARE, V155, P1362, DOI 10.1164/ajrccm.155.4.9105080; TURNER RB, 1990, PEDIATR INFECT DIS J, V9, P832, DOI 10.1097/00006454-199011000-00011; WENZIEN B, 1995, PHYS REV B, V52, P10897, DOI 10.1103/PhysRevB.52.10897	27	111	115	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1169	1177		10.1067/mai.2000.106376	http://dx.doi.org/10.1067/mai.2000.106376			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856152				2022-12-18	WOS:000087781800019
J	Wedi, B; Novacovic, V; Koerner, W; Kapp, A				Wedi, B; Novacovic, V; Koerner, W; Kapp, A			Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression - Inhibitory effects of anti-inflammatory drugs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic urticaria; autoantibodies; histamine release; sulfidoleukotrienes; CD63	CHRONIC IDIOPATHIC URTICARIA; FC-EPSILON-RI; AFFINITY IGE RECEPTOR; HELICOBACTER-PYLORI; NEUTROPHIL ADHERENCE; ALPHA AUTOANTIBODIES; VASCULITIS-SYNDROME; CLINICAL-FEATURES; DAPSONE; ACTIVATION	Background: A role of potential histamine-releasing autoantibodies against the high-affinity IgE receptor on the surface of basophils and mast cells is discussed in the pathogenesis of chronic urticaria. This so-called autoimmune urticaria may be diagnosed by a positive intracutaneous autologous serum skin test, which is found in about 30% of patients with chronic urticaria, Objective: Our purpose was, first, to compare the effect of complement-inactivated sera of 20 patients with chronic urticaria and positive autologous serum skin tests, 20 patients with chronic urticaria and negative skin tests, and 20 control subjects without chronic urticaria (10 atopic and 10 nonatopic subjects) and, second, to analyze the effect of anti-inflammatory drugs on the serum activity, Methods: The following assay systems were used: release of histamine in whole blood samples, surface expression of the activation marker CD63 on basophils, and sulfidoleukotriene de novo production in leukocyte suspensions. Whole blood, basophils, and leukocyte suspensions were obtained from a nonatopic and an atopic donor. Results: Sera of patients with autologous serum skin test positive chronic urticaria resulted not only in significantly increased histamine release compared with skin test-negative chronic urticaria sera hut also in a significant higher induction of basophil CD63 surface expression and sulfidoleukotriene de novo production. However, serum activity was neither characteristic for chronic urticaria nor for chronic urticaria with a positive autologous serum skin test. Preincubation with dapsone, chloroquine, and lidocaine dose dependently resulted in a significant reduction of all histamine release, CD63 expression, and sulfidoleukotriene production, In addition, mizolastine was able to inhibit serum-induced sulfidoleukotriene production. Conclusion: Further studies investigating the in vivo effect of these drugs will have to clarify their role in the management of the subset of patients with chronic urticaria demonstrating serum-induced inflammatory effects.	Hannover Med Univ, Dept Dermatol & Allergol, D-30449 Hannover, Germany	Hannover Medical School	Wedi, B (corresponding author), Hannover Med Univ, Dept Dermatol & Allergol, Ricklinger Str 5, D-30449 Hannover, Germany.		Wedi, Bettina/ABE-3636-2021	Wedi, Bettina/0000-0002-9868-6308; Kapp, Alexander/0000-0002-1748-6276				ANDERSON R, 1985, ANTIMICROB AGENTS CH, V27, P257, DOI 10.1128/AAC.27.2.257; BOOTH SA, 1992, J INVEST DERMATOL, V98, P135, DOI 10.1111/1523-1747.ep12555654; Brostoff J, 1996, ALLERGY, V51, P320; Charous BL, 1998, J ALLERGY CLIN IMMUN, V102, P198, DOI 10.1016/S0091-6749(98)70086-7; Coleman MD, 1997, J PHARM PHARMACOL, V49, P53, DOI 10.1111/j.2042-7158.1997.tb06752.x; COLEMAN MD, 1993, BRIT J DERMATOL, V129, P507, DOI 10.1111/j.1365-2133.1993.tb00476.x; COONEY T, 1977, J CLIN PATHOL, V30, P976, DOI 10.1136/jcp.30.10.976; COX NH, 1991, BRIT J DERMATOL, V124, P69, DOI 10.1111/j.1365-2133.1991.tb03284.x; Debol SM, 1997, J LEUKOCYTE BIOL, V62, P827, DOI 10.1002/jlb.62.6.827; Decco ML, 1999, ANN ALLERG ASTHMA IM, V82, P29, DOI 10.1016/S1081-1206(10)62656-7; Di Campli C, 1998, DIGEST DIS SCI, V43, P1226, DOI 10.1023/A:1018851623109; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; FORTSON JS, 1986, J AM ACAD DERMATOL, V15, P1137, DOI 10.1016/S0190-9622(86)70282-X; Gibbs BF, 1997, INFLAMM RES, V46, pS25; Goldhill J, 1998, ARZNEIMITTEL-FORSCH, V48, P179; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; Greaves MW, 1998, EXP DERMATOL, V7, P11, DOI 10.1111/j.1600-0625.1998.tb00296.x; GRINDULIS KA, 1984, J RHEUMATOL, V11, P776; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; Haas N, 1998, ARCH DERMATOL, V134, P41, DOI 10.1001/archderm.134.1.41; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Horn MP, 1999, EUR J IMMUNOL, V29, P1139, DOI 10.1002/(SICI)1521-4141(199904)29:04<1139::AID-IMMU1139>3.0.CO;2-J; HURST NP, 1987, ANN RHEUM DIS, V46, P750, DOI 10.1136/ard.46.10.750; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; KNOL EF, 1996, EUR RESPIR J, V22, P126; Koyama Y, 1998, BIOCHEM BIOPH RES CO, V246, P841, DOI 10.1006/bbrc.1998.8725; KROGSTAD DJ, 1987, NEW ENGL J MED, V317, P542, DOI 10.1056/NEJM198708273170905; Lacroix-Desmazes S, 1998, J IMMUNOL METHODS, V216, P117, DOI 10.1016/S0022-1759(98)00074-X; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Leynadier F, 1996, ANN ALLERG ASTHMA IM, V76, P163, DOI 10.1016/S1081-1206(10)63417-5; LEZNOFF A, 1983, ARCH DERMATOL, V119, P636, DOI 10.1001/archderm.119.8.636; MILLAR BW, 1984, ACTA DERM-VENEREOL, V64, P433; Moneret-Vautrin DA, 1999, ANN ALLERG ASTHMA IM, V82, P33, DOI 10.1016/S1081-1206(10)62657-9; MOUTHON L, 1995, J IMMUNOL, V154, P5769; MOUTHON L, 1996, CLIN EXP IMMUNOL S, V101, P3; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; Nishimura M, 1998, TRANSFUSION MED, V8, P209, DOI 10.1046/j.1365-3148.1998.00160.x; NURNBERG W, 1995, ACTA DERM-VENEREOL, V75, P54; O'Donnell BF, 1998, BRIT J DERMATOL, V138, P101; Ohnishi T, 1996, CLIN EXP IMMUNOL, V104, P325, DOI 10.1046/j.1365-2249.1996.32737.x; Okada S, 1998, J IMMUNOL, V160, P4010; PERSON JR, 1977, ARCH DERMATOL, V113, P610, DOI 10.1001/archderm.113.5.610; Poon E, 1999, BRIT J DERMATOL, V140, P667; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Sabroe RA, 1997, ARCH DERMATOL, V133, P1003, DOI 10.1001/archderm.133.8.1003; Sabroe RA, 1999, J AM ACAD DERMATOL, V40, P443, DOI 10.1016/S0190-9622(99)70495-0; Sainte-Laudy J, 1998, INFLAMM RES, V47, P401, DOI 10.1007/s000110050351; Sasaki Ryuhei, 1997, Leukemia (Basingstoke), V11, P478; Schultz KR, 1996, BONE MARROW TRANSPL, V18, P625; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Toppe E, 1998, BRIT J DERMATOL, V138, P248; Valsecchi R, 1998, ACTA DERM-VENEREOL, V78, P440; WARNER JA, 1989, J LEUKOCYTE BIOL, V45, P558, DOI 10.1002/jlb.45.6.558; Wedi B, 1998, INT ARCH ALLERGY IMM, V116, P288, DOI 10.1159/000023958; Weidi B, 1996, ALLERGY CLIN IMMUNOL, V8, P113; WISNIESKI JJ, 1995, MEDICINE, V74, P24, DOI 10.1097/00005792-199501000-00003; Zuberbier T, 1995, ACTA DERM-VENEREOL, V75, P484; Zweiman B, 1996, J ALLERGY CLIN IMMUN, V98, P89, DOI 10.1016/S0091-6749(96)70230-0	61	111	133	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					552	560		10.1067/mai.2000.104939	http://dx.doi.org/10.1067/mai.2000.104939			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719307				2022-12-18	WOS:000088946700023
J	MELTZER, S; GOLDBERG, B; LAD, P; EASTON, J				MELTZER, S; GOLDBERG, B; LAD, P; EASTON, J			SUPEROXIDE GENERATION AND ITS MODULATION BY ADENOSINE IN THE NEUTROPHILS OF SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KAISER PERMANENTE MED CTR,DEPT ALLERGY & CLIN IMMUNOL,1515 N VERMONT AVE,LEVEL B,LOS ANGELES,CA 90027; KAISER PERMANENTE MED CTR,REG RES LAB,LOS ANGELES,CA	Kaiser Permanente; Kaiser Permanente					NIADDK NIH HHS [AM30878, AM34550] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM030878] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABIOR BM, 1978, NEW ENGL J MED, V298, P721, DOI 10.1056/NEJM197803302981305; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CRONSTEIN BN, 1985, J IMMUNOL, V135, P1365; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; Goldstein I M, 1977, Inflammation, V2, P309, DOI 10.1007/BF00921010; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; LAD PM, 1985, BIOCHIM BIOPHYS ACTA, V846, P286, DOI 10.1016/0167-4889(85)90076-X; LARSEN GL, 1983, ANNU REV IMMUNOL, V1, P335, DOI 10.1146/annurev.iy.01.040183.002003; LYNCH CJ, 1985, J BIOL CHEM, V260, P1593; MANN JS, 1983, CLIN SCI, V65, pP22; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; NEIJENS HJ, 1984, AM REV RESPIR DIS, V130, P744; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P220; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; PETRONE WF, 1980, P NATL ACAD SCI-BIOL, V77, P1159, DOI 10.1073/pnas.77.2.1159; SANERKIN NG, 1965, J PATHOL BACTERIOL, V89, P535, DOI 10.1002/path.1700890211; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; SHASBY DM, 1982, AM REV RESPIR DIS, V125, P443; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199	23	111	111	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					960	966		10.1016/0091-6749(89)90112-7	http://dx.doi.org/10.1016/0091-6749(89)90112-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2541190				2022-12-18	WOS:A1989U716100018
J	SHEFFER, AL; TONG, AKF; MURPHY, GF; LEWIS, RA; MCFADDEN, ER; AUSTEN, KF				SHEFFER, AL; TONG, AKF; MURPHY, GF; LEWIS, RA; MCFADDEN, ER; AUSTEN, KF			EXERCISE-INDUCED ANAPHYLAXIS - A SERIOUS FORM OF PHYSICAL ALLERGY ASSOCIATED WITH MAST-CELL DE-GRANULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	SHEFFER, AL (corresponding author), BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,75 FRANCIS ST,BOSTON,MA 02115, USA.				NHLBI NIH HHS [HL-17873] Funding Source: Medline; NIAID NIH HHS [AI-10356, AI-22531] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022531, R01AI022531] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAULFIELD JP, 1980, J CELL BIOL, V85, P229; DVORAK AM, 1984, J CELL BIOL, V99, P1678, DOI 10.1083/jcb.99.5.1678; DVORAK AM, 1983, J IMMUNOL, V131, P2965; FREEMAN RG, 1967, AM J CLIN PATHOL, V18, P187; KARNOVASKY MORRIS J., 1967, J CELL BIOL, V35, P213, DOI 10.1083/jcb.35.1.213; KOBAYASI T, 1969, ACTA DERM-VENEREOL, V49, P369; LAGUNOFF D, 1972, J INVEST DERMATOL, V58, P296, DOI 10.1111/1523-1747.ep12540314; ROHLICH P, 1971, J CELL BIOL, V51, P465, DOI 10.1083/jcb.51.2.465; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SHEFFER AL, 1983, J ALLERGY CLIN IMMUN, V71, P311, DOI 10.1016/0091-6749(83)90085-4; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0	13	111	112	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	4					479	484		10.1016/S0091-6749(85)80021-X	http://dx.doi.org/10.1016/S0091-6749(85)80021-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AFY44	3980883				2022-12-18	WOS:A1985AFY4400008
J	TABACHNIK, E; LEVISON, H				TABACHNIK, E; LEVISON, H			INFANTILE BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,INST RES,DEPT PEDIAT,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BEARDSHAW J, 1974, CHEST, V65, P507, DOI 10.1378/chest.65.5.507; BLACKWELL EW, 1974, BRIT J PHARMACOL, V50, P587, DOI 10.1111/j.1476-5381.1974.tb08593.x; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BOESEN I, 1953, Acta Paediatr, V42, P87, DOI 10.1111/j.1651-2227.1953.tb05571.x; BRYAN AC, 1977, DEV LUNG, V6, P445; BUFFUM WP, 1963, PEDIATRICS, V32, P453; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; CHENEY FW, 1968, ANESTHESIOLOGY, V29, P1099, DOI 10.1097/00000542-196811000-00004; DEES SC, 1961, JAMA-J AM MED ASSOC, V175, P365, DOI 10.1001/jama.1961.03040050021005; DENNY FW, 1977, PEDIATR RES, V11, P235; DISNEY M E, 1971, Clinical Allergy, V1, P399, DOI 10.1111/j.1365-2222.1971.tb00791.x; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; ENGEL S, 1962, LUNG STRUCTURE, P25; FERGUSSON DM, 1980, ARCH DIS CHILD, V55, P358, DOI 10.1136/adc.55.5.358; FOUCARD T, 1973, ACTA PAEDIATR SCAND, V62, P633, DOI 10.1111/j.1651-2227.1973.tb17078.x; FREEMAN GL, 1962, AM J DIS CHILD, V104, P330, DOI 10.1001/archpedi.1962.02080030332002; GEUMEI A, 1975, PHARMACOLOGY, V13, P201, DOI 10.1159/000136905; GEUMEI AM, 1976, CHEST, V70, P460, DOI 10.1378/chest.70.4.460; GODFREY S, 1974, BTTA REV BRIT THO TU, V4, P1; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HENDELES L, 1980, DRUG INTELL CLIN PHA, V14, P523; HETZEL MR, 1976, BRIT MED J, V2, P919, DOI 10.1136/bmj.2.6041.919; HOGG JC, 1970, NEW ENGL J MED, V282, P1283, DOI 10.1056/NEJM197006042822302; HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587; HORN MEC, 1972, J HYG, V74, P157; HURST A, 1973, ANN ALLERGY, V31, P460; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; JOHNSTONE DE, 1966, NEW ENGL J MED, V274, P715, DOI 10.1056/NEJM196603312741305; KEENS TG, 1978, J APPL PHYSIOL, V44, P909, DOI 10.1152/jappl.1978.44.6.909; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; LARSSON S, 1977, AM REV RESPIR DIS, V116, P861; LEIFER KN, 1975, ANN ALLERGY, V35, P69; Macklin CC, 1936, ARCH PATHOL, V21, P202; Martin JA, 1980, AM REV RESPIR DIS, V122, P609; MATTHEW DJ, 1977, LANCET, V1, P321; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MOFFET HL, 1967, AM J DIS CHILD, V114, P21, DOI 10.1001/archpedi.1967.02090220027004; MULLER NL, 1979, PEDIATR CLIN N AM, V26, P503; NEWTH CJL, UNPUBLISHED; OGILVIE A. G., 1962, THORAX, V17, P183, DOI 10.1136/thx.17.3.183; OGLE KA, 1977, ANN ALLERGY, V39, P8; PHELAN PD, 1969, AUSTRALIAN PAEDIATRI, V5, P187; POWLES ACP, 1975, NEW ZEAL MED J, V81, P249; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; RADFORD M, 1975, ARCH DIS CHILD, V50, P535, DOI 10.1136/adc.50.7.535; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; ROSEN JP, 1979, PEDIATRICS, V64, P248; RUTTER N, 1975, ARCH DIS CHILD, V50, P719, DOI 10.1136/adc.50.9.719; SAARINEN UM, 1979, LANCET, V2, P163; SAARINEN UM, 1980, LANCET, V1, P166; SHAPIRO GG, 1977, PEDIATRICS, V59, P495; SIBBALD B, 1980, ARCH DIS CHILD, V55, P354, DOI 10.1136/adc.55.5.354; SVEDMYR N, 1978, AM REV RESPIR DIS, V117, P183; WALER SR, 1972, CLIN PHARMACOL THER, V13, P861; WELLIVER RC, 1980, NEW ENGL J MED, V303, P1198, DOI 10.1056/NEJM198011203032103; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; WILLIAMS HE, 1975, RESPIRATORY ILLNESS, P164; WITTIG HJ, 1959, J ALLERGY, V30, P19, DOI 10.1016/0021-8707(59)90054-1; ZWEIMAN B, 1971, J ALLERGY CLIN IMMUN, V48, P283, DOI 10.1016/0091-6749(71)90029-7; 1962, AM REV RESPIR DIS, V85, P762	63	111	113	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	5					339	347		10.1016/0091-6749(81)90077-4	http://dx.doi.org/10.1016/0091-6749(81)90077-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ563	6785335				2022-12-18	WOS:A1981LQ56300002
J	MARTIN, GL; ATKINS, PC; DUNSKY, EH; ZWEIMAN, B				MARTIN, GL; ATKINS, PC; DUNSKY, EH; ZWEIMAN, B			EFFECTS OF THEOPHYLLINE, TERBUTALINE, AND PREDNISONE ON ANTIGEN-INDUCED BRONCHOSPASM AND MEDIATOR RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN, SCH MED, DEPT MED, ALLERGY & IMMUNOL SECT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER; NCRR NIH HHS [5MO1 RR0040] Funding Source: Medline; NIAID NIH HHS [AI07031, R01 AI14332] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS PC, 1979, J ALLERGY CLIN IMMUN, V64, P251, DOI 10.1016/0091-6749(79)90140-4; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BOOJINOORD H, 1970, J ALLERGY, V46, P1; BOOJINOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344; COFFEY RG, 1974, J ALLERGY CLIN IMMUN, V54, P41, DOI 10.1016/S0091-6749(74)80007-2; ELLULMICALLEF R, 1975, LANCET, V2, P1269; GREAVES MW, 1976, CLIN EXP DERMATOL, V1, P327, DOI 10.1111/j.1365-2230.1976.tb01438.x; GREAVES MW, 1976, CLIN EXP DERMATOL, V1, P83, DOI 10.1111/j.1365-2230.1976.tb01401.x; GREAVES MW, 1974, IMMUNOLOGY, V27, P359; GRYGLEWSKI RJ, 1975, PROSTAGLANDINS, V10, P343, DOI 10.1016/S0090-6980(75)80087-6; HONG SL, 1976, P NATL ACAD SCI USA, V73, P1730, DOI 10.1073/pnas.73.5.1730; ISHIZAKA T, 1971, J IMMUNOL, V106, P1267; KILPATRICK SJ, 1973, STATISTICAL PRINCIPL, P155; KRAM JA, 1975, J ALLERGY CLIN IMMUN, V56, P387, DOI 10.1016/0091-6749(75)90132-3; LEVY DA, 1973, J LAB CLIN MED, V81, P291; LICHTENSTEIN LM, 1978, INT ARCH ALLER A IMM, V56, P473, DOI 10.1159/000232059; LINDGREN BR, 1978, SCAND J RESPIR DIS, V59, P333; LIU AYC, 1976, P NATL ACAD SCI USA, V73, P568, DOI 10.1073/pnas.73.2.568; LOGSDEN P, 1974, J ALLERGY CLIN IMMUN, V54, P41; MALKINSON AM, 1975, METABOLISM, V24, P331, DOI 10.1016/0026-0495(75)90114-6; MANCINI RE, 1961, J ALLERGY, V32, P471, DOI 10.1016/0021-8707(61)90001-6; MANGANIELLO V, 1972, J CLIN INVEST, V51, P2763, DOI 10.1172/JCI107096; MORRIS HG, 1978, ALLERGY PRINCIPLES P, P464; MORRISON DC, 1977, J IMMUNOL, V119, P1970; NAKAZAWA T, 1976, J ALLERGY CLIN IMMUN, V58, P1, DOI 10.1016/0091-6749(76)90101-9; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; ORANGE RP, 1971, J EXP MED, V134, pS136; PATTERSON R, 1977, J CLIN INVEST, V59, P217, DOI 10.1172/JCI108631; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V62, P371, DOI 10.1016/0091-6749(78)90139-2; PATTERSON R, 1974, CLIN EXP IMMUNOL, V16, P223; PAULI G, 1979, J ALLERGY CLIN IMMUN, V63, P245, DOI 10.1016/0091-6749(79)90108-8; ROSENBLUM F, 1978, J ALLERGY CLIN IMMUN, V61, P129, DOI 10.1016/0091-6749(78)90241-5; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; RUFFIN RE, 1978, J ALLERGY CLIN IMMUN, V61, P42, DOI 10.1016/0091-6749(78)90472-4; SALVATO G, 1959, EXPERIENTIA, V15, P308, DOI 10.1007/BF02158539; SKOU PS, 1977, EXPERIENTIA, V33, P965; STRANDBERG K, 1977, INT ARCH ALLER A IMM, V53, P520, DOI 10.1159/000231794; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; YAMAMOTO S, 1973, IMMUNOLOGY, V24, P77	41	111	111	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	3					204	212		10.1016/0091-6749(80)90040-8	http://dx.doi.org/10.1016/0091-6749(80)90040-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KH358	7410745	Bronze			2022-12-18	WOS:A1980KH35800006
J	NORMAN, PS				NORMAN, PS			OVERVIEW OF IMMUNOTHERAPY - IMPLICATIONS FOR THE FUTURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NORMAN, PS (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.							AAS K, 1963, ACTA PAEDIATR, V52, P338, DOI 10.1111/j.1651-2227.1963.tb03789.x; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; BARR SE, 1965, J ALLERGY, V36, P47, DOI 10.1016/0021-8707(65)90032-8; BOREL Y, 1976, NATURE, V261, P49, DOI 10.1038/261049a0; CHIORAZZI N, 1976, P NATL ACAD SCI US, V73, P209; CHIPPS BE, 1979, J ALLERGY CLIN IMMUN, V63, P179; CONNELL JT, 1969, J ALLERGY, V43, P22, DOI 10.1016/0021-8707(69)90017-3; DEUSCHL H, 1977, ACTA ALLERGOL, V3, P248; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; FONTANA VJ, 1965, JAMA-J AM MED ASSOC, V183, P895; FORGACS P, 1968, BRIT MED J, V3, P774; FRANKLAND AW, 1954, LANCET, V1, P1055; FRANKLAND AW, 1955, BRIT MED J, V2, P941, DOI 10.1136/bmj.2.4945.941; FUCHS AM, 1959, J ALLERGY, V30, P66, DOI 10.1016/0021-8707(59)90060-7; GOLDEN D, 1979, J ALLERGY CLIN IMMUN, V63, P180; HELANDER E., 1959, ACTA ALLERGOL, V13, P47, DOI 10.1111/j.1398-9995.1959.tb02750.x; HUHTI E, 1974, ANN ALLERGY, V33, P145; ISHIZAKA K, 1975, J IMMUNOL, V114, P110; JOHANSSO.SG, 1974, CLIN ALLERGY, V4, P57, DOI 10.1111/j.1365-2222.1974.tb01363.x; JOHANSSON SG, 1974, CLIN ALLERGY, V4, P255, DOI 10.1111/j.1365-2222.1974.tb01383.x; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; JOHNSTONE DE, 1959, PEDIATRICS, V24, P427; KING TP, 1974, IMMUNOCHEMISTRY, V11, P83, DOI 10.1016/0019-2791(74)90321-8; LEE WY, 1977, NATURE, V267, P618, DOI 10.1038/267618a0; LEVY DA, 1967, J IMMUNOL, V99, P1068; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LICHTENSTEIN LM, 1968, J ALLERGY, V41, P237; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MAY CD, 1970, J ALLERGY, V46, P73, DOI 10.1016/0021-8707(70)90075-4; MILLER ACML, 1974, CLIN ALLERGY, V4, P49, DOI 10.1111/j.1365-2222.1974.tb01362.x; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P384, DOI 10.1016/0091-6749(78)90118-5; NORMAN PS, 1979, J ALLERGY CLIN IMMUN, V63, P167; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; NORMAN PS, 1977, T AM CLIN CLIMAT ASS, V89, P119; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; POTTER M, 1962, NATURE, V193, P1087; REISMAN RE, 1965, INT ARCH ALLER A IMM, V28, P353, DOI 10.1159/000229681; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; SPIEGELMAN J, 1967, ANN ALLERGY, V25, P262; TAKATSU K, 1976, J IMMUNOL, V116, P1257; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TURKELTAUB PC, 1978, J ALLERGY CLIN IMMUN, V61, P171, DOI 10.1016/0091-6749(78)90381-0; TURKELTAUB PC, 1976, J ALLERGY CLIN IMMUN, V57, P232	55	111	111	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	2					87	96		10.1016/0091-6749(80)90191-8	http://dx.doi.org/10.1016/0091-6749(80)90191-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JF199	6153189				2022-12-18	WOS:A1980JF19900002
J	LANDAY, RA; GONZALEZ, MA; TAYLOR, JC				LANDAY, RA; GONZALEZ, MA; TAYLOR, JC			EFFECT OF PHENOBARBITAL ON THEOPHYLLINE DISPOSITION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PURDUE UNIV,SCH PHARM & PHARMACAL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	LANDAY, RA (corresponding author), NATL JEWISH HOSP & RES CTR,DEPT PEDIAT,DENVER,CO 80206, USA.							ALVARES AP, 1976, P NATL ACAD SCI USA, V73, P2501, DOI 10.1073/pnas.73.7.2501; BEAM RE, 1974, AM J MED TECHNOL, V40, P211; BRECKENRIDGE A, 1973, CLIN PHARMACOL THER, V14, P514; BROOKS SM, 1972, NEW ENGL J MED, V286, P1125, DOI 10.1056/NEJM197205252862103; CORNISH HH, 1957, J BIOL CHEM, V228, P315; DATA JL, 1976, NEW ENGL J MED, V294, P699, DOI 10.1056/NEJM197603252941305; HUNT SN, 1976, CLIN PHARMACOL THER, V19, P546; JENNE J, 1975, LIFE SCI, V17, P195, DOI 10.1016/0024-3205(75)90503-2; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; KAPPAS A, 1976, CLIN PHARMACOL THER, V20, P643; MIECH RP, 1975, NEW DIRECTIONS ASTHM, P377; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; PIAFSKY KM, 1977, CLIN PHARMACOL THER, V22, P336; VESELL ES, 1969, J CLIN INVEST, V48, P2202, DOI 10.1172/JCI106186; WEDDLE OH, 1976, J PHARM SCI, V65, P865, DOI 10.1002/jps.2600650616; WILLIAMS JF, 1975, J ALLERGY CLIN IMMUN, V55, P125	16	111	111	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	1					27	29		10.1016/0091-6749(78)90068-4	http://dx.doi.org/10.1016/0091-6749(78)90068-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG870	659737				2022-12-18	WOS:A1978FG87000006
J	WENZEL, FJ; EMANUEL, DA; GRAY, RL				WENZEL, FJ; EMANUEL, DA; GRAY, RL			IMMUNOFLUORESCENT STUDIES IN PATIENTS WITH FARMERS LUNG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BUECHNER HA, 1958, AM J MED, V25, P234, DOI 10.1016/0002-9343(58)90030-5; COHEN HI, 1967, AM J MED, V43, P785, DOI 10.1016/0002-9343(67)90121-0; EMANUEL DA, 1964, AM J MED, V37, P392, DOI 10.1016/0002-9343(64)90195-0; EMANUEL DA, 1966, NEW ENGL J MED, V274, P1413, DOI 10.1056/NEJM196606232742504; EVELAND WC, 1967, AM J PATH, V33, P616; GELL PGH, 1968, CLINICAL ASPECTS IMM, P584; GRAY RL, 1969, APPL MICROBIOL, V17, P454, DOI 10.1128/AEM.17.3.454-456.1969; KAS EA, 1960, AM J CLIN PATH, V34, P52; KOBAYASHI M, 1963, P SOC EXP BIOL MED, V113, P472, DOI 10.3181/00379727-113-28400; PEPYS J, 1966, ANN INTERN MED, V64, P943, DOI 10.7326/0003-4819-64-4-943; PEPYS J, 1963, LANCET, V2, P607; PIMENTEL CJ, 1970, THORAX, V25, P387; RANKIN J, 1967, MED CLIN N AM, V51, P459, DOI 10.1016/S0025-7125(16)33068-1; REED GE, 1965, JAMA, V193, P261; RINDERKNECHT H, 1962, NATURE, V193, P167, DOI 10.1038/193167b0; SAKULA A, 1967, BRIT MED J, V3, P708, DOI 10.1136/bmj.3.5567.708; VANTOORN DW, 1970, THORAX, V25, P399, DOI 10.1136/thx.25.4.399; WILLIAMS CA, 1967, METHODS IMMUNOLOGY I, V1, P321; WILLIAMS J. V., 1963, THORAX, V18, P182, DOI 10.1136/thx.18.2.182	20	111	111	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	4					224	&		10.1016/0091-6749(71)90069-8	http://dx.doi.org/10.1016/0091-6749(71)90069-8			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5566	4937457	Bronze			2022-12-18	WOS:A1971K556600005
J	Zhu, ZZ; Hasegawa, K; Ma, BS; Fujiogi, M; Camargo, CA; Liang, LM				Zhu, Zhaozhong; Hasegawa, Kohei; Ma, Baoshan; Fujiogi, Michimasa; Camargo, Carlos A., Jr.; Liang, Liming			Association of asthma and its genetic predisposition with the risk of severe COVID-19	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Zhu, Zhaozhong; Liang, Liming] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Program Genet Epidemiol & Stat Genet, Boston, MA 02115 USA; [Zhu, Zhaozhong; Hasegawa, Kohei; Fujiogi, Michimasa; Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Zhu, Zhaozhong] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Ma, Baoshan] Dalian Maritime Univ, Coll Informat Sci & Technol, Dalian, Liaoning, Peoples R China; [Liang, Liming] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Dalian Maritime University; Harvard University; Harvard T.H. Chan School of Public Health	Liang, LM (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Program Genet Epidemiol & Stat Genet, Boston, MA 02115 USA.; Liang, LM (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.	lliang@hsph.harvard.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654	National Institutes of Health [R01 AI127507]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by the National Institutes of Health (grant no. R01 AI127507). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding organization was not involved in the collection, management, or analysis of the data; preparation or approval of the manuscript; or decision to submit the manuscript for publication.	Beasley R, 2015, LANCET, V386, P1075, DOI 10.1016/S0140-6736(15)00156-7; Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V382, P2372; Demenais F, 2018, NAT GENET, V50, P42, DOI 10.1038/s41588-017-0014-7; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Jackson DJ, J ALLERGY CLIN IMMUN, DOI [10.1016/jjaci .2020.0.4.00, DOI 10.1016/JJACI.2020.0.4.00]; Jartti T, 2017, J ALLERGY CLIN IMMUN, V140, P895, DOI 10.1016/j.jaci.2017.08.003; Loh PR, 2015, NAT GENET, V47, P284, DOI 10.1038/ng.3190; McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643; Sajuthi Satria P, 2020, bioRxiv, DOI 10.1101/2020.04.09.034454; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; Vilhjalmsson BJ, 2015, AM J HUM GENET, V97, P576, DOI 10.1016/j.ajhg.2015.09.001; World Health Organization, COR DIS 2019 COVID 1, P75; World Health Organization, 2020, CLIN MAN SEV AC RESP; Zhu ZZ, 2020, J ALLERGY CLIN IMMUN, V145, P537, DOI 10.1016/j.jaci.2019.09.035; Zhu ZZ, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01507-2019; Zhu ZZ, 2018, NAT GENET, V50, P857, DOI 10.1038/s41588-018-0121-0	17	110	113	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					327	+		10.1016/j.jaci.2020.06.001	http://dx.doi.org/10.1016/j.jaci.2020.06.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32522462	Green Published, Green Accepted, Bronze			2022-12-18	WOS:000558835000018
J	O'Connor, GT; Lynch, SV; Bloomberg, GR; Kattan, M; Wood, RA; Gergen, PJ; Jaffee, KF; Calatroni, A; Bacharier, LB; Beigelman, A; Sandel, MT; Johnson, CC; Faruqi, A; Santee, C; Fujimura, KE; Fadrosh, D; Boushey, H; Visness, CM; Gern, JE				O'Connor, George T.; Lynch, Susan V.; Bloomberg, Gordon R.; Kattan, Meyer; Wood, Robert A.; Gergen, Peter J.; Jaffee, Katy F.; Calatroni, Agustin; Bacharier, Leonard B.; Beigelman, Avrahman; Sandel, Megan T.; Johnson, Christine C.; Faruqi, Ali; Santee, Clark; Fujimura, Kei E.; Fadrosh, Douglas; Boushey, Homer; Visness, Cynthia M.; Gern, James E.			Early-life home environment and risk of asthma among inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; environment; allergy; allergen; microbiome; stress; depression; smoking	ALLERGIC SENSITIZATION; CHILDHOOD ASTHMA; EXPOSURE; WHEEZE; ENDOTOXIN; STRESS; AIRWAY; ATOPY; INFECTION; INNATE	Background: Environmental exposures in early life appear to play an important role in the pathogenesis of childhood asthma, but the potentially modifiable exposures that lead to asthma remain uncertain. Objective: We sought to identify early-life environmental risk factors for childhood asthma in a birth cohort of high-risk inner-city children. Methods: We examined the relationship of prenatal and early-life environmental factors to the occurrence of asthma at 7 years of age among 442 children. Results: Higher house dust concentrations of cockroach, mouse, and cat allergens in the first 3 years of life were associated with lower risk of asthma (for cockroach allergen: odds ratio per interquartile range increase in concentration, 0.55; 95% CI, 0.36-0.86; P < .01). House dust microbiome analysis using 16S ribosomal RNA sequencing identified 202 and 171 bacterial taxa that were significantly (false discovery rate < 0.05) more or less abundant, respectively, in the homes of children with asthma. A majority of these bacteria were significantly correlated with 1 of more allergen concentrations. Other factors associated significantly positively with asthma included umbilical cord plasma cotinine concentration (odds ratio per geometric SD increase in concentration, 1.76; 95% CI, 1.00-3.09; P = .048) and maternal stress and depression scores. Conclusion: Among high-risk inner-city children, higher indoor levels of pet or pest allergens in infancy were associated with lower risk of asthma. The abundance of a number of bacterial taxa in house dust was associated with increased or decreased asthma risk. Prenatal tobacco smoke exposure and higher maternal stress and depression scores in early life were associated with increased asthma risk.	[O'Connor, George T.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [O'Connor, George T.] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA; [Lynch, Susan V.; Faruqi, Ali; Santee, Clark; Fujimura, Kei E.; Fadrosh, Douglas; Boushey, Homer] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Bloomberg, Gordon R.; Bacharier, Leonard B.; Beigelman, Avrahman] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Kattan, Meyer] Columbia Univ, Dept Pediat, New York, NY 10027 USA; [Wood, Robert A.] Johns Hopkins Univ, Med Ctr, Dept Pediat, Baltimore, MD 21218 USA; [Gergen, Peter J.] NIAID, Rockville, MD USA; [Jaffee, Katy F.; Calatroni, Agustin; Visness, Cynthia M.] Rho Fed Syst Div, Chapel Hill, NC USA; [Johnson, Christine C.; Gern, James E.] Henry Ford Hlth Care Syst, Detroit, MI USA; Univ Wisconsin, Dept Pediat, Madison, WI USA	Boston University; Boston University; University of California System; University of California San Francisco; Washington University (WUSTL); Columbia University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Henry Ford Health System; University of Wisconsin System; University of Wisconsin Madison	O'Connor, GT (corresponding author), Boston Univ, Sch Med, Div Pulm Allergy Sleep & Crit Care Med, Dept Med, 715 Albany St,Rm R304, Boston, MA 02118 USA.	goconnor@bu.edu		Bacharier, Leonard/0000-0003-0432-2704	National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH) [NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, UM2AI117870]; National Center for Research Resources/NIH [RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, 5UL1RR024992-02]; National Center for the Advancement of Translational Research/NIH [UL1TR001079, UL1TR000040]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI114271, UM2AI117870] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for the Advancement of Translational Research/NIH; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by federal funds from the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH), under contract nos. NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, and UM2AI117870. Additional support was provided by the National Center for Research Resources/NIH under grants RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, and 5UL1RR024992-02, and the National Center for the Advancement of Translational Research/NIH under grants UL1TR001079 and UL1TR000040.	[Anonymous], 2018, FLEXIBLE IMPUTATION; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Burke H, 2012, PEDIATRICS, V129, P735, DOI 10.1542/peds.2011-2196; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Chiu YHM, 2012, AM J RESP CRIT CARE, V186, P147, DOI 10.1164/rccm.201201-0162OC; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Douwes J, 2008, EUR RESPIR J, V32, P603, DOI 10.1183/09031936.00033707; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Dunn RR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064133; Feleszko W, 2007, CLIN EXP ALLERGY, V37, P498, DOI 10.1111/j.1365-2222.2006.02629.x; Fuchs O, 2012, J ALLERGY CLIN IMMUN, V130, P382, DOI 10.1016/j.jaci.2012.04.049; Fujimura KE, 2014, P NATL ACAD SCI USA, V111, P805, DOI 10.1073/pnas.1310750111; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Rosa MJ, 2016, ANN ALLERG ASTHMA IM, V116, P306, DOI 10.1016/j.anai.2015.12.025; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Little RRD, 2014, STAT ANAL MISSING DA; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Nickel R, 2002, PEDIAT ALLERG IMM-UK, V13, P7, DOI 10.1034/j.1399-3038.13.s.15.4.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Palomo S, 2013, MAR DRUGS, V11, P1071, DOI 10.3390/md11041071; Romero R, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-4; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Stoltz DJ, 2013, CLIN EXP ALLERGY, V43, P233, DOI 10.1111/cea.12050; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Van Cleave J, 2010, JAMA-J AM MED ASSOC, V303, P623, DOI 10.1001/jama.2010.104; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC; Zhang HX, 2016, BIOINFORMATICS, V32, P3150, DOI 10.1093/bioinformatics/btw351	38	110	111	1	53	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1468	1475		10.1016/j.jaci.2017.06.040	http://dx.doi.org/10.1016/j.jaci.2017.06.040			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28939248	Green Accepted, Bronze			2022-12-18	WOS:000429197800032
J	Palmer, DJ; Sullivan, TR; Gold, MS; Prescott, SL; Makrides, M				Palmer, Debra J.; Sullivan, Thomas R.; Gold, Michael S.; Prescott, Susan L.; Makrides, Maria			Randomized controlled trial of early regular egg intake to prevent egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy prevention; complementary feeding; hereditary risk; egg; food allergy; oral tolerance; randomized controlled trial	INFANTS; CONSUMPTION; EXPOSURE; DISEASES; FOODS; RISK	Background: The ideal age to introduce egg into the infant diet has been debated for the past 2 decades in the context of rising rates of egg allergy. Objective: We sought to determine whether regular consumption of egg protein from age 4 to 6 months reduces the risk of IgE-mediated egg allergy in infants with hereditary risk, but without eczema. Methods: Infants aged 4 to 6 months were randomly allocated to receive daily pasteurized raw whole egg powder (n = 407) or a color-matched rice powder (n = 413) to age 10 months. All infants followed an egg-free diet and cooked egg was introduced to both groups at age 10 months. The primary outcome was IgE-mediated egg allergy defined by a positive pasteurized raw egg challenge and egg sensitization at age 12 months. Results: There was no difference between groups in the percentage of infants with IgE-mediated egg allergy (egg 7.0% vs control 10.3%; adjusted relative risk, 0.75; 95% CI, 0.48-1.17; P = .20). A higher proportion of participants in the egg group stopped taking the study powder because of a confirmed allergic reaction (25 of 407 [6.1%] compared with 6 of 413 [1.5%]). Egg-specific IgG4 levels were substantially higher in the egg group at 12 months (median, 1.22 mgA/L vs control 0.07 mgA/L; P < .0001). Conclusions: We found no evidence that regular egg intake from age 4 to 6 months substantially alters the risk of egg allergy by age 1 year in infants who are at hereditary risk of allergic disease and had no eczema symptoms at study entry.	[Palmer, Debra J.; Prescott, Susan L.] Univ Western Australia, Sch Paediat & Child Hlth, M561, Perth, WA, Australia; [Palmer, Debra J.; Makrides, Maria] Womens & Childrens Hlth Res Inst, Adelaide, SA, Australia; [Sullivan, Thomas R.] Univ Adelaide, Sch Publ Hlth, Adelaide, SA, Australia; [Gold, Michael S.; Makrides, Maria] Univ Adelaide, Sch Med, Womens & Childrens Hlth Network, Adelaide, SA, Australia; [Prescott, Susan L.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Makrides, Maria] South Australian Hlth & Med Res Inst, Hlth Mothers Babies & Children, Adelaide, SA, Australia	University of Western Australia; Womens & Childrens Hospital Australia; University of Adelaide; University of Adelaide; Telethon Kids Institute; University of Western Australia; South Australian Health & Medical Research Institute (SAHMRI)	Palmer, DJ (corresponding author), Univ Western Australia, Sch Paediat & Child Hlth, M561,35 Stirling Hwy, Crawley, WA 6009, Australia.	debbie.palmer@uwa.edu.au	Palmer, Debra/AAH-6160-2019; Palmer, Debra J/L-8554-2013	Palmer, Debra J/0000-0003-2498-8343	Australian National Health and Medical Research Council [626805]	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	The trial was supported by a grant from the Australian National Health and Medical Research Council (ID 626805).	Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99, DOI 10.1097/01.mpg.0000304464.60788.bd; Baker SS, 2000, PEDIATRICS, V106, P346; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Metcalfe JR, 2016, CLIN EXP ALLERGY, V46, P308, DOI 10.1111/cea.12608; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Rubin DB, 2004, MULTIPLE IMPUTATION; Smith KM, 2000, AM J RESP CRIT CARE, V162, pS175, DOI 10.1164/ajrccm.162.supplement_3.15tac7; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Zutavern A, 2004, ARCH DIS CHILD, V89, P303, DOI 10.1136/adc.2002.025353	18	110	113	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1600	+		10.1016/j.jaci.2016.06.052	http://dx.doi.org/10.1016/j.jaci.2016.06.052			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27554812	Bronze			2022-12-18	WOS:000400465300021
J	Kaplan, A; Ferrer, M; Bernstein, JA; Antonova, E; Trzaskoma, B; Raimundo, K; Rosen, K; Omachi, TA; Khalil, S; Zazzali, JL				Kaplan, Allen; Ferrer, Marta; Bernstein, Jonathan A.; Antonova, Evgeniya; Trzaskoma, Benjamin; Raimundo, Karina; Rosen, Karin; Omachi, Theodore A.; Khalil, Sam; Zazzali, James L.			Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Omalizumab; chronic idiopathic urticaria; chronic spontaneous urticaria; responder analysis; complete response; well-controlled urticaria	QUALITY-OF-LIFE; CHRONIC IDIOPATHIC URTICARIA; DAILY DIARY; EPIDEMIOLOGY; MANAGEMENT; DIAGNOSIS; THERAPY; UPDATE; IMPACT	Background: Few data are available that describe response patterns in patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) treated with omalizumab. Objective: We sought to describe response patterns by using data from the 3 pivotal omalizumab CIU/CSU trials. Methods: Every 4 weeks, randomized patients received dosing with placebo or 75, 150, or 300 mg of omalizumab (ASTERIA I: n=318, 24 weeks; ASTERIA II: n=322, 12 weeks) or placebo or 300 mg of omalizumab (GLACIAL: n=335, 24 weeks). Response was defined as well-controlled urticaria (weekly Urticaria Activity Score [UAS7] <= 6) or complete response (UAS7 = 0). Results: Response rates were dose dependent and highest with 300 mg of omalizumab. Some patients responded early (before week 4). At week 12, a higher proportion of patients treated with 300 mg of omalizumab reported a UAS7 <= 6 (26.0% [75 mg of omalizumab], 40.0% [150 mg of omalizumab], 51.9% [300 mg of omalizumab], and 11.3% [placebo] for ASTERIA I; 26.8% [75 mg of omalizumab], 42.7% [150 mg of omalizumab], 65.8% [300 mg of omalizumab], and 19.0% [placebo] for ASTERIA II; and 52.4% [300 mg of omalizumab] and 12.0% [placebo] for GLACIAL) or a UAS7=0 (11.7% [75 mg of omalizumab], 15.0% [150 mg of omalizumab], 35.8% [300 mg of omalizumab], and 8.8% [placebo] for ASTERIA I; 15.9% [75 mg of omalizumab], 22.0% [150 mg of omalizumab], 44.3% [300 mg of omalizumab], and 5.1% [placebo] for ASTERIA II; and 33.7% [300 mg of omalizumab] and 4.8% [placebo] for GLACIAL). In patients receiving 300 mg of omalizumab with 24 weeks of treatment, median time to achieve a UAS7 <= 6 was 6 weeks (ASTERIA I and GLACIAL) and median time to achieve a UAS7 = 0 was 12 or 13 weeks (ASTERIA I and GLACIAL, respectively). Some patients who achieved well-controlled urticaria or complete response sustained response throughout the treatment period. Conclusion: Benefits of omalizumab treatment were evident early (before week 4) in some patients and persisted to week 24. Use of 300 mg of omalizumab demonstrated best results in controlling CIU/CSU symptoms.	[Kaplan, Allen] Med Univ S Carolina, Charleston, SC 29425 USA; [Ferrer, Marta] Univ Navarra, Univ Navarra Clin, Inst Invest Sanitaria Navarra IDISNA Pamplona, E-31080 Pamplona, Spain; [Bernstein, Jonathan A.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Bernstein, Jonathan A.] Bernstein Clin Res Ctr, Cincinnati, OH USA; [Antonova, Evgeniya; Trzaskoma, Benjamin; Raimundo, Karina; Rosen, Karin; Omachi, Theodore A.; Zazzali, James L.] Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA; [Khalil, Sam] Novartis AG, Basel, Switzerland	Medical University of South Carolina; University of Navarra; University System of Ohio; University of Cincinnati; Roche Holding; Genentech; Novartis	Antonova, E (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	antonova.evgeniya@gene.com	Ferrer, Marta/C-4319-2016	Ferrer, Marta/0000-0001-8495-1302; Bernstein, Jonathan/0000-0002-3476-1196; Omachi, Theodore/0000-0001-9167-768X	Genentech, Inc, South San Francisco, California; Novartis Pharma AG, Basel, Switzerland; Genentech, Inc; Novartis Pharmaceuticals Corporation	Genentech, Inc, South San Francisco, California(Roche HoldingGenentech); Novartis Pharma AG, Basel, Switzerland; Genentech, Inc(Roche HoldingGenentech); Novartis Pharmaceuticals Corporation(Novartis)	The funding for ASTERIA I, ASTERIA II, and GLACIAL, as well as this analysis, was provided by Genentech, Inc, South San Francisco, California, and Novartis Pharma AG, Basel, Switzerland. Funding for medical writing support for this manuscript was provided by Genentech, Inc and Novartis Pharmaceuticals Corporation.	Baiardini I, 2005, ALLERGY, V60, P1073, DOI 10.1111/j.1398-9995.2005.00833.x; Bernstein JA, 2014, J ALLERGY CLIN IMMUN, V133, P1270, DOI 10.1016/j.jaci.2014.02.036; Casale TB, 2015, J ALLER CL IMM-PRACT, V3, P743, DOI 10.1016/j.jaip.2015.04.015; Flood E, 2012, 17 ANN M INT SOC PHA; Gaig P, 2004, J INVEST ALLERG CLIN, V14, P214; Kaplan A, 2013, J ALLERGY CLIN IMMUN, V132, P101, DOI 10.1016/j.jaci.2013.05.013; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Mathias SD, 2012, ALLERGY ASTHMA PROC, V33, P186, DOI 10.2500/aap.2012.33.3508; Mathias SD, 2010, ANN ALLERG ASTHMA IM, V105, P142, DOI 10.1016/j.anai.2010.06.011; Maurer M, 2011, ALLERGY, V66, P317, DOI 10.1111/j.1398-9995.2010.02496.x; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Metz M, 2014, J INVEST DERMATOL, V134, pS30; ODonnell BF, 1997, BRIT J DERMATOL, V136, P197; Santos MCP, 2015, EUR ANN ALLERGY CLIN, V47, P38; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Saini SS, 2015, J INVEST DERMATOL, V135, P925, DOI [10.1038/jid.2014.512, 10.1038/jid.2014.306]; Staubach P, 2006, BRIT J DERMATOL, V154, P294, DOI 10.1111/j.1365-2133.2005.06976.x; Stefanacci Richard G, 2013, Manag Care, V22, P37; Uysal P, 2014, J ALLERGY CLIN IMMUN, V133, P914, DOI 10.1016/j.jaci.2013.10.015; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313; Zuberbier T, 2010, CLIN EXP DERMATOL, V35, P869, DOI 10.1111/j.1365-2230.2010.03840.x	21	110	113	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					474	481		10.1016/j.jaci.2015.08.023	http://dx.doi.org/10.1016/j.jaci.2015.08.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26483177	hybrid			2022-12-18	WOS:000369235500016
J	Stott, B; Lavender, P; Lehmann, S; Pennino, D; Durham, S; Schmidt-Weber, CB				Stott, Bryony; Lavender, Paul; Lehmann, Sarah; Pennino, Davide; Durham, Stephen; Schmidt-Weber, Carsten B.			Human IL-31 is induced by IL-4 and promotes T(H)2-driven inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic airway inflammation; T(H)2 cells; IL-31; IL-4; normal human bronchial epithelial cells; IL-33; chromatin immunoprecipitation	T-CELLS; EXPRESSION PATTERNS; EPITHELIAL-CELLS; HUMAN GENOME; CYTOKINE; INTERLEUKIN-31; PROTEIN; HELPER; ACTIVATION; ALLERGEN	Background: The pruritic cytokine IL-31 has been shown to be expressed by murine activated effector T Lymphocytes of a T(H)2 phenotype. Like IL-17 and IL-22, IL-31 is a tissue-signaling cytokine the receptor of which is mainly found on nonimmune cells. An overabundance of IL-31 has been shown in patients with atopic disorders, including dermatitis, as well as asthma, and therefore represents a promising drug target, although its regulation in the context of the human T(H)2 clusters is not yet known. Objective: We sought to address the gene regulation of human IL-31 and to test whether IL-31 possesses a similar proallergic function as members of the human T(H)2 cytokine family, such as IL-4, IL-5, and IL-13. Methods: Polyclonal and purified protein derivative of tuburculin-specific T-cell clones were generated. TH phenotype was determined, and IL-31 was measured by means of ELISA. Gene expression of primary bronchial epithelial cells treated with IL-31 was also measured. Results: IL-31 was expressed by all of the T(H)2 clones and not by T(H)1, TH17, or T(H)22. This expression was dependent on autocrine IL-4 expression from these clones because it could be reduced if blocking antibodies to IL-4 were present. Interestingly, T(H)1 clones were able to express IL-31 if IL-4 was added to culture. This IL-31 expression was transient and did not affect the phenotype of the T(H)1 clones. IL-31 was able to induce proinflammatory genes, such as CCL2 and granulocyte colony-stimulating factor. Conclusion: IL-31 is not a T(H)2 cytokine in the classical sense but is likely to be expressed by a number of cells in an allergic situation in which IL-4 is present and possibly contribute to the allergic reaction.	[Stott, Bryony; Pennino, Davide; Durham, Stephen; Schmidt-Weber, Carsten B.] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; [Lavender, Paul] Kings Coll London, Guys Hosp, MRC, London, England; [Lavender, Paul] Kings Coll London, Guys Hosp, Asthma UK Ctr Allerg Mech Asthma, London, England; [Lehmann, Sarah; Pennino, Davide; Schmidt-Weber, Carsten B.] Helmholtz Ctr Munich, Munich, Germany	Imperial College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Schmidt-Weber, CB (corresponding author), Tech Univ, Ctr Allergy & Environm, Biedersteiner Str 29, D-80802 Munich, Germany.	csweber@tum.de	Schmidt-Weber, Carsten B./AAU-1621-2021	Schmidt-Weber, Carsten B./0000-0002-3203-8084; Lavender, Paul/0000-0001-8710-0263	National Heart and Lung Institute; Medical Research Council (MRC); DFG;  [SFB TR22]; MRC [G9536930] Funding Source: UKRI; Medical Research Council [G9536930, G1000758] Funding Source: researchfish	National Heart and Lung Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); DFG(German Research Foundation (DFG)); ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	B. Stott has been supported by a National Heart and Lung Institute PhD Studentship. P. Lavender has been supported by one or more grants from the Medical Research Council (MRC). S. Lehmann is employed by Klinikum Rechts der Isar. C. B. Schmidt-Weber has been supported by one or more grants from SFB TR22; is a Board member for Jena University; has consultancy arrangements with GLS; is employed by TUM, Helmholtz Association; has provided expert testimony for patent attorneys; has received one or more grants from or has one or more grants pending with DFG, BMBF, Allergopharma, Zeller AG, and Pfizer; has received payments for lecturing and for travel/accommodations/meeting expenses from Allergopharma and Leo Pharma; and has one or more patents (planned, pending, or issued) with PLS Design. The rest of the authors declare that they have no relevant conflicts of interest.	Bando T, 2006, NEUROSCIENCE, V142, P1263, DOI 10.1016/j.neuroscience.2006.07.009; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Boulay JL, 2003, IMMUNITY, V19, P159, DOI 10.1016/S1074-7613(03)00211-5; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; Crack LR, 2011, CLIN EXP ALLERGY, V41, P1555, DOI 10.1111/j.1365-2222.2011.03819.x; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; Dambacher J, 2007, GUT, V56, P1257, DOI 10.1136/gut.2006.118679; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Eyerich S, 2011, EUR J IMMUNOL, V41, P1894, DOI 10.1002/eji.201041197; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Gambichler T, 2008, BRIT J DERMATOL, V158, P1117, DOI 10.1111/j.1365-2133.2008.08498.x; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Ip WK, 2007, IMMUNOLOGY, V122, P532, DOI 10.1111/j.1365-2567.2007.02668.x; Kato M, 2010, INT ARCH ALLERGY IMM, V152, P62, DOI 10.1159/000312127; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; Lei Z, 2008, ALLERGY, V63, P327, DOI 10.1111/j.1398-9995.2007.01566.x; Lloyd CM, 2010, CURR OPIN IMMUNOL, V22, P800, DOI 10.1016/j.coi.2010.10.006; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Murata T, 1998, INT J MOL MED, V1, P551; Nagalakshmi ML, 2004, INT IMMUNOPHARMACOL, V4, P577, DOI 10.1016/j.intimp.2004.01.007; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Park K, 2012, J LEUKOCYTE BIOL, V91, P245, DOI 10.1189/jlb.0111020; Rani A, 2011, J IMMUNOL, V187, P3721, DOI 10.4049/jimmunol.1002354; Romagnani S, 2002, MOL IMMUNOL, V38, P881, DOI 10.1016/S0161-5890(02)00013-5; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; SWAIN SL, 1990, J IMMUNOL, V145, P3796; VERCELLI D, 1990, J IMMUNOL, V144, P570	34	110	123	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					446	+		10.1016/j.jaci.2013.03.050	http://dx.doi.org/10.1016/j.jaci.2013.03.050			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23694808				2022-12-18	WOS:000322631700023
J	Moshous, D; Martin, E; Carpentier, W; Lim, A; Callebaut, I; Canioni, D; Hauck, F; Majewski, J; Schwartzentruber, J; Nitschke, P; Sirvent, N; Frange, P; Picard, C; Blanche, S; Revy, P; Fischer, A; Latour, S; Jabado, N; de Villartay, JP				Moshous, Despina; Martin, Emmanuel; Carpentier, Wassila; Lim, Annick; Callebaut, Isabelle; Canioni, Danielle; Hauck, Fabian; Majewski, Jacek; Schwartzentruber, Jeremy; Nitschke, Patrick; Sirvent, Nicolas; Frange, Pierre; Picard, Capucine; Blanche, Stephane; Revy, Patrick; Fischer, Alain; Latour, Sylvain; Jabado, Nada; de Villartay, Jean-Pierre			Whole-exome sequencing identifies Coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; T-cell immunodeficiency; severe combined immune deficiency; EBV-associated B-cell lymphoproliferation; thymus; invariant natural killer T cell; mucosal-associated invariant T cell	WISKOTT-ALDRICH-SYNDROME; SYNDROME PROTEIN; THYMIC EGRESS; T-LYMPHOCYTE; KINASE ITK; INKT CELL; MUTATIONS; HOMEOSTASIS; MATURATION; GENERATION	Background: Primary immunodeficiencies are a rare group of inborn diseases characterized by a broad clinical and genetic heterogeneity. Substantial advances in the identification of the underlying molecular mechanisms can be achieved through the study of patients with increased susceptibility to specific infections and immune dysregulation. We evaluated 3 siblings from a consanguineous family presenting with EBV-associated B-cell lymphoproliferation at an early age (12, 7 1/2, and 14 months, respectively) and profound naive T-cell lymphopenia. Objective: On the basis of the hypothesis of a rare inborn immunodeficiency of autosomal recessive inheritance, we sought to characterize the underlying genetic defect. Methods: We performed genome-wide homozygosity mapping, followed by whole-exome sequencing. Results: We identified a homozygous inherited missense mutation in the gene encoding Coronin-1A (CORO1A) in the 3 siblings. This mutation, p. V134M, results in the substitution of an evolutionarily conserved amino acid within the beta-propeller domain, which abrogates almost completely the protein expression in the patients' cells. In addition to a significant diminution of naive T-cell numbers, we found impaired development of a diverse T-cell repertoire, near-to-absent invariant natural killer T cells, and severely diminished mucosal-associated invariant T cell numbers. Conclusions: Our findings define a new clinical entity of a primary immunodeficiency with increased susceptibility to EBV-induced lymphoproliferation in patients associated with hypomorphic Coronin-1A mutation.	[Moshous, Despina; Martin, Emmanuel; Hauck, Fabian; Revy, Patrick; Fischer, Alain; Latour, Sylvain; de Villartay, Jean-Pierre] INSERM, U768, Paris, France; [Moshous, Despina; Martin, Emmanuel; Hauck, Fabian; Frange, Pierre; Picard, Capucine; Blanche, Stephane; Revy, Patrick; Fischer, Alain; Latour, Sylvain; de Villartay, Jean-Pierre] Univ Paris Descartes Sorbonne Paris Cite, Inst Imagine, Paris, France; [Moshous, Despina; Canioni, Danielle; Frange, Pierre; Picard, Capucine; Blanche, Stephane; Fischer, Alain; de Villartay, Jean-Pierre] Hop Necker Enfants Malad, AP HP, F-75743 Paris 15, France; [Carpentier, Wassila] Univ Paris 06, Fac Med Pitie Salpetriere, AP HP, Plate Forme Post Genom P3S, Paris, France; [Lim, Annick] Inst Pasteur, Grp Immunoscope, Unite Regulat Immunitaire & Vaccinol, Paris, France; [Callebaut, Isabelle] Univ Paris 06, CNRS, Inst Mineral & Phys Milieux Condenses, Paris, France; [Majewski, Jacek; Schwartzentruber, Jeremy; Jabado, Nada] McGill Univ, Montreal, PQ, Canada; [Majewski, Jacek; Schwartzentruber, Jeremy; Jabado, Nada] Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Majewski, Jacek; Jabado, Nada] McGill Univ, Montreal, PQ, Canada; [Nitschke, Patrick] Univ Paris 05, Serv Bioinformat, Paris, France; [Sirvent, Nicolas] Hop Arnaud Villeneuve, Montpellier, France; [Picard, Capucine] Hop Necker Enfants Malad, AP HP, Ctr Etude Deficits Immunitaires, F-75743 Paris 15, France; [Picard, Capucine] INSERM, U980, Paris, France; [Jabado, Nada] McGill Univ, Dept Pediat, Ctr Hlth, Res Inst, Montreal, PQ H3A 2T5, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paris Cite; McGill University; McGill University; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); McGill University	Moshous, D (corresponding author), Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, 149 Rue Sevres, F-75743 Paris 15, France.	despina.moshous@inserm.fr	Hauck, Fabian/H-5556-2016; Jabado, Nada/AAN-4026-2020; de Villartay, jean pierre/H-9353-2017; Frange, Pierre/O-6311-2017; Moshous, Despina/B-7507-2017; Martin, Emmanuel/F-9743-2016; Picard, Capucine/H-3914-2017; Revy, Patrick/H-8137-2017; Latour, Sylvain/H-3652-2017	de Villartay, jean pierre/0000-0001-5987-0463; Moshous, Despina/0000-0001-6719-3693; Martin, Emmanuel/0000-0003-4211-7373; Picard, Capucine/0000-0001-8788-5056; Revy, Patrick/0000-0003-0758-8022; Hauck, Fabian/0000-0001-9644-2003; Latour, Sylvain/0000-0001-8238-4391; Schwartzentruber, Jeremy/0000-0002-6183-2092	INSERM; Robert A Good/Jeffrey Modell Fellowship in Transplantation and Immunodeficiency; La Ligue Nationale contre le Cancer (Equipe Labellisee La Ligue); ERC PID-IMMUN [249816]; Sidaction	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Robert A Good/Jeffrey Modell Fellowship in Transplantation and Immunodeficiency; La Ligue Nationale contre le Cancer (Equipe Labellisee La Ligue); ERC PID-IMMUN; Sidaction	Supported by institutional grants from INSERM, by the "Robert A Good/Jeffrey Modell Fellowship in Transplantation and Immunodeficiency" to D. M., and by grants from La Ligue Nationale contre le Cancer (Equipe Labellisee La Ligue; to J.-P.V.) and ERC PID-IMMUN (no. 249816; to A.F.).; Disclosure of potential conflict of interest: D. Moshous has received research support from the Robert A Good/Jeffrey Modell Fellowship in Transplantation and Immunodeficiency. P. Frange receives research support from Sidaction. The rest of the authors declare that they have no relevant conflicts of interest.	Abdollahpour H, 2012, BLOOD, V119, P3450, DOI 10.1182/blood-2011-09-378158; Appleton BA, 2006, STRUCTURE, V14, P87, DOI 10.1016/j.str.2005.09.013; Astrakhan A, 2009, J IMMUNOL, V182, P7370, DOI 10.4049/jimmunol.0804256; de Lalla C, 2011, J IMMUNOL, V186, P4490, DOI 10.4049/jimmunol.1003748; de Villartay JP, 2005, J CLIN INVEST, V115, P3291, DOI 10.1172/JCI25178; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Foger N, 2006, SCIENCE, V313, P839, DOI 10.1126/science.1130563; Gottschalk S, 2005, ANNU REV MED, V56, P29, DOI 10.1146/annurev.med.56.082103.104727; Haraldsson MK, 2008, IMMUNITY, V28, P40, DOI 10.1016/j.immuni.2007.11.023; Heslop Helen E, 2005, Hematology Am Soc Hematol Educ Program, P260; Huang W, 2005, J IMMUNOL, V174, P2602, DOI 10.4049/jimmunol.174.5.2602; Huck K, 2009, J CLIN INVEST, V119, P1350, DOI 10.1172/JCI37901; Lalonde E, 2010, HUM MUTAT, V31, P918, DOI 10.1002/humu.21293; Latour S, 2007, CURR OPIN ALLERGY CL, V7, P510, DOI 10.1097/ACI.0b013e3282f1bad6; Le Clerc S, 2009, J INFECT DIS, V200, P1194, DOI 10.1086/605892; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; Lim A, 2002, J IMMUNOL METHODS, V261, P177, DOI 10.1016/S0022-1759(02)00004-2; Linka RM, 2012, LEUKEMIA, V26, P963, DOI 10.1038/leu.2011.371; Locci M, 2009, J EXP MED, V206, P735, DOI 10.1084/jem.20081773; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Mou F, 2012, J EXP MED, V209, P741, DOI 10.1084/jem.20111692; Mueller P, 2008, NAT IMMUNOL, V9, P424, DOI 10.1038/ni1570; Mueller P, 2011, J IMMUNOL, V186, P4039, DOI 10.4049/jimmunol.1003352; Mugnier B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003467; Nehme NT, 2012, BLOOD, V119, P3458, DOI 10.1182/blood-2011-09-378364; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; PANNETIER C, 1997, ANTIGEN T CELL RECEP, P287; Pietersma F, 2008, LEUKEMIA LYMPHOMA, V49, P1028, DOI 10.1080/10428190801911662; Qi Q, 2011, FEBS J, V278, P1970, DOI 10.1111/j.1742-4658.2011.08074.x; Qi QA, 2011, J BIOL CHEM, V286, P138, DOI 10.1074/jbc.M110.148205; Schmid JP, 2011, BLOOD, V117, P1522, DOI 10.1182/blood-2010-07-298372; Shiow LR, 2008, NAT IMMUNOL, V9, P1307, DOI 10.1038/ni.1662; Shiow LR, 2009, CLIN IMMUNOL, V131, P24, DOI 10.1016/j.clim.2008.11.002; Stepensky P, 2011, HAEMATOL-HEMATOL J, V96, P472, DOI 10.3324/haematol.2010.033910; Trifari S, 2006, J IMMUNOL, V177, P7451, DOI 10.4049/jimmunol.177.10.7451	35	110	115	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1594	+		10.1016/j.jaci.2013.01.042	http://dx.doi.org/10.1016/j.jaci.2013.01.042			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23522482	Green Accepted			2022-12-18	WOS:000320532800020
J	Campbell, RL; Hagan, JB; Manivannan, V; Decker, WW; Kanthala, AR; Bellolio, MF; Smith, VD; Li, JTC				Campbell, Ronna L.; Hagan, John B.; Manivannan, Veena; Decker, Wyatt W.; Kanthala, Abhijit R.; Bellolio, Maria Fernanda; Smith, Vernon D.; Li, James T. C.			Evaluation of National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria for the diagnosis of anaphylaxis in emergency department patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; diagnostic criteria; test characteristics	VISITS; MULTICENTER; MANAGEMENT	Background: Diagnostic criteria were proposed at the Second Symposium on the Definition and Management of Anaphylaxis convened by the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN). Validation is needed before these criteria can be widely adapted into clinical practice. Objective: Our aim was to retrospectively assess the diagnostic accuracy of the NIAID/FAAN criteria for the diagnosis of anaphylaxis in emergency department (ED) patients. Methods: A retrospective cohort study of ED patients presenting from April to October 2008 was conducted. Patients given a diagnosis of an allergic reaction or anaphylaxis and a subset of patients with related diagnoses were included. Electronic medical records were reviewed and data were abstracted to determine whether the NIAID/FAAN criteria were met. Records were also independently reviewed in a blinded fashion by 2 experienced attending allergists. Final diagnosis by allergists was considered the reference standard. Results: Of 214 patients, 86 (40.2%) met the NIAID/FAAN criteria for anaphylaxis. Allergists gave 61 (28.5%) patients diagnoses of anaphylaxis, 59 (96.7%) of whom satisfied the NIAID/FAAN criteria. The interrater agreement between allergists was substantial (kappa = 0.77). The test characteristics of the NIAID/FAAN criteria were as follows: sensitivity, 96.7% (95% CI, 88.8% to 99.1%); specificity, 82.4% (95% CI, 75.5% to 87.6%); positive predictive value, 68.6% (95% CI, 58.2% to 77.4%); negative predictive value, 98.4% (95% CI, 94.5% to 99.6%); positive likelihood ratio, 5.48; and negative likelihood ratio, 0.04. Conclusions: These results suggest that the NIAID/FAAN criteria are highly sensitive but less specific and are likely to be useful in the ED for the diagnosis of anaphylaxis. (J Allergy Clin Immunol 2012; 129: 748-52.)	[Campbell, Ronna L.; Manivannan, Veena; Decker, Wyatt W.; Kanthala, Abhijit R.; Bellolio, Maria Fernanda; Smith, Vernon D.] Mayo Clin, Dept Emergency Med, Rochester, MN 55905 USA; [Hagan, John B.; Li, James T. C.] Mayo Clin, Div Allerg Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Campbell, RL (corresponding author), Mayo Clin, Dept Emergency Med, 200 1st St SW, Rochester, MN 55905 USA.	campbell.ronna@mayo.edu		Bellolio, Fernanda/0000-0002-1632-4750; Campbell, Ronna/0000-0001-6305-6990	Department of Emergency Medicine, Mayo Clinic, Rochester, Minn	Department of Emergency Medicine, Mayo Clinic, Rochester, Minn	Supported by a grant from the Small Grants Program of the Department of Emergency Medicine, Mayo Clinic, Rochester, Minn.	Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Campbell RL, 2008, ANN ALLERG ASTHMA IM, V101, P631, DOI 10.1016/S1081-1206(10)60227-X; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Gaeta TJ, 2007, ANN ALLERG ASTHMA IM, V98, P360, DOI 10.1016/S1081-1206(10)60883-6; Higgins JPT, COCHRANE HDB SYSTEMA, P4; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, pe1, DOI 10.1016/j.jaci.2010.06.022; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Macdougall CF, 2002, ARCH DIS CHILD, V86, P236, DOI 10.1136/adc.86.4.236; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Simel DL, 2009, J CLIN EPIDEMIOL, V62, P1292, DOI 10.1016/j.jclinepi.2009.02.007	14	110	119	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					748	752		10.1016/j.jaci.2011.09.030	http://dx.doi.org/10.1016/j.jaci.2011.09.030			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22051698				2022-12-18	WOS:000301189300020
J	Peters, AT; Kato, A; Zhang, N; Conley, DB; Suh, L; Tancowny, B; Carter, D; Carr, T; Radtke, M; Hulse, KE; Seshadri, S; Chandra, R; Grammer, LC; Harris, KE; Kern, R; Schleimer, RP				Peters, Anju T.; Kato, Atsushi; Zhang, Ning; Conley, David B.; Suh, Lydia; Tancowny, Brian; Carter, Derek; Carr, Tara; Radtke, Michael; Hulse, Kathryn E.; Seshadri, Sudarshan; Chandra, Rakesh; Grammer, Leslie C.; Harris, Kathleen E.; Kern, Robert; Schleimer, Robert P.			Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; IL-6; IL-6 receptor; soluble glycoprotein 130; IL-17; phospho-STAT3	GROWTH-FACTOR-BETA; T(H)17 CELL-DIFFERENTIATION; SIGNAL TRANSDUCER; CHRONIC SINUSITIS; SOLUBLE RECEPTOR; IMMUNOGLOBULIN-E; T-H-17 CELLS; IFN-GAMMA; INTERLEUKIN-6; EXPRESSION	Background: IL-6 activates T(H)17 cells and regulates the response of B lymphocytes and regulatory T cells. The IL-6 receptor and the membrane protein, glycoprotein 130 (gp130), form an active signaling complex that signals through signal transducer and activator of transcription 3 (STAT3) and other signaling molecules. Both the IL-6 receptor (IL-6R) and gp130 can be found in soluble forms that regulate the pathway. Objective: We measured IL-6 signaling components and IL-17 in chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), CRS without nasal polyps (CRSsNP), and controls to assess the IL-6 pathway in CRS. Methods: IL-6, soluble IL-6R, soluble gp130 (sgp130), and IL-17 were measured in sinus tissue extracts and in nasal lavage fluid by either cytokine bead array or ELISA. phosphoSTAT3 (p-STAT3) was determined by Western Not and by immunohistochemistry. Results: IL-6 protein was significantly (P <.001) increased in CRSwNP compared with CRSsNP and controls. Soluble IL-6R was also increased in nasal polyp compared with control tissue (P <.01). Despite elevated IL-6 and sIL-6R, IL-17A, E, and F were undetectable in the sinus tissue from most of the patients with CRS and controls. p-STAT3 levels were reduced in the polyp tissue, possibly indicating reduced activity of IL-6 in the tissue. sgp130 was elevated in CRSwNP compared with CRSsNP and controls. Conclusion: p-STAT3 levels are decreased in CRSwNP despite increased levels of IL-6 and sIL-6R and are associated with the absence of an IL-17 response. This may be a response to elevated levels of sgp130, a known inhibitor of IL-6 signaling. These results indicate that IL-6 and its signaling pathway may be altered in CRSwNP. (J Allergy Clin Immunol 2010;125:397-403.)	[Peters, Anju T.; Kato, Atsushi; Zhang, Ning; Suh, Lydia; Tancowny, Brian; Carter, Derek; Carr, Tara; Radtke, Michael; Hulse, Kathryn E.; Seshadri, Sudarshan; Grammer, Leslie C.; Harris, Kathleen E.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA; [Conley, David B.; Chandra, Rakesh; Kern, Robert] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Schleimer, RP (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, 240 E Huron, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu	Seshadri, Sudarshan/J-5544-2016	Seshadri, Sudarshan/0000-0003-4910-8664; Carr, Tara/0000-0002-6397-5396; Hulse, Kathryn/0000-0003-0969-999X; Grammer, Leslie/0000-0001-6860-2014; Kato, Atsushi/0000-0001-9144-3138	NIH [R01 HL068546, R01 HL078860, 1R01 AI072570]; Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546, R01HL068546, R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Trust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by NIH grants R01 HL068546, R01 HL078860, and 1R01 AI072570 and by a grant from the Ernest S. Bazley Trust.	Aarvak T, 1999, J IMMUNOL, V162, P1246; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; AFFORD SC, 1992, J BIOL CHEM, V267, P21612; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P252, DOI 10.1007/s11882-002-0027-9; Bernstein JM, 2004, OTOLARYNG HEAD NECK, V130, P526, DOI 10.1016/j.otohns.2003.12.022; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Bradley DT, 2005, LARYNGOSCOPE, V115, P684, DOI 10.1097/01.mlg.0000161334.67977.5D; Brook I, 2005, J MED MICROBIOL, V54, P595, DOI 10.1099/jmm.0.45767-0; Curnow SJ, 2004, J IMMUNOL, V173, P5290, DOI 10.4049/jimmunol.173.8.5290; Danielsen A, 2006, EUR ARCH OTO-RHINO-L, V263, P282, DOI 10.1007/S00405-005-1031-1; Desgeorges A, 1997, J RHEUMATOL, V24, P1510; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Gevaert P, 2005, ALLERGY, V60, P71, DOI 10.1111/j.1398-9995.2004.00621.x; Ghaffar O, 1998, OTOLARYNG HEAD NECK, V118, P504, DOI 10.1016/S0194-5998(98)70209-8; Goya S, 2003, J PATHOL, V200, P82, DOI 10.1002/path.1321; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; HOUSSIAU FA, 1988, ARTHRITIS RHEUM, V31, P784, DOI 10.1002/art.1780310614; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jones SA, 2005, J IMMUNOL, V175, P3463, DOI 10.4049/jimmunol.175.6.3463; Jones SA, 2002, BBA-MOL CELL RES, V1592, P251, DOI 10.1016/S0167-4889(02)00319-1; Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432-1327.2001.01867.x; Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482; Kaplanski G, 2003, TRENDS IMMUNOL, V24, P25, DOI 10.1016/S1471-4906(02)00013-3; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Kimura A, 2007, P NATL ACAD SCI USA, V104, P12099, DOI 10.1073/pnas.0705268104; Kramer MF, 2000, LARYNGOSCOPE, V110, P1056, DOI 10.1097/00005537-200006000-00031; Kuehnemund M, 2004, LARYNGOSCOPE, V114, P561, DOI 10.1097/00005537-200403000-00032; Lennard CM, 2000, AM J RHINOL, V14, P367, DOI 10.2500/105065800779954329; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Matsuzaki G, 2007, MICROBIOL IMMUNOL, V51, P1139, DOI 10.1111/j.1348-0421.2007.tb04008.x; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Min YG, 1999, AM J RHINOL, V13, P339, DOI 10.2500/105065899781367546; Molet SM, 2003, LARYNGOSCOPE, V113, P1803, DOI 10.1097/00005537-200310000-00027; Morinaka S, 2000, Auris Nasus Larynx, V27, P59, DOI 10.1016/S0385-8146(99)00038-3; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; Osada R, 2003, RHINOLOGY, V41, P80; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Pene J, 2008, J IMMUNOL, V180, P7423, DOI 10.4049/jimmunol.180.11.7423; Polgar A, 2000, Med Sci Monit, V6, P13; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Saito H, 1997, INT ARCH ALLERGY IMM, V114, P81, DOI 10.1159/000237647; SAITO M, 1992, J IMMUNOL, V148, P4066; Sanchez-Segura A, 1998, J ALLERGY CLIN IMMUN, V102, P953, DOI 10.1016/S0091-6749(98)70333-1; Seiberling KA, 2005, LARYNGOSCOPE, V115, P1580, DOI 10.1097/01.mlg.0000168111.11802.9c; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, RES IMMUNOL, V143, P737, DOI 10.1016/0923-2494(92)80013-B; Tripathi A, 2004, LARYNGOSCOPE, V114, P1822, DOI 10.1097/00005537-200410000-00027; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Wang X, 2006, ANN OTO RHINOL LARYN, V115, P450, DOI 10.1177/000348940611500609; Yamamoto M, 2000, J IMMUNOL, V164, P4878, DOI 10.4049/jimmunol.164.9.4878; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	67	110	115	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					397	403		10.1016/j.jaci.2009.10.072	http://dx.doi.org/10.1016/j.jaci.2009.10.072			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159251	Green Accepted			2022-12-18	WOS:000274764000018
J	Bohle, B; Zwoelfer, B; Heratizadeh, A; Jahn-Schmid, B; Antonia, YD; Alter, M; Keller, W; Zuidmeer, L; van Ree, R; Werfel, T; Ebner, C				Bohle, Barbara; Zwoelfer, Bettina; Heratizadeh, Annice; Jahn-Schmid, Beatrice; Antonia, Yuliya Dall; Alter, Mareike; Keller, Walter; Zuidmeer, Laurian; van Ree, Ronald; Werfel, Thomas; Ebner, Christof			Cooking birch pollen-related food: Divergent consequences for IgE- and T cell-mediated reactivity in vitro and in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						birch pollen allergy; food allergy; oral allergy syndrome; atopic dermatitis; pathogenesis-related protein family 10; Bet v 1; cross-reactivity	ORAL ALLERGY SYNDROME; BET V 1; MAJOR ALLERGEN; CROSS-REACTIVITY; MOLECULAR CHARACTERIZATION; BET-V-1; CELERY; IDENTIFICATION; PROTEIN; EPITOPE	Background: The major birch pollen allergen Bet v 1 cross-reacts with homologous food allergens, resulting in IgE-mediated oral allergy syndromes (OASs). To avoid this food, allergy allergologists and guidebooks advise patients to consume birch pollen-related foods after heating. Objective: We sought to evaluate whether cooked Bet v 1-related food allergens induce IgE- and T cell-mediated reactions in vitro and in vivo. Methods: Recombinant Bet v 1, Mal d 1 (apple), Api g I (celery), and Dan c 1 (carrot) were incubated at increasing temperatures. Protein structures were determined by means of circular dichroism. Mediator release was tested in basophil activation assays. PBMCs and Bet v I-specific T-cell lines with known epitope specificity were stimulated with native and cooked food allergens. Patients with birch pollen allergy who experienced OAS and the exacerbation of atopic dermatitis (AD) on ingestion of fresh apple, celery, or carrot were retested in double-blind, placebo-controlled food challenges with the respective foods in cooked form. Results: In vitro, cooked food allergens lost the capacity to bind IgE and to induce mediator release but had the same potency to activate Bet v I-specific T cells as native proteins. In vivo, ingestion of cooked birch pollen-related foods did not induce OAS but caused atopic eczema to worsen. Conclusion: T-cell cross-reactivity between Bet v I and related food allergens occurs independently of IgE cross-reactivity in vitro and in vivo. In patients with AD, the resulting immune reaction can even manifest as late eczematous skin reactions. Therefore the view that cooked pollen-related foods can be consumed without allergologic consequences should be reconsidered. Clinical implications: Symptom-free consumed pollen-related food allergens might cause T cell-mediated late-phase skin reactions in patients with pollen allergy and AD.	Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, A-1090 Vienna, Austria; Hannover Med Sch, Dept Dermatol & Allergol, D-3000 Hannover, Germany; Karl Franzens Univ Graz, Inst Chem, A-8010 Graz, Austria; Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands; Allergy Clin Reumannpl, Vienna, Austria	Medical University of Vienna; Hannover Medical School; University of Graz; University of Amsterdam; Academic Medical Center Amsterdam	Bohle, B (corresponding author), Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Waehringer Guertel 18-20,AKH 3Q, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at	Keller, Walter/AAW-1501-2021; Zuidmeer, Laurian/B-5494-2008; Werfel, Thomas/B-6921-2012	Keller, Walter/0000-0002-2261-958X; Bohle, Barbara/0000-0002-5105-7985; Zuidmeer-Jongejan, Laurian/0000-0003-3245-5555				AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122, DOI 10.1016/S0091-6749(97)70203-3; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Ballmer-Weber BK, 2002, ALLERGY, V57, P228, DOI 10.1034/j.1398-9995.2002.1o3319.x; Bohle B, 2005, CLIN EXP ALLERGY, V35, P1392, DOI 10.1111/j.1365-2222.2005.02332.x; Bohle B, 1998, J IMMUNOL, V160, P2022; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; Breuer K, 2004, ALLERGY, V59, P988, DOI 10.1111/j.1398-9995.2004.00493.x; CRIMI E, 1990, J ALLERGY CLIN IMMUN, V85, P1014, DOI 10.1016/0091-6749(90)90045-6; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jankiewicz A, 1996, INT ARCH ALLERGY IMM, V111, P268, DOI 10.1159/000237377; Karamloo F, 2001, J CHROMATOGR B, V756, P281, DOI 10.1016/S0378-4347(01)00087-1; KARLSSON MG, 1994, APMIS, V102, P753, DOI 10.1111/j.1699-0463.1994.tb05230.x; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.128946; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; Mittag D, 2005, CLIN EXP ALLERGY, V35, P1049, DOI 10.1111/j.1365-2222.2005.02309.x; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; Ohashi Y, 1998, ACTA OTO-LARYNGOL, V118, P243, DOI 10.1080/00016489850154973; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; Scheurer S, 2004, J ALLERGY CLIN IMMUN, V114, P900, DOI 10.1016/j.jaci.2004.06.017; Schimek EM, 2005, J ALLERGY CLIN IMMUN, V116, P1327, DOI 10.1016/j.jaci.2005.09.007; Schocker F, 2000, EUR J NUTR, V39, P172, DOI 10.1007/s003940070021; Seddon B, 2003, NAT IMMUNOL, V4, P680, DOI 10.1038/ni946; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; Wosinska-Becler K, 2004, CLIN EXP ALLERGY, V34, P123, DOI 10.1111/j.1365-2222.2004.01850.x; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x	38	110	122	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					242	249		10.1016/j.jaci.2006.03.011	http://dx.doi.org/10.1016/j.jaci.2006.03.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815162				2022-12-18	WOS:000239184800030
J	Passalacqua, G; Bousquet, PJ; Carlsen, KH; Kemp, J; Lockey, RF; Niggemann, B; Pawankar, R; Price, D; Bousquet, J				Passalacqua, Giovanni; Bousquet, Philippe J.; Carlsen, Kai-Hakon; Kemp, James; Lockey, Richard F.; Niggemann, Bodo; Pawankar, Ruby; Price, David; Bousquet, Jean			ARIA update: I - Systematic review of complementary and alternative medicine for rhinitis and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						complementary-alternative medicine; asthma; rhinitis	SEASONAL ALLERGIC RHINITIS; CHINESE HERBAL MEDICINE; CONTROLLED-TRIAL; DOUBLE-BLIND; BRONCHIAL-ASTHMA; HOMEOPATHIC PREPARATION; ADJUNCTIVE TREATMENT; CLINICAL-EFFICACY; ACUPUNCTURE; PLACEBO	Complementary-alternative medicines are extensively used in the treatment of allergic rhinitis and asthma, but evidence-based recommendations are lacking. To provide evidence-based recommendations, the literature was searched by using MedLine and the Cochrane Library to March 2005 (Key words: Asthma [OR] Rhinitis, [AND] Complementary [OR] Alternative Medicine, [OR] Herbal, [OR] Acupuncture, [OR] Homeopathy, [OR] Alternative Treatment). Randomized trials, preferably double-blind and published in English, were selected. The articles were evaluated by a panel of experts. Quality of reporting was assessed by using the scale validated by Jadad. The methodology of clinical trials with complementary-alternative medicine was frequently inadequate. Meta-analyses provided no clear evidence for the efficacy of acupuncture in rhinitis and asthma. Some positive results were described with homeopathy in good-quality trials in rhinitis, but a number of negative studies were also found. Therefore it is not possible to provide evidence-based recommendations for homeopathy in the treatment of allergic rhinitis, and further trials are needed. A limited number of studies of herbal remedies showed some efficacy in rhinitis and asthma, but the studies were too few to make recommendations. There are also unresolved safety concerns. Therapeutic efficacy of complementary-alternative treatments for rhinitis and asthma is not supported by currently available evidence.	Univ Genoa, Genoa, Italy; Hop A Villeneuve, Serv Malad Resp, Montpellier, France; Norwegian Univ Sport & Phys Med, Oslo, Norway; Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; Univ S Florida, Tampa, FL USA; JA Haley Vet Hosp, Tampa, FL USA; Univ Hosp, Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany; Nippon Med Sch, Dept Otorhinolaryngol, Tokyo 113, Japan; Univ Aberdeen, Dept Gen Practice & Primary Care, Foresterhill Hlth Ctr, Aberdeen, Scotland	University of Genoa; Universite de Montpellier; CHU de Montpellier; University of California System; University of California San Diego; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Nippon Medical School; University of Aberdeen	Passalacqua, G (corresponding author), Dept Internal Med, Padiglione Maragliano,Lgo R Benzi 10, I-16132 Genoa, Italy.	passalacqua@unige.it	Bousquet, Philippe Jean/AAW-8608-2021; Bousquet, Jean/O-4221-2019; Price, David/H-2837-2019	Bousquet, Philippe Jean/0000-0002-0217-5483; Price, David/0000-0002-9728-9992				AAABEL S, 2000, BR HOMEOPATH J, V89, P159; Aabel S, 2000, Br Homeopath J, V89, P169, DOI 10.1054/homp.1999.0440; Balon J, 1998, NEW ENGL J MED, V339, P1013, DOI 10.1056/NEJM199810083391501; Barnes Patricia M, 2004, Adv Data, P1; Barrett B, 1999, ALTERN THER HEALTH M, V5, P40; BEAMON S, 2001, COCHRANE DATABASE SY, V2; Bernstein DI, 2002, ANN ALLERG ASTHMA IM, V88, P272, DOI 10.1016/S1081-1206(10)62008-X; Bielory L, 2004, ANN ALLERG ASTHMA IM, V93, pS45, DOI 10.1016/S1081-1206(10)61486-X; Biernacki W, 1998, RESP MED, V92, P1143, DOI 10.1016/S0954-6111(98)90409-7; Birkel DA, 2000, ALTERN THER HEALTH M, V6, P55; Blanc PD, 2001, CHEST, V120, P1461, DOI 10.1378/chest.120.5.1461; Brinkhaus B, 2004, ALLERGY, V59, P953, DOI 10.1111/j.1398-9995.2004.00540.x; CHRISTENSEN PA, 1984, ALLERGY, V39, P379, DOI 10.1111/j.1398-9995.1984.tb01956.x; Cooper S, 2003, THORAX, V58, P674, DOI 10.1136/thorax.58.8.674; Cucherat M, 2000, EUR J CLIN PHARMACOL, V56, P27, DOI 10.1007/s002280050716; Cupp MJ, 1999, AM FAM PHYSICIAN, V59, P1239; Davies A, 1998, ALTERN THER HEALTH M, V4, P70; DENNIS J, 2000, COCHRANE DATABASE SY; DIAS PLR, 1982, J ROY SOC MED, V75, P245; Doshi V B, 1983, J Postgrad Med, V29, P89; EGASHIRA Y, 1993, ANN NY ACAD SCI, V685, P580, DOI 10.1111/j.1749-6632.1993.tb35921.x; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; Ernst E, 2000, EUR RESPIR J, V15, P969, DOI 10.1183/09031936.00.15596900; Ernst E, 2002, J INTERN MED, V252, P107, DOI 10.1046/j.1365-2796.2002.00999.x; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; Food and Drug Administration HHS, 2004, Fed Regist, V69, P6787; FUNG KP, 1986, LANCET, V2, P1419; Gray RD, 2004, ANN ALLERG ASTHMA IM, V93, P56, DOI 10.1016/S1081-1206(10)61447-0; Gruber W, 2002, THORAX, V57, P222, DOI 10.1136/thorax.57.3.222; Guiney PA, 2005, J AM OSTEOPATH ASSOC, V105, P7; Gupta I, 1998, Eur J Med Res, V3, P511; GUPTA S, 1979, INDIAN J MED RES, V69, P981; Hackman RM, 2000, J ASTHMA, V37, P1, DOI 10.3109/02770900009055424; HOLLOWAY E, 2004, COCHRANE DATABASE SY; HONDRAS MA, 2001, COCHRANE DATABASE SY, V1; HONDRAS MA, 2005, COCHRANE DATABASE SY, V2; Hsu CH, 2005, PEDIATR ALLERGY IMMU, V16, P76, DOI 10.1111/j.1399-3038.2005.00230.x; Hu GR, 2002, ANN ALLERG ASTHMA IM, V88, P478, DOI 10.1016/S1081-1206(10)62386-1; Huntley A, 2000, THORAX, V55, P925, DOI 10.1136/thorax.55.11.925; Huntley A, 2002, THORAX, V57, P127, DOI 10.1136/thorax.57.2.127; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jonas WB, 2003, ANN INTERN MED, V138, P393, DOI 10.7326/0003-4819-138-5-200303040-00009; Joos S, 2000, J ALTERN COMPLEM MED, V6, P519, DOI 10.1089/acm.2000.6.519; KAIK G, 1986, WIEN MED WOCHENSCHR, V136, P637; Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003-4819-135-4-200108210-00011; Kim LS, 2005, ANN PHARMACOTHER, V39, P617, DOI 10.1345/aph.1E387; KLEIJNEN J, 1991, THORAX, V46, P799, DOI 10.1136/thx.46.11.799; Koreck AI, 2005, J ALLERGY CLIN IMMUN, V115, P541, DOI 10.1016/j.jaci.2004.11.005; Lee DKC, 2004, CLIN EXP ALLERGY, V34, P646, DOI 10.1111/j.1365-2222.2004.1903.x; Lee DKC, 2004, CLIN EXP ALLERGY, V34, P110, DOI 10.1111/j.1365-2222.2004.01838.x; LEWITH GT, 2002, BMJ-BRIT MED J, V324, P1; Linde K, 2001, INT J EPIDEMIOL, V30, P526, DOI 10.1093/ije/30.3.526; Linde K, 2001, BMC Complement Altern Med, V1, P3; Linde K, 2001, BMC Complement Altern Med, V1, P4, DOI 10.1186/1472-6882-1-4; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; Malmstrom Monica, 2002, Acupunct Med, V20, P66; Manocha R, 2002, THORAX, V57, P110, DOI 10.1136/thorax.57.2.110; Mathew K, 1974, ASPECTS ALLERGY APPL, V7, P166; McCarney RW, 2004, RESP MED, V98, P687, DOI 10.1016/j.rmed.2004.05.005; MCCARNEY RW, 2004, COCHRANE DATABASE SY, V1; Medici TC, 2002, J ALTERN COMPLEM MED, V8, P737, DOI 10.1089/10755530260511748; MITCHELL P, 1989, AM J ACUPUNCTURE, V17, P5; MORTON AR, 1993, ANN ALLERGY, V70, P295; Neuman I, 1997, ANN ALLERG ASTHMA IM, V78, P399, DOI 10.1016/S1081-1206(10)63202-4; Ng DK, 2004, PEDIATRICS, V114, P1242, DOI 10.1542/peds.2004-0744; NIELSEN NH, 1995, CLIN EXP ALLERGY, V25, P80, DOI 10.1111/j.1365-2222.1995.tb01006.x; Niggemann B, 2004, ALLERGY, V59, P806, DOI 10.1111/j.1398-9995.2004.00495.x; Niggemann B, 2003, ALLERGY, V58, P707, DOI 10.1034/j.1398-9995.2003.00219.x; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; REILLY DT, 1986, LANCET, V2, P881; Sabina AB, 2005, ANN ALLERG ASTHMA IM, V94, P543, DOI 10.1016/S1081-1206(10)61131-3; Saper RB, 2004, JAMA-J AM MED ASSOC, V292, P2868, DOI 10.1001/jama.292.23.2868; Schapowal A, 2002, BMJ-BRIT MED J, V324, P144, DOI 10.1136/bmj.324.7330.144; Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2; Shapira MY, 2002, CHEST, V121, P1396, DOI 10.1378/chest.121.5.1396; Shekelle PG, 1999, BRIT MED J, V318, P593, DOI 10.1136/bmj.318.7183.593; Shenfield G, 2002, J PAEDIATR CHILD H, V38, P252, DOI 10.1046/j.1440-1754.2002.00770.x; SHIVPURI DN, 1972, ANN ALLERGY, V30, P407; SINGH V, 1990, LANCET, V335, P1381, DOI 10.1016/0140-6736(90)91254-8; TANDON MK, 1991, MED J AUSTRALIA, V154, P409, DOI 10.5694/j.1326-5377.1991.tb121134.x; TASHKIN DP, 1985, J ALLERGY CLIN IMMUN, V76, P855, DOI 10.1016/0091-6749(85)90760-2; Taylor MA, 2000, BMJ-BRIT MED J, V321, P471, DOI 10.1136/bmj.321.7259.471; Thiruvengadam K V, 1978, J Indian Med Assoc, V71, P172; Thomas M, 2003, THORAX, V58, P110, DOI 10.1136/thorax.58.2.110; Urata Y, 2002, RESP MED, V96, P469, DOI 10.1053/rmed.2002.1307; Vedanthan PK, 1998, ALLERGY ASTHMA PROC, V19, P3, DOI 10.2500/108854198778557971; Weiser M, 1999, FORSCH KOMPLEMENTMED, V6, P142, DOI 10.1159/000021239; Wen MC, 2005, J ALLERGY CLIN IMMUN, V116, P517, DOI 10.1016/j.jaci.2005.05.029; White A, 2003, THORAX, V58, P317, DOI 10.1136/thorax.58.4.317; *WHO, 1996, WHO TECHN REP SER, V863, P178; WIESENAUER M, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1745; WILLIAMSON L, 1996, ACUPUNCT MED, V14, P6; Wolkenstein E, 1998, Wien Med Wochenschr, V148, P450; World Health Organization, 2002, AC REV AN REP CONTR; Xue CCL, 2003, ALTERN THER HEALTH M, V9, P80; Xue CCL, 2002, AM J CHINESE MED, V30, P1, DOI 10.1142/S0192415X0200020X; 1993, RES GUIDELINES EVALU, P35	99	110	116	3	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1054	1062		10.1016/j.jaci.2005.12.1308	http://dx.doi.org/10.1016/j.jaci.2005.12.1308			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675332				2022-12-18	WOS:000237436300012
J	Silkoff, PE; Lent, AM; Busacker, AA; Katial, RK; Balzar, S; Strand, M; Wenzel, SE				Silkoff, PE; Lent, AM; Busacker, AA; Katial, RK; Balzar, S; Strand, M; Wenzel, SE			Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exhaled nitric oxide; eosinophils; airway; inflammation	AIRWAY INFLAMMATION; NEUTROPHILIC INFLAMMATION; SPUTUM EOSINOPHILS; CLINICAL REMISSION; IN-VITRO; MILD; EXPRESSION; SYNTHASE; CHILDREN; RESPONSIVENESS	Background: The fractional concentration of exhaled nitric oxide (FENO) is increased in asthma, correlates with eosinophilic inflammation, and decreases after steroid therapy. Objective: We sought to examine whether persistent eosinophilia would be accompanied by an increased FENO level despite steroid therapy in patients with severe refractory asthma (SRA) as manifestations of steroid resistance. Methods: Subjects with SRA, subjects with mild-moderate asthma, and healthy control subjects had FENO measured, followed by endobronchial biopsy and bronchoalveolar lavage. Tissue and bronchoalveolar lavage inflammatory cells were assessed for all subjects, and eosinophil status (EOS+[FOS-) was determined for subjects with SRA. Results: Twenty-four subjects with SRA, 15 subjects with moderate-mild asthma, and 17 healthy control subjects were studied. Subjects with EOS+ SRA had significantly higher median FENO levels compared with levels in subjects with EOS- SRA (P =.0084) and all other groups. In subjects with SRA, FENO levels correlated with tissue eosinophils (r(s) = 0.54, P.007), lymphocytes (r(s) = 0.40, P =.003), and mast cells (r(s) 0.44, P =.05). FENO levels of greater than 72.9 ppb were associated with a sensitivity of 0.56 and a specificity of 1.0 for EOS+ status in subjects with SRA. Conclusion: FENO measurement identified the subgroup of subjects with SRA with persistent eosinophilia despite steroid therapy. Further studies are needed on the use of FENO to monitor response to therapy over time in subjects with SRA.	Natl Jewish Med & Res Ctr, Denver, CO USA	National Jewish Health	Silkoff, PE (corresponding author), 715 Bryn Mawr Ave, Narberth, PA 19072 USA.	philsilkoff@hotmail.com	Strand, Matt/AAU-3762-2021; silkoff, philip/S-9037-2016	Strand, Matt/0000-0002-9083-5989; silkoff, philip/0000-0001-6018-5199				ALVING K, 1993, EUR RESPIR J, V6, P1368; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Colon-Semidey AJ, 2000, PEDIATR PULM, V30, P385, DOI 10.1002/1099-0496(200011)30:5<385::AID-PPUL4>3.0.CO;2-#; Conran N, 2001, BRIT J PHARMACOL, V134, P632, DOI 10.1038/sj.bjp.0704295; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; delPozo V, 1997, J IMMUNOL, V158, P859; Dupont LJ, 1998, AM J RESP CRIT CARE, V157, P894, DOI 10.1164/ajrccm.157.3.9709064; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gilchrist M, 2004, BLOOD, V104, P462, DOI 10.1182/blood-2003-08-2990; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Harkins MS, 2004, J ASTHMA, V41, P471, DOI 10.1081/JAS-120033990; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64, DOI 10.1164/ajrccm.161.1.9809100; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Lim S, 2000, THORAX, V55, P184, DOI 10.1136/thorax.55.3.184; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Paoliello-Paschoalatoa AB, 2005, CYTOKINE, V30, P116, DOI 10.1016/j.cyto.2005.01.001; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; SHELHAMER JH, 1995, ANN INTERN MED, V123, P288, DOI 10.7326/0003-4819-123-4-199508150-00008; Silkoff PE, 1998, J ASTHMA, V35, P473, DOI 10.3109/02770909809071000; Sippel JM, 2000, J ALLERGY CLIN IMMUN, V106, P645, DOI 10.1067/mai.2000.109618; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744, DOI 10.1164/ajrccm.164.5.2011026; Thomazzi SM, 2001, BIOCHEM PHARMACOL, V62, P1417, DOI 10.1016/S0006-2952(01)00782-1; Trifilieff A, 2000, J IMMUNOL, V165, P1526, DOI 10.4049/jimmunol.165.3.1526; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953, DOI 10.1164/ajrccm.162.3.9909033; Warke TJ, 2002, THORAX, V57, P383, DOI 10.1136/thorax.57.5.383; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC	43	110	116	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1249	1255		10.1016/j.jaci.2005.09.029	http://dx.doi.org/10.1016/j.jaci.2005.09.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337453				2022-12-18	WOS:000235687000012
J	Sunyer, J; Jarvis, D; Pekkanen, J; Chinn, S; Janson, C; Leynaert, B; Luczynska, C; Garcia-Esteban, R; Burney, P; Anto, JM				Sunyer, J; Jarvis, D; Pekkanen, J; Chinn, S; Janson, C; Leynaert, B; Luczynska, C; Garcia-Esteban, R; Burney, P; Anto, JM		European Comm Resp Health	Geographic variations in the effect of atopy on asthma in the European Community Respiratory Health Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; attributable fraction; house dust mite; allergens	HOUSE-DUST MITE; BRONCHIAL RESPONSIVENESS; INDIVIDUAL ALLERGENS; SERUM IGE; SENSITIZATION; EXPOSURE; RISK; ASSOCIATION; PREVALENCE; SYMPTOMS	Background: Atopy has long been related to asthma. The prevalences of both atopy and asthma have shown substantial variation. Objective: We sought to assess geographic variations in the fraction of asthma attributable to IgE sensitization to specific allergens in the European Community Respiratory Health Survey. Methods: A cross-sectional study was undertaken during the years 1991 and 1992 on 13,558 individuals in 36 centers in 16 countries. Asthma was defined in several ways, variously incorporating reported symptoms, bronchial responsiveness to methacholine, and physician diagnosis. Specific IgE against house dust mite (Dermatophagoides pteronyssinus), cat, timothy grass, Cladosporium herbarum, and a local allergen (birch, Parietaria judaica, or ragweed) were measured. Results: The overall attributable fraction (AF) of asthma symptoms caused by atopy was 30% but varied widely between centers, ranging from 4% to 61%. The overall AF increased to 43% when asthma was based on wheezing and bronchial responsiveness, to 45% with a physician diagnosis of asthma, and to 48% when the patient reported more than 12 attacks in the last year. Between centers, the AF for atopy was significantly correlated with the prevalence of atopy among the asthmatic patients (r = 0.91) and with the sensitization to house dust mite (r = 0.64), as well as with the prevalence of asthma among atopic individuals (r = 0.43) and the prevalence of asthma among nonatopic individuals (r = -0.51). Conclusion: The effect of atopy on the prevalence of asthma varies widely between centers, probably because of variations in factors related to the expression of asthma and to the prevalence of sensitization, particularly to house dust mite.	UPF, IMIM, Environm Resp Res Unit, Barcelona 08003, Spain; Kings Coll London, Dept Publ Hlth Sci, London, England; Nacl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio, Finland; Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; INSERM, Paris, France	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Pompeu Fabra University; University of London; King's College London; Uppsala University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Sunyer, J (corresponding author), UPF, IMIM, Environm Resp Res Unit, C Doctor Aiguader 80, Barcelona 08003, Spain.	jsunyer@imim.es	Sunyer, Jordi/G-6909-2014; Jarvis, Deborah/E-6494-2011; Leynaert, Benedicte/N-5251-2018; Anto, J M/H-2676-2014	Sunyer, Jordi/0000-0002-2602-4110; Anto, J M/0000-0002-4736-8529; Jarvis, Deborah/0000-0002-1753-3896; Burney, Peter/0000-0001-8635-5678; Leynaert, Benedicte/0000-0001-5045-2492; Garcia, Raquel/0000-0002-5663-6388				Boezen HM, 1996, AM J RESP CRIT CARE, V154, P30, DOI 10.1164/ajrccm.154.1.8680695; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; Chinn S, 1998, THORAX, V53, P662, DOI 10.1136/thx.53.8.662; de Marco R, 2002, CLIN EXP ALLERGY, V32, P1405, DOI 10.1046/j.1365-2745.2002.01466.x; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Ponsonby AL, 2002, CHEST, V121, P135, DOI 10.1378/chest.121.1.135; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P53; Soriano JB, 1999, INT J EPIDEMIOL, V28, P728, DOI 10.1093/ije/28.4.728; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; Sunyer J, 2000, AM J RESP CRIT CARE, V162, P930, DOI 10.1164/ajrccm.162.3.9911062; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P303, DOI 10.1093/oxfordjournals.aje.a117252; Wieringa MH, 1997, EUR RESPIR J, V10, P1460, DOI 10.1183/09031936.97.10071460; Zocchetti C, 1997, INT J EPIDEMIOL, V26, P220, DOI 10.1093/ije/26.1.220; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	26	110	110	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1033	1039		10.1016/j.jaci.2004.05.072	http://dx.doi.org/10.1016/j.jaci.2004.05.072			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536406	Bronze			2022-12-18	WOS:000225047800006
J	Kabesch, M; Tzotcheva, I; Carr, D; Hofler, C; Weiland, SK; Fritzsch, C; von Mutius, E; Martinez, FD				Kabesch, M; Tzotcheva, I; Carr, D; Hofler, C; Weiland, SK; Fritzsch, C; von Mutius, E; Martinez, FD			A complete screening of the IL4 gene: Novel polymorphisms and their association with asthma and IgE in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; childhood; IgE; IL-4; IL-13; polymorphism; single nucleotide polymorphisin	INTERLEUKIN-4 PROMOTER POLYMORPHISM; LINKAGE DISEQUILIBRIUM; IL-4 PROMOTER; MARKERS; REGION; DISORDERS; PROTEINS; SEQUENCE; BINDING; CLUSTER	Background: IL-4, a cytokine with immunomodulatory functions, is involved in the upregulation of IgE production characteristic of asthma and allergy. Thus far, 2 single nucleotide polymorphisms (SNPs) in the promoter (C-589T) and 5' untranslated region (C-33T) of the IL4 gene have been identified. Polymorphism C-589T was reported to influence total serum IgE levels and bronchial hyperresponsiveness. However, no study has investigated the putative existence of further SNPs in exons, introns, and flanking regions of the IL4 gene. Objective: A complete screening of the IL4 gene and its flanking regions for new polymorphisms was performed. Large-scale association studies in 1120 German schoolchildren were conducted to determine the effect of all polymorphisms present in the IL4 gene on the phenotypic expression of atopic diseases. Methods: Denaturing HPLC and standard sequencing techniques were performed to detect novel polymorphisms in 33 unrelated subjects unselected for atopic diseases. Linkage disequilibrium was assessed for all polymorphisms in the IL4 gene, and association studies were performed. Results: A total of 16 polymorphisms were identified in the IL4 gene, 14 of which were not reported previously. The pattern of linkage disequilibrium observed in IL4 could not be explained by physical distance. A significant association between a cluster of polymorphisms in strong linkage disequilibrium with each other and a physician's diagnosis of asthma and total serum IgE levels was found. Conclusion: These results indicate a possible involvement of SNPs in the IL4 gene in the development of asthma and the regulation of total serum IgE.	Univ Munich, Childrens Hosp, D-80337 Munich, Germany; Univ Arizona, Resp Sci Ctr, Tucson, AZ USA; Univ Leipzig, Childrens Hosp, Leipzig, Germany; Univ Ulm, Dept Epidemiol, Ulm, Germany	University of Munich; University of Arizona; Leipzig University; Ulm University	Kabesch, M (corresponding author), Univ Munich, Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.		Kabesch, Michael/GZM-1583-2022; Kabesch, Michael/AAB-5701-2020	von Mutius, Erika/0000-0002-8893-4515				Abecasis GR, 2001, AM J HUM GENET, V68, P191, DOI 10.1086/316944; ARAI N, 1989, J IMMUNOL, V142, P274; BRUHN KW, 1993, P NATL ACAD SCI USA, V90, P9707, DOI 10.1073/pnas.90.20.9707; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Dizier MH, 1999, GENET EPIDEMIOL, V16, P84, DOI 10.1002/(SICI)1098-2272(1999)16:1<84::AID-GEPI7>3.0.CO;2-D; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; Elliott K, 2001, J ALLERGY CLIN IMMUN, V108, P285, DOI 10.1067/mai.2001.117180; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Kawashima T, 1998, J MED GENET, V35, P502, DOI 10.1136/jmg.35.6.502; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739, DOI 10.1164/ajrccm.158.6.9712040; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Monticelli S, 2002, MOL IMMUNOL, V38, P1129, DOI 10.1016/S0161-5890(02)00037-8; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; Palmer LJ, 1998, AM J RESP CRIT CARE, V158, P1825, DOI 10.1164/ajrccm.158.6.9804037; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; Song ZM, 1996, J IMMUNOL, V156, P424; Suzuki I, 1999, IMMUNOGENETICS, V49, P738, DOI 10.1007/s002510050677; Suzuki I, 2000, CLIN EXP ALLERGY, V30, P1746, DOI 10.1046/j.1365-2222.2000.00983.x; Walley AJ, 1996, J MED GENET, V33, P689, DOI 10.1136/jmg.33.8.689; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Zhu SK, 2000, AM J RESP CRIT CARE, V161, P1655, DOI 10.1164/ajrccm.161.5.9906086	26	110	116	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					893	898		10.1016/j.jaci.2003.08.033	http://dx.doi.org/10.1016/j.jaci.2003.08.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610476	Bronze			2022-12-18	WOS:000186553300010
J	Michel, O; LeVan, TD; Stern, D; Dentener, M; Thorn, J; Gnat, D; Beijer, ML; Cochaux, P; Holt, PG; Martinez, FD; Rylander, R				Michel, O; LeVan, TD; Stern, D; Dentener, M; Thorn, J; Gnat, D; Beijer, ML; Cochaux, P; Holt, PG; Martinez, FD; Rylander, R			Systemic responsiveness to lipopolysaccharide and polymorphisms in the toll-like receptor 4 gene in human beings	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; lipopolysaccharide; toll-like receptor-4; inflammation; C-reactive protein; leukocytosis	INHALED LIPOPOLYSACCHARIDE; CYTOKINE RELEASE; ENDOTOXIN; TLR4; MICE; MUTATIONS; RESPONSES; DUST; HYPORESPONSIVENESS; UNRESPONSIVENESS	Background: The response to lipopolysaccharide exposure is highly variable and might be a result of genetic diversity between individuals. The toll-like receptor 4 (TLR-4) is the principal receptor for lipopolysacharide. Objectives: We investigated the association between single-nucleotide polymorphisms in the TLR4 locus and levels of systemic inflammatory markers in response to lipopolysaccharide. Methods: Healthy subjects (n = 116) were genotyped for the most frequent polymorphisms found in the promoter and coding region of the TLR4 gene (-2026A/T, -1607T/C, +896A/G, and +1196C/T relative to the translation start site). Subjects were challenged with 20 mug lipopolysaccharide by inhalation. Results: Polymorphisms at +896 and +1196 were in complete linkage disequilibrium, and no homozygotes for the less common allele, G and T respectively, were found. After lipopolysaccharide inhalation, subjects heterozygous for either TLR-4/+896 or TLR4/+1196 had significantly lower numbers of white blood cell counts and lower levels of C-reactive protein and lipopolysaccharide-binding protein compared with homozygotes with the common allele. None of the heterozygous subjects (n = 18) except 1 were high responders to lipopolysaccharide (defined as a rise in C-reactive protein > 10 mg/L), whereas 36 of 98 homozygous subjects were high responders (P < .02). No association was observed between the TLR-4/-2026 and TLR-4/-1607 polymorphisms and lipopolysaccharide responsiveness. Conclusion: The single-nucleotide polymorphisms at position +896 or +1196 in the TLR-4 gene is associated with systemic inflammatory hyporesponsiveness to inhaled lipopolysaccharide.	Free Univ Brussels, CHU St Pierre, Clin Allergol & Resp Dis, CP404-12,Rue Haute 322, B-1000 Brussels, Belgium; Univ Western Perth, Ctr Child Hlth Res, Perth, WA, Australia; Free Univ Brussels, Erasme Hosp, Dept Mol Genet, B-1050 Brussels, Belgium; Univ Gothenburg, Dept Environm Med, Gothenburg, Sweden; Maastricht Univ, Dept Pulmonol, Maastricht, Netherlands; Univ Arizona, Coll Med, Dept Med, Tucson, AZ USA; Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ USA; Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Western Australia; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Gothenburg; Maastricht University; University of Arizona; University of Arizona; University of Arizona	Michel, O (corresponding author), Free Univ Brussels, CHU St Pierre, Clin Allergol & Resp Dis, CP404-12,Rue Haute 322, B-1000 Brussels, Belgium.		Holt, Patrick G/H-1548-2011; michel, olivier/G-5016-2010	Holt, Patrick G/0000-0003-1193-0935; michel, olivier/0000-0002-1528-1277	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K01ES000386] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61892-01] Funding Source: Medline; NIEHS NIH HHS [ES00386] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; COUTINHO A, 1978, IMMUNOGENETICS, V7, P17, DOI 10.1007/BF01843983; FROON AHM, 1995, J INFECT DIS, V171, P1250, DOI 10.1093/infdis/171.5.1250; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; Kuhns DB, 1997, J IMMUNOL, V158, P3959; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Lorenz E, 2001, AM J PHYSIOL-LUNG C, V281, pL1106, DOI 10.1152/ajplung.2001.281.5.L1106; MACKAY I, 2000, NEW ENGL J MED, V344, P338; Martin TR, 2000, AM J RESP CELL MOL, V23, P128, DOI 10.1165/ajrcmb.23.2.f189; MARTINEZ FM, 2003, INNATE IMMUNITY HEAR; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Michel O, 2001, J ALLERGY CLIN IMMUN, V107, P797, DOI 10.1067/mai.2001.114249; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; MICHEL O, 1997, INT J OCCUP ENV HL S, V3, P18; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; NAKANO M, 1992, BACTERIAL ENDOTOXIC, V1, P311; O'Grady NP, 2001, AM J RESP CRIT CARE, V163, P1591, DOI 10.1164/ajrccm.163.7.2009111; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pridmore AC, 2001, J INFECT DIS, V183, P89, DOI 10.1086/317647; Read RC, 2001, J INFECT DIS, V184, P640, DOI 10.1086/322798; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; ROSENSTREICH DL, 1982, CRC CR REV IMMUNOL, V3, P263; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; Rylander R., 1997, INT J OCCUP ENV HEAL, V3, pS1, DOI 10.1179/oeh.1997.3.1.1.; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603, DOI 10.1164/ajrccm.152.2.7633714; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47, DOI 10.1164/ajrccm.151.1.7812571; SMIMOVA I, 2000, GENOME BIOL, V1, P1; SULTZER BM, 1968, NATURE, V219, P1253, DOI 10.1038/2191253a0; THOM J, 1998, THORAX, V53, P1047; VANDERZWAN JC, 1982, CLIN ALLERGY, V12, P547; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15, DOI 10.1164/ajrccm.157.1.9703087; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; Wong PMC, 2001, J BIOL CHEM, V276, P33129, DOI 10.1074/jbc.M105400200; Woolcock AJ, 2000, AM J RESP CRIT CARE, V161, pS215, DOI 10.1164/ajrccm.161.supplement_2.a1q4-14; ZAMEL N, 1984, J APPL PHYSIOL, V56, P936, DOI 10.1152/jappl.1984.56.4.936	49	110	114	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					923	929		10.1016/j.jaci.2003.05.001	http://dx.doi.org/10.1016/j.jaci.2003.05.001			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610481	Bronze			2022-12-18	WOS:000186553300014
J	Engler, RJM; Kenner, J; Leung, DYM				Engler, RJM; Kenner, J; Leung, DYM			Smallpox vaccination: Risk considerations for patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; eczema; smallpox; vaccinia; T cells	VACCINIA VIRUS-INFECTION; CYTOTOXIC T-LYMPHOCYTES; IFN-GAMMA PRODUCTION; CELLS; EXPRESSION; COMPLICATIONS; PROTECTION; RESPONSES; PREVALENCE; CD8+	As the threat of bioterrorism with pathogenic microbes such as smallpox virus (Variola major) increases, the question of widespread voluntary vaccination with smallpox (vaccinia) vaccines is being carefully considered. A major challenge lies in the ability to protect the population from the disease while minimizing the considerable side effects from the vaccine. Individuals with active or quiescent atopic dermatitis are at increased risk for vaccinia complications. The nature of these complications and other considerations are summarized in this rostrum.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy & Immunol, Denver, CO 80206 USA; Walter Reed Army Med Ctr, Allergy Immunol Dept, Washington, DC 20307 USA; Dept Vet Affairs, Tripler Army Med Ctr, Dermatol Serv, Honolulu, HI USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy & Immunol, 1400 Jackson St,Room K926I, Denver, CO 80206 USA.							Albert MR, 2001, NEW ENGL J MED, V344, P375, DOI 10.1056/NEJM200102013440511; Alcami A, 2000, TRENDS MICROBIOL, V8, P410, DOI 10.1016/S0966-842X(00)01830-8; Ambach A, 2001, J ALLERGY CLIN IMMUN, V107, P878, DOI 10.1067/mai.2001.114240; [Anonymous], 2001, MMWR-MORBID MORTAL W, V50, P1; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V108, P281, DOI 10.1067/mai.2001.117259; Barnhill RL., 1998, TXB DERMATOPATHOLOGY; Bastian A, 2001, REGUL PEPTIDES, V101, P157, DOI 10.1016/S0167-0115(01)00282-8; Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357; BINDER D, 1991, J IMMUNOL, V146, P4301; Biron CA, 2001, CURR OPIN IMMUNOL, V13, P458, DOI 10.1016/S0952-7915(00)00241-7; BLANDEN RV, 1974, TRANSPLANT REV, V19, P56; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; BRAS G, 1952, AMA ARCH PATHOL, V54, P149; Breman JG, 2002, NEW ENGL J MED, V346, P1300, DOI 10.1056/NEJMra020025; Campbell DE, 1999, CLIN EXP IMMUNOL, V115, P377; Cohen J, 2001, SCIENCE, V294, P985, DOI 10.1126/science.294.5544.985; COLE GA, 1982, COMPREHENSIVE IMMUNO, P1; COPEMAN PWM, 1964, BRIT MED J, V2, P906, DOI 10.1136/bmj.2.5414.906; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; DEMKOWICZ WE, 1993, J VIROL, V67, P1538, DOI 10.1128/JVI.67.3.1538-1544.1993; DOWNIE A. W., 1958, JOUR HYGIENE, V56, P479; DOWNIE AW, 1969, J HYG-CAMB, V67, P609, DOI 10.1017/S0022172400042066; DOWNIE AW, 1969, J HYG-CAMB, V67, P619, DOI 10.1017/S0022172400042078; Drazen JM, 2002, NEW ENGL J MED, V346, P1262, DOI 10.1056/NEJM2e020038; ELAD B, 1990, J INFECT DIS, V161, P446, DOI 10.1093/infdis/161.3.446; Ennis FA, 2002, J INFECT DIS, V185, P1657, DOI 10.1086/340517; Fauci AS, 2002, NEW ENGL J MED, V346, P1319, DOI 10.1056/NEJM200204253461711; FENNER F, 1988, PATHOGENESIS IMMUNOL, P122; Fritz SB, 2002, J ALLERGY CLIN IMMUN, V109, P214, DOI 10.1067/mai.2002.121947; GALASSO GJ, 1977, J INFECT DIS, V135, P183, DOI 10.1093/infdis/135.1.183; Geiger E, 2000, J ALLERGY CLIN IMMUN, V105, P150, DOI 10.1016/S0091-6749(00)90190-8; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; Haim M, 2000, MIL MED, V165, P287, DOI 10.1093/milmed/165.4.287; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HENDERSON DA, 1999, VACCINES, P74; Higashi N, 2001, J ALLERGY CLIN IMMUN, V108, P607, DOI 10.1067/mai.2001.118601; Hill LW, 1935, ARCH DERMATOL SYPH, V32, P451, DOI 10.1001/archderm.1935.01470030093010; Jackson RJ, 2001, J VIROL, V75, P1205, DOI 10.1128/JVI.75.3.1205-1210.2001; JACKSON TM, 1977, AM J TROP MED HYG, V26, P517, DOI 10.4269/ajtmh.1977.26.517; Kagi D, 1995, EUR J IMMUNOL, V25, P3256, DOI 10.1002/eji.1830251209; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KEMPE CH, 1960, PEDIATRICS, V26, P176; Kimura M, 1998, J ALLERGY CLIN IMMUN, V102, P238, DOI 10.1016/S0091-6749(98)70092-2; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; LANE JM, 1971, AM J EPIDEMIOL, V93, P238, DOI 10.1093/oxfordjournals.aje.a121252; LANE JM, 1971, ANNU REV MED, V22, P251, DOI 10.1146/annurev.me.22.020171.001343; Larsen FS, 2002, IMMUNOL ALLERGY CLIN, V22, P1, DOI 10.1016/S0889-8561(03)00066-3; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1983, J IMMUNOL, V130, P1678; LEVER RS, 1985, CLIN ALLERGY, V15, P479, DOI 10.1111/j.1365-2222.1985.tb02298.x; MACK TM, 1972, AM J TROP MED HYG, V21, P214, DOI 10.4269/ajtmh.1972.21.214; Mahalingam S, 2000, IMMUNOL REV, V177, P127, DOI 10.1034/j.1600-065X.2000.17720.x; MCCARTHY K., 1958, JOUR HYGIENE, V56, P466; McClain DJ, 1997, J INFECT DIS, V175, P756, DOI 10.1086/513968; MCKEE PH, 1996, PATHOLOGY SKIN CLIN, P4; NAKANO J H, 1985, P401; OHMEN JD, 1995, J IMMUNOL, V154, P1956; ONG PY, 2002, J ALLERGY CLIN IMM 2, V109, pA779; RAYCHAUDHURI SP, 1995, INT J DERMATOL, V34, P854, DOI 10.1111/j.1365-4362.1995.tb04421.x; RUBY J, 1991, LYMPHOKINE CYTOK RES, V10, P353; Selin LK, 2001, J IMMUNOL, V166, P6784, DOI 10.4049/jimmunol.166.11.6784; Sharma DP, 1996, J VIROL, V70, P7103, DOI 10.1128/JVI.70.10.7103-7107.1996; Stittelaar KJ, 2001, VACCINE, V19, P3700, DOI 10.1016/S0264-410X(01)00075-5; Sugiura H, 1998, ACTA DERM-VENEREOL, V78, P293; Tanaka-Kataoka M, 1999, CYTOKINE, V11, P593, DOI 10.1006/cyto.1998.0453; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; von Bubnoff D, 2001, J ALLERGY CLIN IMMUN, V108, P329, DOI 10.1067/mai.2001.117457; WALKER RB, 1956, BRIT J DERMATOL, V68, P182, DOI 10.1111/j.1365-2133.1956.tb12805.x	72	110	117	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					357	365		10.1067/mai.2002.128052	http://dx.doi.org/10.1067/mai.2002.128052			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209080				2022-12-18	WOS:000177936900003
J	Ballmer-Weber, BK; Scheurer, S; Fritsche, P; Enrique, E; Cistero-Bahima, A; Haase, T; Wuthrich, B				Ballmer-Weber, BK; Scheurer, S; Fritsche, P; Enrique, E; Cistero-Bahima, A; Haase, T; Wuthrich, B			Component-resolved diagnosis with recombinant allergens in patients with cherry allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; DBPCFC; cherry; recombinant allergens; diagnosis; skin prick testing; cross-reactivity	BIRCH POLLEN ALLERGEN; CONTROLLED FOOD CHALLENGE; CELERY APIUM-GRAVEOLENS; LIPID-TRANSFER PROTEINS; BET-V-I; MAJOR ALLERGEN; CROSS-REACTIVITY; APPLE ALLERGEN; PROFILIN BET-V-2; DOUBLE-BLIND	Background: In pollen-related food allergy, extracts for skin prick tests (SPTs) are often not standardized, and the test reliability is affected by false-negative reactions. Objective: We sought to evaluate a panel of recombinant allergens (RAs) derived from one allergenic food for use in component-resolved in vivo diagnosis, taking cherry as a model food. Methods: Seventy-nine subjects were included in the study: 24 Swiss patients (group 1) with a positive double-blind placebo-controlled food challenge result to cherries, 23 patients with birch pollen allergy but without cherry allergy (group 2). 23 nonatopic subjects (group 3), and 9 Spanish patients with a history of a cherry allergy (group 4). SPTs were performed in duplicate by using recombinant cherry allergens (Bet v 1-related allergen: recombinant (r) Pro av 1; profilin: rPru av 4; and lipid transfer protein: rPru av 3) in concentrations of 10, 50, and 100 mug/mL. Furthermore, IgE reactivity to rPru av 1, rPru av 4, and rPru av 3 was assessed by means of immunoblot analysis. Results: SPT responses with rPru av 1, rPru av 4, and rPru av 3 were positive in 92%, 17%, and 4% of the patients in group 1; in 74%, 30%, and 0% of the patients in group 2; in 0%, 22%, and 89% of the patients in group 4; and negative for all nonatopic subjects (group 3). Thus the sensitivity of a positive SPT response to at least one of the 3 RAs was 96%. The specificities, negative predictive values, and positive predictive values with the 3 RAs were 100%, 96%, and 100% if calculated in relation to the nonatopic control group but 17%, 79%, and 60% when calculated in relation to the control group with birch pollen allergy. The correlation between SPT and immunoblotting results was excellent. Sensitization to rPru av 3 was associated with more severe symptoms than sensitization to rPru av 1. Conclusions: SPTs with RAs proved to be highly sensitive for diagnosis of cherry allergy. Component-resolved in vivo diagnosis with standardized amounts of stable RAs allows us to determine sensitization patterns directly, to correlate them with severity of clinical symptoms, and to analyze geographic differences.	Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Paul Ehrlich Inst, Dept Allergol, D-6070 Langen, Germany; Inst Univ Dexeus, Barcelona, Spain	University of Zurich; University Zurich Hospital; Paul Ehrlich Institute	Ballmer-Weber, BK (corresponding author), Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Gloriastr 31, CH-8091 Zurich, Switzerland.		Scheurer, Stephan/A-6509-2019	Scheurer, Stephan/0000-0002-2859-562X				Arquint O, 1999, J ALLERGY CLIN IMMUN, V104, P1239, DOI 10.1016/S0091-6749(99)70019-9; Asero R, 1999, ANN ALLERG ASTHMA IM, V83, P377, DOI 10.1016/S1081-1206(10)62834-7; Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Ballmer-Weber BK, 2000, ALLERGOLOGIE, V23, P285; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; Crameri R, 1998, INT IMMUNOL, V10, P1211, DOI 10.1093/intimm/10.8.1211; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; Dreborg S, 2001, ALLERGY, V56, P359, DOI 10.1034/j.1398-9995.2001.056005359.x; Duro G, 1997, INT ARCH ALLERGY IMM, V112, P348, DOI 10.1159/000237479; Goldstein Laurence, 1987, PRINCIPLES INTERNAL, P5; Hoffmann-Sommergruber K, 1999, J ALLERGY CLIN IMMUN, V104, P478, DOI 10.1016/S0091-6749(99)70397-0; Inschlag C, 1998, INT ARCH ALLERGY IMM, V116, P22, DOI 10.1159/000023920; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorenz AR, 2001, J CHROMATOGR B, V756, P255, DOI 10.1016/S0378-4347(01)00086-X; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; LYNCH NR, 1994, INT ARCH ALLERGY IMM, V105, P70, DOI 10.1159/000236805; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; POULSEN LK, 1993, CLIN EXP ALLERGY, V23, P61, DOI 10.1111/j.1365-2222.1993.tb02485.x; RASCH D, 1998, VERFAHRENSBIBLIOTHEK, V1; ROSEN JP, 1994, J ALLERGY CLIN IMMUN, V93, P1068, DOI 10.1016/S0091-6749(94)70056-7; RUDESCHKO O, 1995, ALLERGY, V50, P575, DOI 10.1111/j.1398-9995.1995.tb01202.x; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V82, P718, DOI 10.1016/0091-6749(88)90070-X; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; Scheurer S, 2001, J ALLERGY CLIN IMMUN, V107, P724, DOI 10.1067/mai.2001.113864; Scheurer S, 2000, CLIN EXP ALLERGY, V30, P962, DOI 10.1046/j.1365-2222.2000.00821.x; Scheurer S, 2001, J CHROMATOGR B, V756, P315, DOI 10.1016/S0378-4347(01)00090-1; Schmid-Grendelmeier P, 2001, INT ARCH ALLERGY IMM, V125, P96, DOI 10.1159/000053803; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P198; Van Ree R, 2000, ALLERGY CLIN IMMUNOL, V12, P7; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; VIETHS S, 1995, ALLERGY, V50, P421, DOI 10.1111/j.1398-9995.1995.tb01172.x; Vieths S, 1998, ALLERGY, V53, P65, DOI 10.1111/j.1398-9995.1998.tb04965.x	42	110	111	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					167	173		10.1067/mai.2002.125601	http://dx.doi.org/10.1067/mai.2002.125601			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110837				2022-12-18	WOS:000176870300029
J	Fujisawa, T; Kato, Y; Nagase, H; Atsuta, J; Terada, A; Iguchi, K; Kamiya, H; Morita, Y; Kitaura, M; Kawasaki, H; Yoshie, O; Hirai, K				Fujisawa, T; Kato, Y; Nagase, H; Atsuta, J; Terada, A; Iguchi, K; Kamiya, H; Morita, Y; Kitaura, M; Kawasaki, H; Yoshie, O; Hirai, K			Chemokines induce eosinophil degranulation through CCR-3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; degranulation; CC chemokines; eotaxin; CCR3	MAJOR BASIC-PROTEIN; PLATELET-ACTIVATING-FACTOR; MOLECULAR-CLONING; EOTAXIN RECEPTOR; MESSENGER-RNA; EXPRESSION; RANTES; LYMPHOCYTES; MIGRATION; CYTOKINES	Background: Such CC chemokines as eotaxin and RANTES induce preferential eosinophil recruitment in allergic inflammation. They also elicit proinflammatory effector functions of eosinophils, such as enhanced adhesion and superoxide generation. Eosinophil degranulation by chemokines, however, has not been studied in detail. Objective: The purpose of this study was to identify chemokines and their corresponding receptors that induce eosinophil degranulation by using a panel of chemokines and blocking antibodies to candidate receptors. Methods: Highly purified eosinophils were preloaded with Fura-2 and stimulated with a panel of chemokine ligands for 14 known chemokine receptors: CCR1 to CCR8, CXCR1 to CXCR4 CX3CR1, and XCR1. Calcium influx was measured with fluorescence spectrometry. Eosinophils were also stimulated with the chemokines in the presence or absence of IL-5, and levels of eosinophil-derived neurotoxin were measured in the supernatant with RIA. Specific antibodies to chemokine receptors were used to block degranulation. Results: Calcium influx was induced by monocyte chemotactic protein (MCP) 1, MCP3, MCP-4, RANTES, eotaxin, IL-8, and stromal cell-derived factor 1 alpha, which are chemokines that bind several chemokine receptors. However, degranulation was induced only by CCR3 ligands, including MCP3, MCP-4, RANTES, and eotaxin. Priming of eosinophils with IL-5 enhanced CCR3 ligand-induced degranulation but did not cause non-CCR3 ligands to induce eosinophil-derived neurotoxin release. An antibody against CCR3 significantly inhibited degranulation induced by CCR3 ligands, eotaxin, or RANTES. Conclusion: These results suggest that chemokine-induced eosinophil degranulation, a major effector of eosinophil functions, is mediated through only CCR3, although some non-CCR3 ligands induce calcium influx in eosinophils. CCR3 may be an important target in the treatment of eosinophilic inflammation.	Mie Natl Hosp, Dept Pediat, Tsu, Mie 5140125, Japan; Mie Univ, Sch Med, Dept Psychiat, Tsu, Mie 514, Japan; Shionogi Inst Med Sci, Osaka, Japan; Univ Tokyo, Inst Med Sci, Ctr AIDS Res, Tokyo, Japan; Univ Tokyo, Dept Clin Immunol, Tokyo, Japan; Kinki Univ, Sch Med, Dept Bacteriol, Osaka 589, Japan; Univ Tokyo, Sch Med, Dept Resp Med, Tokyo 113, Japan; Univ Tokyo, Sch Med, Dept Bioregulatory Funct, Tokyo 113, Japan	Mie University; Shionogi & Company Limited; University of Tokyo; University of Tokyo; Kindai University (Kinki University); University of Tokyo; University of Tokyo	Fujisawa, T (corresponding author), Mie Natl Hosp, Dept Pediat & Allergy, 357 Osato Kubota, Tsu, Mie 5140125, Japan.		Nagase, Hiroyuki/Y-4367-2019	Nagase, Hiroyuki/0000-0002-0296-5901; Yoshie, Osamu/0000-0003-4353-5809				ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; Adachi T, 1999, J IMMUNOL, V163, P939; ALAM R, 1993, J IMMUNOL, V150, P3442; Bonini JA, 1997, DNA CELL BIOL, V16, P1249, DOI 10.1089/dna.1997.16.1249; DAHINDEN C, 1983, J IMMUNOL, V130, P863; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; EBISAWA M, 1994, J IMMUNOL, V153, P2153; El-Shazly A, 1998, INT ARCH ALLERGY IMM, V117, P55, DOI 10.1159/000053573; Ezeamuzie CI, 1999, BRIT J PHARMACOL, V127, P188, DOI 10.1038/sj.bjp.0702476; FILLEY WV, 1982, LANCET, V2, P11; FUJISAWA T, 1990, J IMMUNOL, V144, P642; Fujisawa T, 2000, J ALLERGY CLIN IMMUN, V105, P126, DOI 10.1016/S0091-6749(00)90187-8; Fujisawa T, 1997, INT ARCH ALLERGY IMM, V114, P81, DOI 10.1159/000237726; Gleich Gerald J., 1996, Allergology International, V45, P35, DOI 10.2332/allergolint.45.35; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hieshima K, 1997, J IMMUNOL, V159, P1140; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; HORIE S, 1994, J IMMUNOL, V152, P5457; Horie S, 1996, J ALLERGY CLIN IMMUN, V98, P371, DOI 10.1016/S0091-6749(96)70161-6; IDE M, 1994, J IMMUNOL METHODS, V168, P187, DOI 10.1016/0022-1759(94)90054-X; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; KANEKO M, 1995, J CLIN INVEST, V95, P2813, DOI 10.1172/JCI117986; Kato M, 1998, AM J RESP CELL MOL, V18, P675, DOI 10.1165/ajrcmb.18.5.2885; KITA H, 1991, J IMMUNOL, V146, P2712; Kitayama J, 1998, J CLIN INVEST, V101, P2017, DOI 10.1172/JCI2688; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; LUKACS NW, 1995, EUR J IMMUNOL, V25, P245, DOI 10.1002/eji.1830250140; MENGELERS HJ, 1994, AM J RESP CRIT CARE, V149, P345, DOI 10.1164/ajrccm.149.2.8306028; MIYAMASU M, 1995, J IMMUNOL, V154, P1339; Nagai K, 1999, IMMUNOLOGY, V96, P176; Nagase H, 1999, ALLERGY, V54, P944, DOI 10.1034/j.1398-9995.1999.00184.x; Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; NEELEY SP, 1994, AM J RESP CELL MOL, V11, P206, DOI 10.1165/ajrcmb.11.2.8049081; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POST TW, 1995, J IMMUNOL, V155, P5299; RAMIS I, 1995, IMMUNOL LETT, V45, P219, DOI 10.1016/0165-2478(95)00018-Z; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Sabroe I, 1999, J IMMUNOL, V162, P2946; Taha RA, 1999, J ALLERGY CLIN IMMUN, V103, P476, DOI 10.1016/S0091-6749(99)70474-4; Takafuji S, 1996, ALLERGY, V51, P563; TALLEY NJ, 1992, GASTROENTEROLOGY, V103, P137, DOI 10.1016/0016-5085(92)91106-E; Ying S, 1999, J IMMUNOL, V163, P6321; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O; ZECKKAPP G, 1995, ALLERGY, V50, P34, DOI 10.1111/j.1398-9995.1995.tb02481.x	52	110	116	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					507	513						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984371				2022-12-18	WOS:000089471900014
J	Wong, JT; Nagy, CS; Krinzman, SJ; MacLean, JA; Bloch, KJ				Wong, JT; Nagy, CS; Krinzman, SJ; MacLean, JA; Bloch, KJ			Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin; acetylsalicylic acid; nonsteroidal anti-inflammatory drug; urticaria; angioedema; desensitization; coronary artery disease	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BRONCHIAL BIOPSIES; SENSITIVE PATIENTS; INDUCED ASTHMA; HYPERSENSITIVITY; PATHOGENESIS; TICLOPIDINE; SYNTHASE; IGE	Background: Acetylsalicylic acid (ASA), commonly known as aspirin, is indicated in the treatment of coronary artery disease (CAD). Many patients are denied treatment with ASA because of a history of ASA or nonsteroidal anti-inflammatory drug (NSAID)-induced urticaria or angioedema. Objective: We sought to develop a safe and practical protocol to allow the administration of ASA to patients with a history of ASA- or NSAID-induced urticaria-angioedema. Methods: Eleven subjects with a history of ASA- or NSAID-induced urticaria-angioedema were challenged-desensitized by oral protocols based on rapidly escalating doses of ASA. Most had CAD, one had a history of pulmonary embolism, and one had refractory chronic sinusitis and asthma. Starting doses ranged from 0.1 to 10 mg and were administered at intervals of 10 to 30 minutes. Dosing was individualized for each patient but followed this general sequence (in milligrams): 0.1, 0.3, 1, 3, 10, 20,40, 81, 162, 325. Results: Nine patients tolerated the procedure without adverse effects and continued taking ASA for periods ranging from 1 to 24 months, without development of urticaria or angioedema. A patient who had a history of chronic idiopathic urticaria in addition to aspirin-induced urticaria had chest tightness during the protocol. Another patient who had continuing urticaria and angioedema associated with antithyroid antibodies developed angioedema several hours after completing the protocol. Conclusion: In patients with historical ASA- or NSAID-induced urticaria-angioedema reactions but who did not have urticaria and angioedema independent of ASA/NSAID, rapid oral challenge-desensitization to ASA was performed safely and permitted patients with CAD and other diseases to receive treatment with ASA.	Massachusetts Gen Hosp, Clin Immunol Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Allergy Unit, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Wong, JT (corresponding author), Massachusetts Gen Hosp, Clin Immunol Unit, Bulfinch 422, Boston, MA 02114 USA.							ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; ASAD SI, 1984, BRIT MED J, V288, P745, DOI 10.1136/bmj.288.6419.745; BLANCA M, 1989, ANN ALLERGY, V62, P295; CAIRNS JA, 1998, CHEST, V114; Chassany O, 1999, PRESSE MED, V28, P18; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; GRZELEWSKARZYMOWSKA I, 1988, ALLERGOL IMMUNOPATH, V16, P305; JUERGENS UR, 1992, J ALLERGY CLIN IMMUN, V90, P636, DOI 10.1016/0091-6749(92)90137-Q; Kawai S, 1998, EUR J PHARMACOL, V347, P87, DOI 10.1016/S0014-2999(98)00078-8; LEE TH, 1993, AM REV RESPIR DIS, V148, P1442, DOI 10.1164/ajrccm/148.6_Pt_1.1442; MCEVOY GK, 1999, AHFS DRUG INFORMATIO; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; SMITH WL, 1994, ANN NY ACAD SCI, V744, P50, DOI 10.1111/j.1749-6632.1994.tb52723.x; STEVENSON DD, 1993, ANN ALLERGY, V71, P417; STEVENSON DD, 1998, ALLERGY PRINCIPLES P, P1225; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; Vane J. R., 1998, AM J MED, V104, p2S, DOI [DOI 10.1016/S0002-9343(97)00203-9, 10.1016/S0002-9343(97)00203-9]; VERSTRAETE M, 1994, BRIT MED BULL, V50, P946, DOI 10.1093/oxfordjournals.bmb.a072936; WONG JT, 1994, J ALLERGY CLIN IMMUN, V94, P189, DOI 10.1016/0091-6749(94)90039-6; Wu KKY, 1998, BIOCHEM PHARMACOL, V55, P543; Yosipovitch G, 1999, J AM ACAD DERMATOL, V41, P473, DOI 10.1016/S0190-9622(99)70124-6; ZHU DX, 1992, ASIAN PAC J ALLERGY, V10, P25	24	110	113	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					997	1001		10.1067/mai.2000.104571	http://dx.doi.org/10.1067/mai.2000.104571			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808182	Bronze			2022-12-18	WOS:000087185000020
J	Fujisawa, T; Kato, Y; Atsuta, J; Terada, A; Iguchi, K; Kamiya, H; Yamada, H; Nakajima, T; Miyamasu, M; Hirai, K				Fujisawa, T; Kato, Y; Atsuta, J; Terada, A; Iguchi, K; Kamiya, H; Yamada, H; Nakajima, T; Miyamasu, M; Hirai, K			Chemokine production by the BEAS-2B human bronchial epithelial cells: Differential regulation of eotaxin, IL-8, and RANTES by T(H)2-and T(H)1-derived cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemokines; bronchial epithelial cells; eotaxin; RANTES; IFN-gamma; IL-4; IL-13; IL-8	BRONCHOALVEOLAR LAVAGE; HUMAN EOSINOPHILS; EXPRESSION; ASTHMA; INFLAMMATION; GLUCOCORTICOIDS; TRANSMIGRATION; INDIVIDUALS; RECRUITMENT; ENDOTHELIUM	Background: Bronchial epithelial cells produce many types of chemokines and may contribute to lung inflammation by recruiting inflammatory cells. The CC chemokine eotaxin is a potent, eosinophil-specific chemoattractant that has been detected in the bronchial epithelium of patients with asthma. Objectives: The aim of this study was to investigate the regulatory mechanisms of chemokine production from bronchial epithelium by inflammatory cytokines, especially T(H)2- and T(H)1-derived cytokines, in bronchial asthma. Methods: BEAS-2B human bronchial epithelial cells were cultured with TNF-alpha, IL-4, IL-13, and IFN-gamma alone or in combination, after which supernatants were assayed for eotaxin, IL-8, and RANTES proteins with ELISA. Reverse transcription-PCR was also performed. Results: TNF-alpha induced production of eotaxin, IL-8, and RANTES in a concentration-dependent manner Both IL-4 and IL-13 synergistically enhanced TNF-alpha-induced eotaxin production, whereas IL-8 plarluction induced by TNF-alpha was significantly down-regulated by the Tea-derived cytokines. IFN-gamma, a T(H)1 cytokine, counteracted the enhancing effects of IL-4 and IL-13 on eotaxin production. RANTES production by TNF-alpha was not affected by IL-4 and IL-13 but was markedly enhanced by IFN-gamma. Conclusions:These results suggest that T(H)2 cytokines are involved in preferential recruitment of eosinophils in bronchial asthma by enhancing eotaxin and reducing IL-8 production from bronchial epithelial cells and that T(H)1 cytokines counteract the effects of T(H)2 cytokines by reducing eotaxin production.	Mie Natl Hosp, Dept Pediat, Tsu, Mie 5140125, Japan; Mie Univ, Sch Med, Dept Psychiat, Tsu, Mie 514, Japan; Univ Tokyo, Sch Med, Dept Allergy & Rheumatol, Tokyo 113, Japan; Univ Tokyo, Sch Med, Dept Bioregulatory Funct, Tokyo 113, Japan	Mie University; University of Tokyo; University of Tokyo	Fujisawa, T (corresponding author), Mie Natl Hosp, Dept Pediat & Allergy, 357 Osato Kubota, Tsu, Mie 5140125, Japan.							Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; Becker S, 1997, AM J PHYSIOL-LUNG C, V272, pL512, DOI 10.1152/ajplung.1997.272.3.L512; de Vries J E, 1993, Semin Immunol, V5, P431, DOI 10.1006/smim.1993.1049; DUBOIS GR, 1994, J INVEST DERMATOL, V102, P843, DOI 10.1111/1523-1747.ep12382362; HOGG JC, 1991, AM REV RESPIR DIS, V143, pS39, DOI 10.1164/ajrccm/143.3_Pt_2.S39; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; Ishii Y, 1998, AM J PHYSIOL-LUNG C, V274, pL171, DOI 10.1152/ajplung.1998.274.1.L171; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; LEVINE SJ, 1993, AM J PHYSIOL, V265, pL360, DOI 10.1152/ajplung.1993.265.4.L360; Li D, 1997, EUR RESPIR J, V10, P1946, DOI 10.1183/09031936.97.10091946; Li L, 1998, J IMMUNOL, V161, P3128; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526, DOI 10.1165/ajrcmb.10.5.8179915; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MacLean JA, 1996, J EXP MED, V184, P1461, DOI 10.1084/jem.184.4.1461; Mattoli S, 1997, BIOCHEM BIOPH RES CO, V236, P299, DOI 10.1006/bbrc.1997.6958; Miyamasu M, 1999, INT IMMUNOL, V11, P1001, DOI 10.1093/intimm/11.6.1001; Mochizuki M, 1998, J IMMUNOL, V160, P60; MOSER R, 1992, J IMMUNOL, V149, P1432; MOSER R, 1993, J LAB CLIN MED, V122, P567; Nakajima T, 1998, FEBS LETT, V434, P226, DOI 10.1016/S0014-5793(98)00863-1; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Shute JK, 1997, AM J RESP CRIT CARE, V155, P1877, DOI 10.1164/ajrccm.155.6.9196089; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; STELLATO C, 1995, J IMMUNOL, V155, P410; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; Teran LM, 1999, AM J RESP CELL MOL, V20, P777, DOI 10.1165/ajrcmb.20.4.3508; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; WANG JH, 1994, J ALLERGY CLIN IMMUN, V94, P1025, DOI 10.1016/0091-6749(94)90121-X; Yamada H, 1997, BIOCHEM BIOPH RES CO, V231, P365, DOI 10.1006/bbrc.1997.6100; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	34	110	112	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				126	133		10.1016/S0091-6749(00)90187-8	http://dx.doi.org/10.1016/S0091-6749(00)90187-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629462				2022-12-18	WOS:000084992100017
J	Hoshino, H; Laan, M; Sjostrand, M; Lotvall, J; Skoogh, BE; Linden, A				Hoshino, H; Laan, M; Sjostrand, M; Lotvall, J; Skoogh, BE; Linden, A			Increased elastase and myeloperoxidase activity associated with neutrophil recruitment by IL-17 in airways in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway inflammation; IL-17; neutrophil activation	NECROSIS-FACTOR-ALPHA; HOST-DEFENSE; CYTOKINES; RELEASE; CELLS; DEGRANULATION; INFLAMMATION; MACROPHAGES; EXPRESSION; RECEPTOR	Background: A recent study demonstrated that intratracheal administration of the T-lymphocyte cytokine IL-17 recruits neutrophils into airways in vivo by C-X-C chemokine release, It is not known whether IL-17 may also activate airway neutrophils. Objective: Our purpose was to evaluate whether IL-17 activates neutrophils in airways in vivo and, if so, whether the proinflammatory cytokine IL-I beta modulates this action of IL-17. Methods: Intratracheal administration of human (h) IL-17 or rat (r) IL-1 beta or hIL-17 plus rIL-1 beta in anesthetized, spontaneously breathing rats was followed by bronchoalveolar lavage (BAL)6 hours later. The BAL fluid was characterized in terms of neutrophil count, of the activity for myeloperoxidase (MPO), and in some cases of the activity for elastase (ELA). Isolated rat neutrophils were stimulated with hIL-17 in vitro, followed by characterization of MPO activity in the cell medium. Results: hIL-17 (1 mu g) increased the ELA and the MPO activity,as well as the neutrophil count in BAL fluid, whereas the proinflammatory cytokine rIL-1 beta (2.5 ng) did not. Pretreatment with rIL-1 beta enhanced IL-17induced ELA and MPO activity, without increasing the neutrophil count. The BAL ELA activity was inhibited by a specific inhibitor of neutrophil serine proteases. Stimulation with hIL-17 in vitro did not increase MPO activity in isolated neutrophils. Conclusion: IL-17 can activate neutrophils in association with their recruitment into the airways in vivo and this effect is probably achieved through induced release of mediators from other airway cells.	Gothenburg Univ, Dept Resp Med & Allergol, Lung Pharmacol Grp, S-41346 Gothenburg, Sweden	University of Gothenburg	Linden, A (corresponding author), Gothenburg Univ, Dept Resp Med & Allergol, Lung Pharmacol Grp, Guldhedsgatan 10A, S-41346 Gothenburg, Sweden.		Laan, Martti/J-5031-2014	Laan, Martti/0000-0002-0448-8627; Linden, Anders/0000-0003-1258-2928; Lotvall, Jan/0000-0001-9195-9249				Albanesi C, 1999, J IMMUNOL, V162, P494; BEDARD M, 1993, AM J RESP CELL MOL, V9, P455, DOI 10.1165/ajrcmb/9.4.455; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; BIETH J, 1974, BIOCHEM MED METAB B, V11, P350, DOI 10.1016/0006-2944(74)90134-3; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; BRANDT E, 1992, J IMMUNOL, V149, P1356; COHEN AB, 1983, AM REV RESPIR DIS, V127, pS3; DULARAY B, 1990, J LEUKOCYTE BIOL, V47, P158, DOI 10.1002/jlb.47.2.158; FERRANTE A, 1988, INT ARCH ALLER A IMM, V86, P82, DOI 10.1159/000234610; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kennedy J, 1996, J INTERF CYTOK RES, V16, P611, DOI 10.1089/jir.1996.16.611; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; Laan M, 1999, J IMMUNOL, V162, P2347; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394, DOI 10.1164/ajrccm.157.2.97-02099; LAURA B, 1996, J LEUKOCYTE BIOL, V59, P427; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MCELVANEY NG, 1997, LUNG, P205; Megyeri P, 1995, IMMUNOLOGY, V86, P629; Molet S, 1999, J ALLERGY CLIN IMMUN, V103, pS107; Ogilvie AC, 1996, J IMMUNOL, V156, P389; REMOLDODONNELL E, 1995, BLOOD, V85, P337; RICHMANEISENSTAT JBY, 1993, AM J PHYSIOL, V264, pL413, DOI 10.1152/ajplung.1993.264.4.L413; SCHUSTER A, 1992, AM J PHYSIOL, V262, pL86, DOI 10.1152/ajplung.1992.262.1.L86; SENIOR RM, 1989, AM REV RESPIR DIS, V139, P1251, DOI 10.1164/ajrccm/139.5.1251; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P505, DOI 10.1164/ajrccm.157.2.9703070; VONESSEN SG, 1995, CHEST, V108, P1425, DOI 10.1378/chest.108.5.1425; WEWERS MD, 1988, J CLIN INVEST, V82, P1260, DOI 10.1172/JCI113724; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; YOO ZB, 1995, J IMMUNOL, V155, P5483	32	110	121	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				143	149		10.1016/S0091-6749(00)90189-1	http://dx.doi.org/10.1016/S0091-6749(00)90189-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629464				2022-12-18	WOS:000084992100019
J	Daffern, PJ; Muilenburg, D; Hugli, TE; Stevenson, DD				Daffern, PJ; Muilenburg, D; Hugli, TE; Stevenson, DD			Association of urinary leukotriene E-4 excretion during aspirin challenges with severity of respiratory responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin-sensitive asthma; aspirin challenge; peptidoleukotrienes; LTE4	SENSITIVE RHINOSINUSITIS-ASTHMA; AIRWAY RESPONSIVENESS; C-4 SYNTHASE; HISTAMINE; DESENSITIZATION; RELEASE; PROSTAGLANDINS	Background: Asthmatics with aspirin- (ASA) sensitive respiratory disease (ASRD) have a spectrum of respiratory reactions during oral ASA challenge that vary in severity and are temporally associated with leukotriene (LT) formation. Objective: This study investigates the relationship of the severity of ASA-induced respiratory reactions to urinary LTE4 excretion. Methods: Asthmatics with suspected ASRD underwent oral ASA challenges. Urinary LTE4 levels were measured at baseline, during the reaction, and after acute ASA desensitization. Results: Asthmatics who had respiratory reactions during oral ASA challenges were divided into 3 groups: asthmatics with naso-ocular reactions and <15% decline from baseline FEV1 values (group 1), asthmatics with a decline in FEV1 of 20% to 30% (group 2), and asthmatics with a decline in FEV1 of >30% (group 3), There were no significant differences in age, baseline FEV1 values, use of inhaled corticosteroids, daily prednisone doses, prednisone bursts, duration of reactions, or average provoking doses of ASA among the groups. At baseline group 3 asthmatics had significantly higher urinary LTE4 levels than those in groups 1 or 2, At the time of respiratory reaction to ASA, the urinary LTE4 levels rose significantly in ail groups but were significantly greater among group 3 asthmatics compared with those in groups 1 and 2, Conclusion: The severity of the respiratory reactions during oral ASA challenges was associated with the degree of elevation of baseline LTE4 synthesis, Our results suggest that asthmatics with ASRD have a spectrum of respiratory tract reactions in which leukotrienes play a distinguishing role.	Scripps Clin, Div Allergy Asthma & Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Stevenson, DD (corresponding author), Scripps Clinic, Div Allergy Asthma & Immunol, 10666 N Torrey Pines Rd,205-W, La Jolla, CA 92037 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010992] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIAID NIH HHS [K08 AI01394-01] Funding Source: Medline; NIDCR NIH HHS [1-RO1-DE10992] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARM JP, 1990, AM REV RESPIR DIS, V142, P1112, DOI 10.1164/ajrccm/142.5.1112; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; GRAVELYN TR, 1988, AM REV RESPIR DIS, V137, P641, DOI 10.1164/ajrccm/137.3.641; KITA H, 1991, J IMMUNOL, V147, P3466; KNAPP HR, 1992, J LAB CLIN MED, V119, P48; KUEHL FA, 1984, BIOCHEM PHARMACOL, V33, P1, DOI 10.1016/0006-2952(84)90362-9; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; LEE TH, 1993, AM REV RESPIR DIS, V148, P1442, DOI 10.1164/ajrccm/148.6_Pt_1.1442; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; MANNING PJ, 1990, J ALLERGY CLIN IMMUN, V86, P211, DOI 10.1016/S0091-6749(05)80068-5; NASSER SMS, 1995, AM J RESP CRIT CARE, V151, P1326, DOI 10.1164/ajrccm.151.5.7735581; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; STEVENSON DD, 1998, ALLERGY PRINCIPLES P, P1225; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; TAUBER AI, 1973, J IMMUNOL, V111, P27; Tenor H, 1996, BRIT J PHARMACOL, V118, P1727, DOI 10.1111/j.1476-5381.1996.tb15598.x	28	110	112	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				559	564		10.1016/S0091-6749(99)70324-6	http://dx.doi.org/10.1016/S0091-6749(99)70324-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482828				2022-12-18	WOS:000082870000016
J	Romano, A; Quaratino, D; Di Fonso, M; Papa, G; Venuti, A; Gasbarrini, G				Romano, A; Quaratino, D; Di Fonso, M; Papa, G; Venuti, A; Gasbarrini, G			A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ampicillin; amoxicillin; delayed hypersensitivity; maculopapular rash; intradermal test; nonimmediate reactions; patch test	BETA-LACTAM ANTIBIOTICS; IMMEDIATE HYPERSENSITIVITY REACTIONS; PENICILLIN ALLERGY; CUTANEOUS REACTIONS; AMOXICILLIN; AMPICILLIN; RASHES	Background: Maculopapular and urticarial rashes are nonimmediate manifestations common during aminopenicillin (AP) treatment, and the former often represent cell-mediated hypersensitivity. Objectives: We sought to determine the significance and incidence of skin test reactions to APs in adults reporting adverse reactions during therapy with these beta-lactams and, particularly, to evaluate the potential of patch tests, delayed-reading skin tests, and challenges in the diagnosis of nonimmediate reactions. Methods: We used skin tests with penicilloylpolylysine, minor determinant mixture, benzylpenicillin, ampicillin, and amoxicillin, as well as patch tests with the last 3 drugs, We also performed in vitro assays for specific IgE and challenges with the suspect penicillin in subjects with nonimmediate reactions. Results: Among the 144 patients reporting nonimmediate manifestations (mostly maculopapular rashes), delayed hypersensitivity was diagnosed in 62 on the basis of positive patch test and/or delayed intradermal test results and responses to challenges; negative reactions to challenges allowed us to reasonably exclude the possibility of allergy in 66 subjects, and the challenge confirmed that 1 patient had linear IgA bullous dermatosis. Definitive diagnoses could not be provided for the remaining 15 subjects, who had negative allergologic test results, because they did not consent to challenges. In 40 of 49 immediate reactors, a diagnosis of IgE-mediated hypersensitivity was made. Conclusions: Both patch and intradermal tests are useful in evaluating nonimmediate reactions to APs. Positive patch test and delayed intradermal responses together indicate delayed hypersensitivity. Intradermal testing appears to be more sensitive than patch testing, but the pattern of positive delayed intradermal test responses and negative patch test responses needs further investigation because of false-positive cases.	CI Columbus, UCSC Allergy Unit, Dept Internal Med & Geriatr, Rome, Italy; IRCCS Oasi Maria SS, Troina, Italy	IRCCS Oasi Maria SS	Romano, A (corresponding author), Complesso Integrato Columbus, Unita Allergol, Via G Moscati 31, I-00168 Rome, Italy.		Romano, Antonino/D-3102-2017	Romano, Antonino/0000-0001-9742-9898				AIHARA M, 1987, Journal of Dermatology (Tokyo), V14, P440; Barbaud AM, 1997, ARCH DERMATOL, V133, P481, DOI 10.1001/archderm.133.4.481; BIERMAN CW, 1972, J AMER MED ASSOC, V220, P1098, DOI 10.1001/jama.220.8.1098; BRAVERMAN LM, 1998, SKIN SIGNS SYSTEMIC; Castro SM, 1996, PEDIATR ASTHMA ALLER, V10, P197, DOI 10.1089/pai.1996.10.197; CHANDRA RK, 1980, ARCH DIS CHILD, V55, P857, DOI 10.1136/adc.55.11.857; CHERRY JD, 1987, TXB PEDIAT INFECT DI, P786; DEHAAN P, 1986, ALLERGY, V41, P75; FINKE SR, 1965, AM J MED, V38, P71, DOI 10.1016/0002-9343(65)90161-0; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; HAVERKOS HW, 1991, REV INFECT DIS, V13, P697; HERTL M, 1993, J INVEST DERMATOL, V101, P794, DOI 10.1111/1523-1747.ep12371697; HERTL M, 1993, BRIT J DERMATOL, V128, P619, DOI 10.1111/j.1365-2133.1993.tb00255.x; KUECHLE MK, 1994, J AM ACAD DERMATOL, V30, P187, DOI 10.1016/S0190-9622(94)70015-X; LEVINE BB, 1966, NEW ENGL J MED, V275, P1115, DOI 10.1056/NEJM196611172752009; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; Romano A, 1997, ARCH DIS CHILD, V76, P513, DOI 10.1136/adc.76.6.513; ROMANO A, 1995, ALLERGY, V50, P113; Romano A, 1998, ANN ALLERG ASTHMA IM, V80, P433, DOI 10.1016/S1081-1206(10)62997-3; Romano A, 1996, ALLERGY, V51, P269; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; TERRADOS S, 1995, ALLERGY, V50, P563, DOI 10.1111/j.1398-9995.1995.tb01200.x; VEGA JM, 1991, ALLERGY, V46, P154, DOI 10.1111/j.1398-9995.1991.tb00560.x; VOORHORST R, 1980, ANN ALLERGY, V45, P100; WARRINGTON RJ, 1993, J ALLERGY CLIN IMMUN, V92, P626, DOI 10.1016/0091-6749(93)90088-W; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x; WILKINSON DS, 1970, ACTA DERM-VENEREOL, V50, P287	28	110	113	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1186	1190		10.1016/S0091-6749(99)70197-1	http://dx.doi.org/10.1016/S0091-6749(99)70197-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359904				2022-12-18	WOS:000080929500031
J	Fritsch, R; Bohle, B; Vollmann, U; Wiedermann, U; Jahn-Schmid, B; Krebitz, M; Breiteneder, H; Kraft, D; Ebner, C				Fritsch, R; Bohle, B; Vollmann, U; Wiedermann, U; Jahn-Schmid, B; Krebitz, M; Breiteneder, H; Kraft, D; Ebner, C			Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oral allergy syndrome; birch pollen; apple; Bet v 1; Mal d 1; IgE; T helper lymphocyte	IMMUNOLOGICAL RELATIONSHIP; ATOPIC PATIENTS; GRASS-POLLEN; BET-V-1; IGE; SENSITIVITY; RESPONSES; EPITOPES; CLONES; IDENTIFICATION	Background: Food allergy to apple is frequent in individuals allergic to tree pollen. The major allergens of birch, Bet v 1, and apple, Mal d 1, have been cloned and sequenced and display a high degree of sequence identity, Leading to IgE crossreactivity. Objective: We sought to investigate cross-reactivity between Bet v 1 and Mal d 1 at the level of allergen-specific T lymphocytes. Methods: PBMCs of 13 patients allergic to birch pollen with oral allergy syndrome to apple were stimulated with rBet v 1 and rMal d 1, respectively, thereby establishing allergen-specific T-cell lines and T-cell clones. rMal d 1-specific T-cell cultures were tested for reactivity with rBet v 1, and rBet v 1-specific T cells were analyzed for reactivity with apple allergen. Cytokine production patterns in response to specific stimulation were evaluated. A selection of cross-reacting T-cell clones was mapped for epitope specificity by the use of overlapping Bet v 1- derived peptides. Results: Nineteen Mal d 1-specific T-cell clones were produced, 79% of which cross-reacted with Bet v 1. Eight of 18 Bet v I-specific T-cell clones cross-reacted with Mal d 1. Six peptides representing cross-reactive T-cell epitopes could be identified. The respective fragments from birch and apple displayed approximately 50% amino acid identity. Seventy percent of the cross-reactive T-cell clones revealed a T-H2-like cytokine production pattern. Conclusion: The results indicate that cross-reactivity between apple and birch pollen Leading to the clinical oral allergy syndrome occurs not only at the serologic, but also at the cellular level.	Univ Vienna, Inst Gen & Expt Pathol, Dept Immunopathol, A-1090 Vienna, Austria	University of Vienna	Ebner, C (corresponding author), Univ Vienna, Inst Gen & Expt Pathol, Dept Immunopathol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Fritsch-sTork, Ruth/G-9702-2012	Bohle, Barbara/0000-0002-5105-7985; Fritsch-Stork, ruth/0000-0003-0217-3629; Wiedermann, Ursula/0000-0002-1302-3223				AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; ANDERSEN KE, 1978, CONTACT DERMATITIS, V4, P73, DOI 10.1111/j.1600-0536.1978.tb03739.x; ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; Bohle B, 1998, J IMMUNOL, V160, P2022; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Breiteneder H, 1996, MOL IMMUNOL, V33, P1039, DOI 10.1016/S0161-5890(96)00064-8; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; deJong EC, 1996, J ALLERGY CLIN IMMUN, V98, P73, DOI 10.1016/S0091-6749(96)70228-2; DEMARTINO M, 1988, ALLERGY, V43, P206; DREBORG S, 1983, ALLERGY, V38, P577; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Eigenmann PA, 1996, PEDIATR ALLERGY IMMU, V7, P12, DOI 10.1111/j.1399-3038.1996.tb00100.x; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; HANNUKSELA M, 1977, CONTACT DERMATITIS, V3, P79, DOI 10.1111/j.1600-0536.1977.tb03603.x; HIGGINS JA, 1995, IMMUNOLOGY, V84, P91; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; Reekers R, 1996, BRIT J DERMATOL, V135, P935, DOI 10.1046/j.1365-2133.1996.d01-1098.x; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; Szepfalusi Z, 1998, J ALLERGY CLIN IMMUN, V101, P514, DOI 10.1016/S0091-6749(98)70359-8; Tuft Louis, 1942, JOUR ALLERGY, V13, P574, DOI 10.1016/S0021-8707(42)90070-4; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; VIEHTS S, 1994, INT ARCH ALLERGY IMM, V104, P399; VIEHTS S, 1994, ALLERGY, V49, P262; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WUTHRICH B, 1983, ALLERGY, V38, P163	42	110	115	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				679	686		10.1016/S0091-6749(98)70287-8	http://dx.doi.org/10.1016/S0091-6749(98)70287-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802379	Bronze			2022-12-18	WOS:000076600400021
J	Umland, SP; Nahrebne, DK; Razac, S; Beavis, A; Pennline, KJ; Egan, RW; Billah, MM				Umland, SP; Nahrebne, DK; Razac, S; Beavis, A; Pennline, KJ; Egan, RW; Billah, MM			The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoid; cytokine; IL-4; IL-5; interferon-gamma; naive T cell; memory T cell	LYMPHOKINE GENE-EXPRESSION; MESSENGER-RNA EXPRESSION; BRONCHOALVEOLAR LAVAGE; CYTOKINE PRODUCTION; ATOPIC ASTHMA; ACTIVATION; INTERLEUKIN-5; EOSINOPHILS; ANTIGEN; SECRETION	This study was conducted to directly compare the in vitro efficacy and potency of several glucocorticoids in inhibiting T-cell cytokine production. The glucocorticoids tested were fluticasone propionate, budesonide, triamcinolone acetonide, and beclomethasone dipropionate, which are currently inhaled therapies for the treatment of allergic airway disease. Also used were betamethasone phosphate and the newly developed mometasone furorate. With a novel cell culture system, purified peripheral blood CD4(+) T cells from normal donors were stimulated with immobilized anti-CD3 and soluble anti-CD28 monoclonal antibodies to induce high levels of IL-4, IL-5, and interferon-gamma. By cell sorting, it was found that the IL-5 produced originated from memory cells, whereas both memory and naive cells produced interferon-gamma. Mometasone and fluticasone inhibited IL-5 and IL-4 similarly (mometasone IL-5 inhibitory concentration of 50% = 0.27 +/- 0.1 nmol/L and IL-4 = 0.19 +/- 0.08 nmol/L). For both cytokines, the results indicate that mometasone and fluticasone were more potent than beclomethasone, triamcinolone, budesonide, and betamethasone. Of clinical importance is the finding that all steroids demonstrated less efficacy versus interferon-gamma than IL-4 and IL-5. Glucocorticoid reduction of Th2 cytokines with lesser effects on interferon-gamma would serve to reverse the exaggerated Th2 response that contributes to pathophysiology observed in allergic disease. Therefore the use of topically active glucocorticoids with low systemic bioactivity for the treatment of allergic inflammation may be particularly effective in modulating the cytokine activity that is an important component of the allergic response.			Umland, SP (corresponding author), SCHERING PLOUGH CORP,RES INST,2015 GALLOPING HILL RD,K15-1-1700,KENILWORTH,NJ 07033, USA.							ADCOCK IM, 1996, AM J RESP CRIT CARE, V154, pS58; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BARNES PJ, 1996, AM J RESP CRIT CARE, V154, pS21; BARNES PJ, 1993, AM REV RESPIR DIS, V148, P1; BETTENS F, 1989, EUR J IMMUNOL, V19, P1569, DOI 10.1002/eji.1830190908; BOOTH H, 1995, AM J RESP CRIT CARE, V152, P45, DOI 10.1164/ajrccm.152.1.7599861; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900, DOI 10.1164/ajrccm.151.6.7767538; BRADDING P, 1993, J IMMUNOL, V151, P3853; Brannan M. D., 1996, Journal of Allergy and Clinical Immunology, V97, P198, DOI 10.1016/S0091-6749(96)80280-6; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; COFFMAN RL, 1986, J IMMUNOL, V136, P949; Conover WJ, 1980, PRACTICAL NONPARAMET; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; COYLE AJ, 1996, AM J RESP CRIT CARE, V153, pA768; DEMEURE CE, 1994, J IMMUNOL, V152, P4775; DUBUCQUOI S, 1994, J EXP MED, V179, P703, DOI 10.1084/jem.179.2.703; GARLISI CG, 1995, CLIN IMMUNOL IMMUNOP, V75, P75, DOI 10.1006/clin.1995.1055; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KeaneMyers A, 1997, J IMMUNOL, V158, P2042; KING CL, 1995, EUR J IMMUNOL, V25, P587, DOI 10.1002/eji.1830250242; KRISTENSSON K, 1992, IMMUNOLOGY, V76, P103; Krouwels FH, 1996, AM J RESP CELL MOL, V14, P388, DOI 10.1165/ajrcmb.14.4.8600944; KUIPER H, 1994, EUR J IMMUNOL, V24, P1956, DOI 10.1002/eji.1830240903; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MARINI M, 1992, CHEST, V102, P661, DOI 10.1378/chest.102.3.661; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NIJHUIS EWP, 1995, INT IMMUNOL, V7, P591, DOI 10.1093/intimm/7.4.591; NONAKA M, 1995, J IMMUNOL, V155, P3234; Popper T. L., 1974, Antiinflammatory agents,, P245; ROBINSON AT, 1993, EUR J IMMUNOL, V23, P61, DOI 10.1002/eji.1830230111; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SCHLEIMER RP, 1993, ALLERGY PRINCIPLES P, P893; SCHLEIMER RP, 1996, TOPICAL GLUCOCORTICO	37	110	113	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					511	519		10.1016/S0091-6749(97)70144-1	http://dx.doi.org/10.1016/S0091-6749(97)70144-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338546				2022-12-18	WOS:A1997YA52900015
J	SORVA, R; MAKINENKILJUNEN, S; JUNTUNENBACKMAN, K				SORVA, R; MAKINENKILJUNEN, S; JUNTUNENBACKMAN, K			BETA-LACTOGLOBULIN SECRETION IN HUMAN-MILK VARIES WIDELY AFTER COWS MILK INGESTION IN MOTHERS OF INFANTS WITH COWS MILK ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BETA-LACTOGLOBULIN; HUMAN MILK; BREAST FEEDING; COWS MILK ALLERGY; INFANTS; INTESTINAL ABSORPTION; POLYETHYLENE GLYCOL	BREAST-FED INFANTS; INTESTINAL PERMEABILITY; FOOD ALLERGY; PASSAGE; ECZEMA; PROTEIN	Background: Cow's milk proteins secreted in human milk may cause cow's milk allergy (CMA) even during exclusive breast-feeding. We studied beta-lactoglobulin levels in human milk of mothers of infants with CMA. We also studied intestinal absorption of macromolecules in the same mothers to see whether it is related to the secretion of beta-lactoglobulin in human milk. Methods: CMA was verified with oral challenge in 46 of 55 infants assessed. beta-lactoglobulin levels were assessed in human milk from 53 of 55 mothers of the infants before (basal sample) and 1 and 2 hours after an oral cow's milk load, which was given after a 24-hour milk-free diet. beta-Lactoglobulin was determined by an ELISA with a detection limit of 0.002 mu g/L. The 6-hour urine recovery of a high-molecular-weight polyethylene glycol (PEG) 3000 was assessed afer an oral load of PEG in 45 of 55 mothers. Results: beta-Lactoglobulin was found in the 1- or 2-hour samples in 75% of the mothers. beta-Lactoglobulin levels were increased in the 1- or 2-hour samples as compared with the basal levels in about half of the mothers. The respective levels were decreased in one third of the mothers whose basal beta-Lactoglobulin levels were higher than in the others. beta-Lactoglobulin was found in none of the three human milk samples in 15% of the mothers. After an oral load of a high-molecular-weight PEG 3000, the 6-hour urine recovery of PEG was similar in the mothers of the infants with CMA and the mothers of infants without CMA. Neither was the urinary recovery of PEG related to the beta-lactoglobulin levels in human milk. Conclusions: The results support the view that beta-lactoglobulin in human milk may contribute to, but does not alone explain, the development of CMA in breast-fed infants.			SORVA, R (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT ALLERG DIS,MEILAHDENTIE 2,SF-00250 HELSINKI,FINLAND.							AXELSSON I, 1986, ACTA PAEDIATR SCAND, V75, P702, DOI 10.1111/j.1651-2227.1986.tb10277.x; BJARNASON I, 1984, LANCET, V2, P1171; BJARNASON I, 1985, BRIT J DERMATOL, V112, P291, DOI 10.1111/j.1365-2133.1985.tb04856.x; BLEUMINK E, 1968, INT ARCH ALLER A IMM, V34, P521, DOI 10.1159/000230147; CANT A, 1985, BRIT MED J, V291, P932, DOI 10.1136/bmj.291.6500.932; CASIMIR GJA, 1989, ANN ALLERGY, V63, P517; FALTHMAGNUSSON K, 1984, CLIN ALLERGY, V14, P277, DOI 10.1111/j.1365-2222.1984.tb02207.x; GLESING B, 1986, ANN ALLERGY, V53, P602; Haahtela T., 1993, ALLERGY, V48, P76; HOST A, 1990, CLIN EXP ALLERGY, V20, P383, DOI 10.1111/j.1365-2222.1990.tb02798.x; JACKSON PG, 1981, LANCET, V1, P1285; JACOBSSON I, 1985, ACTA PAEDIATR SCAND, V74, P342; KILSHAW PJ, 1984, INT ARCH ALLER A IMM, V75, P8, DOI 10.1159/000233582; MACHTINGER S, 1986, J ALLERGY CLIN IMMUN, V77, P341, DOI 10.1016/S0091-6749(86)80115-4; MAKINENKILJUNEN S, 1992, ALLERGY, V47, P347, DOI 10.1111/j.1398-9995.1992.tb02070.x; PAGANELLI R, 1991, ANN ALLERGY, V66, P181; RASANEN L, 1992, CLIN EXP ALLERGY, V22, P385, DOI 10.1111/j.1365-2222.1992.tb03100.x; STUART CA, 1984, CLIN ALLERGY, V14, P533, DOI 10.1111/j.1365-2222.1984.tb02240.x; TRONCONE R, 1987, ACTA PAEDIATR SCAND, V76, P453, DOI 10.1111/j.1651-2227.1987.tb10498.x; WARNER JO, 1980, CLIN ALLERGY, V10, P133, DOI 10.1111/j.1365-2222.1980.tb02090.x	20	110	114	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					787	792		10.1016/0091-6749(94)90259-3	http://dx.doi.org/10.1016/0091-6749(94)90259-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	8163788				2022-12-18	WOS:A1994NH49700012
J	WARRINGA, RAJ; MENGELERS, HJJ; RAAIJMAKERS, JAM; BRUIJNZEEL, PLB; KOENDERMAN, L				WARRINGA, RAJ; MENGELERS, HJJ; RAAIJMAKERS, JAM; BRUIJNZEEL, PLB; KOENDERMAN, L			UP-REGULATION OF FORMYL-PEPTIDE AND INTERLEUKIN-8-INDUCED EOSINOPHIL CHEMOTAXIS IN PATIENTS WITH ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; ALLERGEN PROVOCATION; CHEMOTAXIS; HUMAN EOSINOPHILS	COLONY-STIMULATING FACTOR; PLATELET-ACTIVATING FACTOR; ADHESION MOLECULE-1; BRONCHIAL BIOPSIES; ENDOTHELIAL-CELLS; HUMAN NEUTROPHIL; MESSENGER-RNA; EXPRESSION; SURVIVAL; IL-5	Background: The cytokine granulocyte-macrophage colony-stimulating factors, interleukin-3 and interleukin-5, are important modulators of eosinophilia and eosinophil function. In particular, eosinophil chemotaxis is very sensitive to cytokine priming. Methods: We evaluated chemotactic responses of eosinophils from Patients with allergic asthma. These cells exhibited a primed phenotype as deduced from enhanced responses toward formyl-methionyl-leucyl-phenylalanine and platelet-activating factor and a decreased responsiveness toward granulocyte-macrophage colony-stimulating factor. Bronchoprovocation of patients with allergic asthma with allergen was performed as a possible means to enhance in vivo priming. Results: Indeed, eosinophils isolated 3 hours after allergen challenge exhibited a more pronounced primed phenotype, which was reflected by an induction of responsiveness towards interleukin-& Eosinophil responses induced by platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, complement fragment C5a, interleukin-3, interleukin-5, and granulocyte-macrophage colony-stimulating factor were not significantly altered after allergen challenge. Conclusion: These data provide further evidence that eosinophils are already primed in the peripheral blood of individuals with allergic asthma. This is most likely due to the presence of circulating cytokines in the peripheral blood of those individuals. This in vivo priming results in selective upregulation and downregulation of responses toward various chemotaxins, which may be released in the lungs during allergic inflammation.	UNIV HOSP UTRECHT,DEPT PULM DIS,POB 85500,3500 GA UTRECHT,NETHERLANDS; CENT MIL HOSP UTRECHT,UTRECHT,NETHERLANDS; NETHERLANDS ORG APPL SCI RES,MED BIOL LAB,RIJSWIJK,NETHERLANDS	Utrecht University; Utrecht University Medical Center; Netherlands Organization Applied Science Research			Koenderman, Leo/AAE-7870-2020	Koenderman, Leo/0000-0002-5636-6453				AALBERS R, 1991, AM REV RESPIR DIS, V144, P352, DOI 10.1164/ajrccm/144.2.352; ALTMAN LC, 1981, J CLIN INVEST, V67, P28, DOI 10.1172/JCI110024; ATKINS PC, 1983, CLIN REV ALLERG, V1, P385; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BRUIJNZEEL PLB, 1990, BRIT J PHARMACOL, V99, P798, DOI 10.1111/j.1476-5381.1990.tb13009.x; CHANYEUNG M, 1991, J ALLERGY CLIN IMMUN, V87, P667, DOI 10.1016/0091-6749(91)90386-3; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CORRIGAN CJ, 1988, LANCET, V1, P1129; DEMONCHY JG, 1985, AM REV RESPIR DIS, V426, P373; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FUJISAWA T, 1990, J IMMUNOL, V144, P642; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; HENOCQ E, 1986, LANCET, V1, P1378; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KURIHARA K, 1989, J ALLERGY CLIN IMMUN, V83, P83, DOI 10.1016/0091-6749(89)90480-6; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; MORITA E, 1989, Journal of Dermatology (Tokyo), V16, P348; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SCHRODER JM, 1989, J IMMUNOL, V142, P244; SILBERSTEIN DS, 1987, IMMUNOL TODAY, V8, P380, DOI 10.1016/0167-5699(87)90214-3; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; WALKER C, 1991, J IMMUNOL, V146, P1829; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WARRINGA RAJ, 1991, BLOOD, V77, P2694; WARRINGA RAJ, 1992, BLOOD, V79, P1036; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; YAZDANBAKHSH M, 1985, J IMMUNOL, V135, P1378	40	110	111	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1198	1205		10.1016/0091-6749(93)90323-8	http://dx.doi.org/10.1016/0091-6749(93)90323-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8509580				2022-12-18	WOS:A1993LG74000012
J	TOWNLEY, RG; BEWTRA, A; WILSON, AF; HOPP, RJ; ELSTON, RC; NAIR, N; WATT, GD				TOWNLEY, RG; BEWTRA, A; WILSON, AF; HOPP, RJ; ELSTON, RC; NAIR, N; WATT, GD			SEGREGATION ANALYSIS OF BRONCHIAL RESPONSE TO METHACHOLINE INHALATION CHALLENGE IN FAMILIES WITH AND WITHOUT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,SCH MED,DEPT MED ALLERGY,CALIF 24TH ST,OMAHA,NE 68178; LOUISIANA STATE UNIV,MED CTR,DEPT BIOMETRY & GENET,NEW ORLEANS,LA 70112	Creighton University; Louisiana State University System			Hopp, Russell/K-4578-2019; Wilson, Alexander/C-2320-2009; Wilson, Alexander F./Q-6910-2019					ALPER B, 1982, AM REV RESPIR DIS, V125, P73; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; Elston R C, 1981, Adv Hum Genet, V11, P63; ELSTON RC, 1971, HUM HERED, V21, P523, DOI 10.1159/000152448; ELSTON RC, 1979, AM J HUM GENET, V31, P62; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FORD L, 1984, Journal of Allergy and Clinical Immunology, V73, P125; GERRARD JW, 1978, AM J HUM GENET, V30, P46; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V74, P154, DOI 10.1016/0091-6749(84)90279-3; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; SANTILLI J, 1980, J ALLERGY CLIN IMMUN, V65, P406, DOI 10.1016/0091-6749(80)90232-8; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9	16	110	110	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				101	107		10.1016/0091-6749(86)90330-1	http://dx.doi.org/10.1016/0091-6749(86)90330-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3944368				2022-12-18	WOS:A1986AZD3600018
J	SCHLEIMER, RP; FOX, CC; NACLERIO, RM; PLAUT, M; CRETICOS, PS; TOGIAS, AG; WARNER, JA; KAGEYSOBOTKA, A; LICHTENSTEIN, LM				SCHLEIMER, RP; FOX, CC; NACLERIO, RM; PLAUT, M; CRETICOS, PS; TOGIAS, AG; WARNER, JA; KAGEYSOBOTKA, A; LICHTENSTEIN, LM			ROLE OF HUMAN BASOPHILS AND MAST-CELLS IN THE PATHOGENESIS OF ALLERGIC DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI020136, R01AI008270, R37AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20136, AI 08270, AI 07290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEFUS AD, 1982, J IMMUNOL, V128, P2475; CHANDLER DE, 1979, J APPL PHYSL RESPIR, V46, P467; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CRISP AJ, 1984, ARTHRITIS RHEUM, V27, P845, DOI 10.1002/art.1780270802; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; FOX CC, J IMMUNOL; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; KAGEYSOBOTKA A, 1985, FED P, V44, P784; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LICHTENSTEIN LM, 1983, 11 P INT C ALL CLIN, P11; LICHTENSTEIN LM, 1984, ASTHMA PHYSL IMMUNOP, P1; LLOYD G, 1975, GUT, V16, P861, DOI 10.1136/gut.16.11.861; MACGLASHAN DW, 1980, J IMMUNOL, V124, P2519; MARONE G, 1983, CLIN IMMUNOL IMMUNOP, V28, P334, DOI 10.1016/0090-1229(83)90100-9; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1984, ARCH OTOLARYNGOL, V110, P25; NACLERIO RM, N ENGL J MED; OKUDA M, 1980, CLIN OTOLARYNGOL, V5, P315, DOI 10.1111/j.1365-2273.1980.tb00897.x; PETERS SP, 1984, J IMMUNOL, V132, P1972; PETERS SP, 1982, J IMMUNOL, V129, P797; PETERS SP, 1983, THEORETICAL CLIN ASP, P185; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; PROUD D, AM REV RESPIR DIS; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1985, ANNU REV PHARMACOL, V25, P381, DOI 10.1146/annurev.pharmtox.25.1.381; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; TOGIAS AG, UNPUB J CLIN INVEST; WARNER J, 1985, FED PROC, V44, P1682	33	110	112	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					369	374		10.1016/0091-6749(85)90656-6	http://dx.doi.org/10.1016/0091-6749(85)90656-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	2410478				2022-12-18	WOS:A1985APE8900020
J	MAURIELLO, PM; BARDE, SH; GEORGITIS, JW; REISMAN, RE				MAURIELLO, PM; BARDE, SH; GEORGITIS, JW; REISMAN, RE			NATURAL-HISTORY OF LARGE LOCAL REACTIONS FROM STINGING INSECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14260	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [5 R01 AI 14501] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014501] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRECHT I, 1980, CLIN ALLERGY, V10, P675; BROWN H, 1980, ARCH INTERN MED, V125, P665; CASE RL, 1981, J ALLERGY CLIN IMMUN, V68, P399, DOI 10.1016/0091-6749(81)90139-1; CLAYTON WF, 1983, CLIN ALLERGY, V13, P123, DOI 10.1111/j.1365-2222.1983.tb02579.x; ESKRIDGE EM, 1981, TOXICON, V19, P893, DOI 10.1016/0041-0101(81)90087-8; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GRAFT DE, 1983, J ALLERGY CLIN IMMUN, V69, P124; GREEN AW, 1980, J ALLERGY CLIN IMMUN, V66, P186, DOI 10.1016/0091-6749(80)90037-8; LIGHT W C, 1975, Clinical Allergy, V5, P389, DOI 10.1111/j.1365-2222.1975.tb01878.x; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; 1972, UNPUB INSECT ALLERGY	11	110	112	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					494	498		10.1016/0091-6749(84)90384-1	http://dx.doi.org/10.1016/0091-6749(84)90384-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN620	6491095				2022-12-18	WOS:A1984TN62000006
J	WEINBERGER, M				WEINBERGER, M			THE PHARMACOLOGY AND THERAPEUTIC USE OF THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											WEINBERGER, M (corresponding author), UNIV IOWA, JCP, DEPT PEDIAT, DIV ALLERGY & PULM, IOWA CITY, IA 52242 USA.				NCRR NIH HHS [RR-59] Funding Source: Medline; NIAID NIH HHS [AI 16151-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER MR, 1980, JAMA-J AM MED ASSOC, V244, P2286, DOI 10.1001/jama.244.20.2286; ANDERSSON KE, 1980, EUR J RESPIR DIS, V61, P17; ARANDA JV, 1977, J PEDIATR-US, V90, P467, DOI 10.1016/S0022-3476(77)80718-X; ARANDA JV, 1979, CLIN PERINATOL, V6, P87, DOI 10.1016/S0095-5108(18)31165-5; AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; BADA HS, 1979, J PEDIATR-US, V94, P993, DOI 10.1016/S0022-3476(79)80247-4; BERG MJ, 1982, NEW ENGL J MED, V307, P642, DOI 10.1056/NEJM198209093071102; BERGSTRAND H, 1980, EUR J RESPIR DIS, V61, P37; BERLINGER WG, 1983, CLIN PHARMACOL THER, V33, P351, DOI 10.1038/clpt.1983.44; BORY C, 1979, J PEDIATR-US, V94, P988, DOI 10.1016/S0022-3476(79)80246-2; BOUTROY MJ, 1979, J PEDIATR-US, V94, P996, DOI 10.1016/S0022-3476(79)80248-6; BRISSON GR, 1972, J CLIN INVEST, V51, P232, DOI 10.1172/JCI106808; Brown EA, 1940, NEW ENGL J MED, V223, P843, DOI 10.1056/NEJM194011212232103; Culberson C G, 1979, Trans Am Neurol Assoc, V104, P224; CUSACK B, 1980, BRIT J CLIN PHARMACO, V10, P109, DOI 10.1111/j.1365-2125.1980.tb01726.x; DIETRICH J, 1978, CLIN PHARMACOL THER, V24, P474; DUSDIEKER L, 1982, J PEDIATR-US, V101, P281; EATON ML, 1980, ANN INTERN MED, V92, P758, DOI 10.7326/0003-4819-92-6-758; EHLERS SM, 1978, JAMA-J AM MED ASSOC, V240, P474, DOI 10.1001/jama.240.5.474; ELLIS EF, 1976, PEDIATRICS, V58, P542; FELDMAN CH, 1980, PEDIATRICS, V66, P956; FOSTER LJ, 1979, JAMA-J AM MED ASSOC, V241, P2613, DOI 10.1001/jama.241.24.2613; GIBALDI M, 1975, PHARMACOKINETICS, P2; GINCHANSKY E, 1977, J PEDIATR-US, V91, P655, DOI 10.1016/S0022-3476(77)80527-1; HAMBLETON G, 1977, LANCET, V1, P381; HEMSTREET MP, 1981, J PEDIATR, V99, P153; HENDELES L, 1979, J ALLERGY CLIN IMMUN, V63, P156; HENDELES L, 1978, AM J DIS CHILD, V132, P876; HENDELES L, 1977, DRUG INTEL CLIN PHAR, V11, P12, DOI 10.1177/106002807701100101; HENDELES L, 1977, AM J HOSP PHARM, V34, P525, DOI 10.1093/ajhp/34.5.525; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; HENDELES L, 1978, AM REV RESPIR DIS, V118, P97; HENDELES L, CLIN PHARMACOKINET; Herrmann G, 1938, J LAB CLIN MED, V23, P135; Hirsch S., 1922, KLIN WOCHENSCHR, V1, P615; HORROBIN DF, 1977, PROSTAGLANDINS, V13, P33, DOI 10.1016/0090-6980(77)90040-5; JACKSON JE, 1981, AM REV RESPIR DIS, V123, P615; JACOBS MH, 1976, JAMA-J AM MED ASSOC, V235, P1983, DOI 10.1001/jama.235.18.1983; JENNE J, 1975, LIFE SCI, V17, P195, DOI 10.1016/0024-3205(75)90503-2; JENNE JW, 1977, AM J HOSP PHARM, V34, P408, DOI 10.1093/ajhp/34.4.408; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; JONKMAN JHG, 1981, INT J PHARM, V8, P153, DOI 10.1016/0378-5173(81)90019-3; JUSKO WJ, 1978, CLIN PHARMACOL THER, V24, P406; KAPPAS A, 1976, CLIN PHARMACOL THER, V20, P643; KRAEMER MJ, 1982, PEDIATRICS, V69, P476; LANDAY RA, 1978, J ALLERGY CLIN IMMUN, V62, P27, DOI 10.1016/0091-6749(78)90068-4; LEEDS NH, 1982, J CLIN PHARMACOL, V22, P196, DOI 10.1002/j.1552-4604.1982.tb02162.x; LIU DTY, 1975, AUST NZ J OBSTET GYN, V15, P145, DOI 10.1111/j.1479-828X.1975.tb00876.x; LOUGHNAN PM, 1976, J PEDIATR-US, V88, P874, DOI 10.1016/S0022-3476(76)81136-5; LUNELL E, 1982, EUR J CLIN PHARMACOL, V22, P395, DOI 10.1007/BF00542541; Macht DI, 1921, J PHARMACOL EXP THER, V18, P373; MANGIONE A, 1978, CHEST, V73, P616, DOI 10.1378/chest.73.5.616; MARQUIS JF, 1982, NEW ENGL J MED, V307, P1189, DOI 10.1056/NEJM198211043071906; MASON WD, 1980, J ALLERGY CLIN IMMUN, V66, P119, DOI 10.1016/0091-6749(80)90058-5; MATTHAY RA, 1978, AM J MED, V65, P903, DOI 10.1016/0002-9343(78)90741-6; MATTHAY RA, 1976, THORAX, V31, P470, DOI 10.1136/thx.31.4.470; MAY DC, 1982, J CLIN PHARMACOL, V22, P125, DOI 10.1002/j.1552-4604.1982.tb02659.x; MILSAP RL, 1980, CLIN PHARMACOL THER, V28, P536, DOI 10.1038/clpt.1980.199; MITENKO PA, 1973, CLIN PHARMACOL THER, V14, P509; NASSIF EG, 1981, J PEDIATR-US, V98, P158; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; OGILVIE RI, 1977, EUR J CLIN PHARMACOL, V12, P409, DOI 10.1007/BF00561059; OSMAN MA, 1983, P S SUST REL THEOPH, P47; PEDERSEN S, 1981, BRIT J CLIN PHARMACO, V12, P904, DOI 10.1111/j.1365-2125.1981.tb01329.x; PEDERSEN S, 1984, PEDIATRICS; PIAFSKY KM, 1977, CLIN PHARMACOL THER, V21, P310; PIAFSKY KM, 1977, NEW ENGL J MED, V296, P1495, DOI 10.1056/NEJM197706302962603; POLLOCK J, 1977, PEDIATRICS, V60, P840; POWELL J R, 1982, Clinical Pharmacology and Therapeutics, V31, P261; POWELL JR, 1977, AM REV RESPIR DIS, V116, P17; POWELL JR, 1978, AM REV RESPIR DIS, V118, P229; PRINCE RA, 1981, J ALLERGY CLIN IMMUN, V68, P427, DOI 10.1016/0091-6749(81)90196-2; REITBERG DP, 1981, ANN INTERN MED, V95, P582, DOI 10.7326/0003-4819-95-5-582; RENTON KW, 1981, CLIN PHARMACOL THER, V30, P422, DOI 10.1038/clpt.1981.182; RICHER C, 1982, CLIN PHARMACOL THER, V31, P579, DOI 10.1038/clpt.1982.81; ROBERTS RK, 1981, GASTROENTEROLOGY, V81, P19; SARRAZIN E, 1980, J PEDIATR-US, V97, P825, DOI 10.1016/S0022-3476(80)80280-0; SCOTT PH, 1981, J PEDIATR-US, V99, P476, DOI 10.1016/S0022-3476(81)80354-X; SHAPIRO GG, 1976, PEDIATRICS, V58, P740; SIMONS FER, 1982, AM J DIS CHILD, V136, P790, DOI 10.1001/archpedi.1982.03970450032008; SINTEK C, 1979, J PEDIATR-US, V94, P314, DOI 10.1016/S0022-3476(79)80856-2; STAIB AH, 1980, INT J CLIN PHARM TH, V18, P500; SVEDMYR N, 1977, Scandinavian Journal of Respiratory Diseases Supplementum, V101, P125; TABACHNIK E, 1982, J PEDIATR-US, V100, P489, DOI 10.1016/S0022-3476(82)80467-8; TALSETH T, 1981, ANN ALLERGY, V46, P279; TANGLIU DDS, 1982, CLIN PHARMACOL THER, V31, P358, DOI 10.1038/clpt.1982.46; TAYLOR JW, 1980, DRUG INTEL CLIN PHAR, V14, P638; TRUITT EB, 1950, J PHARMACOL EXP THER, V100, P309; TURNERWARWICK M, 1957, BRIT MED J, V2, P67, DOI 10.1136/bmj.2.5036.67; VICUNA N, 1979, BRIT J CLIN PHARMACO, V7, P33, DOI 10.1111/j.1365-2125.1979.tb00893.x; VOZEH S, 1980, EUR J CLIN PHARMACOL, V18, P473, DOI 10.1007/BF00874658; WECHSLER RL, 1950, J CLIN INVEST, V29, P28, DOI 10.1172/JCI102230; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1981, J PEDIATR-US, V99, P145, DOI 10.1016/S0022-3476(81)80982-1; WEINBERGER M, 1975, CLIN PHARMACOL THER, V17, P585; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; WEINBERGER M, 1983, NEW ENGL J MED, V308, P760, DOI 10.1056/NEJM198303313081306; WEINBERGER M, 1980, DEV PHARMACOL THERAP, V1, P26, DOI 10.1159/000455518; WEINBERGER M, 1978, NEW ENGL J MED, V299, P852, DOI 10.1056/NEJM197810192991603; WEINBERGER M, 1978, J PEDIATR-US, V92, P1, DOI 10.1016/S0022-3476(78)80058-4; WEINBERGER MW, 1976, JAMA-J AM MED ASSOC, V235, P2110, DOI 10.1001/jama.235.19.2110; WYATT R, 1978, J PEDIATR-US, V92, P125, DOI 10.1016/S0022-3476(78)80093-6; ZAROWITZ BJM, 1981, CLIN PHARMACOL THER, V29, P601, DOI 10.1038/clpt.1981.84; ZUIDEMA J, 1979, CURR MED RES OPIN, V6, P14, DOI 10.1185/03007997909115903; ZUIDEMA J, 1981, PHARM WEEKBLAD, V3, P216; ZWILLICH CW, 1975, ANN INTERN MED, V82, P784, DOI 10.7326/0003-4819-82-6-784	106	110	118	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					525	540		10.1016/0091-6749(84)90505-0	http://dx.doi.org/10.1016/0091-6749(84)90505-0			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS045	6371101				2022-12-18	WOS:A1984SS04500001
J	WANNER, A; MAURER, D; ABRAHAM, WM; SZEPFALUSI, Z; SIELCZAK, M				WANNER, A; MAURER, D; ABRAHAM, WM; SZEPFALUSI, Z; SIELCZAK, M			EFFECTS OF CHEMICAL MEDIATORS OF ANAPHYLAXIS ON CILIARY FUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											WANNER, A (corresponding author), MT SINAI MED CTR,DEPT MED,DIV PULM DIS,MIAMI BEACH,FL 33140, USA.			Szepfalusi, Zsolt/0000-0003-4852-3102	NHLBI NIH HHS [HL-20989] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL020989] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED T, 1981, AM REV RESPIR DIS, V124, P110; AUSTEN KF, 1973, ASTHMA PHYSIOLOGY IM, P114; DULFANO MJ, 1982, CELL MOTIL S, V1, P86; FOSTER WM, 1978, AM REV RESPIR DIS, V117, P337; IRAVANI J, 1975, RESPIRATION, V32, P157, DOI 10.1159/000193645; IRAVANI J, 1975, RESPIRATION, V32, P305, DOI 10.1159/000193659; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MAURER DR, 1982, J APPL PHYSIOL, V52, P1018, DOI 10.1152/jappl.1982.52.4.1018; MAURER DR, 1982, CELL MOTIL S, V1, P67; MEZEY RJ, 1978, AM REV RESPIR DIS, V118, P118; PHIPPS R, 1982, FED P, V41, P1687; SCUDI JV, 1951, J PHARMACOL EXP THER, V102, P132; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; VERDUGO P, 1980, NATURE, V283, P764, DOI 10.1038/283764a0; VERDUGO P, 1980, FERTIL STERIL, V33, P193; WANNER A, 1975, J APPL PHYSIOL, V39, P950, DOI 10.1152/jappl.1975.39.6.950	16	110	110	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	6					663	667		10.1016/0091-6749(83)90626-7	http://dx.doi.org/10.1016/0091-6749(83)90626-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RW048	6417215				2022-12-18	WOS:A1983RW04800005
J	ZEISS, CR; KANELLAKES, TM; BELLONE, JD; LEVITZ, D; PRUZANSKY, JJ; PATTERSON, R				ZEISS, CR; KANELLAKES, TM; BELLONE, JD; LEVITZ, D; PRUZANSKY, JJ; PATTERSON, R			IMMUNOGLOBULIN-E - MEDIATED ASTHMA AND HYPERSENSITIVITY PNEUMONITIS WITH PRECIPITATING ANTI-HAPTEN ANTIBODIES DUE TO DIPHENYLMETHANE DISOCYANATE (MDI) EXPOSURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ZEISS, CR (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611, USA.							AVERY SB, 1969, CLIN EXP IMMUNOL, V4, P585; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CHARLES J, 1976, THORAX, V31, P127, DOI 10.1136/thx.31.2.127; FINK JN, 1978, AM REV RESPIR DIS, V118, P955; FINK JN, 1978, ALLERGY PRINCIPLES P, P855; FUCHS S, 1951, Arch Mal Prof, V12, P191; GREENWOOD FC, 1963, BIOCHEM J, V89, P14; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; KONZEN RB, 1966, AM IND HYG ASSOC J, V27, P121, DOI 10.1080/00028896609342803; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; OBRIEN IM, 1979, CLIN ALLERGY, V9, P7, DOI 10.1111/j.1365-2222.1979.tb01517.x; PATTERSON R, 1974, INT ARCH ALLER A IMM, V46, P150, DOI 10.1159/000231119; PEPYS J, 1972, Clinical Allergy, V2, P225, DOI 10.1111/j.1365-2222.1972.tb01287.x; Stokinger H E, 1973, J Occup Med, V15, P564; TAYLOR G, 1970, P ROY SOC MED, V63, P379, DOI 10.1177/003591577006300421; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1973, J IMMUNOL, V110, P414	18	110	110	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	5					346	352		10.1016/0091-6749(80)90211-0	http://dx.doi.org/10.1016/0091-6749(80)90211-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV955	6246152				2022-12-18	WOS:A1980JV95500005
J	HAUSPIE, R; SUSANNE, C; ALEXANDER, F				HAUSPIE, R; SUSANNE, C; ALEXANDER, F			MATURATIONAL DELAY AND TEMPORAL GROWTH RETARDATION IN ASTHMATIC BOYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FREE UNIV BRUSSELS, HUMAN GENET LAB, B-1050 BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel								ADAMS FH, 1954, J PEDIATR-US, V44, P674, DOI 10.1016/S0022-3476(54)80009-6; ALEXANDER F, 1974, ACTA PAEDIATR BELG, V28, P1; ALEXANDER F, 1970, HET KIND, V2, P1; ALEXANDER F, 1967, ACTA ALLERGOL, V23, P161; ANGUELOV G, 1969, B ASS ANAT NANCY, V146, P405; AUBENQUE MAURICE, 1964, BIOTYPOLOGIE, V25, P136; BAILEY KV, 1970, MONOGR SOC RES CHILD, V35, P40, DOI 10.2307/1165812; BAYLEY N, 1952, J PEDIATR-US, V40, P423, DOI 10.1016/S0022-3476(52)80205-7; BLIZZARD RM, 1974, CONTROL ONSET PUBERT, P342; CAMPBELL M, 1949, ARCH DIS CHILD, V24, P294, DOI 10.1136/adc.24.120.294; COHEN MB, 1948, J ALLERGY, V19, P165, DOI 10.1016/0021-8707(48)90049-5; FALLIERS CJ, 1961, J ALLERGY, V32, P420, DOI 10.1016/0021-8707(61)90020-X; FIELD CE, 1961, ARCH DIS CHILD, V36, P587, DOI 10.1136/adc.36.190.587; FRIEDMAN M, 1969, SCAND J RESPIR D S68; FRISCH RE, 1969, HUM BIOL, V41, P536; GRAFFAR M, 1973, COURBES ETABLIES APR; Greulich WW, 1959, RADIOGRAPHIC ATLAS S; HAUSPIE R, 1976, HUM BIOL, V48, P271; HAUSPIE R, 1976, ALLERG IMMUNOL LIEPZ, V8, P7; Hewitt D, 1955, BRIT J PREV SOC MED, V9, P179; HOLT, 1951, TXB PEDIATRICS; KERREBIJN KF, 1969, SCAND J RESPIR D S68; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; Mechem E, 1943, CHILD DEV, V14, P91; MEHRIZI A, 1962, J PEDIATR-US, V61, P418, DOI 10.1016/S0022-3476(62)80373-4; NELSON WE, 1959, TXB PEDIATRICS; PATTERSON HD, 1950, J ROY STAT SOC B, V12, P241; Ponte C, 1970, Pediatrie, V25, P173; POWELL GF, 1967, NEW ENGL J MED, V276, P1271, DOI 10.1056/NEJM196706082762301; SANDERS SS, 1969, BRIT MED J, V3, P25, DOI 10.1136/bmj.3.5661.25; SHUTTLEWORTH F. K., 1937, Monographs of the Society for Research in Child Development, V2; SMITH JM, 1965, ANN ALLERGY, V23, P492; SNYDER RD, 1967, CLIN PEDIATR, V6, P389, DOI 10.1177/000992286700600705; SPOCK A, 1965, ANN ALLERGY, V23, P608; SPROUL A, 1964, J PEDIATR-US, V65, P664, DOI 10.1016/S0022-3476(64)80151-7; TANNER J. M., 1951, HUMAN BIOL, V23, P93; Tanner J. M., 1962, GROWTH ADOLESCENCE, V2nd; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; Tanner JM, 1974, CONTROL ONSET PUBERT, P448; TWIESSELMANN F, 1969, DEVELOPPEMENT BIOMET; VANWIERINGEN JC, 1968, NEDERLAND TWEEDE LAN; VERLINDEN M, 1975, COMMUNICATION; Yates F., 1949, SAMPLING METHODS CEN, VI; 1955, PUBERTAIRE ONTWIKKEL	45	110	117	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	3					200	206		10.1016/0091-6749(77)90150-6	http://dx.doi.org/10.1016/0091-6749(77)90150-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CZ249	190283				2022-12-18	WOS:A1977CZ24900003
J	Copaescu, A; Smibert, O; Gibson, A; Phillips, EJ; Trubiano, JA				Copaescu, Ana; Smibert, Olivia; Gibson, Andrew; Phillips, Elizabeth J.; Trubiano, Jason A.			The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-6; sepsis; cytokine storm; cytokines; COVID-19; SARS-CoV-2; TNF-alpha; JAK; STING; proinflammatory; hyperinflammatory; hemophagocytic lymphohistiocytosis	MACROPHAGE ACTIVATION SYNDROME; CRITICALLY ILL PATIENTS; CONVALESCENT PLASMA; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; PROGNOSTIC MARKER; DIAGNOSTIC MARKER; ORGAN FAILURE; SEVERE SEPSIS; SARS-COV; INTERLEUKIN-6	The coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome coronavirus 2 presents with a spectrum of clinical manifestations from asymptomatic or mild, self-limited constitutional symptoms to a hyperinflammatory state ("cytokine storm") followed by acute respiratory distress syndrome and death. The objective of this study was to provide an evidence-based review of the associated pathways and potential treatment of the hyperinflammatory state associated with severe acute respiratory syndrome coronavirus 2 infection. Dysregulated immune responses have been reported to occur in a smaller subset of those infected with severe acute respiratory syndrome coronavirus 2, leading to clinical deterioration 7 to 10 days after initial presentation. A hyperinflammatory state referred to as cytokine storm in its severest form has been marked by elevation of IL-6, IL-10, TNF-alpha, and other cytokines and severe CD4(+) and CD8(+) T-cell lymphopenia and coagulopathy. Recognition of at-risk patients could permit early institution of aggressive intensive care and antiviral and immune treatment to reduce the complications related to this proinflammatory state. Several reports and ongoing clinical trials provide hope that available immunomodulatory therapies could have therapeutic potential in these severe cases. This review highlights our current state of knowledge of immune mechanisms and targeted immunomodulatory treatment options for the current coronavirus disease 2019 pandemic.	[Copaescu, Ana; Smibert, Olivia; Trubiano, Jason A.] Austin Hlth, Ctr Antibiot Allergy & Res, Dept Infect Dis, Heidelberg, Vic, Australia; [Gibson, Andrew; Phillips, Elizabeth J.] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA, Australia; [Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Infect Dis, Nashville, TN USA; [Trubiano, Jason A.] Univ Melbourne, Dept Oncol, Sir Peter MacCallum Canc Ctr, Parkville, Vic, Australia; [Trubiano, Jason A.] Univ Melbourne, Austin Hlth, Dept Med, Heidelberg, Vic, Australia; [Trubiano, Jason A.] Peter MacCallum Canc Ctr, Natl Ctr Infect Canc, Parkville, Vic, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Murdoch University; Vanderbilt University; Peter Maccallum Cancer Center; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Peter Maccallum Cancer Center	Copaescu, A (corresponding author), Austin Hlth, Ctr Antibiot Allergy & Res, Dept Infect Dis, Heidelberg, Vic, Australia.	ana.copaescu@gmail.com	Copaescu, Ana/AHA-3242-2022	smibert, olivia/0000-0003-1232-5884; Copaescu, Ana-Maria/0000-0002-9183-5032; Gibson, Andrew/0000-0001-9653-3298	National Institutes of Health [1P50GM115305, R21AI139021, 1 R01 HG010863, 1R01AI152183]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	E.J.P. receives support from National Institutes of Health grants 1P50GM115305, R21AI139021, 1 R01 HG010863, and 1R01AI152183.	Acharya D, 2020, NAT REV IMMUNOL, V20, P397, DOI 10.1038/s41577-020-0346-x; Adam N, 2009, J VIROL, V83, P5117, DOI 10.1128/JVI.01601-08; [Anonymous], 2020, CANCER DISCOV, DOI [DOI 10.1038/S41379-019-0362-1, DOI 10.1038/S41421-020-0168-9]; Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001; Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Beutel G, 2011, CRIT CARE, V15, DOI 10.1186/cc10073; Billeter A, 2009, WORLD J SURG, V33, P558, DOI 10.1007/s00268-008-9896-y; Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745; Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419; Cao Yang, 2020, J Allergy Clin Immunol, V146, P137, DOI 10.1016/j.jaci.2020.05.019; Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2; Chalmers S., 2019, WORLD J CRIT CARE ME, V8, P59, DOI [10.5492/wjccm.v8.i5.59, DOI 10.5492/WJCCM.V8.I5.59]; Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9; Chen X, 2020, DETECTABLE SERUM SAR, DOI [10.1101/2020.02.29.2002952., DOI 10.1101/2020.02.29.2002952]; Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9; Choi WS, 2016, INFECT CHEMOTHER, V48, P118, DOI 10.3947/ic.2016.48.2.118; Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8; Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410; Cohen SB, 2004, RHEUM DIS CLIN N AM, V30, P365, DOI 10.1016/j.rdc.2004.01.005; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Faix JD, 2013, CRIT REV CL LAB SCI, V50, P23, DOI 10.3109/10408363.2013.764490; Fala Loretta, 2016, Am Health Drug Benefits, V9, P60; Filipovich A, 2010, BIOL BLOOD MARROW TR, V16, pS82, DOI 10.1016/j.bbmt.2009.11.014; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770; Gouel-Cheron A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033095; Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18; Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100; Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105; Harbarth S, 2001, AM J RESP CRIT CARE, V164, P396, DOI 10.1164/ajrccm.164.3.2009052; Herold T., 2020, J ALLERGY CLIN IMMUN, DOI [10.1101/2020.04.01.20047381., 10.1101/2020.04.01.20047381]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Jekarl DW, 2013, DIAGN MICR INFEC DIS, V75, P342, DOI 10.1016/j.diagmicrobio.2012.12.011; Jones AE, 2009, CRIT CARE MED, V37, P1649, DOI 10.1097/CCM.0b013e31819def97; Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123; Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655; Klaver Y, 2016, CLIN IMMUNOL, V169, P107, DOI 10.1016/j.clim.2016.06.014; Kumar B, 2017, J CLIN IMMUNOL, V37, P638, DOI 10.1007/s10875-017-0439-x; Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Leon MPD, 2020, J PEDIAT INF DIS SOC, V9, P407, DOI 10.1093/jpids/piaa061; Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044; Li XG, 2020, J MED VIROL, V92, P602, DOI 10.1002/jmv.25731; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Ma L, 2016, CYTOKINE, V88, P126, DOI 10.1016/j.cyto.2016.08.033; Maier B, 2007, SHOCK, V28, P668, DOI 10.1097/shk.0b013e318123e64e; Mat-Nor MB, 2016, J CRIT CARE, V33, P245, DOI 10.1016/j.jcrc.2016.01.002; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4; Miettunen PM, 2011, RHEUMATOLOGY, V50, P417, DOI 10.1093/rheumatology/keq218; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Mors K, 2016, IMMUNOBIOLOGY, V221, P904, DOI 10.1016/j.imbio.2016.03.005; National Institutes of Health, 2020, NAT I HLTH COVID 19; Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846; OBrien TR, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa453., DOI 10.1093/CID/CIAA453.]; Ogata A, 2019, MOD RHEUMATOL, V29, P258, DOI [10.1080/14397595.2018.1546357, 10.1080/14397595.2018.1533514]; Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647; Pei JW, 2019, CANCER LETT, V450, P110, DOI 10.1016/j.canlet.2019.02.029; Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026; Pettila V, 2002, INTENS CARE MED, V28, P1220, DOI 10.1007/s00134-002-1416-1; Price CC, 2020, CHEST, V158, P1397, DOI 10.1016/j.chest.2020.06.006; Rajendran K, 2020, J MED VIROL, V92, P1475, DOI 10.1002/jmv.25961; Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/50140-6736(20)31094-1, 10.1016/S0140-6736(20)31094-1]; Risitano AM, 2020, NAT REV IMMUNOL, V20, P343, DOI 10.1038/s41577-020-0320-7; Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554; Roumier M., 2020, INTERLEUKIN 6 BLOCKA, DOI 10.1101/2020.04.20.20061861; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003; Scheller J, 2006, SCAND J IMMUNOL, V63, P321, DOI 10.1111/j.1365-3083.2006.01750.x; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Schulert GS, 2016, J INFECT DIS, V213, P1180, DOI 10.1093/infdis/jiv550; Schulert GS, 2015, ANNU REV MED, V66, P145, DOI 10.1146/annurev-med-061813-012806; Schulert GS, 2014, BEST PRACT RES CL RH, V28, P277, DOI 10.1016/j.berh.2014.03.002; Schumacher N, 2019, CANCERS, V11, DOI 10.3390/cancers11111736; Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402; Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783; Song J, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4618-7; Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x; Spencer S, 2019, J EXP MED, V216, P1986, DOI 10.1084/jem.20190344; Stensballe J, 2009, ACTA ANAESTH SCAND, V53, P515, DOI 10.1111/j.1399-6576.2008.01801.x; Takahashi W, 2016, SHOCK, V46, P254, DOI 10.1097/SHK.0000000000000616; Tanaka T, 2014, CANCER IMMUNOL RES, V2, P288, DOI 10.1158/2326-6066.CIR-14-0022; Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11; Uciechowski P, 2020, ONCOLOGY-BASEL, V98, P131, DOI 10.1159/000505099; Uusitalo-Seppala R, 2011, SCAND J INFECT DIS, V43, P883, DOI 10.3109/00365548.2011.600325; Wan S, CHARACTERISTICS LYMP, DOI [10.1101/2020.02.10.20021832, 10.1101]; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wang Z, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa272, DOI 10.1093/CID/CIAA272.]; Weber ANR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01454; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005; Wu HP, 2009, INFLAMM RES, V58, P385, DOI 10.1007/s00011-009-0003-0; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Xu Zhe, 2020, Lancet Respir Med, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Zhang D, 2020, COVID 19 INFECT INDU, DOI [10.1101/2020.03.24.20042655., DOI 10.1101/2020.03.24.20042655.]; Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393; Zhang X, 2007, VIROLOGY, V365, P324, DOI 10.1016/j.virol.2007.04.009; Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041	109	109	115	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2020	146	3					518	+		10.1016/j.jaci.2020.07.001	http://dx.doi.org/10.1016/j.jaci.2020.07.001			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NO0HS	32896310	Bronze, Green Published			2022-12-18	WOS:000569168900014
J	Mayor, PC; Eng, KH; Singel, KL; Abrams, SI; Odunsi, K; Moysich, KB; Fuleihan, R; Garabedian, E; Lugar, P; Ochs, HD; Bonilla, FA; Buckley, RH; Sullivan, KE; Ballas, ZK; Cunningham-Rundles, C; Segal, BH				Mayor, Paul C.; Eng, Kevin H.; Singel, Kelly L.; Abrams, Scott I.; Odunsi, Kunle; Moysich, Kirsten B.; Fuleihan, Ramsay; Garabedian, Elizabeth; Lugar, Patricia; Ochs, Hans D.; Bonilla, Francisco A.; Buckley, Rebecca H.; Sullivan, Kathleen E.; Ballas, Zuhair K.; Cunningham-Rundles, Charlotte; Segal, Brahm H.			Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cancer; common variable immunodeficiency; leukemia; lymphoma; primary immunodeficiency disease; USIDNET	HEMATOPOIETIC-CELL TRANSPLANTATION; RISK; POPULATION; SPECTRUM; AIDS	Background: We evaluated the overall and site-specific incidence of cancer in subjects with primary immunodeficiency diseases (PIDD) enrolled in the United States Immune Deficiency Network (USIDNET) registry compared with age-adjusted cancer incidence in the Surveillance, Epidemiology and End Results Program (SEER) database. Objective: We hypothesized that subjects with PIDD would have an increased incidence of cancer due to impaired immune function. Methods: Overall and site-specific cancer incidence rates were evaluated in subjects with PIDD (n = 3658) enrolled in the USIDNET registry from 2003 to 2015 and compared with age-adjusted incidence rates in the SEER database. Results: We observed a 1.42-fold excess relative risk of cancer in subjects with PIDD compared with the age-adjusted SEER population (P <.001). Men with PIDD had a 1.91-fold excess relative risk of cancer compared with the age-adjusted male population (P <. 001), while women with PIDD had similar overall cancer rates compared with the age-adjusted female population. Of the 4 most common malignancies in men and women in SEER (lung, colon, breast, and prostate cancers), we found no significant increase in these diagnoses in subjects with PIDD. Significant increases in lymphoma in both men (10-fold increase, P <. 001) and women ( 8.34-fold increase, P <. 001) with PIDD were observed. Conclusions: Excess incidence of cancer occurred in subjects with PIDD. An excess of lymphoma in specific PIDD populations principally drove this increased incidence, while no increased risk of the most common solid tumor malignancies was observed. These data point to a restricted role of the immune system in protecting from specific cancers.	[Mayor, Paul C.; Odunsi, Kunle] Roswell Pk Canc Inst, Dept Surg, Div Gynecol Oncol, Buffalo, NY 14263 USA; [Eng, Kevin H.] Roswell Pk Canc Inst, Dept Biostat & Bioinformat, Buffalo, NY 14263 USA; [Singel, Kelly L.; Abrams, Scott I.; Odunsi, Kunle; Segal, Brahm H.] Roswell Pk Canc Inst, Dept Immunol, Elm & Carlton St, Buffalo, NY 14263 USA; [Moysich, Kirsten B.] Roswell Pk Canc Inst, Dept Epidemiol & Populat Sci, Buffalo, NY 14263 USA; [Segal, Brahm H.] Roswell Pk Canc Inst, Dept Med, Elm & Carlton St, Buffalo, NY 14263 USA; [Fuleihan, Ramsay] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA; [Garabedian, Elizabeth] NHGRI, Bethesda, MD 20892 USA; [Lugar, Patricia; Buckley, Rebecca H.] Duke Univ Hlth Syst, Durham, NC USA; [Ochs, Hans D.] Univ Washington, Seattle, WA 98195 USA; [Ochs, Hans D.] Seattle Childrens Res Inst, Seattle, WA USA; [Bonilla, Francisco A.] Boston Childrens Hosp, Boston, MA USA; [Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Ballas, Zuhair K.] Univ Iowa, Carver Coll Med, Iowa City, IA USA; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, New York, NY USA; [Segal, Brahm H.] SUNY Buffalo, Dept Med, Jacobs Sch Med, Buffalo, NY USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Ann & Robert H. Lurie Children's Hospital of Chicago; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Duke University; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Harvard University; Boston Children's Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Iowa; Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Segal, BH (corresponding author), Roswell Pk Canc Inst, Dept Immunol, Elm & Carlton St, Buffalo, NY 14263 USA.; Segal, BH (corresponding author), Roswell Pk Canc Inst, Dept Med, Elm & Carlton St, Buffalo, NY 14263 USA.	Brahm.Segal@RoswellPark.org	Singel, Kelly L/N-7792-2014; Segal, Brahm/AAW-2706-2020; Buckley, Rebecca/AAB-1578-2019	Singel, Kelly L/0000-0002-8053-4736; Ballas, Zuhair/0000-0001-5569-1230; Knaack, Aaron/0000-0001-7712-1415	Roswell Park Cancer Institute National Cancer Institute Cancer Center [P30CA016056, 5T32CA108456, NLM K01LM012100, T32CA085183, R01CA140622, P50 CA159981, R01CA188900]; United States Immunodeficiency Network and Immune Deficiency Foundation [U24AI086037-06]; NATIONAL CANCER INSTITUTE [P30CA016056, T32CA085183, P30CA086862, T32CA108456, R01CA188900, R01CA140622, P50CA159981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U24AI086037, P01AI061093, R18AI048693] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [K01LM012100] Funding Source: NIH RePORTER	Roswell Park Cancer Institute National Cancer Institute Cancer Center; United States Immunodeficiency Network and Immune Deficiency Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	Supported by Roswell Park Cancer Institute National Cancer Institute Cancer Center support grants (P30CA016056, 5T32CA108456 [to P.C.M.], NLM K01LM012100 [to K.E.], T32CA085183 [to K.L.S.], R01CA140622 [to S.I.A.], P50 CA159981 [to K.O.], R01CA188900 [to B.H.S. and K.B.M.]), and the United States Immunodeficiency Network and Immune Deficiency Foundation (U24AI086037-06).	Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162; Boyle JM, 2007, J CLIN IMMUNOL, V27, P497, DOI 10.1007/s10875-007-9103-1; Cunningham-Rundles C, 2002, AM J HEMATOL, V69, P171, DOI 10.1002/ajh.10050; de Miranda NFCC, 2011, ANN NY ACAD SCI, V1246, P50, DOI 10.1111/j.1749-6632.2011.06322.x; Dhalla F, 2011, CLIN EXP IMMUNOL, V165, P1, DOI 10.1111/j.1365-2249.2011.04384.x; Engels EA, 2011, JAMA-J AM MED ASSOC, V306, P1891, DOI 10.1001/jama.2011.1592; Filipovich A H, 1994, Immunodeficiency, V5, P91; FILIPOVICH AH, 1992, CANCER RES, V52, pS5465; FILIPOVICH AH, 1987, AM J PEDIAT HEMATOL, V9, P183; Gangemi S, 2015, LEUKEMIA RES, V39, P389, DOI 10.1016/j.leukres.2015.02.002; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Hayward AR, 1997, J IMMUNOL, V158, P977; Immune Deficiency Foundation, 2009, PRIM IMM DIS AM 2007; Immune Deficiency Foundation, 2003, PRIM IMM DEF DIS AM; Jonkman-Berk BM, 2015, CLIN IMMUNOL, V156, P154, DOI 10.1016/j.clim.2014.10.003; KERSEY JH, 1974, J PEDIATR-US, V84, P263, DOI 10.1016/S0022-3476(74)80619-0; KERSEY JH, 1988, PEDIATR INFECT DIS J, V7, pS10; KINLEN LJ, 1985, LANCET, V1, P263; Majhail NS, 2011, BRIT J HAEMATOL, V154, P301, DOI 10.1111/j.1365-2141.2011.08756.x; Majhail NS, 2011, BLOOD, V117, P316, DOI 10.1182/blood-2010-07-294629; Mellemkjaer L, 2002, CLIN EXP IMMUNOL, V130, P495, DOI 10.1046/j.1365-2249.2002.02004.x; Musolino C, 2014, LEUKEMIA RES, V38, P1137, DOI 10.1016/j.leukres.2014.08.004; National Institutes of Health, NAT CANC I SURV EP E; Olivero OA, 2007, ENVIRON MOL MUTAGEN, V48, P215, DOI 10.1002/em.20195; Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005; Quinti I, 2007, J CLIN IMMUNOL, V27, P308, DOI 10.1007/s10875-007-9075-1; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; ROBISON LL, 1987, AM J PEDIAT HEMATOL, V9, P189; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Shiels MS, 2011, J NATL CANCER I, V103, P753, DOI 10.1093/jnci/djr076; Shiels MS, 2010, ANN INTERN MED, V153, P452, DOI 10.7326/0003-4819-153-7-201010050-00008; Simard EP, 2010, ARCH INTERN MED, V170, P1337, DOI 10.1001/archinternmed.2010.253; Spinner MA, 2014, BLOOD, V123, P809, DOI 10.1182/blood-2013-07-515528; Suarez F, 2006, BLOOD, V107, P3034, DOI 10.1182/blood-2005-09-3679; Sullivan KE, 2014, J CLIN IMMUNOL, V34, P428, DOI 10.1007/s10875-014-0028-1; Vajdic CM, 2010, BLOOD, V116, P1228, DOI 10.1182/blood-2010-03-272351	36	109	111	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1028	1035		10.1016/j.jaci.2017.05.024	http://dx.doi.org/10.1016/j.jaci.2017.05.024			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28606585	Bronze, Green Accepted			2022-12-18	WOS:000426974800023
J	Rossios, C; Pavlidis, S; Hoda, U; Kuo, CH; Wiegman, C; Russell, K; Sun, K; Loza, MJ; Baribaud, F; Durham, AL; Ojo, O; Lutter, R; Rowe, A; Bansal, A; Auffray, C; Sousa, A; Corfield, J; Djukanovic, R; Guo, YK; Sterk, PJ; Chung, KF; Adcock, IM				Rossios, Christos; Pavlidis, Stelios; Hoda, Uruj; Kuo, Chih-Hsi; Wiegman, Coen; Russell, Kirsty; Sun, Kai; Loza, Matthew J.; Baribaud, Frederic; Durham, Andrew L.; Ojo, Oluwaseun; Lutter, Rene; Rowe, Anthony; Bansal, Aruna; Auffray, Charles; Sousa, Ana; Corfield, Julie; Djukanovic, Ratko; Guo, Yike; Sterk, Peter J.; Chung, Kian Fan; Adcock, Ian M.		Unbiased Biomarkers Prediction Res	Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; eosinophil; neutrophil; exhaled nitric oxide; T-H(2); inflammasome; C-reactive protein; IL-33 receptor; IL-1 alpha; IL-1 beta	AIRWAY INFLAMMATION; GENE-EXPRESSION; CLUSTER-ANALYSIS; PHENOTYPES; DISEASE; SUBPHENOTYPES; BIOMARKER; SUBTYPES; NLRP3	Background: Sputum analysis in asthmatic patients is used to define airway inflammatory processes and might guide therapy. Objective: We sought to determine differential gene and protein expression in sputum samples from patients with severe asthma (SA) compared with nonsmoking patients with mild/moderate asthma. Methods: Induced sputum was obtained from nonsmoking patients with SA, smokers/ex-smokers with severe asthma, nonsmoking patients with mild/moderate asthma (MMAs), and healthy nonsmoking control subjects. Differential cell counts, microarray analysis of cell pellets, and SOMAscan analysis of sputum analytes were performed. CRID3 was used to inhibit the inflammasome in a mouse model of SA. Results: Eosinophilic and mixed neutrophilic/eosinophilic inflammation were more prevalent in patients with SA compared with MMAs. Forty-two genes probes were upregulated (> 2-fold) in nonsmoking patients with severe asthma compared with MMAs, including IL-1 receptor (IL-1R) family and nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain containing 3 (NRLP3) inflammasome members (false discovery rate < 0.05). The inflammasome proteins nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 1 (NLRP1), NLRP3, and nucleotide-binding oligomerization domain (NOD)-like receptor C4 (NLRC4) were associated with neutrophilic asthma and with sputum IL-1 beta protein levels, whereas eosinophilic asthma was associated with an IL-13-induced T-H(2) signature and IL-1 receptor-like 1 (IL1RL1) mRNA expression. These differences were sputum specific because no activation of NLRP3 or enrichment of IL-1R family genes in bronchial brushings or biopsy specimens in patients with SA was observed. Expression of NLRP3 and of the IL-1R family genes was validated in the Airway Disease Endotyping for Personalized Therapeutics cohort. Inflammasome inhibition using CRID3 prevented airway hyperresponsiveness and airway inflammation (both neutrophilia and eosinophilia) in a mouse model of severe allergic asthma. Conclusion: IL1RL1 gene expression is associated with eosinophilic SA, whereas NLRP3 inflammasome expression is highest in patients with neutrophilic SA. T-H(2)-driven eosinophilic inflammation and neutrophil-associated inflammasome activation might represent interacting pathways in patients with SA.	[Rossios, Christos; Hoda, Uruj; Wiegman, Coen; Russell, Kirsty; Durham, Andrew L.; Ojo, Oluwaseun; Chung, Kian Fan; Adcock, Ian M.] Imperial Coll London, Natl Heart Lung Inst, Airways Dis, London, England; [Rossios, Christos; Hoda, Uruj; Wiegman, Coen; Russell, Kirsty; Durham, Andrew L.; Ojo, Oluwaseun; Chung, Kian Fan; Adcock, Ian M.] Royal Brompton & Harefield NHS Trust, Biomed Res Unit, London, England; [Pavlidis, Stelios; Kuo, Chih-Hsi; Sun, Kai; Guo, Yike] Imperial Coll London, Dept Comp, London, England; [Pavlidis, Stelios; Kuo, Chih-Hsi; Sun, Kai; Guo, Yike] Imperial Coll London, Data Sci Inst, London, England; [Pavlidis, Stelios; Loza, Matthew J.; Baribaud, Frederic; Rowe, Anthony] Janssen Res & Dev, High Wycombe, Bucks, England; [Lutter, Rene] Univ Amsterdam, Fac Med, Amsterdam, Netherlands; [Bansal, Aruna] Acclarogen, St Johns Innovat Ctr, Cambridge, England; [Auffray, Charles] Univ Lyon, CNRS ENS UCBL, European Inst Syst Biol & Med, Lyon, France; [Sousa, Ana] GSK, Resp Therapeut Unit, Stockley Pk, England; [Corfield, Julie] AstraZeneca R&D, Molndal, Sweden; [Corfield, Julie] Areteva R&D, Nottingham, England; [Djukanovic, Ratko] Southampton Univ, Fac Med, Southampton, Hants, England; [Djukanovic, Ratko] Univ Hosp Southampton, NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Adcock, Ian M.] Univ Newcastle, Prior Res Ctr Hlth Lungs, Hunter Med Res Inst, Newcastle, NSW, Australia	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital; Imperial College London; Imperial College London; Johnson & Johnson; University of Amsterdam; St Johns Innovation Centre - UK; GlaxoSmithKline; AstraZeneca; University of Southampton; Hunter Medical Research Institute; University of Newcastle	Adcock, IM (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	ian.adcock@imperial.ac.uk	Adcock, Ian/L-3217-2019; Chung, Kian Fan/B-1872-2012; 郭, 伊可/GYD-3212-2022; Sterk, P.J./AAK-8175-2020	Chung, Kian Fan/0000-0001-7101-1426; Djukanovic, Ratko/0000-0001-6039-5612; Loza, Matthew/0000-0002-8609-118X; Durham, Andrew/0000-0003-2372-4688; Sun, Kai/0000-0002-2533-5937; Rossios, Christos/0000-0003-3470-3233; Rowe, Anthony/0000-0003-1829-1179; Adcock, Ian/0000-0003-2101-8843	Innovative Medicines Initiative Joint Undertaking [115010]; European Union's Seventh Framework Programme; IMI (EU) [115446]; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust; Imperial College London; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0514-10085] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish	Innovative Medicines Initiative Joint Undertaking; European Union's Seventh Framework Programme(European Commission); IMI (EU); NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust; Imperial College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes (U-BIOPRED) is supported through an Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115010, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution (www.imi.europa.eu). We would also like to acknowledge help from the IMI-funded eTRIKS project (EU Grant Code no. 115446). This project was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, The National Institute for Health Research or the Department of Health.	Aguilera-Aguirre L, 2009, J IMMUNOL, V183, P5379, DOI 10.4049/jimmunol.0900228; Alevy YG, 2012, J CLIN INVEST, V122, P4555, DOI 10.1172/JCI64896; Athey Brian D, 2013, AMIA Jt Summits Transl Sci Proc, V2013, P6; Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Bruchard M, 2015, NAT IMMUNOL, V16, P859, DOI 10.1038/ni.3202; Chung Kian Fan, 2013, Ann Am Thorac Soc, V10 Suppl, pS109, DOI 10.1513/AnnalsATS.201304-087AW; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Coll RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029539; De Alba J, 2015, CLIN SCI, V129, P973, DOI 10.1042/CS20150292; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hastie AT, 2013, J ALLERGY CLIN IMMUN, V132, P72, DOI 10.1016/j.jaci.2013.03.044; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Mabalirajan U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062916; Migita K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096703; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Morita H, 2012, ALLERGOL INT, V61, P265, DOI 10.2332/allergolint.11-OA-0379; PAVLIDIS S, 2015, AM J RESP CRIT CARE, V191; Pavord ID, 2002, EUR RESPIR J, V20, p40S, DOI 10.1183/09031936.02.00004002; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Rohloff JC, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.49; Schleich F, 2014, RESP MED, V108, P1723, DOI 10.1016/j.rmed.2014.10.007; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Silkoff PE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0299-y; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2014, EUR RESPIR J, V43, P1067, DOI 10.1183/09031936.00105013; Traister RS, 2015, J ALLERGY CLIN IMMUN, V135, P92, DOI 10.1016/j.jaci.2014.06.023; Wiegman CH, 2015, J ALLERGY CLIN IMMUN, V136, P769, DOI 10.1016/j.jaci.2015.01.046; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zhang QL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152724; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zhou Y, 2012, HUM IMMUNOL, V73, P1171, DOI 10.1016/j.humimm.2012.08.016	37	109	111	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					560	570		10.1016/j.jaci.2017.02.045	http://dx.doi.org/10.1016/j.jaci.2017.02.045			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28528200	Bronze, Green Submitted			2022-12-18	WOS:000424410800013
J	Stringari, G; Tripodi, S; Caffarelli, C; Dondi, A; Asero, R; Businco, ADR; Bianchi, A; Candelotti, P; Ricci, G; Bellini, F; Maiello, N; del Giudice, MM; Frediani, T; Sodano, S; Dello Iacono, I; Macri, F; Peparini, I; Dascola, CP; Patria, MF; Varin, E; Peroni, D; Comberiati, P; Chini, L; Moschese, V; Lucarelli, S; Bernardini, R; Pingitore, G; Pelosi, U; Tosca, M; Cirisano, A; Faggian, D; Travaglini, A; Plebani, M; Matricardi, PM				Stringari, Giovanna; Tripodi, Salvatore; Caffarelli, Carlo; Dondi, Arianna; Asero, Riccardo; Businco, Andrea Di Rienzo; Bianchi, Annamaria; Candelotti, Paolo; Ricci, Giampaolo; Bellini, Federica; Maiello, Nunzia; del Giudice, Michele Miraglia; Frediani, Tullio; Sodano, Simona; Dello Iacono, Iride; Macri, Francesco; Peparini, Ilaria; Dascola, Carlotta Povesi; Patria, Maria Francesca; Varin, Elena; Peroni, Diego; Comberiati, Pasquale; Chini, Loredana; Moschese, Viviana; Lucarelli, Sandra; Bernardini, Roberto; Pingitore, Giuseppe; Pelosi, Umberto; Tosca, Mariangela; Cirisano, Anastasia; Faggian, Diego; Travaglini, Alessandro; Plebani, Mario; Matricardi, Paolo Maria		I-PAN	The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; children; component-resolved diagnosis; IgE; panallergens; pollen; profilin; specific immunotherapy	ALLERGEN-SPECIFIC IMMUNOTHERAPY; POLYSENSITIZED PATIENTS; POLLEN ALLERGY; RHINITIS; ASTHMA; IMPACT; MANAGEMENT; GUIDE; REACTIVITY; PROFILES	Background: Sensitization to profilins and other cross-reacting molecules might hinder proper specific immunotherapy (SIT) prescription in polysensitized patients with pollen-related allergic rhinitis (AR). In these patients, component-resolved diagnosis (CRD) might modify SIT prescription by improving the identification of the disease-eliciting pollen sources. Objectives: We sought to measure the effect of CRD on SIT prescription in children with pollen-related AR. Methods: Children (n=651) with moderate-to-severe pollen-related AR were recruited between May 2009 and June 2011 in 16 Italian outpatient clinics. Skin prick test (SPT) reactivity to grass, cypress, olive, mugwort, pellitory, and/or Betulaceae pollen was considered clinically relevant if symptoms occurred during the corresponding peak pollen season. IgE sensitization to Phl p 1, Phl p 5, Bet v 1, Cup a 1, Art v 1, Ole e 1, Par j 2, and Phl p 12 (profilin) was measured by using ImmunoCAP. SIT prescription was modeled on SPT responses first and then remodeled considering also CRD according to GA 2 LEN-European Academy of Allergology and Clinical Immunology guidelines and the opinions of 14 pediatric allergists. Results: No IgE to the respective major allergens was detected in significant proportions of patients with supposed clinically relevant sensitization to mugwort (45/65 [69%]), Betulaceae (146/252 [60%]), pellitory (78/257 [30%]), olive (111/390 [28%]), cypress (28/184 [15%]), and grass (56/568 [10%]). IgE to profilins, polcalcins, or both could justify 173 (37%) of 464 of these SPT reactions. After CRD, the SPT-based decision on SIT prescription or composition was changed in 277 (42%) of 651 or 315 (48%) of 651 children according to the European or American approach, respectively, and in 305 (47%) of 651 children according to the opinion of the 14 local pediatric allergists. Conclusions: In children with pollen-related AR, applying CRD leads to changes in a large proportion of SIT prescriptions as opposed to relying on clinical history and SPT alone. The hypothesis that CRD-guided prescription improves SIT efficacy deserves to be tested.	[Stringari, Giovanna; Matricardi, Paolo Maria] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Stringari, Giovanna; Caffarelli, Carlo; Dascola, Carlotta Povesi] Univ Parma, Dept Clin & Expt Med, Dept Pediat, Unit Allergy & Immunol Evolut Age, I-43100 Parma, Italy; [Tripodi, Salvatore; Businco, Andrea Di Rienzo] Sandro Pertini Hosp, Pediat Allergol Unit, Rome, Italy; [Dondi, Arianna] Ramazzini Hosp, Dept Mother & Child, Pediat Unit, Carpi, Italy; [Dondi, Arianna; Ricci, Giampaolo; Bellini, Federica] Univ Bologna, Dept Med & Surg Sci, Pediat Unit, I-40126 Bologna, Italy; [Asero, Riccardo] Clin San Carlo, Allergy Unit, Milan, Italy; [Bianchi, Annamaria; Candelotti, Paolo] Mazzoni Hosp, Pediat Unit, Ascoli Piceno, Italy; [Maiello, Nunzia; del Giudice, Michele Miraglia] Univ Naples 2, Dept Pediat, Naples, Italy; [Frediani, Tullio; Sodano, Simona; Macri, Francesco; Peparini, Ilaria; Lucarelli, Sandra] Univ Roma La Sapienza, Dept Pediat, I-00185 Rome, Italy; [Dello Iacono, Iride] Fatebenefratelli Hosp, Pediat Unit, Benevento, Italy; [Patria, Maria Francesca] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Pediat Highly Intens Care Unit, Milan, Italy; [Varin, Elena] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Pediat Clin 2, Milan, Italy; [Peroni, Diego; Comberiati, Pasquale] GB Rossi Hosp, Pediat Unit, Verona, Italy; [Chini, Loredana; Moschese, Viviana] Univ Roma Tor Vergata, Policlin tor Vergata, Unit Pediat Allergy & Immunol, Rome, Italy; [Bernardini, Roberto] San Giuseppe Hosp, Pediat Unit, Empoli, Italy; [Pingitore, Giuseppe] Grassi Hosp, Pediat Unit, Rome, Italy; [Pelosi, Umberto] Santa Barbara Hosp, Pediat Unit, Iglesias, Italy; [Tosca, Mariangela] G Gaslini Hosp, Pulm Dis & Allergy Unit, Genoa, Italy; [Cirisano, Anastasia] Pediat Unit, Crotone, Italy; [Faggian, Diego; Plebani, Mario] Univ Padua, Dept Lab Med, I-35100 Padua, Italy; [Travaglini, Alessandro] Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Parma; University Hospital of Parma; Ospedale Sandro Pertini; University of Bologna; Universita della Campania Vanvitelli; Sapienza University Rome; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Rome Tor Vergata; Policlin Tor Vergata; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Padua; University of Rome Tor Vergata	Matricardi, PM (corresponding author), Charite, Dept Paediat Pneumol & Immunol, Augustenburgerpl 1, D-13353 Berlin, Germany.	paolo.matricardi@charite.de	Peroni, Diego G/K-4002-2018; Caffarelli, Carlo/AAC-2488-2022; Comberiati, Pasquale/P-6904-2018; MOSCHESE, VIVIANA/AHE-8931-2022; Plebani, Mario/AAF-4953-2020; Dondi, Arianna/E-4269-2012; pingitore, Giuseppe/ABG-8047-2020; Peroni, Diego/K-8795-2016	Comberiati, Pasquale/0000-0001-5209-9733; MOSCHESE, VIVIANA/0000-0001-7650-0632; Dondi, Arianna/0000-0002-7516-243X; MIRAGLIA DEL GIUDICE, Michele/0000-0002-8369-5957; Peroni, Diego/0000-0002-0234-1373	Thermo Fisher (Phadia); Charite University Hospital, Berlin, Germany; TFS; Allergopharma	Thermo Fisher (Phadia); Charite University Hospital, Berlin, Germany; TFS; Allergopharma	Disclosure of potential conflict of interest: S. Tripodi has received a lecture fee from Thermo Fisher (Phadia). A. Dondi has received consultancy fees from Charite University Hospital, Berlin, Germany. P. M. Matricardi has received research support from TFS and lecture fees from TFS and Allergopharma. The rest of the authors declare that they have no relevant conflicts of interest.	Aceituno E, 2000, CLIN EXP ALLERGY, V30, P1750, DOI 10.1046/j.1365-2222.2000.00949.x; Asero R, 2010, J INVEST ALLERG CLIN, V20, P35; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Assing K, 2007, ALLERGY, V62, P373, DOI 10.1111/j.1398-9995.2006.01280.x; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bousquet J, 2012, ALLERGY, V67, P18, DOI 10.1111/j.1398-9995.2011.02728.x; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Bufe A, 2011, CLIN EXP ALLERGY, V41, P1256, DOI 10.1111/j.1365-2222.2011.03740.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Calderon MA, 2012, J ALLERGY CLIN IMMUN, V129, P929, DOI 10.1016/j.jaci.2011.11.019; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Cox L, 2009, ANN ALLERG ASTHMA IM, V103, P451, DOI 10.1016/S1081-1206(10)60259-1; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; Dondi A, 2013, PEDIAT ALLERG IMM-UK, V24, P742, DOI 10.1111/pai.12136; Douladiris N, 2013, INT ARCH ALLERGY IMM, V162, P65, DOI 10.1159/000353113; Ghunaim N, 2005, ALLERGY, V60, P185, DOI 10.1111/j.1398-9995.2005.00662.x; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196, DOI 10.1016/S0091-6749(98)70384-7; Jauregui I, 2011, PEDIAT ALLERG IMM-UK, V22, P388, DOI 10.1111/j.1399-3038.2010.01108.x; Mari A, 2001, INT ARCH ALLERGY IMM, V125, P57, DOI 10.1159/000053797; Mari A, 2006, INT ARCH ALLERGY IMM, V141, P57, DOI 10.1159/000094254; Passalacqua G, 2013, ALLERGY, V68, P1029, DOI 10.1111/all.12194; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Sastre J, 2012, ALLERGY, V67, P709, DOI 10.1111/j.1398-9995.2012.02808.x; Scala E, 2010, CLIN EXP ALLERGY, V40, P911, DOI 10.1111/j.1365-2222.2010.03470.x; Tozzi AE, 2011, PEDIAT ALLERG IMM-UK, V22, P267, DOI 10.1111/j.1399-3038.2011.01157.x; Tripodi S, 2012, J ALLERGY CLIN IMMUN, V129, P834, DOI 10.1016/j.jaci.2011.10.045; Valenta R, 2007, J INVEST ALLERG CLIN, V17, P36; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Weber RW, 2007, ANN ALLERG ASTHMA IM, V99, P203, DOI 10.1016/S1081-1206(10)60654-0; Zuberbier T, 2010, ALLERGY, V65, P1525, DOI 10.1111/j.1398-9995.2010.02474.x	32	109	110	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					75	+		10.1016/j.jaci.2014.01.042	http://dx.doi.org/10.1016/j.jaci.2014.01.042			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24794684				2022-12-18	WOS:000338930300011
J	Hamsten, C; Tran, TAT; Starkhammar, M; Brauner, A; Commins, SP; Platts-Mills, TAE; van Hage, M				Hamsten, Carl; Tran, Thi Anh T.; Starkhammar, Maria; Brauner, Annelie; Commins, Scott P.; Platts-Mills, Thomas A. E.; van Hage, Marianne			Red meat allergy in Sweden: Association with tick sensitization and B-negative blood groups	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INDUCED ANAPHYLAXIS; HUMAN BASOPHILS; IGE; GALACTOSE-ALPHA-1,3-GALACTOSE; RELEVANCE		[Hamsten, Carl; Tran, Thi Anh T.; van Hage, Marianne] Karolinska Inst, Clin Immunol & Allergy Unit, Dept Med Solna, Stockholm, Sweden; [Hamsten, Carl; Tran, Thi Anh T.; Brauner, Annelie; van Hage, Marianne] St Gorans Univ Hosp, S-11281 Stockholm, Sweden; [Hamsten, Carl] Karolinska Inst, Ctr Inflammatory Dis, Stockholm, Sweden; [Starkhammar, Maria] Soder Sjukhuset, Dept Internal Med, Stockholm, Sweden; [Brauner, Annelie] Karolinska Inst, Div Clin Microbiol, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Commins, Scott P.; Platts-Mills, Thomas A. E.] Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Karolinska Institutet; Saint Goran's Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; University of Virginia	Hamsten, C (corresponding author), Karolinska Inst, Clin Immunol & Allergy Unit, Dept Med Solna, Stockholm, Sweden.	marianne.van.hage@ki.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Hamsten, Carl/0000-0002-1830-9431; Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI085190, T32AI007496] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI007496, K08 AI085190] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Celik GE, 2009, CLIN EXP ALLERGY, V39, P1522, DOI 10.1111/j.1365-2222.2009.03277.x; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Frischmeyer-Guerrerio PA, 2011, CLIN EXP ALLERGY, V41, P61, DOI 10.1111/j.1365-2222.2010.03606.x; Frischmeyer-Guerrerio PA, 2012, J IMMUNOL METHODS, V383, P21, DOI 10.1016/j.jim.2011.12.007; Hamsten C, 2013, ALLERGY, V68, P549, DOI 10.1111/all.12128; Ishmael SS, 2010, J LEUKOCYTE BIOL, V87, P291, DOI 10.1189/jlb.0509336; Jacquenet S, 2009, J ALLERGY CLIN IMMUN, V124, P603, DOI 10.1016/j.jaci.2009.06.014; Morisset M, 2012, ALLERGY, V67, P609, DOI 10.1111/j.1398-9995.2012.02799.x; Nunez R, 2011, J ALLERGY CLIN IMMUN, V128, P1122, DOI 10.1016/j.jaci.2011.07.020; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Rispens T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055566; Ronmark E, 2009, J ALLERGY CLIN IMMUN, V124, P357, DOI 10.1016/j.jaci.2009.05.011; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; Schroeder JT, 2002, MANUAL CLIN LAB IMMU, P899	16	109	110	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1431	1434		10.1016/j.jaci.2013.07.050	http://dx.doi.org/10.1016/j.jaci.2013.07.050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	24094548	Bronze, Green Accepted			2022-12-18	WOS:000327538200024
J	Abonia, JP; Wen, T; Stucke, EM; Grotjan, T; Griffith, MS; Kemme, KA; Collins, MH; Putnam, PE; Franciosi, JP; von Tiehl, KF; Tinkle, BT; Marsolo, KA; Martin, LJ; Ware, SM; Rothenberg, ME				Abonia, J. Pablo; Wen, Ting; Stucke, Emily M.; Grotjan, Tommie; Griffith, Molly S.; Kemme, Katherine A.; Collins, Margaret H.; Putnam, Philip E.; Franciosi, James P.; von Tiehl, Karl F.; Tinkle, Brad T.; Marsolo, Keith A.; Martin, Lisa J.; Ware, Stephanie M.; Rothenberg, Marc E.			High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; eosinophilic gastrointestinal disease; eosinophil; connective tissue disorders; Ehlers-Danlos syndrome; Marfan syndrome; hypermobility syndrome	EHLERS-DANLOS-SYNDROME; AORTIC-ANEURYSM PROGRESSION; GROWTH-FACTOR-BETA; MARFAN-SYNDROME; TGF-BETA; GASTROESOPHAGEAL-REFLUX; SPONTANEOUS RUPTURE; MUTATIONS; LOSARTAN; DISEASE	Background: Eosinophilic esophagitis (EoE) is an emerging chronic inflammatory disease mediated by immune hypersensitization to multiple foods and strongly associated with atopy and esophageal remodeling. Objective: We provide clinical and molecular evidence indicating a high prevalence of EoE in patients with inherited connective tissue disorders (CTDs). Methods: We examined the rate of EoE among patients with CTDs and subsequently analyzed esophageal mRNA transcript profiles in patients with EoE with or without CTD features. Results: We report a cohort of 42 patients with EoE with a CTD-like syndrome, representing 0.8% of patients with CTDs and 1.3% of patients with EoE within our hospital-wide electronic medical record database and our EoE research registry, respectively. An 8-fold risk of EoE in patients with CTDs (relative risk, 8.1; 95% confidence limit, 5.1-12.9; chi(2) 1=5 112.0; P < 10(-3)) was present compared with the general population. Esophageal transcript profiling identified a distinct subset of genes, including COL8A2, in patients with EoE and CTDs. Conclusion: There is a remarkable association of EoE with CTDs and evidence for a differential expression of genes involved in connective tissue repair in this cohort. Thus, we propose stratification of patients with EoE and CTDs into a subset referred to as EoE-CTD.	[Abonia, J. Pablo; Wen, Ting; Stucke, Emily M.; Grotjan, Tommie; Griffith, Molly S.; Kemme, Katherine A.; von Tiehl, Karl F.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Allergy & Immunol, Cincinnati, OH 45221 USA; [Collins, Margaret H.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Pathol & Lab Med, Cincinnati, OH 45221 USA; [Putnam, Philip E.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Gastroenterol Hematol & Nutr, Cincinnati, OH 45221 USA; [Marsolo, Keith A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Biomed Informat, Cincinnati, OH 45221 USA; [Martin, Lisa J.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Biostat & Epidemiol, Cincinnati, OH 45221 USA; [Martin, Lisa J.; Ware, Stephanie M.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Human Genet, Cincinnati, OH 45221 USA; [Ware, Stephanie M.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat,Div Cardiol, Cincinnati, OH 45221 USA; [Franciosi, James P.] Nemours Childrens Hosp, Div Gastroenterol Hepatol & Nutr, Orlando, FL USA; [Tinkle, Brad T.] Advocate Med Grp, Park Ridge, IL USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,ML7028, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org	Ware, Stephanie M./AAF-5577-2020; Martin, Lisa/E-2425-2016	Martin, Lisa/0000-0001-8702-9946; Abonia, Juan/0000-0003-3788-6485	National Institutes of Health, Food Allergy Research and Education; Food Allergy and Anaphylaxis Network; Buckeye Foundation; Campaign Urging Research for Eosinophilic Diseases (CURED) Foundation; Meritage; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083450, R01AI045898, U19AI070235, R37AI045898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392, P30DK090971] Funding Source: NIH RePORTER	National Institutes of Health, Food Allergy Research and Education; Food Allergy and Anaphylaxis Network; Buckeye Foundation; Campaign Urging Research for Eosinophilic Diseases (CURED) Foundation; Meritage; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	J. P. Abonia, E. M. Stucke, M. S. Griffith, K. A. Kemme, M. H. Collins, L. J. Martin, and S. M. Ware have been supported by one or more grants from the National Institutes of Health, Food Allergy Research and Education, the Food Allergy and Anaphylaxis Network, the Buckeye Foundation, and the Campaign Urging Research for Eosinophilic Diseases (CURED) Foundation. M. H. Collins is a volunteer with American Partnership for Eosinophilic Disorders (APFED), TIGERS, and REGID and has been supported by Meritage. L. J. Martin is employed by Cincinnati Children's Hospital Medical Center, has one or more patents (planned, pending, or issued) with Cincinnati Children's Hospital Medical Center, and owns stock/stock options in Sara Lee. M. E. Rothenberg is a Board member for the International Eosinophil Society and the APFED; serves as Consultant and Director of the Scientific Advisory Board of, owns stock/stock options in, and has received one or more payments for travel/accommodations/meeting expenses from Immune Pharm; has received one or more grants from or has one or more grants pending with the National Institutes of Health and the Department of Defense; is the inventor of patents that are owned by Cincinnati Children's Hospital Medical Center; and has potential royalties from Teva Pharmaceuticals for reslizumab. The rest of the authors declare that they have no relevant conflicts of interest.	Abonia JP, 2012, ANNU REV MED, V63, P421, DOI 10.1146/annurev-med-041610-134138; Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P1205, DOI 10.1016/j.jaci.2010.10.031; Aceves SS, 2010, ALLERGY, V65, P109, DOI 10.1111/j.1398-9995.2009.02142.x; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.0.CO;2-O; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Buchman AL, 1996, SOUTHERN MED J, V89, P327, DOI 10.1097/00007611-199603000-00014; CLARK JG, 1980, AM REV RESPIR DIS, V122, P971; DeBrosse CW, 2006, PEDIATR DEVEL PATHOL, V9, P210, DOI 10.2350/11-05-0130.1; Dent J, 2005, GUT, V54, P710, DOI 10.1136/gut.2004.051821; DePaepe A, 1997, AM J HUM GENET, V60, P547; DESCHRYVERKECSKEMETI K, 1984, AM J SURG PATHOL, V8, P171, DOI 10.1097/00000478-198403000-00002; Eliashar R, 1998, POSTGRAD MED J, V74, P495, DOI 10.1136/pgmj.74.874.495; Fuentebella J, 2010, J PEDIATR GASTR NUTR, V51, P283, DOI 10.1097/MPG.0b013e3181e0817b; Gambarin FI, 2009, J CARDIOVASC MED, V10, P354, DOI 10.2459/JCM.0b013e3283232a45; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Gottsch JD, 2005, INVEST OPHTH VIS SCI, V46, P1934, DOI 10.1167/iovs.04-0937; Habashi JP, 2011, SCIENCE, V332, P361, DOI 10.1126/science.1192152; Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287; HABEIN HC, 1977, ROCKY MT MED J, V74, P78; HALL JR, 1984, ANN THORAC SURG, V37, P500, DOI 10.1016/S0003-4975(10)61142-3; He RM, 2008, J THORAC CARDIOV SUR, V136, P922, DOI 10.1016/j.jtcvs.2007.12.063; Henderson CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1570, DOI 10.1016/j.jaci.2012.03.023; Holm TM, 2011, SCIENCE, V332, P358, DOI 10.1126/science.1192149; Jones JA, 2009, J VASC RES, V46, P119, DOI 10.1159/000151766; Judge DP, 2005, LANCET, V366, P1965, DOI 10.1016/S0140-6736(05)67789-6; Kahai S, 2004, MATRIX BIOL, V23, P445, DOI 10.1016/j.matbio.2004.09.004; Kapel RC, 2008, GASTROENTEROLOGY, V134, P1316, DOI 10.1053/j.gastro.2008.02.016; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Lacro RV, 2007, AM HEART J, V154, P624, DOI 10.1016/j.ahj.2007.06.024; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lindsay ME, 2012, NAT GENET, V44, P922, DOI 10.1038/ng.2349; Loeffler I, 2011, J AM SOC NEPHROL, V22, P649, DOI 10.1681/ASN.2010010098; Loeys BL, 2010, J MED GENET, V47, P476, DOI 10.1136/jmg.2009.072785; Lucarini L, 2009, INT J CARDIOL, V131, P281, DOI 10.1016/j.ijcard.2007.07.048; Lwin T, 2011, MODERN PATHOL, V24, P556, DOI 10.1038/modpathol.2010.221; Matt P, 2009, CIRCULATION, V120, P526, DOI 10.1161/CIRCULATIONAHA.108.841981; Matyas G, 2006, HUM MUTAT, V27, P760, DOI 10.1002/humu.20353; Mendis Michael, 2008, AMIA Annu Symp Proc, P1054; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Mizuguchi T, 2004, NAT GENET, V36, P855, DOI 10.1038/ng1392; Moltzer E, 2011, PHARMACOL THERAPEUT, V131, P50, DOI 10.1016/j.pharmthera.2011.04.002; Murphy Shawn N, 2006, AMIA Annu Symp Proc, P1040; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Reis ED, 1998, EUR J SURG, V164, P313; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Singh KK, 2006, HUM MUTAT, V27, P770, DOI 10.1002/humu.20354; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336, DOI 10.1016/S1081-1206(10)61151-9; Steinmann B., 2002, CONNECTIVE TISSUE IT, P431, DOI DOI 10.1002/0471221929.CH9; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Symoens S, 2011, BIOCHEM J, V433, P371, DOI 10.1042/BJ20101061; Wang Y, 2010, J CLIN INVEST, V120, P422, DOI 10.1172/JCI38136; Zhu X, 2009, AM J PHYSIOL-GASTR L, V297, pG550, DOI 10.1152/ajpgi.00148.2009	59	109	112	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					378	386		10.1016/j.jaci.2013.02.030	http://dx.doi.org/10.1016/j.jaci.2013.02.030			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23608731	Green Accepted			2022-12-18	WOS:000322631700015
J	Price, MM; Oskeritzian, CA; Falanga, YT; Harikumar, KB; Allegood, JC; Alvarez, SE; Conrad, D; Ryan, JJ; Milstien, S; Spiegel, S				Price, Megan M.; Oskeritzian, Carole A.; Falanga, Yves T.; Harikumar, Kuzhuvelil B.; Allegood, Jeremy C.; Alvarez, Sergio E.; Conrad, Daniel; Ryan, John J.; Milstien, Sheldon; Spiegel, Sarah			A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sphingosine-1-phosphate; sphingosine kinase; mast cells; nuclear factor kappa B; airway hyperresponsiveness; asthma	FC-EPSILON-RI; FACTOR-KAPPA-B; REGULATES MUCIN PRODUCTION; CYTOKINE PRODUCTION; MULTIPLE FEATURES; GENE-EXPRESSION; MICE; SPHINGOSINE-1-PHOSPHATE; RESPONSES; IMMUNITY	Background: Sphingosine-1-phosphate (S1P), which is produced by 2 sphingosine kinase (SphK) isoenzymes, SphK1 and SphK2, has been implicated in IgE-mediated mast cell responses. However, studies of allergic inflammation in isotype-specific SphK knockout mice have not clarified their contribution, and the role that S1P plays in vivo in a mast cell- and IgE-dependent murine model of allergic asthma has not yet been examined. Objective: We used an isoenzyme-specific SphK1 inhibitor, SK1-I, to investigate the contributions of S1P and SphK1 to mast cell-dependent airway hyperresponsiveness (AHR) and airway inflammation in mice. Methods: Allergic airway inflammation and AHR were examined in a mast cell-dependent murine model of ovalbumin (OVA)-induced asthma. C57BL/6 mice received intranasal delivery of SK1-I before sensitization and challenge with OVA or only before challenge. Results: SK1-I inhibited antigen-dependent activation of human and murine mast cells and suppressed activation of nuclear factor kappa B (NF-kappa B), a master transcription factor that regulates the expression of proinflammatory cytokines. SK1-I treatment of mice sensitized to OVA in the absence of adjuvant, in which mast cell-dependent allergic inflammation develops, significantly reduced OVA-induced AHR to methacholine; decreased numbers of eosinophils and levels of the cytokines IL-4, IL-5, IL-6, IL-13, IFN-gamma, and TNF-alpha and the chemokines eotaxin and CCL2 in bronchoalveolar lavage fluid; and decreased pulmonary inflammation, as well as activation of NF-kappa B in the lungs. Conclusion: S1P and SphK1 play important roles in mast cell-dependent, OVA-induced allergic inflammation and AHR, in part by regulating the NF-kappa B pathway. (J Allergy Clin Immunol 2013;131:501-11.)	[Price, Megan M.; Oskeritzian, Carole A.; Harikumar, Kuzhuvelil B.; Allegood, Jeremy C.; Alvarez, Sergio E.; Milstien, Sheldon; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Conrad, Daniel] Virginia Commonwealth Univ, Sch Med, Dept Microbiol & Immunol, Richmond, VA 23298 USA; [Falanga, Yves T.; Ryan, John J.] Virginia Commonwealth Univ, Dept Biol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Box 980614, Richmond, VA 23298 USA.	sspiegel@vcu.edu	Harikumar, Kuzhuvelil/AAC-2407-2020	Harikumar, Kuzhuvelil/0000-0002-1763-4179	National Institutes of Health (NIH) [RO1AI50094, U19AI077435, K01AR053186]; NIH/NINDS center core grant [5P30NS047463]; National Institutes of Health; Asthma and Allergic Diseases Cooperative Research Centers; NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050094, R01AI101153, R01AI095494, U19AI077435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR053186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047463] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NINDS center core grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Asthma and Allergic Diseases Cooperative Research Centers; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by National Institutes of Health (NIH) grants RO1AI50094 and U19AI077435 (to S. S.) and K01AR053186 (to C.A.O.). The Virginia Commonwealth University microscopy core laboratory is supported in part by the NIH/NINDS center core grant 5P30NS047463.; J. C. Allegood has received grants from the National Institutes of Health. S. Spiegel and D. Conrad have received grants from the Asthma and Allergic Diseases Cooperative Research Centers. J. J. Ryan has received grants from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Brewer JM, 1999, J IMMUNOL, V163, P6448; Broide DH, 2005, P NATL ACAD SCI USA, V102, P17723, DOI 10.1073/pnas.0509235102; Campbell EM, 1999, J IMMUNOL, V163, P2160; Chiba Yoshihiko, 2010, Open Respir Med J, V4, P82, DOI 10.2174/1874306401004010082; Chiba Y, 2010, J PHARMACOL SCI, V114, P304, DOI 10.1254/jphs.10202FP; Choi OH, 1996, NATURE, V380, P634; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Gomez G, 2005, J IMMUNOL, V175, P7602, DOI 10.4049/jimmunol.175.11.7602; Haberberger RV, 2009, J ALLERGY CLIN IMMUN, V124, P933, DOI 10.1016/j.jaci.2009.06.034; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Klemm S, 2006, J EXP MED, V203, P337, DOI 10.1084/jem.20051982; Klemm S, 2006, IMMUNOBIOLOGY, V211, P815, DOI 10.1016/j.imbio.2006.07.001; Kono Y, 2010, PULM PHARMACOL THER, V23, P36, DOI 10.1016/j.pupt.2009.10.005; Kumar A, 2011, CELL SIGNAL, V23, P1144, DOI 10.1016/j.cellsig.2011.02.009; Lai WQ, 2008, J IMMUNOL, V180, P4323, DOI 10.4049/jimmunol.180.6.4323; LIU FT, 1980, J IMMUNOL, V124, P2728; Macey MR, 2010, J IMMUNOL, V184, P4688, DOI 10.4049/jimmunol.0903477; Mathews JA, 2011, ALLERGY, V66, P1193, DOI 10.1111/j.1398-9995.2011.02614.x; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Nakae S, 2007, J ALLERGY CLIN IMMUN, V119, P680, DOI 10.1016/j.jaci.2006.11.701; Nishiuma T, 2008, AM J PHYSIOL-LUNG C, V294, pL1085, DOI 10.1152/ajplung.00445.2007; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; Olivera A, 2007, IMMUNITY, V26, P287, DOI 10.1016/j.immuni.2007.02.008; Olivera A, 2011, ADV EXP MED BIOL, V716, P123, DOI 10.1007/978-1-4419-9533-9_8; Oskeritzian CA, 2008, BLOOD, V111, P4193, DOI 10.1182/blood-2007-09-115451; Paugh SW, 2008, BLOOD, V112, P1382, DOI 10.1182/blood-2008-02-138958; Puneet P, 2010, SCIENCE, V328, P1290, DOI 10.1126/science.1188635; Pushparaj PN, 2009, J IMMUNOL, V183, P221, DOI 10.4049/jimmunol.0803430; Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400; Rogerio AP, 2010, PHARMACOL RES, V61, P288, DOI 10.1016/j.phrs.2009.10.005; Roviezzo F, 2007, AM J RESP CELL MOL, V36, P757, DOI 10.1165/rcmb.2006-0383OC; Roviezzo F, 2010, AM J RESP CELL MOL, V42, P572, DOI 10.1165/rcmb.2009-0108OC; Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Wolters PJ, 2005, CLIN EXP ALLERGY, V35, P82, DOI 10.1111/j.1365-2222.2005.02136.x; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702	46	109	116	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					501	+		10.1016/j.jaci.2012.07.014	http://dx.doi.org/10.1016/j.jaci.2012.07.014			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	22939756	Green Accepted			2022-12-18	WOS:000314661500030
J	Savilahti, EM; Rantanen, V; Lin, JS; Karinen, S; Saarinen, KM; Goldis, M; Makela, MJ; Hautaniemi, S; Savilahti, E; Sampson, HA				Savilahti, Emma M.; Rantanen, Ville; Lin, Jing S.; Karinen, Sirkku; Saarinen, Kristiina M.; Goldis, Marina; Makela, Mika J.; Hautaniemi, Sampsa; Savilahti, Erkki; Sampson, Hugh A.			Early recovery from cow's milk allergy is associated with decreasing IgE and increasing IgG4 binding to cow's milk epitopes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cow's milk allergy; tolerance; epitope; IgE; IgG4; IgA	GRASS-POLLEN IMMUNOTHERAPY; IMMUNOLOGICAL CHANGES; CLINICAL-COURSE; TOLERANCE; ANTIBODIES; CHILDREN; RESPONSES; INFANTS; MUCOSAL; CELLS	Background: The dynamics and balance of allergen-specific IgG4, and IgA binding might contribute to the development of tolerance in patients with cow's milk allergy (CMA). Profiling of antibody binding to cow's milk (CM) protein epitopes might help in predicting the natural history of allergy. Objective: We sought to investigate differences in IgE, IgG4, and IgA binding to CM epitopes over time between patients with early recovery or with persisting CMA. Methods: We studied serum samples at the time of diagnosis (mean age, 7 months), 1 year later, and at follow-up (mean age, 8.6 years) from 11 patients with persisting IgE-mediated CMA at age 8 to 9 years and 12 patients who recovered by age 3 years. We measured the binding of IgE, IgG4, and IgA antibodies to sequential epitopes derived from 5 major CM proteins with a peptide microarray based immunoassay. We analyzed the data with a novel image-processing method together with machine learning prediction. Results: IgE epitope binding patterns were stable over time in patients with persisting CMA, whereas binding decreased in patients who recovered early. Binding patterns of IgE and IgG4 overlapped. Among patients who recovered early, the signal of IgG4 binding increased and that of IgE decreased over time. IgE and IgG4 binding to a panel of alpha(s1)-, alpha(s2)-, beta-, and kappa-casein regions predicted outcome with significant accuracy. Conclusions: Attaining tolerance to CM is associated with decreased epitope binding by IgE and a concurrent increase in corresponding epitope binding by IgG4. (J Allergy Clin Immunol 2010;125:1315-21.)	[Lin, Jing S.; Goldis, Marina; Sampson, Hugh A.] Mt Sinai Sch Med, Div Pediat Allergy, New York, NY 10029 USA; [Lin, Jing S.; Goldis, Marina; Sampson, Hugh A.] Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY 10029 USA; [Savilahti, Emma M.; Saarinen, Kristiina M.; Savilahti, Erkki] Univ Helsinki, Hosp Children & Adolescents, FIN-00014 Helsinki, Finland; [Rantanen, Ville; Karinen, Sirkku; Hautaniemi, Sampsa] Univ Helsinki, Computat Syst Biol Lab, Inst Biomed, Fac Med, FIN-00014 Helsinki, Finland; [Makela, Mika J.] Univ Helsinki, Hosp Allerg & Skin Dis, FIN-00014 Helsinki, Finland; [Rantanen, Ville; Karinen, Sirkku; Hautaniemi, Sampsa] Univ Helsinki, Genome Scale Biol Res Program, Fac Med, FIN-00014 Helsinki, Finland	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki	Sampson, HA (corresponding author), Mt Sinai Sch Med, Div Pediat Allergy, POB 1198, New York, NY 10029 USA.	hugh.sampson@mssm.edu	Lin, Jing/C-8877-2010; Hautaniemi, Sampsa/CAG-0362-2022; Hautaniemi, Sampsa/A-3122-2009	Hautaniemi, Sampsa/0000-0002-7749-2694; Hautaniemi, Sampsa/0000-0002-7749-2694; Makela, Mika/0000-0002-2933-3111; Rantanen, Ville/0000-0002-0105-7071	Helsinki University Central Hospital; Foundation for Pediatric Research (Finland); National Institute of Allergy and Infectious Diseases [AI44326]; Food Allergy Initiative; National Institute of Allergy and Infectious Diseases/National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI044236] Funding Source: NIH RePORTER	Helsinki University Central Hospital; Foundation for Pediatric Research (Finland); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy Initiative; National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by Helsinki University Central Hospital Research Funds, the Foundation for Pediatric Research (Finland), grant AI44326 from the National Institute of Allergy and Infectious Diseases, and a grant from the Food Allergy Initiative.; Disclosure of potential conflict of interest: E. M. Savilahti has received research support from the Foundation for Pediatric Research, Finland, and Helsinki University Central Hospital Research Funds. E. Savilahti has received research support from Helsinki University Central Hospital Research Funds. H. A. Sampson is a consultant for and holds shares in Allertein Pharmaceuticals, LLC; has received research support from the Food Allergy Initiative and the National Institute of Allergy and Infectious Diseases/National Institutes of Health; is a consultant/scientific advisor for the Food Allergy Initiative; and is a part owner of Herbal Springs, LLC. The rest of the authors have declared that they have no conflict of interest.	Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P1293, DOI 10.1046/j.1365-2222.2002.01470.x; Bussmann C, 2007, CLIN EXP ALLERGY, V37, P1277, DOI 10.1111/j.1365-2222.2007.02783.x; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Cocco RR, 2007, CLIN EXP ALLERGY, V37, P831, DOI 10.1111/j.1365-2222.2007.02712.x; Feng YQ, 2003, 2003 INTERNATIONAL CONFERENCE ON MACHINE LEARNING AND CYBERNETICS, VOLS 1-5, PROCEEDINGS, P2085, DOI 10.1109/ICMLC.2003.1259848; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kingsford C, 2008, NAT BIOTECHNOL, V26, P1011, DOI 10.1038/nbt0908-1011; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Lin J, 2009, J ALLERGY CLIN IMMUN, V124, P315, DOI 10.1016/j.jaci.2009.05.024; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Pilette C, 2007, J IMMUNOL, V178, P4658, DOI 10.4049/jimmunol.178.7.4658; Reif DM, 2009, GENES IMMUN, V10, P112, DOI 10.1038/gene.2008.80; Ruiter B, 2007, CLIN EXP ALLERGY, V37, P1103, DOI 10.1111/j.1365-2222.2007.02749.x; Saarinen KM, 2005, J ALLERGY CLIN IMMUN, V116, P869, DOI 10.1016/j.jaci.2005.06.018; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Saarinen KM, 2000, CLIN EXP ALLERGY, V30, P400, DOI 10.1046/j.1365-2222.2000.00732.x; Sathe SK, 2005, BIOTECHNOL ADV, V23, P423, DOI 10.1016/j.biotechadv.2005.05.008; Savilahti EM, 2010, CLIN EXP ALLERGY, V40, P251, DOI 10.1111/j.1365-2222.2009.03409.x; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Vanto T, 2004, J PEDIATR-US, V144, P218, DOI 10.1016/j.jpeds.2003.10.063; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wal JM, 2004, ANN ALLERG ASTHMA IM, V93, pS2, DOI 10.1016/S1081-1206(10)61726-7; Witten I.H., 2005, P DATA MINING LAS VE, P4	32	109	115	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1315	1321		10.1016/j.jaci.2010.03.025	http://dx.doi.org/10.1016/j.jaci.2010.03.025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20462631	Green Accepted			2022-12-18	WOS:000278831000020
J	Torres, MJ; Ariza, A; Mayorga, C; Dona, I; Blanca-Lopez, N; Rondon, C; Blanca, M				Jose Torres, Maria; Ariza, Adriana; Mayorga, Cristobalina; Dona, Inmaculada; Blanca-Lopez, Natalia; Rondon, Carmen; Blanca, Miguel			Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BASOPHIL ACTIVATION; BETA-LACTAMS; ALLERGIC REACTIONS; DIAGNOSIS; RELEASE		[Jose Torres, Maria; Dona, Inmaculada; Rondon, Carmen; Blanca, Miguel] Carlos Haya Hosp, Allergy Serv, Malaga, Spain; [Ariza, Adriana; Mayorga, Cristobalina; Blanca-Lopez, Natalia] Carlos Haya Hosp, Res Unit Allerg Dis, Malaga, Spain	Hospital Carlos Haya; Hospital Carlos Haya	Torres, MJ (corresponding author), Carlos Haya Hosp, Allergy Serv, Malaga, Spain.	mjtorresj@gmail.com	Veguillas, Adriana Ariza/X-3696-2018; Mayorga, Cristobalina/D-7167-2018; Torres, María José/T-3518-2017; Mayorga, Lina/FBO-7730-2022; Torres, Maria/GVU-3391-2022	Veguillas, Adriana Ariza/0000-0003-1524-9602; Mayorga, Cristobalina/0000-0001-8852-8077; Torres, María José/0000-0001-5228-471X; RONDON SEGOVIA, CARMEN/0000-0003-0976-3402				Antunez C, 2006, CURR PHARM DESIGN, V12, P3327, DOI 10.2174/138161206778194042; Blanca M, 2009, ALLERGY, V64, P183, DOI [10.1111/j.1398-9995.2008.01924.x, 10.1111/j.1398-9995.2008.01916.x]; Bousquet PJ, 2005, J ALLERGY CLIN IMMUN, V115, P1314, DOI 10.1016/j.jaci.2005.02.026; EDWARDS RG, 1988, INT ARCH ALLER A IMM, V85, P184, DOI 10.1159/000234500; FERNANDEZRIVAS M, 1995, J ALLERGY CLIN IMMUN, V95, P748, DOI 10.1016/S0091-6749(95)70181-8; Longo N, 2008, J INVEST ALLERG CLIN, V18, P473; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; Mochizuki A, 2003, J ALLERGY CLIN IMMUN, V112, P102, DOI 10.1067/mai.2003.1511; Torres MJ, 2004, CLIN EXP ALLERGY, V34, P1768, DOI 10.1111/j.1365-2222.2004.02110.x	9	109	112	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					502	505		10.1016/j.jaci.2009.11.032	http://dx.doi.org/10.1016/j.jaci.2009.11.032			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159266	Bronze			2022-12-18	WOS:000274764000036
J	Renner, ED; Hartl, D; Rylaarsdam, S; Young, ML; Monaco-Shawver, L; Kleiner, G; Markert, ML; Stiehm, ER; Belohradsky, BH; Upton, MP; Torgerson, TR; Orange, JS; Ochs, HD				Renner, Ellen D.; Hartl, Dominik; Rylaarsdam, Stacey; Young, Marguerite L.; Monaco-Shawver, Linda; Kleiner, Gary; Markert, M. Louise; Stiehm, E. Richard; Belohradsky, Bernd H.; Upton, Melissa P.; Torgerson, Troy R.; Orange, Jordan S.; Ochs, Hans D.			Comel-Netherton syndrome defined as primary immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Comel-Netherton syndrome; SPINK5; LEKTI; immune deficiency; NK-cell cytotoxicity; selective antibody deficiency; IVIG; ichthyosis; bamboo hair; atopic diathesis	WISKOTT-ALDRICH-SYNDROME; MEMORY B-CELLS; PERIPHERAL-BLOOD; ANTIBODY-RESPONSES; IGM SYNDROME; NK CELLS; MUTATIONS; LEKTI; EXPRESSION; ERYTHRODERMA	Background: Mutations in serine protease inhibitor Kazal-type 5 (SPINK5), encoding the serine protease inhibitor lympho-epithelial Kazal-type 5 related inhibitor (LEKTI), cause Comel-Netherton syndrome, an autosomal-recessive disease characterized by congenital ichthyosis, bamboo hair, and atopic diathesis. Despite increased frequency of infections, the immunocompetence of patients with Comel-Netherton syndrome has not been extensively investigated. Objective: To define Comel-Netherton syndrome as a primary immunodeficiency disorder and to explore the benefit of intravenous immunoglobulin replacement therapy. Methods: We enrolled 9 patients with Comel-Netherton syndrome, sequenced SPINK5, and analyzed LEKTI expression by immunohistochemistry. Immune function was assessed by measuring cognate immunity, serum cytokine levels, and natural killer cell cytotoxicity. Results: All patients presented with recurrent skin infections caused predominantly by Staphylococcus aureus. All but 1 reported recurrent respiratory tract infections; 78% had sepsis and/or pneumonia; 67% had recurrent gastrointestinal disease and failure to thrive. Mutations in SPINK5-including 6 novel mutations-were identified in 8 patients. LEKTI expression was decreased or absent in all patients. Immunologic evaluation revealed reduced memory B cells and defective responses to vaccination with Pneumovax and bacteriophage phiX174, characterized by impaired antibody amplification and class-switching. Immune dysregulation was suggested by a skewed T(H)1 phenotype and elevated proinflammatory cytokine levels, whereas serum concentrations of the chemokine (C-C motif) ligand 5 and natural killer cell cytotoxicity were decreased. Treatment with intravenous immunoglobulin resulted in remarkable clinical improvement and temporarily increased natural killer cell cytotoxicity. Conclusion: These data provide new insights into the immunopathology of Comel-Netherton syndrome and demonstrate that this multisystem disorder, characterized by lack of LEKTI expression in epithelial cells, is complicated by cognate and innate immunodeficiency that responds favorably to intravenous immunoglobulin therapy. (J Allergy Clin Immunol 2009;124:536-43.)	[Renner, Ellen D.; Hartl, Dominik; Belohradsky, Bernd H.] Univ Munich, Dr v Haunersches Kinderspital, Munich, Germany; [Upton, Melissa P.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA; [Rylaarsdam, Stacey; Young, Marguerite L.; Torgerson, Troy R.; Ochs, Hans D.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Ochs, Hans D.] Univ Washington, Jeffrey Modell Chair Pediat Immunol Res, Sch Med, Seattle Childrens Res Inst, Seattle, WA 98101 USA; [Monaco-Shawver, Linda; Orange, Jordan S.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA; [Kleiner, Gary] Univ Miami, Batchelor Childrens Res Ctr, Miami, FL USA; [Markert, M. Louise] Duke Univ, Med Ctr, Durham, NC USA; [Stiehm, E. Richard] Univ Calif Los Angeles, Mattel Childrens Hosp, Los Angeles, CA USA	University of Munich; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Miami; Duke University; University of California System; University of California Los Angeles	Ochs, HD (corresponding author), Univ Washington, Jeffrey Modell Chair Pediat Immunol Res, Sch Med, Seattle Childrens Res Inst, 1900 9th Ave, Seattle, WA 98101 USA.	allgau@u.washington.edu	Renner, Ellen/R-7168-2016	Renner, Ellen/0000-0001-9816-8538; orange, jordan/0000-0001-7117-7725	Fritz Thyssen Foundation [Az 10.07.1.159]; American Academy of Allergy; National Institutes of Health [AI-063267, AI-47040, AI-54843, AI-067946, AI-079731, HD-017427]; Jeffrey Modell Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017427, R37HD017427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI067946, R01AI047040, R01AI054843, R21AI079731, R01AI067946, R56AI047040, K08AI063267] Funding Source: NIH RePORTER	Fritz Thyssen Foundation; American Academy of Allergy; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jeffrey Modell Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Fritz Thyssen Foundation (Az 10.07.1.159), the American Academy of Allergy, Asthma and Immunology's Strategic Training in Allergy Research Award 2007 (E.D.R.), National Institutes of Health grants AI-063267 (T.R.T.), AI-47040 and AI-54843 (M.I.M.), AI-067946 and AI-079731 (J.S.O.), HD-017427 (H.D.O), and the Jeffrey Modell Foundation (H.D.O. and J.S.O.).	Agematsu K, 2002, CLIN IMMUNOL, V103, P34, DOI 10.1006/clim.2001.5197; Chan A, 2007, J IMMUNOL, V179, P89, DOI 10.4049/jimmunol.179.1.89; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; COMEL M, 1949, Dermatologica, V98, P133; Cooley S, 2007, BLOOD, V110, P578, DOI 10.1182/blood-2006-07-036228; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Cossarizza A, 2004, JAIDS-J ACQ IMM DEF, V35, P213, DOI 10.1097/00126334-200403010-00001; Day N, 2004, J PEDIATR-US, V144, P524, DOI 10.1016/j.jpeds.2003.11.025; den Dunnen JT, 2000, HUM MUTAT, V15, P7; deWolf K, 1996, DERMATOLOGY, V192, P400, DOI 10.1159/000246431; FINBERG RW, 1992, J PEDIATR-US, V120, P376, DOI 10.1016/S0022-3476(05)80900-X; Folster-Holst R, 1999, BRIT J DERMATOL, V140, P1139; Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053; GREENE SL, 1985, J AM ACAD DERMATOL, V13, P329, DOI 10.1016/S0190-9622(85)70170-3; Gurcan HM, 2007, ANN PHARMACOTHER, V41, P812, DOI 10.1345/aph.1K037; Hachem JP, 2006, J INVEST DERMATOL, V126, P1609, DOI 10.1038/sj.jid.5700288; Hausser I, 1996, PEDIATR DERMATOL, V13, P183, DOI 10.1111/j.1442-200X.1996.tb02615.x; Hoeger PH, 1998, BRIT J DERMATOL, V139, P1055; Jayakumar A, 2005, ARCH BIOCHEM BIOPHYS, V435, P89, DOI 10.1016/j.abb.2004.12.012; JONES SK, 1986, BRIT J DERMATOL, V114, P741, DOI 10.1111/j.1365-2133.1986.tb04885.x; JUDGE MR, 1994, BRIT J DERMATOL, V131, P615, DOI 10.1111/j.1365-2133.1994.tb04971.x; Katugampola RP, 2005, BRIT J DERMATOL, V153, P1041, DOI 10.1111/j.1365-2133.2005.06839.x; Kimmig S, 2002, J EXP MED, V195, P789, DOI 10.1084/jem.20011756; Krasagakis K, 2003, DERMATOLOGY, V207, P182, DOI 10.1159/000071791; Kruetzmann S, 2003, J EXP MED, V197, P939, DOI 10.1084/jem.20022020; Lee WI, 2005, BLOOD, V105, P1881, DOI 10.1182/blood-2003-12-4420; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Magert HJ, 2002, INT J BIOCHEM CELL B, V34, P573, DOI 10.1016/S1357-2725(01)00179-0; Ming J E, 1999, Adv Pediatr, V46, P271; NETHERTON EW, 1958, ARCH DERMATOL, V78, P483, DOI 10.1001/archderm.1958.01560100059009; NETHERTON EW, 1951, AMA ARCH DERM SYPH, V64, P84; Nonoyama S, 1998, J IMMUNOL, V161, P3925; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; OCHS HD, 1993, CLIN IMMUNOL IMMUNOP, V67, pS33, DOI 10.1006/clin.1993.1081; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; OCHS HD, 1980, BLOOD, V55, P243; Orange JS, 2006, CURR OPIN ALLERGY CL, V6, P399, DOI 10.1097/ACI.0b013e3280106b65; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; Raghunath M, 2004, J INVEST DERMATOL, V123, P474, DOI 10.1111/j.0022-202X.2004.23220.x; Roda JM, 2006, J IMMUNOL, V177, P120, DOI 10.4049/jimmunol.177.1.120; Seyama K, 1998, BLOOD, V92, P2421, DOI 10.1182/blood.V92.7.2421.2421_2421_2434; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; SMITH DL, 1995, J ALLERGY CLIN IMMUN, V95, P116, DOI 10.1016/S0091-6749(95)70159-1; STIEHM E, 2004, IMMUNOLOGIC DISORDER; Stryk S, 1999, PEDIATR DERMATOL, V16, P19, DOI 10.1046/j.1525-1470.1999.99005.x; Van Gysel D, 2001, DERMATOLOGY, V202, P99, DOI 10.1159/000051607; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; WILKINSON RD, 1964, ARCH DERMATOL, V89, P46, DOI 10.1001/archderm.1964.01590250052010	49	109	117	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					536	543		10.1016/j.jaci.2009.06.009	http://dx.doi.org/10.1016/j.jaci.2009.06.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19683336	Green Accepted			2022-12-18	WOS:000274315900020
J	Smith, M; Tourigny, MR; Noakes, P; Catherine, A; Tulic, MK; Prescott, SL				Smith, Miranda; Tourigny, Michelle R.; Noakes, Paul; Thornton, Catherine A.; Tulic, Meri K.; Prescott, Susan L.			Children with egg allergy have evidence of reduced neonatal CD4(+)CD25(+)CD127(lo/-) regulatory T cell function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						regulatory T cells; cord blood; neonates; food allergy; allergic disease; egg allergy; cytokines; infants	INTERFERON-GAMMA PRODUCTION; BLOOD MONONUCLEAR-CELLS; CORD-BLOOD; ATOPIC-DERMATITIS; EXPRESSION; RISK; ASSOCIATION; RECEPTORS; RESPONSES; INFANTS	Background: The role of regulatory T (Treg) cells in allergic predisposition is not known. Objective: This study compared the frequency and function of cord blood Treg cells from nonallergic children (n = 18) with those from children who have egg allergy (n = 15) in the first year of life. Methods: CD4(+) effector T cells and autologous antigen-presenting cells isolated from cord blood mononuclear cells were cocultured with or without CD4(+)CD25(+)CD127(lo/-) Treg cells, and cytokine responses to staphylococcal endotoxin B were assessed after 48 hours. Results: The addition of Treg cell populations to cord blood mononuclear cell cultures resulted in significant reduction in IL-10 (P=.002), IL-13 (P=.012), and IFN-gamma (P<.001) production. Consistent with other reports, effector CD4(+) T-cell responses (IFN-gamma and IL-13) tended to be lower in the allergic group. These neonates showed less significant Treg cell-associated suppression of IFN-gamma (P=.015) compared with that seen in the nonallergic group (P=.001). The allergic group was also less likely (44%) to show Treg cell-associated suppression of IFN-gamma effector responses compared with that seen in the nonallergic group (78%, P=.015). The magnitude of suppression (change in IFN-gamma level when CD4(+)CD25(+)CD127(lo/-) Treg cells were added to responding effector T-cell cultures) was significantly lower in the allergic group (P=.004). There were no between-group differences in the circulating CD4(+)CD25(+)CD127(lo/-) Treg cells (as a percentage of cord blood T cells) or in the FOXP3 expression of these cells. Conclusion: This study confirms the presence and activity of Treg cells in cord blood and provides preliminary evidence of differences in neonates who progress to allergic disease in the first year of life.	[Tourigny, Michelle R.] Telethon Inst Child Hlth Res, Perth, WA, Australia; [Thornton, Catherine A.] Univ Coll Swansea, Sch Med, Inst Life Sci, Swansea, W Glam, Wales	Telethon Kids Institute; University of Western Australia; Swansea University	Prescott, SL (corresponding author), Univ Western Australia, Sch Paediat & Child Hlth, Princess Margaret Hosp, POB D184, Perth, WA 6001, Australia.	sprescott@meddent.uwa.edu.au	Tulic, Meri/P-6613-2016; Prescott, Susan/H-5665-2014; Tulic, Meri K/ABB-5138-2020	Tulic, Meri/0000-0002-2661-2369; Tulic, Meri K/0000-0002-2661-2369; Noakes, Paul/0000-0002-2678-1971				Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bellinghausen I, 2005, IMMUNOLOGY, V116, P103, DOI 10.1111/j.1365-2567.2005.02205.x; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Haddeland U, 2005, PEDIAT ALLERG IMM-UK, V16, P104, DOI 10.1111/j.1399-3038.2005.00250.x; Hamalainen HK, 2001, ANAL BIOCHEM, V299, P63, DOI 10.1006/abio.2001.5369; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; Prescott SL, 1998, J IMMUNOL, V160, P4730; PRESCOTT SL, 1939, CLIN EXP ALLERGY, V28, P39; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Taylor AL, 2007, PEDIAT ALLERG IMM-UK, V18, P10, DOI 10.1111/j.1399-3038.2006.00483.x; Upham JW, 1999, J ALLERGY CLIN IMMUN, V104, P370, DOI 10.1016/S0091-6749(99)70381-7; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; Wing K, 2005, IMMUNOLOGY, V115, P516, DOI 10.1111/j.1365-2567.2005.02186.x	28	109	110	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1460	1466		10.1016/j.jaci.2008.03.025	http://dx.doi.org/10.1016/j.jaci.2008.03.025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18455222	Bronze			2022-12-18	WOS:000256771700024
J	Roberts, G; Hurley, C; Turcanu, V; Lack, G				Roberts, G; Hurley, C; Turcanu, V; Lack, G			Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic asthma; children; immunotherapy	PLACEBO-CONTROLLED IMMUNOTHERAPY; EXHALED NITRIC-OXIDE; DOUBLE-BLIND; RUSH IMMUNOTHERAPY; EFFICACY; CHILDREN; RHINOCONJUNCTIVITIS; SAFETY	Background: Few studies have investigated the use of specific immunotherapy (SIT) for childhood seasonal allergic asthma. Objective: We sought to examine the efficacy and safety of SIT with Alutard SQ grass pollen (Phleum pratense Alutard SQ; ALK-Abello, Horsholm, Denmark) in children with seasonal allergic asthma. Methods: A randomized, double-blind, placebo-controlled study assessing the efficacy of grass pollen SIT over 2 pollen seasons was performed. Children (3-16 years) with a history of seasonal allergic asthma sensitized to grass pollen (P pratense) and requiring at least 200 mu g of inhaled beclomethasone equivalent per day were enrolled. Subjects with symptomatic asthma or rhinoconjunctivitis outside the grass pollen season were excluded. The primary outcome measure was a combined asthma symptom-medication score during the second pollen season. Secondary outcome measures included end-point titration skin prick testing and conjunctival and bronchial provocation testing to allergen, sputum eosinophilia, exhaled nitric oxide, and adverse events. Results: Thirty-nine subjects were enrolled. Thirty-five subjects provided data for analysis. The use of SIT was associated with a substantial reduction in asthma symptom-medication score compared with that after placebo (P = .04). There were also significant reductions in cutaneous (P = .002), conjunctival (P = .02), and bronchial (P = .01) reactivity to allergen after SIT compared with that after placebo. The 2 groups had similar levels of airway inflammation, despite a trend toward less inhaled steroid use in the active group. No serious adverse events were reported, and no subjects withdrew because of adverse events. Conclusion: The study has shown that SIT is effective and well tolerated in children with seasonal allergic asthma to grass pollen.	Univ Southampton, Univ Child Hlth, Southampton, Hants, England; St Marys Hosp, Imperial Coll, Sch Med, London, England	University of Southampton; Imperial College London	Roberts, G (corresponding author), Southampton Univ Hosp NHS Trust, Univ Child Hlth, Level F S Acad Block,Tremona Rd, Southampton SO16 6YD, Hants, England.	g.c.roberts@soton.ac.uk		Roberts, Graham/0000-0003-2252-1248; Lack, Gideon/0000-0001-7350-4021				Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; ARMENTIAMEDINA A, 1989, ANN ALLERGY, V63, P127; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 1996, GOOD CLIN PRACT; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Roberts G, 2004, THORAX, V59, P752, DOI 10.1136/thx.2003.008722; SHEFFER AL, 1993, MED CARE, V31, pMS20; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; WARNER JO, 1978, LANCET, V2, P912; Wilson NM, 2001, PEDIATR ALLERGY IMMU, V12, P125, DOI 10.1034/j.1399-3038.2001.012003125.x; WOLF SI, 1994, ANN ALLERGY, V73, P40; 1993, CLIN EXP ALLERGY S3, V23, P1	25	109	114	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					263	268		10.1016/j.jaci.2005.09.054	http://dx.doi.org/10.1016/j.jaci.2005.09.054			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461125				2022-12-18	WOS:000235687300006
J	Ricciardolo, FLM; Caramori, G; Ito, K; Capelli, A; Brun, P; Abatangelo, G; Papi, A; Chung, KF; Adcock, I; Barnes, PJ; Donner, CF; Rossi, A; Di Stefano, A				Ricciardolo, FLM; Caramori, G; Ito, K; Capelli, A; Brun, P; Abatangelo, G; Papi, A; Chung, KF; Adcock, I; Barnes, PJ; Donner, CF; Rossi, A; Di Stefano, A			Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial biopsies; pathology; COPD	NITRIC-OXIDE SYNTHASE; NITROGEN SPECIES PRODUCTION; INHALED CORTICOSTEROIDS; HISTONE DEACETYLASE; TYROSINE NITRATION; OXIDATIVE STRESS; UP-REGULATION; KAPPA-B; PEROXYNITRITE; EXPRESSION	Background: Reactive nitrogen species, formed via the reaction of nitric oxide (NO) with superoxide anion and via (myelo)peroxidase-dependent oxidation of NO2-, have potent proinflammatory and oxidizing actions. Reactive nitrogen species formation and nitrosative stress are potentially involved in chronic obstructive pulmonary disease (COPD) pathogenesis. Objectives: To investigate the expression of markers of nitrosative stress, including nitrotyrosine (NT), inducible NO synthase (iNOS), endothelial NO synthase (eNOS), myeloperoxidase (MPO), and xanthine oxidase (XO) in bronchial biopsies and bronchoalveolar lavage from patients with mild to severe stable COPD compared with control groups (smokers with normal lung function and nonsmokers). Methods: The expression of NT, iNOS, eNOS, MPO and XO in the bronchial mucosa and bronchoalveolar lavage of patients was measured by using immunohistochemistry, Western blotting, and ELISA and correlated with the inflammatory cell profile. Results: Patients with severe COPD in stable phase had higher numbers of NT+ and MPO+ cells in their bronchial submucosa compared with mild/moderate COPD, smokers with normal lung function, and nonsmokers (P <.01). iNOS(+) and eNOS(+) but not XO+ cells were significantly increased in smokers with COPD or normal lung function compared with nonsmokers (P <.05 and P <.01, respectively). In patients with COPD, the number of MPO+ cells was significantly correlated with the number of neutrophils (r = +0.61; P <.0025) in the bronchial submucosa. Furthermore, the number of NT+ and MPO+ cells was negatively correlated with postbronchodilator FEV1. Conclusion: These data suggest that nitrosative stress, mainly mediated by MPO and neutrophilic inflammation, may contribute to the pathogenesis of severe COPD.	IRCCS, Fdn S Maugeri, Med Ctr Rehabil, Div Pulm Dis, Veruno, NO, Italy; IRCCS, Gaslini Inst, Unit Resp Dis, Genoa, Italy; Univ Ferrara, Ctr Ric Asma & Broncopneumopatia Cron Ostrutt, I-44100 Ferrara, Italy; Dept Histol, Padua, Italy; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airways Dis Sect, London, England; Osped Riuniti Bergamo, Dept Pulm Dis, I-24100 Bergamo, Italy	Istituti Clinici Scientifici Maugeri IRCCS; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Ferrara; Imperial College London; Ospedali Riuniti di Bergamo	Di Stefano, A (corresponding author), IRCCS, Fdn S Maugeri, Div Pneumol, Via Revislate 13, I-28010 Veruno, NO, Italy.	adistefano@fsm.it	Adcock, Ian/L-3217-2019; Brun, Paola/K-5729-2016; Caramori, Gaetano/AAS-8611-2020; Ricciardolo, F. L. M./K-5330-2018; Chung, Kian Fan/B-1872-2012; Papi, alberto/AAC-1888-2019; Chung, Kian Fan/I-8456-2019; Di Stefano, Antonino/AAB-8041-2020	Caramori, Gaetano/0000-0002-9807-327X; Ricciardolo, F. L. M./0000-0003-1826-5018; Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Di Stefano, Antonino/0000-0003-3479-0875; Capelli, Armando/0000-0002-9505-2350; Adcock, Ian/0000-0003-2101-8843; Barnes, Peter/0000-0002-5122-4018; PAPI, ALBERTO/0000-0002-6924-4500; Brun, Paola/0000-0002-4204-3549; Rossi, Andrea/0000-0001-7095-7121				Agusti A, 2004, THORAX, V59, P483, DOI 10.1136/thx.2003.017640; Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Barreiro E, 2005, AM J RESP CRIT CARE, V171, P1116, DOI 10.1164/rccm.200407-887OC; Barreiro E, 2003, AM J RESP CELL MOL, V29, P771, DOI 10.1165/rcmb.2003-0138OC; Barua RS, 2003, CIRCULATION, V107, P2342, DOI 10.1161/01.CIR.0000066691.52789.BE; Clini E, 1998, THORAX, V53, P881, DOI 10.1136/thx.53.10.881; Di Stefano A, 1998, AM J RESP CRIT CARE, V158, P1277, DOI 10.1164/ajrccm.158.4.9802078; Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002; Di Stefano A, 2004, CLIN EXP ALLERGY, V34, P1156, DOI 10.1111/j.1365-2222.2004.02030.x; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; *GLOB IN CHRON OBS, 2001, NIH PUBL, V2701; Godber BLJ, 2000, FEBS LETT, V475, P93, DOI 10.1016/S0014-5793(00)01639-2; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; Ichinose M, 2003, EUR RESPIR J, V22, P457, DOI 10.1183/09031936.03.00052002; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Kharitonov SA, 2003, CURR ALLERGY ASTHM R, V3, P121, DOI 10.1007/s11882-003-0024-7; Kleinert H, 2004, EUR J PHARMACOL, V500, P255, DOI 10.1016/j.ejphar.2004.07.030; Lim S, 2000, AM J RESP CRIT CARE, V162, P1912, DOI 10.1164/ajrccm.162.5.9909081; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; NORMAN V, 1965, NATURE, V205, P915, DOI 10.1038/205915b0; Okamoto T, 1997, ARCH BIOCHEM BIOPHYS, V342, P261, DOI 10.1006/abbi.1997.0127; Pinamonti S, 1996, FREE RADICAL BIO MED, V21, P147, DOI 10.1016/0891-5849(96)00030-5; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Ricciardolo FLM, 2003, TRENDS PHARMACOL SCI, V24, P560, DOI 10.1016/j.tips.2003.09.007; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763, DOI 10.1164/ajrccm.155.5.9154889; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; van Straaten JFM, 1998, MODERN PATHOL, V11, P648; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200	36	109	111	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1028	1035		10.1016/j.jaci.2005.06.034	http://dx.doi.org/10.1016/j.jaci.2005.06.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275371				2022-12-18	WOS:000235686700012
J	Brussee, JE; Smit, HA; van Strien, RT; Corver, K; Kerkhof, M; Wijga, AH; Aalberse, RC; Postma, D; Gerritsen, J; Grobbee, DE; de Jongste, JC; Brunekreef, B				Brussee, JE; Smit, HA; van Strien, RT; Corver, K; Kerkhof, M; Wijga, AH; Aalberse, RC; Postma, D; Gerritsen, J; Grobbee, DE; de Jongste, JC; Brunekreef, B			Allergen exposure in infancy and the development of sensitization, wheeze, and asthma at 4 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cohort studies; child; preschool; allergens; house dust mites; cats; dogs; sensitization; wheezing; asthma	HOUSE-DUST MITE; MATERNAL HISTORY; INDOOR ALLERGENS; RISK-FACTOR; 1ST YEAR; CHILDHOOD; ATOPY; PET; QUESTIONNAIRE; POPULATION	Background: The relationship between mite and pet allergen exposure in infancy and the subsequent development of sensitization and asthma is complex. Objective: We prospectively investigated the effect of allergen exposure at 3 months of age on the development of sensitization, wheeze, and physician-diagnosed asthma in the first 4 years of life in a birth cohort of children with and without an atopic mother. Methods: Children participated in the Prevention and Incidence of Asthma and Mite Allergy study. Allergen exposure at 3 months of age was determined from mattress dust samples. Specific IgE to inhalant allergens was measured at 4 years of age, and information about wheeze and physician-diagnosed asthma was collected with yearly questionnaires. Results: Mite and cat allergen exposure in infancy were associated with an increased risk of specific sensitization to house dust mite and cat, respectively, at 4 years of age. There were borderline significant associations between cat allergen exposure and persistent wheeze in the total study population and between dog allergen exposure and persistent wheeze in children with a nonatopic mother. In children with an atopic mother, there was some indication of a positive association between mite allergen exposure and physician-diagnosed asthma. Conclusion: Early house dust mite and cat allergen exposure might lead to sensitization and, in case of cat allergen exposure, to persistent wheeze. Early mite and dog allergen exposure might lead to asthma and persistent wheeze, respectively, but only in subgroups defined by maternal atopy.	Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; Univ Munich, Inst Occupat & Environm Med, Munich, Germany; Erasmus MC, Dept Pediat, Div Resp Med, Rotterdam, Netherlands; Univ Groningen, Dept Epidemiol & Stat, Groningen, Netherlands; Sanquin Res CLB, Dept Immunopathol, Amsterdam, Netherlands; Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands; Univ Groningen Hosp, Dept Paediat Resp Med, Groningen, Netherlands; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands	Netherlands National Institute for Public Health & the Environment; Utrecht University; University of Munich; Erasmus University Rotterdam; Erasmus MC; University of Groningen; University of Groningen; University of Groningen; Utrecht University	Smit, HA (corresponding author), Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, POB 1, NL-3720 BA Bilthoven, Netherlands.	jet.smit@rivm.nl	Grobbee, Diederick/C-7651-2014; Kerkhof, Marjan/A-8846-2008	Grobbee, Diederick/0000-0003-4472-4468; brunekreef, bert/0000-0001-9908-0060				Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Brussee JE, 2004, AM J RESP CRIT CARE, V169, P209, DOI 10.1164/rccm.200306-800OC; Carter PM, 2003, ANN ALLERG ASTHMA IM, V90, P41, DOI 10.1016/S1081-1206(10)63612-5; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; Crestani E, 2004, J ALLERGY CLIN IMMUN, V113, P284, DOI 10.1016/j.jaci.2003.11.009; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; Gehring U, 2004, ENVIRON HEALTH PERSP, V112, P834, DOI 10.1289/ehp.6685; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Lakwijk N, 1998, CLIN EXP ALLERGY, V28, P454; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; Murray CS, 2001, CURR OPIN ALLERGY CL, V1, P407, DOI 10.1097/00130832-200110000-00005; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; Polk S, 2004, AM J RESP CRIT CARE, V170, P273, DOI 10.1164/rccm.200310-1348OC; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Sandin A, 2004, PEDIATR ALLERGY IMMU, V15, P316, DOI 10.1111/j.1399-3038.2004.00166.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; van Strien RT, 2003, CLIN EXP ALLERGY, V33, P490, DOI 10.1046/j.1365-2222.2003.01626.x; van Strien RT, 2002, ENVIRON HEALTH PERSP, V110, pA693, DOI 10.1289/ehp.021100693; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7	29	109	113	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					946	952		10.1016/j.jaci.2005.02.035	http://dx.doi.org/10.1016/j.jaci.2005.02.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867850	Green Published			2022-12-18	WOS:000229055100008
J	Gyllfors, P; Bochenek, G; Overholt, J; Drupka, D; Kumlin, M; Sheller, J; Nizankowska, E; Isakson, PC; Mejza, F; Lefkowith, JB; Dahlen, SE; Szczeklik, A; Murray, JJ; Dahlen, B				Gyllfors, P; Bochenek, G; Overholt, J; Drupka, D; Kumlin, M; Sheller, J; Nizankowska, E; Isakson, PC; Mejza, F; Lefkowith, JB; Dahlen, SE; Szczeklik, A; Murray, JJ; Dahlen, B			Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin intolerance; asthma; nonsteroidal anti-inflammatory drugs; cyclooxygenase inhibition; COX-2	SENSITIVE PATIENTS; ACETYLSALICYLIC-ACID; RHEUMATOID-ARTHRITIS; COX-2 INHIBITORS; LEUKOTRIENE-E4; OSTEOARTHRITIS; TOLERABILITY; PROVOCATION; NIMESULIDE; ROFECOXIB	Background: Subjects with aspirin-intolerant asthma (AIA) respond with bronchoconstriction and extrapulmonary adverse reactions to conventional nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit the cyclooxygenase (COX) step in the biosynthesis of prostaglandins. Recently, 2 isotypes: of COX have been identified, and COX-2-selective NSAIDs have been developed for treatment of inflammatory disorders. Objective: We investigated whether 33 subjects with a typical history of AIA tolerated the new COX-2-selective NSAID celecoxib. Methods: All subjects displayed current aspirin sensitivity in oral or inhalation challenge tests. The subjects first underwent a double-blind, randomized, cross-over, increasing-dose challenge with placebo or celecoxib (10, 30, or 100 ring in suspension) on 2 occasions 7 days apart. Thereafter, all subjects were exposed to 400 mg of celecoxib administered during an open challenge session as two 200-mg doses 2 hours apart. Lung function, clinical symptoms, and urinary excretion of leukotriene E-4 (LTE4) were monitored, with the latter being a,sensitive biochemical marker of aspirin intolerance. Results: There were no changes in lung function or extrapulmonary symptoms during the double-blind sessions or in urinary excretion of LTE4. Also, the highest recommended daily dose of celecoxib was well tolerated, with no symptoms, lung function changes, or alterations in urinary LTE4 levels. Conclusions: A group of subjects with clinically well-documented AIA tolerated acute challenge with the selective COX2 inhibitor celecoxib. The findings indicate that the intolerance reaction in AIA is due to inhibition of COX-1. Large long-term studies of COX-2 inhibitors in AIA should be undertaken.	Karolinska Inst, Karolinska Hosp, Dept Med, Div Resp Med, S-10401 Stockholm, Sweden; Jagiellonian Univ, Dept Med, Krakow, Poland; Vanderbilt Univ, Med Ctr, Dept Med & Pharmacol, Nashville, TN USA; Pharmacia Corp, Chicago, IL USA; Huddinge Univ Hosp, Karolinska Inst, Dept Med, Dept Resp Med, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Jagiellonian University; Vanderbilt University; Pfizer; Karolinska Institutet	Dahlen, SE (corresponding author), Karolinska Inst, Natl Inst Environm Med, SE-17177 Stockholm, Sweden.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRI L, 1994, ANN ALLERGY, V72, P29; Bavbek S, 1999, J ASTHMA, V36, P657, DOI 10.3109/02770909909055417; Bjarnason I, 2001, GUT, V48, P451, DOI 10.1136/gut.48.4.451; Borges MS, 2001, ANN ALLERG ASTHMA IM, V87, P201, DOI 10.1016/S1081-1206(10)62226-0; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495-200059040-00017; DAHLEN B, 1993, EUR RESPIR J, V6, P1018; DAHLEN B, 1994, ALLERGY, V49, P43, DOI 10.1111/j.1398-9995.1994.tb00772.x; Dahlen B, 2001, NEW ENGL J MED, V344, P142, DOI 10.1056/NEJM200101113440215; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Fries JF, 1999, NEW ENGL J MED, V341, P1397; Hartert TV, 2000, AM J RESP CRIT CARE, V162, P637, DOI 10.1164/ajrccm.162.2.9904038; Kosnik M, 1998, ALLERGY, V53, P1231, DOI 10.1111/j.1398-9995.1998.tb03854.x; KUMLIN M, 1995, CLIN EXP ALLERGY, V25, P467, DOI 10.1111/j.1365-2222.1995.tb01079.x; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; Nizankowska E, 2000, EUR RESPIR J, V15, P863, DOI 10.1034/j.1399-3003.2000.15e09.x; RAUD J, 1988, P NATL ACAD SCI USA, V85, P2315, DOI 10.1073/pnas.85.7.2315; Schellenberg RR, 2001, NEW ENGL J MED, V345, P1856, DOI 10.1056/NEJM200112203452518; Scott LJ, 1999, DRUGS, V58, P499, DOI 10.2165/00003495-199958030-00016; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; STEVENSON DD, 1988, ALLERGY PRINCIPLES P, P1537; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Yoshida S, 2000, J ALLERGY CLIN IMMUN, V106, P1201, DOI 10.1067/mai.2000.110926	28	109	115	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1116	1121		10.1067/mai.2003.1450	http://dx.doi.org/10.1067/mai.2003.1450			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743579	Green Published			2022-12-18	WOS:000182904500029
J	Lee, NA; Gelfand, EW; Lee, JJ				Lee, NA; Gelfand, EW; Lee, JJ			Pulmonary T cells and eosinophils: Coconspirators or independent triggers of allergic respiratory pathology?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						T cell; eosinophil; asthma; mouse models; gene knock-out; T-H(2)	MAJOR BASIC-PROTEIN; AIRWAY HYPERRESPONSIVENESS; GAMMA-DELTA; MURINE MODEL; DEFICIENT MICE; INTERFERON-GAMMA; BRONCHIAL-ASTHMA; TH2 CELLS; SYNCYTIAL VIRUS; IN-VIVO	Etiologic discussions of allergic respiratory pathology frequently engender rabid constituencies of pro-T cell or proeosinophil disciples, each claiming, often with religious fervor, the importance of their leukocyte, However increasing evidence suggests that the exclusionary rhetoric from either camp is inadequate to explain many of the pathologic changes occurring in the lung, Data from both asthmatic patient and mouse models of allergic respiratory inflammation suggest that, in addition to cell-autonomous activities, T-cell and eosinophil interactions may be critical to the onset and progression of pulmonary pathology. These studies also suggest that T-lymphocyte subpopulations and eosinophils communicate by means of both direct cell-cell interactions and through the secretion of inflammatory signals. Collectively, the data support an expanded view of T-cell and eosinophil activities in the lung, including both immunoregulative activities and downstream effector functions impinging directly on lung function.	Mayo Clin Scottsdale, Div Hematol Oncol Pulm, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Div Pulm, Scottsdale, AZ 85259 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; National Jewish Health	Lee, NA (corresponding author), Mayo Clin Scottsdale, Div Hematol Oncol Pulm, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.				NHLBI NIH HHS [HL-65228, HL-36577, HL-60793, HL-61005, HL-58723] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058723, R01HL061005, R01HL060793, R56HL058723, R01HL065228, P01HL036577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Allakhverdi Z, 2000, AM J RESP CRIT CARE, V162, P1123, DOI 10.1164/ajrccm.162.3.9910001; AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; BANDEIRA A, 1991, P NATL ACAD SCI USA, V88, P43, DOI 10.1073/pnas.88.1.43; Barner M, 1998, CURR BIOL, V8, P669, DOI 10.1016/S0960-9822(98)70256-8; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Borchers MT, 2001, AM J PHYSIOL-LUNG C, V280, pL813, DOI 10.1152/ajplung.2001.280.4.L813; Born W, 1999, Adv Immunol, V71, P77; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRUIJNZEEL PLB, 1989, EOSINOPHILS ASTHMA, P69; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Castro M, 2000, AM J RESP CELL MOL, V22, P143, DOI 10.1165/ajrcmb.22.2.f174; CHAPMAN ID, 1993, CLIN EXP ALLERGY, V23, P168, DOI 10.1111/j.1365-2222.1993.tb00877.x; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Cohn L, 2001, J IMMUNOL, V166, P2760, DOI 10.4049/jimmunol.166.4.2760; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Coyle AJ, 1996, ANN NY ACAD SCI, V796, P97, DOI 10.1111/j.1749-6632.1996.tb32571.x; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; DEANDRES B, 1990, IMMUNOLOGY, V69, P271; DELPOZO V, 1990, J IMMUNOL, V144, P3117; DELPRETE GF, EUR J PHARM, V23, P1445; Denzler KL, 2000, J IMMUNOL, V165, P5509, DOI 10.4049/jimmunol.165.10.5509; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Domachowske JB, 1998, NUCLEIC ACIDS RES, V26, P5327, DOI 10.1093/nar/26.23.5327; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; Erb KJ, 1996, IMMUNOL CELL BIOL, V74, P206, DOI 10.1038/icb.1996.29; Erjefalt JS, 2000, AM J RESP CRIT CARE, V161, P2074, DOI 10.1164/ajrccm.161.6.9906085; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FILLEY WV, 1982, LANCET, V2, P11; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Foster PS, 1999, AM J RESP CELL MOL, V21, P451, DOI 10.1165/ajrcmb.21.4.f167; FRIGAS E, 1980, LAB INVEST, V42, P35; FUJISAWA T, 1990, AM REV RESPIR DIS, V141, P689, DOI 10.1164/ajrccm/141.3.689; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GARLISI CG, 1995, CLIN IMMUNOL IMMUNOP, V75, P75, DOI 10.1006/clin.1995.1055; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Gelfand EW, 1997, NAT MED, V3, P382, DOI 10.1038/nm0497-382; GLEICH GJ, 1995, INT ARCH ALLERGY IMM, V107, P205, DOI 10.1159/000236978; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565, DOI 10.1164/ajrccm.158.2.9705036; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327, DOI 10.1165/ajrcmb.23.3.3796; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Hamelmann E, 1997, P NATL ACAD SCI USA, V94, P1350, DOI 10.1073/pnas.94.4.1350; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; HENDERSON WR, 1984, IMMUNOLOGY, V51, P679; Herbert DR, 2000, J IMMUNOL, V165, P4544, DOI 10.4049/jimmunol.165.8.4544; HIBBS MS, 1982, BIOCHEM J, V207, P621, DOI 10.1042/bj2070621; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210, DOI 10.1164/ajrccm.157.1.9702074; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P28; Huang TJ, 1999, IMMUNOLOGY, V96, P416; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; Jelinek DF, 2000, ANN ALLERG ASTHMA IM, V84, P375, DOI 10.1016/S1081-1206(10)62267-3; JuliaSerda G, 1996, CHEST, V110, P404, DOI 10.1378/chest.110.2.404; Kanehiro A, 2001, AM J RESP CRIT CARE, V163, P173, DOI 10.1164/ajrccm.163.1.2001118; Kanehiro A, 2000, AM J RESP CRIT CARE, V162, P1132, DOI 10.1164/ajrccm.162.3.9910100; Kay AB, 1997, INT ARCH ALLERGY IMM, V113, P196, DOI 10.1159/000237545; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Krug N, 2000, AM J RESP CRIT CARE, V162, P105, DOI 10.1164/ajrccm.162.1.9908055; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; Lahn M, 2000, J MOL MED, V78, P409, DOI 10.1007/s001090000123; Lahn M, 1999, NAT MED, V5, P1150, DOI 10.1038/13476; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lee NA, 1999, AM J RESP CELL MOL, V21, P298, DOI 10.1165/ajrcmb.21.3.f165; Lee NA, 1997, J IMMUNOL, V158, P1332; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEFRANCOIS L, 1991, J IMMUNOL, V147, P1746; LIM KG, 1995, INT ARCH ALLERGY IMM, V107, P342, DOI 10.1159/000237023; LUCEY DR, 1989, J EXP MED, V169, P327, DOI 10.1084/jem.169.1.327; LUNGARELLA G, 1992, ARCH BIOCHEM BIOPHYS, V292, P128, DOI 10.1016/0003-9861(92)90060-A; MacLean JA, 1999, AM J RESP CELL MOL, V20, P379, DOI 10.1165/ajrcmb.20.3.3291; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; Malm-Erjefalt M, 2001, AM J RESP CELL MOL, V24, P352, DOI 10.1165/ajrcmb.24.3.4357; MARIASSY MJ, 1992, TREATISE PULMONARY T, P63; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; MCBRIDE JT, 1992, TREATISE PULMONARY T, P49; MCCARRICK JW, 1993, TRANSGENIC RES, V2, P183, DOI 10.1007/BF01977348; MCKENNA MG, 1969, ANN NY ACAD SCI, V167, P217, DOI 10.1111/j.1749-6632.1969.tb20446.x; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; MINNICOZZI M, 1994, J IMMUNOL, V153, P2664; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Mould AW, 2000, J IMMUNOL, V164, P2142, DOI 10.4049/jimmunol.164.4.2142; MURRAY MJ, 1992, TREATISE PULMONARY T, P725; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; OTTOLENGHI A, 1970, LIPIDS, V5, P531, DOI 10.1007/BF02532741; PABST R, 1990, AM J RESP CELL MOL, V3, P131, DOI 10.1165/ajrcmb/3.2.131; Pauwels RA, 1998, CLIN EXP ALLERGY, V28, P1; Persson CGA, 1997, TRENDS PHARMACOL SCI, V18, P117, DOI 10.1016/S0165-6147(97)01042-0; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; RENZ H, 1993, J IMMUNOL, V151, P1907; Richards D, 1997, IMMUNOLOGY, V91, P331, DOI 10.1046/j.1365-2567.1997.00274.x; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Saini SS, 1999, J IMMUNOL, V162, P5624; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Schramm CM, 2000, AM J RESP CELL MOL, V22, P218, DOI 10.1165/ajrcmb.22.2.3620; Schwarze J, 1999, J IMMUNOL, V162, P4207; Schwarze J, 1999, J IMMUNOL, V162, P2997; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Sim BC, 1998, CURR BIOL, V8, P701, DOI 10.1016/S0960-9822(98)70276-3; Singer A, 1999, SEMIN IMMUNOL, V11, P273, DOI 10.1006/smim.1999.0183; Stanciu LA, 1997, J ALLERGY CLIN IMMUN, V100, P373, DOI 10.1016/S0091-6749(97)70251-3; Stelts D, 1998, AM J RESP CELL MOL, V18, P463, DOI 10.1165/ajrcmb.18.4.2957; STERN M, 1992, J IMMUNOL, V148, P3543; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; TAKEDA K, 2001, IN PRESS AM J PHYSL; Tang CB, 1998, AM J RESP CRIT CARE, V157, P1120, DOI 10.1164/ajrccm.157.4.9706118; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Tomaki M, 2000, J IMMUNOL, V165, P4040, DOI 10.4049/jimmunol.165.7.4040; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; TURK J, 1982, J BIOL CHEM, V257, P7068; VALBERG PA, 1992, TREATISE PULMONARY T, P681; VANOVERVELD FJ, 1989, CLIN SCI, V77, P297, DOI 10.1042/cs0770297; Walker J, 1998, VACCINE, V16, P1, DOI 10.1016/S0264-410X(97)00164-3; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WILLI KB, 2000, RESP RES, V1, P151; Woerly G, 1999, J EXP MED, V190, P487, DOI 10.1084/jem.190.4.487; Woerly G, 1999, INT ARCH ALLERGY IMM, V118, P95, DOI 10.1159/000024038; WONG DTW, 1991, BLOOD, V78, P2702; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673; Yurovsky VV, 1998, AM J RESP CELL MOL, V18, P370, DOI 10.1165/ajrcmb.18.3.2935; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zimmermann N, 2000, J IMMUNOL, V165, P5839, DOI 10.4049/jimmunol.165.10.5839; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	143	109	110	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					945	957		10.1067/mai.2001.116002	http://dx.doi.org/10.1067/mai.2001.116002			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398070				2022-12-18	WOS:000169454800002
J	Sippel, JM; Holden, WE; Tilles, SA; O'Hollaren, M; Cook, J; Thukkani, N; Priest, J; Nelson, B; Osborne, ML				Sippel, JM; Holden, WE; Tilles, SA; O'Hollaren, M; Cook, J; Thukkani, N; Priest, J; Nelson, B; Osborne, ML			Exhaled nitric oxide levels correlate with measures of disease control in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; nitric oxide; exhaled nitric oxide; disease control; epidemiology	AIRWAY INFLAMMATION; LUNG-FUNCTION; LARGE HMO; GLUCOCORTICOIDS; BUDESONIDE; SYMPTOMS; SEVERITY; TRENDS	Background: Asthma guidelines emphasize maintaining disease control. However, objective measures of asthma disease control are lacking. Objective: We sought to examine the relationship between exhaled nitric oxide (NO) levels and measures of asthma disease control versus asthma disease severity. Methods: We performed a cross-sectional study of 100 patients (age range, 7-80 years) with asthma. We administered a questionnaire to identify characteristics of asthma, performed spirometric testing before and after administration of a bronchodilator, and measured exhaled NO levels in all participants. Results: Exhaled NO was significantly correlated with the Following markers of asthma disease control: asthma symptoms within the past 2 weeks (P = .02), dyspnea score (P = .02), daily use of rescue medications (P = .01), and reversibility of airflow obstruction (P = .02), Exhaled NO levels were not correlated with the following markers of asthma disease severity: history of respiratory failure (P = .20), health care use (P = .08), fixed airflow obstruction (P = .91), or a validated asthma severity score (P = .19), Markers with relevance to both disease control and severity showed either a weak correlation (FEV1 and FEV1 percent predicted) or no correlation (controller drug use) with exhaled NO, Conclusion: We conclude that exhaled NO levels are correlated predominantly with markers of asthma control rather than asthma severity. Monitoring of exhaled NO may be useful in outpatient asthma management.	Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Vet Adm Med Ctr, Pulm & Crit Care Sect, Portland, OR USA; Portland Allergy Clin, Portland, OR USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Osborne, ML (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,L102, Portland, OR 97201 USA.							Barnes PJ, 1996, THORAX, V51, P233, DOI 10.1136/thx.51.3.233; BECKLAKE M, 1991, AM REV RESPIR DIS, V144, P1202; Berlyne G, 2000, LANCET, V355, P1029, DOI 10.1016/S0140-6736(00)02027-4; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; Corradi M, 1998, THORAX, V53, P673, DOI 10.1136/thx.53.8.673; CRAPO RO, 1994, NEW ENGL J MED, V331, P25, DOI 10.1056/NEJM199407073310107; Delen FM, 2000, CHEST, V117, P695, DOI 10.1378/chest.117.3.695; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Dotsch J, 1996, EUR RESPIR J, V9, P2537, DOI 10.1183/09031936.96.09122537; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9, DOI 10.1164/ajrccm/149.2_Pt_2.S9; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Fujimoto K, 1997, CHEST, V112, P1241, DOI 10.1378/chest.112.5.1241; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773, DOI 10.1164/ajrccm.153.6.8665033; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Kimberly B, 1996, AM J RESP CRIT CARE, V153, P829, DOI 10.1164/ajrccm.153.2.8564139; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lim S, 1999, AM J RESP CRIT CARE, V159, P22, DOI 10.1164/ajrccm.159.1.9706006; MUZA SR, 1990, AM REV RESPIR DIS, V141, P909, DOI 10.1164/ajrccm/141.4_Pt_1.909; *NHLBI USPHS, 1997, NIH PUBL; Osborne ML, 1998, AM J RESP CRIT CARE, V157, P123, DOI 10.1164/ajrccm.157.1.9612063; OSBORNE ML, 1995, J CLIN EPIDEMIOL, V48, P1393, DOI 10.1016/0895-4356(95)00065-8; Osborne ML, 1999, CHEST, V115, P85, DOI 10.1378/chest.115.1.85; Piacentini GL, 1998, AM J RESP CRIT CARE, V158, P1299, DOI 10.1164/ajrccm.158.4.9712078; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911, DOI 10.1164/ajrccm.159.3.9802108; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; van Rensen ELJ, 1999, THORAX, V54, P403, DOI 10.1136/thx.54.5.403; VOLLMER WM, 1993, AM REV RESPIR DIS, V147, P347, DOI 10.1164/ajrccm/147.2.347; Vollmer WM, 1998, AM J RESP CRIT CARE, V157, P1079, DOI 10.1164/ajrccm.157.4.9704140; Vollmer WM, 1997, ARCH INTERN MED, V157, P1201, DOI 10.1001/archinte.157.11.1201; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046	35	109	115	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					645	650		10.1067/mai.2000.109618	http://dx.doi.org/10.1067/mai.2000.109618			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031334				2022-12-18	WOS:000089980600007
J	Christodoulopoulos, P; Leung, DYM; Elliott, MW; Hogg, JC; Muro, S; Toda, M; Laberge, S; Hamid, QA				Christodoulopoulos, P; Leung, DYM; Elliott, MW; Hogg, JC; Muro, S; Toda, M; Laberge, S; Hamid, QA			Increased number of glucocorticoid receptor-beta-expressing cells in the airways in fatal asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fatal asthma; steroid insensitivity; glucocorticoid receptor-beta; eosinophils; small airways	STEROID-RESISTANT ASTHMA; MESSENGER-RNA EXPRESSION; ISOFORM; IL-4	Background: We have recently demonstrated an increased number of glucocorticoid receptor-beta (GR beta)-positive cells in steroid-insensitive subjects with severe asthma, Insensitivity to steroids may be a major contributing factor in fatal asthma; however, no such direct evidence has been report previously. Objective: Our aims were to investigate the expression of GR beta immunoreactivity, an endogenous inhibitor of steroid action previously associated with steroid insensitivity, within the airways of patients who died of slow-onset fatal asthma and to compare its expression in patients with emphysema and in nonasthmatic subjects who died of unrelated causes. Sections from airways, both large and small, were obtained from 7 patients who died of asthma, 6 who died from emphysema, and 8 who died from nonpulmonary diseases. Sections from lungs of 6 patients with mild asthma whose lungs were resected for carcinoma were also included as controls. Methods: Tissue samples were processed for immunocytochemistry with a polyclonal antibody to GR beta with use of the avidin-biotin technique and with monoclonal CD3, major basic protein, CD68, and elastase antibodies with the alkaline phosphatase-anti-alkaline phosphatase technique. Sequential immunocytochemistry was performed to phenotype the GR beta immunoreactive cells. Tissue sections from both large (>2 mm) and small (<2 mm) airways were examined. Results: There was a significantly greater number of GR beta immunoreactive cells in fatal asthma compared with emphysema and controls (P < .001 and P < .05, respectively). There was no difference in the expression of GR beta in emphysema compared with controls. GR beta immunoreactivity was also significantly higher in fatal asthma compared with mild asthma, The expression of GR beta in the small airways of patients with severe asthma did not differ significantly from that in the large airways. The majority of GR beta-positive cells were T cells and to a lesser extent eosinophils, macrophages, and neutrophils. Conclusion: The results of this study support the association of GR beta expression with fatal asthma and suggest that alternative anti-inflammatory agents need to be considered in the acute setting for patients who are not responding to steroid therapy.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Univ British Columbia, St Pauls Hosp, Pulm Res Lab, Vancouver, BC V5Z 1M9, Canada; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA	McGill University; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hamid, QA (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.							ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; Brogan IJ, 1999, MOL CELL ENDOCRINOL, V157, P95, DOI 10.1016/S0303-7207(99)00156-2; Cardell BS, 1959, THORAX, V14, P341; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; deCastro M, 1996, MOL MED, V2, P597, DOI 10.1007/BF03401643; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DURHAM SR, 1992, J IMMUNOL, V148, P2390; GIAID A, 1993, LANCET, V341, P1550; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; HEARD BE, 1973, J PATHOL, V110, P319, DOI 10.1002/path.1711100406; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; KAM JC, 1993, J IMMUNOL, V151, P3460; Lee T, 1996, AM J RESP CRIT CARE, V154, pS1, DOI 10.1164/ajrccm/154.2_Pt_2.S1; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Minshall EM, 1998, J ALLERGY CLIN IMMUN, V101, P386, DOI 10.1016/S0091-6749(98)70252-0; MOQBEL R, 1995, J IMMUNOL, V155, P4939; Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963	24	109	115	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					479	484						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984367				2022-12-18	WOS:000089471900010
J	Nomura, I; Tanaka, K; Tomita, H; Katsunuma, T; Ohya, Y; Ikeda, N; Takeda, T; Saito, H; Akasawa, A				Nomura, I; Tanaka, K; Tomita, H; Katsunuma, T; Ohya, Y; Ikeda, N; Takeda, T; Saito, H; Akasawa, A			Evaluation of the staphylococcal exotoxins and their specific IgE in childhood atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; staphylococcal exotoxin; specific IgE; Leicester's disease activity score	SHOCK SYNDROME TOXIN-1; ENTEROTOXINS; SKIN; EXPRESSION; ANTIBODIES	Background: Superantigenic exotoxins produced by Staphylococcus aureus and their specific IgE antibodies are thought to be important precipitating factors of atopic dermatitis (AD), but there are few reports evaluating these 2 factors at the same time, Objective: We examined whether the presence of the exotoxins sampled from the skin of patients with AD and the levels of anti-exotoxin IgE antibodies in their sera correlated with their severity of AD, Methods: Patients with mild-to-severe AD, 1 to 22 years of age, were evaluated by using Leicester's scoring system. Specific IgE antibodies against these exotoxins were determined by using ELISA. S aureus was isolated from 3 different areas of the skin. We examined whether the exotoxin (staphylococcal enterotoxin [SE]A, SEE, SEC, SED, and toxic shock syndrome toxin-1) could be detected. Results: The levels of SEE-specific IgE were correlated with the severity of AD. Ave of 6 patients having very high SEB-specific IgE antibody titers were under 6 years of age, and SEE was most frequently isolated (41%). There was no difference in severity between patients with or without exotoxin-producing S aureus. The severity of 9 patients who had both exotoxin:producing S aureus on the skin and specific IgE antibody against the same exotoxin in sera was significantly higher than that of the other patients. Conclusions: Anti-SEE IgE titers correlate well with the severity: of AD. The presence of exotoxin-producing S aureus may precipitate AD through its specific IgE antibody.	Natl Childrens Hosp, Dept Allergy, Setagaya Ku, Tokyo, Japan; Natl Childrens Med Res Ctr, Dept Allergy, Tokyo 154, Japan; Natl Childrens Med Res Ctr, Dept Infect Dis, Tokyo 154, Japan	National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan	Akasawa, A (corresponding author), Natl Childrens Hosp, Dept Allergy, Setagaya Ku, 3-35-31 Taishido, Tokyo, Japan.			Katsunuma, Toshio/0000-0003-2646-3006; Saito, Hirohisa/0000-0002-6630-8337				Akiyama H, 1996, ARCH DERMATOL RES, V288, P418, DOI 10.1007/BF02507115; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hofer MF, 1995, CLIN EXP ALLERGY, V25, P1218, DOI 10.1111/j.1365-2222.1995.tb03046.x; Jabara HH, 1996, INT IMMUNOL, V8, P1503, DOI 10.1093/intimm/8.10.1503; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MOTALA C, 1986, J ALLERGY CLIN IMMUN, V78, P583, DOI 10.1016/0091-6749(86)90075-8; NEUBER K, 1995, INT ARCH ALLERGY IMM, V107, P179, DOI 10.1159/000236970; Nissen D, 1997, ANN ALLERG ASTHMA IM, V79, P403, DOI 10.1016/S1081-1206(10)63033-5; Saloga J, 1996, J INVEST DERMATOL, V106, P982, DOI 10.1111/1523-1747.ep12338479; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Tada J, 1996, EUR J DERMATOL, V6, P552	15	109	115	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				441	446		10.1016/S0091-6749(99)70390-8	http://dx.doi.org/10.1016/S0091-6749(99)70390-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452768				2022-12-18	WOS:000082364800039
J	Kodama, A; Horikawa, T; Suzuki, T; Ajiki, W; Takashima, T; Harada, S; Ichihashi, M				Kodama, A; Horikawa, T; Suzuki, T; Ajiki, W; Takashima, T; Harada, S; Ichihashi, M			Effect of stress on atopic dermatitis: Investigation in patients after the Great Hanshin Earthquake	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; stress; earthquake; environment; bathing	CELL-MEDIATED-IMMUNITY; IGE; DISEASE; ADULTS; UPDATE; SKIN; RISK	Background: Although a variety of factors are responsible for atopic dermatitis (AD), very little is known about the effect of stress caused by a natural disaster on AD symptoms. Objective: This study was conducted to assess the effect of stress or trauma on the symptoms of AD. Methods: One thousand four hundred fifty-seven patients with AD (745 males and 712 females), diagnosed by using the criteria of the Japanese Dermatology Association, were enrolled in the study. The data were obtained from a self-administered questionnaire given to patients with AD after experiencing the Great Hanshin Earthquake. The data were analyzed by multivariate logistic regression analysis. Patients were divided into 3 groups: area A, severe damage to buildings and houses; area B, mild damage; and control area, no damage. Results: Exacerbation of skin symptoms was found in 38% and 34% of patients in areas A and B, respectively, whereas similar exacerbation was seen in 7% of control patients. Nine percent and 5% of the patients in areas A and B, respectively, showed improvement in their symptoms compared with 1% in the control group, The earthquake caused stress in 63% and 48% of the patients in areas A and B, respectively, but fewer patients felt stress in undamaged areas (19%). Multiple logistic regression analysis revealed that of the factors examined here, subjective distress is the factor that is most responsible for the exacerbation of skin symptoms (odds ratio, 2.98; 95% confidence interval, 2.25-3.96). Conclusion: The results presented here strongly suggest that stress caused by a natural disaster influences AD symptoms.	Kobe Univ, Sch Med, Dept Dermatol, Chuo Ku, Kobe, Hyogo 6500017, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Canc Control & Stat, Osaka, Japan	Kobe University; Osaka Medical Center for Cancer & Cardiovascular Diseases	Horikawa, T (corresponding author), Kobe Univ, Sch Med, Dept Dermatol, Chuo Ku, 7-5-1 Kusunokicho, Kobe, Hyogo 6500017, Japan.							ANAND P, 1991, BRIT J DERMATOL, V124, P547, DOI 10.1111/j.1365-2133.1991.tb04948.x; ARNETZ BB, 1991, ACTA DERM-VENEREOL, P9; Baba S, 1996, LANCET, V347, P307, DOI 10.1016/S0140-6736(96)90473-0; BLESLOW NE, 1989, IARC SCI PUBLICATION, V82; BRUIJNZEELKOOME.C, 1986, ARCH DERMATOL RES, V278, P199; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CLARK RAF, 1989, J AM ACAD DERMATOL, V21, P863, DOI 10.1016/S0190-9622(89)70269-3; COULSON IH, 1990, BRIT J DERMATOL, V122, P343, DOI 10.1111/j.1365-2133.1990.tb08282.x; Dhabhar FS, 1997, BRAIN BEHAV IMMUN, V11, P286, DOI 10.1006/brbi.1997.0508; Dhabhar FS, 1996, J IMMUNOL, V156, P2608; EHLERS A, 1995, J CONSULT CLIN PSYCH, V63, P624, DOI 10.1037/0022-006X.63.4.624; GARRISON CZ, 1993, AM J EPIDEMIOL, V138, P522, DOI 10.1093/oxfordjournals.aje.a116886; GINSBURG IH, 1993, INT J DERMATOL, V32, P656, DOI 10.1111/j.1365-4362.1993.tb04021.x; Gupta MA, 1996, J AM ACAD DERMATOL, V34, P1030, DOI 10.1016/S0190-9622(96)90284-4; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; *JAP DERM ASS, 1996, J DERMATOL TOKYO, V23, P66; KATSOUYANNI K, 1986, INT J EPIDEMIOL, V15, P326, DOI 10.1093/ije/15.3.326; KUBOTA Y, 1992, Journal of Dermatology (Tokyo), V19, P177, DOI 10.1111/j.1346-8138.1992.tb03202.x; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LEUNG DYM, 1995, J INVEST DERMATOL, V105, pS37, DOI 10.1111/1523-1747.ep12315250; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; MICHEL FB, 1994, ALLERGY, V49, P28, DOI 10.1111/j.1398-9995.1994.tb04235.x; Miller T W, 1992, Int J Soc Psychiatry, V38, P215, DOI 10.1177/002076409203800305; MITCHELL EB, 1982, LANCET, V1, P127; MORREN MA, 1994, J AM ACAD DERMATOL, V31, P467, DOI 10.1016/S0190-9622(94)70213-6; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; NEUBER K, 1992, IMMUNOLOGY, V75, P23; RABIN BS, 1989, CRIT REV IMMUNOL, V9, P279; ROBERTS DLL, 1984, BRIT J DERMATOL, V110, P735, DOI 10.1111/j.1365-2133.1984.tb04714.x; Rook GAW, 1997, LANCET, V349, P1831, DOI 10.1016/S0140-6736(97)01164-1; Rothe MJ, 1996, J AM ACAD DERMATOL, V35, P1, DOI 10.1016/S0190-9622(96)90486-7; *SAS I INC, 1996, LOGISTIC PROC SAS ST; SUZUKI S, 1995, LANCET, V345, P981, DOI 10.1016/S0140-6736(95)90727-0; Tabata N, 1997, ARCH DERMATOL RES, V289, P410, DOI 10.1007/s004030050213; TREVISAN M, 1992, AM J EPIDEMIOL, V135, P632, DOI 10.1093/oxfordjournals.aje.a116342; TRICHOPOULOS D, 1981, LANCET, V26, P441; UEHARA M, 1976, ARCH DERMATOL, V112, P951, DOI 10.1001/archderm.112.7.951	37	109	116	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					173	176		10.1016/S0091-6749(99)70130-2	http://dx.doi.org/10.1016/S0091-6749(99)70130-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400856				2022-12-18	WOS:000081738900026
J	Apter, AJ; Reisine, ST; Affleck, G; Barrows, E; ZuWallack, RL				Apter, AJ; Reisine, ST; Affleck, G; Barrows, E; ZuWallack, RL			The influence of demographic and socioeconomic factors on health-related quality of life in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; health-related quality of life; socioeconomic status	OF-LIFE; QUESTIONNAIRE; OUTCOMES; SF-36	Background: Although health-related quality of life (HRQL) in asthma is strongly influenced by disease severity, demographic and socioeconomic variables may also be important factors. Objective: We related demographics, asthma severity, and socioeconomic factors to HRQL, Methods: We interviewed 50 patients with moderate or severe asthma recruited from outpatient health center-based clinics to determine demographics, socioeconomic status, asthma severity, medication use, and HRQL, For HRQL, the mean total score of the Asthma Quality of Life Questionnaire (AQLQ) and the Medical Outcomes Study Short-Form 36 questionnaires physical and mental component summary scores (PCS and MCS, respectively) were used. Results: The mean patient age was 46 +/- 14 years, and the FEV1 was 75% +/- 21% of predicted value. Twenty-nine subjects had been hospitalized for asthma, 29 belonged to a minority racial/ethnic group, and 16 had less than 12 years of education. The mean total AQLQ score was 4.12 +/- 1.42, the PCS was 37 +/- 10, and the MCS was 45 +/- 13. In univariate analyses, severity (nighttime awakenings, prednisone use, and a history of emergency department visits), racial/ethnic group (African American, white, or Hispanic), and socioeconomic status-(low educational level, unemployed, family income under $20,000, public assistance, or no health insurance) were related to HRQL, These factors explained 67% of the variance of AQLQ and 48% of the variance of the PCS. Much of the quality of life variance was shared among these variables. Explanatory variables were not related to MCS in multivariate analysis. Conclusion: Socioeconomic status is an additional important independent factor influencing HRQL in asthma In this study it was difficult to separate out the unique effects of socioeconomic status and race/ethnicity.	Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA; Univ Connecticut, Ctr Hlth, Dept Behav Sci & Community Hlth, Farmington, CT USA; Univ Connecticut, Ctr Hlth, Gen Clin Res Ctr, Farmington, CT USA; Univ Connecticut, Ctr Hlth, Dept Community Med & Hlth Care, Farmington, CT USA; St Francis Hosp & Med Ctr, Dept Med, Hartford, CT 06105 USA	University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut; Saint Francis Hospital & Medical Center	Apter, AJ (corresponding author), Hosp Univ Penn, Sect Allergy & Immunol, Silverstein 3,3400 Spruce St, Philadelphia, PA 19104 USA.				NCRR NIH HHS [MO I-RRO6192] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; *EXP PAN REP, 1991, NATL I HLTH PUBL; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; JOHNSON PA, 1995, MED CARE, V33, P145; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; Leidy NK, 1998, QUAL LIFE RES, V7, P127, DOI 10.1023/A:1008853325724; LEIDY NK, 1998, AM J RESP CRIT CARE, V157, pA752; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; Ware J.E, 1994, PHYS MENTAL HLTH SUM; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	17	109	110	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				72	78		10.1016/S0091-6749(99)70528-2	http://dx.doi.org/10.1016/S0091-6749(99)70528-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	158JM	9893188	Bronze			2022-12-18	WOS:000078112300012
J	VANVYVE, T; CHANEZ, P; BERNARD, A; BOUSQUET, J; GODARD, P; LAUWERIJS, R; SIBILLE, Y				VANVYVE, T; CHANEZ, P; BERNARD, A; BOUSQUET, J; GODARD, P; LAUWERIJS, R; SIBILLE, Y			PROTEIN-CONTENT IN BRONCHOALVEOLAR LAVAGE FLUID OF PATIENTS WITH ASTHMA AND CONTROL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHOALVEOLAR LAVAGE; ASTHMA; PROTEINS; SECRETORY COMPONENT; CLARA PROTEIN (CC10)	POLYMERIC IMMUNOGLOBULIN-A; INTERSTITIAL LUNG-DISEASE; CLARA CELL PROTEIN; SECRETORY IGA; BRONCHIAL LAVAGE; RESPIRATORY MEMBRANE; ALVEOLAR MACROPHAGES; ALLERGIC ASTHMATICS; PLASMA EXUDATION; HISTAMINE LEVELS	Background: Secretory component (SC), Clara cell protein (CC10) and to some extent, IgM are proteins locally synthetized in airways. Albumin, alpha 2-macroglobulin and alpha 1-antitrypsin are mainly plasma proteins. In patients with asthma, blood proteins may occur in greater amounts in bronchoalveolar lavage fluid (BALF) than in control subjects because of plasma extravasation. These proteins were measured in BALF to define markers of local synthesis and plasma exudation. Methods: Twenty-four patients with asthma (mean age, 40 +/- 3.1 years) and 24 control subjects (mean age, 29 +/- 11 years) were tested. Five aliquots of saline solution (50 mi) were instilled, and the recovered BALF was stored. Clara cell protein was measured by a sensitive immunoassay technique based on the agglutination of latex particles. SC, immunoglobulins, alpha 2-macroglobulin, alpha 1-antitrypsin, and albumin were measured by an immunoradiometric assay. Protein concentrations were normalized to albumin. Results: In BALF from patients with asthma there was a significant increase in alpha 2-macroglobulin and IgM and a significant decrease of SC, alpha 1-antitrypsin, and Clara cell protein compared with control subjects. Also, the ratio to albumin was significantly increased for alpha 2-macroglobulin and IgM and decreased for SC. There was no correlation between the severity of asthma and the amount of proteins, proteins. Conclusions: BALF protein content is significantly different in patients with asthma and cona ol subjects, for proteins produced locally and derived from plasma.	CHU MONTPELLIER,SERV MALAD RESP,MONTPELLIER,FRANCE; UNIV CATHOLIQUE LOUVAIN,PNEUMOL UNIT,BRUSSELS,BELGIUM; UNIV CATHOLIQUE LOUVAIN,IND TOXICOL & OCCUPAT MED UNIT,BRUSSELS,BELGIUM	Universite de Montpellier; CHU de Montpellier; Universite Catholique Louvain; Universite Catholique Louvain			Bousquet, Jean/O-4221-2019; BERNARD, Alfred M/A-6511-2010	BERNARD, Alfred M/0000-0003-3171-3743; chanez, pascal/0000-0003-4059-0917				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; BEAVEN MA, 1976, NEW ENGL J MED, V294, P30, DOI 10.1056/NEJM197601012940108; BERNARD A, 1992, EUR RESPIR J, V5, P1231; BERNARD A, 1992, CLIN CHIM ACTA, V207, P239, DOI 10.1016/0009-8981(92)90122-7; BERNARD A, 1991, CLIN CHIM ACTA, V201, P231, DOI 10.1016/0009-8981(91)90374-L; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRANDTZAEG P, 1981, CLIN EXP IMMUNOL, V44, P221; BROERS JLV, 1992, LAB INVEST, V66, P337; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CHUNG KF, 1990, EUR RESPIR J, V3, P329; DANIELE RP, 1985, ANN INTERN MED, V102, P93, DOI 10.7326/0003-4819-102-1-93; DELACROIX DL, 1985, AM REV RESPIR DIS, V132, P829; DELACROIX DL, 1982, J CLIN INVEST, V70, P230, DOI 10.1172/JCI110610; DELACROIX DL, 1981, J IMMUNOL METHODS, V40, P345, DOI 10.1016/0022-1759(81)90366-5; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; GOODMAN MR, 1981, AM REV RESPIR DIS, V123, P115; HOL BEA, 1991, INT ARCH ALLER A IMM, V96, P12, DOI 10.1159/000235528; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; JARJOUR NN, 1991, AM REV RESPIR DIS, V144, P83, DOI 10.1164/ajrccm/144.1.83; JONES KP, 1990, EUR RESPIR J, V3, P152; LAM S, 1985, CHEST, V88, P856, DOI 10.1378/chest.88.6.856; LAM S, 1987, J ALLERGY CLIN IMMUN, V80, P44, DOI 10.1016/S0091-6749(87)80189-6; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; LOW RB, 1978, AM REV RESPIR DIS, V118, P863; MARCHANDISE FXP, 1989, EUR RESPIR J, V2, P623; MARCY TW, 1987, AM REV RESPIR DIS, V135, P1276; MERRILL W, 1982, AM REV RESPIR DIS, V126, P617; MERRILL WW, 1980, AM REV RESPIR DIS, V122, P156; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; OUT TA, 1991, EUR RESPIR J, V4, pS148; PERSSON CGA, 1991, EUR RESPIR J, V4, P1268; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; REYNOLDS HY, 1974, J LAB CLIN MED, V84, P559; REYNOLDS HY, 1987, AM REV RESPIR DIS, V135, P250; ROSSEN RD, 1968, J IMMUNOL, V100, P706; SCHRIVER EE, 1992, AM REV RESPIR DIS, V145, P762, DOI 10.1164/ajrccm/145.4_Pt_1.762; SINGH G, 1988, BIOCHIM BIOPHYS ACTA, V950, P329, DOI 10.1016/0167-4781(88)90129-7; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; VANDEGRAAF EA, 1991, LUNG, V169, P275, DOI 10.1007/BF02714163; VANDEGRAAF EA, 1991, AM REV RESPIR DIS, V143, P362, DOI 10.1164/ajrccm/143.2.362; VANDEGRAAF EA, 1991, CLIN CHIM ACTA, V196, P27, DOI 10.1016/0009-8981(91)90205-Q; VANVYVE T, 1992, AM REV RESPIR DIS, V146, P116, DOI 10.1164/ajrccm/146.1.116; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689; VONWICHERT P, 1993, AM REV RESPIR DIS, V147, P148, DOI 10.1164/ajrccm/147.1.148; WARD C, 1993, THORAX, V48, P518, DOI 10.1136/thx.48.5.518; WARD C, 1992, AM REV RESPIR DIS, V146, P444, DOI 10.1164/ajrccm/146.2.444; WATER R, 1986, AM REV RESPIR DIS, V133, P882; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WHITE R, 1980, LUNG, V158, P9, DOI 10.1007/BF02713697; 1962, AM REV RESPIR DIS, V85, P762	52	109	115	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				60	68		10.1016/S0091-6749(95)70153-2	http://dx.doi.org/10.1016/S0091-6749(95)70153-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822665	Bronze			2022-12-18	WOS:A1995QC31200009
J	RAK, S; BJORNSON, A; HAKANSON, L; SORENSON, S; VENGE, P				RAK, S; BJORNSON, A; HAKANSON, L; SORENSON, S; VENGE, P			THE EFFECT OF IMMUNOTHERAPY ON EOSINOPHIL ACCUMULATION AND PRODUCTION OF EOSINOPHIL CHEMOTACTIC ACTIVITY IN THE LUNG OF SUBJECTS WITH ASTHMA DURING NATURAL POLLEN EXPOSURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; INFLAMMATION; IMMUNOTHERAPY; BRONCHOALVEOLAR LAVAGE; EOSINOPHIL; BIRCH ALLERGY	CATIONIC PROTEIN; SEASON; RESPONSIVENESS	Two groups of birch pollen-allergic patients with seasonal rhinoconjunctivitis and asthma were followed during two consecutive birch-pollen seasons, one group, N = 10, during a season with high pollen load, and one group, N = 15, during a season of low pollen load. Half the patients were treated with immunotherapy (IT) for 3 and 4 years, respectively. The other half of the patients served as control group (non-IT). Bronchoalveolar lavage (BAL) was performed once before each season and once during the pollen season. Eosinophil (EOS) numbers in BAL were increased (p < 0.01) during the season with high pollen load but not in the season with a low pollen load, and this increment was absent in the IT-treated group. Also, the EOS cationic protein levels were raised in the non-IT-treated group during the season with a high pollen load. The levels of EOS and neutrophil chemotactic activity were raised in BAL in both seasons in the non-IT-treated group compared with the IT-treated group (p < 0.02, p < 0.003, p < 0.04, and p < 0.005 in high- and low-load pollen season, respectively). Serum and BAL eosinophil chemotactic activity (ECA) were positively correlated (p < 0.001). We conclude that there is an influx of active EOSs into the lung of pollen-allergic patients with asthma during a pollen season, which may be abrogated by IT. Furthermore, the generation of ECA appears to be an extremely sensitive marker of antigenic exposure, and the potent inhibition of the generation of ECA by IT may provide a clue as to the mechanism of this treatment.	CENT HOSP VASTERAS, DEPT LUNG MED, INFLAMMAT RES LAB, VASTERAS, SWEDEN; UNIV HOSP UPPSALA, DEPT CLIN CHEM, UPPSALA, SWEDEN; AB DRACO, S-22101 LUND, SWEDEN	Vasteras Central Hospital; Uppsala University; Uppsala University Hospital								ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; Freeman J, 1911, LANCET, V2, P814; GRIFFIN E, 1991, J ALLERGY CLIN IMMUN, V87, P548, DOI 10.1016/0091-6749(91)90014-F; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V83, P933, DOI 10.1016/0091-6749(89)90108-5; HAKANSSON L, 1990, J ALLERGY CLIN IMMUN, V85, P743, DOI 10.1016/0091-6749(90)90193-8; HOLGATE ST, 1991, CLIN EXP ALLERGY, V21, P11, DOI 10.1111/j.1365-2222.1991.tb01758.x; LAM S, 1985, CHEST, V87, P740, DOI 10.1378/chest.87.6.740; LOWHAGEN O, 1983, EUR J RESPIR DIS, V64, P466; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; Noon L, 1911, LANCET, V1, P1572; OLOFSSON T, 1977, SCAND J HAEMATOL, V18, P73; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; STAFFORD WP, 1984, ANN ALLERGY, V52, P401; VENGE P, 1977, LANCET, V2, P373; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x	21	109	113	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					878	888		10.1016/0091-6749(91)90244-I	http://dx.doi.org/10.1016/0091-6749(91)90244-I			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744358				2022-12-18	WOS:A1991GW26200008
J	BOUSQUET, J; LEBEL, B; CHANAL, I; MOREL, A; MICHEL, FB				BOUSQUET, J; LEBEL, B; CHANAL, I; MOREL, A; MICHEL, FB			ANTIALLERGIC ACTIVITY OF H1-RECEPTOR ANTAGONISTS ASSESSED BY NASAL CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INSERM,U58,F-34100 MONTPELLIER,FRANCE; IMMUNOTECH,MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	BOUSQUET, J (corresponding author), CHU MONTPELLIER,HOP AIGUELONGUE,MALAD RESP CLIN,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					BANTZ EW, 1987, J ALLERGY CLIN IMMUN, V80, P99, DOI 10.1016/S0091-6749(87)80198-7; BARLOW JLR, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1215; BARNETT A, 1984, AGENTS ACTIONS, V14, P590, DOI 10.1007/BF01978891; BATENHORST RL, IN PRESS EUR J CLIN; BLUMSTEIN GI, 1937, J ALLERGY, V8, P321; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1987, INT ARCH ALLER A IMM, V82, P550, DOI 10.1159/000234277; BOUSQUET J, IN PRESS CLIN ALLERG; BROWN MS, 1987, ARCH OTOLARYNGOL, V113, P179; CHAND N, 1987, ANN ALLERGY, V58, P344; CHENG HC, 1982, DRUG DEVELOP RES, V2, P181, DOI 10.1002/ddr.430020208; CHURCH MK, 1980, BRIT J PHARMACOL, V70, P307, DOI 10.1111/j.1476-5381.1980.tb07937.x; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CRETICOS P S, 1984, Journal of Allergy and Clinical Immunology, V73, P141; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DUGUE P, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1206; FABRE J, 1988, J ALLERGY CLIN IMMUN, V81, P311, DOI 10.1016/0091-6749(88)90805-6; KREUTNER W, 1987, ALLERGY, V42, P57, DOI 10.1111/j.1398-9995.1987.tb02188.x; MACLOUF J, 1986, PROSTAGLANDINS, V31, P123, DOI 10.1016/0090-6980(86)90230-3; MIADONNA A, 1986, J ALLERGY CLIN IMMUN, V77, P177; MICHEL FB, 1987, J ALLERGY CLIN IMMUN, V79, P247; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1984, ARCH OTOLARYNGOL, V110, P25; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NACLERIO RM, 1986, J ALLERGY CLIN IMMUN, V78, P874, DOI 10.1016/0091-6749(86)90233-2; OEI HD, 1987, J ALLERGY CLIN IMMUN, V79, P190; Pepys J., 1975, BR J HOSP MED, V14, P412; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; ROMAN IJ, 1986, ANN ALLERGY, V57, P253; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; ROSSONI G, 1984, ARCH INT PHARMACOD T, V268, P128; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; SKASSABROCIEK W, 1986, J ALLERGY CLIN IMMUN, V77, P137; TASAKA K, 1986, ANN ALLERGY, V56, P464; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; TOGIAS AG, 1986, AM REV RESPIR DIS, V133, P1133; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P225, DOI 10.1001/jama.255.2.225	40	109	109	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				881	887		10.1016/0091-6749(88)90094-2	http://dx.doi.org/10.1016/0091-6749(88)90094-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	2461406				2022-12-18	WOS:A1988R170800025
J	TAUDORF, E; LAURSEN, LC; LANNER, A; BJORKSTEN, B; DREBORG, S; SOBORG, M; WEEKE, B				TAUDORF, E; LAURSEN, LC; LANNER, A; BJORKSTEN, B; DREBORG, S; SOBORG, M; WEEKE, B			ORAL IMMUNOTHERAPY IN BIRCH POLLEN HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV HOSP COPENHAGEN,MED DEPT TTA,ALLERGY UNIT,COPENHAGEN,DENMARK; LINKOPING UNIV HOSP,DEPT PAEDIAT,S-58185 LINKOPING,SWEDEN; PHARMACIA AB,DIV ALLERGY & DIAGNOST,UPPSALA,SWEDEN; CTY HOSP,DEPT MED B,HILLEROD,DENMARK	University of Copenhagen; Linkoping University; Pfizer; Pharmacia Corporation								BJORKSTEN B, 1986, J ALLERGY CLIN IMMUN, V77, P214; BJORKSTEN B, 1986, ALLERGY, V41, P290, DOI 10.1111/j.1398-9995.1986.tb02031.x; BLACK JH, 1939, ALLERGY, V10, P156; COHEN SH, 1979, J ALLERGY CLIN IMMUN, V64, P270, DOI 10.1016/0091-6749(79)90143-X; COOPER PJ, 1984, CLIN ALLERGY, V14, P541, DOI 10.1111/j.1365-2222.1984.tb02242.x; Curtis H. H, 1900, MEDICAL NEWSLETTER, V77, P16; DREBORG S, IN PRESS SKIN TEST R; Feinberg SM, 1940, J AMER MED ASSOC, V115, P23; FINNEY DJ, 1978, STATISTICAL METHOD B; HOLLANDER M, 1973, NONPARAMETRIC STAT, P78; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; OSTERBALLE O, 1980, ALLERGY, V35, P473, DOI 10.1111/j.1398-9995.1980.tb01795.x; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; REBIEN W, 1982, EUR J PEDIATR, V138, P341, DOI 10.1007/BF00442513; STEMMANN EA, 1979, PRAX KLIN PNEUMOL, V33, P302; TAUDORF E, 1985, ALLERGY, V40, P321, DOI 10.1111/j.1398-9995.1985.tb00243.x; TAUDORF E, 1985, ALLERGY, V40, P344, DOI 10.1111/j.1398-9995.1985.tb00245.x; THIBERGE N, 1942, NEW ORL MED SURG J, V94, P390; Touart MD, 1922, NY MED J, V116, P199; URBANEK R, 1982, MONATSSCHR KINDERH, V130, P150; URBANEK R, 1938, DTSCH MED WOCHENSCHR, V38, P1433; WAHN U, 1976, MONATSSCHR KINDERH, V124, P245; WORTMANN F, 1979, ALLERGOLOGIE, V5, P243; WORTMANN F, 1977, ALLERGOL IMMUNOPATH, V15, P15	25	109	109	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					153	161		10.1016/0091-6749(87)90124-2	http://dx.doi.org/10.1016/0091-6749(87)90124-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	3301985				2022-12-18	WOS:A1987J657500006
J	HOFFMAN, DR; YAMAMOTO, FY; GELLER, B; HADDAD, Z				HOFFMAN, DR; YAMAMOTO, FY; GELLER, B; HADDAD, Z			SPECIFIC IGE ANTIBODIES IN ATOPIC ECZEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA; UNIV SO CALIF,LOS ANGELES CTY MED CTR,DIV PEDIAT ALLERGY & IMMUNOL,GEN LAB BLDG 1G38,1129 N,LOS ANGELES,CA 90033	University of Southern California; University of Southern California								BESNIER E, 1892, ANN DERMATOL SYPHIL, V3, P634; BUCKLEY RH, 1973, BRENNEMANS PRACTICE, pCH64; CLAUSEN CR, 1969, J IMMUNOL, V103, P768; CLENDENNING WE, 1973, J INVEST DERMATOL, V61, P233, DOI 10.1111/1523-1747.ep12676481; GUREVITCH AW, 1973, ARCH DERM, V107, P812; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; HOFFMAN DR, 1974, PEDIATRICS, V54, P151; HOFFMAN DW, IN PRESS; HOLT E, 1965, J PEDIATRICS, V66, P153; JOHNSON P, 1965, EUR POLYM J, V1, P63; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; NORINS AL, 1971, PEDIATR CLIN N AM, V18, P801; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; OKAMURA K, 1971, J IMMUNOL, V107, P1682; ROSTENBERG A, 1971, IMMUNOLOGICAL DISEAS, pCH53; STONE SP, 1973, ARCH DERMATOL, V108, P806, DOI 10.1001/archderm.108.6.806; WIDE L, 1967, LANCET, V2, P1105	18	109	109	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	4					256	267		10.1016/0091-6749(75)90145-1	http://dx.doi.org/10.1016/0091-6749(75)90145-1			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	W1385		Bronze			2022-12-18	WOS:A1975W138500007
J	Wawrzyniak, P; Wawrzyniak, M; Wanke, K; Sokolowska, M; Bendelja, K; Ruckert, B; Globinska, A; Jakiela, B; Kast, JI; Idzko, M; Akdis, M; Sanak, M; Akdis, CA				Wawrzyniak, Paulina; Wawrzyniak, Marcin; Wanke, Kerstin; Sokolowska, Milena; Bendelja, Kreso; Ruckert, Beate; Globinska, Anna; Jakiela, Bogdan; Kast, Jeannette I.; Idzko, Marco; Akdis, Mubeccel; Sanak, Marek; Akdis, Cezmi A.			Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; bronchial epithelial cells; epigenetic; tight junctions; T(H)2 cells; IL-4; IL-13; histone deacetylase	SKIN BARRIER; MECHANISMS; EXPRESSION; DISEASE; INNATE; CELLS; DYSFUNCTION; IMMUNOLOGY; JUNCTIONS; RESPONSES	Background: Tight junctions (TJs) form a barrier on the apical side of neighboring epithelial cells in the bronchial mucosa. Changes in their integrity might play a role in asthma pathogenesis by enabling the paracellular influx of allergens, toxins, and microbes to the submucosal tissue. Objective: The regulation of bronchial epithelial TJs by T(H)2 cells and their cytokines and their involvement in epigenetic regulation of barrier function were investigated. Methods: The expression, regulation, and function of TJs were determined in air-liquid interface (ALI) cultures of control and asthmatic primary human bronchial epithelial cells (HBECs) by means of analysis of transepithelial electrical resistance, paracellular flux, mRNA expression, Western blotting, and immunofluorescence staining. Results: HBECs from asthmatic patients showed a significantly low TJ integrity in ALI cultures compared with HBECs from healthy subjects. TH2 cell numbers and levels of their cytokines, IL-4 and IL-13, decreased barrier integrity in ALI cultures of HBECs from control subjects but not in HBECs from asthmatic patients. They induced a physical separation of the TJs of adjacent cells in immunofluorescence staining of the TJ molecules occludin and zonula occludens-1. We observed that expression of histone deacetylases (HDACs) 1 and 9, and Silent information regulator genes (sirtuins [SIRTs]) 6 and 7 were significantly high in HBECs from asthmatic patients. IL-4 and IL-13 significantly increased the expression of HDACs and SIRTs. The role of HDAC activation on epithelial barrier leakiness was confirmed by HDAC inhibition, which improved barrier integrity through increased synthesis of TJ molecules in epithelium from asthmatic patients to the level seen in HBECs from control subjects. Conclusion: Our data demonstrate that barrier leakiness in asthmatic patients is induced by TH2 cells, IL-4, and IL-13 and HDAC activity. The inhibition of endogenous HDAC activity reconstitutes defective barrier by increasing TJ expression.	[Wawrzyniak, Paulina; Wawrzyniak, Marcin; Wanke, Kerstin; Sokolowska, Milena; Ruckert, Beate; Globinska, Anna; Kast, Jeannette I.; Akdis, Mubeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CK CARE, Davos, Switzerland; [Jakiela, Bogdan; Sanak, Marek] Jagiellonian Univ, Coll Med, Dept Med, PL-31007 Krakow, Poland; [Idzko, Marco] Univ Hosp Freiburg, Dept Pneumol, Freiburg, Germany; [Bendelja, Kreso] Inst Immunol, Zagreb, Croatia	Swiss Institute of Allergy & Asthma Research; University of Zurich; Jagiellonian University; Collegium Medicum Jagiellonian University; University of Freiburg	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	akdiasac@siaf.uzh.ch	Wawrzyniak, Marcin/AAT-9094-2021; Akdis, Cezmi/AAV-4844-2020; Jakiela, Bogdan/CAA-1861-2022; Wawrzyniak, Paulina/AAD-7265-2020; Sanak, Marek/AAV-1628-2021; Wawrzyniak, Paulina/HCG-8924-2022; Wawrzyniak, Marcin/E-5878-2017; Wawrzyniak, Paulina/AAG-3548-2019	Wawrzyniak, Marcin/0000-0002-6911-8010; Akdis, Cezmi/0000-0001-8020-019X; Jakiela, Bogdan/0000-0003-0444-981X; Wawrzyniak, Paulina/0000-0001-9641-2103; Sanak, Marek/0000-0001-7635-8103; Sokolowska, Milena/0000-0001-9710-6685; Bendelja, Kreso/0000-0002-6017-3355	Swiss National Science Foundation [310030_156823, 320030_140772]; Switzerland through the Swiss to Polish Contribution to the enlarged European Union [PSPB-072/2010]; European Commission [261357, 260895]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Switzerland through the Swiss to Polish Contribution to the enlarged European Union; European Commission(European CommissionEuropean Commission Joint Research Centre)	Supported by Swiss National Science Foundation grants 310030_156823, and 320030_140772, a Research grant from Switzerland through the Swiss to Polish Contribution to the enlarged European Union (PSPB-072/2010), the European Commission's Seventh Framework Programme under grant agreement no. 261357 (MeDALL), and the European Commission's Seventh Framework Programme under grant agreement no. 260895 (PREDICTA).	Akdis CA, 2014, J CLIN INVEST, V124, P4678, DOI 10.1172/JCI78891; Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Alvarez-Errico D, 2015, NAT REV IMMUNOL, V15, P7, DOI 10.1038/nri3777; Arts J, 2009, CLIN CANCER RES, V15, P6841, DOI 10.1158/1078-0432.CCR-09-0547; Bai JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118286; Bird L, 2015, NAT REV IMMUNOL, V15, DOI [10.1038/nri3812, 10.1038/nri3827]; Blume C, 2013, EUR RESPIR J, V42, P87, DOI 10.1183/09031936.00075612; Bordin M, 2004, MOL CANCER RES, V2, P692; Chun P, 2015, ARCH PHARM RES, V38, P1, DOI 10.1007/s12272-014-0494-2; Corner BS, 2015, PHARMACOL THERAPEUT, V147, P91, DOI 10.1016/j.pharmthera.2014.11.006; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; ELIA C, 1988, J SUBMICR CYTOL PATH, V20, P509; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Hackett TL, 2011, AM J RESP CELL MOL, V45, P1090, DOI 10.1165/rcmb.2011-0031OC; Hall JA, 2013, J CLIN INVEST, V123, P973, DOI 10.1172/JCI64094; Harb H, 2015, J ALLERGY CLIN IMMUN, V135, P15, DOI 10.1016/j.jaci.2014.11.009; Holtzman MJ, 2014, NAT REV IMMUNOL, V14, P686, DOI 10.1038/nri3739; Holtzman MJ, 2012, J CLIN INVEST, V122, P2741, DOI 10.1172/JCI60325; Issa JP, 2014, J CLIN INVEST, V124, P24, DOI 10.1172/JCI69735; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; Kast JI, 2012, J ALLERGY CLIN IMMUN, V130, P544, DOI 10.1016/j.jaci.2012.04.044; Kicic A, 2010, AM J RESP CRIT CARE, V181, P889, DOI 10.1164/rccm.200907-1071OC; Klunker S, 2009, J EXP MED, V206, P2701, DOI 10.1084/jem.20090596; Kojima T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/947072; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Kubo T, 2015, J ALLERGY CLIN IMMUN, V136, P1413, DOI 10.1016/j.jaci.2015.05.006; Lam HC, 2013, J CLIN INVEST, V123, P5212, DOI 10.1172/JCI69636; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Livyatan I, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.33; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Ming M, 2015, J ALLERGY CLIN IMMUN, V135, P936, DOI 10.1016/j.jaci.2014.09.035; Mortaz Esmaeil, 2011, Tanaffos, V10, P7; Parker J, 2010, PEDIATR RES, V67, P17, DOI 10.1203/PDR.0b013e3181c0b200; Post S, 2013, ALLERGY, V68, P1117, DOI 10.1111/all.12202; Rackley CR, 2012, J CLIN INVEST, V122, P2724, DOI 10.1172/JCI60519; Robert T, 2011, NATURE, V471, P74, DOI 10.1038/nature09803; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Shaw JG, 2014, J THORAC DIS, V6, P1532, DOI 10.3978/j.issn.2072-1439.2014.11.33; Shen L, 2012, ANN NY ACAD SCI, V1258, P9, DOI 10.1111/j.1749-6632.2012.06613.x; Sokolowska M, 2015, J IMMUNOL, V194, P5472, DOI 10.4049/jimmunol.1401343; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Venugopal B, 2013, CLIN CANCER RES, V19, P4262, DOI 10.1158/1078-0432.CCR-13-0312; Voraphani N, 2014, MUCOSAL IMMUNOL, V7, P1175, DOI 10.1038/mi.2014.6; Wang LQ, 2015, J CLIN INVEST, V125, P1111, DOI 10.1172/JCI77088; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Whitsett JA, 2015, NAT IMMUNOL, V16, P27, DOI 10.1038/ni.3045; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Yang IV, 2012, J ALLERGY CLIN IMMUN, V130, P1243, DOI 10.1016/j.jaci.2012.07.052; Yu HS, 2015, J ALLERGY CLIN IMMUN, V135, P827, DOI 10.1016/j.jaci.2014.10.040	56	108	115	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					93	103		10.1016/j.jaci.2016.03.050	http://dx.doi.org/10.1016/j.jaci.2016.03.050			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27312821	Green Published, Bronze			2022-12-18	WOS:000393996800011
J	Ramakrishnan, VR; Hauser, LJ; Feazel, LM; Ir, D; Robertson, CE; Frank, DN				Ramakrishnan, Vijay R.; Hauser, Leah J.; Feazel, Leah M.; Ir, Diana; Robertson, Charles E.; Frank, Daniel N.			Sinus microbiota varies among chronic rhinosinusitis phenotypes and predicts surgical outcome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sinusitis; chronic rhinosinusitis; bacteria; microbiome; pyrosequencing; sinus surgery outcomes; 16S rRNA; 16S rDNA	STAPHYLOCOCCUS-AUREUS; MAXILLARY SINUS; COMMENSAL BACTERIA; ASTHMA; PRIMERS; SURGERY; ALLERGY; AIRWAY; COMPLEXITY; SECRETIONS	Background: Chronic rhinosinusitis (CRS) is a prevalent multifactorial disease process in which bacteria are believed to play a role in the propagation of inflammation. Multiple subtypes of CRS have been described based on clinical and pathologic features, but a detailed examination of the sinus microbiota in patients with CRS and its clinical subtypes has yet to be performed. Objective: We sought to examine the resident microbiota of CRS subtypes and determine whether bacterial diversity is a predictor of disease outcomes. Methods: Sinus swabs from patients with CRS and healthy subjects collected during endoscopic sinus surgery were analyzed by means of molecular phylogenetic analysis of 16S rDNA pyrosequences. Results: Fifty-six patients with CRS and 26 control subjects were studied. Biodiversity was similar between the CRS and control groups. Among the CRS subtypes examined, only 2 conditions (presence of purulence and comorbid condition of asthma) were associated with significant alterations in microbial community composition. In 27 patients with CRS who were followed postoperatively, those with better outcomes had more diverse bacterial communities present at the time of surgery, along with higher relative abundances of Actinobacteria. Conclusion: Analysis of microbiota in a large cohort reveals that particular CRS phenotypes (asthma and purulence) are characterized by distinct compositions of resident bacterial communities. We found that bacterial diversity and composition are predictors of surgical outcome, promoting the concept of community ecology in patients with CRS.	[Ramakrishnan, Vijay R.; Hauser, Leah J.] Univ Colorado, Sch Med, Dept Otolaryngol Head & Neck Surg, Aurora, CO 80045 USA; [Feazel, Leah M.; Ir, Diana; Frank, Daniel N.] Univ Colorado, Sch Med, Div Infect Dis, Aurora, CO 80045 USA; [Robertson, Charles E.; Frank, Daniel N.] Univ Colorado, Sch Med, Microbiome Res Consortium, Aurora, CO 80045 USA; [Robertson, Charles E.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Boulder	Ramakrishnan, VR (corresponding author), Univ Colorado, Sch Med, Dept Otolaryngol Head & Neck Surg, 12631 E 17th Ave,B205, Aurora, CO 80045 USA.	vijay.ramakrishnan@ucdenver.edu		ROBERTSON, CHARLES/0000-0002-4136-4121; Ramakrishnan, Vijay/0000-0003-2748-0705	National Institutes of Health [HG005964]; Flight Attendants Medical Research Institute [CIA13006]; University of Colorado Department of Otolaryngology institutional review board approved study (COMIRB) [11-1442]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R21HG005964] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendants Medical Research Institute; University of Colorado Department of Otolaryngology institutional review board approved study (COMIRB); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Supported in part by National Institutes of Health grant HG005964 (to D.N.F.), Flight Attendants Medical Research Institute grant CIA13006 (to D.N.F.), and a University of Colorado Department of Otolaryngology institutional review board approved study (COMIRB protocol no. 11-1442).	Abreu NA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003783; Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Aurora R, 2013, JAMA OTOLARYNGOL, V139, P1328, DOI 10.1001/jamaoto.2013.5465; AUST R, 1974, ACTA OTO-LARYNGOL, V78, P264, DOI 10.3109/00016487409126354; AUST R, 1979, Rhinology (Utrecht), V17, P245; Bachert C, 2009, ALLERGY, V64, P520, DOI 10.1111/j.1398-9995.2009.01964.x; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Boase S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-210; Boyd EL, 2002, ALLERGY IMMUNOLOGY O, P81; Cabrera-Rubio R, 2012, J CLIN MICROBIOL, V50, P3562, DOI 10.1128/JCM.00767-12; CARENFELT C, 1978, ACTA OTO-LARYNGOL, V85, P116, DOI 10.3109/00016487809121431; CARENFELT C, 1977, ACTA OTO-LARYNGOL, V84, P138, DOI 10.3109/00016487709123952; Costello EK, 2012, SCIENCE, V336, P1255, DOI 10.1126/science.1224203; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384; Feazel LM, 2012, LARYNGOSCOPE, V122, P467, DOI 10.1002/lary.22398; Feazel LM, 2011, INT FORUM ALLERGY RH, V1, P451, DOI 10.1002/alr.20071; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Frank DN, 2008, CURR OPIN GASTROEN, V24, P4, DOI 10.1097/MOG.0b013e3282f2b0e8; Frank DN, 2011, TRENDS MICROBIOL, V19, P427, DOI 10.1016/j.tim.2011.06.005; Frank DN, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-362; Frank JA, 2008, APPL ENVIRON MICROB, V74, P2461, DOI 10.1128/AEM.02272-07; GLIKLICH RE, 1995, OTOLARYNG HEAD NECK, V113, P104, DOI 10.1016/S0194-5998(95)70152-4; Godoy JM, 2011, OTOLARYNG HEAD NECK, V145, P673, DOI 10.1177/0194599811407279; Goleva E, 2013, AM J RESP CRIT CARE, V188, P1193, DOI 10.1164/rccm.201304-0775OC; Grice EA, 2012, ADV EXP MED BIOL, V946, P55, DOI 10.1007/978-1-4614-0106-3_4; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hastan D, 2011, ALLERGY, V66, P1216, DOI 10.1111/j.1398-9995.2011.02646.x; Hauser LJ, 2015, INT FORUM ALLERGY RH, V5, P3, DOI 10.1002/alr.21428; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Ivanov II, 2008, CELL HOST MICROBE, V4, P337, DOI 10.1016/j.chom.2008.09.009; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; JOUSIMIESSOMER HR, 1988, J CLIN MICROBIOL, V26, P1926, DOI 10.1128/JCM.26.10.1926-1933.1988; Lane D.J., 1991, NUCL ACID TECHNIQUES, P115, DOI DOI 10.1007/S00227-012-2133-0; Lemon KP, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004183; Levine JM, 1999, OIKOS, V87, P15, DOI 10.2307/3546992; LUND VJ, 1995, ANN OTO RHINOL LARYN, V104, P17, DOI 10.1177/000348949510410s02; Magurran A.E., 2004, MEASURING BIOL DIVER; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; Mattos JL, 2011, INT FORUM ALLERGY RH, V1, P3, DOI 10.1002/alr.20003; McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012; Merkley M, 2014, AM RHIN SOC ANN M OR; Nadkarni MA, 2002, MICROBIOL-SGM, V148, P257, DOI 10.1099/00221287-148-1-257; Oksanen J., **DATA OBJECT**; Poutahidis T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078898; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Pruesse E, 2012, BIOINFORMATICS, V28, P1823, DOI 10.1093/bioinformatics/bts252; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; R Team DC, 2005, R LANG ENV STAT COMP; Ramakrishnan VR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085507; Ramakrishnan VR, 2013, INT FORUM ALLERGY RH, V3, P921, DOI 10.1002/alr.21204; Ramakrishnan VR, 2013, INT FORUM ALLERGY RH, V3, P267, DOI 10.1002/alr.21101; Robertson CE, 2013, BIOINFORMATICS, V29, P3100, DOI 10.1093/bioinformatics/btt526; Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, pS1, DOI 10.1016/j.otohns.2007.06.726; Schloss PD, 2007, ANNU REV MICROBIOL, V61, P23, DOI 10.1146/annurev.micro.61.011507.151712; Schloss PD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027310; Senior BA, 1998, LARYNGOSCOPE, V108, P151, DOI 10.1097/00005537-199802000-00001; Sistek D, 2001, EUR RESPIR J, V17, P214, DOI 10.1183/09031936.01.17202140; Smith TL, 2013, INT FORUM ALLERGY RH, V3, P4, DOI 10.1002/alr.21065; Soler ZM, 2011, LARYNGOSCOPE, V121, P2672, DOI 10.1002/lary.21847; Soler ZM, 2010, OTOLARYNG HEAD NECK, V143, P621, DOI 10.1016/j.otohns.2010.07.014; Stephenson MF, 2010, J OTOLARYNGOL-HEAD N, V39, P182, DOI 10.2310/7070.2009.090060; Sudo N, 1997, J IMMUNOL, V159, P1739; Swanson PA, 2011, P NATL ACAD SCI USA, V108, P8803, DOI 10.1073/pnas.1010042108; Sze MA, 2012, AM J RESP CRIT CARE, V185, P1073, DOI 10.1164/rccm.201111-2075OC; Tabas I, 2013, SCIENCE, V339, P166, DOI 10.1126/science.1230720; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Venkatraman G, 2010, ARCH OTOLARYNGOL, V136, P426, DOI 10.1001/archoto.2010.58; WESTRIN KM, 1994, ACTA OTO-LARYNGOL, P18; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Yan ML, 2013, CELL HOST MICROBE, V14, P631, DOI 10.1016/j.chom.2013.11.005; Zhang N, 2005, RHINOLOGY, V43, P162	76	108	111	2	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					334	+		10.1016/j.jaci.2015.02.008	http://dx.doi.org/10.1016/j.jaci.2015.02.008			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25819063				2022-12-18	WOS:000359004900014
J	Buehring, B; Viswanathan, R; Binkley, N; Busse, W				Buehring, Bjoern; Viswanathan, Ravi; Binkley, Neil; Busse, William			Glucocorticoid-induced osteoporosis: An update on effects and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Glucocorticoid; inhaled and oral corticosteroid; asthma; growth; osteoporosis; bisphosphonates	BONE-MINERAL DENSITY; INHALED BECLOMETHASONE DIPROPIONATE; LONG-TERM TREATMENT; FLUTICASONE PROPIONATE; CORTICOSTEROID USE; CHILDHOOD ASTHMA; INTERNATIONAL-SOCIETY; VERTEBRAL FRACTURE; OFFICIAL POSITIONS; BISPHOSPHONATE USE	Glucocorticoids remain a cornerstone of guideline-based management of persistent asthma and allergic diseases. Glucocorticoid-induced osteoporosis (GIO) is the most common iatrogenic cause of secondary osteoporosis and an issue of concern for physicians treating patients with inhaled or oral glucocorticoids either continuously or intermittently. Patients with GIO experience fragility fractures at better dual-energy x-ray absorptiometry T-scores than those with postmenopausal or age-related osteoporosis. This might be explained, at least in part, by the effects of glucocorticoids not only on osteoclasts but also on osteoblasts and osteocytes. Effective options to detect and manage GIO exist, and a management algorithm has been published by the American College of Rheumatology to provide treatment guidance for clinicians. This review will summarize GIO epidemiology and pathophysiology and assess the role of inhaled and oral glucocorticoids in asthmatic adults and children, with particular emphasis on the effect of such therapies on bone health. Lastly, we will review the American College of Rheumatology GIO guidelines and discuss diagnostic and therapeutic strategies to mitigate the risk of GIO and fragility fractures.	[Buehring, Bjoern; Binkley, Neil] Univ Wisconsin, Sch Med & Publ Hlth, Osteoporosis Res Program, Div Geriatr & Gerontol, Madison, WI 53705 USA; [Buehring, Bjoern; Binkley, Neil] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA; [Viswanathan, Ravi; Busse, William] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Sect Allergy Pulm & Crit Care, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison	Buehring, B (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Osteoporosis Res Program, Sect Geriatr & Gerontol,Dept Med, 2870 Univ Ave,Suite 100, Madison, WI 53705 USA.	bbuehring@medicine.wisc.edu; rviswanathan@medicine.wisc.edu	Buehring, Bjoern/AAC-7951-2019; Buehring, Bjoern/L-5581-2013	Buehring, Bjoern/0000-0003-3841-624X; Buehring, Bjoern/0000-0003-3841-624X	Merck; Lilly; Amgen; Novartis; GlaxoSmithKline; MedImmune; Genentech; Boston Scientific; ICON; National Institutes of Health (NIH)/National Institutes of Allergy and Infectious Diseases; NIH/National Heart, Lung, and Blood Institute	Merck(Merck & Company); Lilly(Eli Lilly); Amgen(Amgen); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Genentech(Roche HoldingGenentech); Boston Scientific(Boston Scientific); ICON; National Institutes of Health (NIH)/National Institutes of Allergy and Infectious Diseases; NIH/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	N. Binkley has consultant arrangements with Merck and Lilly and has received grants from Merck, Lilly, and Amgen. W. Busse is on the Merck Board; has received consultancy fees from Amgen, Novartis, GlaxoSmithKline, MedImmune, Genentech, Boston Scientific, and ICON; has received research support from the National Institutes of Health (NIH)/National Institutes of Allergy and Infectious Diseases and the NIH/National Heart, Lung, and Blood Institute; and has received royalties from Elsevier. The rest of the authors declare they have no relevant conflicts of interest.	Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; Agertoft L, 2005, J ALLERGY CLIN IMMUN, V115, P940, DOI 10.1016/j.jaci.2005.01.066; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; Allen HD, 2000, PEDIATR PULM, V29, P188, DOI 10.1002/(SICI)1099-0496(200003)29:3<188::AID-PPUL6>3.0.CO;2-K; Bachrach LK, 2009, J CLIN ENDOCR METAB, V94, P400, DOI 10.1210/jc.2008-1531; Bachrach Laura Keyes, 2007, Endocr Pract, V13, P513; Baim S, 2008, J CLIN DENSITOM, V11, P6, DOI 10.1016/j.jocd.2007.12.002; Bhalla AK, 2010, BEST PRACT RES CL RH, V24, P313, DOI 10.1016/j.berh.2010.01.006; Bianchi ML, 2007, BONE, V41, P486, DOI 10.1016/j.bone.2007.07.008; Bischoff-Ferrari Heike A, 2011, Curr Osteoporos Rep, V9, P116, DOI 10.1007/s11914-011-0059-y; Bogunovic L, 2009, CURR OPIN PEDIATR, V21, P77, DOI 10.1097/MOP.0b013e32831ec338; Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320; Bouxsein ML, 2005, BEST PRACT RES CL RH, V19, P897, DOI 10.1016/j.berh.2005.07.004; Buehring B, 2010, OSTEOPOROSIS INT, V21, P487, DOI 10.1007/s00198-009-0972-4; Burnham JM, 2012, CURR OPIN RHEUMATOL, V24, P548, DOI 10.1097/BOR.0b013e328356b0c2; Busse WW, 2013, J ALLERGY CLIN IMMUN, V131, pAB230, DOI 10.1016/j.jaci.2012.12.1486; Chauhan BF, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009611.pub3; Compston J, 2010, NAT REV RHEUMATOL, V6, P82, DOI 10.1038/nrrheum.2009.259; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Cover RA, 2000, J ALLERGY CLIN IMMUN, V106, P651; Dam TT, 2010, OSTEOPOROSIS INT, V21, P1341, DOI 10.1007/s00198-009-1076-x; Deal CL, 2013, CLEV CLIN J MED, V80, P117, DOI 10.3949/ccjm.80a.11094; den Uyl D, 2011, CLIN EXP RHEUMATOL, V29, pS93; Derendorf H, 2006, EUR RESPIR J, V28, P1042, DOI 10.1183/09031936.00074905; Dore RK, 2010, ANN RHEUM DIS, V69, P872, DOI 10.1136/ard.2009.112920; Ducharme FM, 2003, PEDIATRICS, V111, P376, DOI 10.1542/peds.111.2.376; Durrani SR, 2011, J ALLERGY CLIN IMMUN, V128, P439, DOI 10.1016/j.jaci.2011.06.002; Ebeling PR, 1998, J BONE MINER RES, V13, P1283, DOI 10.1359/jbmr.1998.13.8.1283; Ferguson AC, 2007, RESP MED, V101, P118, DOI 10.1016/j.rmed.2006.04.009; Frost HM, 2004, ANGLE ORTHOD, V74, P3; Fuerst T, 2009, OSTEOPOROSIS INT, V20, P1199, DOI 10.1007/s00198-008-0806-9; Gregson RK, 1998, OSTEOPOROSIS INT, V8, P418, DOI 10.1007/s001980050085; Griffiths AL, 2004, PEDIATR PULM, V37, P116, DOI 10.1002/ppul.10396; Grossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hansen KE, 2011, J BONE MINER RES, V26, P1989, DOI 10.1002/jbmr.362; Harris M, 2001, J PAEDIATR CHILD H, V37, P67, DOI 10.1046/j.1440-1754.2001.00628.x; HERRALA J, 1994, BONE, V15, P621, DOI 10.1016/8756-3282(94)90309-3; Hofbauer LC, 2010, EUR J ENDOCRINOL, V162, P1009, DOI 10.1530/EJE-10-0015; Horlings CGC, 2008, NAT CLIN PRACT NEURO, V4, P504, DOI 10.1038/ncpneuro0886; Inoue T, 1999, J ASTHMA, V36, P159, DOI 10.3109/02770909909056312; Ioannis SP, 2011, HORM-INT J ENDOCRINO, V10, P280, DOI 10.14310/horm.2002.1319; Jones A, 2002, Cochrane Database Syst Rev, pCD003537, DOI 10.1002/14651858.CD003537; Kamboj Manmohan K, 2007, Adolesc Med State Art Rev, V18, P24; Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134; Kelly HW, 2008, PEDIATRICS, V122, pE53, DOI 10.1542/peds.2007-3381; Kelly HW, 2012, NEW ENGL J MED, V367, P904, DOI 10.1056/NEJMoa1203229; Kelly HW, 2003, J ALLERGY CLIN IMMUN, V112, P469, DOI 10.1067/mai.2003.1718; Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ; Leonard MB, 2007, PEDIATRICS, V119, pS166, DOI 10.1542/peds.2006-2023J; Lewiecki EM, 2008, OSTEOPOROSIS INT, V19, P1369, DOI 10.1007/s00198-008-0689-9; Maricic M, 2011, RHEUM DIS CLIN N AM, V37, P415, DOI 10.1016/j.rdc.2011.07.003; Masud T, 2011, J CLIN DENSITOM, V14, P194, DOI 10.1016/j.jocd.2011.05.010; Matsumoto H, 2001, CHEST, V120, P1468, DOI 10.1378/chest.120.5.1468; Mazziotti G, 2007, ARQ BRAS ENDOCRINOL, V51, P1404, DOI 10.1590/S0004-27302007000800028; McNicholl DM, 2010, CURR DRUG SAF, V5, P182, DOI 10.2174/157488610790936178; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; National Osteoporosis Foundation, 2013, CLIN GUID PREV TREAT; PACKE GE, 1992, THORAX, V47, P414, DOI 10.1136/thx.47.6.414; Papapoulos SE, 2011, HORM RES PAEDIAT, V76, P24, DOI 10.1159/000329151; Pedersen S, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e92; Pfeifer M, 2004, J BONE MINER RES, V19, P1208, DOI 10.1359/JBMR.040507; Pope E, 2007, PEDIATRICS, V119, pE1239, DOI 10.1542/peds.2006-2962; Qi WX, 2013, INT J CLIN ONCOL; Reid IR, 2012, NAT REV RHEUMATOL, V8, P90, DOI 10.1038/nrrheum.2011.181; Rodd C, 2012, ARTHRIT CARE RES, V64, P122, DOI 10.1002/acr.20589; Schimmer BP, 2011, GOODMAN GILMANS PHAR, V12th; Schousboe JT, 2008, J CLIN DENSITOM, V11, P92, DOI 10.1016/j.jocd.2007.12.008; Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001; Sharek PJ, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.1.e8; Silverman SL, 2009, AM J MED, V122, P33, DOI 10.1016/j.amjmed.2008.12.005; Silverstein MD, 1997, J ALLERGY CLIN IMMUN, V99, P466, DOI 10.1016/S0091-6749(97)70072-1; Steinbuch M, 2004, OSTEOPOROSIS INT, V15, P323, DOI 10.1007/s00198-003-1548-3; Stoloff SW, 2011, CURR OPIN ALLERGY CL, V11, P337, DOI 10.1097/ACI.0b013e328348a813; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Thomas T, 2013, J BONE MINER RES, V28; Van Bever HP, 1999, PEDIATR PULM, V27, P369, DOI 10.1002/(SICI)1099-0496(199906)27:6<369::AID-PPUL2>3.3.CO;2-S; van Staa TP, 2006, CALCIFIED TISSUE INT, V79, P129, DOI 10.1007/s00223-006-0019-1; Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283; van Staa TP, 2004, OSTEOPOROSIS INT, V15, P785, DOI 10.1007/s00198-004-1606-5; van Staa TP, 2001, J BONE MINER RES, V16, P581, DOI 10.1359/jbmr.2001.16.3.581; Van Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913; von Scheven Emily, 2007, Curr Osteoporos Rep, V5, P128; Ward L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005324.pub2; Ward LM, 2005, HORM RES, V64, P209, DOI 10.1159/000088976; Weatherall M, 2008, CLIN EXP ALLERGY, V38, P1451, DOI 10.1111/j.1365-2222.2008.03029.x; Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; WOLTHERS OD, 1990, BRIT MED J, V301, P145, DOI 10.1136/bmj.301.6744.145; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3; Zhang C, 2012, J MUSCULOSKEL NEURON, V12, P174	92	108	117	0	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1019	1030		10.1016/j.jaci.2013.08.040	http://dx.doi.org/10.1016/j.jaci.2013.08.040			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24176682				2022-12-18	WOS:000326235600001
J	Saunders, SP; Goh, CSM; Brown, SJ; Palmer, CNA; Porter, RM; Cole, C; Campbell, LE; Gierlinski, M; Barton, GJ; Schneider, G; Balmain, A; Prescott, AR; Weidinger, S; Baurecht, H; Kabesch, M; Gieger, C; Lee, YA; Tavendale, R; Mukhopadhyay, S; Turner, SW; Madhok, VB; Sullivan, FM; Relton, C; Burn, J; Meggitt, S; Smith, CH; Allen, MA; Barker, JNWN; Reynolds, NJ; Cordell, HJ; Irvine, AD; McLean, WHI; Sandilands, A; Fallon, PG				Saunders, Sean P.; Goh, Christabelle S. M.; Brown, Sara J.; Palmer, Colin N. A.; Porter, Rebecca M.; Cole, Christian; Campbell, Linda E.; Gierlinski, Marek; Barton, Geoffrey J.; Schneider, Georg; Balmain, Allan; Prescott, Alan R.; Weidinger, Stephan; Baurecht, Hansjoerg; Kabesch, Michael; Gieger, Christian; Lee, Young-Ae; Tavendale, Roger; Mukhopadhyay, Somnath; Turner, Stephen W.; Madhok, Vishnu B.; Sullivan, Frank M.; Relton, Caroline; Burn, John; Meggitt, Simon; Smith, Catherine H.; Allen, Michael A.; Barker, Jonathan N. W. N.; Reynolds, Nick J.; Cordell, Heather J.; Irvine, Alan D.; McLean, W. H. Irwin; Sandilands, Aileen; Fallon, Padraic G.			Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; association; atopic dermatitis; atopy; eczema; filaggrin; flaky tail; Matt; mattrin; mouse; mutation; Tmem79	GENOME-WIDE ASSOCIATION; BARRIER FUNCTION; SUSCEPTIBILITY LOCI; FILAGGRIN; SKIN; PROTEIN; MUTATIONS; HAIR; MODEL; MICE	Background: Atopic dermatitis (AD) is a major inflammatory condition of the skin caused by inherited skin barrier deficiency, with mutations in the filaggrin gene predisposing to development of AD. Support for barrier deficiency initiating AD came from flaky tail mice, which have a frameshift mutation in Flg and also carry an unknown gene, matted, causing a matted hair phenotype. Objective: We sought to identify the matted mutant gene in mice and further define whether mutations in the human gene were associated with AD. Methods: A mouse genetics approach was used to separate the matted and Flg mutations to produce congenic single-mutant strains for genetic and immunologic analysis. Next-generation sequencing was used to identify the matted gene. Five independently recruited AD case collections were analyzed to define associations between single nucleotide polymorphisms (SNPs) in the human gene and AD. Results: The matted phenotype in flaky tail mice is due to a mutation in the Tmem79/Matt gene, with no expression of the encoded protein mattrin in the skin of mutant mice. Matt(ft) mice spontaneously have dermatitis and atopy caused by a defective skin barrier, with mutant mice having systemic sensitization after cutaneous challenge with house dust mite allergens. Meta-analysis of 4,245 AD cases and 10,558 population-matched control subjects showed that a missense SNP, rs6694514, in the human MATT gene has a small but significant association with AD. Conclusion: In mice mutations in Matt cause a defective skin barrier and spontaneous dermatitis and atopy. A common SNP in MATT has an association with AD in human subjects.	[Saunders, Sean P.; Porter, Rebecca M.; Irvine, Alan D.; Fallon, Padraic G.] Univ Dublin Trinity Coll, Sch Med, Dublin 2, Ireland; [Saunders, Sean P.; Irvine, Alan D.; Fallon, Padraic G.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin, Ireland; [Saunders, Sean P.; Fallon, Padraic G.] Univ Dublin Trinity Coll, Trinity Biomed Sci Inst, Dublin 2, Ireland; [Goh, Christabelle S. M.; Brown, Sara J.; Porter, Rebecca M.; Cole, Christian; Campbell, Linda E.; McLean, W. H. Irwin; Sandilands, Aileen] Univ Dundee, Ctr Dermatol & Genet Med, Dundee DD1 4HN, Scotland; [Palmer, Colin N. A.; Tavendale, Roger] Univ Dundee, Biomed Res Inst, Dundee DD1 4HN, Scotland; [Cole, Christian; Gierlinski, Marek; Barton, Geoffrey J.] Univ Dundee, Bioinformat Res Grp, Dundee DD1 4HN, Scotland; [Balmain, Allan] Univ Dundee, Div Cell Signalling & Immunol, Dundee DD1 4HN, Scotland; [Madhok, Vishnu B.; Sullivan, Frank M.] Univ Dundee, Dundee DD1 4HN, Scotland; [Schneider, Georg] ASTAR, Bioinformat Inst, Singapore, Singapore; [Balmain, Allan] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Weidinger, Stephan; Baurecht, Hansjoerg] Univ Hosp Schleswig Holstein, Dept Dermatol Allergy & Venerol, Kiel, Germany; [Kabesch, Michael] Childrens Hosp Regensburg, Dept Pediat Pneumol & Allergy, Regensburg, Germany; [Gieger, Christian] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Neuherberg, Germany; [Lee, Young-Ae] Charite, D-13353 Berlin, Germany; [Lee, Young-Ae] Max Delbruck Ctr Mol Med MDC, Berlin, Germany; [Mukhopadhyay, Somnath] Royal Alexandra Childrens Hosp, Brighton & Sussex Med Sch, Acad Dept Paediat, Brighton, E Sussex, England; [Turner, Stephen W.] Univ Aberdeen, Dept Child Hlth, Aberdeen AB9 1FX, Scotland; [Madhok, Vishnu B.; Sullivan, Frank M.] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Meggitt, Simon] Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Smith, Catherine H.; Allen, Michael A.; Barker, Jonathan N. W. N.] Kings Coll London, St Johns Inst Dermatol, London WC2R 2LS, England; [Reynolds, Nick J.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Paediat Dermatol, Dublin, Ireland	Trinity College Dublin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; Trinity College Dublin; University of Dundee; University of Dundee; University of Dundee; University of Dundee; University of Dundee; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Kiel; Schleswig Holstein University Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Brighton; University of Sussex; University of Aberdeen; Newcastle University - UK; Newcastle University - UK; University of London; King's College London; Newcastle University - UK; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin	Fallon, PG (corresponding author), Univ Dublin Trinity Coll, Trinity Biomed Sci Inst, Dublin 2, Ireland.	w.h.i.mclean@dundee.ac.uk; pfallon@tcd.ie	Kabesch, Michael/GZM-1583-2022; Relton, Caroline/AAC-5904-2019; Brown, Sara J/AAF-7095-2019; Palmer, Colin NA/C-7053-2008; Fallon, Padraic/Y-2711-2019; Sullivan, Frank/L-8286-2019; Barton, Geoffrey J/C-6267-2011; Barton, Geoffrey/N-1037-2019; Irvine, Alan D/A-3982-2008; Turner, Stephen/GXM-4654-2022; Prescott, Alan/Y-5956-2018; Kabesch, Michael/AAB-5701-2020; Weidinger, Stephan/C-8461-2011; Baurecht, Hansjorg/C-4035-2013; Smith, Catherine/G-5268-2012	Brown, Sara J/0000-0002-3232-5251; Palmer, Colin NA/0000-0002-6415-6560; Fallon, Padraic/0000-0002-8401-7293; Sullivan, Frank/0000-0002-6623-4964; Barton, Geoffrey/0000-0002-9014-5355; Irvine, Alan D/0000-0002-9048-2044; Prescott, Alan/0000-0002-0747-7317; Weidinger, Stephan/0000-0003-3944-252X; Gierlinski, Marek/0000-0001-9149-3514; Burn, John/0000-0002-9823-2322; Reynolds, Nick/0000-0002-6484-825X; Cole, Christian/0000-0002-2560-2484; Baurecht, Hansjorg/0000-0002-9265-5594; Saunders, Sean/0000-0003-1689-3598; Relton, Caroline/0000-0003-2052-4840; Cordell, Heather/0000-0002-1879-5572; Gieger, Christian/0000-0001-6986-9554; Smith, Catherine/0000-0001-9918-1144; Barker, Jonathan/0000-0002-9030-183X; McLean, William Henry Irwin/0000-0001-5539-5757; Porter, Rebecca/0000-0001-6748-0916	Wellcome Trust [092530/Z/10/Z, 090066/B/09/Z, WT086398MA, 087436, 099177/Z/12/Z, 098439/Z/12/Z]; Interdisciplinary Training Programme for Clinicians in Translational Medicine and Therapeutics; Medical Research Council [G0802780]; National Children's Research Centre; National Cancer Institute [NCI U01 CA141455]; Scottish Executive Health Department [CZB/4/285]; Cancer Research UK [15934] Funding Source: researchfish; Medical Research Council [MC_UU_12013/2] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10282] Funding Source: researchfish; Chief Scientist Office [CZG/2/487, CZH/4/418] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [U01CA141455] Funding Source: NIH RePORTER; MRC [MC_UU_12013/2, G0802780] Funding Source: UKRI	Wellcome Trust(Wellcome Trust); Interdisciplinary Training Programme for Clinicians in Translational Medicine and Therapeutics; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Children's Research Centre; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Scottish Executive Health Department; Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Chief Scientist Office; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Wellcome Trust (Programme grant 092530/Z/10/Z to W. H. I. M., A. D. I., G. J. B., and P. G. F.; Bioresources grant 090066/B/09/Z to A. D. I., W. H. I. M., and S. J. B.; Clinical Intermediate Fellowship WT086398MA to S. J. B.; and Senior Fellowship 087436 to H. J. C.); the Interdisciplinary Training Programme for Clinicians in Translational Medicine and Therapeutics (to N. J. R.); Wellcome Trust Bioresources grant 099177/Z/12/Z (to C. N. A. P.); the Medical Research Council (Programme grant G0802780 to W. H. I. M.); the Science Foundation Ireland (to P. G. F.); the National Children's Research Centre (to P. G. F. and A. D. I.); and the National Cancer Institute (NCI U01 CA141455 to A. B.). The Centre for Dermatology and Genetic Medicine, University of Dundee, is supported by a Wellcome Trust Strategic Award (098439/Z/12/Z to W. H. I. M. and G. J. B.). The PAGES, BREATHE, and GS:3D cohorts were funded by the Scottish Executive Health Department (CZB/4/285).	Chamlin SL, 2002, J AM ACAD DERMATOL, V47, P198, DOI 10.1067/mjd.2002.124617; Deckers IAG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039803; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Gupta J, 2008, J ALLERGY CLIN IMMUN, V121, P725, DOI 10.1016/j.jaci.2007.12.1161; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jakobsson PJ, 2000, AM J RESP CRIT CARE, V161, pS20, DOI 10.1164/ajrccm.161.supplement_1.ltta-5; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kizawa K, 2004, METH MOL B, V289, P209; Kizawa K, 2011, BIOCHIMIE, V93, P2038, DOI 10.1016/j.biochi.2011.05.028; Molina DM, 2008, CURR OPIN STRUC BIOL, V18, P442, DOI 10.1016/j.sbi.2008.04.005; Moniaga CS, 2013, AM J PATHOL, V182, P841, DOI 10.1016/j.ajpath.2012.11.039; Moniaga Catharina Sagita, 2011, Inflammation & Allergy Drug Targets, V10, P477; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; OKEEFE EJ, 1993, J INVEST DERMATOL, V101, pS65, DOI 10.1111/1523-1747.ep12362866; Oyoshi MK, 2012, IMMUNITY, V37, P747, DOI 10.1016/j.immuni.2012.06.018; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Quigley DA, 2009, NATURE, V458, P505, DOI 10.1038/nature07683; Rice RH, 1999, ANAT RECORD, V254, P231; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Strong CD, 2010, HUM MOL GENET, V19, P1453, DOI 10.1093/hmg/ddq019; Sugarman JL, 2003, ARCH DERMATOL, V139, P1417, DOI 10.1001/archderm.139.11.1417; Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851; Sundberg JP., 1984, HDB MOUSE MUTATIONS, V2, P269	31	108	111	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1121	1129		10.1016/j.jaci.2013.08.046	http://dx.doi.org/10.1016/j.jaci.2013.08.046			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24084074	hybrid, Green Published, Green Submitted			2022-12-18	WOS:000326235600011
J	Busse, W; Buhl, R; Vidaurre, CF; Blogg, M; Zhu, J; Eisner, MD; Canvin, J				Busse, William; Buhl, Roland; Vidaurre, Carlos Fernandez; Blogg, Martin; Zhu, Jin; Eisner, Mark D.; Canvin, Janice			Omalizumab and the risk of malignancy: Results from a pooled analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergy; IgE; anti-IgE; omalizumab; malignancy; pooled analysis	ANTI-IGE ANTIBODY; ANTIIMMUNOGLOBULIN-E THERAPY; HUMANIZED MONOCLONAL-ANTIBODY; CANCER INCIDENCE; ALLERGIC-ASTHMA; IMMUNOGLOBULIN-E; SAFETY; TOLERABILITY; EFFICACY; IMMUNOTHERAPY	Background: Since initial registration, the omalizumab clinical trial database has expanded considerably, with a doubling of patients exposed in the clinical trial environment. Previous pooled data (2003) from phase I to III studies of omalizumab showed a numeric imbalance in malignancies arising in omalizumab recipients (0.5%) compared with control subjects (0.2%). The previous analysis was based on limited available data, warranting further investigation. Objective: We sought to examine the incidence of malignancy using comprehensive pooled data from clinical trials of omalizumab-treated patients. Methods: This pooled analysis included data from 67 phase I to IV clinical trials. The prespecified primary analysis assessed the incidence of primary malignancy in 32 randomized, doubleblind, placebo-controlled (RDBPC) trials. Results: There were 11,459 unique patients in all clinical trials (7,789 received omalizumab). The primary analysis identified malignancies in 25 patients (RDBPC trials): 14 in 4,254 omalizumab-treated patients and 11 in 3,178 placebo-treated patients. Incidence rates per 1,000 patient-years of observation time for omalizumab-and placebo-treated patients were 4.14 (95% CI, 2.26-6.94) and 4.45 (95% CI, 2.22-7.94), respectively; the corresponding rate ratio was 0.93 (95% CI, 0.39-2.27). Primary malignancies were of varying histologic type and occurred in a number of different organ systems; no cluster of histologies was identified. Conclusions: In this pooled analysis no association was observed between omalizumab treatment and risk of malignancy in RDBPC trials; the rate ratio was below unity. The data suggest that a causal relationship between omalizumab therapy and malignancy is unlikely. (J Allergy Clin Immunol 2012;129:983-9.)	[Busse, William] Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53792 USA; [Buhl, Roland] Johannes Gutenberg Univ Mainz, Dept Pulm, Univ Hosp, Mainz, Germany; [Vidaurre, Carlos Fernandez] Novartis Pharmaceut, E Hanover, NJ USA; [Blogg, Martin; Canvin, Janice] Novartis Horsham Res Ctr, Horsham, W Sussex, England; [Zhu, Jin; Eisner, Mark D.] Genentech Inc, San Francisco, CA 94080 USA	University of Wisconsin System; University of Wisconsin Madison; Johannes Gutenberg University of Mainz; University Hospital Mainz; Novartis; Novartis; Roche Holding; Genentech	Busse, W (corresponding author), Univ Wisconsin, Sch Med, Dept Med, K4-910 CSC,MC 9988,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu		Canvin, Janice/0000-0001-9609-7182	Novartis Pharma AG, Switzerland; Genentech, Inc.; National Institutes of Health/National Institute of Allergy and Infectious Diseases; National Institutes of Health/National Heart, Lung, and Blood Institute; Novartis; AstraZeneca; GlaxoSmithKline; MedImmune; Ception	Novartis Pharma AG, Switzerland; Genentech, Inc.(Roche HoldingGenentech); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Novartis(Novartis); AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Ception	Supported by Novartis Pharma AG, Switzerland, and Genentech, Inc.; W. Busse is on advisory boards for Centocor and Merck; has consultant arrangements with AstraZeneca, Boehringer Ingelheim, Novartis, TEVA, GlaxoSmithKline, Amgen, Pfizer, MedImmune, and Genentech; and receives research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, the National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, AstraZeneca, GlaxoSmithKline, MedImmune, and Ception. R. Buhl is on the speakers' bureau for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Nycomed, and Pfizer and is on advisory boards for Boehringer Ingelheim, Novartis, and Nycomed. C. Fernandez Vidaurre, M. Blogg, and J. Canvin are employed by Novartis. J. Zhu and M. D. Eisner are employed by Genentech. Received for publication September 2, 2011; revised December 23, 2011; accepted for publication January 5, 2012.	Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Ayres JG, 2004, ALLERGY, V59, P701, DOI 10.1111/j.1398-9995.2004.00533.x; Berger W, 2003, ANN ALLERG ASTHMA IM, V91, P182, DOI 10.1016/S1081-1206(10)62175-8; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; Bousquet J, 2011, ALLERGY, V66, P671, DOI 10.1111/j.1398-9995.2010.02522.x; Bousquet J, 2003, ALLERGY S, V58, pA4; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse W, 2001, CURR OPIN ALLERGY CL, V1, P105, DOI 10.1097/00130832-200102000-00017; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Chanez P, 2010, RESP MED, V104, P1608, DOI 10.1016/j.rmed.2010.07.011; Chervinsky P, 2003, ANN ALLERG ASTHMA IM, V91, P160, DOI 10.1016/S1081-1206(10)62171-0; Chuchalin A, 2005, EUR RESP J S49, V26, pP421; Chuchalin A, 2005, EUR RESP J S49, V26, p48S; Chung K, 2007, ALLERGY, V62, P210; Chung KF, 2004, EXPERT OPIN PHARMACO, V5, P439, DOI 10.1517/eoph.5.2.439.26465; Corren J, 2009, CLIN EXP ALLERGY, V39, P788, DOI 10.1111/j.1365-2222.2009.03214.x; Corren J, 1996, J ALLERGY CLIN IMMUN, V97, P251; Corren J, 2011, J ALLERGY CLIN IMMUN, V127, P398, DOI 10.1016/j.jaci.2010.09.043; Cruz AA, 2007, CLIN EXP ALLERGY, V37, P197, DOI 10.1111/j.1365-2222.2007.02650.x; D'Amato G, 2009, EUR ANN ALLERGY CLIN, V41, P135; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Eisner M, 2011, EUR RESP J S55, V38, pA3954; ERIKSSON NE, 1995, ALLERGY, V50, P718, DOI 10.1111/j.1398-9995.1995.tb01212.x; European Medicines Evaluation Agency, OM XOLAIR SUMM PROD; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Fernandez C, 2005, P AM THORAC SOC, V2, pA359; Gonzalez-Perez A, 2006, PHARMACOEPIDEM DR S, V15, P131, DOI 10.1002/pds.1163; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Ji J, 2009, BRIT J CANCER, V100, P829, DOI 10.1038/sj.bjc.6604890; KALLEN B, 1993, EUR RESPIR J, V6, P694; Kopp MV, 2009, CLIN EXP ALLERGY, V39, P271, DOI 10.1111/j.1365-2222.2008.03121.x; Kornmann O, 2010, EUR RESP J S54, V36, pP3997; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Kulus M, 2010, CURR MED RES OPIN, V26, P1285, DOI 10.1185/03007991003771338; Lanier B, 2009, J ALLERGY CLIN IMMUN, V124, P1210, DOI 10.1016/j.jaci.2009.09.021; Leynadier F, 2004, J ALLERGY CLIN IMMUN, V113, P360, DOI 10.1016/j.jaci.2003.11.020; Long AA, 2009, ANN ALLERG ASTHMA IM, V103, P212, DOI 10.1016/S1081-1206(10)60184-6; Massanari M, 2010, J ALLERGY CLIN IMMUN, V125, P383, DOI 10.1016/j.jaci.2009.11.022; Maurer M, 2011, J ALLERGY CLIN IMMUN, V128, P202, DOI 10.1016/j.jaci.2011.04.038; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Milgrom H, 2005, P AM THORAC SOC, V2, pA358; MILLS PK, 1992, AM J EPIDEMIOL, V136, P287, DOI 10.1093/oxfordjournals.aje.a116494; Molimard M, 2010, RESP MED, V104, P1381, DOI 10.1016/j.rmed.2010.06.001; Nagakura T, 2008, CLIN EXP ALLERGY, V38, P329, DOI 10.1111/j.1365-2222.2007.02894.x; National Cancer Institute, SURV EP END RES; Nayak A, 2003, ALLERGY ASTHMA PROC, V24, P323; Nopp A, 2007, ALLERGY, V62, P1175, DOI 10.1111/j.1398-9995.2007.01476.x; Novartis US and Genentech, OM XOL LAB; Ohta Ken, 2010, Allergology International, V59, P167, DOI 10.2332/allergolint.09-OA-0137; Ohta K, 2009, RESPIROLOGY, V14, P1156, DOI 10.1111/j.1440-1843.2009.01633.x; Okubo Kimihiro, 2006, Allergol Int, V55, P379, DOI 10.2332/allergolint.55.379; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Riviere G., 2011, J BIOEQUIV AVAILAB, V3, P144; Riviere GJ, 2009, EUR RESP J S53, V34, pE1873; Saini S, 2011, J ALLERGY CLIN IMMUN, V128, P567, DOI 10.1016/j.jaci.2011.06.010; Saini SS, 1999, J IMMUNOL, V162, P5624; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P308, DOI 10.1159/000237010; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Somerville L, 2009, EUR RESP J S53, V34, pE1876; Tan RA, 2011, EXPERT OPIN DRUG SAF, V10, P463, DOI 10.1517/14740338.2011.563840; VESTERINEN E, 1993, INT J EPIDEMIOL, V22, P976, DOI 10.1093/ije/22.6.976; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Wang H, 2006, INT J CANCER, V119, P695, DOI 10.1002/ijc.21883; Ward A. C., 2009, EPIDEMIOL PERSPECT I, V6, P2, DOI [10.1186/1742-5573-6-2, DOI 10.1186/1742-5573-6-2]; Zielen S, 2009, EUR RESP J S53, V34, pE1869	73	108	111	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					983	U482		10.1016/j.jaci.2012.01.033	http://dx.doi.org/10.1016/j.jaci.2012.01.033			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22365654				2022-12-18	WOS:000302144600012
J	Dai, XJ; Sayama, K; Tohyama, M; Shirakata, Y; Hanakawa, Y; Tokumaru, S; Yang, LJ; Hirakawa, S; Hashimoto, K				Dai, Xiuju; Sayama, Koji; Tohyama, Mikiko; Shirakata, Yuji; Hanakawa, Yasushi; Tokumaru, Sho; Yang, Lujun; Hirakawa, Satoshi; Hashimoto, Koji			Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Keratinocytes; house dust mite; caspase-1; IL-1 beta; IL-18; NLRP3; inflammasome; Dermatophagoides pteronyssinus; Der p 1	INNATE IMMUNE-RESPONSE; ATOPIC-DERMATITIS; NALP3 INFLAMMASOME; TH2 CYTOKINES; IL-18; PROTEIN; CELLS; FILAGGRIN; SENSITIZATION; RECRUITMENT	Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder caused by multiple factors. Among them, house dust mite (HDM) allergens are important in the development of AD. In airway allergy, HDM allergens activate innate immunity. However, information regarding the activation of innate immunity by HDM allergens in the skin is limited. Objectives: The inflammasome is a key regulator of pathogen recognition and inflammation. We investigated whether HDM allergens activate the inflammasome in epidermal keratinocytes. Methods: Keratinocytes were stimulated with Dermatophagoides pteronyssinus, and the activation of caspase-1 and secretion of IL-1 beta and IL-18 were examined. Formation of the inflammasome was studied by analyzing the subcellular distributions of inflammasome proteins. The importance of specific inflammasome proteins was studied by knocking down their expression through transfection of keratinocytes with lentiviral particles carrying short hairpin RNAs (shRNAs). Results: D pteronyssinus activated caspase-1 and induced caspase-1-dependent release of IL-1b and IL-18 from keratinocytes. Moreover, D pteronyssinus stimulated assembly of the inflammasome by recruiting apoptosis-associated specklike protein containing a caspase-recruitment domain (ASC), caspase-1, and nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin-domain containing 3 (NLRP3) to the perinuclear region. Finally, infection with lentiviral particles carrying ASC, caspase-1, or NLRP3 shRNAs suppressed the release of IL-1 beta and IL-18 from the keratinocytes. Activation of the NLRP3 inflammasome by D pteronyssinus was dependent on cysteine protease activity. Conclusion: House dust mite allergens are danger signals for the skin. In addition, HDM-induced activation of the NLRP3 inflammasome may play a pivotal role in the pathogenesis of AD. (J Allergy Clin Immunol 2011;127:806-14.)	[Dai, Xiuju; Sayama, Koji; Tohyama, Mikiko; Shirakata, Yuji; Hanakawa, Yasushi; Tokumaru, Sho; Yang, Lujun; Hirakawa, Satoshi; Hashimoto, Koji] Ehime Univ, Grad Sch Med, Dept Dermatol, Matsuyama, Ehime 7910295, Japan	Ehime University	Hashimoto, K (corresponding author), Ehime Univ, Grad Sch Med, Dept Dermatol, Matsuyama, Ehime 7910295, Japan.	sayama@m.ehime-u.ac.jp			Ministries of Health, Labor, and Welfare and Education, Culture, Sports, Science and Technology, Japan	Ministries of Health, Labor, and Welfare and Education, Culture, Sports, Science and Technology, Japan	Supported by grants from the Ministries of Health, Labor, and Welfare and Education, Culture, Sports, Science and Technology, Japan.	Adam E, 2006, J BIOL CHEM, V281, P6910, DOI 10.1074/jbc.M507140200; Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Bryan NB, 2009, J IMMUNOL, V182, P3173, DOI 10.4049/jimmunol.0802367; Chiou YL, 2009, J CELL PHYSIOL, V220, P311, DOI 10.1002/jcp.21764; Craven RR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007446; Dai XJ, 2008, J DERMATOL SCI, V50, P53, DOI 10.1016/j.jdermsci.2007.10.011; Dai XJ, 2006, J INVEST DERMATOL, V126, P1574, DOI 10.1038/sj.jid.5700294; Darsow U, 2005, J EUR ACAD DERMATOL, V19, P286, DOI 10.1111/j.1468-3083.2005.01249.x; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Dokmeci E, 2008, SEMIN CUTAN MED SURG, V27, P138, DOI 10.1016/j.sder.2008.04.006; Feldmeyer L, 2007, CURR BIOL, V17, P1140, DOI 10.1016/j.cub.2007.05.074; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gutgesell C, 2001, BRIT J DERMATOL, V145, P70, DOI 10.1046/j.1365-2133.2001.04283.x; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hitomi Y, 2009, J ALLERGY CLIN IMMUN, V124, P779, DOI 10.1016/j.jaci.2009.07.044; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Iversen L, 2008, EXPERT REV MOL DIAGN, V8, P697, DOI 10.1586/14737159.8.6.697; Kato T, 2009, ALLERGY, V64, P1366, DOI 10.1111/j.1398-9995.2009.02023.x; Kauffman Henk F, 2006, Clin Mol Allergy, V4, P5, DOI 10.1186/1476-7961-4-5; Kawai T, 2009, INT IMMUNOL, V21, P317, DOI 10.1093/intimm/dxp017; Keller M, 2008, CELL, V132, P818, DOI 10.1016/j.cell.2007.12.040; Kikuchi Y, 2006, J IMMUNOL, V177, P1609, DOI 10.4049/jimmunol.177.3.1609; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Konishi H, 2002, P NATL ACAD SCI USA, V99, P11340, DOI 10.1073/pnas.152337799; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Li HF, 2009, J IMMUNOL, V183, P1528, DOI 10.4049/jimmunol.0901080; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Martinon F, 2007, SEMIN IMMUNOPATHOL, V29, P213, DOI 10.1007/s00281-007-0079-y; Martinon F, 2010, EUR J IMMUNOL, V40, P616, DOI 10.1002/eji.200940168; Munoz-Planillo R, 2009, J IMMUNOL, V183, P3942, DOI 10.4049/jimmunol.0900729; Murphy JE, 2000, J INVEST DERMATOL, V114, P602, DOI 10.1046/j.1523-1747.2000.00917.x; Nakamura Y, 2009, J EXP MED, V206, P1037, DOI 10.1084/jem.20082179; Osterlund C, 2009, CLIN EXP ALLERGY, V39, P1199, DOI 10.1111/j.1365-2222.2009.03284.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; Ricci G, 2000, BRIT J DERMATOL, V143, P379, DOI 10.1046/j.1365-2133.2000.03666.x; Schafer T, 2008, ALLERGY, V63, P244, DOI 10.1111/j.1398-9995.2007.01573.x; Schafer T, 2008, CURR OPIN ALLERGY CL, V8, P418, DOI 10.1097/ACI.0b013e32830e71a7; SIMPSON R J, 1989, Protein Sequences and Data Analysis, V2, P17; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Terada M, 2006, P NATL ACAD SCI USA, V103, P8816, DOI 10.1073/pnas.0602900103; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Thompson PJ, 1998, CLIN EXP ALLERGY, V28, P110; Thompson PJ, 1998, CLIN EXP ALLERGY, V28, P7; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Verhaeghe B, 2002, ALLERGY, V57, P825, DOI 10.1034/j.1398-9995.2002.23539.x; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; WANG H, 2007, NOVART FDN SYMP, V280, P160; WANG H, 2007, NOVART FDN SYMP, V280, P85; Wang Haichao, 2007, Novartis Found Symp, V280, P73; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Wild JS, 2000, J IMMUNOL, V164, P2701, DOI 10.4049/jimmunol.164.5.2701; Xu DM, 2000, EUR J IMMUNOL, V30, P3147, DOI 10.1002/1521-4141(200011)30:11<3147::AID-IMMU3147>3.0.CO;2-J; Yamanaka K, 2000, J IMMUNOL, V165, P997, DOI 10.4049/jimmunol.165.2.997	62	108	111	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					806	U486		10.1016/j.jaci.2010.12.006	http://dx.doi.org/10.1016/j.jaci.2010.12.006			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21272927				2022-12-18	WOS:000288018400036
J	Stone, SF; Cotterell, C; Isbister, GK; Holdgate, A; Brown, SGA				Stone, Shelley F.; Cotterell, Claire; Isbister, Geoffrey K.; Holdgate, Anna; Brown, Simon G. A.		Emergency Dept Anaphylaxis Investi	Elevated serum cytokines during human anaphylaxis: Identification of potential mediators of acute allergic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis/physiopathology; cytokines; chemokines; IL-10; IL-6; IL-2; TNFRI; histamine; mast cell tryptase	INSECT-STING CHALLENGE; REGULATORY T-CELLS; INTERLEUKIN-6; ACTIVATION; HISTAMINE; SEVERITY; SHOCK	Background: Anaphylaxis is generally unanticipated and requires emergency management. Therefore, the biological mediators in human beings have been difficult to define. Objective: Our aim was to identify cytokines and chemokines whose concentrations increase during anaphylaxis in human beings and to determine how each correlates with severity. Methods: We measured the concentrations of potential mediators, including cytokines, chemokines, mast cell tryptase (MCT), and histamine, over 3 time points in 76 patients presenting to emergency departments with anaphylaxis and correlated these with a global severity scale, hypotension, and hypoxia. Results: IL-2, IL-6, IL-10, TNF receptor 1, MCT, and histamine were significantly elevated in patients with severe reactions (n = 36) compared with moderate reactions (n = 40) and healthy controls. Histamine levels peaked at emergency department arrival, whereas other mediators peaked later. IL-4, IL-5, IL-13, IFN-gamma, and TNF-alpha were marginally elevated in severe reactions compared with healthy controls but did not correlate with reaction severity. Severe reactions tended to be either hypotensive (n = 19) or hypoxemic (n = 12). Levels of IL-6, IL-10, TNF receptor 1, MCT, and histamine correlated with hypotension. No mediator correlated with hypoxemia or other respiratory features. Conclusion: This study confirms that the concentrations of a number of cytokines are elevated in blood during anaphylaxis in human beings and that some correlate with the presence of hypotension. Others were only marginally elevated within a concentration range that available assays do not reliably detect. During respiratory reactions, mediators may be largely confined to the airways so that blood concentrations do not reflect activity. (J Allergy Clin Immunol 2009;124:786-92.)	[Stone, Shelley F.; Cotterell, Claire; Brown, Simon G. A.] Royal Perth Hosp, Western Australian Inst Med Res, Ctr Clin Res Emergency Med, Perth, WA 6000, Australia; [Stone, Shelley F.; Cotterell, Claire; Brown, Simon G. A.] Univ Western Australia, Nedlands, WA 6009, Australia; [Isbister, Geoffrey K.] Menzies Sch Hlth Res, Darwin, NT, Australia; [Isbister, Geoffrey K.] Calvary Mater Hosp, Dept Clin Toxicol, Newcastle, NSW, Australia; [Isbister, Geoffrey K.] Calvary Mater Hosp, Dept Emergency Med, Newcastle, NSW, Australia; [Holdgate, Anna] Univ New S Wales, Sydney, NSW, Australia; [Holdgate, Anna] Liverpool Hosp, Emergency Med Res Unit, Sydney, NSW, Australia; [Brown, Simon G. A.] Fremantle Hosp, Dept Emergency Med, Fremantle, WA, Australia	Royal Perth Hospital; University of Western Australia; University of Western Australia; Charles Darwin University; Menzies School of Health Research; Calvary Mater Newcastle Hospital; Calvary Mater Newcastle Hospital; University of New South Wales Sydney; Liverpool Hospital; University of Western Australia	Stone, SF (corresponding author), Royal Perth Hosp, Western Australian Inst Med Res, Ctr Clin Res Emergency Med, Level 6,MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.	Shelley.Stone@uwa.edu.au	Fatovich, Daniel M/A-4658-2010; Stone, Shelley/C-3804-2013; Isbister, Geoffrey K/G-8052-2015; Flow, CMCA/C-4191-2013	Isbister, Geoffrey K/0000-0003-1519-7419; Brown, Simon/0000-0002-9961-0890	Food Allergy and Anaphylaxis Network; Fremantle Hospital Medical Research Foundation; Royal Perth Hospital Medical Research Foundation; University of Western Australia; National Health and Medical Research Council (Australia); Royal Hobart Hospital	Food Allergy and Anaphylaxis Network; Fremantle Hospital Medical Research Foundation; Royal Perth Hospital Medical Research Foundation; University of Western Australia; National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia); Royal Hobart Hospital	Supported by grants from the Food Allergy and Anaphylaxis Network, the Fremantle Hospital Medical Research Foundation, and the Royal Perth Hospital Medical Research Foundation.; S. F Stone has received research support from the University of Western Australia and the Royal Perth Hospital Medical Research Foundation. G. K. Isbister and A. Holdgate have received research support from the National Health and Medical Research Council (Australia). S. G. A. Brown has received research support from the University of Western Australia, the Royal Perth Hospital Medical Research Foundation, the National Health and Medical Research Council (Australia), the Food Allergy and Anaphylaxis Network, and the Royal Hobart Hospital. C. Cotterell has declared that she has no conflict of interest.	Aderka Dan, 1996, Cytokine and Growth Factor Reviews, V7, P231, DOI 10.1016/S1359-6101(96)00026-3; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brown Simon G A, 2004, Emerg Med Australas, V16, P120, DOI 10.1111/j.1742-6723.2004.00562.x; Castells M, 2006, IMMUNOL ALLERGY CLIN, V26, P465, DOI 10.1016/j.iac.2006.05.005; Conti P, 2002, ALLERGY ASTHMA PROC, V23, P331; Cornejo-Garcia JA, 2007, ALLERGY, V62, P1429, DOI 10.1111/j.1398-9995.2007.01542.x; Fallon PG, 2001, J IMMUNOL, V166, P2712, DOI 10.4049/jimmunol.166.4.2712; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Knoops L, 2005, J IMMUNOL, V175, P335, DOI 10.4049/jimmunol.175.1.335; Lin RY, 2001, ANN ALLERG ASTHMA IM, V87, P412, DOI 10.1016/S1081-1206(10)62923-7; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; Ogawa Y, 2007, IMMUNOL ALLERGY CLIN, V27, P249, DOI 10.1016/j.iac.2007.03.013; Ono E, 2009, CLIN EXP ALLERGY, V39, P72, DOI 10.1111/j.1365-2222.2008.03104.x; RADERMECKER M, 1994, ALLERGY, V49, P641, DOI 10.1111/j.1398-9995.1994.tb00133.x; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Scabeni S, 2008, J IMMUNOL, V180, P4433, DOI 10.4049/jimmunol.180.7.4433; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Tousoulis D, 2003, HEART, V89, P993, DOI 10.1136/heart.89.9.993; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERLINDEN PWG, 1993, BLOOD, V82, P1740; VANDERLINDEN PWG, 1993, ANN INTERN MED, V118, P161, DOI 10.7326/0003-4819-118-3-199302010-00001; Wu K, 2007, CELL MOL IMMUNOL, V4, P269; Zhang XM, 2004, INT IMMUNOL, V16, P249, DOI 10.1093/intimm/dxh029	24	108	110	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					786	792		10.1016/j.jaci.2009.07.055	http://dx.doi.org/10.1016/j.jaci.2009.07.055			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767073				2022-12-18	WOS:000270802800025
J	Simons, FER; Clark, S; Camargo, CA				Simons, F. Estelle R.; Clark, Sunday; Camargo, Carlos A., Jr.			Anaphylaxis in the community: Learning from the survivors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epinephrine; adrenaline; autoinjector; anaphylaxis; acute allergic reaction; food allergy; insect sting allergy	EMERGENCY-DEPARTMENT VISITS; FOOD-INDUCED ANAPHYLAXIS; LONG-TERM MANAGEMENT; ALLERGIC REACTIONS; EPINEPHRINE; CHILDREN; MULTICENTER	Background: Most studies of anaphylaxis in the community focus on persons at risk who might, or might not, have experienced anaphylaxis. Objective: We sought to focus on survivors of anaphylaxis in the community and their experiences in using, or not using, an epinephrine autoinjector for first-aid treatment. Methods: An e-mail survey was conducted. Responses were anonymous and could not be traced to any person or location. Anaphylaxis was defined as the most severe sudden-onset allergic reaction ever experienced by the participants or a person for whom they were responsible (eg, a child). There were 17 core multiple-choice questions for all participants, with 16 additional questions for users who injected epinephrine either into themselves or someone else, and I additional question for nonusers. Results: Of the 1885 participants, 500 (27%) were epinephrine users, and 1385 (73%) were nonusers. The groups were similar with regard to multisystem organ involvement (82% vs 78%, P = .07) and many other aspects of anaphylaxis; however, epinephrine users were more likely (all P < .05) to report respiratory or shock symptoms; to report peanut, fish, or insect sting triggers; to be asthmatic; and to have taken or been given asthma medication on the day of the episode. Epinephrine users reported problems in deciding whether to give the injection, repeat the dose, and/or go to an emergency department. Nonusers reported not injecting epinephrine for various reasons, including use of an H-1-antihistamine (38%), no prescription for epinephrine (28%), and/or a mild anaphylaxis episode (13%). Conclusions: In a unique population composed of 1885 survivors of anaphylaxis in the community, users of epinephrine autoinjectors for first-aid treatment were outnumbered by nonusers. The insights reported by epinephrine users and the reasons why nonusers did not inject epinephrine are documented. (J Allergy Clin Immunol 2009;124:301-6.)	[Simons, F. Estelle R.] Univ Manitoba, Dept Pediat & Child Hlth, CHIR Natl Training Program Allergy & Asthma, Fac Med, Winnipeg, MB, Canada; [Simons, F. Estelle R.] Univ Manitoba, Dept Immunol, CHIR Natl Training Program Allergy & Asthma, Fac Med, Winnipeg, MB, Canada; [Clark, Sunday] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15260 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA USA	University of Manitoba; University of Manitoba; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Simons, FER (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca	Clark, Sunday/AAA-5458-2021; Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654				Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Gaeta TJ, 2007, ANN ALLERG ASTHMA IM, V98, P360, DOI 10.1016/S1081-1206(10)60883-6; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Johnson TL, 2006, ANN ALLERG ASTHMA IM, V97, P694, DOI 10.1016/S1081-1206(10)61102-7; Kemp SF, 2008, ALLERGY, V63, P1061, DOI 10.1111/j.1398-9995.2008.01733.x; Ko J, 2006, ANN ALLERG ASTHMA IM, V97, P365, DOI 10.1016/S1081-1206(10)60802-2; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; McLean-Tooke APC, 2003, BMJ-BRIT MED J, V327, P1332, DOI 10.1136/bmj.327.7427.1332; Mehl A, 2005, ALLERGY, V60, P1440, DOI 10.1111/j.1398-9995.2005.00909.x; Mehr S, 2007, PEDIAT ALLERG IMM-UK, V18, P448, DOI 10.1111/j.1399-3038.2007.00529.x; Nurmatov U, 2008, J ALLERGY CLIN IMMUN, V122, P353, DOI 10.1016/j.jaci.2008.05.028; Oren E, 2007, ANN ALLERG ASTHMA IM, V99, P429, DOI 10.1016/S1081-1206(10)60568-6; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pumphrey RSH, 2003, J ALLERGY CLIN IMMUN, V112, P451, DOI 10.1067/mai.2003.1614; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sheikh J, 2008, ANN ALLERG ASTHMA IM, V100, P389, DOI 10.1016/S1081-1206(10)60604-7; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, P537, DOI 10.1016/j.jaci.2007.06.025; Simons FER, 2009, ANN ALLERG ASTHMA IM, V102, P282, DOI 10.1016/S1081-1206(10)60332-8; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Simons FER, 2002, J ALLERGY CLIN IMMUN, V110, P647, DOI 10.1067/mai.2002.127860; Soar J, 2008, RESUSCITATION, V77, P157, DOI 10.1016/j.resuscitation.2008.02.001; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39, DOI 10.1016/S1081-1206(10)61367-1	30	108	109	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					301	306		10.1016/j.jaci.2009.03.050	http://dx.doi.org/10.1016/j.jaci.2009.03.050			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19540575				2022-12-18	WOS:000268860400017
J	Nakamura, Y; Miyata, M; Ohba, T; Ando, T; Hatsushika, K; Suenaga, F; Shimokawa, N; Ohnuma, Y; Katoh, R; Ogawa, H; Nakao, A				Nakamura, Yuki; Miyata, Masanori; Ohba, Tetsuro; Ando, Takashi; Hatsushika, Kyosuke; Suenaga, Fumiko; Shimokawa, Naomi; Ohnuma, Yuko; Katoh, Ryohei; Ogawa, Hideoki; Nakao, Atsuhito			Cigarette smoke extract induces thymic stromal lymphopoietin expression, leading to T(H)2-type immune responses and airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cigarette smoke; thymic stromal lymphopoietin; asthma; T(H)2	OBSTRUCTIVE PULMONARY-DISEASE; ALLERGIC SENSITIZATION; ASTHMA; CELLS; PROTECTION; TOLERANCE; TSLP	Background: Both active and passive smoking are considered to be risk factors for asthma development. However, the precise mechanisms involved remain elusive. Recently, thymic stromal lymphopoietin (TSLP) has been shown to play a key role in the development of T(H)2-type allergic inflammation in patients with asthma. Objective: The aim of this study was to investigate whether there was a causal relationship between cigarette smoke exposure and TSLP expression in the lung. Methods: We examined the effects of repeated intranasal exposure of cigarette smoke extract (CSE) on TSLP mRNA and protein expression in the mouse lung by means of real-time PCR, Western blotting, and immunohistochemistry. We also examined the effects of intranasal exposure of CSE plus ovalbumin (OVA) on T(H)2-type immune responses and lung pathology. Results: Repeated exposure of CSE induced TSLP mRNA and protein expression, which was inhibited by treatment with antioxidative N-acetylcysteine and by TNF-alpha receptor I deficiency. In addition, the intranasal exposure of CSE simultaneously with OVA induced OVA-specific T(H)2-type immune responses and airway inflammation, which were inhibited by the blockade of the TSLP activity. Conclusion: CSE induced TSLP expression in the mouse lung in an oxidative stress-dependent and TNF-a receptor I-dependent manner, and when challenged simultaneously with an antigen, CSE promoted the development of airway inflammation in association with TH2-type immune responses. (J Allergy Clin Immunol 2008;122:1208-14.)	[Nakamura, Yuki; Miyata, Masanori; Ohba, Tetsuro; Ando, Takashi; Hatsushika, Kyosuke; Suenaga, Fumiko; Shimokawa, Naomi; Ohnuma, Yuko; Nakao, Atsuhito] Univ Yamanashi, Fac Med, Dept Immunol, Chuo Ku, Yamanashi 4093898, Japan; [Katoh, Ryohei] Univ Yamanashi, Fac Med, Dept Human Pathol, Yamanashi 4093898, Japan; [Ogawa, Hideoki; Nakao, Atsuhito] Juntendo Univ, Sch Med, Atopy Res Ctr, Tokyo 113, Japan	University of Yamanashi; University of Yamanashi; Juntendo University	Nakao, A (corresponding author), Univ Yamanashi, Fac Med, Dept Immunol, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.	anakao@yamanashi.ac.jp			Ministry of Education, Culture. Sports, Science, and Technology, Japan	Ministry of Education, Culture. Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Supported in part by grants from the Ministry of Education, Culture. Sports, Science, and Technology, Japan.	Ando T, 2007, J ALLERGY CLIN IMMUN, V120, P916, DOI 10.1016/j.jaci.2007.05.023; Arruda LK, 2005, CURR OPIN ALLERGY CL, V5, P153, DOI 10.1097/01.all.0000162308.89857.6c; Barnes PJ, 2003, ANNU REV MED, V54, P113, DOI 10.1146/annurev.med.54.101601.152209; FLODIN U, 1995, EPIDEMIOLOGY, V6, P503, DOI 10.1097/00001648-199509000-00007; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; HOLT PG, 1995, ALLERGY, V50, P34, DOI 10.1111/j.1398-9995.1995.tb04274.x; Kanamaru Y, 2005, J IMMUNOL, V174, P4193, DOI 10.4049/jimmunol.174.7.4193; Kasai A, 2006, CANCER RES, V66, P7143, DOI 10.1158/0008-5472.CAN-05-4541; Kinnula VL, 2005, THORAX, V60, P693, DOI 10.1136/thx.2004.037473; Koyama K, 2007, BIOCHEM BIOPH RES CO, V357, P99, DOI 10.1016/j.bbrc.2007.03.081; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Leonard WJ, 2002, NAT IMMUNOL, V3, P605, DOI 10.1038/ni0702-605; McDevitt AL, 2001, GENE, V267, P23, DOI 10.1016/S0378-1119(01)00392-4; Moerloose KB, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-49; Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P2157, DOI 10.1089/ars.2007.1811; Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004; Thomson NC, 2007, CURR ALLERGY ASTHM R, V7, P303, DOI 10.1007/s11882-007-0045-8; Zhang KQ, 2007, AM J PHYSIOL-LUNG C, V293, pL375, DOI 10.1152/ajplung.00045.2007; Ziegler SF, 2006, NAT IMMUNOL, V7, P709, DOI 10.1038/ni1360	20	108	112	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1208	1214		10.1016/j.jaci.2008.09.022	http://dx.doi.org/10.1016/j.jaci.2008.09.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18926564				2022-12-18	WOS:000261711800021
J	Bender, B; Zhang, LN				Bender, Bruce; Zhang, Lening			Negative affect, medication adherence, and asthma control in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; control; children; affect; adherence	QUALITY-OF-LIFE; INNER-CITY CHILDREN; DEPRESSIVE SYMPTOMS; MENTAL-DISORDERS; FUNCTIONAL STATUS; PEDIATRIC ASTHMA; I THINK; CHILDHOOD; ADULTS; INDIVIDUALS	Background: Negative affect including depression is known to be associated with asthma control, but whether and how it influences control in children with asthma is not understood. Objective: The objective of this investigation was to evaluate whether negative affect and medication nonadherence each predict decreased symptom control, and whether the relationship between negative affect and disease control is explained by children's adherence to asthma medications. Methods: Participants included 104 children 8 to 18 years old being treated with an inhaled corticosteroid delivered by metered-dose inhaler for asthma diagnosed by their health care providers. Children and parents independently rated asthma symptoms and completed questionnaires assessing sad and anxious affect. Electronic devices were attached to each participant's metered-dose inhaler to measure adherence. At study completion, records were collected to confirm reports of health events. Results: Both child and parent negative affect scores predicted symptom scores, whether reported by child or parent, and child negative affect scores predicted school absence because of asthma. In a lagged analysis taking into account time sequence, medication adherence predicted prednisone bursts but not subjective symptom scores. Nonadherence did not explain the relationship between negative affect and symptom scores, but parent negative affect predicted prednisone bursts even when controlling for level of adherence. Conclusion: Although both negative affect and adherence were predictive of asthma control, the relationship of each to asthma control was distinctly different. Accuracy of symptom perception may be influenced by patient and parent affect characteristics.	[Bender, Bruce] Natl Jewish Med & Res Center, Dept Pediat, Denver, CO 80206 USA; [Zhang, Lening] Natl Jewish Med & Res Center, Dept Biostat & Bioinformat, Denver, CO 80206 USA		Bender, B (corresponding author), Natl Jewish Med & Res Center, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	benderb@njc.org			General Clinical Research Centers [M01-RR00051]; National Heart, Lung, and Blood Institute [5R01HL64199]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064199] Funding Source: NIH RePORTER	General Clinical Research Centers(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by General Clinical Research Centers grant M01-RR00051 and National Heart, Lung, and Blood Institute grant 5R01HL64199.	Afari N, 2001, J CLIN PSYCHOL MED S, V8, P245, DOI 10.1023/A:1011912712262; ALLEN GM, 1994, THORAX, V49, P881, DOI 10.1136/thx.49.9.881; Annett RD, 2001, J PEDIATR-US, V139, P854, DOI 10.1067/mpd.2001.119444; BAIARDINI I, 2006, J INVESTIG ALLERGOL, V16, P315; Bartlett SJ, 2004, PEDIATRICS, V113, P229, DOI 10.1542/peds.113.2.229; Bartlett SJ, 2002, J ASTHMA, V39, P47, DOI 10.1081/JAS-120000806; BENDER B, 1997, CURR OPIN PEDIATR, V9, P590; Bender BG, 2006, AM J RESP CRIT CARE, V173, P953, DOI 10.1164/rccm.200511-1706PP; Bender BG, 2000, ARCH PEDIAT ADOL MED, V154, P706, DOI 10.1001/archpedi.154.7.706; Bender BG, 2007, PEDIATRICS, V120, pE471, DOI 10.1542/peds.2006-3457; Bender BG, 2007, ANN ALLERG ASTHMA IM, V98, P322, DOI 10.1016/S1081-1206(10)60877-0; Brown ES, 2000, PRIMARY CARE PSYCHIA, V6, P155, DOI 10.1185/135525700543389; Carr RE, 1996, J ABNORM PSYCHOL, V105, P137, DOI 10.1037/0021-843X.105.1.137; Cluley S, 2001, RESP MED, V95, P37, DOI 10.1053/rmed.2000.0968; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; Eisner MD, 2005, ANN ALLERG ASTHMA IM, V94, P566, DOI 10.1016/S1081-1206(10)61135-0; Ettinger A, 2004, NEUROLOGY, V63, P1008, DOI 10.1212/01.WNL.0000138430.11829.61; GIBSON NA, 1995, THORAX, V50, P1274, DOI 10.1136/thx.50.12.1274; Goodwin RD, 2005, AM J PUBLIC HEALTH, V95, P717, DOI 10.2105/AJPH.2003.019109; Goodwin RD, 2004, PSYCHOL MED, V34, P1465, DOI 10.1017/S0033291704002739; Goodwin RD, 2003, GEN HOSP PSYCHIAT, V25, P479, DOI 10.1016/S0163-8343(03)00071-9; Goodwin RD, 2003, ARCH GEN PSYCHIAT, V60, P1125, DOI 10.1001/archpsyc.60.11.1125; Hopkinson J, 2003, BEHAV MODIF, V27, P251, DOI 10.1177/0145445503251605; Jonasson G, 2000, ARCH DIS CHILD, V83, P330, DOI 10.1136/adc.83.4.330; Kalsekar Iftekhar D, 2006, Manag Care Interface, V19, P39; KAZDIN AE, 1982, J CHILD PSYCHOL PSYC, V23, P437, DOI 10.1111/j.1469-7610.1982.tb00089.x; KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995; KOVACS M, 1981, ACTA PAEDOPSYCHIATR, V46, P305; Kovacs M, 1977, DEPRESSION CHILDHOOD, P1; Lehrer PM, 1996, PSYCHOSOM MED, V58, P413, DOI 10.1097/00006842-199609000-00004; Mancuso CA, 2000, J GEN INTERN MED, V15, P301, DOI 10.1046/j.1525-1497.2000.07006.x; McQuaid EL, 2001, J DEV BEHAV PEDIATR, V22, P430, DOI 10.1097/00004703-200112000-00011; McQuaid EL, 2003, J PEDIATR PSYCHOL, V28, P323, DOI 10.1093/jpepsy/jsg022; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Miller BD, 1997, J AM ACAD CHILD PSY, V36, P669, DOI 10.1097/00004583-199705000-00018; MILLER BD, 1994, J AM ACAD CHILD PSY, V33, P1236, DOI 10.1097/00004583-199411000-00004; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; *NHLBI, 1997, 2 NHLBI US DEP HHS; O'Connor SL, 2004, J ASTHMA, V41, P663, DOI 10.1081/JAS-200026434; PADUR JS, 1995, J ASTHMA, V32, P345, DOI 10.3109/02770909509082759; Pais-Ribeiro J, 2007, EPILEPSY BEHAV, V11, P33, DOI 10.1016/j.yebeh.2007.04.010; Price MR, 2002, ANN ALLERG ASTHMA IM, V89, P572, DOI 10.1016/S1081-1206(10)62104-7; Radloff L, 1986, COMMUNITY SURVEYS PS, P177; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reynolds C.R., 1985, REVISED CHILDRENS MA; REYNOLDS CR, 1978, J ABNORM CHILD PSYCH, V6, P271, DOI 10.1007/BF00919131; REYNOLDS CR, 1981, PERCEPT MOTOR SKILL, V53, P702, DOI 10.2466/pms.1981.53.3.702; REYNOLDS CR, 1980, J CONSULT CLIN PSYCH, V48, P774, DOI 10.1037/0022-006X.48.6.774; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P1049, DOI 10.1016/j.jaci.2005.02.008; Scott KM, 2007, GEN HOSP PSYCHIAT, V29, P123, DOI 10.1016/j.genhosppsych.2006.12.006; Smith A, 2006, CHEST, V130, P1034, DOI 10.1378/chest.130.4.1034; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; Walders N, 2005, J PEDIATR-US, V146, P177, DOI 10.1016/j.jpeds.2004.10.014; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Wing RR, 2002, J PSYCHOSOM RES, V53, P877, DOI 10.1016/S0022-3999(02)00315-X; Wood BL, 2006, J AM ACAD CHILD PSY, V45, P1494, DOI 10.1097/01.chi.0000237711.81378.46; Ziegelstein RC, 2000, ARCH INTERN MED, V160, P1818, DOI 10.1001/archinte.160.12.1818	57	108	108	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					490	495		10.1016/j.jaci.2008.05.041	http://dx.doi.org/10.1016/j.jaci.2008.05.041			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18602153				2022-12-18	WOS:000259234000007
J	Stein, ML; Villanueva, JM; Buckmeier, BK; Yamada, Y; Filipovich, AH; Assa'ad, AH; Rothenberg, ME				Stein, Miguel L.; Villanueva, Joyce M.; Buckmeier, Bridget K.; Yamada, Yoshiyuki; Filipovich, Alexandra H.; Assa'ad, Amal H.; Rothenberg, Marc E.			Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anti-IL-5; cytokines; eosinophilia; esophagitis; hypereosinophilic; IL-5; inflammation; mepolizumab	IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; HUMAN INTERLEUKIN-5; ANTI-INTERLEUKIN-5 ANTIBODY; MONOCLONAL-ANTIBODY; LYMPHOCYTES; CELLS; ESOPHAGITIS; EXPRESSION; SCH55700; ASTHMA	Background: Anti-IL-5 might be a useful therapeutic agent for eosinophilic disorders, yet its immunologic consequences have not been well characterized. Objective: We sought to characterize the hematologic and immunologic effects of anti-IL-5 in human subjects. Methods: The effects of 3-month infusions of mepolizumab were assessed in 25 patients with a variety of eosinophilic syndromes. Samples with increased IL-5 levels after therapy were analyzed by using size exclusion filtration. Immunoreactive IL-5 fraction and plasma samples were subsequently precipitated with saturating concentrations of protein A/G. Results: Twenty-three patients responded to anti-IL-5 therapy with a decrease in blood eosinophil counts and a reduced percentage of CCR3(+) cells by 20- and 13-fold, respectively (P < .0001). Responsiveness was not related to the levels of baseline plasma IL-5 or the presence of FIP1L1-PDGFPA fusion gene. Persistently decreased blood eosinophilia remained for 3 months after final infusion in 76% of subjects. Therapy was associated with a large increase in blood IL-5 levels, likely because of a circulating IL-5/mepolizumab complex precipitated with protein A/G, a significant increase in eosinophil IL-5 receptor et expression, and increased percentage of CD4(+) and CD8(+) cells producing intracellular IL-5 (P < .05). Additionally, anti-IL-5 therapy decreased eotaxin-stimulated eosinophil shape change ex vivo. Conclusions: Anti-IL-5 therapy induces a dramatic and sustained decrease in blood eosinophilia (including CCR3(+) cells), decreased eosinophil activation, and increased circulating levels of IL-5 in a variety of eosinophilic disorders. Increased levels of IL-5 receptor alpha and lymphocyte IL-5 production after anti-IL-5 therapy suggest an endogenous IL-5 autoregulatory pathway.	[Stein, Miguel L.; Buckmeier, Bridget K.; Yamada, Yoshiyuki; Assa'ad, Amal H.; Rothenberg, Marc E.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Villanueva, Joyce M.; Filipovich, Alexandra H.] Cincinnati Childrens Hosp Med Ctr, Div Hematol Oncol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR008084] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR008084, M01 RR 08084, M01 RR008084-110217] Funding Source: Medline; FDA HHS [FD-R 002313] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); FDA HHS		Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Kim YJ, 2004, J ALLERGY CLIN IMMUN, V114, P1449, DOI 10.1016/j.jaci.2004.08.027; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Klion AD, 2004, BLOOD, V103, P2939, DOI 10.1182/blood-2003-10-3620; Klion AD, 2006, J ALLERGY CLIN IMMUN, V117, P1292, DOI 10.1016/j.jaci.2006.02.042; Kogawa K, 2002, BLOOD, V99, P61, DOI 10.1182/blood.V99.1.61; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; MINAMITAKE Y, 1990, J BIOCHEM-TOKYO, V107, P292, DOI 10.1093/oxfordjournals.jbchem.a123041; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; OWEN WF, 1989, J EXP MED, V170, P343, DOI 10.1084/jem.170.1.343; PETERSEN CM, 1992, EXP CELL RES, V201, P160, DOI 10.1016/0014-4827(92)90360-K; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; RENNICK DM, 1990, BLOOD, V76, P312; Rosenberg HF, 2007, J ALLERGY CLIN IMMUN, V119, P1303, DOI 10.1016/j.jaci.2007.03.048; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Roufosse F, 2000, BRIT J HAEMATOL, V109, P540, DOI 10.1046/j.1365-2141.2000.02097.x; Sabroe I, 1999, J IMMUNOL, V162, P2946; SAMOSZUK M, 1990, BLOOD, V75, P13; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; SOLBACH W, 1982, J EXP MED, V156, P1250, DOI 10.1084/jem.156.4.1250; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Swartz JM, 2006, BLOOD, V108, P2420, DOI 10.1182/blood-2006-04-015933; Tavernier J, 2000, BLOOD, V95, P1600, DOI 10.1182/blood.V95.5.1600.005k22_1600_1607; Zia-Amirhosseini P, 1999, J PHARMACOL EXP THER, V291, P1060; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P97, DOI 10.1067/mai.2003.3	35	108	111	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1473	1483		10.1016/j.jaci.2008.02.033	http://dx.doi.org/10.1016/j.jaci.2008.02.033			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18410960	Green Accepted			2022-12-18	WOS:000256771700026
J	Steinke, JW; Borish, L				Steinke, JW; Borish, L			Cytokines and chemokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						interleukin; cytokine; chemokine; T cell	RECEPTOR; INTERLEUKIN-10; INDUCTION; IL-19	Cytokines and chemokines are secreted proteins with growth, differentiation, and activation functions that regulate the nature of immune responses. Cytokines are involved in nearly every facet of immunity and inflammation, from induction of the innate immune response to the generation of cytotoxic T cells and the development of antibodies by the humoral immune system. The combination of cytokines that are produced in response to an immune insult determines which arm of the immune system will be activated. For this update, recent advances in our understanding of cytokines will be discussed, which includes the IL-10, IL-17, and IL-27 families.	Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA	University of Virginia	Steinke, JW (corresponding author), Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Beirne Carter Ctr Immunol Res, POB 801355, Charlottesville, VA 22908 USA.	js3ch@virginia.edu						Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460; Conti P, 2003, IMMUNOL LETT, V88, P171, DOI 10.1016/S0165-2478(03)00087-7; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Fickenscher H, 2004, INT IMMUNOPHARMACOL, V4, P609, DOI 10.1016/j.intimp.2004.01.004; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gallagher G, 2004, INT IMMUNOPHARMACOL, V4, P615, DOI 10.1016/j.intimp.2004.01.005; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P1265, DOI 10.1016/j.jaci.2004.10.019; Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003; Liao SC, 2004, J IMMUNOL, V173, P6712, DOI 10.4049/jimmunol.173.11.6712; Nagalakshmi ML, 2004, INT IMMUNOPHARMACOL, V4, P577, DOI 10.1016/j.intimp.2004.01.007; Sheikh F, 2004, J IMMUNOL, V172, P2006, DOI 10.4049/jimmunol.172.4.2006; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Villarino AV, 2004, J IMMUNOL, V173, P715, DOI 10.4049/jimmunol.173.2.715	16	108	119	3	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		1			S441	S445		10.1016/j.jaci.2005.07.001	http://dx.doi.org/10.1016/j.jaci.2005.07.001			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VS	16455343				2022-12-18	WOS:000235865400004
J	Di Lorenzo, G; Pacor, ML; Mansueto, P; Pellitteri, ME; Lo Bianco, C; Ditta, V; Martinelli, N; Rini, GB				Di Lorenzo, G; Pacor, ML; Mansueto, P; Pellitteri, ME; Lo Bianco, C; Ditta, V; Martinelli, N; Rini, GB			Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic idiopathic urticaria; desloratadine; montelukast	LEUKOTRIENE RECEPTOR ANTAGONIST; DOUBLE-BLIND; EFFICACY; CYCLOSPORINE; ZAFIRLUKAST; CETIRIZINE; IMPROVES; SAFETY	Background: H-1-receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H-1-receptor antagonists. Objective: We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo. Methods: One hundred sixty patients aged 18 to 69 years (mean +/- SD, 43.9 +/- 13.4 years) with a history of moderate CIU were selected. A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study design was used. Patients were treated with 5 mg of desloratadine once daily (n = 40), 10 mg of montelukast once daily (n = 40), 5 mg of desloratadine (n = 40) in the morning plus montelukast in the evening, or matched placebo (n = 40). Assessment of treatment efficacy was based on scores of daily cutaneous symptoms evaluated reflectively and instantaneously. Results: Only the group treated with desloratadine as monotherapy or as combined therapy concluded the whole study. Twenty-seven of the 40 patients in the montelukast group and 35 of the 40 patients in the placebo group discontinued the treatment. As reflective evaluation, all groups showed significant differences compared with the placebo group in terms of total symptom score, number of hives, and size of largest hive. In addition to the pruritus, only the groups treated with desloratadine as monotherapy or combined therapy showed significant differences compared with those receiving placebo, whereas there were no differences between the montelukast and placebo groups. Finally, no differences were found between the desloratadine group and the desloratadine plus montelukast group. The instantaneous evaluation demonstrated similar results regarding the desloratadine group and the desloratadine plus montelukast group versus the placebo group, whereas there were no significant differences between the group treated with montelukast alone and the placebo group for pruritus and size of largest hive. No differences were found between the group treated with desloratadine alone and the desloratadine plus montelukast group. Conclusions: The results of this comparative study demonstrate that desloratadine is highly effective for the treatment of patients affected by CIU. In addition, the regular combined therapy of desloratadine plus montelukast does not seem to offer a substantial advantage with respect to desloratadine as monotherapy in patients affected by moderate CIU.	Univ Palermo, Dipartimento Med Clin & Patol Emergenti, I-90127 Palermo, Italy; Univ Verona, Dipartimento Med Clin & Med Sperimentale, I-37100 Verona, Italy	University of Palermo; University of Verona	Di Lorenzo, G (corresponding author), Univ Palermo, Dipartimento Med Clin & Patol Emergenti, Via Vespro 141, I-90127 Palermo, Italy.	dilo601@unipa.it	Martinelli, Nicola/J-5622-2016; Mansueto, Pasquale/K-3458-2016	Martinelli, Nicola/0000-0001-6465-5119; Mansueto, Pasquale/0000-0002-0406-0583; Di Lorenzo, Gabriele/0000-0002-0197-5665				Asero R, 2000, ANN ALLERG ASTHMA IM, V85, P156, DOI 10.1016/S1081-1206(10)62457-X; Asero R, 2001, ALLERGY, V56, P456, DOI 10.1034/j.1398-9995.2001.056005456.x; Bagenstose SE, 2004, J ALLERGY CLIN IMMUN, V113, P134, DOI 10.1016/j.jaci.2003.10.002; Bensch GW, 1999, J ALLERGY CLIN IMMUN, V103, pS154; Berkun Y, 2000, ALLERGY, V55, P203, DOI 10.1034/j.1398-9995.2000.00538.x; Chu TJ, 1998, J ALLERGY CLIN IMMUN, V101, pS155; Di Lorenzo G, 2002, ALLERGY, V57, P1180, DOI 10.1034/j.1398-9995.2002.23767.x; Ellis MH, 1998, J ALLERGY CLIN IMMUN, V102, P876, DOI 10.1016/S0091-6749(98)70032-6; Erbagci Z, 2002, J ALLERGY CLIN IMMUN, V110, P484, DOI 10.1067/mai.2002.126676; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; FRADIN MS, 1991, J AM ACAD DERMATOL, V25, P1065, DOI 10.1016/0190-9622(91)70308-O; Gaig P, 2000, J INVEST ALLERG CLIN, V10, P342; GOLDSOBEL AB, 1986, J ALLERGY CLIN IMMUN, V78, P867, DOI 10.1016/0091-6749(86)90232-0; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; Greaves M, 2000, J ALLERGY CLIN IMMUN, V105, P664, DOI 10.1067/mai.2000.105706; Hani N, 2000, ACTA DERM-VENEREOL, V80, P229; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; Monroe E, 2003, J AM ACAD DERMATOL, V48, P535, DOI 10.1067/mjd.2003.143; Nettis E, 2001, ARCH DERMATOL, V137, P99; Norris JG, 1998, J ALLERGY CLIN IMMUN, V101, pS128; O'Donnell BF, 1998, BRIT J DERMATOL, V138, P101; Ohnishi-Inoue Y, 1998, BRIT J DERMATOL, V138, P483; Pacor ML, 2002, CLIN EXP ALLERGY, V32, P397, DOI 10.1046/j.1365-2222.2002.01260.x; Pacor ML, 2004, ALLERGY, V59, P192, DOI 10.1046/j.1398-9995.2003.00380.x; Pacor ML, 2001, CLIN EXP ALLERGY, V31, P1607, DOI 10.1046/j.1365-2222.2001.01189.x; Perez C, 2001, J ALLERGY CLIN IMMUN, V108, P1060, DOI 10.1067/mai.2001.120275; Reimers A, 2002, CLIN EXP ALLERGY, V32, P1763, DOI 10.1046/j.1365-2222.2002.01536.x; Ring J, 2001, INT J DERMATOL, V40, P72, DOI 10.1046/j.1365-4362.2001.00186.x; Sabroe RA, 1999, J AM ACAD DERMATOL, V40, P443, DOI 10.1016/S0190-9622(99)70495-0; Spector S, 1998, J ALLERGY CLIN IMMUN, V101, P572; Tedeschi A, 2000, ALLERGY, V55, P1097, DOI 10.1034/j.1398-9995.2000.00826.x	32	108	110	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					619	625		10.1016/j.jaci.2004.06.018	http://dx.doi.org/10.1016/j.jaci.2004.06.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356567	Green Published			2022-12-18	WOS:000223799600023
J	Markert, ML; Alexieff, MJ; Li, J; Sarzotti, M; Ozaki, DA; Devlin, BH; Sempowski, GD; Rhein, ME; Szabolcs, P; Hale, LP; Buckley, RH; Coyne, KE; Rice, HE; Mahaffey, SM; Skinner, MA				Markert, ML; Alexieff, MJ; Li, J; Sarzotti, M; Ozaki, DA; Devlin, BH; Sempowski, GD; Rhein, ME; Szabolcs, P; Hale, LP; Buckley, RH; Coyne, KE; Rice, HE; Mahaffey, SM; Skinner, MA			Complete DiGeorge syndrome: Development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; DiGeorge syndrome; thymus; transplantation; immunodeficiency	SEVERE COMBINED IMMUNODEFICIENCY; CHARGE ASSOCIATION; MARROW TRANSPLANTATION; THYMIC OUTPUT; REPERTOIRE; SPECTRUM; SUBPOPULATIONS; IDENTIFICATION; ENGRAFTMENT; PREDICTION	Background: Five patients with DiGeorge syndrome presented with infections, skin rashes, and lymphadenopathy after the newborn period. T-cell counts and function varied greatly in each patient. Initial laboratory testing did not suggest athymia in these patients. Objective: The purpose of this study was to determine whether the patients had significant immunodeficiency. Methods: Research testing of peripheral blood included immunoscope evaluation of T-cell receptor beta variable gene segment repertoire diversity, quantification of T-cell receptor rearrangement excision circles, and detection of naive T cells (expressing CD45RA and CD62L). Results: The patients were classified as having DiGeorge syndrome on the basis of syndromic associations and heart, parathyroid, and immune abnormalities. Immunoscope evaluation revealed that the T-cell repertoires were strikingly oligoclonal in all patients. There were few recent thymic emigrants, as indicated by the very low numbers of naive T cells (<50/mm(3)) and the absence of T-cell receptor rearrangement excision circles. These studies showed that all 5 patients were athymic. Two patients died, one from infection. No thymus was found during the complete autopsy performed on one patient. Conclusion: Patients with DiGeorge syndrome, skin rash, and lymphadenopathy should undergo analysis of naive T-cell numbers and of T-cell receptor beta variability segment repertoire to determine whether they are athymic, even if they have T cells with mitogen responsiveness. It is important for physicians to realize that patients with complete DiGeorge syndrome remain profoundly immunodeficient after development of these atypical features (rash, lymphadenopathy, and oligoclonal T cells). Prompt diagnosis is necessary for appropriate management.	DUMC, Dept Pediat, Durham, NC 27710 USA; DUMC, Dept Immunol, Durham, NC 27710 USA; DUMC, Dept Med, Durham, NC 27710 USA; DUMC, Dept Pathol, Durham, NC 27710 USA; DUMC, Dept Surg, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Markert, ML (corresponding author), DUMC, Dept Pediat, Box 3068, Durham, NC 27710 USA.		Buckley, Rebecca/AAB-1578-2019; Li, Dapeng/HGE-1586-2022	Li, Dapeng/0000-0003-0571-5876; Sempowski, Gregory/0000-0003-0391-6594	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047040] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 47040] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson P, 1995, Curr Top Microbiol Immunol, V198, P131; ARCHER E, 1990, CUTIS, V45, P455; BASTIAN J, 1989, J PEDIATR-US, V115, P391, DOI 10.1016/S0022-3476(89)80837-6; Blake KD, 1998, CLIN PEDIATR, V37, P159, DOI 10.1177/000992289803700302; Brooks EG, 1999, BLOOD, V93, P242, DOI 10.1182/blood.V93.1.242.401k27_242_250; Collard HR, 1999, CLIN IMMUNOL, V91, P156, DOI 10.1006/clim.1999.4691; CONLEY ME, 1979, J PEDIATR-US, V94, P883, DOI 10.1016/S0022-3476(79)80207-3; Davis CM, 1997, J CLIN IMMUNOL, V17, P167, DOI 10.1023/A:1027382600143; de Lonlay-Debeney P, 1997, J MED GENET, V34, P986, DOI 10.1136/jmg.34.12.986; Denianke KS, 2001, BONE MARROW TRANSPL, V28, P227, DOI 10.1038/sj.bmt.1703128; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5; DRISCOLL DA, 1992, AM J HUM GENET, V50, P924; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; GEHA RS, 1983, J IMMUNOL, V130, P2493; GOSSEYE S, 1982, HELV PAEDIATR ACTA, V37, P471; JUNKER AK, 1989, J PEDIATR-US, V114, P596, DOI 10.1016/S0022-3476(89)80702-4; KEY G, 1993, LAB INVEST, V68, P629; Klein AK, 2001, BIOL BLOOD MARROW TR, V7, P454, DOI 10.1016/S1083-8791(01)80013-6; LIN AE, 1987, AM J DIS CHILD, V141, P1010, DOI 10.1001/archpedi.1987.04460090087034; Markert ML, 1998, J PEDIATR-US, V132, P15, DOI 10.1016/S0022-3476(98)70478-0; Markert ML, 1999, NEW ENGL J MED, V341, P1180, DOI 10.1056/NEJM199910143411603; Markert ML, 2003, BLOOD, V102, P1121, DOI 10.1182/blood-2002-08-2545; Markert ML, 1997, J IMMUNOL, V158, P998; MARKERT ML, 2004, IN PRESS BLOOD; Ocejo-Vinyals JG, 2000, ARCH DIS CHILD, V83, P165, DOI 10.1136/adc.83.2.165; PAGON RA, 1981, J PEDIATR-US, V99, P223, DOI 10.1016/S0022-3476(81)80454-4; PICKER LJ, 1993, J IMMUNOL, V150, P1105; Pirovano S, 2003, IMMUNOL LETT, V86, P93, DOI 10.1016/S0165-2478(02)00291-2; POLLACK MS, 1982, NEW ENGL J MED, V307, P662, DOI 10.1056/NEJM198209093071106; Ryan AK, 1997, J MED GENET, V34, P798, DOI 10.1136/jmg.34.10.798; Sarzotti M, 2003, J IMMUNOL, V170, P2711, DOI 10.4049/jimmunol.170.5.2711; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Thomas R A, 1987, Am J Med Genet Suppl, V3, P43; Van Esch H, 1999, GENET COUNSEL, V10, P59; Wang R, 2002, J PEDIATR-US, V141, P611, DOI 10.1067/mpd.2002.128891; WILSON DI, 1992, AM J HUM GENET, V51, P957	37	108	111	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					734	741		10.1016/j.jaci.2004.01.766	http://dx.doi.org/10.1016/j.jaci.2004.01.766			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100681				2022-12-18	WOS:000220956600023
J	Osterballe, M; Bindslev-Jensen, C				Osterballe, M; Bindslev-Jensen, C			Threshold levels in food challenge and specific IgE in patients with egg allergy: Is there a relationship?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; specific IgE; egg; threshold	CHILDREN; TESTS	Background: Previously published articles described a relationship between food-specific IgE and the outcome of food challenge in children with egg allergy. These investigations defined different levels of predictive values in different study populations and thus pointed toward the possibility of a certain level of specific IgE to egg white predicting a positive outcome in food challenge. Objective: The purpose of this study was to determine the utility of specific IgE in estimating threshold level to predict a positive outcome in food challenge. Methods: Fifty-six children were evaluated for egg allergy by titrated oral challenges. Sera were analyzed for specific IgE to egg white in 56 patients by using the Magic Lite test and 32 of 56 patients also by the CAP test. Values of specific IgE to egg white were compared to the outcome of challenges and the threshold level. Results: The diagnostic level of specific IgE predicting clinical reactivity in this population with greater than 95% certainty was identified as 10.8 standardized units/mL (Magic Lite) and 1.5 kilounits of allergen-specific lgE/L (CAP), respectively. We found no significant relationship between the specific IgE concentration (egg white) and the challenge threshold level. Conclusion: Although the specific IgE concentration correlated to a positive outcome in food challenge, there was no significant relationship between the quantification of specific IgE and the challenge threshold level. Therefore the standardized food challenge still remains the gold standard in the diagnosis of food allergy.	Odense Univ Hosp, Dept Dermatol, Allergy Ctr, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital	Osterballe, M (corresponding author), Odense Univ Hosp, Dept Dermatol, Allergy Ctr, Sdr Blvd 29, DK-5000 Odense C, Denmark.		Bindslev-Jensen, Carsten/H-1877-2011	Bindslev-Jensen, Carsten/0000-0002-8940-038X				Bindslev-Jensen C, 2002, ALLERGY, V57, P741, DOI 10.1034/j.1398-9995.2002.23797.x; Bland JM, 2000, INTRO MED STAT; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; WOODHEAD JS, 1989, J BIOLUM CHEMILUM, V4, P611, DOI 10.1002/bio.1170040180; Wuthrich B, 2000, J INVEST ALLERG CLIN, V10, P59; Wuthrich B, 2001, ALLERGY, V56, P102, DOI 10.1034/j.1398-9995.2001.00930.x	14	108	112	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					196	201		10.1067/mai.2003.1603	http://dx.doi.org/10.1067/mai.2003.1603			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847499				2022-12-18	WOS:000184010600030
J	Erbagci, Z				Erbagci, Z			The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: A single-blind, placebo-controlled, crossover clinical study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic idiopathic urticaria; treatment; leukotriene antagonist; montelukast; placebo; urticaria activity score; crossover study	THERAPEUTIC AGENT; HISTAMINE; RESPONSES; FEXOFENADINE	Background: Chronic idiopathic urticaria (CIU) might be refractory to standard therapies. For the patients with severe unremitting CIU who have failed to benefit from conventional therapy with antihistamines, other effective and safe therapeutic modalities are required. Objective: A randomized, single-blind, placebo-controlled crossover study was conducted to evaluate the efficacy and safety of the new selective leukotriene antagonist montelukast sodium in the treatment of refractory CIU. Methods: Thirty patients with refractory CIU were enrolled in the trial. After informed consent was obtained, patients were randomly assigned to 2 groups. The patients in group A received 10 mg/d montelukast and a nonsedating H-1 antihistamine (cetirizine) when needed for 6 weeks. After a 2-week washout period, they received placebo for 6 weeks and the same H-1 antihistamine as needed. Group B received the treatment vice versa. Improvement was monitored by using the self-estimated urticaria activity score, which is the sum of the wheal number score and the itch severity score, and the antihistamine counts used in each study period. Results: More significant decreases occurred in urticaria activity scores with montelukast therapy compared with those with placebo therapy (P<.001). H-1 antihistamine use was also significantly less frequent during the montelukast period (P<.001). There were no significant side effects with montelukast therapy. Conclusion: The present study results suggest that montelukast might be an effective and safe therapeutic agent in the treatment of refractory CIU.	Gaziantep Univ Med Fac, Dept Dermatol, Gaziantep, Turkey	Gaziantep University	Erbagci, Z (corresponding author), Gazimuhtarpasa Bulvari, Gecit 1 1-5, TR-27090 Gaziantep, Turkey.							Andoh T, 1998, EUR J PHARMACOL, V353, P93, DOI 10.1016/S0014-2999(98)00440-3; Asero R, 2000, ANN ALLERG ASTHMA IM, V85, P156, DOI 10.1016/S1081-1206(10)62457-X; Asero R, 2001, ALLERGY, V56, P456, DOI 10.1034/j.1398-9995.2001.056005456.x; Bensch G, 1999, ANN ALLERG ASTHMA IM, V83, P348, DOI 10.1016/S1081-1206(10)62677-4; Berkun Y, 2000, ALLERGY, V55, P203, DOI 10.1034/j.1398-9995.2000.00538.x; BERNSTEIN JA, 1991, J ALLERGY CLIN IMMUN, V87, P93, DOI 10.1016/0091-6749(91)90217-C; Capella GL, 2001, EUR J DERMATOL, V11, P209; Carucci JA, 1998, ARCH DERMATOL, V134, P785, DOI 10.1001/archderm.134.7.785; Chu TJ, 1998, J ALLERGY CLIN IMMUN, V101, pS155; Ellis MH, 1998, J ALLERGY CLIN IMMUN, V102, P876, DOI 10.1016/S0091-6749(98)70032-6; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; Hani N, 2000, ACTA DERM-VENEREOL, V80, P229; KRAUSE LB, 1984, LANCET, V2, P929; Markham A, 1998, DRUGS, V56, P251, DOI 10.2165/00003495-199856020-00010; MAXWELL DL, 1990, J ALLERGY CLIN IMMUN, V86, P759, DOI 10.1016/S0091-6749(05)80180-0; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Nettis E, 2001, ARCH DERMATOL, V137, P99; Norris JG, 1998, J ALLERGY CLIN IMMUN, V101, pS128; O'Donnell BF, 1998, BRIT J DERMATOL, V138, P101; Ohnishi-Inoue Y, 1998, BRIT J DERMATOL, V138, P483; Pacor ML, 2001, CLIN EXP ALLERGY, V31, P1607, DOI 10.1046/j.1365-2222.2001.01189.x; Sabroe RA, 1997, ARCH DERMATOL, V133, P1003, DOI 10.1001/archderm.133.8.1003; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Simons FER, 2001, ANN ALLERG ASTHMA IM, V86, P44, DOI 10.1016/S1081-1206(10)62354-X; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Spector S, 1998, J ALLERGY CLIN IMMUN, V101, P572; Tharp MD, 1996, J ALLERGY CLIN IMMUN, V98, pS325, DOI 10.1016/S0091-6749(96)80118-7; Volovitz B, 1999, J ALLERGY CLIN IMMUN, V104, P1162, DOI 10.1016/S0091-6749(99)70008-4; Wedi B, 2000, J ALLERGY CLIN IMMUN, V105, P552, DOI 10.1067/mai.2000.104939; Yanase DJ, 2001, J AM ACAD DERMATOL, V44, P89, DOI 10.1067/mjd.2001.111352	31	108	115	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					484	488		10.1067/mai.2002.126676	http://dx.doi.org/10.1067/mai.2002.126676			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209099				2022-12-18	WOS:000177936900022
J	Kulig, M; Klettke, U; Wahn, V; Forster, J; Bauer, CP; Wahn, U				Kulig, M; Klettke, U; Wahn, V; Forster, J; Bauer, CP; Wahn, U		MAS Study Grp	Development of seasonal allergic rhinitis during the first 7 years of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; allergic sensitization; atopic family history; children	LATE-ONSET; CHILDREN; ASTHMA; PREVALENCE; SENSITIZATION; ATOPY; RISK; SYMPTOMS; GERMANY; ECZEMA	Background: Against the background of the controversial discussion about an increase in allergic rhinitis in recent years, intraindividual longitudinal data is lacking for IgE-mediated seasonal allergic rhinitis (SAR), Little is known about the development of SAR in terms of prevalence and incidence rates from birth to school age. Objective: In a prospective birth cohort, we investigated the development of sensitization and symptoms of SAR. SAR should be defined with high specificity, and associated risk factors should be determined. Methods: Annual longitudinal data about seasonal allergic symptoms and sensitization was available for 587 children from birth to their seventh birthday The definition of SAR was based on a combination of exposure-related symptoms and sensitization. Results: Up to 7 years of age, SAR developed in 15% of the children. Incidence and prevalence of symptoms and sensitization were low during early childhood (<2%) and increased steadily with age. Children in which SAR had already developed in the second year all were born in spring or early summer, resulting in at least two seasons of pollen exposure before manifestation of SAR. Risk factors assessed by multiple logistic regression analysis were male sex (odds ratio [OR] = 2.4), atopic mothers (OR = 2.6) and fathers (OR = 3.6) having allergic rhinitis themselves, first-born child (OR = 2.0), early sensitization to food (OR = 3.3), and atopic dermatitis (OR = 2.5), whereas early wheezing was not associated with SAR. Conclusion: The development of SAR is characterized by a marked increase in prevalence and incidence after the second year of life. Our longitudinal data further indicate that in combination with the risk of allergic predisposition, at least 2 seasons of pollen allergen exposure are needed before allergic rhinitis becomes clinically manifest.	Tech Univ, Childrens Hosp, Munich, Germany; Univ Freiburg, Childrens Hosp, Freiburg, Germany; Humboldt Univ, Dept Pediat Pneumol & Immunol, Berlin, Germany; Humboldt Univ, Charite Hosp, Inst Social Med & Epidemiol, Berlin, Germany	Technical University of Munich; University of Munich; University of Freiburg; Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kulig, M (corresponding author), Univ Klinikum Charite, Inst Arbeitsmed Sozialmed & Epidemiol, D-10098 Berlin, Germany.							ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; BENER A, 1994, EUR J EPIDEMIOL, V10, P271, DOI 10.1007/BF01719349; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; Duhme H, 1998, EUR RESPIR J, V11, P840, DOI 10.1183/09031936.98.11040840; Hosmer DW, 1989, APPL LOGISTIC REGRES; Jones NS, 1998, J LARYNGOL OTOL, V112, P1019, DOI 10.1017/S0022215100142380; KUEHR J, 1995, J ALLERGY CLIN IMMUN, V95, P655, DOI 10.1016/S0091-6749(95)70168-0; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LUCK W, 1985, J PEDIAT, V99, P763; Martinez FD, 1998, EUR RESPIR J, V12, p3S; MEINERT R, 1994, ALLERGY, V49, P526, DOI 10.1111/j.1398-9995.1994.tb01124.x; POYSA L, 1991, ALLERGY, V46, P161, DOI 10.1111/j.1398-9995.1991.tb00564.x; Remes ST, 1998, ALLERGY, V53, P682, DOI 10.1111/j.1398-9995.1998.tb03954.x; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; SCHAFER T, 1993, ALLERGY, V48, P291, DOI 10.1111/j.1398-9995.1993.tb00731.x; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; VARONIER HS, 1984, HELV PAEDIATR ACTA, V39, P129; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; Weeke E R, 1992, Rhinol Suppl, V13, P5; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Wright AL, 1998, EUR RESPIR J, V12, p17S; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	26	108	118	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					832	839		10.1067/mai.2000.110098	http://dx.doi.org/10.1067/mai.2000.110098			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080703	Bronze			2022-12-18	WOS:000167865200005
J	Neukirch, C; Henry, C; Leynaert, B; Liard, R; Bousquet, J; Neukirch, F				Neukirch, C; Henry, C; Leynaert, B; Liard, R; Bousquet, J; Neukirch, F			Is sensitization to Alternaria alternata a risk factor for severe asthma? A population-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INSERM, U408, Paris, France; INSERM, U454, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Neukirch, C (corresponding author), Univ Paris 07, BP 416, F-75870 Paris 18, France.		Bousquet, Jean/O-4221-2019; Leynaert, Benedicte/N-5251-2018	Leynaert, Benedicte/0000-0001-5045-2492				Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P514, DOI 10.1016/S0091-6749(96)70084-2; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Ronchetti R, 1997, EUR RESPIR J, V10, P1248, DOI 10.1183/09031936.97.10061248; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1	5	108	110	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					709	711		10.1016/S0091-6749(99)70247-2	http://dx.doi.org/10.1016/S0091-6749(99)70247-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200024	Bronze			2022-12-18	WOS:000079723900028
J	Pierkes, M; Bellinghausen, I; Hultsch, T; Metz, G; Knop, J; Saloga, J				Pierkes, M; Bellinghausen, I; Hultsch, T; Metz, G; Knop, J; Saloga, J			Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; wasp venom; histamine; leukotrienes; cytokines; sulfidoleukotrienes (LTC4, LTD4, LTE4)	HUMAN IGE SYNTHESIS; BEE VENOM; INTERFERON-GAMMA; ATOPIC-DERMATITIS; LEUKOTRIENE GENERATION; TH2 CLONES; INTERLEUKIN-4; LYMPHOCYTES; EXPRESSION; MODULATION	Background: Recent studies provide evidence that venom immunotherapy (VIT) alters the pattern of cytokine production by inducing an allergen-specific T-cell shift in cytokine expression from T-H2 (IL-4, IL-5) to T-H1 (IFN-gamma) cytokines and also inducing the production of IL-10. Objective: This study was carried out to analyze whether these changes in cytokine production of T cells already observed 1 week after the initiation of VIT in subjects with wasp venom allergy also influence the reactivity of effector cells, such as mast cells and basophils. Methods: All subjects included in this study had a history of severe systemic allergic reactions to wasp stings and positive skin test responses with venom and venom-specific IgE in the sera. Peripheral blood leukocytes were isolated before and after the initiation of VIT (rush therapy reaching a maintenance dose of 100 mu g venom injected subcutaneously within 1 week) and preincubated with or without addition of IL-10, IFN-gamma, IL-10 + IFN-gamma, anti-IL-10, or anti-IFN-gamma. After stimulation with wasp venom, histamine and sulfidoleukotriene release were assessed by ELISA and compared with spontaneous release and total histamine content. Results: After the induction of VIT, venom-induced absolute and relative histamine and sulfidoleukotriene release were reduced. This was at least partially due to the induction of IFN-gamma and IL-10 production, because (1) neutralization of IL-10 and IFN-gamma by mAbs partially restored the release after the initiation of VIT and (2) the addition of exogenous IFN-gamma and IL-10 caused a statistically significant diminution of the venom-induced histamine and sulfidoleukotriene release before VIT, Depletion of CD2(+) T cells also restored the releasability after VIT. Conclusion: These data indicate that T cells (producing IL-10 and IFN-gamma after VIT) play a key role for the inhibition of histamine and sulfidoleukotriene release of effector cells.	Johannes Gutenberg Univ Mainz, Hautklin, Dept Dermatol, Clin Res Grp, D-55131 Mainz, Germany; Stadt Klinikum Wiesbaden, Dept Dermatol, Wiesbaden, Germany	Johannes Gutenberg University of Mainz	Saloga, J (corresponding author), Johannes Gutenberg Univ Mainz, Hautklin, Dept Dermatol, Clin Res Grp, Langenbeckstr 1, D-55131 Mainz, Germany.							AALBERSE RC, 1983, CLIN REV ALLERG, V1, P289; Akoum H, 1996, IMMUNOLOGY, V87, P593, DOI 10.1046/j.1365-2567.1996.506585.x; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; CARBALLIDO JM, 1994, J ALLERGY CLIN IMMUN, V93, P758, DOI 10.1016/0091-6749(94)90256-9; FERRANTE A, 1986, INT ARCH ALLER A IMM, V81, P284, DOI 10.1159/000234148; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; Jutel M, 1996, CLIN EXP ALLERGY, V26, P1112, DOI 10.1111/j.1365-2222.1996.tb00496.x; JUTEL M, 1995, J IMMUNOL, V154, P4187; KURIMOTO Y, 1991, EUR J IMMUNOL, V21, P361, DOI 10.1002/eji.1830210217; Lagier B, 1997, CLIN EXP IMMUNOL, V108, P545, DOI 10.1046/j.1365-2249.1997.3791276.x; LEUNG DYM, 1993, CLIN REV ALLERG, V11, P447; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; MAGGI E, 1992, J IMMUNOL, V148, P2142; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Miadonna A, 1997, ALLERGY, V52, P992, DOI 10.1111/j.1398-9995.1997.tb02419.x; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; NUSSLEIN HG, 1991, INT ARCH ALLER A IMM, V95, P257, DOI 10.1159/000235438; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; RADERMECKER M, 1994, ALLERGY, V49, P641, DOI 10.1111/j.1398-9995.1994.tb00133.x; RANDOLPH CC, 1986, J ALLERGY CLIN IMMUN, V77, P823, DOI 10.1016/0091-6749(86)90379-9; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; STEPHAN V, 1989, ALLERGY, V44, P453, DOI 10.1111/j.1398-9995.1989.tb04182.x; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295	30	108	114	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				326	332		10.1016/S0091-6749(99)70509-9	http://dx.doi.org/10.1016/S0091-6749(99)70509-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949326				2022-12-18	WOS:000078630100022
J	James, JM; Sixbey, JP; Helm, RM; Bannon, GA; Burks, AW				James, JM; Sixbey, JP; Helm, RM; Bannon, GA; Burks, AW			Wheat alpha-amylase inhibitor: A second route of allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						wheat; allergen; hypersensitivity; food hypersensitivity; baker's asthma; alpha-amylase inhibitor; anaphylaxis; grass allergy; cereal grain	EXERCISE-INDUCED ANAPHYLAXIS; MAJOR PEANUT ALLERGEN; ARA-H-I; ATOPIC-DERMATITIS; FOOD HYPERSENSITIVITY; BAKERS ASTHMA; IGE-BINDING; SKIN-TEST; FLOUR; IDENTIFICATION	Background: Low molecular weight allergens may be responsible for hypersensitivity reactions after the ingestion of wheat. Objective: The purpose of this investigation was to identify relevant, low molecular weight allergens after the ingestion of what protein. Methods: Serum samples were collected from seven children with wheat allergy and one adult with baker's asthma. Control serum samples were collected from wheat-tolerant patients. Wheat extracts were prepared and separated by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 12.5% gels revealing numerous protein bands. IgE immunoblot analysis of crude wheat extracts identified multiple IgE-binding proteins. Wheat proteins were separated further with two-dimensional gel electrophoresis, which was followed by IgE immunoblotting investigations. Results: Immunoblot analysis identified a 15 kd wheat protein that bound IgE from all five children with wheat allergy who were evaluated. No IgE binding to this wheat protein was demonstrated in any of the control subjects. Samples representing the 15 kd wheat protein (isoelective point, 5.85) were selected. The N-terminal peptide sequence of this protein (residues 1 to 20) matched to a what alpha-amylase inhibitor. Conclusion: These data demonstrate that wheat alpha-amylase inhibitor is a relevant allergen in patients experiencing hypersensitivity reactions after the ingestion of wheat protein. This wheat protein, which has been implicated as an important allergen in patients with baker's asthma, represents a sensitizing allergen after both ingestion and inhalation.	UNIV ARKANSAS MED SCI HOSP, ARKANSAS CHILDRENS HOSP, RES INST, DEPT BIOCHEM, LITTLE ROCK, AR 72202 USA; UNIV ARKANSAS MED SCI HOSP, ARKANSAS CHILDRENS HOSP, RES INST, DEPT MOL BIOL, LITTLE ROCK, AR 72202 USA	Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	James, JM (corresponding author), UNIV ARKANSAS MED SCI HOSP, ARKANSAS CHILDRENS HOSP, RES INST, DEPT PEDIAT, 800 MARSHALL ST, LITTLE ROCK, AR 72202 USA.							ARMENTIA A, 1993, CLIN EXP ALLERGY, V23, P410, DOI 10.1111/j.1365-2222.1993.tb00347.x; ARMENTIA A, 1990, ANN ALLERGY, V65, P149; BALDO BA, 1982, PROG ALLERGY, V30, P1; BALDO BA, 1978, CLIN ALLERGY, V8, P109, DOI 10.1111/j.1365-2222.1978.tb00456.x; BERNHISELBROADBENT J, 1994, J ALLERGY CLIN IMMUN, V93, P1047, DOI 10.1016/S0091-6749(94)70054-0; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BJORKSTEN F, 1977, CLIN ALLERGY, V7, P473, DOI 10.1111/j.1365-2222.1977.tb01478.x; BLANDS J, 1976, INT ARCH ALLER A IMM, V52, P392, DOI 10.1159/000231706; BLEUMINK E, 1968, INT ARCH ALLER A IMM, V34, P521, DOI 10.1159/000230147; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; BUSINCO L, 1989, ALLERGY, V44, P70, DOI 10.1111/j.1398-9995.1989.tb04320.x; GOMEZ L, 1990, FEBS LETT, V261, P85, DOI 10.1016/0014-5793(90)80642-V; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; JAMES JM, 1992, PEDIATR ALLERGY IMMU, V3, P67; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; KATSUNUMA T, 1992, ANN ALLERGY, V68, P184; KUSHIMOTO H, 1985, ARCH DERMATOL, V121, P355, DOI 10.1001/archderm.121.3.355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PFEIL T, 1990, INT ARCH ALLER A IMM, V91, P224, DOI 10.1159/000235121; PRICHARD MG, 1985, CLIN ALLERGY, V15, P203, DOI 10.1111/j.1365-2222.1985.tb02274.x; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SANCHEZMONGE R, 1992, BIOCHEM J, V281, P401, DOI 10.1042/bj2810401; SANDIFORD CP, 1995, CLIN EXP ALLERGY, V25, P340, DOI 10.1111/j.1365-2222.1995.tb01052.x; STURGESS RP, 1990, GUT, V31, pA590; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; SUTTON R, 1982, CLIN ALLERGY, V12, P63, DOI 10.1111/j.1365-2222.1982.tb03127.x; VOORHORST R, 1973, ANN ALLERGY, V31, P195; WALSH BJ, 1985, J ALLERGY CLIN IMMUN, V76, P23, DOI 10.1016/0091-6749(85)90799-7	33	108	112	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					239	244		10.1016/S0091-6749(97)70103-9	http://dx.doi.org/10.1016/S0091-6749(97)70103-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042052				2022-12-18	WOS:A1997WH83100015
J	NELSON, HS; OPPENHEIMER, J; VATSIA, GA; BUCHMEIER, A				NELSON, HS; OPPENHEIMER, J; VATSIA, GA; BUCHMEIER, A			A DOUBLE-BLIND, PLACEBO-CONTROLLED EVALUATION OF SUBLINGUAL IMMUNOTHERAPY WITH STANDARDIZED CAT EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SUBLINGUAL; IMMUNOTHERAPY; CAT ALLERGY	HOUSE DUST MITE; ALLERGIC RHINITIS; EFFICACY; THERAPY; ASTHMA	Background: In light of the controversial status of sublingual immunotherapy in patients with allergic rhinitis, we undertook a double-blind study of this form of treatment. Methods: Forty-one subjects with cat allergy presenting as rhinoconjunctivitis underwent 105 days of sublingual immunotherapy, with 20 subjects receiving a standardized cat extract (total dose approximately 4,500, 000 allergy units) and 21 a matching placebo. Effectiveness of treatment was assessed by changes in symptoms and nasal-blockage index during 90 minutes of exposure in an apartment containing cat dander, which was performed before and after the course of treatment. Changes in cat-specific IgG and IgE levels and skin-test reactions were also monitored. Results: Although there were fewer symptoms and less nasal obstruction on cat dander exposure at the end of the study the changes were not significantly different in those receiving active or placebo treatment. Specific IgG and IgE levels and prick skin test results did not change significantly during the course of the study. Conclusions: We conclude that sublingual immunotherapy with high-dose standardized cat extract was no more effective than placebo in reducing symptoms or affecting immunologic measures of cat sensitivity.			NELSON, HS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DIV ALLERGY IMMUNOL,1400 JACKSON ST,DENVER,CO 80206, USA.							AMLSTEDT S, 1987, CLIN ALLERGY, V17, P85, DOI 10.1111/j.1365-2222.1987.tb02323.x; GRIECO MH, 1982, JAMA-J AM MED ASSOC, V247, P3106, DOI 10.1001/jama.247.22.3106; HANSEL FK, 1953, CLIN ALLERGY, P828; HAUGAARD L, 1992, ALLERGY, V47, P249, DOI 10.1111/j.1398-9995.1992.tb00658.x; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TAYLOR G, 1973, J ALLERGY CLIN IMMUN, V52, P193, DOI 10.1016/0091-6749(73)90057-2; VANNIEKERK CH, 1987, CLIN ALLERGY, V17, P507	10	108	109	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					229	236		10.1016/0091-6749(93)90166-D	http://dx.doi.org/10.1016/0091-6749(93)90166-D			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349933	Bronze			2022-12-18	WOS:A1993LT46900003
J	BRITTON, JR; HANLEY, SP; TATTERSFIELD, AE				BRITTON, JR; HANLEY, SP; TATTERSFIELD, AE			THE EFFECT OF AN ORAL LEUKOTRIENE-D4 ANTAGONIST L-649,923 ON THE RESPONSE TO INHALED ANTIGEN IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BRITTON, JR (corresponding author), CITY HOSP NOTTINGHAM,RESP MED UNIT,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.		Britton, John R/G-9705-2011					BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BARNES NC, UNPUB EFFECT ORAL LE; BISGAARD H, 1985, BRIT MED J, V290, P1468, DOI 10.1136/bmj.290.6480.1468; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; HOLROYDE MC, 1981, LANCET, V2, P17; JONES TR, 1986, CAN J PHYSIOL PHARM, V64, P1068, DOI 10.1139/y86-183; LEE TH, 1981, LANCET, V2, P304; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; PIPER PJ, 1983, BRIT MED BULL, V39, P255, DOI 10.1093/oxfordjournals.bmb.a071829; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; SHAW RJ, 1985, THORAX, V40, P215; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; ZAKRZEWSKI JT, 1985, BRIT J CLIN PHARMACO, V19, pP574	20	108	108	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					811	816		10.1016/0091-6749(87)90214-4	http://dx.doi.org/10.1016/0091-6749(87)90214-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3571772				2022-12-18	WOS:A1987H434900017
J	HOLGATE, ST; HARDY, C; ROBINSON, C; AGIUS, RM; HOWARTH, PH				HOLGATE, ST; HARDY, C; ROBINSON, C; AGIUS, RM; HOWARTH, PH			THE MAST-CELL AS A PRIMARY EFFECTOR CELL IN THE PATHOGENESIS OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HOLGATE, ST (corresponding author), SOUTHAMPTON GEN HOSP, CTR BLOCK, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.			Robinson, Clive/0000-0001-6253-7864; Howarth, Peter/0000-0003-0619-7927				ADKINSON NF, 1983, IMMUNOPHARMACOLOGY L, V19, P55; AGIUS RM, 1985, THORAX, V40, P220; AGIUS RM, 1985, THORAX, V40, P214; AGIUS RM, 1985, THORAX, V40, P760, DOI 10.1136/thx.40.10.760; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1984, J ALLERGY CLIN IMMUN, V73, P341, DOI 10.1016/0091-6749(84)90406-8; BACH MK, 1984, BIOCHEM PHARMACOL, V33, P515, DOI 10.1016/0006-2952(84)90300-9; BARNES PJ, B EUR PHYSIOPATHOL R; BOOJNOORD H, 1972, CLIN ALLERGY, V2, P43; BROSTOFF J, BR J PHARM; BURKA JF, 1985, BRIT J PHARMACOL, V85, P611; CAPRON A, 1985, INT ARCH ALLER A IMM, V77, P107, DOI 10.1159/000233762; CAPRON M, 1981, J IMMUNOL, V126, P2087; CAULFIELD JP, 1980, J CELL BIOL, V85, P299, DOI 10.1083/jcb.85.2.299; CHURCH M K, 1985, British Journal of Pharmacology, V86, p509P; CONNELL JT, 1971, J AMER MED ASSOC, V215, P769, DOI 10.1001/jama.215.5.769; CUNDELL DR, UNPUB J ALLERGY CLIN; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DALQUEN P, 1985, ASTHMA BRONCHIAL HYP, V19, P189; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P303, DOI 10.1111/apm.1966.66.3.303; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FLINT KC, 1985, CLIN SCI, V68, pP33; FLINT KC, 1985, THORAX, V40, P716; FOREMAN JC, 1984, J ALLERGY CLIN IMMUN, V74, P127, DOI 10.1016/0091-6749(84)90274-4; FOX B, 1981, J CLIN PATHOL, V34, P1333, DOI 10.1136/jcp.34.12.1333; FOX CC, 1985, INT ARCH ALLER A IMM, V77, P130, DOI 10.1159/000233767; GREEN K, 1974, LANCET, V2, P1419; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HEAVEY DJ, 1984, BRIT J CLIN PHARMACO, V18, P915, DOI 10.1111/j.1365-2125.1984.tb02564.x; HEAVEY DJ, BR J CLIN PHARM; HEGARDT B, 1982, ALLERGY, V37, P407, DOI 10.1111/j.1398-9995.1982.tb02319.x; HOLGATE ST, 1984, J IMMUNOL, V133, P2138; HOLGATE ST, 1985, J ALLERGY CLIN IMMUN, V75, P140, DOI 10.1016/0091-6749(85)90279-9; HOLGATE ST, 1985, J ALLERGY CLIN IMMUN, V76, P375, DOI 10.1016/0091-6749(85)90657-8; HOLGATE ST, 1985, INT ARCH ALLER A IMM, V77, P47, DOI 10.1159/000233752; HOLROYDE MC, 1981, LANCET, V2, P17; HOWARTH PH, 1984, J ALLERGY CLIN IMMUN, V73, P391, DOI 10.1016/0091-6749(84)90414-7; HOWARTH PH, AM REV RESPIR DIS; HUGLI T E, 1981, Critical Reviews in Immunology, V1, P321; IHLE JN, 1983, J IMMUNOL, V131, P282; JEFFREY P, 1984, IMMUNOLOGY LUNG UPPE, P1; JOHNSON HG, 1983, INT ARCH ALLER A IMM, V70, P169, DOI 10.1159/000233317; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KALINER M, MAST CELL HETEROGENE; KING SJ, P NATL ACAD SCI US; KLEEBERGER SR, 1985, FED PROC, V44, P490; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; LAMB D, 1982, THORAX, V37, P334, DOI 10.1136/thx.37.5.334; LEUNG KBP, 1985, CLIN SCI, V68, pP7, DOI 10.1042/cs068007Pa; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LEWIS RA, 1985, ASTHMA PHYSL IMMUNOP, P63; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MCFADDEN ER, 1984, J ALLERGY CLIN IMMUN, V73, P413, DOI 10.1016/0091-6749(84)90347-6; MILLER HRP, 1980, BIOL CELLULAIRE, V39, P229; MOODLEY I, 1983, CLIN SCI, V64, pP12; MORGAN DJR, 1982, THORAX, V37, P788; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; NEIJENS HJ, 1982, CLIN ALLERGY, V12, P577, DOI 10.1111/j.1365-2222.1982.tb02556.x; OATES JA, 1984, ASTHMA PHYSL IMMUNOP, P55; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; Pepys J, 1967, J R Coll Physicians Lond, V2, P42; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PRIDE NB, CLIN ALLERGY; RAZIN E, 1984, J IMMUNOL, V132, P1479; RAZIN E, 1982, J BIOL CHEM, V257, P7229; REES PJ, 1985, THORAX, V40, P603, DOI 10.1136/thx.40.8.603; ROBERTS LJ, 1985, CLIN RES, V33, pA162; ROBINSON C, 1985, J ALLERGY CLIN IMMUN, V76, P265, DOI 10.1016/0091-6749(85)90640-2; ROBINSON C, 1985, CLIN SCI, V68, P103, DOI 10.1042/cs0680103; ROBINSON C, 1985, J ALLERGY CLIN IMMUN, V76, P140, DOI 10.1016/0091-6749(85)90691-8; ROBINSON C, BIOCH PHARM; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SIBBALD B, 1979, THORAX, V34, P332, DOI 10.1136/thx.34.3.332; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; SMITH RJ, 1982, BIOCHEM BIOPH RES CO, V109, P943, DOI 10.1016/0006-291X(82)92031-9; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; STEVENS R, MAST CELL HETEROGENE; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; SZCZEKLIK A, 1982, EUR J RESPIR DIS, V63, P376; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; VAUGHAN JH, 1972, ASTHMA PHYSL IMMUNOP, P1; WARDLAW AJ, 1985, J ALLERGY CLIN IMMUN, V75, P193, DOI 10.1016/0091-6749(85)90489-0; WELLS PD, 1977, EXP PARASITOL, V43, P326, DOI 10.1016/0014-4894(77)90037-6; WHITE J, 1983, BRIT J DIS CHEST, V77, P215; WOODBURY RG, 1981, METHOD ENZYMOL, V80, P588; WOODBURY RG, 1982, IMMUNOLOGY, V46, P487; YURT R, 1977, J EXP MED, V146, P1405, DOI 10.1084/jem.146.5.1405; YURT RW, 1977, J IMMUNOL, V118, P1201	94	108	108	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					274	282		10.1016/S0091-6749(86)80104-X	http://dx.doi.org/10.1016/S0091-6749(86)80104-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	2418090				2022-12-18	WOS:A1986A089900002
J	ZEISS, CR; LOCKEY, RF				ZEISS, CR; LOCKEY, RF			REFRACTORY PERIOD TO ASPIRIN IN A PATIENT WITH ASPIRIN-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611; UNIV S FLORIDA,DEPT MED,TAMPA,FL 33620	Northwestern University; State University System of Florida; University of South Florida								Cooke RA, 1919, J AMER MED ASSOC, V73, P759, DOI 10.1001/jama.1919.02610360029008; DELANEY JC, 1973, ANN INTERN MED, V79, P761, DOI 10.7326/0003-4819-79-5-761_1; FEINBERG AR, 1951, J ALLERGY, V22, P74, DOI 10.1016/0021-8707(51)90133-5; FRIEDLAENDER S, 1947, ANN INTERN MED, V26, P734, DOI 10.7326/0003-4819-26-5-734; Gardner E, 1940, AM J MED SCI, V200, P390, DOI 10.1097/00000441-194009000-00015; GIRALDO B, 1969, ANN INTERN MED, V71, P479, DOI 10.7326/0003-4819-71-3-479; GIRARD JP, 1969, HELV MED ACTA, V35, P86; HANSEN-PRUSS O. C., 1949, ANN ALLERGY, V7, P219; LOCKEY RF, 1973, ANN INTERN MED, V78, P57, DOI 10.7326/0003-4819-78-1-57; MATHEWS KP, 1950, J LAB CLIN MED, V36, P416; MAUR KV, 1974, J ALLERGY CLIN IMMUN, V54, P380; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MILLER FF, 1971, ANN ALLERGY, V29, P263; Prickman LE, 1937, J AMER MED ASSOC, V108, P445, DOI 10.1001/jama.1937.02780060011004; SALE ERNST B., 1948, ACTA ALLERGOL, V1, P47, DOI 10.1111/j.1398-9995.1948.tb03302.x; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SAMTER M, UNPUBLISHED; SETTIPANE GA, 1974, J ALLERGY CLIN IMMUN, V53, P200, DOI 10.1016/0091-6749(74)90081-5; STUART MJ, 1972, NEW ENGL J MED, V287, P1105, DOI 10.1056/NEJM197211302872201; VANSELOW NA, 1967, ANN INTERN MED, V66, P568, DOI 10.7326/0003-4819-66-3-568; WALTON C H, 1957, Can Med Assoc J, V76, P1016; WALTON CHA, 1951, CAN MED ASSOC J, V64, P187; YUNGINGER JW, 1971, J PEDIATR, V82, P218; YURCHAK AM, 1970, J ALLERGY, V46, P245, DOI 10.1016/0021-8707(70)90028-6	25	108	108	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	5					440	448		10.1016/0091-6749(76)90059-2	http://dx.doi.org/10.1016/0091-6749(76)90059-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BR201	770552	Bronze			2022-12-18	WOS:A1976BR20100007
J	GODFREY, S				GODFREY, S			EXERCISE-INDUCED ASTHMA - CLINICAL, PHYSIOLOGICAL, AND THERAPEUTIC IMPLICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HAMMERSMITH HOSP,DEPT PAEDIAT & NEONATAL MED,DU CANE RD,LONDON W12 OHS,ENGLAND	Imperial College London								ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; BENATAR SR, 1974, CLIN SCI MOL MED, V46, P317, DOI 10.1042/cs0460317; BIANCO S, 1974, BMJ-BRIT MED J, V4, P18, DOI 10.1136/bmj.4.5935.18; BURR ML, 1974, ARCH DIS CHILD, V49, P923, DOI 10.1136/adc.49.12.923; DAY G, 1973, ARCH DIS CHILD, V48, P355, DOI 10.1136/adc.48.5.355; Floyer J., 1698, TREATISE ASTHMA; GODFREY S, 1974, CLIN SCI MOL MED, V46, P265, DOI 10.1042/cs0460265; GODFREY S, 1973, J PSYCHOSOM RES, V17, P293, DOI 10.1016/0022-3999(73)90106-2; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P199, DOI 10.1016/0091-6749(73)90058-4; GODFREY S, 1974, BTTA REV BRIT THO TU, V4, P1; GODFREY S, IN PRESS; GODFREY S, TO BE PUBLISHED; GOLD WM, 1972, J APPL PHYSIOL, V33, P719, DOI 10.1152/jappl.1972.33.6.719; GROSS GN, 1974, CHEST, V66, P397, DOI 10.1378/chest.66.4.397; JONES RHT, 1966, BMJ-BRIT MED J, V2, P976, DOI 10.1136/bmj.2.5520.976; JONES RS, 1972, THORAX, V27, P572, DOI 10.1136/thx.27.5.572; KONIG P, 1973, ARCH DIS CHILD, V48, P942, DOI 10.1136/adc.48.12.942; KONIG P, 1972, ARCH DIS CHILD, V47, P578, DOI 10.1136/adc.47.254.578; KONIG P, 1974, J ALLERGY CLIN IMMUN, V54, P14, DOI 10.1016/S0091-6749(74)80003-5; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; KONIG P, 1974, J ALLERG CL, V54, P257; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SILVERMAN M, 1972, BMJ-BRIT MED J, V3, P378, DOI 10.1136/bmj.3.5823.378; SILVERMAN M, 1972, BMJ-BRIT MED J, V1, P207, DOI 10.1136/bmj.1.5794.207; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P419, DOI 10.1136/adc.47.253.419; SLY RM, 1970, ANN ALLERGY, V28, P1; SLY RM, 1967, J ALLERGY, V40, P93, DOI 10.1016/0021-8707(67)90102-5; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823	28	108	109	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	1					1	17		10.1016/0091-6749(75)90029-9	http://dx.doi.org/10.1016/0091-6749(75)90029-9			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AH615	805807	Bronze			2022-12-18	WOS:A1975AH61500001
J	JAFFE, CJ; ATKINSON, JP; GELFAND, JA; FRANK, MM				JAFFE, CJ; ATKINSON, JP; GELFAND, JA; FRANK, MM			HEREDITARY ANGIOEDEMA - USE OF FRESH FROZEN PLASMA FOR PROPHYLAXIS IN PATIENTS UNDERGOING ORAL-SURGERY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,LAB CLIN INVEST,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Gelfand, Jeffrey A/G-1885-2018	Gelfand, Jeffrey A/0000-0002-4118-5676; Atkinson, John/0000-0002-2514-3441				ALKJAERSIG N, 1959, J BIOL CHEM, V234, P832; ATKINSON JW, IN PRESS; CARPENTER CB, 1969, J CLIN INVEST, V48, P1495, DOI 10.1172/JCI106116; COHEN G, 1972, ANN ALLERGY, V30, P690; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1969, J CLIN INVEST, V48, P642, DOI 10.1172/JCI106022; DONALDSON VH, 1972, NEW ENGL J MED, V286, P835, DOI 10.1056/NEJM197204132861510; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; GAITHER TA, 1974, J IMMUNOL, V113, P574; GRUBER UF, 1967, ANN SURG, V165, P41, DOI 10.1097/00000658-196701000-00005; HUTCHISON JL, 1960, J LAB CLIN MED, V56, P734; KLEMPERE.MR, 1969, J CLIN INVEST, V48, pA44; LANDERMAN NS, 1962, J ALLERGY, V33, P316, DOI 10.1016/0021-8707(62)90031-X; LUNDH B, 1968, Clinical and Experimental Immunology, V3, P733; PENCE HL, 1974, J ALLERGY CLIN IMMUN, V53, P298, DOI 10.1016/0091-6749(74)90109-2; PICKERING RJ, 1969, LANCET, V1, P326; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; ROSEN FS, 1969, NEW ENGL J MED, V280, P1356, DOI 10.1056/NEJM196906122802414; RUDDY S, 1967, MECHANISMS INFLAMMAT, P231	20	108	110	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	6					386	393		10.1016/0091-6749(75)90077-9	http://dx.doi.org/10.1016/0091-6749(75)90077-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AE593	1138015				2022-12-18	WOS:A1975AE59300005
J	BUSSE, WW; REED, CE; HOEHNE, JH				BUSSE, WW; REED, CE; HOEHNE, JH			WHERE IS ALLERGIC REACTION IN RAGWEED ASTHMA .2. DEMONSTRATION OF RAGWEED ANTIGEN IN AIRBORNE PARTICLES SMALLER THAN POLLEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; KNOX RB, 1970, NATURE, V225, P1066, DOI 10.1038/2251066a0; NADEL JA, 1962, J APPL PHYSIOL, V17, P861, DOI 10.1152/jappl.1962.17.6.861; REBHUN J, 1954, J ALLERGY, V25, P407, DOI 10.1016/0021-8707(54)90005-2; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671	5	108	108	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	5					289	&		10.1016/0091-6749(72)90027-9	http://dx.doi.org/10.1016/0091-6749(72)90027-9			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N9856	5076354				2022-12-18	WOS:A1972N985600004
J	Schmetzer, O; Lakin, E; Topal, FA; Preusse, P; Freier, D; Church, MK; Maurer, M				Schmetzer, Oliver; Lakin, Elisa; Topal, Fatih A.; Preusse, Patricia; Freier, Denise; Church, Martin K.; Maurer, Marcus			IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-24; IgE; autoantibody; autoallergen; autoallergy; type I hypersensitivity; chronic spontaneous urticaria; wheal and flare; protein microarray; urticaria activity score	FC-EPSILON-RI; DIFFERENTIATION-ASSOCIATED GENE-7; INFLAMMATORY-BOWEL-DISEASE; ANTITHYROID ANTIBODIES; ALPHA AUTOANTIBODIES; HEALTHY DONORS; RECEPTOR; KERATINOCYTES; AUTOIMMUNITY; EXPRESSION	Background: The efficacy of omalizumab (anti-IgE) and increased IgE levels in patients with chronic spontaneous urticaria (CSU) suggest autoallergic mechanisms. Objective: We sought to identify autoallergic targets of IgE in patients with CSU. Methods: Serum samples of patients with CSU together with those of patients with idiopathic anaphylaxis and healthy control subjects (7 of each) were screened for IgE autoantibodies by using an array of more than 9000 proteins. Sera of 1062 patients with CSU and 482 healthy control subjects were used in an IgE-anti IL-24 specific ELISA to investigate the association of IgE-anti-IL-24 and CSU. Results: By using array analyses, more than 200 IgE autoantigens were found in patients with CSU that were not found in control subjects. Of the 31 IgE autoantigens detected in more than 70% of patients, 8 were soluble or membrane bound and expressed in the skin. Of these, only IgE autoantibodies to IL-24 were found in all patients with CSU. In vitro studies showed IL-24 to release histamine from human mast cells sensitized with purified IgE of patients with CSU but not control subjects. By using ELISA, mean SD levels of IgE-anti IL-24 were 0.52 0.24 IU/mL in patients with CSU and 0.27 0.08 IU/mL in control subjects, with 80% of patients with CSU but only 20% of control subjects having levels greater than 0.33 IU/ mL (P <.0001). IgE-anti IL-24 showed acceptable predictive properties for CSU, with a likelihood ratio of 3.9. Clinically, IgE-anti IL-24 levels showed an association with disease activity, as assessed by the urticaria activity score and with reduced basophil counts. Conclusion: Our findings show that patients with CSU frequently exhibit IgE autoantibodies against many autoantigens and that IL-24 is a common, specific, and functional autoantigen of IgE antibodies in patients with CSU.	[Schmetzer, Oliver; Lakin, Elisa; Topal, Fatih A.; Preusse, Patricia; Freier, Denise; Church, Martin K.; Maurer, Marcus] Charite Univ Med Berlin, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schmetzer, O (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany.	oliver.schmetzer@charite.de	Maurer, Marcus/ABG-2174-2020	Maurer, Marcus/0000-0002-4121-481X; Topal, Fatih Alexander/0000-0003-1340-105X; Schmetzer, Oliver/0000-0002-9956-2091	Almirall; FAES Pharma; Menarini; MSD; Novartis; UCB Pharma; Sanofi-Aventis; Uriach; Genentech; FAES; Moxie	Almirall(Almirall); FAES Pharma; Menarini(Menarini Group); MSD; Novartis(Novartis); UCB Pharma(UCB Pharma SA); Sanofi-Aventis(Sanofi-Aventis); Uriach; Genentech(Roche HoldingGenentech); FAES; Moxie	M. K. Church has consultant arrangements with FAES Pharma; has received grants from Almirall, FAES Pharma, Menarini, MSD, Novartis, UCB Pharma, Sanofi-Aventis, and Uriach; and has received payment for manuscript preparation from FAES Pharma. M. Maurer has board memberships with Novartis, Genentech, Uriach, Menarini, FAES, and Moxie; has consultant arrangements with Novartis, Genentech, Uriach, Menarini, FAES, and Moxie; has provided expert testimony for Novartis, Genentech, Uriach, Menarini, FAES, and Moxie; has received grants from Novartis, Genentech, Uriach, Menarini, FAES, and Moxie; and has received payment for lectures from Novartis, Genentech, Uriach, Menarini, FAES, and Moxie. The rest of the authors declare that they have no relevant conflicts of interest.	Altrichter S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014794; Andoh A, 2009, J IMMUNOL, V183, P687, DOI 10.4049/jimmunol.0804169; Bar-Sela S, 1999, J ALLERGY CLIN IMMUN, V103, P1216, DOI 10.1016/S0091-6749(99)70204-6; Bray G W, 1942, Postgrad Med J, V18, P112; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Concha LB, 2004, ALLERGY ASTHMA PROC, V25, P293; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; Fonseca-Camarillo G, 2014, CLIN EXP IMMUNOL, V177, P64, DOI 10.1111/cei.12285; Fux M, 2005, J IMMUNOL METHODS, V307, P107, DOI 10.1016/j.jim.2005.09.014; Grabenhenrich L, 2016, J ALLERGY CLIN IMMUN, V137, P1751, DOI 10.1016/j.jaci.2016.01.043; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Grattan CEH, 2001, J INVEST DERM SYMP P, V6, P139, DOI 10.1046/j.0022-202x.2001.00027.x; Hatada Y, 2013, INT ARCH ALLERGY IMM, V161, P154, DOI 10.1159/000350388; Henault J, 2016, NAT IMMUNOL, V17, P196, DOI 10.1038/ni.3326; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Hofmann SR, 2012, CLIN IMMUNOL, V143, P116, DOI 10.1016/j.clim.2012.02.005; Horn MP, 1999, EUR J IMMUNOL, V29, P1139, DOI 10.1002/(SICI)1521-4141(199904)29:04<1139::AID-IMMU1139>3.0.CO;2-J; Kolkhir P, 2017, CLIN EXP ALLERGY, V47, P19, DOI 10.1111/cea.12870; Kolkhir P, 2017, J ALLERGY CLIN IMMUN, V139, P1772, DOI 10.1016/j.jaci.2016.08.050; Kumari S, 2013, IMMUNITY, V39, P899, DOI 10.1016/j.immuni.2013.10.009; Leng RX, 2011, EXPERT OPIN THER TAR, V15, P119, DOI 10.1517/14728222.2011.534461; Mozena JD, 2010, J INVEST DERMATOL, V130, P1860, DOI 10.1038/jid.2010.35; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; Poindexter NJ, 2010, EXP DERMATOL, V19, P714, DOI 10.1111/j.1600-0625.2010.01077.x; RORSMAN H, 1962, ACTA ALLERGOL, V17, P168, DOI 10.1111/j.1398-9995.1962.tb02937.x; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Sahoo Anupama, 2012, Immune Netw, V12, P1, DOI 10.4110/in.2012.12.1.1; Schmetzer O, 2014, J IMMUNOL METHODS, V413, P62, DOI 10.1016/j.jim.2014.07.003; Tong AW, 2005, MOL THER, V11, P160, DOI 10.1016/j.ymthe.2004.09.021; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Vultaggio A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121857; Zhu HL, 2015, GENOM PROTEOM BIOINF, V13, P210, DOI 10.1016/j.gpb.2015.09.001; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	34	107	111	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					876	882		10.1016/j.jaci.2017.10.035	http://dx.doi.org/10.1016/j.jaci.2017.10.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29208545	Bronze			2022-12-18	WOS:000443726500020
J	Povsic, TJ; Lawrence, MG; Lincoff, AM; Mehran, R; Rusconi, CP; Zelenkofske, SL; Huang, Z; Sailstad, J; Armstrong, PW; Steg, PG; Bode, C; Becker, RC; Alexander, JH; Adkinson, NF; Levinson, AI				Povsic, Thomas J.; Lawrence, Monica G.; Lincoff, A. Michael; Mehran, Roxana; Rusconi, Christopher P.; Zelenkofske, Steven L.; Huang, Zhen; Sailstad, Jeffrey; Armstrong, Paul W.; Steg, P. Gabriel; Bode, Christoph; Becker, Richard C.; Alexander, John H.; Adkinson, N. Franklin; Levinson, Arnold I.		REGULATE-PCI Investigators	Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							POLYETHYLENE-GLYCOL; ANAPHYLAXIS; TRIAL		[Povsic, Thomas J.; Huang, Zhen; Alexander, John H.] Duke Med, Duke Clin Res Inst, Durham, NC 27710 USA; [Lawrence, Monica G.] Univ Virginia, Charlottesville, VA USA; [Lincoff, A. Michael] Cleveland Clin, Coordinating Ctr Clin Res C5Res, Cleveland, OH 44106 USA; [Mehran, Roxana] Mt Sinai Sch Med, New York, NY USA; [Rusconi, Christopher P.; Zelenkofske, Steven L.] Regado Biosci, Basking Ridge, NJ USA; [Sailstad, Jeffrey] Sailstad & Associates Inc, Durham, NC USA; [Armstrong, Paul W.] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada; [Steg, P. Gabriel] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France; [Steg, P. Gabriel] AP HP, Paris, France; [Steg, P. Gabriel] Imperial Coll, NHLI, Royal Brompton Hosp, London, England; [Bode, Christoph] Univ Freiburg, Freiburg, Germany; [Becker, Richard C.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Adkinson, N. Franklin] Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA; [Levinson, Arnold I.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	Duke University; University of Virginia; Cleveland Clinic Foundation; Icahn School of Medicine at Mount Sinai; University of Alberta; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Imperial College London; Royal Brompton Hospital; University of Freiburg; University System of Ohio; University of Cincinnati; Johns Hopkins University; Johns Hopkins Medicine; University of Pennsylvania; Pennsylvania Medicine	Povsic, TJ (corresponding author), Duke Med, Duke Clin Res Inst, Durham, NC 27710 USA.	thomas.povsic@duke.edu	Alexander, John/GVS-7271-2022; Mehran, Roxana/ABF-4160-2021; STEG, Philippe Gabriel/Z-1567-2019	STEG, Philippe Gabriel/0000-0001-6896-2941; Alexander, John/0000-0002-1444-2462; Armstrong, Paul/0000-0002-0460-3445				Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Ganson NJ, 2016, J ALLERGY CLIN IMMUN, V137, P1610, DOI 10.1016/j.jaci.2015.10.034; Garay RP, 2012, EXPERT OPIN DRUG DEL, V9, P1319, DOI 10.1517/17425247.2012.720969; Hershfield MS, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4500; Jiao D, 2013, ALLERGY, V68, P236, DOI 10.1111/all.12089; Lee SH, 2015, INTEST RES, V13, P90, DOI 10.5217/ir.2015.13.1.90; Lincoff AM, 2016, LANCET, V387, P349, DOI 10.1016/S0140-6736(15)00515-2; Povsic TJ, 2013, EUR HEART J, V34, P2481, DOI 10.1093/eurheartj/ehs232; Shah S, 2013, J CLIN PHARMACOL, V53, P352, DOI 10.1177/0091270012447122	9	107	107	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1712	1715		10.1016/j.jaci.2016.04.058	http://dx.doi.org/10.1016/j.jaci.2016.04.058			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27522158	Bronze			2022-12-18	WOS:000390019300030
J	Nagakumar, P; Denney, L; Fleming, L; Bush, A; Lloyd, CM; Saglani, S				Nagakumar, Prasad; Denney, Laura; Fleming, Louise; Bush, Andrew; Lloyd, Clare M.; Saglani, Sejal			Type 2 innate lymphoid cells in induced sputum from children with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLAMMATION; CYTOKINES; IL-33		[Nagakumar, Prasad; Denney, Laura; Fleming, Louise; Bush, Andrew; Lloyd, Clare M.; Saglani, Sejal] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Nagakumar, Prasad; Fleming, Louise; Bush, Andrew; Saglani, Sejal] Royal Brompton Hosp, London SW3 6LY, England	Imperial College London; Royal Brompton Hospital	Saglani, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England.; Saglani, S (corresponding author), Royal Brompton Hosp, London SW3 6LY, England.	s.saglani@imperial.ac.uk	Fleming, Louise/ABD-7452-2020; Saglani, Sejal/AAE-5072-2019	Fleming, Louise/0000-0002-7268-7433; Lloyd, Clare/0000-0001-8977-6726	Wellcome Trust [107059/Z/15/Z] Funding Source: researchfish; Asthma UK [11/051, AUK-AC-2012-01, AUK-IG-2014-269] Funding Source: researchfish; Medical Research Council [MR/J010529/1] Funding Source: Medline; MRC [MR/J010529/1] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Bracken M, 2009, ARCH DIS CHILD, V94, P780, DOI 10.1136/adc.2008.152140; Brasier AR, 2008, J ALLERGY CLIN IMMUN, V121, P30, DOI 10.1016/j.jaci.2007.10.015; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Forsberg A, 2014, J ALLERGY CLIN IMMUN, V134, P228, DOI 10.1016/j.jaci.2014.01.027; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; Lay JC, 2011, INHAL TOXICOL, V23, P392, DOI 10.3109/08958378.2011.575568; Mjosberg J, 2012, EUR J IMMUNOL, V42, P1093, DOI 10.1002/eji.201242549; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; SIGN, 2014, THORAX, V69, P1; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365	13	107	109	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					624	+		10.1016/j.jaci.2015.06.038	http://dx.doi.org/10.1016/j.jaci.2015.06.038			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26277593	Bronze, Green Submitted			2022-12-18	WOS:000369235500037
J	Nolte, H; Maloney, J; Nelson, HS; Bernstein, DI; Lu, S; Li, ZL; Kaur, A; Zieglmayer, P; Zieglmayer, R; Lemell, P; Horak, F				Nolte, Hendrik; Maloney, Jennifer; Nelson, Harold S.; Bernstein, David I.; Lu, Susan; Li, Ziliang; Kaur, Amarjot; Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick; Horak, Friedrich			Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen immunotherapy; allergic rhinoconjunctivitis; house dust mite; sublingual immunotherapy tablet; dose response; dose related; onset of action; environmental exposure chamber; nasal symptoms; ocular symptoms	RANDOMIZED CONTROLLED-TRIAL; CHALLENGE CHAMBER; ALLERGIC RHINITIS; DOUBLE-BLIND; NORTH-AMERICAN; PLACEBO; POLLEN; SAFETY; ADULTS; UNIT	Background: The magnitude of effect of sublingual immunotherapy for house dust mite (HDM)-induced allergic rhinitis with or without conjunctivitis is uncertain, partly because there are few well-controlled trials with well-defined doses. Objective: We sought to determine the dose-related efficacy and onset of action of the HDM sublingual immunotherapy tablet MK-8237 (Merck/ALK-Abello) using the Vienna Challenge Chamber. Methods: In this randomized, double-blind, single-site trial, adults with HDM-induced allergic rhinitis with or without conjunctivitis and with or without asthma (n = 124) received 12 developmental units (DU) of MK-8237, 6 DU of MK-8237, or placebo daily for 24 weeks. Subjects underwent 6-hour exposure challenges at screening and weeks 8, 16, and 24. The total nasal symptom score (TNSS) during chamber challenge at week 24 was the primary end point. The TNSS was the sum of 4 nasal symptom scores (maximum = 12). Total ocular symptom scores (TOSSs; 2 symptoms; maximum = 6) and total symptom scores (TSSs; TSS = TNSS plus TOSS; maximum = 18) were secondary end points. Results: Dose- and time-dependent improvements with MK-8237 versus placebo were observed. At week 24, TNSS improvement relative to placebo was 48.6% (95% CI, 35.3% to 60.2%) with 12 DU of MK-8237 and 26.6% (95% CI, 11.2% to 39.6%) with 6 DU of MK-8237. Statistically significant improvements for TNSSs were also observed at weeks 8 (12 DU of MK-8237) and 16 (6 and 12 DU of MK-8237) and for TOSSs and TSSs by both doses at week 24. MK-8237 was well tolerated. No investigator-assessed anaphylactic allergic reactions or reactions requiring epinephrine were observed. Conclusions: MK-8237, 12 DU, reduced nasal and ocular symptoms and exceeded World Allergy Organization-established clinical efficacy criteria (>= 20% improvement vs placebo). The onset of action for 12 DU of MK-8237 was week 8. MK-8237, 12 DU, is appropriate for further evaluation to determine the magnitude of effect in an uncontrolled allergen exposure environment.	[Nolte, Hendrik; Maloney, Jennifer; Lu, Susan; Li, Ziliang; Kaur, Amarjot] Merck & Co Inc, Kenilworth, NJ USA; [Nelson, Harold S.] Natl Jewish Hlth, Div Allergy & Immunol, Dept Med, Denver, CO USA; [Bernstein, David I.] Univ Cincinnati, Bernstein Allergy Grp, Cincinnati, OH USA; [Bernstein, David I.] Univ Cincinnati, Div Allergy & Immunol, Cincinnati, OH USA; [Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick; Horak, Friedrich] Vienna Challenge Chamber, Vienna, Austria	Merck & Company; National Jewish Health; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Nolte, H (corresponding author), Merck & Co Inc, 1 Merck Dr, Whitehouse Stn, NJ 08889 USA.	Hendrik.nolte@merck.com	Zieglmayer, Petra/AAG-1006-2020	Lemell, Patrick/0000-0003-0262-4047	Merck Co.	Merck Co.(Merck & Company)	Supported by Merck & Co.	ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; Bergmann KC, 2014, J ALLERGY CLIN IMMUN, V133, P1608, DOI 10.1016/j.jaci.2013.11.012; Bozek A, 2013, CLIN EXP ALLERGY, V43, P242, DOI 10.1111/cea.12039; Calderon MA, 2011, ALLERGY, V66, P1345, DOI 10.1111/j.1398-9995.2011.02669.x; Calderon MA, 2013, J ALLERGY CLIN IMMUN, V132, P1322, DOI 10.1016/j.jaci.2013.09.004; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-6; Corzo JL, 2014, J INVEST ALLERG CLIN, V24, P154; Creticos PS, 2013, J ALLERGY CLIN IMMUN, V131, P1342, DOI 10.1016/j.jaci.2013.03.019; Devillier P, 2011, ALLERGY, V66, P163, DOI 10.1111/j.1398-9995.2010.02473.x; Durham SR, 2014, ALLERGY, V69, P617, DOI 10.1111/all.12373; Ellis AK, 2013, ANN ALLERG ASTHMA IM, V111, P323, DOI 10.1016/j.anai.2013.07.019; Hsu NM, 2012, INT FORUM ALLERGY RH, V2, P280, DOI 10.1002/alr.21037; Jacobs RL, 2012, J ALLERGY CLIN IMMUN, V130, P122, DOI 10.1016/j.jaci.2012.03.031; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; Mosbech H, 2014, J ALLERGY CLIN IMMUN, V134, P568, DOI 10.1016/j.jaci.2014.03.019; Nolte H, 2013, ANN ALLERG ASTHMA IM, V110, P450, DOI 10.1016/j.anai.2013.03.013; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Riechelmann H, 2010, AM J RHINOL ALLERGY, V24, pE104, DOI 10.2500/ajra.2010.24.3508; Roux M, 2013, J ALLERGY CLIN IMMUN, V131, pAB37, DOI 10.1016/j.jaci.2012.12.816; Stubner P, 2004, CURR MED RES OPIN, V20, P891, DOI 10.1185/030079904125003700; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Wang DH, 2013, LARYNGOSCOPE, V123, P1334, DOI 10.1002/lary.23935; Yukselen A, 2013, ASIAN PAC J ALLERGY, V31, P233, DOI 10.12932/AP0276.31.3.2013; Zieglmayer P, 2008, CURR MED RES OPIN, V24, P1833, DOI 10.1185/03007990802155792	25	107	108	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1494	U165		10.1016/j.jaci.2014.12.1911	http://dx.doi.org/10.1016/j.jaci.2014.12.1911			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25636947				2022-12-18	WOS:000355933400012
J	Magnani, A; Brosselin, P; Beaute, J; de Vergnes, N; Mouy, R; Debre, M; Suarez, F; Hermine, O; Lortholary, O; Blanche, S; Fischer, A; Mahlaoui, N				Magnani, Alessandra; Brosselin, Pauline; Beaute, Julien; de Vergnes, Nathalie; Mouy, Richard; Debre, Marianne; Suarez, Felipe; Hermine, Olivier; Lortholary, Olivier; Blanche, Stephane; Fischer, Alain; Mahlaoui, Nizar			Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic granulomatous disease; inflammation; primary immunodeficiency; granuloma; inflammatory bowel diseases; macrophage; granulomatous; interstitial lung disease	QUALITY-OF-LIFE; CLINICAL-FEATURES; CROHNS-DISEASE; ALPHA BLOCKADE; COMPLICATIONS; THALIDOMIDE; CGD; HYPERINFLAMMATION; CHILDREN; CARRIERS	Background: Chronic granulomatous disease (CGD) is a rare phagocytic disorder that results in not only infections but also potentially severe inflammatory manifestations that can be difficult to diagnose and treat. Objective: To describe inflammatory manifestations in a single-center cohort of patients with CGD. Methods: Medical records of patients treated at Necker-Enfants Malades Hospital (Paris, France) between 1968 and 2009 and registered at the French National Reference Center for Primary Immunodeficiencies (CEREDIH) were retrospectively reviewed. Results: In a study population of 98 patients, a total of 221 inflammatory episodes were recorded in 68 individuals (69.4%). The incidence rate of inflammatory episodes was 0.15 per person-year (0.18 in patients with X-linked [XL] CGD and 0.08 in patients with autosomal-recessive [AR] CGD). The most commonly affected organs were the gastrointestinal tract (in 88.2% of the patients), lungs (26.4%), the urogenital tract (17.6%), and eyes (8.8%). Inflammation at other sites (the skin, central nervous system, and tympanum) and autoimmune manifestations (lupus, arthritis, etc) were recorded in 19.1% and 10.3% of the patients, respectively. Granuloma was found in 50% of the 44 histological analyses reviewed. The risk of inflammatory episodes was 2-fold higher in patients with XL-CGD than in patients with AR-CGD (relative risk, 2.22; 95% CI, 1.43-3.46). Conclusions: Patients with XL-CGD have a higher risk of developing inflammatory episodes than do patients with AR-CGD. Although the most commonly affected organ is the gastrointestinal tract, other sites can be involved, making the management of patients with CGD a complex, multidisciplinary task.	[Magnani, Alessandra; Mouy, Richard; Debre, Marianne; Blanche, Stephane; Fischer, Alain; Mahlaoui, Nizar] Hop Univ Necker Enfants Malades, AP HP, Serv Immunohematol & Rhumatol Pediat, Paris, France; [Magnani, Alessandra; Brosselin, Pauline; Beaute, Julien; de Vergnes, Nathalie; Debre, Marianne; Suarez, Felipe; Hermine, Olivier; Lortholary, Olivier; Blanche, Stephane; Fischer, Alain; Mahlaoui, Nizar] Hop Necker Enfants Malad, AP HP, Ctr Reference Deficits Immunitaires Hereditaires, Paris, France; [Magnani, Alessandra; Brosselin, Pauline; de Vergnes, Nathalie; Suarez, Felipe; Hermine, Olivier; Lortholary, Olivier; Blanche, Stephane; Fischer, Alain; Mahlaoui, Nizar] Univ Paris 05, Inst Imagine, Sorbonne Paris Cite, Paris, France; [Suarez, Felipe; Hermine, Olivier] Hop Univ Necker Enfants Malades, AP HP, Serv Hematol Adultes, Paris, France; [Lortholary, Olivier] Hop Univ Necker Enfants Malades, AP HP, Serv Malad Infect & Trop, Paris, France; [Fischer, Alain] Coll France, Paris, France; [Mahlaoui, Nizar] Hop Univ Necker Enfants Malades, INSERM, Lab Genet Humaine Malad Infect, U1163, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mahlaoui, N (corresponding author), Hop Necker Enfants Malad, AP HP, Ctr Reference Deficits Immunitaires Hereditaires, Paris, France.	nizar.mahlaoui@nck.aphp.fr	Mahlaoui, Nizar/J-7928-2017; Hermine, Olivier/Q-7072-2018; Magnani, Alessandra/H-8231-2017; MAHLAOUI, Nizar/AAH-6103-2020	Mahlaoui, Nizar/0000-0002-0030-8094; Magnani, Alessandra/0000-0002-0674-9288; MAHLAOUI, Nizar/0000-0002-0030-8094; Hermine, Olivier/0000-0003-2574-3874	French Ministry of Health; French Association of Patients with Primary Immunodeficiencies (IRIS: Immuno-deficience primitive-recherche-information-soutien); LFB; CSL Behring; Baxter Biosciences; GSK; Pfizer; Octapharma; Orphan-Europe	French Ministry of Health; French Association of Patients with Primary Immunodeficiencies (IRIS: Immuno-deficience primitive-recherche-information-soutien); LFB; CSL Behring; Baxter Biosciences; GSK(GlaxoSmithKline); Pfizer(Pfizer); Octapharma; Orphan-Europe	This study was funded by the French Ministry of Health and received additional support from the French Association of Patients with Primary Immunodeficiencies (IRIS: Immuno-deficience primitive-recherche-information-soutien). The Centre de Reference des Deficits Immunitaires Hereditaires (CEREDIH) received unrestricted educational grants from LFB, CSL Behring, Baxter Biosciences, GSK, Pfizer, Octapharma, and Orphan-Europe.	Ahlin A, 1995, ACTA PAEDIATR, V84, P1386, DOI 10.1111/j.1651-2227.1995.tb13575.x; Alimchandani M, 2013, AM J SURG PATHOL, V37, P1365, DOI 10.1097/PAS.0b013e318297427d; Alvarez-Downing MM, 2013, DIS COLON RECTUM, V56, P609, DOI 10.1097/DCR.0b013e3182781504; Arlet JB, 2008, EUR J GASTROEN HEPAT, V20, P142, DOI 10.1097/MEG.0b013e328277ef5f; Barese CN, 2004, J PEDIAT HEMATOL ONC, V26, P209, DOI 10.1097/00043426-200403000-00014; Beaute J, 2010, CLIN IMMUNOL, V135, P264, DOI 10.1016/j.clim.2010.02.021; BRIDGES RA, 1959, AMA J DIS CHILD, V97, P387, DOI 10.1001/archpedi.1959.02070010389004; Cale CM, 2007, CLIN EXP IMMUNOL, V148, P79, DOI 10.1111/j.1365-2249.2007.03321.x; Cole T, 2013, J ALLERGY CLIN IMMUN, V132, P1150, DOI 10.1016/j.jaci.2013.05.031; Cole T, 2013, J CLIN IMMUNOL, V33, P8, DOI 10.1007/s10875-012-9758-0; De Ravin SS, 2008, J ALLERGY CLIN IMMUN, V122, P1097, DOI 10.1016/j.jaci.2008.07.050; Deffert C, 2011, J ALLERGY CLIN IMMUN, V128, P675, DOI 10.1016/j.jaci.2011.04.028; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Goldblatt D, 1999, J PEDIATR-US, V134, P780, DOI 10.1016/S0022-3476(99)70299-4; Gungor T, 2014, LANCET, V383, P436, DOI [10.1016/s0140-6736(13)62069-3, 10.1016/S0140-6736(13)62069-3]; Hasui M, 1999, PEDIATR INT, V41, P589; Holland SM, 2010, CLIN REV ALLERG IMMU, V38, P3, DOI 10.1007/s12016-009-8136-z; Huang A, 2006, COLORECTAL DIS, V8, P637, DOI 10.1111/j.1463-1318.2006.01030.x; Jones LBKR, 2008, CLIN EXP IMMUNOL, V152, P211, DOI 10.1111/j.1365-2249.2008.03644.x; Kawai T, 2013, CLIN IMMUNOL, V147, P122, DOI 10.1016/j.clim.2013.03.004; Kobayashi S, 2008, EUR J PEDIATR, V167, P1389, DOI 10.1007/s00431-008-0680-7; Koker MY, 2013, J ALLERGY CLIN IMMUN, V132, P1156, DOI 10.1016/j.jaci.2013.05.039; Levine S, 2005, HISTOPATHOLOGY, V47, P508, DOI 10.1111/j.1365-2559.2005.02258.x; Liu S, 2009, INFLAMM BOWEL DIS, V15, P1213, DOI 10.1002/ibd.20890; Mahdaviani SA, 2013, EXPERT REV CLIN IMMU, V9, P153, DOI [10.1586/ECI.12.98, 10.1586/eci.12.98]; Marciano BE, 2004, PEDIATRICS, V114, P462, DOI 10.1542/peds.114.2.462; Mariette X, 2010, ANN RHEUM DIS, V69, P400, DOI 10.1136/ard.2009.117762; Marks DJB, 2009, AM J GASTROENTEROL, V104, P117, DOI 10.1038/ajg.2008.72; Martinez CA, 2012, J ALLERGY CLIN IMMUN, V129, P176, DOI 10.1016/j.jaci.2011.10.005; Martire B, 2008, CLIN IMMUNOL, V126, P155, DOI 10.1016/j.clim.2007.09.008; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Noel N, 2013, J ALLERGY CLIN IMMUN, V132, P997, DOI 10.1016/j.jaci.2013.04.059; Reyes SOL, 2011, J ALLERGY CLIN IMMUN, V127, P543, DOI 10.1016/j.jaci.2010.10.049; Rosenzweig SD, 2008, J CLIN IMMUNOL, V28, pS67, DOI 10.1007/s10875-007-9160-5; Rosenzweig SD, 2009, EXPERT REV CLIN IMMU, V5, P45, DOI 10.1586/1744666X.5.1.45; Salmon-Ceron D, 2011, ANN RHEUM DIS, V70, P616, DOI 10.1136/ard.2010.137422; Schappi MG, 2008, SEMIN IMMUNOPATHOL, V30, P255, DOI 10.1007/s00281-008-0119-2; Schappi MG, 2003, J PEDIATR GASTR NUTR, V36, P623, DOI 10.1097/00005176-200305000-00006; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Seger RA, 2010, NETH J MED, V68, P334; Sokol H, 2009, AM J GASTROENTEROL, V104, P1069, DOI 10.1038/ajg.2009.56; Soler-Palacin P, 2007, ALLERGOL IMMUNOPATH, V35, P83, DOI 10.1157/13106774; Uzel G, 2010, CLIN INFECT DIS, V51, P1429, DOI 10.1086/657308; van den Berg JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005234; van der Have M, 2014, J CROHNS COLITIS, V8, P93, DOI 10.1016/j.crohns.2013.04.007; Wang YJ, 2013, J CLIN IMMUNOL, V33, P917, DOI 10.1007/s10875-013-9899-9; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; Wolach B, 2008, CLIN IMMUNOL, V129, P103, DOI 10.1016/j.clim.2008.06.012	48	107	110	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					655	+		10.1016/j.jaci.2014.04.014	http://dx.doi.org/10.1016/j.jaci.2014.04.014			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24985400	Bronze			2022-12-18	WOS:000341372400019
J	De Boever, EH; Ashman, C; Cahn, AP; Locantore, NW; Overend, P; Pouliquen, IJ; Serone, AP; Wright, TJ; Jenkins, MM; Panesar, IS; Thiagarajah, SS; Wenzel, SE				De Boever, Erika H.; Ashman, Claire; Cahn, Anthony P.; Locantore, Nicholas W.; Overend, Phil; Pouliquen, Isabelle J.; Serone, Adrian P.; Wright, Tracey J.; Jenkins, Mair M.; Panesar, Inderpal S.; Thiagarajah, Sivayogan S.; Wenzel, Sally E.			Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: A randomized trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-13; IL13R alpha 1; IL13R alpha 2; efficacy; safety; pharmacokinetics; pharmacodynamics	MONOCLONAL-ANTIBODIES; UNCONTROLLED DISEASE; IL-13; INFLAMMATION; RECEPTOR; INTERLEUKIN-13; HYPERRESPONSIVENESS; QUESTIONNAIRE; EXPRESSION; INDUCTION	Background: Approximately 5% to 10% of asthmatic patients achieve incomplete symptom control on current therapies. The association of IL-13 with asthma pathology and reduced corticosteroid sensitivity suggests a potential benefit of anti-IL-13 therapy in refractory asthma. GSK679586, a humanized mAb, inhibits IL-13 binding to both IL-13 receptor alpha 1 and alpha 2. Objectives: We sought to evaluate the efficacy and safety of GSK679586 in patients with severe asthma refractory to maximally indicated doses of inhaled corticosteroids. Methods: Patients who remained symptomatic (Asthma Control Questionnaire score >= 1.5) after uptitration to 1000 mu g/d fluticasone propionate or greater were randomized to 3 once-monthly intravenous infusions of 10 mg/kg GSK679586 (n = 99) or placebo (n = 99). Results: Treatment differences in adjusted mean change from baseline over 12 weeks were nonsignificant for Asthma Control Questionnaire symptom scores (the primary end point; GSK679586 = -0.31, placebo = -0.17, P = .058) and FEV1 (GSK679586 = -0.01, placebo = 0.03, P = .276). Similar analyses in patients with increased serum IgE levels, blood eosinophil counts, or both were also negative. Incidence of asthma exacerbations was similar between treatments. Most adverse events were nonserious and unrelated to treatment. Two GSK679586-treated patients had treatment-related serious adverse events (lethargy and supraventricular extrasystoles). Conclusions: Although well tolerated, GSK679586 did not demonstrate clinically meaningful improvements in asthma control, pulmonary function, or exacerbations in patients with severe asthma. Further studies are needed to determine whether therapies targeting IL-13, the functionally related IL-4 cytokine, or both can provide clinical benefit in patients with severe refractory asthma or a subpopulation of these patients beyond that achievable with high-dose corticosteroids.	[De Boever, Erika H.] GlaxoSmithKline, Alternat Discovery & Dev, King Of Prussia, PA USA; [Ashman, Claire; Wright, Tracey J.] GlaxoSmithKline, Biopharm Res, Stevenage, Herts, England; [Cahn, Anthony P.] GlaxoSmithKline, Resp Discovery Med, Stevenage, Herts, England; [Locantore, Nicholas W.] GlaxoSmithKline, Resp Med Dev, Res Triangle Pk, NC USA; [Overend, Phil] GlaxoSmithKline, Biopharm Clin Stat 2, Stevenage, Herts, England; [Pouliquen, Isabelle J.] GlaxoSmithKline, Clin Pharmacol Modeling & Simulat, Middlesex, England; [Serone, Adrian P.] Genentech Inc, Res & Early Dev, San Francisco, CA USA; [Jenkins, Mair M.] GlaxoSmithKline, Emerging Markets R&D, Brentford, England; [Panesar, Inderpal S.] ISP Pharma, Birmingham, W Midlands, England; [Thiagarajah, Sivayogan S.] Janssen Pharmaceut, Global Med Safety, High Wycombe, Bucks, England; [Wenzel, Sally E.] Univ Pittsburgh, Med Ctr, Asthma Inst, Pittsburgh, PA USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Roche Holding; Genentech; GlaxoSmithKline; Johnson & Johnson; Janssen Pharmaceuticals; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	De Boever, EH (corresponding author), GlaxoSmithKline UW2291, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.	erika.h.deboever@gsk.com	Serone, Adrian/AAF-1918-2020	Serone, Adrian/0000-0002-4615-3438; Wenzel, Sally/0000-0002-4242-0164	GlaxoSmithKline Research and Development; GlaxoSmithKline; ISP Pharma; Array Biopharma	GlaxoSmithKline Research and Development(GlaxoSmithKline); GlaxoSmithKline(GlaxoSmithKline); ISP Pharma; Array Biopharma(Pfizer)	The design, conduct, analysis, and publication of this research were sponsored by GlaxoSmithKline Research and Development. S. E. W. received compensation from GlaxoSmithKline for participation in a study-related advisory board meeting and help with study design and has also received consultancy fees from GlaxoSmithKline. I. S. P. received compensation from GlaxoSmithKline for study management. S. S. T. is a former employee of GlaxoSmithKline. A. P. S. is a shareholder of GlaxoSmithKline and former full-time employee of the company. P.O. is a shareholder and employee of GlaxoSmithKline currently on sabbatical at LSHTM University of London.; I. S. Panesar has received one or more consulting fees or honoraria from ISP Pharma. S. S. Thiagarajah and A. P. Serone were formerly employed by and own stock/stock options in GlaxoSmithKline and are currently employed by and own stock/stock options in Janssen Pharmaceutical Companies of Johnson & Johnson and Genentech, respectively. S. E. Wenzel has been supported by one or more grants from GlaxoSmithKline, has consultancy arrangements with Janssen Pharmaceutical Companies of Johnson & Johnson, has received one or more grants from or has one or more grants pending with Array Biopharma, and owns stock/stock options in Amgen, MedImmune, and Sanofi Aventis. The rest of the authors are employed by and own stock/stock options in GlaxoSmithKline.	Allahverdian S, 2008, AM J RESP CELL MOL, V38, P153, DOI 10.1165/rcmb.2007-0173OC; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bradding P, 2010, CURR OPIN ALLERGY CL, V10, P54, DOI 10.1097/ACI.0b013e32833489a9; Breekveldt-Postma NS, 2008, CURR MED RES OPIN, V24, P975, DOI [10.1185/030079908X280518, 10.1185/030079908X280518 ]; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Dirks NL, 2010, CLIN PHARMACOKINET, V49, P633, DOI 10.2165/11535960-000000000-00000; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Fulkerson PC, 2006, AM J RESP CELL MOL, V35, P337, DOI 10.1165/rcmb.2005-0474OC; Green RH, 2007, CURR OPIN ALLERGY CL, V7, P43, DOI 10.1097/ACI.0b013e3280118a32; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Hodsman P, 2013, BRIT J CLIN PHARMACO, V75, P118, DOI 10.1111/j.1365-2125.2012.04334.x; Jatakanon A, 1999, THORAX, V54, P108, DOI 10.1136/thx.54.2.108; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330, DOI 10.1164/ajrccm.162.4.9912138; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kasaian MT, 2011, J IMMUNOL, V187, P561, DOI 10.4049/jimmunol.1100467; Kraft M, 2001, J ALLERGY CLIN IMMUN, V107, P602, DOI 10.1067/mai.2001.113760; LAN KKG, 1988, BIOMETRICS, V44, P579, DOI 10.2307/2531870; LaPorte SL, 2008, CELL, V132, P259, DOI 10.1016/j.cell.2007.12.030; Littell RC, 2006, SAS MIXED MODELS; Lupardus PJ, 2010, STRUCTURE, V18, P332, DOI 10.1016/j.str.2010.01.003; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Newcomb DC, 2013, CURR OPIN IMMUNOL, V25, P755, DOI 10.1016/j.coi.2013.08.002; Newcomb DC, 2011, J ALLERGY CLIN IMMUN, V127, P1006, DOI 10.1016/j.jaci.2010.11.043; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Ruiz-Gonzalez V, 2009, INT J DERMATOL, V48, P846, DOI 10.1111/j.1365-4632.2008.03924.x; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; Shah DK, 2013, MABS-AUSTIN, V5, P297, DOI 10.4161/mabs.23684; Spahn JD, 1996, J IMMUNOL, V157, P2654; Strober W, 2009, CURR MOL MED, V9, P740, DOI 10.2174/156652409788970652; Sullivan SD, 2007, ALLERGY, V62, P126, DOI 10.1111/j.1398-9995.2006.01254.x; Tabrizi M, 2010, AAPS J, V12, P33, DOI 10.1208/s12248-009-9157-5; Townley RG, 2009, ANN ALLERG ASTHMA IM, V102, P190, DOI 10.1016/S1081-1206(10)60080-4; Wenzel S, INHALED PITRAKINRA I; Wenzel Sally, 2003, Paediatr Respir Rev, V4, P306, DOI 10.1016/S1526-0542(03)00095-2; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yang GY, 2004, CYTOKINE, V28, P224, DOI 10.1016/j.cyto.2004.08.007; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	43	107	108	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					989	+		10.1016/j.jaci.2014.01.002	http://dx.doi.org/10.1016/j.jaci.2014.01.002			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24582316	Bronze			2022-12-18	WOS:000333531700006
J	Nijman, IJ; van Montfrans, JM; Hoogstraat, M; Boes, ML; van de Corput, L; Renner, ED; van Zon, P; van Lieshout, S; Elferink, MG; van der Burg, M; Vermont, CL; van der Zwaag, B; Janson, E; Cuppen, E; van Amstel, JKP; van Gijn, ME				Nijman, Isaac J.; van Montfrans, Joris M.; Hoogstraat, Marlous; Boes, Marianne L.; van de Corput, Lisette; Renner, Ellen D.; van Zon, Patrick; van Lieshout, Stef; Elferink, Martin G.; van der Burg, Mirjam; Vermont, Clementien L.; van der Zwaag, Bert; Janson, Esther; Cuppen, Edwin; van Amstel, Johannes K. Ploos; van Gijn, Marielle E.			Targeted next-generation sequencing: A novel diagnostic tool for primary immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; diagnosis; genetics; next-generation sequencing	GENOMIC ENRICHMENT; WHOLE-EXOME; IDENTIFICATION; MUTATIONS	Background: Primary immunodeficiency (PID) disorders are a heterogeneous group of inherited disorders caused by a variety of monogenetic immune defects. Thus far, mutations in more than 170 different genes causing PIDs have been described. A clear genotype-phenotype correlation is often not available, which makes a genetic diagnosis in patients with PIDs complex and laborious. Objective: We sought to develop a robust, time-effective, and cost-effective diagnostic method to facilitate a genetic diagnosis in any of 170 known PID-related genes by using next-generation sequencing (NGS). Methods: We used both targeted array-based and in-solution enrichment combined with a SOLiD sequencing platform and a bioinformatic pipeline developed in house to analyze genetic changes in the DNA of 41 patients with PIDs with known mutations and 26 patients with undiagnosed PIDs. Results: This novel NGS-based method accurately detected point mutations (sensitivity and specificity >99% in covered regions) and exonic deletions (100% sensitivity and specificity). For the 170 genes of interest, the DNA coverage was greater than 203 in 90% to 95%. Nine PID-related genes proved not eligible for evaluation by using this NGS-based method because of inadequate coverage. The NGS method allowed us to make a genetic diagnosis in 4 of 26 patients who lacked a genetic diagnosis despite routine functional and genetic testing. Three of these patients proved to have an atypical presentation of previously described PIDs. Conclusion: This novel NGS tool facilitates accurate simultaneous detection of mutations in 161 of 170 known PID-related genes. In addition, these analyses will generate more insight into genotype-phenotype correlations for the different PID disorders.	[Nijman, Isaac J.; van Zon, Patrick; van Lieshout, Stef; Elferink, Martin G.; van der Zwaag, Bert; Janson, Esther; Cuppen, Edwin; van Amstel, Johannes K. Ploos; van Gijn, Marielle E.] Univ Med Ctr Utrecht, Dept Med Genet, NL-3508 AB Utrecht, Netherlands; [van Montfrans, Joris M.; Boes, Marianne L.] Univ Med Ctr Utrecht, Dept Pediat Immunol & Infect Dis, NL-3508 AB Utrecht, Netherlands; [Hoogstraat, Marlous] Univ Med Ctr Utrecht, Dept Med Oncol, NL-3508 AB Utrecht, Netherlands; [van de Corput, Lisette] Univ Med Ctr Utrecht, Dept Immunol, NL-3508 AB Utrecht, Netherlands; [Renner, Ellen D.] Univ Munich, Univ Childrens Hosp, Dept Immunol, Munich, Germany; [van der Burg, Mirjam] Univ Med Ctr Rotterdam, Dept Immunol, Erasmus MC, Rotterdam, Netherlands; [Vermont, Clementien L.] Leiden Univ, Dept Pediat Infect Dis Immunol & Stem Cell Transp, Med Ctr, NL-2300 RA Leiden, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Gijn, ME (corresponding author), Univ Med Ctr Utrecht, Dept Med Genet, Lundlaan 6, NL-3508 AB Utrecht, Netherlands.	m.e.vangijn@umcutrecht.nl	Cuppen, Edwin/F-5696-2011; Cuppen, Edwin/H-2389-2016; Hoogstraat, Marlous/ABD-2968-2021; Renner, Ellen/R-7168-2016; Vermont, Clementien/GVT-8580-2022	Cuppen, Edwin/0000-0002-0400-9542; Cuppen, Edwin/0000-0002-0400-9542; Renner, Ellen/0000-0001-9816-8538; Boes, Marianne/0000-0003-2590-1692; Nijman, Isaac/0000-0002-1840-1158; Hoogstraat, Marlous/0000-0002-4916-1177	Vrienden van het Wilhelmina Kinderziekenhuis Foundation; Fonds Nuts Ohra [16.13004]; NGI [93515510]; German Research Foundation [DFG RE2799/3-1]	Vrienden van het Wilhelmina Kinderziekenhuis Foundation; Fonds Nuts Ohra; NGI; German Research Foundation(German Research Foundation (DFG))	Supported by the Vrienden van het Wilhelmina Kinderziekenhuis Foundation and Fonds Nuts Ohra (grant no. 16.13004 to M.E.v.G., J.M.v.M., L.v.d.C., and M.L.B.), NGI (Horizon Valorization grant no. 93515510 to M.E.v.G.), and the German Research Foundation (grant no. DFG RE2799/3-1 to E.D.R.).	Abraham Roshini S, 2011, Clin Mol Allergy, V9, P6, DOI 10.1186/1476-7961-9-6; Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; Aradhya S, 2001, HUM MOL GENET, V10, P2557, DOI 10.1093/hmg/10.22.2557; Badolato R, 2012, BLOOD, V119, P3185, DOI 10.1182/blood-2012-01-404350; Brown L, 2011, BLOOD, V117, P3243, DOI 10.1182/blood-2010-08-300384; Chou J, 2012, CURR OPIN ALLERGY CL, V12, P623, DOI 10.1097/ACI.0b013e3283588ca6; de Greef JC, 2011, AM J HUM GENET, V88, P796, DOI 10.1016/j.ajhg.2011.04.018; Ghosh S, 2012, SCAND J IMMUNOL, V75, P350, DOI 10.1111/j.1365-3083.2011.02658.x; Harakalova M, 2011, NAT PROTOC, V6, P1870, DOI 10.1038/nprot.2011.396; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Hoischen A, 2010, HUM MUTAT, V31, P492, DOI 10.1002/humu.21221; Iglewicz B., 1993, DETECT HANDLE OUTLIE; Joshi AY, 2009, MAYO CLIN PROC, V84, P16, DOI [10.4065/84.1.16, 10.1016/S0025-6196(11)60802-1]; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Moshous D, 2013, J ALLERGY CLIN IMMUN, V131, P1594, DOI 10.1016/j.jaci.2013.01.042; Nijman IJ, 2010, NAT METHODS, V7, P913, DOI 10.1038/nmeth.1516; Noack D, 2001, BLOOD, V97, P305, DOI 10.1182/blood.V97.1.305; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Resnick ES, 2012, CURR OPIN ALLERGY CL, V12, P595, DOI 10.1097/ACI.0b013e32835914b9; Slatter MA, 2011, ANN NY ACAD SCI, V1238, P122, DOI 10.1111/j.1749-6632.2011.06243.x; Valencia CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053083; van der Burg M, 2011, EUR J PEDIATR, V170, P561, DOI 10.1007/s00431-011-1452-3; Yong PFK, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4069; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	24	107	112	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					529	+		10.1016/j.jaci.2013.08.032	http://dx.doi.org/10.1016/j.jaci.2013.08.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24139496				2022-12-18	WOS:000332397100029
J	Busse, W; Spector, S; Rosen, K; Wang, Y; Alpan, O				Busse, William; Spector, Sheldon; Rosen, Karin; Wang, Yan; Alpan, Oral			High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RECOMBINANT HUMAN DEOXYRIBONUCLEASE; RETICULAR BASEMENT-MEMBRANE; EXHALED NITRIC-OXIDE; STATUS-ASTHMATICUS; DIFFICULT ASTHMA; ALLERGIC-ASTHMA; FATAL ASTHMA; HUMAN DNASE; CHILDREN; AIRWAYS		[Busse, William] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA; [Spector, Sheldon] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA; [Rosen, Karin; Wang, Yan] Genentech Inc, San Francisco, CA 94080 USA; [Alpan, Oral] O&O Alpan LLC, Sect Immunopathogenesis, Fairfax, VA USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Roche Holding; Genentech	Busse, W (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA.	rosen.karin@gene.com		Wang, Yan/0000-0003-3430-2210				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 2012, GLOB STRAT ASTHM MAN; [Anonymous], 2010, OM XOL LAB; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Boogaard R, 2008, THORAX, V63, P141, DOI 10.1136/thx.2007.081703; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chung KF, 2004, EXPERT OPIN PHARMACO, V5, P439, DOI 10.1517/eoph.5.2.439.26465; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; Durward A, 2000, CRIT CARE MED, V28, P560, DOI 10.1097/00003246-200002000-00045; Fuchs SI, 2008, PEDIATR PULM, V43, P731, DOI 10.1002/ppul.20825; Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983; GERSHAN WM, 1994, PEDIATR PULM, V18, P268, DOI 10.1002/ppul.1950180414; Global Initiative for Asthma, 2002, NHLBI WHO WORKSH; GREALLY P, 1995, LANCET, V346, P1423, DOI 10.1016/S0140-6736(95)92436-1; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; Massanari M, 2010, RESP MED, V104, P188, DOI 10.1016/j.rmed.2009.09.011; MAXWELL GM, 1985, J ASTHMA, V22, P131, DOI 10.3109/02770908509073131; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Donnell AE, 1998, CHEST, V113, P1329, DOI 10.1378/chest.113.5.1329; Patel A, 2000, BRIT J ANAESTH, V84, P505, DOI 10.1093/oxfordjournals.bja.a013479; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Payne DNR, 2004, THORAX, V59, P862, DOI 10.1136/thx.2003.017244; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Polgar G, 1971, PULMONARY FUNCTION T; Price David, 2008, Prim Care Respir J, V17, P62, DOI 10.3132/pcrj.2008.00031; Prussin Calman, 2003, Journal of Allergy and Clinical Immunology, V111, pS486; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rogers DF, 2004, CURR OPIN PHARMACOL, V4, P241, DOI 10.1016/j.coph.2004.01.011; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138, DOI 10.1164/ajrccm/143.1.138; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P308, DOI 10.1159/000237010; Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; van der Giessen LJ, 2007, PEDIATR PULM, V42, P624, DOI 10.1002/ppul.20636; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; Walsh LJ, 1999, THORAX, V54, P296, DOI 10.1136/thx.54.4.296; Zapletal A., 1977, Z ERKR ATMUNGSORGANE, V149, P343	39	107	113	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					485	+		10.1016/j.jaci.2013.02.032	http://dx.doi.org/10.1016/j.jaci.2013.02.032			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23591271	hybrid			2022-12-18	WOS:000322631700031
J	Muehleisen, B; Gallo, RL				Muehleisen, Beda; Gallo, Richard L.			Vitamin D in allergic disease: Shedding light on a complex problem	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; allergy; immune function; atopic dermatitis; asthma	ANTIMICROBIAL PEPTIDE EXPRESSION; 25-HYDROXYVITAMIN D LEVELS; REGULATORY T-CELLS; 1,25-DIHYDROXYVITAMIN D-3; D-RECEPTOR; D SUPPLEMENTATION; ATOPIC-DERMATITIS; CHILDHOOD ASTHMA; D DEFICIENCY; SKIN	Vitamin D is unique among nutritional factors because the intake of this special vitamin represents the sum of vitamin D obtained from diet, nutritional supplements, and endogenous production after exposure to sunlight. The current recommended nutritional intake requirements reflect needs based on its established role in calcium absorption and bone health. However, recent studies have revealed that vitamin D has important functions in the immune system and might influence the course of immune-mediated disorders, including atopic dermatitis and asthma. This review discusses the scientific rationale for a role for vitamin D in immune function, gives an update on allergic disease associations with lower vitamin D serum levels, and discusses recent observations relating to vitamin D in immune function. (J Allergy Clin Immunol 2013;131:324-9.)	[Muehleisen, Beda; Gallo, Richard L.] Univ Calif San Diego, Div Dermatol, La Jolla, CA 92093 USA; [Gallo, Richard L.] Vet Adm San Diego Healthcare Syst, San Diego, CA USA	University of California System; University of California San Diego	Gallo, RL (corresponding author), MC 0869,9500 Gilman Dr, La Jolla, CA 92093 USA.	rgallo@ucsd.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861	Swiss National Science Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	B. Muehleisen has received a grant for Advanced Researchers from the Swiss National Science Foundation. R. L. Gallo declares that he has no conflicts of interest.	Back O, 2009, ACTA DERM-VENEREOL, V89, P28, DOI 10.2340/00015555-0541; Biggs L, 2010, J EXP MED, V207, P455, DOI 10.1084/jem.20091725; Bikle DD, 2010, J STEROID BIOCHEM, V121, P308, DOI 10.1016/j.jsbmb.2010.03.027; Bogh MKB, 2010, J INVEST DERMATOL, V130, P546, DOI 10.1038/jid.2009.323; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Buchau AS, 2010, J IMMUNOL, V184, P369, DOI 10.4049/jimmunol.0902110; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Campbell GR, 2011, J BIOL CHEM, V286, P18890, DOI 10.1074/jbc.M110.206110; Chang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012925; Christakos S, 1996, BIOCHEM J, V316, P361, DOI 10.1042/bj3160361; Daynes RA, 1996, INFECT IMMUN, V64, P1100, DOI 10.1128/IAI.64.4.1100-1109.1996; De Luca G, 2010, J MATERN-FETAL NEO M, V23, P80, DOI 10.3109/14767058.2010.509931; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Erkkola M, 2009, CLIN EXP ALLERGY, V39, P875, DOI 10.1111/j.1365-2222.2009.03234.x; Fabri M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003045; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; Gallo RL, 2012, NAT REV IMMUNOL, V12, P503, DOI 10.1038/nri3228; Ghoreishi M, 2009, J IMMUNOL, V182, P6071, DOI 10.4049/jimmunol.0804064; Gibney KB, 2008, CLIN INFECT DIS, V46, P443, DOI 10.1086/525268; Goleva E, 2012, J ALLERGY CLIN IMMUN, V129, P1243, DOI 10.1016/j.jaci.2012.01.044; Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com; Gorman S, 2010, J STEROID BIOCHEM, V121, P247, DOI 10.1016/j.jsbmb.2010.02.034; Gorman S, 2010, IMMUNOLOGY, V130, P181, DOI 10.1111/j.1365-2567.2009.03222.x; Hartmann B, 2011, ALLERGY, V66, P540, DOI 10.1111/j.1398-9995.2010.02513.x; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Hawker NP, 2007, J INVEST DERMATOL, V127, P874, DOI 10.1038/sj.jid.5700624; Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385; Hong SP, 2008, J INVEST DERMATOL, V128, P2880, DOI 10.1038/jid.2008.169; Hughes AM, 2011, PEDIAT ALLERG IMM-UK, V22, P327, DOI 10.1111/j.1399-3038.2010.01099.x; Hypponen E, 2009, ALLERGY, V64, P613, DOI 10.1111/j.1398-9995.2008.01865.x; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Jirapongsananuruk O, 2000, J ALLERGY CLIN IMMUN, V106, P981, DOI 10.1067/mai.2000.110101; Jorde R, 2010, CYTOKINE, V50, P175, DOI 10.1016/j.cyto.2009.12.006; Khoo AL, 2011, CLIN EXP IMMUNOL, V164, P72, DOI 10.1111/j.1365-2249.2010.04315.x; Kreindler JL, 2010, J CLIN INVEST, V120, P3242, DOI 10.1172/JCI42388; Kull I, 2006, J ALLERGY CLIN IMMUN, V118, P1299, DOI 10.1016/j.jaci.2006.08.022; LEMIRE JM, 1995, J NUTR, V125, pS1704, DOI 10.1093/jn/125.suppl_6.1704S; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P1075, DOI 10.1016/j.jaci.2008.03.005; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Loser K, 2009, INT IMMUNOPHARMACOL, V9, P587, DOI 10.1016/j.intimp.2009.01.024; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; Majak P, 2011, J ALLERGY CLIN IMMUN, V127, P1294, DOI 10.1016/j.jaci.2010.12.016; Matheu V, 2003, J ALLERGY CLIN IMMUN, V112, P585, DOI [10.1016/S0091-6749(03)01855-4, 10.1037/mai.2003.1703]; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Muehleisen B, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003759; Muthian G, 2006, J NEUROSCI RES, V83, P1299, DOI 10.1002/jnr.20826; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Nurmatov U, 2011, J ALLERGY CLIN IMMUN, V127, P724, DOI 10.1016/j.jaci.2010.11.001; Nwaru BI, 2010, PEDIAT ALLERG IMM-UK, V21, P29, DOI 10.1111/j.1399-3038.2009.00949.x; Palmer MT, 2011, J BIOL CHEM, V286, P997, DOI 10.1074/jbc.M110.163790; Peroni DG, 2011, BRIT J DERMATOL, V164, P1078, DOI 10.1111/j.1365-2133.2010.10147.x; Piemonti L, 2000, J IMMUNOL, V164, P4443, DOI 10.4049/jimmunol.164.9.4443; Robinson DS, 2009, CLIN EXP ALLERGY, V39, P1314, DOI 10.1111/j.1365-2222.2009.03301.x; Rosen CJ, 2012, J CLIN ENDOCR METAB, V97, P1146, DOI 10.1210/jc.2011-2218; Sadeghi K, 2006, EUR J IMMUNOL, V36, P361, DOI 10.1002/eji.200425995; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Schauber J, 2006, IMMUNOLOGY, V118, P509, DOI 10.1111/j.1365-2567.2006.02399.x; Sharief S, 2011, J ALLERGY CLIN IMMUN, V127, P1195, DOI 10.1016/j.jaci.2011.01.017; Sidbury R, 2008, BRIT J DERMATOL, V159, P245, DOI 10.1111/j.1365-2133.2008.08601.x; Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094; Vahavihu K, 2010, BRIT J DERMATOL, V163, P321, DOI 10.1111/j.1365-2133.2010.09767.x; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Wu SP, 2010, AM J PATHOL, V177, P686, DOI 10.2353/ajpath.2010.090998; Yu SH, 2008, P NATL ACAD SCI USA, V105, P20834, DOI 10.1073/pnas.0808700106; Yuk JM, 2009, CELL HOST MICROBE, V6, P231, DOI 10.1016/j.chom.2009.08.004	66	107	110	1	38	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					324	329		10.1016/j.jaci.2012.12.1562	http://dx.doi.org/10.1016/j.jaci.2012.12.1562			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23374263				2022-12-18	WOS:000314661500007
J	Cox, LS; Casale, TB; Nayak, AS; Bernstein, DI; Creticos, PS; Ambroisine, L; Melac, M; Zeldin, RK				Cox, Linda S.; Casale, Thomas B.; Nayak, Anjuli S.; Bernstein, David I.; Creticos, Peter S.; Ambroisine, Laurence; Melac, Michel; Zeldin, Robert K.			Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: The importance of allergen-specific serum IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Double-blind; placebo-controlled trial; allergy; allergic rhinoconjunctivitis; grass pollen; specific immunotherapy; sublingual immunotherapy tablet; combined score; grass-specific IgE	INTRADERMAL SKIN-TESTS; QUALITY-OF-LIFE; IMMUNOTHERAPY TABLETS; FATAL REACTIONS; UNITED-STATES; PRICK TESTS; RHINITIS; SAFETY; DIAGNOSIS; CHILDREN	Background: Previous trials have demonstrated the efficacy, safety, and optimal dosage of the 5-grass pollen sublingual tablet for adults and children with grass pollen-induced allergic rhinoconjunctivitis. Objectives: We sought to evaluate the efficacy and safety of 300 index of reactivity (IR) 5-grass pollen sublingual tablet in US adults. Methods: Adults with grass pollen allergy and Rhinoconjunctivitis Total Symptom Scores of 12 or greater (scale, 0-18) during the previous grass pollen season were randomized in a double-blind, placebo-controlled study to receive 300IR 5-grass pollen sublingual tablet or placebo starting 4 months before and continuing through the pollen season. The primary efficacy end point was the daily Combined Score (CS; scale, 0-3), which integrates symptoms and rescue medication use. Results: Four hundred seventy-three participants were randomized. The mean daily CS over the pollen period was significantly lower in the active treatment group versus the placebo group (least-squares mean difference: 20.13; 95% CI, -0.19 to -0.06; P = .0003; relative reduction: 28.2%; 95% CI, 13.0% to 43.4%). In placebo-treated participants, the daily CS least-squares mean was 0.32 in the subgroup with baseline timothy grass-specific serum IgE of less than 0.1 kU/L (n = 23) and 0.46 in those with baseline timothy grass-specific serum IgE of 0.1 kU/L or greater (n = 204). The most frequent reported adverse events were oral pruritus, throat irritation, and nasopharyngitis. There were no reports of anaphylaxis, and no actively treated participant received epinephrine. Conclusion: In US adults with grass pollen-induced allergic rhinoconjunctivitis, preseasonal and coseasonal treatment with 300IR 5-grass pollen sublingual tablet demonstrated clinically meaningful efficacy, especially in study subjects with measurable timothy grass-specific serum IgE. Use of 300IR 5-grass pollen sublingual tablet was safe and well tolerated. A requirement for a measurable level of allergen-specific serum IgE should be considered in future studies in this field. (J Allergy Clin Immunol 2012;130:1327-34.)	[Cox, Linda S.] Nova SE Univ, Ft Lauderdale, FL 33314 USA; [Casale, Thomas B.] Creighton Univ, Dept Med, Div Allergy & Immunol, Omaha, NE 68178 USA; [Nayak, Anjuli S.] Sneeze Wheeze & Itch Associates LLC, Normal, IL USA; [Bernstein, David I.] Univ Cincinnati, Coll Med, Div Immunol Allergy & Rheumatol, Cincinnati, OH USA; [Creticos, Peter S.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Ambroisine, Laurence; Melac, Michel; Zeldin, Robert K.] Stallergenes SA, Antony, France	Nova Southeastern University; Creighton University; University System of Ohio; University of Cincinnati; Johns Hopkins University; Stallergenes Greer	Cox, LS (corresponding author), 5333 N Dixie Highway, Ft Lauderdale, FL 33334 USA.	lindaswolfcox@msn.com	m, m/GZB-2153-2022; Casale, Thomas B/K-4334-2013; Cox, Linda/AAP-1697-2021	Casale, Thomas B/0000-0002-3149-7377; Cox, Linda/0000-0002-5258-6870	Stallergenes SA, Antony, France; Genentech/Novartis; Teva; Baxter; Thermo Fisher and Stallergenes; Stallergenes; Merck/Schering-Plough; Merck; Greer; ALK Abello; AHRQ; Greer Laboratories	Stallergenes SA, Antony, France; Genentech/Novartis(Roche HoldingGenentech); Teva(Teva Pharmaceutical Industries); Baxter; Thermo Fisher and Stallergenes; Stallergenes; Merck/Schering-Plough(Merck & CompanySchering Plough Corporation); Merck(Merck & Company); Greer; ALK Abello; AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Greer Laboratories	Supported by Stallergenes SA, Antony, France.; L. S. Cox has received consulting fees, honoraria for lectures, and/or research funding from Genentech/Novartis, Teva, Baxter, Thermo Fisher and Stallergenes. T. B. Casale has received consultancy fees from Stallergenes; has received research support from Stallergenes and Merck/Schering-Plough; is on the World Allergy Organization Board of Directors; and is the American Academy of Allergy, Asthma & Immunology (AAAAI) Executive VP. A. S. Nayak is an employee of Sneeze, Wheeze, and Itch Associates LLC and has received research grants, educational support, honoraria, and/or consultancy fees from Stallergenes. D. I. Bernstein has received research support from Stallergenes, Merck, and Greer; is a member of the AAAAI Immunotherapy Committee; and has received consultancy and advisory fees from Merck and ALK Abello. P. S. Creticos is a consultant to Circassia, Greer Laboratories Merck/Schering-Plough, Stallergenes, and UpToDate; has received grant support from AHRQ, Greer Laboratories, Merck/Schering-Plough, and Stallergenes; and has committee assignments for the AAAAI and American College of Allergy, Asthma & Immunology. The rest of the authors declare that they have no relevant conflicts of interest.	Amin HS, 2006, J ALLERGY CLIN IMMUN, V117, P169, DOI 10.1016/j.jaci.2005.10.010; Benninger M, 2010, ANN ALLERG ASTHMA IM, V104, P13, DOI 10.1016/j.anai.2009.11.020; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Blaiss MS, 2007, ALLERGY ASTHMA PROC, V28, P393, DOI 10.2500/aap.2007.28.3013; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Cox L, 2008, J ALLERGY CLIN IMMUN, V122, P432, DOI 10.1016/j.jaci.2008.06.007; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; Cox L, 2009, ANN ALLERG ASTHMA IM, V103, P451, DOI 10.1016/S1081-1206(10)60259-1; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Di Lorenzo G, 2009, J ALLERGY CLIN IMMUN, V123, P1103, DOI 10.1016/j.jaci.2009.02.012; Didier A, 2009, ALLERGY, V64, P166, DOI 10.1111/j.1398-9995.2008.01767.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Didier A, 2011, J ALLERGY CLIN IMMUN, V128, P559, DOI 10.1016/j.jaci.2011.06.022; Grouin JM, 2011, CLIN EXP ALLERGY, V41, P1282, DOI 10.1111/j.1365-2222.2011.03700.x; Hamilton RG, 2010, J ALLERGY CLIN IMMUN, V126, P33, DOI 10.1016/j.jaci.2010.03.014; Hankin CS, 2010, ANN ALLERG ASTHMA IM, V104, P79, DOI 10.1016/j.anai.2009.11.010; *HEALTHSTAR COMM I, 2006, ALL AM LANDM SURV NA; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Leger D, 2006, ARCH INTERN MED, V166, P1744, DOI 10.1001/archinte.166.16.1744; Malling HJ, 2009, CLIN EXP ALLERGY, V39, P387, DOI 10.1111/j.1365-2222.2008.03152.x; Meltzer EO, 2001, J ALLERGY CLIN IMMUN, V108, pS45, DOI 10.1067/mai.2001.115566; Moingeon P, 2008, INT ARCH ALLERGY IMM, V146, P338, DOI 10.1159/000121468; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Nelson HS, 2007, J ALLERGY CLIN IMMUN, V119, P769, DOI 10.1016/j.jaci.2007.01.036; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Penagos M, 2008, ALLERGY, V63, P1280, DOI 10.1111/j.1398-9995.2008.01808.x; Pradalier A, 2007, ALLERGY, V62, P1331, DOI 10.1111/j.1398-9995.2007.01374.x; Rodrigo GJ, 2006, ANN ALLERG ASTHMA IM, V96, P779, DOI 10.1016/S1081-1206(10)61339-7; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Sharma HP, 2008, J ALLERGY CLIN IMMUN, V121, P933, DOI 10.1016/j.jaci.2008.01.023; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7	34	107	107	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1327	+		10.1016/j.jaci.2012.08.032	http://dx.doi.org/10.1016/j.jaci.2012.08.032			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23122534	Bronze			2022-12-18	WOS:000311641100013
J	Tepper, RS; Wise, RS; Covar, R; Irvin, CG; Kercsmar, CM; Kraft, M; Liu, MC; O'Connor, GT; Peters, SP; Sorkness, R; Togias, A				Tepper, Robert S.; Wise, Robert S.; Covar, Ronina; Irvin, Charles G.; Kercsmar, Carolyn M.; Kraft, Monica; Liu, Mark C.; O'Connor, George T.; Peters, Stephen P.; Sorkness, Ronald; Togias, Alkis			Asthma outcomes: Pulmonary physiology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Spirometry; airway responsiveness; peak expiratory flow monitoring; lung volumes; gas exchange	PEAK EXPIRATORY FLOW; EXERCISE-INDUCED BRONCHOCONSTRICTION; COLD-AIR CHALLENGE; EXHALED NITRIC-OXIDE; METHACHOLINE-INDUCED BRONCHOCONSTRICTION; NONSPECIFIC BRONCHIAL RESPONSIVENESS; LEUKOTRIENE-RECEPTOR ANTAGONIST; NASAL INSPIRATORY FLOW; LUNG-FUNCTION; BRONCHODILATOR RESPONSIVENESS	Background: Outcomes of pulmonary physiology have a central place in asthma clinical research. Objective: At the request of National Institutes of Health (NIH) institutes and other federal agencies, an expert group was convened to provide recommendations on the use of pulmonary function measures as asthma outcomes that should be assessed in a standardized fashion in future asthma clinical trials and studies to allow for cross-study comparisons. Methods: Our subcommittee conducted a comprehensive search of PubMed to identify studies that focused on the validation of various airway response tests used in asthma clinical research. The subcommittee classified the instruments as core (to be required in future studies), supplemental (to be used according to study aims and in a standardized fashion), or emerging (requiring validation and standardization). This work was discussed at an NIH-organized workshop in March 2010 and finalized in September 2011. Results: A list of pulmonary physiology outcomes that applies to both adults and children older than 6 years was created. These outcomes were then categorized into core, supplemental, and emerging. Spirometric outcomes (FEV1, forced vital capacity, and FEV1/forced vital capacity ratio) are proposed as core outcomes for study population characterization, for observational studies, and for prospective clinical trials. Bronchodilator reversibility and prebronchodilator and postbronchodilator FEV1 also are core outcomes for study population characterization and observational studies. Conclusions: The subcommittee considers pulmonary physiology outcomes of central importance in asthma and proposes spirometric outcomes as core outcomes for all future NIH-initiated asthma clinical research. (J Allergy Clin Immunol 2012; 129: S65-87.)	[Togias, Alkis] NIAID, DAIT, NIH, Bethesda, MD 20892 USA; [Tepper, Robert S.] Indiana Univ, Indianapolis, IN 46204 USA; [Wise, Robert S.; Liu, Mark C.] Johns Hopkins Univ, Baltimore, MD USA; [Covar, Ronina] Natl Jewish Hlth, Denver, CO USA; [Irvin, Charles G.] Univ Vermont, Burlington, VT 05405 USA; [Kercsmar, Carolyn M.] Cincinnati Childrens Hosp, Cincinnati, OH USA; [Kraft, Monica] Duke Univ, Durham, NC 27706 USA; [O'Connor, George T.] Boston Univ, Boston, MA 02215 USA; [Peters, Stephen P.] Wake Forest Univ, Winston Salem, NC 27109 USA; [Sorkness, Ronald] Univ Wisconsin, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Indiana University System; Indiana University-Purdue University Indianapolis; Johns Hopkins University; National Jewish Health; University of Vermont; Cincinnati Children's Hospital Medical Center; Duke University; Boston University; Wake Forest University; University of Wisconsin System; University of Wisconsin Madison	Togias, A (corresponding author), NIAID, DAIT, NIH, 6610 Rockledge Dr, Bethesda, MD 20892 USA.	togiasa@niaid.nih.gov		Wise, Robert/0000-0002-8353-2349; O'Connor, George/0000-0002-6476-3926	National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Environmental Health Sciences; Agency for Healthcare Research and Quality; Merck Childhood Asthma Network; Robert Wood Johnson Foundation; US Environmental Protection Agency; GlaxoSmithKline; Boehringer-Ingelheim; Merck; Forest; NIH; American Lung Association; Asthmatx; Eumedics; Novartis; Genentech; MedImmune; Sanofi-Aventis; Amgen	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Merck Childhood Asthma Network; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); US Environmental Protection Agency(United States Environmental Protection Agency); GlaxoSmithKline(GlaxoSmithKline); Boehringer-Ingelheim(Boehringer Ingelheim); Merck(Merck & Company); Forest; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lung Association; Asthmatx; Eumedics; Novartis(Novartis); Genentech(Roche HoldingGenentech); MedImmune(AstraZenecaMedimmune); Sanofi-Aventis(Sanofi-Aventis); Amgen(Amgen)	The Asthma Outcomes work shop was funded by contributions from the National Institute of Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; the Agency for Healthcare Research and Quality; and the Merck Childhood Asthma Network, as well as by a grant from the Robert Wood Johnson Foundation. Contributions from the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; and the US Environmental Protection Agency funded the publication of this article and all other articles in this supplement.; Disclosure of potential conflict of interest: R. S. Tepper has received research support from the NHLBI. R. S. Wise is a consultant for GlaxoSmithKline, AstraZeneca, Novartis, Boehringer-Ingelheim, Merck, and Sunovion; and has received research support from GlaxoSmithKline, Boehringer-Ingelheim, Merck, and Forest. R. Covar has received research support from the NHLBI. C. G. Irvin has received research support from the NIH and the American Lung Association. M. Kraft has received research support from GlaxoSmithKline, Merck, Asthmatx, Eumedics, Novartis, and Genentech. M. C. Liu has received research support from GlaxoSmithKline, MedImmune, Sanofi-Aventis, and Amgen. G. T. O'Connor is a consultant for Sunovion Inc and has received research support from Novartis. R. Sorkness has received research support from the NIH. The rest of the authors declare that they have no relevant conflicts of interest.	Anderson SD, 2008, CURR OPIN PULM MED, V14, P39, DOI 10.1097/MCP.0b013e3282f197f6; Anderson SD, 2006, CLIN REV ALLERG IMMU, V31, P163, DOI 10.1385/CRIAI:31:2:163; Anderson SD, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-4; ANDERSON SD, 1985, EUR J RESPIR DIS, V67, P20; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758, DOI 10.1164/ajrccm.156.3.9701113; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; [Anonymous], 1999, Am J Respir Crit Care Med, V160, P2104; [Anonymous], 2008, PROV US PACK INS; Ansarin K, 2001, EUR RESPIR J, V17, P934, DOI 10.1183/09031936.01.17509340; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14, DOI 10.1164/arrd.1986.133.1.14; AQUILINA AT, 1983, THORAX, V38, P766, DOI 10.1136/thx.38.10.766; Aurora P, 2005, AM J RESP CRIT CARE, V171, P249, DOI 10.1164/rccm.200407-895OC; Barben J, 2003, PEDIATR PULM, V36, P490, DOI 10.1002/ppul.10378; BECKLAKE MR, 1952, THORAX, V7, P111, DOI 10.1136/thx.7.1.111; Bentur Lea, 2005, BMC Pediatr, V5, P19, DOI 10.1186/1471-2431-5-19; Berman AR, 1996, AM J RESP CRIT CARE, V154, P418, DOI 10.1164/ajrccm.154.2.8756816; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; BIBI H, 1991, PEDIATR PULM, V10, P244, DOI 10.1002/ppul.1950100404; Bisgaard H, 2000, AM J RESP CRIT CARE, V162, P187, DOI 10.1164/ajrccm.162.1.9910039; Bisgaard H, 2005, CHEST, V128, P355, DOI 10.1378/chest.128.1.355; Black LD, 2004, J APPL PHYSIOL, V96, P1808, DOI 10.1152/japplphysiol.01170.2003; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; BRAND PLP, 1992, THORAX, V47, P429, DOI 10.1136/thx.47.6.429; BRAND PLP, 1991, AM REV RESPIR DIS, V143, P916, DOI 10.1164/ajrccm/143.5_Pt_1.916; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120, DOI 10.1164/ajrccm.158.4.9802087; Brannan JD, 2000, AM J RESP CRIT CARE, V161, P2096, DOI 10.1164/ajrccm.161.6.9908096; Brannan JD, 2006, EUR RESPIR J, V27, P944, DOI 10.1183/09031936.06.00078205; BRITTON J, 1994, EUR RESPIR J, V7, P881; Brouwer AFJ, 2008, EUR RESPIR J, V32, P1262, DOI 10.1183/09031936.00148107; Brown RH, 2006, J APPL PHYSIOL, V101, P30, DOI 10.1152/japplphysiol.01190.2005; Burke RR, 2009, J ASTHMA, V46, P740, DOI 10.1080/02770900903082589; Calverley PMA, 2003, THORAX, V58, P659, DOI 10.1136/thorax.58.8.659; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Chapman DG, 2008, EUR RESPIR J, V32, P1563, DOI 10.1183/09031936.00114007; Chhabra SK, 2005, J ASTHMA, V42, P367, DOI 10.1081/JAS-200062992; Cockcroft DW, 2005, CHEST, V127, P839, DOI 10.1378/chest.127.3.839; COLEBATCH HJ, 1973, J APPL PHYSIOL, V34, P143, DOI 10.1152/jappl.1973.34.2.143; COLLARD P, 1994, CHEST, V105, P1426, DOI 10.1378/chest.105.5.1426; CORRE KA, 1985, ANN EMERG MED, V14, P45, DOI 10.1016/S0196-0644(85)80735-6; COULTAS DB, 1988, AM REV RESPIR DIS, V138, P1386, DOI 10.1164/ajrccm/138.6.1386; Cournand A, 1941, J CLIN INVEST, V20, P681, DOI 10.1172/JCI101261; Covar RA, 2006, J ALLERGY CLIN IMMUN, V117, P709, DOI 10.1016/j.jaci.2006.01.010; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Currie GP, 2003, CLIN EXP ALLERGY, V33, P783, DOI 10.1046/j.1365-2222.2003.01688.x; Davis Beth E, 2005, Can Respir J, V12, P26; De Baets F, 2005, PEDIATR PULM, V39, P301, DOI 10.1002/ppul.20185; DEAL EC, 1978, J APPL PHYSIOL, V45, P238, DOI 10.1152/jappl.1978.45.2.238; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; DOERSHUK CF, 1974, AM REV RESPIR DIS, V109, P452; Donohue James F, 2005, COPD, V2, P111; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; Dundas I, 2005, THORAX, V60, P13, DOI 10.1136/thx.2004.029934; Duong M, 2008, CHEST, V133, P404, DOI 10.1378/chest.07-2048; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V63, P104, DOI 10.1016/0091-6749(79)90199-4; Eid N, 2000, PEDIATRICS, V105, P354, DOI 10.1542/peds.105.2.354; ELIASSON AH, 1992, CHEST, V102, P347, DOI 10.1378/chest.102.2.347; ENBERG RN, 1991, ANN ALLERGY, V67, P371; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215, DOI 10.1164/ajrccm/143.6.1215; Enright PL, 2004, AM J RESP CRIT CARE, V169, P235, DOI 10.1164/rccm.200204-347OC; Enright PL, 1997, CHEST, V112, P895, DOI 10.1378/chest.112.4.895; FILUK RB, 1989, CHEST, V95, P948, DOI 10.1378/chest.95.5.948; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; FOURIE PR, 1988, PEDIATR PULM, V4, P2, DOI 10.1002/ppul.1950040103; Frank R, 2001, AM J RESP CRIT CARE, V164, P1253, DOI 10.1164/ajrccm.164.7.2010043; Frey U, 2005, NATURE, V438, P667, DOI 10.1038/nature04176; Fruchter O, 2009, J ASTHMA, V46, P951, DOI 10.3109/02770900903265796; Fuhlbrigge AL, 2006, PEDIATRICS, V118, pE347, DOI 10.1542/peds.2005-2962; GALDESSEBALDT M, 1985, J PEDIATR-US, V107, P526, DOI 10.1016/S0022-3476(85)80009-3; Gannon PFG, 1997, EUR RESPIR J, V10, pS57; Gelb AF, 2002, CHEST, V121, P715, DOI 10.1378/chest.121.3.715; GODFREY S, 1991, THORAX, V46, P488, DOI 10.1136/thx.46.7.488; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; Goedhart Dick M, 2006, COPD, V3, P33, DOI 10.1080/15412550500493261; GOLD WM, 1967, J APPL PHYSIOL, V23, P433, DOI 10.1152/jappl.1967.23.4.433; Goldberg S, 2001, CHEST, V120, P482, DOI 10.1378/chest.120.2.482; Goldstein MF, 2001, CHEST, V119, P1001, DOI 10.1378/chest.119.4.1001; Guntupalli KK, 2008, J ASTHMA, V45, P903, DOI 10.1080/02770900802386008; GUYATT GH, 1988, ARCH INTERN MED, V148, P1949, DOI 10.1001/archinte.148.9.1949; HABY MM, 1995, EUR RESPIR J, V8, P729; HABY MM, 1994, EUR RESPIR J, V7, P43, DOI 10.1183/09031936.94.07010043; Hakim F, 2007, CHEST, V131, P180, DOI 10.1378/chest.06-1402; Hall GL, 2007, THORAX, V62, P521, DOI 10.1136/thx.2006.067835; Hallen H, 1999, ACTA OTO-LARYNGOL, V119, P921; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hankinson JL, 1998, EUR RESPIR J, V11, P787; Hansen JE, 2008, RESP MED, V102, P1777, DOI 10.1016/j.rmed.2008.06.019; Herpel LB, 2006, AM J RESP CRIT CARE, V173, P1106, DOI 10.1164/rccm.200506-975OC; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; HIGGINS BG, 1992, AM REV RESPIR DIS, V145, P588, DOI 10.1164/ajrccm/145.3.588; HIGGINS BG, 1993, THORAX, V48, P899, DOI 10.1136/thx.48.9.899; HILBERG O, 1989, J APPL PHYSIOL, V66, P295, DOI 10.1152/jappl.1989.66.1.295; Hilberg O, 2002, ALLERGY, V57, P5, DOI 10.1046/j.0908-665x.2001.all.doc.x; HOLMSTROM M, 1990, Rhinology (Utrecht), V28, P191; Horsley AR, 2008, THORAX, V63, P135, DOI 10.1136/thx.2007.082628; IRVIN CG, 1987, SEMIN RESPIR MED, V8, P201, DOI 10.1055/s-2007-1012658; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; Jayet PY, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-131; JONES RS, 1963, ARCH DIS CHILD, V38, P539, DOI 10.1136/adc.38.202.539; Joos GF, 2003, EUR RESPIR J, V21, P1050, DOI 10.1183/09031936.03.00008403; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; Kainu A, 2008, CHEST, V134, P387, DOI 10.1378/chest.07-2207; KAMINSKY DA, 1995, AM J RESP CRIT CARE, V152, P1784, DOI 10.1164/ajrccm.152.6.8520737; Kaminsky DA, 1997, AM J RESP CRIT CARE, V155, P1260, DOI 10.1164/ajrccm.155.4.9105064; Kaminsky DA, 2000, AM J RESP CRIT CARE, V162, P179, DOI 10.1164/ajrccm.162.1.9806079; Kawai M, 2007, RESP MED, V101, P2488, DOI 10.1016/j.rmed.2007.07.001; Kelly AM, 2002, J EMERG MED, V22, P15, DOI 10.1016/S0736-4679(01)00431-0; Kersten ETG, 2009, PEDIATR PULM, V44, P655, DOI 10.1002/ppul.21034; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Koga T, 2006, J ASTHMA, V43, P71, DOI 10.1080/02770900500448662; KONIG P, 1989, ALLERGY PROC, V10, P345, DOI 10.2500/108854189778959830; Koskela HO, 2003, CHEST, V124, P1341, DOI 10.1378/chest.124.4.1341; Kostikas K, 2008, COPD, V5, P171, DOI 10.1080/15412550802093009; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1551, DOI 10.1164/ajrccm.163.7.2008013; Kraft M, 2006, CHEST, V130, P1726, DOI 10.1378/chest.130.6.1726; Lall CA, 2007, EUR RESPIR J, V30, P260, DOI 10.1183/09031936.00064006; Lambert PC, 2004, STAT MED, V23, P3821, DOI 10.1002/sim.1951; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Lazo-Velasquez JC, 2005, PEDIATR PULM, V40, P457, DOI 10.1002/ppul.20275; LEBOWITZ MD, 1982, CHEST, V81, P566, DOI 10.1378/chest.81.5.566; Lee SY, 2006, PEDIATR PULM, V41, P1161, DOI 10.1002/ppul.20506; Lee WW, 2000, AM J EMERG MED, V18, P427, DOI 10.1053/ajem.2000.7330; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Loeb JS, 2008, PEDIATR PULM, V43, P1020, DOI 10.1002/ppul.20908; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; MANSELL A, 1974, J APPL PHYSIOL, V37, P297, DOI 10.1152/jappl.1974.37.3.297; Mansur AH, 2008, RESP MED, V102, P42, DOI 10.1016/j.rmed.2007.08.007; Martin RJ, 1997, CHEST, V112, P53, DOI 10.1378/chest.112.1.53; MARTIN TR, 1987, J APPL PHYSIOL, V63, P2042, DOI 10.1152/jappl.1987.63.5.2042; Mattke S, 2009, PEDIATRICS, V123, pS199, DOI 10.1542/peds.2008-2233K; McCormack MC, 2008, RESP CARE, V53, P583; MCFADDEN ER, 1985, J CLIN INVEST, V76, P1007, DOI 10.1172/JCI112052; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; McFadden ER, 1996, AM J RESP CRIT CARE, V153, P942, DOI 10.1164/ajrccm.153.3.8630577; MEAD J, 1967, J APPL PHYSIOL, V22, P95, DOI 10.1152/jappl.1967.22.1.95; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; MODL M, 1995, EUR RESPIR J, V8, P1742, DOI 10.1183/09031936.95.08101742; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Naqvi M, 2007, J ASTHMA, V44, P639, DOI 10.1080/02770900701554441; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; National Asthma Education and Prevention Program NH Lung and Blood Institute National Institutes of Health US Department of Health and Human Services., 2007, 3 US DEP HLTH HUM SE; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; Nielsen KG, 2000, AM J RESP CRIT CARE, V162, P1500, DOI 10.1164/ajrccm.162.4.2002019; Nielsen KG, 2000, AM J RESP CRIT CARE, V161, P1805, DOI 10.1164/ajrccm.161.6.9905098; Nielsen KG, 2001, AM J RESP CRIT CARE, V164, P554, DOI 10.1164/ajrccm.164.4.2006119; OBYRNE PM, 1983, AM REV RESPIR DIS, V128, P611; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P1520, DOI 10.1164/ajrccm/140.6.1520; ODONNELL WJ, 1992, AM REV RESPIR DIS, V146, P1518, DOI 10.1164/ajrccm/146.6.1518; Oostveen E, 2003, EUR RESPIR J, V22, P1026, DOI 10.1183/09031936.03.00089403; PAOLETTI P, 1995, AM J RESP CRIT CARE, V151, P1770, DOI 10.1164/ajrccm.151.6.7767519; Parsons JP, 2007, MED SCI SPORT EXER, V39, P1487, DOI 10.1249/mss.0b013e3180986e45; PATTEMORE PK, 1993, CLIN EXP ALLERGY, V23, P886, DOI 10.1111/j.1365-2222.1993.tb00273.x; Paull K, 2005, PEDIATR PULM, V39, P311, DOI 10.1002/ppul.20161; Peebles RS, 2001, J ALLERGY CLIN IMMUN, V107, P805; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; PERESS L, 1976, AM J MED, V61, P165, DOI 10.1016/0002-9343(76)90165-0; Peters SP, 2008, ALLERGY ASTHMA PROC, V29, P499, DOI 10.2500/aap.2008.29.3147; PHILLIPS YY, 1985, AM REV RESPIR DIS, V131, P31; POOL JB, 1989, RESP MED, V83, P433, DOI 10.1016/S0954-6111(89)80077-0; Porsbjerg C, 2008, CLIN EXP ALLERGY, V38, P43, DOI 10.1111/j.1365-2222.2007.02878.x; QUACKENBOSS JJ, 1991, AM REV RESPIR DIS, V143, P323, DOI 10.1164/ajrccm/143.2.323; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reddel HK, 2005, THORAX, V60, P164, DOI 10.1136/thx.2004.030437; REDDEL HK, 1995, AM J RESP CRIT CARE, V151, P1320, DOI 10.1164/ajrccm.151.5.7735580; Reid DW, 2003, RESPIROLOGY, V8, P479, DOI 10.1046/j.1440-1843.2003.00495.x; REISMAN J, 1987, PEDIATR PULM, V3, P251, DOI 10.1002/ppul.1950030410; Remes ST, 2002, THORAX, V57, P120, DOI 10.1136/thorax.57.2.120; Riccioni G, 2001, ALLERGY ASTHMA PROC, V22, P5, DOI 10.2500/108854101778249221; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; Ruppel GL, 2003, MANUAL PULMONARY FUN; Santanello NC, 1999, EUR RESPIR J, V14, P23, DOI 10.1034/j.1399-3003.1999.14a06.x; Saydain G, 2004, CHEST, V125, P446, DOI 10.1378/chest.125.2.446; SCHUMACHER MJ, 1989, J ALLERGY CLIN IMMUN, V83, P711, DOI 10.1016/0091-6749(89)90001-8; SEPPALA OP, 1990, RESP MED, V84, P387, DOI 10.1016/S0954-6111(08)80073-X; Silkoff PE, 1999, AM J RHINOL, V13, P131, DOI 10.2500/105065899782106689; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; SMITH HR, 1992, CHEST, V101, P1577, DOI 10.1378/chest.101.6.1577; SOLWAY J, 1985, AM REV RESPIR DIS, V132, P666; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Spooner CH, 1998, COCHRANE LIB, V3; STANBROOK MB, 1995, CHEST, V107, P992, DOI 10.1378/chest.107.4.992; Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC; Stanojevic S, 2009, AM J RESP CRIT CARE, V180, P547, DOI 10.1164/rccm.200903-0323OC; Starling-Schwanz R, 2005, ALLERGY, V60, P795, DOI 10.1111/j.1398-9995.2005.00779.x; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Stocks J, 1996, INFANT RESP FUNCTION; Subbarao P, 2006, J ALLERGY CLIN IMMUN, V117, P1008, DOI 10.1016/j.jaci.2005.11.048; Sutherland ER, 2004, J ALLERGY CLIN IMMUN, V113, P1046, DOI 10.1016/j.jaci.2004.03.016; Sverrild A, 2009, J ALLERGY CLIN IMMUN, V124, P928, DOI 10.1016/j.jaci.2009.06.028; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tantucci C, 1999, EUR RESPIR J, V14, P295; Taplidou SA, 2007, COMPUT BIOL MED, V37, P1073, DOI 10.1016/j.compbiomed.2006.09.007; Tashkin DP, 2008, EUR RESPIR J, V31, P742, DOI 10.1183/09031936.00129607; TATTERSFIELD AE, 1979, BRIT J CLIN PHARMACO, V8, P307, DOI 10.1111/j.1365-2125.1979.tb04711.x; Ulrik CS, 2009, ALLERGY ASTHMA PROC, V30, P64, DOI 10.2500/aap.2009.30.3196; Van de Louw A, 2001, INTENS CARE MED, V27, P1606; van Grunsven PM, 1999, THORAX, V54, P316, DOI 10.1136/thx.54.4.316; VANDERHEIDE S, 1994, J ALLERGY CLIN IMMUN, V93, P470, DOI 10.1016/0091-6749(94)90356-5; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; Verbanck S, 2004, AM J RESP CRIT CARE, V170, P414, DOI 10.1164/rccm.200401-037OC; Verbanck S, 2003, J APPL PHYSIOL, V94, P1380, DOI 10.1152/japplphysiol.00588.2002; Vilozni D, 2007, CHEST, V132, P497, DOI 10.1378/chest.07-0052; Vilozni D, 2009, PEDIATR PULM, V44, P885, DOI 10.1002/ppul.21072; WAALKENS JH, 1993, EUR RESPIR J, V6, P652; Wagner EM, 1998, AM J RESP CRIT CARE, V157, P447, DOI 10.1164/ajrccm.157.2.9611043; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WALL MA, 1985, J APPL PHYSIOL, V59, P274, DOI 10.1152/jappl.1985.59.1.274; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502, DOI 10.1164/ajrccm/148.6_Pt_1.1502; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Weiler JM, 2005, ANN ALLERG ASTHMA IM, V94, P65, DOI 10.1016/S1081-1206(10)61288-4; WEISS JW, 1983, J ALLERGY CLIN IMMUN, V72, P140, DOI 10.1016/0091-6749(83)90521-3; WEITZMAN RH, 1974, AM J MED, V57, P767, DOI 10.1016/0002-9343(74)90851-1; WOOLCOCK AJ, 1968, AM REV RESPIR DIS, V98, P788; Yamaguchi M, 2009, PULM PHARMACOL THER, V22, P326, DOI 10.1016/j.pupt.2009.01.005; Yoshikawa T, 1998, EUR RESPIR J, V12, P879, DOI 10.1183/09031936.98.12040879	224	107	109	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3		S			S65	S87		10.1016/j.jaci.2011.12.986	http://dx.doi.org/10.1016/j.jaci.2011.12.986			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	901OL	22386510	Green Accepted			2022-12-18	WOS:000300976600006
J	Castro-Rodriguez, JA				Castro-Rodriguez, Jose A.			The Asthma Predictive Index: A very useful tool for predicting asthma in young children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Infants; preschoolers; wheezing; asthma; clinical score; asthma predictive index	PRESCHOOL-CHILDREN; LUNG-FUNCTION; HIGH-RISK; RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; AIRWAY DISEASE; WHEEZY INFANTS; BIRTH COHORT; EARLY-LIFE; FOLLOW-UP	Recurrent wheezing is a common problem in young children: approximately 40% of children wheeze in their first year of life. However, only 30% of preschoolers with recurrent wheezing still have asthma at the age of 6 years. Nevertheless, asthma, the most prevalent chronic disease in children, is difficult to diagnose in infants and preschoolers. This article reviews the importance of determining at an early age which infants/preschoolers will have asthma later in life, analyzes the pros and cons of different predictive indices, and discusses the efficacy of the Asthma Predictive Index. (J Allergy Clin Immunol 2010;126:212-6.)	[Castro-Rodriguez, Jose A.] Pontificia Univ Catolica Chile, Sch Med, Dept Pediat, Santiago, Chile; [Castro-Rodriguez, Jose A.] Pontificia Univ Catolica Chile, Sch Med, Dept Family Med, Santiago, Chile	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile	Castro-Rodriguez, JA (corresponding author), Lira 44,1er Piso,Casilla 114-D, Santiago, Chile.	jacastro17@hotmail.com	Castro-Rodriguez, Jose A./ABA-6591-2021; Castro-Rodriguez, Jose A./ABA-2760-2021	Castro-Rodriguez, Jose A./0000-0002-0708-4281; 				Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; [Anonymous], 2007, EXPERT PANEL REPORT; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Becker AB, 2008, J ALLERGY CLIN IMMUN, V122, P1136, DOI 10.1016/j.jaci.2008.10.038; Beigelman A, 2009, ANN ALLERG ASTHMA IM, V103, P108, DOI 10.1016/S1081-1206(10)60162-7; Bisgaard H, 1997, PEDIATR PULM, P27; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045; Clough JB, 1999, AM J RESP CRIT CARE, V160, P1473, DOI 10.1164/ajrccm.160.5.9807019; Delacourt C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001180; Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616; Ehlenfield DR, 2000, PEDIATRICS, V105, P79, DOI 10.1542/peds.105.1.79; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Just J, 2008, CLIN EXP ALLERGY, V38, P767, DOI 10.1111/j.1365-2222.2008.02966.x; Karakoc F, 2002, CLIN EXP ALLERGY, V32, P51, DOI 10.1046/j.0022-0477.2001.01273.x; Kuehni CE, 2002, EUR RESPIR J, V20, P880, DOI 10.1183/09031936.02.00258502; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Martinez FD, 1999, ALLERGY, V54, P24, DOI 10.1111/j.1398-9995.1999.tb04384.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; Moeller A, 2008, J ALLERGY CLIN IMMUN, V121, P705, DOI 10.1016/j.jaci.2007.11.008; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37, DOI 10.1164/ajrccm.163.1.2005013; Piippo-Savolainen E, 2007, ALLERGY ASTHMA PROC, V28, P454, DOI 10.2500/aap.2007.28.3022; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Roberts G, 2009, J ALLERGY CLIN IMMUN, V124, P911, DOI 10.1016/j.jaci.2009.09.034; Silverman M, 1997, ARCH DIS CHILD, V77, P62, DOI 10.1136/adc.77.1.62; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; van de Kant KDG, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-210; Wright AL, 2006, PEDIATR PULM, V41, P318, DOI 10.1002/ppul.20373; Yuan Y., 2012, ANAL RISK FACTORS CH; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; Zuidgeest MGP, 2009, ANN FAM MED, V7, P32, DOI 10.1370/afm.910	38	107	115	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					212	216		10.1016/j.jaci.2010.06.032	http://dx.doi.org/10.1016/j.jaci.2010.06.032			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624655				2022-12-18	WOS:000281203800003
J	Gao, PS; Rafaels, NM; Mu, DG; Hand, T; Murray, T; Boguniewicz, M; Hata, T; Schneider, L; Hanifin, JM; Gallo, RL; Gao, L; Beaty, TH; Beck, LA; Leung, DYM; Barnes, KC				Gao, Pei-Song; Rafaels, Nicholas M.; Mu, Deguang; Hand, Tracey; Murray, Tanda; Boguniewicz, Mark; Hata, Tissa; Schneider, Lynda; Hanifin, Jon M.; Gallo, Richard L.; Gao, Li; Beaty, Terri H.; Beck, Lisa A.; Leung, Donald Y. M.; Barnes, Kathleen C.			Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Gao, Pei-Song; Rafaels, Nicholas M.; Mu, Deguang; Hand, Tracey; Gao, Li; Barnes, Kathleen C.] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21218 USA; [Murray, Tanda; Beaty, Terri H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Boguniewicz, Mark; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Hata, Tissa; Gallo, Richard L.] Univ Calif San Diego, Div Dermatol, San Diego, CA 92103 USA; [Schneider, Lynda] Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Hanifin, Jon M.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA; [Beck, Lisa A.] Univ Rochester, Med Ctr, Dept Dermatol, Rochester, NY 14642 USA; [Mu, Deguang] Fourth Mil Med Univ, Tangdu Hosp, Dept Resp Med, Xian 710032, Peoples R China	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Jewish Health; University of California System; University of California San Diego; Harvard University; Boston Children's Hospital; Oregon Health & Science University; University of Rochester; Air Force Military Medical University	Gao, PS (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21218 USA.	kbarnes@jhmi.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861				Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Cui YH, 2008, GENETICS, V179, P637, DOI 10.1534/genetics.107.082370; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Harada M, 2009, AM J RESP CELL MOL, V40, P368, DOI 10.1165/rcmb.2008-0041OC; Hunninghake GM, 2008, AM J RESP CRIT CARE, V177, P830, DOI 10.1164/rccm.200711-1697OC; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Neale BM, 2004, AM J HUM GENET, V75, P353, DOI 10.1086/423901; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Tay YK, 1999, ASIAN PAC J ALLERGY, V17, P137	10	107	112	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1403	1407		10.1016/j.jaci.2010.03.016	http://dx.doi.org/10.1016/j.jaci.2010.03.016			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH		Green Accepted			2022-12-18	WOS:000278831000036
J	Goldbach-Mansky, R; Kastner, DL				Goldbach-Mansky, Raphaela; Kastner, Daniel L.			Autoinflammation: The prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoinflammatory diseases; neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurologic; cutaneous, and arthritis (CINCA); cryopin-associated periodic syndromes (CAPS); deficiency of the IL-1 receptor antagonist; NLRP3; IL1RN; IL-1 receptor antagonist; anakinra; neonatal disorder; genetic disease; IL-1	INTERLEUKIN-1 RECEPTOR ANTAGONIST; JUVENILE IDIOPATHIC ARTHRITIS; ENCODING MEVALONATE KINASE; HYPERIMMUNOGLOBULINEMIA-D; ARTICULAR SYNDROME; CARD15 MUTATIONS; CIAS1 MUTATIONS; HYPER-IGD; KAPPA-B; ANAKINRA	The discovery of the genetic causes of a rare group of immune-mediated inflammatory conditions that mimic infections and allergic conditions in their clinical presentation and the molecular understanding of the function of the mutated molecules in these diseases has led to a revolution in our understanding of the pathogenesis of systemic and local inflammation. The proteins mutated in a number of these so-called autoinflammatory diseases are part of, or regulate the activity of, intracellular molecular complexes, the inflammasomes, that sense "danger" to the body and coordinate an initial immune response. Our understanding of specific triggers of the inflammasomes, coupled with the recognition that inflammasomes are critical for activation of the proinflammatory cytokine IL-1, has provided a rational and very effective target in the treatment of a number of these rare autoinflammatory diseases. In addition, the ongoing discovery of the role of inflammasomes and IL-1 activation and secretion in a number of genetically complex disorders have fundamentally changed our view of disease pathogenesis in a growing number of disorders that were heretofore not even thought of as "immunologic" diseases. (J Allergy Clin Immunol 2009; 124:1141-9.)	[Goldbach-Mansky, Raphaela; Kastner, Daniel L.] NIAMSD, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Goldbach-Mansky, R (corresponding author), NIAMS, NIH, Bldg 10,Rm 6D-47B,10 Ctr Dr, Bethesda, MD 20892 USA.	goldbacr@mail.nih.gov	Goldbach-Mansky, Raphaela/N-5917-2017		Intramural NIH HHS [Z01 AR041138-05, Z01 AR041138-06, ZIA AR041138-07, Z01 AR041139-05, Z01 AR041139-06, ZIA AR041139-07] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041123, ZIAAR041083, ZIAAR041139, ZIAAR041138] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Aksentijevich I, 1997, CELL, V90, P797; Aksentijevich I, 2007, ARTHRITIS RHEUM-US, V56, P1273, DOI 10.1002/art.22491; Aksentijevich I, 2009, NEW ENGL J MED, V360, P2426, DOI 10.1056/NEJMoa0807865; ANSELL BM, 1975, P ROY SOC MED, V68, P584, DOI 10.1177/003591577506800922; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Arostegui JI, 2007, ARTHRITIS RHEUM-US, V56, P3805, DOI 10.1002/art.22966; BALAVOINE JF, 1986, J CLIN INVEST, V78, P1120, DOI 10.1172/JCI112669; Bernot A, 1997, NAT GENET, V17, P25; Bodar EJ, 2005, NETH J MED, V63, P260; Botsios C, 2008, ANN INTERN MED, V149, P284, DOI 10.7326/0003-4819-149-4-200808190-00018; Cailliez M, 2006, J INHERIT METAB DIS, V29, P763, DOI 10.1007/s10545-006-0408-7; Cain BS, 1998, J AM COLL SURGEONS, V186, P337, DOI 10.1016/S1072-7515(98)00036-2; Dierselhuis MP, 2005, RHEUMATOLOGY, V44, P406, DOI 10.1093/rheumatology/keh479; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Drenth JPH, 1999, NAT GENET, V22, P178, DOI 10.1038/9696; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Ferguson PJ, 2005, J MED GENET, V42, P551, DOI 10.1136/jmg.2005.030759; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CJ, 1994, CRIT CARE MED, V22, P12, DOI 10.1097/00003246-199401000-00008; Fitzgerald AA, 2005, ARTHRITIS RHEUM-US, V52, P1794, DOI 10.1002/art.21061; Gattorno M, 2008, ARTHRITIS RHEUM, V58, P1516, DOI 10.1002/art.23475; Gattorno M, 2008, ARTHRITIS RHEUM, V58, P1505, DOI 10.1002/art.23437; Gattringer R, 2007, EUR J CLIN INVEST, V37, P912, DOI 10.1111/j.1365-2362.2007.01868.x; Godinho FMV, 2005, ANN RHEUM DIS, V64, P647, DOI 10.1136/ard.2004.026617; Goldbach-Mansky R, 2008, ARTHRITIS RHEUM-US, V58, P2432, DOI 10.1002/art.23620; Goldbach-Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137; Hacham M, 2000, ADV EXP MED BIOL, V479, P185; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; Hill SC, 2007, PEDIATR RADIOL, V37, P145, DOI 10.1007/s00247-006-0358-0; Hoffman HM, 2008, ARTHRITIS RHEUM, V58, P2443, DOI 10.1002/art.23687; Hoffman HM, 2001, J ALLERGY CLIN IMMUN, V108, P615, DOI 10.1067/mai.2001.118790; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Houten SM, 1999, NAT GENET, V22, P175, DOI 10.1038/9691; Jeru I, 2008, P NATL ACAD SCI USA, V105, P1614, DOI 10.1073/pnas.0708616105; Kanazawa N, 2005, BLOOD, V105, P1195, DOI 10.1182/blood-2004-07-2972; Kuijk LM, 2007, ANN RHEUM DIS, V66, P1545, DOI 10.1136/ard.2007.071498; Lachmann HJ, 2009, NEW ENGL J MED, V360, P2416, DOI 10.1056/NEJMoa0810787; Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213; Lequerre T, 2008, ANN RHEUM DIS, V67, P302, DOI 10.1136/ard.2007.076034; Lieberman A, 1998, J AM ACAD DERMATOL, V39, P290, DOI 10.1016/S0190-9622(98)70094-5; Lovell DJ, 2008, NEW ENGL J MED, V359, P810, DOI 10.1056/NEJMoa0706290; Masters SL, 2009, ANNU REV IMMUNOL, V27, P621, DOI 10.1146/annurev.immunol.25.022106.141627; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; McGonagle D, 2007, ANN RHEUM DIS, V66, P1683, DOI 10.1136/ard.2007.073759; McGonagle D, 2006, PLOS MED, V3, P1242, DOI 10.1371/journal.pmed.0030297; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; MUCKLE TJ, 1979, BRIT J DERMATOL, V100, P87, DOI 10.1111/j.1365-2133.1979.tb03572.x; MUCKLE TJ, 1962, Q J MED, V31, P235; O'Dell JR, 2004, NEW ENGL J MED, V350, P2591, DOI 10.1056/NEJMra040226; Pascual V, 2005, J EXP MED, V201, P1479, DOI 10.1084/jem.20050473; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Prieur A M, 1987, Scand J Rheumatol Suppl, V66, P57; PRIEUR AM, 1980, REV RHUM, V47, P645; PRIEUR AM, 1981, J PEDIATR-US, V99, P79, DOI 10.1016/S0022-3476(81)80961-4; Quartier P, 2008, ARCH PEDIATRIE, V15, P865, DOI 10.1016/S0929-693X(08)71944-4; Reddy S, 2009, NEW ENGL J MED, V360, P2438, DOI 10.1056/NEJMoa0809568; Reiff Andreas, 2005, Curr Rheumatol Rep, V7, P434, DOI 10.1007/s11926-005-0047-2; Roldan R, 2008, JOINT BONE SPINE, V75, P504, DOI 10.1016/j.jbspin.2008.04.001; Ryan JG, 2008, J ALLERGY CLIN IMMUN, V121, P260, DOI 10.1016/j.jaci.2007.09.021; Sacre K, 2008, J RHEUMATOL, V35, P357; Schneider DS, 2002, CELL, V109, P537, DOI 10.1016/S0092-8674(02)00764-X; Shinkai K, 2008, CLIN EXP DERMATOL, V33, P1, DOI 10.1111/j.1365-2230.2007.02540.x; Simon A, 2004, AM J MED, V117, P208, DOI 10.1016/j.amjmed.2004.02.039; So A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2143; Thornton BD, 2007, AM J KIDNEY DIS, V49, P477, DOI 10.1053/j.ajkd.2006.10.026; Towne JE, 2004, J BIOL CHEM, V279, P13677, DOI 10.1074/jbc.M400117200; Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832; Wise CA, 2002, HUM MOL GENET, V11, P961, DOI 10.1093/hmg/11.8.961; Ye ZM, 2008, CURR OPIN IMMUNOL, V20, P3, DOI 10.1016/j.coi.2008.01.003	72	107	124	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1141	1149		10.1016/j.jaci.2009.11.016	http://dx.doi.org/10.1016/j.jaci.2009.11.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	20004775	Green Published, Green Accepted			2022-12-18	WOS:000273071500002
J	Kumar, R; Yu, YX; Story, RE; Pongracic, JA; Gupta, R; Pearson, C; Ortiz, K; Bauchner, HC; Wang, XB				Kumar, Rajesh; Yu, Yunxian; Story, Rachel E.; Pongracic, Jacqueline A.; Gupta, Ruchi; Pearson, Colleen; Ortiz, Kathryn; Bauchner, Howard C.; Wang, Xiaobin			Prematurity, chorioamnionitis, and the development of recurrent wheezing: A prospective birth cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chorioamnionitis; prematurity; recurrent wheezing	ENVIRONMENTAL TOBACCO-SMOKE; PERINATAL RISK-FACTORS; MATERNAL SMOKING; PRETERM DELIVERY; CHILDHOOD ASTHMA; ATOPIC-DERMATITIS; AMNIOTIC-FLUID; UNITED-STATES; FOLLOW-UP; PREGNANCY	Background: Prematurity (<37 weeks) has been inconsistently associated with asthma and wheezing. Chorioamnionitis may promote both prematurity and inflammatory pathways in infants' airways. Objective: To investigate the relationship of prematurity and chorioamnionitis with the development of early childhood recurrent wheezing. Methods: The Boston Birth Cohort (n = 1096) were followed prospectively from birth to a mean age of 2.2 +/- 2 years. Perinatal and postnatal clinical data and placental pathology were collected. The primary outcome was recurrent wheezing ( >= 2 physician documented episodes). Secondary outcomes included physician-diagnosed asthma, food allergy, and eczema. Preterm children were grouped by gestational age into moderately (33-36.9 weeks) and very preterm (<33 weeks) with and without chorioamnionitis, and compared with term children without chorioamnionitis (reference group). Chorioamnionitis was diagnosed either by intrapartum fever or by placental histology findings. Logistic regression models were performed to investigate the independent and joint associations of degree of prematurity and chorioamnionitis. Results: Prematurity was associated with recurrent wheezing (odds ratio [OR], 1.7; 95% CI, 1.2-2.6). However, when subjects were grouped by degree of prematurity with or without chorioamnionitis, the highest risk of wheezing (OR, 4.0; 95% CI, 2.0-8.0) and physician-diagnosed asthma (OR, 4.4; 95% CI, 2.2-8.7) was present in the very preterm children with chorioamnionitis. The effect on both wheezing (OR, 5.4; 95% CI, 2.4-12.0) and asthma (OR, 5.2; 95% CI, 2.3-11.9) was greater in African Americans. Neither prematurity nor chorioamnionitis was associated with food allergy or eczema. Conclusion: We found a strong joint effect of prematurity and chorioamnionitis on early childhood wheezing. This effect was stronger in African American subjects.	[Kumar, Rajesh; Story, Rachel E.; Pongracic, Jacqueline A.] Childrens Mem Hosp, Div Allergy, Chicago, IL 60614 USA; [Yu, Yunxian; Gupta, Ruchi; Wang, Xiaobin] Childrens Mem Hosp, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60614 USA; [Yu, Yunxian; Gupta, Ruchi; Wang, Xiaobin] Childrens Mem Res Ctr, Chicago, IL USA; [Pearson, Colleen; Ortiz, Kathryn; Bauchner, Howard C.] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02215 USA; [Pearson, Colleen; Ortiz, Kathryn; Bauchner, Howard C.] Boston Med Ctr, Boston, MA USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Boston University; Boston Medical Center	Kumar, R (corresponding author), Childrens Mem Hosp, Div Allergy, 2300 Childrns Plaza,Box 60, Chicago, IL 60614 USA.	rkumar@childrensmemorial.org		Kumar, Rajesh/0000-0002-1962-7108; Bauchner, Howard/0000-0002-8368-9805	NHLBI NIH HHS [K23 HL093023-01, K23 HL093023] Funding Source: Medline; NICHD NIH HHS [R01 HD041702] Funding Source: Medline; NIEHS NIH HHS [R21 ES011666] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD041702] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL093023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES011666] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Akinbami LJ, 2002, AMBUL PEDIATR, V2, P382, DOI 10.1367/1539-4409(2002)002<0382:RAIDIC>2.0.CO;2; Benirschke K., 2000, PATHOLOGY HUMAN PLAC; Benn CS, 2002, J ALLERGY CLIN IMMUN, V110, P72, DOI 10.1067/mai.2002.125833; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; Calvani M, 2004, ALLERGY, V59, P99, DOI 10.1046/j.1398-9995.2003.00338.x; CHELLAM VG, 1985, BRIT J OBSTET GYNAEC, V92, P808, DOI 10.1111/j.1471-0528.1985.tb03050.x; DEMARTINO M, 1989, BIOL NEONATE, V56, P301, DOI 10.1159/000243138; GEM JE, 2002, PEDIATR ALLERGY IMMU, V13, P386; GIBBS RS, 1982, J INFECT DIS, V145, P1, DOI 10.1093/infdis/145.1.1; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429, DOI 10.1164/ajrccm.163.2.2006009; Goetghebuer T, 2004, CLIN EXP ALLERGY, V34, P801, DOI 10.1111/j.1365-2222.2004.1947.x; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; Goldenberg RL, 2002, NUTR REV, V60, pS19, DOI 10.1301/00296640260130696; Gupta M, 2007, J MATERN-FETAL NEO M, V20, P39, DOI 10.1080/14767050601156861; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P136, DOI 10.2105/AJPH.94.1.136; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Jacobsson B, 2005, BJOG-INT J OBSTET GY, V112, P719, DOI 10.1111/j.1471-0528.2005.00536.x; Langston C, 1997, ARCH PATHOL LAB MED, V121, P449; Lannero E, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-3; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Magnusson LL, 2005, CLIN EXP ALLERGY, V35, P1550, DOI 10.1111/j.1365-2222.2005.02374.x; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; MITCHELL MD, 1990, PROSTAG LEUKOTR ESS, V41, P35, DOI 10.1016/0952-3278(90)90128-8; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; MUELLERHEUBACH E, 1990, OBSTET GYNECOL, V75, P622; Murtha AP, 2007, OBSTET GYNECOL, V109, P121, DOI 10.1097/01.AOG.0000250474.35369.12; Noakes PS, 2006, EUR RESPIR J, V28, P721, DOI 10.1183/09031936.06.00050206; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Olesen AB, 1997, BRIT MED J, V314, P1003, DOI 10.1136/bmj.314.7086.1003; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Rasanen M, 2000, THORAX, V55, P25, DOI 10.1136/thorax.55.1.25; Roberts EM, 2002, J NATL MED ASSOC, V94, P215; Rusconi F, 2007, AM J RESP CRIT CARE, V175, P16, DOI 10.1164/rccm.200512-1978OC; Schmitz T, 2007, J IMMUNOL, V178, P1115, DOI 10.4049/jimmunol.178.2.1115; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; Steffensen FH, 2000, EPIDEMIOLOGY, V11, P185, DOI 10.1097/00001648-200003000-00018; TURKELTAUB PC, 1991, ANN ALLERGY, V67, P147; VONMUTIUS E, 1993, J PEDIATR-US, V123, P223, DOI 10.1016/S0022-3476(05)81692-0; Wang XB, 2002, JAMA-J AM MED ASSOC, V287, P195, DOI 10.1001/jama.287.2.195; Xu BZ, 1999, INT J EPIDEMIOL, V28, P723, DOI 10.1093/ije/28.4.723; Yuan W, 2003, EUR J EPIDEMIOL, V18, P763, DOI 10.1023/A:1025390420122	45	107	109	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					878	884		10.1016/j.jaci.2008.01.030	http://dx.doi.org/10.1016/j.jaci.2008.01.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18313129	Green Accepted, Bronze			2022-12-18	WOS:000254884000011
J	Farkas, H; Jakab, L; Temesszentandrasi, G; Visy, B; Harmat, G; Fust, G; Szeplaki, G; Fekete, B; Karadi, I; Varga, L				Farkas, Henriette; Jakab, Laszlo; Temesszentandrasi, Gyoergy; Visy, Beata; Harmat, Gyoergy; Fust, George; Szeplaki, Gabor; Fekete, Bela; Karadi, Istvan; Varga, Lilian			Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human C1-inhibitor concentrate; treatment; hereditary angioneurotic edema; hereditary angioedema	C1 INHIBITOR CONCENTRATE; FRESH-FROZEN PLASMA; ANGIONEUROTIC-EDEMA; REPLACEMENT THERAPY; TERM PROPHYLAXIS; DEFICIENCY; MANAGEMENT; TRANSFUSION; DIAGNOSIS; CHILDREN	Background: C1-inhibitor (C1-INH) is a serine protease inhibitor regulating the complement, kinin-kallikrein, coagulation, and fibrinolytic systems. Hereditary angioedema (HAE) is caused by an inherited deficiency of C1-INH characterized by sudden, recurrent edematous swellings of the subcutaneous or submucosal tissues. The optional therapy for the acute management of HAE is administration of human C1-INH (hC1-INH) concentrate. However, hC1-INH is not available in many countries, in which case fresh frozen plasma is an alternative. Objective: To summarize our experience with hC1-INH concentrate in patients with HAE. Methods: Clinical and laboratory information on the effectiveness and safety of hC1-INH administered to relieve 468 acute edematous attacks in 61 patients with HAE was analyzed. Results: Severe abdominal or subcutaneous attacks and laryngeal edema were consistently relieved by the administration of 500 U hC1-INH concentrate. Symptoms improved within 15 to 60 minutes of administration. Progression of the attacks was never observed, and there were no recurrent attacks within 72 hours. hC1-INH concentrate requirements did not change after repeated use. hC1-INH concentrate proved effective in the management of 94 attacks in 22 children and 6 attacks in 4 pregnant women. Adverse reactions, viral infections, and antibody formation against the purified protein did not occur. Conclusion: The administration of hC1-INH concentrate in HAE is highly effective and safe for the treatment of acute attacks and short-term prophylaxis and in pediatric patients and pregnant women. Clinical implications: Human C1-INH concentrate is effective and safe for the treatment of acute HAE attacks as well as for short-term prophylaxis.	Heim Pal Pediat Hosp, Budapest, Hungary		Farkas, H (corresponding author), Semmelweis Univ, Fac Med, Dept Internal Med 3, H-1125 Budapest 4, Kutvolgyi, Hungary.	farkash@kut.sote.hu	Varga, Lilian/F-2491-2010	Farkas, Henriette/0000-0003-2929-1721; Karadi, Istvan/0000-0002-8253-2654; Varga, Lilian/0000-0002-5484-364X; Szeplaki, Gabor/0000-0003-3795-1240				Abinun M, 1999, LANCET, V353, P2242, DOI 10.1016/S0140-6736(05)76288-7; AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Agostoni A, 2001, DRUG SAFETY, V24, P599, DOI 10.2165/00002018-200124080-00004; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Bork K, 2005, TRANSFUSION, V45, P1774, DOI 10.1111/j.1537-2995.2005.00602.x; BORK K, 1989, J ALLERGY CLIN IMMUN, V83, P677, DOI 10.1016/0091-6749(89)90082-1; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; Bouillet L, 2003, DERMATOLOGY, V206, P106, DOI 10.1159/000068456; Bowen T, 2004, J ALLERGY CLIN IMMUN, V114, P629, DOI 10.1016/j.jaci.2004.06.043; CHING EP, 1991, AM J CLIN PATHOL, V96, P201, DOI 10.1093/ajcp/96.2.201; CICARDI M, 1982, AM J MED SCI, V284, P2, DOI 10.1097/00000441-198207000-00001; De Serres J, 2003, TRANSFUS APHER SCI, V29, P247, DOI 10.1016/j.transci.2003.08.006; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; Donaldson VH, 1996, J LAB CLIN MED, V128, P438, DOI 10.1016/S0022-2143(96)80017-5; Farkas H, 2003, TRANSFUS APHER SCI, V29, P229, DOI 10.1016/j.transci.2003.08.003; Farkas H, 2002, PEDIAT ALLERG IMM-UK, V13, P153, DOI 10.1034/j.1399-3038.2002.01014.x; Farkas H, 2001, EUR J GASTROEN HEPAT, V13, P1225, DOI 10.1097/00042737-200110000-00016; FARKAS H, 2007, IN PRESS PEDIATRICS; Gajic O, 2005, MAYO CLIN PROC, V80, P766; Gilstad CW, 2003, CURR OPIN HEMATOL, V10, P419, DOI 10.1097/00062752-200311000-00004; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; HASHIM SW, 1984, AM J SURG, V147, P560, DOI 10.1016/0002-9610(84)90022-9; JAFFE CJ, 1975, J ALLERGY CLIN IMMUN, V55, P386, DOI 10.1016/0091-6749(75)90077-9; Kaplan AP, 2005, J AM ACAD DERMATOL, V53, P373, DOI 10.1016/j.jaad.2004.09.032; Kaplan AP, 2001, J INVEST ALLERG CLIN, V11, P211; KREUZ W, 1999, BIOMED PROG, V12, P1; Kunschak M, 1998, TRANSFUSION, V38, P540, DOI 10.1046/j.1537-2995.1998.38698326333.x; LEIMGRUBER A, 1993, INT ARCH ALLERGY IMM, V101, P107, DOI 10.1159/000236506; Levi M, 2006, J ALLERGY CLIN IMMUN, V117, P904, DOI 10.1016/j.jaci.2006.01.002; MacLennan S, 2006, J TRAUMA, V60, pS46, DOI 10.1097/01.ta.0000199546.22925.31; Mohr M, 1996, ANAESTHESIST, V45, P626, DOI 10.1007/s001010050295; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; PICKERING RJ, 1969, LANCET, V1, P326; SIM TC, 1990, AM J MED, V88, P656, DOI 10.1016/0002-9343(90)90535-L; Sonntag J, 1997, TRANSFUSION, V37, P798, DOI 10.1046/j.1537-2995.1997.37897424401.x; Varga L, 2007, MOL IMMUNOL, V44, P1454, DOI 10.1016/j.molimm.2006.04.020; Visy B, 2004, CLIN ENDOCRINOL, V60, P508, DOI 10.1111/j.1365-2265.2004.02009.x; Zuraw BL, 2005, CLIN IMMUNOL, V114, P10, DOI 10.1016/j.clim.2004.08.001	39	107	108	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					941	947		10.1016/j.jaci.2007.06.026	http://dx.doi.org/10.1016/j.jaci.2007.06.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17761272				2022-12-18	WOS:000250157700031
J	Lehtinen, P; Ruohola, A; Vanto, T; Vuorinen, T; Ruuskanen, O; Jartti, T				Lehtinen, Pasi; Ruohola, Aino; Vanto, Tirno; Vuorinen, Tytti; Ruuskanen, Olli; Jartti, Tuomas			Prednisolone reduces recurrent wheezing after a first wheezing episode associated with rhinovirus infection or eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recurrent wheezing; rhinovirus; eczema; atopy; prednisolone; child	RESPIRATORY-SYNCYTIAL-VIRUS; RANDOMIZED CONTROLLED-TRIAL; INHALED CORTICOSTEROIDS; CHILDHOOD ASTHMA; AIRWAY RESPONSIVENESS; ACUTE BRONCHIOLITIS; ALLERGIC SUBJECTS; HIGH-RISK; AGE 13; CHILDREN	Background: Rhinovirus-induced early wheezing has been suggested as a new important risk factor for recurrent wheezing. Objective: We sought to investigate the risk factors for recurrent wheezing and to determine post hoc the efficacy of prednisolone in risk groups. Methods: We followed for 1 year 118 children (median age, 1.1 years) who had had their first episode of wheezing and had participated in a trial comparing prednisolone with placebo in hospitalized children. Demographics and laboratory data were obtained at study entry. The follow-up outcome was recurrent wheezing (3 physician-confirmed episodes). Results: Recurrent wheezing was diagnosed in 44 (37%) children. Independent risk factors were age < I year, atopy, and maternal asthma. The probability of recurrent wheezing was higher in rhinovirus than respiratory syncytial virus (RSV)-affected children among placebo recipients (hazard ratio, 5.05; 95% CI, 1.00-25.41). Prednisolone decreased the probability of recurrent wheezing in children with eczema (0.15; 95% Cl, 0.04-0.63) but not in those without eczema (1.89; 95% CI, 0.83-4.29; P =.007 for interaction). Prednisolone was associated with less recurrent wheezing in the rhinovirus group (0.19; 95% Cl, 0.05-0.71), but not in the RSV (2.12-1 95 % Cl, 0.46-9.76) or in the RSV/rhinovirus-negative groups (2.03; 95% C1, 0.83-5.00; P =.017 for interaction). Conclusion: Rhinovirus-induced early wheezing is a major viral risk factor for recurrent wheezing. Prednisolone may prevent recurrent wheezing in rhinovirus-affected first-time wheezers. The presence of eczema may also influence the response to prednisolone. Clinical implications: A prospective trial is needed to test the hypothesis that prednisolone reduces recurrent wheezing in rhinovirus-affected wheezing children.	Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland; Univ Turku, Dept Virol, SF-20500 Turku, Finland	University of Turku; University of Turku	Jartti, T (corresponding author), Sirkkalankatu 4C 59, FIN-20520 Turku, Finland.	tuomas.jartti@utu.fi						Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Brooks GD, 2003, AM J RESP CRIT CARE, V168, P1091, DOI 10.1164/rccm.200306-737OC; Bulow SM, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e77; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; De Boeck K, 1997, J PEDIATR-US, V131, P919, DOI 10.1016/S0022-3476(97)70044-1; Ehlenfield DR, 2000, PEDIATRICS, V105, P79, DOI 10.1542/peds.105.1.79; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gold DR, 2006, NEW ENGL J MED, V354, P2058, DOI 10.1056/NEJMe068058; Grunberg K, 2001, AM J RESP CRIT CARE, V164, P1816; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Hoebee B, 2004, J INFECT DIS, V189, P239, DOI 10.1086/380908; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Jacques J, 2006, J CLIN VIROL, V35, P463, DOI 10.1016/j.jcv.2005.11.009; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Jartti T, 2006, PEDIATR INFECT DIS J, V25, P482, DOI 10.1097/01.inf.0000215226.69696.0c; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Lagakos SW, 2006, NEW ENGL J MED, V354, P1667, DOI 10.1056/NEJMp068070; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; Malmstrom K, 2006, J ALLERGY CLIN IMMUN, V118, P591, DOI 10.1016/j.jaci.2006.04.032; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Oommen A, 2003, LANCET, V362, P1433, DOI 10.1016/S0140-6736(03)14685-5; OSUNDWA VM, 1993, EUR J PEDIATR, V152, P1001, DOI 10.1007/BF01957225; Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; Roosevelt G, 1996, LANCET, V348, P292, DOI 10.1016/S0140-6736(96)02285-4; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; SIMS DG, 1978, BRIT MED J, V1, P11, DOI 10.1136/bmj.1.6104.11; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; STORR J, 1987, LANCET, V1, P879; van Woensel JBM, 2000, PEDIATR PULM, V30, P92; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wright AL, 2002, CLIN REV ALLERG IMMU, V22, P33, DOI 10.1385/CRIAI:22:1:033; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396	41	107	113	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					570	575		10.1016/j.jaci.2006.11.003	http://dx.doi.org/10.1016/j.jaci.2006.11.003			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17196244	Bronze, Green Published			2022-12-18	WOS:000244925000007
J	McGirt, LY; Beck, LA				McGirt, Laura Y.; Beck, Lisa A.			Innate immune defects in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopic dermatitis; eczema; innate immunity	STAPHYLOCOCCUS-AUREUS; ANTIMICROBIAL PEPTIDES; STRATUM-CORNEUM; SOLUBLE CD14; PEPTIDOGLYCAN RECOGNITION; CYTOKINE MILIEU; BREAST-MILK; EXPRESSION; SKIN; DEFICIENCY	Atopic dermatitis (AD) is a common, chronic inflammatory skin disease that becomes clinically apparent in the pediatric population. It is well recognized that subjects with AD have an increased susceptibility to cutaneous colonization and infection with bacteria, fungi, and viruses. The notion that subjects with AD have a cutaneous immune defect has received widespread acceptance, and several plausible explanations for this have been proposed. We will review the evidence that this susceptibility to cutaneous infection is at least in part due to a defect in the first line of defense against microbes, namely the innate immune system.	Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Sch Med, Div Clin Immunol & Allergy, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Dermatol, Sch Med, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Beck, LA (corresponding author), Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Sch Med, Div Clin Immunol & Allergy, 5501 Hopkins Bayview Circle,Rm 3A62, Baltimore, MD 21224 USA.	lab@jhmi.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045839, N01AI040029] Funding Source: NIH RePORTER; NIAID NIH HHS [N01 AI 40029, R01 AI045839] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Aittoniemi J, 2005, CLIN EXP IMMUNOL, V142, P120, DOI 10.1111/j.1365-2249.2005.02881.x; Arikawa J, 2002, J INVEST DERMATOL, V119, P433, DOI 10.1046/j.1523-1747.2002.01846.x; Arzumanyan VG, 2000, B EXP BIOL MED+, V129, P601, DOI 10.1007/BF02434889; Bankova LG, 2006, J ALLERGY CLIN IMMUN, V117, pS236, DOI 10.1016/j.jaci.2005.12.934; Brandrup F, 1999, BRIT J DERMATOL, V140, P180; Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; Carretero M, 2004, FASEB J, V18, P1931, DOI 10.1096/fj.04-1515fje; CLEMMENSEN OJ, 1983, SEMIN DERMATOL, V2, P26; Dziarski R, 2003, CELL MOL LIFE SCI, V60, P1793, DOI 10.1007/s00018-003-3019-6; Elias PM, 2005, J INVEST DERMATOL, V125, P183, DOI 10.1111/j.0022-202X.2005.23668.x; Esche C, 2005, J INVEST DERMATOL, V125, P615, DOI 10.1111/j.0022-202X.2005.23841.x; Gadjeva M, 2004, CLIN EXP IMMUNOL, V138, P304, DOI 10.1111/j.1365-2249.2004.02616.x; Gardner ET, 2006, J ALLERGY CLIN IMMUN, V117, pS14, DOI 10.1016/j.jaci.2005.12.060; Girardin SE, 2004, EUR J IMMUNOL, V34, P1777, DOI 10.1002/eji.200425095; Hara J, 2000, J INVEST DERMATOL, V115, P406, DOI 10.1046/j.1523-1747.2000.00072.x; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Hogaboam CM, 2004, J LEUKOCYTE BIOL, V75, P805, DOI 10.1189/jlb.0703325; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; Izadpanah A, 2005, J AM ACAD DERMATOL, V52, P381, DOI 10.1016/j.jaad.2004.08.026; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Johansson C, 2003, BRIT J DERMATOL, V148, P479, DOI 10.1046/j.1365-2133.2003.05093.x; Jones CA, 2002, J ALLERGY CLIN IMMUN, V109, P858, DOI 10.1067/mai.2002.123535; Kollisch G, 2005, IMMUNOLOGY, V114, P531, DOI 10.1111/j.1365-2567.2005.02122.x; Koppelman GH, 2003, CURR OPIN ALLERGY CL, V3, P347, DOI 10.1097/01.all.0000092604.76804.2a; Leung DYM, 2003, CURR OPIN PEDIATR, V15, P399, DOI 10.1097/00008480-200308000-00008; LEVER R, 1988, BRIT J DERMATOL, V119, P189, DOI 10.1111/j.1365-2133.1988.tb03201.x; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Lu JH, 2002, BBA-GEN SUBJECTS, V1572, P387, DOI 10.1016/S0304-4165(02)00320-3; McGirt L, 2006, J INVEST DERMATOL, V126, P116; McInturff JE, 2005, J INVEST DERMATOL, V125, P1, DOI 10.1111/j.0022-202X.2004.23459.x; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Menzies BE, 2005, INFECT IMMUN, V73, P5241, DOI 10.1128/IAI.73.8.5241-5244.2005; MICHAELSSON G, 1973, ACTA DERM-VENEREOL, V53, P279; Miller LS, 2006, IMMUNITY, V24, P79, DOI 10.1016/j.immuni.2005.11.011; MROWIETZ U, 1988, J ALLERGY CLIN IMMUN, V82, P1027, DOI 10.1016/0091-6749(88)90140-6; NILSSON EJ, 1992, J AM ACAD DERMATOL, V27, P29, DOI 10.1016/0190-9622(92)70151-5; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park HJ, 2005, J INVEST DERMATOL, V124, P751, DOI 10.1111/j.0022-202X.2005.23656.x; Remitz A, 2001, J ALLERGY CLIN IMMUN, V107, P196, DOI 10.1067/mai.2001.112131; Rieg S, 2005, J IMMUNOL, V174, P8003, DOI 10.4049/jimmunol.174.12.8003; Rinaldi AC, 2002, CURR OPIN CHEM BIOL, V6, P799, DOI 10.1016/S1367-5931(02)00401-5; ROGGE JL, 1976, ARCH DERMATOL, V112, P1391, DOI 10.1001/archderm.112.10.1391; Rothenbacher D, 2005, CLIN EXP ALLERGY, V35, P1014, DOI 10.1111/j.1365-2222.2005.02298.x; Savage PB, 2002, FEMS MICROBIOL LETT, V217, P1; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; Schleimer Robert P, 2004, Proc Am Thorac Soc, V1, P222, DOI 10.1513/pats.200402-018MS; SCHOPP J, 2003, NAT REV MOL CELL BIO, V4, P95; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Shi L, 2004, J EXP MED, V199, P1379, DOI 10.1084/jem.20032207; Sohn MH, 2003, ALLERGY ASTHMA PROC, V24, P67; Song PI, 2002, J INVEST DERMATOL, V119, P424, DOI 10.1046/j.1523-1747.2002.01847.x; SONG PI, 2004, J INVEST DERMATOL, V122, pA754; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Terui T, 1998, EXP DERMATOL, V7, P327, DOI 10.1111/j.1600-0625.1998.tb00332.x; Voss E, 2004, J INVEST DERMATOL, V123; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Zdolsek HA, 2004, CLIN EXP ALLERGY, V34, P532, DOI 10.1111/j.1365-2222.2004.1921.x	66	107	116	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					202	208		10.1016/j.jaci.2006.04.033	http://dx.doi.org/10.1016/j.jaci.2006.04.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815156	Bronze			2022-12-18	WOS:000239184800024
J	Bolhaar, STHP; van de Weg, WE; van Ree, R; Gonzalez-Mancebo, E; Zuidmeer, L; Bruijnzeel-Koomen, CAFM; Fernandez-Rivas, M; Jansen, J; Hoffmann-Sommergruber, KH; Knulst, AC; Gilissen, LJWJ				Bolhaar, STHP; van de Weg, WE; van Ree, R; Gonzalez-Mancebo, E; Zuidmeer, L; Bruijnzeel-Koomen, CAFM; Fernandez-Rivas, M; Jansen, J; Hoffmann-Sommergruber, KH; Knulst, AC; Gilissen, LJWJ			In vivo assessment with prick-to-prick testing and double-blind, placebo-controlled food challenge of allergenicity of apple cultivars	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; hypoallergenicity; food; Bet v 1; Mal d 1; Mal d 3; double-blind; placebo-controlled.food challenge	LIPID TRANSFER PROTEIN; BIRCH POLLEN ALLERGEN; ROSACEAE FRUITS; SKIN-TESTS; IGE; IDENTIFICATION; EXTRACTS; HAZELNUT; CLONING; POTATO	Background: Apple cultivars have been reported to differ in allergenicity on the basis of in vitro and skin prick tests with apple extracts. Objectives: We sought to evaluate the efficacy of the prick-to-prick method in assessing differences in allergenicity of apple cultivars and to confirm differences by means of double-blind, placebo-controlled food challenge (DBPCFC). Methods: Intra-assay and intracultivar variation of prick-to-prick test results were determined in 6 Dutch and 8 Spanish patients with apple allergy by using 5 apples of the cultivars Golden Delicious, Fuji, and Ecolette in duplicate. In addition, 21 cultivars were screened for allergenicity in 15 Dutch patients with birch pollen and apple allergy. Two selected cultivars (Golden Delicious and Santana) were tested with DBPCFCs. The influence of storage conditions on allergenicity was assessed in 5 cultivars. Results: Intra-assay variation of skin prick testing was 3.9%, and intracultivar variation was 4.1%. A ranking of 21 cultivars was made on the basis of prick-to-prick tests in 9 patients. Apple cultivars were classified as of low, intermediate, and high allergenicity, with a significant difference between low and high allergenicity (P < .001). A significant difference in allergenicity determined between Golden Delicious and Santana cultivars (P < .05) was confirmed by means of DBPCFC. With 5 cultivars, controlled atmosphere (2.5% oxygen/1% carbon dioxide) was shown to reduce allergenicity (P < .001) by 15% compared with storage at 2 degrees C. Conclusions: Prick-to-prick testing with fresh apples is a reproducible method of assessing allergenicity. Apples can be classified as of low or high allergenicity for the majority of patients. This was confirmed by using DBPCFCs. Selection of cultivars and control of storage conditions are both viable strategies for reduction of symptoms in patients with apple allergy.	Univ Utrecht Hosp, Dept Dermatol, Utrecht, Netherlands; Plant Res Int, Wageningen, Netherlands; Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands; Fdn Hosp Alcorcon, Unidad Alergia, Alcorcon, Spain; Med Univ Vienna, Dept Pathofysiol, Vienna, Austria; Allergy Consortium, Wageningen, Netherlands	Utrecht University; Utrecht University Medical Center; Alcorcon Foundation University Hospital; Medical University of Vienna	Bolhaar, STHP (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol & Allergol, Heidelberglaan 100 G02-124, NL-3584 CX Utrecht, Netherlands.	S.Bolhaar@umcutrecht.nl	Van de Weg, Eric W/G-3225-2011; gilisen, luud/F-5496-2017; Zuidmeer, Laurian/B-5494-2008	Van de Weg, Eric W/0000-0002-9443-5974; Zuidmeer-Jongejan, Laurian/0000-0003-3245-5555; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ANDERSEN KE, 1978, CONTACT DERMATITIS, V4, P73, DOI 10.1111/j.1600-0536.1978.tb03739.x; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI 10.1111/j.1365-2222.2004.1939.x; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; COOK R, 2003, MARKETING APPLES GLO; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; Fernandez-Rivas M, 1999, CLIN EXP ALLERGY, V29, P1239, DOI 10.1046/j.1365-2222.1999.00628.x; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; Gilissen LJWJ, 2005, J ALLERGY CLIN IMMUN, V115, P364, DOI 10.1016/j.jaci.2004.10.014; HoffmannSommergruber K, 1996, ADV EXP MED BIOL, V409, P219; Hsieh LS, 1995, J ALLERGY CLIN IMMUN, V96, P960, DOI 10.1016/S0091-6749(95)70234-2; Kerkhof M, 1996, ALLERGY, V51, P770, DOI 10.1111/j.1398-9995.1996.tb04465.x; KUEHR J, 1992, CLIN EXP ALLERGY, V22, P839, DOI 10.1111/j.1365-2222.1992.tb02829.x; LAHTI A, 1980, ALLERGY, V35, P297, DOI 10.1111/j.1398-9995.1980.tb01770.x; LLEONART R, 1992, ANN ALLERGY, V69, P128; MARZBAN G, 2005, IN PRESS PLANT SCI; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V104, P1099, DOI 10.1016/S0091-6749(99)70095-3; POULSEN LK, 1993, CLIN EXP ALLERGY, V23, P61, DOI 10.1111/j.1365-2222.1993.tb02485.x; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; SKAMSTRUP HK, 2001, J CHROMATOGR B, V756, P19; Son DY, 1999, EUR J NUTR, V38, P201, DOI 10.1007/s003940050063; van Ree R, 1997, CRC DERMAT, P289; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VIETHS S, 1994, ALLERGY, V49, P262, DOI 10.1111/j.1398-9995.1994.tb02659.x; VIETHS S, 1994, INT ARCH ALLERGY IMM, V104, P399, DOI 10.1159/000236698; Vieths S, 1998, ALLERGY, V53, P65, DOI 10.1111/j.1398-9995.1998.tb04965.x; Wensing M, 2002, CLIN EXP ALLERGY, V32, P1757, DOI 10.1046/j.1365-2222.2002.01555.x	33	107	110	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1080	1086		10.1016/j.jaci.2005.07.004	http://dx.doi.org/10.1016/j.jaci.2005.07.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275380				2022-12-18	WOS:000235686700021
J	Oskeritzian, CA; Zhao, W; Min, HK; Xia, HZ; Pozez, A; Kiev, J; Schwartz, LB				Oskeritzian, CA; Zhao, W; Min, HK; Xia, HZ; Pozez, A; Kiev, J; Schwartz, LB			Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; human; IL-6; complement; tryptase; chymase; C5a; substance P; CD88	FC-EPSILON-RI; INDUCED HISTAMINE-RELEASE; MEDIATOR RELEASE; SUBSTANCE-P; HUMAN BASOPHILS; SKIN; CHYMASE; EXPRESSION; C5A; TRYPTASE	Background: MCT and MCTC types of human mast cells (MCs) are distinguished from one another on the basis of the protease compositions of their secretory granules, but their functional and developmental relationships have been uncertain. Objective: These studies better define the functional properties and developmental relationship Of MCT and MCTC cells. Methods: Mast cells were dispersed from human skin and lung, purified with anti-Kit antibody, and separated into CD88(+) and CD88(-) populations by cell sorting. These cells were evaluated by immunocytochemistry with antitryptase and antichymase mAbs; for chymase and tryptase mRNA by real-time RT-PCR; for conversion Of MCT to MCTC cells during cell culture with recombinant human stem cell factor and recombinant human IL-6; and for degranulation and leukotriene C-4 (LTC4) secretion when stimulated with anti-Fc epsilon RI, substance P, C5a, and compound 48/80. Results: Mature MCT and MCTC cells were separated from One another on the basis of selective expression of CD88, the C5aR, on MCTC cells. Lung MG(T) cells had negligible levels of chymase mRNA and retained their MCT phenotype in culture. Mature MCTC cells from skin and lung degranulated in response to Fc epsilon RI cross-linking, C5a, compound 48/80, and substance P. Lung MCTC cells released LTC4 on activation, but no LTC4 was detected when skin-derived MCTC cells were activated. MCT cells from lung degranulated and released LTC4 in response to anti-Fc epsilon RI and substance P, but not to C5a and compound 48/80. Conclusion: These observations functionally distinguish MCT from MCTC types of human mast cells and suggest important differences that may affect their participation in diseases such as asthma and urticaria.	Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Pediat, Richmond, VA USA; Virginia Commonwealth Univ, Dept Surg, Richmond, VA USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Schwartz, LB (corresponding author), Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol Allergy & Immunol, POB 980263, Richmond, VA 23298 USA.	lbschwar@vcu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027517, R01AI020487, K08AI057357] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 20487, R01 AI020487, R01 AI027517, K08 AI057357, K08 AI 057357, R01 AI 27517] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn K, 2000, J ALLERGY CLIN IMMUN, V106, P321, DOI 10.1067/mai.2000.108107; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; Bischoff SC, 2004, NEUROGASTROENT MOTIL, V16, P185, DOI 10.1111/j.1365-2982.2004.00502.x; Bischoff SC, 1999, P NATL ACAD SCI USA, V96, P8080, DOI 10.1073/pnas.96.14.8080; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; CHURCH MK, 1991, INT ARCH ALLER A IMM, V94, P310, DOI 10.1159/000235393; COLUMBO M, 1992, J IMMUNOL, V149, P599; CRAIG SS, 1989, LAB INVEST, V60, P147; DVORAK AM, 1992, J LEUKOCYTE BIOL, V51, P557, DOI 10.1002/jlb.51.6.557; EBERTZ JM, 1987, J INVEST DERMATOL, V88, P682, DOI 10.1111/1523-1747.ep12470339; Ferrer M, 1999, J ALLERGY CLIN IMMUN, V104, P169, DOI 10.1016/S0091-6749(99)70129-6; FUREDER W, 1995, J IMMUNOL, V155, P3152; Ghannadan M, 1998, J INVEST DERMATOL, V111, P689, DOI 10.1046/j.1523-1747.1998.00359.x; GIBSON PG, 1993, AM REV RESPIR DIS, V148, P80, DOI 10.1164/ajrccm/148.1.80; HEANEY LG, 1994, AGENTS ACTIONS, V41, pC19, DOI 10.1007/BF02007748; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; IRANI AMA, 1991, J IMMUNOL, V147, P247; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; Kambe N, 2000, J IMMUNOL METHODS, V240, P101, DOI 10.1016/S0022-1759(00)00174-5; Kambe N, 2001, BLOOD, V97, P2045, DOI 10.1182/blood.V97.7.2045; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; Kiener HP, 1998, ARTHRITIS RHEUM-US, V41, P233, DOI 10.1002/1529-0131(199802)41:2<233::AID-ART7>3.0.CO;2-V; Krug N, 2001, AM J RESP CRIT CARE, V164, P1841, DOI 10.1164/ajrccm.164.10.2010096; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; LOUIS RE, 1990, INT ARCH ALLER A IMM, V92, P329, DOI 10.1159/000235160; LOWMAN MA, 1988, J ALLERGY CLIN IMMUN, V81, P574, DOI 10.1016/0091-6749(88)90199-6; Nissen D, 1998, INFLAMM RES, V47, P501, DOI 10.1007/s000110050365; Oskeritzian CA, 1999, J IMMUNOL, V163, P5105; Oskeritzian CA, 2004, J IMMUNOL, V172, P593, DOI 10.4049/jimmunol.172.1.593; PATELLA V, 1995, J IMMUNOL, V154, P2855; RISKE F, 1991, J BIOL CHEM, V266, P11245; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; Shimizu Y, 2002, CLIN EXP ALLERGY, V32, P872, DOI 10.1046/j.1365-2222.2002.01373.x; Toru H, 1998, BLOOD, V91, P187, DOI 10.1182/blood.V91.1.187.187_187_195; Werfel T, 1996, SCAND J IMMUNOL, V44, P30, DOI 10.1046/j.1365-3083.1996.d01-272.x; Wojta J, 2002, BLOOD, V100, P517, DOI 10.1182/blood.V100.2.517; XIA HZ, 1995, J IMMUNOL, V154, P5472	39	107	111	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1162	1168		10.1016/j.jaci.2005.02.022	http://dx.doi.org/10.1016/j.jaci.2005.02.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940129	Green Accepted			2022-12-18	WOS:000229815400009
J	Raap, U; Goltz, C; Deneka, N; Bruder, M; Renz, H; Kapp, A; Wedi, B				Raap, U; Goltz, C; Deneka, N; Bruder, M; Renz, H; Kapp, A; Wedi, B			Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosinophil functions compared with that seen in nonatopic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; neurotrophins; atopic dermatitis; apoptosis; chemotasis; brain-derived neurotrophic factor	NERVE GROWTH-FACTOR; PERIPHERAL-BLOOD EOSINOPHILS; RECEPTOR TYROSINE KINASE; MEMORY B-LYMPHOCYTES; T-CELL-CLONES; IN-VITRO; AIRWAY INFLAMMATION; ENDOTHELIAL-CELLS; DISEASE-ACTIVITY; MAST-CELLS	Background: Recently, the pivotal role of brain-derived neurotrophic factor (BDNF) has been described in allergic asthma. However, the role of this neurotrophin in atopic dermatitis (AD) still remains unknown. Objective: The aim of this study was to investigate the functional role of BDNF on eosinophils and to assess BDNF levels in patients with AD and nonatopic control subjects. Methods: p75 Neurotrophin receptor and tyrosine kinase B receptor expression was demonstrated by using FACS analysis and immunohistochemistry. BDNF levels were assessed with ELISA and FACS analysis. Chemotactic activity (modified Boyden chamber assay), eosinophil cationic protein release (fluoroenzyme immunoassay), respiratory burst (lucigenin-dependent chemiluminescence), and apoptosis (Nicoletti protocol and Annexin-V method) assays were used to assess BDNF functional activity. Results: BDNF levels were increased in serum, plasma, eosinophils, and supernatants of stimulated eosinophils from patients with AD compared with levels seen in nonatopic control subjects (P <.05-.001). In addition, p75 neurotrophin receptor and tyrosine kinase B expression was higher on eosinophils from patients with AD compared with that seen on eosinophils from nonatopic control subjects (P <.05-.001). Eosinophil apoptosis was inhibited by BDNF (P <.05-.01) and chemotactic index was increased (P <.001) in BDNF-stimulated eosinophils front patients with AD, whereas this effect was not shown in eosinophils from nonatopic control subjects. However, no response of BDNF through the release of eosinophil cationic protein or reactive oxygen species was found. Conclusion: This study provides the first evidence for a functional role of BDNF on eosinophils from patients with AD, probably mediated by an increased expression of BDNF receptors compared with that seen in nonatopic control subjects. In addition, higher intracellular, serum, and plasma BDNF levels, as well as the release of BDNF by cosinophils, underline the particular importance of BDNF in patients with AD. pointing to new pathophysiologic aspects of this chronic inflammatory skin disease.	Hannover Med Univ, Dept Dermatol & Allergol, D-30449 Hannover, Germany; Univ Marburg, Dept Clin Chem & Mol Diagnost, D-35032 Marburg, Germany	Hannover Medical School; Philipps University Marburg	Raap, U (corresponding author), Hannover Med Univ, Dept Dermatol & Allergol, Rieklingerstr 5, D-30449 Hannover, Germany.	mail@ulrike-raap.de	Wedi, Bettina/ABE-3636-2021	Wedi, Bettina/0000-0002-9868-6308; Kapp, Alexander/0000-0002-1748-6276				ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; ALOE L, 1994, P NATL ACAD SCI USA, V91, P10440, DOI 10.1073/pnas.91.22.10440; Asaumi K, 2000, BONE, V26, P625, DOI 10.1016/S8756-3282(00)00281-7; Berro AI, 2004, J IMMUNOL, V173, P2174, DOI 10.4049/jimmunol.173.3.2174; Bierbaum H, 2003, ANN NY ACAD SCI, V1010, P225, DOI 10.1196/annals.1299.040; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; Braun A, 1998, EUR J IMMUNOL, V28, P3240, DOI 10.1002/(SICI)1521-4141(199810)28:10<3240::AID-IMMU3240>3.0.CO;2-U; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; Fox AJ, 2001, EUR J PHARMACOL, V424, P159, DOI 10.1016/S0014-2999(01)01138-4; Hamada A, 1996, BRIT J HAEMATOL, V93, P299, DOI 10.1046/j.1365-2141.1996.5151055.x; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KAPP A, 1993, ALLERGY, V48, P1, DOI 10.1111/j.1398-9995.1993.tb02167.x; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; Kerzel S, 2003, AM J RESP CELL MOL, V28, P170, DOI 10.1165/rcmb.4811; Kim H, 2004, J BIOL CHEM, V279, P33538, DOI 10.1074/jbc.M404115200; Kimata H, 2003, PHYSIOL BEHAV, V80, P395, DOI 10.1016/j.physbeh.2003.09.004; Kobayashi H, 2001, NEUROSCI LETT, V305, P157, DOI 10.1016/S0304-3940(01)01854-7; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Lambiase A, 1997, J ALLERGY CLIN IMMUN, V100, P408, DOI 10.1016/S0091-6749(97)70256-2; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; LEVIMONTALCINI R, 1995, J NEUROL SCI, V130, P119, DOI 10.1016/0022-510X(95)00007-O; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Liot G, 2004, EXP NEUROL, V187, P38, DOI 10.1016/j.expneurol.2004.01.002; Marconi A, 2003, J INVEST DERMATOL, V121, P1515, DOI 10.1111/j.1523-1747.2003.12624.x; MAZUREK N, 1986, FEBS LETT, V198, P315, DOI 10.1016/0014-5793(86)80428-8; Micera A, 2001, P NATL ACAD SCI USA, V98, P6162, DOI 10.1073/pnas.101130898; Miller FD, 2002, SCIENCE, V295, P1471, DOI 10.1126/science.1069897; Monleon E, 2004, J HISTOCHEM CYTOCHEM, V52, P145, DOI 10.1177/002215540405200201; Nassenstein C, 2003, J EXP MED, V198, P455, DOI 10.1084/jem.20010897; Noga O, 2003, CLIN EXP ALLERGY, V33, P649, DOI 10.1046/j.1365-2222.2003.01586.x; Noga O, 2002, CLIN EXP ALLERGY, V32, P1348, DOI 10.1046/j.1365-2745.2002.01442.x; Path G, 2002, AM J RESP CRIT CARE, V166, P818, DOI 10.1164/rccm.200202-134OC; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Saini HS, 2004, J NEUROCHEM, V89, P951, DOI 10.1111/j.1471-4159.2004.02365.x; Sanico AM, 2000, AM J RESP CRIT CARE, V161, P1631, DOI 10.1164/ajrccm.161.5.9908028; Solomon A, 1998, J ALLERGY CLIN IMMUN, V102, P454, DOI 10.1016/S0091-6749(98)70135-6; Tam SY, 1997, BLOOD, V90, P1807, DOI 10.1182/blood.V90.5.1807; Tanaka A, 2004, BIOCHEM BIOPH RES CO, V313, P1009, DOI 10.1016/j.bbrc.2003.12.036; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Toyoda M, 2003, CLIN EXP ALLERGY, V33, P950, DOI 10.1046/j.1365-2222.2003.01719.x; Toyoda M, 2002, BRIT J DERMATOL, V147, P71, DOI 10.1046/j.1365-2133.2002.04803.x; Virchow JC, 1998, AM J RESP CRIT CARE, V158, P2002, DOI 10.1164/ajrccm.158.6.9803023; Wedi B, 1999, INT ARCH ALLERGY IMM, V118, P234, DOI 10.1159/000024083; Wedi B, 1998, J ALLERGY CLIN IMMUN, V102, P1013, DOI 10.1016/S0091-6749(98)70340-9; Wedi B, 2002, J ALLERGY CLIN IMMUN, V109, P477, DOI 10.1067/mai.2002.121702; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536, DOI 10.1016/S0091-6749(97)70147-7	50	107	111	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1268	1275		10.1016/j.jaci.2005.02.007	http://dx.doi.org/10.1016/j.jaci.2005.02.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940146				2022-12-18	WOS:000229815400026
J	Balzar, S; Chu, HW; Silkoff, P; Cundall, M; Trudeau, JB; Strand, M; Wenzel, S				Balzar, S; Chu, HW; Silkoff, P; Cundall, M; Trudeau, JB; Strand, M; Wenzel, S			Increased TGF-beta 2 in severe asthma with eosinophilia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TGF-beta; eosinophils; connective tissue growth factor	GROWTH-FACTOR-BETA; MATRIX METALLOPROTEINASE EXPRESSION; BRONCHIAL EPITHELIAL-CELLS; HUMAN DERMAL FIBROBLASTS; SMOOTH-MUSCLE CELLS; TISSUE INHIBITOR; TGF-BETA; PERIPHERAL-BLOOD; DOWN-REGULATION; TNF-ALPHA	Background: Airway eosinophilia and thickened subepithelial basement membrane have previously been reported to increase with increases in TGF-beta expression. However, little is known regarding the expression of specific TGF-beta isoforms (TGF-beta1, TGF-beta2, and TGF-beta3) in asthma, despite recent evidence suggesting that isoforms may have differing biologic activities. Objective: This study examined airway tissue expression of the 3 TGF-beta isoforms and several downstream pathway elements in 48 patients with severe asthma with or without persistent - eosinophilia, 14 patients with mild asthma, and 21 normal subjects. Methods: Immunochemistry/immunofluorescence, quantitative real-time PCR and enzyme immunoassay were used to evaluate the 3 TGF-beta isoforms, their receptors, collagen I deposition, connective tissue growth factor expression, and tissue inhibitor of metalloproteinases 1 levels. Results: Of the isoforms, only TGF-beta2 was different among the groups and increased in severe asthma (overall P <.0001). The increase was due to severe asthma tissue eosinophils which, unlike eosinophils in other groups, expressed high amounts of TGF-beta2. Subjects with severe asthma also had the thickest subbasement membrane and highest tissue inhibitor of metalloproteinases I levels. In contrast, TGF-P receptor 1 and connective tissue growth factor were both consistently downregulated in asthma, regardless of severity. Conclusion: TGF-beta2, expressed mainly by eosinophils, is the predominant isoform expressed in severe asthma, and is associated with increased profibrotic responses. Decreased expression of TGF-beta receptor 1 and connective tissue growth factor in all asthma severity groups suggests a degree of activation of the TGF-beta pathway in airway tissue of all asthmatic compared with normal airways.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Balzar, S (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	balzars@njc.org	Strand, Matt/AAU-3762-2021; silkoff, philip/S-9037-2016	Strand, Matt/0000-0002-9083-5989; silkoff, philip/0000-0001-6018-5199	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040600] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00051] Funding Source: Medline; NHLBI NIH HHS [HL-64087] Funding Source: Medline; NIAID NIH HHS [AI-40600] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; Bartram U, 2004, CHEST, V125, P754, DOI 10.1378/chest.125.2.754; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487, DOI 10.1164/ajrccm.164.8.2101070; Burgess JK, 2003, AM J RESP CRIT CARE, V167, P71, DOI 10.1164/rccm.200205-416OC; Chen KH, 2003, CURR EYE RES, V26, P363, DOI 10.1076/ceyr.26.5.363.15442; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Chu HW, 2000, J ALLERGY CLIN IMMUN, V106, P1115; Coste A, 1998, ARCH OTOLARYNGOL, V124, P1361, DOI 10.1001/archotol.124.12.1361; Daniels JT, 2003, AM J PATHOL, V163, P2043, DOI 10.1016/S0002-9440(10)63562-6; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Fu MG, 2001, J BIOL CHEM, V276, P45888, DOI 10.1074/jbc.M105490200; GROTENDORST GR, 1989, J CELL PHYSIOL, V140, P396, DOI 10.1002/jcp.1041400226; Hartner A, 2003, J MOL MED-JMM, V81, P32, DOI 10.1007/s00109-002-0403-x; Hetzel M, 2003, THORAX, V58, P778, DOI 10.1136/thorax.58.9.778; Jude EB, 2002, DIABETIC MED, V19, P440, DOI 10.1046/j.1464-5491.2002.00692.x; Kim BC, 2003, J CELL PHYSIOL, V195, P331, DOI 10.1002/jcp.10301; Leask Andrew, 2002, Curr Rheumatol Rep, V4, P136, DOI 10.1007/s11926-002-0009-x; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Mautino G, 1999, LAB INVEST, V79, P39; Mautino G, 1999, AM J RESP CRIT CARE, V160, P324, DOI 10.1164/ajrccm.160.1.9808087; Mautino G, 1999, J ALLERGY CLIN IMMUN, V104, P530, DOI 10.1016/S0091-6749(99)70319-2; McKaig BC, 2003, AM J PATHOL, V162, P1355, DOI 10.1016/S0002-9440(10)63931-4; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Ohkawara Y, 2000, AM J RESP CELL MOL, V23, P444, DOI 10.1165/ajrcmb.23.4.3875; OVERALL CM, 1994, ANN NY ACAD SCI, V732, P51, DOI 10.1111/j.1749-6632.1994.tb24724.x; OVERALL CM, 1995, J CELL PHYSIOL, V164, P17, DOI 10.1002/jcp.1041640104; Phipps S, 2002, J IMMUNOL, V169, P4604, DOI 10.4049/jimmunol.169.8.4604; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; ROCHE WR, 1989, LANCET, V1, P520; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Schwingshackl A, 1999, J ALLERGY CLIN IMMUN, V104, P983, DOI 10.1016/S0091-6749(99)70079-5; SLAVIN J, 1994, GROWTH FACTORS, V11, P205, DOI 10.3109/08977199409046918; Streilein JW, 2002, DNA CELL BIOL, V21, P453, DOI 10.1089/10445490260099746; Synek M, 1996, AM J RESP CRIT CARE, V154, P224, DOI 10.1164/ajrccm.154.1.8680684; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Wen FQ, 2002, AM J RESP CELL MOL, V26, P484, DOI 10.1165/ajrcmb.26.4.4784; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Woerly G, 2002, J LEUKOCYTE BIOL, V72, P769; Yamane K, 2003, J IMMUNOL, V171, P3855, DOI 10.4049/jimmunol.171.7.3855; Yu L, 2003, KIDNEY INT, V64, P844, DOI 10.1046/j.1523-1755.2003.00162.x	43	107	113	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					110	117		10.1016/j.jaci.2004.09.034	http://dx.doi.org/10.1016/j.jaci.2004.09.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637555				2022-12-18	WOS:000226267000015
J	Kanny, G; Pichler, W; Morisset, M; Franck, P; Marie, B; Kohler, C; Renaudin, JM; Beaudouin, E; Sainte Laudy, J; Moneret-Vautrin, DA				Kanny, G; Pichler, W; Morisset, M; Franck, P; Marie, B; Kohler, C; Renaudin, JM; Beaudouin, E; Sainte Laudy, J; Moneret-Vautrin, DA			T cell-mediated reactions to iodinated contrast media: Evaluation by skin and lymphocyte activation tests	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adverse drug reaction; drug allergy; iodinated contrast media; patch test; intradermal test; T cell-mediated hypersensitivity; cross-sensitivity; multiple drug allergy	DELAYED ADVERSE-REACTIONS; HYPERSENSITIVITY; ALLERGY; UROGRAPHY; TRANSFORMATION; INJECTION; DIAGNOSIS	Background: In addition to immediate reactions, late adverse reactions to iodinated contrast media (ICM) were reported in 2% to 5% of patients exposed to ICM and, as a consequence, have recently gained more attention. A few well-documented case reports postulate a hypersensitivity mechanism. Objective: The aim of this study is to demonstrate a T cell-mediated mechanism to the ICM by using in vitro and ex vivo tests. Methods: We analyzed 12 patients with 13 adverse ICM reactions, 9 of whom were women. Clinical history suggested an immune reaction to ICM. Skin tests (skin prick, intradermal, and patch tests) were performed with various ICM and read after 15 minutes and 24 and 48 hours. Skin biopsy specimens of positive test sites of 11 patients were evaluated by means of immunohistology. T-cell reactivity to ICM in vitro was analyzed with lymphocyte activation tests. Results: Seven patients showed generalized maculopapular eruptions, one of them with fever; 4 had a so-called drug hypersensitivity syndrome with exanthema, eosinophilia, and fever; 1 had maculopapular eruptions and fever; 1 had late-onset urticaria with loss of consciousness; and 1 had facial edema and respiratory distress. An immune reaction to ICM was inferred from positive skin prick test (2 patients), positive patch test (10 patients), and positive intradermal test (9 patients) at 24 and 48 hours. Skin biopsy specimens revealed a T-cell infiltrate in the dermis with predominantly CD4(+) T cells in 8 patients, CD8(+) T cells in I patient, and equal numbers in 1 patient. Cross-sensitivities to several ICM were observed (9/12). Other drug allergies were noted in 6 of the 12 patients. Conclusions: Delayed reactions to ICM are most likely caused by immune reactions to these drugs and can elicit different clinical features. The involvement of T cells is suggested by positive skin test, as well as positive proliferative responses, to the drugs in vitro. A high degree of cross-reactivity with other than the eliciting ICM was observed. Moreover, 50% of these patients reported another drug hypersensitivity, suggesting a predisposition to immune reactivity in some patients.	Univ Nancy, Hop Cent, Dept Internal Med Clin Immunol & Allergol, F-54035 Nancy, France; Inselspital Bern, Div Allergol, Clin Rheumatol & Clin Immunol Allergol, Bern, Switzerland; Fac Med Vandoeuvre Nancy, Immunol Lab, F-54505 Vandoeuvre Les Nancy, France; Lab Immunol & Allergol, Paris, France	CHU de Nancy; Universite de Lorraine; University of Bern; University Hospital of Bern; Universite de Lorraine	Kanny, G (corresponding author), Univ Nancy, Hop Cent, Dept Internal Med Clin Immunol & Allergol, 29 Ave Lattre de Tassigny, F-54035 Nancy, France.	g.kanny@chu-nancy.fr	Kanny, Gisèle/AHA-8910-2022; Morisset, Martine/A-3084-2017	Pichler, Werner J./0000-0002-8117-359X; Morisset, Martine/0000-0002-4028-703X				Akiyama M, 1998, ACAD RADIOL, V5, pS159, DOI 10.1016/S1076-6332(98)80092-5; Asero R, 2001, Curr Allergy Rep, V1, P18, DOI 10.1007/s11882-001-0092-5; BENSON PM, 1990, J AM ACAD DERMATOL, V23, P379, DOI 10.1016/0190-9622(90)70227-9; BOROFSKY HB, 1993, ADV XRAY CONTRAST, V1, P58; Brockow K, 2002, ALLERGY, V57, P45; Brockow K, 1999, J ALLERGY CLIN IMMUN, V104, P1107, DOI 10.1016/S0091-6749(99)70096-5; Brockow K, 1999, Allerg Immunol (Paris), V31, P49; BURTON JL, 1999, AUSTRALAS RADIOL, V43, P360; CHOYKE PL, 1992, RADIOLOGY, V183, P111, DOI 10.1148/radiology.183.1.1549655; Christiansen C, 2000, EUR RADIOL, V10, P1965, DOI 10.1007/s003300000543; Christiansen C, 2002, CURR OPIN ALLERGY CL, V2, P333, DOI 10.1097/00130832-200208000-00007; Courvoisier S, 1998, ALLERGY, V53, P1221, DOI 10.1111/j.1398-9995.1998.tb03846.x; Gall H, 1999, CONTACT DERMATITIS, V40, P248, DOI 10.1111/j.1600-0536.1999.tb06058.x; GonzaloGarijo MA, 1997, ALLERGY, V52, P875, DOI 10.1111/j.1398-9995.1997.tb02164.x; GOODFELLOW T, BR J RADIOL, V59, P620; Hari Y, 2001, CLIN EXP ALLERGY, V31, P1398, DOI 10.1046/j.1365-2222.2001.01164.x; Hosoya T, 2000, Radiat Med, V18, P39; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kanny G, 1993, Allerg Immunol (Paris), V25, P425; Kanny G, 2001, EUR J DERMATOL, V11, P134; KANSAKI T, 1991, J DERMATOL, V18, P528; Kohler C, 1997, ANAL CELL PATHOL, V14, P51, DOI 10.1155/1997/376292; LANG DM, 1993, ARCH INTERN MED, V153, P2033, DOI 10.1001/archinte.153.17.2033; Mikkonen R, 2000, ACTA RADIOL, V41, P390; Moneret-Vautrin DA, 2001, REV MED INTERNE, V22, P969, DOI 10.1016/S0248-8663(01)00455-6; Munechika H, 2003, EUR RADIOL, V13, P185, DOI 10.1007/s00330-002-1339-9; Nyfeler B, 1997, CLIN EXP ALLERGY, V27, P175, DOI 10.1111/j.1365-2222.1997.tb00690.x; PANTO PN, 1986, BRIT J RADIOL, V59, P41, DOI 10.1259/0007-1285-59-697-41; Pichler WJ, 1998, ALLERGY, V53, P225, DOI 10.1111/j.1398-9995.1998.tb03881.x; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; PICHLER WJ, 2003, P 21 EAACI C 2002 NA, P193; REYNOLDS NJ, 1993, BRIT J DERMATOL, V129, P82, DOI 10.1111/j.1365-2133.1993.tb03317.x; Romano A, 2002, RADIOLOGY, V225, P466, DOI 10.1148/radiol.2251011654; Rosado A, 2001, AM J ROENTGENOL, V176, P262, DOI 10.2214/ajr.176.1.1760262; Rydberg J, 1998, ACTA RADIOL, V39, P219; SABBAH A, 1996, ACI INT, V8, P116; SAVADER SJ, 1995, J INTERVENT RADIOL, V10, P115; SAVILL JS, 1988, POSTGRAD MED J, V64, P392, DOI 10.1136/pgmj.64.751.392; Schick E, 1996, CONTACT DERMATITIS, V35, P312, DOI 10.1111/j.1600-0536.1996.tb02403.x; VAILLANT L, 1990, CLIN EXP DERMATOL, V15, P232, DOI 10.1111/j.1365-2230.1990.tb02079.x; Watanabe H, 1999, DERMATOLOGY, V198, P291, DOI 10.1159/000018133; Webb JAW, 2003, EUR RADIOL, V13, P181, DOI 10.1007/s00330-002-1650-5; Yasuda R, 1998, INVEST RADIOL, V33, P1, DOI 10.1097/00004424-199801000-00001; YOSHIKAWA H, 1992, RADIOLOGY, V183, P737, DOI 10.1148/radiology.183.3.1584929; ZUKIWSKI AA, 1990, CANCER, V65, P1521, DOI 10.1002/1097-0142(19900401)65:7<1521::AID-CNCR2820650712>3.0.CO;2-Y	45	107	115	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					179	185		10.1016/j.jaci.2004.09.012	http://dx.doi.org/10.1016/j.jaci.2004.09.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637566				2022-12-18	WOS:000226267000026
J	Becker, JM; Rogers, J; Rossini, G; Mirchandani, H; D'Alonzo, GE				Becker, JM; Rogers, J; Rossini, G; Mirchandani, H; D'Alonzo, GE			Asthma deaths during sports: Report of a 7-year experience	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; competitive athlete; recreational athlete; asthma mortality; sudden death; cardiac death; mild intermittent asthma	SUDDEN-DEATH; HIGH-SCHOOL; EXERCISE; FITNESS; LESSONS; HISTORY; TRENDS	Background: Asthma mortality and the mortality of athletes during sports have been described separately in detail in the medical literature. However, asthma has not been reported as a cause of death in competitive athletes. Objective: The object of this study was to raise the awareness of physicians, coaches, trainers, and parents that children and adults can have fatal asthma exacerbations during and immediately after participating in sports. Methods: The Temple Sports Asthma Research Center identified athletes from 1993 until 2000 who died during or after sporting activity by using the nationwide Burrell's Information Service. Once a possible asthma-related sports death was identified, the autopsy report was requested from the coroner or medical examiner, and an attempt was made to contact the family. Contact with the family was limited to information about the death, medical history, sports involvement, and any medication usage by the person who had died. Secondary sources, including news reports, were used to confirm whether the subject died of asthma during or immediately after a sporting activity. Results: Two hundred sixty-three possible cases were identified. Sixty-one deaths met the criteria for study inclusion. White deaths outnumbered black deaths by 2 to 1. Deaths among male subjects predominated. Most subjects were younger than the age of 20 years, with the most prevalent age group being between 10 to 14 years old. Fifty-one percent (18 of 35) of the competitive athletes had their fatal event while participating in organized sport, 14 in a practice situation and 4 deaths during a game or meet setting. Basketball and track were the 2 most frequent activities performed at the time of the fatal event. Conclusion: The subjects who had fatal asthma exacerbations were usually white male subjects between the ages of 10 and 20 years. Mild intermittent or persistent asthma by history was commonly identified. Sudden fatal asthma exacerbations occur in both competitive and recreational athletes and can be precipitated by sporting activity.	Drexel Univ, Coll Med, Dept Pediat, St Christophers Hosp Children,Sect Allergy Asthma, Philadelphia, PA 19134 USA; Temple Univ, Sch Med, Div Pulm & Crit Care Med, Dept Med, Philadelphia, PA USA; Temple Univ, Sch Med, Div Pulm & Crit Care Med, Dept Sports Med, Philadelphia, PA USA	Drexel University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Becker, JM (corresponding author), Drexel Univ, Coll Med, Dept Pediat, St Christophers Hosp Children,Sect Allergy, Front St Erie Ave, Philadelphia, PA 19134 USA.							Ades PA, 2000, MED CLIN N AM, V84, P251, DOI 10.1016/S0025-7125(05)70217-0; Barr RG, 2000, EUR RESPIR J, V15, P266, DOI 10.1034/j.1399-3003.2000.15b08.x; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; Bourjeily G, 2000, CLIN CHEST MED, V21, P763, DOI 10.1016/S0272-5231(05)70183-0; Campbell MJ, 1997, BRIT MED J, V314, P1439, DOI 10.1136/bmj.314.7092.1439; Cantu RC, 1999, PHYSICIAN SPORTSMED, V27, P35, DOI 10.3810/psm.1999.08.945; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; Counil FP, 2003, J PEDIATR-US, V142, P179, DOI 10.1067/mpd.2003.83; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; Kukafka DS, 1998, CHEST, V114, P1613, DOI 10.1378/chest.114.6.1613; KUNITOH H, 1992, ANN ALLERGY, V69, P111; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; McFadden ER, 1997, ANN INTERN MED, V127, P142, DOI 10.7326/0003-4819-127-2-199707150-00009; MOLFINO NA, 1991, NEW ENGL J MED, V324, P285, DOI 10.1056/NEJM199101313240502; Neder JA, 1999, THORAX, V54, P202, DOI 10.1136/thx.54.3.202; O'Grady M, 2000, RHEUM DIS CLIN N AM, V26, P617, DOI 10.1016/S0889-857X(05)70159-9; Paluska SA, 2000, SPORTS MED, V29, P167, DOI 10.2165/00007256-200029030-00003; ROBERTSON CF, 1992, PEDIATR PULM, V13, P95, DOI 10.1002/ppul.1950130207; RUPP NT, 1993, ANN ALLERGY, V70, P339; Shadick NA, 1999, J ALLERGY CLIN IMMUN, V104, P123, DOI 10.1016/S0091-6749(99)70123-5; SLY RM, 1994, ANN ALLERGY, V73, P259; Sothern MS, 2001, PEDIATR CLIN N AM, V48, P995, DOI 10.1016/S0031-3955(05)70353-9; Strunk RC, 1998, IMMUNOL ALLERGY CLIN, V18, P85, DOI 10.1016/S0889-8561(05)70349-0; Strunk RC, 1999, J ALLERGY CLIN IMMUN, V104, P763, DOI 10.1016/S0091-6749(99)70285-X; Thomas SD, 1999, CHEST, V116, p135S, DOI 10.1378/chest.116.suppl_2.135S; WASSERFALLEN JB, 1990, AM REV RESPIR DIS, V142, P108, DOI 10.1164/ajrccm/142.1.108; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323	30	107	110	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					264	267		10.1016/j.jaci.2003.10.052	http://dx.doi.org/10.1016/j.jaci.2003.10.052			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767440				2022-12-18	WOS:000188885700013
J	Manfredi, M; Severino, M; Testi, S; Macchia, D; Ermini, G; Pichler, WJ; Campi, P				Manfredi, M; Severino, M; Testi, S; Macchia, D; Ermini, G; Pichler, WJ; Campi, P			Detection of specific IgE to quinolones	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adverse drug reaction; serum IgE; quinolones	ANAPHYLACTOID REACTIONS; HEMOLYTIC-ANEMIA; CIPROFLOXACIN; PATIENT; SHOCK; HYPERSENSITIVITY; FAILURE	Background: In the last years, immediate reactions to quinolone antibiotics have been observed with increasing frequency, mainly urticaria, angioedema, and shock. No test was available because of the high incidence of false-positive results on skin tests. Thus the pathogenesis, value of diagnostic procedures, and cross-reactivity have not been evaluated in a systematic way. Objective: We sought to assess whether these reactions are IgE mediated and whether an in vitro test for quinolone-specific IgE is useful in the diagnosis and understanding of cross-reactivity. Methods: We assayed specific serum IgE to quinolones using epoxy-activated sepharose 6B as the solid phase in 55 patients with immediate adverse reactions; specificity of IgE binding was demonstrated by inhibition tests. Results: The test yielded positive results in 30 (54.5%) patients who were tested 1 to 48 months after the reaction had occurred. The quinolone-specific IgE seems to disappear more slowly in atopic patients. The cross-reactivity between various quinolones allowed us to identify a common structural motif within quinolones that might be responsible for clinical and serologic cross-reactivity. Conclusion: A substantial portion of immediate reactions to quinolones appear to be IgE mediated. Cross-reactivity of IgE among different quinolones is frequent and suggests that a common avoidance of quinolones should be attempted in all patients with respective symptoms.	Nuovo Osped San Giovanni Dio, Allergol & Immunol Clin, I-50143 Florence, Italy; Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland	Presidio Ospedaliero San Giovanni di Dio; University of Bern; University Hospital of Bern	Campi, P (corresponding author), Nuovo Osped San Giovanni Dio, Allergol & Immunol Clin, Via Torregalli 3, I-50143 Florence, Italy.			Macchia, Donatella/0000-0001-9143-4186; Pichler, Werner J./0000-0002-8117-359X				ALONSO MD, 1993, ALLERGY, V48, P296, DOI 10.1111/j.1398-9995.1993.tb00733.x; Arata J, 1998, ANTIMICROB AGENTS CH, V42, P3141, DOI 10.1128/AAC.42.12.3141; Arboit F, 1997, REV FR ALLERGOL, V37, P15, DOI 10.1016/S0335-7457(97)80204-3; ASSOUAD M, 1995, ANN INTERN MED, V122, P396, DOI 10.7326/0003-4819-122-5-199503010-00026; BALDO BA, 1990, MONOGR ALLERGY, V28, P11; BLUM MD, 1994, CLIN INFECT DIS, V18, P946, DOI 10.1093/clinids/18.6.946; Campi P, 2003, CURR OPIN ALLERGY CL, V3, P275, DOI [10.1097/00130832-200308000-00007, 10.1097/01.all.0000083950.99396.79]; COLAS C, 1993, J ALLERGY CLIN IMMUN, V91, P365; CORREIA O, 1994, ARCH DERMATOL, V130, P808, DOI 10.1001/archderm.130.6.808; DAVILA I, 1993, ALLERGY, V48, P388, DOI 10.1111/j.1398-9995.1993.tb02413.x; DAVIS H, 1989, ANN INTERN MED, V111, P1041, DOI 10.7326/0003-4819-111-12-1041; DEAMER RL, 1992, ANN PHARMACOTHER, V26, P1081, DOI 10.1177/106002809202600905; DRAGO F, 1994, BRIT J DERMATOL, V131, P448, DOI 10.1111/j.1365-2133.1994.tb08538.x; Fernandez M, 1995, ALLERGY S26, V50, P211; GeaBanacloche JC, 1996, J ALLERGY CLIN IMMUN, V97, P1426, DOI 10.1016/S0091-6749(96)70218-X; GERBER D, 1985, S AFR MED J, V67, P999; GRASSMICK BK, 1992, ANN PHARMACOTHER, V26, P636, DOI 10.1177/106002809202600504; HARLE DG, 1987, INT ARCH ALLER A IMM, V84, P277, DOI 10.1159/000234435; KAWADA A, 1994, CONTACT DERMATITIS, V31, P182, DOI 10.1111/j.1600-0536.1994.tb01962.x; KURATA M, 1995, INFLAMM RES, V44, P461, DOI 10.1007/BF01837910; KURUMAJI Y, 1992, CONTACT DERMATITIS, V26, P5, DOI 10.1111/j.1600-0536.1992.tb00860.x; Lantner RR, 1995, J ALLERGY CLIN IMMUN, V96, P1001, DOI 10.1016/S0091-6749(95)70240-7; Lucena MI, 2000, CLIN INFECT DIS, V30, P400, DOI 10.1086/313680; MAGUIRE RB, 1994, AM J HEMATOL, V46, P363, DOI 10.1002/ajh.2830460420; MARSEPOIL T, 1985, PRESSE MED, V14, P1712; MILLER MS, 1991, PEDIATR INFECT DIS J, V10, P164, DOI 10.1097/00006454-199102000-00020; Munoz-Pereira M, 1995, ALLERGY S26, V50, P211; PACE JL, 1989, BRIT MED J, V299, P658, DOI 10.1136/bmj.299.6700.658; PETERS B, 1989, BRIT MED J, V298, P605, DOI 10.1136/bmj.298.6673.605-b; Pham NH, 1996, CLIN EXP ALLERGY, V26, P1155, DOI 10.1111/j.1365-2222.1996.tb00502.x; PINZANI V, 1992, THERAPIE, V47, P440; REANO M, 1995, ALLERGY S26, V50, P212; SEROPIAN E, 1976, ALLERGOL IMMUNOPATH, V4, P435; SOETIKNO RM, 1993, ANN PHARMACOTHER, V27, P1404, DOI 10.1177/106002809302701118; TAFANI O, 1982, BRIT MED J, V285, P936, DOI 10.1136/bmj.285.6346.936-a; VALDIVIESO R, 1988, ALLERGY, V43, P71, DOI 10.1111/j.1398-9995.1988.tb02046.x; VIELUF D, 1991, Journal of Allergy and Clinical Immunology, V87, P228, DOI 10.1016/0091-6749(91)91638-A; WURTZ RM, 1989, LANCET, V1, P955	38	107	115	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					155	160		10.1016/j.jaci.2003.09.035	http://dx.doi.org/10.1016/j.jaci.2003.09.035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713922	Bronze			2022-12-18	WOS:000187837900021
J	Erpenbeck, VJ; Hohlfeld, JM; Volkmann, B; Hagenberg, A; Geldmacher, H; Braun, A; Krug, N				Erpenbeck, VJ; Hohlfeld, JM; Volkmann, B; Hagenberg, A; Geldmacher, H; Braun, A; Krug, N			Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; IL-9; segmental allergen challenge; real-time PCR	CELL GROWTH-FACTOR; PULMONARY INFLAMMATION; RECEPTOR EXPRESSION; AIRWAY INFLAMMATION; T-CELLS; INTERLEUKIN-9; EOSINOPHILS; ANTIBODY; CD4(+)	Background: IL-9 is a T(H)2 cell-derived cytokine that might be involved in the pathophysiology of allergic diseases. Little is known about its expression and release during the allergic response in the human lung. Objective: The expression of IL-9 was measured in 10 atopic subjects with mild asthma and 5 nonatopic healthy control subjects at baseline and 24 hours after segmental sham and allergen challenge. Methods: IL-9 protein was measured in bronchoalveolar lavage (BAL) fluid by means of ELISA and detected within the BAL cells by means of immunocytochemistry. Furthermore, IL9 mRNA expression of BAL cells was detected by means of real-time PCR. Results: Although only low or undetectable amounts of IL9 mRNA and IL-9 protein were present in nonatopic control subjects and atopic asthmatic patients at baseline, there was an increase after segmental allergen challenge in the atopic subjects. Lymphocytes were identified as major cellular sources of IL-9 production by means of immunocytochemistry. Furthermore. IL-9 protein and IL9 mRNA expression correlated with eosinophil numbers in BAL fluid. Conclusions: These findings demonstrate that IL-9 is specifically upregulated after local allergen challenge in the lungs of atopic asthmatic patients. Lymphocytes are the major cellular source of IL-9. The increased expression and its correlation with eosinophil numbers suggest a potential role for IL-9 in the late phase of the allergic response. (J Allergy Clin Immunol 2003:111:1319-27.).	Fraunhofer Inst Toxicol & Expt Med, D-30625 Hannover, Germany; Hannover Med Sch, Dept Resp Med, D-3000 Hannover, Germany	Fraunhofer Gesellschaft; Hannover Medical School	Erpenbeck, VJ (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Nikolai Fuchs Str 1a, D-30625 Hannover, Germany.		Braun, Armin/B-8750-2009	Braun, Armin/0000-0002-1142-1463; Hohlfeld, Jens/0000-0003-2646-6186				Bhathena PR, 2000, LUNG, V178, P149, DOI 10.1007/s004080000018; Cheng G, 2002, AM J RESP CRIT CARE, V166, P409, DOI 10.1164/rccm.2105079; Dong Q, 1999, EUR J IMMUNOL, V29, P2130, DOI 10.1002/(SICI)1521-4141(199907)29:07<2130::AID-IMMU2130>3.0.CO;2-S; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; Gounni AS, 2000, J ALLERGY CLIN IMMUN, V106, P460, DOI 10.1067/mai.2000.109172; Gounni AS, 2000, BLOOD, V96, P2163; HOUSSIAU FA, 1992, J IMMUNOL, V148, P3147; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; Jenmalm MC, 2001, CLIN EXP ALLERGY, V31, P1528, DOI 10.1046/j.1365-2222.2001.01190.x; Krug N, 2001, AM J RESP CELL MOL, V25, P125, DOI 10.1165/ajrcmb.25.1.4194; Kung TT, 2001, AM J RESP CELL MOL, V25, P600, DOI 10.1165/ajrcmb.25.5.4533; Levitt RC, 1999, J ALLERGY CLIN IMMUN, V103, pS485, DOI 10.1016/S0091-6749(99)70165-X; Little FF, 2001, AM J RESP CELL MOL, V25, P347, DOI 10.1165/ajrcmb.25.3.4349; Louahed J, 2001, BLOOD, V97, P1035, DOI 10.1182/blood.V97.4.1035; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; MODI WS, 1991, CYTOGENET CELL GENET, V57, P114, DOI 10.1159/000133126; OBRIEN PJ, 2002, AM J RESP CRIT CARE, V165, pA202; RENAULD JC, 1993, CANCER INVEST, V11, P635, DOI 10.3109/07357909309011682; SCHMITT E, 1994, J IMMUNOL, V153, P3989; Sedgwick JB, 1996, J IMMUNOL METHODS, V198, P15, DOI 10.1016/0022-1759(96)00139-1; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Toda M, 2002, J ALLERGY CLIN IMMUN, V109, P246, DOI 10.1067/mai.2002.121555; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; Ying S, 2002, CLIN EXP ALLERGY, V32, P866, DOI 10.1046/j.1365-2222.2002.01376.x; 1992, CLIN EXP ALLERGY S1, V22, P1	27	107	121	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1319	1327		10.1067/mai.2003.1485	http://dx.doi.org/10.1067/mai.2003.1485			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789235				2022-12-18	WOS:000183424700023
J	Marshall, JD; Abtahi, S; Eiden, JJ; Tuck, S; Milley, R; Haycock, F; Reid, MJ; Kagey-Sobotka, A; Creticos, PS; Lichtenstein, LM; Van Nest, G				Marshall, JD; Abtahi, S; Eiden, JJ; Tuck, S; Milley, R; Haycock, F; Reid, MJ; Kagey-Sobotka, A; Creticos, PS; Lichtenstein, LM; Van Nest, G			Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; T(H)1/T(H)2; cytokines; immunotherapy	IFN-GAMMA PRODUCTION; IN-VITRO; CPG OLIGODEOXYNUCLEOTIDES; DENDRITIC CELLS; T-CELLS; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; BACTERIAL-DNA; B-CELLS; INFLAMMATION; ACTIVATION	Background: Recent studies have demonstrated that bacterially derived immunostimulatory sequences (ISSs) of DNA can activate the mammalian innate immune system and promote the development of T(H)1 cells. Promotion of T(H)1 immunity by means of immunotherapy in allergic patients has led to the alleviation of symptoms that result from allergen-specific T(H)2 responses. Objective: Our purpose was to investigate whether the T(H)1-enhancing properties of ISSs could be used to alter the T(H)2-dominated immune response of allergic PBMCs in vitro. Methods: Ragweed protein-Iinked ISS (PLI) was generated from a specific, highly active 22-base ISS and Amb a 1, the immunodominant allergen in ragweed pollen, to combine the T(H)1-enhancing properties of ISSs with allergen selectivity, and its activity was investigated in PBMC cultures from subjects with ragweed allergy. Results: PLI was markedly successful at reversing the dominant allergen-induced T(H)2 profile while greatly enhancing IFN-gamma production. Delivering ISSs in a linked form proved to be much more effective at modulating the resulting cytokine profile than delivering free ISSs in a mixture with unlinked Amb a 1. PLI also demonstrated cytokine-modulating properties, even when used to stimulate cells that had already been primed for 6 days with Amb a 1. The antigen specificity of the action of PLI was confirmed by the observations that PLI enhances Arab a 1-specific T-cell proliferation. Conclusion: These data indicate that delivery of ISSs within an antigen-specific context exhibits potent cytokine-modulating activity and, combined with its reduced allergenicity, makes this molecule a strong candidate for use in improved immunotherapy applications.	Dynavax Technol Corp, Berkeley, CA 94710 USA; Johns Hopkins Univ, Ctr Asthma & Allergy, Baltimore, MD 21224 USA	Johns Hopkins University	Van Nest, G (corresponding author), Dynavax Technol Corp, 717 Potter St,Ste 100, Berkeley, CA 94710 USA.		Marshall, Jason/ABA-2542-2020	Marshall, Jason/0000-0002-7864-803X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, R01AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08270] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bauer M, 1999, IMMUNOLOGY, V97, P699, DOI 10.1046/j.1365-2567.1999.00811.x; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Broide D, 1998, J IMMUNOL, V161, P7054; Cho HJ, 2000, NAT BIOTECHNOL, V18, P509, DOI 10.1038/75365; CRETICOS PS, 2000, P AAAAI 56 ANN M SAN; Fujimura T, 1997, J ALLERGY CLIN IMMUN, V100, P274, DOI 10.1016/S0091-6749(97)70236-7; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Hartmann G, 1999, GENE THER, V6, P893, DOI 10.1038/sj.gt.3300880; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Iho S, 1999, J IMMUNOL, V163, P3642; Jakob T, 1998, J IMMUNOL, V161, P3042; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258, DOI 10.1016/S0091-6749(99)70022-9; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Liang H, 1996, J CLIN INVEST, V98, P1119, DOI 10.1172/JCI118894; Liu HM, 1998, BLOOD, V92, P3730, DOI 10.1182/blood.V92.10.3730.422k20_3730_3736; Maggi E, 1998, IMMUNOTECHNOLOGY, V3, P233, DOI 10.1016/S1380-2933(97)10005-7; MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264; MARSHALL JD, 1995, J IMMUNOL, V155, P111; Martin-Orozco E, 1999, INT IMMUNOL, V11, P1111, DOI 10.1093/intimm/11.7.1111; Parronchi P, 1999, J IMMUNOL, V163, P5946; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Schwartz DA, 1999, J IMMUNOL, V163, P224; Shirota H, 2000, J IMMUNOL, V164, P5575, DOI 10.4049/jimmunol.164.11.5575; Sonehara K, 1996, J INTERF CYTOK RES, V16, P799, DOI 10.1089/jir.1996.16.799; Sur S, 1999, J IMMUNOL, V162, P6284; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Vabulas RM, 2000, J IMMUNOL, V164, P2372, DOI 10.4049/jimmunol.164.5.2372; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; Weiner GJ, 1997, P NATL ACAD SCI USA, V94, P10833, DOI 10.1073/pnas.94.20.10833; YAMAMOTO S, 1992, MICROBIOL IMMUNOL, V36, P983, DOI 10.1111/j.1348-0421.1992.tb02102.x; YAMAMOTO T, 1994, JPN J CANCER RES, V85, P775, DOI 10.1111/j.1349-7006.1994.tb02947.x	32	107	117	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					191	197		10.1067/mai.2001.116984	http://dx.doi.org/10.1067/mai.2001.116984			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496233				2022-12-18	WOS:000170584600004
J	Hashimoto, S; Gon, Y; Takeshita, I; Maruoka, S; Horie, T				Hashimoto, S; Gon, Y; Takeshita, I; Maruoka, S; Horie, T			IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase-dependent pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-4; IL-13; human lung fibroblast; myofibroblast; mitogen-activated protein kinase; c-Jun NH2-terminal kinase	ACTIVATED PROTEIN-KINASE; BRONCHIAL EPITHELIAL-CELLS; HEMATOPOIETIC GROWTH-FACTORS; HUMAN SYNOVIAL FIBROBLASTS; N-TERMINAL KINASE; IN-VITRO; TRANSFORMING GROWTH-FACTOR-BETA-1; SIGNAL-TRANSDUCTION; CYTOKINE SYNTHESIS; HUMAN MONOCYTES	Background: Myofibroblasts play a role in the airway remodeling response of bronchial asthma, IL-4 and IL-13 are possibly involved in the airway remodeling response by inducing extracellular matrix production by fibroblasts, However, the roles of these cytokines in inducing the phenotypic modulation of human lung fibroblasts (HLFs) to myofibroblasts and the intracellular signal have not been determined, Objective: We examined the effect of IL-4 and IL-13 on inducing the phenotypic modulation of HLFs to myofibroblasts characterized by alpha -smooth muscle actin and examined the role of the mitogen-activated protein (MAP) kinase superfamily in inducing the myofibroblastic phenotype of the HLF to clarify these issues, Methods: Phosphorylation and activities of c-Jun NH2-terminal kinase (JNK), p38 MAP kinase, and extracellular signal-regulated kinase (Erk) were examined by using Western blotting. and in vitro kinase assay, Expression of a-smooth muscle actin in IL-4- and IL-13-stimulated HLFs was analyzed by means of Western blotting, Results: The results showed that (1) IL-4 and IL-13 increased alpha -smooth muscle actin expression in a dose- and time-dependent manner; (2) IL-4 and IL-13 induced increases in JNK and Erk phosphorylation and activity but not p38 MAP kinase activity; (3) CEP-1347 and PD 98059 attenuated IL-4- and IL13-induced JNK and Erk activity, respectively; and (4) CEP-1347, but not PD 98059, attenuated IL-4- and IL13-induced alpha -smooth muscle actin expression, Conclusion: These results indicate that IL-4 and IL-13 are capable of inducing the phenotypic modulation of HLFs to myofibroblasts, and JNK, but not p38 MAP kinase and Erk, regulates IL-4- and IL-13-induced phenotypic modulation of HLFs to myofibroblasts.	Nihon Univ, Sch Med, Dept Internal Med 1, Itabashi Ku, Tokyo 1738610, Japan	Nihon University	Hashimoto, S (corresponding author), Nihon Univ, Sch Med, Dept Internal Med 1, Itabashi Ku, 30-1 Oyaguchikmimchi, Tokyo 1738610, Japan.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035, DOI 10.1164/ajrccm.160.3.9902064; Chuang LM, 1996, J BIOCHEM-TOKYO, V120, P111; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Doucet C, 1998, INT IMMUNOL, V10, P1421, DOI 10.1093/intimm/10.10.1421; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Feng NP, 1998, LAB INVEST, V78, P591; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; Hashimoto S, 1999, AM J RESP CRIT CARE, V159, P634, DOI 10.1164/ajrccm.159.2.9712090; Hashimoto S, 2001, AM J RESP CRIT CARE, V163, P152, DOI 10.1164/ajrccm.163.1.2005069; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Khew-Goodall Y, 1999, ARTERIOSCL THROM VAS, V19, P1421, DOI 10.1161/01.ATV.19.6.1421; Kujime K, 2000, J IMMUNOL, V164, P3222, DOI 10.4049/jimmunol.164.6.3222; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LESLIE KO, 1992, CELL MOTIL CYTOSKEL, V22, P92, DOI 10.1002/cm.970220203; Levings MK, 1999, BLOOD, V93, P3694, DOI 10.1182/blood.V93.11.3694.411a33_3694_3702; Maroney AC, 1998, J NEUROSCI, V18, P104; Matsumoto K, 1998, J ALLERGY CLIN IMMUN, V101, P825, DOI 10.1016/S0091-6749(98)70311-2; Mattey DL, 1997, ANN RHEUM DIS, V56, P426, DOI 10.1136/ard.56.7.426; Murata T, 1998, INT IMMUNOL, V10, P1103, DOI 10.1093/intimm/10.8.1103; Niiro H, 1998, BIOCHEM BIOPH RES CO, V250, P200, DOI 10.1006/bbrc.1998.9287; Phan SH, 1996, KIDNEY INT, V49, pS46; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; ROCHE WR, 1991, CLIN EXP ALLERGY, V21, P545, DOI 10.1111/j.1365-2222.1991.tb00845.x; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Spoelstra FM, 1999, EUR RESPIR J, V14, P759, DOI 10.1034/j.1399-3003.1999.14d06.x; Suttles J, 1999, J BIOL CHEM, V274, P5835, DOI 10.1074/jbc.274.9.5835; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; Wery S, 1996, J BIOL CHEM, V271, P8529, DOI 10.1074/jbc.271.15.8529; Yokozeki M, 1997, EXP CELL RES, V231, P328, DOI 10.1006/excr.1997.3473; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	48	107	114	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1001	1008		10.1067/mai.2001.114702	http://dx.doi.org/10.1067/mai.2001.114702			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398077				2022-12-18	WOS:000169454800010
J	BUCCA, C; ROLLA, G; SCAPPATICCI, E; CHIAMPO, F; BUGIANI, M; MAGNANO, M; DALBERTO, M				BUCCA, C; ROLLA, G; SCAPPATICCI, E; CHIAMPO, F; BUGIANI, M; MAGNANO, M; DALBERTO, M			EXTRATHORACIC AND INTRATHORACIC AIRWAY RESPONSIVENESS IN SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SINUSITIS; BRONCHIAL HYPERRESPONSIVENESS; EXTRATHORACIC AIRWAY HYPERRESPONSIVENESS; PHARYNGITIS; PHARYNGOBRONCHIAL REFLEX	BRONCHIAL-ASTHMA; PULMONARY-FUNCTION; INHALED HISTAMINE; CHILDREN; DISEASE; STANDARDIZATION; OBSTRUCTION; CHALLENGE	Background: Asthma associated with sinusitis is supposed to be sustained by bronchoconstrictive reflexes originating in extrathoracic airway (EA) receptors. Objective: The study was designed to evaluate the relationship between EA responsiveness and bronchial responsiveness in sinusitis. Methods: We performed histamine inhalation challenge in 106 patients with chronic sinusitis, during disease exacerbation and after treatment with antimicrobials and nasal flunisolide (100 mu g daily) for 2 weeks. Forced expiratory volume in 1 second (FEV(1)) and maximal mid-inspiratory flow (MIF(50)) were the respective indexes of bronchial and EA narrowing; the histamine concentrations causing a 20% fall in FEV(1) (PC20) and 25% drop in MIF(50) (PC(25)MIF(50)) were used as thresholds of bronchial and EA responsiveness. Threshold of 8 mg/ml or less were assumed to indicate bronchial hyperresponsiveness (B-HR) or EA hyperresponsiveness (EA-HR). Results: During sinusitis exacerbation 76 patients had EA-HR, which in 46 was associated with B-HR. The values of PC20 were closely related with those of PC(25)MIF(50) (p < 0.001). EA-HR and B-HR were strongly associated with pharyngitis. After treatment, mean PC(25)MIF(50) and PC20 were significantly increased (p < 0.001). The improvement of PC(25)MIF(50) was closely related to that of PC20 (p < 0.001) and to the decrease in neutrophils in nasal lavage (p < 0.05). EA-HR reversed in 58 patients and improved in 10; B-HR reversed in 29 and improved in 12. Conclusions: Our findings suggest that in sinusitis, B-HR may be sustained by constrictive reflexes originating in pharyngeal receptors, made hypersensitive by seeding of the inflammatory process.	UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,TURIN,ITALY	University of Turin			Rolla, Giovanni/C-9901-2009; Bucca, Caterina/C-9886-2009	Rolla, Giovanni/0000-0001-5997-7172; Bucca, Caterina/0000-0002-9941-9236				ACRES JC, 1981, CHEST, V80, P207, DOI 10.1378/chest.80.2.207; ADINOFF AD, 1987, SEMIN RESPIR MED, V8, P308, DOI 10.1055/s-2007-1012669; AITKIN M, 1979, STATISTICAL MODELLIN, P119; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BERMAN SZ, 1974, J ALLERGY CLIN IMMUN, V53, P311, DOI 10.1016/0091-6749(74)90111-0; BUCCA C, 1991, ALLERGY, V46, P147, DOI 10.1111/j.1398-9995.1991.tb00559.x; BUCCA C, 1990, American Review of Respiratory Disease, V141, pA730; BUSSE WW, 1989, ASTHMA BASIC MECHANI, P483; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CORREN J, 1990, American Review of Respiratory Disease, V141, pA177; CUMMINGS NP, 1983, PEDIATR RES, V17, P373; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FRIDAY GA, 1988, CLIN CHEST MED, V9, P557; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; GWALTNEY JM, 1992, J ALLERGY CLIN IMMUN, V90, P457, DOI 10.1016/0091-6749(92)90169-3; HABIB MP, 1979, J APPL PHYSIOL, V47, P51, DOI 10.1152/jappl.1979.47.1.51; HARGREAVE FE, 1985, AIRWAY RESPONSIVENES, P122; IRVIN CG, 1992, J ALLERGY CLIN IMMUN, V90, P521, DOI 10.1016/0091-6749(92)90179-6; JOUSIMIESSOMER HR, 1989, J CLIN MICROBIOL, V27, P2736, DOI 10.1128/JCM.27.12.2736-2743.1989; JOUSIMIESSOMER HR, 1988, J CLIN MICROBIOL, V26, P1919, DOI 10.1128/JCM.26.10.1919-1925.1988; JUNTUNEN K, 1984, LARYNGOSCOPE, V94, P249, DOI 10.1288/00005537-198402000-00022; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V78, P1, DOI 10.1016/0091-6749(86)90106-5; MILLER RD, 1973, AM REV RESPIR DIS, V108, P475; PHIPATAN.CS, 1974, ARCH OTOLARYNGOL, V100, P109; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RACHELEFSKY GS, 1985, J ALLERGY CLIN IMMUN, V69, P382; SHIM C, 1972, AM REV RESPIR DIS, V106, P233, DOI 10.1164/arrd.1972.106.2.233; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; WALD ER, 1986, PEDIATRICS, V77, P795	32	107	110	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				52	59		10.1016/S0091-6749(95)70152-4	http://dx.doi.org/10.1016/S0091-6749(95)70152-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822664				2022-12-18	WOS:A1995QC31200008
J	RIEDEL, F; KRAMER, M; SCHEIBENBOGEN, C; RIEGER, CHL				RIEDEL, F; KRAMER, M; SCHEIBENBOGEN, C; RIEGER, CHL			EFFECTS OF SO2 EXPOSURE ON ALLERGIC SENSITIZATION IN THE GUINEA-PIG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											RIEDEL, F (corresponding author), UNIV MARBURG,DEPT PEDIAT,DEUTSCHHAUSSTR 12,D-3550 MARBURG,FED REP GER.			Scheibenbogen, Carmen/0000-0002-8554-9638				BOUCHER RC, 1980, LAB INVEST, V43, P94; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; DIXON M, 1983, J PHYSIOL-LONDON, V337, P89, DOI 10.1113/jphysiol.1983.sp014613; DODGE R, 1985, AM J EPIDEMIOL, V121, P720, DOI 10.1093/aje/121.5.720; DORSCH W, 1984, N-S ARCH PHARMACOL, V325, P275, DOI 10.1007/BF00495955; DORSCH W, 1981, PFLUG ARCH EUR J PHY, V391, P236, DOI 10.1007/BF00596177; DOUGLAS JWB, 1966, BRIT J PREV SOC MED, V20, P1; FINKLEA JF, 1974, US EPA PUBLICATION, V46; GERRARD JW, 1980, AM REV RESPIR DIS, V122, P577; HOGG JC, 1982, EUR J RESP DIS S, V122, P17; ISLAM MS, 1972, B PHYSIO-PATHOL RESP, V8, P509; ISLAM MS, 1972, INT ARCH ARBEITSMED, V29, P221, DOI 10.1007/BF00539250; KING TP, 1966, ADV IMMUNOLOGY, P77; LEVY D, 1977, AM REV RESPIR DIS, V116, P167; MATSUMURA Y, 1970, AM REV RESPIR DIS, V102, P430; MULLER G, 1986, J PEDIATR-US, V109, P869, DOI 10.1016/S0022-3476(86)80716-8; MURLAS CG, 1985, AM REV RESPIR DIS, V131, P314; NAUMAN RV, 1960, ANAL CHEM, V32, P1307, DOI 10.1021/ac60166a023; OSEBOLD JW, 1980, J ENVIRON PATHOL TOX, V3, P221; OVARY Z, 1963, J EXP MED, V117, P951, DOI 10.1084/jem.117.6.951; PARISH WE, 1970, J IMMUNOL, V105, P1296; Spinaci S, 1985, Pediatr Pulmonol, V1, P262, DOI 10.1002/ppul.1950010508; SULTZ HA, 1970, AM J PUBLIC HEALTH N, V60, P891, DOI 10.2105/AJPH.60.5.891; UNAI M, 1986, ARCH ENV HLTH, V41, P29; VAI F, 1980, AM REV RESPIR DIS, V121, P851; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; WELTY C, 1984, AM REV RESPIR DIS, V130, P198; ZEIDBERG LD, 1961, AM REV RESPIR DIS, V84, P489; ZWEIMAN B, 1972, J ALLERGY CLIN IMMUN, V50, P305, DOI 10.1016/0091-6749(72)90029-2	30	107	107	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					527	534		10.1016/0091-6749(88)90961-X	http://dx.doi.org/10.1016/0091-6749(88)90961-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3170998				2022-12-18	WOS:A1988Q639900001
J	BURKS, AW; SAMPSON, HA				BURKS, AW; SAMPSON, HA			DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF ORAL CROMOLYN IN CHILDREN WITH ATOPIC-DERMATITIS AND DOCUMENTED FOOD HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, DIV IMMUNOL, CMSC 1103, BALTIMORE, MD 21205 USA; UNIV ARKANSAS, FAYETTEVILLE, AR 72701 USA	Johns Hopkins University; University of Arkansas System; University of Arkansas Fayetteville					NCRR NIH HHS [RR-30] Funding Source: Medline; NIAID NIH HHS [AI 19116] Funding Source: Medline; NIAID NIH HHS [AI24439] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON JA, 1984, NIH842442 PUBL, P163; BAHNA SL, 1983, ANN ALLERGY, V51, P574; BASOMBA A, 1977, ACTA ALLERGOL, P95; BERNSTEIN IL, 1978, ANN INTERN MED, V89, P228, DOI 10.7326/0003-4819-89-2-228; BIENENSTOCK J, 1985, 12 P INT C ALL CLIN, P150; BOLIN TD, 1980, GUT, V21, P848, DOI 10.1136/gut.21.10.848; BROSTOFF J, 1979, LANCET, V1, P1268; BUISSERET P, 1980, AM J CLIN NUTR, V33, P865, DOI 10.1093/ajcn/33.4.865; BUSINCO L, 1983, ANN ALLERGY, V51, P47; BUSINCO L, 1986, ANN ALLERGY, V57, P433; CANONICA GW, 1986, CLIN IMMUNOL IMMUNOP, V41, P154, DOI 10.1016/0090-1229(86)90059-0; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; DAHL R, 1978, CLIN ALLERGY, V8, P419, DOI 10.1111/j.1365-2222.1978.tb01491.x; DAHL R, 1978, ALLERGY, V33, P120, DOI 10.1111/j.1398-9995.1978.tb01520.x; DAHL R, 1981, ALLERGY, V36, P161, DOI 10.1111/j.1398-9995.1981.tb01831.x; DANNAEUS A, 1979, CLIN ALLERGY, V9, P263, DOI 10.1111/j.1365-2222.1979.tb01552.x; DAUGBJERG PS, 1984, ALLERGY, V39, P535, DOI 10.1111/j.1398-9995.1984.tb00875.x; ELKON KB, 1977, S AFR MED J, V52, P838; ESTEBAN MM, 1977, ACTA ALLERGOL, P102; FALTHMAGNUSSON K, 1984, CLIN ALLERGY, V14, P277, DOI 10.1111/j.1365-2222.1984.tb02207.x; FREIER S, 1977, Acta Allergologica Supplementum, V32, P109; FREIER S, 1973, LANCET, V1, P913; GERRARD JW, 1979, ANN ALLERGY, V42, P135; GRAHAM P, 1984, BRIT J DERMATOL, V110, P457, DOI 10.1111/j.1365-2133.1984.tb04661.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; HARRIES MG, 1978, CLIN ALLERGY, V8, P423, DOI 10.1111/j.1365-2222.1978.tb01492.x; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; KINGSLEY PJ, 1974, LANCET, V2, P1011; KOCOSHIS S, 1979, JAMA-J AM MED ASSOC, V242, P1169; LINDSKOV R, 1983, ALLERGY, V38, P161, DOI 10.1111/j.1398-9995.1983.tb01601.x; MOLKHOU P, 1981, ANN ALLERGY, V47, P173; NIZAMI RM, 1977, ANN ALLERGY, V39, P102; ORTOLANI C, 1983, ANN ALLERGY, V50, P105; PAGANELLI R, 1979, LANCET, V1, P1270; RELEULMICALLEF R, 1983, THORAX, V38, P527; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SAMPSON HA, 1988, ANN ALLERGY, P60; SOGN D, 1986, J ALLERGY CLIN IMMUN, V78, P238, DOI 10.1016/0091-6749(86)90017-5; VAZ GA, 1978, LANCET, V1, P1066; WATSON JBG, 1979, ARCH DIS CHILD, V54, P77, DOI 10.1136/adc.54.1.77; ZANUSSI C, 1983, ANN ALLERGY, V51, P307	43	107	111	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					417	423		10.1016/0091-6749(88)90910-4	http://dx.doi.org/10.1016/0091-6749(88)90910-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	3279094				2022-12-18	WOS:A1988M099300008
J	FAGAN, DL; SLAUGHTER, CA; CAPRA, JD; SULLIVAN, TJ				FAGAN, DL; SLAUGHTER, CA; CAPRA, JD; SULLIVAN, TJ			MONOCLONAL-ANTIBODIES TO IMMUNOGLOBULIN-G4 INDUCE HISTAMINE-RELEASE FROM HUMAN BASOPHILS INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS, HLTH SCI CTR, DEPT INTERNAL MED, ALLERGY & CLIN IMMUNOL SECT, DALLAS, TX 75235 USA; UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas								ANDERSEN BR, 1968, NATURE, V217, P174, DOI 10.1038/217174a0; ANDREW DW, 1980, CLIN IMMUNOLOGY, P1; BACH MK, 1971, J EXP MED, V133, P772, DOI 10.1084/jem.133.4.772; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; ESTESS P, 1980, J EXP MED, V151, P863, DOI 10.1084/jem.151.4.863; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GALLY JA, 1978, IMMUNOLOGICAL DISEAS, P49; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; GRANT JA, 1972, J IMMUNOL, V109, P20; GREY HM, 1964, J EXP MED, V120, P253, DOI 10.1084/jem.120.2.253; HENSON PM, 1977, J IMMUNOL, V119, P2179; HIRAYAMA N, 1982, P NATL ACAD SCI-BIOL, V79, P613, DOI 10.1073/pnas.79.2.613; ISHIZAKA K, 1978, IMMUNOLOGICAL DISEAS, P164; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LICHTENSTEIN LM, 1970, IMMUNOLOGY, V19, P831; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; NAKAGAWA T, 1981, CLIN ALLERGY, V11, P21, DOI 10.1111/j.1365-2222.1981.tb01561.x; Natvig J B, 1973, Adv Immunol, V16, P1, DOI 10.1016/S0065-2776(08)60295-3; PARISH WE, 1970, J IMMUNOL, V105, P1296; PARISH WE, 1978, IMMEDIATE HYPERSENSI, P277; STANWORTH D R, 1973, Clinical Allergy, V3, P37, DOI 10.1111/j.1365-2222.1973.tb01307.x; UGOLINI V, 1980, P NATL ACAD SCI-BIOL, V77, P6764, DOI 10.1073/pnas.77.11.6764; VITETTA ES, 1979, B LYMPHOCYTES IMMUNE, P233; YOUNT WJ, 1968, J EXP MED, V127, P633, DOI 10.1084/jem.127.3.633	25	107	110	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					399	404		10.1016/0091-6749(82)90031-8	http://dx.doi.org/10.1016/0091-6749(82)90031-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PQ105	6182178				2022-12-18	WOS:A1982PQ10500013
J	POPA, VT				POPA, VT			BRONCHODILATING ACTIVITY OF AN H-1 BLOCKER, CHLORPHENIRAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CHICAGO,PRITZKER SCH MED,DEPT MED,DIV PULM,CHICAGO,IL 60637	University of Chicago								[Anonymous], 1959, Thorax, V14, P286, DOI 10.1136/thx.14.4.286; ARBESMAN CE, 1947, NEW YORK STATE J MED, V47, P1775; ARBESMAN CE, 1948, J ALLERGY, V19, P178, DOI 10.1016/0021-8707(48)90051-3; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; BASS H, 1973, CHEST, V63, P171, DOI 10.1378/chest.63.2.171; BEAUDRY PH, 1962, J ALLERGY, V33, P210, DOI 10.1016/0021-8707(62)90087-4; BOOIJNOO.H, 1970, J ALLERGY, V46, P1, DOI 10.1016/0021-8707(70)90055-9; BOOIJNORD H, 1957, INT ARCH ALLERGY APP, V10, P6; BROWLEE KA, 1965, STATISTICAL THEORY M, P499; CAMPBELL AER, 1963, BRIT J DIS CHEST, V57, P153, DOI 10.1016/S0366-0850(63)80061-7; Collier H O, 1970, Adv Drug Res, V5, P95; CRIEP LH, 1948, J ALLERGY, V19, P304, DOI 10.1016/0021-8707(48)90110-5; CROMPTON GK, 1968, THORAX, V23, P46, DOI 10.1136/thx.23.1.46; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; DOMIZI DB, 1970, FAL DECUS P, P19; EYERMANN CH, 1946, J ALLERGY, V17, P210, DOI 10.1016/0021-8707(46)90146-3; FEINBERG SM, 1950, ANTIHISTAMINES THEIR; FINGL E, 1975, PHARMACOLOGICAL BASI, P31; GOLDSTEIN A, 1964, BIOSTATISTICS INTRO, P129; GROSS NJ, 1975, AM REV RESPIR DIS, V112, P823; HAWKINS DF, 1955, BRIT J PHARM CHEMOTH, V10, P230, DOI 10.1111/j.1476-5381.1955.tb00088.x; HERXHEIMER H, 1949, BMJ-BRIT MED J, V2, P901, DOI 10.1136/bmj.2.4633.901; HUME K. M., 1957, THORAX, V12, P276, DOI 10.1136/thx.12.3.276; INNERS IR, 1975, PHARMACOL BASIS, P522; KARLIN JM, 1970, ANN ALLERGY, V30, P342; LEULLAN EC, 1955, AM REV TUBERC, V72, P783; LEVIN SJ, 1946, J ALLERGY, V17, P145, DOI 10.1016/0021-8707(46)90004-4; LEVY L, 1947, J ALLERGY, V18, P244, DOI 10.1016/0021-8707(47)90048-8; MACKLEM PT, 1967, ARCH ENVIRON HEALTH, V14, P5, DOI 10.1080/00039896.1967.10664685; MCGAVACK TH, 1947, AM J MED SCI, V213, P418, DOI 10.1097/00000441-194704000-00005; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; MUITTARI A, 1963, ACTA ALLERGOL, V18, P263, DOI 10.1111/j.1398-9995.1963.tb03180.x; ORANGE RP, 1971, J EXP MED, V134, pS136; Pandit P R, 1973, Indian J Med Sci, V27, P920; PEETS EA, 1972, J PHARMACOL EXP THER, V180, P464; POPA VT, 1976, CHEST, V70, P205, DOI 10.1378/chest.70.2.205; RADERMECHER U, 1971, IMMUNOLOGICAL DISEAS, P886; ROTH EE, 1965, DRILLS PHARMACOLOGY; SIMONSSON BG, 1964, ACTA ALLERGOL, V19, P305, DOI 10.1111/j.1398-9995.1964.tb03251.x; STANESCU D, 1976, RESPIRATION, V33, P1; STANESCU DC, 1973, THORAX, V28, P716, DOI 10.1136/thx.28.6.716; TOZZI S, 1974, AGENTS ACTIONS, V414, P264; WALDBOTT GL, 1946, J ALLERGY, V17, P142, DOI 10.1016/0021-8707(46)90003-2; WALDBOTT GL, 1947, J ALLERGY, V19, P313; WEISS WI, 1948, J ALLERGY, V19, P271, DOI 10.1016/0021-8707(48)90064-1; 1972, ANN ALLERGY, V30, P95	47	107	107	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	1					54	63		10.1016/0091-6749(77)90177-4	http://dx.doi.org/10.1016/0091-6749(77)90177-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CS828	13094				2022-12-18	WOS:A1977CS82800009
J	ORGEL, HA; HAMBURGER, RN; BAZARAL, M; GORRIN, H; GROSHONG, T; LENOIR, M; MILLER, JR; WALLACE, W				ORGEL, HA; HAMBURGER, RN; BAZARAL, M; GORRIN, H; GROSHONG, T; LENOIR, M; MILLER, JR; WALLACE, W			DEVELOPMENT OF IGE AND ALLERGY IN INFANCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF,SAN DIEGO,SCH MED,PEDIAT DEPT,PEDIAT IMMUNOL & ALLERGY DIV,LA JOLLA,CA 92037	University of California System; University of California San Diego								ARBESMAN CE, 1972, J ALLERGY CLIN IMMUN, V49, P72, DOI 10.1016/0091-6749(72)90058-9; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P288, DOI 10.1016/0091-6749(74)90015-3; BAZARAL M, 1971, J IMMUNOL, V107, P794; BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; Cooke RA, 1916, J IMMUNOL, V1, P201; GERRARD JW, 1974, J PEDIATR-US, V85, P660, DOI 10.1016/S0022-3476(74)80510-X; GERRARD JW, 1973, ACTA PAEDIATR S S234, P3; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HOGARTHSCOTT RS, 1971, CLIN EXP IMMUNOL, V9, P571; JOHANSSO.SG, 1967, LANCET, V2, P951; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; MONTO AS, 1974, JAMA-J AM MED ASSOC, V227, P164, DOI 10.1001/jama.227.2.164; ORGEL HA, 1974, J ALLERGY CLIN IMMUN, V53, P213, DOI 10.1016/0091-6749(74)90083-9; POLMAR SH, 1972, J CLIN INVEST, V51, P326, DOI 10.1172/JCI106817; ROWE D S, 1970, Bulletin of the World Health Organization, V43, P609; SPITZ E, 1972, J ALLERGY CLIN IMMUN, V49, P337, DOI 10.1016/0091-6749(72)90132-7; TAYLOR, 1973, LANCET, V2, P111; VAN ARSDEL P P Jr, 1959, Acta Genet Stat Med, V9, P101; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5	20	107	107	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	4					296	307		10.1016/0091-6749(75)90104-9	http://dx.doi.org/10.1016/0091-6749(75)90104-9			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AS523	1176721				2022-12-18	WOS:A1975AS52300007
J	Tuijnenburg, P; Allen, HL; Burns, SO; Greene, D; Jansen, MH; Staples, E; Stephens, J; Carss, KJ; Biasci, D; Baxendale, H; Thomas, M; Chandra, A; Kiani-Alikhan, S; Longhurst, HJ; Seneviratne, SL; Oksenhendler, E; Simeoni, I; de Bree, GJ; Tool, ATJ; van Leeuwen, EMM; Ebberink, EHTM; Meijer, AB; Tuna, S; Whitehorn, D; Brown, M; Turro, E; Thrasher, AJ; Smith, KGC; Thaventhiran, JE; Kuijpers, TW				Tuijnenburg, Paul; Allen, Hana Lango; Burns, Siobhan O.; Greene, Daniel; Jansen, Machiel H.; Staples, Emily; Stephens, Jonathan; Carss, Keren J.; Biasci, Daniele; Baxendale, Helen; Thomas, Moira; Chandra, Anita; Kiani-Alikhan, Sorena; Longhurst, Hilary J.; Seneviratne, Suranjith L.; Oksenhendler, Eric; Simeoni, Ilenia; de Bree, Godelieve J.; Tool, Anton T. J.; van Leeuwen, Ester M. M.; Ebberink, Eduard H. T. M.; Meijer, Alexander B.; Tuna, Salih; Whitehorn, Deborah; Brown, Matthew; Turro, Ernest; Thrasher, Adrian J.; Smith, Kenneth G. C.; Thaventhiran, James E.; Kuijpers, Taco W.		NIHR BioResource-Rare Dis	Loss-of-function nuclear factor kappa B subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cells; common variable immunodeficiency; nuclear factor kappa B1	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ANHIDROTIC ECTODERMAL DYSPLASIA; HYPER-IGM SYNDROME; HETEROZYGOUS MUTATIONS; ANTIBODY DEFICIENCY; NONSENSE MUTATION; WHOLE-GENOME; 11 CARD11; IN-VIVO; CELLS	Background: The genetic cause of primary immunodeficiency disease (PID) carries prognostic information. Objective: We conducted a whole-genome sequencing study assessing a large proportion of the NIHR BioResource-Rare Diseases cohort. Methods: In the predominantly European study population of principally sporadic unrelated PID cases (n = 846), a novel Bayesian method identified nuclear factor kappa B subunit 1 (NFKB1) as one of the genes most strongly associated with PID, and the association was explained by 16 novel heterozygous truncating, missense, and gene deletion variants. This accounted for 4% of common variable immunodeficiency (CVID) cases (n = 390) in the cohort. Amino acid substitutions predicted to be pathogenic were assessed by means of analysis of structural protein data. Immunophenotyping, immunoblotting, and ex vivo stimulation of lymphocytes determined the functional effects of these variants. Detailed clinical and pedigree information was collected for genotype-phenotype cosegregation analyses. Results: Both sporadic and familial cases demonstrated evidence of the noninfective complications of CVID, including massive lymphadenopathy (24%), unexplained splenomegaly (48%), and autoimmune disease (48%), features prior studies correlated with worse clinical prognosis. Although partial penetrance of clinical symptoms was noted in certain pedigrees, all carriers have a deficiency in B-lymphocyte differentiation. Detailed assessment of B-lymphocyte numbers, phenotype, and function identifies the presence of an increased CD21(low) B-cell population. Combined with identification of the disease-causing variant, this distinguishes between healthy subjects, asymptomatic carriers, and clinically affected cases. Conclusion: We show that heterozygous loss-of-function variants in NFKB1 are the most common known monogenic cause of CVID, which results in a temporally progressive defect in the formation of immunoglobulin-producing B cells.	[Tuijnenburg, Paul; Jansen, Machiel H.; Kuijpers, Taco W.] Emma Childrens Hosp, Dept Pediat Hematol Immunol & Infect Dis, Amsterdam, Netherlands; [Tuijnenburg, Paul; Jansen, Machiel H.; van Leeuwen, Ester M. M.; Kuijpers, Taco W.] Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands; [de Bree, Godelieve J.; Kuijpers, Taco W.] Acad Med Ctr, Dept Internal Med, Amsterdam, Netherlands; [Allen, Hana Lango; Greene, Daniel; Stephens, Jonathan; Carss, Keren J.; Simeoni, Ilenia; Tuna, Salih; Whitehorn, Deborah; Brown, Matthew; Turro, Ernest] Univ Cambridge, Dept Haematol, Cambridge, England; [Staples, Emily; Biasci, Daniele; Baxendale, Helen; Chandra, Anita; Smith, Kenneth G. C.; Thaventhiran, James E.] Univ Cambridge, Dept Med, Cambridge, England; [Allen, Hana Lango; Greene, Daniel; Stephens, Jonathan; Carss, Keren J.; Tuna, Salih; Whitehorn, Deborah; Brown, Matthew; Turro, Ernest] NHS Blood & Transplant Cambridge, Cambridge, England; [NIHR BioResource-Rare Dis] NIHR BioResource Rare Dis, Cambridge Biomed Campus, Cambridge, England; [Burns, Siobhan O.; Seneviratne, Suranjith L.] UCL, Inst Immun & Transplantat, Royal Free London NHS Fdn Trust, Dept Immunol, London, England; [Thomas, Moira] Queen Elizabeth Univ Hosp, Dept Immunol, Glasgow, Lanark, Scotland; [Kiani-Alikhan, Sorena] Royal Surrey Cty Hosp, Dept Immunol, Guildford, Surrey, England; [Longhurst, Hilary J.] Barts Hlth NHS Trust, Dept Immunol, London, England; [Oksenhendler, Eric] Hop St Louis, AP HP, Dept Clin Immunol, Paris, France; [Tool, Anton T. J.] Sanquin Res, Dept Blood Cell Res, Amsterdam, Netherlands; [Ebberink, Eduard H. T. M.; Meijer, Alexander B.] Sanquin Res, Dept Plasma Prot, Amsterdam, Netherlands; [Thrasher, Adrian J.] UCL Great Ormond St Inst Child Hlth, Mol & Cellular Immunol Sect, London, England; [Thrasher, Adrian J.] Great Ormond St Hosp NHS Trust London, London, England	Emma Children's Hospital; University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Cambridge; University of Cambridge; University of London; University College London; Royal Free London NHS Foundation Trust; Queen Elizabeth University Hospital (QEUH); Royal Surrey County Hospital; Barts Health NHS Trust; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of London; University College London	Kuijpers, TW (corresponding author), Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.; Thaventhiran, JE (corresponding author), Addenbrookes Hosp, Box 157,Hills Rd, Cambridge CB2 0QQ, England.	jedt2@cam.ac.uk; t.w.kuijpers@amc.nl	Savic, Sinisa/Q-6217-2019; Ponsford, Mark J/ABA-3891-2020; Brown, Matthew A/E-5749-2010; Booth, Claire/I-3667-2016; Sargur, Ravishankar/C-2270-2009	Savic, Sinisa/0000-0001-7910-0554; Ponsford, Mark J/0000-0002-0236-1059; Brown, Matthew A/0000-0003-0538-8211; Haimel, Matthias/0000-0002-0320-0214; , Jesmeen/0000-0003-4169-8209; Booth, Claire/0000-0002-2626-5037; Lango Allen, Hana/0000-0002-7803-8688; Sargur, Ravishankar/0000-0002-8535-630X; Daugherty, Louise/0000-0003-4546-6667; Edgar, John David Moore/0000-0003-2969-4475; Megy, Karyn/0000-0002-2826-3879; Meacham, Stuart/0000-0002-3667-6059; Stephens, Jonathan/0000-0003-2020-9330; Kingston, Nathalie/0000-0002-9190-2231; Thrasher, Adrian/0000-0002-6097-6115; james, roger/0000-0002-0058-1357; Klein, Nigel/0000-0003-3925-9258; Turro, Ernest/0000-0002-1820-6563; Smith, Kenneth/0000-0003-3829-4326; QASIM, WASEEM/0000-0001-8353-4494; Carss, Keren/0000-0003-4939-156X; Matser, Vera/0000-0002-2010-6844; Burns, Siobhan/0000-0002-3356-9506	National Institute for Health Research England [RG65966]; Center of Immunodeficiencies Amsterdam (CIDA); MRC Clinician Scientist Fellowship [MR/L006197/1]; Wellcome Trust [104807/Z/14/Z]; National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust; University College London; MRC [MR/L006197/1] Funding Source: UKRI	National Institute for Health Research England(National Institute for Health Research (NIHR)); Center of Immunodeficiencies Amsterdam (CIDA); MRC Clinician Scientist Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust; University College London(General Electric); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by The National Institute for Health Research England (grant no. RG65966) and the Center of Immunodeficiencies Amsterdam (CIDA). J.E.T. is supported by an MRC Clinician Scientist Fellowship (MR/L006197/1). A.J.T. is supported by both the Wellcome Trust (104807/Z/14/Z) and the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London.	aan de Kerk DJ, 2013, J IMMUNOL, V190, P5012, DOI 10.4049/jimmunol.1201807; Bousfiha A, 2015, J CLIN IMMUNOL, V35, P727, DOI 10.1007/s10875-015-0198-5; Boztug H, 2016, J CLIN IMMUNOL, V36, P533, DOI 10.1007/s10875-016-0306-1; Brennan PJ, 2013, NAT REV IMMUNOL, V13, P101, DOI 10.1038/nri3369; Burns SO, 2014, J ALLERGY CLIN IMMUN, V134, P215, DOI 10.1016/j.jaci.2013.12.1093; Carson KR, 2009, BLOOD, V113, P4834, DOI 10.1182/blood-2008-10-186999; Carss KJ, 2017, AM J HUM GENET, V100, P75, DOI 10.1016/j.ajhg.2016.12.003; Casanova JL, 2015, P NATL ACAD SCI USA, V112, pE7128, DOI 10.1073/pnas.1521651112; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Durali D, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00241; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; Gathmann B, 2014, J ALLERGY CLIN IMMUN, V134, P116, DOI 10.1016/j.jaci.2013.12.1077; Geisler F, 2007, GASTROENTEROLOGY, V132, P2489, DOI 10.1053/j.gastro.2007.03.033; Greene D, 2017, AM J HUM GENET, V101, P104, DOI 10.1016/j.ajhg.2017.05.015; Greil J, 2013, J ALLERGY CLIN IMMUN, V131, P1376, DOI 10.1016/j.jaci.2013.02.012; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Kaustio M, 2017, J ALLERGY CLIN IMMUN, V140, P782, DOI 10.1016/j.jaci.2016.10.054; Kuehn HS, 2016, NEW ENGL J MED, V374, P1032, DOI 10.1056/NEJMoa1512234; Lougaris V, 2017, J ALLERGY CLIN IMMUN, V139, P349, DOI 10.1016/j.jaci.2016.05.045; Maffucci P, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00220; Torres JM, 2014, J CLIN INVEST, V124, P5239, DOI 10.1172/JCI77493; McKinnon ML, 2014, J ALLERGY CLIN IMMUN, V133, P1458, DOI 10.1016/j.jaci.2013.10.045; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Mellemkjaer L, 2002, CLIN EXP IMMUNOL, V130, P495, DOI 10.1046/j.1365-2249.2002.02004.x; Mousallem T, 2014, BLOOD, V124, P2046, DOI 10.1182/blood-2014-04-571265; MUELLER BU, 1995, J PEDIATR-US, V126, P1, DOI 10.1016/S0022-3476(95)70491-4; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Oksenhendler E, 2008, CLIN INFECT DIS, V46, P1547, DOI 10.1086/587669; Orange JS, 2011, J ALLERGY CLIN IMMUN, V127, P1360, DOI 10.1016/j.jaci.2011.02.039; Palazzo E, 2012, JOINT BONE SPINE, V79, P351, DOI 10.1016/j.jbspin.2011.11.002; Pannicke U, 2013, NEW ENGL J MED, V369, P2504, DOI 10.1056/NEJMoa1309199; Pasparakis M, 2006, CELL DEATH DIFFER, V13, P861, DOI 10.1038/sj.cdd.4401870; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Punwani D, 2015, J CLIN IMMUNOL, V35, P135, DOI 10.1007/s10875-014-0125-1; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rieux-Laucat F, 2014, SCIENCE, V345, P1560, DOI 10.1126/science.1260791; Schipp C, 2016, HAEMATOLOGICA, V101, pE392, DOI 10.3324/haematol.2016.145136; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sivakumar V, 2003, J EXP MED, V197, P1613, DOI 10.1084/jem.20022234; Snapper CM, 1996, J IMMUNOL, V156, P183; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Tan CS, 2010, LANCET NEUROL, V9, P425, DOI 10.1016/S1474-4422(10)70040-5; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tao ZH, 2014, P NATL ACAD SCI USA, V111, P15946, DOI 10.1073/pnas.1408552111; Vajdic CM, 2010, BLOOD, V116, P1228, DOI 10.1182/blood-2010-03-272351; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; van Schouwenburg PA, 2015, CLIN IMMUNOL, V160, P301, DOI 10.1016/j.clim.2015.05.020; Voce DJ, 2015, ONCOGENE, V34, P2807, DOI 10.1038/onc.2014.211; Webb B., 2014, CURR PROTOC BIOINFOR, V5.6, P32, DOI [10.1002/0471250953.bi0506s47, DOI 10.1002/0471250953.BI0506S47]; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Winfield JB, 1997, CLIN EXP IMMUNOL, V109, P1, DOI 10.1046/j.1365-2249.1997.00439.x; Yoshioka T, 2013, J CLIN IMMUNOL, V33, P1165, DOI 10.1007/s10875-013-9924-z; Zarrei M, 2015, NAT REV GENET, V16, P172, DOI 10.1038/nrg3871; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012	62	106	108	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1285	1296		10.1016/j.jaci.2018.01.039	http://dx.doi.org/10.1016/j.jaci.2018.01.039			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29477724	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000446327300026
J	Kolbinger, F; Loesche, C; Valentin, MA; Jiang, XY; Cheng, Y; Jarvis, P; Peters, T; Calonder, C; Bruin, G; Polus, F; Aigner, B; Lee, DM; Bodenlenz, M; Sinner, F; Pieber, TR; Patel, DD				Kolbinger, Frank; Loesche, Christian; Valentin, Marie-Anne; Jiang, Xiaoyu; Cheng, Yi; Jarvis, Philip; Peters, Thomas; Calonder, Claudio; Bruin, Gerard; Polus, Florine; Aigner, Birgit; Lee, David M.; Bodenlenz, Manfred; Sinner, Frank; Pieber, Thomas Rudolf; Patel, Dhavalkumar D.			beta-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-17; psoriasis; secukinumab; beta-defensin 2; biomarker; dermal interstitial fluid; microperfusion; psoriatic arthritis; ankylosing spondylitis; rheumatoid arthritis; multiple sclerosis; autoimmunity	HUMAN BETA-DEFENSIN-2; ATOPIC-DERMATITIS; PLAQUE PSORIASIS; GENE-EXPRESSION; DOUBLE-BLIND; TNF-ALPHA; SECUKINUMAB; SERUM; IL-17; KERATINOCYTES	Background: IL-17A is a key driver of human autoimmune diseases, particularly psoriasis. Objective: We sought to determine the role of IL-17A in psoriasis pathogenesis and to identify a robust and measurable biomarker of IL-17A-driven pathology. Methods: We studied 8 healthy subjects and 8 patients with psoriasis before and after administration of secukinumab, a fully human anti-IL-17A mAb, and used a combination of classical techniques and a novel skin microperfusion assay to evaluate the expression of 170 proteins in blood, nonlesional skin, and lesional skin. For validation, we also tested stored sera from 601 patients with a variety of autoimmune diseases. Results: IL-17A was specifically expressed in lesional compared with nonlesional psoriatic skin (9.8 vs 0.8 pg/mL, P <.001). Proteomic and gene transcription analyses revealed dysregulated antimicrobial peptides, proinflammatory cytokines, and neutrophil chemoattractants, levels of which returned to normal after treatment with secukinumab. beta-Defensin 2 (BD-2) was identified as a biomarker of IL-17A-driven pathology by comparing protein expression in patients with psoriasis versus that in healthy subjects (5746 vs 82 pg/mL in serum, P <.0001; 2747 vs <218 pg/mL in dermis, P <.001), responsiveness to secukinumab therapy, and synergistic induction by IL-17A and TNF-alpha in epidermal keratinocytes. In a validation set of sera from 601 patients with autoimmune diseases thought to be IL-17A driven, we found that BD-2 levels are most highly increased in patients with psoriatic skin lesions, and in patients with psoriasis, BD-2 levels correlated well with IL-17A levels (r = 0.70, n = 199, P <.001) and Psoriasis Area and Severity Index scores (r = 0.53, n 5 281, P <.001). Conclusion: IL-17A is a primary driver of skin pathology in patients with psoriasis, and serum BD-2 is an easily measurable biomarker of IL-17A-driven skin pathology.	[Kolbinger, Frank; Loesche, Christian; Valentin, Marie-Anne; Jiang, Xiaoyu; Peters, Thomas; Calonder, Claudio; Bruin, Gerard; Polus, Florine; Lee, David M.; Patel, Dhavalkumar D.] Novartis Inst BioMed Res, Basel, Switzerland; [Kolbinger, Frank; Loesche, Christian; Valentin, Marie-Anne; Jiang, Xiaoyu; Peters, Thomas; Calonder, Claudio; Bruin, Gerard; Polus, Florine; Lee, David M.; Patel, Dhavalkumar D.] Novartis Inst BioMed Res, Shanghai, Peoples R China; [Cheng, Yi; Jarvis, Philip] Novartis Pharmaceut, Basel, Switzerland; [Cheng, Yi; Jarvis, Philip] Novartis Pharmaceut, Shanghai, Peoples R China; [Aigner, Birgit; Bodenlenz, Manfred; Sinner, Frank; Pieber, Thomas Rudolf] Joanneum Res Forsch Gesell MbH, HLTH Inst Biomed & Hlth Sci, Weiz, Austria; [Aigner, Birgit; Sinner, Frank; Pieber, Thomas Rudolf] Med Univ Graz, Div Endocrinol & Metab, Dept Internal Med, Graz, Austria; [Jiang, Xiaoyu] Merrimack Pharmaceut, Cambridge, MA USA; [Lee, David M.] Roche, Basel, Switzerland	Novartis; Novartis; Novartis; Medical University of Graz; Roche Holding	Patel, DD (corresponding author), Forum 1, CH-4002 Basel, Switzerland.	dhavalkumar.patel@novartis.com	Peters, Thomas/GQB-3622-2022	Pieber, Thomas/0000-0003-3554-0405; Loesche, Christian/0000-0001-6505-0349; Bodenlenz, Manfred/0000-0001-7246-5120				Bodenlenz M, 2013, SKIN RES TECHNOL, V19, P474, DOI 10.1111/srt.12071; Bodenlenz M, 2012, EUR J PHARM BIOPHARM, V81, P635, DOI 10.1016/j.ejpb.2012.04.009; Chiricozzi A, 2013, EXPERT OPIN INV DRUG, V22, P993, DOI 10.1517/13543784.2013.806483; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Clausen ML, 2013, BRIT J DERMATOL, V169, P587, DOI 10.1111/bjd.12419; Dragatin C, 2016, EXP DERMATOL, V25, P157, DOI 10.1111/exd.12863; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586; Gambichler T, 2012, ARCH DERMATOL RES, V304, P471, DOI 10.1007/s00403-012-1227-3; Gambichler T, 2011, REGUL PEPTIDES, V167, P163, DOI 10.1016/j.regpep.2011.02.001; Ghannam S, 2011, J IMMUNOL, V186, P1411, DOI 10.4049/jimmunol.1000597; Griffiths CEM, 2015, LANCET, V386, P541, DOI 10.1016/S0140-6736(15)60125-8; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harper EG, 2009, J INVEST DERMATOL, V129, P2175, DOI 10.1038/jid.2009.65; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Jansen PAM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004725; Johansen C, 2009, BRIT J DERMATOL, V160, P319, DOI 10.1111/j.1365-2133.2008.08902.x; Johansen C, 2016, J INVEST DERMATOL, V136, P1608, DOI 10.1016/j.jid.2016.04.012; Kanda N, 2012, IMMUNOBIOLOGY, V217, P436, DOI 10.1016/j.imbio.2011.10.010; Krueger JG, 2015, J ALLERGY CLIN IMMUN, V136, P116, DOI 10.1016/j.jaci.2015.01.018; Krueger JG, 2012, J ALLERGY CLIN IMMUN, V130, P145, DOI 10.1016/j.jaci.2012.04.024; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lebwohl M, 2015, NEW ENGL J MED, V373, P1318, DOI 10.1056/NEJMoa1503824; Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005; Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036; Niyonsaba F, 2004, IMMUNOLOGY, V111, P273, DOI 10.1111/j.0019-2805.2004.01816.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Patel DD, 2015, IMMUNITY, V43, P1040, DOI 10.1016/j.immuni.2015.12.003; Patel DD, 2013, ANN RHEUM DIS, V72, P116, DOI 10.1136/annrheumdis-2012-202371; Rahman A, 2011, CLIN EXP IMMUNOL, V163, P123, DOI 10.1111/j.1365-2249.2010.04282.x; Reich K, 2015, EXP DERMATOL, V24, P529, DOI 10.1111/exd.12710; Rich P, 2013, BRIT J DERMATOL, V168, P402, DOI 10.1111/bjd.12112; Rohrl J, 2010, J IMMUNOL, V184, P6688, DOI 10.4049/jimmunol.0903984; Rohrl J, 2010, J BIOL CHEM, V285, P7028, DOI 10.1074/jbc.M109.091090; Russell CB, 2014, J IMMUNOL, V192, P3828, DOI 10.4049/jimmunol.1301737; Schroder JM, 1999, INT J BIOCHEM CELL B, V31, P645, DOI 10.1016/S1357-2725(99)00013-8; Thaci D, 2015, J AM ACAD DERMATOL, V73, P400, DOI 10.1016/j.jaad.2015.05.013; Vordenbaumen S, 2010, LUPUS, V19, P1648, DOI 10.1177/0961203310377089; Wright JF, 2008, J IMMUNOL, V181, P2799, DOI 10.4049/jimmunol.181.4.2799; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yilmaz SB, 2012, ARCH DERMATOL RES, V304, P465, DOI 10.1007/s00403-012-1229-1; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094	43	106	109	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					923	+		10.1016/j.jaci.2016.06.038	http://dx.doi.org/10.1016/j.jaci.2016.06.038			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27502297	hybrid			2022-12-18	WOS:000397295800025
J	Shin, HW; Kim, DK; Park, MH; Eun, KM; Lee, M; So, D; Kong, IG; Phd, JHMM; Yang, MS; Jin, HR; Park, JW; Kim, DW				Shin, Hyun-Woo; Kim, Dong-Kyu; Park, Min-Hyun; Eun, Kyoung Mi; Lee, Mingyu; So, Daeho; Kong, Il Gyu; Mo, Ji-Hun; Yang, Min-Suk; Jin, Hong Ryul; Park, Jong-Wan; Kim, Dae Woo			IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal polyp; IL-25; sinusitis; allergy; animal models	INNATE LYMPHOID-CELLS; SKIN BARRIER DYSFUNCTION; MAST-CELLS; INTERLEUKIN-17 FAMILY; ATOPIC-DERMATITIS; MOUSE MODEL; IN-VIVO; INFLAMMATION; RESPONSES; CYTOKINE	Background: Chronic rhinosinusitis (CRS) with nasal polyps (NPs) in Western populations is associated with T(H)2 cytokine polarization. IL-25, an IL-17 family cytokine, was recently reported to induce T(H)2-type immune responses and to contribute to several allergic diseases, such as atopic dermatitis and asthma. However, the role of IL-25 in Asian patients with nasal polyposis remains unclear. Objective: We sought to determine the role of IL-25 in Asian patients with nasal polyposis and CRS. Methods: We investigated IL-25 expression and its cellular origins in NPs of human subjects using immunohistochemistry (IHC), quantitative RT-PCR, and ELISA of NP tissues. Correlations between IL-25 expression and expression of other inflammatory markers in NP tissues were also explored. Anti IL-25 neutralizing antibody was administered in an ovalbumin-and staphylococcal enterotoxin B-induced murine NP model to confirm the function of IL-25 during nasal polypogenesis. Results: IL-25 expression was upregulated in NP mucosa from patients with CRS with NPs compared with uncinate process tissue from control subjects and those with CRS without NPs. Overexpression of epithelial IL-25 was confirmed by using IHC, and double IHC staining showed that tryptase-positive cells were one of the main sources of IL-25 among immune cells. Furthermore, IL-17 receptor B levels were also increased in immune cells of patients with NPs compared with those in control subjects. In NPs IL-25 mRNA expression positively correlated with the expression of several inflammatory markers, including T-box transcription factor, RAR-related orphan receptor C, GATA3, eosinophil cationic protein, TGF-beta 1, and TGF-beta 2. IL-25 was more abundant in the murine NP model compared with control mice, and similar correlations between IL-25 and inflammatory markers were observed in murine models. Anti-IL-25 treatment reduced the number of polyps, mucosal edema thickness, collagen deposition, and infiltration of inflammatory cells, such as eosinophils and neutrophils. This treatment also inhibited expression of local inflammatory cytokines, such as IL-4 and IFN-gamma. Furthermore, expression of CCL11, CXCL2, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in the nasal mucosa was suppressed in the anti-IL-25-treated group. Conclusion: Our results suggest that IL-25 secreted from the sinonasal epithelia and infiltrating mast cells plays a crucial role in the pathogenesis of CRS with NPs in Asian patients. In addition, our results suggest the novel possibility of treating nasal polyposis with anti-IL-25 therapy.	[Shin, Hyun-Woo; Lee, Mingyu; So, Daeho; Park, Jong-Wan] Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Dept Pharmacol, Seoul 156707, South Korea; [Shin, Hyun-Woo] Seoul Natl Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea; [Kong, Il Gyu] Seoul Natl Univ Hosp, Healthcare Syst Gangnam Ctr, Seoul, South Korea; [Kim, Dong-Kyu] Hallym Univ, Coll Med, Chuncheon Sacred Heart Hosp, Dept Otorhinolaryngol, Chunchcon, South Korea; [Park, Min-Hyun; Eun, Kyoung Mi; Jin, Hong Ryul; Kim, Dae Woo] Seoul Natl Univ, Coll Med, Boramae Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, 425 Shindaebang 2-Dong, Seoul 156707, South Korea; [Yang, Min-Suk] Seoul Natl Univ, Coll Med, Boramae Med Ctr, Dept Internal Med, Seoul 156707, South Korea; [Mo, Ji-Hun] Dankook Univ, Coll Med, Dept Otorhinolaryngol, Cheonan, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Hallym University; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Dankook University	Kim, DW (corresponding author), Seoul Natl Univ, Coll Med, Boramae Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, 425 Shindaebang 2-Dong, Seoul 156707, South Korea.		Mo, Ji-Hun/E-5586-2011	Mo, Ji-Hun/0000-0003-1331-364X; Kim, Dong-Kyu/0000-0003-4917-0177; Park, Min-Hyun/0000-0003-4156-7639	Seoul Metropolitan Government Seoul National University (SMG-SNU) Boramae Medical Center [03-2013-7]; SK Telecom Research Fund [06-2012-109]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [0411-20130037]	Seoul Metropolitan Government Seoul National University (SMG-SNU) Boramae Medical Center; SK Telecom Research Fund; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning	Supported by a clinical research grant-in-aid from the Seoul Metropolitan Government Seoul National University (SMG-SNU) Boramae Medical Center (03-2013-7), by SK Telecom Research Fund (06-2012-109), and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (0411-20130037).	Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Banerji A, 2007, AM J RHINOL, V21, P19, DOI 10.2500/ajr.2007.21.2979; Cao PP, 2014, CLIN EXP ALLERGY, V44, P690, DOI 10.1111/cea.12304; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Chin D, 2013, CURR OPIN OTOLARYNGO, V21, P23, DOI 10.1097/MOO.0b013e32835bc3f9; Deleuran M, 2012, CHEM IMMUNOL ALLERGY, V96, P45, DOI 10.1159/000331871; Dolgachev V, 2009, J IMMUNOL, V183, P5705, DOI 10.4049/jimmunol.0901666; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gregory LG, 2013, THORAX, V68, P82, DOI 10.1136/thoraxjnl-2012-202003; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; Hams E, 2014, P NATL ACAD SCI USA, V111, P367, DOI 10.1073/pnas.1315854111; Hastan D, 2011, ALLERGY, V66, P1216, DOI 10.1111/j.1398-9995.2011.02646.x; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Ikeda K, 2003, BLOOD, V101, P3594, DOI 10.1182/blood-2002-09-2817; Kim DW, 2011, AM J RHINOL ALLERGY, V25, pE255, DOI 10.2500/ajra.2011.25.3727; Kim DK, 2014, J ALLERGY CLIN IMMUN, V133, pAB169, DOI 10.1016/j.jaci.2013.12.609; Kim SW, 2013, ALLERGY, V68, P862, DOI 10.1111/all.12132; Kim SW, 2013, LARYNGOSCOPE, V123, P1075, DOI 10.1002/lary.23786; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Kouzaki H, 2013, AM J RESP CELL MOL, V49, P741, DOI 10.1165/rcmb.2012-0304OC; Lam M, 2013, INT FORUM ALLERGY RH, V3, P121, DOI 10.1002/alr.21082; Lee KI, 2014, AM J RHINOL ALLERGY, V28, P208, DOI 10.2500/ajra.2014.28.4055; Marijsse GS, 2014, AM J RESP CRIT CARE, V189, P1284, DOI 10.1164/rccm.201311-2011LE; Meltzer EO, 2006, J ALLERGY CLIN IMMUN, V118, pS17, DOI 10.1016/j.jaci.2006.09.005; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Rhee CS, 2004, IMMUNOLOGY, V113, P106, DOI 10.1111/j.1365-2567.2004.01930.x; Seys SF, 2013, CLIN EXP ALLERGY, V43, P1009, DOI 10.1111/cea.12125; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shin HW, 2012, AM J RESP CRIT CARE, V185, P944, DOI 10.1164/rccm.201109-1706OC; Soler ZM, 2012, AM J RHINOL ALLERGY, V26, P110, DOI 10.2500/ajra.2012.26.3741; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Van Crombruggen K, 2011, J ALLERGY CLIN IMMUN, V128, P728, DOI 10.1016/j.jaci.2011.07.049; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	40	106	109	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1476	+		10.1016/j.jaci.2015.01.003	http://dx.doi.org/10.1016/j.jaci.2015.01.003			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25725991	Bronze			2022-12-18	WOS:000355933400010
J	Herberth, G; Bauer, M; Gasch, M; Hinz, D; Roder, S; Olek, S; Kohajda, T; Rolle-Kampczyk, U; von Bergen, M; Sack, U; Borte, M; Lehmann, I				Herberth, Gunda; Bauer, Mario; Gasch, Michaela; Hinz, Denise; Roeder, Stefan; Olek, Sven; Kohajda, Tibor; Rolle-Kampczyk, Ulrike; von Bergen, Martin; Sack, Ulrich; Borte, Michael; Lehmann, Irina		Lifestyle Environm Factors Their I	Maternal and cord blood miR-223 expression associates with prenatal tobacco smoke exposure and low regulatory T-cell numbers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						miR-223; miR-155; regulatory T cells; cord blood; pregnancy; tobacco smoke	VOLATILE ORGANIC-COMPOUNDS; DIFFERENTIAL DNA METHYLATION; CIRCULATING MICRORNA; CIGARETTE-SMOKING; PERIPHERAL-BLOOD; FOXP3; PREGNANCY; ASTHMA; RESPONSES; INDUCE	Background: There is evidence that microRNAs (miRNAs) are sensitive to environmental stressors, including tobacco smoke. On the other hand, miRNAs are involved in immune regulation, such as regulatory T (Treg) cell differentiation. The aim of the present study was to investigate the association between prenatal tobacco smoke exposure, miRNAs, and Treg cell numbers. Methods: Within a prospective mother-child study (Lifestyle and Environmental Factors and Their Influence on Newborns Allergy Risk), we analyzed the expression of miR-155 and miR-223 together with Treg cell numbers in maternal blood during pregnancy, as well as in cord blood (n = 441). Tobacco smoke exposure was assessed based on questionnaire answers and maternal urine cotinine levels. Additionally, the concentration of smoking-related volatile organic compounds was measured in dwellings of study participants. Results: Both maternal and cord blood miR-223 expressions were positively correlated with maternal urine cotinine levels. An association was also found between maternal miR-223 expression and indoor concentrations of benzene and toluene. High miR-223 expression was associated with lower Treg cell numbers in maternal and cord blood. Furthermore, children with lower Treg cell numbers at birth had a higher risk of atopic dermatitis during the first 3 years of life. The concentration of the toluene metabolite S-benzylmercapturic acid in maternal urine was associated with decreased cord blood, but not maternal blood, miR-155 expression. A relationship between miR-155 expression and Treg cell numbers was not found. Conclusions: For the first time, we show that maternal tobacco smoke exposure during pregnancy correlates with the level of miRNA-223 expression in blood, with an effect on children's cord blood Treg cell numbers and subsequent allergy risk.	[Herberth, Gunda; Bauer, Mario; Gasch, Michaela; Hinz, Denise; Lehmann, Irina] UFZ Helmholtz Ctr Environm Res, Dept Environm Immunol, D-04318 Leipzig, Germany; [Roeder, Stefan] UFZ Helmholtz Ctr Environm Res, Core Facil Studies, D-04318 Leipzig, Germany; [Kohajda, Tibor; Rolle-Kampczyk, Ulrike; von Bergen, Martin] UFZ Helmholtz Ctr Environm Res, Dept Metabol, D-04318 Leipzig, Germany; [Olek, Sven] Epiontis GmbH, Ivana Tuerbachova Lab Epigenet, Berlin, Germany; [von Bergen, Martin] Aalborg Univ, Dept Biotechnol Chem & Environm Engn, Aalborg, Denmark; [Sack, Ulrich] Univ Leipzig, Inst Clin Immunol, D-04109 Leipzig, Germany; [Borte, Michael] Univ Leipzig, Childrens Hosp, Municipal Hosp St Georg, Acad Teaching Hosp, D-04109 Leipzig, Germany	Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Epiontis GmbH; Aalborg University; Leipzig University; Leipzig University	Herberth, G (corresponding author), UFZ Helmholtz Ctr Environm Res, Dept Environm Immunol, Permoserstr 15, D-04318 Leipzig, Germany.	gunda.herberth@ufz.de; irina.lehmann@ufz.de	Bauer, Mario/AAZ-7540-2021; Sack, Ulrich/J-6301-2015; von Bergen, Martin/D-7960-2011; Rolle-Kampczyk, Ulrike E./D-4786-2015	Sack, Ulrich/0000-0002-7813-0492; von Bergen, Martin/0000-0003-2732-2977; Rolle-Kampczyk, Ulrike E./0000-0002-7728-6284; Lehmann, Irina/0000-0001-8875-5587; Herberth, Gunda/0000-0003-0212-3509	Helmholtz Centre for Environmental Research-UFZ	Helmholtz Centre for Environmental Research-UFZ(Helmholtz Association)	The LINA study was supported by Helmholtz institutional funding (Helmholtz Centre for Environmental Research-UFZ).	Allantaz F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029979; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Ballabio E, 2010, BLOOD, V116, P1105, DOI 10.1182/blood-2009-12-256719; Baltimore D, 2008, NAT IMMUNOL, V9, P839, DOI 10.1038/ni.f.209; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737594; Benowitz NL, 2009, AM J EPIDEMIOL, V170, P885, DOI 10.1093/aje/kwp215; Bollati V, 2010, ENVIRON HEALTH PERSP, V118, P763, DOI 10.1289/ehp.0901300; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Chiaretti S, 2010, HAEMATOL-HEMATOL J, V95, P1114, DOI 10.3324/haematol.2009.015099; Chung S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023488; Cobb BS, 2006, J EXP MED, V203, P2519, DOI 10.1084/jem.20061692; Ezzie ME, 2012, THORAX, V67, P122, DOI 10.1136/thoraxjnl-2011-200089; Felli N, 2009, HAEMATOL-HEMATOL J, V94, P479, DOI 10.3324/haematol.2008.002345; Feltens R, 2010, TOXICOL APPL PHARM, V242, P100, DOI 10.1016/j.taap.2009.09.020; Flouris AD, 2012, FOOD CHEM TOXICOL, V50, P3600, DOI 10.1016/j.fct.2012.07.025; Fulci V, 2010, HUM IMMUNOL, V71, P206, DOI 10.1016/j.humimm.2009.11.008; Gallo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030679; Herberth G, 2011, ALLERGY, V66, P1065, DOI 10.1111/j.1398-9995.2011.02587.x; Herberth G, 2013, INT J HYG ENVIR HEAL, V216, P309, DOI 10.1016/j.ijheh.2012.06.002; Hinz D, 2012, ALLERGY, V67, P380, DOI 10.1111/j.1398-9995.2011.02767.x; Hinz D, 2010, CLIN EXP ALLERGY, V40, P419, DOI 10.1111/j.1365-2222.2009.03434.x; Izzotti A, 2009, FASEB J, V23, P806, DOI 10.1096/fj.08-121384; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412; Kohlhaas S, 2009, J IMMUNOL, V182, P2578, DOI 10.4049/jimmunol.0803162; Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x; Lehmann I, 2002, ENVIRON TOXICOL, V17, P203, DOI 10.1002/tox.10055; Lehmann I, 2002, ALLERGY, V57, P129, DOI 10.1046/j.0105-4538.2002.00001.x; Liston A, 2008, J EXP MED, V205, P1993, DOI 10.1084/jem.20081062; Lu LF, 2009, IMMUNITY, V30, P80, DOI 10.1016/j.immuni.2008.11.010; Maccani Matthew A., 2012, Frontiers in Genetics, V3, P53, DOI 10.3389/fgene.2012.00053; Mogel I, 2011, TOXICOLOGY, V289, P28, DOI 10.1016/j.tox.2011.07.006; O'Connell RM, 2012, ANNU REV IMMUNOL, V30, P295, DOI 10.1146/annurev-immunol-020711-075013; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Rehwagen M, 2003, INDOOR AIR, V13, P283, DOI 10.1034/j.1600-0668.2003.00206.x; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; Schlink U, 2010, SCI TOTAL ENVIRON, V408, P3840, DOI 10.1016/j.scitotenv.2009.12.002; Sonkoly E, 2010, J ALLERGY CLIN IMMUN, V126, P581, DOI 10.1016/j.jaci.2010.05.045; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wan ES, 2012, HUM MOL GENET, V21, P3073, DOI 10.1093/hmg/dds135; Weisse K, 2012, CLIN EXP ALLERGY, V42, P1337, DOI 10.1111/j.1365-2222.2012.04024.x; Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361; Wong QWL, 2008, GASTROENTEROLOGY, V135, P257, DOI 10.1053/j.gastro.2008.04.003; Yang IV, 2012, J ALLERGY CLIN IMMUN, V130, P1243, DOI 10.1016/j.jaci.2012.07.052; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563	47	106	110	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					543	+		10.1016/j.jaci.2013.06.036	http://dx.doi.org/10.1016/j.jaci.2013.06.036			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	23978443				2022-12-18	WOS:000332397100031
J	Slager, RE; Otulana, BA; Hawkins, GA; Yen, YP; Peters, SP; Wenzel, SE; Meyers, DA; Bleecker, ER				Slager, Rebecca E.; Otulana, Babatunde A.; Hawkins, Gregory A.; Yen, Yu Ping; Peters, Stephen P.; Wenzel, Sally E.; Meyers, Deborah A.; Bleecker, Eugene R.			IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pharmacogenetics; pitrakinra; IL-4 receptor; asthma therapy; IL-4 receptor antagonist	RANDOMIZED CONTROLLED TRIAL; PERSISTENT ASTHMA; IL-4/IL-13 ANTAGONIST; INTERLEUKIN-4; SALMETEROL; CHALLENGE; THERAPY	Background: This is the first large pharmacogenetic investigation of the inflammatory IL-4/IL-13 pathway in patients with moderate-to-severe asthma. We analyzed genomic DNA from participants in a 12-week placebo-controlled efficacy trial of pitrakinra (1, 3, or 10 mg twice daily), a novel IL-4/IL-13 pathway antagonist (Clinicaltrials.gov NCT00801853). Objectives: The primary hypothesis for this analysis is that amino acid changes in the 3' end of the IL-4 receptor alpha gene (IL4RA) or closely proximal variants would predict reductions in asthma exacerbations for subjects randomized to pitrakinra therapy. Methods: Nineteen IL4RA single nucleotide polymorphisms (SNPs) were tested in 407 non-Hispanic white subjects for association with the primary clinical end point of asthma exacerbations and changes in secondary end points for asthma symptom scores. Results: The most consistent pharmacogenetic associations were observed for the correlated tagging SNPs rs8832 and rs1029489 in the IL4RA 3' untranslated and proximal regions, respectively. Subjects homozygous for the rs8832 common G allele randomized to pitrakinra (placebo group nonsignificant) had decreased asthma exacerbations and decreased nocturnal awakenings and activities limited by asthma. There was also a significant pitrakinra dose-response relationship (placebo/1 000mg/3 mg/10 mg) for exacerbations in subjects homozygous for the common allele in rs1029489 (P = .005) and rs8832 (P = .009) and the intronic SNPs rs3024585, rs3024622, and rs4787956 (P = .03). Conclusion: This study demonstrates a significant pharmacogenetic interaction between anti-IL-4 receptor alpha therapy and IL4RA gene variation, identifying an asthma subgroup that is more responsive to therapy with this antagonist. (J Allergy Clin Immunol 2012; 130:516-22.)	[Slager, Rebecca E.; Hawkins, Gregory A.; Peters, Stephen P.; Meyers, Deborah A.; Bleecker, Eugene R.] Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27157 USA; [Otulana, Babatunde A.; Yen, Yu Ping] Aerovance, Berkeley, CA USA; [Wenzel, Sally E.] Univ Pittsburgh, Med Ctr, Dept Med, Pulm Allergy & Crit Care Med Div, Pittsburgh, PA USA	Wake Forest University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bleecker, ER (corresponding author), Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27157 USA.	ebleeck@wakehealth.edu		Wenzel, Sally/0000-0002-4242-0164	Aerovance; Bayer Healthcare; National Institute of Heart, Lung, and Blood [HL065899, HL101487, HL089992]; National Institutes of Health (NIH); NIH; GlaxoSmithKline; Sanofi-Aventis; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065899, K12HL089992, RC2HL101487] Funding Source: NIH RePORTER	Aerovance; Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); National Institute of Heart, Lung, and Blood(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); Sanofi-Aventis(Sanofi-Aventis); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by Aerovance, Bayer Healthcare, and the National Institute of Heart, Lung, and Blood grants HL065899, HL101487, and HL089992.; R. E. Slager has received grants from the National Institutes of Health (NIH) and research support from Aerovance. B. A. Otulana and Y. P. Yen are employees of Aerovance. G. A. Hawkins has received research support from Aerovance. S. P. Peters has received research support from the NIH. S. E. Wenzel has consulted for Genentech, and has received research support from Aerovance, GlaxoSmithKline, and Sanofi-Aventis. D. A. Meyers and E. R. Bleecker have consulted for and received research support from Aerovance.	Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bleecker ER, 2007, LANCET, V370, P2118, DOI 10.1016/S0140-6736(07)61906-0; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; Getz EB, 2009, J CLIN PHARMACOL, V49, P1025, DOI 10.1177/0091270009341183; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Kay AB, 2006, CHEM IMMUNOL ALLERGY, V91, P59; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; O'Byrne PM, 2004, TRENDS PHARMACOL SCI, V25, P244, DOI 10.1016/j.tips.2004.03.008; Oh CK, 2010, EUR RESPIR REV, V19, P46, DOI 10.1183/09059180.00007609; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Slager RE, 2010, J ALLERGY CLIN IMMUN, V126, P875, DOI 10.1016/j.jaci.2010.08.001; Tomkinson A, 2010, ALLERGY, V65, P69, DOI 10.1111/j.1398-9995.2009.02156.x; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Wenzel SE, 2010, EUR RESP SOC 20 ANN, pP3980; Wenzel SE, 2011, AM J RESP CRIT CARE, V183, pA6179	24	106	122	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					516	+		10.1016/j.jaci.2012.03.030	http://dx.doi.org/10.1016/j.jaci.2012.03.030			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22541248	Green Accepted			2022-12-18	WOS:000307002200036
J	Eberlein, B; Krischan, L; Darsow, U; Ollert, M; Ring, J				Eberlein, Bernadette; Krischan, Lilian; Darsow, Ulf; Ollert, Markus; Ring, Johannes			Double positivity to bee and wasp venom: Improved diagnostic procedure by recombinant allergen-based IgE testing and basophil activation test including data about cross-reactive carbohydrate determinants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Insect venom allergy; basophil activation test; CD63; recombinant allergens; rApi m 1; rVes v 5; bromelain; horseradish peroxidase	HYMENOPTERA; EXPRESSION; CD63; IMMUNOTHERAPY	Background: Specific IgE (sIgE) antibodies to both bee and wasp venom can be due to a sensitivity to both insect venoms or due to cross-reactive carbohydrate determinants (CCDs). Objective: Investigating whether a basophil activation test (BAT) with both venoms as well as with bromelain and horseradish peroxidase (HRP) or recombinant allergen-based IgE testing can improve the diagnostic procedure. Methods: Twenty-two Hymenoptera-venom allergic patients with sIgE antibodies to both bee and wasp venom were studied. sIgE antibodies to MUXF3 CCD, bromelain, HRP, rApi m 1, and rVes v 5 were determined, and a BAT (Flow2 CAST) with venom extracts, bromelain, and HRP was performed. Further recombinant allergen-based IgE testing was done by using an ELISA, if required. The reactivity of basophils was calculated from the insect venom concentration at half-maximum stimulation. Results: Double positivity/double negativity/single positivity to rApi m 1 and rVes v 5 was seen in 12/1/9 patients. Further recombinant allergen-based IgE testing in the last ones revealed positive results to the other venom in all cases except one. BAT was double positive/double negative/single positive in 6/2/14 patients. Four patients with negative results in sIgE antibodies to CCDs had positive results in BAT. BAT with bromelain/HRP showed a sensitivity of 50%/81% and a specificity of 91%/90%. Conclusion: Component-resolved IgE testing elucidates the pattern of double positivity, showing a majority of true double sensitizations independent of CCD sensitization. BAT seems to add more information about the culprit insect even if the true clinical relevance of BAT is not completely determined because of ethical limitations on diagnostic sting challenges. BAT with HRP is a good method to determine sensitivity to CCDs. (J Allergy Clin Immunol 2012;130:155-61.)	[Eberlein, Bernadette; Krischan, Lilian; Darsow, Ulf; Ollert, Markus; Ring, Johannes] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-80802 Munich, Germany	Technical University of Munich	Eberlein, B (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.	eberlein@lrz.tum.de	Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152; Ollert, Markus W./0000-0002-8055-0103	BUHLMANN Laboratories AG, Schoenenbuch, Switzerland; Christine Kuhne-Center of Allergy Research and Education (CK-CARE)	BUHLMANN Laboratories AG, Schoenenbuch, Switzerland; Christine Kuhne-Center of Allergy Research and Education (CK-CARE)	This study was supported by BUHLMANN Laboratories AG, Schoenenbuch, Switzerland, and the Christine Kuhne-Center of Allergy Research and Education (CK-CARE).	Blank S, 2011, ALLERGY, V66, P1322, DOI 10.1111/j.1398-9995.2011.02667.x; Blank S, 2010, J IMMUNOL, V184, P5403, DOI 10.4049/jimmunol.0803709; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Eberlein-Konig B, 2006, ALLERGY, V61, P1084, DOI 10.1111/j.1398-9995.2006.01122.x; Eberlein-Konig B, 2006, J INVEST ALLERG CLIN, V16, P5; Ebo DG, 2007, CYTOM PART B-CLIN CY, V72B, P196, DOI 10.1002/cyto.b.20142; Erdmann SM, 2004, ALLERGY, V59, P1102, DOI 10.1111/j.1398-9995.2004.00624.x; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V127, P265, DOI 10.1016/j.jaci.2010.06.042; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Kosnik Mitja, 2009, Allergy Asthma Clin Immunol, V5, P11, DOI 10.1186/1710-1492-5-11; Mertens M, 2010, CLIN EXP ALLERGY, V40, P1333, DOI 10.1111/j.1365-2222.2010.03535.x; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Nopp A, 2009, ALLERGY, V64, P811, DOI 10.1111/j.1398-9995.2008.01900.x; Peternelj A, 2009, WIEN KLIN WOCHENSCHR, V121, P344, DOI 10.1007/s00508-009-1174-y; RING J, 1977, LANCET, V1, P466; Scherer K, 2008, INT ARCH ALLERGY IMM, V146, P122, DOI 10.1159/000113515; Seismann Henning, 2010, Clin Mol Allergy, V8, P7, DOI 10.1186/1476-7961-8-7; Sturm GJ, 2004, ALLERGY, V59, P1110, DOI 10.1111/j.1398-9995.2004.00400.x; Sturm GJ, 2011, J ALLERGY CLIN IMMUN, V128, P247, DOI 10.1016/j.jaci.2011.02.021; Sturm GJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020842	21	106	108	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					155	161		10.1016/j.jaci.2012.02.008	http://dx.doi.org/10.1016/j.jaci.2012.02.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22421265				2022-12-18	WOS:000306644800023
J	Holgate, ST				Holgate, Stephen T.			Pathophysiology of asthma: What has our current understanding taught us about new therapeutic approaches?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; biologic agents; T(H)2; epithelium; new treatments	NECROSIS-FACTOR-ALPHA; SEVERE PERSISTENT ASTHMA; CHEMOKINE RECEPTOR 4; FC-EPSILON-RI; MONOCLONAL-ANTIBODY; ALLERGIC-ASTHMA; ATOPIC ASTHMA; T-CELLS; INTERLEUKIN-4 RECEPTOR; AIRWAY INFLAMMATION	Current asthma therapy is based on the use of adrenergic bronchodilator and anti-inflammatory drugs the specificity, efficacy, duration of action, and safety of which have been derived through classical pharmacology and medicinal chemistry. That asthma is a T(H)2-type inflammatory disorder frequently associated with atopy and allergic comorbidities has led to a concentrated effort to find treatments that act selectively on this pathway. A systematic literature review was undertaken, as well as a review of the Web site Clinicaltrials.gov for ongoing trials. Targets have included T cells themselves and their associated cytokines, chemokines, and receptors mostly targeted with biological agents. With the exception of anti-human IgE, none of these have met the expectations predicted from animal models and human in vitro tests. For most of these new therapies, only a very small subpopulation appears to respond. A case is made for a different approach to drug discovery based on acquiring a greater understanding of asthma stratification, the relevant pathways involved, and the development of appropriate diagnostic tests enabling the targeting of selective treatments to those asthmatic phenotypes most likely to respond. The recognition that asthma is more than allergy mandates improved predictive animal models and an appreciation that many of the environmental insults that initiate, consolidate, and exacerbate asthma operate through an epithelium functioning in a disorderly fashion. An integrated model that places the epithelium at the forefront of asthma pathogenesis suggests that greater emphasis should be placed on therapeutics that increase the airways' resistance against the inhaled environment rather than focusing only on suppression of inflammation. (J Allergy Clin Immunol 2011;128:495-505.)	Univ Southampton, Sir Henry Wellcome Labs, Sch Med, Div Infect Inflammat & Immun,Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton	Holgate, ST (corresponding author), Univ Southampton, Sir Henry Wellcome Labs, Sch Med, Div Infect Inflammat & Immun,Southampton Gen Hosp, Level F,S Block 810, Southampton SO16 6YD, Hants, England.	sth@soton.ac.uk			Medical Research Council UK; British Lung Foundation; Environmental Protection UK; MRC [G0800766, G19/34] Funding Source: UKRI; Medical Research Council [G0800766, G19/34] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10021] Funding Source: researchfish	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Lung Foundation; Environmental Protection UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Disclosure of potential conflict of interest: S. T. Holgate is Nonexecutive Director of Synairgen, has consultant arrangements with Novartis and MSD, receives research support from the Medical Research Council UK, is Vice President of the British Lung Foundation, and is Vice President of Environmental Protection UK.	Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Antoniu SA, 2010, CURR OPIN MOL THER, V12, P770; Baines KJ, 2010, EUR RESPIR J, V35, P522, DOI 10.1183/09031936.00027409; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Bateman ED, 2008, ALLERGY, V63, P932, DOI 10.1111/j.1398-9995.2008.01724.x; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Beasley R, 2007, RESPIROLOGY, V12, pS18, DOI 10.1111/j.1440-1843.2007.01046.x; Bel Elisabeth, 2005, Treat Respir Med, V4, P365, DOI 10.2165/00151829-200504060-00002; Bellou A, 2005, CURR ALLERGY ASTHM R, V5, P149, DOI 10.1007/s11882-005-0089-6; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032; Bisaccioni C, 2009, CLINICS, V64, P769, DOI 10.1590/S1807-59322009000800010; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Bosco A, 2010, MUCOSAL IMMUNOL, V3, P399, DOI 10.1038/mi.2010.13; Bottema RWB, 2010, INT ARCH ALLERGY IMM, V153, P259, DOI 10.1159/000314366; Brandelius A, 2011, PULM PHARMACOL THER, V24, P59, DOI 10.1016/j.pupt.2010.10.004; Brusselle G, 2009, RESP MED, V103, P1633, DOI 10.1016/j.rmed.2009.06.014; Busse WW, 2008, AM J RESP CRIT CARE, V178, P1002, DOI 10.1164/rccm.200708-1200OC; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P1237, DOI 10.1016/j.jaci.2010.04.005; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P803, DOI 10.1016/j.jaci.2009.11.048; Byrd JC, 2007, CLIN CANCER RES, V13, P4448, DOI 10.1158/1078-0432.CCR-06-1463; Campbell JD, 2010, ALLERGY, V65, P1141, DOI 10.1111/j.1398-9995.2010.02336.x; Canonica GW, 2007, ALLERGY, V62, P668, DOI 10.1111/j.1398-9995.2007.01352.x; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Chen G, 2010, J IMMUNOL, V184, P6133, DOI 10.4049/jimmunol.1000223; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; Corren J, 2008, J ALLERGY CLIN IMMUN, V121, P506, DOI 10.1016/j.jaci.2007.11.026; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Dahlen SE, 2011, NEW ENGL J MED, V364, P1769, DOI 10.1056/NEJMe1100937; Dal Negro RW, 2011, EUR ANN ALLERGY CLIN, V43, P22; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; de Groot EP, 2010, EUR RESPIR J, V36, P671, DOI 10.1183/09031936.00185709; Di Domenico Monica, 2011, Inflammation & Allergy Drug Targets, V10, P2; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Durrant DM, 2010, IMMUNOL INVEST, V39, P526, DOI 10.3109/08820131003615498; Eggel A, 2011, ALLERGY, V66, P961, DOI 10.1111/j.1398-9995.2011.02546.x; Erin EM, 2006, AM J RESP CRIT CARE, V174, P753, DOI 10.1164/rccm.200601-072OC; Fishman-Lobell J, 2001, J IMMUNOL METHODS, V257, P71, DOI 10.1016/S0022-1759(01)00447-1; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Foster PS, 2002, TRENDS MOL MED, V8, P162, DOI 10.1016/S1471-4914(02)02302-X; Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC; Gauvreau GM, 2011, AM J RESP CRIT CARE, V183, P1007, DOI 10.1164/rccm.201008-1210OC; Getz EB, 2009, J CLIN PHARMACOL, V49, P1025, DOI 10.1177/0091270009341183; Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hargreave FE, 2007, CURR OPIN ALLERGY CL, V7, P102, DOI 10.1097/ACI.0b013e328013e3c2; Hart TK, 2002, CLIN EXP IMMUNOL, V130, P93, DOI 10.1046/j.1365-2249.2002.01973.x; Hidi R, 2000, J IMMUNOL, V164, P412, DOI 10.4049/jimmunol.164.1.412; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Holdom MD, 2011, NAT STRUCT MOL BIOL, V18, P571, DOI 10.1038/nsmb.2044; Holgate ST, 2011, EUR RESPIR J, V37, P1352, DOI 10.1183/09031936.00063510; Holgate ST, 2011, EUR J CLIN INVEST; Holgate S, 2009, RESP MED, V103, P1098, DOI 10.1016/j.rmed.2009.03.008; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holgate ST, 2010, DISCOV MED, V9, P439; Holgate ST, 2010, CLIN SCI, V118, P439, DOI 10.1042/CS20090474; Holt PG, 2011, CHEST, V139, P1165, DOI 10.1378/chest.10-2397; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Hunt J, 2008, J BIOL CHEM, V283, P29882, DOI 10.1074/jbc.M804742200; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jaffar ZH, 1999, J IMMUNOL, V163, P6283; Jartti T, 2010, PEDIAT ALLERG IMM-UK, V21, P1008, DOI 10.1111/j.1399-3038.2010.01059.x; Jartti T, 2011, PEDIAT ALLERG IMM-UK, V22, P350, DOI 10.1111/j.1399-3038.2011.01170.x; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; Kakkar T, 2011, PHARM RES; Kim S, 2010, J ALLERGY CLIN IMMUN, V125, P1336, DOI 10.1016/j.jaci.2010.03.028; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; Kon OM, 2001, EUR RESPIR J, V18, P45, DOI 10.1183/09031936.01.00064101; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lin KW, 2011, BIOCH BIOPHYS ACTA; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Lordan JL, 2001, J ALLERGY CLIN IMMUN, V108, P976, DOI 10.1067/mai.2001.119740; Lowe PJ, 2011, BRIT J CLIN PHARMACO, V72, P306, DOI 10.1111/j.1365-2125.2011.03962.x; Lowe PJ, 2009, BRIT J CLIN PHARMACO, V68, P61, DOI 10.1111/j.1365-2125.2009.03401.x; Maeda Y, 2011, AM J RESP CRIT CARE; Menzella F, 2011, ALLERGY ASTHMA CL IM, V7, DOI 10.1186/1710-1492-7-9; Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382; Morjaria JB, 2008, THORAX, V63, P584, DOI 10.1136/thx.2007.086314; Morjaria JB, 2011, CURR OPIN ALLERGY CL, V11, P58, DOI 10.1097/ACI.0b013e3283423245; Morjaria Jaymin B, 2009, Expert Rev Respir Med, V3, P299, DOI 10.1586/ers.09.11; Mouthuy J, 2011, AM J RESP CRIT CARE; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Oh CK, 2010, EUR RESPIR REV, V19, P46, DOI 10.1183/09059180.00007609; Oh Chad K., 2011, Inflammation & Allergy Drug Targets, V10, P180; Oh CK, 2010, BRIT J CLIN PHARMACO, V69, P645, DOI 10.1111/j.1365-2125.2010.03647.x; Pace E, 2011, J ASTHMA, V48, P387, DOI 10.3109/02770903.2011.561512; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x; Park SW, 2005, CHEST, V128, P1921, DOI 10.1378/chest.128.4.1921; Parker JM, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-14; Pease JE, 2011, BIOCHEM J, V434, P11, DOI 10.1042/BJ20101132; Prakash TP, 2008, J MED CHEM, V51, P2766, DOI 10.1021/jm701537z; Price D, 2011, NEW ENGL J MED, V364, P1695, DOI 10.1056/NEJMoa1010846; Prieto L, 2006, INT ARCH ALLERGY IMM, V139, P122, DOI 10.1159/000090387; Rech AJ, 2009, ANN NY ACAD SCI, V1174, P99, DOI 10.1111/j.1749-6632.2009.04939.x; Reyes CL, 2009, IDRUGS, V12, P692; Robinson DS, 2010, J ALLERGY CLIN IMMUN, V126, P1081, DOI 10.1016/j.jaci.2010.06.025; Rolland JM, 2010, CURR OPIN ALLERGY CL, V10, P559, DOI 10.1097/ACI.0b013e32833ff2b2; Rosenwasser LJ, 2003, J ALLERGY CLIN IMMUN, V112, P563, DOI 10.1067/mai.2003.1709; Roussel L, 2010, J IMMUNOL, V184, P4531, DOI 10.4049/jimmunol.0903162; Saha SK, 2008, J ALLERGY CLIN IMMUN, V121, P685, DOI 10.1016/j.jaci.2008.01.005; SAKULA A, 1985, THORAX, V40, P887, DOI 10.1136/thx.40.12.887; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schiff M, 2011, RHEUMATOLOGY, V50, P437, DOI 10.1093/rheumatology/keq287; Schwartz HJ, 2002, ALLERGY ASTHMA PROC, V23, P15; Shalev I, 2011, SEMIN IMMUNOL; Shanafelt AB, 1998, P NATL ACAD SCI USA, V95, P9454, DOI 10.1073/pnas.95.16.9454; Shirtcliffe P, 2011, CURR OPIN PULM MED, V17, P72, DOI 10.1097/MCP.0b013e328341f181; Siddiqui S, 2010, CHEST, V137, P797, DOI 10.1378/chest.09-1839; Silvestri M, 2006, CLIN EXP ALLERGY, V36, P1373, DOI 10.1111/j.1365-2222.2006.02502.x; Slager RE, 2010, J ALLERGY CLIN IMMUN, V126, P875, DOI 10.1016/j.jaci.2010.08.001; Smurthwaite Lyn, 2002, Curr Allergy Asthma Rep, V2, P231, DOI 10.1007/s11882-002-0024-z; Stevens PT, 2008, CLIN EXP ALLERGY, V38, P1901, DOI 10.1111/j.1365-2222.2008.03093.x; Strempel JM, 2010, J IMMUNOL, V184, P1309, DOI 10.4049/jimmunol.0804162; Tieu DD, 2010, J ALLERGY CLIN IMMUN, V125, P667, DOI 10.1016/j.jaci.2009.11.045; Vijayanand P, 2010, J IMMUNOL, V184, P4568, DOI 10.4049/jimmunol.0901342; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Whitsett JA, 2006, PEDIATR CLIN N AM, V53, P873, DOI 10.1016/j.pcl.2006.08.009; Wigginton SJ, 2008, CLIN EXP ALLERGY, V38, P313, DOI 10.1111/j.1365-2222.2007.02896.x; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yano H, 2007, CLIN CANCER RES, V13, P6494, DOI 10.1158/1078-0432.CCR-07-1324	133	106	111	0	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					495	505		10.1016/j.jaci.2011.06.052	http://dx.doi.org/10.1016/j.jaci.2011.06.052			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21807404				2022-12-18	WOS:000294283400007
J	Zhang, BD; Alysandratos, KD; Angelidou, A; Asadi, S; Sismanopoulos, N; Delivanis, DA; Weng, ZY; Miniati, A; Vasiadi, M; Katsarou-Katsari, A; Miao, BC; Leeman, SE; Kalogeromitros, D; Theoharides, TC				Zhang, Bodi; Alysandratos, Konstantinos-Dionysios; Angelidou, Asimenia; Asadi, Shahrzad; Sismanopoulos, Nikolaos; Delivanis, Danae-Anastasia; Weng, Zuyi; Miniati, Alexandra; Vasiadi, Magdalini; Katsarou-Katsari, Alexandra; Miao, Benchun; Leeman, Susan E.; Kalogeromitros, Dimitrios; Theoharides, Theoharis C.			Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: Relevance to atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; degranulation; inflammation; mast cells; mitochondria; substance P; TNF	FC-EPSILON-RI; SUBSTANCE-P; INFLAMMATORY DISEASE; ACTIVATION; FISSION; SKIN; IGE; STIMULATION; MECHANISMS; INHIBITION	Background: Mast cells derive from hematopoietic cell precursors and participate in tissue allergic, immune, and inflammatory processes. They secrete many mediators, including preformed TNF, in response to allergic, neuropeptide, and environmental triggers. However, regulation of mast cell degranulation is not well understood. Objective: We investigated the role of mitochondrial dynamics in degranulation of human cultured mast cells. Methods: Human umbilical cord blood-derived mast cells (hCBMCs) and Laboratory of Allergic Diseases 2 (LAD2) mast cells were examined by confocal and differential interference contrast microscopy during activation by IgE/antigen and substance P (SP). Mast cells in control and atopic dermatitis (AD) skin were evaluated by transmission electron microscopy. LAD2 cells were pretreated with mitochondrial division inhibitor, a dynamin-related protein 1 (Drp1) inhibitor, and small interfering RNA for Drp1, which is necessary for mitochondrial fission and translocation. Calcineurin and Drp1 gene expression was analyzed in stimulated LAD2 cells and AD skin biopsies. Results: Stimulation of hCBMCs with IgE/antigen or LAD2 cells with SP leads to rapid (30 minutes) secretion of preformed TNF. Degranulation is accompanied by mitochondrial translocation from a perinuclear location to exocytosis sites. Extracellular calcium depletion prevents these effects, indicating calcium requirement. The calcium-dependent calcineurin and Drp1 are activated 30 minutes after SP stimulation. Reduction of Drp1 activity by mitochondrial division inhibitor and decrease of Drp1 expression using small interfering RNA inhibit mitochondrial translocation, degranulation, and TNF secretion. Mitochondrial translocation is also evident by transmission electron microscopy in skin mast cells from AD biopsies, in which gene expression of calcineurin, Drp1, and SP is higher than in normal skin. Conclusion: Human mast cell degranulation requires mitochondrial dynamics, also implicated in AD. (J Allergy Clin Immunol 2011;127:1522-31.)	[Zhang, Bodi; Alysandratos, Konstantinos-Dionysios; Angelidou, Asimenia; Asadi, Shahrzad; Sismanopoulos, Nikolaos; Delivanis, Danae-Anastasia; Weng, Zuyi; Miniati, Alexandra; Vasiadi, Magdalini; Theoharides, Theoharis C.] Tufts Univ, Sch Med, Dept Mol Physiol & Pharmacol, Mol Immunopharmacol & Drug Discovery Lab, Boston, MA 02111 USA; [Zhang, Bodi; Theoharides, Theoharis C.] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; [Miao, Benchun] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Nutr & Canc Biol Lab, Boston, MA 02111 USA; [Theoharides, Theoharis C.] Tufts Univ, Sch Med, Dept Internal Med, Boston, MA 02111 USA; [Theoharides, Theoharis C.] Tufts Med Ctr, Boston, MA USA; [Alysandratos, Konstantinos-Dionysios; Angelidou, Asimenia; Miniati, Alexandra; Vasiadi, Magdalini; Kalogeromitros, Dimitrios; Theoharides, Theoharis C.] Attikon Gen Hosp, Allergy Sect, Allergy Clin Res Unit, Athens, Greece; [Katsarou-Katsari, Alexandra] Univ Athens, Sch Med, A Syggros Hosp, Dept Dermatol 1, GR-10679 Athens, Greece; [Leeman, Susan E.] Boston Univ, Sch Med, Dept Pharmacol, Boston, MA 02215 USA	Tufts University; Tufts University; Tufts University; United States Department of Agriculture (USDA); Tufts University; Tufts Medical Center; University Hospital Attikon; Athens Medical School; National & Kapodistrian University of Athens; Boston University	Theoharides, TC (corresponding author), Tufts Univ, Sch Med, Dept Mol Physiol & Pharmacol, Mol Immunopharmacol & Drug Discovery Lab, Room M&V 208,136 Harrison Ave, Boston, MA 02111 USA.	theoharis.theoharides@tufts.edu	weng, zuyi/J-4147-2015; Zhang, Bodi/G-6452-2010; Zhang, Bodi/ABI-6738-2020	Leeman, Susan/0000-0002-0951-5364	NIH [R01 AR47652]; Galenica SA (Athens, Greece); Hellenic State Scholarships Foundation (Athens, Greece); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047652] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Galenica SA (Athens, Greece); Hellenic State Scholarships Foundation (Athens, Greece); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported in part by NIH grant R01 AR47652 to T.C.T.; We thank Dr A. S. Kirshenbaum and Dr Dean Metcalfe (National Institutes of Health, Bethesda, Md) for the generous supply of LAD2 mast cells. We also thank Dr Orian Shirihai (Boston University Medical School, Boston, Mass) for kindly providing the Drp1 inhibitor mdivi-1 and for useful discussions and encouragement. Thanks are also due to Dr James A. Marchand (Tufts University, Boston, Mass) for his useful comments on this article. We thank Biovitrum AB (Stockholm, Sweden) for their kind gift of rhSCF. B.Z. is supported by a graduate student fellowship from Galenica SA (Athens, Greece). K.-D. A. and A. A. are recipients of postgraduate scholarships from the Hellenic State Scholarships Foundation (Athens, Greece). Rose Fountotos (Montreal, Canada) participated as a high school trainee during summer 2010.	BEUTLER B, 1995, J INVEST MED, V43, P227; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Blank U, 2004, TRENDS IMMUNOL, V25, P266, DOI 10.1016/j.it.2004.03.005; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Campello S, 2006, J EXP MED, V203, P2879, DOI 10.1084/jem.20061877; Cassano N, 2006, INT J IMMUNOPATH PH, V19, P237; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Cereghetti GM, 2008, P NATL ACAD SCI USA, V105, P15803, DOI 10.1073/pnas.0808249105; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200; DOUGLAS WW, 1977, J PHYSIOL-LONDON, V270, P691, DOI 10.1113/jphysiol.1977.sp011976; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gibbs BF, 2001, EXP DERMATOL, V10, P312, DOI 10.1034/j.1600-0625.2001.100503.x; Gong JA, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-34; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018; Haas RH, 2010, DEV DISABIL RES REV, V16, P144, DOI 10.1002/ddrr.112; Inagaki N, 2010, EUR J PHARMACOL, V626, P283, DOI 10.1016/j.ejphar.2009.09.043; Jahani-Asl A, 2007, EMBO REP, V8, P912, DOI 10.1038/sj.embor.7401077; JOHNSON RG, 1980, FEBS LETT, V120, P75, DOI 10.1016/0014-5793(80)81050-7; Kaasik A, 2001, CIRC RES, V89, P153, DOI 10.1161/hh1401.093440; Kawakami T, 2009, CURR OPIN IMMUNOL, V21, P666, DOI 10.1016/j.coi.2009.09.006; Kempuraj D, 2008, BRIT J PHARMACOL, V155, P1076, DOI 10.1038/bjp.2008.356; Kempuraj D, 1999, BLOOD, V93, P3338, DOI 10.1182/blood.V93.10.3338.410k05_3338_3346; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417; Kraft S, 2004, INT ARCH ALLERGY IMM, V135, P62, DOI 10.1159/000080231; Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365-2567.2007.02705.x; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Molina AJA, 2009, DIABETES, V58, P2303, DOI 10.2337/db07-1781; MORRIS RL, 1993, J CELL SCI, V104, P917; O'Connor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061; Olszewski MB, 2007, J IMMUNOL, V178, P5701, DOI 10.4049/jimmunol.178.9.5701; Pereira U, 2010, BRIT J DERMATOL, V163, P70, DOI 10.1111/j.1365-2133.2010.09757.x; PRABHAKAR NR, 1989, PEPTIDES, V10, P1003, DOI 10.1016/0196-9781(89)90182-4; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Quintana A, 2007, P NATL ACAD SCI USA, V104, P14418, DOI 10.1073/pnas.0703126104; Rigopoulos D, 2008, EXPERT OPIN BIOL TH, V8, P123, DOI 10.1517/14712598.8.1.123; Saotome M, 2008, P NATL ACAD SCI USA, V105, P20728, DOI 10.1073/pnas.0808953105; Sengoku T, 2000, INT J IMMUNOPHARMACO, V22, P189, DOI 10.1016/S0192-0561(99)00076-4; Simpson EL, 2010, CURR MED RES OPIN, V26, P633, DOI 10.1185/03007990903512156; Siraganian RP, 2003, CURR OPIN IMMUNOL, V15, P639, DOI 10.1016/j.coi.2003.09.010; Sockolov ME, 2009, J DERMATOL TREAT, V20, P319, DOI 10.3109/09546630902936778; Suzuki R, 1999, J IMMUNOL, V163, P2410; Tatemoto K, 2006, BIOCHEM BIOPH RES CO, V349, P1322, DOI 10.1016/j.bbrc.2006.08.177; Theoharides TC, 1998, ENDOCRINOLOGY, V139, P403, DOI 10.1210/en.139.1.403; Theoharides TC, 2006, ANN NY ACAD SCI, V1088, P78, DOI 10.1196/annals.1366.025; Theoharides TC, 2010, P NATL ACAD SCI USA, V107, P4448, DOI 10.1073/pnas.1000803107; Tuluc F, 2009, TRENDS IMMUNOL, V30, P271, DOI 10.1016/j.it.2009.03.006; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697	51	106	110	2	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1522	U318		10.1016/j.jaci.2011.02.005	http://dx.doi.org/10.1016/j.jaci.2011.02.005			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21453958	Green Accepted, Bronze			2022-12-18	WOS:000291048500032
J	Zielen, S; Kardos, P; Madonini, E				Zielen, Stefan; Kardos, Peter; Madonini, Enzo			Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Subcutaneous immunotherapy; allergoid; house dust mite; asthma control; children; hypoallergenic preparation; controlled trial; efficacy; safety; Dermatophagoides pteronyssinus	HOUSE-DUST MITE; INHALED CORTICOSTEROIDS; SUBLINGUAL IMMUNOTHERAPY; DOSE REDUCTION; CHILDHOOD; BUDESONIDE; MANAGEMENT; MONTELUKAST; EFFICACY; MODERATE	Background: Asthma control is now recognized as the main goal of asthma therapy. Guidelines recommend finding the lowest effective dose of inhaled corticosteroids in children with persistent asthma. Objective: The aim of this study was to investigate the efficacy of an allergen-specific immunotherapy with a high-dose hypoallergenic mite preparation (allergoid) as steroid-sparing agent in children with allergic asthma. Methods: Sixty-five children with asthma (Global Initiative for Asthma treatment levels II and III; 6-17 years old), after reaching asthma control with inhaled steroids during a 5-month baseline period, were randomized for subcutaneous mite allergoid immunotherapy (SCIT) plus fluticasone propionate (FP) or FP therapy alone for 2 years. During 2 subsequent 5-month winter periods, steroid therapy was adjusted according to predefined dose steps, determining and comparing the changes in FP dosages and the lowest FP dose sufficient to maintain asthma control. Immunologic and functional investigations were also carried out. Results: Children treated with house dust mite SCIT plus FP were able to significantly reduce the FP dose by more steps (P < .05), compared with the control group on FP alone. The mean daily dose in the immunotherapy group decreased from 330.3 mu g in the baseline period to 151.5 mu g after 2 treatment years, whereas in the control group the dose decreased from 290.6 mu g to 206.3 mu g. Compared with the control group, significant improvement was also observed in morning peak expiratory flow (P = .0315). Significantly increased levels of specific IgG(1) (P = .0001) and IgG(4) (P < .0001) were also observed. Conclusion: Adding a mite allergoid SCIT to pharmacologic treatment is an effective and safe strategy to reduce corticosteroid doses while maintaining disease control in children with mite-induced allergic asthma. (J Allergy Clin Immunol 2010; 126:942-9.)	[Zielen, Stefan] Goethe Univ Frankfurt, Pediat Clin, Frankfurt, Germany; [Kardos, Peter] Maingau Clin, Grp Practice, Frankfurt, Germany; [Kardos, Peter] Maingau Clin, Ctr Pneumol, Frankfurt, Germany; [Madonini, Enzo] San Carlo Hosp, Pneumol Unit, Milan, Italy	Goethe University Frankfurt; San Carlo Borromeo Hospital	Madonini, E (corresponding author), Via Cicognara 6, I-20129 Milan, Italy.	enzo.madonini@gmail.com	Zielen, Stefan/AAD-7243-2020		Allergopharma Joachim Ganzer KG, Reinbek, Germany; Allergopharma; MSD; Bencard; Boehringner Ingelheim; AstraZeneca	Allergopharma Joachim Ganzer KG, Reinbek, Germany; Allergopharma; MSD; Bencard; Boehringner Ingelheim(Boehringer Ingelheim); AstraZeneca(AstraZeneca)	Supported by Allergopharma Joachim Ganzer KG, Reinbek, Germany.; S. Zielen has received research support from Allergopharma, MSD, and Bencard. P. Kardos has received research support from Boehringner Ingelheim and AstraZeneca, is on the QAB and Omalizumab Advisory Board for Novartis and the Mundipharma Advisory Board, and has given presentations for GlaxoSmithKline, Mundipharma, AstraZeneca, Novartis, Bionorica, Cefalon, and Janssen-Cilag. E. Madonini is a consultant for Allergopharma SPA.	Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Adkinson NF, 2001, AM J RESP CRIT CARE, V164, P2140; Allen David B, 2006, Adv Pediatr, V53, P101, DOI 10.1016/j.yapd.2006.04.006; Allen DB, 2005, ENDOCRIN METAB CLIN, V34, P555, DOI 10.1016/j.ecl.2005.04.013; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Barnes PJ, 1996, NEW ENGL J MED, V334, P531, DOI 10.1056/NEJM199602223340811; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Blumberga G, 2006, ALLERGY, V61, P843, DOI 10.1111/j.1398-9995.2006.01088.x; Bousquet J, 1997, NEW ENGL J MED, V336, P1912; Bousquet J, 2001, AM J RESP CRIT CARE, V164, P2139, DOI 10.1164/ajrccm.164.12.2110107a; Bousquet Jean, 2004, Clin Allergy Immunol, V18, P511; Coifman RE, 1997, NEW ENGL J MED, V336, P1911; Cools M, 2000, ALLERGY, V55, P69, DOI 10.1034/j.1398-9995.2000.00191.x; De Vries TW, 2006, EUR J CLIN PHARMACOL, V62, P343, DOI 10.1007/s00228-006-0102-6; DesRoches A, 1997, NEW ENGL J MED, V336, P1912; Dokic D, 2005, Prilozi, V26, P113; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Finegold I, 2003, J ASTHMA, V40, P31, DOI 10.1081/JAS-120022427; Foresi A, 2005, CHEST, V127, P117, DOI 10.1378/chest.127.1.117; FREW A, 2005, ACI INT S, V1, P527; Gordon BR, 1997, NEW ENGL J MED, V336, P1912; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Hawkins G, 2003, BMJ-BRIT MED J, V326, P1115, DOI 10.1136/bmj.326.7399.1115; Humbert M, 2008, ALLERGY, V63, P592, DOI 10.1111/j.1398-9995.2008.01654.x; James LK, 2008, CLIN EXP ALLERGY, V38, P1074, DOI 10.1111/j.1365-2222.2008.02976.x; Joos S, 2008, THORAX, V63, P453, DOI 10.1136/thx.2007.081596; Jorres RA, 1997, CHEST, V111, P866, DOI 10.1378/chest.111.4.866; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; Jutel Marek, 2008, V94, P158, DOI 10.1159/000155000; Kanniess F, 2002, EUR RESPIR J, V20, P1080, DOI 10.1183/09031936.02.00304202; Kelly HW, 2008, PEDIATRICS, V122, pE53, DOI 10.1542/peds.2007-3381; Li AM, 2008, RESPIROLOGY, V13, P400, DOI 10.1111/j.1440-1843.2007.01222.x; Malling Hans-Jorgen, 2008, Clin Allergy Immunol, V21, P343; Marguet C, 2004, ARCH PEDIATRIE, V11, p113S, DOI 10.1016/S0929-693X(04)90011-5; Marinkovich VA, 1997, NEW ENGL J MED, V336, P1912; MUNOZ MFM, 2004, ALLERGOL IMMUNOPATH, V32, P133; Nagaya H, 2006, INT ARCH ALLERGY IMM, V139, P9, DOI 10.1159/000089517; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1225, DOI 10.1164/ajrccm.154.5.8912729; O'Byrne PM, 2008, CHEST, V134, P1192, DOI 10.1378/chest.08-1018; Oppenheimer J, 2007, ANN ALLERG ASTHMA IM, V98, P205, DOI 10.1016/S1081-1206(10)60707-7; Ozdemir C, 2007, PEDIATR ALLERGY IMMU, V18, P508, DOI 10.1111/j.1399-3038.2007.00549.x; Passalacqua G, 2002, ALLERGY, V57, P275, DOI 10.1034/j.1398-9995.2002.03264.x; Pauwels R, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04889.x; Peters SP, 2008, ALLERGY ASTHMA PROC, V29, P499, DOI 10.2500/aap.2008.29.3147; Peters SP, 2007, NEW ENGL J MED, V356, P2027; Pham-Thi N, 2007, PEDIAT ALLERG IMM-UK, V18, P47, DOI 10.1111/j.1399-3038.2006.00475.x; Rachelefsky G, 2009, PEDIATRICS, V123, P353, DOI 10.1542/peds.2007-3273; Robinson PD, 2009, PEDIATR CLIN N AM, V56, P191, DOI 10.1016/j.pcl.2008.10.008; Ross RN, 2000, CLIN THER, V22, P329, DOI 10.1016/S0149-2918(00)80037-5; Schubert R, 2009, INT ARCH ALLERGY IMM, V148, P251, DOI 10.1159/000161585; Strunk RC, 2008, J ALLERGY CLIN IMMUN, V122, P1138, DOI 10.1016/j.jaci.2008.09.028; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Thomas M, 2009, J ALLERGY CLIN IMMUN, V123, P116, DOI 10.1016/j.jaci.2008.09.035; Wray BB, 1997, NEW ENGL J MED, V336, P1911	58	106	117	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					942	949		10.1016/j.jaci.2010.06.002	http://dx.doi.org/10.1016/j.jaci.2010.06.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20624650	Bronze			2022-12-18	WOS:000283727100007
J	Sutherland, ER; King, TS; Icitovic, N; Ameredes, BT; Bleecker, E; Boushey, HA; Calhoun, WJ; Castro, M; Cherniack, RM; Chinchilli, VM; Craig, TJ; Denlinger, L; DiMango, EA; Fahy, JV; Israel, E; Jarjour, N; Kraft, M; Lazarus, SC; Lemanske, RF; Peters, SP; Ramsdell, J; Sorkness, CA; Szefler, SJ; Walter, MJ; Wasserman, SI; Wechsler, ME; Chu, HW; Martin, RJ				Sutherland, E. Rand; King, Tonya S.; Icitovic, Nikolina; Ameredes, Bill T.; Bleecker, Eugene; Boushey, Homer A.; Calhoun, William J.; Castro, Mario; Cherniack, Reuben M.; Chinchilli, Vernon M.; Craig, Timothy J.; Denlinger, Loren; DiMango, Emily A.; Fahy, John V.; Israel, Elliot; Jarjour, Nizar; Kraft, Monica; Lazarus, Stephen C.; Lemanske, Robert F., Jr.; Peters, Stephen P.; Ramsdell, Joe; Sorkness, Christine A.; Szefler, Stanley J.; Walter, Michael J.; Wasserman, Stephen I.; Wechsler, Michael E.; Chu, Hong Wei; Martin, Richard J.		Natl Heart Lung Blood Inst Asthma	A trial of clarithromycin for the treatment of suboptimally controlled asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; infection; antibiotic	BRONCHIAL EPITHELIAL-CELLS; CHLAMYDIA-PNEUMONIAE; MYCOPLASMA-PNEUMONIAE; METHYLPREDNISOLONE ELIMINATION; STREPTOCOCCUS-PNEUMONIAE; MACROLIDE RESISTANCE; INFECTION; AIRWAY; ROXITHROMYCIN; EXPRESSION	Background: PCR studies have demonstrated evidence of Mycoplasma pneumoniae and Chlamydophila pneumoniae in the lower airways of patients with asthma. Objective: To test the hypothesis that clarithromycin would improve asthma control in individuals with mild-to-moderate persistent asthma that was not well controlled despite treatment with low-dose inhaled corticosteroids. Methods: Adults with an Asthma Control Questionnaire score >= 1.5 after a 4-week period of treatment with fluticasone propionate were entered into a PCR-stratified randomized, controlled trial to evaluate the effect of 16 weeks of either clarithromycin or placebo, added to fluticasone, on asthma control in individuals with or without lower airway PCR evidence of M pneumoniae or C pneumoniae. Results: A total of 92 participants were randomized. Twelve (13%) subjects demonstrated PCR evidence of M pneumoniae or C pneumoniae in endobronchial biopsies; 80 were PCR-negative for both organisms. In PCR-positive participants, clarithromycin yielded a 0.4 +/- 0.4 unit improvement in the Asthma Control Questionnaire score, with a 0.1 +/- 0.3 unit improvement in those allocated to placebo. This between-group difference of 0.3 +/- 0.5 (P = 5.6) was neither clinically nor statistically significant. In PCR-negative participants, a nonsignificant between-group difference of 0.2 +/- 0.2 units (P = 5.3) was observed. Clarithromycin did not improve lung function or airway inflammation but did improve airway hyperresponsiveness, increasing the methacholine PC(20) by 1.2 +/- 0.5 doubling doses (P = .02) in the study population. Conclusion: Adding clarithromycin to fluticasone in adults with mild-to-moderate persistent asthma that was suboptimally controlled by low-dose inhaled corticosteroids alone did not further improve asthma control. Although there was an improvement in airway hyperresponsiveness with clarithromycin, this benefit was not accompanied by improvements in other secondary outcomes. (J Allergy Clin Immunol 2010;126:747-53.)	[Sutherland, E. Rand; Cherniack, Reuben M.; Szefler, Stanley J.; Chu, Hong Wei; Martin, Richard J.] Natl Jewish Hlth, Denver, CO 80206 USA; [King, Tonya S.; Icitovic, Nikolina; Chinchilli, Vernon M.; Craig, Timothy J.] Penn State Univ, Coll Med, Hershey, PA USA; [Ameredes, Bill T.; Calhoun, William J.] Univ Texas Galveston, Med Branch, Galveston, TX 77550 USA; [Bleecker, Eugene; Peters, Stephen P.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; [Boushey, Homer A.; Fahy, John V.; Lazarus, Stephen C.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Castro, Mario; Walter, Michael J.] Washington Univ, Sch Med, St Louis, MO USA; [DiMango, Emily A.] Columbia Univ, Med Ctr, New York, NY USA; [Israel, Elliot; Wechsler, Michael E.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Kraft, Monica] Duke Univ, Sch Med, Durham, NC USA; [Wasserman, Stephen I.] Univ Calif San Diego, San Diego Med Ctr, San Diego, CA 92103 USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	National Jewish Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Texas System; University of Texas Medical Branch Galveston; Wake Forest University; University of California System; University of California San Francisco; Washington University (WUSTL); Columbia University; Harvard University; Brigham & Women's Hospital; Duke University; University of California System; University of California San Diego; University of Wisconsin System; University of Wisconsin Madison	Sutherland, ER (corresponding author), Natl Jewish Hlth, 1400 Jackson St,J-201, Denver, CO 80206 USA.	sutherlande@njhealth.org	Wechsler, Michael/AAC-5506-2019; Wechsler, Michael/B-3979-2013	Wechsler, Michael/0000-0003-3505-2946; Calhoun, William/0000-0001-7075-712X	NIH/NHLBI [U10 HL074227, 074231, 074204, 074212, 074073, 074206, 074208, 074225, 074218, K23 HL04385]; NIH [UL1-RR025011]; National Institutes of Health; Novartis; Boehringer-Ingelheim; GlaxoSmithKline; Genentech; Forest; Merck; GE Healthcare; Biomark; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; Schering- Plough; Compleware/Sandoz; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004385, U10HL074212, U10HL074073, U10HL074204, U10HL074231, U10HL074206, U10HL074208, U10HL074227, U10HL074218, U10HL074225] Funding Source: NIH RePORTER	NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); Boehringer-Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); Forest; Merck(Merck & Company); GE Healthcare(General ElectricGE Healthcare); Biomark; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Schering- Plough(Merck & CompanySchering Plough Corporation); Compleware/Sandoz; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by NIH/NHLBI U10 HL074227, 074231, 074204, 074212, 074073, 074206, 074208, 074225, 074218, NIH/NHLBI K23 HL04385, and NIH UL1-RR025011.; Disclosure of potential conflict of interest: E. R. Sutherland is an advisor and data and safety monitoring board member for GlaxoSmithKline, an advisor for Dey, LP, and a data and safety monitoring board member for Merck and has received research support from the National Institutes of Health, Novartis, and Boehringer-Ingelheim. E. Bleecker is an advisor/consultant for Aerovance, AstraZeneca, BoehringerIngelheim, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Wyeth and has received research support from Aerovance, Amgen, AstraZeneca, BoehringerIngelheim, Centocor, Ception, Genentech, GlaxoSmithKline, Novartis, Pfizer, Wyeth, and the National Institutes of Health. H. A. Boushey has consulted for KaloBios, has served on advisory committees for Pharmaxis and GlaxoSmithKline, and has received research support from GlaxoSmithKline. M. Castro, V. M. Chinchilli, and M. J. Walter have received research support from the National Institutes of Health. T. J. Craig has given talks for Teva, Merck, AstraZeneca, and Novartis and has received research support from GlaxoSmithKline, Boehringer-Ingelheim, Genentech, and Forest. J. V. Fahy has consulted for Amira, Cytokinetics, Abbott, GlaxoSmithKline, and Amgen and has received research support from Genentech and the National Institutes of Health. E. Israel has received research support from the National Institutes of Health and provided legal consultation or expert witness testimony on the subject of asthma. N. Jarjour has consulted for Asthmatx and Genentech and has received research support from GlaxoSmithKline, Merck, and MedImmune. M. Kraft, through Duke University, has received research support from Merck, GlaxoSmithKline, GE Healthcare, Biomark, and the National Institutes of Health. S. C. Lazarus and R. J. Martin have received research support from the National Heart, Lung, and Blood Institute. R. F. Lemanske, Jr, has given talks for Merck, Medicus Group, and the Fund for Medical Research and Education (Detroit); has consulted for Map Pharmaceuticals, Gray Consulting, Smith Research, Inc, Quintiles/Innovax, International Meetings and Science, and Scienomics; and has given talks and consulted for AstraZeneca. S. P. Peters has served on advisory boards and/or given talks for Abbott, AdvancMed, Asthmatx, AstraZeneca, BristolMeyers Squibb, Creative Educational Concepts, Dey, Dyson, Cephalon, Genentech, Integrity Continuing Education, MediCine, Merck, RAD Foundation, and Teva and has received research support from the National Institutes of Health, National Heart, Lung, and Blood Institute, and National Institute of Allergy and Infectious Diseases. C. A. Sorkness has served on advisory boards for GlaxoSmithKline, ScheringPlough, AstraZeneca, and Novartis and has received research support from Schering- Plough and Compleware/Sandoz. S. J. Szefler has consulted for GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and has received research support from the National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, GlaxoSmithKline, and National Institute of Environmental Health Sciences/Environmental Protection Agency. S. I. Wasserman has received research support from Merck, consulted for Schering, and provided legal consultation or expert witness testimony on the subject of mold allergy. The rest of the authors have declared that they have no conflict of interest.	Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bergman M, 2006, ANTIMICROB AGENTS CH, V50, P3646, DOI 10.1128/AAC.00234-06; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Black PN, 2001, AM J RESP CRIT CARE, V164, P536, DOI 10.1164/ajrccm.164.4.2011040; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Busse WW, 2005, AM J RESP CRIT CARE, V172, P807, DOI 10.1164/rccm.200407-966WS; DAUTZENBERG B, 1995, CHEST, V107, P1035, DOI 10.1378/chest.107.4.1035; Fost DA, 1999, J ALLERGY CLIN IMMUN, V103, P1031, DOI 10.1016/S0091-6749(99)70175-2; GAYDOS CA, 1992, J CLIN MICROBIOL, V30, P796, DOI 10.1128/JCM.30.4.796-800.1992; GAYDOS CA, 1994, J CLIN MICROBIOL, V32, P903, DOI 10.1128/JCM.32.4.903-905.1994; *GLAXOSMITHKLINE, 1997, NN19960000500 GLAXOS, P1; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hyde TB, 2001, JAMA-J AM MED ASSOC, V286, P1857, DOI 10.1001/jama.286.15.1857; Jarjour NN, 1998, AM J RESP CRIT CARE, V157, P692, DOI 10.1164/ajrccm.157.3.9705020; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 2004, ASTHMA CONTROL QUEST; Kadota J, 2003, RESP MED, V97, P844, DOI 10.1016/S0954-6111(03)00042-8; Kraft M, 2008, EUR RESPIR J, V31, P43, DOI 10.1183/09031936.00103307; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563; National Institutes of Health, 2007, NIH PUBL, V02-3659; Patel KB, 1996, ANTIMICROB AGENTS CH, V40, P2375, DOI 10.1128/AAC.40.10.2375; Pocock SJ, 1997, CONTROL CLIN TRIALS, V18, P530, DOI 10.1016/S0197-2456(97)00008-1; POCOCK SJ, 1997, CONTROL CLIN TRIALS, V18, P46; Richeldi L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002997.pub3; Shimizu T, 1997, J ASTHMA, V34, P211, DOI 10.3109/02770909709068191; SHIMIZU T, 1994, CHEST, V106, P458, DOI 10.1378/chest.106.2.458; Simpson JL, 2008, AM J RESP CRIT CARE, V177, P148, DOI 10.1164/rccm.200707-1134OC; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; Takizawa H, 1998, EUR RESPIR J, V12, P57, DOI 10.1183/09031936.98.12010057; Takizawa H, 1997, AM J RESP CRIT CARE, V156, P266, DOI 10.1164/ajrccm.156.1.9612065; TAMAOKI J, 1995, J ALLERGY CLIN IMMUN, V95, P853, DOI 10.1016/S0091-6749(95)70129-X; Wechsler ME, 2009, LANCET, V374, P1754, DOI 10.1016/S0140-6736(09)61492-6; WILLIAMSON J, 1994, J INFECT DIS, V170, P1052, DOI 10.1093/infdis/170.4.1052; Zhanel George G, 2005, Treat Respir Med, V4 Suppl 1, P13; 2008, GLOBAL STRATEGY ASTH	38	106	110	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					747	753		10.1016/j.jaci.2010.07.024	http://dx.doi.org/10.1016/j.jaci.2010.07.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920764	Green Accepted			2022-12-18	WOS:000282510000010
J	Simon, MR; Chinchilli, VM; Phillips, BR; Sorkness, CA; Lemanske, RF; Szefler, SJ; Taussig, L; Bacharier, LB; Morgan, W				Simon, Michael R.; Chinchilli, Vernon M.; Phillips, Brenda R.; Sorkness, Christine A.; Lemanske, Robert F., Jr.; Szefler, Stanley J.; Taussig, Lynn; Bacharier, Leonard B.; Morgan, Wayne		Natl Heart Lung Blood Inst	Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FEF25-75; bronchodilator responsiveness; asthma; FEV1/FVC ratio; canonical correlations; ROC curves	EXHALED NITRIC-OXIDE; PULMONARY-FUNCTION; SMALL AIRWAYS; CHILDHOOD ASTHMA; LUNG-FUNCTION; METHACHOLINE; PREDICTORS; SEVERITY; EXPOSURE; MARKERS	Background: The assumption that the assessment of forced expiratory flow between 25% and 75% of vital capacity (FEF25-75) does not provide additional information in asthmatic children with normal FEV1 percent predicted has not been adequately tested. Objective: We sought to determine whether the measurement of FEF25-75 percent predicted offers advantages over FEV1 percent predicted and FEV1/forced vital capacity (FVC) percent predicted for the evaluation of childhood asthma. Methods: This is a secondary analysis of data from the Pediatric Asthma Controller Trial and the Characterizing the Response to a Leukotriene Receptor Antagonist and Inhaled Corticosteroid trials. Pearson correlation coefficients, Pearson partial correlation coefficients, canonical correlations, and receiver operating characteristic (ROC) curves were constructed. Results: Among 437 children with normal FEV1 percent predicted, FEF25-75 percent predicted, and FEV1/FVC percent predicted were (1) positively correlated with log(2) methacholine PC20, (2) positively correlated with morning and evening peak expiratory flow percent predicted, and (3) negatively correlated with log(10) fraction of exhaled nitric oxide and bronchodilator responsiveness. Pearson partial correlations and canonical correlations indicated that FEF25-75 percent predicted was better correlated with bronchodilator responsiveness and log(2) methacholine PC20 than were FEV1 percent predicted or FEV1/FVC percent predicted. In the ROC curve analysis, FEF25-75 at 65% of predicted value had a 90% sensitivity and a 67% specificity for detecting a 20% increase in FEV1 after albuterol inhalation. Conclusion: FEF25-75 percent predicted was well correlated with bronchodilator responsiveness in asthmatic children with normal FEV1. FEF25-75 percent predicted should be evaluated in clinical studies of asthma in children and might be of use in predicting the presence of clinically relevant reversible airflow obstruction. (J Allergy Clin Immunol 2010;126:527-34.)	[Chinchilli, Vernon M.; Phillips, Brenda R.] Penn State Hershey Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA; [Simon, Michael R.] William Beaumont Hosp, Div Clin Immunol & Allergy, Royal Oak, MI 48072 USA; [Simon, Michael R.] Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA; [Simon, Michael R.] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA; [Sorkness, Christine A.; Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Heath, Madison, WI USA; [Sorkness, Christine A.; Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Med, Sch Med & Publ Heath, Madison, WI USA; [Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Taussig, Lynn] Univ Denver, Div Nat Sci & Math, Denver, CO USA; [Bacharier, Leonard B.] Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA; [Bacharier, Leonard B.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Morgan, Wayne] Univ Arizona, Coll Med, Resp Sci Ctr, Tucson, AZ USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Beaumont Health; Wayne State University; Wayne State University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; National Jewish Health; University of Denver; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); University of Arizona	Chinchilli, VM (corresponding author), Penn State Hershey Coll Med, Dept Publ Hlth Sci, A210,600 Centerview Dr,Suite 2200, Hershey, PA 17033 USA.	vchinchi@psu.edu		Bacharier, Leonard/0000-0003-0432-2704	National Heart, Lung, and Blood Institute [5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, 5U10HL064313]; Schering-Plough; Compleware/Sandoz; National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI); NIH/National Institute of Allergy and Infectious Diseases; GlaxoSmithKline; National Institute of Environmental Health Sciences; Environmental Protection Agency; National Institutes of Health/University of Wisconsin; Novartis; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR000036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064305, U10HL064295, U10HL064313, U10HL064288, U10HL064287, U10HL064307] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Schering-Plough(Merck & CompanySchering Plough Corporation); Compleware/Sandoz; National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); GlaxoSmithKline(GlaxoSmithKline); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Environmental Protection Agency(United States Environmental Protection Agency); National Institutes of Health/University of Wisconsin(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants 5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, and 5U10HL064313 from the National Heart, Lung, and Blood Institute. This study was carried out in part in the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036) and National Jewish (M01 RR00051).; Disclosure of potential conflict of interest: C. A. Sorkness is on advisory boards for GlaxoSmithKline, Schering-Plough, AstraZeneca, and Novartis and receives research support from Schering-Plough and Compleware/Sandoz. R. L. Lemanske is on the speakers' bureau for Merck, AstraZeneca, Doembecher Children's Hospital, Washington University, Medicus Group, Park Nicolet Institute, the American College of Allergy, Asthma & Immunology, the LA Allergy Society, Michigan Allergy/Asthma Society, the Medical College of Wisconsin, the Fund for Medical Research and Education (Detroit), Children's Hospital of Minnesota, the Toronto Allergy Society, AAAAI, Beaumont Hospital (Detroit), the University of Illinois, the Canadian Society of Allergy and Clinical Immunology, and New York Presbyterian; is a consultant for AstraZeneca, Map Pharmaceuticals, Gray Consulting, Smith Research, the Merck Childhood Asthma Network, Novartis, Quintiles/Innovax, RC Horowitz & Co, International Meetings and Science, and Scienomics; is an author for Up-to-Date; and is a textbook editor for Elsevier, Inc. S. J. Szelfer has consultant arrangements with GlaxoSmithKline, Genentech, Merck, Boerhinger Ingelheim, Novartis, and Schering-Plough and receives research support from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI), NIH/National Institute of Allergy and Infectious Diseases, GlaxoSmithKline, the National Institute of Environmental Health Sciences, and the Environmental Protection Agency. L. B. Bacharier receives honoraria from AstraZeneca and serves on advisory boards for Genentech, GlaxoSmithKline, Merck, Schering-Plough, and Aerocrine. W. Morgan is a consultant for the Cystic Fibrosis Foundation, Genentech, and Novartis and receives research support from the National Institutes of Health/University of Wisconsin, and Novartis. The rest of the authors have declared that they have no conflict of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Arets HGM, 2001, EUR RESPIR J, V18, P655, DOI 10.1183/09031936.01.00204301; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262, DOI 10.1164/ajrccm.159.1.9804063; Battaglia S, 2005, THORAX, V60, P639, DOI 10.1136/thx.2004.035279; Chiang CH, 1997, J ASTHMA, V34, P15, DOI 10.3109/02770909709071199; Childhood Asthma Management Program, 1994, CHILDH ASTHM MAN PRO; de Lange EE, 2006, CHEST, V130, P1055, DOI 10.1378/chest.130.4.1055; Eigen H, 2001, AM J RESP CRIT CARE, V163, P619, DOI 10.1164/ajrccm.163.3.2002054; Frank R, 2001, AM J RESP CRIT CARE, V164, P1253, DOI 10.1164/ajrccm.164.7.2010043; GELB AF, 1973, NEW ENGL J MED, V288, P395, DOI 10.1056/NEJM197302222880805; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565, DOI 10.1164/ajrccm.158.2.9705036; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Johnson RA, 2007, APPL MULTIVARIATE ST; JONES RS, 1966, BRIT MED J, V2, P972, DOI 10.1136/bmj.2.5520.972; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Langley SJ, 2003, ANN ALLERG ASTHMA IM, V91, P398, DOI 10.1016/S1081-1206(10)61688-2; LEBECQUE P, 1993, PEDIATR PULM, V16, P19, DOI 10.1002/ppul.1950160105; LEBOWITZ MD, 1987, AM REV RESPIR DIS, V136, P69, DOI 10.1164/ajrccm/136.1.69; MCFADDEN ER, 1972, AM J MED, V52, P725, DOI 10.1016/0002-9343(72)90078-2; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Ownby DR, 2000, AM J RESP CRIT CARE, V161, P1578, DOI 10.1164/ajrccm.161.5.9812156; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; Sharma S, 2008, J ALLERGY CLIN IMMUN, V122, P921, DOI 10.1016/j.jaci.2008.09.004; Sippel JM, 2000, J ALLERGY CLIN IMMUN, V106, P645, DOI 10.1067/mai.2000.109618; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tantisira KG, 2006, J ALLERGY CLIN IMMUN, V117, P1264, DOI 10.1016/j.jaci.2006.01.050; Ueda T, 2006, J ALLERGY CLIN IMMUN, V118, P1019, DOI 10.1016/j.jaci.2006.07.032; Valletta EA, 1997, J ASTHMA, V34, P127, DOI 10.3109/02770909709075657; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; WOOLCOCK AJ, 1969, J CLIN INVEST, V48, P1097, DOI 10.1172/JCI106066; ZWEIG MH, 1993, CLIN CHEM, V39, P561	39	106	115	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					527	U217		10.1016/j.jaci.2010.05.016	http://dx.doi.org/10.1016/j.jaci.2010.05.016			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20638110	Green Accepted			2022-12-18	WOS:000281512500018
J	Sly, PD; Kusel, M; Holt, PG				Sly, Peter D.; Kusel, Merci; Holt, Patrick G.			Do early-life viral infections cause asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic sensitization; human rhinovirus; IgE; respiratory syncytial virus; T cells; wheeze	BRONCHIAL EPITHELIAL-CELLS; IFN-GAMMA PROMOTER; EARLY-CHILDHOOD; RISK; METHYLATION; RHINOVIRUS; PATTERNS; CPG	Epidemiologic associations between viral lower respiratory infections (LRIs) and asthma in later childhood are well known. However, the question of whether such infections cause asthma or unmask asthma in a susceptible host has still not been settled. Most early evidence centered on the role of the respiratory syncytial virus; however, recent studies highlight a potential role for human rhinovirus as a risk factor for asthma. The links between early-life viral LRI and subsequent asthma are generally via wheeze; however, the presence of wheeze does not give any information about why the child is wheezing. Wheeze in early life is, at best, a fuzzy phenotype and not specific for subsequent asthma. The risk of asthma after viral LRI is increased in the presence of allergic sensitization in early life and if the infection is more severe. Atopy-associated mechanisms also appear to be involved in viral-induced acute exacerbations of asthma, especially in prolonging symptomatology after the virus has been cleared from the lungs. Breaking the nexus between viral respiratory infections and asthma may be possible with interventions designed to inhibit atopy-related effectors mechanisms from participating in the host response to respiratory viral infections. (J Allergy Clin Immunol 2010125:1202-5.)	[Sly, Peter D.] Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6872, Australia; Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Sly, PD (corresponding author), Univ Western Australia, Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.	peters@ichr.uwa.edu.au	Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201	National Health and Medical Research Council, Australia	National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by grants from the National Health and Medical Research Council, Australia.	Adcock IM, 2007, CURR OPIN IMMUNOL, V19, P694, DOI 10.1016/j.coi.2007.07.016; Bartlett NW, 2009, CURR OPIN ALLERGY CL, V9, P395, DOI 10.1097/ACI.0b013e32833066fa; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Frohlich A, 2009, SCIENCE, V324, P1576, DOI 10.1126/science.1172815; Gern JE, 2009, CURR OPIN ALLERGY CL, V9, P73, DOI 10.1097/ACI.0b013e32831f8f1b; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Khaitov MR, 2009, ALLERGY, V64, P375, DOI 10.1111/j.1398-9995.2008.01826.x; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Martinez FD, 2009, ALLERGOL IMMUNOPATH, V37, P249, DOI 10.1016/j.aller.2009.06.008; Papadopoulos NG, 2007, CURR OPIN ALLERGY CL, V7, P91, DOI 10.1097/ACI.0b013e328013d501; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Thomsen SF, 2009, AM J RESP CRIT CARE, V179, P1091, DOI 10.1164/rccm.200809-1471OC; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; White GP, 2006, PEDIAT ALLERG IMM-UK, V17, P557, DOI 10.1111/j.1399-3038.2006.00465.x; Zhang GC, 2009, AM J RESP CRIT CARE, V179, P205, DOI 10.1164/rccm.200803-438OC	20	106	110	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1202	1205		10.1016/j.jaci.2010.01.024	http://dx.doi.org/10.1016/j.jaci.2010.01.024			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20304476				2022-12-18	WOS:000278831000003
J	Rondon, C; Fernandez, J; Lopez, S; Campo, P; Dona, I; Torres, MJ; Mayorga, C; Blanca, M				Rondon, Carmen; Fernandez, Javier; Lopez, Soledad; Campo, Paloma; Dona, Inmaculada; Torres, Maria J.; Mayorga, Cristobalina; Blanca, Miguel			Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ECP; grass; local allergic rhinitis; nasal allergen provocation test; nasal lavage; nasal specific IgE; tryptase	NONALLERGIC RHINITIS; IDIOPATHIC RHINITIS; ACOUSTIC RHINOMETRY; PROVOCATION; MUCOSA; RELEASE; ABSENCE; PATHOPHYSIOLOGY; EOSINOPHILIA; RESPONSES	Background: Evidence exists of a new form of local allergic rhinitis (LAR) with local production of specific IgE (sIgE) and a positive response to nasal allergen provocation test (NAPT) in patients previously diagnosed with idiopathic rhinitis. However, the immunologic mechanisms involved are still poorly understood. Objective: We explored the involvement of nasal sIgE, eosinophil, and mast cell activation in the response to NAPT with grass pollen (NAPT-grass) in a group of patients already classified with LAR. Methods: Out-of-spring NAPT-grass was performed in 30 patients with LAR and 30 healthy controls. Nasal symptoms, acoustic rhinometry, and nasal lavage were performed at baseline and 15 minutes and 1, 6, and 24 hours post-NAPT. Tryptase, eosinophilic cationic protein (ECP), and total and sIgE to grass pollen were measured in nasal lavage by immunoassays. Results: NAPT-grass was positive in all patients with LAR. We detected significant increases of tryptase and ECP in 40% and 43%, respectively, at 15 minutes and 1, 6, and 24 hours post-NAPT compared with baseline (P < .05). sIgE was increased in 30%, with significant increases at I and 6 hours (P < .05) and 24 hours (P = .002) post-NAPT. The maximum release of tryptase was detected 15 minutes after NAPT, whereas the maximum release of ECP and sIgE was detected 24 hours after challenge. NAPT-grass was negative in all healthy controls, with no increase in tryptase, ECP, total IgE, or sIgE. Conclusion: These results demonstrate that patients with LAR had local production of sIgE and mast cell/eosinophil activation induced by nasal exposure to grass pollen. (J Allergy Clin Immunol 2009;124:1005-11.)	[Rondon, Carmen; Campo, Paloma; Dona, Inmaculada; Torres, Maria J.; Blanca, Miguel] Carlos Haya Hosp, Allergy Serv, Malaga, Spain; [Fernandez, Javier] Hosp Univ Elche, Allergy Serv, Alicante, Spain; [Lopez, Soledad; Mayorga, Cristobalina] Carlos Haya Hosp, Res Lab, Fdn IMABIS, Malaga, Spain	Hospital Carlos Haya; FIMABIS; Hospital Carlos Haya	Rondon, C (corresponding author), Hosp Civil, Lab Invest, Pabellon 5,Plaza Hosp Civil, Malaga 29009, Spain.	carmenrs61@gmail.com	Mayorga, Cristobalina/D-7167-2018; Lopez, Soledad/O-5873-2015; Torres, Maria/GVU-3391-2022; Torres, María José/T-3518-2017; Fernandez, Javier/B-6425-2018; Mayorga, Lina/FBO-7730-2022	Mayorga, Cristobalina/0000-0001-8852-8077; Lopez, Soledad/0000-0003-3727-1843; Torres, María José/0000-0001-5228-471X; Fernandez, Javier/0000-0003-1065-7199; RONDON SEGOVIA, CARMEN/0000-0003-0976-3402	Spanish Health Ministry [PI081572]; "Consejeria de Salud" Andalusia government [PI0181]; FIS network RIRAAF [RD07/0064]	Spanish Health Ministry(Instituto de Salud Carlos IIISpanish Government); "Consejeria de Salud" Andalusia government; FIS network RIRAAF	This work was supported by grants from Spanish Health Ministry (FIS) (PI081572), "Consejeria de Salud" Andalusia government (PI0181) and FIS network RIRAAF (RD07/0064).	Bachert C, 2006, ALLERGY, V61, P693, DOI 10.1111/j.1398-9995.2006.01054.x; BLACKELY CH, 1873, EXPT RES CAUSE NATUR, P2991; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; DAHL R, 1990, RHINITIS ASTHMA SIMI, P203; Damm M, 2006, LARYNGO RHINO OTOL, V85, P361, DOI 10.1055/s-2005-921113; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Gallego AJ, 2006, AM J RHINOL, V20, P560, DOI 10.2500/ajr.2006.20.2951; GRAAFINTVELD C, 1997, THORAX, V52, P143; GRONBORG H, 1993, ALLERGY, V48, P87, DOI 10.1111/j.1398-9995.1993.tb00691.x; HOWARTH PH, 2003, ALLERGY PRINCIPLES P, V2, P1391; HUGGINS KG, 1975, LANCET, V2, P148; JOHANSSON SG, 1991, ALLERGY, V56, P813; Kim JK, 2006, ACTA OTO-LARYNGOL, V126, P390, DOI 10.1080/00016480500401068; Kramer MF, 2006, AM J OTOLARYNG, V27, P190, DOI 10.1016/j.amjoto.2005.09.013; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; Lopuhaa CE, 2003, INT ARCH ALLERGY IMM, V130, P266, DOI 10.1159/000070213; Molgaard E, 2007, ALLERGY, V62, P1033, DOI 10.1111/j.1398-9995.2007.01355.x; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2049, DOI 10.1164/ajrccm.152.6.8520775; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; Powe DG, 2004, ALLERGY, V59, P204, DOI 10.1046/j.1398-9995.2003.00315.x; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; Rondon C, 2008, ALLERGY, V63, P1352, DOI 10.1111/j.1398-9995.2008.01695.x; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Settipane Russell A, 2007, Clin Allergy Immunol, V19, P23; TOGIAS A, 1985, AM J MED, V79, P26, DOI 10.1016/0002-9343(85)90084-1; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; Wagenmann M, 2005, ALLERGY, V60, P1132, DOI 10.1111/j.1398-9995.2005.00867.x; WANG C, 1995, ARS COMBINATORIA, V40, P3; Wierzbicki DA, 2008, ANN ALLERG ASTHMA IM, V100, P533, DOI 10.1016/S1081-1206(10)60051-8	33	106	111	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1005	1011		10.1016/j.jaci.2009.07.018	http://dx.doi.org/10.1016/j.jaci.2009.07.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19796796				2022-12-18	WOS:000272108000020
J	Commins, SP; Platts-Mills, TAE				Commins, Scott P.; Platts-Mills, Thomas A. E.			Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; cross-reactive carbohydrate determinant; alpha-gal; glycosylation	IGE; ALLERGY; TICK; MEAT; GLYCOSYLATION; ANTIBODY; EPITOPE; POLLEN; BEEF	Anaphylaxis is a severe allergic reaction that can rapidly progress and occasionally be fatal. In instances in which the triggering allergen is not obvious, establishing the cause of anaphylaxis is pivotal to long-term management. Assigning cause is limited, however, by the number of known exposures associated with anaphylaxis. Therefore identification of novel causative agents can provide an important step forward in facilitating new, allergen-specific approaches to management. In contrast to the view that carbohydrate-directed IgE has minimal, if any, clinical significance, recent data suggest that IgE antibodies to carbohydrate epitopes can be an important factor in anaphylaxis that might otherwise appear to be idiopathic. Here we review the evidence relating to carbohydrates in food allergy and anaphylaxis and discuss the implications of a new mammalian cross-reactive carbohydrate determinant. (J Allergy Clin Immunol 2009;124:652-7.)	[Commins, Scott P.] Univ Virginia Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	University of Virginia	Commins, SP (corresponding author), Univ Virginia Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA USA.	spc7w@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	ImClone; Phadia; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070364, R01AI020565] Funding Source: NIH RePORTER	ImClone; Phadia(Phadia); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	T A. E. Platts-Mills has received research support from ImClone and Phadia. S. P. Commins has declared that he has no conflict of interest.	AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Adedoyin J, 2007, J ALLERGY CLIN IMMUN, V119, P640, DOI 10.1016/j.jaci.2006.11.637; Aparicio VF, 2005, J INVEST ALLERG CLIN, V15, P228; Buelens K, 2008, CIRC RES, V102, P295, DOI 10.1161/CIRCRESAHA.107.157099; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Foetisch K, 2003, J ALLERGY CLIN IMMUN, V111, P889, DOI 10.1067/mai.2003.173; Francischetti IMB, 2009, FRONT BIOSCI-LANDMRK, V14, P2051, DOI 10.2741/3363; Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x; GAUCI M, 1989, CLIN EXP ALLERGY, V19, P279, DOI 10.1111/j.1365-2222.1989.tb02384.x; Gronlund H, 2009, J ALLERGY CLIN IMMUN, V123, P1189, DOI 10.1016/j.jaci.2009.03.011; Guilloux L, 2009, INT ARCH ALLERGY IMM, V149, P91, DOI 10.1159/000189190; Hilger C, 2005, J ALLERGY CLIN IMMUN, V115, P617, DOI 10.1016/j.jaci.2004.11.052; ISHIHARA H, 1979, J BIOL CHEM, V254, P715; Jacquenet S, 2009, J ALLERGY CLIN IMMUN, V124, P603, DOI 10.1016/j.jaci.2009.06.014; Jefferis R, 2009, NAT REV DRUG DISCOV, V8, P226, DOI 10.1038/nrd2804; Jerath MR, 2009, J ALLERGY CLIN IMMUN, V123, P260, DOI 10.1016/j.jaci.2008.09.046; Jin C, 2008, J ALLERGY CLIN IMMUN, V121, P185, DOI 10.1016/j.jaci.2007.07.047; Mamikoglu B, 2005, OTOLARYNG HEAD NECK, V133, P534, DOI 10.1016/j.otohns.2005.07.016; Mari A, 2002, INT ARCH ALLERGY IMM, V129, P286, DOI 10.1159/000067591; Tangvoranuntakul P, 2003, P NATL ACAD SCI USA, V100, P12045, DOI 10.1073/pnas.2131556100; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Werfel SJ, 1997, J ALLERGY CLIN IMMUN, V99, P293, DOI 10.1016/S0091-6749(97)70045-9; WONG KN, 2006, 15 ANN C EUR AC ALL	25	106	110	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					652	657		10.1016/j.jaci.2009.08.026	http://dx.doi.org/10.1016/j.jaci.2009.08.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19815111	Green Accepted			2022-12-18	WOS:000270802800004
J	Mattsson, L; Lundgren, T; Everberg, H; Larsson, H; Lidholm, J				Mattsson, Lars; Lundgren, Thomas; Everberg, Henrik; Larsson, Hakan; Lidholm, Jonas			Prostatic kallikrein: A new major dog allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; recombinant allergen; dog dander; allergy; IgE antibody; Can f 1; Can f 2; Can f 3; Can f 5; kallikrein; lipocalin	ESTERASE MESSENGER-RNA; ARGININE ESTERASE; CROSS-REACTIVITY; PROTEINS; PURIFICATION; CAT; IDENTIFICATION; EXPRESSION; ANTIGEN; URINE	Background: Dog dander is an important cause of respiratory allergy, but the spectrum of known dog allergens appears incomplete. Two lipocalins, Can f I and Can f 2, and serum albumin, Can f 3, have been characterized in detail but do not fully account for the IgE antibody-binding activity of dog dander extract. Allergen activity has previously been detected in dog urine but not further characterized. Objective: We sought to identify, characterize, and assess the importance of allergen components in dog urine. Methods: Dog urine was fractionated by means of size exclusion chromatography and examined for IgE antibody binding. A protein present in one fraction displaying IgE antibody-binding activity was identified by means of N-terminal sequencing and mass spectrometry. A recombinant form of the protein was produced in Pichia pastoris. IgE antibody binding to dog allergen components among sera of 37 subjects with dog allergy was determined by means of ImmunoCAP analysis. Results: An IgE antibody-binding protein was isolated from dog urine and identified as prostatic kallikrein. A closely related or identical protein was detected in dog dander. The recombinant prostatic kallikrein displayed immunologic and biochemical properties similar to those of the natural protein and bound IgE antibodies from 26 (70%) of 37 sera of subjects with dog allergy, 14 of which reacted to none of Can f 1, Can f 2, or Can f 3. The dog allergen identified here was found to cross-react with human prostate-specific antigen, a key culprit in IgE-mediated vaginal reactions to semen. Conclusion: Prostatic kallikrein is a new major dog allergen. (J Allergy Clin Immunol 2009;123:362-8.)	[Mattsson, Lars; Lundgren, Thomas; Everberg, Henrik; Larsson, Hakan; Lidholm, Jonas] Phadia AB, SE-75137 Uppsala, Sweden	Thermo Fisher Scientific; Phadia	Lidholm, J (corresponding author), Phadia AB, SE-75137 Uppsala, Sweden.	jonas.lidholm@phadia.com		Lidholm, Jonas/0000-0002-7779-3411				Basagana M, 2008, J ALLERGY CLIN IMMUN, V121, P233, DOI 10.1016/j.jaci.2007.10.008; Bayard C, 1996, BBA-GEN SUBJECTS, V1290, P129, DOI 10.1016/0304-4165(96)00006-2; BOUTIN Y, 1988, CLIN ALLERGY, V18, P287, DOI 10.1111/j.1365-2222.1988.tb02871.x; Cabanas R, 2000, J INVEST ALLERG CLIN, V10, P71; CHAPDELAINE P, 1988, MOL CELL ENDOCRINOL, V56, P63, DOI 10.1016/0303-7207(88)90009-3; CHAPDELAINE P, 1988, FEBS LETT, V232, P187, DOI 10.1016/0014-5793(88)80414-9; CHAPDELAINE P, 1984, J ANDROL, V5, P206; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; GORDON S, 1993, J ALLERGY CLIN IMMUN, V92, P298, DOI 10.1016/0091-6749(93)90173-D; Habeck LL, 2001, PROSTATE, V46, P298, DOI 10.1002/1097-0045(20010301)46:4<298::AID-PROS1036>3.0.CO;2-J; Heuze-Vourc'h N, 2006, BIOL CHEM, V387, P687, DOI 10.1515/BC.2006.087; HOFFMAN DR, 1980, ANN ALLERGY, V45, P205; ISAACS WB, 1983, J BIOL CHEM, V258, P6610; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; LAZURE C, 1984, FEBS LETT, V175, P1, DOI 10.1016/0014-5793(84)80557-8; Moverare R, 2008, INT ARCH ALLERGY IMM, V146, P203, DOI 10.1159/000115888; OHMAN JL, 1978, J AM VET MED ASSOC, V172, P1403; Saarelainen S, 2004, CLIN EXP ALLERGY, V34, P1576, DOI 10.1111/j.1365-2222.2004.02071.x; SCHUMACHER MJ, 1980, MOL IMMUNOL, V17, P1087, DOI 10.1016/0161-5890(80)90105-4; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V63, P435, DOI 10.1016/0091-6749(79)90219-7; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278; SPITZAUER S, 1993, INT ARCH ALLERGY IMM, V100, P60, DOI 10.1159/000236389; TAYLOR AN, 1977, LANCET, V2, P847; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V117, P213, DOI 10.1016/j.jaci.2005.09.040	27	106	109	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					362	368		10.1016/j.jaci.2008.11.021	http://dx.doi.org/10.1016/j.jaci.2008.11.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19135239				2022-12-18	WOS:000263495000011
J	Slavin, RG; Ferioli, C; Tannenbaum, SJ; Martin, C; Blogg, M; Lowe, PJ				Slavin, Raymond G.; Ferioli, Catarina; Tannenbaum, Stacey J.; Martin, Carmen; Blogg, Martin; Lowe, Philip J.			Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; omalizumab; pharmacokinetics; pharmacodynamics; IgE	FC-EPSILON-RI; DOWN-REGULATION; EXPRESSION; EFFICACY; ANTIBODY	Background: Physicians have questioned whether omalizumab can be discontinued or the dose reduced after clinical improvement is seen in patients with severe asthma. Objectives: To examine the relationships among omalizumab, free IgE, and clinical outcomes in a randomized, placebo-controlled trial in patients with severe persistent allergic asthma following a posology based on pretreatment total IgE and body weight. Methods: A pharmacokinetic-pharmacodynamic binding model was used to calculate free IgE, omalizumab, and total IgE concentrations during the 28-week treatment and 16-week follow-up of the INvestigation of Omalizumab in seVere Asthma TrEatment (INNOVATE) study. These were plotted against the mean changes in the total asthma symptom score, morning peak expiratory flow, and rescue medication use for physician-defined treatment responders and nonresponders. Results: The model accurately fitted omalizumab and free and total IgE, allowing reconstruction of the entire time course for each patient. Free IgE was rapidly suppressed below the 50 ng/mL (20.8 IU/mL) target, although there was a notable period before clinical measures stabilized. After treatment cessation, free IgE and omalizumab returned toward baseline and, after a delay, asthma symptoms re-emerged. Model-derived omalizumab and free IgE concentrations correlated well with changes in clinical outcomes, particularly in omalizumab-treated responders. Asthma symptoms exhibited different correlations during response onset compared with response offset (hysteresis), indicative of physiological time delays between changes in IgE levels and pulmonary function. Conclusion: Omalizumab and free IgE correlated well with clinical symptoms. Reducing omalizminab doses below those in the dosing table cannot be recommended; the resulting increase in free IgE would cause a deterioration in asthma control. (J Allergy Clin Immunol 2009;123:107-13.)	[Ferioli, Catarina; Lowe, Philip J.] Novartis Pharma AG, Modeling & Simulat, CH-4056 Basel, Switzerland; [Slavin, Raymond G.] St Louis Univ, Sch Med, St Louis, MO 63103 USA; [Tannenbaum, Stacey J.] Novartis Pharmaceut, E Hanover, NJ USA; [Martin, Carmen; Blogg, Martin] Novartis Horsham Res Ctr, Horsham, W Sussex, England	Novartis; Saint Louis University; Novartis; Novartis	Lowe, PJ (corresponding author), Novartis Pharma AG, Modeling & Simulat, Lichtstr 35, CH-4056 Basel, Switzerland.	phil.lowe@novartis.com	Lowe, Phil/K-8483-2019	Lowe, Philip/0000-0003-4074-8227; Tannenbaum, Stacey/0000-0002-1531-1405	Novartis Pharma AG	Novartis Pharma AG	Supported by Novartis Pharma AG.	Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Bousquet J, 2007, RESP MED, V101, P1483, DOI 10.1016/j.rmed.2007.01.011; Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Corren J, 2005, J ALLERGY CLIN IMMUN, V115, P202, DOI 10.1016/j.jaci.2004.09.035; *GINA, NIH PUB; Hayashi N, 2007, BRIT J CLIN PHARMACO, V63, P548, DOI 10.1111/j.1365-2125.2006.02803.x; Hochhaus G, 2003, CURR MED RES OPIN, V19, P491, DOI 10.1185/030079903125002171; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Meno-Tetang GML, 2005, BASIC CLIN PHARMACOL, V96, P182, DOI 10.1111/j.1742-7843.2005.pto960307.x; Ng CM, 2005, PHARM RES-DORDR, V22, P1088, DOI 10.1007/s11095-005-5642-4; *NOV PHARM AG, DAT FIL; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Saini SS, 1999, J IMMUNOL, V162, P5624; 2007, OMALIZUMAB XOLAIR SU	22	106	113	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					107	113		10.1016/j.jaci.2008.09.050	http://dx.doi.org/10.1016/j.jaci.2008.09.050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19130931	Bronze			2022-12-18	WOS:000262793900017
J	Strunk, RC; Weiss, ST; Yates, KP; Tonascia, J; Zeiger, RS; Szefler, SJ				Strunk, Robert C.; Weiss, Scott T.; Yates, Katherine P.; Tonascia, James; Zeiger, Robert S.; Szefler, Stanley J.		CAMP Res Grp	Mild to moderate asthma affects lung growth in children and adolescents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mild to moderate persistent asthma; childhood; adolescence; lung growth; airway obstruction	MANAGEMENT PROGRAM CAMP; CHILDHOOD ASTHMA; PULMONARY-FUNCTION; FOLLOW-UP; VENTILATORY FUNCTION; YOUNG-ADULTS; LONGITUDINAL POPULATION; RESPIRATORY ILLNESS; CLINICAL REMISSION; RISK-FACTORS	Background: The effect of childhood asthma on lung growth is unclear. Objective: To show the effect of mild to moderate childhood asthma on lung growth. Methods: A total of 1041 children with mild to moderate asthma from the Childhood Asthma Management Program (CAMP) were compared with 5415 children without asthma from the Harvard Six Cities Study (H6CS). Sex-age-specific comparisons of lung growth in CAMP with the H6CS were made by using repeated-measures multiple linear regression models. Sex-age-specific percentages of children with asthma with abnormal (< 5th percentile of H6CS) pulmonary function values were calculated. Results: In both boys and girls, the ratio of FEV1 to forced vital capacity (FVC) was significantly lower for children with than without asthma (P < .001), with corresponding increases for children with asthma in FVC (P < .001). FEV1 was lower for boys with asthma than for boys without asthma (P < .001), but not for girls (P =.14). Percentages of CAMP children with abnormal FEVt/FVC ratios increased with age for both sexes (P < .001). The patterns of lung growth for children with asthma compared with children without asthma did not differ among children treated for 4.3 years with budesonide or nedocromil and placebo during the CAMP trial. Conclusion: Mild to moderate asthma results in a pattern of airway obstruction that increases in magnitude from age 5 to 18 years. Clinical implications: Periodic spirometry is needed to monitor children with asthma for signs of increasing airway obstruction with appropriate intervention following national guidelines.	Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA; Childrens Hosp, St Louis, MO USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Kaiser Permanente So California Reg, Dept Allergy, San Diego, CA USA; Natl Jewish Med & Res Ctr, Div Pediat Clin Pharmacol, Dept Pediat, Denver, CO USA	Washington University (WUSTL); St. Louis Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California San Diego; Kaiser Permanente; National Jewish Health	Strunk, RC (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, 1 Childrens Pl, St Louis, MO 63110 USA.	strunk@kids.wustl.edu		Zeiger, Robert/0000-0001-5788-5063	NCRR NIH HHS [RR00036, M01RR00051, M01RR0099718-24, M01RR02719-14] Funding Source: Medline; NHLBI NIH HHS [N01-HR-16049, N01-HR-16048, N01-HR-16047, N01-HR-16046, N01-HR-16045, N01-HR-16044, N01-HR-16050, N01-HR-16051, N01-HR-16052] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR016044, N01HR016049, N01HR016047, N01HR016052, N01HR016051, N01HR016050, N01HR016048, N01HR016046, N01HR016045] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR002719] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Apostol GG, 2002, AM J RESP CRIT CARE, V166, P166, DOI 10.1164/rccm.2007035; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Berhane K, 2000, AM J RESP CRIT CARE, V162, P1723, DOI 10.1164/ajrccm.162.5.2001116; BLACKHALL MI, 1970, ARCH DIS CHILD, V45, P363, DOI 10.1136/adc.45.241.363; BORSBOOM GJJM, 1993, AM REV RESPIR DIS, V147, P372, DOI 10.1164/ajrccm/147.2.372; BURROWS B, 1977, AM REV RESPIR DIS, V115, P751; BURROWS B, 1990, MED CLIN N AM, V74, P547, DOI 10.1016/S0025-7125(16)30539-9; CADE JF, 1973, AUST NZ J MED, V3, P545, DOI 10.1111/j.1445-5994.1973.tb04293.x; CANNY GJ, 1988, J ALLERGY CLIN IMMUN, V82, P1, DOI 10.1016/0091-6749(88)90042-5; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; COOPER DM, 1977, CHEST, V71, P361, DOI 10.1378/chest.71.3.361; FERRIS BG, 1979, AM REV RESPIR DIS, V120, P767; GOLD DR, 1994, AM J RESP CRIT CARE, V149, P1198, DOI 10.1164/ajrccm.149.5.8173760; GREEN M, 1974, J APPL PHYSIOL, V37, P67, DOI 10.1152/jappl.1974.37.1.67; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; KERREBIJN KF, 1978, BRIT MED J, V1, P886, DOI 10.1136/bmj.1.6117.886; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LEBOWITZ MD, 1987, AM REV RESPIR DIS, V136, P69, DOI 10.1164/ajrccm/136.1.69; Limb SL, 2005, J ALLERGY CLIN IMMUN, V116, P1213, DOI 10.1016/j.jaci.2005.09.024; Mandhane PJ, 2005, AM J RESP CRIT CARE, V172, P45, DOI 10.1164/rccm.200412-1738OC; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MARTIN AJ, 1980, BRIT MED J, V281, P1397; Martinez FD, 2003, NEW ENGL J MED, V349, P1473, DOI 10.1056/NEJMe030041; MEAD J, 1980, AM REV RESPIR DIS, V121, P339; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Ulrik CS, 1999, AM J RESP CRIT CARE, V160, P40, DOI 10.1164/ajrccm.160.1.9806059; ULRIK CS, 1995, RESP MED, V89, P547, DOI 10.1016/0954-6111(95)90156-6; von Mutius E, 2002, AM J RESP CRIT CARE, V165, P1467, DOI 10.1164/rccm.2204011; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; Warke TJ, 2002, EUR RESPIR J, V19, P284, DOI 10.1183/09031936.02.00882002; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; Weiss ST, 2000, AM J RESP CRIT CARE, V162, P50, DOI 10.1164/ajrccm.162.1.9811005; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	41	106	109	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1040	1047		10.1016/j.jaci.2006.07.053	http://dx.doi.org/10.1016/j.jaci.2006.07.053			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088127				2022-12-18	WOS:000244282300007
J	Nanda, A; O'Connor, M; Anand, M; Dreskin, SC; Zhang, LE; Hines, B; Lane, D; Wheat, W; Routes, JM; Sawyer, R; Rosenwasser, LJ; Nelson, HS				Nanda, A; O'Connor, M; Anand, M; Dreskin, SC; Zhang, LE; Hines, B; Lane, D; Wheat, W; Routes, JM; Sawyer, R; Rosenwasser, LJ; Nelson, HS			Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; cat immunotherapy; cluster; dose response; cat extract; immunologic response	DOUBLE-BLIND PLACEBO; VENOM IMMUNOTHERAPY; CLINICAL EFFICACY; NASAL CHALLENGE; CELLS; IGE; INTERLEUKIN-10; GENERATION; DANDER	Background: The immunologic response to allergen immunotherapy with 3 serial 5-fold doses of cat extract has been studied after approximately 5 weeks of immunotherapy. The highest dose containing 15 mug of Fel d 1 produced the most consistent and favorable response. It is unknown whether the comparative response on reaching a maintenance dose is maintained with long-term maintenance therapy. Objective: The purpose of this investigation was to evaluate the immunologic responses with these 3 serial doses of cat hair and dander extract at baseline, after reaching the maintenance dose (approximately 5 weeks), and after 1 year of maintenance immunotherapy. Methods: Twenty-eight patients with cat allergy randomized in a double-blind study were assigned to one of 4 treatment groups: placebo or cat hair and dander extract containing 0.6 mug of Fel d 1, 3 mug of Fel d 1, and 15 mug of Fel d 1 at maintenance. Studies included skin prick tests and late cutaneous reactions with cat hair and dander extract, titrated nasal challenges with the extract, serum cat allergen-specific IgG4 and IgE measurement, and flow cytometric and ELISA analysis of whole blood and intranasal cytokines (TGF-beta, IL-10, IFN-gamma, IL-4, and IL-5). Results: Twenty-six subjects completed the study. After both 5 weeks and I year, significant and dose-dependent differences were seen with total symptom scores on nasal challenge (P <.0001), with titrated skin prick testing with cat dander extract at 5 weeks (P =.014) and 1 year (P <.0001), and with cat-specific IgG4 measurement at 5 weeks (P =.004) and I year (P =.003). At 1 year, neither flow cytometry of whole blood nor ELISA evaluation of nasal cytokines demonstrated any significant differences among the treatment groups. Conclusion: The response to titrated nasal allergen challenge, titrated skin prick testing, and allergen-specific IgG4 measurement to cat immunotherapy at 5 weeks is predictive of the response at 1 year.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy,Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Biostat, Gen Clin Res Ctr, Denver, CO USA; Natl Jewish Med & Res Ctr, Div Environm & Occupat Hlth Sci, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; National Jewish Health	Nelson, HS (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Div Clin Immunol & Allergy,Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	nelsonh@njc.org	Routes, john/AAA-4833-2021	Routes, john/0000-0001-8378-3773	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00051] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; Antony PA, 2002, J IMMUNOTHER, V25, P202, DOI 10.1097/00002371-200205000-00002; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; Coligan JE, 2004, CURRENT PROTOCOLS IM; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; Dreskin SC, 2002, J IMMUNOL METHODS, V268, P189, DOI 10.1016/S0022-1759(02)00206-5; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS712; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; Guyer B., 2004, Journal of Allergy and Clinical Immunology, V113, pS28, DOI 10.1016/j.jaci.2003.12.058; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Jutel M, 1996, CLIN EXP ALLERGY, V26, P1112, DOI 10.1111/j.1365-2222.1996.tb00496.x; MAJCHEL AM, 1992, J ALLERGY CLIN IMMUN, V90, P85, DOI 10.1016/S0091-6749(06)80014-X; NAGAYA H, 1984, J ALLERGY CLIN IMMUN, V75, P388; Nelson HS, 2004, J ALLERGY CLIN IMMUN, V113, P635, DOI 10.1016/j.jaci.2004.01.741; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P41, DOI 10.1067/mai.2000.107197; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; Smith T. R., 2004, Journal of Allergy and Clinical Immunology, V113, pS254, DOI 10.1016/j.jaci.2004.01.383; TAMIR R, 1987, J ALLERGY CLIN IMMUN, V79, P591, DOI 10.1016/S0091-6749(87)80154-9; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; BD BIOSCIENCES IMMUN	29	106	112	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1339	1344		10.1016/j.jaci.2004.08.049	http://dx.doi.org/10.1016/j.jaci.2004.08.049			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577832				2022-12-18	WOS:000225577400013
J	Oddy, WH; Halonen, M; Martinez, FD; Lohman, IC; Stern, DA; Kurzius-Spencer, M; Guerra, S; Wright, AL				Oddy, WH; Halonen, M; Martinez, FD; Lohman, IC; Stern, DA; Kurzius-Spencer, M; Guerra, S; Wright, AL			TGF-beta in human milk is associated with wheeze in infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						breast feeding; wheeze; cytokines; TGF-beta; human milk; infancy	GROWTH-FACTOR-BETA; MAMMARY-GLAND; BREAST-MILK; CYTOKINES; ILLNESS; EXPRESSION; REGULATOR; ALLERGY; ASTHMA; TRACT	Background: Cytokines secreted in human milk might play important roles in newborn health and in the development of infant immune responses. We investigated the relationship of the concentration and dose of cytokines in human milk to infant wheeze at 1 year of age. Objective: Our objective was to test whether the cytokines in milk could account for some of the apparent protective effect of breast-feeding against wheeze in the first year of life. Methods: Data on breast-feeding and infant wheeze were collected prospectively from birth to 1 year from 243 mothers participating in the Infant Immune Study in Tucson, Arizona. Breast milk samples obtained at a mean age of 11 days postpartum were assayed by means of ELISA for concentrations of TGF-beta1, IL-10, TNF-alpha, and the soluble form of CD14. The dose of each cytokine was assessed for a relationship with wheeze in bivariate and logistic regression analyses. Results: Increasing duration of breast-feeding was significantly associated with a decreased prevalence of wheeze (P = .039). There was wide variability in levels of each cytokine in milk, as well as variability between women in the amount of each cytokine produced. There was a significant inverse association between the dose of TGF-beta1 received through milk with the percentage of wheeze (P = .017), and the relationship was linear (P = .006). None of the other cytokines showed a linear relationship with wheeze. In multivariate analyses the risk of wheeze was significantly decreased (odds ratio, 0.22; 95% CI 0.05-0.89; P = .034) with increasing TGF-beta1 dose (long breast-feeding and medium-high TGF-beta1 level compared with short breast-feeding and low TGF-beta1 level). Conclusion: This analysis shows that the dose of TGF-beta1 received from milk has a significant relationship with infant wheeze, which might account for at least some of the protective effect of breast-feeding against wheeze.	Univ Arizona, Arizona Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85724 USA; Curtin Univ Technol, Dept Nutr Dietet & Food Sci, Perth, WA 6001, Australia; Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia	University of Arizona; University of Arizona Health Sciences; Curtin University; University of Western Australia	Wright, AL (corresponding author), Univ Arizona, Arizona Hlth Sci Ctr, Arizona Resp Ctr, 1501 N Campbell Ave, Tucson, AZ 85724 USA.		Kurzius-Spencer, Margaret/D-1898-2009	Halonen, Marilyn/0000-0001-9606-935X	NIAID NIH HHS [AI42268] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042268] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHUCKTEISH F, 1996, ANN TROP PAEDIATR, V16, P227; Baker D, 1998, J EPIDEMIOL COMMUN H, V52, P451, DOI 10.1136/jech.52.7.451; BENDTZEN K, 1994, IMMUNOL LETT, V43, P111, DOI 10.1016/0165-2478(94)00153-7; BERNT KM, 1999, ACTA PAEDIATR, V430, pS27; Bottcher MF, 2000, PEDIATR RES, V47, P157, DOI 10.1203/00006450-200001000-00026; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; Buts JP, 1998, ARCH PEDIATRIE, V5, P298, DOI 10.1016/S0929-693X(97)89374-8; Chinoy MR, 1998, PEDIATR PULM, V25, P244, DOI 10.1002/(SICI)1099-0496(199804)25:4<244::AID-PPUL5>3.0.CO;2-K; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; Ellis LA, 1997, J NUTR, V127, pS985, DOI 10.1093/jn/127.5.985S; Garofalo RP, 1999, CLIN PERINATOL, V26, P361, DOI 10.1016/S0095-5108(18)30057-5; Goldman AS, 1996, J MAMMARY GLAND BIOL, V1, P251, DOI 10.1007/BF02018078; Goldman AS, 1998, PEDIATR RES, V43, P155, DOI 10.1203/00006450-199802000-00001; Goldman AS, 2000, J NUTR, V130, p426S, DOI 10.1093/jn/130.2.426S; Grainger DJ, 2000, CYTOKINE GROWTH F R, V11, P133, DOI 10.1016/S1359-6101(99)00037-4; Hanson LA, 1998, ANN ALLERG ASTHMA IM, V81, P523, DOI 10.1016/S1081-1206(10)62704-4; Hasselbalch H, 1999, EUR J PEDIATR, V158, P964, DOI 10.1007/s004310051258; Hawkes JS, 2002, CYTOKINE, V17, P182, DOI 10.1006/cyto.2002.0987; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; Letterio JJ, 2000, CYTOKINE GROWTH F R, V11, P81, DOI 10.1016/S1359-6101(99)00031-3; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; NODA K, 1984, GANN, V75, P109; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; PORRO E, 1993, J ASTHMA, V30, P23, DOI 10.3109/02770909309066376; Raisler J, 1999, AM J PUBLIC HEALTH, V89, P25, DOI 10.2105/AJPH.89.1.25; Robertson CF, 1998, MED J AUSTRALIA, V168, P434, DOI 10.5694/j.1326-5377.1998.tb139022.x; Saarinen KM, 2000, ADV EXP MED BIOL, V478, P121; SAITO S, 1993, CLIN EXP IMMUNOL, V94, P220, DOI 10.1111/j.1365-2249.1993.tb06004.x; Srivastava MD, 1996, RES COMMUN MOL PATH, V93, P263; STOECK M, 1989, J IMMUNOL, V143, P3258; TUBOLY S, 2002, INTEGRATING POPULATI, P338; WRIGHT AL, 1989, BRIT MED J, V299, P946, DOI 10.1136/bmj.299.6705.946; Zhao Y, 2000, AM J PHYSIOL-LUNG C, V278, pL1231, DOI 10.1152/ajplung.2000.278.6.L1231	40	106	114	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					723	728		10.1016/S0091-6749(03)01941-9	http://dx.doi.org/10.1016/S0091-6749(03)01941-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564350				2022-12-18	WOS:000185831200011
J	Bachert, C; Gevaert, P; Howarth, P; Holtappels, G; van Cauwenberge, P; Johansson, SGO				Bachert, C; Gevaert, P; Howarth, P; Holtappels, G; van Cauwenberge, P; Johansson, SGO			IgE to Staphylococcus aureus enterotoxins in serum is related to severity of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Ghent Univ Hosp, Dept Otorhinolaryngol, B-9000 Ghent, Belgium; Univ Southampton, Resp Cell & Mol Biol Res Div, Southampton, Hants, England; Karolinska Hosp, Dept Clin Immunol, S-10401 Stockholm, Sweden	Ghent University; Ghent University Hospital; University of Southampton; Karolinska Institutet; Karolinska University Hospital	Bachert, C (corresponding author), Ghent Univ Hosp, Dept Otorhinolaryngol, B-9000 Ghent, Belgium.		Bachert, Claus/J-8825-2012; Gevaert, Philippe/AAP-1892-2020; Gevaert, Philippe/ABA-4588-2021	Gevaert, Philippe/0000-0002-1629-8468; Howarth, Peter/0000-0003-0619-7927				Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; FLEISCHER B, 1994, APMIS, V102, P3, DOI 10.1111/j.1699-0463.1994.tb04839.x; Hauk PJ, 1999, J ALLERGY CLIN IMMUN, V104, P37, DOI 10.1016/S0091-6749(99)70111-9; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Herz U, 1999, EUR J IMMUNOL, V29, P1021, DOI 10.1002/(SICI)1521-4141(199903)29:03<1021::AID-IMMU1021>3.0.CO;2-3	5	106	111	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1131	1132		10.1016/S0091-6749(03)70044-X	http://dx.doi.org/10.1016/S0091-6749(03)70044-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743582				2022-12-18	WOS:000182904500032
J	Kemp, SF; deShazo, RD; Moffitt, JE; Williams, DF; Buhner, WA				Kemp, SF; deShazo, RD; Moffitt, JE; Williams, DF; Buhner, WA			Expanding habitat of the imported fire ant (Solenopsis invicta): A public health concern	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						imported fire ant; Solenopsis invicta; Solenopsis richteri; whole-body vaccine; venom vaccine immunotherapy; anaphylaxis; hypersensitivity reactions; chemical control measures	STINGS; VENOM; ALLERGY; HYPERSENSITIVITY; IMMUNOTHERAPY; ANAPHYLAXIS; SENSITIVITY; COMPONENTS; INDOORS	Residents in the southeastern United States would hardly describe life with the aggressive imported fire ant as peaceful coexistence. The continued spread of these insects has produced agricultural problems, changes in the ecosystem, and increasing numbers of subjects with sting sequelae, including hypersensitivity reactions, secondary infections, and rare neurologic sequelae. Evolutionary changes have facilitated their expansion northward into Virginia and westward into California, and increasing urbanization will likely permit further expansion. Recent reports of building invasion with sting attacks inside occupied dwellings, including health care facilities, heighten public health concerns. This article reviews the medically important entomology, clinical aspects of stings, and the current approaches to chemical control of fire ants. We also propose directions for future research and treatment.	Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; USDA, Agr Res Stn Med Agr & Vet Entomol, Gainesville, FL USA	University of Mississippi; University of Mississippi Medical Center; United States Department of Agriculture (USDA)	Kemp, SF (corresponding author), Univ Mississippi, Med Ctr, Jackson, MS 39216 USA.							Adams C.T., 1986, P48; ADAMS CT, 1981, J MED ENTOMOL, V18, P378, DOI 10.1093/jmedent/18.5.378; BAER H, 1979, TOXICON, V17, P397, DOI 10.1016/0041-0101(79)90267-8; BRAND JM, 1972, TOXICON, V10, P259, DOI 10.1016/0041-0101(72)90011-6; BUTCHER BT, 1988, J ALLERGY CLIN IMMUN, V82, P770, DOI 10.1016/0091-6749(88)90078-4; Caldwell S T, 1999, J S C Med Assoc, V95, P231; CANDIOTTI KA, 1993, INT ARCH ALLERGY IMM, V102, P417, DOI 10.1159/000236592; deShazo R, 1996, ANN ALLERG ASTHMA IM, V77, P85, DOI 10.1016/S1081-1206(10)63492-8; DESHAZO RD, 1984, J ALLERGY CLIN IMMUN, V74, P841, DOI 10.1016/0091-6749(84)90188-X; DESHAZO RD, 1994, J ALLERGY CLIN IMMUN, V93, P847, DOI 10.1016/0091-6749(94)90376-X; DESHAZO RD, 1995, SOUTHERN MED J, V88, P712, DOI 10.1097/00007611-199507000-00003; deShazo RD, 1999, ANN INTERN MED, V131, P424, DOI 10.7326/0003-4819-131-6-199909210-00005; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; DIAZ JD, 1989, SOUTH MED J, V82, P775, DOI 10.1097/00007611-198906000-00026; Duplantier JE, 1998, J ALLERGY CLIN IMMUN, V101, P855, DOI 10.1016/S0091-6749(98)70318-5; Ford JL, 1997, J ALLERGY CLIN IMMUN, V100, P425, DOI 10.1016/S0091-6749(97)70259-8; FOX RW, 1982, J ALLERGY CLIN IMMUN, V70, P120, DOI 10.1016/0091-6749(82)90239-1; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Freeman TM, 1997, ANN ALLERG ASTHMA IM, V78, P369, DOI 10.1016/S1081-1206(10)63198-5; GLANCEY B M, 1973, Journal of the Georgia Entomological Society, V8, P237; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; HANNAN CJ, 1986, J ALLERGY CLIN IMMUN, V78, P331, DOI 10.1016/S0091-6749(86)80085-9; HOFFMAN DR, 1995, ALLERGY, V50, P535, DOI 10.1111/j.1398-9995.1995.tb01196.x; JAMES FK, 1976, J ALLERGY CLIN IMMUN, V58, P110, DOI 10.1016/0091-6749(76)90112-3; LOCKEY RF, 1974, J ALLERGY CLIN IMMUN, V54, P132, DOI 10.1016/0091-6749(74)90050-5; Lofgren C.S., 1986, P36; Lofgren C.S., 1986, P227; LOFGREN CS, 1975, ANNU REV ENTOMOL, V20, P1, DOI 10.1146/annurev.en.20.010175.000245; MACKAY WP, 1992, J KANSAS ENTOMOL SOC, V65, P39; Moffitt JE, 1997, ANN ALLERG ASTHMA IM, V79, P125, DOI 10.1016/S1081-1206(10)63098-0; PORTER SD, 1992, J ECON ENTOMOL, V85, P1155; Prahlow JA, 1998, AM J FOREN MED PATH, V19, P137, DOI 10.1097/00000433-199806000-00007; REISMAN RE, 1994, NEW ENGL J MED, V331, P523, DOI 10.1056/NEJM199408253310808; RHOADES RB, 1989, J ALLERGY CLIN IMMUN, V84, P159, DOI 10.1016/0091-6749(89)90319-9; Stafford CT, 1996, ANN ALLERG ASTHMA IM, V77, P87, DOI 10.1016/S1081-1206(10)63493-X; STAFFORD CT, 1990, ANN ALLERGY, V64, P368; Swanson G P, 1990, Tex Med, V86, P39; TRACY JM, 1995, J ALLERGY CLIN IMMUN, V95, P824, DOI 10.1016/S0091-6749(95)70125-7; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; Tschinkel W.R., 1986, P72; Vinson S. Bradleigh, 1997, American Entomologist, V43, P23; WILLIAMS DF, 1994, WESTV STUD, P282; WILLIAMS DF, 1983, FLA ENTOMOL, V66, P162, DOI 10.2307/3494561; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	48	106	110	7	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					683	691		10.1067/mai.2000.105707	http://dx.doi.org/10.1067/mai.2000.105707			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756216				2022-12-18	WOS:000086604100004
J	Skov, L; Olsen, JV; Giorno, R; Schlievert, PM; Baadsgaard, O; Leung, DYM				Skov, L; Olsen, JV; Giorno, R; Schlievert, PM; Baadsgaard, O; Leung, DYM			Application of staphylococcal enterotoxin B on normal and atopic skin induces up-regulation of T cells by a superantigen-mediated mechanism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						superantigen; staphylococcal enterotoxin B; T-cell receptor V beta; atopic dermatitis	TOXIC SHOCK SYNDROME; TUMOR-NECROSIS-FACTOR; ANTIGEN EXPRESSION; LESIONAL SKIN; HLA-DR; DERMATITIS; AUREUS; KERATINOCYTES; RECEPTOR; ECZEMA	Background: The skin of patients with inflammatory skin diseases such as atopic dermatitis is frequently colonized with Staphylococcus aureus. Colonization with S aureus has been reported to exacerbate atopic dermatitis. Recent studies have demonstrated that S aureus isolated from the skin of patients with atopic dermatitis releases bacterial toxins that act as superantigens. We have previously applied the staphylococcal superantigen staphylococcal enterotoxin B (SEB) on intact human skin and found that the application led to induction of dermatitis. Objective: The purpose of the study was to determine whether superantigen-induced dermatitis is primarily due to a T cell-superantigen-mediated reaction or represents nonspecific cytokine-driven inflammation. Methods: We applied SEE, vehicle, and sodium lauryl sulfate on normal skin in healthy (n = 6) and atopic subjects (n = 6) and biopsy specimens were taken from all treated areas. The biopsy specimens from all subjects and peripheral blood from the atopic subjects were analyzed for the T-cell receptor (TCR) V beta repertoire with mAbs against TCR V beta 2, 3, 8.1, 12, 14, and 17. Results: From all subjects, both healthy and patients with atopic dermatitis, skin biopsy specimens from SEE-treated areas demonstrated selective accumulation of T cells expressing SEE-reactive TCR V beta 12 and 17 (P < .05). This selective up-regulation was not found in the sodium lauryl sulfate-treated areas. Conclusion: Our data strongly support that superantigen-induced T-cell activation is involved in the dermatitis seen after experimental application of SEE on intact skin.	Univ Copenhagen, Gentofte Hosp, Dept Dermatol, Copenhagen, Denmark; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80202 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80202 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA	University of Copenhagen; Herlev & Gentofte Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Minnesota System; University of Minnesota Twin Cities	Skov, L (corresponding author), Gentofte Univ Hosp, Dept Dermatol, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark.		Skov, Lone/W-3575-2018	Schlievert, Patrick/0000-0001-8314-9369; Skov, Lone/0000-0002-4784-9680	NHLBI NIH HHS [HL36577, HL37260] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R37HL037260, P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARKER JNWN, 1987, J AM ACAD DERMATOL, V16, P1175, DOI 10.1016/S0190-9622(87)70153-4; BIEBER T, 1989, CLIN EXP DERMATOL, V14, P35, DOI 10.1111/j.1365-2230.1989.tb00880.x; BLOMSTERHAUTAMAA DA, 1988, METHOD ENZYMOL, V165, P37; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; CARR MM, 1986, IMMUNOLOGY, V59, P223; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; Ezepchuk YV, 1996, J INVEST DERMATOL, V107, P603, DOI 10.1111/1523-1747.ep12583377; FAST DJ, 1988, J IMMUNOL, V140, P949; GIORNO R, 1984, SURV SYN PATHOL RES, V3, P165; GOODYEAR HM, 1993, CLIN EXP DERMATOL, V18, P300, DOI 10.1111/j.1365-2230.1993.tb02202.x; Ha SJ, 1998, ACTA DERM-VENEREOL, V78, P424; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HAUSER C, 1985, DERMATOLOGICA, V170, P35, DOI 10.1159/000249493; JUPIN C, 1988, J EXP MED, V167, P752, DOI 10.1084/jem.167.3.752; LEUNG DYM, 1995, J CLIN INVEST, V96, P2106, DOI 10.1172/JCI118263; LEUNG DYM, 1993, J INVEST DERMATOL, V100, P225, DOI 10.1111/1523-1747.ep12468941; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEVER R, 1988, BRIT J DERMATOL, V119, P189, DOI 10.1111/j.1365-2133.1988.tb03201.x; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MCFADDEN JP, 1993, BRIT J DERMATOL, V128, P631, DOI 10.1111/j.1365-2133.1993.tb00257.x; MURPHY GF, 1983, J INVEST DERMATOL, V81, P181, DOI 10.1111/1523-1747.ep12543766; Neuber K, 1996, ACTA DERM-VENEREOL, V76, P214; Strange P, 1996, ARCH DERMATOL, V132, P27, DOI 10.1001/archderm.132.1.27; Travers JB, 1999, J CLIN INVEST, V104, P1181, DOI 10.1172/JCI6835; VOLEPLATZER B, 1984, J EXP MED, V159, P1784; WAKITA H, 1995, J INVEST DERMATOL, V105, P536, DOI 10.1111/1523-1747.ep12323426	28	106	110	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					820	826		10.1067/mai.2000.105524	http://dx.doi.org/10.1067/mai.2000.105524			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756235				2022-12-18	WOS:000086604100023
J	Pastorello, EA; Pravettoni, V; Farioli, L; Ispano, M; Fortunato, D; Monza, M; Giuffrida, MG; Rivolta, F; Scibola, E; Ansaloni, R; Incorvaia, C; Conti, A; Ortolani, C				Pastorello, EA; Pravettoni, V; Farioli, L; Ispano, M; Fortunato, D; Monza, M; Giuffrida, MG; Rivolta, F; Scibola, E; Ansaloni, R; Incorvaia, C; Conti, A; Ortolani, C			Clinical role of a lipid transfer protein that acts as a new apple-specific allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						oral allergy syndrome; vegetable allergens; apple; birch pollinosis; immunoblotting; lipid transfer protein	BIRCH POLLEN; PROFILIN; FRUITS; PEACH	Background: Allergy to apple is commonly associated with birch pollinosis because the two share homologous allergens. However, some patients have apple allergy but no birch pollinosis, suggesting that there are allergens that do not crossreact with birch, Objective: The aim of the study was to evaluate the IgE reactivity pattern to an apple extract in subjects with allergic reactions to apple, with and without birch hay fever. Methods: Forty-three patients with oral allergy syndrome for apple and positive open food challenge, skin prick test, and serum specific IgE antibodies to apple were admitted to the study. Thirty-two had birch pollinosis (documented by specific IgE for birch) and II were not allergic to birch. The IgE reactivity pattern to apple extract was identified by SDS-PAGE and immunoblotting. The consistent allergen, a 9-kd protein, was then purified by HPLC and characterized by periodic acid-Schiff staining, isoelectric point, and N-terminal amino acid sequencing. Results: The sera from 28% of patients allergic to apple with birch pollinosis, but from all patients allergic only to apple, recognized the 9-kd protein. This protein has an isoelectric point of 7.5 and is not glycosylated. Determination of its partial amino acid sequence showed that it belongs to the family of Lipid transfer proteins, which act as major allergens in Prunoideae fruits. Conclusions: These results indicate that a lipid transfer protein is an important allergen in patients allergic to apple but not to birch pollen. The prevalent IgE reactivity to this allergen in subjects with no birch pollinosis and the physicochemical characteristics of this protein suggest that sensitization may occur through the oral route.	Osped Maggiore, Div Gen Med 3, Ist Ric & Cura Carattere Sci, Allergy Ctr, Milan, Italy; Osped Med Lavoro, Unita Operat, Milan, Italy; Niguarda Ca Granda Hosp, Bizzozzero Div, Milan, Italy; Natl Res Council, Turin, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico	Pastorello, EA (corresponding author), Padiglione Granelli, Div Gen Med 3, Via Francesco Sforza 35, I-20122 Milan, Italy.		Giuffrida, Maria Gabriella/AAY-6314-2020; PASTORELLO, ELIDE ANNA/E-3897-2017	Giuffrida, Maria Gabriella/0000-0002-1297-2558; PASTORELLO, ELIDE ANNA/0000-0002-3753-1783				BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; Hsieh LS, 1995, J ALLERGY CLIN IMMUN, V96, P960, DOI 10.1016/S0091-6749(95)70234-2; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; KIVITY S, 1994, CLIN EXP ALLERGY, V24, P19, DOI 10.1111/j.1365-2222.1994.tb00911.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOWAT A, 1982, ALLERGY, V37, P437; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; PASTORELLO EA, 1997, FOOD ALLERGY ADVERSE, P221; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; Tuft Louis, 1942, JOUR ALLERGY, V13, P574, DOI 10.1016/S0021-8707(42)90070-4; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VIETHS S, 1994, ALLERGY, V49, P262, DOI 10.1111/j.1398-9995.1994.tb02659.x; VIETHS S, 1995, ALLERGY, V50, P421, DOI 10.1111/j.1398-9995.1995.tb01172.x; Warburg O., 1942, BIOCHEM Z, V310, P384	21	106	107	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					1099	1106		10.1016/S0091-6749(99)70095-3	http://dx.doi.org/10.1016/S0091-6749(99)70095-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550759				2022-12-18	WOS:000083778400038
J	Barnes, PJ				Barnes, PJ			Effect of beta-agonists on inflammation cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						beta(2)-adrenergic receptors; mast cell; eosinophil; T-lymphocyte; neutrophil; plasma exudation; sensory nerve	LUNG MAST-CELLS; RECEPTOR MESSENGER-RNA; ALBUTEROL-INDUCED BRONCHOPROTECTION; REGULAR INHALED SALBUTAMOL; BRONCHIAL EPITHELIAL-CELLS; HUMAN ALVEOLAR MACROPHAGES; CILIARY BEAT FREQUENCY; PROTEIN KINASE-C; ADRENERGIC RECEPTORS; DOWN-REGULATION	Although the major action of racemic beta(2)-agonists on the air ways is relaxation of airway smooth muscle, these drugs have several other effects mediated through beta(2)-adrenergic receptors expressed on other cell types. These additional actions of beta(2)-agonists may contribute to the efficacy of beta(2)-agonists in relieving asthma symptoms, beta(2)-agonists inhibit plasma exudation in the airways by acting on beta(2)-receptors on postcapillary venule cells, They inhibit the secretion of bronchoconstrictor mediators from airway mast cells and inhibit effects on release of mediators from eosinophils, macrophages, T-lymphocytes, and neutrophils, In addition, beta(2)-agonists may have an inhibitory effect on the release of neuropeptides from sensory nerves, The effect of beta(2)-agonists on mediator release from structural cells in the airways such as epithelial cells is uncertain. Despite all of these inhibitory effects on inflammatory cells in vitro, beta(2)-agonists do not appear to reduce the chronic inflammation of asthma, Desensitization is more readily seen in inflammatory cells than in airway smooth muscle cells and may account for this discrepancy Corticosteroids mag increase expression of beta(2)-receptors in inflammatory cells to overcome the desensitization in response to chronic beta(2)-agonist exposure.	Univ London Imperial Coll Sci Technol & Med, Dept Thorac Med, Natl Heart & Lung Inst, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Thorac Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.			Barnes, Peter/0000-0002-5122-4018				Adcock IM, 1996, EUR RESPIR J, V9, P160, DOI 10.1183/09031936.96.09010160; ADCOCK IM, 1994, AM J RESP CRIT CARE, V149, pA1026; Anderson R, 1996, BRIT J PHARMACOL, V117, P1387, DOI 10.1111/j.1476-5381.1996.tb15297.x; BACHELET M, 1991, J ALLERGY CLIN IMMUN, V88, P322, DOI 10.1016/0091-6749(91)90093-4; BAI TR, 1993, AM J RESP CELL MOL, V8, P325, DOI 10.1165/ajrcmb/8.3.325; BALUK P, 1994, AM J PHYSIOL, V266, pL461, DOI 10.1152/ajplung.1994.266.4.L461; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, P838, DOI 10.1164/ajrccm.152.3.7663795; BARNES PJ, 1982, NATURE, V299, P444, DOI 10.1038/299444a0; BISHOPRIC NH, 1980, J ALLERGY CLIN IMMUN, V65, P29, DOI 10.1016/0091-6749(80)90173-6; BJORCK T, 1992, AM REV RESPIR DIS, V145, P1087; Bloemen PGM, 1997, AM J PHYSIOL-LUNG C, V272, pL580, DOI 10.1152/ajplung.1997.272.4.L580; Borger P, 1998, AM J RESP CELL MOL, V19, P400, DOI 10.1165/ajrcmb.19.3.2765; BOSCHETTO P, 1989, AM REV RESPIR DIS, V139, P416, DOI 10.1164/ajrccm/139.2.416; BOUVIER M, 1987, J BIOL CHEM, V262, P3106; Bowden JJ, 1997, EUR J PHARMACOL, V338, P83, DOI 10.1016/S0014-2999(97)01272-7; BOWDEN JJ, 1994, J APPL PHYSIOL, V77, P397, DOI 10.1152/jappl.1994.77.1.397; BUSSE WW, 1984, J ALLERGY CLIN IMMUN, V73, P404, DOI 10.1016/0091-6749(84)90416-0; BUTCHERS PR, 1980, BRIT J PHARMACOL, V71, P663, DOI 10.1111/j.1476-5381.1980.tb10987.x; CARSTAIRS JR, 1984, EUR J PHARMACOL, V103, P189, DOI 10.1016/0014-2999(84)90211-5; CARSTAIRS JR, 1985, AM REV RESPIR DIS, V132, P541; Chong LK, 1998, BRIT J PHARMACOL, V123, P1009, DOI 10.1038/sj.bjp.0701703; CHONG LK, 1995, AM J RESP CELL MOL, V13, P540, DOI 10.1165/ajrcmb.13.5.7576689; Chong LK, 1997, BRIT J PHARMACOL, V121, P717, DOI 10.1038/sj.bjp.0701185; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; CUSHLEY MJ, 1985, J ALLERGY CLIN IMMUN, V75, P272, DOI 10.1016/0091-6749(85)90057-0; DAVIS DB, 1990, AM J PHYSIOL, V258, pC71; DEVALIA JL, 1992, PULM PHARMACOL, V5, P257, DOI 10.1016/0952-0600(92)90068-R; DIDIER M, 1987, J IMMUNOL, V139, P1179; Drury DEJ, 1998, BRIT J PHARMACOL, V124, P711, DOI 10.1038/sj.bjp.0701897; ERJEFALT I, 1991, AM REV RESPIR DIS, V143, P1008, DOI 10.1164/ajrccm/143.5_Pt_1.1008; Evans DW, 1997, THORAX, V52, P136, DOI 10.1136/thx.52.2.136; FELDMAN RD, 1987, J IMMUNOL, V139, P3355; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Folkerts G, 1998, TRENDS PHARMACOL SCI, V19, P334, DOI 10.1016/S0165-6147(98)01232-2; Fuller R W, 1988, Pulm Pharmacol, V1, P101, DOI 10.1016/S0952-0600(88)80006-1; GALANT SP, 1980, J CLIN INVEST, V65, P577, DOI 10.1172/JCI109702; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; HADJOKAS NE, 1995, J ALLERGY CLIN IMMUN, V95, P735, DOI 10.1016/S0091-6749(95)70179-6; HAMID QA, 1991, EUR J PHARM-MOLEC PH, V206, P133, DOI 10.1016/0922-4106(91)90021-9; Hjemdahl P, 1996, AM J RESP CRIT CARE, V153, P576, DOI 10.1164/ajrccm.153.2.8564101; HJEMDAHL P, 1990, BRIT J CLIN PHARMACO, V30, P673, DOI 10.1111/j.1365-2125.1990.tb03835.x; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; HUANG LY, 1993, J BIOL CHEM, V268, P25769; HUI KP, 1992, AGENTS ACTIONS, V32, P29; IMAI E, 1993, J BIOL CHEM, V268, P5353; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ITABASHI S, 1992, EUR J PHARMACOL, V218, P187, DOI 10.1016/0014-2999(92)90165-Z; KAMIKAWA Y, 1990, J PHARM PHARMACOL, V42, P131, DOI 10.1111/j.2042-7158.1990.tb05369.x; KARIMAN K, 1980, LUNG, V158, P41, DOI 10.1007/BF02713701; KELSEN SG, 1995, AM J RESP CRIT CARE, V152, P1774, DOI 10.1164/ajrccm.152.6.8520736; Kelsen SG, 1997, AM J PHYSIOL-LUNG C, V272, pL916, DOI 10.1152/ajplung.1997.272.5.L916; KITA H, 1991, J IMMUNOL, V146, P2712; Kraft M, 1997, CHEST, V111, P1249, DOI 10.1378/chest.111.5.1249; KRIFF S, 1993, J CLIN INVEST, V91, P344; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Leff AR, 1997, PULM PHARMACOL THER, V10, P97, DOI 10.1006/pupt.1997.0082; LIGGETT SB, 1989, AM REV RESPIR DIS, V139, P552, DOI 10.1164/ajrccm/139.2.552; MAISEL AS, 1989, CLIN PHARMACOL THER, V46, P429, DOI 10.1038/clpt.1989.161; Mak JCW, 1996, EUR J PHARMACOL, V302, P215, DOI 10.1016/0014-2999(96)00104-5; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; MAK JCW, 1994, EUR J PHARM-MOLEC PH, V269, P35, DOI 10.1016/0922-4106(94)90023-X; MAK JCW, 1995, AM J PHYSIOL, V12, pL41; MAK JCW, 1994, AM J RESP CRIT CAR S, V149, P1027; MARTIN CAE, 1993, BRIT J PHARMACOL, V110, P1311, DOI 10.1111/j.1476-5381.1993.tb13961.x; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; MEURS H, 1987, J ALLERGY CLIN IMMUN, V80, P326, DOI 10.1016/0091-6749(87)90039-X; MEURS H, 1982, J ALLERGY CLIN IMMUN, V70, P272, DOI 10.1016/0091-6749(82)90063-X; MUNOZ NM, 1995, J PHARMACOL EXP THER, V273, P850; MUNOZ NM, 1994, J PHARMACOL EXP THER, V268, P1339; NIALS AT, 1994, EUR J PHARMACOL, V251, P127, DOI 10.1016/0014-2999(94)90392-1; NICHOL G, 1990, THORAX, V45, P694, DOI 10.1136/thx.45.9.694; Nielson CP, 1998, AM J RESP CRIT CARE, V157, P184, DOI 10.1164/ajrccm.157.1.9704070; NISHIKAWA M, 1993, EUR J PHARM-MOLEC PH, V247, P131, DOI 10.1016/0922-4106(93)90070-P; NISHIKAWA M, 1994, AM J RESP CELL MOL, V10, P91, DOI 10.1165/ajrcmb.10.1.8292387; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; OCONNOR BJ, 1994, AM J RESP CRIT CARE, V150, P381, DOI 10.1164/ajrccm.150.2.8049819; OCONNOR BJ, 1991, THORAX, V46; OConnor J, 1995, PULM PHARMACOL, V8, P237, DOI 10.1006/pulp.1995.1032; Oddera S, 1998, J ASTHMA, V35, P401, DOI 10.3109/02770909809048948; Penn RB, 1996, AM J PHYSIOL-LUNG C, V271, pL601, DOI 10.1152/ajplung.1996.271.4.L601; PETERS MJ, 1995, EUR J PHARM-MOLEC PH, V289, P275, DOI 10.1016/0922-4106(95)90104-3; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; PORT JD, 1992, J BIOL CHEM, V267, P24103; RABE KF, 1993, EUR J PHARMACOL, V231, P305, DOI 10.1016/0014-2999(93)90466-U; Rabe KF, 1991, FUND CLIN PHARM, V5, pA402; ROBERTS JA, 1992, AM REV RESPIR DIS, V145, P418; SANDERSON MJ, 1989, AM REV RESPIR DIS, V139, P432, DOI 10.1164/ajrccm/139.2.432; Seldon PM, 1998, AM J RESP CRIT CARE, V157, P803, DOI 10.1164/ajrccm.157.3.9707116; SELDON PM, 1995, MOL PHARMACOL, V48, P747; SPINA D, 1989, AM REV RESPIR DIS, V140, P1410, DOI 10.1164/ajrccm/140.5.1410; SULAKVELIDZE I, 1994, AM J RESP CRIT CARE, V149, P232, DOI 10.1164/ajrccm.149.1.7509246; SVENSSON C, 1995, ALLERGY, V50, P884, DOI 10.1111/j.1398-9995.1995.tb02494.x; Taylor DA, 1997, AM J RESP CRIT CARE, V156, P1731, DOI 10.1164/ajrccm.156.6.9703047; TAYLOR IK, 1992, J ALLERGY CLIN IMMUN, V89, P575, DOI 10.1016/0091-6749(92)90325-V; Teixeira MM, 1997, EUR J PHARMACOL, V323, P255, DOI 10.1016/S0014-2999(97)00030-7; THOMAS RF, 1993, MOL PHARMACOL, V43, P343; TOKUYAMA K, 1991, EUR J PHARMACOL, V193, P35, DOI 10.1016/0014-2999(91)90197-X; TURKI J, 1995, AM J PHYSIOL, V269, P709; VERLEDEN GM, 1993, J APPL PHYSIOL, V74, P1195, DOI 10.1152/jappl.1993.74.3.1195; Volcheck GW, 1998, J ALLERGY CLIN IMMUN, V101, pS35; Weston MC, 1998, GEN PHARMACOL-VASC S, V31, P715, DOI 10.1016/S0306-3623(98)00080-9; Yates DH, 1998, THORAX, V53, P110, DOI 10.1136/thx.53.2.110; Yates DH, 1997, AM J RESP CRIT CARE, V156, P988, DOI 10.1164/ajrccm.156.3.9610051; YUKAWA T, 1990, AM REV RESPIR DIS, V141, P1446, DOI 10.1164/ajrccm/141.6.1446; Zetterlund A, 1998, RESP MED, V92, P162, DOI 10.1016/S0954-6111(98)90089-0	109	106	112	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	2	S			S10	S17		10.1016/S0091-6749(99)70269-1	http://dx.doi.org/10.1016/S0091-6749(99)70269-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	233GX	10452784				2022-12-18	WOS:000082419400002
J	Baur, X; Degens, PO; Sander, I				Baur, X; Degens, PO; Sander, I			Baker's asthma: Still among the most frequent occupational respiratory disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						baker's asthma; allergens; wheat flour; rye flour; alpha-amylase; soy bean flour; lung function; inhalative challenge tests	BRONCHIAL HYPERRESPONSIVENESS; LUNG-FUNCTION; WHEAT-FLOUR; WORKERS; SENSITIZATION; EXPOSURE; SYMPTOMS; AMYLASE; DUST; REACTIVITY	Background: Baker's asthma and rhinitis are among the most frequent occupational respiratory disorders. Objective: The aim of the study was to evaluate the frequency of work-related symptoms and the clinical relevance of sensitization to allergens in screened and symptomatic bakers. Methods: Eighty-nine bakers participating in a screening study and 104 bakers filing a claim for compensation were examined with regard to occupational and clinical case history, lung function parameters, and sensitization to bakery allergens by skin prick tests, specific IgE analyses, and inhalative challenge tests. Results: A high prevalence of respiratory disorders, abnormal lung function parameters, and sensitization to bakery allergens exists, Most frequently, bakers with workplace-related respiratory symptoms showed sensitization to wheat flour (64%), rye flour (52%), soy bean flour (25%), and alpha-amylase (21%). The correlation between these sensitizations and asthma case history and inhalative challenge test responses was significant. However, approximately 29% of the bakers with respiratory symptoms showed no sensitization to these bakery allergens, whereas 32% of the sensitized bakers in the screening group had no workplace-related symptoms, Atopic status defined by skin prick test sensitization to common allergens or elevated total IgE levels was found to be a risk factor for the development of sensitization to bakery allergens and respiratory symptoms. On the other hand, there is evidence for an increased frequency of elevated total IgE as the result of occupational allergen exposure because respective findings were observed in bakers without symptoms. Conclusion: Sensitization to bakery allergens seems to be the main cause of baker's asthma and rhinitis but cannot explain the asthma case history in each case. Further methods are required to objectively assume irritative pathomechanisms. Our findings indicate the necessity for an improved primary prevention of exposure to inhalative noxae in bakeries.	Ruhr Univ Bochum, Res Inst Occupat Med, D-44789 Bochum, Germany	Ruhr University Bochum	Baur, X (corresponding author), Ruhr Univ Bochum, Res Inst Occupat Med, Burkle de la Camp Pl 1, D-44789 Bochum, Germany.		Sander, Ingrid/R-8940-2017	Sander, Ingrid/0000-0002-5014-4112				AMMON J, 1993, ATEMWEG LUNGENKRANK, V19, P303; ANDREJS A, 1994, OBSTRUKTIVE ATEMWEGS, V2, P178; Baltsch J, 1990, Pneumologie, V44, P681; BAUR X, 1994, INT ARCH OCC ENV HEA, V66, P141, DOI 10.1007/BF00380772; BAUR X, 1988, DEUT MED WOCHENSCHR, V113, P1275, DOI 10.1055/s-2008-1067805; BAUR X, 1994, CLIN EXP ALLERGY, V24, P465, DOI 10.1111/j.1365-2222.1994.tb00935.x; BAUR X, 1986, LANCET, V1, P43; Baur X, 1998, AM J IND MED, V33, P114; BAUR X, 1998, IN PRESS CLIN EXP AL; BAUR X, 1996, ARBEITSMED SOZIALMED, V31, P70; BURDORF A, 1994, ANN OCCUP HYG, V38, P67, DOI 10.1093/annhyg/38.1.67; Burstyn I, 1997, ANN OCCUP HYG, V41, P609, DOI 10.1016/S0003-4878(97)00031-8; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHANYEUNG M, 1993, ASTHMA WORKPLACE, P229; COCKCROFT DW, 1983, THORAX, V38, P523, DOI 10.1136/thx.38.7.523; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P579, DOI 10.1136/oem.51.9.579; DEZOTTI R, 1994, OCCUP ENVIRON MED, V51, P548, DOI 10.1136/oem.51.8.548; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; HOUBA R, 1996, THESIS LANDBOUWUNIVE, P25; *HVBG, 1997, HAUPTVERBAND GEWERBL; IVERSEN M, 1989, THORAX, V44, P645, DOI 10.1136/thx.44.8.645; JARVINEN KAJ, 1979, ANN ALLERGY, V42, P192; Knoch M., 1995, European Respiratory Journal, V8, p104S; KREMER AM, 1995, EUR RESPIR J, V8, P53, DOI 10.1183/09031936.95.08010053; MALO JL, 1988, THORAX, V43, P371, DOI 10.1136/thx.43.5.371; MATTHYS H, 1993, RESPIRATION, V60, P343; MEREDITH S, 1993, J EPIDEMIOL COMMUN H, V47, P459, DOI 10.1136/jech.47.6.459; MERGET R, 1995, INT ARCH ALLERGY IMM, V107, P406, DOI 10.1159/000237055; Mohorn M, 1991, Pneumologie, V45 Suppl 2, P651; MUSK AW, 1989, BRIT J IND MED, V46, P636; NIEUWENHUIJSEN MJ, 1994, OCCUP ENVIRON MED, V51, P584, DOI 10.1136/oem.51.9.584; PIERARD P, 1997, ALLERGY CLIN IMMUN S, V4, P169; PRICHARD MG, 1984, BRIT J IND MED, V41, P450; Sander I, 1998, Pneumologie, V52, P440; Sander I, 1998, J ALLERGY CLIN IMMUN, V102, P256, DOI 10.1016/S0091-6749(98)70109-5; Sander I, 1997, INT ARCH ALLERGY IMM, V112, P378, DOI 10.1159/000237483; Schlegel J, 1995, Pneumologie, V49, P383; SCHMITZSCHUMANN M, 1991, DEUT MED WOCHENSCHR, V115, P695; Smith TA, 1997, OCCUP MED-OXFORD, V47, P21, DOI 10.1093/occmed/47.1.21; THIEL H, 1980, CHEST, V78, P400, DOI 10.1378/chest.78.2.400; Toren K, 1996, OCCUP ENVIRON MED, V53, P757, DOI 10.1136/oem.53.11.757; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; ZUSKIN E, 1994, ANN ALLERGY, V73, P521; [No title captured]	44	106	108	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				984	997		10.1016/S0091-6749(98)70337-9	http://dx.doi.org/10.1016/S0091-6749(98)70337-9			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847440				2022-12-18	WOS:000077690700017
J	King, TP; Lu, G; Gonzalez, M; Qian, NF; Soldatova, L				King, TP; Lu, G; Gonzalez, M; Qian, NF; Soldatova, L			Yellow jacket venom allergens, hyaluronidase and phospholipase: Sequence similarity and antigenic cross-reactivity with their hornet and wasp homologs and possible implications for clinical allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; yellow-jacket; antigen 5; hyaluronidase; phospholipase; hornet; wasp	AMINO-ACID-SEQUENCES; HYMENOPTERA VENOM; PROTEIN ALLERGENS; T-CELL; IMMUNOTHERAPY	Three known allergens of yellow jacket (Vespula vulgaris) venom are antigen 5, hyaluronidase, and phospholipase. Yellow jacket antigen 5 has been previously cloned and expressed in bacteria; it contains 204 amino acid residues, and it has 69% and 60% sequence identities with the homologous proteins of white-faced hornet (Dolichovespula maculata) and wasp (Polistes annularis), respectively. These studies are now extended to yellow jacket hyaluronidase and phospholipase; they contain 331 and 300 amino acid residues, respectively, and they show 92% and 67% sequence identity with their homologs of white-faced hornet. Tests with the natural and the recombinant vespid allergens in mice indicate partial antigenic cross-reactivity of their homologous proteins at both B- and T-cell levels. There is greater cross-reactivity among hornet and yellow jacket allergens than that among hornet or yellow jacket and wasp allergens. The order of cross-reaction of the three vespid allergens is hyaluronidase > antigen 5 > phospholipase. The continuous (linear) B-cell epitopes of vespid allergens show greater cross-reactivity than their discontinuous epitopes do. The discontinuous B-cell epitopes are immunodominant for all vespid allergens. The low degree of cross-reactivity of the immunodominant discontinuous B-cell epitopes of vespid allergens should be taken into consideration in selection of venoms for immunotherapy of patients with sensitivity to multiple vespids.			King, TP (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.		Gonzalez, Manuel A/A-3404-2013		NIAID NIH HHS [AI-17021] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017021] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNARD R, 1994, BICTECHNIQUES, V16, P169; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P57; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1980, ANN ALLERGY, V45, P276; HOFFMAN DR, 1994, INT ARCH ALLERGY IMM, V104, P184, DOI 10.1159/000236728; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; HOFFMAN DR, 1994, J ALLERGY CLIN IMMUN, V93, P223; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X; KING TP, 1984, ARCH BIOCHEM BIOPHYS, V230, P1, DOI 10.1016/0003-9861(84)90080-8; KING TP, 1995, J IMMUNOL, V154, P577; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU G, 1993, J IMMUNOL, V150, P2823; LU G, 1995, J BIOL CHEM, V270, P4457, DOI 10.1074/jbc.270.9.4457; NORMAN PS, 1993, CURR OPIN IMMUNOL, V5, P968, DOI 10.1016/0952-7915(93)90114-8; REISMAN RE, 1994, NEW ENGL J MED, V331, P523, DOI 10.1056/NEJM199408253310808; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; SLOANLANCASTER J, 1995, CURR OPIN IMMUNOL, V7, P103, DOI 10.1016/0952-7915(95)80035-2; SOLDATOVA L, 1993, FEBS LETT, V320, P145, DOI 10.1016/0014-5793(93)80080-E; VALENTINE MD, 1995, INSECT VENOM ALLERGY, V2, P1367; WYPCH J, 1989, INT ARCH ALLER A IMM, V89, P60	30	106	119	1	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					588	600		10.1016/S0091-6749(96)70093-3	http://dx.doi.org/10.1016/S0091-6749(96)70093-3			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828537	Bronze			2022-12-18	WOS:A1996VJ42800016
J	deBlic, J; Delacourt, C; LeBourgeois, M; Mahut, B; Ostinelli, J; Caswell, C; Scheinmann, P				deBlic, J; Delacourt, C; LeBourgeois, M; Mahut, B; Ostinelli, J; Caswell, C; Scheinmann, P			Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						infantile asthma; inhaled corticosteroids; nebulized budesonide	BECLOMETHASONE DIPROPIONATE; INHALED BUDESONIDE; BRONCHOPULMONARY DYSPLASIA; WHEEZY BRONCHITIS; JET NEBULIZERS; DRUG DELIVERY; FOLLOW-UP; CHILDREN; RESPONSIVENESS; SYMPTOMS	Background and objective: Treatments with inhaled corticosteroids yielded conflicting results in infants with severe asthma. The purpose of this study was to assess the efficacy of nebulized budesonide on the control of asthma in this age group. Methods: In a double-blind, placebo-controlled study, 40 infants with severe asthma received either nebulized budesonide (1 mg) or placebo twice daily for 12 weeks, followed by a follow-up period of lip to 12 weeks. A jet nebulizer driven by an air compressor was used to administer budesonide and placebo. Results: Fewer patients in the budesonide group had an exacerbation during the treatment period (40%) compared with the placebo group (53%, p < 0.01). The duration of oral steroid therapy was shorter in the budesonide group than in the placebo group (median number of days of exacerbation as a proportion of the total treatment time, 0% vs 14.5%; p < 0.05). The incidence of daytime (p < 0.05) and nighttime wheezing (p < 0.01) was lower in the budesonide group than in the placebo group during the treatment period The proportion of patients without an exacerbation of asthma during the entire 24 weeks was 28% for those patients who had received budesonide and 0% for those patients who had received placebo. Asthma improved in more patients in the budesonide group (17 of 19, 89%) than in the placebo group (7 of 16, 44%; p < 0.005). These results should improve and modify the treatment of infants with severe asthma. Conclusion: Nebulized budesonide (1 mg twice daily) is a well-tolerated and efficient treatment for severe infantile asthma.	LABS ASTRA FRANCE,NANTERRE,FRANCE		deBlic, J (corresponding author), HOP ENFANTS MALAD,SERV PNEUMOL & ALLERGOL PEDIAT,149 RUE SEVRES,F-75730 PARIS,FRANCE.		Delacourt, Christophe/K-6161-2019					AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; ALVINE GF, 1992, CHEST, V101, P316, DOI 10.1378/chest.101.2.316; BISGAARD H, 1990, LANCET, V336, P649, DOI 10.1016/0140-6736(90)92147-A; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; CARLSEN K, 1988, ARCH DIS CHILD, V63, P1428, DOI 10.1136/adc.63.12.1428; CARLSEN KCL, 1992, ARCH DIS CHILD, V67, P1077; CLOUTIER MM, 1993, PEDIATR PULM, V15, P111, DOI 10.1002/ppul.1950150208; CONNETT GJ, 1993, ARCH DIS CHILD, V69, P351, DOI 10.1136/adc.69.3.351; EPSTEIN SW, 1993, CHEST, V103, P1313, DOI 10.1378/chest.103.5.1313a; EVERARD ML, 1992, ARCH DIS CHILD, V67, P586, DOI 10.1136/adc.67.5.586; EVERARD ML, 1992, ARCH DIS CHILD, V67, P580, DOI 10.1136/adc.67.5.580; FALCONER A, 1993, PEDIATR PULM, V15, P209, DOI 10.1002/ppul.1950150405; GODFREY S, 1987, LANCET, V2, P852; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HULTQUIST C, 1989, LANCET, V1, P380; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356, DOI 10.1136/adc.68.3.356; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; KEREM E, 1993, J PEDIATR-US, V123, P313, DOI 10.1016/S0022-3476(05)81710-X; KONIG P, 1992, PEDIATR PULM, V13, P209, DOI 10.1002/ppul.1950130407; MAAYAN C, 1986, PEDIATR PULM, V2, P9, DOI 10.1002/ppul.1950020106; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; MILNER AD, 1993, EUR RESPIR REV, V3, P329; NEWMAN SP, 1988, EUR RESP J S2, V1, P211; NOBLE V, 1992, ARCH DIS CHILD, V67, P285, DOI 10.1136/adc.67.3.285; OCALLAGHAN C, 1990, THORAX, V45, P109, DOI 10.1136/thx.45.2.109; PEDERSEN W, 1987, ALLERGY, V42, P272, DOI 10.1111/j.1398-9995.1987.tb02209.x; TABACHNIK E, 1981, J ALLERGY CLIN IMMUN, V67, P339, DOI 10.1016/0091-6749(81)90077-4; VANBEVER HP, 1990, PEDIATR PULM, V9, P177, DOI 10.1002/ppul.1950090310; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; WARNER JO, 1993, EUR RESPIR REV, V3, P326; WILSON NM, 1989, ARCH DIS CHILD, V64, P1194, DOI 10.1136/adc.64.8.1194; WILSON NM, 1992, ARCH DIS CHILD, V67, P491, DOI 10.1136/adc.67.4.491; YUKSEL B, 1992, THORAX, V47, P910, DOI 10.1136/thx.47.11.910; 1991, J ALLERGY CLIN IMMUN, V88, P425	34	106	108	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					14	20		10.1016/S0091-6749(96)70221-X	http://dx.doi.org/10.1016/S0091-6749(96)70221-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765813				2022-12-18	WOS:A1996VA69200002
J	RAMSEY, B; RICHARDSON, MA				RAMSEY, B; RICHARDSON, MA			IMPACT OF SINUSITIS IN CYSTIC-FIBROSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		SINUSITIS; CYSTIC FIBROSIS	RESPIRATORY VIRAL-INFECTIONS; BRONCHIAL REACTIVITY; SWEAT GLANDS; NASAL POLYPS; GENE; IDENTIFICATION; ALLERGY; ATOPY; ASSOCIATION; INVITRO	The cause of cystic fibrosis has been determined to be faulty ionic transport of chloride across the apical membrane of epithelial cells lining exocrine glands. The subnormal ionic transport leads to dehydration of extra cellular fluids and the development of thickened inspissated mucous secretions. The vast majority of patients with cystic fibrosis develop sinus disease with panopacification of the sinuses present in 90% to 100% of patients older than 8 months of age. Indications for surgical management of sinusitis in children with cystic fibrosis include (1) chronic nasal obstruction with mouth breathing, (2) chronic purulent draining nasal secretions unresponsive to medical treatment, and (3) persistent headaches thought to be related to sinusitis. Operative therapy is based on computerized tomographic scan findings and can be performed endoscopically. Postoperative management is critical for ensuring successful surgical results. Antibiotics, topical steroids, and cleansing of the surgical fields must be performed on a regular basis to ensure adequate healing. The impact of sinusitis on the cystic fibrosis population is significant. Approximately 20% of patients will eventually require surgical treatment of their sinuses. Chronic sinusitis may cause deformities of the external nasal skeleton, a loss of the sense of smell, and headaches.	CHILDRENS HOSP & MED CTR,DIV OTOLARYNGOL,SEATTLE,WA 98105; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT OTOLARYNGOL HEAD & NECK SURG,SEATTLE,WA 98195	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	RICHARDSON, MA (corresponding author), CHILDRENS HOSP & MED CTR,CTR CYST FIBROSIS,4800 SAND POINT WAY NE,SEATTLE,WA 98105, USA.							ADAMS GL, 1980, ARCH OTOLARYNGOL, V106, P127; CARENFELT C, 1977, ACTA OTO-LARYNGOL, V84, P138, DOI 10.3109/00016487709123952; CEPERO R, 1987, OTOLARYNG HEAD NECK, V97, P356, DOI 10.1177/019459988709700403; CUYLER JP, 1989, J OTOLARYNGOL, V18, P173; DESPONS J, 1965, LARYNGOSCOPE, V75, P475; DRAKELEE AB, 1989, J LARYNGOL OTOL, V103, P753, DOI 10.1017/S0022215100109983; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FULON JT, 1963, ARCH OTOLARYNGOL, V78, P192; HUANG NN, 1961, J PEDIATR-US, V59, P512, DOI 10.1016/S0022-3476(61)80234-5; IACCOCCO VF, 1963, AM J DIS CHILD, V106, P115; JAFFE BF, 1977, OTOLARYNG CLIN N AM, V10, P81; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KING VV, 1991, CLIN REV ALLERG, V9, P143; KLINE MW, 1985, PEDIATR INFECT DIS J, V4, P72, DOI 10.1097/00006454-198501000-00019; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; Kopp W, 1991, FUNCTIONAL ENDOSCOPI; LEDESMAMEDINA J, 1980, PEDIATR RADIOL, V9, P61, DOI 10.1007/BF00977665; LEMNA WK, 1990, NEW ENGL J MED, V322, P291, DOI 10.1056/NEJM199002013220503; MEARNS M, 1967, LANCET, V1, P538; MELLIS CM, 1978, PEDIATRICS, V61, P446; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; NEELY J G, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P313; OPPENHEIMER EH, 1979, LAB INVEST, V40, P455; PITCHERWILMOTT RW, 1982, ARCH DIS CHILD, V57, P582, DOI 10.1136/adc.57.8.582; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RACHELEFSKY GS, 1974, AM J DIS CHILD, V128, P355, DOI 10.1001/archpedi.1974.02110280085010; RAMSEY BW, 1989, AM J DIS CHILD, V143, P662, DOI 10.1001/archpedi.1989.02150180040017; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; SHAPIRO ED, 1982, J INFECT DIS, V146, P589, DOI 10.1093/infdis/146.5.589; SILVERMAN M, 1978, ARCH DIS CHILD, V53, P873, DOI 10.1136/adc.53.11.873; SLAVIN RG, 1986, J RESPIR DIS, V7, P61; STERN RC, 1982, AM J DIS CHILD, V136, P1067, DOI 10.1001/archpedi.1982.03970480033008; Taussig LM., 1984, CYSTIC FIBROSIS; TEPPER RS, 1991, CLIN REV ALLERG, V9, P159; TOBIN MJ, 1980, THORAX, V35, P807, DOI 10.1136/thx.35.11.807; WANG EEL, 1984, NEW ENGL J MED, V311, P1653, DOI 10.1056/NEJM198412273112602; WARNER JO, 1976, ARCH DIS CHILD, V51, P507, DOI 10.1136/adc.51.7.507; WILMOTT RW, 1991, CLIN REV ALLERG, V9, P29; WOOD RE, 1976, AM REV RESPIR DIS, V113, P833; 1990, CYSTIC FIBROSIS F DA	44	106	115	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			547	552		10.1016/0091-6749(92)90183-3	http://dx.doi.org/10.1016/0091-6749(92)90183-3			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527348				2022-12-18	WOS:A1992JP52100024
J	RASMUSSEN, JB; ERIKSSON, LO; MARGOLSKEE, DJ; TAGARI, P; WILLIAMS, VC; ANDERSSON, KE				RASMUSSEN, JB; ERIKSSON, LO; MARGOLSKEE, DJ; TAGARI, P; WILLIAMS, VC; ANDERSSON, KE			LEUKOTRIENE-D(4) RECEPTOR BLOCKADE INHIBITS THE IMMEDIATE AND LATE BRONCHOCONSTRICTOR RESPONSES TO INHALED ANTIGEN IN PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LEUKOTRIENES; BRONCHIAL PROVOCATION TESTS; ASTHMA; EARLY ASTHMATIC RESPONSE; LATE ASTHMATIC RESPONSE	HUMAN INTRALOBAR AIRWAYS; ATOPIC SUBJECTS; ANTAGONIST; CHALLENGE; RELEASE; MK-571; POTENT; LUNG; D4; IDENTIFICATION	We have tested the hypothesis that leukotriene D4 (LTD4) receptor activation is involved in the development of antigen-induced bronchoconstriction. In two studies, patients with asthma received infusions of placebo or MK-571, a potent and specific LTD4 receptor antagonist (450 mg or 37.5 mg total dose, respectively). Antigen was inhaled during test-drug administration, and FEV1 was measured for 10 hours after challenge. Urine samples were collected for measurement of LTE4; plasma samples were drawn repeatedly for assay of MK-571. MK-571 infusions inhibited both immediate (0 to 3 hours) and late (3 to 10 hours) asthmatic responses. For the high MK-571 dose, the extent of inhibition, as assessed by the area under the curve of FEV1 versus time was 88% (p = 0.01) and 63% (p = 0.01), for immediate and late responses, respectively. The low MK-571 dose also inhibited both responses but to a minor extent. Mean urinary LTE4 excretion was elevated after antigen challenge and was unaffected by administration of the LTD4 receptor antagonist. The present study demonstrates that MK-571 inhibits antigen-induced asthma in a dose-related fashion; it had no effect on antigen-induced increases in urinary LTE4 excretions. The results suggest that LTD4 receptor activation plays an important role in antigen-induced asthma.	UNIV LUND HOSP,DEPT CLIN PHARMACOL,S-22185 LUND,SWEDEN; MERCK SHARP & DOHME LTD,RAHWAY,NJ 07065; MERCK FROSST CTR THERAPEUT RES,DEPT PHARMACOL,POINTE CLAIRE,QUEBEC,CANADA	Lund University; Skane University Hospital; Merck & Company; Merck & Company	RASMUSSEN, JB (corresponding author), UNIV LUND,MALMO GEN HOSP,DEPT PULM MED,ALLERGY SECT,S-21401 MALMO,SWEDEN.							BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BRITTON JR, 1987, J ALLERGY CLIN IMMUN, V79, P811, DOI 10.1016/0091-6749(87)90214-4; BUCKNER CK, 1986, J PHARMACOL EXP THER, V237, P558; BUCKNER CK, 1990, J PHARMACOL EXP THER, V252, P77; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; FULLER RW, 1989, J ALLERGY CLIN IMMUN, V83, P939, DOI 10.1016/0091-6749(89)90109-7; GRIZZLE JE, 1965, BIOMETRICS, V21, P467, DOI 10.2307/2528104; GRIZZLE JE, 1974, BIOMETRICS, V30, P727; HIGGINS DA, 1987, J ALLERGY CLIN IMMUN, V79, P141; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; KIPS JC, 1991, AM REV RESPIR DIS, V144, P617, DOI 10.1164/ajrccm/144.3_Pt_1.617; LEWIS MA, 1985, BIOCHEM PHARMACOL, V34, P4311, DOI 10.1016/0006-2952(85)90290-4; LINDMAN HR, 1980, INTRO BIVARIATE MULT; MALTBY NH, 1990, J ALLERGY CLIN IMMUN, V85, P3, DOI 10.1016/0091-6749(90)90214-O; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MONG S, 1984, PROSTAGLANDINS, V28, P805, DOI 10.1016/0090-6980(84)90036-4; RASMUSSEN JB, 1991, ALLERGY, V46, P266, DOI 10.1111/j.1398-9995.1991.tb00584.x; RASMUSSEN JB, 1992, IN PRESS ALLERGY; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCADDING JG, 1983, ASTHMA, P1; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; SOLER M, 1991, J APPL PHYSIOL, V70, P617, DOI 10.1152/jappl.1991.70.2.617; TAGARI P, 1989, CLIN CHEM, V35, P388; TAYLOR GW, 1989, LANCET, V1, P584; TOCCO DJ, 1990, DRUG METAB DISPOS, V18, P388; VANHECKEN A, 1989, EUR J CLIN PHARMACOL, V36, P13; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; WINER BJ, 1962, STATISTICAL PRINCIPL; 1980, ATS NEWS         SPR, P11	33	106	106	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					193	201		10.1016/0091-6749(92)90071-9	http://dx.doi.org/10.1016/0091-6749(92)90071-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1323587				2022-12-18	WOS:A1992JJ42300008
J	ALVAREZ, J; SURS, W; LEUNG, DYM; IKLE, D; GELFAND, EW; SZEFLER, SJ				ALVAREZ, J; SURS, W; LEUNG, DYM; IKLE, D; GELFAND, EW; SZEFLER, SJ			STEROID-RESISTANT ASTHMA - IMMUNOLOGICAL AND PHARMACOLOGICAL FEATURES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN MONOCYTE FUNCTION; METHYLPREDNISOLONE ELIMINATION; TROLEANDOMYCIN; GLUCOCORTICOIDS; INHIBITION; CORTICOSTEROIDS; HYDROCORTISONE; PROLIFERATION; INTERLEUKIN-2; SUPPRESSION	Glucocorticoids play an important role in asthma therapy; however, a subset of patients are poorly responsive. We evaluated immunologic and pharmacologic features of 17 patients with steroid-resistant (SR) asthma (six male and 11 female patients) between the ages of 16 and 69 years (mean age, 29 years). SR asthma was defined as failure to improve morning prebronchodilator FEV1 > 60% predicted after a 2-week course of oral prednisone (mean dose, 45 mg/day). These patients were compared to 24 steroid-sensitive (SS) patients, aged 5 to 70 years (mean age, 17 years; 17 male and seven female patients), and 47 healthy control subjects, aged 20 to 40 years. Mean prednisone dose in SS patients was 25 mg/day. Steroid pharmacokinetics were evaluated in six patients with SR asthma. All studies were within normal limits. Peripheral blood mononuclear cells (PBMCs) from all subjects were stimulated with 10-mu-g/ml of phytohemagglutinin and incubated for 72 hours with 10(-5) to 10(-9) mol/L of methylprednisolone (Mpn). The Mpn dose-response curve for PBMCs from patients with SR asthma demonstrated a significant (p < 0.05) increase in DNA synthesis, that is, more T cell proliferation than PBMCs stimulated with phytohemagglutinin in the presence of Mpn, as compared to SS patients and normal subjects. This augmentation of DNA synthesis was reversible with 10-mu-g/ml of troleandomycin in vitro. We conclude that PBMCs from patients with SR asthma demonstrate altered response to Mpn in the presence of a T cell mitogen. This abnormality in cellular response may contribute to persistent airway inflammation in patients with SR asthma despite glucocorticoid therapy. Furthermore, this immunologic abnormality appears to be reversible.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST,RM K926,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PREVENT MED & BIOMETR,DENVER,CO 80262; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT BIOSTAT,DENVER,CO 80206; RAYMOND & BEVERLY SACKLER FDN,DENVER,CO	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health			Ikle, David/AAK-7541-2020	Ikle, David/0000-0003-0091-5246	NHLBI NIH HHS [HL-36577] Funding Source: Medline; NIAID NIH HHS [AI-26490] Funding Source: Medline; FDA HHS [FD-R-000278] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026490] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FDA HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; CHAI H, 1973, J ALLERGY CLIN IMMUN, V51, P65, DOI 10.1016/S0091-6749(73)80001-6; COBURG AJ, 1970, SURG GYNECOL OBSTETR, V131, P933; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CRABTREE GR, 1979, NATURE, V279, P338, DOI 10.1038/279338a0; DALE DC, 1975, J CLIN INVEST, V56, P808, DOI 10.1172/JCI108159; DUMONT FJ, 1990, J IMMUNOL, V144, P251; EBLING WF, 1984, J CHROMATOGR, V305, P271, DOI 10.1016/S0378-4347(00)83342-3; GILLIS S, 1979, J IMMUNOL, V123, P1624; HAYNES BF, 1978, J CLIN INVEST, V61, P703, DOI 10.1172/JCI108982; HILL MR, 1990, CLIN PHARMACOL THER, V48, P390, DOI 10.1038/clpt.1990.167; HORST HJ, 1987, CLIN EXP IMMUNOL, V68, P156; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; KAPLAN MP, 1983, TRANSPLANT P, V15, P407; KERN JA, 1988, J CLIN INVEST, V81, P237, DOI 10.1172/JCI113301; LAMBERTS SWJ, 1989, CANCER RES, V49, pS2217; MIYATAKE H, 1991, CHEST, V99, P670, DOI 10.1378/chest.99.3.670; PICCOLELLA E, 1985, J IMMUNOL, V134, P1166; POZNANSKY MC, 1985, CLIN EXP IMMUNOL, V61, P135; RINEHART JJ, 1975, NEW ENGL J MED, V292, P236, DOI 10.1056/NEJM197501302920504; RINEHART JJ, 1974, J CLIN INVEST, V54, P1337, DOI 10.1172/JCI107880; ROCCI ML, 1983, COMPUT PROG BIOMED, V16, P203, DOI 10.1016/0010-468X(83)90082-X; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; SNYDER DS, 1982, J IMMUNOL, V129, P1803; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; THOMPSON J, 1970, Journal of Experimental Medicine, V131, P429, DOI 10.1084/jem.131.3.429; THOMPSON J, 1973, J EXP MED, V137, P10, DOI 10.1084/jem.137.1.10; VEDECKIS WV, 1989, CANCER RES, V49, pS2295; YU DTY, 1978, TRANSPLANTATION, V25, P163	32	106	107	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					714	721		10.1016/0091-6749(92)90379-G	http://dx.doi.org/10.1016/0091-6749(92)90379-G			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545093				2022-12-18	WOS:A1992HJ34000011
J	SAURAT, JH; SCHIFFERLI, J; STEIGER, G; DAYER, JM; DIDIERJEAN, L				SAURAT, JH; SCHIFFERLI, J; STEIGER, G; DAYER, JM; DIDIERJEAN, L			ANTI-INTERLEUKIN-1-ALPHA AUTOANTIBODIES IN HUMANS - CHARACTERIZATION, ISOTYPE DISTRIBUTION, AND RECEPTOR-BINDING INHIBITION - HIGHER FREQUENCY IN SCHNITZLER SYNDROME (URTICARIA AND MACROGLOBULINEMIA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGA AUTOANTIBODIES; IGG4 AUTOANTIBODIES; INTERLEUKIN-1 PLASMA CLEARANCE; SCHNITZLER SYNDROME; URTICARIA; AND MACROGLOBULINEMIA	NECROSIS FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; IMMUNE-COMPLEXES; INTERLEUKIN-1; SERA; IL-1-ALPHA; DERMATOSIS; DISEASES; IGM	Since autoantibodies (Abs) to cytokines may modify their biologic activities, high-affinity binding factors for interleukin-1-alpha (IL-1-alpha-BF) were characterized in human sera. IL-1-alpha-BF was identified as IgG (1) by sucrose density-gradient centrifugation followed by immunodiffusion autoradiography, (2) by ligand-blotting method, (3) by ligand binding to affinity-immobilized serum IgG, and (4) by IgG affinity purification followed by sucrose density-gradient centrifugation. IL-1-alpha-binding activity resided in the F(ab)2 fragment. The apparent equilibrium constant was in the range of IgG found after immunization with conventional antigens (i.e., 10(-9) to 10(-10) mol/L). Anti-IL-1-alpha-IgG auto-Abs represented only an extremely small fraction of total IgG (< 1/10(-5)). Some sera with IL-1-alpha-BF and purified IgG thereof were able to inhibit by 96% to 98% the binding of human recombinant IL-1-alpha to its receptor on murine thymoma EL4-6.1 cells, whereas other sera did not. When I-125-labeled anti-IL-1-alpha-IgG complexes were injected into rats, they prolonged the plasma half-life of I-125-labeled IL-1-alpha several fold and altered its tissue distribution. The predominant class was IgG (12/19), mainly IgG4 (9/19), but in five of the sera, anti-IL-1-alpha-IgA was also detected. In a screening of 271 sera, IL-1-alpha-BF was detected in 17/98 normal subjects and was not more frequent in several control groups of patients, except in patients with Schnitzler's syndrome (fever, chronic urticaria, bone pain, and monoclonal IgM paraprotein) (6/9; p < 0.005). The pathologic significance of these auto-Abs remains to be determined.	UNIV GENEVA,HOP CANTONAL,DIV NEPHROL,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,HOP CANTONAL,DEPT MED,DIV IMMUNOL & ALLERGY,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva	SAURAT, JH (corresponding author), UNIV GENEVA,HOP CANTONAL,DEPT DERMATOL,CH-1211 GENEVA 4,SWITZERLAND.							ASTON R, 1989, MOL IMMUNOL, V26, P435, DOI 10.1016/0161-5890(89)90103-X; BENDTZEN K, 1989, IMMUNOL TODAY, V10, P222, DOI 10.1016/0167-5699(89)90254-5; BONNETBLANC JM, 1990, DERMATOLOGICA, V181, P41, DOI 10.1159/000247858; DAYER JM, 1989, INTERLEUKIN 1 INFLAM, P283; DIDIERJEAN L, 1990, J INVEST DERMATOL, V94, P393; DOUTRE MS, 1990, J AM ACAD DERMATOL, V22, P143, DOI 10.1016/S0190-9622(08)80029-1; Ferrante A, 1990, PEDIATR INFECT DIS J, V9, P516, DOI [10.1097/00006454-199008001-00004, DOI 10.1097/00006454-199008001-00004]; FLOTTE TJ, 1986, J IMMUNOL, V136, P491; FOMSGAARD A, 1989, SCAND J IMMUNOL, V30, P219, DOI 10.1111/j.1365-3083.1989.tb01204.x; JANIER M, 1989, J AM ACAD DERMATOL, V20, P206, DOI 10.1016/S0190-9622(89)70023-2; MAAK T, 1979, KIDNEY INT, V16, P251; PUJOL RM, 1989, J AM ACAD DERMATOL, V20, P855, DOI 10.1016/S0190-9622(89)80127-6; RUBIN RH, 1989, NEW ENGL J MED, V321, P935, DOI 10.1056/NEJM198910053211404; SCHIFFERLI JA, 1985, J CLIN INVEST, V76, P2127, DOI 10.1172/JCI112217; SCHNITZLER L, 1989, ANN DERMATOL VENER, V116, P547; SECKINGER P, 1987, J IMMUNOL, V139, P1541; SHELLEY WB, 1987, ACTA DERM-VENEREOL, V67, P438; SUZUKI H, 1989, ARTHRITIS RHEUM, V32, P1528, DOI 10.1002/anr.1780321206; SUZUKI H, 1990, J IMMUNOL, V145, P2140; SVENSON M, 1989, SCAND J IMMUNOL, V29, P489, DOI 10.1111/j.1365-3083.1989.tb01149.x; VANDERZEE JS, 1986, J IMMUNOL, V137, P3566; YOUNT WJ, 1988, MONOGR ALLERGY, V23, P41	22	106	110	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1991	88	2					244	256		10.1016/0091-6749(91)90335-L	http://dx.doi.org/10.1016/0091-6749(91)90335-L			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB225	1831824				2022-12-18	WOS:A1991GB22500014
J	MELTZER, EO; ORGEL, HA; BRONSKY, EA; FURUKAWA, CT; GROSSMAN, J; LAFORCE, CF; LEMANSKE, RF; PAULL, BD; PEARLMAN, DS; RATNER, PH; SPECTOR, SL; TINKELMAN, DG; VANAS, A; ROGENES, PR				MELTZER, EO; ORGEL, HA; BRONSKY, EA; FURUKAWA, CT; GROSSMAN, J; LAFORCE, CF; LEMANSKE, RF; PAULL, BD; PEARLMAN, DS; RATNER, PH; SPECTOR, SL; TINKELMAN, DG; VANAS, A; ROGENES, PR			A DOSE-RANGING STUDY OF FLUTICASONE PROPIONATE AQUEOUS NASAL SPRAY FOR SEASONAL ALLERGIC RHINITIS ASSESSED BY SYMPTOMS, RHINOMANOMETRY, AND NASAL CYTOLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MELTZER, EO (corresponding author), ALLERGY & ASTHMA MED GRP & RES CTR, 3444 KEARNY VILLA RD, SUITE 100, SAN DIEGO, CA 92123 USA.							ANDERSSON M, 1988, J ALLERGY CLIN IMMUN, V82, P1019, DOI 10.1016/0091-6749(88)90139-X; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; CONNELL JT, 1982, ANN ALLERGY, V49, P179; EDSBACKER S, 1985, EUR J CLIN PHARMACOL, V29, P477, DOI 10.1007/BF00613465; HASTIE R, 1979, LAB INVEST, V40, P554; INCAUDO G, 1980, J ALLERGY CLIN IMMUN, V65, P41, DOI 10.1016/0091-6749(80)90175-X; JALOWAYSKI AA, 1983, J ALLERGY CLIN IMMUN, V71, P89, DOI 10.1016/0091-6749(83)90125-2; KWASELOW A, 1985, ALLERGY, V40, P363, DOI 10.1111/j.1398-9995.1985.tb00248.x; LINDQVIST N, 1989, CLIN EXP ALLERGY, V19, P71, DOI 10.1111/j.1365-2222.1989.tb02347.x; Meltzer EO, 1988, AM J RHINOL, V2, P47, DOI DOI 10.2500/105065888781693212; MELTZER EO, 1987, IMMUNOL ALLERGY CLIN, V7, P57; MUNCH E, 1981, CLIN ALLERGY, V11, P303, DOI 10.1111/j.1365-2222.1981.tb01598.x; MYGIND N, 1982, CLIN OTOLARYNGOL, V7, P343, DOI 10.1111/j.1365-2273.1982.tb01918.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NACLERIO RM, 1988, J ALLERGY CLIN IMMUN, V82, P927; Naito K., 1989, AM J RHINOL, V3, P93; OKUDA M, 1983, ANN ALLERGY, V50, P116; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; OKUDA M, 1980, CLIN OTOLARYNGOL, V5, P315, DOI 10.1111/j.1365-2273.1980.tb00897.x; OKUDA M, 1985, ANN ALLERGY, V54, P69; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; SMALL P, 1982, J ALLERGY CLIN IMMUN, V70, P178, DOI 10.1016/0091-6749(82)90039-2; VANAS A, 1989, J ALLERGY CLIN IMMUN, V83, P301; WELCH MJ, 1988, ANN ALLERGY, V60, P166; WELCH MJ, 1985, ANN ALLERGY, V55, P577	28	106	106	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					221	230		10.1016/S0091-6749(05)80069-7	http://dx.doi.org/10.1016/S0091-6749(05)80069-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2200821				2022-12-18	WOS:A1990DV31600012
J	BONINI, S; BONINI, S; VECCHIONE, A; NAIM, DM; ALLANSMITH, MR; BALSANO, F				BONINI, S; BONINI, S; VECCHIONE, A; NAIM, DM; ALLANSMITH, MR; BALSANO, F			INFLAMMATORY CHANGES IN CONJUNCTIVAL SCRAPINGS AFTER ALLERGEN PROVOCATION IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ROME LA SAPIENZA,DEPT MED,I-00185 ROME,ITALY; UNIV ROME LA SAPIENZA,DEPT PATHOL,I-00185 ROME,ITALY; EYE RES INST,BOSTON,MA; UNIV ROME TOR VERGATA,DEPT OPTHALMOL,DEPT PATHOL,ROME,ITALY; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Sapienza University Rome; Sapienza University Rome; University of Rome Tor Vergata; Harvard University; Harvard Medical School			Bonini, Sergio/T-6594-2019; Bonini, Stefano/A-2250-2012	Bonini, Sergio/0000-0003-0079-3031; Bonini, Stefano/0000-0002-7787-2144	NATIONAL EYE INSTITUTE [R01EY002099] Funding Source: NIH RePORTER; NEI NIH HHS [EY02099] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGARWAL K, 1982, CLIN ALLERGY, V12, P489, DOI 10.1111/j.1365-2222.1982.tb01647.x; ALLANSMITH MR, 1984, J ALLERGY CLIN IMMUN, V73, P49, DOI 10.1016/0091-6749(84)90483-4; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DESHAZO RD, 1983, ANN ALLERGY, V51, P166; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; DVORACEK JE, 1984, J ALLERGY CLIN IMMUN, V73, P363, DOI 10.1016/0091-6749(84)90409-3; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GREINER JV, 1985, AM J OPHTHALMOL, V100, P45, DOI 10.1016/S0002-9394(14)74981-5; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; LARSEN GL, 1985, J ALLERGY CLIN IMMUN, V76, P665, DOI 10.1016/0091-6749(85)90668-2; LEMANSKE RF, 1982, IMMUNOLOGY, V45, P561; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1968, 6 P INT C ALL, P221; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TANNENBAUM S, 1980, J IMMUNOL, V125, P325	23	106	110	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				462	469		10.1016/0091-6749(88)90020-6	http://dx.doi.org/10.1016/0091-6749(88)90020-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170994				2022-12-18	WOS:A1988Q322900021
J	ENBERG, RN; LEICKLY, FE; MCCULLOUGH, J; BAILEY, J; OWNBY, DR				ENBERG, RN; LEICKLY, FE; MCCULLOUGH, J; BAILEY, J; OWNBY, DR			WATERMELON AND RAGWEED SHARE ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HENRY FORD HOSP,DEPT MED,DIV ALLERGY,2799 W GRAND BLVD,DETROIT,MI 48202; HENRY FORD HOSP,DEPT PEDIAT,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital								ADOLPHSON CR, 1980, MANUAL CLIN IMMUNOLO, P783; ANDERSON JA, 1984, NIH842442 PUBL, P7; ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; FOX DJ, 1976, DOCUMENTATION MIDAS; GOLDEN DBK, 1984, ANN ALLERGY, V53, P444; JELKS ML, 1985, ALLERGY, P283; LAHTI A, 1980, ALLERGY, V35, P297, DOI 10.1111/j.1398-9995.1980.tb01770.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; Parker SP, 1982, SYNOPSIS CLASSIFICAT; ROWE MS, 1986, J ALLERGY CLIN IMMUN, V77, P714, DOI 10.1016/0091-6749(86)90416-1; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WINTER A, 1975, PREPARATIVE FLATBED, P198; BIORAD IMMUNOBLOT GO	16	106	108	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					867	875		10.1016/0091-6749(87)90234-X	http://dx.doi.org/10.1016/0091-6749(87)90234-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3584742	Bronze			2022-12-18	WOS:A1987H904400006
J	HOWE, W; VENABLES, KM; TOPPING, MD; DALLY, MB; HAWKINS, R; LAW, JS; TAYLOR, AJN				HOWE, W; VENABLES, KM; TOPPING, MD; DALLY, MB; HAWKINS, R; LAW, JS; TAYLOR, AJN			TETRACHLOROPHTHALIC ANHYDRIDE ASTHMA - EVIDENCE FOR SPECIFIC LGE ANTIBODY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,LONDON SW3 6HP,ENGLAND; EMPLOYMENT MED ADVISORY SERV,NEWCASTLE,ENGLAND; DRYBURN HOSP,DURHAM,ENGLAND	Royal Brompton Hospital								CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHESTER EH, 1977, CLIN ALLERGY, V7, P15, DOI 10.1111/j.1365-2222.1977.tb01419.x; COTES JE, 1979, LUNG FUNCTION ASSESS; FAWCETT IW, 1977, CLIN ALLERGY, V7, P1, DOI 10.1111/j.1365-2222.1977.tb01418.x; Hamilton A, 1974, IND TOXICOLOGY; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; PURNELL CJ, 1981, 2ND P INT C AN TECHN; SCHLUETER DP, 1978, J OCCUP ENVIRON MED, V20, P183, DOI 10.1097/00043764-197803000-00006; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Yman L, 1975, Dev Biol Stand, V29, P151; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; 1977, MATERIAL SAFETY DATA; 1981, CMND8121	13	106	106	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					5	11		10.1016/0091-6749(83)90539-0	http://dx.doi.org/10.1016/0091-6749(83)90539-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ461	6822691				2022-12-18	WOS:A1983PZ46100001
J	Jevnikar, Z; Ostling, J; Calven, J; Thorn, K; Israelsson, E; Oberg, L; Singhania, A; Lau, LCK; Wilson, SJ; Ward, JA; Chauhan, A; Sousa, AR; De Meulder, B; Loza, MJ; Baribaud, F; Sterk, PJ; Chung, KF; Sun, K; Guo, YK; Adcock, IM; Payne, D; Dahlen, B; Chanez, P; Shaw, DE; Krug, N; Hohlfeld, JM; Sandstrom, T; Djukanovic, R; James, A; Hinks, TSC; Howarth, PH; Vaarala, O; van Geest, M; Olsson, H				Jevnikar, Zala; Ostling, Jorgen; Calven, Jenny; Thorn, Kristofer; Israelsson, Elisabeth; Oberg, Lisa; Singhania, Akul; Lau, Laurie C. K.; Wilson, Susan J.; Ward, Jonathan A.; Chauhan, Anoop; Sousa, Ana R.; De Meulder, Bertrand; Loza, Matthew J.; Baribaud, Frederic; Sterk, Peter J.; Chung, Kian Fan; Sun, Kai; Guo, Yike; Adcock, Ian M.; Payne, Debbie; Dahlen, Barbro; Chanez, Pascal; Shaw, Dominick E.; Krug, Norbert; Hohlfeld, Jens M.; Sandstrom, Thomas; Djukanovic, Ratko; James, Anna; Hinks, Timothy S. C.; Howarth, Peter H.; Vaarala, Outi; van Geest, Marleen; Olsson, Henric		Unbiased Biomarkers Prediction Re	Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; lung epithelium; transcriptomics; hierarchical clustering; IL-6 signaling; exacerbation frequency; eosinophils; airway inflammation; remodeling; epithelial integrity	CHITINASE-LIKE PROTEIN; INTERLEUKIN-6 RECEPTOR; MATRIX METALLOPROTEINASES; BARRIER FUNCTION; SEVERITY; DISEASE; TARGET; CELLS; HYPERRESPONSIVENESS; DYSFUNCTION	Background: Although several studies link high levels of IL-6 and soluble IL-6 receptor (sIL-6R) to asthma severity and decreased lung function, the role of IL-6 trans-signaling (IL-6TS) in asthmatic patients is unclear. Objective: We sought to explore the association between epithelial IL-6TS pathway activation and molecular and clinical phenotypes in asthmatic patients. Methods: An IL-6TS gene signature obtained from air-liquid interface cultures of human bronchial epithelial cells stimulated with IL-6 and sIL-6R was used to stratify lung epithelial transcriptomic data (Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes [U-BIOPRED] cohorts) by means of hierarchical clustering. IL-6TS-specific protein markers were used to stratify sputum biomarker data (Wessex cohort). Molecular phenotyping was based on transcriptional profiling of epithelial brushings, pathway analysis, and immunohistochemical analysis of bronchial biopsy specimens. Results: Activation of IL-6TS in air-liquid interface cultures reduced epithelial integrity and induced a specific gene signature enriched in genes associated with airway remodeling. The IL-6TS signature identified a subset of patients with IL-6TS-high asthma with increased epithelial expression of IL-6TS-inducible genes in the absence of systemic inflammation. The IL-6TS-high subset had an overrepresentation of frequent exacerbators, blood eosinophilia, and submucosal infiltration of T cells and macrophages. In bronchial brushings Toll-like receptor pathway genes were upregulated, whereas expression of cell junction genes was reduced. Sputum sIL-6R and IL-6 levels correlated with sputum markers of remodeling and innate immune activation, in particular YKL-40, matrix metalloproteinase 3, macrophage inflammatory protein 1 beta, IL-8, and IL-1 beta. Conclusions: Local lung epithelial IL-6TS activation in the absence of type 2 airway inflammation defines a novel subset of asthmatic patients and might drive airway inflammation and epithelial dysfunction in these patients.	[Jevnikar, Zala; Ostling, Jorgen; Calven, Jenny; Thorn, Kristofer; Israelsson, Elisabeth; Oberg, Lisa; Vaarala, Outi; van Geest, Marleen; Olsson, Henric] AstraZeneca, IMED Biotech Unit, Dept Biosci Resp Inflammat & Autoimmun, Gothenburg, Sweden; [Calven, Jenny] Univ Gothenburg, Inst Med, Krefting Res Ctr, Dept Internal Med & Clin Nutr, Gothenburg, Sweden; [Singhania, Akul; Lau, Laurie C. K.; Wilson, Susan J.; Ward, Jonathan A.; Hinks, Timothy S. C.; Howarth, Peter H.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England; [Djukanovic, Ratko; Hinks, Timothy S. C.; Howarth, Peter H.] Southampton Univ Hosp, NIHR Southampton Resp Biomed Res Unit, Southampton, Hants, England; [Wilson, Susan J.; Ward, Jonathan A.] Univ Southampton, Fac Med, Histochem Res Unit, Southampton, Hants, England; [Chauhan, Anoop] Portsmouth Hosp NHS Trust, Portsmouth, Hants, England; [Sousa, Ana R.] GlaxoSmithKline, Discovery Med, Brentford, England; [De Meulder, Bertrand] Univ Lyon, CNRS ENS UCBL INSERM, CIRI UMR5308, European Inst Syst Biol & Med, Lyon, France; [Loza, Matthew J.; Baribaud, Frederic] Johnson & Johnson, Janssen R&D, Spring House, PA USA; [Sterk, Peter J.] Acad Med Ctr, Dept Resp Med, Amsterdam, Netherlands; [Chung, Kian Fan; Adcock, Ian M.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Chung, Kian Fan; Adcock, Ian M.] Royal Brompton & Harefield NHS Fdn Trust, Royal Brompton Biomed Res Unit, London, England; [Chung, Kian Fan; Adcock, Ian M.] Imperial Coll London, London, England; [Sun, Kai; Guo, Yike] Imperial Coll London, Dept Comp & Data Sci Inst, London, England; [Payne, Debbie] Univ Manchester, Ctr Integrated Genom Med Res, Manchester, Lancs, England; [Dahlen, Barbro] Karolinska Univ Hosp, Stockholm, Sweden; [Dahlen, Barbro] Ctr Allergy Res, Stockholm, Sweden; [James, Anna] Karolinska Inst, Inst Environm Med, Expt Asthma & Allergy Res, Stockholm, Sweden; [Chanez, Pascal] Univ Mediterranee, Marseille, France; [Shaw, Dominick E.] Univ Nottingham, Resp Biomed Res Unit, Nottingham, England; [Krug, Norbert; Hohlfeld, Jens M.] Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany; [Krug, Norbert; Hohlfeld, Jens M.] German Ctr Lung Res, Hannover, Germany; [Hohlfeld, Jens M.] Hannover Med Sch, Dept Resp Med, Hannover, Germany; [Sandstrom, Thomas] Umea Univ, Dept Publ Hlth & Clin Med, Med, Umea, Sweden; [Hinks, Timothy S. C.] Univ Oxford, NDM Expt Med, Resp Med Unit, John Radcliffe Hosp, Oxford, England	AstraZeneca; University of Gothenburg; University of Southampton; University of Southampton; University of Southampton; Portsmouth Hospitals NHS Trust; GlaxoSmithKline; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson USA; University of Amsterdam; Academic Medical Center Amsterdam; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Imperial College London; Imperial College London; University of Manchester; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; UDICE-French Research Universities; Aix-Marseille Universite; University of Nottingham; Fraunhofer Gesellschaft; Hannover Medical School; Umea University; University of Oxford	Jevnikar, Z (corresponding author), AstraZeneca, IMED Biotech Unit, Dept Biosci Resp Inflammat & Autoimmun, Gothenburg, Sweden.	Zala.Rojnik@astrazeneca.com	Sterk, P.J./AAK-8175-2020; Musiał, Jacek/U-5930-2018; James, Anna/AAY-9937-2021; Singhania, Akul/I-4633-2019; 郭, 伊可/GYD-3212-2022; Caruso, Massimo/P-4161-2016; Chung, Kian Fan/B-1872-2012	Musiał, Jacek/0000-0002-8994-0036; Singhania, Akul/0000-0002-6941-3618; Caruso, Massimo/0000-0002-4412-2080; Chung, Kian Fan/0000-0001-7101-1426; Vestbo, Jorgen/0000-0001-6355-6362; Schofield, James/0000-0003-4542-6614; Ward, Jon/0000-0002-9278-0002; Pahus, Laurie/0000-0002-5265-2874; Singer, Florian/0000-0003-3471-5664; Fleming, Louise/0000-0002-7268-7433; MONTUSCHI, Paolo/0000-0001-5589-1750; Djukanovic, Ratko/0000-0001-6039-5612; chanez, pascal/0000-0003-4059-0917; Brinkman, Paul/0000-0003-4546-8478; Adcock, Ian/0000-0003-2101-8843; Olsson, Henric/0000-0002-5101-8871; Fowler, Stephen/0000-0002-4524-1663; Howarth, Peter/0000-0003-0619-7927; Murray, Clare/0000-0002-8961-8055; Knox, Alan/0000-0002-5906-4143; Hashimoto, Simone/0000-0001-8995-3817; Ax, Elisabeth/0000-0001-7553-5059	IMED Biotech Unit, AstraZeneca; Swedish Foundation for Strategic Research (SSF); European Union; European Federation of Pharmaceutical Industries and Associations [115010]; Medical Research Council [G0800649]; Wellcome Trust Clinical Research Fellowship [088365/z/09/z, 104553/z/14/z]; Academy of Medical Sciences; NIHR Southampton Respiratory Biomedical Research Unit; National Institute for Health Research through the Primary Care Research Network; National Institute for Health Research through Academic Clinical Fellowship; Faculty of Medicine, University of Southampton; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; Wellcome Trust [076472/2/05/Z]; MRC [G0800649] Funding Source: UKRI	IMED Biotech Unit, AstraZeneca(AstraZeneca); Swedish Foundation for Strategic Research (SSF)(Swedish Foundation for Strategic Research); European Union(European Commission); European Federation of Pharmaceutical Industries and Associations; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust Clinical Research Fellowship(Wellcome Trust); Academy of Medical Sciences(Academy of Medical Sciences (AMS)); NIHR Southampton Respiratory Biomedical Research Unit; National Institute for Health Research through the Primary Care Research Network; National Institute for Health Research through Academic Clinical Fellowship; Faculty of Medicine, University of Southampton; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the IMED Biotech Unit, AstraZeneca. E.A. was supported by the Swedish Foundation for Strategic Research (SSF). The Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes (U-BIOPRED) Consortium receives funding from the European Union and from the European Federation of Pharmaceutical Industries and Associations as an IMI JU funded project (no. 115010). The Wessex Severe Asthma Cohort was funded by the Medical Research Council (G0800649). T.S.C.H. was supported by Wellcome Trust Clinical Research Fellowship (088365/z/09/z and 104553/z/14/z) and by the Academy of Medical Sciences. Infrastructure support was funded by the NIHR Southampton Respiratory Biomedical Research Unit. We acknowledge the support of the National Institute for Health Research through the Primary Care Research Network and through an Academic Clinical Fellowship (to T.S.C.H.). A.S. was supported by the Faculty of Medicine, University of Southampton. I.M.A. and K.F.C. are supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. I.M.A. is also supported by theWellcome Trust (076472/2/05/Z).	Alvarez JV, 2004, CANCER BIOL THER, V3, P1045, DOI 10.4161/cbt.3.11.1172; Arnold P, 2017, SCI REP-UK, V7, DOI 10.1038/srep44053; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Chu DK, 2015, ALLERGY ASTHMA CL IM, V11, DOI 10.1186/s13223-015-0081-1; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Clarke TB, 2011, CELL HOST MICROBE, V9, P404, DOI 10.1016/j.chom.2011.04.012; Corr SC, 2014, MUCOSAL IMMUNOL, V7, P57, DOI 10.1038/mi.2013.24; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI [10.1139/Y08-004, 10.1139/y08-004]; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Fahy JV, 2016, ANN AM THORAC SOC, V13, pS78, DOI 10.1513/AnnalsATS.201508-515MG; Farahi N, 2017, HUM MOL GENET, V26, P1584, DOI 10.1093/hmg/ddx053; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Garbers C, 2011, J BIOL CHEM, V286, P14804, DOI 10.1074/jbc.M111.229393; Ghebre MA, 2015, J ALLERGY CLIN IMMUN, V135, P63, DOI 10.1016/j.jaci.2014.06.035; Hackett TL, 2013, AM J RESP CELL MOL, V49, P662, DOI 10.1165/rcmb.2013-0124OC; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hinks TSC, 2016, J ALLERGY CLIN IMMUN, V138, P61, DOI 10.1016/j.jaci.2015.11.020; Hinks TSC, 2015, J ALLERGY CLIN IMMUN, V136, P323, DOI 10.1016/j.jaci.2015.01.014; Holub MC, 1999, IMMUNOL LETT, V68, P121; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Johnston LK, 2016, J IMMUNOL, V197, P3445, DOI 10.4049/jimmunol.1600611; Konradsen JR, 2013, J ALLERGY CLIN IMMUN, V132, P328, DOI 10.1016/j.jaci.2013.03.003; Kuhn C, 2000, AM J RESP CELL MOL, V22, P289, DOI 10.1165/ajrcmb.22.3.3690; Kuo CHS, 2017, AM J RESP CRIT CARE, V195, P443, DOI 10.1164/rccm.201512-2452OC; Lefaudeux D, 2017, J ALLERGY CLIN IMMUN, V139, P1797, DOI 10.1016/j.jaci.2016.08.048; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298, DOI 10.1164/ajrccm.159.4.9708080; McLoughlin RM, 2005, P NATL ACAD SCI USA, V102, P9589, DOI 10.1073/pnas.0501794102; Mukherjee S, 2016, BRAZ J INFECT DIS, V20, P193, DOI 10.1016/j.bjid.2015.10.011; Neveu WA, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-28; Ostridge K, 2016, THORAX, V71, P126, DOI 10.1136/thoraxjnl-2015-207428; Patel IS, 2002, THORAX, V57, P759, DOI 10.1136/thorax.57.9.759; Peters MC, 2016, LANCET RESP MED, V4, P574, DOI 10.1016/S2213-2600(16)30048-0; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Radsak MP, 2004, J IMMUNOL, V172, P4956, DOI 10.4049/jimmunol.172.8.4956; Rincon M, 2012, TRENDS IMMUNOL, V33, P571, DOI 10.1016/j.it.2012.07.003; Rose-John S, 2007, EXPERT OPIN THER TAR, V11, P613, DOI 10.1517/14728222.11.5.613; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Scheller J, 2014, SEMIN IMMUNOL, V26, P2, DOI 10.1016/j.smim.2013.11.002; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Simoes DCM, 2009, AM J RESP CRIT CARE, V179, P894, DOI 10.1164/rccm.200807-1081OC; Singhania A, 2018, AM J RESP CELL MOL, V58, P261, DOI 10.1165/rcmb.2017-0162OC; Singhania A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168680; Suzuki Ryujiro, 2004, Treat Respir Med, V3, P17, DOI 10.2165/00151829-200403010-00003; Sweerus K, 2017, J ALLERGY CLIN IMMUN, V139, P72, DOI 10.1016/j.jaci.2016.02.035; Thorley AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021827; Tsuzuki H, 2017, IMMUNOLOGY, V150, P64, DOI 10.1111/imm.12667; Turan N, 2018, CLIN EXP ALLERGY, V48, P475, DOI 10.1111/cea.13085; Ullah MA, 2015, J ALLERGY CLIN IMMUN, V136, P1065, DOI 10.1016/j.jaci.2015.02.032; Virchow JC, 1996, J ALLERGY CLIN IMMUN, V98, pS27; Walev I, 1996, P NATL ACAD SCI USA, V93, P7882, DOI 10.1073/pnas.93.15.7882; Wilson SJ, 2016, EUR RESPIR J, V48, P1307, DOI 10.1183/13993003.01129-2016; Woessner R, 2013, CANCER RES, V73, P931, DOI DOI 10.1016/J.BMCL.2011.03.009; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Yan I, 2016, J LEUKOCYTE BIOL, V99, P749, DOI 10.1189/jlb.3A0515-207R; YOKOYAMA A, 1995, AM J RESP CRIT CARE, V151, P1354, DOI 10.1164/ajrccm.151.5.7735584; Yokoyama A, 1997, AM J RESP CRIT CARE, V156, P1688, DOI 10.1164/ajrccm.156.5.9610070; Zhang JG, 2016, EXP THER MED, V12, P2753, DOI 10.3892/etm.2016.3662	61	105	108	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					577	590		10.1016/j.jaci.2018.05.026	http://dx.doi.org/10.1016/j.jaci.2018.05.026			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29902480	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000457718700018
J	Bachert, C; Zhang, N; Hellings, PW; Bousquet, J				Bachert, Claus; Zhang, Nan; Hellings, Peter W.; Bousquet, Jean			Endotype-driven care pathways in patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Chronic rhinosinusitis; nasal polyps; pharmacotherapy; surgery; biologics; endotypes; type 2 inflammation; integrated care pathways	ENDOSCOPIC SINUS SURGERY; NASAL POLYPS; STAPHYLOCOCCUS-AUREUS; RANDOMIZED-TRIAL; SEVERE ASTHMA; OMALIZUMAB; INFLAMMATION; CELLS; IGE; EXPRESSION	Chronic rhinosinusitis (CRS) has been differentiated clinically into CRS without nasal polyps and CRS with nasal polyps, with both forms subjected to glucocorticosteroid and antibiotic treatments and, if not successful, to nasal and sinus surgery tailored to endoscopic and computed tomographic scan findings. The elaboration of endotypes based on pathomechanisms involving different immune responses offers new possibilities in terms of prediction of prognosis and risks and sophisticated guidance in personalized pharmacotherapy, surgical approaches, and innovative treatment approaches in the CRS field with various biologics. Surgical approaches can vary from classical functional endoscopic sinus surgery to extended and "reboot'' approaches, with the idea to completely remove the dysfunctional and inflamed mucosa and replace it with a newly grown healthy mucosa. Biologics in this field are targeting the type 2 cytokines IL-4, IL-5, and IL-13, as well as IgE. Phase I and II study results are promising, and phase III studies are currently being performed. The development of endotype-driven integrated care pathways appreciating these innovations are now needed for the management of CRS.	[Bachert, Claus; Zhang, Nan] Univ Ghent, Upper Airways Res Lab, C Heymanslaan 10, B-9000 Ghent, Belgium; [Bachert, Claus; Zhang, Nan] Ghent Univ Hosp, Dept Otorhinolaryngol, C Heymanslaan 10, B-9000 Ghent, Belgium; [Bachert, Claus] Univ Stockholm, Karolinska Inst, Div ENT Dis, CLINTEC, Stockholm, Sweden; [Hellings, Peter W.] Leuven Univ Hosp, Dept Otorhinolaryngol, Leuven, Belgium; [Bousquet, Jean] CHU Montpellier, Montpellier, France	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Karolinska Institutet; Stockholm University; KU Leuven; University Hospital Leuven; Universite de Montpellier; CHU de Montpellier	Bachert, C (corresponding author), Univ Ghent, Upper Airways Res Lab, C Heymanslaan 10, B-9000 Ghent, Belgium.; Bachert, C (corresponding author), Ghent Univ Hosp, Dept Otorhinolaryngol, C Heymanslaan 10, B-9000 Ghent, Belgium.	Claus.Bachert@ugent.be	Bousquet, Jean/O-4221-2019; Zhang, Nan/AAQ-3944-2020; Bachert, Claus/J-8825-2012	Bousquet, Jean/0000-0002-4061-4766				Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Bachert C, 2017, J PROTEOMICS; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2017, J ALLERGY CLIN IMMUN, V140, P1024, DOI 10.1016/j.jaci.2017.05.044; Bachert C, 2016, J ALLER CL IMM-PRACT, V4, P621, DOI 10.1016/j.jaip.2016.05.004; Bachert C, 2016, J ALLER CL IMM-PRACT, V4, P629, DOI 10.1016/j.jaip.2015.12.008; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Bachert C, 2012, PEDIAT ALLERG IMM-UK, V23, P2, DOI 10.1111/j.1399-3038.2012.01318.x; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Benninger MS, 2015, OTOLARYNG HEAD NECK, V152, P546, DOI 10.1177/0194599814565606; Bousquet J, 2007, RESP MED, V101, P1483, DOI 10.1016/j.rmed.2007.01.011; Bousquet J, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0137-4; Bousquet J, 2014, EUR RESPIR J, V44, P304, DOI 10.1183/09031936.00014614; Bousquet J, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01782-2017; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Chalermwatanachai T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136068; De Schryver E, 2017, RHINOLOGY, V55, P152, DOI 10.4193/Rhino16.314; DeConde AS, 2017, LARYNGOSCOPE, V127, P550, DOI 10.1002/lary.26391; Dennis SK, 2016, LARYNSCOPE INVESTIG, V1, P130, DOI 10.1002/lio2.32; Domingo C, 2011, INTERN MED J, V41, P525, DOI 10.1111/j.1445-5994.2011.02481.x; Esquivel A, 2017, AM J RESP CRIT CARE, V196, P985, DOI 10.1164/rccm.201701-0120OC; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fokkens WJ, 2017, RHINOLOGY, V55, P298, DOI [10.4193/Rhin17.221, 10.4193/Rhino17.221]; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Gurrola J, 2017, J ALLERGY CLIN IMMUN, V140, P1499, DOI 10.1016/j.jaci.2017.10.006; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; Hastan D, 2011, ALLERGY, V66, P1216, DOI 10.1111/j.1398-9995.2011.02646.x; Hellings PW, 2017, ALLERGY, V72, P1297, DOI 10.1111/all.13162; Hopkins C, 2015, RHINOLOGY, V53, P18, DOI [10.4193/Rhin14.077, 10.4193/Rhino14.077]; Hopkins C, 2009, LARYNGOSCOPE, V119, P2459, DOI 10.1002/lary.20653; Hosemann W., 1993, Acta Oto-Rhino-Laryngologica Belgica, V47, P73; Huang ZX, 2017, AM J RHINOL ALLERGY, V31, pE8, DOI 10.2500/ajra.2017.31.4405; Jankowski R, 2006, Rev Laryngol Otol Rhinol (Bord), V127, P131; Jonstam K, 2017, J ALLERGY CLIN IMMUN, V140, P1705, DOI 10.1016/j.jaci.2017.07.031; Kantor DB, 2016, AM J RESP CRIT CARE, V194, P1552; Kew KM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002997.pub4; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Maxfield AZ, 2018, OTOLARYNG HEAD NECK, V158, P181, DOI 10.1177/0194599817737967; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Morrissey DK, 2016, INT FORUM ALLERGY RH, V6, P820, DOI 10.1002/alr.21739; Mortuaire G, 2017, EUR ANN OTORHINOLARY; Parulekar AD, 2016, CURR OPIN PULM MED, V22, P59, DOI 10.1097/MCP.0000000000000231; Pepper AN, 2017, J ALLER CL IMM-PRACT, V5, P909, DOI 10.1016/j.jaip.2017.04.038; Pettipher R, 2014, ALLERGY, V69, P1223, DOI 10.1111/all.12451; Rosenfeld RM, 2015, OTOLARYNG HEAD NECK, V152, pS1, DOI 10.1177/0194599815572097; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Schmidt F, 2017, J PROTEOMICS, V155, P31, DOI 10.1016/j.jprot.2017.01.008; STAMMBERGER H, 1990, EUR ARCH OTO-RHINO-L, V247, P63; Steelant B, 2018, J ALLERGY CLIN IMMUN, V141, P951, DOI 10.1016/j.jaci.2017.08.039; Stentzel S, 2017, J ALLERGY CLIN IMMUN, V139, P492, DOI 10.1016/j.jaci.2016.03.045; Takabayashi T, 2013, AM J RESP CRIT CARE, V187, P49, DOI 10.1164/rccm.201207-1292OC; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Teufelberger AR, 2018, J ALLERGY CLIN IMMUN, V141, P549, DOI 10.1016/j.jaci.2017.05.004; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; van der Veen J, 2017, ALLERGY, V72, P282, DOI 10.1111/all.12983; Van Roey GA, 2017, J ALLERGY CLIN IMMUN, V140, P89, DOI 10.1016/j.jaci.2016.11.015; Van Zele T, 2014, AM J RHINOL ALLERGY, V28, P192, DOI 10.2500/ajra.2014.28.4033; Van Zele T, 2010, J ALLERGY CLIN IMMUN, V125, P1069, DOI 10.1016/j.jaci.2010.02.020; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Wechsler ME, 2012, J ALLERGY CLIN IMMUN, V130, P563, DOI 10.1016/j.jaci.2012.07.027; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Wynn R, 2004, LARYNGOSCOPE, V114, P811, DOI 10.1097/00005537-200405000-00004; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zhang Y, 2015, ALLERGY ASTHMA IMMUN, V7, P367, DOI 10.4168/aair.2015.7.4.367; Zhang Y, 2017, J ALLERGY CLIN IMMUN, V140, P1230, DOI 10.1016/j.jaci.2017.09.009	67	105	113	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1543	1551		10.1016/j.jaci.2018.03.004	http://dx.doi.org/10.1016/j.jaci.2018.03.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29731100				2022-12-18	WOS:000432148200001
J	Anto, JM; Bousquet, J; Akdis, M; Auffray, C; Keil, T; Momas, I; Postma, DS; Valenta, R; Wickman, M; Cambon-Thomsen, A; Haahtela, T; Lambrecht, BN; Carlsen, KCL; Koppelman, GH; Sunyer, J; Zuberbier, T; Annesi-Maesano, I; Arno, A; Bindslev-Jensen, C; De Carlo, G; Forastiere, F; Heinrich, J; Kowalski, ML; Maier, D; Melen, E; Smit, HA; Standl, M; Wright, J; Asarnoj, A; Benet, M; Ballardini, N; Garcia-Aymerich, J; Gehring, U; Guerra, S; Hohmann, C; Kull, I; Lupinek, C; Pinart, M; Skrindo, I; Westman, M; Smagghe, D; Akdis, C; Andersson, N; Bachert, C; Ballereau, S; Ballester, F; Basagana, X; Bedbrook, A; Bergstrom, A; von Berg, A; Brunekreef, B; Burte, E; Carlsen, KH; Chatzi, L; Coquet, JM; Curin, M; Demoly, P; Eller, E; Fantini, MP; von Hertzen, L; Hovland, V; Jacquemin, B; Just, J; Keller, T; Kiss, R; Kogevinas, M; Koletzko, S; Lau, S; Lehmann, I; Lemonnier, N; Makela, M; Mestres, J; Mowinckel, P; Nadif, R; Nawijn, MC; Pellet, J; Pin, I; Porta, D; Ranciere, F; Rial-Sebbag, E; Saeys, Y; Schuijs, MJ; Siroux, V; Tischer, CG; Torrent, M; Varraso, R; Wenzel, K; Xu, CJ				Anto, Josep M.; Bousquet, Jean; Akdis, Mubeccel; Auffray, Charles; Keil, Thomas; Momas, Isabelle; Postma, Dirkje S.; Valenta, Rudolf; Wickman, Magnus; Cambon-Thomsen, Anne; Haahtela, Tari; Lambrecht, Bart N.; Carlsen, Karin C. Lodrup; Koppelman, Gerard H.; Sunyer, Jordi; Zuberbier, Torsten; Annesi-Maesano, Isabelle; Arno, Albert; Bindslev-Jensen, Carsten; De Carlo, Giuseppe; Forastiere, Francesco; Heinrich, Joachim; Kowalski, Marek L.; Maier, Dieter; Melen, Erik; Smit, Henriette A.; Standl, Marie; Wright, John; Asarnoj, Anna; Benet, Marta; Ballardini, Natalia; Garcia-Aymerich, Judith; Gehring, Ulrike; Guerra, Stefano; Hohmann, Cynthia; Kull, Inger; Lupinek, Christian; Pinart, Mariona; Skrindo, Ingebjorg; Westman, Marit; Smagghe, Delphine; Akdis, Cezmi; Andersson, Niklas; Bachert, Claus; Ballereau, Stephane; Ballester, Ferran; Basagana, Xavier; Bedbrook, Anna; Bergstrom, Anna; von Berg, Andrea; Brunekreef, Bert; Burte, Emilie; Carlsen, Kai-Hakon; Chatzi, Leda; Coquet, Jonathan M.; Curin, Mirela; Demoly, Pascal; Eller, Esben; Fantini, Maria Pia; von Hertzen, Leena; Hovland, Vergard; Jacquemin, Benedicte; Just, Jocelyne; Keller, Theresa; Kiss, Renata; Kogevinas, Manolis; Koletzko, Sibylle; Lau, Susanne; Lehmann, Irina; Lemonnier, Nicolas; Maekelae, Mika; Mestres, Jordi; Mowinckel, Peter; Nadif, Rachel; Nawijn, Martijn C.; Pellet, Johan; Pin, Isabelle; Porta, Daniela; Ranciere, Fanny; Rial-Sebbag, Emmanuelle; Saeys, Yvan; Schuijs, Martijn J.; Siroux, Valerie; Tischer, Christina G.; Torrent, Mathies; Varraso, Raphaelle; Wenzel, Kalus; Xu, Cheng-Jian			Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopic dermatitis; allergy; rhinitis	EUROPEAN INNOVATION PARTNERSHIP; REGULATORY B-CELLS; BIRTH COHORT; PRECISION MEDICINE; ATOPIC-DERMATITIS; CHILDHOOD ASTHMA; IMMUNOLOGICAL REACTIVITY; CLINICAL SYMPTOMS; SYSTEMS MEDICINE; CHRONIC DISEASES	Asthma, rhinitis, and eczema are complex diseases with multiple genetic and environmental factors interlinked through IgEassociated and non-IgE-associated mechanisms. Mechanisms of the Development of ALLergy (MeDALL; EU FP7-CP-IP; project no: 261357; 2010-2015) studied the complex links of allergic diseases at the clinical and mechanistic levels by linking epidemiologic, clinical, and mechanistic research, including in vivo and in vitro models. MeDALL integrated 14 European birth cohorts, including 44,010 participants and 160 cohort follow-ups between pregnancy and age 20 years. Thirteen thousand children were prospectively followed after puberty by using a newly standardized MeDALL Core Questionnaire. A microarray developed for allergen molecules with increased IgE sensitivity was obtained for 3,292 children. Estimates of air pollution exposure from previous studies were available for 10,000 children. Omics data included those from historical genome-wide association studies (23,000 children) and DNA methylation (2,173), targeted multiplex biomarker (1,427), and transcriptomic (723) studies. Using classical epidemiology and machine-learning methods in 16,147 children aged 4 years and 11,080 children aged 8 years, MeDALL showed the multimorbidity of eczema, rhinitis, and asthma and estimated that only 38% of multimorbidity was attributable to IgE sensitization. MeDALL has proposed a new vision of multimorbidity independent of IgE sensitization, and has shown that monosensitization and polysensitization represent 2 distinct phenotypes. The translational component of MeDALL is shown by the identification of a novel allergic phenotype characterized by polysensitization and multimorbidity, which is associated with the frequency, persistence, and severity of allergic symptoms. The results of MeDALL will help integrate personalized, predictive, preventative, and participatory approaches in allergic diseases.	[Anto, Josep M.; Sunyer, Jordi; Kowalski, Marek L.; Benet, Marta; Garcia-Aymerich, Judith; Guerra, Stefano; Pinart, Mariona; Basagana, Xavier; Jacquemin, Benedicte; Kogevinas, Manolis; Pin, Isabelle; Torrent, Mathies] Ctr Res Environm Epidemiol CREAL, ISGLoBAL, Barcelona, Spain; [Anto, Josep M.; Sunyer, Jordi; Maier, Dieter; Garcia-Aymerich, Judith; Kogevinas, Manolis; Siroux, Valerie; Wenzel, Kalus] Hosp del Mar, IMIM, Res Inst, Barcelona, Spain; [Anto, Josep M.; Sunyer, Jordi; Melen, Erik; Garcia-Aymerich, Judith; Kogevinas, Manolis; Torrent, Mathies] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain; [Anto, Josep M.; Sunyer, Jordi; Smit, Henriette A.; Garcia-Aymerich, Judith; Brunekreef, Bert; Kogevinas, Manolis] UPF, Barcelona, Spain; [Bousquet, Jean; Wright, John] Univ Hosp, Montpellier, France; [Bousquet, Jean; Wright, John] MACVIA France, MAlad Chron Vieillissement Actif France, Montpellier, France; [Bousquet, Jean; Burte, Emilie; Nadif, Rachel; Varraso, Raphaelle] INSERM, U1168, Ageing & Chron Dis Epidemiol & Publ Hlth Approach, Villejuif, France; [Bousquet, Jean; Burte, Emilie; Nadif, Rachel; Varraso, Raphaelle] Univ Versaille St Quentin En Yvelynes, UVSQ, UMR S 1168, Montigny Le Bretonneux, France; [Akdis, Mubeccel; Akdis, Cezmi] Univ Zurich, SIAF, Swiss Inst Allergy & Asthma Res, Davos, Switzerland; [Auffray, Charles; Ballereau, Stephane; Pellet, Johan] Univ Lyon, UCBL, ENS, CNRS,European Inst Syst Biol & Med, Lyon, France; [Keil, Thomas] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany; [Momas, Isabelle; Ranciere, Fanny] Paris Descartes Univ, Sorbonne Paris Cite, Dept Publ Hlth & Hlth Prod, EA 4064, Paris, France; [Momas, Isabelle; Ranciere, Fanny] Paris Municipal Dept Social Act Childhood & Hlth, Paris, France; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Valenta, Rudolf; Lupinek, Christian; Curin, Mirela; Kiss, Renata] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Wickman, Magnus; Ballardini, Natalia] Soder Sjukhuset, Sachs Children & Youth Hosp, Stockholm, Sweden; [Wickman, Magnus; Ballardini, Natalia] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Cambon-Thomsen, Anne; Rial-Sebbag, Emmanuelle] UMR Inserm U1027, Toulouse, France; [Cambon-Thomsen, Anne; Rial-Sebbag, Emmanuelle] Univ Toulouse III Paul Sabatier, Toulouse, France; [Haahtela, Tari; von Hertzen, Leena; Maekelae, Mika] Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland; [Lambrecht, Bart N.; Coquet, Jonathan M.; Saeys, Yvan; Schuijs, Martijn J.] Univ Ghent, VIB Inflammat Res Ctr, Ghent, Belgium; [Carlsen, Karin C. Lodrup; Skrindo, Ingebjorg] Univ Oslo, Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Carlsen, Karin C. Lodrup; Skrindo, Ingebjorg] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway; [Koppelman, Gerard H.; Nawijn, Martijn C.; Xu, Cheng-Jian] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, NL-9700 AB Groningen, Netherlands; [Zuberbier, Torsten] Charite Univ Med Berlin, Allergy Ctr Charite, Dept Dermatol, Berlin, Germany; [Zuberbier, Torsten] Global Allergy & Asthma European Network, GA2LEN, Berlin, Germany; [Annesi-Maesano, Isabelle] INSERM, EPAR U707, Paris, France; [Annesi-Maesano, Isabelle] EPAR UMR S UPMC, Paris 6, Paris, France; [Arno, Albert] Onmed Networks, Barcelona, Spain; [Bindslev-Jensen, Carsten; Eller, Esben] Odense Univ Hosp, Dept Dermatol, Odense, Denmark; [Bindslev-Jensen, Carsten; Eller, Esben] Odense Univ Hosp, Allergy Ctr, Odense, Denmark; [De Carlo, Giuseppe] EFA European Federat Allergy & Airways Dis Patien, Brussels, Belgium; [Forastiere, Francesco; Porta, Daniela] Reg Hlth Serv Lazio Reg, Dept Epidemiol, Rome, Italy; [Heinrich, Joachim; Standl, Marie; Tischer, Christina G.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany; [Kowalski, Marek L.; Pin, Isabelle] Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland; [Maier, Dieter; Siroux, Valerie; Wenzel, Kalus] Biomax Informat AG, Munich, Germany; [Melen, Erik; Torrent, Mathies] Soder Sjukhuset, Sachs Children & Youth Hosp, Stockholm, Sweden; [Melen, Erik; Torrent, Mathies] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Smit, Henriette A.; Brunekreef, Bert] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Wright, John] Bradford Royal Infirm, Bradford Inst Hlth Res, Stockholm, Sweden; [Asarnoj, Anna] Karolinska Inst, Dept Med Solna, Clin Immunol & Allergy Unit, Stockholm, Sweden; [Asarnoj, Anna] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Dept Pediat Pulmonol & Allergy, Stockholm, Sweden; [Ballardini, Natalia] Kings Coll London, St Johns Inst Dermatol, London, England; [Gehring, Ulrike; Brunekreef, Bert] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Hohmann, Cynthia; Keller, Theresa] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Kull, Inger] Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden; [Westman, Marit] Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden; [Westman, Marit] Karolinska Univ Hosp, Dept ENT Dis, Stockholm, Sweden; [Smagghe, Delphine] Inserm Transfert, Paris, France; [Andersson, Niklas; Bergstrom, Anna] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Bachert, Claus] Ghent Univ Hosp, ENT Dept, Ghent, Belgium; [Ballester, Ferran] Ctr Publ Hlth Res CSISP, Environm & Hlth Area, Valencia, Spain; [Ballester, Ferran] Univ Valencia, CIBERESP, Dept Nursing, Valencia, Spain; [von Berg, Andrea] Marien Hosp, Res Inst, Dept Pediat, Wesel, Germany; [Carlsen, Kai-Hakon; Hovland, Vergard; Mowinckel, Peter] Oslo Univ Hosp, Dept Paediat, Oslo, Norway; [Carlsen, Kai-Hakon; Hovland, Vergard; Mowinckel, Peter] Univ Oslo, Oslo, Norway; [Chatzi, Leda] Univ Crete, Fac Med, Dept Social Med, Creteil, France; [Demoly, Pascal; Xu, Cheng-Jian] Montpellier Univ Hosp, Dept Resp Dis, Montpellier, France; [Fantini, Maria Pia] Univ Bologna, Alma Mater Studiorum, Dept Med & Publ Hlth, Bologna, Italy; [Just, Jocelyne] Hop Enfants Armand Trousseau, APHP, Ctr Asthme & Allergies, Dept Allergol, Paris, France; [Just, Jocelyne] UPMC Univ Paris, Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, Equipe EPAR, Paris, France; [Koletzko, Sibylle] Ludwig Maximilians Univ Munchen, Div Paediat Gastroenterol & Hepatol, Munich, Germany; [Lau, Susanne] Charite Med Univ Berlin, Dept Pediat Pneumol & Immunol, Berlin, Germany; [Lehmann, Irina] UFZ, Helmholtz Ctr Environm Res, Dept Environm Immunol, Core Facil Studies, Leipzig, Germany; [Lemonnier, Nicolas] Inst Adv Biosci, Inst Albert Bonniot Grenoble, Grenoble, France; [Mestres, Jordi] Chemotargets SL, Barcelona, Spain; [Mestres, Jordi] Hosp del Mar, IMIM, GRIB Unit, Chemogen Lab, Barcelona, Spain; [Pin, Isabelle] CHU Grenoble, Dept Pediat, Grenoble, France; [Siroux, Valerie] INSERM, U823, Grenoble, France; [Torrent, Mathies] Ib Salut, Area Salut Menorca, Menorca, Spain	ISGlobal; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Pompeu Fabra University; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Swiss Institute of Allergy & Asthma Research; University of Zurich; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg; UDICE-French Research Universities; Universite Paris Cite; University of Groningen; Medical University of Vienna; Sodersjukhuset Hospital; Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Helsinki; Helsinki University Central Hospital; Flanders Institute for Biotechnology (VIB); Ghent University; University of Oslo; University of Oslo; University of Groningen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Medical University Lodz; Biomax Informatics; Sodersjukhuset Hospital; Karolinska Institutet; Utrecht University; Utrecht University Medical Center; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of London; King's College London; Utrecht University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Karolinska Institutet; Ghent University; Ghent University Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Valencia; St. Marien Hospital; University of Oslo; University of Oslo; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite de Montpellier; CHU de Montpellier; University of Bologna; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Atencio Primaria de Menorca	Anto, JM (corresponding author), IMIM, ISGlobal Barcelona, Hlth Serv Res Unit, Barcelona, Spain.; Bousquet, J (corresponding author), CHU Montpellier, F-34295 Montpellier 5, France.	jmanto@isglobal.org; jean.bousquet@orange.fr	Anto, J M/H-2676-2014; Koppelman, Gerard/AAG-9187-2020; Asarnoj, Anna/ABC-4112-2020; Demoly, Pascal/Y-9938-2019; Ballereau, Stephane/AAM-4883-2020; Varraso, Raphaelle/R-8740-2016; Emilie, Burte/AAA-5048-2022; Xu, Cheng-Jian/G-9144-2018; Wright, John/H-1624-2012; Bousquet, Jean/O-4221-2019; J, Garcia-Aymerich/G-6867-2014; Andersson, Niklas/AAN-1633-2020; siroux, valerie/N-1865-2013; Coquet, Jonathan M/A-5551-2015; Akdis, Cezmi/AAV-4844-2020; Jacquemin, Benedicte/D-8948-2018; Nadif, Rachel/R-2876-2016; Lemonnier, Nathanael/K-5393-2016; Lupinek, Christian/I-3311-2019; PIN, Isabelle/N-3020-2013; Bindslev-Jensen, Carsten/H-1877-2011; Annesi-Maesano, Isabella/D-9173-2016; Kogevinas, Manolis/C-3918-2017; Saeys, Yvan/C-1311-2009; Lambrecht, Bart N/K-2484-2014; Bachert, Claus/J-8825-2012; Mestres, Jordi/B-3673-2009; Pinart Gilberga, Mariona/GLS-8842-2022; Heinrich, Joachim/N-1720-2013; Basagaña, Xavier/C-3901-2017; Sunyer, Jordi/G-6909-2014; Ranciere, Fanny/F-1502-2018; Forastiere, Francesco/J-9067-2016; Porta, Daniela/J-9042-2016	Anto, J M/0000-0002-4736-8529; Demoly, Pascal/0000-0001-7827-7964; Ballereau, Stephane/0000-0002-8479-3110; Varraso, Raphaelle/0000-0002-3338-7825; Xu, Cheng-Jian/0000-0003-1586-4672; Wright, John/0000-0001-9572-7293; J, Garcia-Aymerich/0000-0002-7097-4586; Andersson, Niklas/0000-0001-9785-7462; siroux, valerie/0000-0001-7329-7237; Coquet, Jonathan M/0000-0002-5967-4857; Akdis, Cezmi/0000-0001-8020-019X; Jacquemin, Benedicte/0000-0003-1273-9892; Nadif, Rachel/0000-0003-4938-9339; Lemonnier, Nathanael/0000-0002-3994-8697; Lupinek, Christian/0000-0002-8612-8245; Bindslev-Jensen, Carsten/0000-0002-8940-038X; Annesi-Maesano, Isabella/0000-0002-6340-9300; Kogevinas, Manolis/0000-0002-9605-0461; Saeys, Yvan/0000-0002-0415-1506; Lambrecht, Bart N/0000-0003-4376-6834; Mestres, Jordi/0000-0002-5202-4501; Pinart Gilberga, Mariona/0000-0002-8223-1325; Heinrich, Joachim/0000-0002-9620-1629; Basagaña, Xavier/0000-0002-8457-1489; Sunyer, Jordi/0000-0002-2602-4110; Nawijn, Martijn/0000-0003-3372-6521; Valenta, Rudolf/0000-0001-5944-3365; Ranciere, Fanny/0000-0003-3485-2247; Zuberbier, Torsten/0000-0002-1466-8875; Standl, Marie/0000-0002-5345-2049; Lehmann, Irina/0000-0001-8875-5587; Koppelman, Gerard/0000-0001-8567-3252; Gehring, Ulrike/0000-0003-3612-5780; Bousquet, Jean/0000-0002-4061-4766; Curin, Mirela/0000-0003-2575-4127; momas, isabelle/0000-0003-4344-3787; Ballardini, Natalia/0000-0001-6759-346X; Benet Mora, Marta/0000-0001-9600-3510; Forastiere, Francesco/0000-0002-9162-5684; Makela, Mika/0000-0002-2933-3111; Porta, Daniela/0000-0002-3431-2729; Asarnoj, Anna/0000-0002-0797-2369				Aguilera I, 2009, ENVIRON HEALTH PERSP, V117, P1322, DOI 10.1289/ehp.0800256; Agusti A, 2015, AM J RESP CRIT CARE, V191, P391, DOI 10.1164/rccm.201410-1935PP; Algar OG, 2004, INDOOR AIR, V14, P298, DOI 10.1111/j.1600-0668.2004.00256.x; Amat F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131369; Angus DC, 2015, JAMA-J AM MED ASSOC, V314, P767, DOI 10.1001/jama.2015.7762; Anto JM, 2012, J ALLERGY CLIN IMMUN, V129, P943, DOI 10.1016/j.jaci.2012.01.047; Asarnoj A, 2016, J ALLERGY CLIN IMMUN, V137, P813, DOI 10.1016/j.jaci.2015.09.052; Ballardini N, 2016, ALLERGY, V71, P342, DOI 10.1111/all.12798; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; Bloomfield SF, 2016, PERSPECT PUBLIC HEAL, V136, P213, DOI 10.1177/1757913916650225; Bourret Rodolphe, 2015, World Hosp Health Serv, V51, P36; Bousquet J, 2007, ALLERGY, V62, P216, DOI 10.1111/j.1398-9995.2007.01307.x; Bousquet J, 2016, ALLERGY, V71, P1513, DOI 10.1111/all.12880; Bousquet J, 2015, ALLERGY, V70, P1372, DOI 10.1111/all.12686; Bousquet J, 2015, ALLERGY, V70, P1062, DOI 10.1111/all.12637; Bousquet J, 2015, THORAX, V70, P595, DOI 10.1136/thoraxjnl-2014-206304; Bousquet J, 2014, EUR GERIATR MED, V5, P406, DOI 10.1016/j.eurger.2014.0.013; Bousquet J, 2014, EUR GERIATR MED, V5, P361, DOI 10.1016/j.eurger.2014.09.010; Bousquet J, 2014, EUR RESPIR J, V44, P304, DOI 10.1183/09031936.00014614; Bousquet J, 2011, ALLERGY, V66, P596, DOI 10.1111/j.1398-9995.2010.02534.x; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; Bousquet J, 2009, ALLERGY, V64, P969, DOI 10.1111/j.1398-9995.2009.02059.x; BOUSQUET J, 1982, ALLERGY, V37, P397, DOI 10.1111/j.1398-9995.1982.tb02318.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V87, P737, DOI 10.1016/0091-6749(91)90397-7; Bousquet J, 2015, STRATEGIC INTELLIGEN; Bousquet J, 2016, J ALLERGY CLIN IMMUN, V138, P367, DOI 10.1016/j.jaci.2016.03.025; Bousquet J, 2016, EUR RESPIR J, V47, P1028, DOI 10.1183/13993003.01856-2015; Bousquet J, 2014, CURR PHARM DESIGN, V20, P5928, DOI 10.2174/1381612820666140314115505; Bousquet J, 2014, J ALLERGY CLIN IMMUN, V133, P1535, DOI 10.1016/j.jaci.2014.01.018; Bousquet J, 2013, INT ARCH ALLERGY IMM, V161, P1, DOI 10.1159/000343018; Bousquet J, 2011, GENOME MED, V3, DOI 10.1186/gm259; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Burte E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136191; Canonica GW, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0079-7; Carlsen KCL, 2015, INT ARCH ALLERGY IMM, V167, P57, DOI 10.1159/000431359; Carlsen KCL, 2002, PEDIAT ALLERG IMM-UK, V13, P29, DOI 10.1034/j.1399-3038.13.s.15.2.x; Cayer DM, 2016, HUM MOL GENET, V25, pR182, DOI 10.1093/hmg/ddw214; Chanez P, 1996, ALLERGY, V51, P850; Chatzi L, 2009, AM J EPIDEMIOL, V170, P829, DOI 10.1093/aje/kwp211; Clarisse B, 2009, PEDIAT ALLERG IMM-UK, V20, P126, DOI 10.1111/j.1399-3038.2008.00743.x; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Custovic A, 2015, THORAX, V70, P799, DOI 10.1136/thoraxjnl-2015-206781; Dai X, 2016, J ASTHMA; Eeftens M, 2012, ENVIRON SCI TECHNOL, V46, P11195, DOI 10.1021/es301948k; Fuertes E, 2014, INT J HYG ENVIR HEAL, V217, P819, DOI 10.1016/j.ijheh.2014.05.004; Gabet S, 2016, PEDIAT ALLERG IMM-UK, V27, P831, DOI 10.1111/pai.12622; Galli SJ, 2016, J ALLERGY CLIN IMMUN, V137, P1289, DOI 10.1016/j.jaci.2016.03.006; Garcia-Aymerich J, 2015, ALLERGY, V70, P973, DOI 10.1111/all.12640; Gehring U, 2015, LANCET RESP MED, V3, P933, DOI 10.1016/S2213-2600(15)00426-9; Gensollen T, 2016, SCIENCE, V352, P539, DOI 10.1126/science.aad9378; Gruzieva O, 2017, ENVIRON HEALTH PERSP, V125, P104, DOI 10.1289/EHP36; Guerra S, 2015, LANCET RESP MED, V3, P613, DOI 10.1016/S2213-2600(15)00196-4; Haahtela T, 2008, ALLERGY, V63, P634, DOI 10.1111/j.1398-9995.2008.01712.x; Heinrich J, 2002, EUR RESPIR J, V20, P617, DOI 10.1183/09031936.02.02322001; Hernan MA, 2015, AM J EPIDEMIOL, V181, P103, DOI 10.1093/aje/kwu272; Herr M, 2012, J ALLERGY CLIN IMMUN, V130, P389, DOI 10.1016/j.jaci.2012.05.054; Hohmann C, 2014, INT ARCH ALLERGY IMM, V163, P215, DOI 10.1159/000357732; Hood L, 2011, NAT REV CLIN ONCOL, V8, P184, DOI 10.1038/nrclinonc.2010.227; Host A, 2002, PEDIATR ALLERGY IMMU, V13, P23, DOI 10.1034/j.1399-3038.13.s.15.7.x; Hovland V, 2014, PEDIAT ALLERG IMM-UK, V25, P351, DOI 10.1111/pai.12241; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Joubert BR, 2016, AM J HUM GENET, V98, P680, DOI 10.1016/j.ajhg.2016.02.019; Just J, 2016, CLIN EXP ALLERGY, V46, P1596, DOI 10.1111/cea.12791; Just J, 2014, PEDIAT ALLERG IMM-UK, V25, P668, DOI 10.1111/pai.12287; Just J, 2012, EUR RESPIR J, V40, P55, DOI 10.1183/09031936.00123411; Just J, 2012, J ALLERGY CLIN IMMUN, V130, P103, DOI 10.1016/j.jaci.2012.02.041; Kast JI, 2012, J ALLERGY CLIN IMMUN, V130, P544, DOI 10.1016/j.jaci.2012.04.044; Keil T, 2010, ALLERGY, V65, P482, DOI 10.1111/j.1398-9995.2009.02171.x; Khaltaev N, 2007, GLOBAL SURVEILLANCE; Kim Na Yeon, 2015, Korean J Pediatr, V58, P330, DOI 10.3345/kjp.2015.58.9.330; Kubo T, 2015, J ALLERGY CLIN IMMUN, V136, P1413, DOI 10.1016/j.jaci.2015.05.006; Kucuksezer UC, 2013, J ALLERGY CLIN IMMUN, V131, P875, DOI 10.1016/j.jaci.2012.10.051; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Maier D, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-38; Marcum JA, 2016, J EVAL CLIN PRACT; Marenholz I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9804; Martinez FD, 2007, EUR RESPIR J, V29, P179, DOI 10.1183/09031936.00087906; McBride D, 2012, PEDIAT ALLERG IMM-UK, V23, P230, DOI 10.1111/j.1399-3038.2011.01254.x; Molter A, 2015, EUR RESPIR J, V45, P610, DOI 10.1183/09031936.00083614; Muraro A, 2016, ALLERGY, V71, P583, DOI 10.1111/all.12819; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Nickel R, 2005, CLIN EXP ALLERGY, V35, P619, DOI 10.1111/j.1365-2222.2005.02237.x; Nickel Renate, 2002, Paediatr Respir Rev, V3, P169, DOI 10.1016/S1526-0542(02)00190-2; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Pedersen M, 2013, LANCET RESP MED, V1, P695, DOI 10.1016/S2213-2600(13)70192-9; PENE J, 1994, IMMUNOLOGY, V81, P58; Pinart M, 2015, INT ARCH ALLERGY IMM, V168, P110, DOI 10.1159/000442414; Pinart M, 2014, LANCET RESP MED, V2, P131, DOI 10.1016/S2213-2600(13)70277-7; Pongracic JA, 2016, J ALLERGY CLIN IMMUN, V138, P1030, DOI 10.1016/j.jaci.2016.06.059; Porta D, 2007, EPIDEMIOL PREV, V31, P303; Price DB, 2015, LANCET RESP MED, V3, P849, DOI 10.1016/S2213-2600(15)00367-7; Prosperi MCF, 2014, PEDIAT ALLERG IMM-UK, V25, P71, DOI 10.1111/pai.12139; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; Raynor P, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-327; REID MJ, 1988, NEW ENGL REG ALLERGY, V9, P225; Rudin A, 2001, ALLERGY, V56, P1042, DOI 10.1034/j.1398-9995.2001.00991.x; Ruokolainen L, 2016, CURR OPIN ALLERGY CL, V16, P421, DOI 10.1097/ACI.0000000000000304; Samolinski B, 2012, ALLERGY, V67, P726, DOI 10.1111/j.1398-9995.2012.02822.x; Samolinski B, 2012, LANCET, V379, pE45, DOI 10.1016/S0140-6736(12)60514-5; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Simpson A, 2015, J ALLERGY CLIN IMMUN, V136, P1224, DOI 10.1016/j.jaci.2015.03.027; Siroux V, 2016, J ALLERGY CLIN IMMUN; Skrindo I, 2015, PEDIAT ALLERG IMM-UK, V26, P239, DOI 10.1111/pai.12366; Slama R, 2009, ENVIRON HEALTH PERSP, V117, P1313, DOI 10.1289/ehp.0800465; Smit HA, 2015, LANCET RESP MED, V3, P973, DOI 10.1016/S2213-2600(15)00428-2; Soyka MB, 2012, IMMUNOTHERAPY-UK, V4, P389, DOI [10.2217/IMT.12.10, 10.2217/imt.12.10]; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Sucharew H, 2010, PEDIAT ALLERG IMM-UK, V21, P253, DOI 10.1111/j.1399-3038.2009.00952.x; Svanes C, 2010, THORAX, V65, P14, DOI 10.1136/thx.2008.112136; Taal HR, 2012, NAT GENET, V44, P532, DOI 10.1038/ng.2238; Tillander H, 2014, J ALLERGY CLIN IMMUN, V133, P580, DOI 10.1016/j.jaci.2013.09.009; Van Cauwenberge P, 2005, ALLERGY, V60, P858, DOI 10.1111/j.1398-9995.2005.00822.x; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; van Dijk EL, 2014, TRENDS GENET, V30, P418, DOI 10.1016/j.tig.2014.07.001; Venter C, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0111-1; von Berg A, 2010, CLIN EXP ALLERGY, V40, P627, DOI 10.1111/j.1365-2222.2009.03444.x; von Mutius E, 2016, J ALLERGY CLIN IMMUN, V137, P680, DOI 10.1016/j.jaci.2015.12.1301; Vrijheid M, 2012, ENVIRON HEALTH PERSP, V120, P29, DOI 10.1289/ehp.1103823; Wegrzyn AS, 2015, J ALLERGY CLIN IMMUN, V136, P194, DOI 10.1016/j.jaci.2014.12.1866; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Wesemann DR, 2016, IMMUNITY, V44, P728, DOI 10.1016/j.immuni.2016.02.002; Westman M, 2015, J ALLERGY CLIN IMMUN, V135, P1199, DOI 10.1016/j.jaci.2014.10.042; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wijga A, 2001, CLIN EXP ALLERGY, V31, P576, DOI 10.1046/j.1365-2222.2001.01072.x; Wright J, 2013, INT J EPIDEMIOL, V42, P978, DOI 10.1093/ije/dys112; Zoratti EM, 2016, J ALLERGY CLIN IMMUN, V138, P1016, DOI 10.1016/j.jaci.2016.06.061	135	105	113	3	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					388	399		10.1016/j.jaci.2016.12.940	http://dx.doi.org/10.1016/j.jaci.2016.12.940			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	28183433	Green Published, Bronze			2022-12-18	WOS:000397002400002
J	Sala-Cunill, A; Bjorkqvist, J; Senter, R; Guilarte, M; Cardona, V; Labrador, M; Nickel, KF; Butler, L; Luengo, O; Kumar, P; Labberton, L; Long, A; Di Gennaro, A; Kenne, E; Jamsa, A; Krieger, T; Schluter, H; Fuchs, T; Flohr, S; Hassiepen, U; Cumin, F; McCrae, K; Maas, C; Stavrou, E; Renne, T				Sala-Cunill, Anna; Bjoerkqvist, Jenny; Senter, Riccardo; Guilarte, Mar; Cardona, Victoria; Labrador, Moises; Nickel, Katrin F.; Butler, Lynn; Luengo, Olga; Kumar, Parvin; Labberton, Linda; Long, Andy; Di Gennaro, Antonio; Kenne, Ellinor; Jaemsae, Anne; Krieger, Thorsten; Schlueter, Hartmut; Fuchs, Tobias; Flohr, Stefanie; Hassiepen, Ulrich; Cumin, Frederic; McCrae, Keith; Maas, Coen; Stavrou, Evi; Renne, Thomas			Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; mast cell; bradykinin; mouse models; tryptase; contact system	ADVERSE CLINICAL EVENTS; COAGULATION-FACTOR-XII; IN-VIVO; BRADYKININ FORMATION; PLATELET POLYPHOSPHATES; HEREDITARY ANGIOEDEMA; VASCULAR-PERMEABILITY; CHONDROITIN SULFATE; CONVERTING-ENZYME; STING ANAPHYLAXIS	Background: Anaphylaxis is an acute, potentially lethal, multisystem syndrome resulting from the sudden release of mast cell-derived mediators into the circulation. Objectives and Methods: We report here that a plasma protease cascade, the factor XII-driven contact system, critically contributes to the pathogenesis of anaphylaxis in both murine models and human subjects. Results: Deficiency in or pharmacologic inhibition of factor XII, plasma kallikrein, high-molecular-weight kininogen, or the bradykinin B2 receptor, but not the B1 receptor, largely attenuated allergen/IgE-mediated mast cell hyperresponsiveness in mice. Reconstitutions of factor XII null mice with human factor XII restored susceptibility for allergen/IgE-mediated hypotension. Activated mast cells systemically released heparin, which provided a negatively charged surface for factor XII autoactivation. Activated factor XII generates plasma kallikrein, which proteolyzes kininogen, leading to the liberation of bradykinin. We evaluated the contact system in patients with anaphylaxis. In all 10 plasma samples immunoblotting revealed activation of factor XII, plasma kallikrein, and kininogen during the acute phase of anaphylaxis but not at basal conditions or in healthy control subjects. The severity of anaphylaxis was associated with mast cell degranulation, increased plasma heparin levels, the intensity of contact system activation, and bradykinin formation. Conclusions: In summary, the data collectively show a role of the contact system in patients with anaphylaxis and support the hypothesis that targeting bradykinin generation and signaling provides a novel and alternative treatment strategy for anaphylactic attacks.	[Sala-Cunill, Anna; Guilarte, Mar; Cardona, Victoria; Labrador, Moises; Luengo, Olga] Hosp Univ Vall dHebron, Dept Internal Med, Allergy Sect, Barcelona, Spain; [Sala-Cunill, Anna; Guilarte, Mar; Cardona, Victoria; Labrador, Moises; Luengo, Olga] Univ Autonoma Barcelona, Inst Recerca Vall dHebron, Allergy Res Unit, E-08193 Barcelona, Spain; [Sala-Cunill, Anna; Bjoerkqvist, Jenny; Senter, Riccardo; Nickel, Katrin F.; Butler, Lynn; Kumar, Parvin; Labberton, Linda; Di Gennaro, Antonio; Kenne, Ellinor; Jaemsae, Anne; Fuchs, Tobias; Renne, Thomas] Karolinska Inst, Dept Mol Med & Surg, Clin Chem, SE-17176 Stockholm, Sweden; [Sala-Cunill, Anna; Bjoerkqvist, Jenny; Senter, Riccardo; Nickel, Katrin F.; Butler, Lynn; Kumar, Parvin; Labberton, Linda; Di Gennaro, Antonio; Kenne, Ellinor; Jaemsae, Anne; Fuchs, Tobias; Renne, Thomas] Univ Hosp, Stockholm, Sweden; [Bjoerkqvist, Jenny; Nickel, Katrin F.; Butler, Lynn; Kumar, Parvin; Labberton, Linda; Di Gennaro, Antonio; Kenne, Ellinor; Jaemsae, Anne; Fuchs, Tobias; Renne, Thomas] Karolinska Inst, Ctr Mol Med, SE-17176 Stockholm, Sweden; [Senter, Riccardo] Univ Padua, Dept Med, Padua, Italy; [Nickel, Katrin F.; Butler, Lynn; Long, Andy; Krieger, Thorsten; Schlueter, Hartmut; Fuchs, Tobias; Renne, Thomas] Univ Med Ctr Hamburg Eppendorf, Inst Clin Chem & Lab Med, Hamburg, Germany; [Flohr, Stefanie; Hassiepen, Ulrich; Cumin, Frederic] Novartis Inst Biomed Res, Basel, Switzerland; [McCrae, Keith] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH USA; [McCrae, Keith] Cleveland Clin, Dept Cellular & Mol Med, Cleveland, OH USA; [Maas, Coen] Univ Med Ctr Utrecht, Dept Clin Chem & Haematol, Utrecht, Netherlands; [Stavrou, Evi] Case Western Reserve Univ, Dept Med, Div Hematol & Oncol, Cleveland, OH 44106 USA; [Stavrou, Evi] Univ Hosp Case Med Ctr, Cleveland, OH USA	Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Karolinska Institutet; Karolinska Institutet; University of Padua; University of Hamburg; University Medical Center Hamburg-Eppendorf; Novartis; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Utrecht University; Utrecht University Medical Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital	Renne, T (corresponding author), Karolinska Inst, Dept Mol Med & Surg, Clin Chem, SE-17176 Stockholm, Sweden.	thomas@renne.net	Labrador Horrillo, Moisés/O-6434-2016; Cardona, Victoria/GRX-4196-2022; Stavrou, Evi X./AAV-4204-2020; Kenne, Ellinor/HCH-1218-2022; Luengo, Olga/N-4108-2015	Labrador Horrillo, Moisés/0000-0003-3222-2380; Stavrou, Evi X./0000-0002-6075-7609; Luengo, Olga/0000-0002-8905-2776; Kumar, Parvin/0000-0003-2324-4465; Kenne, Ellinor/0000-0002-2784-5244; Cardona, Victoria/0000-0003-2197-9767; Maas, Coen/0000-0003-4593-0976; Renne, Thomas/0000-0003-4594-5975; Bjorkqvist, Jenny/0000-0003-1256-1908; Guilarte, Mar/0000-0001-7242-9584; Sala Cunill, Anna/0000-0002-2178-1067	Spanish Ministerio de Ciencia e Innovacion; Instituto de Salud Carlos III; Fondo de Investigacion Sanitaria [CM09/00212, PI10/01871]; Spanish Society of Allergy and Clinical Immunology (SEAIC); Vetenskapsradet [K2013-65X-21462-04-5]; Hjart-Lungfonden [20110500]; German Research Society [SFB841, TP B8 SFB877, TP A11]; Stockholms lans landsting [2110471]; Cancerfonden [100615]; European Research Council [ERC-StG-2012-311575_F-12]	Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); Spanish Society of Allergy and Clinical Immunology (SEAIC); Vetenskapsradet(Swedish Research Council); Hjart-Lungfonden; German Research Society(German Research Foundation (DFG)); Stockholms lans landsting; Cancerfonden(Swedish Cancer Society); European Research Council(European Research Council (ERC)European Commission)	Supported in part by grants from the Spanish Ministerio de Ciencia e Innovacion, Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria: CM09/00212 to A.S.-C. and PI10/01871 to M.L. and the Spanish Society of Allergy and Clinical Immunology (SEAIC). Also supported by Vetenskapsradet (K2013-65X-21462-04-5), Hjart-Lungfonden (20110500), the German Research Society (SFB841, TP B8 & SFB877, TP A11), Stockholms lans landsting (2110471), Cancerfonden (100615), and a European Research Council grant (ERC-StG-2012-311575_F-12) to T.R.	Auer J, 1911, J EXP MED, V14, P476, DOI 10.1084/jem.14.5.476; Bengtsson U, 1996, CLIN EXP ALLERGY, V26, P1387, DOI 10.1111/j.1365-2222.1996.tb00540.x; Bjorkqvist J, 2013, THROMB HAEMOSTASIS, V110, P399, DOI 10.1160/TH13-03-0258; Bjorkqvist J, 2013, THROMB HAEMOSTASIS, V109, P368, DOI 10.1160/TH12-08-0549; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Brunnee T, 1997, CLIN EXP ALLERGY, V27, P653; Bulger HA, 1918, J INFECT DIS, V23, P522; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; Cugno M, 1997, BLOOD, V89, P3213, DOI 10.1182/blood.V89.9.3213; Cui J, 2005, J HYPERTENS, V23, P55, DOI 10.1097/00004872-200501000-00013; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Guerrini M, 2008, NAT BIOTECHNOL, V26, P669, DOI 10.1038/nbt1407; GUNNAR RM, 1983, J AM COLL CARDIOL, V1, P154, DOI 10.1016/S0735-1097(83)80019-9; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Herwald H, 1998, NAT MED, V4, P298, DOI 10.1038/nm0398-298; HOJIMA Y, 1984, BLOOD, V63, P1453; Huang TJ, 1999, AM J RESP CRIT CARE, V160, P1717, DOI 10.1164/ajrccm.160.5.9901029; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Iwaki T, 2006, THROMB HAEMOSTASIS, V95, P1003, DOI 10.1160/TH06-03-0128; Joseph K, 2002, P NATL ACAD SCI USA, V99, P896, DOI 10.1073/pnas.022626899; Kahn R, 2002, LANCET, V360, P535, DOI 10.1016/S0140-6736(02)09743-X; Kaplan AP, 2010, CHEM IMMUNOL ALLERGY, V95, P67, DOI 10.1159/000315938; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; Kemp SF, 2002, J ALLERGY CLIN IMMUN, V110, P341, DOI 10.1067/mai.2002.126811; Kenne E, 2014, DRUG DISCOV TODAY; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; Korhonen H, 2009, J EXP MED, V206, P411, DOI 10.1084/jem.20082150; Krieter DH, 1998, KIDNEY INT, V53, P1026, DOI 10.1111/j.1523-1755.1998.00837.x; Larsson M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3006804; Lee JK, 2011, CLIN EXP ALLERGY, V41, P923, DOI 10.1111/j.1365-2222.2011.03779.x; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Lombardini Cristina, 2009, Am J Emerg Med, V27, DOI 10.1016/j.ajem.2009.02.005; Longhurst H, 2012, LANCET, V379, P474, DOI 10.1016/S0140-6736(11)60935-5; Maas C, 2012, THROMB RES, V129, pS73, DOI 10.1016/j.thromres.2012.02.039; Marceau F, 1997, CAN J PHYSIOL PHARM, V75, P725, DOI 10.1139/cjpp-75-6-725; Maurer M, 2011, ALLERGY, V66, P1397, DOI 10.1111/j.1398-9995.2011.02686.x; MAZZI G, 1994, HAEMATOLOGICA, V79, P283; Merkulov S, 2008, BLOOD, V111, P1274, DOI 10.1182/blood-2007-06-092338; Mingomataj EC, 2012, J INVEST ALLERG CLIN, V22, P237; Muller F, 2011, CURR OPIN HEMATOL, V18, P349, DOI 10.1097/MOH.0b013e3283497e61; Muller F, 2009, CELL, V139, P1143, DOI 10.1016/j.cell.2009.11.001; Nickel KF, 2013, BLOOD, V122, P3847, DOI 10.1182/blood-2013-09-525840; Noga O, 1999, INT ARCH ALLERGY IMM, V120, P310, DOI 10.1159/000024284; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Nussberger J, 1999, J ALLERGY CLIN IMMUN, V104, P1321, DOI 10.1016/S0091-6749(99)70030-8; Oschatz C, 2011, IMMUNITY, V34, P258, DOI 10.1016/j.immuni.2011.02.008; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Parashchanka A, 2011, ACTA ANAESTH BELG, V62, P207; PINCKARD RN, 1975, J IMMUNOL, V115, P525; PIXLEY RA, 1987, ARCH BIOCHEM BIOPHYS, V256, P490, DOI 10.1016/0003-9861(87)90606-0; Prado GN, 2002, J CELL PHYSIOL, V193, P275, DOI 10.1002/jcp.10175; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; PROUD D, 1988, BIOCHEM PHARMACOL, V37, P1473, DOI 10.1016/0006-2952(88)90008-1; RATNOFF OD, 1983, BLOOD, V61, P132; Raynolds MV, 1995, EUR HEART J, V16, P23, DOI 10.1093/eurheartj/16.suppl_K.23; Renne T, 2005, J IMMUNOL, V175, P3377, DOI 10.4049/jimmunol.175.5.3377; Renne T, 2005, J EXP MED, V202, P271, DOI 10.1084/jem.20050664; Renne T, 2012, BLOOD, V120, P4296, DOI 10.1182/blood-2012-07-292094; Sala-Cunill A, 2013, INT ARCH ALLERGY IMM, V160, P192, DOI 10.1159/000339749; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SAMUEL M, 1992, J BIOL CHEM, V267, P19691; Schmaier AH, 2008, J CLIN INVEST, V118, P3006, DOI 10.1172/JCI36617; Shariat-Madar Z, 2002, J BIOL CHEM, V277, P17962, DOI 10.1074/jbc.M106101200; SIEBECK M, 1994, J APPL PHYSIOL, V77, P2675, DOI 10.1152/jappl.1994.77.6.2675; Simons FER, 2011, ALLERGY, V66, P31, DOI 10.1111/j.1398-9995.2011.02629.x; Skidgel RA, 2003, AM J PHYSIOL-HEART C, V284, pH1886, DOI 10.1152/ajpheart.00164.2003; Su JB, 2000, CIRCULATION, V101, P1848, DOI 10.1161/01.CIR.101.15.1848; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Turner P, 2001, J ALLERGY CLIN IMMUN, V107, P105, DOI 10.1067/mai.2001.111145; VANDERLINDEN PWG, 1993, BLOOD, V82, P1732, DOI 10.1182/blood.V82.6.1732.bloodjournal8261732; WAEBER G, 1988, CIRC SHOCK, V26, P375; Wang Jinn-Li, 2005, Acta Paediatrica Taiwanica, V46, P164; Wood RA, 2014, J ALLERGY CLIN IMMUN, V133, P461, DOI 10.1016/j.jaci.2013.08.016; ZIMMERMANN RE, 1986, INT ARCH ALLER A IMM, V81, P375	77	105	106	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					1031	+		10.1016/j.jaci.2014.07.057	http://dx.doi.org/10.1016/j.jaci.2014.07.057			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25240785				2022-12-18	WOS:000352238600026
J	Rosenberg, SL; Miller, GE; Brehm, JM; Celedon, JC				Rosenberg, Stacy L.; Miller, Gregory E.; Brehm, John M.; Celedon, Juan C.			Stress and asthma: Novel insights on genetic, epigenetic, and immunologic mechanisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; psychosocial stress; immune system; neuroendocrine system; genetics	IMPROVED LUNG-FUNCTION; PUERTO-RICAN; SOCIOECONOMIC-STATUS; AIRWAY INFLAMMATION; ADCYAP1R1 GENOTYPE; EXPOSURE; CHILDREN; ASSOCIATION; CHILDHOOD; EXPRESSION	In the United States the economically disadvantaged and some ethnic minorities are often exposed to chronic psychosocial stressors and disproportionately affected by asthma. Current evidence suggests a causal association between chronic psychosocial stress and asthma or asthma morbidity. Recent findings suggest potential mechanisms underlying this association, including changes in the methylation and expression of genes that regulate behavioral, autonomic, neuroendocrine, and immunologic responses to stress. There is also evidence suggesting the existence of susceptibility genes that predispose chronically stressed youth to both post-traumatic stress disorder and asthma. In this review we critically examine published evidence and suggest future directions for research in this field.	[Rosenberg, Stacy L.; Brehm, John M.; Celedon, Juan C.] Univ Pittsburgh, UPMC, Childrens Hosp Pittsburgh, Div Pediat Pulm Med Allergy & Immunol, Pittsburgh, PA 15260 USA; [Miller, Gregory E.] Northwestern Univ, Dept Psychol, Evanston, IL USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University	Celedon, JC (corresponding author), UPMC, Childrens Hosp Pittsburgh, 4401 Penn Ave,Suite 9130,Rangos Bldg, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu			National Institutes of Health (NIH) [HL079966, HL117191]; National Institutes of Health [HD052892]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117191, R01HL079966] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants HL079966 and HL117191 from the National Institutes of Health (NIH). J.C.C. served as a single-time consultant for Genentech in 2011 on a topic unrelated to this manuscript. J.M.B.'s contribution was supported by grant HD052892 from the National Institutes of Health.	Akinbami Lara J, 2012, NCHS Data Brief, P1; Almli LM, 2013, AM J MED GENET B, V162B, P262, DOI 10.1002/ajmg.b.32145; Azad MB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038669; Bahreinian S, 2013, AM J RESP CRIT CARE, V187, P144, DOI 10.1164/rccm.201201-0025OC; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Brackbill RM, 2009, JAMA-J AM MED ASSOC, V302, P502, DOI 10.1001/jama.2009.1121; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; Chang SC, 2012, MOL PSYCHIATR, V17, P239, DOI 10.1038/mp.2011.118; Chen E, 2009, THORAX, V64, P38, DOI 10.1136/thx.2007.095091; Chen E, 2007, BRAIN BEHAV IMMUN, V21, P993, DOI 10.1016/j.bbi.2007.03.009; Chen E, 2007, AM J RESP CRIT CARE, V176, P644, DOI 10.1164/rccm.200610-1473OC; Chen E, 2011, J ALLERGY CLIN IMMUN, V128, P970, DOI 10.1016/j.jaci.2011.06.040; Chen W, 2013, AM J RESP CRIT CARE, V187, P584, DOI 10.1164/rccm.201210-1789OC; Chiu YHM, 2014, J ALLERGY CLIN IMMUN, V133, P713, DOI 10.1016/j.jaci.2013.09.023; Clougherty JE, 2010, ENVIRON HEALTH PERSP, V118, P769, DOI 10.1289/ehp.0901631; Cohen RT, 2008, AM J RESP CRIT CARE, V178, P453, DOI 10.1164/rccm.200711-1629OC; Cohen RT, 2007, CHEST, V131, P1331, DOI 10.1378/chest.06-1917; Coogan PF, 2013, J ALLERGY CLIN IMMUN, V131, P1058, DOI 10.1016/j.jaci.2012.10.023; David MMA, 1996, AM J RESP CRIT CARE, V153, P1285, DOI 10.1164/ajrccm.153.4.8616555; Dijkstra A, 2008, J ALLERGY CLIN IMMUN, V121, P1510, DOI 10.1016/j.jaci.2008.04.015; Elekes K, 2011, PEPTIDES, V32, P1439, DOI 10.1016/j.peptides.2011.05.008; Ferreira MAR, 2011, EUR J HUM GENET, V19, P458, DOI 10.1038/ejhg.2010.191; FODA HD, 1995, PEPTIDES, V16, P1057, DOI 10.1016/0196-9781(95)00087-Z; Forno E, 2012, AM J RESP CRIT CARE, V185, P1033, DOI 10.1164/rccm.201202-0350ED; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Hashimoto H, 2009, J NEUROCHEM, V110, P595, DOI 10.1111/j.1471-4159.2009.06168.x; Hunninghake GM, 2008, J ALLERGY CLIN IMMUN, V122, P93, DOI 10.1016/j.jaci.2008.03.015; Hunninghake GM, 2006, AM J RESP CRIT CARE, V173, P143, DOI 10.1164/rccm.200508-1232SO; Irwin MR, 2011, NAT REV IMMUNOL, V11, P625, DOI 10.1038/nri3042; Islam T, 2011, AM J RESP CRIT CARE, V184, P822, DOI 10.1164/rccm.201104-0720OC; Kang DH, 2010, BIOL PSYCHOL, V84, P66, DOI 10.1016/j.biopsycho.2009.10.005; Kano S, 2013, MOL PSYCHIATR, V18, P742, DOI 10.1038/mp.2012.98; Kim WJ, 2009, RESPIROLOGY, V14, P260, DOI 10.1111/j.1440-1843.2008.01425.x; Kinhult J, 2000, EUR RESPIR J, V15, P243, DOI 10.1034/j.1399-3003.2000.15b04.x; Kirschbaum C, 2009, PSYCHONEUROENDOCRINO, V34, P32, DOI 10.1016/j.psyneuen.2008.08.024; Klinnert MD, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e69; Kruschinski C, 2008, J IMMUNOL, V180, P3919, DOI 10.4049/jimmunol.180.6.3919; Lange NE, 2011, J ALLERGY CLIN IMMUN, V127, P734, DOI 10.1016/j.jaci.2010.11.010; Lauenstein HD, 2011, CLIN EXP ALLERGY, V41, P592, DOI 10.1111/j.1365-2222.2010.03636.x; Levanen B, 2013, J ALLERGY CLIN IMMUN, V131, P894, DOI 10.1016/j.jaci.2012.11.039; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Marin TJ, 2009, PSYCHOSOM MED, V71, P378, DOI 10.1097/PSY.0b013e318199dbc3; Martinez-Taboas A, 2006, J TRAUMA STRESS, V19, P439, DOI 10.1002/jts.20144; Matthews KA, 2011, ANNU REV PSYCHOL, V62, P501, DOI 10.1146/annurev.psych.031809.130711; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Miller GE, 2009, P NATL ACAD SCI USA, V106, P14716, DOI 10.1073/pnas.0902971106; Miller GE, 2009, J ALLERGY CLIN IMMUN, V123, P824, DOI 10.1016/j.jaci.2008.12.019; Ngoc LP, 2005, CURR OPIN ALLERGY CL, V5, P161, DOI 10.1097/01.all.0000162309.97480.45; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Peters JL, 2012, ALLERGY, V67, P545, DOI 10.1111/j.1398-9995.2012.02791.x; Purugganan OH, 2000, PEDIATRICS, V106, P949; Ressler KJ, 2011, NATURE, V470, P492, DOI 10.1038/nature09856; Rogers AJ, 2009, PHARMACOGENOMICS, V10, P1231, DOI [10.2217/pgs.09.86, 10.2217/PGS.09.86]; Spitzer C, 2011, EUR RESPIR J, V37, P1068, DOI 10.1183/09031936.00028010; Sternthal MJ, 2011, J ALLERGY CLIN IMMUN, V128, P337, DOI 10.1016/j.jaci.2011.05.008; Stevens JS, 2014, P NATL ACAD SCI USA, V111, P3158, DOI 10.1073/pnas.1318954111; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tsartsali L, 2012, NEUROIMMUNOMODULAT, V19, P88, DOI 10.1159/000329592; Vermeiren R, 2003, PEDIATRICS, V111, P535, DOI 10.1542/peds.111.3.535; Wang L, 2013, J AFFECT DISORDERS, V150, P156, DOI 10.1016/j.jad.2013.01.010; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2008, AM J RESP CRIT CARE, V177, P129, DOI 10.1164/rccm.200710-1526ED; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC; Wright RJ, 2010, BIOL PSYCHOL, V84, P46, DOI 10.1016/j.biopsycho.2010.01.007; Yonas MA, 2012, CURR OPIN ALLERGY CL, V12, P202, DOI 10.1097/ACI.0b013e32835090c9	69	105	106	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1009	1015		10.1016/j.jaci.2014.07.005	http://dx.doi.org/10.1016/j.jaci.2014.07.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	AT4UN	25129683	Green Accepted			2022-12-18	WOS:000344938900003
J	Farah, CS; King, GG; Brown, NJ; Downie, SR; Kermode, JA; Hardaker, KM; Peters, MJ; Berend, N; Salome, CM				Farah, Claude S.; King, Gregory G.; Brown, Nathan J.; Downie, Sue R.; Kermode, Jessica A.; Hardaker, Kate M.; Peters, Matthew J.; Berend, Norbert; Salome, Cheryl M.			The role of the small airways in the clinical expression of asthma in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ventilation heterogeneity; small airways; asthma control; symptoms; inflammation; asthma; adults	VENTILATION HETEROGENEITY; CONTROL QUESTIONNAIRE; LUNG-FUNCTION; END-POINTS; INFLAMMATION; POPULATION; HYPERRESPONSIVENESS; STANDARDIZATION; DETERMINANT; OBSTRUCTION	Background: The clinical relevance of increased ventilation heterogeneity, a marker of small-airways disease, in asthmatic patients is unclear. Ventilation heterogeneity is an independent determinant of airway hyperresponsiveness (AHR), improves with bronchodilators and inhaled corticosteroids (ICSs), and worsens during exacerbations, but its relationship to asthma control is unknown. Objective: We sought to determine the association between ventilation heterogeneity and current asthma control before and after ICS treatment. Methods: Adult subjects with asthma had lung function and asthma control (5-item Asthma Control Questionnaire [ACQ-5 score] >= 1.5 = poorly controlled, ACQ-5 score <= 0.75 = well controlled) measured at baseline. A subgroup with AHR had repeat measurements after 3 months of high-dose ICS treatment. The indices of ventilation heterogeneity in the regions of the lung where gas transport occurs predominantly through convection (ventilation heterogeneity in convection-dependent airways [Scond]) and through diffusion (ventilation heterogeneity in diffusion-dependent airways [Sacin]) were derived by using the multiple-breath nitrogen washout technique. Results: At baseline (n = 105), subjects with poorly controlled asthma had worse FEV1, fraction of exhaled nitric oxide measured at 200 mL/s (FENO), Scond, and Sacin values. In the treatment group (n 5 50) spirometric, FENO, residual volume (RV)/total lung capacity (TLC), AHR, and Scond values significantly improved. Asthma control also improved (mean ACQ-5 score, 1.3-0.7; P < .0001). The change in ACQ-5 score correlated with changes in FENO (r(s) = 0.31, P = .03), Sacin (r(s) = 0.32, P = .02), and Scond (r(s) = 0.41, P = .003) values. The independent predictors of a change in asthma control were changes in Scond and Sacin values (model r(2) = 0.20, P = .005). Conclusions: Current asthma control is associated with markers of small-airways disease. Improvements in ventilation heterogeneity with anti-inflammatory therapy are associated with improvements in symptoms. Sensitive measures of small-airway function might be useful in monitoring the response to therapy in asthmatic subjects. (J Allergy Clin Immunol 2012;129:381-7.)	[Farah, Claude S.] Woolcock Inst Med Res, Airway Physiol Grp, Glebe, NSW 2050, Australia; [Farah, Claude S.; King, Gregory G.; Brown, Nathan J.; Downie, Sue R.; Kermode, Jessica A.; Hardaker, Kate M.; Peters, Matthew J.; Berend, Norbert; Salome, Cheryl M.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Farah, Claude S.; King, Gregory G.; Brown, Nathan J.; Downie, Sue R.; Kermode, Jessica A.; Hardaker, Kate M.; Berend, Norbert; Salome, Cheryl M.] Cooperat Res Ctr Asthma & Airways, Glebe, NSW, Australia; [King, Gregory G.] Royal N Shore Hosp, Dept Resp Med, St Leonards, NSW 2065, Australia; [Peters, Matthew J.] Concord Hosp, Dept Resp Med, Concord, NSW, Australia	University of Sydney; Woolcock Institute of Medical Research; University of Sydney; Royal North Shore Hospital; Concord Repatriation General Hospital	Farah, CS (corresponding author), Woolcock Inst Med Res, Airway Physiol Grp, POB M77,Missenden Rd, Glebe, NSW 2050, Australia.	cfarah@med.usyd.edu.au	Brown, Nathan J/H-8347-2019; Brown, Nathan/H-4317-2011; Farah, Claude S/G-6217-2012; Downie, Sue/ABD-4831-2021	Brown, Nathan J/0000-0001-7149-8895; Brown, Nathan/0000-0001-7149-8895; Farah, Claude S/0000-0003-2489-227X; Downie, Sue/0000-0002-8742-6519; Peters, Matthew/0000-0002-9649-8741	National Health and Medical Research Council (NHMRC) of Australia; Cooperative Research Centre for Asthma and Airways (CRCAA); Cooperative Research Centre for Asthma; GlaxoSmithKline; National Health and Medical Research Council	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cooperative Research Centre for Asthma and Airways (CRCAA)(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); Cooperative Research Centre for Asthma(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); GlaxoSmithKline(GlaxoSmithKline); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Supported by research grants from the National Health and Medical Research Council (NHMRC) of Australia and the Cooperative Research Centre for Asthma and Airways (CRCAA). Pharmaxis Ltd provided the mannitol kits for the bronchial challenge.; C. S. Farah has received honoraria from AstraZeneca, GlaxoSmithKline, and Novartis. G. G. King has received research support from the Cooperative Research Centre for Asthma, the National Health and Medical Research Council, and GlaxoSmithKline and has provided legal consultation/expert witness testimony for GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim. C. M. Salome has received research support from the Cooperative Research Centre for Asthma and Airways, the National Health and Medical Research Council of Australia, and GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758, DOI 10.1164/ajrccm.156.3.9701113; Aurora P, 2011, AM J RESP CRIT CARE, V183, P752, DOI 10.1164/rccm.200911-1646OC; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2010, J ALLERGY CLIN IMMUN, V125, P600, DOI 10.1016/j.jaci.2009.11.033; Boulet Louis-Philippe, 2002, Can Respir J, V9, P417; Bourdin A, 2006, ALLERGY, V61, P85, DOI 10.1111/j.1398-9995.2006.00970.x; Carlton BG, 2005, J ASTHMA, V42, P529, DOI 10.1081/JAS-200067000; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Cazzoletti L, 2007, J ALLERGY CLIN IMMUN, V120, P1360, DOI 10.1016/j.jaci.2007.09.019; CRAPO RO, 1982, B EUR PHYSIOPATH RES, V18, P419; CRAWFORD ABH, 1985, J APPL PHYSIOL, V59, P838, DOI 10.1152/jappl.1985.59.3.838; Downie SR, 2007, THORAX, V62, P684, DOI 10.1136/thx.2006.069682; Farah CS, 2011, CHEST, V140, P659, DOI 10.1378/chest.11-0027; FERRER A, 1993, AM REV RESPIR DIS, V147, P579, DOI 10.1164/ajrccm/147.3.579; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hanxiang N, 2008, INT J CLIN PRACT, V62, P599, DOI 10.1111/j.1742-1241.2007.01373.x; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 2001, RESP MED, V95, P319, DOI 10.1053/rmed.2001.1034; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Lahzami S, 2011, EUR RESPIR J, V38, P1180, DOI 10.1183/09031936.00018311; LOUGHEED MD, 1995, AM J RESP CRIT CARE, V152, P911; Lutchen KR, 2001, AM J RESP CRIT CARE, V164, P207, DOI 10.1164/ajrccm.164.2.2008119; MCCARTHY DS, 1972, AM J MED, V52, P747, DOI 10.1016/0002-9343(72)90080-0; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; National Asthma Council Australia Ltd (NAC), 2006, ASTHM MAN HDB; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; O'Byrne PM, 2010, EUR RESPIR J, V36, P269, DOI 10.1183/09031936.00124009; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911, DOI 10.1164/ajrccm.159.3.9802108; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Venegas JG, 2005, NATURE, V434, P777, DOI 10.1038/nature03490; Verbanck S, 1999, AM J RESP CRIT CARE, V159, P1545, DOI 10.1164/ajrccm.159.5.9809017; Verbanck S, 2004, AM J RESP CRIT CARE, V170, P414, DOI 10.1164/rccm.200401-037OC; Verbanck S, 1997, J APPL PHYSIOL, V83, P1907, DOI 10.1152/jappl.1997.83.6.1907; VERBANCK S, 1990, J APPL PHYSIOL, V69, P2269, DOI 10.1152/jappl.1990.69.6.2269; Verbanck S, 2003, J APPL PHYSIOL, V94, P1380, DOI 10.1152/japplphysiol.00588.2002; Verbanck S, 2006, J ALLERGY CLIN IMMUN, V118, P340, DOI 10.1016/j.jaci.2006.04.056; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; Wechsler ME, 2011, NEW ENGL J MED, V365, P119, DOI 10.1056/NEJMoa1103319; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; Zhang J, 2002, EUR RESPIR J, V20, P1102, DOI 10.1183/09031936.02.02402001	47	105	109	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					381	U162		10.1016/j.jaci.2011.11.017	http://dx.doi.org/10.1016/j.jaci.2011.11.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22188824	Bronze			2022-12-18	WOS:000299951700012
J	Romano, A; Gaeta, F; Valluzzi, RL; Caruso, C; Rumi, G; Bousquet, PJ				Romano, Antonino; Gaeta, Francesco; Valluzzi, Rocco Luigi; Caruso, Cristiano; Rumi, Gabriele; Bousquet, Philippe Jean			IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of penicillins, monobactams, and carbapenems	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aztreonam; carbapenems; cephalosporin allergy; cross-reactivity; penicillins; skin tests; tolerability	IMMEDIATE ALLERGIC REACTIONS; ANTIBIOTIC USE; BETA-LACTAMS; AZTREONAM; DIAGNOSIS; RECOGNITION; AMOXICILLIN; MEROPENEM; IMIPENEM; CHILDREN	Background: There have been few studies regarding the cross-reactivity and tolerability of penicillins, aztreonam, and carbapenems in large samples of subjects with cephalosporin allergy. Objective: We sought to evaluate the possibility of using penicillins, monobactams, and carbapenems in subjects with cephalosporin allergy who especially require them. Methods: We conducted a prospective study of 98 consecutive subjects who had 106 immediate reactions (mostly anaphylactic shock) to cephalosporins and had positive skin test results for these drugs. To assess the cross-reactivity with penicillins, monobactams, and carbapenems and the tolerability of such alternative beta-lactams, all subjects underwent skin tests and serum-specific IgE assays with penicillin reagents, as well as skin tests with aztreonam, imipenem/cilastatin, and meropenem. Subjects with negative test results were challenged with meropenem, imipenem/cilastatin, aztreonam, and amoxicillin. Results: Positive allergologic test results to penicillins were displayed by 25 (25.5%) subjects, including 1 with positive results to all reagents tested and another with a positive result to aztreonam. Another subject had positive results to both ceftazidime and aztreonam. A reaction to cephalosporins with side-chain structures similar or identical to those of penicillins was a significant predictor of cross-reactivity because of an increased 3-fold risk of positive results on allergologic tests with penicillin determinants. Challenges with alternative b-lactams were tolerated, with the exception of 1 urticarial reaction to imipenem/cilastatin. Conclusions: About 25% of subjects with cephalosporin allergy had positive results to penicillins, 3.1% to aztreonam, 2% to imipenem/cilastatin, and 1% to meropenem. In those who especially require alternative beta-lactams, pretreatment skin tests are advisable because negative results indicate tolerability of the beta-lactam concerned. (J Allergy Clin Immunol 2010;126:994-9.)	[Romano, Antonino; Gaeta, Francesco; Valluzzi, Rocco Luigi; Caruso, Cristiano; Rumi, Gabriele] Allergy Unit, I-00168 Rome, Italy; [Romano, Antonino] IRCCS Oasi Maria SS, Troina, Italy; [Bousquet, Philippe Jean] Hop Caremeau, BESPIM, GHU Caremau, Dept Biostat Epidemiol Rech Clin Sante Publ & Inf, Nimes, France; [Bousquet, Philippe Jean] Hop Arnaud Villeneuve, Montpellier, France	IRCCS Oasi Maria SS; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Montpellier	Romano, A (corresponding author), Allergy Unit, Complesso Integrato Columbus,Via G Moscati 31, I-00168 Rome, Italy.	antoninoromano@h-columbus.it	Bousquet, Philippe Jean/AAW-8608-2021; Valluzzi, Rocco Luigi/Q-3879-2019; Gaeta, Francesco/AAC-7107-2020; Romano, Antonino/D-3102-2017; Bousquet, Jean/O-4221-2019; caruso, cristiano/AAR-9502-2020; Rumi, Gabriele/M-8291-2018	Bousquet, Philippe Jean/0000-0002-0217-5483; Valluzzi, Rocco Luigi/0000-0003-0029-6254; Gaeta, Francesco/0000-0003-2942-7633; Romano, Antonino/0000-0001-9742-9898; caruso, cristiano/0000-0001-7631-029X; Rumi, Gabriele/0000-0001-5990-9129	MURST (Italian Ministry for University, Scientific and Technological Research)	MURST (Italian Ministry for University, Scientific and Technological Research)(Ministry of Education, Universities and Research (MIUR))	Supported by MURST (Italian Ministry for University, Scientific and Technological Research).	Antunez C, 2006, J ALLERGY CLIN IMMUN, V117, P404, DOI 10.1016/j.jaci.2005.10.032; Atanaskovic-Markovic M, 2008, ALLERGY, V63, P237, DOI 10.1111/j.1398-9995.2007.01532.x; Atanaskovic-Markovic M, 2009, J ALLERGY CLIN IMMUN, V124, P167, DOI 10.1016/j.jaci.2009.02.031; AUDICANA M, 1994, ALLERGY, V49, P108, DOI 10.1111/j.1398-9995.1994.tb00809.x; Baldo BA, 1999, CLIN EXP ALLERGY, V29, P744; Blanca M, 2002, CLIN EXP ALLERGY, V32, P192, DOI 10.1046/j.1365-2222.2002.01299.x; Blanca M, 2009, ALLERGY, V64, P183, DOI [10.1111/j.1398-9995.2008.01924.x, 10.1111/j.1398-9995.2008.01916.x]; Brockow K, 2002, ALLERGY, V57, P45; CADARSO AI, 1990, LANCET, V336, P746, DOI 10.1016/0140-6736(90)92238-D; Cars O, 2001, LANCET, V357, P1851, DOI 10.1016/S0140-6736(00)04972-2; Ferech M, 2006, J ANTIMICROB CHEMOTH, V58, P401, DOI 10.1093/jac/dkl188; Gueant JL, 2006, CURR PHARM DESIGN, V12, P3335, DOI 10.2174/138161206778194060; GUEANT JL, 1995, MOL IMMUNOL, V32, P259, DOI 10.1016/0161-5890(94)00152-Q; Joint Task Force on Practice Parameters tAAoA Asthma and Immunology the American Academy of Allergy Asthma and Immunology and the Joint Council of Allergy Asthma and Immunology, 1999, ANN ALLERG ASTHMA IM, V83, P665, DOI DOI 10.1016/S1081-1206(10)62890-6; Kelkar PS, 2001, NEW ENGL J MED, V345, P804, DOI 10.1056/NEJMra993637; Madaan A, 2004, IMMUNOL ALLERGY CLIN, V24, P463, DOI 10.1016/j.iac.2004.03.009; MARTIN JA, 1992, CLIN INFECT DIS, V14, P592, DOI 10.1093/clinids/14.2.592; McCaig LF, 2003, EMERG INFECT DIS, V9, P432; Miranda A, 1996, J ALLERGY CLIN IMMUN, V98, P671, DOI 10.1016/S0091-6749(96)70101-X; MOSS RB, 1991, J ALLERGY CLIN IMMUN, V87, P78, DOI 10.1016/0091-6749(91)90215-A; Novalbos A, 2001, CLIN EXP ALLERGY, V31, P438, DOI 10.1046/j.1365-2222.2001.00992.x; Patriarca G, 2008, INT J IMMUNOPATH PH, V21, P375, DOI 10.1177/039463200802100215; Pham NH, 1996, J MOL RECOGNIT, V9, P287, DOI 10.1002/(SICI)1099-1352(199607)9:4<287::AID-JMR340>3.3.CO;2-C; Pichichero ME, 1998, J PEDIATR-US, V132, P137, DOI 10.1016/S0022-3476(98)70499-8; Pichichero ME, 2005, PEDIATRICS, V115, P1048, DOI 10.1542/peds.2004-1276; Pimiento AP, 1998, ALLERGY, V53, P624, DOI 10.1111/j.1398-9995.1998.tb03944.x; Romano A, 2006, NEW ENGL J MED, V354, P2835, DOI 10.1056/NEJMc053529; Romano A, 2005, CLIN EXP ALLERGY, V35, P1234, DOI 10.1111/j.1365-2222.2005.02317.x; Romano A, 1999, J ALLERGY CLIN IMMUN, V104, P1113, DOI 10.1016/S0091-6749(99)70100-4; Romano A, 2004, ANN INTERN MED, V141, P16, DOI 10.7326/0003-4819-141-1-200407060-00010; Romano A, 2002, ALLERGY, V57, P52, DOI 10.1034/j.1398-9995.57.s72.18.x; Romano A, 2000, J ALLERGY CLIN IMMUN, V106, P1177; ROMANO A, 1997, INT J IMMUNOPATHO S2, V10, P187; Romano A, 2008, PEDIATRICS, V122, P521, DOI 10.1542/peds.2007-3178; Romano A, 2007, ANN INTERN MED, V146, P266, DOI 10.7326/0003-4819-146-4-200702200-00005; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; Solensky R, 2001, IMMUNOL ALLERGY CLIN, V21, P679; Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x; VEGA JM, 1991, ALLERGY, V46, P196, DOI 10.1111/j.1398-9995.1991.tb00570.x; Zar JH, 1999, BIOSTATISTICAL ANAL	41	105	112	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					994	999		10.1016/j.jaci.2010.06.052	http://dx.doi.org/10.1016/j.jaci.2010.06.052			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20888035				2022-12-18	WOS:000283727100015
J	O'Regan, GM; Kemperman, PMJH; Sandilands, A; Chen, HJ; Campbell, LE; Kroboth, K; Watson, R; Rowland, M; Puppels, GJ; McLean, WHI; Caspers, PJ; Irvine, AD				O'Regan, Grainne M.; Kemperman, Patrick M. J. H.; Sandilands, Aileen; Chen, Huijia; Campbell, Linda E.; Kroboth, Karin; Watson, Rosemarie; Rowland, Marion; Puppels, Gerwin J.; McLean, W. H. Irwin; Caspers, Peter J.; Irvine, Alan D.			Raman profiles of the stratum corneum define 3 filaggrin genotype-determined atopic dermatitis endophenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; confocal Raman spectroscopy; eczema; filaggrin; hyperlinearity; natural moisturizing factor; transepidermal water loss; tyrosine	OF-FUNCTION MUTATIONS; EPIDERMAL BARRIER FUNCTION; CAUSE ICHTHYOSIS VULGARIS; DRY SKIN; COMPREHENSIVE ANALYSIS; POLYETHYLENE-GLYCOLS; PROFILAGGRIN GENE; UNINVOLVED SKIN; SCHOOL-CHILDREN; MOLECULAR-LEVEL	Background: Filaggrin (FLG) has a central role in the pathogenesis of atopic dermatitis (AD). FLG is a complex repetitive gene; highly population-specific mutations and multiple rare mutations make routine genotyping complex. Furthermore, the mechanistic pathways through which mutations in FLG predispose to AD are unclear. Objectives: We sought to determine whether specific Raman microspectroscopic natural moisturizing factor (NMF) signatures of the stratum corneum could be used as markers of FLG genotype in patients with moderate-to-severe AD. Methods: The composition and function of the stratum corneum in 132 well-characterized patients with moderate-to-severe AD were assessed by means of confocal Raman microspectroscopy and measurement of transepidermal water loss (TEWL). These parameters were compared with FLG genotype and clinical assessment. Results: Three subpopulations closely corresponding with FLG genotype were identified by using Raman spectroscopy. The Raman signature of NMF discriminated between FLG-associated AD and non-FLG-associated AD (area under the curve, 0.94; 95% CI, 0.91-0.99). In addition, within the subset of FLG-associated AD, NMF distinguished between patients with 1 versus 2 mutations. Five novel FLG mutations were found on rescreening outlying patients with Raman signatures suggestive of undetected mutations (R3418X, G1138X, S1040X, 10085delC, and L2933X). TEWL did not associate with FLG genotype subgroups. Conclusions: Raman spectroscopy permits rapid and highly accurate stratification of FLG-associated AD. FLG mutations do not influence TEWL within established moderate-to-severe AD. (J Allergy Clin Immunol 2010;126:574-80.)	[O'Regan, Grainne M.; Watson, Rosemarie; Irvine, Alan D.] Our Ladys Hosp Sick Children, Dept Paediat Dermatol, Dublin 12, Ireland; [O'Regan, Grainne M.; Rowland, Marion; Irvine, Alan D.] Our Ladys Hosp Sick Children, Natl Childrens Res Ctr, Dublin 12, Ireland; [Kemperman, Patrick M. J. H.; Puppels, Gerwin J.; Caspers, Peter J.] Erasmus MC, Dept Dermatol & Venerol, Ctr Opt Diagnost & Therapy, Rotterdam, Netherlands; [Sandilands, Aileen; Chen, Huijia; Campbell, Linda E.; Kroboth, Karin; McLean, W. H. Irwin] Univ Dundee, Inst Med Sci, Epithelial Genet Grp, Dundee, Scotland; [Rowland, Marion] UCD Sch Med & Med Sci, Dublin, Ireland; [Irvine, Alan D.] Trinity Coll Dublin, Dept Med, Dublin, Ireland; [Puppels, Gerwin J.; Caspers, Peter J.] River Diagnost BV, Rotterdam, Netherlands	Our Ladys Children Hospital Crumlin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; Erasmus University Rotterdam; Erasmus MC; University of Dundee; University College Dublin; Trinity College Dublin	Irvine, AD (corresponding author), Our Ladys Hosp Sick Children, Dept Paediat Dermatol, Dublin 12, Ireland.	irvinea@tcd.ie	Irvine, Alan D/A-3982-2008; McLean, William HI/C-6352-2009; rowland, marion/AAL-2446-2020	Irvine, Alan D/0000-0002-9048-2044; Caspers, Peter/0000-0002-6122-5049; McLean, William Henry Irwin/0000-0001-5539-5757	British Skin Foundation; Medical Research Council; Children's Medical and Research Foundation, Dublin, Ireland; Medical Research Council [G0700314] Funding Source: researchfish; MRC [G0700314] Funding Source: UKRI	British Skin Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Children's Medical and Research Foundation, Dublin, Ireland; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Filaggrin research in the McLean laboratory is funded by grants from the British Skin Foundation, Medical Research Council, and donations from families affected by atopic dermatitis in the Tayside Region of Scotland. G.M.O'R. and A.D.I. are supported by the Children's Medical and Research Foundation, Dublin, Ireland.	Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bouwstra JA, 2008, J INVEST DERMATOL, V128, P378, DOI 10.1038/sj.jid.5700994; Brown SJ, 2009, BRIT J DERMATOL, V161, P884, DOI 10.1111/j.1365-2133.2009.09339.x; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Caspers PJ, 2003, BIOPHYS J, V85, P572, DOI 10.1016/S0006-3495(03)74501-9; Caspers PJ, 2001, J INVEST DERMATOL, V116, P434, DOI 10.1046/j.1523-1747.2001.01258.x; Daly LE, 2000, INTERPRETATION USES, V5th, P381; Eberlein-Konig B, 2000, ACTA DERM-VENEREOL, V80, P188; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elias PM, 2008, CURR ALLERGY ASTHM R, V8, P299, DOI 10.1007/s11882-008-0048-0; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; Ginger RS, 2005, ARCH DERMATOL RES, V297, P235, DOI 10.1007/s00403-005-0590-8; Hata M, 2002, LAB INVEST, V82, P1451, DOI 10.1097/01.LAB.0000036874.83540.2B; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hubiche T, 2007, ACTA DERM-VENEREOL, V87, P499, DOI 10.2340/00015555-0329; Jakasa I, 2007, J INVEST DERMATOL, V127, P129, DOI 10.1038/sj.jid.5700582; Jakasa I, 2006, EXP DERMATOL, V15, P801, DOI 10.1111/j.1600-0625.2006.00478.x; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Krien PM, 2000, J INVEST DERMATOL, V115, P414, DOI 10.1046/j.1523-1747.2000.00083.x; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; Nakagawa N, 2004, J INVEST DERMATOL, V122, P755, DOI 10.1111/j.0022-202X.2004.22317.x; Nemoto-Hasebe I, 2009, J INVEST DERMATOL, V129, P682, DOI 10.1038/jid.2008.280; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; Rawlings AV, 2005, J INVEST DERMATOL, V124, P1099, DOI 10.1111/j.1523-1747.2005.23726.x; RAWLINGS AV, 1994, J INVEST DERMATOL, V103, P731, DOI 10.1111/1523-1747.ep12398620; RESING KA, 1989, J BIOL CHEM, V264, P1837; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2007, J INVEST DERMATOL, V127, P1282, DOI 10.1038/sj.jid.5700876; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; Segre J, 2003, CURR OPIN CELL BIOL, V15, P778, DOI 10.1016/j.ceb.2003.10.001; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Sergeant A, 2009, J INVEST DERMATOL, V129, P1042, DOI 10.1038/jid.2008.324; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Toulza E, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r107; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wong KK, 2007, AM J HUM GENET, V80, P91, DOI 10.1086/510560; Wu ZH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005227	49	105	106	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					574	U270		10.1016/j.jaci.2010.04.038	http://dx.doi.org/10.1016/j.jaci.2010.04.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20621340	Green Published, hybrid			2022-12-18	WOS:000281512500025
J	Schimke, LF; Sawalle-Belohradsky, J; Roesler, J; Wollenberg, A; Rack, A; Borte, M; Rieber, N; Cremer, R; Maass, E; Dopfer, R; Reichenbach, J; Wahn, V; Hoenig, M; Jansson, AF; Roesen-Wolff, A; Schaub, B; Seger, R; Hill, HR; Ochs, HD; Torgerson, TR; Belohradsky, BH; Renner, ED				Schimke, Lena F.; Sawalle-Belohradsky, Julie; Roesler, Joachim; Wollenberg, Andreas; Rack, Anita; Borte, Michael; Rieber, Nikolaus; Cremer, Reinhold; Maass, Eberhart; Dopfer, Roland; Reichenbach, Janine; Wahn, Volker; Hoenig, Manfred; Jansson, Annette F.; Roesen-Wolff, Angela; Schaub, Bianca; Seger, Reinhard; Hill, Harry R.; Ochs, Hans D.; Torgerson, Troy R.; Belohradsky, Bernd H.; Renner, Ellen D.			Diagnostic approach to the hyper-IgE syndromes: Immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; dedicator of cytogenesis 8 protein (DOCK8); hyper-IgE syndrome; Job syndrome; National Institutes of Health score; signal transducer and activator of transcription 3 (STAT3); T(H)17 cells; tyrosine kinase 2 (TYK2)	STAT3 MUTATIONS; TH17 CELLS; T-CELLS; DEFICIENCY; SUSCEPTIBILITY; INFECTIONS; DOCK8	Background: Hyper-IgE syndromes (HIES) are primary immunodeficiency disorders characterized by Staphylococcus aureus abscesses, recurrent pneumonia, increased serum IgE levels, and eczema. The association of heterozygous signal transducer and activator of transcription 3 (STAT3) mutations with autosomal dominant (AD)-HIES allows the differentiation of AD-HIES from disorders associated with eczema and increased serum IgE levels, such as other primary immunodeficiencies and atopic dermatitis. Objective: To facilitate early diagnosis of AD-HIES to initiate appropriate therapy. Methods: The clinical phenotype (suggested by a National Institutes of Health [NIH] score of >= 40 points), STAT3 genotype, and TH17 cell counts were compared in a cohort of 78 patients suspected of having HIES. Results: Heterozygous STAT3 missense mutations and in-frame deletions were identified in 48 patients, all but 2 with an NIH score >= 40 points. Patients with STAT3 mutations with HIES showed significantly lower T(H)17 cell counts compared with patients with wild-type STAT3 and control subjects. Only 1 patient with wild-type STAT3 had both an NIH score >= 40 points and abnormal TH17 cell counts (<= 0.2% of CD4(+) cells), with this exception being identified with a homozygous dedicator of cytogenesis 8 protein (DOCK8) mutation. Pathologic shedding of primary teeth was present in 3 patients with wild-type STAT3 and 33 patients with STAT3 mutations. Internal abscesses and severe infections were exclusively seen in patients with STAT3 mutations, who also had increased pneumatocele formation and skeletal or connective tissue manifestations compared with patients with wild-type STAT3. Conclusion: We expanded the number of STAT3 mutations and validated that the NIH score sensitively identifies patients with HIES. Based on our patient cohort, we propose key findings that, when combined with TH17 cell numbers, predict patients with AD-HIES with STAT3 mutations, supporting early diagnosis of AD-HIES. (J Allergy Clin Immunol 2010;126:611-7.)	[Schimke, Lena F.; Sawalle-Belohradsky, Julie; Roesler, Joachim; Rack, Anita; Rieber, Nikolaus; Jansson, Annette F.; Roesen-Wolff, Angela; Schaub, Bianca; Belohradsky, Bernd H.; Renner, Ellen D.] Univ Munich, Dr Von Haunerschen Kinderspital, Univ Childrens Hosp, D-80337 Munich, Germany; [Borte, Michael] Municipal Hosp St Georg, Leipzig, Germany; [Cremer, Reinhold] Childrens Hosp, Cologne, Germany; [Maass, Eberhart] Olga Hosp, Stuttgart, Germany; [Reichenbach, Janine; Seger, Reinhard] Univ Childrens Hosp, Zurich, Switzerland; [Wahn, Volker] Univ Childrens Hosp, Charite, Berlin, Germany; [Hoenig, Manfred] Univ Childrens Hosp, Ulm, Germany; [Hill, Harry R.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Ochs, Hans D.; Torgerson, Troy R.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; General Hospital of N. Ionia Agia Olga; Klinikum Stuttgart; University Children's Hospital Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Utah System of Higher Education; University of Utah; University of Washington; University of Washington Seattle	Renner, ED (corresponding author), Univ Munich, Dr Von Haunerschen Kinderspital, Univ Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Ellen.Renner@med.uni-muenchen.de	Renner, Ellen/R-7168-2016; Reichenbach, Janine/U-2171-2018; Schaub, Bianca/B-9935-2019	Renner, Ellen/0000-0001-9816-8538; Reichenbach, Janine/0000-0002-9008-1312; Schaub, Bianca/0000-0003-1652-8873	National Institutes of Health [AI063267-01, HD017427-41]; USIDnET [N01A130070]; Jeffrey Modell and Immune Deficiency Foundations; Fritz-Thyssen Foundation [Az. 10.07.1.159]; Ludwig Maximilians University FoFoLe [680/658]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017427, R37HD017427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI063267] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USIDnET; Jeffrey Modell and Immune Deficiency Foundations; Fritz-Thyssen Foundation; Ludwig Maximilians University FoFoLe; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Data included in this publication are part of a medical thesis at the School of Medicine, Ludwig Maximilians University, Munich (L. F. S.). This work was supported by National Institutes of Health grant AI063267-01 and USIDnET grant N01A130070 (T. R. T.), National Institutes of Health grant HD017427-41 and grants from the Jeffrey Modell and Immune Deficiency Foundations (H.D.O.), and the Fritz-Thyssen Foundation (Az. 10.07.1.159) and Ludwig Maximilians University FoFoLe grant (no. 680/658) (E. D. R.).	Al Khatib S, 2009, J ALLERGY CLIN IMMUN, V124, P342, DOI 10.1016/j.jaci.2009.05.004; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; DAVIS SD, 1966, LANCET, V1, P1013; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; den Dunnen JT, 2000, HUM MUTAT, V15, P7; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Eyerich K, 2008, J INVEST DERMATOL, V128, P2640, DOI 10.1038/jid.2008.139; Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Freeman AF, 2009, PEDIATR RES, V65, p32R, DOI 10.1203/PDR.0b013e31819dc8c5; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Grimbacher B, 1999, AM J HUM GENET, V65, P735, DOI 10.1086/302547; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Jiao H, 2008, MOL IMMUNOL, V46, P202, DOI 10.1016/j.molimm.2008.07.001; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Korn T, 2007, SEMIN IMMUNOL, V19, P362, DOI 10.1016/j.smim.2007.10.007; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Levy DE, 2007, NEW ENGL J MED, V357, P1655, DOI 10.1056/NEJMe078197; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Maluish A, 1986, MANUAL CLIN LAB IMMU, P274; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; Ochs HD, 2009, J ALLERGY CLIN IMMUN, V123, P977, DOI 10.1016/j.jaci.2009.03.030; Renner ED, 2004, J PEDIATR-US, V144, P93, DOI 10.1016/S0022-3476(03)00449-9; Renner ED, 2008, J ALLERGY CLIN IMMUN, V122, P181, DOI 10.1016/j.jaci.2008.04.037; Renner ED, 2007, NEW ENGL J MED, V357, P1667, DOI 10.1056/NEJMc076367; Schaub B, 2008, ALLERGY, V63, P1438, DOI 10.1111/j.1398-9995.2008.01685.x; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1016/j.jaci.2003.07.001; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	34	105	107	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					611	U350		10.1016/j.jaci.2010.06.029	http://dx.doi.org/10.1016/j.jaci.2010.06.029			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816194				2022-12-18	WOS:000281512500030
J	Ayuso, R; Sanchez-Garcia, S; Lin, J; Fu, ZY; Ibanez, MD; Carrillo, T; Blanco, C; Goldis, M; Bardina, L; Sastre, J; Sampson, HA				Ayuso, Rosalia; Sanchez-Garcia, Silvia; Lin, Jing; Fu, Zhiyan; Dolores Ibanez, Maria; Carrillo, Teresa; Blanco, Carlos; Goldis, Marina; Bardina, Ludmila; Sastre, Joaquin; Sampson, Hugh A.			Greater epitope recognition of shrimp allergens by children than by adults suggests that shrimp sensitization decreases with age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; Crustacea; shellfish; shrimp; tropomyosin; arginine kinase; sarcoplasmic calcium-binding protein; myosin light chain; IgE epitope	IGE-BINDING EPITOPES; PEANUT ALLERGEN; MOLECULAR CHARACTERIZATION; MICROARRAY IMMUNOASSAY; EMERGENCY-DEPARTMENT; MUTATIONAL ANALYSIS; PEN A-1; MILK; IDENTIFICATION; FOOD	Background: Shellfish allergy is a long-lasting disorder typically affecting adults. Despite its high prevalence, there is limited information about allergenic shrimp proteins and the epitopes implicated in such allergic reactions. Objective: We sought to identify the IgE-binding epitopes of the 4 shrimp allergens and to characterize epitope recognition profiles of children and adults with shrimp allergy. Methods: Fifty-three subjects, 34 children and 19 adults, were selected with immediate allergic reactions to shrimp, increased shrimp-specific serum IgE levels, and positive immunoblot binding to shrimp. Study subjects and 7 nonatopic control subjects were tested by means of peptide microarray for IgE binding with synthetic overlapping peptides spanning the sequences of Litopenaeus vannamei shrimp tropornyosin, arginine kinase (AK), myosin light chain (MLC), and sarcoplasmic calcium-binding protein (SCP). The Wilcoxon test was used to determine significant differences in z scores between patients and control subjects. Results: The median shrimp IgE level was 4-fold higher in children than in adults (47 vs 12.5 kU(A)/L). The frequency of allergen recognition was higher in children (tropomyosin, 81% [94% for children and 61% for adults]; MLC, 57% [70% for children and 31% for adults]; AK, 51% [67% for children and 21% for adults]; and SCP, 45% [59% for children and 21% for adults]), whereas control subjects showed negligible binding. Seven IgE-binding regions were identified in tropomyosin by means of peptide microarray, confirming previously identified shrimp epitopes. In addition, 3 new epitopes were identified in tropomyosin (epitopes 1, 3, and 5b-c), 5 epitopes were identified in MLC, 3 epitopes were identified in SCP, and 7 epitopes were identified in AK. Interestingly, frequency of individual epitope recognition, as well as intensity of IgE binding, was significantly greater in children than in adults for all 4 proteins. Conclusions: Children with shrimp allergy have greater shrimp-specific IgE antibody levels and show more intense binding to shrimp peptides and greater epitope diversity than adults. (J Allergy Clin Immunol 2010;125:1286-93.)	[Ayuso, Rosalia; Lin, Jing; Fu, Zhiyan; Goldis, Marina; Bardina, Ludmila; Sampson, Hugh A.] Mt Sinai Sch Med, Div Allergy & Immunol, New York, NY 10029 USA; [Ayuso, Rosalia; Lin, Jing; Fu, Zhiyan; Goldis, Marina; Bardina, Ludmila; Sampson, Hugh A.] Mt Sinai Sch Med, Jaffe Food Allergy Res Inst, New York, NY 10029 USA; [Sanchez-Garcia, Silvia; Sastre, Joaquin] Fdn Jimenez Diaz, Allergy Sect, E-28040 Madrid, Spain; [Sanchez-Garcia, Silvia; Dolores Ibanez, Maria] Hosp Infantil Univ Nino Jesus, Sect Allergy, Madrid, Spain; [Carrillo, Teresa] Hosp Univ Dr Negrin, Sect Allergy & Resp Dis, Las Palmas Gran Canaria, Spain; [Blanco, Carlos] Hosp Univ Princesa, Sect Allergy, Madrid, Spain	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Hospital de La Princesa	Ayuso, R (corresponding author), Mt Sinai Sch Med, Div Allergy & Immunol, 1 Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	rosalia.ayuso@mssm.edu	Lin, Jing/C-8877-2010; Blanco, Carlos/B-3895-2012; Silvia, Sanchez-Garcia/B-5206-2017	Blanco, Carlos/0000-0002-2893-6594; Silvia, Sanchez-Garcia/0000-0002-0808-0645	Food Allergy Initiative; World Allergy Organization; Novartis; GlaxoSmithKline; Stallergenes; UCB; Phadia; National Institutes of Allergy and Infectious Diseases/National Institutes of Health; ALK-Abello	Food Allergy Initiative; World Allergy Organization; Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); Stallergenes; UCB(UCB Pharma SA); Phadia(Phadia); National Institutes of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ALK-Abello	R. Ayuso receives research support from the Food Allergy Initiative. S. Sanchez-Garcia has a short-term fellowship with the World Allergy Organization. J. Sastre receives lecture fees from Novartis. GlaxoSmithKline, Stallergenes, and UCB: has consultant arrangements with Phadia, Schering-Plough. and GlaxoSmithKline; and receives research support from Phadia. GlaxoSmithKline. and ALK-Abello. H. A. Sampson has consultant arrangements with and is a 4% shareholder in Allertein Pharmaceuticals: receives research support from the Food Allergy Initiative and the National Institutes of Allergy and Infectious Diseases/National Institutes of Health; is a consultant/scientific advisor for the Food Allergy Initiative; has served as President of the American Academy of Allergy, Asthma & Immunology; and is 45% owner of Herbal Springs, LLC. The rest of the authors have declared that they have no conflict of interest.	Asturias JA, 1999, J IMMUNOL, V162, P4342; Ayuso R, 2002, INT ARCH ALLERGY IMM, V127, P27, DOI 10.1159/000048166; Ayuso R, 2002, INT ARCH ALLERGY IMM, V129, P38, DOI 10.1159/000065172; Ayuso R, 2002, J ALLERGY CLIN IMMUN, V109, pS94, DOI 10.1016/S0091-6749(02)81383-5; Ayuso R, 2008, J ALLERGY CLIN IMMUN, V122, P795, DOI 10.1016/j.jaci.2008.07.023; Ayuso R, 2009, J ALLERGY CLIN IMMUN, V124, P114, DOI 10.1016/j.jaci.2009.04.016; Beyer K, 2005, J ALLERGY CLIN IMMUN, V116, P704, DOI 10.1016/j.jaci.2005.05.007; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Chen Jia-Jie, 2008, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V26, P356; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Cooke SK, 1997, J IMMUNOL, V159, P2026; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; DAUL CB, 1988, J ALLERGY CLIN IMMUN, V81, P1180, DOI 10.1016/0091-6749(88)90888-3; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Garcia-Orozco KD, 2007, INT ARCH ALLERGY IMM, V144, P23, DOI 10.1159/000102610; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; Lin J, 2009, CURR OPIN ALLERGY CL, V9, P357, DOI 10.1097/ACI.0b013e32832d05ba; Lin J, 2009, J ALLERGY CLIN IMMUN, V124, P315, DOI 10.1016/j.jaci.2009.05.024; Liu Tzu-Hsuan, 2008, Pediatrics and Neonatology, V49, P58, DOI 10.1016/S1875-9572(08)60014-5; Martinez A, 1997, Allergol Immunopathol (Madr), V25, P118; Matsumoto N, 2009, PEPTIDES, V30, P1840, DOI 10.1016/j.peptides.2009.07.005; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Piromrat K, 2008, ASIAN PAC J ALLERGY, V26, P121; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; Sanchez-Garcia S, 2009, J ALLERGY CLIN IMMUN, V123, pS23, DOI 10.1016/j.jaci.2008.12.102; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Storey JD, 2004, J R STAT SOC B, V66, P187, DOI 10.1111/j.1467-9868.2004.00439.x; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Yu CJ, 2003, J IMMUNOL, V170, P445, DOI 10.4049/jimmunol.170.1.445	41	105	119	2	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1286	1293		10.1016/j.jaci.2010.03.010	http://dx.doi.org/10.1016/j.jaci.2010.03.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20471069				2022-12-18	WOS:000278831000016
J	Semlali, A; Jacques, E; Koussih, L; Gounni, AS; Chakir, J				Semlali, Abdelhabib; Jacques, Eric; Koussih, Latifa; Gounni, Abdelilah S.; Chakir, Jamila			Thymic stromal lymphopoietin-induced human asthmatic airway epithelial cell proliferation through an IL-13-dependent pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; cytokines; engineered bronchial tissue; epithelial cells	GROWTH-FACTOR RECEPTOR; HUMAN BRONCHIAL FIBROBLASTS; IGM(+) B-CELLS; IN-VITRO; EXPRESSION; IL-13; INFLAMMATION; REPAIR; CLONING; TSLP	Background: Thymic stromal lymphopoietin (TSLP) plays a pivotal role in the initiation of allergic airway inflammation. This cytokine is produced by several cell types, including human epithelial cells. Objective: We sought to determine the effect of TSLP on proliferation and repair of epithelial cells isolated from asthmatic patients and healthy subjects. Methods: Expression of TSLP receptor (TSLPR) and its response to inhaled corticosteroids was evaluated on bronchial biopsy specimens of healthy control subjects and asthmatic patients by means of immunohistochemistry. TSLPR, TSLP, and IL-13 mRNA expression was determined by means of quantitative PCR, and protein expression was measured by means of ELISA and Western blotting in epithelial cells isolated from asthmatic subjects compared with those isolated from healthy control subjects. The effect of TSLP on cell proliferation and wound healing was performed. Results: TSLPR is expressed by bronchial epithelial cells in bronchial biopsy specimens and in cultured cells, with no difference between asthmatic patients and healthy control subjects. Inhaled corticosteroids did not affect this expression. TSLP mRNA and protein levels were significantly higher in epithelial cells isolated from asthmatic patients compared with those from healthy control subjects. TSLP stimulated IL-13 production by bronchial epithelial cells. TSLP induced airway epithelial cell proliferation and enhanced epithelial injury repair. This effect was abrogated with IL-13 neutralization. Conclusions: Our data indicate that epithelial cells express TSLPR and that TSLP induces bronchial epithelial cell proliferation and increases injury repair through IL-13 production. This suggests that TSLP and IL-13 loops play a homeostatic role on epithelial cell proliferation and repair. (J Allergy Clin Immunol 2010;125:844-50.)	[Semlali, Abdelhabib; Jacques, Eric; Chakir, Jamila] Univ Laval, Ctr Rech, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Koussih, Latifa] Univ Manitoba, CUSB, Winnipeg, MB, Canada; [Koussih, Latifa; Gounni, Abdelilah S.] Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada	Laval University; University of Manitoba; University of Manitoba	Chakir, J (corresponding author), Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, 2725 Chemin, Ste Foy, PQ G1V 4G5, Canada.	jamila.chakir@fmed.ulaval.ca	Semlali, Abdelhabib/AAP-7043-2020; Gounni, Abdelilah Soussi/AAH-3456-2020	Semlali, Abdelhabib/0000-0002-1643-0377; Gounni, Abdelilah/0000-0003-1265-6560; Soussi Gounni, Abdelilah/0000-0002-7282-0388	Canadian Institutes of Health Research (CIHR); Fonds de la Recherche en Sante du Quebec	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec)	Supported by the Canadian Institutes of Health Research (CIHR). Dr Chakir is the recipient of Chercheur-Boursier Awards front the Fonds de la Recherche en Sante du Quebec. Dr Semlali is the recipient of a GSK/CIHR fellowship.	Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Allahverdian S, 2008, AM J RESP CELL MOL, V38, P153, DOI 10.1165/rcmb.2007-0173OC; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; ARM JP, 1992, ADV IMMUNOL, V51, P323, DOI 10.1016/S0065-2776(08)60491-5; BARROW RE, 1993, LUNG, V171, P335, DOI 10.1007/BF00165699; Bergeron C, 2003, CLIN EXP ALLERGY, V33, P1389, DOI 10.1046/j.1365-2222.2003.01785.x; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chu EK, 2005, AM J RESP CELL MOL, V32, P373, DOI 10.1165/rcmb.2004-0266OC; Dorscheid DR, 2001, AM J PHYSIOL-LUNG C, V281, pL982, DOI 10.1152/ajplung.2001.281.4.L982; Favier J, 2002, AM J PATHOL, V161, P1235, DOI 10.1016/S0002-9440(10)64400-8; FRIEND SL, 1994, EXP HEMATOL, V22, P321; Goulet F, 1996, AM J RESP CELL MOL, V15, P312, DOI 10.1165/ajrcmb.15.3.8810634; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Isaksen DE, 1999, J IMMUNOL, V163, P5971; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Levin SD, 1999, J IMMUNOL, V162, P677; Li L, 1999, J IMMUNOL, V162, P2477; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Pourazar J, 2004, RESP MED, V98, P821, DOI 10.1016/j.rmed.2004.02.025; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Reche PA, 2001, J IMMUNOL, V167, P336, DOI 10.4049/jimmunol.167.1.336; Richter A, 2002, AM J RESP CELL MOL, V27, P85, DOI 10.1165/ajrcmb.27.1.4789; Semiali A, 2008, AM J RESP CELL MOL, V38, P202, DOI 10.1165/rcmb.2007-0031OC; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134, DOI 10.1152/ajplung.2001.280.1.L134; Sims JE, 2000, J EXP MED, V192, P671, DOI 10.1084/jem.192.5.671; Singhera GK, 2008, EXP LUNG RES, V34, P579, DOI 10.1080/01902140802369372; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Zhang KQ, 2007, AM J PHYSIOL-LUNG C, V293, pL375, DOI 10.1152/ajplung.00045.2007; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	36	105	111	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					844	850		10.1016/j.jaci.2010.01.044	http://dx.doi.org/10.1016/j.jaci.2010.01.044			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20236697				2022-12-18	WOS:000276787900009
J	Ozcan, E; Notarangelo, LD; Geha, RS				Ozcan, Esra; Notarangelo, Luigi D.; Geha, Raif S.			Primary immune deficiencies with aberrant IgE production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						IgE; primary immune deficiency; HIES; WAS; IPEX; Omenn syndrome	WISKOTT-ALDRICH-SYNDROME; REGULATORY T-CELLS; HYPERIMMUNOGLOBULIN-E SYNDROME; THYMIC STROMAL LYMPHOPOIETIN; VERSUS-HOST-DISEASE; IMMUNOGLOBULIN-E; INTERFERON-GAMMA; EPSILON TRANSCRIPTION; SWITCH RECOMBINATION; SYNDROME PROTEIN	IgE antibodies play a central role in the pathogenesis of atopic diseases and in host immunity against parasitic infections. IgE has potent activities on mast cells and basophils. IgE class switching is a very tightly controlled process, and serum IgE levels are very low compared with other immunoglobulin isotypes. Transcription factors that activate or inhibit the IgE, gene promoter, as well as T(H)1 and T(H)2 cytokines are important in the regulation of IgE levels. Hyper-IgE syndrome; Wiskott-Aldrich syndrome; immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX); Omenn syndrome; and atypical complete DiGeorge syndrome are primary immune deficiencies that are associated with elevated serum IgE levels. Increased IgE levels in IPEX, Wiskott-Aldrich syndrome and Omenn syndrome are likely related to increased T(H)2 cytokine production caused by decreased a number or function of CD4(+)CD25(+)forkhead box protein P3(+) regulatory T cells. The link between signal transducer and activator of transcription 3 mutations and elevated serum IgE levels in hyper-IgE syndrome is unclear. Insight into IgE regulation provided by the study of primary immune deficiencies with elevated IgE has important implications for allergic diseases. (J Allergy Clin Immunol 2008; 122:1054-62.)	[Geha, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 1 Blackfan Circle, Boston, MA 02115 USA.	Raif.Geha@childrens.harvard.edu	Notarangelo, Luigi D/F-9718-2016	Notarangelo, Luigi D/0000-0002-8335-0262	National Institutes of Health [P01-AI-031541, P01-AI-076210]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by National Institutes of Health grants P01-AI-031541 and P01-AI-076210	Adriani M, 2007, CLIN IMMUNOL, V124, P41, DOI 10.1016/j.clim.2007.02.001; Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; Avery DT, 2008, BLOOD, V112, P1784, DOI 10.1182/blood-2008-02-142745; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Bryson KJ, 2008, MICROBES INFECT, V10, P834, DOI 10.1016/j.micinf.2008.03.009; Cannarile MA, 2006, NAT IMMUNOL, V7, P1317, DOI 10.1038/ni1403; Caven TH, 2007, CELL IMMUNOL, V247, P49, DOI 10.1016/j.cellimm.2007.07.007; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Chen XF, 2003, CHINESE J ELECTRON, V12, P50; de Lafaille MAC, 2001, J EXP MED, V194, P1349, DOI 10.1084/jem.194.9.1349; de Lafaille MAC, 2004, SPRINGER SEMIN IMMUN, V25, P295, DOI 10.1007/s00281-003-0144-0; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Devriendt K, 2001, NAT GENET, V27, P313, DOI 10.1038/85886; DEVRIES JE, 1993, RES IMMUNOL, V144, P597, DOI 10.1016/S0923-2494(05)80009-4; DIETRICH PY, 1992, BLOOD, V80, P2419; Du JW, 2007, LEUKEMIA LYMPHOMA, V48, P1618, DOI 10.1080/10428190701474357; Dupuis-Girod S, 2003, PEDIATRICS, V111, pE622, DOI 10.1542/peds.111.5.e622; Eberting CLD, 2004, ARCH DERMATOL, V140, P1119, DOI 10.1001/archderm.140.9.1119; FINKELMAN FD, 1994, J EXP MED, V179, P1563, DOI 10.1084/jem.179.5.1563; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Garraud O, 1999, J ALLERGY CLIN IMMUN, V103, P333, DOI 10.1016/S0091-6749(99)70510-5; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; GEHA RS, 1980, J ALLERGY CLIN IMMUN, V66, P78, DOI 10.1016/0091-6749(80)90142-6; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Grimbacher B, 1999, AM J HUM GENET, V65, P735, DOI 10.1086/302547; Grimbacher B, 2005, IMMUNOL REV, V203, P244, DOI 10.1111/j.0105-2896.2005.00228.x; Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904; Grimbacher B, 2002, ALLERGY, V57, P995, DOI 10.1034/j.1398-9995.2002.02168.x; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; GRUNEBAUM E, 2008, J ALLERGY CLIN  1007; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Hoshino T, 2001, J IMMUNOL, V166, P7014, DOI 10.4049/jimmunol.166.12.7014; Hoshino T, 2000, EUR J IMMUNOL, V30, P1998, DOI 10.1002/1521-4141(200007)30:7<1998::AID-IMMU1998>3.0.CO;2-U; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Humblet-Baron S, 2007, J CLIN INVEST, V117, P407, DOI 10.1172/JCI29539; Ito R, 2003, ALLERGY, V58, P329, DOI 10.1034/j.1398-9995.2003.00099.x; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Khiong K, 2007, J CLIN INVEST, V117, P1270, DOI 10.1172/JCI30513; King C, 2004, CELL, V117, P265, DOI 10.1016/S0092-8674(04)00335-6; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kronenberg M, 2005, NATURE, V435, P598, DOI 10.1038/nature03725; Kusunoki T, 2003, J ALLERGY CLIN IMMUN, V111, P136, DOI 10.1067/mai.2003.29; Levy DE, 2007, NEW ENGL J MED, V357, P1655, DOI 10.1056/NEJMe078197; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Ling JC, 2007, CLIN IMMUNOL, V122, P255, DOI 10.1016/j.clim.2006.10.005; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Maillard MH, 2007, J EXP MED, V204, P381, DOI 10.1084/jem.20061338; Maizels N, 2003, NAT IMMUNOL, V4, P7, DOI 10.1038/ni0103-7; Mao C, 2001, J IMMUNOL, V167, P1522, DOI 10.4049/jimmunol.167.3.1522; Marangoni F, 2007, J EXP MED, V204, P369, DOI 10.1084/jem.20061334; Markert ML, 2007, BLOOD, V109, P4539, DOI 10.1182/blood-2006-10-048652; Marrella V, 2008, TRENDS IMMUNOL, V29, P133, DOI 10.1016/j.it.2007.12.001; Marrella V, 2007, J CLIN INVEST, V117, P1260, DOI 10.1172/JCI30928; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Milner JD, 2007, P NATL ACAD SCI USA, V104, P576, DOI 10.1073/pnas.0610289104; Minegishi Y, 2007, CURR OPIN ALLERGY CL, V7, P506, DOI 10.1097/ACI.0b013e3282f1baea; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Moulding DA, 2007, J EXP MED, V204, P2213, DOI 10.1084/jem.20062324; Nakano H, 2003, INT IMMUNOL, V15, P611, DOI 10.1093/intimm/dxg062; Netea MG, 2005, EUR J CLIN INVEST, V35, P718, DOI 10.1111/j.1365-2362.2005.01564.x; Nguyen DD, 2007, GASTROENTEROLOGY, V133, P1188, DOI 10.1053/j.gastro.2007.07.010; Notarangelo LD, 2002, BLOOD, V99, P2268, DOI 10.1182/blood.V99.6.2268; Notarangelo LD, 2006, CURR OPIN ALLERGY CL, V6, P443, DOI 10.1097/01.all.0000246616.47708.2f; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Peled JU, 2008, ANNU REV IMMUNOL, V26, P481, DOI 10.1146/annurev.immunol.26.021607.090236; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PENG Y, 2005, J ZHONGHUA WAI KE ZH, V43, P274; Renner ED, 2004, J PEDIATR-US, V144, P93, DOI 10.1016/S0022-3476(03)00449-9; Renner ED, 2007, NEW ENGL J MED, V357, P1667, DOI 10.1056/NEJMc076367; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rieger K, 2006, BLOOD, V107, P1717, DOI 10.1182/blood-2005-06-2529; Roifman CM, 2008, J ALLERGY CLIN IMMUN, V121, P1056, DOI 10.1016/j.jaci.2007.12.1148; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Salagianni M, 2007, J IMMUNOL, V178, P4771, DOI 10.4049/jimmunol.178.8.4771; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shang XZ, 2006, CELL IMMUNOL, V241, P66, DOI 10.1016/j.cellimm.2006.07.011; Shibata F, 2007, EUR J HAEMATOL, V79, P81, DOI 10.1111/j.1600-0609.2007.00874.x; Sugai M, 2003, NAT IMMUNOL, V4, P25, DOI 10.1038/ni874; Suto A, 2002, BLOOD, V100, P4565, DOI 10.1182/blood-2002-04-1115; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Torgerson TR, 2007, J ALLERGY CLIN IMMUN, V120, P744, DOI 10.1016/j.jaci.2007.08.044; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Trifari S, 2006, J IMMUNOL, V177, P7451, DOI 10.4049/jimmunol.177.10.7451; TURUL T, 2008, EUR J PEDIAT    0529; VILLA A, 1995, NAT GENET, V9, P414, DOI 10.1038/ng0495-414; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wolf D, 2007, TRANSPLANTATION, V83, P1107, DOI 10.1097/01.tp.0000260140.04815.77; Wood PMD, 2005, EUR J PEDIATR, V164, P741, DOI 10.1007/s00431-005-1745-5; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Yoshimoto T, 1997, P NATL ACAD SCI USA, V94, P3948, DOI 10.1073/pnas.94.8.3948	106	105	107	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1054	1062		10.1016/j.jaci.2008.10.023	http://dx.doi.org/10.1016/j.jaci.2008.10.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	19084106				2022-12-18	WOS:000261711800002
J	Kisich, KO; Carspecken, CW; Fieve, S; Boguniewicz, M; Leung, DYM				Kisich, Kevin O.; Carspecken, Charles W.; Fieve, Stephanie; Boguniewicz, Mark; Leung, Donald Y. M.			Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antimicrobial peptides; defensins; human; bacterial infections; skin; keratinocytes	INNATE IMMUNE-RESPONSE; CYTOKINE MILIEU; EXPRESSION; KERATINOCYTES; DEFICIENCY; CELLS; IL-13	Background: Individuals with atopic dermatitis (AD) have frequent colonization and infection with Staphylococcus aureus. Rapid elimination of S aureus depends on constitutive synthesis and mobilization of human beta-defensin-3 (HBD-3). Objective: To determine whether keratinocytes in AD, compared with normal, skin are less able to kill S aureus rapidly, and to assess the potential role that abnormally low mobilization of HBD-3 onto S aureus has in this process. Methods: Skin samples from 10 normal individuals and 10 patients with AD were compared for synthesis and mobilization of HBD-3 onto surface-associated S aureus. Furthermore, keratinocytes from 10 individuals were studied for the effects of T(H)2 cytokines on the ability of the cells to synthesize and mobilize HBD-3, and to kill S aureus. Results: Keratinocytes in skin biopsies from subjects with AD were defective in killing S aureus relative to normal individuals (P <.001). The constitutive levels of HBD-3 in the epidermal keratinocytes were similar between normal individuals and those with AD. However, the cells of patients with AD were unable to mobilize HBD-3 efficiently to kill S aureus. Physiologic Ca++ was essential for development of normal HBD-3 levels by cultured human keratinocytes. Mobilization of HBD-3 and the ability to kill S aureus were significantly (P <.05) inhibited by IL-4 and IL-13. Antagonism of IL-4/10/13 with antibodies significantly (P <.01) improved mobilization of HBD-3 onto the surface of S aureus by skin from patients with AD. Conclusion: Patients with AD have problems with S aureus skin infection. This is a result of increased levels of T(H)2 cytokines, which inhibit keratinocyte mobilization of HBD-3.	[Kisich, Kevin O.; Carspecken, Charles W.; Fieve, Stephanie; Boguniewicz, Mark; Leung, Donald Y. M.] Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy Immunol, Denver, CO 80206 USA; [Kisich, Kevin O.; Carspecken, Charles W.; Boguniewicz, Mark; Leung, Donald Y. M.] Univ Colorado, Hlth Sci Ctr, Dept Pediat, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy Immunol, 1400 Jackson St,Room K926I, Denver, CO 80206 USA.	leungd@njc.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-40029] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albanesi C, 2007, J IMMUNOL, V179, P984, DOI 10.4049/jimmunol.179.2.984; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bevins CL, 2004, CURR OPIN GASTROEN, V20, P572, DOI 10.1097/00001574-200411000-00012; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Chung HJ, 2008, J CLIN MICROBIOL, V46, P991, DOI 10.1128/JCM.00698-07; Elias PM, 2002, J INVEST DERMATOL, V119, P1269, DOI 10.1046/j.1523-1747.2002.19622.x; Elias PM, 2002, J INVEST DERMATOL, V119, P1128, DOI 10.1046/j.1523-1747.2002.19512.x; Fehrenbach K, 2007, MOL IMMUNOL, V44, P2087, DOI 10.1016/j.molimm.2006.09.011; Fridkin SK, 2005, NEW ENGL J MED, V352, P1436, DOI 10.1056/NEJMoa043252; GROSS GN, 1978, INFECT IMMUN, V21, P7, DOI 10.1128/IAI.21.1.7-9.1978; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; Kisich KO, 2007, J INVEST DERMATOL, V127, P2368, DOI 10.1038/sj.jid.5700861; Kisich KO, 2002, INFECT IMMUN, V70, P4591, DOI 10.1128/IAI.70.8.4591-4599.2002; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; Leung DYM, 1997, CLIN EXP IMMUNOL, V107, P25; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Liu AY, 2002, J INVEST DERMATOL, V118, P275, DOI 10.1046/j.0022-202x.2001.01651.x; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; Nhieu GT, 2004, BIOL CELL, V96, P93, DOI 10.1016/j.biocel.2003.10.006; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Remitz A, 2001, J ALLERGY CLIN IMMUN, V107, P196, DOI 10.1067/mai.2001.112131; Silliman CC, 2003, J LEUKOCYTE BIOL, V73, P511, DOI 10.1189/jlb.0402179; STALDER JF, 1994, BRIT J DERMATOL, V131, P536	30	105	107	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					62	68		10.1016/j.jaci.2008.04.022	http://dx.doi.org/10.1016/j.jaci.2008.04.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18538383				2022-12-18	WOS:000257605100010
J	Romieu, I; Barraza-Villarreal, A; Escamilla-Nunez, C; Almstrand, AC; Diaz-Sanchez, D; Sly, PD; Olin, AC				Romieu, Isabelle; Barraza-Villarreal, Albino; Escamilla-Nunez, Consuelo; Almstrand, Ann-Charlotte; Diaz-Sanchez, David; Sly, Peter D.; Olin, Anna-Carin			Exhaled breath malondialdehyde as a marker of effect of exposure to air pollution in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; clinical immunology; environment; epidemiology; pediatrics	OXIDATIVE STRESS; MEXICO-CITY; DNA-DAMAGE; OZONE EXPOSURE; IN-VIVO; CONDENSATE; LUNG; ANTIOXIDANT; GLUTATHIONE; ALDEHYDES	Background: Assessment of the adverse effects of oxidative stress related to air pollution is limited by the lack of biological markers of dose to the lungs. Objective: We evaluated the use of exhaled breath condensate (EBC) malondialdehyde as a biomarker of exposure to traffic-related pollution in children with asthma as part of a panel study in Mexico City. Methods: Standard spirometry and collection of EBC and nasal lavage were performed. Environmental monitoring sites were located within 5 km of the children's homes and schools. Data were analyzed by using generalized estimating equations. Results: A total of 480 samples of malondialdehyde were obtained from 107 patients with asthma, with a median level of 18.7 (interquartile range [IQR], 12.4-28.7) nmol. Ambient particulates less than 2.5 mu g/m(3) and ozone levels on the day of sampling were significantly associated with higher malondialdehyde levels. A 14.2-mu g/m(3) (IQR) increase in 8-hour moving average particulates less than 2.5 mu g/m(3) in size was associated with a 1.12-nmol increase in malondialdehyde and 4 15.9-ppb (IQR) increase in 8-hour moving average ozone with a 1.16-nmol increase in malondialdehyde. Malondialdehyde levels were inversely associated with forced vital capacity and FEV(1) and positively associated with IL-8 levels in nasal lavage. Conclusion: Exhaled breath condensate malondialdehyde was related to both air pollution exposure and changes in lung function and inflammatory markers.	[Romieu, Isabelle; Barraza-Villarreal, Albino; Escamilla-Nunez, Consuelo] Inst Nacl Salud Publ, Cuernavaca 62508, Morelos, Mexico; [Almstrand, Ann-Charlotte; Olin, Anna-Carin] Sahlgrens Univ Hosp, Dept Occupat & Environm Med, S-41345 Gothenburg, Sweden; [Diaz-Sanchez, David] Univ Calif Los Angeles, Los Angeles, CA USA; [Sly, Peter D.] Curtin Univ Technol, WHO, Collaborating Ctr Res Child Environm Hlth, Perth, WA 6001, Australia; [Sly, Peter D.] Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia	Instituto Nacional de Salud Publica; Sahlgrenska University Hospital; University of California System; University of California Los Angeles; Curtin University; World Health Organization; University of Western Australia	Romieu, I (corresponding author), Inst Nacl Salud Publ, 655 Avendia Univ,Col Santa Maria Ahuacatitlan, Cuernavaca 62508, Morelos, Mexico.	iromieu@correo.insp.mx	Sly, Peter D/F-1486-2010; Olin, Anna-Carin/ABH-2627-2021	Sly, Peter D/0000-0001-6305-2201; Escamilla, Consuelo/0000-0001-5619-2572				ANEMIYA T, 1973, ECONOMETRICA, V41, P997; Arbak P, 2004, J OCCUP HEALTH, V46, P281, DOI 10.1539/joh.46.281; Behndig AF, 2006, EUR RESPIR J, V27, P359, DOI 10.1183/09031936.06.00136904; Borm PJA, 2007, OCCUP ENVIRON MED, V64, P73, DOI 10.1136/oem.2006.029090; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; BROWN RK, 1994, PEDIATR RES, V36, P487, DOI 10.1203/00006450-199410000-00013; Corradi M, 2003, AM J RESP CRIT CARE, V167, P395, DOI 10.1164/rccm.200206-507OC; Frampton MW, 1999, AM J RESP CRIT CARE, V159, P1134, DOI 10.1164/ajrccm.159.4.9807057; Goldoni M, 2004, ENVIRON HEALTH PERSP, V112, P1293, DOI 10.1289/ehp.7108; Halliwell B, 2000, AM J CLIN NUTR, V72, P1082; Isik B, 2005, INHAL TOXICOL, V17, P695, DOI 10.1080/08958370500189883; Kadiiska MB, 1997, CHEM RES TOXICOL, V10, P1104, DOI 10.1021/tx970049r; Kelly FJ, 2003, OCCUP ENVIRON MED, V60, P612, DOI 10.1136/oem.60.8.612; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; Larstad M, 2002, J CHROMATOGR B, V766, P107, DOI 10.1016/S0378-4347(01)00437-6; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; LIANG KY, 1986, BIOMETRIKA, V73, P132; Marnett LJ, 2002, TOXICOLOGY, V181, P219, DOI 10.1016/S0300-483X(02)00448-1; Orman A, 2005, TOXICOLOGY, V207, P15, DOI 10.1016/j.tox.2004.07.021; OSIAS PP, 2004, PEDIATR ALLERGY IMMU, V15, P4; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Perez-Padilla R, 2003, PEDIATR PULM, V35, P177, DOI 10.1002/ppul.10232; Profita M, 2006, J ALLERGY CLIN IMMUN, V118, P1068, DOI 10.1016/j.jaci.2006.07.028; RAMIREZAGUILAR M, 2004, PERSONAL EXPOSURE AS, P26; Risom L, 2005, MUTAT RES-FUND MOL M, V592, P119, DOI 10.1016/j.mrfmmm.2005.06.012; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Romieu I, 2004, THORAX, V59, P8; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Sorensen M, 2003, ENVIRON HEALTH PERSP, V111, P161, DOI 10.1289/ehp.5646; *STAT CORP, 1996, STAT SOFTW REL 5 0; Takizawa H, 2004, CURR OPIN ALLERGY CL, V4, P355, DOI 10.1097/00130832-200410000-00005; *US DEP HHS NIH NH, 1998, NIH PUBL; Vega E, 2004, J AIR WASTE MANAGE, V54, P786, DOI 10.1080/10473289.2004.10470952; Zar J. H., 1996, BIOSTATISTICAL ANAL	34	105	111	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					903	909		10.1016/j.jaci.2007.12.004	http://dx.doi.org/10.1016/j.jaci.2007.12.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18234317	Bronze			2022-12-18	WOS:000254884000014
J	Frossard, CP; Steidler, L; Eigenmann, PA				Frossard, Christophe P.; Steidler, Lothar; Eigenmann, Philippe A.			Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; anaphylaxis; tolerance; T-lymphocytes; beta-lactoglobulin; IL-10	DENDRITIC CELL-FUNCTION; MURINE MODEL; INTESTINAL MICROFLORA; T-CELLS; B-CELLS; ALLERGY; ANAPHYLAXIS; TOLERANCE; INTERLEUKIN-10; LYMPHOCYTES	Background: Because tolerance to food is potentially modulated by IL-10, strategies to prevent food allergy should favor an increased delivery of IL-10 to the gut. Objectives: We hypothesized that administration of a Lactococcus lactis transfected to secrete murine IL-10 could prevent sensitization in a mouse model of food allergy. Methods: Before each oral sensitization with beta-lactoglobulin in the presence of cholera toxin, young mice were administered the transfected Lactococcus lactis. Antigen-induced anaphylaxis after oral challenge assessed clinical protection achieved by the pretreatment. Serum and feces antigen-specific antibody concentrations were sequentially measured. Antibody titers were correlated with antibody and IL-10-secreting cell numbers in the spleen and in Peyer patches. Results: Pretreatment with transfected Lactococcus lactis contributed to diminish anaphylaxis significantly, and inhibit antigen-specific serum IgE and IgG(1) production strongly. In addition, transfected Lactococcus lactis increased the production of antigen-specific IgA in the gut. Variations of antibody levels in the serum and the gut correlated with the numbers of antibody-producing cells. In addition, the presence of exogenous IL-10 in the gut by transfected Lactococcus lactis induced IL-10 secretion by Peyer patches cells. Increased IL-10 titers were also measured in the plasma. Conclusion: These results suggest that a microorganism bioengineered to deliver IL-10 in the gut can decrease food- induced anaphylaxis and provide an option to prevent IgE-type sensitization to common food allergens. Clinical implications: Nonpathogenic IL-10-producing microorganisms in the gut could have a potential to prevent systemic food-induced anaphylaxis.	Univ Hosp Geneva, Dept Pediat, CH-1211 Geneva 14, Switzerland; Natl Univ Ireland Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland	University of Geneva; University College Cork	Eigenmann, PA (corresponding author), Univ Hosp Geneva, Dept Pediat, 6 Rue Willy Donze, CH-1211 Geneva 14, Switzerland.	Philippe.Eigenmann@hcuge.ch	Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826				Adel-Patient K, 2000, J IMMUNOL METHODS, V235, P21, DOI 10.1016/S0022-1759(99)00210-0; Adel-Patient K, 2005, CLIN EXP ALLERGY, V35, P539, DOI 10.1111/j.1365-2222.2005.02225.x; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Braat H, 2004, AM J CLIN NUTR, V80, P1618, DOI 10.1093/ajcn/80.6.1618; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Christensen HR, 2002, J IMMUNOL, V168, P171, DOI 10.4049/jimmunol.168.1.171; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; Eigenmann PA, 2003, ALLERGY, V58, P1217, DOI 10.1046/j.1398-9995.2003.00303.x; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Fayette J, 1997, J EXP MED, V185, P1909, DOI 10.1084/jem.185.11.1909; Frossard CP, 2004, J ALLERGY CLIN IMMUN, V113, P958, DOI 10.1016/j.jaci.2003.12.017; Frossard CP, 2001, PEDIATR RES, V49, P417, DOI 10.1203/00006450-200103000-00018; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; SNIDER DP, 1994, J IMMUNOL, V153, P647; SONODA E, 1989, J EXP MED, V170, P1415, DOI 10.1084/jem.170.4.1415; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575	26	105	115	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					952	959		10.1016/j.jaci.2006.12.615	http://dx.doi.org/10.1016/j.jaci.2006.12.615			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17316776				2022-12-18	WOS:000245729500026
J	Lazaar, AL; Panettieri, RA				Lazaar, AL; Panettieri, RA			Airway smooth muscle: A modulator of airway remodeling in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; signal transduction; smooth muscle; proliferation; synthetic function	ENDOTHELIAL GROWTH-FACTOR; EXTRACELLULAR-MATRIX PROTEINS; ENHANCE EOSINOPHIL SURVIVAL; CELL-PROLIFERATION; MAST-CELL; GENE-EXPRESSION; DNA-SYNTHESIS; BRONCHIAL-ASTHMA; TGF-BETA; PHOSPHOINOSITIDE 3-KINASE	Asthma is a disease characterized, in part, by airway hyperresponsiveness and inflammation. Although asthma typically induces reversible airway obstruction, in some patients with asthma, airflow obstruction can become irreversible. Such obstruction might be a consequence of persistent structural changes in the airway wall caused by the frequent stimulation of airway smooth muscle (ASM) by contractile agonists, inflammatory mediators, and growth factors. Traditional concepts concerning airway inflammation have focused on trafficking leukocytes and on the effects of inflammatory mediators, cytokines, and chemokines secreted by these cells. Recent studies suggest that ASM cells might modulate airway remodeling by secreting cytokines, growth factors, or matrix proteins and by expressing cell adhesion molecules and other potential costimulatory molecules. These ASM cell functions might directly or indirectly modulate submucosal airway inflammation and promote airway remodeling.	Univ Penn, Sch Med, Allergy & Crit Care Div, Philadelphia, PA 19104 USA	University of Pennsylvania	Lazaar, AL (corresponding author), Univ Penn, Sch Med, Allergy & Crit Care Div, BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	alazaar@mail.med.upenn.edu	panettieri, reynold/AAG-9485-2019		NHLBI NIH HHS [P01 HL067663, P50 HL067663, HL-67663, R01 HL064042, HL-64042] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067663, P50HL067663, R01HL064042] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amrani Y, 2003, AM J PHYSIOL-LUNG C, V284, pL1063, DOI 10.1152/ajplung.00363.2002; Asai K, 2003, CLIN EXP ALLERGY, V33, P595, DOI 10.1046/j.1365-2222.2003.01576.x; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Black PN, 1996, AM J PHYSIOL-LUNG C, V271, pL910, DOI 10.1152/ajplung.1996.271.6.L910; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BROWN JK, 1995, AM J RESP CELL MOL, V13, P227, DOI 10.1165/ajrcmb.13.2.7626290; Brown JK, 2002, AM J PHYSIOL-LUNG C, V282, pL197, DOI 10.1152/ajplung.2002.282.2.L197; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carlin SM, 2003, AM J PHYSIOL-LUNG C, V284, pL1020, DOI 10.1152/ajplung.00092.2002; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; Coutts A, 2001, AM J PHYSIOL-LUNG C, V280, pL999, DOI 10.1152/ajplung.2001.280.5.L999; DE S, 1995, J APPL PHYSIOL, V78, P1555, DOI 10.1152/jappl.1995.78.4.1555; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; Elshaw SR, 2004, BRIT J PHARMACOL, V142, P1318, DOI 10.1038/sj.bjp.0705883; Faffe DS, 2003, AM J PHYSIOL-LUNG C, V285, pL907, DOI 10.1152/ajplung.00120.2003; Fernandes D, 1999, AM J RESP CELL MOL, V21, P77, DOI 10.1165/ajrcmb.21.1.3396; Foda HD, 1999, AM J PHYSIOL-LUNG C, V277, pL174, DOI 10.1152/ajplung.1999.277.1.L174; Freyer AM, 2004, AM J RESP CELL MOL, V31, P440, DOI 10.1165/rcmb.2003-0241OC; Freyer AM, 2001, AM J RESP CELL MOL, V25, P569, DOI 10.1165/ajrcmb.25.5.4605; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Goncharova EA, 2003, AM J RESP CELL MOL, V29, P19, DOI 10.1165/rcmb.2002-0254OC; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; Hakonarson H, 2001, J IMMUNOL, V166, P293, DOI 10.4049/jimmunol.166.1.293; Hakonarson H, 1999, J CLIN INVEST, V104, P657, DOI 10.1172/JCI7137; Hallsworth MP, 1998, AM J RESP CELL MOL, V19, P910, DOI 10.1165/ajrcmb.19.6.3275; Hirst SJ, 2000, AM J RESP CELL MOL, V23, P335, DOI 10.1165/ajrcmb.23.3.3990; Hirst Stuart J, 2004, J Allergy Clin Immunol, V114, pS2, DOI 10.1016/j.jaci.2004.04.039; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Howarth Peter H, 2004, J Allergy Clin Immunol, V114, pS32, DOI 10.1016/j.jaci.2004.04.041; Jarai G, 2004, EUR J PHARMACOL, V497, P255, DOI 10.1016/j.ejphar.2004.06.055; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; Johnson PRA, 2000, AM J RESP CRIT CARE, V162, P2145, DOI 10.1164/ajrccm.162.6.9909111; Johnson PRA, 2004, J ALLERGY CLIN IMMUN, V113, P690, DOI 10.1016/j.jaci.2003.12.312; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Karpova AY, 1997, AM J PHYSIOL-LUNG C, V272, pL558, DOI 10.1152/ajplung.1997.272.3.L558; Kassel O, 1999, EUR RESPIR J, V13, P951, DOI 10.1034/j.1399-3003.1999.13e04.x; Kazi AS, 2004, AM J PHYSIOL-LUNG C, V286, pL539, DOI 10.1152/ajplung.00130.2003; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com; Krymskaya VP, 2004, FASEB J, V18, P428, DOI 10.1096/fj.04-2869fje; Krymskaya VP, 2000, AM J RESP CELL MOL, V23, P546, DOI 10.1165/ajrcmb.23.4.4115; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V277, pL65; Krymskaya VP, 2001, AM J PHYSIOL-LUNG C, V280, pL1009, DOI 10.1152/ajplung.2001.280.5.L1009; Larsen K, 2004, AM J RESP CRIT CARE, V170, P1049, DOI 10.1164/rccm.200404-507OC; Lazaar AL, 1997, AM J RESP CELL MOL, V16, P38, DOI 10.1165/ajrcmb.16.1.8998077; Lazaar AL, 2002, J IMMUNOL, V169, P1014, DOI 10.4049/jimmunol.169.2.1014; Lazaar AL, 1998, J IMMUNOL, V161, P3120; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; Nguyen TTB, 2005, AM J RESP CRIT CARE, V171, P217, DOI 10.1164/rccm.200408-1046OC; Orsini MJ, 1999, AM J PHYSIOL-LUNG C, V277, pL479, DOI 10.1152/ajplung.1999.277.3.L479; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Pandya HC, 2002, AM J PHYSIOL-LUNG C, V283, pL1220, DOI 10.1152/ajplung.00268.2001; Parameswaran K, 2004, EUR RESPIR J, V24, P545, DOI 10.1183/09031936.04.00113103; Parameswaran K, 2002, AM J RESP CRIT CARE, V166, P738, DOI 10.1164/rccm.200204-291OC; Potter-Perigo S, 2004, AM J RESP CELL MOL, V30, P101, DOI 10.1165/rcmb.2003-0050OC; Rajah R, 1996, AM J PHYSIOL-LUNG C, V271, pL1014, DOI 10.1152/ajplung.1996.271.6.L1014; Ramos-Barbon D, 2005, J CLIN INVEST, V115, P1580, DOI 10.1172/JCI19711; Robinson DS, 2004, J ALLERGY CLIN IMMUN, V114, P58, DOI 10.1016/j.jaci.2004.03.034; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Saunders MA, 1997, BRIT J PHARMACOL, V120, P545, DOI 10.1038/sj.bjp.0700998; Schmidt M, 2003, J IMMUNOL, V171, P380, DOI 10.4049/jimmunol.171.1.380; Scott PH, 1996, BIOCHEM J, V318, P965, DOI 10.1042/bj3180965; Simon AR, 2002, AM J PHYSIOL-LUNG C, V282, pL1296, DOI 10.1152/ajplung.00315.2001; Strieter RM, 2002, CHEST, V122, p298S, DOI 10.1378/chest.122.6_suppl.298S; Thangam EB, 2005, FASEB J, V19, P798, DOI 10.1096/fj.04-2797fje; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Tliba O, 2003, J BIOL CHEM, V278, P50615, DOI 10.1074/jbc.M303680200; TOLLOCZKO B, 2005, P AM THORAC SOC, V2, pA27; Tran MUT, 2004, CLIN EXP ALLERGY, V34, P1627, DOI 10.1111/j.1365-2222.2004.02057.x; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Walker TR, 1998, MOL PHARMACOL, V54, P1007, DOI 10.1124/mol.54.6.1007; Wen FQ, 2003, J ALLERGY CLIN IMMUN, V111, P1307, DOI 10.1067/mai.2003.1455; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Xie SP, 2005, AM J PHYSIOL-LUNG C, V288, pL68, DOI 10.1152/ajplung.00156.2004; Yu Q, 2000, GENE DEV, V14, P163; Zhang S, 1996, EUR RESPIR J, V9, P1839, DOI 10.1183/09031936.96.09091839; Zheng XY, 2004, AM J PHYSIOL-LUNG C, V287, pL1165, DOI 10.1152/ajplung.00171.2004	86	105	113	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					488	495		10.1016/j.jaci.2005.06.030	http://dx.doi.org/10.1016/j.jaci.2005.06.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159613	Bronze			2022-12-18	WOS:000235686500002
J	Rautava, S; Kalliomaki, M; Isolauri, E				Rautava, S; Kalliomaki, M; Isolauri, E			New therapeutic strategy for combating the increasing burden of allergic disease: Probiotics - A nutrition, allergy, mucosal immunology and intestinal microbiota (NAMI) research group report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; atopic disease; host-microbe cross-talk; hygiene hypothesis; intestinal microbiota; probiotics	CASEI STRAIN SHIROTA; GROWTH-FACTOR-BETA; ESCHERICHIA-COLI; EPITHELIAL-CELLS; ATOPIC DISEASE; T-CELLS; LACTOBACILLUS STRAINS; IMMUNE-RESPONSES; MICROFLORA; BACTERIA	The dietary approach to reducing the risk of atopic diseases in infancy is evolving from passive allergen avoidance to active stimulation of the immature immune system, the aim of which is to support the establishment of tolerance. The intestinal mucosa and the mucosa-associated immune system are the primary loci of allergen contact and induction of immune responsiveness. In this review we discuss cross-talk between the intestinal microbiota and the host as it pertains to healthy immunologic maturation. Understanding these complex phenomena provides the rationale for the use of probiotics in reducing the risk and nutritional management of atopic disease.	Univ Turku, Dept Paediat, FIN-20520 Turku, Finland	University of Turku	Isolauri, E (corresponding author), Univ Turku, Dept Paediat, FIN-20520 Turku, Finland.	erika.isolauri@utu.fi		Rautava, Samuli/0000-0003-0935-3593				Agarwal R, 2003, J PEDIATR GASTR NUTR, V36, P397, DOI 10.1097/00005176-200303000-00019; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Benn CS, 2004, BRIT MED J, V328, P1223, DOI 10.1136/bmj.38069.512245.FE; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516, DOI 10.1067/mai.2001.118130; Boudeau J, 2003, ALIMENT PHARM THER, V18, P45, DOI 10.1046/j.1365-2036.2003.01638.x; BRANDTZAEG P, 1995, APMIS, V103, P1, DOI 10.1111/j.1699-0463.1995.tb01073.x; Cario E, 2002, AM J PATHOL, V160, P165, DOI 10.1016/S0002-9440(10)64360-X; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; GERRARD JW, 1976, ANN ALLERGY, V37, P91; Gluck U, 2003, AM J CLIN NUTR, V77, P517; Helin T, 2002, ALLERGY, V57, P243, DOI 10.1034/j.1398-9995.2002.1s3299.x; ISOLAURI E, 1990, DIGEST DIS SCI, V35, P360, DOI 10.1007/BF01537415; ISOLAURI E, 1993, GASTROENTEROLOGY, V105, P1643, DOI 10.1016/0016-5085(93)91059-Q; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; ISOLAURI E, 1993, PEDIATR RES, V33, P548, DOI 10.1203/00006450-199306000-00002; Isolauri E, 2002, CURR OPIN ALLERGY CL, V2, P263, DOI 10.1097/00130832-200206000-00018; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Karlsson H, 2002, INFECT IMMUN, V70, P6688, DOI 10.1128/IAI.70.12.6688-6696.2002; Lammers KM, 2003, FEMS IMMUNOL MED MIC, V38, P165, DOI 10.1016/S0928-8244(03)00144-5; Lievin-Le Moal V, 2002, GUT, V50, P803, DOI 10.1136/gut.50.6.803; Ludviksson BR, 2000, EUR J IMMUNOL, V30, P2101, DOI 10.1002/1521-4141(200007)30:7<2101::AID-IMMU2101>3.0.CO;2-P; Ma DL, 2004, INFECT IMMUN, V72, P5308, DOI 10.1128/IAI.72.9.5308-5314.2004; Mack DR, 2003, GUT, V52, P827, DOI 10.1136/gut.52.6.827; Mack DR, 1999, AM J PHYSIOL-GASTR L, V276, pG941, DOI 10.1152/ajpgi.1999.276.4.G941; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Madsen K, 2001, GASTROENTEROLOGY, V121, P580, DOI 10.1053/gast.2001.27224; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; McNaught CE, 2002, GUT, V51, P827, DOI 10.1136/gut.51.6.827; MEURMAN JH, 1994, MICROB ECOL HEALTH D, V7, P295, DOI 10.3109/08910609409141368; Nagler-Anderson C, 2000, CRIT REV IMMUNOL, V20, P103; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Newberry RD, 1999, NAT MED, V5, P900, DOI 10.1038/11341; Otte JM, 2004, GASTROENTEROLOGY, V126, P1054, DOI 10.1053/j.gastro.2004.01.007; Otte JM, 2004, AM J PHYSIOL-GASTR L, V286, pG613, DOI 10.1152/ajpgi.00341.2003; Perez-Machado MA, 2003, EUR J IMMUNOL, V33, P2307, DOI 10.1002/eji.200323308; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Petitprez K, 1999, SCAND J IMMUNOL, V49, P14; Piccinni MP, 1998, NAT MED, V4, P1020, DOI 10.1038/2006; Pochard P, 2002, J ALLERGY CLIN IMMUN, V110, P617, DOI 10.1067/mai.2002.128528; Pohjavuori E, 2004, J ALLERGY CLIN IMMUN, V114, P131, DOI 10.1016/j.jaci.2004.03.036; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rautava S, 2004, J PEDIATR GASTR NUTR, V38, P378, DOI 10.1097/00005176-200404000-00004; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273; Resta-Lenert S, 2003, GUT, V52, P988, DOI 10.1136/gut.52.7.988; Rosenfeldt V, 2004, J PEDIATR-US, V145, P612, DOI 10.1016/j.jpeds.2004.06.068; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; SANDERSON IR, 1993, GASTROENTEROLOGY, V104, P622, DOI 10.1016/0016-5085(93)90436-G; Shida K, 2002, CLIN EXP ALLERGY, V32, P563, DOI 10.1046/j.0954-7894.2002.01354.x; Spanhaak S, 1998, EUR J CLIN NUTR, V52, P899, DOI 10.1038/sj.ejcn.1600663; STAVNEZER J, 1995, J IMMUNOL, V155, P1647; Steidler L, 2003, NAT BIOTECHNOL, V21, P785, DOI 10.1038/nbt840; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sudo N, 1997, J IMMUNOL, V159, P1739; Tannock GW, 2000, APPL ENVIRON MICROB, V66, P2578, DOI 10.1128/AEM.66.6.2578-2588.2000; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; Venturi A, 1999, ALIMENT PHARM THER, V13, P1103; von der Weid T, 2001, CLIN DIAGN LAB IMMUN, V8, P695, DOI 10.1128/CDLI.8.4.695-701.2001; Wehkamp J, 2004, INFECT IMMUN, V72, P5750, DOI 10.1128/IAI.72.10.5750-5758.2004; Yan F, 2002, J BIOL CHEM, V277, P50959, DOI 10.1074/jbc.M207050200; Zeiger R S, 1994, Pediatr Allergy Immunol, V5, P33, DOI 10.1111/j.1399-3038.1994.tb00346.x	62	105	114	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					31	37		10.1016/j.jaci.2005.02.010	http://dx.doi.org/10.1016/j.jaci.2005.02.010			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990769	Bronze			2022-12-18	WOS:000235686300004
J	Bagenstose, SE; Levin, L; Bernstein, JA				Bagenstose, SE; Levin, L; Bernstein, JA			The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chronic urticaria; autologous serum; zafirlukast; leukotriene D-4 antagonist; cetirizine; H-1 antagonist; visual analog scale; treatment effectiveness score; autoantibodies; combination therapy	LEUKOTRIENE RECEPTOR ANTAGONIST; CHRONIC IDIOPATHIC URTICARIA; DOUBLE-BLIND; PLACEBO; HISTAMINE; AUTOANTIBODIES; EFFICACY; CYCLOSPORINE; MONTELUKAST; LTB4	Background: Because leukotrienes have potent local effects on cutaneous vasculature, leukotriene antagonists might be effective in the treatment of chronic urticaria. Objective: A double-blinded, placebo-controlled trial comparing cetirizine 10 mg daily in combination with zafirlukast 20 mg twice a day versus cetirizine 10 mg daily and placebo was conducted to determine whether subjects with chronic urticaria benefit from add-on therapy with a leukotriene-modifying agent. Methods: Patients 12 years or older with a history of chronic urticaria (more than 6 weeks in duration) required diary documentation of 6 or more hives on at least 2 days/week and a suboptimal response to HI-antagonist therapy for enrollment. At baseline, all subjects were skin tested to autologous serum to assess for the potential presence of FcepsilonR1 or IgE autoantibodies. Subjects meeting the initial entry criteria were treated with cetirizine 10 mg a day and placebo twice daily for I week. Those patients with persistent hives were randomized to receive cetirizine 10 mg daily and zafirlukast 20 mg twice a day or cetirizine 10 mg daily and placebo. At each successive weekly visit, physician and patient treatment effectiveness score (TES) and visual analog scale (VAS) ratings were recorded. Statistical analysis used generalizing estimating equations to compare the effect of combination therapy versus monotherapy on TES and VAS ratings. Results were adjusted for baseline rating, recruiting center, and autologous serum skin test (ASST). A separate analysis evaluated patients with positive ASST results receiving combination therapy versus monotherapy. Results: Combination therapy with zafirlukast demonstrated a modest but significantly greater improvement compared with cetirizine monotherapy in physician and patient recorded VAS ratings at visit 4 and across treatment visits 4 through 6 (P <.05 unless stated otherwise). Subjects with ASST positive results receiving combination therapy as compared with subjects with negative ASST results exhibited a significant improvement in patient recorded VAS ratings across visits 4 through 6. Subgroup analysis of subjects with ASST positive results receiving combination therapy versus monotherapy showed improvement in physician recorded TES at visit 5, physician recorded VAS at visits 4 and 5 and across visits 4 through 6, as well as for patient recorded VAS at visit 5. There were no significant results for patients with ASST negative results. Conclusion: The results of this study indicate that only patients with autoimmune (ASST positive) chronic urticaria refractory to HI-antagonist monotherapy might benefit from the addition of the leukotriene D-4-receptor antagonist zafirlukast to their treatment regimen. These results also suggest that routine screening of patients with chronic urticaria with the ASST might be useful in formulating therapeutic algorithms in the management of chronic urticaria.	Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Ctr Biostat Serv, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Bernstein, JA (corresponding author), Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol, 231 Albert Sabin Way ML 563, Cincinnati, OH 45267 USA.			Bernstein, Jonathan/0000-0002-3476-1196				ANDRI L, 1993, ALLERGY, V48, P358, DOI 10.1111/j.1398-9995.1993.tb02406.x; Bernstein JA, 2002, ANN ALLERG ASTHMA IM, V89, P212, DOI 10.1016/S1081-1206(10)61941-2; BERNSTEIN JA, 1991, J ALLERGY CLIN IMMUN, V87, P93, DOI 10.1016/0091-6749(91)90217-C; BISGAARD H, 1987, J INVEST DERMATOL, V88, P109, DOI 10.1111/1523-1747.ep12525225; Breneman DL, 1996, ANN PHARMACOTHER, V30, P1075, DOI 10.1177/106002809603001001; Brostoff J, 1996, ALLERGY, V51, P320; DARIMI K, 2000, EXP HEMATOL, V28, P626; Erbagci Z, 2002, J ALLERGY CLIN IMMUN, V110, P484, DOI 10.1067/mai.2002.126676; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Ferrer M, 2002, INT ARCH ALLERGY IMM, V129, P254, DOI 10.1159/000066772; Fiebiger E, 1998, J CLIN INVEST, V101, P243, DOI 10.1172/JCI511; Finkelman FD, 1997, ANNU REV IMMUNOL, V15, P505, DOI 10.1146/annurev.immunol.15.1.505; Finn AF, 1999, J ALLERGY CLIN IMMUN, V104, P1071, DOI 10.1016/S0091-6749(99)70091-6; Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; LEVISCHAFFER F, 1991, IMMUNOLOGY, V72, P174; Pacor ML, 2001, CLIN EXP ALLERGY, V31, P1607, DOI 10.1046/j.1365-2222.2001.01189.x; Parsad D, 2001, J DERMATOL, V28, P299, DOI 10.1111/j.1346-8138.2001.tb00137.x; Reimers A, 2002, CLIN EXP ALLERGY, V32, P1763, DOI 10.1046/j.1365-2222.2002.01536.x; RINKEMA LE, 1984, J PHARMACOL EXP THER, V230, P550; RUITENBER EJ, 1976, NATURE, V264, P258, DOI 10.1038/264258a0; Sabroe RA, 1999, BRIT J DERMATOL, V140, P446; Sabroe RA, 1998, J ALLERGY CLIN IMMUN, V102, P651, DOI 10.1016/S0091-6749(98)70283-0; SHAREEAH A M A, 1992, International Journal of Dermatology, V31, P355; Shirasaki H, 2002, CLIN EXP ALLERGY, V32, P1007, DOI 10.1046/j.1365-2222.2002.01425.x; Simons F.E.R., 1998, ALLERGY PRINCIPLES P, P612; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Toubi E, 1997, ALLERGY, V52, P312, DOI 10.1111/j.1398-9995.1997.tb00996.x; WARDLAW AJ, 1989, J ALLERGY CLIN IMMUN, V84, P19, DOI 10.1016/0091-6749(89)90173-5	31	105	108	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					134	140		10.1016/j.jaci.2003.10.002	http://dx.doi.org/10.1016/j.jaci.2003.10.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713918				2022-12-18	WOS:000187837900018
J	Kagan, RS; Joseph, L; Dufresne, C; Gray-Donald, K; Turnbu, E; St Pierre, Y; Clarke, AE				Kagan, RS; Joseph, L; Dufresne, C; Gray-Donald, K; Turnbu, E; St Pierre, Y; Clarke, AE			Prevalence of peanut allergy in primary-school children in Montreal, Canada	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; prevalence; skin prick testing; peanut specific IgE measurement; double-blind; placebo-controlled food challenge	SKIN PRICK TESTS; TREE NUT ALLERGY; NATURAL-HISTORY; FOOD ALLERGY; DOUBLE-BLIND; ANAPHYLACTIC REACTIONS; IGE CONCENTRATIONS; EPIDEMIOLOGY; ASSOCIATION; POPULATION	Background: Peanut allergy is receiving increasing attention. Only one study has estimated the prevalence in North America, but it did not corroborate history with diagnostic testing. Objective: We estimated the prevalence of peanut allergy in Montreal by administering questionnaires regarding peanut ingestion to children in kindergarten through grade 3 in randomly selected schools. Methods: Respondents were stratified as follows: (1) peanut tolerant, (2) never-rarely ingest peanut, (3) convincing history of peanut allergy, and (4) uncertain history of peanut allergy. Groups 2, 3, and 4 underwent peanut skin prick tests (SPTs), and if the responses were positive in groups 2 or 4, measurement of peanut-specific IgE were undertaken. Children in group 3 with a positive SPT response were considered allergic to peanut without further testing. Children in groups 2 and 4 with peanut-specific IgE levels of less than 15 kU/L underwent oral peanut challenges. Results: Of the 7768 children surveyed, 4339 responded, 94.6% in group 1. The prevalence of peanut allergy was 1.50% (95% CI, 1.16%-1.92%). When multiple imputation was used to incorporate data on those responding to the questionnaire but withdrawing before testing, the estimated prevalence increased to 1.76% (95% CI, 1.38%-2.21%). When data regarding the peanut allergy status of nonresponders (as declared to the school before the study) were also incorporated, the estimated prevalence was 1.34% (95% CI, 1.08%-1.64%). Conclusion: Our prevalence study is the first in North America to corroborate history with confirmatory testing and the largest worldwide to incorporate these techniques. We have shown that, even with conservative assumptions, prevalence exceeds 1.0%.	McGill Univ, Ctr Hlth, Dept Pediat, Div Clin Immunol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Ctr Hlth, Dept Pediat, Div Allergy & Rheumatol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Hlth Sci Ctr, Dept Med, Div Clin Epidemiol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Epidemiol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Biostat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Assoc Quebecoise Allergies Alimentaires, Montreal, PQ H3A 2T5, Canada; McGill Univ, Sch Dietet & Human Nutr, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Med, Div Clin Immunol Allergy, Montreal, PQ H3A 2T5, Canada	McGill University; McGill University; McGill University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McGill University; McGill University; McGill University; McGill University; McGill University	Clarke, AE (corresponding author), Montreal Gen Hosp, Div Clin Epidemiol, Room L10-413,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.							Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Burks W, 2003, J CLIN INVEST, V111, P950, DOI 10.1172/JCI200318233; Cochrane WG, 1997, SAMPLING TECHNIQUES, Vthird; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Eigenmann PA, 1998, PEDIAT ALLERG IMM-UK, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Kagan R, 2003, ANN ALLERG ASTHMA IM, V90, P640, DOI 10.1016/S1081-1206(10)61869-8; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; Kmetic A, 2002, EPIDEMIOLOGY, V13, P437, DOI 10.1097/00001648-200207000-00012; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2003, J IMMUNOL, V170, P3289, DOI 10.4049/jimmunol.170.6.3289; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; Pucar F, 2001, CLIN EXP ALLERGY, V31, P40, DOI 10.1046/j.1365-2222.2001.00962.x; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Rubin DB, 2004, MULTIPLE IMPUTATION; Sampson HA, 1996, PEDIAT ALLERG IMM-UK, V7, P42, DOI 10.1111/j.1399-3038.1996.tb00394.x; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V82, P718, DOI 10.1016/0091-6749(88)90070-X; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2002, ANN ALLERG ASTHMA IM, V88, P350, DOI 10.1016/S1081-1206(10)62363-0; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Spergel JM, 2000, ANN ALLERG ASTHMA IM, V85, P473, DOI 10.1016/S1081-1206(10)62574-4; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	42	105	105	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1223	1228		10.1016/j.jaci.2003.09.026	http://dx.doi.org/10.1016/j.jaci.2003.09.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657887				2022-12-18	WOS:000187154200030
J	Sutherland, ER; Martin, RJ				Sutherland, ER; Martin, RJ			Airway inflammation in chronic obstructive pulmonary disease: Comparisons with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						inflammation; chronic obstructive pulmonary disease; small airway; asthma; lymphocyte	PERIPHERAL AIRWAYS; CHRONIC-BRONCHITIS; T-LYMPHOCYTES; LUNG-FUNCTION; MACROPHAGE METALLOELASTASE; STRUCTURAL-CHANGES; ALVEOLAR TISSUE; SMOKERS; SMOKING; METHACHOLINE	Chronic obstructive pulmonary disease (COPD) is a progressive syndrome of expiratory airflow limitation caused by chronic inflammation of the airways and lung parenchyma. The airway inflammatory response in COPD is initiated by smoking in the overwhelming majority of cases, and chronic exposure to cigarette smoke initiates a series of events that causes damage to central airways, peripheral airways, and terminal airspaces, leading to physiologic and clinical abnormalities. Although COPD shares some clinical features with asthma, another prevalent airway inflammatory disease, there are distinct differences in the phenotypic characteristics of airway inflammation between COPD and asthma. The eosinophil is the most prominent inflammatory cell in asthma, with mast cells, lymphocytes, and macrophages playing important but less prominent roles. In COPD the cellular composition of the airway inflammatory infiltrate differs, with neutrophils, macrophages, and lymphocytes assuming prominence and the eosinophil playing a minor role, except in the setting of exacerbations. The contrasting inflammatory phenotypes of asthma and COPD have important implications for clinical and physiologic manifestations of disease, as well as for therapy.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Martin, RJ (corresponding author), 1400 Jackson St, Denver, CO 80206 USA.		Sutherland, Everett Rand/B-7666-2008					Amin K, 2003, THORAX, V58, P135, DOI 10.1136/thorax.58.2.135; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Arias Elizabeth, 2003, Natl Vital Stat Rep, V51, P1; BOSKEN CH, 1990, AM REV RESPIR DIS, V142, P563, DOI 10.1164/ajrccm/142.3.563; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Churg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC; Churg A, 2002, AM J RESP CELL MOL, V27, P368, DOI 10.1165/rcmb.4791; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666, DOI 10.1164/ajrccm.152.5.7582312; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Fujimoto K, 1999, CHEST, V115, P697, DOI 10.1378/chest.115.3.697; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Hogg JC, 2002, THORAX, V57, P830, DOI 10.1136/thorax.57.9.830; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Lams BEA, 1998, AM J RESP CRIT CARE, V158, P1518, DOI 10.1164/ajrccm.158.5.9802121; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; LUSUARDI M, 1994, THORAX, V49, P1211, DOI 10.1136/thx.49.12.1211; Majo J, 2001, EUR RESPIR J, V17, P946, DOI 10.1183/09031936.01.17509460; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; O'Donnell DE, 1999, AM J RESP CRIT CARE, V160, P542, DOI 10.1164/ajrccm.160.2.9901038; O'Donnell DE, 2001, AM J RESP CRIT CARE, V164, P770, DOI 10.1164/ajrccm.164.5.2012122; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852, DOI 10.1164/ajrccm.155.3.9117016; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511, DOI 10.1164/ajrccm.158.5.9804028; Retamales I, 2001, AM J RESP CRIT CARE, V164, P469, DOI 10.1164/ajrccm.164.3.2007149; Rutgers SR, 2000, THORAX, V55, P12, DOI 10.1136/thorax.55.1.12; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301, DOI 10.1164/ajrccm/147.2.301; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822, DOI 10.1164/ajrccm.157.3.9709027; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646, DOI 10.1164/ajrccm.150.6.7952628; Shapiro SD, 1999, AM J RESP CRIT CARE, V160, pS29, DOI 10.1164/ajrccm.160.supplement_1.9; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802, DOI 10.1164/ajrccm.153.6.8665038; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; Turato G, 2002, AM J RESP CRIT CARE, V166, P105, DOI 10.1164/rccm.2111084; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WRIGHT JL, 1983, AM REV RESPIR DIS, V127, P474, DOI 10.1164/arrd.1983.127.4.474	42	105	110	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					819	827		10.1016/S0091-6749(03)02011-6	http://dx.doi.org/10.1016/S0091-6749(03)02011-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610463				2022-12-18	WOS:000186553300001
J	Wen, FQ; Liu, XD; Manda, W; Terasaki, Y; Kobayashi, T; Abe, S; Fang, QH; Ertl, R; Manouilova, L; Rennard, SI				Wen, FQ; Liu, XD; Manda, W; Terasaki, Y; Kobayashi, T; Abe, S; Fang, QH; Ertl, R; Manouilova, L; Rennard, SI			T(H)2 cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)2/T(H)1 cytokines; transforming growth factor-beta; corticosteroids; vascular endothelial growth factor; human airway smooth muscle cells	PROTEIN-KINASE-C; INTERFERON-GAMMA; ASTHMATIC AIRWAYS; EOTAXIN RELEASE; MESSENGER-RNA; MILD ASTHMA; EXPRESSION; RESPONSIVENESS; INFLAMMATION; RECEPTOR	Background: T(H)2 and T(H)1 cytokines have opposite effects on many aspects of the inflammatory response. Methods: This study was designed to determine if cytokines possibly present in asthma can modulate airway smooth muscle cell (ASMC) production of vascular endothelial growth factor (VEGF) and thus contribute to altered airway vascularity. ASMC were incubated for 24 hours with various concentrations of T(H)2 cytokines (IL-4, IL-5, IL-10, and IL-13); transforming growth factor (TGF)-1, TGF-beta2, or TGF-beta3; and IL-1beta or TNF-alpha with or without IFN-gamma. Budesonide and exogenous prostaglandin (PG)E, were also evaluated. Postculture media were assayed for VEGF and PGE(2) by ELISA. Results: IL-4, IL-5, and IL-13 alone but not IL-10 enhanced VEGF production by ASMC in a concentration-dependent manner. IFN-gamma alone inhibited spontaneous VEGF release by ASMC and concentration-dependently attenuated IL-4-augmented, IL-5-augmented, or IL-13-augmented production of VEGF (P < .01). All three TGF-beta isoforms augmented VEGF production, which was reduced by IFN-gamma (P < .005). IL-1beta also increased VEGF production, but this was not affected by IFN-gamma (P > .05). TNF-alpha alone had little effect on VEGF release by ASMC. Production of VEGF stimulated by all cytokines was inhibited by budesonide. Exogenous PGE(2) increased VEGF release, but cytokine modulation of PGE(2) release did not always correlate with VEGF release. Conclusions: T(H)2 cytokines and TGF-beta stimulate ASMC release of VEGE This can be inhibited by IFN-gamma and glucocorticoids. (J.Allergy Clin Immunol 2003;111:1307-18.).	Univ Nebraska, Med Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rennard, SI (corresponding author), Univ Nebraska, Med Ctr, 985125 Nebraska Med Ctr, Omaha, NE 68198 USA.				NHLBI NIH HHS [R01 HL 64088-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064088] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Barnes PJ, 1996, AM J RESP CRIT CARE, V154, pS21, DOI 10.1164/ajrccm/154.2_Pt_2.S21; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; Berse B, 1999, CLIN EXP IMMUNOL, V115, P176; Carroll NG, 1997, AM J RESP CRIT CARE, V155, P689, DOI 10.1164/ajrccm.155.2.9032214; Charan NB, 1997, EUR RESPIR J, V10, P1173, DOI 10.1183/09031936.97.10051173; Cohn L, 2001, J IMMUNOL, V166, P2760, DOI 10.4049/jimmunol.166.4.2760; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; CROBETT L, 2002, AM J CRIT CARE MED, V165, pA114; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Grunstein MM, 2001, AM J PHYSIOL-LUNG C, V281, pL1130, DOI 10.1152/ajplung.2001.281.5.L1130; GURUJEYALAKSHMI G, 1995, EXP LUNG RES, V21, P791, DOI 10.3109/01902149509050842; Hakonarson H, 2002, J ALLERGY CLIN IMMUN, V110, P624, DOI 10.1067/mai.2002.128529; HALL IP, 1995, AM J PHYSIOL-LUNG C, V268, pL1, DOI 10.1152/ajplung.1995.268.1.L1; HALLIP, 1995, AM J PHYSIOL, V268, pL1; Hirst SJ, 1998, AM J RESP CRIT CARE, V158, pS201, DOI 10.1164/ajrccm.158.supplement_2.13tac190; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; Hogg JC, 1999, THORAX, V54, P283, DOI 10.1136/thx.54.4.283; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Jeffery PK, 1998, THORAX, V53, P129, DOI 10.1136/thx.53.2.129; John M, 1997, J IMMUNOL, V158, P1841; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Lee CG, 2002, J BIOL CHEM, V277, P35466, DOI 10.1074/jbc.M206395200; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Liu XD, 2002, AM J PHYSIOL-LUNG C, V282, pL1049, DOI 10.1152/ajplung.00321.2001; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; ODONNELL RA, 2002, ASTHMA COPD, P67; Orsida BE, 1999, THORAX, V54, P289, DOI 10.1136/thx.54.4.289; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Pang LH, 1998, J IMMUNOL, V161, P2509; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pang LH, 1997, AM J PHYSIOL-LUNG C, V273, pL1132, DOI 10.1152/ajplung.1997.273.6.L1132; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417, DOI 10.1164/ajrccm.159.5.9805080; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHARMA HS, 2002, AM J RESP CRIT CARE, V165, pA810; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Weltman JK, 2000, EXPERT OPIN INV DRUG, V9, P491, DOI 10.1517/13543784.9.3.491; Wen FQ, 2002, AM J RESP CELL MOL, V26, P484, DOI 10.1165/ajrcmb.26.4.4784; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu YK, 2001, J ALLERGY CLIN IMMUN, V108, P989, DOI 10.1067/mai.2001.120193; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703	55	105	112	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1307	1318		10.1067/mai.2003.1455	http://dx.doi.org/10.1067/mai.2003.1455			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789234				2022-12-18	WOS:000183424700022
J	Jakob, T; Ring, J; Udey, MC				Jakob, T; Ring, J; Udey, MC			Multistep navigation of Langerhans/dendritic cells in and out of the skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Langerhans cells; dendritic cells; migration-trafficking; adhesion; chemokines; skin; allergy; immune regulation	HUMAN PERIPHERAL-BLOOD; CPG-CONTAINING OLIGODEOXYNUCLEOTIDES; INFLAMMATORY PROTEIN 3-ALPHA; CADHERIN-MEDIATED ADHESION; CUTANEOUS DENDRITIC CELLS; NECROSIS-FACTOR-ALPHA; DRAINING LYMPH-NODES; CONTACT HYPERSENSITIVITY; CHEMOKINE RECEPTORS; TH1 RESPONSES	Langerhans cells (LCs) are specialized antigen-presenting cells that reside in the epidermis as sentinels of the immune system. LCs constantly monitor the epidermal microenvironment by taking up antigen and processing it into fragments that can be recognized by cells of the adaptive immune response. Because of their unique migratory ability, LCs can transport antigen from the epidermis to regional lymph nodes, where they can initiate systemic immune responses. The mechanisms of LC trafficking thus seem to be of particular relevance for the induction and maintenance of cutaneous immunity. LCs or their putative precursors express surface molecules that allow them to home to skin and localize in the epidermis for prolonged periods of time. Tissue injury, microbial infection, and other perturbants of epidermal homeostasis (eg, contact allergens) provide danger signals, leading to a local production of proinflammatory cytokines that induce LC mobilization to the lymphoid tissue. At the same time, signals are generated that recruit LC precursors into the skin to maintain the epidermal LC population. Distinct pairs of chemokines and their receptors control the migration from blood to epidermis and from there to the regional lymphatics. In addition, trafficking is controlled at the level of cell adhesion, where LCs downregulate some adhesion molecules to exit the epidermis and upregulate others to migrate across the extracellular matrix and home to T-cell areas of regional lymphoid tissue. The improved understanding of mechanisms that regulate LC trafficking might offer new opportunities for therapeutic interventions to suppress, stimulate, or deviate cutaneous immune responses.	Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Div Environm Dermatol & Allergy GSF TUM, D-80802 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergy GSF TUM, Neuherberg, Germany; NCI, Dermatol Branch, NIH, Bethesda, MD 20892 USA	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jakob, T (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Div Environm Dermatol & Allergy GSF TUM, Biedersteiner Str 29, D-80802 Munich, Germany.		Jakob, Thilo/J-1621-2012; Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				AIBA S, 1993, J INVEST DERMATOL, V100, P143, DOI 10.1111/1523-1747.ep12462783; AIBA S, 1990, J IMMUNOL, V145, P2791; Antonopoulos H, 2001, J IMMUNOL, V166, P3672, DOI 10.4049/jimmunol.166.6.3672; BORKOWSKI TA, 1994, EUR J IMMUNOL, V24, P2767, DOI 10.1002/eji.1830241129; Borkowski TA, 1997, J CLIN INVEST, V100, P575, DOI 10.1172/JCI119567; Borkowski TA, 1996, J EXP MED, V184, P2417, DOI 10.1084/jem.184.6.2417; BRAND CU, 1992, J INVEST DERMATOL, V99, pS109, DOI 10.1111/1523-1747.ep12669997; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; CHEN HD, 1986, J INVEST DERMATOL, V86, P630, DOI 10.1111/1523-1747.ep12275627; CRUZ PD, 1990, J IMMUNOL, V144, P2486; Cumberbatch M, 2000, IMMUNOLOGY, V100, P21, DOI 10.1046/j.1365-2567.2000.00014.x; CUMBERBATCH M, 1992, IMMUNOLOGY, V75, P257; Cumberbatch M, 1999, ARCH DERMATOL RES, V291, P357, DOI 10.1007/s004030050422; Cumberbatch M, 1997, ARCH DERMATOL RES, V289, P277, DOI 10.1007/s004030050193; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; ENK AH, 1993, J IMMUNOL, V150, P3698; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Geissmann F, 1998, J EXP MED, V187, P961, DOI 10.1084/jem.187.6.961; Geissmann F, 1999, J IMMUNOL, V162, P4567; GIROLOMONI G, 1993, J INVEST DERMATOL, V100, P282, DOI 10.1111/1523-1747.ep12469769; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HOLT PG, 1994, J IMMUNOL, V153, P256; Jakob T, 1999, J INVEST DERMATOL, V112, P102, DOI 10.1046/j.1523-1747.1999.00475.x; Jakob T, 1999, INT ARCH ALLERGY IMM, V118, P457, DOI 10.1159/000024163; Jakob T, 1997, J IMMUNOL, V159, P2693; Jakob T, 1998, J IMMUNOL, V161, P3042; Jakob T, 1998, J IMMUNOL, V160, P4067; Jakob T, 1999, Adv Dermatol, V14, P209; Jenne L, 2001, TRENDS IMMUNOL, V22, P102, DOI 10.1016/S1471-4906(00)01813-5; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; Kobayashi Y, 1997, IMMUNOLOGY, V90, P496, DOI 10.1046/j.1365-2567.1997.00212.x; Kobayashi Y, 1999, J IMMUNOL, V163, P5989; KOSZIK F, 1994, J INVEST DERMATOL, V102, P773, DOI 10.1111/1523-1747.ep12377706; LESSARD RJ, 1968, J INVEST DERMATOL, V50, P171, DOI 10.1038/jid.1968.20; Lin CL, 1998, EUR J IMMUNOL, V28, P4114, DOI 10.1002/(SICI)1521-4141(199812)28:12<4114::AID-IMMU4114>3.0.CO;2-C; Lutz MB, 2000, EUR J IMMUNOL, V30, P1048, DOI 10.1002/(SICI)1521-4141(200004)30:4<1048::AID-IMMU1048>3.0.CO;2-W; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; PICKER LJ, 1990, J IMMUNOL, V145, P3247; Price AA, 1997, J EXP MED, V186, P1725, DOI 10.1084/jem.186.10.1725; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Riedl E, 2000, J IMMUNOL, V165, P1381, DOI 10.4049/jimmunol.165.3.1381; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Robert C, 1999, J EXP MED, V189, P627, DOI 10.1084/jem.189.4.627; Saeki H, 1999, J IMMUNOL, V162, P2472; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sato K, 2000, J IMMUNOL, V164, P2285, DOI 10.4049/jimmunol.164.5.2285; Schuler G, 1997, J EXP MED, V186, P1183, DOI 10.1084/jem.186.8.1183; Schwarzenberger K, 1996, J INVEST DERMATOL, V106, P553, DOI 10.1111/1523-1747.ep12344019; SHIBAKI A, 1995, J INVEST DERMATOL, V104, P42, DOI 10.1111/1523-1747.ep12613476; STINGL G, 1980, IMMUNOL REV, V53, P149, DOI 10.1111/j.1600-065X.1980.tb01043.x; Strunk D, 1997, J EXP MED, V185, P1131, DOI 10.1084/jem.185.6.1131; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.bi.59.070190.001321; TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Vassileva G, 1999, J EXP MED, V190, P1183, DOI 10.1084/jem.190.8.1183; Wang B, 1999, J IMMUNOL, V162, P277; Wang BH, 1997, J IMMUNOL, V159, P6148; Wang M, 1999, P NATL ACAD SCI USA, V96, P6885, DOI 10.1073/pnas.96.12.6885; Weiss JM, 1997, J CELL BIOL, V137, P1137, DOI 10.1083/jcb.137.5.1137; WOLFF K, 1991, EPIDERMAL LANGERHANS, P1; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Yanagihara S, 1998, J IMMUNOL, V161, P3096; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	66	105	113	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					688	696		10.1067/mai.2001.118797	http://dx.doi.org/10.1067/mai.2001.118797			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692090				2022-12-18	WOS:000172523800005
J	Golden, DBK; Kwiterovich, KA; Kagey-Sobotka, A; Lichtenstein, LM				Golden, DBK; Kwiterovich, KA; Kagey-Sobotka, A; Lichtenstein, LM			Discontinuing venom immunotherapy: Extended observations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						venom immunotherapy; hymenoptera; insect sting allergy	YELLOW JACKET VENOM; STING CHALLENGE; NATURAL-HISTORY; HONEYBEE VENOM; ALLERGY; ANAPHYLAXIS; SEVERITY; HYPERSENSITIVITY; EPIDEMIOLOGY; SYMPTOMS	Background: Our studies of discontinuing venom immunotherapy after at least 5 years hart led to the conclusion that the residual risk of a systemic reaction to a sting was in the range of 5% to 10% in adults, and no severe or life-threatening reaction occurred with 270 challenge stings in 74 patients after 1 to 5 p-ears without venom immunotherapy. Objective: The objective of this study;vas to extend our observation of patients who discontinue venom immunotherapy over 5 to 10 years and to determine which patients are at higher risk for a reaction. Methods: Patients who discontinued venom immunotherapy were surveyed for 3 consecutive years to determine the frequency of systemic reactions to;idd stings and the Fate of venom sensitivity. The evaluation included the 74 patients previously studied (group 1) and 51 additional patients followed after stopping therapy in am clinical center (group 2). Results: Of the original 74 patients, II had field stings again after 3 to 7 years without venom immunotherapy, with one systemic reaction (dyspnea). Of the 51 patients in the other group, 15 were stung, of whom four (26%) had systemic reactions, including respiratory symptoms requiring epinephrine. Review of group 1 and group 2 revealed that half of the patients vi bo had systemic reactions to a sting after stopping venom immunotherapy had a history of a systemic reaction occurring during venom immunotherapy (to an injection or a sting). Systemic reactions occurred in three patients who had negative skin test reactions; all three had very Iom hut detectable venom-specific serum IgE antibody levels as determined by RAST and had a history of systemic reactions during venom immunotherapy. Greater severity of the pretreatment reaction mas not associated with higher frequency of reaction to stings after stopping therapy hut mas associated with greater severity if a reaction did occur, Conclusions: Venom immunotherapy (yellow jacket/mixed vespid) in adults can be discontinued after 5 to 6 years with a 5% to 10% residual risk of a systemic reaction. Risk factors may include history of a systemic reaction during venom immunotherapy, persistent strongly positive skin test sensitivity, and the severity of the pretreatment reaction.	Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Golden, DBK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, 5501 Hopkins Bayview Blvd, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08270] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUSQUET J, 1988, ANN ALLERGY, V61, P63; GOLDBERG A, 1994, J ALLERGY CLIN IMMUN, V93, P997, DOI 10.1016/S0091-6749(94)70047-8; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1989, ALLERGY PROC, V10, P103, DOI 10.2500/108854189778960964; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V83, P273; GOLDEN DBK, 1987, J ALLERGY CLIN IMMUN, V79, P126; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V89, P291; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P57; HAMILTON RG, 1981, J ALLERGY CLIN IMMUN, V67, P14, DOI 10.1016/0091-6749(81)90039-7; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P791; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1994, J ALLERGY CLIN IMMUN, V94, P651, DOI 10.1016/0091-6749(94)90167-8; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1991, J ALLERGY CLIN IMMUN, V87, P618, DOI 10.1016/0091-6749(91)90378-2; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889	25	105	105	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					298	305		10.1016/S0091-6749(98)70239-8	http://dx.doi.org/10.1016/S0091-6749(98)70239-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525443	hybrid			2022-12-18	WOS:000072593900003
J	MAKINENKILJUNEN, S				MAKINENKILJUNEN, S			BANANA ALLERGY IN PATIENTS WITH IMMEDIATE-TYPE HYPERSENSITIVITY TO NATURAL-RUBBER LATEX - CHARACTERIZATION OF CROSS-REACTING ANTIBODIES AND ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NATURAL RUBBER; LATER; BANANA; CROSS-REACTIVITY; RAST INHIBITION; IMMUNOSPOT; CROSSED IMMUNOELECTROPHORESIS	BIRCH POLLEN-ALLERGY; CONTACT URTICARIA; GLOVE CONTACT; ANAPHYLAXIS; ANTIGENS; SENSITIZATION; CHESTNUT; IGE	Background: An association between allergy to Inter and banana has been reported. Even though cross-reacting IgE antibodies have been demonstrated in no study has the existence of structurally similar allergens been confirmed. In the present study banana allergy was studied in a large series of patients with latex allergy. Specific IgE antibodies were characterized for cross-reactivity and compared with pollen RAST results. Latex and banana extracts were investigated for common antigens and allergens. Methods: Latex-, banana-, and pollen-specific (birch, timothy, mugwort) IgE were measured in 47 sera from patients with latex allergy. Thirty-one patients were skin prick tested with banana and questioned for possible reactions after eating bananas. Several RAST inhibition and immunospot inhibition studies were used to characterize cross-reacting IgE antibodies. Structurally similar antigens and allergens were evaluated with crossed-line immunoelectrophoresis and crossed-line radioimmunoelectrophoresis, respectively. Results: Later RAST results were positive in 31 (66%) and banana RAST results were positive in 26 (55%) of the 47 sera. Of the 31 latex PAST-positive sera, 25 (81%) were also banana RAST-positive. Results from latex RAST correlated significantly with results from banana RAST (p < 0.001), but not with those from pollen RAST (p > 0.05). Banana skin prick test results were positive in 11 (35%) of the 31 patients tested. Symptoms after eating bananas were reported by 16 (52%) of the 31 patients. In inhibition studies the binding of IgE antibodies to solid-phase banana and to several later preparations was inhibited by latex and banana, respectively. In crossed-line immunoelectrophoresis at least one antigen from banana fused with an antigen from latex, which also bound IgE antibodies in autoradiography (crossed-line radioimmunoelectrophoresis). Conclusions: Patients with latex allergy have symptoms caused by banana and show positive skin test and specific IgE test results. Cross-reacting IgE antibodies were confirmed by several inhibition techniques. For the first time, a structurally similar antigen/allergen was demonstrated.			MAKINENKILJUNEN, S (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT DERMATOL & ALLERG DIS,MEILAHDENTIE 2,SF-00250 HELSINKI,FINLAND.							ALENIUS H, 1991, INT ARCH ALLER A IMM, V96, P376, DOI 10.1159/000235525; ANIBARRO B, 1993, ALLERGY, V48, P130, DOI 10.1111/j.1398-9995.1993.tb00698.x; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; DECORRES LF, 1993, ANN ALLERGY, V70, P35; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; JAGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; MAKINENKILJUNEN S, 1992, LANCET, V339, P1608, DOI 10.1016/0140-6736(92)91872-6; MAKINENKILJUNEN S, 1992, J ALLERGY CLIN IMMUN, V90, P230, DOI 10.1016/0091-6749(92)90076-E; MAKINENKILJUNEN S, 1993, J ALLERGY CLIN IMMUN, V91, P242; MAKINENKILJUNEN S, 1992, ALLERGY, V47, P65; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; RODRIGUEZ M, 1993, ANN ALLERGY, V70, P31; ROSS BD, 1992, J ALLERGY CLIN IMMUN, V90, P409, DOI 10.1016/S0091-6749(05)80023-5; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; Yman L, 1975, Dev Biol Stand, V29, P151; YOUNG MC, 1992, J ALLERGY CLIN IMMUN, V89, P226	25	105	107	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					990	996		10.1016/S0091-6749(94)70046-X	http://dx.doi.org/10.1016/S0091-6749(94)70046-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006321	Bronze			2022-12-18	WOS:A1994NT17200006
J	GAUTRIN, D; BOULET, LP; BOUTET, M; DUGAS, M; BHERER, L; LARCHEVEQUE, RT; LAVIOLETTE, M; COTE, J; MALO, JL				GAUTRIN, D; BOULET, LP; BOUTET, M; DUGAS, M; BHERER, L; LARCHEVEQUE, RT; LAVIOLETTE, M; COTE, J; MALO, JL			IS REACTIVE AIRWAYS DYSFUNCTION SYNDROME A VARIANT OF OCCUPATIONAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						OCCUPATIONAL EXPOSURE; OCCUPATIONAL DISEASES; CHLORINE; BRONCHIAL DISEASES	TOLUENE DIISOCYANATE; MUCOSAL INFLAMMATION; PERSISTENT ASTHMA; SULFUR-DIOXIDE; ACETIC-ACID; EXPOSURE; INHALATION; OBSTRUCTION; DISEASE; VOLUME	Background: Reactive airways dysfunction syndrome (RADS) or irritant-induced asthma is a syndrome that leaves subjects with asthma-like symptoms after one or more exposures to a high concentration of an irritant substance. The degree of reversibility of airway obstruction in subjects with RADS is nevertheless unknown, as is the degree of associated lesions at the airway level. Methods: We compared the acute reversibility of forced expiratory volume in 1 second (FEV(1)) after inhalation of albuterol (200 mu g) in 15 subjects with RADS (12 cases caused by chlorine inhalation) with that of 30 subjects with occupational asthma (OA) caused by various agents. They were paired according to baseline airway obstruction (61% and 63% of predicted value in the RADS and OA groups), requirement for medication (bronchodilator only-7 of Is subjects with RADS and 14 of 30 subjects with OA-as compared with bronchodilator + inhaled steroids in 8 of 15 subjects with RADS and 16 of 30 subjects with OA, respectively), and interval since removal from exposure (means of 30 and 24 months in the RADS and OA groups). In addition, five nonsmokers with RADS who had not received inhaled steroids underwent bronchoscopy with lavage and bronchial biopsies less than 2 years after the exposure. Results: The percentage increase in FEV(1) over baseline after inhalation of albuterol was 10%+/-9% in the RADS group and 19%+/-16% in the OA group (p = 0.005). Only 2 of is subjects (13%) with RADS and 12 of 30 subjects (40%) with OA showed an improvement in FET(1), of 20% or greater after inhalation of albuterol. Bronchoalveolar lavage showed an increased number of cells with a predominance of lymphocytes, and biopsy specimens showed increased basement membrane thickness in the five subjects with RADS who underwent bronchoscopy. Conclusion: Subjects with RADS are generally left with less airway reversibility than those with OA. We suggest that this difference is secondary to distinct pathologic changes.	SACRE COEUR HOSP,DEPT CHEST MED,MONTREAL,PQ H4J 1C5,CANADA; LAVAL HOSP,DEPT CHEST MED,QUEBEC CITY,PQ,CANADA; DEPT COMMUNITY HLTH,HULL,PQ,CANADA	Universite de Montreal								[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BERNSTEIN DI, 1993, ASTHMA WORKPLACE, P1; BOULET LP, 1988, CHEST, V94, P476, DOI 10.1378/chest.94.3.476; BOULET LP, 1993, J ALLERGY CLIN IMMUN, V91, P883, DOI 10.1016/0091-6749(93)90346-H; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; CHARAN NB, 1979, AM REV RESPIR DIS, V119, P555; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DESCHAMPS D, 1992, BRIT J IND MED, V49, P523; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FLURY KE, 1983, MAYO CLIN PROC, V58, P389; HARKONEN H, 1983, AM REV RESPIR DIS, V128, P890; HASAN FM, 1983, ARCH ENVIRON HEALTH, V38, P76, DOI 10.1080/00039896.1983.10543984; HOWARTH PH, 1991, INT ARCH ALLER A IMM, V94, P266, DOI 10.1159/000235379; KENNEDY SM, 1991, AM REV RESPIR DIS, V143, P74, DOI 10.1164/ajrccm/143.1.74; KERN DG, 1991, AM REV RESPIR DIS, V144, P1058, DOI 10.1164/ajrccm/144.5.1058; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LAGIER F, 1990, REV MAL RESPIR, V7, P337; LUO JCJ, 1990, BRIT J IND MED, V47, P239; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; MURPHY DMF, 1976, CHEST, V69, P372, DOI 10.1378/chest.69.3.372; PAGGIARO P, 1990, CHEST, V98, P536, DOI 10.1378/chest.98.3.536; RAJAN KG, 1989, BRIT J IND MED, V46, P67; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160, DOI 10.1164/ajrccm/145.1.160	25	105	107	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				12	22		10.1016/0091-6749(94)90228-3	http://dx.doi.org/10.1016/0091-6749(94)90228-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	8308178				2022-12-18	WOS:A1994MT78100002
J	WICKMAN, M; GRAVESEN, S; NORDVALL, SL; PERSHAGEN, G; SUNDELL, J				WICKMAN, M; GRAVESEN, S; NORDVALL, SL; PERSHAGEN, G; SUNDELL, J			INDOOR VIABLE DUST-BOUND MICROFUNGI IN RELATION TO RESIDENTIAL CHARACTERISTICS, LIVING HABITS, AND SYMPTOMS IN ATOPIC AND CONTROL CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MICROFUNGI; FLOOR DUST; INDOOR CLIMATE; BUILDING CHARACTERISTICS; LIVING HABITS; ATOPY	AIRBORNE FUNGI SURVEY; ENVIRONMENTAL-FACTORS; MOLD GROWTH; HOUSE DUST; ASTHMA; HOMES; PREVALENCE; DISEASE; ALLERGY; CROUP	Floor dust was collected in the wintertime from the homes of 61 children sensitized to house dust mites, 57 children with sensitization to other aeroallergens, and 57 nonatopic control children. The dust was cultivated and microfungal growth was identified microscopically. Indoor humidity was measured, and condensation on windowpanes was registered during 1 winter week. Housing and sociodemographic and symptom data were obtained by a questionnaire. Penicillium, Alternaria, and Cladosporium were the three most common microfungi. The mean total number of colony-forming units per 30 mg of dust was significantly lower in the homes of the two atopic groups than in homes of the control group, which may be a result of allergen-sanitation measures. High colony-forming unit counts appeared to be related to damp housing. Weak associations were found between the occurrence of viable fungi in dust and allergic symptoms among the house dust mite-sensitized children. However, no consistent association between viable mold growth and sensitization to molds was observed. The health implications of indoor fungal exposure still remain unclear.	KAROLINSKA INST,DEPT ENVIRONM HYG,S-10401 STOCKHOLM 60,SWEDEN; AS ALK,ALLERGOL LAB,HORSHOLM,DENMARK; KAROLINSKA HOSP,DEPT CLIN IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA HOSP,DEPT ENVIRONM HLTH & INFECT DIS CONTROL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,INST ENVIRONM MED,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	WICKMAN, M (corresponding author), ST GORANS CHILDRENS HOSP,DEPT PEDIAT,BOX 12500,S-11281 STOCKHOLM,SWEDEN.		Sundell, Jan H/B-2857-2012	Pershagen, Goran/0000-0002-9701-1130				Aas K, 1974, ACTA ALLERGOL, V29, P239; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BANERJEE UC, 1987, GRANA, V26, P103, DOI 10.1080/00173138709428910; CORNFIELD J, 1956, 3RD P BERK S STAT PR; DAVIES R. R., 1960, TRANS BRIT MYCOL SOC, V43, P617; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GRAVESEN S, 1972, ACTA ALLERGOL, V27, P337, DOI 10.1111/j.1398-9995.1972.tb01433.x; GRAVESEN S, 1979, ALLERGY, V34, P135, DOI 10.1111/j.1398-9995.1979.tb01562.x; GRAVESEN S, 1978, ALLERGY, V33, P269; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HIRSCH SR, 1976, ANN ALLERGY, V36, P30; HYDE H A, 1973, Clinical Allergy, V3, P109, DOI 10.1111/j.1365-2222.1973.tb01315.x; HYDE H A, 1972, Clinical Allergy, V2, P153, DOI 10.1111/j.1365-2222.1972.tb01280.x; ISHII A, 1979, ALLERGY, V34, P379, DOI 10.1111/j.1398-9995.1979.tb02007.x; KOZAK PP, 1979, ANN ALLERGY, V43, P88; LUMPKINS ED, 1976, ANN ALLERGY, V36, P40; LUMPKINS ED, 1976, ANN ALLERGY, V31, P361; MALLING HJ, 1986, ALLERGY, V41, P342, DOI 10.1111/j.1398-9995.1986.tb00311.x; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MOSBECH H, 1986, ALLERGY, V41, P373, DOI 10.1111/j.1398-9995.1986.tb00315.x; NORDVALL SL, 1990, PEDIATR ALLERGY IMMU, V1, P68; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PLATT SD, 1989, BRIT MED J, V298, P1673, DOI 10.1136/bmj.298.6689.1673; POPP W, 1989, ALLERGY, V44, P572, DOI 10.1111/j.1398-9995.1989.tb04202.x; RIPE E, 1962, ACTA ALLERGOL, V18, P130; STRACHAN DP, 1988, BMJ-BRIT MED J, V297, P1223, DOI 10.1136/bmj.297.6658.1223; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; Warner JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; ZACH M, 1990, LUNG, V168, P353, DOI 10.1007/BF02718152; ZACH M, 1981, ARCH DIS CHILD, V56, P336, DOI 10.1136/adc.56.5.336; 613 COMM EUR COMM CO	35	105	106	0	18	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1992	89	3					752	759		10.1016/0091-6749(92)90384-E	http://dx.doi.org/10.1016/0091-6749(92)90384-E			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HJ340	1545096	Bronze			2022-12-18	WOS:A1992HJ34000016
J	BOSSO, JV; SCHWARTZ, LB; STEVENSON, DD				BOSSO, JV; SCHWARTZ, LB; STEVENSON, DD			TRYPTASE AND HISTAMINE-RELEASE DURING ASPIRIN-INDUCED RESPIRATORY REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASPIRIN; ASPIRIN-SENSITIVE RHINOSINUSITIS; NONSTEROIDAL ANTIINFLAMMATORY DRUG; FEV; MAST CELL	HUMAN MAST-CELLS; ASTHMATIC-PATIENTS; BRONCHIAL-ASTHMA; PLASMA HISTAMINE; BRONCHOCONSTRICTION; ANAPHYLAXIS; CHALLENGE; INTESTINE	The involvement of mast cells in the pathogenesis of aspirin (ASA)-induced respiratory reactions was investigated by measuring serum levels of tryptase, a neutral protease that is a specific marker of mast cell activation. ASA challenges were performed in 17 ASA-sensitive patients with asthma and rhinosinusitis, and tryptase and histamine levels were measured in their venous blood samples. In three subjects who experienced moderate to severe respiratory reactions extending to the skin and/or gastrointestinal tract, marked elevations of tryptase levels in postreaction serum samples (peak levels, 51.9 and 40.0 ng/ml) were discovered in two of these three subjects, and a small elevation of tryptase occurred in the serum of the third subject (3.1 ng/ml peak). Plasma histamine levels in postreaction samples were significantly elevated over baseline values in all three subjects (DELTA mean plasma histamine, 238 pg/ml versus 56 pg/ml for the remaining 14 subjects; p < 0.04). In the remaining 14 subjects, who experienced similar respiratory reactions without extrapulmonary symptoms during aspirin challenge, changes in tryptase and histamine levels were not observed.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV RHEUMATOL ALLERGY & IMMUNOL, RICHMOND, VA 23298 USA	Scripps Research Institute; Virginia Commonwealth University			Bosso, John/L-7326-2019		NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIAID NIH HHS [AI-20487] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020487, R01AI020487, R21AI020487] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CASTELLS M, 1987, J IMMUNOL, V138, P2814; CHRISTIE P, 1990, Journal of Allergy and Clinical Immunology, V85, P264; COHAN VL, 1989, AM REV RESPIR DIS, V140, P951, DOI 10.1164/ajrccm/140.4.951; CRAIG SS, 1986, AM J PATHOL, V124, P427; DELANEY JC, 1976, CLIN ALLERGY, V6, P177, DOI 10.1111/j.1365-2222.1976.tb01896.x; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; MARTELLI NA, 1977, THORAX, V32, P684, DOI 10.1136/thx.32.6.684; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1985, J IMMUNOL, V134, P526; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1975, ARCH INTERN MED, V135, P777, DOI 10.1001/archinte.135.6.777; STEVENSON DD, 1985, POSTGRAD MED, V78, P111, DOI 10.1080/00325481.1985.11699116; STEVENSON DD, 1976, CLIN ALLERGY, V6, P493, DOI 10.1111/j.1365-2222.1976.tb01934.x; SZCZEKLIK A, 1979, THORAX, V34, P654, DOI 10.1136/thx.34.5.654; VANLEEUWEN WS, 1928, MUCH MED WOECHENSCHR, V75, P1588; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2	23	105	106	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					830	837		10.1016/0091-6749(91)90238-J	http://dx.doi.org/10.1016/0091-6749(91)90238-J			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1720795	Bronze			2022-12-18	WOS:A1991GW26200002
J	SEDGWICK, JB; VRTIS, RF; GOURLEY, MF; BUSSE, WW				SEDGWICK, JB; VRTIS, RF; GOURLEY, MF; BUSSE, WW			STIMULUS-DEPENDENT DIFFERENCES IN SUPEROXIDE ANION GENERATION BY NORMAL HUMAN EOSINOPHILS AND NEUTROPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN, DEPT MED, ALLERGY SECT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015685, P50AI010404, R01AI023181] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 10404, AI 15685, AI 23181] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOSTI JM, 1987, J ALLERGY CLIN IMMUN, V79, P496, DOI 10.1016/0091-6749(87)90368-X; AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; BAEHNER RL, 1971, BRIT J HAEMATOL, V20, P277, DOI 10.1111/j.1365-2141.1971.tb07038.x; BASS DA, 1981, J INFECT DIS, V143, P719, DOI 10.1093/infdis/143.5.719; BESWICK PH, 1981, CLIN EXP IMMUNOL, V43, P399; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; DECHATELET LR, 1977, BLOOD, V50, P525; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DESIMONE C, 1986, IMMUNOL LETT, V12, P37, DOI 10.1016/0165-2478(86)90078-7; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; KAJITA T, 1985, INT ARCH ALLER A IMM, V78, P406, DOI 10.1159/000233922; KHALIFE J, 1986, J IMMUNOL, V137, P1659; KLEBANOFF SJ, 1977, INFECT IMMUN, V17, P167, DOI 10.1128/IAI.17.1.167-173.1977; LEARN DB, 1982, AGENTS ACTIONS, V12, P485, DOI 10.1007/BF01965931; PALMBLAD J, 1984, J IMMUNOL, V132, P3041; PETRECCIA DC, 1987, J LEUKOCYTE BIOL, V41, P283, DOI 10.1002/jlb.41.4.283; PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1; PINCUS SH, 1982, J INVEST DERMATOL, V79, P53, DOI 10.1111/1523-1747.ep12510590; PINCUS SH, 1981, BLOOD, V58, P1175; PONTREMOLI S, 1986, BIOCHEM BIOPH RES CO, V136, P228, DOI 10.1016/0006-291X(86)90898-3; PRIN L, 1986, CLIN EXP IMMUNOL, V63, P249; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; ROBERTS RL, 1985, BLOOD, V65, P433; ROOS D, 1984, J BIOL CHEM, V259, P1770; SHULT PA, 1985, J LAB CLIN MED, V106, P638; SPRY CJF, 1978, SCHWEIZ MED WSCHR, V108, P1572; SPRY CJF, 1985, IMMUNOL TODAY, V6, P332, DOI 10.1016/0167-5699(85)90130-6; TAUBER AI, 1979, INFLAMMATION, V3, P261, DOI 10.1007/BF00914183; VALLOTA EH, 1973, J EXP MED, V137, P1109, DOI 10.1084/jem.137.5.1109; VANGELDER BF, 1962, BIOCHIM BIOPHYS ACTA, V58, P593, DOI 10.1016/0006-3002(62)90073-2; WINQVIST I, 1984, IMMUNOLOGY, V51, P1; WRIGHT DG, 1977, J IMMUNOL, V119, P1068; YAMASHITA T, 1985, ARCH BIOCHEM BIOPHYS, V241, P447, DOI 10.1016/0003-9861(85)90569-7; YAZDANBAKHSH M, 1987, BLOOD, V70, P379; YAZDANBAKHSH M, 1987, J IMMUNOL, V138, P3443; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0	40	105	106	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				876	883		10.1016/0091-6749(88)90945-1	http://dx.doi.org/10.1016/0091-6749(88)90945-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	2836491				2022-12-18	WOS:A1988N703600017
J	THARP, MD; KAGEYSOBOTKA, A; FOX, CC; MARONE, G; LICHTENSTEIN, LM; SULLIVAN, TJ				THARP, MD; KAGEYSOBOTKA, A; FOX, CC; MARONE, G; LICHTENSTEIN, LM; SULLIVAN, TJ			FUNCTIONAL-HETEROGENEITY OF HUMAN MAST-CELLS FROM DIFFERENT ANATOMIC SITES - INVITRO RESPONSES TO MORPHINE-SULFATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,DALLAS,TX 75235; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; UNIV NAPLES,DEPT MED,I-80138 NAPLES,ITALY	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; Johns Hopkins University; University of Naples Federico II	THARP, MD (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT DERMATOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019801] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05426-23] Funding Source: Medline; NIAID NIH HHS [AI 19801] Funding Source: Medline; PHS HHS [S07] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARRETT KE, 1983, AGENTS ACTIONS, V13, P122, DOI 10.1007/BF01967313; BARRETT KE, 1985, J INVEST DERMATOL, V84, P22, DOI 10.1111/1523-1747.ep12274607; BATCHELOR KW, 1980, IMMUNOLOGY, V41, P271; BEFUS AD, 1982, J IMMUNOL, V128, P2475; BERGSTRESSER PR, 1984, J INVEST DERMATOL, V83, P214, DOI 10.1111/1523-1747.ep12263584; BINAZZI M, 1959, ITALIAN GENERAL REV, V1, P17; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; EADY RAJ, 1979, BRIT J DERMATOL, V100, P623, DOI 10.1111/j.1365-2133.1979.tb08065.x; FITZPATRICK TB, 1979, DERMATOLOGY GENERAL, P12; FOX CC, 1985, J IMMUNOL, V135, P483; HERMENS JM, 1985, ANESTHESIOLOGY, V62, P124, DOI 10.1097/00000542-198502000-00005; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; KATZ HR, 1983, P NATL ACAD SCI-BIOL, V80, P5916, DOI 10.1073/pnas.80.19.5916; KOBAYASHI T, 1986, J IMMUNOL, V136, P1378; LEVISCHAFFER F, 1986, FASEB J, V45, P1104; LEWIS RA, 1974, J EXP MED, V140, P1133, DOI 10.1084/jem.140.5.1133; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOWENSTEIN E, 1969, NEW ENGL J MED, V281, P1389, DOI 10.1056/NEJM196912182812503; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; OKA K, 1985, P NATL ACAD SCI USA, V82, P1852, DOI 10.1073/pnas.82.6.1852; PEARCE FL, 1982, KLIN WOCHENSCHR, V60, P954, DOI 10.1007/BF01716954; PEARCE FL, 1980, AGENTS ACTIONS, V10, P124, DOI 10.1007/BF02024193; PEARCE FL, 1985, INT ARCH ALLER A IMM, V77, P274, DOI 10.1159/000233808; PEARCE FL, 1982, J IMMUNOL, V128, P2481; PHILBIN DM, 1981, ANESTHESIOLOGY, V55, P292, DOI 10.1097/00000542-198109000-00019; PHILBIN DM, 1982, KLIN WOCHENSCHR, V60, P1056, DOI 10.1007/BF01716971; RAZIN E, 1982, J BIOL CHEM, V257, P7229; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; SELDIN DC, 1986, J IMMUNOL, V136, P2222; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; SNYDER SH, 1966, J PHARMACOL EXP THER, V153, P544; THARP MD, 1984, J ALLERGY CLIN IMMUN, V74, P159, DOI 10.1016/0091-6749(84)90280-X; THARP MD, 1983, J IMMUNOL, V130, P1896; THARP MD, 1985, J INVEST DERMATOL, V84, P292; THARP MD, 1985, J HISTOCHEM CYTOCHEM, V33, P27, DOI 10.1177/33.1.2578142; VERBURG KM, 1983, LIFE SCI, V32, P2855, DOI 10.1016/0024-3205(83)90322-3	36	105	108	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					646	653		10.1016/S0091-6749(87)80162-8	http://dx.doi.org/10.1016/S0091-6749(87)80162-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	2435777				2022-12-18	WOS:A1987G972000015
J	FREIDHOFF, LR; EHRLICHKAUTZKY, E; GRANT, JH; MEYERS, DA; MARSH, DG				FREIDHOFF, LR; EHRLICHKAUTZKY, E; GRANT, JH; MEYERS, DA; MARSH, DG			A STUDY OF THE HUMAN IMMUNE-RESPONSE TO LOLIUM-PERENNE (RYE) POLLEN AND ITS COMPONENTS, LOL-P-I AND LOL-P-II (RYE-I AND RYE-II) .1. PREVALENCE OF REACTIVITY TO THE ALLERGENS AND CORRELATIONS AMONG SKIN-TEST, IGE ANTIBODY, AND IGG ANTIBODY DATA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FREIDHOFF, LR (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239, USA.				NIAID NIH HHS [AI-19727, AI-20059] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019727, R55AI019727, R01AI020059] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; AXELSON NH, 1973, SCAND J IMMUNOL S1, V2; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; FREIDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274, DOI 10.1016/0091-6749(83)90032-5; FREIDHOFF LR, 1981, AM J MED GENET, V9, P323, DOI 10.1002/ajmg.1320090409; FREIDHOFF LR, 1985, J ALLERGY CLIN IMMUN, V75, P156, DOI 10.1016/0091-6749(85)90340-9; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; FREIDHOFF LR, GENETIC ENV FACTORS; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HULL WM, 1979, J ALLERGY CLIN IMMUN, V63, P193; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P101, DOI 10.1016/0019-2791(66)90291-6; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P91, DOI 10.1016/0019-2791(66)90290-4; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; JOHNSON P, 1965, EUR POLYM J, V1, P63; LICHTENSTEIN LM, 1969, J ALLERGY, V44, P307, DOI 10.1016/0021-8707(69)90035-5; LOWENSTEIN H, 1981, J IMMUNOL, V126, P943; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MARSH DG, 1980, J ALLERGY CLIN IMMUN, V65, P322, DOI 10.1016/0091-6749(80)90208-0; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1985, FED PROC, V44, P968; MARSH DG, 1966, INT ARCH ALLER A IMM, V29, P521, DOI 10.1159/000229739; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; MARSH DG, 1975, ANTIGENS, V3, P271; MULLIGAN JJ, 1966, J IMMUNOL, V96, P324; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; PLATTSMILLS TAE, 1981, J ALLERGY CLIN IMMUN, V67, P129, DOI 10.1016/0091-6749(81)90008-7; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; ROEBBER M, 1985, J IMMUNOL, V134, P3062; ROEBBER M, 1982, J IMMUNOL, V129, P120; ROEBBER M, 1983, J IMMUNOL, V131, P706; SANTILLI J, 1980, J ALLERGY CLIN IMMUN, V65, P406, DOI 10.1016/0091-6749(80)90232-8; VAZ NM, 1970, SCIENCE, V168, P852, DOI 10.1126/science.168.3933.852; 1982, BMDP STATISTICAL SOF	37	105	111	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1190	1201		10.1016/0091-6749(86)90271-X	http://dx.doi.org/10.1016/0091-6749(86)90271-X			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3782681				2022-12-18	WOS:A1986F302600017
J	ADKINSON, NF				ADKINSON, NF			RISK-FACTORS FOR DRUG ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ADKINSON, NF (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,BALTIMORE,MD 21239, USA.							ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; ADKINSON NF, 1977, DRUG DESIGN ADVERSE, P123; ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P822; ADKINSON NF, 1983, 11 P INT C ALL CLIN, P55; BATCHELO.FR, 1965, NATURE, V206, P362, DOI 10.1038/206362a0; BERKOWITZ M, 1953, Ann Allergy, V11, P561; BORDER WA, 1974, NEW ENGL J MED, V291, P381, DOI 10.1056/NEJM197408222910803; DEWECK A, 1980, CLIN IMMUNOLOGY, P419; DUDLEY KH, 1971, J PHARMACOL EXP THER, V179, P505; EISEN HN, 1959, CELLULAR HUMORAL ASP; ELLMAN L, 1971, CLIN EXP IMMUNOL, V9, P927; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; HERMAN R, 1979, CUTIS, V24, P232; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; KANTOR FS, 1963, J EXP MED, V117, P55, DOI 10.1084/jem.117.1.55; KNAUER KA, 1983, ALLERGY PRINCIPLES P, P673; KRAPIN D, 1962, NEW ENGL J MED, V267, P820, DOI 10.1056/NEJM196210182671607; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1969, INT ARCH ALLER A IMM, V35, P445, DOI 10.1159/000230197; LEVINE BB, 1961, J EXP MED, V114, P875, DOI 10.1084/jem.114.6.875; McDevitt H O, 1969, Adv Immunol, V11, P31, DOI 10.1016/S0065-2776(08)60477-0; PARKER C, 1980, CLIN IMMUNOLOGY, P1220; PARKER CW, 1965, FED PROC, V24, P51; PARKER CW, 1975, NEW ENGL J MED, V292, P957, DOI 10.1056/NEJM197505012921806; PARKER CW, 1975, NEW ENGL J MED, V292, P511, DOI 10.1056/NEJM197503062921006; PARKER CW, 1975, NEW ENGL J MED, V292, P732, DOI 10.1056/NEJM197504032921407; PARKER CW, 1962, J EXP MED, V115, P821, DOI 10.1084/jem.115.4.821; PERRY HM, 1973, AM J MED, V54, P58, DOI 10.1016/0002-9343(73)90084-3; PETZ LD, 1976, PROGR HEMATOLOGY, V9; RYTEL MW, 1963, JAMA-J AM MED ASSOC, V186, P894; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3; TOMPKINS RK, 1977, ANN INTERN MED, V86, P481, DOI 10.7326/0003-4819-86-4-481; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974	38	105	108	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					567	572		10.1016/0091-6749(84)90108-8	http://dx.doi.org/10.1016/0091-6749(84)90108-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6491103				2022-12-18	WOS:A1984TQ16300005
J	KALINER, MM				KALINER, MM			HYPOTHESES ON THE CONTRIBUTION OF LATE-PHASE ALLERGIC RESPONSES TO THE UNDERSTANDING AND TREATMENT OF ALLERGIC DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											KALINER, MM (corresponding author), NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,ROOM 11C205,BETHESDA,MD 20205, USA.							ALLISON F, 1955, J EXP MED, V102, P669, DOI 10.1084/jem.102.6.669; ASBOEHAN.G, 1969, BRIT J DERMATOL, VS 81, P2, DOI 10.1111/j.1365-2133.1969.tb12838.x; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS PC, 1979, J ALLERGY CLIN IMMUN, V64, P251, DOI 10.1016/0091-6749(79)90140-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CLARKE PS, 1982, J ASTHMA, V19, P91, DOI 10.3109/02770908209104741; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CONNELL JT, 1968, J ALLERGY, V41, P101; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; Cooke RA, 1922, J IMMUNOL, V7, P219; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DVORACEK JE, 1984, J ALLERGY CLIN IMMUN, V73, P363, DOI 10.1016/0091-6749(84)90409-3; FLOMAN Y, 1976, PROSTAGLANDINS, V12, P403, DOI 10.1016/0090-6980(76)90021-6; GLATT M, 1977, AGENTS ACTIONS, V7, P321, DOI 10.1007/BF01969563; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GOETZL EJ, 1975, P NATL ACAD SCI USA, V72, P4123, DOI 10.1073/pnas.72.10.4123; GOETZL EJ, 1980, NEW ENGL J MED, V303, P822, DOI 10.1056/NEJM198010023031421; GRONNEBERG R, 1981, ALLERGY, V36, P201, DOI 10.1111/j.1398-9995.1981.tb01835.x; GRYGLEWSKI RJ, 1975, PROSTAGLANDINS, V10, P343, DOI 10.1016/S0090-6980(75)80087-6; HARRIES MG, 1981, ANN ALLERGY, V46, P156; KALINER M, FED P; KAY AB, 1971, J EXP MED, V133, P602, DOI 10.1084/jem.133.3.602; LEMANSKE R, 1982, CRC CRIT REV IMMUNOL, V1, P547; LEMANSKE RF, 1983, J ALLERGY CLIN IMMUN, V72, P94, DOI 10.1016/0091-6749(83)90058-1; LEMANSKE RF, 1983, J IMMUNOL, V131, P929; LEMANSKE RF, 1982, IMMUNOLOGY, V45, P561; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; Menkin V, 1940, AM J PHYSIOL, V129, P0691, DOI 10.1152/ajplegacy.1940.129.3.691; MIDDLETON E, 1975, NEW DIRECTIONS ASTHM, P433; MYGIND N, 1977, CLIN ALLERGY, V7, P69, DOI 10.1111/j.1365-2222.1977.tb01426.x; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NORMAN PS, 1983, J ALLERGY CLIN IMMUN, V72, P421, DOI 10.1016/0091-6749(83)90577-8; OERTEL H, 1981, J ALLERGY CLIN IMMUN, V68, P238, DOI 10.1016/0091-6749(81)90190-1; OERTEL HL, 1981, J IMMUNOL, V127, P1398; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PELIKAN Z, 1982, ANN ALLERGY, V49, P283; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PIPKORN U, 1982, ALLERGY, V37, P359, DOI 10.1111/j.1398-9995.1982.tb01922.x; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; SCHUMACHER MJ, 1979, J ALLERGY CLIN IMMUN, V64, P202, DOI 10.1016/0091-6749(79)90096-4; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; SHEA C, 1978, ANN CLIN LAB SCI, V8, P30; SLOTT RI, 1975, J ALLERGY CLIN IMMUN, V55, P232, DOI 10.1016/0091-6749(75)90142-6; SLOTT RI, 1974, J ALLERGY CLIN IMMUN, V54, P229, DOI 10.1016/0091-6749(74)90065-7; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; TAYLOR G, 1971, Clinical Allergy, V1, P407, DOI 10.1111/j.1365-2222.1971.tb00792.x; TOLONE G, 1979, BRIT J EXP PATHOL, V60, P269; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; Walker I C, 1917, J Med Res, V35, P487; WARD PA, 1966, J EXP MED, V124, P209, DOI 10.1084/jem.124.2.209; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; ZWEIMAN B, 1976, J ALLERGY CLIN IMMUN, V58, P657, DOI 10.1016/0091-6749(76)90177-9	59	105	106	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					311	315		10.1016/0091-6749(84)90401-9	http://dx.doi.org/10.1016/0091-6749(84)90401-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6366029				2022-12-18	WOS:A1984SK15500002
J	SCHIMPFF, SC; BENNETT, JE				SCHIMPFF, SC; BENNETT, JE			ABNORMALITIES IN CELL-MEDIATED-IMMUNITY IN PATIENTS WITH CRYPTOCOCCUS-NEOFORMANS INFECTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,SECT CLIN MYCOL,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ATKINSON AJ, 1968, AM REV RESPIR DIS, V97, P637; BENNETT JE, 1974, INFECTIOUS DISEASES, P945; BINDSCHADLER DD, 1968, ANN INTERN MED, V69, P45, DOI 10.7326/0003-4819-69-1-45; DEWBERRY WM, 1967, ANN INTERN MED, V67, P724; DIAMOND RD, 1972, J INFECT DIS, V125, P367, DOI 10.1093/infdis/125.4.367; DIAMOND RD, 1973, J INFECT DIS, V127, P694, DOI 10.1093/infdis/127.6.694; GRAYBILL JR, 1974, CELL IMMUNOL, V14, P12, DOI 10.1016/0008-8749(74)90164-6; LEWIS JL, 1972, AM J MED, V53, P315, DOI 10.1016/0002-9343(72)90174-X; ROCKLIN RE, 1970, J IMMUNOL, V104, P95; ROSENBERG SA, 1970, J IMMUNOL, V105, P1447; SMITH KA, 1972, CELL IMMUNOL, V5, P597, DOI 10.1016/0008-8749(72)90111-6	11	105	105	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	6					430	441		10.1016/0091-6749(75)90082-2	http://dx.doi.org/10.1016/0091-6749(75)90082-2			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AE593	1094054				2022-12-18	WOS:A1975AE59300010
J	MENDELSON, LM; MELTZER, EO; HAMBURGER, RN				MENDELSON, LM; MELTZER, EO; HAMBURGER, RN			ANAPHYLAXIS-LIKE REACTIONS TO CORTICOSTEROID-THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF, SAN DIEGO, PEDIAT DEPT, BOX 109, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego								COMAISH S, 1969, BRIT J DERMATOL, V81, P919, DOI 10.1111/j.1365-2133.1969.tb15974.x; HOLLANDER JL, 1953, 8 P INT C RHEUM DIS; KAHN G, 1971, ANN ALLERGY, V29, P480; KENDALL P H, 1958, Ann Phys Med, V4, P170; KING RA, 1960, LANCET, V2, P1093; MORRISON RT, 1968, ORGANIC CHEMISTRY; OGARRA JA, 1962, BMJ-BRIT MED J, P615, DOI 10.1136/bmj.1.5278.615; REDMOND AP, 1967, J ALLERGY, V39, P51, DOI 10.1016/0021-8707(67)90127-X; SCHORR WF, 1968, J AMER MED ASSOC, V204, P859, DOI 10.1001/jama.204.10.859	9	105	107	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	3					125	131		10.1016/0091-6749(74)90049-9	http://dx.doi.org/10.1016/0091-6749(74)90049-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U0308	4850575				2022-12-18	WOS:A1974U030800001
J	Arrieta, MC; Arevalo, A; Stiemsma, L; Dimitriu, P; Chico, ME; Loor, S; Vaca, M; Boutin, RCT; Morien, E; Jin, ML; Turvey, SE; Walter, J; Parfrey, LW; Cooper, PJ; Finlay, B				Arrieta, Marie-Claire; Arevalo, Andrea; Stiemsma, Leah; Dimitriu, Pedro; Chico, Martha E.; Loor, Sofia; Vaca, Maritza; Boutin, Rozlyn C. T.; Morien, Evan; Jin, Mingliang; Turvey, Stuart E.; Walter, Jens; Parfrey, Laura Wegener; Cooper, Philip J.; Finlay, Brett			Associations between infant fungal and bacterial dysbiosis and childhood atopic wheeze in a nonindustrialized setting	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; wheeze; gut microbiome; mycobiome; short-chain fatty acids; nonindustrialized setting	ALLERGIC AIRWAY DISEASE; GUT MICROBIOTA; ASTHMA; DIVERSITY; SHIFTS; TOOL; AGE	Background: Asthma is the most prevalent chronic disease of childhood. Recently, we identified a critical window early in the life of both mice and Canadian infants during which gut microbial changes (dysbiosis) affect asthma development. Given geographic differences in human gut microbiota worldwide, we studied the effects of gut microbial dysbiosis on atopic wheeze in a population living in a distinct developing world environment. Objective: We sought to determine whether microbial alterations in early infancy are associated with the development of atopic wheeze in a nonindustrialized setting. Methods: We conducted a case-control study nested within a birth cohort from rural Ecuador in which we identified 27 children with atopic wheeze and 70 healthy control subjects at 5 years of age. We analyzed bacterial and eukaryotic gut microbiota in stool samples collected at 3 months of age using 16S and 18S sequencing. Bacterial metagenomes were predicted from 16S rRNA data by using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States and categorized by function with Kyoto Encyclopedia of Genes and Genomes ontology. Concentrations of fecal short-chain fatty acids were determined by using gas chromatography. Results: As previously observed in Canadian infants, microbial dysbiosis at 3 months of age was associated with later development of atopic wheeze. However, the dysbiosis in Ecuadorian babies involved different bacterial taxa, was more pronounced, and also involved several fungal taxa. Predicted metagenomic analysis emphasized significant dysbiosis-associated differences in genes involved in carbohydrate and taurine metabolism. Levels of the fecal short-chain fatty acids acetate and caproate were reduced and increased, respectively, in the 3-month stool samples of children who went on to have atopic wheeze. Conclusions: Our findings support the importance of fungal and bacterial microbiota during the first 100 days of life on the development of atopic wheeze and provide additional support for considering modulation of the gut microbiome as a primary asthma prevention strategy.	[Arrieta, Marie-Claire; Boutin, Rozlyn C. T.; Finlay, Brett] Univ British Columbia, Michael Smith Labs, 301-2185 East Mall, Vancouver, BC V6T 1Z4, Canada; [Arrieta, Marie-Claire; Boutin, Rozlyn C. T.; Finlay, Brett] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC, Canada; [Dimitriu, Pedro; Finlay, Brett] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC, Canada; [Morien, Evan; Parfrey, Laura Wegener] Univ British Columbia, Dept Zool, Vancouver, BC, Canada; [Morien, Evan; Parfrey, Laura Wegener] Univ British Columbia, Dept Bot, Vancouver, BC, Canada; [Finlay, Brett] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada; [Arrieta, Marie-Claire] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Arrieta, Marie-Claire] Univ Calgary, Dept Pediat, Calgary, AB, Canada; [Arevalo, Andrea; Cooper, Philip J.] Univ Int Ecuador, Fac Ciencias Med Salud & Vida, Quito, Ecuador; [Stiemsma, Leah; Turvey, Stuart E.] Univ British Columbia, BC Childrens Hosp, Dept Pediat, Vancouver, BC, Canada; [Stiemsma, Leah] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA; [Chico, Martha E.; Loor, Sofia; Vaca, Maritza; Cooper, Philip J.] Fdn Ecuatoriana Invest Salud, Quito, Ecuador; [Jin, Mingliang; Walter, Jens] Univ Alberta, Dept Agr Food & Nutrit Sci, Edmonton, AB, Canada; [Cooper, Philip J.] St Georges Univ London, Inst Infect & Immun, London, England	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of Calgary; University of Calgary; BC Childrens Hospital; University of British Columbia; University of California System; University of California Los Angeles; University of Alberta; St Georges University London	Finlay, B (corresponding author), Univ British Columbia, Michael Smith Labs, 301-2185 East Mall, Vancouver, BC V6T 1Z4, Canada.	bfinlay@msl.ubc.ac	Turvey, Stuart/HGV-1191-2022; Boutin, Rozlyn C.T./AAD-3203-2022; Parfrey, Laura/AAA-6139-2019; Walter, Jens/AAA-7636-2020; Arrieta, Marie-Claire/AAU-2427-2021; Parfrey, Laura Wegener/AAE-1402-2019	Boutin, Rozlyn C.T./0000-0003-1598-0104; Walter, Jens/0000-0003-1754-172X; Parfrey, Laura Wegener/0000-0001-6959-7616; Turvey, Stuart/0000-0003-1599-1065; Arrieta, Marie-Claire/0000-0002-4490-3370; Cooper, Philip/0000-0002-6770-6871	Canadian Institutes of Health Research (CIHR); Allergen grants; ECUAVIDA cohort by theWellcome Trust [088862/Z/09/Z]; T32 Training Grant from the National Institutes of Health [5T32CA009142-37]; NATIONAL CANCER INSTITUTE [T32CA009142] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Allergen grants; ECUAVIDA cohort by theWellcome Trust; T32 Training Grant from the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by the Canadian Institutes of Health Research (CIHR) and Allergen grants to BFF and the ECUAVIDA cohort by theWellcome Trust (grant 088862/Z/09/Z). L.T.S. is supported on a T32 Training Grant from the National Institutes of Health (5T32CA009142-37).	Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Arrieta MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00427; Asher I, 2014, INT J TUBERC LUNG D, V18, P1269, DOI 10.5588/ijtld.14.0170; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Berger SA, 2011, SYST BIOL, V60, P291, DOI 10.1093/sysbio/syr010; Campbell JM, 1997, J NUTR, V127, P130, DOI 10.1093/jn/127.1.130; Caporaso JG, 2010, BIOINFORMATICS, V26, P266, DOI 10.1093/bioinformatics/btp636; Comeau AM, 2017, MSYSTEMS, V2, DOI 10.1128/mSystems.00127-16; Cooper PJ, 2009, ALLERGY, V64, P5, DOI 10.1111/j.1398-9995.2008.01902.x; Cooper PJ, 2015, INT J EPIDEMIOL, V44, P1517, DOI 10.1093/ije/dyu128; Cooper PJ, 2012, CURR OPIN ALLERGY CL, V12, P171, DOI 10.1097/ACI.0b013e3283510967; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Erb-Downward JR, 2007, INFECT IMMUN, V75, P3498, DOI 10.1128/IAI.00232-07; Eren AM, 2015, ISME J, V9, P968, DOI 10.1038/ismej.2014.195; Eren AM, 2013, METHODS ECOL EVOL, V4, P1111, DOI 10.1111/2041-210X.12114; Escobar JS, 2014, BMC MICROBIOL, V14, DOI 10.1186/s12866-014-0311-6; Fallani M, 2010, J PEDIATR GASTR NUTR, V51, P77, DOI 10.1097/MPG.0b013e3181d1b11e; Forno E, 2015, THORAX, V70, P898, DOI 10.1136/thoraxjnl-2015-207199; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Kim YG, 2014, CELL HOST MICROBE, V15, P95, DOI 10.1016/j.chom.2013.12.010; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Kuczynski Justin, 2012, Curr Protoc Microbiol, VChapter 1, DOI [10.1002/0471250953.bi1007s36, 10.1002/9780471729259.mc01e05s27]; Kurtzman CP, 2008, FEMS YEAST RES, V8, P939, DOI 10.1111/j.1567-1364.2008.00419.x; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Madeeha IR, 2016, INT J FOOD SCI NUTR, V67, P865, DOI 10.1080/09637486.2016.1201791; Mallol J, 2013, ALLERGOL IMMUNOPATH, V41, P73, DOI 10.1016/j.aller.2012.03.001; Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6; Martinez I, 2015, CELL REP, V11, P527, DOI 10.1016/j.celrep.2015.03.049; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Morgan XC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r79; Neuwirth E, 2011, RCOLORBREWER COLORBR; Noverr MC, 2005, INFECT IMMUN, V73, P30, DOI 10.1128/IAI.73.1.30-38.2005; Noverr MC, 2004, INFECT IMMUN, V72, P6206, DOI 10.1128/IAI.72.11.6206-6210.2004; Noverr MC, 2001, INFECT IMMUN, V69, P2957, DOI 10.1128/IAI.69.5.2957-2963.2001; Oksanen J, 2020, VEGAN COMMUNITY ECOL; Parks DH, 2014, BIOINFORMATICS, V30, P3123, DOI 10.1093/bioinformatics/btu494; Ploner A, 2012, HEATPLUS HEATMAPS RO; Pollard KS, 2005, STAT BIOL HEALTH, P249; Prevost-Boure NC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024166; Russell SL, 2015, J ALLERGY CLIN IMMUN, V135, P100, DOI 10.1016/j.jaci.2014.06.027; Russell SL, 2013, GUT MICROBES, V4, P158, DOI 10.4161/gmic.23567; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033; Stiemsma LT, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-016-0173-6; Stiemsma LT, 2016, CLIN SCI, V130, P2199, DOI 10.1042/CS20160349; Takaro TK, 2015, J EXPO SCI ENV EPID, V25, P580, DOI 10.1038/jes.2015.7; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Underhill DM, 2014, NAT REV IMMUNOL, V14, P405, DOI 10.1038/nri3684; Wheeler ML, 2016, CELL HOST MICROBE, V19, P865, DOI 10.1016/j.chom.2016.05.003; WHO, 1985, DIAGN TECHN INT PAR; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wickham H, 2011, J STAT SOFTW, V40, P1, DOI 10.18637/jss.v040.i01; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Yilmaz P, 2014, NUCLEIC ACIDS RES, V42, pD643, DOI 10.1093/nar/gkt1209	57	104	104	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					424	+		10.1016/j.jaci.2017.08.041	http://dx.doi.org/10.1016/j.jaci.2017.08.041			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29241587	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000440664400012
J	Akin, C				Akin, Cem			Mast cell activation syndromes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; mastocytosis; mast cell activation syndrome; anaphylaxis; tryptase	ADVANCED SYSTEMIC MASTOCYTOSIS; EHLERS-DANLOS-SYNDROME; SERUM TRYPTASE; PEDIATRIC MASTOCYTOSIS; IDIOPATHIC ANAPHYLAXIS; TACHYCARDIA SYNDROME; CONSENSUS PROPOSAL; ALLERGIC DISEASES; DISORDERS; CLASSIFICATION	Mast cell activation is common and possibly necessary for maintenance of survival. Disordered mast cell activation occurs when mast cells are pathologically overproduced or if their activation is out of proportion to the perceived threat to homeostasis. Mast cell activation syndrome refers to a group of disorders with diverse causes presenting with episodic multisystem symptoms as the result of mast cell mediator release. Despite introduction of diagnostic criteria and some advances in treatment in the last decade, many areas of mast cell activation syndrome are in need of research. This article reviews our current knowledge about the various types of mast cell activation disorders, their treatment, and areas of uncertainty in need of future investigation.	[Akin, Cem] Univ Michigan, Div Allergy & Clin Immunol, 24 Frank Lloyd Wright Dr,POB 442,Suite H-2100, Ann Arbor, MI 48106 USA	University of Michigan System; University of Michigan	Akin, C (corresponding author), Univ Michigan, Div Allergy & Clin Immunol, 24 Frank Lloyd Wright Dr,POB 442,Suite H-2100, Ann Arbor, MI 48106 USA.	cemakin@med.umich.edu						Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Alvarez-Twose I, 2016, J ALLERGY CLIN IMMUN, V137, P168, DOI 10.1016/j.jaci.2015.05.008; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; [Anonymous], 2015, KIT MUTATION ANAL MA; [Anonymous], 2017, MASITINIB TREATMENT; Barete S, 2015, BLOOD, V126, P1009, DOI 10.1182/blood-2014-12-614743; Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, P680, DOI 10.1016/j.jaci.2008.11.018; Brockow K, 2014, IMMUNOL ALLERGY CLIN, V34, P283, DOI 10.1016/j.iac.2014.01.003; Butterfield JH, 2010, PROSTAG OTH LIPID M, V92, P73, DOI 10.1016/j.prostaglandins.2010.03.003; Cahill KN, 2017, NEW ENGL J MED, V376, P1911, DOI 10.1056/NEJMoa1613125; Carter MC, 2002, ARCH DIS CHILD, V86, P315, DOI 10.1136/adc.86.5.315; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Cheung I, 2015, J ALLERGY CLIN IMMUN, V135, pAB65, DOI 10.1016/j.jaci.2014.12.1146; Doyle LA, 2014, AM J SURG PATHOL, V38, P832, DOI 10.1097/PAS.0000000000000190; Fanning LB, 2013, ANN ALLERG ASTHMA IM, V111, P155, DOI 10.1016/j.anai.2013.06.031; Fellinger C, 2014, ALLERGOL IMMUNOPATH, V42, P544, DOI 10.1016/j.aller.2014.05.002; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; Gaudenzio N, 2016, J CLIN INVEST, V126, P3981, DOI 10.1172/JCI85538; Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098; Gulen T, 2017, CURR OPIN ALLERGY CL; HORAN RF, 1990, J ALLERGY CLIN IMMUN, V85, P852, DOI 10.1016/0091-6749(90)90067-E; Krauth MT, 2009, CLIN EXP ALLERGY, V39, P1711, DOI 10.1111/j.1365-2222.2009.03353.x; Le QT, 2011, J IMMUNOL, V187, P1912, DOI 10.4049/jimmunol.1001806; Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Metcalfe DD, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0094-3; Molderings GJ, 2011, INTERNAL MED, V50, P611, DOI 10.2169/internalmedicine.50.4640; PARDINI S, 1991, ACTA HAEMATOL-BASEL, V85, P220; Patterson R, 1997, ANN ALLERG ASTHMA IM, V79, P138, DOI 10.1016/S1081-1206(10)63100-6; Prieto-Garcia A, 2012, J BIOL CHEM, V287, P7834, DOI 10.1074/jbc.M111.325712; Ravi A, 2014, J ALLER CL IMM-PRACT, V2, P775, DOI 10.1016/j.jaip.2014.06.011; Regan JA, 2017, J ALLERGY CLIN IMMUN; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Seneviratne SL, 2017, AM J MED GENET C, V175, P226, DOI 10.1002/ajmg.c.31555; Shibao C, 2005, HYPERTENSION, V45, P385, DOI 10.1161/01.HYP.0000158259.68614.40; Smiljkovic D, 2017, ALLERGY; Sokol KC, 2014, J ALLER CL IMM-PRACT, V2, P266, DOI 10.1016/j.jaip.2014.03.009; Tefferi A, 2001, NEW ENGL J MED, V344, P307, DOI 10.1056/NEJM200101253440415; Theoharides TC, 2015, NEW ENGL J MED, V373, P163, DOI 10.1056/NEJMra1409760; Tkaczyk C, 2004, BLOOD, V104, P207, DOI 10.1182/blood-2003-08-2769; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760; Valent P, 2010, BLOOD, V116, P5812, DOI 10.1182/blood-2010-08-292144; Vysniauskaite M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124912; NON TRADITIONAL REF	50	104	105	3	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					349	355		10.1016/j.jaci.2017.06.007	http://dx.doi.org/10.1016/j.jaci.2017.06.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28780942				2022-12-18	WOS:000406855500003
J	Perkin, MR; Logan, K; Marrs, T; Radulovic, S; Craven, J; Flohr, C; Lack, G				Perkin, Michael R.; Logan, Kirsty; Marrs, Tom; Radulovic, Suzana; Craven, Joanna; Flohr, Carsten; Lack, Gideon		EAT Study Team	Enquiring About Tolerance (EAT) study: Feasibility of an early allergenic food introduction regimen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; diet; allergens; infancy; breastfeeding	ATOPIC-DERMATITIS; PEANUT ALLERGY; HIGH-RISK; INFANTS; SENSITIZATION; CONSUMPTION; PREVALENCE; CHILDREN; METAANALYSIS; ASTHMA	Background: The influence of early exposure to allergenic foods on the subsequent development of food allergy remains uncertain. Objective: We sought to determine the feasibility of the early introduction of multiple allergenic foods to exclusively breastfed infants from 3 months of age and the effect on breastfeeding performance. Methods: We performed a randomized controlled trial. The early introduction group (EIG) continued breastfeeding with sequential introduction of 6 allergenic foods: cow's milk, peanut, hard-boiled hen's egg, sesame, whitefish (cod), and wheat; the standard introduction group followed the UK infant feeding recommendations of exclusive breastfeeding for around 6 months with no introduction of allergenic foods before 6 months of age. Results: One thousand three hundred three infants were enrolled. By 5 months of age, the median frequency of consumption of all 6 foods was 2 to 3 times per week for every food in the EIG and no consumption for every food in the standard introduction group (P < .001 for every comparison). By 6 months of age, nonintroduction of the allergenic foods in the EIG was less than 5% for each of the 6 foods. Achievement of the stringent per-protocol consumption target for the EIG proved more difficult (42% of evaluable EIG participants). Breastfeeding rates in both groups significantly exceeded UK government data for equivalent mothers (P < .001 at 6 and at 9 months of age). Conclusion: Early introduction, before 6 months of age, of at least some amount of multiple allergenic foods appears achievable and did not affect breastfeeding. This has important implications for the evaluation of food allergy prevention strategies.	[Perkin, Michael R.] Univ London, Populat Hlth Res Inst, London, England; [Perkin, Michael R.; Logan, Kirsty; Marrs, Tom; Radulovic, Suzana; Craven, Joanna; Flohr, Carsten; Lack, Gideon] Kings Coll London, Dept Paediat Allergy, Div Asthma Allergy & Lung Biol, London WC2R 2LS, England; [Flohr, Carsten] Guy & St Thomas Hosp NHS Fdn Trust, St Johns Inst Dermatol, London, England	University of London; University of London; King's College London; University of London; King's College London	Lack, G (corresponding author), Guys & St Thomas NHS Fdn Trust, Kings Coll London, St Thomas Hosp,Paediat Allergy, Clin Acad Paediat Allergy Serv,Childrens Allergie, Westminster Bridge Rd, London SE1 7EH, England.	gideon.lack@kcl.ac.uk	Perkin, Michael/AID-7491-2022	Lack, Gideon/0000-0001-7350-4021; Perkin, Michael/0000-0001-9272-2585	UK Food Standards Agency (FSA); Medical Research Council (MRC); UK National Institute for Health Research (NIHR) [NIHRCS/01/2008/009]; MRC [MC_G1001205] Funding Source: UKRI; Medical Research Council [MC_PC_15020, MC_G1001205] Funding Source: researchfish	UK Food Standards Agency (FSA); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The main components of the EAT study are jointly funded by the UK Food Standards Agency (FSA) and the Medical Research Council (MRC). The skin-related aspects of the study are supported by the UK National Institute for Health Research (NIHR) through an NIHR Clinician Scientist Award (NIHRCS/01/2008/009) held by C.F. The views expressed in this publication are those of the authors and not necessarily those of the FSA, MRC, NHS, NIHR, Wellcome Trust, or UK Department of Health.	Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99, DOI 10.1097/01.mpg.0000304464.60788.bd; Bolling K, 2005, INFANT FEEDING SURVE; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P630, DOI 10.1016/j.jaci.2013.02.034; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P623, DOI 10.1016/j.jaci.2013.02.035; Collin SM, 2015, CLIN EXP ALLERGY, V45, P200, DOI 10.1111/cea.12380; Dalal I, 2002, ALLERGY, V57, P362, DOI 10.1034/j.1398-9995.2002.1s3412.x; Department of Health, 2003, INF FEED REC; Department of Health, 2008, WEAN START SOL FOOD; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; FALTHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P868, DOI 10.1016/S0091-6749(87)80279-8; Farahmand S, 2009, SKIN RES TECHNOL, V15, P392, DOI 10.1111/j.1600-0846.2009.00376.x; Flohr C, 2014, J INVEST DERMATOL, V134, P345, DOI 10.1038/jid.2013.298; Gray C, 2012, CURR ALLERGY CLIN IM, V25, P24; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hentze S., 2006, AGE INTRO FREQUENCY; Hill DJ, 2008, CLIN EXP ALLERGY, V38, P161, DOI 10.1111/j.1365-2222.2007.02861.x; Hornell A, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e38; Johnke H, 2006, PEDIAT ALLERG IMM-UK, V17, P591, DOI 10.1111/j.1399-3038.2006.00453.x; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Kelleher M, 2015, J ALLERGY CLIN IMMUN, V135, P930, DOI 10.1016/j.jaci.2014.12.013; Koplin JJ, 2013, CLIN EXP ALLERGY, V43, P826, DOI 10.1111/cea.12090; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Kung SJ, 2014, CLIN REV ALLERG IMMU, V46, P241, DOI 10.1007/s12016-012-8341-z; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; McAndrew F, 2012, INFANT FEEDING SURVE; Nwaru BI, 2014, ALLERGY, V69, P992, DOI 10.1111/all.12423; Nwaru BI, 2014, ALLERGY, V69, P62, DOI 10.1111/all.12305; Obeng BB, 2011, INT ARCH ALLERGY IMM, V155, P63, DOI 10.1159/000318704; Office for National Statistics, 2011, 2011 CENS AGGR DAT E; Palmer DJ, 2013, J ALLERGY CLIN IMMUN, V132, P387, DOI 10.1016/j.jaci.2013.05.002; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Reilly JJ, 2005, BRIT J NUTR, V94, P56, DOI 10.1079/BJN20051464; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; SAARINEN UM, 1980, LANCET, V1, P166; Schafer T, 2001, ALLERGY, V56, P1172, DOI 10.1034/j.1398-9995.2001.00196.x; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; World Health Organization, 2009, INF YOUNG CHILD FEED; World Health Organization (WHO), 2011, EXCLUSIVE BREASTFEED; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; Ziyab AH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032721	43	104	106	2	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1477	+		10.1016/j.jaci.2015.12.1322	http://dx.doi.org/10.1016/j.jaci.2015.12.1322			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26896232	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000376180200024
J	Tauber, M; Balica, S; Hsu, CY; Jean-Decoster, C; Lauze, C; Redoules, D; Viode, C; Schmitt, AM; Serre, G; Simon, M; Paul, CF				Tauber, Marie; Balica, Stefana; Hsu, Chiung-Yueh; Jean-Decoster, Catherine; Lauze, Christophe; Redoules, Daniel; Viode, Cecile; Schmitt, Anne-Marie; Serre, Guy; Simon, Michel; Paul, Carle F.			Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TOPICAL CORTICOSTEROIDS; ECZEMA		[Tauber, Marie; Balica, Stefana; Paul, Carle F.] Toulouse Univ, Dept Dermatol, Hop Larrey, Toulouse, France; [Balica, Stefana; Hsu, Chiung-Yueh; Serre, Guy; Simon, Michel; Paul, Carle F.] CNRS, UMR5165, Toulouse, France; [Balica, Stefana; Hsu, Chiung-Yueh; Serre, Guy; Simon, Michel; Paul, Carle F.] Fac Med Toulouse, INSERM, U1056, U317, F-31073 Toulouse, France; [Balica, Stefana; Hsu, Chiung-Yueh; Serre, Guy; Simon, Michel; Paul, Carle F.] Univ Toulouse, UDEAR, Toulouse, France; [Jean-Decoster, Catherine; Lauze, Christophe; Redoules, Daniel; Viode, Cecile; Schmitt, Anne-Marie] Pierre Fabre Dermocosmet, Toulouse, France	CHU de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Paul, CF (corresponding author), Toulouse Univ, Dept Dermatol, Hop Larrey, Toulouse, France.; Paul, CF (corresponding author), CNRS, UMR5165, Toulouse, France.; Paul, CF (corresponding author), Fac Med Toulouse, INSERM, U1056, U317, F-31073 Toulouse, France.; Paul, CF (corresponding author), Univ Toulouse, UDEAR, Toulouse, France.	paul.c@chu-toulouse.fr	Simon, Michel/B-7308-2011	Simon, Michel/0000-0003-3655-6329; Paul, Carle/0000-0003-0165-5263; HSU, Chiung-Yueh/0000-0002-4671-0919				[Anonymous], 1993, DERMATOL BASEL SWITZ, V186, P23; Banerjee I, 2015, J MOL CELL CARDIOL, V79, P133, DOI 10.1016/j.yjmcc.2014.11.003; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Casas C, 2008, SKIN PHARMACOL PHYS, V21, P260, DOI 10.1159/000143391; Emerson RM, 2000, BRIT J DERMATOL, V142, P288, DOI 10.1046/j.1365-2133.2000.03300.x; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Leung DYM, 2009, BRIT J DERMATOL, V161, P435, DOI 10.1111/j.1365-2133.2009.09145.x; Nemoto-Hasebe I, 2009, J INVEST DERMATOL, V129, P682, DOI 10.1038/jid.2008.280; NILSSON EJ, 1992, J AM ACAD DERMATOL, V27, P29, DOI 10.1016/0190-9622(92)70151-5; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Qu J, 2002, ANALYST, V127, P66, DOI 10.1039/b108422b	11	104	109	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1272	+		10.1016/j.jaci.2015.07.052	http://dx.doi.org/10.1016/j.jaci.2015.07.052			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26559326	Bronze			2022-12-18	WOS:000373351200044
J	Rebane, A; Zimmermann, M; Aab, A; Baurecht, H; Koreck, A; Karelson, M; Abram, K; Metsalu, T; Pihlap, M; Meyer, N; Folster-Holst, R; Nagy, N; Kemeny, L; Kingo, K; Vilo, J; Illig, T; Akdis, M; Franke, A; Novak, N; Weidinger, S; Akdis, CA				Rebane, Ana; Zimmermann, Maya; Aab, Alar; Baurecht, Hansjoerg; Koreck, Andrea; Karelson, Maire; Abram, Kristi; Metsalu, Tauno; Pihlap, Maire; Meyer, Norbert; Foelster-Holst, Regina; Nagy, Nikoletta; Kemeny, Lajos; Kingo, Kulli; Vilo, Jaak; Illig, Thomas; Akdis, Muebeccel; Franke, Andre; Novak, Natalija; Weidinger, Stephan; Akdis, Cezmi A.			Mechanisms of IFN-gamma-induced apoptosis of human skin keratinocytes in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cytokine; mRNA expression array; atopic eczema; inflammation; allergy	RECEPTOR EXPRESSION; ATONIC DERMATITIS; GENE-EXPRESSION; IN-SITU; ASSOCIATION; ECZEMA; CELLS; DISEASES; VARIANT; ABNORMALITIES	Background: Enhanced apoptosis of keratinocytes is the main cause of eczema and spongiosis in patients with the common inflammatory skin disease atopic dermatitis (AD). Objective: The aim of the study was to investigate molecular mechanisms of AD-related apoptosis of keratinocytes. Methods: Primary keratinocytes isolated from patients with AD and healthy donors were used to study apoptosis by using annexin V/7-aminoactinomycin D staining. Illumina mRNA Expression BeadChips, quantitative RT-PCR, and immunofluorescence were used to study gene expression. In silico analysis of candidate genes was performed on genome-wide single nucleotide polymorphism data. Results: We demonstrate that keratinocytes of patients with AD exhibit increased IFN-gamma-induced apoptosis compared with keratinocytes from healthy subjects. Further mRNA expression analyses revealed differential expression of apoptosis-related genes in AD keratinocytes and skin and the upregulation of immune system-related genes in skin biopsy specimens of chronic AD lesions. Three apoptosis-related genes (NOD2, DUSP1, and ADM) and 8 genes overexpressed in AD skin lesions (CCDC109B, CCL5, CCL8, IFI35, LYN, RAB31, IFITM1, and IFITM2) were induced by IFN-gamma in primary keratinocytes. The protein expression of IFITM1, CCL5, and CCL8 was verified in AD skin. In line with the functional studies and AD-related mRNA expression changes, in silico analysis of genome-wide single nucleotide polymorphism data revealed evidence of an association between AD and genetic markers close to or within the IFITM cluster or RAB31, DUSP1, and ADM genes. Conclusion: Our results demonstrate increased IFN-g responses in skin of patients with AD and suggest involvement of multiple new apoptosis-and inflammation-related factors in the development of AD. (J Allergy Clin Immunol 2012;129:1297-306.)	[Rebane, Ana; Zimmermann, Maya; Aab, Alar; Meyer, Norbert; Akdis, Muebeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CH-7270 Davos, Switzerland; [Rebane, Ana; Pihlap, Maire] Univ Tartu, Fac Med, Tartu, Estonia; [Baurecht, Hansjoerg; Foelster-Holst, Regina; Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol, Campus Kiel, Germany; [Koreck, Andrea; Nagy, Nikoletta; Kemeny, Lajos] Univ Szeged, Dept Dermatol & Allergol, Szeged, Hungary; [Karelson, Maire; Abram, Kristi; Kingo, Kulli] Tartu Univ Hosp, Dept Dermatol, Tartu, Estonia; [Metsalu, Tauno; Vilo, Jaak] Univ Tartu, Inst Comp Sci, Tartu, Estonia; [Nagy, Nikoletta; Kemeny, Lajos] Hungarian Acad Sci, Dermatol Res Grp, Szeged, Hungary; [Kingo, Kulli] Univ Tartu, Ctr Mol & Clin Med, Dept Physiol, Tartu, Estonia; [Illig, Thomas] Helmholtz Zentrum Munich, Inst Epidemiol, Munich, Germany; [Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, Hannover, Germany; [Franke, Andre] Univ Kiel, Inst Clin Mol Biol, D-24098 Kiel, Germany; [Novak, Natalija] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany	Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Tartu; University of Kiel; Schleswig Holstein University Hospital; Szeged University; University of Tartu; Hungarian Academy of Sciences; University of Tartu; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Hannover Medical School; University of Kiel; University of Bonn	Rebane, A (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	ana.rebane@siaf.uzh.ch	Kemeny, Lajos/ABF-1339-2021; Aab, Alar/G-8177-2017; Baurecht, Hansjoerg/C-4035-2013; Weidinger, Stephan/C-8461-2011; Nagy, Nikoletta/AAJ-6631-2020; Aab, Alar/AAF-7859-2021; Kingo, Külli/H-3603-2012; Franke, Andre/B-2151-2010; Vilo, Jaak/A-7183-2008; Akdis, Cezmi/AAV-4844-2020; Vilo, Jaak/AAK-2228-2020; Rebane, Ana/D-4279-2013	Kemeny, Lajos/0000-0002-2119-9501; Aab, Alar/0000-0001-7661-0284; Baurecht, Hansjoerg/0000-0002-9265-5594; Weidinger, Stephan/0000-0003-3944-252X; Nagy, Nikoletta/0000-0001-8576-7953; Franke, Andre/0000-0003-1530-5811; Vilo, Jaak/0000-0001-5604-4107; Akdis, Cezmi/0000-0001-8020-019X; Vilo, Jaak/0000-0001-5604-4107; Rebane, Ana/0000-0001-6051-1361; Kingo, Kulli/0000-0001-6301-9612	Swiss National Science Foundation [32-132899, 32-112306]; Christine Kuhne Center for Allergy Research and Education (CK-CARE); Estonian Ministry of Education and Research [SF0180021s07, SF0180043s07]; Estonian Science Foundation [ESF8350, ETF7437]; SCIEX Programme NMS-CH; EST-BIOREG; DFG [WE2678/4-1]; Swiss National Foundation; European Union; German Research Council; Astellas; ALK-Abello; Novartis; PREDICTA; MeDALL; Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research and Education	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Christine Kuhne Center for Allergy Research and Education (CK-CARE); Estonian Ministry of Education and Research(Ministry of Education and Research, Estonia); Estonian Science Foundation; SCIEX Programme NMS-CH; EST-BIOREG; DFG(German Research Foundation (DFG)); Swiss National Foundation(Swiss National Science Foundation (SNSF)); European Union(European Commission); German Research Council(German Research Foundation (DFG)); Astellas(Astellas Pharmaceuticals); ALK-Abello; Novartis(Novartis); PREDICTA; MeDALL; Global Allergy and Asthma European Network; Christine Kuhne Center for Allergy Research and Education	Supported by Swiss National Science Foundation grants 32-132899 and 32-112306, the Christine Kuhne Center for Allergy Research and Education (CK-CARE), Estonian Ministry of Education and Research targeted funds SF0180021s07 and SF0180043s07, and Estonian Science Foundation grants ESF8350 and ETF7437. A. R. was supported by fellowships from the SCIEX Programme NMS-CH and EST-BIOREG. S. W. is supported by a Heisenberg professorship of the DFG (WE2678/4-1).; Disclosure of potential conflict of interest: M. Akdis receives research support from the Swiss National Foundation and the European Union. N. Novak has received research support from the German Research Council; has received lecture fees from Astellas and ALK-Abello; and is on an advisory board for LEO Pharma. C. A. Akdis has received research support from Novartis, PREDICTA, the Swiss National Science Foundation, MeDALL, the Global Allergy and Asthma European Network, and the Christine Kuhne Center for Allergy Research and Education and has consulted for Actellion, Aventis, Stallergenes, and Allergopharma. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis CA, 2000, CURR OPIN IMMUNOL, V12, P641, DOI 10.1016/S0952-7915(00)00156-4; Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Akkoc T, 2008, J ALLERGY CLIN IMMUN, V121, P652, DOI 10.1016/j.jaci.2007.12.1171; Albertin G, 2003, INT J MOL MED, V11, P635; Bai BX, 2005, J DERMATOL SCI, V39, P189, DOI 10.1016/j.jdermsci.2005.06.003; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Brown SJ, 2008, J INVEST DERMATOL, V128, P1591, DOI 10.1038/sj.jid.5701206; Contassot E, 2007, DERMATOL CLIN, V25, P487, DOI 10.1016/j.det.2007.06.010; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fujita PA, 2011, NUCLEIC ACIDS RES, V39, pD876, DOI 10.1093/nar/gkq963; Greisenegger EK, 2010, J EUR ACAD DERMATOL, V24, P607, DOI 10.1111/j.1468-3083.2009.03469.x; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Gros E, 2011, J ALLERGY CLIN IMMUN, V128, P1015, DOI 10.1016/j.jaci.2011.05.043; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; Kakurai M, 2001, J INVEST DERMATOL, V116, P743, DOI 10.1046/j.1523-1747.2001.01306.x; Klunker S, 2003, J IMMUNOL, V171, P1078, DOI 10.4049/jimmunol.171.2.1078; Kollerits B, 2009, HUM MOL GENET, V18, P4669, DOI 10.1093/hmg/ddp424; Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; Lue ZR, 2009, J DERMATOL SCI, V54, P126, DOI 10.1016/j.jdermsci.2008.12.006; Marenholz I, 2011, J INVEST DERMATOL, V131, P1644, DOI 10.1038/jid.2011.90; MATSUE H, 1995, ARCH DERMATOL RES, V287, P315, DOI 10.1007/BF01105085; Meyer N, 2010, J ALLERGY CLIN IMMUN, V125, P858, DOI 10.1016/j.jaci.2010.01.016; Nickel RG, 2000, J IMMUNOL, V164, P1612, DOI 10.4049/jimmunol.164.3.1612; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Novak N, 2002, J INVEST DERMATOL, V119, P870, DOI 10.1046/j.1523-1747.2002.00191.x; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Saito H, 2005, INT ARCH ALLERGY IMM, V137, P319, DOI 10.1159/000086464; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Sugiura H, 2005, BRIT J DERMATOL, V152, P146, DOI 10.1111/J.1365-2133.2005.06352.X; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Vasilopoulos Y, 2007, ALLERGY, V62, P514, DOI 10.1111/j.1398-9995.2007.01350.x; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Zimmermann M, 2011, J ALLERGY CLIN IMMUN, V127, P200, DOI 10.1016/j.jaci.2010.11.005	43	104	105	1	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1297	1306		10.1016/j.jaci.2012.02.020	http://dx.doi.org/10.1016/j.jaci.2012.02.020			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22445417	Bronze			2022-12-18	WOS:000303418000018
J	Wilson, SR; Rand, CS; Cabana, MD; Foggs, MB; Halterman, JS; Olson, L; Vollmer, WM; Wright, RJ; Taggart, V				Wilson, Sandra R.; Rand, Cynthia S.; Cabana, Michael D.; Foggs, Michael B.; Halterman, Jill S.; Olson, Lynn; Vollmer, William M.; Wright, Rosalind J.; Taggart, Virginia			Asthma outcomes: Quality of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma burden; asthma-related well-being; health perceptions; health status; patient-reported outcomes	GEORGES-RESPIRATORY-QUESTIONNAIRE; CHILDRENS HEALTH SURVEY; GENERIC CORE SCALES; PEDIATRIC-ASTHMA; YOUNG-ADULTS; CHILDHOOD ASTHMA; SELF-MANAGEMENT; LONGITUDINAL CHANGES; TAIWANESE PATIENTS; EDUCATION-PROGRAM	Background: "Asthma-related quality of life" (QOL) refers to the perceived impact that asthma has on the patient's QOL. Objective: National Institutes of Health institutes and other federal agencies convened an expert group to recommend standardized measures of the impact of asthma on QOL for use in future asthma clinical research. Methods: We reviewed published documentation regarding the development and psychometric evaluation; clinical research use since 2000; and extent to which the content of each existing QOL instrument provides a unique, reliable, and valid assessment of the intended construct. We classified instruments as core (required in future studies), supplemental (used according to the study's aims and standardized), or emerging (requiring validation and standardization). This work was discussed at an National Institutes of Health-organized workshop convened in March 2010 and finalized in September 2011. Results: Eleven instruments for adults and 6 for children were identified for review. None qualified as core instruments because they predominantly measured indicators of asthma control (symptoms and/or functional status); failed to provide a distinct, reliable score measuring all key dimensions of the intended construct; and/or lacked adequate psychometric data. Conclusions: In the absence of existing instruments that meet the stated criteria, currently available instruments are classified as either supplemental or emerging. Research is strongly recommended to develop and evaluate instruments that provide a distinct, reliable measure of the patient's perception of the impact of asthma on all of the key dimensions of QOL, an important outcome that is not captured in other outcome measures. (J Allergy Clin Immunol 2012; 129: S88-123.)	[Taggart, Virginia] NHLBI, DLD, NIH, Bethesda, MD 20892 USA; [Wilson, Sandra R.] Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA; [Rand, Cynthia S.] Johns Hopkins Univ, Baltimore, MD USA; [Cabana, Michael D.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Foggs, Michael B.] Advocate Hlth Care, Oak Brook, IL USA; [Halterman, Jill S.] Univ Rochester, Rochester, NY 14627 USA; [Olson, Lynn] Amer Acad Pediat, Elk Grove Village, IL USA; [Vollmer, William M.] Kaiser Permanente, Portland, OR USA; [Wright, Rosalind J.] Harvard Univ, Sch Med, Boston, MA USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Palo Alto Medical Foundation Research Institute; Johns Hopkins University; University of California System; University of California San Francisco; University of Rochester; American Academy of Pediatrics; Kaiser Permanente; Harvard University; Harvard Medical School	Taggart, V (corresponding author), NHLBI, DLD, NIH, 6701 Rockledge Dr, Bethesda, MD 20892 USA.	taggartv@nih.gov			National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Environmental Health Sciences; Agency for Healthcare Research and Quality; Merck Childhood Asthma Network; Robert Wood Johnson Foundation; US Environmental Protection Agency; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL114396] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Merck Childhood Asthma Network; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); US Environmental Protection Agency(United States Environmental Protection Agency); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Asthma Outcomes workshop was funded by contributions from the National Institute of Allergy and Infectious Diseases; the National Heart, Lung, and Blood Institute; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; the Agency for Healthcare Research and Quality; and the Merck Childhood Asthma Network, as well as by a grant from the Robert Wood Johnson Foundation. Contributions from the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Institute of Environmental Health Sciences; and the US Environmental Protection Agency funded the publication of this article and all other articles in this supplement.	Adams R, 2005, RESPIROLOGY, V10, P587, DOI 10.1111/j.1440-1843.2005.00754.x; Adams RJ, 2004, RESPIROLOGY, V9, P87, DOI 10.1111/j.1440-1843.2003.00538.x; Adams RJ, 2000, J ASTHMA, V37, P131, DOI 10.3109/02770900009055436; Al-Akour N, 2008, INT J NURS PRACT, V14, P418, DOI 10.1111/j.1440-172X.2008.00715.x; Alvim CG, 2009, J ASTHMA, V46, P186, DOI 10.1080/02770900802604129; American Psychological Association and National Council on Measurement in Education, 1999, STAND ED PSYCH TEST; Annett RD, 2003, J ASTHMA, V40, P577, DOI 10.1081/JAS-120019030; Asmussen L, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e71; Backer V, 2007, INT J TUBERC LUNG D, V11, P463; Barley EA, 1998, RESP MED, V92, P1207, DOI 10.1016/S0954-6111(98)90423-1; Barley EA, 2006, QUAL LIFE RES, V15, P801, DOI 10.1007/s11136-005-5466-z; Bayliss MS, 2000, QUAL LIFE RES, V9, P451, DOI 10.1023/A:1008939328060; Belloch A, 2003, J ASTHMA, V40, P945, DOI 10.1081/JAS-120024595; Boran P, 2008, TURKISH J PEDIATR, V50, P18; Bushnell DM, 2003, J ASTHMA, V40, P751, DOI 10.1081/JAS-120023501; Caro JJ, 2001, QUAL LIFE RES, V10, P683, DOI 10.1023/A:1013811109820; Chan KS, 2005, MED CARE, V43, P256, DOI 10.1097/00005650-200503000-00008; Choi JY, 2009, RES NURS HEALTH, V32, P140, DOI 10.1002/nur.20285; Clougherty JE, 2009, J URBAN HEALTH, V86, P214, DOI 10.1007/s11524-008-9341-4; Cordina M, 2001, PHARMACOTHERAPY, V21, P1196, DOI 10.1592/phco.21.15.1196.33894; Dimich-Ward H, 2007, J OCCUP ENVIRON MED, V49, P1040, DOI 10.1097/JOM.0b013e31814b2e5c; Drotar D, 2004, AMBUL PEDIATR, V4, P353, DOI 10.1367/1539-4409(2004)4<353:MCHSQC>2.0.CO;2; Ehrs PO, 2006, CHEST, V129, P925, DOI 10.1378/chest.129.4.925; Eisner MD, 2005, ANN ALLERG ASTHMA IM, V94, P566, DOI 10.1016/S1081-1206(10)61135-0; Eisner MD, 2002, ANN ALLERG ASTHMA IM, V89, P46, DOI 10.1016/S1081-1206(10)61910-2; El Rhazi K, 2006, INT J TUBERC LUNG D, V10, P1273; Everhart RS, 2009, J PEDIATR PSYCHOL, V34, P966, DOI 10.1093/jpepsy/jsn145; Feifer RA, 2004, DIS MANAG HEALTH OUT, V12, P93, DOI 10.2165/00115677-200412020-00003; Forrest CB, 2003, PEDIATRICS, V111, P171, DOI 10.1542/peds.111.1.171; Gallefoss F, 2003, PATIENT EDUC COUNS, V49, P91, DOI 10.1016/S0738-3991(02)00051-4; Garcia-Marcos L, 2007, J INVEST ALLERG CLIN, V17, P249; Graham DM, 2000, ALLERGY ASTHMA PROC, V21, P151, DOI 10.2500/108854100778148990; Greenley RN, 2008, ANN ALLERG ASTHMA IM, V100, P106, DOI 10.1016/S1081-1206(10)60418-8; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Haave E, 2004, SCAND J PSYCHOL, V45, P163, DOI 10.1111/j.1467-9450.2004.00391.x; Halterman JS, 2004, J ASTHMA, V41, P645, DOI 10.1081/JAS-200026410; Hommel KA, 2002, J CLIN PSYCHOL MED S, V9, P185, DOI 10.1023/A:1016066709714; HYLAND ME, 1994, QUAL LIFE RES, V3, P121, DOI 10.1007/BF00435255; HYLAND ME, 1991, J PSYCHOSOM RES, V35, P99, DOI 10.1016/0022-3999(91)90011-C; Hyland ME, 1996, QUAL LIFE RES, V5, P469, DOI 10.1007/BF00540019; Incalzi RA, 2001, CHEST, V120, P734, DOI 10.1378/chest.120.3.734; JONES PW, 1991, THORAX, V46, P676, DOI 10.1136/thx.46.9.676; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Joshi AV, 2006, J ASTHMA, V43, P521, DOI 10.1080/02770900600857010; Josie KL, 2007, ANN ALLERG ASTHMA IM, V98, P218, DOI 10.1016/S1081-1206(10)60710-7; Juniper EF, 1997, EUR RESPIR J, V10, P2285, DOI 10.1183/09031936.97.10102285; Juniper EF, 1999, EUR RESPIR J, V14, P1038, DOI 10.1183/09031936.99.14510389; Juniper EF, 2004, EUR RESPIR J, V23, P287, DOI 10.1183/09031936.04.00064204; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Juniper EF, 2001, EUR RESPIR J, V18, P38, DOI 10.1183/09031936.01.00088301; Katz PP, 2004, J CLIN EPIDEMIOL, V57, P259, DOI 10.1016/j.jclinepi.2003.08.007; Kauppinen R, 2001, RESP MED, V95, P56, DOI 10.1053/rmed.2000.0971; Kercsmar CM, 2006, ENVIRON HEALTH PERSP, V114, P1574, DOI 10.1289/ehp.8742; Kimura Tomoaki, 2009, Allergology International, V58, P71, DOI 10.2332/allergolint.O-07-531; King MT, 2009, QUAL LIFE RES, V18, P301, DOI 10.1007/s11136-009-9448-4; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250, DOI 10.1097/00006842-197305000-00008; Kondo T, 2000, INTERNAL MED, V39, P798, DOI 10.2169/internalmedicine.39.798; Kullowatz A, 2007, RESP MED, V101, P638, DOI 10.1016/j.rmed.2006.06.002; Lavoie KL, 2006, RESP MED, V100, P648, DOI 10.1016/j.rmed.2005.08.001; Lemanske RF, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e55; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; Lobo FA, 2008, J ASTHMA, V45, P27, DOI 10.1080/02770900701815495; Lowery EP, 2007, QUAL LIFE RES, V16, P1605, DOI 10.1007/s11136-007-9274-5; Lozano P, 2004, ARCH PEDIAT ADOL MED, V158, P875, DOI 10.1001/archpedi.158.9.875; Mancuso CA, 2001, J CLIN EPIDEMIOL, V54, P263, DOI 10.1016/S0895-4356(00)00307-3; Mangiapane S, 2005, ANN PHARMACOTHER, V39, P1817, DOI 10.1345/aph.1G180; Marks G B, 2000, Respirology, V5, P45, DOI 10.1046/j.1440-1843.2000.00225.x; MARKS GB, 1993, J CLIN EPIDEMIOL, V46, P1103, DOI 10.1016/0895-4356(93)90109-E; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; Mattke S, 2009, PEDIATRICS, V123, pS199, DOI 10.1542/peds.2008-2233K; McCauley E, 2007, GEN HOSP PSYCHIAT, V29, P214, DOI 10.1016/j.genhosppsych.2007.02.003; McTaggart-Cowan HM, 2008, QUAL LIFE RES, V17, P453, DOI 10.1007/s11136-008-9309-6; Meszaros A, 2005, QUAL LIFE RES, V14, P191, DOI 10.1007/s11136-004-3927-4; Meszaros A, 2003, ALLERGY, V58, P624, DOI 10.1034/j.1398-9995.2003.00207.x; Mora PA, 2009, QUAL LIFE RES, V18, P371, DOI 10.1007/s11136-009-9443-9; Moy ML, 2001, AM J RESP CRIT CARE, V163, P924, DOI 10.1164/ajrccm.163.4.2008014; Murphy KR, 2003, PEDIATRICS, V112, pE212, DOI 10.1542/peds.112.3.e212; Mussaffi H, 2007, ARCH DIS CHILD, V92, P678, DOI 10.1136/adc.2006.111971; Nishimura K, 2004, J ASTHMA, V41, P141, DOI 10.1081/JAS-120026070; Nishimura K, 2008, J ASTHMA, V45, P615, DOI 10.1080/02770900802127014; Nishiyama O, 2003, J ASTHMA, V40, P281, DOI 10.1081/JAS-120018327; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Norman GR, 1997, J CLIN EPIDEMIOL, V50, P869, DOI 10.1016/S0895-4356(97)00097-8; Norman GR, 2001, MED CARE, V39, P1039, DOI 10.1097/00005650-200110000-00002; Oga T, 2002, CHEST, V122, P1228, DOI 10.1378/chest.122.4.1228; Oga T, 2005, J CLIN EPIDEMIOL, V58, P532, DOI 10.1016/j.jclinepi.2004.09.012; Oga T, 2007, RESP MED, V101, P2133, DOI 10.1016/j.rmed.2007.05.009; Oh EG, 2008, J ASTHMA, V45, P882, DOI 10.1080/02770900802252069; Okelo SO, 2004, J PEDIATR-US, V145, P523, DOI 10.1016/j.jpeds.2004.06.043; Olson LM, 2007, PEDIATRICS, V119, pE93, DOI 10.1542/peds.2005-3211; Osman LM, 2000, AM J RESP CRIT CARE, V161, P498, DOI 10.1164/ajrccm.161.2.9904063; Osman LM, 2001, EUR RESPIR J, V17, P254, DOI 10.1183/09031936.01.17202540; Pilotto LS, 2003, J ASTHMA, V40, P163, DOI 10.1081/JAS-120017987; Pinnock H, 2005, J CLIN EPIDEMIOL, V58, P809, DOI 10.1016/j.jclinepi.2005.01.010; Poachanukoon O, 2006, PEDIAT ALLERG IMM-UK, V17, P207, DOI 10.1111/j.1399-3038.2005.00349.x; Quirk FH, 1994, THORAX, V49, P1075; Radecki Linda, 2008, Pediatric Asthma Allergy & Immunology, V21, P89, DOI 10.1089/pai.2008.0001; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reichenberg K, 2000, ACTA PAEDIATR, V89, P989; Reichenberg K, 2001, ACTA PAEDIATR, V90, P45; Ricci G, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-30; Riley AW, 2004, AMBUL PEDIATR, V4, P371, DOI 10.1367/A03-178R.1; Rimington LD, 2001, THORAX, V56, P266, DOI 10.1136/thorax.56.4.266; Rosenzweig JRC, 2004, RESP MED, V98, P1157, DOI 10.1016/j.rmed.2004.04.001; Rydstrom I, 2005, J CLIN NURS, V14, P739, DOI 10.1111/j.1365-2702.2005.01135.x; Sanjuas C, 2002, QUAL LIFE RES, V11, P729, DOI 10.1023/A:1020897816228; Sanjuas C, 2001, J CLIN EPIDEMIOL, V54, P182, DOI 10.1016/S0895-4356(00)00297-3; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P1049, DOI 10.1016/j.jaci.2005.02.008; Schatz M, 2007, QUAL LIFE RES, V16, P345, DOI 10.1007/s11136-006-9103-2; Schmier J, 2003, J ASTHMA, V40, P383, DOI 10.1081/JAS-120018708; Seid M, 2010, J ASTHMA, V47, P170, DOI 10.3109/02770900903533966; Senn S, 1998, BRIT MED J, V317, P537; Shames RS, 2004, ANN ALLERG ASTHMA IM, V92, P611, DOI 10.1016/S1081-1206(10)61426-3; Sharek PJ, 2002, PEDIATRICS, V110, P797, DOI 10.1542/peds.110.4.797; Skoner DP, 2005, PEDIATR PULM, V40, P477, DOI 10.1002/ppul.20288; Smith JR, 2005, J ASTHMA, V42, P437, DOI 10.1081/JAS-200067949; Somerville A, 2004, SWISS MED WKLY, V134, P91; Sundberg R, 2005, RESP MED, V99, P321, DOI 10.1016/j.rmed.2004.08.006; Szende A, 2004, PHARMACOECONOMICS, V22, P537; Tan WC, 2004, QUAL LIFE RES, V13, P551, DOI 10.1023/B:QURE.0000018495.36759.46; Tauler E, 2001, QUAL LIFE RES, V10, P81, DOI 10.1023/A:1016622519987; van Gent R, 2007, EUR J PEDIATR, V166, P843, DOI 10.1007/s00431-006-0358-y; van Gent R, 2007, J ALLERGY CLIN IMMUN, V119, P591, DOI 10.1016/j.jaci.2006.11.007; Varni JW, 2004, J BEHAV MED, V27, P297, DOI 10.1023/B:JOBM.0000028500.53608.2c; Vazquez MI, 2000, PSYCHOL REP, V86, P31; Vila G, 2003, PSYCHOSOMATICS, V44, P319, DOI 10.1176/appi.psy.44.4.319; Vollmer WM, 2006, AM J MANAG CARE, V12, P725; von Berg A, 2007, PEDIAT ALLERG IMM-UK, V18, P391, DOI 10.1111/j.1399-3038.2007.00538.x; Walders N, 2006, CHEST, V129, P292, DOI 10.1378/chest.129.2.292; Wang KY, 2004, J FORMOS MED ASSOC, V103, P205; Wang KY, 2001, J FORMOS MED ASSOC, V100, P455; Warschburger P, 2004, J ASTHMA, V41, P463, DOI 10.1081/JAS-120033989; Willems DCM, 2008, J EVAL CLIN PRACT, V14, P600, DOI 10.1111/j.1365-2753.2007.00936.x; Win T, 2008, CAN RESPIR J, V15, P133, DOI 10.1155/2008/129070; Wood BL, 2007, J PEDIATR PSYCHOL, V32, P542, DOI 10.1093/jpepsy/jsl044; Wood BL, 2007, J PEDIATR PSYCHOL, V32, P552, DOI 10.1093/jpepsy/Jsl043; Wood PR, 2007, J ALLERGY CLIN IMMUN, V120, P1368, DOI 10.1016/j.jaci.2007.09.025; Young NL, 2001, CAN J PUBLIC HEALTH, V92, P30, DOI 10.1007/BF03404839; Zandieh Fariborz, 2006, Iran J Allergy Asthma Immunol, V5, P79; Ziora D, 2007, J PHYSIOL PHARMACOL, V58, P801	146	104	108	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3		S			S88	S123		10.1016/j.jaci.2011.12.988	http://dx.doi.org/10.1016/j.jaci.2011.12.988			36	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	901OL	22386511	Green Accepted			2022-12-18	WOS:000300976600007
J	Peden, D; Reed, CE				Peden, David; Reed, Charles E.			Environmental and occupational allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergens; indoor environment; mites; cockroaches; mice; pets; molds; pollens; humidity; water damage; air pollution; occupational asthma; climate change	INNER-CITY CHILDREN; COMMUNITY AIR-POLLUTION; INDOOR NITROGEN-DIOXIDE; HOUSE-DUST MITE; ASTHMATIC-CHILDREN; MOUSE ALLERGEN; TOBACCO-SMOKE; RESPIRATORY SYMPTOMS; DIESEL EXHAUST; ENDOTOXIN EXPOSURE	Airborne allergens are the major cause of allergic rhinitis and asthma. Daily exposure comes from indoor sources, chiefly at home but occasionally at schools or offices. Seasonal exposure to outdoor allergens, pollens, and molds is another important source. Exposure to unusual substances at work causes occupational asthma, accounting for about 5% of asthma in adults. Indoor and outdoor air pollutants trigger airway inflammation and increase the severity of asthma. Diesel exhaust particles increase the production of IgE antibodies. Identification and reduction of exposure to allergens is a very important part of the management of respiratory allergic diseases. The first section of this chapter discusses domestic allergens, arthropods (mites and cockroaches), molds, and mammals (pets and mice). Indoor humidity and water damage are important factors in the production of mite and mold allergens, and discarded human food items are important sources of proliferation of cockroaches and mice. Means of identifying and reducing exposure are presented. The second section discusses outdoor allergens: pollens and molds. The particular plants or molds and the amount of exposure to these allergens is determined by the local climate, and local pollen and mold counts are available to determine the time and amount of exposure. Climate change is already having an important effect on the distribution and amount of outdoor allergens. The third section discusses indoor and outdoor air pollution and methods that individuals can take to reduce indoor pollution in addition to eliminating cigarette smoking. The fourth section discusses the diagnosis and management of occupational asthma. (J Allergy Clin Immunol 2010;125:S150-60.)	[Peden, David] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; [Reed, Charles E.] Mayo Clin, Dept Med, Rochester, MN USA	University of North Carolina; University of North Carolina Chapel Hill; Mayo Clinic	Reed, CE (corresponding author), 9193 Bald Eagle Rd,POB 158, Boulder Jct, WI 54512 USA.	cereed@centurytel.net		Peden, David/0000-0003-4526-4627	National Institutes of Health, National Institute of Allergy and Infectious Diseases; National Institute of Environmental Health Sciences; National Heart, Lung, and Blood Institute	National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Disclosure of potential conflict of interest: D. Peden is a consultant for ICAGEN, GlaxoSmithKline, Genentech, and Funxional Therapeutics Ltd and has received research support from the National Institutes of Health, National Institute of Allergy and Infectious Diseases, and National Institute of Environmental Health Sciences, and National Heart, Lung, and Blood Institute. C. E. Reed has declared that he has no conflict of interest.	Alberg AJ, 2005, J CLIN ONCOL, V23, P3175, DOI 10.1200/JCO.2005.10.462; Alexis N, 2000, INHAL TOXICOL, V12, P1205; Alexis NE, 2004, CLIN IMMUNOL, V111, P126, DOI 10.1016/j.clim.2003.12.002; Alexis NE, 2008, ENVIRON HEALTH PERSP, V116, P799, DOI 10.1289/ehp.10981; Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V113, P109, DOI 10.1016/j.jaci.2003.10.042; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Arjomandi M, 2005, AM J RESP CRIT CARE, V172, P427, DOI 10.1164/rccm.200502-272OC; BARNES PJ, 1994, POSTGRAD MED J, V70, P319, DOI 10.1136/pgmj.70.823.319; Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; Beach J, 2007, CHEST, V131, P569, DOI 10.1378/chest.06-0492; Becker WM, 2006, CURR OPIN ALLERGY CL, V6, P470, DOI 10.1097/01.all.0000246622.34247.21; BERNSTEIN IL, 2006, ASTHMA WORKPLACE; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Biette GB, 2008, RESP CARE, V53, P602; Boulet LP, 2007, CURR OPIN ALLERGY CL, V7, P96, DOI 10.1097/ACI.0b013e328013ccd8; Breysse PN, 2005, ENVIRON RES, V98, P167, DOI 10.1016/j.envres.2004.07.018; Brims Fraser, 2005, Pediatr Infect Dis J, V24, pS152, DOI 10.1097/01.inf.0000188152.49558.49; Brunekreef B, 2005, EUR RESPIR J, V26, P309, DOI 10.1183/09031936.05.00001805; BRUNEKREEF B, 1990, J AIR WASTE MANAGE, V40, P1252, DOI 10.1080/10473289.1990.10466779; Burge HA, 2000, ENVIRON HEALTH PERSP, V108, P653, DOI 10.2307/3454401; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.2307/3433607; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Chan-Yeung M, 1999, CLIN EXP ALLERGY, V29, P762; Chan-Yeung M, 2003, RESPIROLOGY, V8, P131, DOI 10.1046/j.1440-1843.2003.00453.x; Chauhan AJ, 2003, BRIT MED BULL, V68, P95, DOI 10.1093/bmb/ldg022; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Christiani DC, 2008, OCCUP ENVIRON MED, V65, P430, DOI 10.1136/oem.2007.033977; Clancy L, 2002, LANCET, V360, P1210, DOI 10.1016/S0140-6736(02)11281-5; Curtin-Brosnan J, 2008, ANN ALLERG ASTHMA IM, V101, P517, DOI 10.1016/S1081-1206(10)60291-8; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164, DOI 10.1111/j.1365-2222.1994.tb03323.x; D'Amato G, 2005, CLIN EXP ALLERGY, V35, P1113, DOI 10.1111/j.1365-2222.2005.02328.x; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573, DOI 10.1289/ehp.02110s4573; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Dhala Atiya, 2006, Clin Occup Environ Med, V5, P139; Diaz-Sanchez D, 2003, CURR ALLERGY ASTHM R, V3, P146, DOI 10.1007/s11882-003-0027-4; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; Diaz-Sanchez D, 2006, J ALLERGY CLIN IMMUN, V118, P441, DOI 10.1016/j.jaci.2006.04.047; Diette GB, 2007, ENVIRON HEALTH PERSP, V115, P1665, DOI 10.1289/ehp.10088; Dykewicz MS, 2009, J ALLERGY CLIN IMMUN, V123, P519, DOI 10.1016/j.jaci.2009.01.061; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223, DOI 10.1080/00039896.1994.9937471; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V107, pS403, DOI 10.1067/mai.2001.113673; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V108, P685, DOI 10.1067/mai.2001.119569; Eisner M D, 2005, Exp Lung Res, V31 Suppl 1, P8; Erwin EA, 2003, IMMUNOL ALLERGY CLIN, V23, P469, DOI 10.1016/S0889-8561(03)00004-3; Esch RE, 2009, MIDDLETONS ALLERGY P, V1, P509, DOI [10.1016/j.jbi.2012.09.002, DOI 10.1016/B978-0-323-05659-5.00032-2]; Etzel RA, 2003, PEDIATRICS, V112, P233; Finn Patricia W, 2009, Proc Am Thorac Soc, V6, P260, DOI 10.1513/pats.200807-064RM; Fishwick D, 2008, THORAX, V63, P240, DOI 10.1136/thx.2007.083444; Fonacier LS, 2010, J ALLERGY CLIN IMMUN, V125, pS138, DOI 10.1016/j.jaci.2009.05.039; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Gergen PJ, 2001, RESP PHYSIOL, V128, P39, DOI 10.1016/S0034-5687(01)00263-8; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Gordian ME, 2003, ARCH ENVIRON HEALTH, V58, P42, DOI 10.3200/AEOH.58.1.42-47; Gotzsche PC, 2008, ALLERGY, V63, P646, DOI 10.1111/j.1398-9995.2008.01690.x; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Gupta D, 2006, Indian J Chest Dis Allied Sci, V48, P31; Hazucha MJ, 1996, EUR J APPL PHYSIOL O, V73, P17, DOI 10.1007/BF00262805; Holz O, 2002, CLIN EXP ALLERGY, V32, P681, DOI 10.1046/j.1365-2222.2002.01358.x; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33, DOI 10.1164/ajrccm.160.1.9808119; Jones Shawn C, 2006, J Ky Med Assoc, V104, P281; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56, DOI 10.1164/ajrccm.153.1.8542163; Kan HD, 2005, BIOMED ENVIRON SCI, V18, P159; Kauffman HF, 2003, CURR ALLERGY ASTHM R, V3, P430, DOI 10.1007/s11882-003-0080-z; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198, DOI 10.1016/S0091-6749(99)70013-8; KOENIG JQ, 1991, J TOXICOL-CLIN TOXIC, V29, P401, DOI 10.3109/15563659109000366; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717, DOI 10.1016/S0091-6749(99)70280-0; KOREN HS, 1995, INT ARCH ALLERGY IMM, V107, P236, DOI 10.1159/000236989; Kuo HW, 2002, ARCH ENVIRON HEALTH, V57, P194, DOI 10.1080/00039890209602936; Le Moual N, 2008, AM J RESP CRIT CARE, V177, P4, DOI 10.1164/rccm.200703-415PP; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Mar TF, 2004, INHAL TOXICOL, V16, P809, DOI 10.1080/08958370490506646; Marks GB, 2007, J ALLERGY CLIN IMMUN, V120, P530, DOI 10.1016/j.jaci.2007.07.012; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Matsui EC, 2008, IMMUNOL ALLERGY CLIN, V28, P665, DOI 10.1016/j.iac.2008.03.004; Matsui EC, 2007, J ALLERGY CLIN IMMUN, V120, P956, DOI 10.1016/j.jaci.2007.07.053; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; MICHEL O, 1995, INT ARCH ALLERGY IMM, V108, P298, DOI 10.1159/000237168; Mishra V, 2003, ENVIRON HEALTH PERSP, V111, P71, DOI 10.1289/ehp.5559; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204, DOI 10.1093/oxfordjournals.aje.a116073; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Nicholson PJ, 2005, OCCUP ENVIRON MED, V62, P290, DOI 10.1136/oem.2004.016287; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103a; O'Driscoll B Ronan, 2005, BMC Pulm Med, V5, P4, DOI 10.1186/1471-2466-5-4; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P220; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pacheco KA, 2003, AM J RESP CRIT CARE, V167, P983, DOI 10.1164/rccm.2112062; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103, DOI 10.1289/ehp.02110s1103; Passannante AN, 1998, J APPL PHYSIOL, V85, P1863, DOI 10.1152/jappl.1998.85.5.1863; Peden D.B., 1999, AIR POLLUTION HLTH, P865; Peden DB, 1997, ALLERGY, V52, P37, DOI 10.1111/j.1398-9995.1997.tb04869.x; Peden DB, 2002, ENVIRON HEALTH PERSP, V110, P565, DOI 10.1289/ehp.110-1241207; Peden DB, 2001, ANN ALLERG ASTHMA IM, V87, P12, DOI 10.1016/S1081-1206(10)62334-4; PEDEN DB, 2009, MIDDLETONS ALLERGY P, P495; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Phipatanakul W, 2004, ANN ALLERG ASTHMA IM, V92, P420, DOI 10.1016/S1081-1206(10)61777-2; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Platts-Mills TAE, 2008, J ALLERGY CLIN IMMUN, V122, P694, DOI 10.1016/j.jaci.2008.07.045; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; PlattsMills TAE, 1997, CIBA F SYMP, V206, P173; PLATTSMILLS TAE, 1990, ALLERGY PROC, V11, P269, DOI 10.2500/108854190778879729; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90, DOI 10.1080/00039896.1991.9937434; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Reed CE, 2008, J ALLERGY CLIN IMMUN, V121, P601, DOI 10.1016/j.jaci.2007.10.032; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Rios JLM, 2004, ANN ALLERG ASTHMA IM, V92, P629, DOI 10.1016/S1081-1206(10)61428-7; Robays LJ, 2009, MUCOSAL IMMUNOL, V2, P206, DOI 10.1038/mi.2009.7; Romieu I, 2008, EUR RESPIR J, V31, P179, DOI 10.1183/09031936.00128106; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300, DOI 10.1164/ajrccm.154.2.8756798; Romieu I, 2004, THORAX, V59, P8; Samet JM, 2001, AM J RESP CRIT CARE, V164, P819, DOI 10.1164/ajrccm.164.5.2008003; Saxon A, 2000, IMMUNOPHARMACOLOGY, V48, P325, DOI 10.1016/S0162-3109(00)00234-4; Schei MA, 2004, J EXPO ANAL ENV EPID, V14, pS110, DOI 10.1038/sj.jea.7500365; SCHELEGLE ES, 1987, AM REV RESPIR DIS, V136, P1350, DOI 10.1164/ajrccm/136.6.1350; Sharma HP, 2007, PEDIATR CLIN N AM, V54, P103, DOI 10.1016/j.pcl.2006.11.007; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; Singh N, 2002, CURR OPIN PULM MED, V8, P117, DOI 10.1097/00063198-200203000-00007; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; Sunyer J, 2002, THORAX, V57, P687, DOI 10.1136/thorax.57.8.687; Tarlo SM, 2008, CHEST, V134, p1S, DOI 10.1378/chest.08-0201; Tavernier G, 2006, J ALLERGY CLIN IMMUN, V117, P656, DOI 10.1016/j.jaci.2005.12.1311; Teague WG, 2001, PEDIATR CLIN N AM, V48, P1167, DOI 10.1016/S0031-3955(05)70367-9; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; Trenga CA, 2001, ARCH ENVIRON HEALTH, V56, P242, DOI 10.1080/00039890109604448; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; Vagaggini B, 2001, AM J RESP CRIT CARE, V164, P2172, DOI 10.1164/ajrccm.164.12.2009090; van Strien RT, 2004, EPIDEMIOLOGY, V15, P471, DOI 10.1097/01.ede.0000129511.61698.d8; van Strien RT, 2004, ALLERGY, V59, P645, DOI 10.1111/j.1398-9995.2004.00470.x; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843, DOI 10.1111/j.1365-2222.1994.tb01807.x; WANG JH, 1995, J ALLERGY CLIN IMMUN, V96, P669, DOI 10.1016/S0091-6749(95)70266-0; WANG JH, 1995, INT ARCH ALLERGY IMM, V107, P103, DOI 10.1159/000236944; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; Wisnewski AV, 2007, CURR OPIN ALLERGY CL, V7, P138, DOI 10.1097/ACI.0b013e3280895d22; YING RL, 1990, AM REV RESPIR DIS, V142, P817, DOI 10.1164/ajrccm/142.4.817	146	104	111	5	69	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S150	S160		10.1016/j.jaci.2009.10.073	http://dx.doi.org/10.1016/j.jaci.2009.10.073			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176257				2022-12-18	WOS:000280170600014
J	Fairley, JA; Baum, CL; Brandt, DS; Messingham, KAN				Fairley, Janet A.; Baum, Christian L.; Brandt, Debra S.; Messingham, Kelly A. N.			Pathogenicity of IgE in autoimmunity: Successful treatment of bullous pemphigoid with omalizumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HUMAN SKIN; AUTOANTIBODIES; THERAPY; MICE		[Fairley, Janet A.; Baum, Christian L.; Brandt, Debra S.; Messingham, Kelly A. N.] Univ Iowa, Carver Coll Med, Dept Dermatol, Iowa City, IA 52242 USA; [Fairley, Janet A.] Vet Adm Med Ctr, Iowa City, IA USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Fairley, JA (corresponding author), Univ Iowa, Carver Coll Med, Dept Dermatol, Iowa City, IA 52242 USA.	janet-fairley@uiowa.edu	; Messingham, Kelly/AAD-8388-2020	Fairley, Janet/0000-0002-8203-0486; Messingham, Kelly/0000-0003-4630-0722	NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024980, UL1RR024979] Funding Source: NIH RePORTER; Veterans Affairs [I01CX000317] Funding Source: NIH RePORTER; VA [5I01CX000317-02] Funding Source: Federal RePORTER; NCRR NIH HHS [KL2 RR024980, UL1 RR024979, 1UL1RR024979] Funding Source: Medline; CSRD VA [I01 CX000317] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Veterans Affairs(US Department of Veterans Affairs); VA(US Department of Veterans Affairs); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); CSRD VA		Corren J, 2008, J ALLERGY CLIN IMMUN, V121, P506, DOI 10.1016/j.jaci.2007.11.026; Dimson OG, 2003, J INVEST DERMATOL, V120, P784, DOI 10.1046/j.1523-1747.2003.12146.x; Fairley JA, 2005, J INVEST DERMATOL, V125, P467, DOI 10.1111/j.0022-202X.2005.23853.x; Fairley JA, 2007, J INVEST DERMATOL, V127, P2605, DOI 10.1038/sj.jid.5700958; Hamilton RG, 2005, J IMMUNOL METHODS, V303, P81, DOI 10.1016/j.jim.2005.06.008; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Zone JJ, 2007, J INVEST DERMATOL, V127, P1167, DOI 10.1038/sj.jid.5700681	7	104	108	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					704	705		10.1016/j.jaci.2008.11.035	http://dx.doi.org/10.1016/j.jaci.2008.11.035			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19152970	Green Accepted, Bronze			2022-12-18	WOS:000264731200035
J	Strunk, RC; Bacharier, LB; Phillips, BR; Szefler, SJ; Zeiger, RS; Chinchilli, VM; Martinez, FD; Lemanske, RF; Taussig, LM; Mauger, DT; Morgan, WJ; Sorkness, CA; Paul, IM; Guilbert, T; Krawiec, M; Covar, R; Larsen, G				Strunk, Robert C.; Bacharier, Leonard B.; Phillips, Brenda R.; Szefler, Stanley J.; Zeiger, Robert S.; Chinchilli, Vernon M.; Martinez, Fernando D.; Lemanske, Robert F., Jr.; Taussig, Lynn M.; Mauger, David T.; Morgan, Wayne J.; Sorkness, Christine A.; Paul, Ian M.; Guilbert, Theresa; Krawiec, Marzena; Covar, Ronina; Larsen, Gary		Natl Heart Lung & Blood Inst	Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; moderate to severe; children; macrolide; leukotriene receptor antagoinst; clinical trial	RANDOMIZED CONTROLLED-TRIAL; LOW-DOSE TROLEANDOMYCIN; INCREASED FREQUENCY; PERSISTENT ASTHMA; CHILDREN; PNEUMONIAE; THERAPY; HYPERRESPONSIVENESS; ELIMINATION; REDUCTION	Background: Clinical trials in children with moderate-to-severe persistent asthma are limited. Objective: We sought to determine whether azithromycin or montelukast are inhaled corticosteroid sparing. Methods: The budesonide dose (with salmeterol [50 mu g] twice daily) necessary to achieve control was determined in children 6 to 17 years of age with moderate-to-severe persistent asthma. After a budesonide-stable period of 6 weeks, children were randomized in a double-masked, parallel, multicenter study to receive once-nightly azithromycin, montelukast, or matching placebos plus the established controlling dose of budesonide (minimum, 400 mu g twice daily) and salmeterol twice daily. Primary outcome was time from randomization to inadequate asthma control after sequential budesonide dose reduction. Results: Of 292 children screened, only 55 were randomized. Inadequate adherence to study medication (n = 80) and improved asthma control under close medical supervision (n 49) were the major reasons for randomization failure. A futility analysis was requested by the Data Safety Monitoring Board. In data available for analyses, no differences were noted for either treatment compared with placebo in time to inadequate control status (median: azithromycin, 8.4 weeks [95% confidence limit, 4.3-17.3]; montelukast, 13.9 weeks [95% confidence limit, 4.7-20.6]; placebo, 19.1 weeks [95% confidence limit, 11.7-infinity]), with no difference between the groups (log-rank test, P = .49). The futility analysis indicated that even if the planned sample size was reached, the results of this negative study were unlikely to be different, and the trial was prematurely terminated. Conclusion: Based on these results, neither azithromycin nor montelukast is likely to be an effective inhaled corticosteroid-sparing alternative in children with moderate-to-severe persistent asthma. (J Allergy Clin Immunol 2008;122:1138-44.)	[Strunk, Robert C.; Bacharier, Leonard B.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA; [Strunk, Robert C.; Bacharier, Leonard B.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Phillips, Brenda R.; Chinchilli, Vernon M.; Mauger, David T.; Paul, Ian M.] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Zeiger, Robert S.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Zeiger, Robert S.] Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA; [Szefler, Stanley J.; Taussig, Lynn M.; Krawiec, Marzena; Covar, Ronina; Larsen, Gary] Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; [Martinez, Fernando D.; Morgan, Wayne J.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; [Guilbert, Theresa] Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California San Diego; Kaiser Permanente; National Jewish Health; University of Arizona; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Strunk, RC (corresponding author), 1 Childrens Pl, St Louis, MO 63110 USA.	strunk@kids.wustl.edu	Paul, Ian/AAD-9813-2020	Bacharier, Leonard/0000-0003-0432-2704; Zeiger, Robert/0000-0001-5788-5063; Paul, Ian/0000-0002-6344-8609; Guilbert, Theresa/0000-0002-6932-712X	National Institutes of Health (NIH); National Heart, Lung. and Blood Institute (NHLBI); Ross Pharmaceuticals; Sanofi Aventis; Genentech; Novartis; GlaxoSmithKline; National Honey Board; Johnson Johnson; Altus Pharmaceuticals; Ross Abbott Laboratories; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064288, U10HL064295, U10HL064287, U10HL064307, U10HL064313, U10HL064305] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung. and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Ross Pharmaceuticals; Sanofi Aventis(Sanofi-Aventis); Genentech(Roche HoldingGenentech); Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); National Honey Board; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Altus Pharmaceuticals; Ross Abbott Laboratories(Abbott Laboratories); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Disclosure of potential conflict of interest: L. B. Bacharier has received honoraria front AstraZeneca. Genentech. GlaxoSmithKline, Merck, and Aerocrine and has served on air advisory board for Schering-Plough. S. J. Szefler has served as a consultant for AstraZeneca. GlaxoSmithKline. Aventis. Genentech, and Merck and has received research support from the National Institutes of Health (NIH), the National Heart, Lung. and Blood Institute (NHLBI). and Ross Pharmaceuticals. R. S. Zeiger has served as a consultant for Aerocrine, AstraZeneca. GlaxoSmithKline, Genentech, Merck, Schering. and Novartis and has received research support from Sanofi Aventis and Genentech. V. M. Chinchilli has received research support from the NIH and NHLBI. F. D. Martinez has received lecture fees front and has served on all advisory board for Merck and has served as it consultant for GlaxoSmithKline. R. F. Lemanske has received speaker honoraria from Merck: has served as a consultant for MAP Pharmaceuticals and has received research support from the NHLBI. D. T. Manger the Cystic Fibrosis Foundation and Genentech and has received research support from the NIH. C.A. Sorkness has served as a consultant for GlaxoSmithKline and Novartis and has received research support front Novartis, the NHLBI, and the National Institute of Allergy and infections Diseases (NIAID). I. M. Paul has served as it consultant for McNeil Consumer Healthcare, the Consumer Healthcare Products Association. and Reckitt Brackiser Healthcare International and has received research support from GlaxoSmithKline, the National Honey Board. and Johnson & Johnson. T. Guilbert has received honoraria for serving as a consultant, speaker, or both for GlaxoSmithKline, AstraZeneca, Merck, and Antidote (formerly World Medical Conferences CME Programs) and has received research support from Altus Pharmaceuticals, Inspire H. M, Krawiee has served on the speakers' bureau for Pharmaceuticals, and the NI Merck and GlaxoSmithKline has served its a consultant on a peer-reviewed publication for Adelphi has served as a consultant for Parexel and Novartis and has provided legal consultation or expert witness testimony on the topic of pediatric asthma. R. Covar has served as a consultant for Merck and has received research funding from Ross Abbott Laboratories and AstraZeneca. G. Larsen has served oil an asthma advisory board for Genentech and has received research funding from the NIH. The rest of the authors have declared that they have no conflict of interest.	BALL BD, 1990, ANN ALLERGY, V65, P37; Biscardi S, 2004, CLIN INFECT DIS, V38, P1341, DOI 10.1086/392498; Biscione GL, 2004, EUR RESPIR J, V24, P745, DOI 10.1183/09031936.04.00049004; Black PN, 2001, AM J RESP CRIT CARE, V164, P536, DOI 10.1164/ajrccm.164.4.2011040; *DEP HLTH HUM SERV, 2007, 3 DEP HLTH HUM SERV; Fost DA, 1999, J ALLERGY CLIN IMMUN, V103, P1031, DOI 10.1016/S0091-6749(99)70175-2; Gencay M, 2001, AM J RESP CRIT CARE, V163, P1097, DOI 10.1164/ajrccm.163.5.2003162; Jaffe A, 2001, PEDIATR PULM, V31, P464, DOI 10.1002/ppul.1076; Johnston NW, 2007, PEDIATRICS, V120, pE702, DOI 10.1542/peds.2006-3317; Jones CA, 2007, J ALLERGY CLIN IMMUN, V119, P1445, DOI 10.1016/j.jaci.2007.02.031; KAMADA AK, 1993, J ALLERGY CLIN IMMUN, V91, P873, DOI 10.1016/0091-6749(93)90345-G; Kostadima E, 2004, EUR RESPIR J, V23, P714, DOI 10.1183/09031936.04.00118404; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; McCoy K, 2006, J ALLERGY CLIN IMMUN, V118, P1226, DOI 10.1016/j.jaci.2006.09.006; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; *NAT HEART LUNG BL, 2002, NAT ASTHM ED PREV PR; ODA H, 1994, CHEST, V106, P1116, DOI 10.1378/chest.106.4.1116; Saiman L, 2003, JAMA-J AM MED ASSOC, V290, P1749, DOI 10.1001/jama.290.13.1749; Simons FER, 2001, J PEDIATR-US, V138, P694, DOI 10.1067/mpd.2001.112899; *US PHARM NAT FORM, 2005, US PHARM CONV, V1, P2412; Visser MJ, 2004, EUR RESPIR J, V24, P420, DOI 10.1183/09031936.04.00023904	22	104	107	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1138	1144		10.1016/j.jaci.2008.09.028	http://dx.doi.org/10.1016/j.jaci.2008.09.028			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18951618	Green Accepted			2022-12-18	WOS:000261711800011
J	Menzies, D; Nair, A; Meldrum, KT; Fleming, D; Barnes, M; Lipworth, BJ				Menzies, Daniel; Nair, Arun; Meldrum, Karen T.; Fleming, Dawn; Barnes, Martyn; Lipworth, Brian J.			Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; simvastatin; nitric oxide; inflammation; methacholine challenge; sputum eosinophils; clinical trial	C-REACTIVE PROTEIN; STATIN THERAPY; NITRIC-OXIDE; DISEASE; ATORVASTATIN; METHACHOLINE; PRAVASTATIN; COUNTS; CELLS; MODEL	Background: Statins lower cholesterol and also exhibit anti-inflammatory properties. In vitro and animal studies have suggested they may be useful for the treatment of a number of inflammatory conditions. Objective: To evaluate the in vivo therapeutic potential of simvastatin as an anti-inflammatory agent in patients with asthma. Methods: Potential signal from treatment effect was optimized by withdrawing all anti-inflammatory treatment for the duration of the study. Participants received 1 month of daily simvastatin and 1 month of daily placebo in a randomized, double-blind crossover trial. A total of 16 patients completed per protocol. Asthmatic inflammation was evaluated by measuring exhaled tidal nitric oxide, alveolar nitric oxide, sputum and peripheral eosinophil count, methacholine hyperresponsiveness, salivary eosinophilic cationic protein, and C-reactive protein. Measurements of dynamic and static lung volumes and of cholesterol were also made. Results: After initial withdrawal of usual asthma medication, there was a 1.43 geometric mean fold increase (ie, 43% difference) in fraction of exhaled nitric oxide (95% CI, 1.15 to 1.78; P =.004). Compared with placebo, simvastatin led to a 0.86 geometric mean fold decrease (95% Cl, 0.7 to 1.04; P = .15) in exhaled nitric oxide (ie, a 14% difference) and a-0.18 doubling dilution shift (95% CI, -1.90 to 1.55; P = 1.0) in methacholine hyperresponsiveness. There were no significant differences in other inflammatory outcomes, lung volumes, or airway resistance between simvastatin and placebo. Treatment with simvastatin led to a significant reduction (P < .005) of total and low-density lipoprotein cholesterol. Conclusion: There is no evidence to suggest simvastatin has anti-inflammatory activity in patients with asthma. Clinical implications: Simvastatin is not useful for the treatment of asthma.	Ninewells Hosp & Med Sch, Asthma & Allergy Res Grp, Dept Med Therapeut, Dundee DD1 9SY, Scotland; Ninewells Hosp & Med Sch, Dept Pathol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Lipworth, BJ (corresponding author), Ninewells Hosp & Med Sch, Asthma & Allergy Res Grp, Dept Med Therapeut, Dundee DD1 9SY, Scotland.	brianlipworth@googlemail.com		Smith, Karen/0000-0002-3968-7458				Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Arnaud C, 2005, ARTERIOSCL THROM VAS, V25, P1231, DOI 10.1161/01.ATV.0000163840.63685.0c; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bucca C, 2005, ANN INTERN MED, V142, P310, DOI 10.7326/0003-4819-142-4-200502150-00024; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dykstra ML, 2001, TRAFFIC, V2, P160, DOI 10.1034/j.1600-0854.2001.020302.x; Fardon TC, 2006, ANN ALLERG ASTHMA IM, V96, P422, DOI 10.1016/S1081-1206(10)60909-X; Fardon TC, 2004, ANN ALLERG ASTHMA IM, V93, P365, DOI 10.1016/S1081-1206(10)61396-8; Fehr T, 2004, ATHEROSCLEROSIS, V175, P83, DOI 10.1016/j.atherosclerosis.2004.02.016; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Hillyard DZ, 2004, ATHEROSCLEROSIS, V175, P305, DOI 10.1016/j.atherosclerosis.2004.03.018; Hillyard DZ, 2004, ATHEROSCLEROSIS, V172, P219, DOI 10.1016/j.atherosclerosis.2003.11.004; Johnson BA, 2003, AM J RESP CRIT CARE, V167, P1271, DOI 10.1164/rccm.200205-410OC; Kiener PA, 2001, INT IMMUNOPHARMACOL, V1, P105, DOI 10.1016/S0162-3109(00)00272-1; Kono H, 2002, J IMMUNOL, V169, P193, DOI 10.4049/jimmunol.169.1.193; Krauth MT, 2006, ALLERGY, V61, P281, DOI 10.1111/j.1398-9995.2006.00997.x; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Lawman S, 2004, J IMMUNOL, V173, P7641, DOI 10.4049/jimmunol.173.12.7641; Lee LH, 2005, AM J RESP CRIT CARE, V172, P987, DOI 10.1164/rccm.200501-041OC; Li WM, 2006, IMMUNOL CELL BIOL, V84, P274, DOI 10.1111/j.1440-1711.2006.01430.x; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Luo FM, 2004, CHEST, V126, p721S, DOI 10.1378/chest.126.4_MeetingAbstracts.721S; McKay A, 2004, J IMMUNOL, V172, P2903, DOI 10.4049/jimmunol.172.5.2903; Miller W, 2005, AM BOOK REV, V26, P19; Nagashima T, 2006, ARTHRITIS RHEUM-US, V54, P579, DOI 10.1002/art.21564; PEDERSEN TR, 1994, LANCET, V344, P1383; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Schmekel B, 2001, RESP MED, V95, P670, DOI 10.1053/rmed.2001.1123; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Tikiz C, 2005, J RHEUMATOL, V32, P2095; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653, DOI 10.1152/jappl.1998.85.2.653; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Wang WK, 2005, IEEE ELECTR DEVICE L, V26, P5, DOI 10.1109/LED.2004.840395; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Yilmaz A, 2006, J LEUKOCYTE BIOL, V79, P529, DOI 10.1189/jlb.0205064; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	42	104	114	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					328	335		10.1016/j.jaci.2006.10.014	http://dx.doi.org/10.1016/j.jaci.2006.10.014			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17141851				2022-12-18	WOS:000244327900009
